Gene	"Gene synonym"	Ensembl	"Gene description"	Uniprot	Chromosome	Position	"Protein class"	"Biological process"	"Molecular function"	"Disease involvement"	Evidence	"HPA evidence"	"UniProt evidence"	"NeXtProt evidence"	"MS evidence"	"RNA tissue specificity"	"RNA tissue distribution"	"RNA tissue specificity score"	"RNA tissue specific NX"	"RNA single cell type specificity"	"RNA single cell type distribution"	"RNA single cell type specificity score"	"RNA single cell type specific NX"	"RNA cancer specificity"	"RNA cancer distribution"	"RNA cancer specificity score"	"RNA cancer specific FPKM"	"RNA brain regional specificity"	"RNA brain regional distribution"	"RNA brain regional specificity score"	"RNA brain regional specific NX"	"RNA blood cell specificity"	"RNA blood cell distribution"	"RNA blood cell specificity score"	"RNA blood cell specific NX"	"RNA blood lineage specificity"	"RNA blood lineage distribution"	"RNA blood lineage specificity score"	"RNA blood lineage specific NX"	"RNA cell line specificity"	"RNA cell line distribution"	"RNA cell line specificity score"	"RNA cell line specific NX"	"RNA mouse brain regional specificity"	"RNA mouse brain regional distribution"	"RNA mouse brain regional specificity score"	"RNA mouse brain regional specific pTPM"	"RNA pig brain regional specificity"	"RNA pig brain regional distribution"	"RNA pig brain regional specificity score"	"RNA pig brain regional specific pTPM"	Antibody	"Reliability (IH)"	"Reliability (Mouse Brain)"	"Reliability (IF)"	"Subcellular location"	"Secretome location"	"CCD Protein"	"CCD Transcript"	"Blood concentration - Conc. blood IM [pg/L]"	"Blood concentration - Conc. blood MS [pg/L]"	"Subcellular main location"	"Subcellular additional location"	"Antibody RRID"	"Pathology prognostics - Breast cancer"	"Pathology prognostics - Cervical cancer"	"Pathology prognostics - Colorectal cancer"	"Pathology prognostics - Endometrial cancer"	"Pathology prognostics - Glioma"	"Pathology prognostics - Head and neck cancer"	"Pathology prognostics - Liver cancer"	"Pathology prognostics - Lung cancer"	"Pathology prognostics - Melanoma"	"Pathology prognostics - Ovarian cancer"	"Pathology prognostics - Pancreatic cancer"	"Pathology prognostics - Prostate cancer"	"Pathology prognostics - Renal cancer"	"Pathology prognostics - Stomach cancer"	"Pathology prognostics - Testis cancer"	"Pathology prognostics - Thyroid cancer"	"Pathology prognostics - Urothelial cancer"	"Tissue RNA - adipose tissue [NX]"	"Tissue RNA - adrenal gland [NX]"	"Tissue RNA - amygdala [NX]"	"Tissue RNA - appendix [NX]"	"Tissue RNA - basal ganglia [NX]"	"Tissue RNA - bone marrow [NX]"	"Tissue RNA - breast [NX]"	"Tissue RNA - cerebellum [NX]"	"Tissue RNA - cerebral cortex [NX]"	"Tissue RNA - cervix, uterine [NX]"	"Tissue RNA - colon [NX]"	"Tissue RNA - corpus callosum [NX]"	"Tissue RNA - ductus deferens [NX]"	"Tissue RNA - duodenum [NX]"	"Tissue RNA - endometrium 1 [NX]"	"Tissue RNA - epididymis [NX]"	"Tissue RNA - esophagus [NX]"	"Tissue RNA - fallopian tube [NX]"	"Tissue RNA - gallbladder [NX]"	"Tissue RNA - heart muscle [NX]"	"Tissue RNA - hippocampal formation [NX]"	"Tissue RNA - hypothalamus [NX]"	"Tissue RNA - kidney [NX]"	"Tissue RNA - liver [NX]"	"Tissue RNA - lung [NX]"	"Tissue RNA - lymph node [NX]"	"Tissue RNA - midbrain [NX]"	"Tissue RNA - olfactory region [NX]"	"Tissue RNA - ovary [NX]"	"Tissue RNA - pancreas [NX]"	"Tissue RNA - parathyroid gland [NX]"	"Tissue RNA - pituitary gland [NX]"	"Tissue RNA - placenta [NX]"	"Tissue RNA - pons and medulla [NX]"	"Tissue RNA - prostate [NX]"	"Tissue RNA - rectum [NX]"	"Tissue RNA - retina [NX]"	"Tissue RNA - salivary gland [NX]"	"Tissue RNA - seminal vesicle [NX]"	"Tissue RNA - skeletal muscle [NX]"	"Tissue RNA - skin 1 [NX]"	"Tissue RNA - small intestine [NX]"	"Tissue RNA - smooth muscle [NX]"	"Tissue RNA - spinal cord [NX]"	"Tissue RNA - spleen [NX]"	"Tissue RNA - stomach 1 [NX]"	"Tissue RNA - testis [NX]"	"Tissue RNA - thalamus [NX]"	"Tissue RNA - thymus [NX]"	"Tissue RNA - thyroid gland [NX]"	"Tissue RNA - tongue [NX]"	"Tissue RNA - tonsil [NX]"	"Tissue RNA - urinary bladder [NX]"	"Tissue RNA - vagina [NX]"	"Tissue RNA - B-cells [NX]"	"Tissue RNA - dendritic cells [NX]"	"Tissue RNA - granulocytes [NX]"	"Tissue RNA - monocytes [NX]"	"Tissue RNA - NK-cells [NX]"	"Tissue RNA - T-cells [NX]"	"Tissue RNA - total PBMC [NX]"	"Cell RNA - A-431 [NX]"	"Cell RNA - A549 [NX]"	"Cell RNA - AF22 [NX]"	"Cell RNA - AN3-CA [NX]"	"Cell RNA - ASC diff [NX]"	"Cell RNA - ASC TERT1 [NX]"	"Cell RNA - BEWO [NX]"	"Cell RNA - BJ [NX]"	"Cell RNA - BJ hTERT+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ [NX]"	"Cell RNA - BJ hTERT+ SV40 Large T+ RasG12V [NX]"	"Cell RNA - CACO-2 [NX]"	"Cell RNA - CAPAN-2 [NX]"	"Cell RNA - Daudi [NX]"	"Cell RNA - EFO-21 [NX]"	"Cell RNA - fHDF/TERT166 [NX]"	"Cell RNA - GAMG [NX]"	"Cell RNA - HaCaT [NX]"	"Cell RNA - HAP1 [NX]"	"Cell RNA - HBEC3-KT [NX]"	"Cell RNA - HBF TERT88 [NX]"	"Cell RNA - HDLM-2 [NX]"	"Cell RNA - HEK 293 [NX]"	"Cell RNA - HEL [NX]"	"Cell RNA - HeLa [NX]"	"Cell RNA - Hep G2 [NX]"	"Cell RNA - HHSteC [NX]"	"Cell RNA - HL-60 [NX]"	"Cell RNA - HMC-1 [NX]"	"Cell RNA - HSkMC [NX]"	"Cell RNA - hTCEpi [NX]"	"Cell RNA - hTEC/SVTERT24-B [NX]"	"Cell RNA - hTERT-HME1 [NX]"	"Cell RNA - hTERT-RPE1 [NX]"	"Cell RNA - HUVEC TERT2 [NX]"	"Cell RNA - JURKAT [NX]"	"Cell RNA - K-562 [NX]"	"Cell RNA - Karpas-707 [NX]"	"Cell RNA - LHCN-M2 [NX]"	"Cell RNA - MCF7 [NX]"	"Cell RNA - MOLT-4 [NX]"	"Cell RNA - NB-4 [NX]"	"Cell RNA - NTERA-2 [NX]"	"Cell RNA - OE19 [NX]"	"Cell RNA - PC-3 [NX]"	"Cell RNA - REH [NX]"	"Cell RNA - RH-30 [NX]"	"Cell RNA - RPMI-8226 [NX]"	"Cell RNA - RPTEC TERT1 [NX]"	"Cell RNA - RT4 [NX]"	"Cell RNA - SCLC-21H [NX]"	"Cell RNA - SH-SY5Y [NX]"	"Cell RNA - SiHa [NX]"	"Cell RNA - SK-BR-3 [NX]"	"Cell RNA - SK-MEL-30 [NX]"	"Cell RNA - SuSa [NX]"	"Cell RNA - T-47d [NX]"	"Cell RNA - THP-1 [NX]"	"Cell RNA - TIME [NX]"	"Cell RNA - U-138 MG [NX]"	"Cell RNA - U-2 OS [NX]"	"Cell RNA - U-2197 [NX]"	"Cell RNA - U-251 MG [NX]"	"Cell RNA - U-266/70 [NX]"	"Cell RNA - U-266/84 [NX]"	"Cell RNA - U-698 [NX]"	"Cell RNA - U-87 MG [NX]"	"Cell RNA - U-937 [NX]"	"Cell RNA - WM-115 [NX]"	"Blood RNA - basophil [NX]"	"Blood RNA - classical monocyte [NX]"	"Blood RNA - eosinophil [NX]"	"Blood RNA - gdT-cell [NX]"	"Blood RNA - intermediate monocyte [NX]"	"Blood RNA - MAIT T-cell [NX]"	"Blood RNA - memory B-cell [NX]"	"Blood RNA - memory CD4 T-cell [NX]"	"Blood RNA - memory CD8 T-cell [NX]"	"Blood RNA - myeloid DC [NX]"	"Blood RNA - naive B-cell [NX]"	"Blood RNA - naive CD4 T-cell [NX]"	"Blood RNA - naive CD8 T-cell [NX]"	"Blood RNA - neutrophil [NX]"	"Blood RNA - NK-cell [NX]"	"Blood RNA - non-classical monocyte [NX]"	"Blood RNA - plasmacytoid DC [NX]"	"Blood RNA - T-reg [NX]"	"Blood RNA - total PBMC [NX]"	"Brain RNA - amygdala [NX]"	"Brain RNA - basal ganglia [NX]"	"Brain RNA - cerebellum [NX]"	"Brain RNA - cerebral cortex [NX]"	"Brain RNA - hippocampal formation [NX]"	"Brain RNA - hypothalamus [NX]"	"Brain RNA - midbrain [NX]"	"Brain RNA - olfactory region [NX]"	"Brain RNA - pons and medulla [NX]"	"Brain RNA - thalamus [NX]"	"Single Cell Type RNA - Alveolar cells type 1 [NX]"	"Single Cell Type RNA - Alveolar cells type 2 [NX]"	"Single Cell Type RNA - B-cells [NX]"	"Single Cell Type RNA - Basal glandular cells [NX]"	"Single Cell Type RNA - Basal keratinocytes [NX]"	"Single Cell Type RNA - Bipolar cells [NX]"	"Single Cell Type RNA - Cardiomyocytes [NX]"	"Single Cell Type RNA - Cholangiocytes [NX]"	"Single Cell Type RNA - Ciliated cells [NX]"	"Single Cell Type RNA - Club cells [NX]"	"Single Cell Type RNA - Collecting duct cells [NX]"	"Single Cell Type RNA - Cone photoreceptor cells [NX]"	"Single Cell Type RNA - Cytotrophoblasts [NX]"	"Single Cell Type RNA - Distal tubular cells [NX]"	"Single Cell Type RNA - Ductal cells [NX]"	"Single Cell Type RNA - Early spermatids [NX]"	"Single Cell Type RNA - Endothelial cells [NX]"	"Single Cell Type RNA - Enterocytes [NX]"	"Single Cell Type RNA - Erythroid cells [NX]"	"Single Cell Type RNA - Exocrine glandular cells [NX]"	"Single Cell Type RNA - Extravillous trophoblasts [NX]"	"Single Cell Type RNA - Fibroblasts [NX]"	"Single Cell Type RNA - Glandular cells [NX]"	"Single Cell Type RNA - granulocytes [NX]"	"Single Cell Type RNA - Hepatocytes [NX]"	"Single Cell Type RNA - Hofbauer cells [NX]"	"Single Cell Type RNA - Horizontal cells [NX]"	"Single Cell Type RNA - Intestinal endocrine cells [NX]"	"Single Cell Type RNA - Ito cells [NX]"	"Single Cell Type RNA - Kupffer cells [NX]"	"Single Cell Type RNA - Late spermatids [NX]"	"Single Cell Type RNA - Leydig cells [NX]"	"Single Cell Type RNA - Macrophages [NX]"	"Single Cell Type RNA - Melanocytes [NX]"	"Single Cell Type RNA - monocytes [NX]"	"Single Cell Type RNA - Mucus-secreting cells [NX]"	"Single Cell Type RNA - Muller glia cells [NX]"	"Single Cell Type RNA - Pancreatic endocrine cells [NX]"	"Single Cell Type RNA - Paneth cells [NX]"	"Single Cell Type RNA - Peritubular cells [NX]"	"Single Cell Type RNA - Proximal tubular cells [NX]"	"Single Cell Type RNA - Rod photoreceptor cells [NX]"	"Single Cell Type RNA - Sertoli cells [NX]"	"Single Cell Type RNA - Smooth muscle cells [NX]"	"Single Cell Type RNA - Spermatocytes [NX]"	"Single Cell Type RNA - Spermatogonia [NX]"	"Single Cell Type RNA - Suprabasal keratinocytes [NX]"	"Single Cell Type RNA - Syncytiotrophoblasts [NX]"	"Single Cell Type RNA - T-cells [NX]"	"Single Cell Type RNA - Undifferentiated cells [NX]"	"Single Cell Type RNA - Urothelial cells [NX]"
ABAT	GABAT	ENSG00000183044	"4-aminobutyrate aminotransferase"	P80404	16	8674565-8784575	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Neurotransmitter degradation"	"Aminotransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 53.3;liver: 136.5;pancreas: 54.2"	"Cell type enhanced"	"Detected in many"	19	"Hepatocytes: 234.8;Proximal tubular cells: 72.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Hep G2: 45.3;MCF7: 29.1;RH-30: 25.6;T-47d: 15.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041528, HPA041690"	Enhanced	Supported	Supported	Mitochondria		No	No		1500000	Mitochondria		"HPA041528: AB_10795690, HPA041690: AB_10794674"	"unprognostic (1.77e-2)"	"unprognostic (3.27e-1)"	"unprognostic (1.00e-1)"	"unprognostic (2.71e-1)"	"unprognostic (2.90e-1)"	"unprognostic (2.05e-1)"	"prognostic favorable (5.36e-5)"	"prognostic favorable (5.93e-4)"	"unprognostic (1.71e-1)"	"unprognostic (1.30e-1)"	"unprognostic (1.56e-2)"	"unprognostic (1.04e-1)"	"prognostic favorable (5.44e-8)"	"unprognostic (2.10e-1)"	"unprognostic (2.48e-2)"	"unprognostic (3.80e-1)"	"unprognostic (1.50e-2)"	2.1	12.6	26.1	2.7	39.3	1.7	3.2	19.9	43.3	2.2	5.2	10.9	0.1	17.5	2.1	5.0	3.0	2.8	2.7	6.2	20.4	30.9	53.3	136.5	2.8	2.8	24.5	26.1	5.3	54.2	4.0	22.1	2.3	14.3	9.9	4.2	2.6	2.6	2.5	1.4	2.1	8.4	2.1	14.1	2.5	3.9	6.3	11.8	1.0	12.7	0.4	3.3	6.4	1.1	2.2	1.9	8.8	5.8	1.6	2.5	1.8	0.2	0.0	12.1	6.9	1.9	0.7	0.5	1.4	0.8	0.7	0.2	4.5	0.3	1.4	0.5	0.8	0.4	3.1	0.8	2.8	0.9	0.8	0.6	2.0	0.0	45.3	3.1	0.4	3.1	2.5	1.3	1.2	0.5	0.3	0.2	3.9	0.3	1.0	0.2	29.1	0.7	0.2	1.0	8.5	0.1	3.5	25.6	0.6	0.4	7.2	1.9	5.8	0.7	0.4	0.0	2.5	15.9	1.2	0.2	0.2	2.0	0.9	0.0	1.1	0.1	0.3	0.3	2.1	1.4	1.1	3.1	4.1	2.5	3.6	1.1	0.8	1.7	1.7	1.9	2.2	1.1	1.8	8.8	1.6	5.8	0.3	1.6	1.8	26.1	39.3	19.9	35.1	20.4	30.9	24.5	26.1	14.3	11.8	0.0	5.8	12.2	3.3	1.3	16.6	8.9	15.3	2.7	7.9	1.8	3.9	1.2	19.9	1.2	8.3	1.4	10.3	0.0	5.5	1.2	2.1	9.6	1.1	234.8	4.3	33.4	15.0	5.5	9.1	6.0	3.4	5.4	1.7	0.0	4.9	48.7	6.3	6.5	4.2	72.0	6.0	0.0	2.5	1.5	0.9	0.5	1.1	7.2	6.8	4.2
ABCA1	"ABC1, HDLDT1, TGD"	ENSG00000165029	"ATP binding cassette subfamily A member 1"	O95477	9	104781002-104928237	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism, Transport"	Translocase	"Atherosclerosis, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Alveolar cells type 1: 98.3;Hepatocytes: 162.2;Kupffer cells: 103.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"eosinophil: 11.6;neutrophil: 10.6"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 11.6"	"Cell line enhanced"	"Detected in many"		"HSkMC: 17.0;U-87 MG: 39.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA057283, CAB069889"	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"CAB069889: AB_10002789, HPA057283: AB_2683396"	"unprognostic (1.58e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.80e-1)"	"unprognostic (7.47e-3)"	"unprognostic (1.85e-1)"	"unprognostic (9.22e-2)"	"unprognostic (9.80e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.28e-3)"	"unprognostic (2.14e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.00e-3)"	"unprognostic (2.51e-2)"	"unprognostic (6.71e-2)"	"unprognostic (2.57e-1)"	25.7	38.1	6.3	9.8	13.1	15.8	23.0	2.3	8.5	8.2	14.8	8.0	6.5	4.4	7.8	9.6	7.0	7.9	13.6	10.7	7.5	3.7	7.1	33.3	12.7	29.4	18.9	2.3	8.7	5.4	1.8	3.3	20.1	10.2	9.4	9.4	7.7	6.3	8.7	21.3	12.1	8.1	25.2	16.1	12.8	7.3	8.8	8.0	16.9	5.8	2.2	5.0	16.4	20.0	1.8	0.2	11.6	1.5	0.1	0.6	0.1	0.0	2.7	2.2	0.0	6.5	2.5	2.0	2.8	10.9	0.9	1.0	0.4	0.4	3.8	3.1	2.8	10.7	0.0	1.2	0.1	0.8	0.0	0.0	0.4	0.9	9.5	11.8	0.0	6.7	17.0	0.7	11.1	0.2	10.6	1.0	0.3	0.0	9.8	0.2	0.3	2.3	5.2	3.1	0.5	0.8	0.0	0.0	0.2	1.8	1.8	0.3	0.1	2.9	0.5	0.6	4.5	0.0	1.9	1.0	3.0	0.2	3.9	3.1	3.8	1.8	2.3	39.0	0.0	0.0	2.2	0.8	11.6	0.2	1.0	0.2	1.2	0.3	0.0	0.2	1.8	0.6	0.0	10.6	0.1	1.5	0.1	0.1	0.1	6.3	13.1	2.3	4.0	7.5	3.7	18.9	2.3	10.2	8.0	98.3	9.4	5.1	4.8	26.4	11.9	7.8	12.7	2.7	9.1	10.4	45.2	21.2	0.0	3.8	1.5	9.3	3.2	0.0	1.4	4.6	28.8	3.1	46.1	162.2	63.2	0.0	8.7	25.2	103.3	0.7	28.7	31.4	25.3	2.8	2.4	0.1	4.9	3.5	26.5	17.0	5.5	45.3	16.4	1.2	0.7	16.9	7.4	4.4	2.3	8.9
ABCC1	"GS-X, MRP, MRP1"	ENSG00000103222	"ATP binding cassette subfamily C member 1"	P33527	16	15949577-16143074	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	Transport	"Hydrolase, Translocase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 7.5;eosinophil: 3.1;T-reg: 2.1"	"Group enriched"	"Detected in many"	7	"granulocytes: 7.5;T-cells: 2.1"	"Cell line enhanced"	"Detected in many"		"EFO-21: 39.0"	"Low region specificity"	"Detected in all"							"HPA002380, HPA076011"	Uncertain		Supported	"Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane"	"Cell Junctions"	"HPA002380: AB_1844432, HPA076011: "	"unprognostic (9.97e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.05e-2)"	"unprognostic (2.94e-1)"	"unprognostic (4.89e-2)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (5.42e-5)"	"unprognostic (3.42e-1)"	"unprognostic (3.31e-1)"	"unprognostic (4.07e-2)"	"unprognostic (9.78e-3)"	"unprognostic (7.19e-2)"	"prognostic unfavorable (1.55e-6)"	"unprognostic (1.84e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.43e-2)"	"unprognostic (1.80e-2)"	8.9	8.2	2.4	8.3	3.1	8.4	9.6	4.4	5.0	8.3	10.7	2.6	15.5	3.5	10.5	12.7	14.7	5.6	9.6	8.0	2.1	2.4	4.5	1.6	10.9	12.2	3.0	2.1	6.8	5.8	18.4	4.2	5.2	4.1	9.6	4.1	12.0	16.9	10.9	20.8	6.6	8.2	16.4	4.0	9.2	10.9	15.1	2.3	26.8	15.7	12.6	15.6	15.3	11.8	0.7	0.5	7.5	0.5	0.4	2.1	0.2	2.3	24.7	0.1	6.5	5.7	3.5	1.3	7.3	8.9	6.3	6.6	3.9	17.8	6.7	39.0	14.0	5.9	6.7	2.0	7.1	4.8	11.8	2.3	8.3	14.4	14.3	17.1	3.0	21.5	7.5	4.8	1.8	1.0	5.4	6.9	12.9	8.4	3.4	1.9	4.6	5.3	2.8	3.9	3.3	3.6	18.9	3.7	3.3	2.3	8.3	3.6	5.9	9.2	10.0	2.4	6.6	3.5	1.6	0.7	0.4	1.5	5.2	5.8	6.4	3.2	2.3	3.3	3.1	0.7	7.5	0.1	3.1	0.6	0.4	0.6	0.7	0.5	0.6	0.5	0.3	0.6	0.6	0.0	0.4	0.5	0.3	2.1	0.2	2.4	3.1	4.4	5.0	2.1	2.4	3.0	2.1	4.1	2.3	23.8	6.4	10.4	6.8	7.8	3.1	5.3	5.1	2.7	12.5	5.2	21.6	0.6	3.3	8.7	7.2	6.2	1.1	0.0	5.5	2.2	3.3	13.8	20.9	0.2	7.2	4.8	17.9	8.6	15.5	11.0	6.9	10.2	3.3	6.4	7.2	1.2	8.5	3.5	6.3	1.4	8.3	0.0	3.1	2.4	5.9	4.4	0.5	9.6	3.1	8.4
ABCC2	"CMOAT, cMRP, DJS, MRP2"	ENSG00000023839	"ATP binding cassette subfamily C member 2"	Q92887	10	99782732-99852192	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	Transport	Translocase	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 28.4;kidney: 25.6;liver: 74.3"	"Cell type enriched"	"Detected in some"	6	"Hepatocytes: 52.9"	"Cancer enhanced"	"Detected in many"		"liver cancer: 24.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 4.1"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 4.1"	"Group enriched"	"Detected in some"	5	"A549: 60.2;Hep G2: 60.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA071145	Enhanced					NA	NA					"HPA071145: "	"unprognostic (1.49e-3)"	"unprognostic (5.92e-2)"	"unprognostic (1.59e-1)"	"unprognostic (3.67e-1)"	"unprognostic (1.93e-2)"	"unprognostic (2.33e-1)"	"unprognostic (2.51e-1)"	"unprognostic (7.15e-3)"	"unprognostic (5.68e-2)"	"unprognostic (2.01e-1)"	"unprognostic (4.30e-1)"	"unprognostic (1.40e-3)"	"prognostic unfavorable (1.93e-5)"	"unprognostic (1.31e-1)"	"unprognostic (3.22e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.26e-2)"	0.8	0.3	0.1	0.1	0.1	0.1	1.1	0.3	0.1	0.2	13.4	0.1	0.1	16.1	0.3	0.5	0.2	0.4	13.7	0.2	0.1	0.1	25.6	74.3	0.3	0.1	0.1	0.1	0.2	0.6	0.0	0.1	1.2	0.1	0.3	0.0	0.1	0.3	0.1	0.6	0.6	28.4	0.1	0.2	0.8	0.4	0.4	0.1	0.1	0.3	0.4	0.1	0.7	0.3	0.3	0.7	4.1	0.2	0.1	0.5	0.0	0.0	60.2	0.9	3.0	4.6	3.5	1.0	0.1	0.3	0.1	0.2	12.9	0.1	0.1	0.1	0.2	0.1	0.3	0.1	0.1	0.2	0.1	0.1	0.0	0.2	60.0	0.1	0.0	0.2	0.6	4.1	0.4	0.4	0.1	0.1	0.1	0.0	0.1	0.0	0.2	0.0	0.4	0.1	11.2	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.1	0.9	7.4	0.1	0.0	0.1	0.1	0.1	0.2	0.3	0.1	0.2	0.0	0.0	4.9	1.0	0.3	4.1	0.2	0.3	0.3	0.0	0.4	0.2	0.3	0.1	0.3	0.3	0.3	0.1	1.3	0.1	0.1	0.7	0.5	0.0	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.8	0.1	0.0	0.2	0.4	2.5	4.0	0.0	0.0	0.0	0.2	0.0	0.0	1.6	0.0	0.0	0.0	0.3	0.0	0.0	0.2	1.1	52.9	0.2	0.0	0.0	0.6	1.3	0.2	0.3	0.0	5.0	0.0	0.0	0.2	0.1	0.0	0.0	9.1	1.4	0.0	0.4	0.7	0.3	0.0	1.4	0.0	0.0	0.0
ABCC8	"ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2"	ENSG00000006071	"ATP binding cassette subfamily C member 8"	Q09428	11	17392498-17476879	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	"Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 28.0;pancreas: 25.5;pituitary gland: 26.6"	"Group enriched"	"Detected in some"	8	"Bipolar cells: 39.2;Intestinal endocrine cells: 21.0"	"Cancer enriched"	"Detected in some"	9	"pancreatic cancer: 16.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"A549: 4.7;AN3-CA: 3.8;SCLC-21H: 6.7"					"Low region specificity"	"Detected in all"			"CAB011451, HPA042318"	Approved		Approved	"Nucleoli,Golgi apparatus,Cytosol"		No	NA			Nucleoli	"Golgi apparatus, Cytosol"	"CAB011451: , HPA042318: AB_2677947"	"unprognostic (4.30e-2)"	"unprognostic (1.02e-1)"	"unprognostic (5.09e-2)"	"unprognostic (4.73e-2)"	"unprognostic (9.48e-3)"	"unprognostic (2.23e-1)"	"unprognostic (4.46e-3)"	"unprognostic (2.53e-3)"	"unprognostic (6.04e-2)"	"unprognostic (2.34e-2)"	"unprognostic (8.72e-3)"	"unprognostic (1.13e-1)"	"unprognostic (2.22e-2)"	"unprognostic (1.96e-2)"	"unprognostic (6.88e-5)"	"unprognostic (2.72e-2)"	"unprognostic (1.85e-1)"	1.3	6.7	4.4	0.8	6.1	0.9	4.0	28.0	12.3	3.0	1.3	2.6	7.7	1.9	3.1	3.7	0.8	1.2	0.9	2.9	5.1	4.8	1.0	0.8	2.9	0.8	3.6	7.2	0.9	25.5	1.0	26.6	1.6	8.5	2.8	1.3	0.7	0.9	8.5	2.3	1.1	1.5	1.3	4.0	0.9	3.5	1.1	2.3	0.0	6.2	0.0	0.8	0.7	0.8	0.1	0.0	0.5	0.0	0.1	0.2	0.0	0.0	4.7	0.1	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.1	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.7	0.9	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.9	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.1	0.5	0.1	0.0	0.0	0.0	0.0	4.4	6.1	28.0	12.3	5.1	4.8	3.6	7.2	8.5	2.3	0.0	0.0	0.0	0.0	0.0	39.2	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	1.1	0.0	0.0	0.1	0.0	21.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.7	0.0	0.0	0.0	1.2	0.0	1.6	0.0	0.2	0.1	0.0	0.0	0.0	0.1
ABCC9	"CMD1O, SUR2"	ENSG00000069431	"ATP binding cassette subfamily C member 9"	O60706	12	21797401-21942529	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	Transport	Receptor	"Atrial fibrillation, Cardiomyopathy, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Alveolar cells type 2: 47.6;Hepatocytes: 84.7;Sertoli cells: 129.4;Smooth muscle cells: 47.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 17.6;BJ hTERT+: 10.1;CACO-2: 16.0;HSkMC: 21.0;U-138 MG: 17.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007279	Uncertain		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA007279: AB_1844435"	"unprognostic (4.82e-2)"	"unprognostic (3.62e-2)"	"unprognostic (5.51e-4)"	"unprognostic (1.09e-1)"	"unprognostic (1.09e-1)"	"unprognostic (8.30e-2)"	"unprognostic (3.17e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.47e-2)"	"unprognostic (8.72e-2)"	"unprognostic (2.51e-2)"	"unprognostic (3.57e-1)"	"prognostic unfavorable (1.85e-5)"	"unprognostic (2.66e-2)"	"unprognostic (1.21e-2)"	"unprognostic (3.10e-3)"	"unprognostic (8.22e-5)"	21.6	4.7	5.5	2.6	5.4	1.2	25.8	1.5	8.6	12.4	6.8	4.8	5.1	3.0	15.3	6.3	9.1	9.5	9.6	26.2	5.7	2.6	5.6	31.1	6.2	2.7	2.9	4.2	11.8	5.8	1.7	2.7	2.8	5.5	7.0	1.6	10.8	4.8	8.4	33.2	3.3	4.1	17.1	4.9	3.5	9.1	3.4	4.2	0.1	6.3	14.5	1.2	9.5	8.4	1.6	0.9	1.8	0.8	0.5	0.9	0.0	0.6	0.1	7.5	0.2	17.6	8.0	0.2	4.1	10.1	4.5	2.3	16.0	0.7	0.3	0.8	0.4	0.5	0.2	0.0	0.0	4.7	0.2	0.1	0.3	0.5	0.2	0.0	0.3	0.4	21.0	0.0	4.5	1.7	0.3	0.0	0.3	0.2	0.9	0.2	0.9	0.2	0.2	1.0	0.8	0.4	0.3	0.2	0.2	0.0	0.8	0.3	1.2	0.2	0.4	0.1	1.2	0.8	0.2	0.2	17.5	1.3	1.5	5.3	0.8	0.8	0.3	4.3	0.2	0.3	0.9	0.5	0.4	0.9	0.4	0.6	0.7	0.7	0.7	0.2	1.6	0.6	0.8	1.8	0.5	0.8	0.9	0.4	0.0	5.5	5.4	1.5	8.6	5.7	2.6	2.9	4.2	5.5	4.2	32.8	47.6	0.0	1.0	3.1	0.4	27.8	0.0	36.1	39.8	0.0	0.0	0.2	0.0	0.0	0.2	4.9	0.0	0.0	0.2	0.1	10.6	0.4	22.1	84.7	0.1	1.6	0.0	11.1	3.3	0.0	0.3	2.1	10.1	0.0	0.0	13.1	0.1	0.0	0.4	0.0	1.1	129.4	47.2	0.5	0.7	1.9	0.2	0.0	0.0	1.4
ABL1	"ABL, c-ABL, JTK7, p150"	ENSG00000097007	"ABL proto-oncogene 1, non-receptor tyrosine kinase"	P00519	9	130713946-130887675	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Autophagy, Cell adhesion, DNA damage, DNA repair, Endocytosis"	"DNA-binding, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002686, HPA027251, HPA027280, HPA028409"	Supported		Enhanced	"Nucleoplasm,Nuclear bodies"		Yes	No			Nucleoplasm	"Nuclear bodies"	"CAB002686: , HPA027251: AB_1844453, HPA027280: AB_1844454, HPA028409: AB_10601011"	"unprognostic (4.82e-2)"	"unprognostic (3.99e-2)"	"unprognostic (5.55e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.75e-3)"	"unprognostic (1.89e-3)"	"unprognostic (2.34e-1)"	"unprognostic (2.54e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.06e-1)"	20.1	11.6	12.4	15.0	18.1	10.7	22.0	6.7	16.0	28.9	34.3	29.1	12.1	11.9	26.6	16.9	21.4	20.8	30.9	14.2	10.3	8.4	9.9	6.7	13.8	8.7	24.1	9.4	24.2	12.2	27.7	14.5	13.6	17.1	27.3	15.8	19.4	14.6	18.0	10.8	14.2	17.0	66.6	14.3	10.8	21.9	9.8	21.2	5.8	19.5	11.4	9.1	35.8	31.9	3.1	3.1	1.1	5.0	2.4	2.6	1.6	7.2	16.1	17.2	20.8	25.3	30.9	6.3	12.7	19.9	14.9	12.6	12.6	9.4	11.9	7.3	16.8	15.3	14.0	8.7	11.7	11.0	7.4	5.4	7.8	27.4	10.7	17.3	11.9	10.9	22.5	12.9	26.6	16.5	20.8	20.6	15.4	43.5	9.5	18.1	13.7	15.1	9.8	19.1	11.3	11.9	17.5	22.3	12.8	15.1	8.5	16.1	20.1	21.3	8.3	10.2	10.5	16.2	11.0	23.6	57.2	14.8	21.8	19.9	2.9	6.8	15.9	23.5	9.9	18.1	0.2	2.1	1.1	2.0	1.2	2.6	3.1	2.0	1.9	2.0	1.4	1.9	1.7	0.2	2.4	5.0	3.1	0.9	1.6	12.4	18.1	6.7	16.0	10.3	8.4	24.1	9.4	17.1	21.2	8.9	9.9	4.2	6.4	8.1	6.2	5.8	12.7	5.3	5.7	14.0	11.8	11.3	1.7	12.6	3.1	14.3	15.4	0.0	9.5	3.5	27.8	8.1	2.3	13.4	13.7	9.5	21.2	20.3	13.7	7.4	25.9	6.5	5.0	3.6	15.7	15.7	14.3	20.3	24.1	8.4	9.7	19.4	21.0	11.9	13.6	5.9	12.7	7.9	19.1	6.4
AC008397.2		ENSG00000285188	"CAMP-specific 3',5'-cyclic phosphodiesterase 4C "	Q08493	19	18207961-18255419	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 22.4;intestine: 15.6;pancreas: 14.2"	"Group enriched"	"Detected in some"	8	"Alveolar cells type 1: 8.9;Alveolar cells type 2: 8.8"									"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 3.7;U-2197: 1.6;U-87 MG: 4.8"									"HPA048975, HPA054218"	Uncertain		Approved	"Midbody ring,Centrosome,Cytosol"		NA	NA			"Centrosome, Cytosol"	"Midbody ring"	"HPA048975: AB_2680581, HPA054218: "																		0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	1.2	1.9	15.6	0.0	0.0	1.3	1.1	3.6	4.0	1.0	22.4	0.6	0.0		0.6	0.0	2.0	0.0	0.0	0.0	0.0	14.2	0.0	0.0	0.8	0.0	0.0	1.7	0.0	2.1	1.1	3.7	0.0	8.0	0.6	0.0	0.4	7.1	0.2	0.0	0.0	0.4	0.8	4.1	0.7	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	3.7	0.1	0.0	0.0	0.2	0.0	0.3	0.3	0.4	0.0	0.1	0.5	0.0	0.0	0.2	0.1	0.0	0.1	0.2	0.9	0.0	0.0	0.3	0.4	0.0	0.8	0.0	0.3	0.0	0.0	0.3	0.7	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.0	0.4	0.1	0.0	0.1	0.3	0.1	0.0	0.0	0.2	0.7	0.1	0.2	0.0	0.0	0.2	1.6	0.0	0.3	0.2	0.1	4.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											8.9	8.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ACAA1		ENSG00000060971	"Acetyl-CoA acyltransferase 1"	P09110	3	38103129-38137242	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism"	"Acyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 152.1"	"Cell type enhanced"	"Detected in all"	9	"Hepatocytes: 651.0;Proximal tubular cells: 601.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"OE19: 51.9;SK-BR-3: 82.5"					"Low region specificity"	"Detected in all"			"HPA006764, HPA007244"	Enhanced		Supported	Peroxisomes		NA	NA		4300000	Peroxisomes		"HPA006764: AB_1078085, HPA007244: AB_1078084"	"prognostic favorable (3.00e-4)"	"unprognostic (5.57e-2)"	"unprognostic (4.54e-2)"	"prognostic favorable (7.53e-4)"	"unprognostic (2.63e-1)"	"prognostic favorable (1.23e-4)"	"unprognostic (9.35e-3)"	"unprognostic (2.91e-2)"	"unprognostic (8.11e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.24e-1)"	"unprognostic (4.90e-1)"	"prognostic favorable (6.99e-9)"	"unprognostic (1.72e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.50e-2)"	"unprognostic (1.65e-2)"	9.5	12.7	11.0	5.6	11.9	9.6	10.2	8.1	14.3	6.7	16.1	12.5	10.6	23.4	4.9	13.3	12.1	4.6	16.0	17.7	10.2	8.9	48.7	152.1	8.2	5.9	14.0	9.4	5.0	19.2	7.4	5.9	6.8	11.0	13.4	12.4	7.3	11.5	9.4	9.8	6.2	23.8	4.8	12.7	10.0	8.5	4.4	10.9	5.7	9.3	10.1	10.2	9.4	7.0	9.2	47.0	32.8	45.2	17.8	19.3	18.8	8.1	8.9	3.0	9.5	13.1	7.7	10.6	7.5	10.9	8.6	8.2	11.9	9.2	4.8	5.4	12.0	4.2	5.4	8.2	12.7	4.7	7.0	8.5	6.2	7.9	33.7	8.5	14.3	14.0	14.2	9.1	7.4	5.3	5.4	11.6	11.8	5.8	5.7	9.5	10.6	13.8	10.2	3.2	51.9	10.8	3.1	5.8	8.1	24.2	24.2	2.6	4.1	7.3	82.5	5.2	4.4	8.5	11.5	8.4	5.2	5.0	10.4	10.3	7.6	4.8	3.8	8.5	12.5	8.3	15.3	29.9	32.8	13.6	40.7	11.4	9.2	13.1	13.3	47.0	8.7	13.0	12.1	20.4	17.8	45.2	27.7	19.3	18.8	11.0	11.9	8.1	14.3	10.2	8.9	14.0	9.4	11.0	10.9	38.7	31.4	45.5	55.9	29.7	37.5	2.4	109.5	17.4	19.4	62.8	13.7	77.1	140.9	89.4	3.0	25.4	292.3	23.3	69.3	52.5	32.7	64.1	18.5	651.0	74.1	7.9	52.9	34.4	86.5	6.4	33.1	68.8	55.6	86.6	63.2	33.0	78.8	122.8	31.1	601.4	14.2	32.3	25.8	17.5	11.7	31.0	83.1	42.0	60.0	69.8
ACE	"ACE1, CD143, DCP1"	ENSG00000159640	"Angiotensin I converting enzyme"	P12821	17	63477061-63498380	"Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"intestine: 205.6"	"Group enriched"	"Detected in many"	25	"Early spermatids: 470.5;Late spermatids: 1015.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.7"	"Group enriched"	"Detected in many"	23	"B-cells: 3.7;monocytes: 2.0;T-cells: 1.9"	"Group enriched"	"Detected in some"	4	"ASC TERT1: 36.7;HUVEC TERT2: 18.7"									"CAB002426, CAB002921, HPA029298, HPA069790"	Enhanced		Approved	Vesicles	"Secreted to blood"	NA	NA	104000000	92000000	Vesicles		"CAB002426: AB_442052, CAB002921: , HPA029298: AB_10960255, HPA069790: AB_2686197"	"unprognostic (4.72e-2)"	"unprognostic (4.16e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.06e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.37e-1)"	"unprognostic (1.54e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.25e-2)"	"unprognostic (3.13e-2)"	"unprognostic (2.38e-1)"	"unprognostic (7.66e-2)"	"unprognostic (9.07e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.76e-2)"	6.8	2.0	0.5	2.4	4.2	0.0	2.9	0.5	1.1	5.3	83.2	0.7	37.7	46.4	4.5	5.1	1.7	1.5	4.4	4.7	0.6	0.7	2.6	1.4	16.3	2.2	0.4	0.7	1.4	3.0	3.6	3.6	3.6	0.8	3.4	1.4	1.7	2.5	20.1	3.6	1.3	205.6	2.4	0.6	1.4	1.9	32.6	1.3	0.5	6.9	3.1	2.2	1.7	1.6	3.7	0.1	0.0	2.0	0.0	1.9	0.4	0.0	0.0	0.0	0.0	1.5	36.7	0.4	1.3	2.7	0.0	0.0	0.5	3.2	0.7	1.1	6.2	0.0	0.0	1.7	0.0	0.0	0.0	0.7	3.5	0.0	0.0	0.8	0.0	0.0	2.4	0.0	0.0	0.0	0.6	18.7	0.0	3.1	0.0	0.0	0.6	0.0	0.8	0.3	6.3	0.4	0.1	0.2	0.5	0.0	0.0	4.6	3.2	0.0	0.0	0.0	0.7	1.6	0.2	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.4	0.6	0.9	3.7	1.9	1.4	0.1	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.4	0.5	4.2	0.5	1.1	0.6	0.7	0.4	0.7	0.8	1.3	0.0	3.5	0.0	1.5	1.3	3.1	1.4	0.0	0.0	1.2	0.0	0.0	0.1	0.0	3.4	470.5	13.5	29.6	0.0	0.4	0.1	1.0	6.0	6.9	0.0	4.4	0.0	17.3	2.5	18.5	1015.1	4.0	5.1	3.3	0.0	8.7	1.9	0.7	10.2	2.5	10.7	1.0	0.0	0.9	8.1	3.4	0.1	0.1	0.9	8.6	2.1
ACE2		ENSG00000130234	"Angiotensin I converting enzyme 2"	Q9BYF1	X	15561033-15602148	"Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	"Host-virus interaction"	"Carboxypeptidase, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"intestine: 122.0"	"Cell type enhanced"	"Detected in many"	13	"Cholangiocytes: 61.1;Enterocytes: 38.8;Proximal tubular cells: 45.6;Sertoli cells: 19.4"	"Cancer enhanced"	"Detected in many"		"renal cancer: 26.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.4;HaCaT: 4.1;Hep G2: 2.5;NB-4: 2.2;RPMI-8226: 2.1;RT4: 2.5;SH-SY5Y: 2.8;SuSa: 1.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA000288, CAB026174, CAB026213, CAB080024, CAB080025, CAB080027, CAB080028"	Enhanced				"Secreted to blood"	NA	NA		85000			"CAB026174: , CAB026213: , CAB080024: AB_10864415, CAB080025: AB_2809589, CAB080027: AB_2665870, CAB080028: AB_2665871, HPA000288: AB_1078160"	"unprognostic (1.40e-1)"	"unprognostic (7.26e-2)"	"unprognostic (2.76e-2)"	"unprognostic (5.71e-2)"	"unprognostic (2.51e-1)"	"unprognostic (5.26e-2)"	"prognostic favorable (4.21e-4)"	"unprognostic (2.34e-2)"	"unprognostic (6.74e-3)"	"unprognostic (2.54e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.74e-1)"	"prognostic favorable (2.12e-5)"	"unprognostic (1.94e-1)"	"unprognostic (9.62e-2)"	"unprognostic (2.11e-1)"	"unprognostic (7.10e-2)"	4.5	0.4	0.2	0.8	0.2	0.0	2.3	0.2	0.2	0.4	49.1	0.2	2.3	46.0	0.4	2.7	1.2	0.6	16.4	10.5	0.2	0.1	23.2	1.2	0.8	0.6	0.2	0.2	1.3	1.6	0.0	0.2	1.0	0.2	0.5	1.3	0.2	1.1	1.2	0.7	0.2	122.0	0.3	0.2	0.2	0.5	17.9	0.2	0.2	4.5	0.5	0.2	0.4	0.9	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.2	0.0	0.4	0.0	0.7	0.0	2.4	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.7	0.0	0.4	4.1	0.2	0.1	0.0	0.1	0.1	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.1	0.2	0.2	0.0	0.0	2.1	0.4	2.5	0.6	2.8	0.1	0.3	0.2	1.9	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.0	0.3	2.2	0.5	0.1	0.0	9.8	61.1	0.0	0.0	0.0	0.0	2.9	3.3	0.5	0.4	0.0	38.8	0.0	0.7	0.2	0.0	0.4	0.0	0.8	0.7	0.0	6.9	0.0	0.0	1.1	7.8	0.0	0.0	0.0	1.2	0.0	0.9	4.2	5.6	45.6	0.0	19.4	0.0	1.1	0.7	0.1	10.6	0.0	3.3	1.6
ACHE	YT	ENSG00000087085	"Acetylcholinesterase (Cartwright blood group)"	P22303	7	100889994-100896974	"Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Neurotransmitter degradation"	"Blood group antigen, Hydrolase, Serine esterase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 43.8;skeletal muscle: 98.2"	"Cell type enhanced"	"Detected in many"	7	"Enterocytes: 45.5;Erythroid cells: 46.7;Exocrine glandular cells: 34.7;Horizontal cells: 52.4;Paneth cells: 52.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 8.2;CACO-2: 12.9;K-562: 15.2;Karpas-707: 25.2;U-2 OS: 6.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA027098			Approved	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	NA	NA		650000	"Golgi apparatus"	Vesicles	"HPA027098: AB_2672111"	"unprognostic (2.23e-1)"	"unprognostic (9.44e-2)"	"unprognostic (2.71e-2)"	"unprognostic (5.80e-3)"	"prognostic unfavorable (5.27e-4)"	"unprognostic (2.49e-1)"	"unprognostic (2.54e-1)"	"unprognostic (1.36e-2)"	"unprognostic (2.48e-2)"	"unprognostic (8.92e-2)"	"unprognostic (2.65e-2)"	"unprognostic (1.78e-1)"	"prognostic unfavorable (3.88e-5)"	"unprognostic (2.95e-1)"	"unprognostic (2.59e-2)"	"unprognostic (9.28e-2)"	"unprognostic (8.38e-2)"	1.4	4.8	5.8	3.5	16.1	10.3	1.4	22.8	11.8	1.4	4.2	2.7	1.4	5.7	1.9	2.6	2.8	1.8	3.1	4.5	5.5	43.8	1.4	1.8	1.8	5.9	22.2	4.8	1.7	1.6	7.0	3.2	2.0	37.9	3.3	3.4	4.6	6.5	3.3	98.2	1.4	7.9	1.9	8.7	2.3	2.1	1.9	2.6	3.5	1.6	15.9	3.2	2.1	1.2	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.3	0.2	0.5	0.0	8.2	0.3	0.0	0.1	0.2	12.9	0.3	0.0	0.5	0.0	1.2	0.4	2.2	0.1	0.0	4.4	0.5	0.2	0.0	0.1	0.0	0.0	0.4	0.4	0.0	0.1	0.0	0.0	0.0	0.1	15.2	25.2	0.1	3.6	0.0	0.1	1.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.7	1.4	0.0	1.0	0.0	3.7	0.0	0.0	0.1	0.7	6.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.8	16.1	22.8	11.8	5.5	43.8	22.2	4.8	37.9	2.6	0.0	0.0	0.0	21.7	0.7	7.2	4.5	0.0	0.0	0.0	0.0	0.0	5.4	0.0	6.2	0.0	2.3	45.5	46.7	34.7	1.9	4.2	17.2	0.0	0.0	0.7	52.4	3.4	1.3	0.0	0.0	0.6	0.0	1.7	8.2	7.6	11.9	30.0	52.6	0.7	1.0	4.3	0.0	3.3	3.9	4.5	0.9	5.9	0.0	3.3	11.2
ACTN1		ENSG00000072110	"Actinin alpha 1"	P12814	14	68874143-68979440	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Actin-binding	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Extravillous trophoblasts: 304.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 71.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004303, HPA006035"	Approved		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA		780000000	"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB004303: AB_626633, HPA006035: AB_1078095"	"unprognostic (4.40e-2)"	"unprognostic (1.03e-3)"	"unprognostic (2.49e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (2.49e-4)"	"unprognostic (6.19e-3)"	"prognostic unfavorable (7.63e-5)"	"unprognostic (3.62e-1)"	"unprognostic (3.23e-2)"	"unprognostic (3.16e-2)"	"unprognostic (1.71e-1)"	"prognostic unfavorable (9.08e-10)"	"unprognostic (2.87e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.05e-3)"	"prognostic unfavorable (8.00e-4)"	27.6	10.8	18.7	33.1	28.4	31.0	38.8	4.1	20.0	30.5	101.8	3.1	43.7	11.6	80.3	24.6	48.3	38.7	53.3	31.2	9.9	6.2	11.2	20.3	23.9	23.1	4.7	15.0	27.8	12.4	2.3	7.9	22.0	8.7	43.2	26.4	11.1	30.1	72.7	7.1	14.6	25.9	135.4	10.3	19.4	52.3	9.5	9.6	7.0	9.3	9.9	11.3	81.1	53.1	0.0	8.8	71.8	12.5	0.7	22.0	14.9	85.1	26.3	16.2	12.3	28.8	19.1	60.9	75.3	72.2	79.3	59.3	21.0	19.8	0.0	26.5	74.3	32.0	37.2	12.8	79.4	100.3	0.4	3.8	11.6	13.8	17.5	52.0	8.3	1.4	24.3	15.6	49.2	56.1	57.1	43.4	4.8	5.5	0.1	62.1	24.2	0.9	17.7	12.7	21.5	20.1	5.8	30.2	3.2	30.2	22.5	5.8	7.0	65.4	9.9	18.2	51.2	14.8	16.9	54.7	112.7	44.9	13.0	65.5	11.7	4.5	0.3	32.6	11.5	59.2	11.2	12.5	25.6	1.1	5.7	1.4	0.0	4.6	2.5	8.8	0.0	22.0	18.7	71.8	0.7	1.6	0.4	1.8	14.9	18.7	28.4	4.1	20.0	9.9	6.2	4.7	15.0	8.7	9.6	35.7	33.8	3.4	113.1	106.0	70.3	54.6	48.4	36.1	29.6	40.1	231.7	130.6	3.3	153.8	29.8	133.1	4.5	46.7	126.5	304.9	96.9	72.4	7.0	87.3	76.3	17.5	37.0	130.8	82.0	7.0	33.1	65.6	28.7	116.4	48.6	4.7	162.5	31.6	230.9	6.3	85.7	174.6	230.4	9.7	11.7	52.2	56.0	17.5	44.3	58.4
ADA		ENSG00000196839	"Adenosine deaminase"	P00813	20	44619522-44652233	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell adhesion, Nucleotide metabolism"	Hydrolase	"Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 64.0;intestine: 142.2;lymphoid tissue: 99.0"	"Cell type enhanced"	"Detected in many"	10	"Extravillous trophoblasts: 90.2;Leydig cells: 39.1;monocytes: 49.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 64.0"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"JURKAT: 61.5;MOLT-4: 198.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001399, CAB004307, HPA023884"	Enhanced		Supported	"Plasma membrane,Cytosol"		No	No		650000	"Plasma membrane"	Cytosol	"CAB004307: AB_626634, HPA001399: AB_1078099, HPA023884: AB_1844573"	"unprognostic (4.30e-2)"	"unprognostic (6.89e-2)"	"unprognostic (3.96e-2)"	"prognostic unfavorable (1.23e-7)"	"unprognostic (9.33e-2)"	"unprognostic (9.07e-3)"	"prognostic unfavorable (6.77e-5)"	"prognostic unfavorable (2.20e-4)"	"unprognostic (1.59e-1)"	"unprognostic (2.16e-1)"	"unprognostic (3.66e-2)"	"unprognostic (3.48e-1)"	"prognostic unfavorable (2.94e-14)"	"unprognostic (2.29e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.82e-1)"	8.1	3.2	2.5	5.4	6.5	5.3	5.1	0.9	5.0	2.8	7.4	5.0	1.8	142.2	1.7	3.4	4.6	2.4	3.0	9.2	2.7	0.8	1.3	2.1	2.8	8.9	3.6	2.3	1.2	2.4	0.8	0.3	1.8	3.9	1.8	1.5	0.7	2.6	1.3	2.0	2.8	5.0	2.1	1.3	9.5	19.7	1.6	6.1	99.0	2.8	2.1	7.6	3.6	2.6	1.3	41.6	0.5	64.0	16.9	10.3	9.6	1.4	4.0	2.0	1.4	3.9	5.5	3.3	1.4	0.8	1.4	1.0	1.8	1.5	4.0	1.7	1.9	2.7	0.2	1.4	5.9	0.8	0.3	1.8	0.8	0.7	1.4	1.6	0.6	2.2	26.2	2.5	0.5	0.9	1.3	5.4	61.5	2.0	3.3	0.6	3.4	198.0	2.9	0.5	1.8	1.4	10.7	2.8	9.9	0.2	0.0	0.0	0.9	2.1	0.4	2.5	2.7	0.4	1.9	1.7	1.0	2.0	2.2	0.2	4.3	2.7	8.3	0.3	3.3	0.9	0.0	1.8	0.2	8.7	30.7	5.7	1.3	7.3	10.3	6.8	1.0	5.7	8.1	0.5	16.9	64.0	41.6	5.3	9.6	2.5	6.5	0.9	5.0	2.7	0.8	3.6	2.3	3.9	6.1	0.0	3.4	12.7	3.0	11.4	0.0	1.9	0.0	2.7	0.0	1.8	0.0	2.3	0.0	3.7	0.1	16.2	0.5	0.0	17.9	90.2	16.7	0.9	0.0	2.9	27.6	0.0	0.0	6.7	13.4	1.5	39.1	14.4	8.5	49.5	1.4	2.9	8.2	0.0	2.5	2.1	0.0	12.9	16.1	0.4	1.3	12.2	3.1	30.5	3.3	2.4
ADH1A	ADH1	ENSG00000187758	"Alcohol dehydrogenase 1A (class I), alpha polypeptide"	P07327	4	99276367-99291028	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	322	"liver: 250.3"	"Cell type enriched"	"Detected in some"	10	"Hepatocytes: 212.0"	"Cancer enriched"	"Detected in some"	251	"liver cancer: 165.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"ASC diff: 11.2"									"CAB009562, HPA047814, HPA060902"	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA		12000000	"Plasma membrane, Cytosol"		"CAB009562: AB_2257984, HPA047814: AB_2680163, HPA060902: AB_2684384"	"unprognostic (5.89e-2)"	"unprognostic (6.16e-2)"		"unprognostic (1.20e-1)"	"unprognostic (2.07e-1)"	"unprognostic (4.40e-1)"	"prognostic favorable (2.38e-4)"	"unprognostic (2.78e-3)"		"unprognostic (4.25e-1)"	"unprognostic (4.79e-3)"	"unprognostic (6.21e-2)"	"unprognostic (9.36e-2)"	"unprognostic (3.25e-2)"	"unprognostic (1.40e-1)"		"unprognostic (2.86e-2)"	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	250.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	11.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.1	0.0	1.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	20.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	212.0	0.0	0.0	0.0	7.4	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0
ADH1B	ADH2	ENSG00000196616	"Alcohol dehydrogenase 1B (class I), beta polypeptide"	P00325	4	99304964-99352760	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adipose tissue: 253.5;liver: 466.3"	"Cell type enriched"	"Detected in many"	38	"Hepatocytes: 3603.2"	"Cancer enriched"	"Detected in many"	31	"liver cancer: 223.1"	"Group enriched"	"Detected in some"	5	"midbrain: 2.3;pons and medulla: 1.6"	"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	7	"ASC diff: 394.3"									"HPA047814, HPA060902"	Supported		Approved	"Plasma membrane,Cytosol"		NA	NA		16000000	"Plasma membrane, Cytosol"		"HPA047814: AB_2680163, HPA060902: AB_2684384"	"unprognostic (5.13e-2)"	"unprognostic (9.80e-3)"	"unprognostic (6.59e-2)"	"unprognostic (5.56e-2)"	"unprognostic (9.49e-2)"	"unprognostic (5.53e-2)"	"unprognostic (1.54e-3)"	"unprognostic (1.04e-2)"	"unprognostic (6.51e-2)"	"unprognostic (2.73e-2)"	"unprognostic (7.47e-3)"	"unprognostic (7.79e-2)"	"prognostic unfavorable (7.87e-4)"	"unprognostic (4.60e-3)"	"unprognostic (2.33e-1)"	"unprognostic (2.58e-1)"	"unprognostic (1.60e-2)"	253.5	12.3	0.2	21.8	0.0	0.4	78.7	0.2	0.4	18.3	60.0	0.4	5.7	3.5	12.8	14.4	33.5	22.3	31.9	24.2	0.3	0.0	9.2	466.3	43.8	17.5	2.3	0.1	18.0	8.7	0.8	5.3	0.9	1.6	30.7	10.1	2.3	11.2	3.9	20.5	11.9	25.4	30.8	2.4	5.9	10.9	18.0	0.2	0.2	16.1	9.7	2.0	42.3	76.0	0.6	0.2	1.2	0.3	0.8	0.4	0.0	0.0	0.0	0.0	0.0	394.3	57.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.0	12.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.3	0.2	0.1	0.1	0.2	0.4	0.1	0.0	0.6	0.3	0.4	1.2	0.8	0.1	0.2	0.1	0.0	0.2	0.0	0.2	0.0	0.3	0.0	2.3	0.1	1.6	0.2	0.0	4.3	14.0	0.4	19.8	0.0	8.9	66.2	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.4	9.2	0.0	46.7	0.0	0.0	81.0	0.3	1.1	3603.2	0.1	0.0	0.0	93.9	77.5	0.0	51.2	1.0	27.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	6.5	43.7	0.0	0.0	11.4	0.1	12.5	0.0	0.1
ADH1C	ADH3	ENSG00000248144	"Alcohol dehydrogenase 1C (class I), gamma polypeptide"	P00326	4	99336492-99353027	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"intestine: 47.1;liver: 149.4;stomach 1: 43.1"	"Cell type enhanced"	"Detected in many"	15	"Exocrine glandular cells: 606.8;Hepatocytes: 378.8;Undifferentiated cells: 355.3"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 238.2"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"ASC TERT1: 5.2;HSkMC: 15.4"									"HPA047814, HPA060902"	Supported		Supported	"Plasma membrane,Cytosol"		NA	NA		9700000	"Plasma membrane, Cytosol"		"HPA047814: AB_2680163, HPA060902: AB_2684384"	"unprognostic (3.98e-2)"	"unprognostic (9.88e-3)"	"unprognostic (7.04e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.14e-1)"	"unprognostic (1.57e-1)"	"prognostic favorable (4.55e-4)"	"prognostic favorable (2.99e-4)"	"unprognostic (8.25e-2)"	"unprognostic (8.89e-3)"	"unprognostic (7.95e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.12e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.70e-1)"	"unprognostic (9.37e-2)"	4.7	0.0	0.0	18.5	0.0	0.0	1.1	0.0	0.0	1.1	37.9	0.0	1.1	43.4	0.3	1.2	1.7	0.0	12.0	2.0	0.0		8.3	149.4	1.1	0.0	0.2	0.0	1.1	11.4	0.0	0.0	0.0	0.0	2.5	13.6	0.0	1.1	0.8	6.0	0.0	47.1	0.9	0.5	0.0	43.1	1.6	0.0	0.0	0.5	2.0	0.2	1.3	0.7	0.2	0.2	0.3	0.1	0.1	0.3	0.1	0.0	2.3	0.0	0.1	1.8	5.2	1.1	0.0	0.7	0.1	0.0	0.0	0.0	0.2	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.6	0.3	0.1	0.5	1.4	0.3	15.4	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.4	1.0	0.4	0.0	0.1	0.1	0.9	2.2	0.9	0.0	0.4	1.6	0.7	0.8	0.0	0.0	0.2	0.0	0.1	0.0	0.6	0.3	0.2	0.1	0.0	0.3	0.0	0.8	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.2	0.0	0.1	0.3	0.1	0.0	0.2	0.0	0.1											3.0	5.3	1.5	3.6	0.0	0.0	0.8	50.9	80.3	45.5	27.9	0.0	0.0	0.0	141.2	2.4	0.0	51.2	23.3	606.8	0.0	0.0	1.2	0.0	378.8	0.0	0.0	20.7	12.9	12.9	0.6	9.8	0.0	0.0	3.6	36.7	0.0	99.5	63.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	355.3	2.0
ADK	AK	ENSG00000156110	"Adenosine kinase"	P55263	10	74151185-74709303	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Purine salvage"	"Kinase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 71.9"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB032876, HPA038391, HPA038409, HPA075222"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA		320000	"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB032876: AB_2242229, HPA038391: AB_2675990, HPA038409: AB_10675798, HPA075222: "	"unprognostic (1.55e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.88e-1)"	"unprognostic (2.62e-2)"	"unprognostic (2.52e-2)"	"prognostic unfavorable (1.93e-4)"	"prognostic favorable (9.91e-4)"	"unprognostic (2.64e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.55e-1)"	"unprognostic (8.15e-3)"	"unprognostic (2.51e-1)"	"unprognostic (1.89e-3)"	"unprognostic (2.03e-1)"	"unprognostic (2.88e-2)"	"unprognostic (4.97e-3)"	"unprognostic (2.95e-2)"	13.8	10.7	11.8	13.6	25.4	12.1	14.5	11.2	11.8	9.5	9.3	9.0	9.6	8.8	6.6	10.6	29.4	8.9	6.3	15.7	9.8	11.1	19.0	71.9	15.1	17.9	12.3	9.3	5.2	12.6	15.1	23.5	43.2	11.6	8.7	10.8	8.5	13.1	11.4	18.1	20.8	6.4	8.3	13.2	11.3	7.4	11.9	10.3	13.4	20.8	24.1	21.9	12.6	14.7	49.3	23.0	5.4	21.6	6.5	15.7	9.8	38.1	8.6	9.1	12.2	9.2	14.2	21.0	33.2	26.3	25.7	28.9	24.1	39.8	20.0	8.3	13.3	12.1	34.9	10.7	35.3	41.2	13.4	12.3	12.7	14.1	25.9	10.5	20.3	5.2	13.0	23.3	18.7	46.6	19.0	22.3	9.3	10.1	6.5	19.3	21.3	23.9	27.5	2.6	17.8	60.9	23.1	15.8	17.2	28.1	21.0	7.2	8.5	14.6	56.7	11.0	8.5	37.7	15.4	19.1	8.5	15.7	22.7	27.3	9.4	10.6	22.6	16.1	29.3	5.2	1.3	10.1	1.4	4.5	18.0	10.0	29.7	9.5	8.2	23.0	49.3	7.9	6.5	5.4	6.5	21.6	16.7	15.7	9.8	11.8	25.4	11.2	11.8	9.8	11.1	12.3	9.3	11.6	10.3	77.4	57.2	37.1	62.9	83.7	14.5	53.3	35.7	34.8	76.2	29.6	53.0	120.6	77.9	60.0	55.9	14.7	5.9	0.0	58.9	113.1	27.2	33.9	19.8	112.8	36.3	11.1	10.4	14.7	21.4	22.9	15.5	40.6	45.5	31.5	11.5	10.0	45.7	14.0	11.3	48.3	27.9	6.5	32.8	13.3	12.2	84.8	89.7	20.3	19.9	57.0
ADORA1	RDC7	ENSG00000163485	"Adenosine A1 receptor"	P30542	1	203090654-203167405	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 38.7"	"Group enriched"	"Detected in some"	4	"granulocytes: 23.0;Muller glia cells: 40.0"	"Cancer enhanced"	"Detected in many"		"glioma: 24.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 19.7;MCF7: 11.9;RH-30: 32.7;RPTEC TERT1: 15.9;SK-BR-3: 17.7;U-138 MG: 10.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044383			Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA044383: AB_2678921"	"unprognostic (3.93e-3)"	"unprognostic (8.16e-2)"	"unprognostic (6.16e-2)"	"unprognostic (2.38e-3)"	"unprognostic (2.25e-2)"	"unprognostic (2.34e-1)"	"unprognostic (4.64e-2)"	"unprognostic (4.17e-2)"	"unprognostic (3.04e-1)"	"unprognostic (4.80e-3)"	"unprognostic (1.42e-1)"	"unprognostic (2.98e-1)"	"unprognostic (2.96e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.27e-1)"	"unprognostic (4.13e-2)"	"unprognostic (5.76e-4)"	4.5	1.0	19.7	2.6	21.7	0.8	6.1	9.7	38.7	1.1	1.6	27.4	0.0	2.0	2.0	1.6	1.6	2.0	1.8	13.8	19.8	12.1	4.2	1.0	2.8	1.4	22.8	13.4	0.8	15.5	15.5	0.9	8.9	25.0	1.2	1.6	1.8	8.9	1.3	2.0	1.9	1.8	1.3	20.7	7.4	1.6	16.3	15.9	0.0	3.2	0.0	1.4	3.4	0.3	0.0	0.6	0.0	0.1	0.0	0.0	0.1	0.1	1.4	0.3	0.1	0.1	0.8	0.1	1.0	1.5	0.4	0.2	19.7	0.3	0.0	4.5	3.6	2.4	0.0	0.3	0.0	0.1	0.0	0.5	0.0	0.2	0.0	0.3	0.0	0.0	0.4	0.0	0.4	0.0	3.2	0.0	3.2	0.0	0.0	3.1	11.9	0.0	0.0	5.1	0.0	0.0	0.0	32.7	1.0	15.9	0.0	0.3	0.4	2.1	17.7	0.2	1.9	1.0	0.4	0.0	10.6	5.4	0.0	5.7	0.0	0.1	0.0	5.3	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	19.7	21.7	9.7	25.7	19.8	12.1	22.8	13.4	25.0	15.9	0.0	0.0	0.0	0.0	0.0	0.5	2.5	5.1	0.0	0.0	3.5	0.0	0.0	0.0	7.2	0.1	0.0	0.0	0.0	3.0	1.0	0.7	0.0	23.0	0.0	0.9	0.0	0.0	0.0	1.3	0.0	0.0	0.4	1.7	0.0	0.0	40.0	0.5	0.0	0.7	1.0	0.7	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0
ADORA2A	"ADORA2, RDC8"	ENSG00000128271	"Adenosine A2a receptor"	P29274	22	24417879-24442360	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"blood: 22.8;bone marrow: 28.1;brain: 43.9;lymphoid tissue: 59.0"	"Cell type enriched"	"Detected in single"	25	"monocytes: 19.0"	"Not detected"	"Not detected"			"Region enriched"	"Detected in all"	8	"basal ganglia: 43.9"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 15.4;Karpas-707: 21.2;RPMI-8226: 15.0;SK-BR-3: 30.4;U-266/70: 21.2;U-266/84: 27.7;U-698: 21.7"	"Region enriched"	"Detected in some"	10	"basal ganglia: 357.5"	"Region enriched"	"Detected in single"	92	"basal ganglia: 166.0"	"CAB001943, HPA065566, HPA075997"	Enhanced	Supported				NA	NA					"CAB001943: , HPA065566: , HPA075997: AB_2732298"	"unprognostic (7.30e-2)"	"unprognostic (2.42e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.04e-1)"	"unprognostic (7.44e-2)"	"unprognostic (1.88e-3)"	"unprognostic (9.85e-2)"	"unprognostic (3.63e-1)"	"unprognostic (2.88e-2)"	"unprognostic (4.57e-3)"	"unprognostic (2.15e-3)"	"unprognostic (1.87e-3)"	"unprognostic (6.81e-4)"	"unprognostic (1.50e-1)"	"unprognostic (9.78e-3)"	"unprognostic (1.30e-1)"	"unprognostic (7.10e-3)"	1.0	2.4	1.9	10.4	43.9	28.1	1.5	3.4	3.8	0.8	2.0	1.7	0.3	5.4	1.4	1.4	1.0	0.9	2.4	3.5	2.4	1.8	3.5	4.3	5.1	14.8	2.6	1.6	1.2	0.8	0.0	2.1	1.4	2.3	1.6	0.8	3.3	2.7	1.5	1.2	0.9	2.6	0.7	1.3	7.5	2.8	2.0	5.7	59.0	1.3	0.9	8.6	3.8	1.3	17.7	1.1	13.7	9.0	2.2	22.8	11.2	0.2	0.3	0.4	0.1	0.2	0.1	0.4	0.2	9.5	0.5	1.0	1.7	0.1	15.4	1.0	0.3	1.0	0.3	0.9	0.0	0.0	1.8	2.7	0.2	0.0	2.2	0.2	0.3	7.7	0.1	0.0	2.9	0.0	0.2	3.4	2.2	0.1	21.2	0.0	0.2	5.3	1.6	0.6	2.0	0.0	0.2	0.7	15.0	0.0	0.1	1.5	8.9	0.4	30.4	0.1	0.4	0.4	1.5	0.2	0.9	1.5	0.2	0.1	21.2	27.7	21.7	4.8	5.2	0.1	3.0	0.8	4.8	8.6	2.6	20.1	9.6	16.1	16.9	1.1	17.7	22.8	18.3	13.7	2.2	9.0	1.1	21.4	11.2	1.9	43.9	3.4	3.8	2.4	1.8	2.6	1.6	2.3	5.7	0.0	0.3	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ADORA2B		ENSG00000170425	"Adenosine A2b receptor"	P29275	17	15944917-15975746	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	12	"Basal keratinocytes: 65.4;Suprabasal keratinocytes: 56.2;Urothelial cells: 26.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 12.8;myeloid DC: 8.4"	"Group enriched"	"Detected in many"	86	"dendritic cells: 8.4;granulocytes: 12.8;monocytes: 4.5"	"Cell line enhanced"	"Detected in many"		"GAMG: 50.2;HMC-1: 50.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA073747			Uncertain	Cytosol		NA	NA			Cytosol		"HPA073747: "	"unprognostic (6.04e-3)"	"unprognostic (1.22e-1)"	"unprognostic (8.14e-2)"	"unprognostic (1.32e-2)"	"unprognostic (4.68e-1)"	"unprognostic (7.88e-3)"	"unprognostic (2.64e-4)"	"unprognostic (1.44e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.18e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.66e-9)"	"unprognostic (2.07e-1)"	"unprognostic (3.49e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.84e-1)"	1.5	1.5	7.6	4.5	9.1	1.6	1.8	7.3	8.7	2.9	15.3	2.4	0.0	0.8	1.7	1.5	11.1	2.2	3.8	1.2	6.6	3.0	0.6	0.7	4.1	1.0	1.9	5.4	0.6	2.8	0.4	1.9	9.0	5.2	1.7	12.8	10.5	1.9	0.7	0.7	10.4	1.6	2.8	3.9	0.7	2.6	0.7	2.6	0.1	0.6	4.4	4.5	6.8	5.6	0.0	8.4	12.8	4.5	0.0	0.0	1.5	10.0	5.5	0.1	0.2	1.8	3.5	0.2	1.9	8.7	5.7	7.1	2.6	10.5	1.3	2.4	1.7	50.2	15.8	2.4	14.5	7.6	2.8	5.5	9.7	1.8	3.8	7.1	0.0	50.7	2.0	6.2	8.1	18.9	9.8	2.8	1.5	0.4	0.0	5.6	2.6	0.6	1.9	0.6	21.6	7.8	0.0	0.1	0.0	5.8	2.7	0.2	0.3	4.3	1.0	2.6	4.3	0.0	1.5	2.4	2.0	5.4	5.6	9.0	0.8	0.0	0.0	8.1	0.0	2.8	12.8	4.0	2.6	0.0	4.5	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	0.4	0.0	2.3	0.1	0.0	1.5	7.6	9.1	7.3	8.7	6.6	3.0	1.9	5.4	5.2	2.6	3.0	3.4	0.0	12.7	65.4	0.0	1.2	2.5	8.1	7.9	0.0	0.0	10.1	0.0	6.2	0.3	0.6	4.9	0.0	0.8	2.8	6.1	11.9	0.0	0.0	4.6	0.0	2.4	0.0	2.7	0.0	0.0	5.1	6.8	0.0	1.4	7.4	0.8	4.8	0.0	0.0	0.5	0.0	1.9	0.5	1.2	56.2	5.1	0.0	3.7	26.7
ADORA3	AD026	ENSG00000282608	"Adenosine A3 receptor"	P0DMS8	1	111499429-111503760	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	4	"blood: 88.6;brain: 25.5"	"Cell type enhanced"	"Detected in some"	26	"Hofbauer cells: 17.7;Kupffer cells: 53.6;Late spermatids: 12.4"									"Cell type enriched"	"Detected in some"	40	"eosinophil: 88.6"	"Lineage enriched"	"Detected in many"	40	"granulocytes: 88.6"	"Cell line enriched"	"Detected in some"	9	"HMC-1: 48.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA																							5.2	13.4	8.7	3.1	12.0	0.0	4.5	1.0	6.7	3.7	5.2	10.3	0.0	3.5	0.5	1.0	1.8	2.8	4.8	1.6	7.5		1.9	2.1	2.8	3.8	17.7	2.2	1.2	1.0	0.9	1.2	2.0	12.1	1.0	4.2	2.7	1.1	1.9	0.5	0.0	7.9	3.8	25.5	1.5	2.2	1.1	13.3	0.4	0.5	0.0	1.9	3.4	0.0	0.0	2.2	88.6	1.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.0	0.0	0.0	0.0	48.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.2	88.6	0.0	0.7	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.3	0.0	0.3	0.4	0.0	0.3											0.0	0.0	0.9	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.2	0.0	0.0	0.0	0.0	0.2	0.0	6.9	0.0	17.7	0.0	0.0	2.5	53.6	12.4	0.3	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0
ADRA1A	"ADRA1C, ADRA1L1"	ENSG00000120907	"Adrenoceptor alpha 1A"	P35348	8	26748150-26867273	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"liver: 45.1"	"Group enriched"	"Detected in some"	15	"Early spermatids: 50.8;Hepatocytes: 14.0;Late spermatids: 20.6"	"Cancer enhanced"	"Detected in some"		"liver cancer: 0.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"ASC diff: 1.3;HAP1: 1.7;JURKAT: 2.0;NTERA-2: 2.3;U-2 OS: 1.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029678, HPA029679, HPA076693"	Approved	Supported	Supported	Nucleoplasm,Vesicles,Cytosol		NA	NA			Cytosol	"Nucleoplasm, Vesicles"	"HPA029678: AB_10602108, HPA029679: AB_2673143, HPA076693: "	"unprognostic (1.27e-1)"		"unprognostic (1.68e-2)"		"unprognostic (1.99e-1)"	"unprognostic (3.57e-1)"	"unprognostic (5.04e-4)"	"unprognostic (1.97e-1)"	"unprognostic (9.55e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.58e-2)"	"unprognostic (7.47e-2)"	"unprognostic (1.71e-2)"	"unprognostic (6.06e-3)"	"unprognostic (7.41e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.30e-1)"	14.5	0.7	7.1	1.1	3.9	0.3	3.4	6.2	4.9	0.9	1.5	5.9	4.9	1.0	1.8	2.0	0.9	0.6	0.5	10.1	11.6	2.0	0.8	45.1	3.9	1.4	4.7	4.7	1.0	0.5	0.3	0.6	0.3	3.8	10.2	0.7	0.6	4.6	11.2	0.6	0.9	1.3	2.4	1.9	7.0	1.2	0.5	4.2	0.0	0.6	0.1	0.6	0.6	0.7	0.3	0.0	0.3	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.2	2.3	0.4	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.5	0.3	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.3	0.0	0.2	0.3	0.2	0.0	0.0	0.0	0.0	7.1	3.9	6.2	4.9	11.6	2.0	4.7	4.7	3.8	4.2	0.0	0.0	0.0	0.0	0.1	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	50.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.0	0.0	1.3	0.0	20.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0
ADRA1B		ENSG00000170214	"Adrenoceptor alpha 1B"	P35368	5	159865080-159972544	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 21.6;liver: 20.3;lymphoid tissue: 17.4"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 13.2;HaCaT: 6.7;TIME: 11.1;U-2 OS: 9.3;U-251 MG: 7.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA074416			Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA074416: AB_2686688"	"unprognostic (4.93e-3)"	"unprognostic (2.94e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavorable (6.00e-5)"	"prognostic unfavorable (6.98e-4)"	"unprognostic (4.08e-3)"	"unprognostic (1.67e-3)"	"unprognostic (1.68e-1)"	"unprognostic (6.12e-2)"	"prognostic favorable (2.67e-4)"	"unprognostic (2.28e-1)"	"unprognostic (1.37e-1)"	"prognostic unfavorable (1.40e-6)"	"unprognostic (5.24e-4)"	"unprognostic (2.54e-1)"	"prognostic favorable (3.19e-5)"	"unprognostic (1.59e-2)"	5.3	2.9	5.3	0.9	9.0	0.4	2.3	1.3	21.6	0.9	1.2	0.7	0.8	1.2	1.5	3.6	1.1	3.6	1.3	3.3	6.2	5.8	7.4	20.3	4.7	2.3	1.2	13.9	6.2	0.8	1.0	0.8	1.1	5.2	1.6	1.1	0.9	1.0	1.9	1.6	1.3	1.7	1.2	0.9	17.4	0.9	0.8	0.5	0.0	2.0	0.0	1.1	0.8	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.7	0.3	0.0	2.4	0.9	0.1	0.5	0.2	0.6	0.3	0.0	4.3	0.0	13.2	3.9	5.2	6.7	0.0	0.6	0.3	0.0	0.3	0.0	1.7	0.0	5.1	0.0	0.0	2.8	0.0	0.0	0.2	1.8	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.7	0.0	4.5	0.0	0.4	0.0	0.0	0.3	0.4	2.3	0.1	0.0	11.1	0.1	9.3	0.0	7.1	0.0	0.0	0.0	3.4	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	9.0	1.3	21.6	6.2	5.8	1.2	13.9	5.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ADRA1D	"ADRA1, ADRA1A, ADRA1R"	ENSG00000171873	"Adrenoceptor alpha 1D"	P25100	20	4220631-4249074	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 17.7"	"Cell type enhanced"	"Detected in single"	18	"Smooth muscle cells: 1.0"	"Low cancer specificity"	"Detected in some"			"Group enriched"	"Detected in many"	4	"cerebral cortex: 7.4;hippocampal formation: 17.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 2.8;BJ: 12.0;CAPAN-2: 5.4;fHDF/TERT166: 7.1"	"Group enriched"	"Detected in many"	4	"cerebral cortex: 23.5;hippocampal formation: 31.8;olfactory region: 11.0"	"Low region specificity"	"Detected in many"			HPA038789	Uncertain					NA	NA					"HPA038789: AB_10673475"	"unprognostic (5.37e-2)"	"unprognostic (4.65e-1)"	"unprognostic (8.73e-2)"	"unprognostic (7.75e-11)"	"unprognostic (7.83e-3)"	"unprognostic (1.54e-2)"	"unprognostic (7.62e-2)"	"unprognostic (7.82e-4)"	"unprognostic (4.41e-3)"	"unprognostic (8.37e-2)"	"unprognostic (6.09e-2)"	"unprognostic (7.24e-3)"	"unprognostic (7.71e-7)"	"unprognostic (5.21e-3)"	"unprognostic (2.76e-1)"	"unprognostic (6.01e-3)"	"unprognostic (3.32e-5)"	2.5	1.1	1.9	0.5	2.8	0.3	1.0	0.1	7.4	9.1	2.4	1.4	1.1	0.6	4.7	1.8	0.9	3.5	1.2	0.4	17.7	1.7	0.5	0.4	2.9	1.5	0.5	1.1	1.0	1.2	0.4	0.0	0.7	2.9	8.8	1.0	0.0	0.8	6.0	1.2	0.4	0.8	1.6	0.5	3.6	2.5	1.5	0.0	0.0	0.9	0.0	0.4	3.3	6.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.2	0.0	0.0	0.0	0.0	12.0	2.1	0.8	0.3	0.5	5.4	0.0	0.0	7.1	0.6	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.7	0.3	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.5	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	2.8	0.1	7.4	17.7	1.7	0.5	1.1	2.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0
ADRA2A	"ADRA2, ADRA2R, ADRAR"	ENSG00000150594	"Adrenoceptor alpha 2A"	P08913	10	111077163-111080907	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 84.9"	"Cell type enhanced"	"Detected in many"	21	"Cholangiocytes: 63.7;Paneth cells: 72.4;Smooth muscle cells: 182.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 8.2;ASC TERT1: 10.1;HEL: 14.8;HeLa: 8.0;HSkMC: 24.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.87e-2)"	"unprognostic (1.63e-2)"	"unprognostic (1.38e-1)"	"prognostic favorable (8.06e-4)"	"unprognostic (1.36e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.78e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.03e-1)"	"unprognostic (4.64e-3)"	"unprognostic (5.86e-2)"	"unprognostic (5.63e-2)"	"unprognostic (3.08e-6)"	"unprognostic (1.45e-1)"	"unprognostic (3.70e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.89e-3)"	29.9	1.3	1.4	8.0	1.8	0.2	25.4	4.3	8.1	28.2	7.5	0.7	3.0	8.5	12.4	3.9	2.1	2.6	84.9	5.6	1.7	4.0	3.8	1.1	2.8	18.8	1.5	2.3	15.5	26.2	1.5	1.7	3.4	3.8	10.4	3.5	2.2	4.8	7.4	1.5	6.8	4.9	5.7	1.1	32.2	3.5	3.5	0.0	0.0	5.9	7.1	16.6	9.8	15.9	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	8.2	10.1	0.0	0.0	0.0	0.9	1.9	0.0	0.0	0.0	0.1	4.6	0.0	0.0	0.0	0.0	0.8	0.0	0.0	14.8	8.0	0.0	0.0	0.0	0.0	24.2	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.1	1.4	1.8	4.3	8.1	1.7	4.0	1.5	2.3	3.8	0.0	0.0	2.2	0.0	0.4	9.2	0.0	1.4	63.7	0.0	2.3	0.0	0.0	0.1	0.0	1.1	2.6	0.6	5.4	0.0	3.1	0.1	5.2	0.7	6.9	0.0	0.1	0.0	11.9	0.6	0.3	1.0	20.8	0.0	27.0	0.0	1.2	0.0	0.3	72.4	4.6	0.3	0.0	6.5	182.3	2.7	0.1	5.4	0.1	0.0	9.2	0.6
ADRA2B	"ADRA2L1, ADRA2RL1, ADRARL1"	ENSG00000274286	"Adrenoceptor alpha 2B"	P18089	2	96112875-96116245	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	4	"Sertoli cells: 32.3"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 5.1;EFO-21: 3.3;HAP1: 1.8;NTERA-2: 1.8;SuSa: 3.1"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA066029, HPA074948"	Approved		Supported	Vesicles,Cytosol		NA	NA			Vesicles	Cytosol	"HPA066029: AB_2685599, HPA074948: "	"unprognostic (6.16e-2)"	"unprognostic (1.31e-2)"	"unprognostic (1.76e-2)"	"unprognostic (4.93e-4)"	"unprognostic (1.84e-2)"	"unprognostic (5.24e-2)"	"unprognostic (6.80e-5)"	"unprognostic (4.85e-2)"	"unprognostic (1.69e-1)"	"unprognostic (3.16e-2)"	"unprognostic (8.34e-2)"	"unprognostic (2.54e-1)"	"unprognostic (2.21e-1)"	"unprognostic (4.43e-2)"	"unprognostic (3.39e-1)"	"unprognostic (1.36e-1)"	"unprognostic (6.55e-2)"	4.9	2.2	0.3	0.4	2.2	1.2	8.1	0.1	0.7	4.5	4.0	1.9	0.2	0.5	1.3	7.5	4.3	0.8	3.2	6.1	0.5		2.9	7.5	0.3	0.2	4.4	0.0	5.0	2.3	1.0	0.0	1.3	3.3	3.3	0.4	0.9	1.8	2.9	8.0	0.3	1.2	2.1	0.6	4.8	0.7	2.6	1.9	0.0	2.1	1.8	0.0	3.8	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	3.3	0.0	0.3	0.2	1.8	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.7	0.0	0.1	1.8	0.1	0.3	0.0	0.0	0.4	0.0	0.3	1.4	0.0	0.0	1.2	0.0	3.1	0.3	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.2	1.0	0.0	2.0	0.0	1.4	1.2	1.8	0.0	0.4	0.0	0.2	0.0	0.7	0.0	0.0	0.5	0.1	0.4	0.9	0.0	0.0	0.3	0.0	2.4	3.1	0.3	0.0	1.7	0.9	1.7	0.0	0.1	0.0	0.1	0.0	0.4	0.0	0.0	32.3	8.0	0.0	0.2	1.3	0.3	0.0	0.0	0.3
ADRA2C	"ADRA2L2, ADRA2RL2, ADRARL2"	ENSG00000184160	"Adrenoceptor alpha 2C"	P18825	4	3766348-3768526	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"cervix, uterine: 35.1"	"Cell type enhanced"	"Detected in some"	13	"Collecting duct cells: 12.2;Muller glia cells: 5.2;Smooth muscle cells: 4.1"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"basal ganglia: 9.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Hep G2: 11.1;MCF7: 18.4;NTERA-2: 6.5;OE19: 7.3;SCLC-21H: 7.1;SH-SY5Y: 8.5"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in all"	6	"basal ganglia: 41.4"	HPA057688	Uncertain					NA	NA					"HPA057688: AB_2683503"	"unprognostic (1.44e-2)"	"unprognostic (2.21e-3)"	"unprognostic (1.23e-1)"	"unprognostic (2.02e-2)"	"unprognostic (4.70e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.12e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.88e-1)"	"unprognostic (3.71e-1)"	"unprognostic (3.24e-2)"	"unprognostic (9.08e-3)"	"unprognostic (1.01e-2)"	"unprognostic (6.00e-2)"	"unprognostic (2.63e-1)"	"unprognostic (1.72e-1)"	"unprognostic (6.48e-2)"	6.5	2.4	2.1	1.0	9.8	0.4	9.2	0.5	2.6	35.1	1.5	0.6	12.8	1.0	20.3	18.0	2.1	6.4	5.5	3.0	1.2	1.0	9.2	1.3	2.0	1.2	0.7	1.6	7.6	4.1	0.5	4.2	27.6	1.1	7.3	0.6	3.6	0.8	24.6	2.6	2.1	0.9	3.0	0.7	7.5	0.7	6.2	2.0	0.2	0.8	1.9	0.5	2.1	8.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.1	0.1	0.5	0.0	0.2	0.4	0.0	0.0	0.0	2.0	1.2	0.0	2.1	0.3	0.7	0.0	0.2	0.0	0.0	0.0	5.7	0.0	0.0	11.1	0.6	0.0	0.8	0.9	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	2.7	18.4	0.0	0.0	6.5	7.3	0.0	0.0	6.0	0.0	0.0	0.3	7.1	8.5	2.5	0.0	0.1	1.7	6.1	0.1	0.0	0.0	4.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	9.8	0.5	1.4	1.2	1.0	0.7	1.6	1.1	2.0	0.0	0.0	0.0	0.1	0.0	1.4	0.9	2.5	0.0	0.0	12.2	0.0	0.8	3.3	0.4	0.0	0.5	0.0	0.0	0.0	0.2	0.7	0.2	0.0	0.0	0.3	3.2	0.0	1.3	0.0	0.0	1.4	0.0	0.0	0.0	0.0	5.2	0.2	0.0	3.5	1.8	0.0	0.0	4.1	0.0	0.7	0.0	1.4	0.0	0.0	0.1
ADRB1	ADRB1R	ENSG00000043591	"Adrenoceptor beta 1"	P08588	10	114044056-114046908	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"heart muscle: 48.0;placenta: 41.7"	"Cell type enhanced"	"Detected in many"	12	"Cardiomyocytes: 80.0;Cytotrophoblasts: 56.3;Sertoli cells: 51.8;Syncytiotrophoblasts: 32.2"	"Cancer enriched"	"Detected in many"	10	"prostate cancer: 12.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 1.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 10.2;PC-3: 4.0;THP-1: 6.9;TIME: 8.9;U-937: 5.2"	"Group enriched"	"Detected in many"	4	"amygdala: 10.0;basal ganglia: 7.3;cerebral cortex: 17.1;hippocampal formation: 11.3;thalamus: 6.9"	"Low region specificity"	"Detected in many"			HPA067972	Enhanced					NA	NA					"HPA067972: AB_2685936"	"unprognostic (1.45e-3)"	"unprognostic (1.18e-3)"	"unprognostic (1.44e-1)"	"unprognostic (4.92e-2)"	"unprognostic (3.22e-1)"	"unprognostic (8.88e-2)"	"unprognostic (9.28e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.77e-4)"	"unprognostic (1.33e-1)"	"unprognostic (7.80e-3)"	"unprognostic (1.53e-1)"	"unprognostic (1.85e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.44e-1)"	4.3	1.0	6.9	1.1	14.0	1.3	5.9	1.0	10.7	0.8	3.1	0.8	0.0	1.8	0.9	0.9	1.9	0.8	0.9	48.0	5.6	2.4	1.7	2.5	18.3	0.9	3.5	4.4	0.8	2.4	0.9	1.2	41.7	2.6	6.5	1.6	4.5	10.7	0.8	3.1	0.9	2.3	0.9	1.3	1.7	1.4	1.0	2.5	0.0	1.0	0.0	1.1	1.1	0.4	1.4	1.9	0.1	1.3	0.0	0.5	0.1	2.1	1.3	0.2	1.3	0.0	0.0	0.3	0.1	0.1	0.2	0.2	0.5	1.6	0.3	0.4	0.0	0.6	0.4	0.1	0.1	0.3	10.2	0.6	0.4	0.2	0.2	0.0	0.4	0.7	0.0	1.1	0.0	2.1	0.2	0.3	1.6	0.1	0.1	0.2	1.2	1.6	1.4	0.5	0.3	4.0	0.3	0.4	0.1	0.0	1.7	0.2	0.4	0.0	0.8	0.1	0.5	0.3	6.9	8.9	0.3	0.1	0.2	0.2	0.0	0.1	0.5	0.0	5.2	0.2	0.0	1.3	0.0	0.5	0.9	0.0	0.6	0.1	0.3	1.9	1.4	0.0	0.4	0.1	0.0	0.1	0.2	0.0	0.1	6.9	14.0	1.0	10.7	5.6	2.4	3.5	4.4	2.6	2.5	17.9	8.5	0.0	4.2	0.9	4.7	80.0	5.1	12.0	13.6	0.0	0.0	56.3	1.7	0.0	0.1	0.7	0.0	0.0	0.2	2.1	3.7	7.1	0.0	0.2	3.9	12.7	0.0	0.6	2.4	0.0	0.0	0.6	1.7	0.0	3.1	0.7	0.1	0.3	0.4	0.0	1.2	51.8	0.8	0.5	0.0	0.0	32.2	1.5	0.4	3.1
ADRB2	"ADRB2R, ADRBR, B2AR, BAR"	ENSG00000169252	"Adrenoceptor beta 2"	P07550	5	148825245-148828687	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 34.6"	"Group enriched"	"Detected in many"	4	"Alveolar cells type 1: 104.2;Basal keratinocytes: 344.2;granulocytes: 116.5;Suprabasal keratinocytes: 214.5"	"Low cancer specificity"	"Detected in many"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTCEpi: 24.5;hTERT-HME1: 25.4;PC-3: 10.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003431, HPA075322"	Uncertain		Uncertain	Cytosol		NA	NA			Cytosol		"HPA003431: AB_1845333, HPA075322: "	"unprognostic (2.28e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.17e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.17e-1)"	"unprognostic (9.35e-3)"	"unprognostic (5.54e-2)"	"unprognostic (2.34e-1)"	"unprognostic (9.85e-2)"	"unprognostic (3.17e-2)"	"unprognostic (2.23e-1)"	"prognostic favorable (3.15e-9)"	"unprognostic (1.55e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.49e-1)"	"unprognostic (7.65e-2)"	11.7	0.2	0.7	0.9	0.4	4.6	13.8	0.0	0.3	6.1	0.9			0.3	0.9	0.2	6.4	1.4	1.1	2.8	0.7	0.3	0.2	6.0	8.5	1.1	0.9		0.0	0.0	0.5	0.0	4.0		3.8	0.7		3.3	0.1	4.4	15.9	1.3	1.2	1.0	3.7	2.9	0.0			0.5		2.0	2.3	5.4	4.8	6.1	14.0	10.8	7.3	34.6	9.6	7.6	0.0	0.0	0.0	0.3	0.0	0.0	1.5	4.4	2.0	2.3	0.0	3.3	0.0	2.1	0.4	7.4	6.8	0.0	9.2	2.3	0.0	0.2	0.0	1.6	0.0	0.2	0.0	3.8	0.0	24.5	0.6	25.4	1.7	0.9	0.0	0.0	2.9	5.3	0.0	0.0	4.2	0.1	0.0	10.5	2.2	1.4	4.3	1.1	1.9	0.0	0.0	1.8	0.2	0.6	0.9	0.0	2.3	4.1	0.0	1.8	2.5	1.1	0.7	0.0	0.1	0.0	5.0	0.8	3.5	4.7	14.0	34.6	7.8	25.7	4.8	8.2	20.9	5.3	3.0	1.4	12.9	7.6	7.3	10.8	6.1	0.4	9.6											104.2	33.5	11.1	31.2	344.2	0.2	12.4	0.0	8.1	33.0	0.0	0.0	0.3	0.0	1.4	0.2	17.5	0.0	0.0	0.2	0.2	6.1	16.2	116.5	11.9	14.7	0.0	2.9	6.7	12.7	0.4	0.0	16.5	28.7	1.0	1.4	3.5	5.3	0.0	0.0	0.0	4.8	0.0	3.6	0.0	0.0	214.5	0.5	35.5	0.8	48.5
ADRB3		ENSG00000188778	"Adrenoceptor beta 3"	P13945	8	37962991-37966965	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Diabetes mellitus, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"gallbladder: 23.9;ovary: 15.7;smooth muscle: 10.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enhanced"	"Detected in single"		"amygdala: 1.3"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HeLa: 2.4;Karpas-707: 1.0;U-2 OS: 1.3"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			HPA061969	Uncertain					NA	NA					"HPA061969: AB_2732674"	"unprognostic (1.70e-1)"	"unprognostic (2.24e-1)"	"unprognostic (6.64e-3)"	"unprognostic (5.41e-1)"	"unprognostic (1.07e-2)"	"unprognostic (1.07e-1)"		"unprognostic (1.14e-1)"	"unprognostic (9.49e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.06e-3)"	"unprognostic (3.77e-2)"	"unprognostic (2.29e-8)"	"unprognostic (1.10e-3)"	"unprognostic (2.81e-2)"	"unprognostic (5.37e-2)"	"unprognostic (6.06e-3)"	0.4	0.1	1.3	1.9	0.3	0.3	0.3	0.0	0.8	1.6	2.3	0.0	0.0	0.4	0.9	1.9	1.7	5.3	23.9	0.1	0.2	0.1	0.1	0.0	0.2	1.2	0.0	0.0	15.7	0.0	0.0	0.0	4.7	0.0	4.1	0.4	0.0	0.0	0.1	0.0	0.1	0.9	10.8	0.0	0.0	3.0	0.2	0.0	0.0	0.0	0.0	0.1	9.9	1.5	0.9	0.2	1.2	0.4	0.8	0.5	0.0	0.2	0.2	0.1	0.1	0.3	0.7	0.0	0.1	0.0	0.1	0.0	0.0	0.6	0.3	0.0	0.3	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.0	2.4	0.4	0.8	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.3	0.2	1.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.3	0.0	0.0	0.2	0.1	0.4	0.4	0.4	1.3	0.1	0.0	0.2	0.1	0.1	0.2	0.1	0.0	1.0	0.3	0.3	0.1	0.1	0.4	0.7	0.2	0.1	0.0	0.9	0.2	0.2	1.2	0.8	0.4	0.2	0.5	0.0	1.3	0.3	0.0	0.8	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0
AGTR1	"AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R"	ENSG00000144891	"Angiotensin II receptor type 1"	P30556	3	148697784-148743008	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"liver: 29.6;placenta: 44.9"	"Group enriched"	"Detected in many"	5	"Leydig cells: 134.3;Sertoli cells: 142.3"	"Group enriched"	"Detected in many"	8	"breast cancer: 9.6;liver cancer: 9.8;prostate cancer: 6.8;renal cancer: 2.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 64.4;ASC TERT1: 9.0;BJ hTERT+ SV40 Large T+: 12.3;HBF TERT88: 19.4;HSkMC: 11.7"					"Low region specificity"	"Detected in many"			HPA003596	Enhanced		Uncertain	Vesicles		NA	NA			Vesicles		"HPA003596: AB_1845163"	"unprognostic (2.19e-1)"	"unprognostic (1.17e-1)"	"unprognostic (8.78e-2)"	"unprognostic (2.48e-4)"	"unprognostic (5.28e-3)"	"unprognostic (1.55e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.28e-2)"	"unprognostic (3.26e-2)"	"unprognostic (3.08e-2)"	"unprognostic (9.25e-3)"	"unprognostic (4.11e-2)"	"unprognostic (4.79e-2)"	"unprognostic (3.21e-3)"	"unprognostic (1.46e-1)"	"unprognostic (2.54e-1)"	"unprognostic (5.41e-3)"	18.8	11.6	0.0	0.1	0.0	0.0	10.8	0.0	0.0	0.8	5.5			0.0	0.6	0.5	0.5	2.2	1.6	3.1	0.0	0.1	5.7	29.6	2.6	0.0	0.9		0.8	0.6	0.6	0.8	44.9		1.3	1.0		1.0	1.0	2.9	4.4	0.7	1.1	0.0	2.3	1.7	0.2			4.1		0.0	4.2	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	64.4	9.0	0.0	0.0	1.3	12.3	7.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	19.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.7	0.0	1.1	0.6	0.3	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	1.1	0.0	0.2	3.1	0.0	5.7	5.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.8	0.2	0.0	0.0	6.6	0.2	13.7	1.2	0.0	26.8	0.6	0.0	22.7	29.4	0.8	0.2	134.3	0.0	1.7	0.0	0.0	4.5	0.8	0.0	7.1	0.0	0.0	142.3	15.5	0.0	0.4	1.5	0.2	0.0	0.0	0.0
AKR1C2	"BABP, DD, DD2, DDH2, HAKRD, MCDR2, TDD"	ENSG00000151632	"Aldo-keto reductase family 1 member C2"	P52895	10	4987400-5018031	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Lipid metabolism, Steroid metabolism"	Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 71.9;liver: 122.7;tongue: 111.8"	"Cell type enhanced"	"Detected in many"	14	"Cholangiocytes: 135.0;Hepatocytes: 341.7;Pancreatic endocrine cells: 140.7"	"Group enriched"	"Detected in many"	6	"cervical cancer: 21.7;head and neck cancer: 31.5;liver cancer: 50.2;lung cancer: 69.0;urothelial cancer: 35.7"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	5	"plasmacytoid DC: 1.4"	"Lineage enriched"	"Detected in single"	5	"dendritic cells: 1.4"	"Group enriched"	"Detected in some"	4	"A549: 130.6;ASC diff: 162.1;Hep G2: 243.7;OE19: 168.2;RT4: 74.6"									"CAB047304, HPA068265"	Enhanced		Approved	"Nucleoplasm,Nucleoli fibrillar center,Endoplasmic reticulum,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Nucleoli fibrillar center, Endoplasmic reticulum"	"CAB047304: , HPA068265: AB_2685966"	"unprognostic (6.77e-2)"	"unprognostic (8.88e-3)"	"unprognostic (3.02e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.72e-2)"	"unprognostic (2.86e-2)"	"unprognostic (8.65e-2)"	"unprognostic (5.03e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.02e-1)"	"unprognostic (6.25e-3)"	"unprognostic (8.58e-2)"	"unprognostic (1.09e-2)"	"unprognostic (8.60e-3)"	"unprognostic (1.46e-2)"	"unprognostic (8.30e-2)"	60.4	4.0	1.8	2.0	3.3	0.0	71.9	2.5	2.1	1.3	2.9	1.0	1.2	5.5	1.0	3.0	17.4	1.5	19.4	9.3	1.7	2.3	4.8	122.7	5.9	1.1	4.7	0.9	1.9	2.4	0.0	1.8	0.1	4.2	8.1	2.4	2.0	12.0	2.4	19.8	4.2	2.4	4.4	3.9	0.6	26.2	2.3	2.6	0.1	4.2	111.8	5.5	25.3	11.9	0.0	1.4	0.3	0.0	0.0	0.0	0.0	0.0	130.6	0.1	13.8	162.1	5.6	0.0	0.0	0.5	0.0	0.1	0.5	0.0	0.0	0.7	0.9	0.6	3.6	0.0	0.6	0.0	0.0	0.0	0.0	36.8	243.7	0.3	0.0	0.0	14.5	8.2	0.6	0.6	0.0	0.0	0.0	5.0	0.0	1.3	0.2	0.0	0.0	0.0	168.2	0.0	0.0	0.0	2.1	1.2	74.6	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.2	0.5	0.3	0.1	4.8	0.0	0.0	0.0	0.0	1.7	1.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.8	3.3	2.5	2.1	1.7	2.3	4.7	0.9	4.2	2.6	11.9	3.2	0.0	3.2	10.5	1.8	3.7	135.0	18.7	19.4	0.0	0.0	0.0	0.0	12.3	18.3	8.7	9.3	0.0	93.5	0.1	15.0	4.5	0.0	341.7	0.1	3.2	1.7	12.3	13.7	5.6	73.4	1.1	8.5	1.0	2.8	33.8	140.7	7.0	73.9	2.6	2.6	0.0	7.6	0.3	0.3	11.8	0.0	1.3	7.4	79.1
AKR1D1	SRD5B1	ENSG00000122787	"Aldo-keto reductase family 1 member D1"	P51857	7	138002324-138117986	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Bile acid catabolism, Lipid degradation, Lipid metabolism, Steroid metabolism"	Oxidoreductase	"Disease mutation, FDA approved drug targets, Intrahepatic cholestasis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	38	"liver: 103.2"	"Group enriched"	"Detected in some"	41	"Early spermatids: 50.2;Hepatocytes: 96.2;Late spermatids: 85.4"	"Cancer enriched"	"Detected in single"	77	"liver cancer: 20.1"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in single"	20	"Hep G2: 16.9"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			HPA057002	Enhanced		Approved	Nucleoplasm,Cytosol		No	NA			Nucleoplasm	Cytosol	"HPA057002: AB_2683308"	"unprognostic (2.38e-1)"	"unprognostic (1.65e-2)"			"unprognostic (1.02e-2)"	"unprognostic (1.52e-2)"	"prognostic favorable (9.91e-5)"	"unprognostic (6.11e-2)"	"unprognostic (2.31e-1)"	"unprognostic (1.30e-1)"	"unprognostic (6.87e-2)"	"unprognostic (2.94e-1)"	"unprognostic (9.68e-3)"	"unprognostic (2.90e-1)"	"unprognostic (5.80e-2)"	"unprognostic (3.11e-1)"	"unprognostic (1.67e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	103.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.5	2.7	0.5	0.7	0.7	0.2	0.2	0.0	0.2	0.2	0.0	0.0	0.5	0.1	0.0	0.1	0.0	0.8	0.3	0.2	0.1	0.0	0.6	0.3	0.0	0.0	0.2	0.3	0.1	0.4	0.3	16.9	0.0	0.5	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.3	0.0	0.0	0.3	0.2	0.1	0.0	0.2	0.1	0.4	0.0	0.3	0.0	0.2	0.2	0.2	0.1	0.1	0.1	0.2	0.4	0.3	0.2	0.1	0.3	0.2	0.3	0.3	0.2	0.2	0.3	0.3	2.7	0.5	0.6	0.4	0.4	0.3	0.6	0.4	0.4	0.3	1.1	0.5	0.7	1.8	0.7	0.5	0.5	0.5	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	50.2	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	96.2	0.4	0.0	0.0	1.3	1.9	85.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.2	0.0	0.2	0.0	0.0	0.1
ALAD	"ALADH, PBGS"	ENSG00000148218	"Aminolevulinate dehydratase"	P13716	9	113386317-113401333	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Heme biosynthesis, Porphyrin biosynthesis"	"Allosteric enzyme, Lyase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 84.2"	"Cell type enhanced"	"Detected in all"	4	"Erythroid cells: 70.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021023, HPA022124"	Enhanced					NA	NA		44000000			"HPA021023: AB_1844716, HPA022124: AB_1844717"	"unprognostic (2.75e-1)"	"unprognostic (6.26e-2)"	"prognostic unfavorable (7.33e-5)"	"prognostic favorable (5.64e-4)"	"unprognostic (4.16e-2)"	"unprognostic (9.49e-2)"	"prognostic favorable (8.80e-5)"	"unprognostic (2.87e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.62e-1)"	"unprognostic (3.31e-2)"	"prognostic favorable (1.65e-4)"	"unprognostic (1.75e-1)"	"unprognostic (1.22e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.31e-2)"	19.9	70.3	24.1	6.4	26.3	27.3	13.7	14.0	24.8	8.3	10.5	28.3	8.8	11.6	7.5	11.5	14.6	6.8	13.0	23.3	24.6	20.8	29.9	84.2	8.4	5.9	37.5	20.6	12.3	18.8	24.1	7.2	10.2	27.9	14.5	10.2	9.8	37.2	15.1	10.6	15.6	10.7	8.9	40.1	5.9	18.1	5.4	28.6	4.7	10.9	6.6	7.5	9.0	8.0	7.6	12.1	19.1	13.1	5.5	9.7	7.6	3.3	5.8	4.6	6.4	32.2	22.1	29.3	9.1	15.3	6.0	7.7	8.1	7.0	4.7	5.6	12.9	4.6	12.4	3.3	6.3	3.5	11.7	4.2	9.3	7.3	10.6	7.3	8.5	8.0	18.7	4.7	5.5	2.4	23.9	11.8	7.9	3.5	7.0	9.9	24.5	9.8	8.4	2.3	24.4	11.6	7.7	8.0	8.1	9.4	7.1	4.2	4.0	11.6	14.1	8.3	8.7	14.8	9.8	12.8	5.4	4.1	10.6	5.1	10.5	9.8	3.7	15.1	7.9	5.8	7.2	11.5	19.1	9.7	13.1	5.4	5.9	8.4	5.4	12.1	7.6	8.1	8.9	5.6	5.5	12.7	4.9	8.5	7.6	24.1	26.3	14.0	24.8	24.6	20.8	37.5	20.6	27.9	28.6	14.9	14.1	10.2	9.3	6.3	12.5	50.8	17.8	10.7	9.1	14.0	25.5	36.1	11.6	14.5	4.7	12.8	25.6	70.0	23.3	18.1	9.4	7.0	13.9	55.7	15.4	4.8	8.7	12.9	16.7	6.9	10.9	10.2	11.8	5.4	13.8	5.8	15.3	28.8	13.8	42.7	14.9	6.5	9.9	6.2	7.5	8.0	9.5	6.9	16.9	6.8
ALDH2		ENSG00000111275	"Aldehyde dehydrogenase 2 family (mitochondrial)"	P05091	12	111766887-111817529	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 279.7"	"Cell type enhanced"	"Detected in all"	9	"Hepatocytes: 770.8;monocytes: 1397.7;Proximal tubular cells: 645.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"classical monocyte: 45.8;myeloid DC: 46.6"	"Group enriched"	"Detected in many"	4	"dendritic cells: 46.6;monocytes: 45.8"	"Cell line enhanced"	"Detected in many"		"ASC diff: 25.4;HHSteC: 28.4;OE19: 41.9;SK-BR-3: 57.1;THP-1: 25.4"									HPA051065	Approved					NA	NA		1400000			"HPA051065: AB_2681332"	"unprognostic (9.22e-3)"	"unprognostic (1.20e-2)"	"unprognostic (4.14e-3)"	"prognostic favorable (2.63e-4)"	"unprognostic (1.16e-1)"	"unprognostic (1.32e-3)"	"prognostic favorable (3.95e-7)"	"unprognostic (5.62e-3)"	"unprognostic (3.00e-1)"	"unprognostic (1.16e-1)"	"unprognostic (8.22e-2)"	"unprognostic (1.51e-1)"	"prognostic favorable (5.24e-6)"	"unprognostic (9.70e-2)"	"unprognostic (3.40e-1)"	"unprognostic (1.50e-2)"	"prognostic unfavorable (7.71e-4)"	88.9	34.0	42.1	17.0	44.6	9.9	39.6	14.3	30.9	10.4	25.3	17.5	16.8	25.6	9.0	11.6	26.4	10.3	28.5	45.0	30.9	24.2	59.0	279.7	38.1	13.3	34.1	32.6	16.1	14.0	2.2	7.6	4.0	30.6	13.5	26.2	13.1	17.9	30.7	40.1	43.5	25.5	29.4	26.6	8.0	34.9	9.5	23.8	3.3	12.0	28.1	18.2	17.0	22.9	1.4	46.6	10.8	45.8	0.7	0.2	21.7	2.4	3.6	5.3	9.1	25.4	3.8	17.4	2.6	4.7	1.2	0.9	6.5	3.4	0.1	13.0	5.7	3.4	4.5	0.0	1.3	0.7	0.1	1.7	0.2	2.3	17.6	28.4	0.2	0.2	6.9	6.5	4.2	0.1	5.1	7.6	0.2	4.8	0.8	1.1	0.1	0.2	6.3	7.0	41.9	0.6	0.1	0.1	0.5	8.8	0.1	2.1	6.6	6.4	57.1	0.0	10.1	5.7	25.4	0.3	0.1	4.8	0.1	0.1	1.5	0.8	6.9	6.3	0.2	0.1	0.9	45.8	10.8	0.1	20.1	0.2	1.4	0.0	0.1	46.6	1.2	0.1	0.1	2.3	0.7	5.0	15.5	0.1	21.7	42.1	44.6	14.3	30.9	30.9	24.2	34.1	32.6	30.6	23.8	137.0	197.2	37.4	126.5	53.2	67.9	333.7	140.1	95.0	178.6	62.8	17.7	50.7	338.2	110.9	3.4	72.6	272.6	70.0	195.0	101.4	59.3	72.9	29.0	770.8	132.7	33.4	53.0	106.2	211.9	7.0	73.9	169.3	33.7	1397.7	184.2	107.6	110.7	325.4	140.0	645.3	34.9	45.3	77.3	2.7	3.2	109.0	35.2	13.8	218.4	82.3
ALDH3B2	ALDH8	ENSG00000132746	"Aldehyde dehydrogenase 3 family member B2"	P48448	11	67662162-67681200	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"breast: 28.1;esophagus: 48.2;lymphoid tissue: 34.2;skin 1: 38.7"	"Cell type enhanced"	"Detected in some"	10	"Collecting duct cells: 5.2;Cytotrophoblasts: 8.5;Extravillous trophoblasts: 8.0;Suprabasal keratinocytes: 12.9;Syncytiotrophoblasts: 12.2;Urothelial cells: 6.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"MCF7: 31.6;SK-BR-3: 32.7"					"Not detected"	"Not detected"			HPA045132	Approved					NA	NA					"HPA045132: AB_10795993"	"unprognostic (2.25e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.65e-1)"	"unprognostic (8.65e-2)"		"unprognostic (2.13e-1)"	"unprognostic (6.09e-2)"	"unprognostic (3.12e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.48e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.59e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.15e-2)"	"unprognostic (5.92e-2)"	0.1	0.0	0.1	0.1	0.1	0.0	28.1	0.1	0.1	6.7	0.1	0.1	5.0	0.0	1.5	2.4	48.2	1.5	0.1	0.1	0.1	0.0	0.6	0.1	0.6	0.1	0.1	0.1	0.4	0.1	0.6	0.3	11.2	0.1	1.8	0.0	0.1	17.1	4.6	0.1	38.7	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.8	0.1	25.7	34.2	4.6	11.6	1.0	0.1	0.6	0.2	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.5	1.8	1.6	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.6	2.6	0.0	0.0	4.3	0.0	0.0	0.0	0.1	0.0	4.7	0.0	0.0	0.0	32.7	0.0	0.2	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.2	0.6	0.0	0.2	0.0	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	2.9	0.0	1.5	1.4	0.0	0.3	0.0	0.0	0.0	5.2	0.0	8.5	1.7	0.3	0.0	0.0	0.0	0.0	0.2	8.0	0.4	1.5	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	12.2	0.0	0.0	6.2
ALK	CD246	ENSG00000171094	"ALK receptor tyrosine kinase"	Q9UM73	2	29192774-29921566	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 8.1;pituitary gland: 17.9"	"Group enriched"	"Detected in some"	12	"Early spermatids: 36.6;Late spermatids: 30.9"	"Group enriched"	"Detected in some"	5	"glioma: 1.0;melanoma: 1.5;ovarian cancer: 0.7;thyroid cancer: 1.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"SH-SY5Y: 27.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010694	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA010694: AB_1078133"	"unprognostic (4.96e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.45e-1)"	"unprognostic (4.56e-7)"	"unprognostic (7.17e-2)"	"unprognostic (1.71e-1)"	"unprognostic (9.07e-3)"	"unprognostic (6.29e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.01e-1)"	"unprognostic (2.67e-4)"	"unprognostic (3.70e-2)"	"unprognostic (2.06e-2)"	"unprognostic (7.15e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.61e-2)"	1.8	3.1	3.6	1.2	4.4	0.3	1.1	0.5	8.1	0.7	2.1	2.0	0.0	0.7	0.5	0.5	0.6	0.5	1.2	0.4	3.4	4.9	0.4	0.5	1.1	0.5	2.7	4.2	0.6	0.4	0.4	17.9	0.5	5.5	0.5	1.2	2.4	0.9	0.8	0.3	0.9	1.5	0.9	2.1	0.5	0.8	4.9	0.9	0.0	1.6	0.0	0.3	0.6	1.2	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	3.6	0.0	0.0	0.1	0.3	27.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	3.2	0.0	4.1	0.0	0.1	0.0	0.7	0.0	0.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	3.6	4.4	0.5	5.9	3.4	4.9	2.7	4.2	5.5	0.9	0.0	0.0	0.0	0.0	0.0	1.5	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	30.9	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0
ALOX5	5-LOX	ENSG00000012779	"Arachidonate 5-lipoxygenase"	P09917	10	45374176-45446119	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Leukotriene biosynthesis"	"Dioxygenase, Hydrolase, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 45.2;bone marrow: 39.9;lymphoid tissue: 41.8"	"Cell type enhanced"	"Detected in many"	13	"granulocytes: 194.3;Hofbauer cells: 78.7;Kupffer cells: 81.6;Macrophages: 81.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BEWO: 7.9;CAPAN-2: 6.1;Daudi: 22.3;HMC-1: 16.0;Karpas-707: 7.0;RT4: 10.5;U-266/70: 10.5;U-698: 7.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA071285	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA071285: AB_2686379"	"unprognostic (2.57e-2)"	"unprognostic (2.81e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.75e-2)"	"unprognostic (7.98e-3)"	"unprognostic (1.26e-1)"	"unprognostic (5.32e-2)"	"unprognostic (8.69e-2)"	"unprognostic (1.86e-2)"	"unprognostic (6.91e-2)"	"unprognostic (5.04e-2)"	"unprognostic (3.42e-1)"	"prognostic unfavorable (1.80e-5)"	"unprognostic (5.59e-3)"	"unprognostic (4.22e-2)"	"unprognostic (1.53e-1)"	"prognostic favorable (7.18e-4)"	7.4	3.9	2.9	18.3	7.4	39.9	5.8	13.2	3.2	3.4	6.5	6.4	1.0	4.5	3.2	4.7	4.9	5.4	8.0	6.1	3.9	2.6	4.8	2.6	34.7	36.9	9.0	1.7	2.6	10.0	1.3	1.7	11.2	6.1	7.8	3.4	3.2	6.6	3.4	1.1	2.9	14.4	7.8	8.4	41.8	4.5	2.0	6.2	2.4	3.0	1.4	16.7	27.2	10.5	14.8	11.1	45.2	21.3	0.0	0.5	9.5	0.0	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	0.0	6.1	22.3	0.8	0.0	0.0	0.3	0.2	0.0	0.0	0.4	0.2	4.3	0.0	0.0	0.0	0.0	16.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	7.0	0.0	0.0	0.0	0.3	0.0	1.0	0.0	0.1	0.0	0.8	0.3	10.5	0.5	0.0	0.0	0.2	0.0	0.1	0.1	0.5	0.0	0.0	1.2	0.0	0.0	10.5	1.9	7.4	0.0	0.1	0.0	36.7	21.3	27.0	0.0	20.0	0.1	14.8	0.5	0.2	11.1	10.4	0.0	0.0	45.2	0.0	19.6	0.3	0.1	9.5	2.9	7.4	13.2	3.2	3.9	2.6	9.0	1.7	6.1	6.2	14.9	58.3	34.9	5.4	1.0	0.8	2.0	15.3	4.0	12.5	8.7	2.0	0.5	0.0	19.2	0.4	0.7	2.1	0.0	18.9	1.4	0.6	3.3	194.3	0.6	78.7	0.0	6.8	2.5	81.6	1.1	0.3	81.2	0.0	18.0	0.7	0.3	17.8	0.0	0.0	0.0	0.2	12.9	0.7	0.4	0.8	1.3	3.4	1.3	0.4	35.5
ALPPL2		ENSG00000163286	"Alkaline phosphatase, placental like 2"	P10696	2	232406843-232410714	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"fallopian tube: 4.2;lung: 9.4"	"Cell type enhanced"	"Detected in some"	28	"Alveolar cells type 1: 6.0;Ciliated cells: 1.4;Club cells: 2.3"	"Cancer enhanced"	"Detected in many"		"endometrial cancer: 49.1;testis cancer: 64.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"CAPAN-2: 21.4;HaCaT: 15.7;SuSa: 25.7"									"CAB020698, HPA038764, HPA038765, HPA051699"	Approved		Approved	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"CAB020698: , HPA038764: AB_2676194, HPA038765: AB_2676195, HPA051699: AB_2681577"		"unprognostic (1.39e-1)"	"unprognostic (6.63e-3)"	"unprognostic (1.27e-2)"		"unprognostic (2.89e-1)"		"unprognostic (1.46e-1)"		"unprognostic (1.26e-1)"	"unprognostic (1.69e-3)"			"unprognostic (1.65e-1)"	"unprognostic (2.67e-1)"		"unprognostic (6.72e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	1.0	0.0	0.0	0.2	1.5	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	9.4	0.0	0.0	0.0	1.5	0.0	0.0	0.0	1.9	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.6	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.4	21.4	0.0	0.0	0.0	0.0	15.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.2	0.0	25.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.4	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.0	0.0
AMY2A	AMY2	ENSG00000243480	"Amylase, alpha 2A (pancreatic)"	P04746	1	103616811-103625780	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Carbohydrate metabolism"	"Glycosidase, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	31	"pancreas: 1849.4"	"Cell type enriched"	"Detected in some"	68	"Exocrine glandular cells: 849.6"	"Cancer enriched"	"Detected in single"	2010	"pancreatic cancer: 200.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"THP-1: 1.0;U-2 OS: 1.3"									"HPA045394, HPA045399, CAB045960, HPA046980"	Enhanced				"Secreted to digestive system"	NA	NA		77000000			"CAB045960: AB_2226891, HPA045394: AB_2679311, HPA045399: AB_2679313, HPA046980: AB_2679889"					"unprognostic (3.27e-1)"					"unprognostic (1.78e-3)"	"unprognostic (3.24e-2)"			"unprognostic (1.29e-1)"		"unprognostic (2.13e-2)"		0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.9	1849.4	0.0	0.2	0.2	0.2	0.2	0.0	0.2	59.9	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.3	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.8	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.9	1.5	0.0	0.0	0.0	849.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	12.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.4
ANO1	"DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A"	ENSG00000131620	"Anoctamin 1"	Q5XXA6	11	70078302-70189528	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Developmental protein, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"ductus deferens: 142.4;epididymis: 38.5;salivary gland: 122.9;seminal vesicle: 93.6"	"Cell type enhanced"	"Detected in many"	12	"Early spermatids: 56.2;Hepatocytes: 117.3;Late spermatids: 50.1;Sertoli cells: 45.3;Smooth muscle cells: 42.3;Suprabasal keratinocytes: 40.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"A-431: 32.9;CAPAN-2: 50.5;HaCaT: 61.6;OE19: 43.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA032148, HPA057356"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA032148: AB_2674180, HPA057356: AB_2732610"	"unprognostic (2.73e-1)"	"unprognostic (7.91e-2)"	"unprognostic (3.66e-2)"	"prognostic favorable (4.58e-6)"	"unprognostic (1.90e-1)"	"prognostic unfavorable (7.28e-5)"	"unprognostic (1.16e-3)"	"prognostic unfavorable (2.40e-4)"	"unprognostic (2.13e-2)"	"unprognostic (3.51e-1)"	"prognostic unfavorable (1.70e-4)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (4.09e-6)"	"unprognostic (1.56e-1)"	"unprognostic (1.06e-1)"	"unprognostic (8.85e-3)"	"unprognostic (1.81e-1)"	6.9	0.4	1.1	2.1	1.1	0.0	17.2	1.6	1.4	9.7	5.3	1.1	142.4	0.2	14.2	38.5	3.6	11.7	10.6	6.9	1.1	0.2	2.6	24.4	4.4	1.5	1.0	1.0	3.9	4.5	0.5	2.0	6.2	1.5	7.2	1.7	1.7	122.9	93.6	3.4	19.1	1.8	5.7	1.0	1.1	9.5	7.6	0.9	1.1	8.9	8.1	3.8	4.5	5.9	0.0	0.0	0.0	0.0	0.0	0.3	0.0	32.9	1.3	0.0	1.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	50.5	0.0	0.6	0.0	0.0	61.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.2	43.3	4.8	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.0	10.5	0.2	0.3	3.9	0.1	0.1	0.0	0.3	0.0	0.8	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	1.1	1.6	1.4	1.1	0.2	1.0	1.0	1.5	0.9	0.0	0.0	0.0	18.1	15.8	0.0	2.8	25.5	0.0	1.2	0.0	0.0	1.1	0.0	2.9	56.2	2.2	0.0	0.0	0.0	0.6	3.5	9.1	4.6	117.3	0.2	0.0	0.0	4.9	1.6	50.1	1.7	0.9	5.0	0.0	11.4	1.0	0.6	0.0	1.4	0.4	0.3	45.3	42.3	1.4	1.5	40.8	3.4	0.0	0.2	17.8
ANXA1	"ANX1, LPC1"	ENSG00000135046	"Annexin A1"	P04083	9	73151757-73170393	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Adaptive immunity, Immunity, Inflammatory response, Innate immunity"	"Phospholipase A2 inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 432.6;tongue: 235.4"	"Cell type enhanced"	"Detected in many"	10	"granulocytes: 2387.0;Syncytiotrophoblasts: 5914.0;Urothelial cells: 4139.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA011271, HPA011272, CAB013023, CAB035987, CAB058693"	Enhanced		Enhanced	"Nucleoplasm,Plasma membrane,Cytosol"	"Secreted to blood"	NA	Yes		77000000	"Plasma membrane, Cytosol"	Nucleoplasm	"CAB013023: AB_2533983, CAB035987: , CAB058693: AB_2665585, HPA011271: AB_1844883, HPA011272: AB_1844884"	"unprognostic (2.53e-2)"	"unprognostic (1.31e-1)"	"unprognostic (9.08e-2)"	"prognostic favorable (5.71e-5)"	"unprognostic (1.53e-2)"	"unprognostic (4.28e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.54e-3)"	"unprognostic (1.47e-1)"	"unprognostic (9.82e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.55e-2)"	"prognostic favorable (4.57e-5)"	"prognostic unfavorable (6.19e-6)"	52.7	3.5	2.7	11.5	3.3	81.4	45.9	0.9	2.5	61.5	8.5	3.6	5.5	2.4	6.9	11.2	432.6	11.9	14.9	8.9	3.2	2.5	9.1	2.1	37.3	7.6	4.3	1.9	11.7	2.4	0.5	6.3	149.5	13.5	12.9	4.4	6.4	93.0	7.2	7.9	11.6	6.4	12.3	6.5	5.9	5.9	5.6	3.1	3.9	21.7	235.4	153.3	18.0	83.1	0.7	98.9	146.2	79.1	27.3	52.5	102.8	66.2	104.7	4.7	4.9	66.8	63.6	0.3	114.8	71.8	47.5	32.2	3.0	59.9	0.1	38.0	100.1	105.0	81.6	10.1	69.5	37.7	37.5	0.7	5.1	31.1	0.1	53.3	11.0	2.5	36.6	57.6	48.0	94.4	44.0	67.3	6.0	21.0	2.8	58.5	0.2	19.5	6.0	5.9	26.5	42.6	0.0	26.7	0.2	106.8	14.0	0.0	0.0	39.5	1.0	26.5	65.5	0.2	1.7	83.1	55.7	35.1	76.5	58.9	0.4	0.1	0.2	128.7	10.3	83.8	146.2	79.1	141.1	52.2	21.5	52.5	0.7	47.0	45.9	98.9	0.2	13.7	25.4	8.6	27.3	19.3	3.5	8.3	102.8	2.7	3.3	0.9	2.5	3.2	2.5	4.3	1.9	13.5	3.1	541.9	512.9	7.3	2232.0	752.1	0.0	11.9	17.8	1060.0	889.5	59.3	0.0	1215.0	0.0	156.6	6.3	398.1	0.8	0.0	20.0	1352.9	735.1	1709.3	2387.0	2.5	570.9	0.0	5.1	113.5	449.6	2.3	206.0	1058.5	291.8	475.3	1.8	0.2	431.7	0.0	8.9	3.1	0.0	64.7	275.6	0.7	2.9	522.6	5914.0	282.4	0.5	4139.3
ANXA3	ANX3	ENSG00000138772	"Annexin A3"	P12429	4	78551519-78610451	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Phospholipase A2 inhibitor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 83.0"	"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 1: 547.9;Ductal cells: 468.5;Exocrine glandular cells: 274.5;Pancreatic endocrine cells: 473.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	319	"neutrophil: 51.3"	"Lineage enriched"	"Detected in single"	319	"granulocytes: 51.3"	"Cell line enhanced"	"Detected in many"		"A-431: 51.5;CACO-2: 52.8;CAPAN-2: 71.5;EFO-21: 43.8;hTERT-HME1: 72.9;OE19: 61.8;RPTEC TERT1: 61.4"	"Low region specificity"	"Detected in all"							"HPA013398, HPA013431"	Enhanced		Enhanced	"Plasma membrane"		NA	NA		7400000	"Plasma membrane"		"HPA013398: AB_1844861, HPA013431: AB_1844862"	"unprognostic (2.66e-1)"	"unprognostic (5.65e-3)"	"unprognostic (4.92e-3)"	"unprognostic (8.67e-2)"	"unprognostic (2.41e-1)"	"unprognostic (5.02e-3)"	"unprognostic (4.17e-2)"	"unprognostic (1.87e-1)"	"unprognostic (5.09e-2)"	"unprognostic (2.10e-3)"	"prognostic unfavorable (1.28e-4)"	"unprognostic (4.82e-2)"	"prognostic favorable (8.48e-6)"	"unprognostic (2.23e-1)"	"unprognostic (2.02e-2)"	"unprognostic (7.20e-2)"	"unprognostic (3.30e-2)"	20.3	1.1	4.0	7.1	7.4	83.0	16.2	2.4	6.8	7.0	8.5	2.3	0.9	4.2	3.4	4.2	25.0	4.6	11.7	20.5	5.2	5.2	19.8	1.6	46.0	5.7	6.6	5.6	2.8	14.7	6.5	5.8	33.7	10.4	18.8	7.4	2.6	50.8	3.6	14.2	4.1	9.3	5.3	4.0	11.0	23.4	1.8	5.0	2.0	45.3	13.6	7.4	2.8	5.9	0.1	0.0	51.3	0.1	0.0	0.0	0.5	51.5	9.8	0.1	0.1	0.1	0.2	0.0	0.6	0.0	1.5	1.4	52.8	71.5	0.0	43.8	1.8	0.0	20.4	0.0	37.7	2.3	0.2	0.4	4.6	21.1	3.1	6.1	0.6	0.0	0.3	33.4	0.5	72.9	7.6	14.9	1.2	0.1	0.0	0.2	2.0	0.2	0.0	1.6	61.8	7.2	0.0	0.1	0.0	61.4	5.9	0.0	0.0	30.4	7.5	2.1	25.3	1.3	0.6	18.9	0.1	6.8	0.0	11.6	0.4	0.6	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	51.3	0.0	0.1	0.0	0.0	0.5	4.0	7.4	2.4	6.8	5.2	5.2	6.6	5.6	10.4	5.0	547.9	38.9	0.0	51.1	22.0	0.0	6.4	58.6	36.1	144.5	36.6	0.0	172.1	14.9	468.5	0.9	32.1	19.7	0.0	274.5	87.0	24.3	117.9	4.7	0.4	16.1	0.0	5.2	20.3	0.0	0.0	2.8	1.7	5.0	36.1	30.9	0.8	473.1	58.5	0.4	1.1	0.3	0.0	9.5	1.2	0.7	5.8	52.5	0.5	28.7	32.0
AOC3	"HPAO, VAP-1, VAP1"	ENSG00000131471	"Amine oxidase, copper containing 3"	Q16853	17	42851184-42858130	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Cell adhesion"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	19	"Peritubular cells: 70.4;Sertoli cells: 116.4;Smooth muscle cells: 56.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	13	"neutrophil: 1.2"	"Lineage enriched"	"Detected in single"	13	"granulocytes: 1.2"	"Cell line enriched"	"Detected in some"	18	"ASC diff: 85.5"	"Low region specificity"	"Detected in many"							"HPA000980, CAB025797"	Enhanced		Approved	"Golgi apparatus,Cytosol"	"Secreted - unknown location"	NA	NA		240000000	Cytosol	"Golgi apparatus"	"CAB025797: , HPA000980: AB_1078170"	"unprognostic (2.20e-1)"	"unprognostic (4.49e-2)"	"prognostic unfavorable (3.68e-4)"	"unprognostic (2.97e-2)"	"unprognostic (1.17e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.22e-1)"	"unprognostic (2.15e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.00e-2)"	"unprognostic (2.95e-1)"	"unprognostic (9.02e-2)"	"prognostic unfavorable (1.79e-5)"	"unprognostic (5.61e-2)"	"unprognostic (1.67e-1)"	"unprognostic (8.39e-2)"	"prognostic unfavorable (6.98e-4)"	97.0	11.5	0.4	18.7	1.0	0.0	67.7	0.5	1.3	26.9	44.3	1.0	16.3	3.6	44.7	34.8	36.1	18.5	50.9	12.1	0.4	0.4	5.8	8.3	48.0	7.9	0.5	1.2	23.8	2.4	2.2	1.3	10.8	2.0	36.5	9.4	32.1	8.0	24.7	7.7	5.5	15.0	79.2	0.6	7.5	17.7	16.2	0.3	1.0	6.6	11.6	2.6	75.9	20.9	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	85.5	0.1	1.3	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.2	0.0	0.0	0.1	0.2	0.0	0.2	0.3	1.5	0.1	0.1	4.7	0.2	0.0	0.2	0.9	0.2	0.1	0.2	0.0	0.0	0.5	0.0	0.4	0.1	0.0	0.0	0.3	0.1	0.0	0.1	0.2	0.2	0.7	0.0	0.5	0.0	0.1	0.0	0.0	0.5	0.6	0.0	0.0	0.0	0.0	0.7	0.3	0.1	1.2	1.4	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.4	1.0	0.5	1.3	0.4	0.4	0.5	1.2	2.0	0.3	3.0	8.9	0.8	0.0	2.6	0.0	3.2	0.0	1.4	3.4	0.0	0.0	0.1	0.0	0.1	3.8	4.7	0.0	0.0	0.2	0.1	2.6	0.2	1.1	0.0	1.1	0.0	0.0	22.7	3.0	2.1	3.1	0.5	3.3	0.0	0.0	0.4	0.1	0.0	70.4	0.7	0.5	116.4	56.5	0.9	0.7	1.6	0.2	0.0	0.0	0.3
APEX1	"APE, APE-1, APEN, APEX, APX, HAP1, REF-1, REF1"	ENSG00000100823	"Apurinic/apyrimidinic endodeoxyribonuclease 1"	P27695	14	20455191-20457772	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA recombination, DNA repair, Transcription, Transcription regulation"	"Activator, DNA-binding, Endonuclease, Exonuclease, Hydrolase, Nuclease, Repressor, RNA-binding"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA000956, HPA002564, CAB004294, CAB047307"	Supported		Supported	Nucleoplasm		Yes	No		98000	Nucleoplasm		"CAB004294: AB_626685, CAB047307: , HPA000956: AB_2666158, HPA002564: AB_1078174"	"unprognostic (2.80e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.55e-2)"	"unprognostic (4.74e-3)"	"unprognostic (1.97e-2)"	"unprognostic (5.88e-2)"	"prognostic unfavorable (7.82e-5)"	"unprognostic (4.21e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.42e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.83e-2)"	"unprognostic (2.54e-1)"	"unprognostic (7.08e-2)"	43.9	52.8	30.6	33.2	32.5	55.6	43.6	24.1	44.9	38.5	41.9	37.3	28.4	44.1	53.2	30.1	40.7	42.9	46.4	34.4	28.0	27.4	44.4	61.3	31.8	44.5	30.2	31.1	64.7	48.4	31.8	21.7	29.4	34.4	36.1	39.8	36.0	35.5	38.9	53.2	41.2	37.6	40.9	30.1	51.0	41.7	20.9	28.3	73.2	51.2	38.5	48.4	41.8	32.7	35.0	53.0	1.5	23.7	20.6	32.5	38.4	44.6	54.9	49.3	45.4	34.7	50.1	42.5	42.0	45.2	62.6	54.3	40.0	44.4	86.3	37.5	32.0	33.5	47.9	58.6	44.4	58.2	38.5	25.0	34.9	32.5	66.7	36.5	110.9	36.3	51.7	49.0	40.7	40.4	50.2	52.2	35.7	40.5	28.4	50.1	43.5	71.0	46.7	48.5	50.7	49.7	79.0	55.4	36.2	52.5	60.3	59.5	37.8	45.5	56.8	45.1	36.3	34.5	50.2	33.7	33.0	55.4	33.2	39.1	38.2	66.1	58.2	14.8	70.5	41.7	0.1	23.7	1.5	19.0	20.5	25.9	35.0	23.8	22.6	46.8	31.4	32.5	28.3	1.5	20.6	12.4	53.0	14.1	38.4	30.6	32.5	24.1	44.9	28.0	27.4	30.2	31.1	34.4	28.3	59.6	45.2	101.2	74.7	94.4	52.3	42.8	86.6	72.3	79.6	64.6	39.3	161.9	127.6	119.2	16.8	57.5	33.9	0.0	91.3	165.4	86.9	49.2	78.7	65.2	158.8	27.0	115.1	39.3	80.7	4.0	74.5	109.4	60.8	100.0	78.8	68.5	83.2	73.7	60.5	126.7	45.4	51.8	136.6	6.3	43.7	84.8	84.9	76.1	136.8	42.5
APP	AD1	ENSG00000142192	"Amyloid beta precursor protein"	P05067	21	25880550-26171128	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Cell adhesion, Endocytosis, Notch signaling pathway"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Alzheimer disease, Amyloidosis, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"plasmacytoid DC: 24.0"	"Lineage enriched"	"Detected in many"	6	"dendritic cells: 24.0"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000157, HPA001462"	Enhanced		Approved	"Golgi apparatus,Vesicles"		NA	NA		15000000	"Golgi apparatus"	Vesicles	"CAB000157: AB_323833, HPA001462: AB_1078185"	"unprognostic (3.30e-1)"	"unprognostic (1.02e-2)"	"unprognostic (1.90e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.92e-1)"	"unprognostic (3.69e-3)"	"unprognostic (2.54e-1)"	"unprognostic (8.22e-2)"	"unprognostic (1.28e-1)"	"unprognostic (9.45e-2)"	"unprognostic (4.28e-2)"	"unprognostic (5.35e-2)"	"prognostic favorable (2.79e-6)"	"unprognostic (3.77e-2)"	"unprognostic (2.46e-1)"	"unprognostic (5.23e-2)"	"unprognostic (2.08e-3)"	44.8	92.5	89.9	26.3	109.3	21.2	79.9	64.5	139.1	51.7	63.4	86.9	72.0	39.7	52.2	57.2	33.0	57.6	63.4	69.1	104.6	97.7	102.2	54.5	50.2	12.9	97.4	95.8	58.9	57.1	36.4	34.1	79.7	83.2	49.2	59.6	48.9	47.2	66.6	17.2	38.2	34.9	69.3	109.0	26.3	37.9	32.2	67.5	13.9	85.0	21.5	16.7	52.5	58.4	1.5	24.0	0.9	3.9	0.3	1.5	1.8	31.2	40.4	44.3	36.9	60.4	75.0	47.9	63.4	84.6	32.2	37.9	23.2	76.7	0.0	73.9	49.6	42.0	21.4	27.0	74.5	27.3	1.1	21.8	0.0	24.4	16.3	59.0	29.6	1.6	67.5	82.4	37.7	69.3	133.1	144.0	13.0	0.0	3.2	50.5	35.0	0.5	0.3	34.8	51.2	36.1	19.4	42.7	26.0	109.0	22.0	22.6	33.0	68.0	44.8	31.8	63.1	39.6	32.3	153.9	71.7	30.4	26.1	29.9	19.6	0.2	0.3	58.3	0.1	68.8	0.4	3.9	0.0	0.1	1.2	0.2	0.5	1.4	0.5	3.4	1.5	1.5	0.4	0.9	0.3	0.9	24.0	0.3	1.8	89.9	109.3	64.5	124.6	104.6	97.7	97.4	95.8	83.2	67.5	101.3	43.6	31.5	195.4	161.4	26.5	130.8	282.8	120.5	119.4	476.3	27.5	341.9	48.0	308.0	33.6	371.9	139.3	0.0	158.2	112.6	202.6	156.7	8.1	105.8	67.9	79.4	156.1	527.9	77.8	43.7	224.6	45.9	153.5	92.8	307.0	330.4	178.5	181.4	279.0	124.0	22.1	116.4	133.6	37.0	87.7	92.8	461.7	25.5	256.5	110.0
AR	"AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1"	ENSG00000169083	"Androgen receptor"	P10275	X	67544032-67730619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 49.0"	"Cell type enhanced"	"Detected in many"	14	"Hepatocytes: 189.5;Leydig cells: 72.2;Peritubular cells: 81.3;Sertoli cells: 64.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"plasmacytoid DC: 5.4"	"Lineage enriched"	"Detected in single"	16	"dendritic cells: 5.4"	"Cell line enhanced"	"Detected in some"		"AF22: 11.3;BJ hTERT+: 9.8;HAP1: 14.4;LHCN-M2: 12.6;RH-30: 20.9;T-47d: 8.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000001, HPA004733, CAB065764"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB000001: AB_2060174, CAB065764: AB_10620739, HPA004733: "	"unprognostic (1.34e-1)"	"unprognostic (8.10e-3)"	"unprognostic (2.49e-2)"	"unprognostic (5.95e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.35e-2)"	"prognostic favorable (8.77e-4)"	"unprognostic (4.99e-2)"	"unprognostic (1.72e-1)"	"unprognostic (7.79e-2)"	"unprognostic (2.30e-1)"	"unprognostic (2.29e-1)"	"prognostic favorable (1.03e-8)"	"unprognostic (8.23e-3)"	"unprognostic (8.90e-2)"	"unprognostic (4.23e-2)"	"unprognostic (7.97e-2)"	10.1	1.2	0.9	1.6	0.9	0.1	10.7	0.4	1.6	34.4	1.9	2.4	25.4	0.2	20.5	20.5	2.2	17.5	4.3	5.7	0.9	1.5	6.3	49.0	1.5	0.2	1.2	0.7	14.4	1.0	0.1	2.3	0.3	1.9	28.0	0.5	3.8	1.6	36.1	8.1	3.9	1.1	7.6	1.9	0.9	1.6	9.3	1.2	5.4	3.1	2.0	1.2	6.3	13.1	0.0	5.4	0.3	0.0	0.1	0.0	0.1	0.0	4.7	11.3	0.0	0.0	0.1	0.0	6.0	9.8	0.4	0.1	0.2	0.0	0.0	0.0	0.7	0.0	0.0	14.4	0.0	0.1	0.0	1.9	0.0	1.1	0.0	0.7	0.0	0.0	4.6	0.0	1.7	0.0	0.0	3.5	0.1	4.1	1.9	12.6	1.2	0.0	0.0	4.5	0.0	0.0	0.0	20.9	0.0	0.3	0.0	0.0	0.0	0.0	0.2	0.0	3.2	8.8	5.3	0.2	0.2	2.0	0.1	3.0	0.0	0.0	0.0	4.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.1	0.0	5.4	0.0	0.1	0.9	0.9	0.4	1.6	0.9	1.5	1.2	0.7	1.9	1.2	0.0	5.3	0.0	18.1	8.7	0.6	31.3	12.7	6.7	19.4	3.5	0.0	1.9	1.7	7.5	0.9	4.9	0.0	0.0	0.0	0.1	9.4	31.9	1.1	189.5	0.7	0.0	0.0	14.7	1.6	1.6	72.2	2.1	10.1	2.8	0.0	0.2	1.0	0.0	81.3	22.3	0.3	64.7	12.3	0.5	1.0	14.1	0.8	0.0	0.0	15.9
ASIC1	"ACCN2, BNaC2, hBNaC2"	ENSG00000110881	"Acid sensing ion channel subunit 1"	P78348	12	50057548-50083611	"FDA approved drug targets, Predicted membrane proteins"	"Calcium transport, Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"brain: 43.7"	"Cell type enhanced"	"Detected in some"	12	"Bipolar cells: 3.1;Ciliated cells: 6.7;Club cells: 2.3;Horizontal cells: 3.2"	"Cancer enhanced"	"Detected in many"		"glioma: 12.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 23.0;SH-SY5Y: 17.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA058870			Supported	"Golgi apparatus,Plasma membrane"		NA	NA			"Golgi apparatus, Plasma membrane"		"HPA058870: AB_2683841"	"unprognostic (5.32e-3)"	"unprognostic (1.70e-1)"	"unprognostic (4.00e-2)"	"unprognostic (3.56e-2)"	"unprognostic (2.41e-1)"	"unprognostic (3.48e-3)"	"unprognostic (2.92e-3)"	"unprognostic (3.00e-2)"	"unprognostic (1.72e-1)"	"unprognostic (9.37e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.86e-3)"	"unprognostic (6.97e-7)"	"unprognostic (7.19e-2)"	"unprognostic (3.73e-1)"	"unprognostic (2.78e-3)"	"unprognostic (8.27e-5)"	2.5	1.7	13.9	1.8	20.3	0.8	2.9	20.1	43.7	5.3	3.1	12.8	0.3	2.3	2.5	1.2	3.4	3.6	4.0	2.2	12.3	14.3	1.6	0.9	1.3	1.3	12.9	8.5	1.4	1.4	5.2	0.5	1.5	10.2	4.5	2.5	1.8	5.6	3.4	1.3	1.5	2.5	3.6	5.4	1.1	4.3	1.4	11.0	0.4	1.1	0.0	1.0	2.6	1.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	1.9	4.3	5.7	12.9	1.7	2.7	3.2	1.4	3.7	2.5	2.5	3.0	1.5	1.2	3.0	0.8	1.5	2.0	5.6	4.7	1.4	1.2	15.4	3.9	6.1	1.8	2.5	5.7	14.5	6.8	2.3	0.4	0.6	23.0	0.4	15.2	2.5	0.1	2.0	2.4	5.5	11.3	2.4	4.4	7.6	5.6	5.4	2.6	1.2	0.2	8.5	17.9	3.2	1.1	2.0	1.0	7.0	3.8	0.4	2.5	8.4	1.7	0.7	0.0	0.0	0.0	3.2	5.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.0	0.3	13.9	20.3	20.1	18.3	12.3	14.3	12.9	8.5	10.2	11.0	0.0	0.0	0.0	0.2	0.0	3.1	0.9	0.0	6.7	2.3	1.8	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.9	0.6	0.0	0.0	0.3	3.2	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	1.4	0.1	0.0	1.1	0.8	0.5	0.0	0.2	0.0	0.7	0.0	0.2	0.0	0.0	0.1
ATIC	"AICARFT, IMPCHASE, PURH"	ENSG00000138363	"5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase"	P31939	2	215311817-215349773	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Purine biosynthesis"	"Hydrolase, Multifunctional enzyme, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cytotrophoblasts: 144.4;Extravillous trophoblasts: 132.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013462, HPA021012"	Supported		Approved	"Plasma membrane,Cytosol"		NA	NA		3400000	Cytosol	"Plasma membrane"	"CAB013462: , HPA021012: AB_1845169"	"unprognostic (1.41e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.13e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.81e-2)"	"prognostic unfavorable (1.99e-7)"	"unprognostic (1.86e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.83e-1)"	"unprognostic (6.31e-3)"	"unprognostic (9.21e-2)"	"prognostic unfavorable (8.77e-4)"	"unprognostic (1.00e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.18e-2)"	"unprognostic (4.39e-3)"	19.4	27.4	21.1	23.0	28.4	16.9	24.8	12.1	32.3	20.6	26.7	29.1	18.1	23.4	27.9	15.6	19.1	21.9	19.1	18.2	20.3	21.1	23.1	35.6	17.3	36.1	29.7	19.9	23.4	32.9	25.1	21.1	31.1	24.4	21.9	35.9	19.5	14.4	29.4	35.5	17.0	20.6	26.7	21.7	29.0	20.4	15.0	28.0	46.3	16.1	13.5	35.3	27.6	18.0	21.7	13.4	2.9	8.9	19.6	22.8	10.0	20.5	31.1	17.4	29.5	23.4	23.7	8.7	21.0	18.3	24.0	27.6	60.0	32.2	29.9	26.0	21.9	33.8	21.6	38.2	31.7	34.5	22.3	36.9	36.4	26.7	53.7	30.3	45.6	18.7	20.0	24.3	32.1	38.8	16.6	16.0	29.0	47.0	25.0	33.0	30.3	39.7	22.2	66.8	32.9	17.5	36.9	25.0	26.8	25.5	33.2	27.3	18.9	16.9	20.8	23.7	40.4	34.1	16.2	14.1	20.4	21.1	26.3	13.2	31.6	41.2	62.1	17.7	25.4	29.4	2.9	6.0	0.1	13.2	8.9	22.8	21.7	18.6	20.0	13.4	13.2	18.9	17.5	0.7	19.6	7.4	11.7	17.7	10.0	21.1	28.4	12.1	32.3	20.3	21.1	29.7	19.9	24.4	28.0	11.9	17.1	19.3	23.5	13.4	9.6	18.5	25.5	26.8	19.4	22.7	3.9	144.4	23.2	32.2	0.8	6.3	13.5	0.0	42.8	132.7	23.3	16.1	24.3	18.7	46.4	9.5	18.5	4.3	15.0	0.0	22.2	18.7	28.7	32.5	29.9	20.6	30.0	21.0	32.2	44.0	12.8	25.8	19.8	3.2	40.3	7.4	79.8	21.5	52.7	17.4
ATP1A1		ENSG00000163399	"ATPase Na+/K+ transporting subunit alpha 1"	P05023	1	116372668-116410261	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"	Translocase	"Cancer-related genes, Charcot-Marie-Tooth disease, Epilepsy, FDA approved drug targets, Mental retardation, Neurodegeneration, Neuropathy, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"intestine: 195.4;parathyroid gland: 194.4"	"Cell type enhanced"	"Detected in all"	5	"Enterocytes: 917.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"SK-MEL-30: 254.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018702, CAB069993"	Enhanced					NA	NA		380000			"CAB018702: AB_626713, CAB069993: AB_2060979"	"unprognostic (6.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (6.91e-2)"	"unprognostic (1.42e-2)"	"unprognostic (6.80e-2)"	"unprognostic (2.15e-1)"	"prognostic unfavorable (1.42e-4)"	"unprognostic (1.80e-1)"	"unprognostic (1.21e-2)"	"unprognostic (6.32e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.65e-1)"	"prognostic favorable (8.98e-8)"	"unprognostic (4.75e-2)"	"unprognostic (1.17e-1)"	"unprognostic (3.11e-2)"	"prognostic unfavorable (4.01e-4)"	17.4	25.6	22.4	16.2	40.3	10.5	26.9	74.2	67.4	17.8	121.9	14.2	56.1	92.3	13.1	38.3	34.9	17.7	65.8	41.1	26.1	18.7	162.7	34.6	35.1	9.6	19.2	27.6	17.4	78.6	194.4	25.0	19.2	34.1	22.1	65.7	24.1	84.4	53.7	19.0	40.5	195.4	17.7	20.7	13.7	25.0	17.0	13.9	9.1	101.2	13.7	16.2	14.2	23.1	10.3	22.0	6.4	29.7	10.4	30.2	17.2	33.7	12.4	12.9	6.5	26.0	25.3	66.6	20.2	40.3	24.9	35.4	49.8	24.2	26.7	28.6	23.9	25.3	44.1	25.5	42.6	36.3	9.8	28.3	15.5	23.5	42.0	19.9	38.9	21.9	28.1	71.5	29.0	38.3	35.2	30.5	16.3	25.6	25.8	22.0	67.0	15.7	14.1	30.4	53.6	25.0	15.2	30.3	23.6	90.1	34.8	12.7	11.2	31.4	59.6	254.2	33.2	15.7	22.6	26.9	14.2	19.9	36.7	40.9	12.5	9.7	20.5	43.6	22.5	83.4	6.4	13.3	6.1	23.2	20.9	24.8	10.3	26.4	24.9	22.0	5.3	30.2	22.0	1.6	10.4	29.7	11.1	20.3	17.2	22.4	40.3	74.2	67.4	26.1	18.7	19.2	27.6	34.1	13.9	256.1	246.7	58.7	265.3	245.9	76.0	62.7	540.1	113.8	203.6	731.0	375.0	70.1	316.7	432.8	25.0	117.9	917.6	93.5	278.3	130.8	110.9	297.5	43.8	66.4	114.8	96.9	169.4	90.9	77.6	11.5	109.0	130.5	197.4	47.7	304.0	513.0	192.4	264.8	94.7	289.6	141.6	32.3	179.2	17.9	27.5	235.0	56.5	95.6	365.5	236.0
ATP2C1	"ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1"	ENSG00000017260	"ATPase secretory pathway Ca2+ transporting 1"	P98194	3	130850595-131016712	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	Translocase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010207, HPA035116, HPA069684"	Supported		Supported	"Golgi apparatus"		NA	NA		28000	"Golgi apparatus"		"CAB010207: AB_2061744, HPA035116: AB_10673106, HPA069684: AB_2686169"	"unprognostic (1.52e-1)"	"unprognostic (1.37e-1)"	"unprognostic (2.74e-2)"	"unprognostic (1.08e-1)"	"unprognostic (2.99e-1)"	"unprognostic (1.32e-2)"	"prognostic unfavorable (5.06e-6)"	"unprognostic (7.66e-2)"	"unprognostic (6.52e-2)"	"unprognostic (2.45e-1)"	"prognostic unfavorable (1.52e-4)"	"unprognostic (8.44e-2)"	"prognostic favorable (1.55e-4)"	"unprognostic (2.19e-1)"	"unprognostic (1.95e-1)"	"unprognostic (3.73e-2)"	"unprognostic (3.06e-1)"	18.6	22.9	29.6	14.5	29.4	20.4	36.8	24.5	34.6	22.2	21.6	23.0	14.3	14.4	19.3	18.0	16.9	23.4	16.8	19.2	31.6	32.3	28.0	17.1	30.7	16.0	31.8	25.4	18.5	14.6	47.6	31.0	19.6	26.7	54.0	22.4	18.1	20.3	16.6	16.1	21.3	16.0	19.2	44.6	11.1	18.7	16.0	25.6	20.5	21.7	15.5	15.4	19.3	29.6	4.7	7.6	21.6	7.0	8.7	7.2	4.9	36.6	14.4	14.5	13.9	40.6	32.9	15.6	40.1	53.5	20.2	25.5	23.4	30.3	13.3	27.9	37.9	28.1	43.7	27.2	22.1	29.6	28.7	9.8	35.4	15.3	10.8	25.9	14.1	43.2	25.8	22.3	21.2	24.1	36.9	21.3	16.9	10.2	24.3	24.8	16.3	13.8	11.3	16.4	20.0	15.7	10.0	14.4	20.9	37.2	24.7	22.4	13.4	34.5	10.8	20.2	21.6	16.0	11.6	29.1	21.5	12.0	27.6	18.4	15.7	19.0	19.7	22.2	10.6	17.9	21.6	7.0	12.1	6.3	6.0	5.9	4.7	6.2	5.6	7.6	2.9	4.3	4.3	3.5	8.7	7.0	6.6	7.2	4.9	29.6	29.4	24.5	34.6	31.6	32.3	31.8	25.4	26.7	25.6	35.7	45.2	11.3	32.9	34.9	26.4	27.0	40.8	24.1	23.9	43.6	19.6	13.5	5.0	32.7	12.6	25.1	15.9	0.0	33.1	24.1	29.4	68.4	27.7	24.6	26.6	77.9	34.2	22.7	18.3	14.0	15.0	28.6	20.3	19.8	31.3	22.6	44.4	25.9	13.8	18.6	33.2	6.5	24.2	15.2	14.9	46.2	14.8	13.8	29.3	33.5
ATP4A	ATP6A	ENSG00000105675	"ATPase H+/K+ transporting alpha subunit"	P20648	19	35550043-35563658	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Hydrogen ion transport, Ion transport, Potassium transport, Transport"	Translocase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"stomach 1: 120.1"	"Group enriched"	"Detected in some"	4	"Early spermatids: 7.3;Late spermatids: 15.2"	"Cancer enriched"	"Detected in single"	21	"stomach cancer: 5.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"THP-1: 1.2;U-138 MG: 1.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			"HPA039154, HPA076684"	Enhanced					NA	NA		790000			"HPA039154: AB_10672772, HPA076684: "	"unprognostic (3.54e-2)"	"unprognostic (6.98e-3)"		"unprognostic (2.77e-2)"	"unprognostic (1.43e-1)"	"unprognostic (5.84e-3)"		"unprognostic (4.96e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.50e-1)"	"unprognostic (9.68e-2)"	"unprognostic (1.47e-3)"	"unprognostic (3.90e-3)"	"unprognostic (3.92e-2)"	"unprognostic (4.86e-2)"	"unprognostic (1.23e-1)"	"unprognostic (2.18e-1)"	0.1	0.2	0.1	0.1	0.6	0.0	0.1	0.1	0.6	0.1	0.1	3.4	0.1	0.0	0.1	0.1	4.9	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	2.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	2.1	0.1	0.1	120.1	0.1	0.1	0.7	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	1.2	0.0	1.5	0.3	0.0	0.0	0.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.1	0.6	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.2	0.6	0.0	0.0	1.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.9	2.6	0.0	0.0	0.0	0.0	0.0
ATP4B	ATP6B	ENSG00000186009	"ATPase H+/K+ transporting beta subunit"	P51164	13	113648804-113658186	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Cell adhesion, Hydrogen ion transport, Ion transport, Potassium transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"stomach 1: 156.3"	"Cell type enriched"	"Detected in single"	6	"Distal tubular cells: 1.7"	"Cancer enriched"	"Detected in some"	12	"stomach cancer: 8.9"	"Region enriched"	"Detected in single"	9	"cerebral cortex: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"REH: 3.9;RPMI-8226: 1.6;SCLC-21H: 2.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA045400, HPA052649"	Enhanced					NA	NA					"HPA045400: AB_2679314, HPA052649: AB_2681900"	"unprognostic (9.92e-2)"	"unprognostic (2.19e-1)"		"unprognostic (2.66e-1)"	"unprognostic (4.86e-1)"			"unprognostic (6.43e-3)"	"unprognostic (7.81e-3)"	"unprognostic (1.95e-1)"	"unprognostic (3.22e-1)"	"unprognostic (6.50e-2)"	"unprognostic (6.65e-4)"	"unprognostic (2.25e-1)"	"unprognostic (2.78e-1)"	"unprognostic (3.78e-2)"		0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	1.0	0.1	0.1	2.0	0.1	0.0	0.1	0.1	1.5	1.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	6.5	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	156.3	0.1	0.1	0.6	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.2	0.1	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	3.9	0.0	1.6	0.0	0.0	2.6	0.9	0.2	0.7	0.0	0.0	0.1	0.8	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	1.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
ATP6V1B2	"ATP6B2, HO57, VATB, Vma2, VPP3"	ENSG00000147416	"ATPase H+ transporting V1 subunit B2"	P21281	8	20197367-20226819	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters"	"Hydrogen ion transport, Ion transport, Transport"	Hydrolase	"Deafness, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 116.0"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 69.7;eosinophil: 47.6;intermediate monocyte: 62.5;myeloid DC: 34.5;neutrophil: 116.0;non-classical monocyte: 54.1"	"Group enriched"	"Detected in all"	10	"dendritic cells: 34.5;granulocytes: 116.0;monocytes: 69.7"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008147	Enhanced		Supported	Vesicles		NA	NA		240000	Vesicles		"HPA008147: AB_1845195"	"unprognostic (1.90e-1)"	"unprognostic (7.24e-3)"	"unprognostic (3.62e-2)"	"unprognostic (2.57e-1)"	"unprognostic (2.84e-2)"	"unprognostic (5.59e-3)"	"unprognostic (1.76e-2)"	"unprognostic (3.78e-2)"	"unprognostic (4.68e-2)"	"unprognostic (4.23e-3)"	"unprognostic (1.29e-2)"	"unprognostic (1.34e-1)"	"prognostic favorable (8.41e-4)"	"unprognostic (2.41e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.47e-2)"	"unprognostic (5.25e-2)"	17.1	29.9	31.7	25.8	45.0	14.4	13.2	39.2	72.9	12.2	13.9	15.9	5.5	16.2	10.6	12.2	15.3	10.3	14.8	13.9	33.8	47.8	53.9	18.0	22.8	17.5	46.9	47.1	10.9	12.2	18.8	23.6	18.5	64.2	11.0	16.5	17.3	12.8	10.9	18.2	18.2	21.1	15.0	19.2	20.9	10.7	24.0	12.7	10.3	12.7	9.3	17.5	14.3	12.4	4.9	34.5	116.0	69.7	4.8	7.1	51.1	10.8	18.2	22.7	7.4	31.0	19.2	20.4	24.5	15.7	31.6	32.7	20.5	6.4	19.3	10.0	23.3	32.2	9.3	17.9	16.3	33.7	8.1	12.0	13.4	8.2	15.7	36.4	9.5	28.0	17.1	14.9	19.6	18.1	34.9	19.7	25.8	19.9	18.7	33.7	6.1	27.8	11.3	16.8	16.0	8.0	11.5	29.2	10.0	29.2	17.2	17.6	25.4	11.8	16.0	77.9	19.6	20.9	17.5	20.8	15.9	12.2	26.2	19.5	7.6	10.2	22.7	22.0	22.8	40.3	15.9	69.7	47.6	5.7	62.5	6.2	4.9	5.9	6.1	34.5	4.3	6.1	6.0	116.0	4.8	54.1	8.4	7.1	51.1	31.7	45.0	39.2	69.0	33.8	47.8	46.9	47.1	64.2	12.7	23.8	20.2	30.3	24.8	51.5	100.1	14.0	12.7	12.0	11.4	27.9	96.2	100.2	68.0	38.5	22.5	24.8	23.6	46.7	33.2	46.1	30.0	15.5	21.9	30.6	167.3	179.6	71.4	28.3	171.7	15.9	18.1	165.7	99.5	87.4	19.6	39.2	37.2	20.4	26.5	193.9	117.5	12.9	37.6	83.9	46.7	62.6	104.2	27.7	20.0	18.2
ATP6V1C1	"ATP6C, ATP6D, VATC, Vma5"	ENSG00000155097	"ATPase H+ transporting V1 subunit C1"	P21283	8	103021063-103073051	"FDA approved drug targets, Predicted intracellular proteins, Transporters"	"Hydrogen ion transport, Ion transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023943, HPA057297"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA023943: AB_1845197, HPA057297: AB_2683402"	"unprognostic (5.73e-3)"	"unprognostic (3.30e-1)"	"unprognostic (1.09e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.52e-2)"	"unprognostic (3.35e-2)"	"prognostic unfavorable (8.82e-4)"	"unprognostic (3.29e-2)"	"unprognostic (3.87e-1)"	"unprognostic (5.62e-2)"	"unprognostic (1.19e-1)"	"unprognostic (5.59e-2)"	"unprognostic (3.98e-2)"	"unprognostic (1.23e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.88e-1)"	"unprognostic (2.83e-1)"	17.1	23.1	25.1	16.8	36.7	6.5	15.7	26.2	58.8	13.6	11.1	11.4	7.6	12.1	14.1	10.9	10.6	12.2	13.7	19.0	28.5	28.0	35.0	18.1	12.9	15.9	23.2	33.3	14.4	12.9	21.3	29.2	20.2	45.1	13.2	13.7	11.5	10.4	12.2	11.7	8.5	12.8	14.5	15.0	14.3	12.1	13.0	12.5	10.7	26.9	8.4	15.6	15.5	10.7	10.6	16.3	27.9	24.3	10.0	12.5	10.8	29.1	17.5	9.3	6.9	24.4	15.8	11.5	21.9	21.8	24.6	29.1	12.9	29.6	18.8	25.1	17.4	39.3	11.8	18.3	17.0	35.2	12.3	14.1	18.3	13.3	15.3	26.0	9.8	22.1	15.1	22.2	33.0	15.9	14.8	18.5	12.2	23.3	15.4	27.3	13.2	18.3	7.2	8.1	26.5	17.0	10.6	16.4	14.2	27.5	21.0	11.9	10.2	12.3	11.7	38.3	17.3	24.5	11.6	22.0	14.3	14.5	31.7	15.3	20.2	7.3	17.9	27.7	20.4	13.8	8.4	17.4	20.6	9.1	24.3	10.2	10.6	7.7	8.9	16.3	10.2	9.0	9.7	27.9	10.0	22.1	8.8	12.5	10.8	25.1	36.7	26.2	58.8	28.5	28.0	23.2	33.3	45.1	12.5	29.8	23.7	18.1	27.2	31.0	29.7	39.1	12.7	41.5	18.2	29.6	15.7	32.6	54.7	34.3	128.0	23.1	13.6	23.3	27.3	30.1	23.0	29.4	23.1	15.3	87.3	35.0	15.0	18.4	45.4	117.5	22.5	45.4	18.6	26.2	12.6	31.4	26.9	14.4	17.3	112.2	20.4	19.4	32.5	10.5	20.2	28.7	62.6	17.5	13.4	25.0
AVPR1A	AVPR1	ENSG00000166148	"Arginine vasopressin receptor 1A"	P37288	12	63142759-63150942	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 34.9;liver: 71.2"	"Group enriched"	"Detected in some"	9	"Hepatocytes: 50.5;Sertoli cells: 77.6;Smooth muscle cells: 34.1"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	12	"ASC diff: 6.9;Karpas-707: 15.4;U-266/84: 10.7"	"Group enriched"	"Detected in some"	5	"basal ganglia: 7.1;hypothalamus: 4.4"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.49e-1)"	"unprognostic (2.82e-1)"	"unprognostic (9.90e-3)"	"unprognostic (2.90e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.43e-3)"	"unprognostic (3.79e-2)"	"unprognostic (2.60e-1)"	"unprognostic (3.58e-6)"	"unprognostic (1.45e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.38e-3)"	"unprognostic (4.65e-3)"	"unprognostic (1.25e-1)"	"unprognostic (4.77e-2)"	"unprognostic (4.66e-4)"	26.4	34.9	0.3	2.8	0.3	0.0	6.3	0.2	0.4	9.7	4.2	0.5	1.1	0.2	16.5	2.1	2.5	3.7	3.4	2.5	0.3	0.3	4.2	71.2	0.7	1.5	0.3	0.0	3.8	1.5	1.1	1.0	1.2	0.6	3.2	0.5	0.5	1.1	2.4	4.4	1.3	0.8	7.5	0.3	0.5	1.5	1.8	0.0	0.6	6.1	3.0	0.4	6.2	2.6	0.0	0.0	0.9	0.0	0.0	0.0	1.2	0.2	0.3	0.7	0.0	6.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	10.7	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	1.2	0.3	0.3	0.2	0.4	0.3	0.3	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.1	1.0	0.1	3.2	2.5	0.0	0.0	5.2	0.0	0.1	0.0	0.0	0.3	0.9	0.0	0.0	0.0	0.2	0.7	0.0	0.0	50.5	0.2	0.0	0.0	0.6	1.3	0.0	2.6	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.3	77.6	34.1	0.2	0.2	0.3	0.1	0.0	0.0	0.3
AVPR1B	AVPR3	ENSG00000198049	"Arginine vasopressin receptor 1B"	P47901	1	206109692-206117699	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	23	"pituitary gland: 52.8"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in some"		"renal cancer: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 1.0;NTERA-2: 1.0;PC-3: 3.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA075404	Enhanced					NA	NA					"HPA075404: AB_2732291"		"unprognostic (4.87e-2)"		"unprognostic (1.44e-1)"	"unprognostic (4.82e-1)"			"unprognostic (2.82e-1)"		"unprognostic (2.87e-1)"	"unprognostic (1.08e-2)"	"unprognostic (3.33e-1)"	"unprognostic (2.96e-2)"	"unprognostic (6.23e-2)"	"unprognostic (7.65e-2)"	"unprognostic (1.86e-1)"	"unprognostic (6.66e-3)"	0.0	0.0	0.2	0.2	0.2	0.0	0.0	0.6	0.5	0.1	1.3	0.0	0.0	1.0	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.6	0.0	0.0	0.1	0.0	0.0	0.0	2.1	0.0	52.8	0.1	0.1	0.2	0.8	0.0	0.0	0.4	0.0	0.0	1.0	0.1	0.0	0.0	2.2	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.5	1.0	0.0	3.6	0.0	0.0	0.2	0.0	0.3	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.6	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
AVPR2	"DIR, DIR3, V2R"	ENSG00000126895	"Arginine vasopressin receptor 2"	P30518	X	153902531-153907166	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Diabetes insipidus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 8.9"	"Cell type enriched"	"Detected in some"	8	"Collecting duct cells: 47.1"	"Low cancer specificity"	"Detected in many"							"Group enriched"	"Detected in some"	26	"intermediate monocyte: 6.2;non-classical monocyte: 5.3"	"Lineage enriched"	"Detected in single"	28	"monocytes: 6.2"	"Cell line enhanced"	"Detected in some"		"EFO-21: 5.7;SCLC-21H: 6.6;U-266/84: 6.0;U-698: 6.3"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	18	"cerebellum: 7.9"							NA	NA						"unprognostic (3.05e-2)"	"unprognostic (5.62e-2)"	"unprognostic (1.99e-4)"	"unprognostic (2.50e-4)"	"unprognostic (2.76e-1)"	"unprognostic (7.10e-6)"	"unprognostic (3.80e-3)"	"unprognostic (1.17e-1)"	"unprognostic (2.20e-1)"	"unprognostic (2.56e-2)"	"unprognostic (4.21e-2)"	"unprognostic (1.91e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.87e-1)"	"unprognostic (4.38e-1)"	"unprognostic (9.83e-2)"	8.9	0.1	0.0	0.1	0.0	0.9	7.1	1.2	0.0	2.1	1.5			0.7	2.7	0.0	0.8	2.6	1.4	6.3	0.0	0.0	4.7	0.0	1.9	1.1	0.0		0.1	0.6	0.2	0.0	0.1		1.1	0.0		1.2	0.8	4.3	2.2	1.3	1.0	0.0	0.0	1.2	0.0			1.9		0.2	1.8	2.1	0.0	0.2	0.0	6.2	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.4	2.8	5.7	0.0	0.9	0.0	0.0	0.0	0.0	1.9	0.2	2.2	0.9	0.0	0.1	2.8	2.2	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	2.7	0.0	0.1	1.4	1.6	0.2	0.0	0.1	2.5	1.1	2.5	0.1	0.0	6.6	1.2	0.1	0.0	0.1	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.2	1.1	6.0	6.3	0.0	1.6	0.1	0.0	0.1	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.2											3.0	2.2	0.0	0.0	0.9	0.0	1.4	0.0	1.4	0.0	47.1	0.0	0.0	0.0	0.0	0.1	5.8	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.1	0.0	0.0	0.0	0.1
BCHE	"CHE1, CHE2, E1"	ENSG00000114200	Butyrylcholinesterase	P06276	3	165772904-165837472	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Serine esterase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"liver: 145.4"	"Cell type enriched"	"Detected in many"	10	"Hepatocytes: 360.7"	"Group enriched"	"Detected in many"	6	"glioma: 24.0;liver cancer: 13.7;melanoma: 18.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"Karpas-707: 131.7"	"Low region specificity"	"Detected in all"							HPA001560	Approved				"Secreted to blood"	NA	NA		13000000000			"HPA001560: AB_1078271"	"unprognostic (4.74e-2)"	"unprognostic (2.00e-1)"	"unprognostic (9.21e-4)"	"unprognostic (8.19e-8)"	"unprognostic (2.66e-2)"	"prognostic unfavorable (1.06e-4)"	"unprognostic (1.44e-1)"	"unprognostic (5.04e-2)"	"unprognostic (6.15e-2)"	"unprognostic (9.59e-2)"	"unprognostic (5.15e-2)"	"unprognostic (3.65e-2)"	"unprognostic (3.18e-3)"	"unprognostic (4.46e-5)"	"unprognostic (2.17e-2)"	"unprognostic (5.92e-2)"	"unprognostic (4.26e-4)"	14.0	3.9	6.7	6.2	4.3	0.4	1.9	3.6	9.1	24.4	15.5	4.7	8.3	1.8	20.2	13.4	20.0	18.0	2.2	7.8	6.1	4.4	2.8	145.4	3.7	0.7	5.5	2.7	10.3	1.1	0.4	1.2	0.5	4.7	4.7	5.3	0.7	1.0	10.5	1.1	2.8	6.4	13.9	3.4	3.7	1.9	1.8	6.1	1.0	0.8	0.4	0.5	9.7	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	14.3	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.2	0.0	0.0	0.0	5.4	0.0	0.0	0.1	0.9	0.0	1.0	0.0	0.1	0.0	0.0	0.0	1.1	0.0	0.0	4.2	0.2	0.0	1.4	4.4	0.6	5.2	0.0	131.7	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	4.8	10.9	0.1	0.0	0.0	0.1	0.0	0.0	7.5	0.0	5.8	0.0	0.0	3.2	0.0	0.0	1.3	0.5	0.0	0.2	1.3	0.0	14.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	4.3	3.6	4.3	6.1	4.4	5.5	2.7	4.7	6.1	0.0	0.0	0.0	0.3	4.8	0.9	4.3	12.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.1	1.5	0.0	0.0	0.0	0.0	2.2	0.2	0.0	360.7	0.1	1.6	0.0	6.2	5.3	5.5	2.0	0.0	18.6	0.0	0.0	34.4	0.0	0.0	0.0	2.9	1.0	0.0	4.6	0.3	0.1	3.0	0.0	0.0	0.0	0.1
BCL2	"Bcl-2, PPP1R50"	ENSG00000171791	"BCL2, apoptosis regulator"	P10415	18	63123346-63320128	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Apoptosis		"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"gdT-cell: 2.3;MAIT T-cell: 7.6;memory B-cell: 5.2;memory CD4 T-cell: 6.3;memory CD8 T-cell: 3.8;naive B-cell: 4.1;naive CD4 T-cell: 5.1;naive CD8 T-cell: 4.5;T-reg: 6.7"	"Group enriched"	"Detected in many"	8	"B-cells: 5.2;T-cells: 7.6"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 22.8;U-266/70: 79.4"	"Low region specificity"	"Detected in all"							"CAB000003, HPA055295"	Enhanced		Supported	"Nucleoplasm,Nuclear membrane"		NA	NA			"Nuclear membrane"	Nucleoplasm	"CAB000003: AB_2064429, HPA055295: AB_2682776"	"unprognostic (1.11e-3)"	"prognostic favorable (5.13e-5)"	"unprognostic (5.49e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.05e-3)"	"unprognostic (2.88e-1)"	"unprognostic (1.93e-3)"	"unprognostic (4.78e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.23e-2)"	"unprognostic (8.51e-2)"	"prognostic favorable (1.29e-8)"	"unprognostic (6.67e-2)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (2.47e-4)"	"unprognostic (2.63e-1)"	12.9	3.0	10.1	15.7	9.4	5.3	24.6	4.7	8.4	14.8	7.8	7.4	9.1	5.0	17.1	9.3	4.7	12.2	9.2	6.5	10.0	8.1	8.5	2.3	5.0	14.6	10.8	5.6	18.2	2.9	19.6	7.0	22.4	9.2	8.4	5.9	10.8	5.4	15.7	20.0	6.3	10.5	8.6	9.3	17.8	5.4	3.5	10.5	21.0	35.6	2.9	13.4	7.9	16.4	5.2	0.3	0.7	0.2	0.7	7.6	1.9	0.5	0.1	2.3	1.8	2.8	0.4	0.8	0.2	0.2	0.8	0.5	1.1	0.1	0.0	0.4	0.2	1.5	0.1	2.1	0.3	0.4	13.6	0.4	0.1	0.6	0.2	0.5	12.4	1.8	0.5	0.2	0.9	1.9	0.3	0.2	1.4	0.2	22.8	0.4	0.4	2.6	5.4	0.5	0.2	0.4	11.7	0.5	8.8	3.9	1.9	1.9	1.8	0.0	0.0	2.8	0.5	0.1	10.5	0.1	3.0	1.0	0.3	1.5	79.4	10.4	0.9	0.5	8.8	1.7	0.7	0.0	0.0	2.3	0.0	7.6	5.2	6.3	3.8	0.1	4.1	5.1	4.5	0.1	0.7	0.2	0.3	6.7	1.9	10.1	9.4	4.7	8.4	10.0	8.1	10.8	5.6	9.2	10.5	0.0	0.6	41.9	30.2	17.3	1.0	15.4	17.8	0.0	3.4	7.0	0.0	8.5	13.3	2.5	0.2	3.5	0.8	0.0	0.0	0.9	10.3	31.5	15.1	1.5	8.3	0.0	5.2	3.7	10.4	2.1	8.1	16.9	43.9	29.7	9.9	18.9	0.3	0.0	13.1	13.5	0.5	25.8	10.8	0.3	0.6	15.4	41.1	28.7	10.6	39.2
BCR	"ALL, BCR1, CML, D22S11, D22S662, PHL"	ENSG00000186716	"BCR, RhoGEF and GTPase activating protein"	P11274	22	23179704-23318037	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"GTPase activation, Guanine-nucleotide releasing factor, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Ito cells: 62.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"K-562: 44.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010421, CAB018545, HPA038337"	Approved		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"	Nucleoplasm	"CAB010421: AB_2274682, CAB018545: AB_2063918, HPA038337: AB_10675795"	"unprognostic (7.46e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.15e-3)"	"unprognostic (1.16e-1)"	"unprognostic (5.35e-2)"	"unprognostic (1.45e-1)"	"unprognostic (5.08e-2)"	"unprognostic (1.44e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.81e-1)"	"unprognostic (9.46e-2)"	"unprognostic (2.39e-2)"	"prognostic favorable (9.15e-10)"	"unprognostic (1.47e-1)"	"unprognostic (7.10e-2)"	"unprognostic (4.10e-2)"	"unprognostic (7.43e-2)"	14.5	8.4	24.0	9.1	41.2	26.7	10.5	14.2	26.5	13.6	9.7	10.3	10.6	8.7	9.2	13.9	19.3	10.8	8.3	7.8	20.9	13.0	16.3	8.3	11.3	10.9	16.0	15.6	8.8	12.9	14.5	14.9	15.7	14.2	7.0	6.8	8.3	15.5	9.7	3.4	12.8	8.7	9.0	9.5	9.1	14.0	9.6	15.4	11.8	16.6	5.5	9.2	9.2	8.8	1.5	0.8	1.2	1.0	2.8	6.6	2.5	19.0	8.2	12.7	13.0	7.6	5.2	19.2	6.9	6.5	6.4	5.2	14.4	7.7	13.3	12.9	5.9	6.2	19.6	1.3	19.2	1.8	25.4	13.2	11.6	11.3	11.4	9.9	10.7	6.1	4.4	13.0	9.5	8.4	11.4	22.3	9.6	44.4	6.3	2.9	12.5	10.0	8.4	10.7	15.1	8.1	13.2	5.1	8.7	9.9	12.1	11.7	11.1	12.6	10.9	5.2	8.5	6.9	8.8	25.1	3.8	0.4	6.2	5.7	1.4	5.8	4.7	9.9	8.1	5.9	0.0	1.0	0.0	6.6	0.4	2.3	1.4	3.3	3.3	0.8	1.5	2.6	3.6	1.2	2.8	1.0	0.8	1.6	2.5	24.0	41.2	14.2	24.9	20.9	13.0	16.0	15.6	14.2	15.4	8.9	11.5	3.0	9.5	13.7	24.0	7.3	20.4	2.7	19.4	17.4	21.6	10.5	8.3	12.4	3.9	22.4	11.1	0.0	14.1	5.9	7.3	10.2	10.4	18.4	6.0	22.3	19.1	62.0	10.8	7.7	8.1	5.4	5.0	6.4	12.0	13.4	21.8	5.8	5.3	14.3	8.0	0.0	8.6	1.6	6.8	13.8	9.0	9.2	11.2	11.5
BDKRB2	BK-2	ENSG00000168398	"Bradykinin receptor B2"	P30411	14	96204679-96244166	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Cholangiocytes: 15.3;Ciliated cells: 13.4"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"cerebellum: 13.5;pons and medulla: 5.7"	"Cell type enhanced"	"Detected in single"		"memory CD8 T-cell: 1.2"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 22.8;BJ hTERT+: 41.8;U-87 MG: 18.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA003551, HPA050841"	Approved		Supported	"Golgi apparatus,Vesicles,Plasma membrane"		NA	NA			"Plasma membrane"	"Golgi apparatus, Vesicles"	"HPA003551: , HPA050841: AB_2681254"	"unprognostic (1.03e-1)"	"unprognostic (7.90e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.83e-1)"	"unprognostic (8.79e-3)"	"unprognostic (2.68e-2)"	"unprognostic (1.93e-1)"	"unprognostic (4.66e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.84e-2)"	"unprognostic (3.19e-1)"	"unprognostic (1.72e-1)"	"unprognostic (3.32e-3)"	"unprognostic (3.11e-2)"	"unprognostic (9.40e-2)"	"unprognostic (9.90e-2)"	"unprognostic (1.49e-2)"	9.0	1.2	1.5	3.7	1.0	0.0	4.7	13.5	1.1	12.2	9.0	1.3	4.4	5.6	8.5	12.7	14.9	5.1	21.1	4.3	0.8	0.7	12.1	0.7	2.2	0.4	0.9	0.3	4.7	6.8	0.9	1.1	2.9	5.7	6.9	9.2	0.9	3.1	11.3	2.7	4.0	10.3	11.3	1.3	0.4	4.2	3.2	0.0	0.6	3.6	13.9	4.4	16.7	13.5	0.0	0.9	0.0	0.0	0.0	1.2	0.0	0.7	2.7	0.0	4.9	7.4	22.8	0.0	2.4	41.8	1.4	1.7	0.1	4.6	0.0	0.1	3.8	1.6	6.5	0.0	1.0	1.2	0.5	0.0	0.0	0.5	0.0	3.6	0.0	0.0	6.9	3.3	4.2	2.1	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	8.8	0.0	0.0	1.0	0.0	1.4	0.0	1.5	0.5	0.8	6.9	0.0	1.0	0.4	0.0	0.0	0.1	0.1	1.4	0.0	0.1	0.0	0.0	18.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.5	1.0	13.5	1.1	0.8	0.7	0.9	0.3	5.7	0.0	3.0	1.9	0.0	0.5	8.1	0.0	0.5	15.3	13.4	9.1	8.7	0.0	0.5	6.6	10.2	0.0	4.2	8.9	0.0	3.5	1.9	6.1	0.8	0.0	0.0	0.2	0.0	6.8	3.1	0.0	0.0	0.9	0.6	5.0	0.0	5.0	0.0	4.5	4.5	1.1	0.0	0.0	0.0	2.0	0.0	0.0	5.1	3.3	0.0	0.7	2.4
BGLAP	OCN	ENSG00000242252	"Bone gamma-carboxyglutamate protein"	P02818	1	156241962-156243321	"FDA approved drug targets, Predicted secreted proteins"	Biomineralization		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 11.0"	"Cell type enhanced"	"Detected in some"	13	"Melanocytes: 3.3;Sertoli cells: 6.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	16	"NK-cell: 2.2;plasmacytoid DC: 4.2"	"Group enriched"	"Detected in many"	16	"dendritic cells: 4.2;NK-cells: 2.2"	"Cell line enhanced"	"Detected in some"		"hTERT-RPE1: 7.5;U-87 MG: 6.4"														"Secreted to blood"	NA	NA	15500000	430000				"unprognostic (2.50e-2)"	"unprognostic (4.49e-2)"	"unprognostic (3.82e-4)"	"unprognostic (1.13e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.44e-5)"	"unprognostic (2.63e-2)"	"unprognostic (6.54e-2)"	"unprognostic (5.64e-2)"	"unprognostic (2.00e-1)"	"unprognostic (1.53e-3)"	"unprognostic (4.70e-2)"	"unprognostic (9.67e-6)"	"unprognostic (3.02e-2)"	"unprognostic (1.72e-1)"	"unprognostic (4.34e-2)"	"unprognostic (8.64e-3)"	1.6	0.7	6.0	6.7	6.9	2.2	1.4	5.2	11.0	1.1	9.3	6.2	0.0	3.2	4.8	1.4	0.8	2.3	1.7	0.7	4.3	2.9	1.2	1.6	1.4	2.3	6.2	6.8	3.4	0.8	1.5	1.3	3.1	9.7	2.1	3.4	0.0	3.6	2.8	2.2	6.8	6.4	3.9	8.4	2.1	2.3	0.3	4.1	0.6	1.6	0.0	1.2	0.7	1.2	0.0	4.2	0.2	0.0	2.2	0.1	0.1	0.3	0.7	1.6	0.5	0.0	0.5	1.2	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.4	0.0	0.7	0.6	0.0	0.4	0.0	1.8	0.9	0.0	2.0	1.1	0.5	0.0	0.4	0.0	0.6	0.6	0.6	7.5	0.6	1.5	0.5	2.2	0.0	1.9	0.0	1.4	0.8	0.1	0.3	0.9	0.1	1.4	0.6	0.0	0.2	1.8	0.6	0.3	0.7	0.3	1.1	0.0	0.0	0.0	0.4	0.4	0.4	2.7	2.5	1.4	6.4	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	2.2	0.0	4.2	0.0	0.1	6.0	6.9	5.2	11.0	4.3	2.9	6.2	6.8	9.7	4.1	0.0	0.0	0.0	0.9	1.3	0.2	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.1	0.1	0.7	0.0	0.0	0.2	0.2	1.1	0.6	0.0	0.0	0.2	0.0	0.0	1.3	0.0	0.0	1.4	0.0	3.3	0.0	0.1	0.3	0.0	0.0	0.4	1.1	0.5	6.5	0.0	0.5	0.9	1.1	0.3	0.0	0.6	0.7
BLVRB	"FLR, SDR43U1"	ENSG00000090013	"Biliverdin reductase B"	P30043	19	40447765-40465840	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 137.6"	"Cell type enhanced"	"Detected in all"	13	"Erythroid cells: 2523.0;Hofbauer cells: 895.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"classical monocyte: 73.4"	"Group enriched"	"Detected in all"	7	"dendritic cells: 54.8;monocytes: 73.4"	"Cell line enhanced"	"Detected in many"		"A549: 81.2;K-562: 73.7;OE19: 64.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041698, HPA041937"	Enhanced		Supported	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"		No	No		440000000	Cytosol	"Nucleoplasm, Vesicles, Plasma membrane"	"HPA041698: AB_10796781, HPA041937: AB_10794308"	"unprognostic (1.86e-1)"	"unprognostic (1.14e-2)"	"unprognostic (4.23e-1)"	"unprognostic (1.50e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.46e-1)"	"unprognostic (9.92e-2)"	"unprognostic (1.20e-2)"	"unprognostic (8.56e-2)"	"unprognostic (1.35e-1)"	"prognostic unfavorable (3.90e-4)"	"unprognostic (2.30e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.02e-1)"	"unprognostic (5.11e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.92e-2)"	36.9	17.9	10.9	12.8	12.2	137.6	28.9	3.5	10.9	17.0	26.7	7.7	18.5	20.9	14.1	19.6	45.3	14.6	19.0	31.0	8.2	8.6	31.8	72.4	37.3	30.0	11.7	9.6	21.3	19.4	5.7	5.6	32.2	13.8	22.9	7.7	17.5	27.1	22.1	43.4	16.7	26.4	22.1	9.7	47.1	31.1	7.6	7.9	6.6	24.3	42.9	24.4	29.9	22.1	8.6	54.8	9.1	73.4	4.0	5.3	34.4	34.2	81.2	1.1	12.1	11.3	10.9	9.6	4.3	12.7	5.9	11.5	15.9	31.1	11.5	33.5	7.7	19.2	11.0	4.1	9.4	1.2	19.5	3.5	17.5	12.2	9.6	26.1	0.2	5.1	10.6	17.9	7.9	4.4	6.0	6.2	4.3	73.7	20.9	6.9	53.2	0.9	1.0	0.3	64.3	22.7	8.1	3.8	18.6	7.4	23.1	0.0	1.8	13.1	34.7	13.2	1.6	33.7	2.6	6.7	15.8	16.9	24.2	2.3	11.4	13.4	4.3	41.1	6.9	6.1	5.0	73.4	2.6	4.6	33.7	4.4	8.6	4.0	4.0	54.8	5.4	4.2	3.3	9.1	4.0	16.9	11.5	5.3	34.4	10.9	12.2	3.5	10.9	8.2	8.6	11.7	9.6	13.8	7.9	205.4	126.9	50.2	283.1	114.9	10.9	116.8	180.9	95.0	73.9	92.5	5.9	76.7	225.5	197.9	7.2	54.2	483.6	2523.0	231.2	82.2	103.0	212.9	41.6	520.7	895.0	9.5	43.0	55.9	549.4	16.6	115.1	152.9	136.7	94.6	130.3	62.8	228.4	480.5	88.4	302.1	11.3	32.3	73.1	2.1	3.6	114.0	62.5	43.7	144.8	253.2
BMPR1A	"ACVRLK3, ALK3, CD292"	ENSG00000107779	"Bone morphogenetic protein receptor type 1A"	P36894	10	86756601-86932838	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB019398	Approved		Approved	Cytosol		NA	NA			Cytosol		"CAB019398: "	"unprognostic (1.36e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.34e-1)"	"unprognostic (9.61e-2)"	"unprognostic (1.05e-3)"	"unprognostic (9.34e-2)"	"prognostic unfavorable (8.93e-4)"	"unprognostic (3.64e-1)"	"unprognostic (2.38e-2)"	"unprognostic (1.53e-1)"	"unprognostic (9.24e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.32e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.07e-1)"	8.9	7.0	9.4	7.9	12.4	0.9	10.7	14.1	9.2	19.4	20.6	10.9	7.7	6.2	16.3	12.3	8.4	10.9	10.8	11.0	7.7	6.1	8.2	4.6	7.4	2.9	7.3	7.6	16.1	10.6	10.0	14.0	7.4	8.5	12.8	9.3	10.9	12.6	14.2	8.4	11.3	9.8	16.5	12.2	3.4	12.1	7.8	9.2	0.3	19.4	7.8	5.7	16.0	11.4	1.8	1.1	3.6	0.8	0.9	1.4	0.3	7.3	3.7	14.3	12.1	7.5	4.8	2.5	7.4	7.7	4.3	5.1	6.2	6.4	2.2	3.4	9.4	3.1	7.8	6.3	8.0	6.4	2.4	3.6	2.8	3.5	10.3	4.0	3.8	19.7	4.2	3.4	5.8	4.3	6.4	0.0	4.1	4.4	1.5	5.0	3.1	2.6	3.1	7.7	2.6	1.7	0.0	5.6	0.0	8.9	6.9	1.4	4.6	8.2	4.2	4.9	18.2	7.1	1.9	3.7	3.1	5.0	6.4	6.8	0.4	6.8	2.8	2.7	2.6	2.5	2.0	0.8	0.6	1.4	0.5	0.9	1.8	1.4	1.2	0.3	1.5	1.0	1.1	3.6	0.9	0.6	1.1	0.7	0.3	9.4	12.4	14.1	9.2	7.7	6.1	7.3	7.6	8.5	9.2	32.8	24.8	0.0	6.7	10.8	6.0	19.0	10.2	13.4	9.1	10.4	19.6	10.0	1.7	9.8	0.6	2.1	9.0	0.0	8.1	0.7	13.3	12.9	15.0	7.2	2.7	11.1	17.3	8.0	4.0	1.7	31.1	3.5	8.5	1.0	13.6	12.9	7.7	3.5	29.4	4.7	19.0	6.5	14.1	2.3	3.6	8.5	4.2	0.0	10.0	4.2
BMPR2	"BMPR-II, BMPR3, BRK-3, PPH1, T-ALK"	ENSG00000204217	"Bone morphogenetic protein receptor type 2"	Q13873	2	202376936-202567751	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"		"Kinase, Receptor, Serine/threonine-protein kinase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA017385, HPA049014"	Approved		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA017385: AB_1845397, HPA049014: AB_2680599"	"unprognostic (2.17e-1)"	"unprognostic (9.00e-2)"	"unprognostic (2.35e-1)"	"unprognostic (2.73e-1)"	"unprognostic (1.67e-1)"	"unprognostic (2.55e-1)"	"unprognostic (4.30e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.18e-2)"	"unprognostic (1.10e-2)"	"unprognostic (2.13e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.29e-2)"	"unprognostic (1.21e-3)"	"unprognostic (9.20e-2)"	"unprognostic (1.18e-1)"	"unprognostic (3.40e-1)"	18.1	15.0	12.1	9.8	14.2	1.1	10.2	9.5	17.1	15.7	11.7	8.2	6.5	5.5	12.9	10.2	10.6	10.3	13.2	14.6	10.8	13.5	10.7	11.5	24.9	4.4	10.4	14.5	12.0	7.0	15.5	6.1	21.7	10.8	11.0	7.7	11.4	7.1	9.1	10.6	7.2	8.1	15.3	7.5	8.9	7.2	12.9	3.8	3.9	11.6	5.2	5.4	11.1	8.9	1.6	2.6	0.9	2.7	1.1	3.6	0.9	5.7	5.4	5.6	8.8	14.0	13.6	10.8	12.0	12.1	10.5	10.5	4.7	8.7	2.0	14.0	24.2	9.0	10.9	7.3	9.3	16.5	6.0	5.0	6.1	5.8	7.3	9.7	1.7	4.8	9.9	8.8	7.7	10.3	16.2	30.2	2.5	3.9	10.0	12.9	10.8	1.4	1.6	3.1	2.8	5.0	3.9	11.0	3.0	8.9	12.3	5.7	5.7	12.8	7.6	14.1	14.3	5.9	4.0	33.3	21.4	11.4	7.3	7.2	1.4	1.7	0.6	5.1	3.9	6.2	0.5	2.0	0.9	3.4	1.8	2.5	1.5	1.3	2.2	2.3	1.6	2.7	1.4	0.6	1.1	2.7	2.6	3.6	0.9	12.1	14.2	9.5	17.1	10.8	13.5	10.4	14.5	10.8	3.8	98.3	38.9	17.1	16.1	29.8	51.7	46.4	12.7	21.4	39.8	19.2	76.6	14.0	1.7	27.3	2.4	119.4	12.7	0.0	24.7	19.4	40.9	19.9	23.1	15.5	16.2	33.4	24.1	109.2	20.0	2.3	31.4	17.4	40.5	15.4	16.3	38.7	36.3	20.9	40.3	10.7	29.9	64.7	45.7	17.7	11.1	31.5	16.7	13.8	13.4	22.7
BRAF	BRAF1	ENSG00000157764	"B-Raf proto-oncogene, serine/threonine kinase"	P15056	7	140719327-140924928	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001328, CAB004552, HPA071048"	Approved		Approved	Vesicles,Cytosol		No	No			Vesicles	Cytosol	"CAB004552: AB_626760, HPA001328: AB_1078296, HPA071048: AB_2686336"	"unprognostic (2.98e-3)"	"unprognostic (5.66e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.66e-3)"	"unprognostic (2.44e-1)"	"unprognostic (1.48e-2)"	"unprognostic (2.07e-2)"	"unprognostic (4.23e-2)"	"unprognostic (4.07e-2)"	"unprognostic (1.58e-2)"	"unprognostic (6.53e-2)"	"unprognostic (1.91e-2)"	"unprognostic (3.79e-3)"	"unprognostic (2.08e-1)"	"unprognostic (1.76e-1)"	"unprognostic (8.01e-2)"	"unprognostic (5.46e-2)"	13.1	12.1	20.1	16.5	20.4	27.8	14.2	29.9	21.5	12.4	12.3	9.5	12.5	9.3	15.3	17.0	11.8	11.5	12.0	13.6	13.2	12.2	13.7	12.8	15.9	13.3	9.9	17.8	16.8	13.2	28.9	24.8	13.7	15.3	14.5	11.0	10.7	11.6	16.6	12.9	15.6	10.5	13.0	10.9	12.3	12.0	24.9	12.2	13.5	16.6	7.5	12.1	18.6	18.1	2.6	1.9	7.5	2.4	7.0	5.6	1.1	5.5	4.7	6.9	8.3	8.4	11.0	11.1	6.2	6.6	5.0	7.2	5.1	6.0	9.5	4.8	6.4	8.0	3.1	6.1	4.9	9.3	8.8	5.0	6.2	4.6	4.7	7.2	10.0	6.2	7.3	5.6	5.3	11.1	7.4	5.8	7.1	9.7	17.1	8.8	2.9	13.3	10.5	6.4	5.4	3.0	8.7	5.9	7.7	4.9	10.7	8.1	6.8	7.2	4.4	6.5	7.1	4.1	6.8	8.6	5.5	4.2	11.7	5.0	19.8	11.2	15.2	8.9	10.1	5.9	3.3	2.0	7.5	3.1	1.7	2.1	2.6	3.0	2.4	1.6	2.6	5.6	2.8	4.1	7.0	2.4	1.9	2.7	1.1	20.1	20.4	29.9	21.5	13.2	12.2	9.9	17.8	15.3	12.2	20.8	34.2	19.5	20.3	19.2	29.1	12.7	5.1	24.1	25.0	24.4	33.4	12.4	6.6	10.9	55.6	17.1	7.5	0.0	8.6	10.3	13.1	23.9	24.3	8.7	7.9	23.8	18.4	8.6	14.8	30.8	15.3	17.2	15.1	10.0	8.1	11.8	12.5	6.6	9.6	9.6	32.5	6.5	17.3	33.7	23.0	21.0	63.2	17.5	8.1	23.8
BTK	"AGMX1, ATK, IMD1, PSCTK1, XLA"	ENSG00000010671	"Bruton tyrosine kinase"	Q06187	X	101349447-101390796	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Apoptosis, Immunity, Innate immunity, Transcription, Transcription regulation"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 77.5;lymphoid tissue: 37.0"	"Cell type enhanced"	"Detected in some"	19	"B-cells: 86.8;granulocytes: 203.6;Hofbauer cells: 50.3;Kupffer cells: 53.4;Macrophages: 53.0;monocytes: 52.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 77.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 29.5;HEL: 40.9;HMC-1: 147.5;U-937: 21.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001198, HPA002028, CAB016689"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA		610000	"Plasma membrane, Cytosol"		"CAB016689: AB_1611894, HPA001198: AB_1078305, HPA002028: AB_1078306"	"unprognostic (3.19e-2)"	"unprognostic (2.51e-3)"	"unprognostic (1.06e-2)"	"unprognostic (3.66e-2)"	"unprognostic (5.69e-2)"	"unprognostic (3.76e-3)"	"unprognostic (6.55e-2)"	"unprognostic (3.58e-3)"	"unprognostic (6.02e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.08e-3)"	"unprognostic (7.80e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.14e-2)"	7.3	2.4	3.3	23.5	5.6	14.0	2.6	0.8	3.6	2.3	3.0	4.7	0.3	2.2	1.9	2.6	2.4	2.0	3.7	3.3	3.3	2.5	2.2	2.5	10.7	25.1	5.4	1.2	1.2	1.5	0.2	1.4	3.2	4.1	2.5	4.5	1.5	3.2	1.0	1.0	2.5	12.9	3.3	10.8	37.0	3.1	1.3	6.3	4.0	1.7	1.8	36.7	5.8	2.0	13.7	13.2	77.5	20.7	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.9	0.0	0.0	0.0	16.4	147.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.6	0.3	0.0	0.0	0.0	11.5	0.2	0.0	0.0	12.3	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	9.8	0.0	0.0	0.0	0.0	0.0	0.3	0.2	14.0	0.0	21.4	0.0	77.5	11.3	19.3	0.0	18.1	0.0	13.7	0.0	0.0	13.2	13.7	0.0	0.0	4.5	0.0	20.7	6.0	0.0	6.1	3.3	5.6	0.8	3.6	3.3	2.5	5.4	1.2	4.1	6.3	3.0	12.8	86.8	0.1	0.9	0.0	0.4	0.0	0.0	1.2	0.0	0.0	1.1	0.0	0.0	0.2	0.6	0.0	23.3	0.0	0.4	0.5	0.0	203.6	0.0	50.3	0.0	0.0	1.3	53.4	0.0	0.3	53.0	3.3	52.3	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.3	0.4	1.6	0.3	1.6	0.8	0.0	0.1
C1R		ENSG00000159403	"Complement C1r"	P00736	12	7080209-7092607	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Innate immunity"	"Hydrolase, Protease, Serine protease"	"Disease mutation, Ehlers-Danlos syndrome, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 370.2"	"Group enriched"	"Detected in many"	5	"Fibroblasts: 462.9;Hepatocytes: 1385.8;Leydig cells: 1057.9;Peritubular cells: 364.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"eosinophil: 2.0;gdT-cell: 1.6;MAIT T-cell: 2.0;memory CD4 T-cell: 1.4;memory CD8 T-cell: 3.4;naive CD4 T-cell: 2.8;naive CD8 T-cell: 2.9;neutrophil: 2.5;NK-cell: 3.2;T-reg: 1.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 2.5;NK-cells: 3.2;T-cells: 3.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 181.7;ASC TERT1: 92.7;BJ hTERT+: 80.0;BJ hTERT+ SV40 Large T+ RasG12V: 49.3;HSkMC: 107.4"					"Low region specificity"	"Detected in all"			"HPA001251, HPA001551"	Uncertain		Uncertain	Nucleoplasm,Cytosol	"Secreted to blood"	NA	NA		14000000000	"Nucleoplasm, Cytosol"		"HPA001251: AB_2666252, HPA001551: AB_10754818"	"unprognostic (1.55e-2)"	"unprognostic (8.97e-2)"	"unprognostic (3.46e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.47e-2)"	"unprognostic (2.66e-2)"	"unprognostic (1.94e-2)"	"unprognostic (2.05e-1)"	"unprognostic (2.50e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.21e-1)"	"unprognostic (4.16e-2)"	"prognostic unfavorable (1.94e-14)"	"unprognostic (3.54e-2)"	"unprognostic (2.25e-2)"	"unprognostic (6.13e-2)"	"unprognostic (2.59e-2)"	45.8	17.4	2.6	18.1	3.8	0.0	82.0	1.4	2.8	36.7	24.5	2.4	11.2	5.0	27.2	66.8	38.1	33.3	46.7	49.5	1.9	1.8	27.5	370.2	25.3	46.8	3.5	2.0	103.5	11.4	1.4	6.3	10.3	4.6	47.8	15.3	17.7	12.8	13.2	16.0	10.7	14.4	53.2	6.2	35.1	19.8	39.3	1.9	2.3	30.6	20.7	15.1	46.8	83.8	0.4	0.0	2.5	0.4	3.2	3.4	0.8	0.1	1.5	0.1	1.3	181.7	92.7	0.1	20.4	80.0	24.2	49.3	0.2	0.3	0.0	0.6	15.9	1.6	0.3	1.7	0.8	3.4	1.9	0.1	0.0	0.6	0.6	34.9	0.1	0.2	107.4	0.5	11.0	0.8	18.4	0.4	0.1	0.0	2.5	3.1	0.0	0.9	0.1	0.8	0.0	0.1	1.1	0.5	0.1	0.1	0.9	0.0	0.3	14.7	0.4	0.4	0.2	0.0	0.0	0.0	5.8	0.9	26.7	0.1	0.1	0.4	0.0	8.3	0.1	0.8	0.0	0.4	2.0	1.6	0.1	2.0	0.0	1.4	3.4	0.0	0.4	2.8	2.9	2.5	3.2	0.0	0.0	1.4	0.8	2.6	3.8	1.4	2.8	1.9	1.8	3.5	2.0	4.6	1.9	20.8	84.7	28.4	53.6	48.5	0.2	14.6	168.2	6.7	34.2	17.4	2.0	2.9	3.3	164.2	3.5	51.3	0.3	23.3	39.1	4.8	462.9	14.1	9.3	1385.8	10.3	0.0	0.0	128.9	25.4	9.4	1057.9	10.1	50.6	2.8	0.6	15.1	74.1	0.6	364.9	5.0	0.9	168.1	97.8	5.7	4.1	35.0	4.3	13.1	0.7	9.8
C1S		ENSG00000182326	"Complement C1s"	P09871	12	6988259-7071032	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Innate immunity"	"Hydrolase, Protease, Serine protease"	"Disease mutation, Ehlers-Danlos syndrome, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 351.6"	"Cell type enhanced"	"Detected in many"	21	"Hepatocytes: 2464.3;Leydig cells: 1104.9;Peritubular cells: 601.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	10	"neutrophil: 6.2"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 6.2"	"Cell line enhanced"	"Detected in many"		"ASC diff: 99.3;ASC TERT1: 132.1;BJ hTERT+: 42.1;HSkMC: 70.1"					"Low region specificity"	"Detected in all"			"CAB016722, HPA018852"	Supported		Approved	Nucleoplasm,Cytosol	"Secreted to blood"	NA	NA	93000000000	13000000000	Nucleoplasm	Cytosol	"CAB016722: , HPA018852: AB_1847112"	"unprognostic (2.72e-3)"	"unprognostic (7.31e-2)"	"unprognostic (9.37e-2)"	"unprognostic (1.39e-2)"	"unprognostic (1.05e-2)"	"unprognostic (9.63e-2)"	"prognostic favorable (7.73e-4)"	"unprognostic (6.38e-2)"	"unprognostic (1.16e-1)"	"unprognostic (6.14e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.85e-2)"	"prognostic unfavorable (7.44e-15)"	"unprognostic (2.02e-2)"	"unprognostic (5.68e-3)"	"unprognostic (1.19e-2)"	"unprognostic (5.39e-2)"	48.7	16.6	3.3	18.7	4.1	0.0	55.7	1.9	3.1	35.3	31.1	2.9	12.7	6.8	32.2	50.0	38.3	46.4	47.2	34.4	2.5	1.1	18.0	351.6	31.4	21.1	6.3	3.2	98.8	15.5	1.9	6.0	8.5	6.5	52.1	18.6	26.1	14.6	12.4	18.2	14.7	19.2	47.6	8.8	32.5	24.6	37.2	2.3	3.2	30.5	22.7	18.8	48.6	73.0	0.2	0.1	6.2	0.3	0.2	0.1	0.0	0.0	2.2	0.1	1.3	99.3	132.1	0.4	17.9	42.1	9.5	17.4	0.0	0.2	0.0	2.4	22.2	2.5	0.1	0.0	0.2	0.8	0.0	0.0	0.0	0.6	4.7	29.9	0.2	0.1	70.1	0.3	7.7	0.5	11.9	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	1.2	0.0	0.0	0.0	0.1	0.1	0.3	0.3	0.0	0.1	10.9	0.2	0.2	2.1	0.0	0.0	0.0	4.4	0.3	16.9	0.0	0.0	0.0	0.1	9.5	0.1	0.2	0.6	0.3	0.2	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.2	0.1	0.1	6.2	0.2	0.1	0.1	0.0	0.0	3.3	4.1	1.9	3.1	2.5	1.1	6.3	3.2	6.5	2.3	14.9	34.2	18.3	17.5	67.8	0.6	21.4	152.8	6.7	20.5	3.5	0.0	2.9	1.7	170.0	5.7	37.8	0.0	46.7	37.9	3.5	388.0	7.4	4.7	2464.3	7.1	4.8	0.0	105.6	49.3	8.8	1104.9	9.4	84.4	1.8	0.0	15.1	43.6	0.0	601.8	4.1	0.9	135.8	123.7	5.0	4.1	47.0	2.2	4.3	0.0	3.0
C3	"ARMD9, C3a, C3b, CPAMD1"	ENSG00000125730	"Complement C3"	P01024	19	6677704-6730562	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Complement alternate pathway, Complement pathway, Fatty acid metabolism, Immunity, Inflammatory response, Innate immunity, Lipid metabolism"		"Age-related macular degeneration, Disease mutation, FDA approved drug targets, Hemolytic uremic syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	10	"liver: 611.7"	"Cell type enriched"	"Detected in many"	5	"Hepatocytes: 4080.2"	"Cancer enhanced"	"Detected in all"		"liver cancer: 1213.6"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 13.3"	"Group enriched"	"Detected in many"	4	"granulocytes: 4.2;monocytes: 13.3"	"Group enriched"	"Detected in many"	7	"BJ hTERT+: 48.5;EFO-21: 102.2;Hep G2: 105.6;HSkMC: 75.4;SiHa: 28.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003563, CAB004209, HPA020432"	Enhanced				"Secreted to blood"	NA	NA	1260000000000	250000000000			"CAB004209: AB_627277, HPA003563: AB_1847117, HPA020432: AB_1847118"	"unprognostic (3.26e-3)"	"unprognostic (3.91e-1)"	"unprognostic (3.92e-1)"	"unprognostic (5.98e-3)"	"unprognostic (3.31e-1)"	"unprognostic (1.04e-1)"	"prognostic favorable (8.11e-4)"	"unprognostic (1.99e-1)"	"unprognostic (9.26e-2)"	"unprognostic (5.80e-2)"	"unprognostic (8.12e-3)"	"unprognostic (5.48e-2)"	"prognostic unfavorable (1.09e-5)"	"unprognostic (2.63e-2)"	"unprognostic (2.49e-2)"	"unprognostic (6.03e-3)"	"unprognostic (3.88e-1)"	59.7	34.1	9.3	20.0	19.6	1.0	47.3	0.7	10.2	28.3	17.8	13.9	3.7	3.2	9.1	19.9	17.9	38.8	37.9	57.6	7.0	4.1	21.6	611.7	22.6	25.2	12.3	2.2	42.4	22.2	3.1	3.0	2.7	12.8	12.7	9.6	3.9	18.7	7.6	6.8	5.8	15.1	19.1	29.6	1.6	12.6	11.2	10.7	0.1	10.3	3.2	14.1	25.2	38.2	1.2	0.8	4.2	13.3	2.0	0.4	0.8	8.4	3.0	0.0	0.0	1.5	5.1	10.3	0.7	48.5	0.9	1.7	0.5	6.7	0.2	102.2	0.0	7.5	6.3	0.0	5.8	0.9	3.1	0.0	0.4	4.5	105.6	2.3	0.8	1.2	75.4	1.7	8.4	3.8	1.3	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	4.4	0.8	0.0	0.0	28.2	0.0	0.0	0.0	2.3	1.1	0.4	0.8	1.0	0.6	0.4	0.2	0.5	0.5	10.4	0.6	0.0	1.7	1.5	0.9	0.4	2.7	0.3	0.7	0.3	0.2	0.8	1.2	0.4	0.4	4.2	2.0	13.3	0.7	0.2	0.8	9.3	19.6	0.7	10.2	7.0	4.1	12.3	2.2	12.8	10.7	71.5	405.7	102.4	11.5	24.5	0.0	13.3	822.9	29.4	84.2	15.7	0.0	1.2	5.0	273.3	34.0	21.5	0.3	70.0	114.7	2.1	60.9	11.5	4.7	4080.2	36.1	0.0	0.0	120.9	123.3	75.5	209.4	25.1	33.7	25.2	0.6	0.5	589.9	0.0	10.3	39.2	3.7	6.5	22.8	3.2	7.9	19.2	2.3	24.5	0.4	12.3
C4A	"C4, C4A2, C4A3, C4A4, C4A6, C4B, C4S, CO4, CPAMD2, RG"	ENSG00000244731	"Complement C4A (Rodgers blood group)"	P0C0L4	6	31982024-32002681	"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Inflammatory response, Innate immunity"	"Blood group antigen"	"Disease mutation, FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 49.5"	"Cell type enhanced"	"Detected in some"	21	"Alveolar cells type 1: 8.9;Alveolar cells type 2: 36.1;Ciliated cells: 8.1;Club cells: 25.0"	"Cancer enhanced"	"Detected in many"		"liver cancer: 27.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 25.4;HSkMC: 36.1;U-266/70: 8.4;U-266/84: 16.0"									"CAB009811, CAB032603, HPA046356, HPA048287, HPA050103"	Supported				"Secreted to blood"	NA	NA	342000000	98000000000			"CAB009811: AB_2066891, CAB032603: AB_2290613, HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016"	"unprognostic (2.13e-1)"	"unprognostic (3.02e-2)"	"unprognostic (3.74e-2)"	"unprognostic (3.10e-1)"	"unprognostic (5.29e-2)"	"unprognostic (3.09e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.00e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.70e-1)"	"unprognostic (3.15e-1)"	"unprognostic (4.47e-2)"	"unprognostic (3.20e-2)"	"unprognostic (5.20e-2)"	"unprognostic (3.97e-2)"	"unprognostic (8.63e-2)"	2.7	17.5	1.3	4.3	1.1	0.0	3.3	0.0	0.1	0.4	3.0			2.9	1.6	5.8	0.7	3.5	0.8	2.7	0.7	0.9	12.8	49.5	6.7	1.4	0.9		8.0	2.6	0.0	2.2	0.0		1.5	1.7		1.3	0.0	0.0	0.1	1.2	0.0	0.7	2.9	4.1	0.3			8.1		1.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.2	0.0	25.4	0.2	0.0	0.0	0.4	0.0	0.0	0.0	36.1	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.1	8.4	16.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											8.9	36.1	0.0	0.0	0.0	0.0	4.7	0.0	8.1	25.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.7	0.0	0.0	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C4B	"C4B1, C4B3, C4F, CH, CO4, CPAMD3"	ENSG00000224389	"Complement C4B (Chido blood group)"	P0C0L5	6	32014762-32035418	"Blood group antigen proteins, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement pathway, Immunity, Inflammatory response, Innate immunity"	"Blood group antigen"	"FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adrenal gland: 30.7;liver: 52.4"	"Group enriched"	"Detected in some"	4	"Alveolar cells type 2: 95.9;Cardiomyocytes: 44.1;Club cells: 42.1"	"Cancer enhanced"	"Detected in many"		"liver cancer: 33.8"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"Karpas-707: 53.7"									"HPA046356, HPA048287, HPA050103"	Approved				"Secreted to blood"	NA	NA		97000000000			"HPA046356: AB_2679635, HPA048287: AB_2680341, HPA050103: AB_2681016"	"unprognostic (1.29e-1)"	"unprognostic (2.99e-2)"	"unprognostic (5.50e-3)"	"unprognostic (1.30e-1)"	"unprognostic (8.09e-2)"	"unprognostic (6.24e-2)"	"unprognostic (6.09e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.81e-2)"	"unprognostic (1.12e-1)"	"unprognostic (6.24e-2)"	"unprognostic (6.86e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.12e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.99e-3)"	"unprognostic (1.11e-2)"	3.7	30.7	0.9	0.0	0.7	0.0	1.3	0.0	0.9	0.7	2.3			0.9	1.4	0.0	0.0	4.7	2.4	2.6	0.4	0.9	7.2	52.4	2.0	0.7	0.7		7.2	2.7	1.0	1.8	0.5		0.5	2.7		2.0	0.4	0.0	0.0	1.0	3.8	0.6	1.4	0.8	0.7			5.7		1.6	2.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	3.3	0.2	0.0	10.5	0.0	0.0	0.0	1.2	0.0	0.0	0.0	53.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											3.0	95.9	0.0	0.0	0.0	0.0	44.1	0.0	14.7	42.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	1.1	3.4	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
C5	"C5a, C5b, CPAMD4"	ENSG00000106804	"Complement C5"	P01031	9	120952335-121050276	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Complement alternate pathway, Complement pathway, Cytolysis, Immunity, Inflammatory response, Innate immunity"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	55	"liver: 259.9"	"Cell type enriched"	"Detected in many"	12	"Hepatocytes: 458.7"	"Cancer enriched"	"Detected in many"	17	"liver cancer: 73.0"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 20.5;Hep G2: 21.6"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			HPA029339	Supported				"Secreted to blood"	NA	NA	113000000000	46000000000			"HPA029339: AB_10601125"	"unprognostic (2.51e-1)"	"unprognostic (5.88e-3)"	"unprognostic (2.50e-3)"	"unprognostic (1.57e-2)"	"unprognostic (5.05e-2)"	"unprognostic (9.52e-3)"	"prognostic favorable (9.43e-4)"	"unprognostic (1.83e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.35e-2)"	"unprognostic (4.41e-2)"	"unprognostic (1.46e-5)"	"unprognostic (5.91e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.67e-2)"	"unprognostic (2.75e-1)"	0.5	0.3	0.4	0.3	0.5	0.3	0.4	0.3	0.3	0.4	1.1	0.3	0.3	0.7	0.5	0.7	0.3	0.6	0.4	0.3	0.4	0.3	1.1	259.9	2.3	0.3	0.4	0.3	0.7	4.7	0.8	0.7	0.3	0.4	0.6	0.2	0.3	0.3	0.4	0.3	0.7	3.2	0.3	0.5	0.3	1.2	0.4	0.3	0.3	0.3	0.3	0.3	0.5	0.4	1.8	2.1	1.8	1.6	0.1	1.2	0.5	1.1	20.5	4.7	8.3	6.1	7.1	0.2	2.5	2.6	0.7	1.5	0.6	2.0	3.0	0.1	1.3	2.8	8.1	0.2	0.2	1.1	0.6	0.0	1.2	1.0	21.6	1.1	0.7	0.5	3.1	0.4	1.5	2.7	1.3	0.7	1.2	0.5	2.8	1.6	4.0	0.3	0.1	1.2	5.0	8.0	1.8	2.1	0.3	1.3	0.6	1.2	4.9	1.1	0.0	2.0	3.4	1.6	2.7	0.9	2.1	0.1	5.5	2.4	1.7	1.2	1.2	1.6	2.8	5.0	0.0	1.6	1.8	0.3	0.4	1.2	1.8	0.6	0.5	2.1	1.0	0.5	0.3	0.1	0.1	0.1	0.1	0.1	0.5	0.4	0.5	0.3	0.3	0.4	0.3	0.4	0.3	0.4	0.3	6.0	25.8	2.2	1.0	0.9	4.5	0.6	38.2	5.3	12.5	1.8	0.0	0.1	1.7	0.1	1.3	0.5	0.0	0.0	0.4	0.0	0.8	0.7	0.0	458.7	1.5	6.4	0.0	8.0	12.9	1.7	2.8	3.1	0.0	1.8	0.4	3.9	1.1	0.0	8.5	7.8	2.5	0.0	1.2	1.8	2.3	1.1	0.0	0.7	0.9	0.1
CA1	Car1	ENSG00000133742	"Carbonic anhydrase 1"	P00915	8	85327608-85379014	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"bone marrow: 156.0;intestine: 203.6"	"Cell type enriched"	"Detected in some"	19	"Erythroid cells: 11890.7"	"Group enriched"	"Detected in some"	10	"colorectal cancer: 3.4;stomach cancer: 0.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	1207	"HEL: 169.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA006558, CAB025790"	Enhanced					NA	NA		7800000000			"CAB025790: , HPA006558: AB_1845989"	"unprognostic (1.44e-1)"	"unprognostic (7.56e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.57e-3)"	"unprognostic (2.08e-2)"	"unprognostic (1.66e-1)"	"unprognostic (2.84e-2)"	"unprognostic (2.03e-2)"		"unprognostic (1.73e-2)"	"unprognostic (6.12e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.04e-1)"	"unprognostic (5.61e-2)"	"unprognostic (3.01e-2)"	"unprognostic (2.38e-1)"	"unprognostic (3.95e-2)"	1.8	0.4	0.5	11.5	0.5	156.0	0.4	0.3	0.4	0.3	95.4	1.5	0.0	0.0	0.3	0.0	0.6	0.7	0.0	17.6	0.5	0.4	0.8	2.9	32.2	0.2	0.9	0.0	0.8	0.5	0.0	1.0	24.0	0.6	1.1	203.6	2.6	0.3	0.1	3.1	0.2	0.4	3.2	0.5	14.3	0.3	0.3	0.0	0.2	7.5	0.0	0.2	4.5	16.0	0.7	0.7	0.0	0.3	0.0	0.1	7.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	169.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	7.5	0.5	0.5	0.3	0.4	0.5	0.4	0.9	0.0	0.6	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	624.8	11890.7	0.0	0.0	0.0	0.1	23.0	0.6	0.0	0.0	44.0	1.3	1.6	0.0	0.0	0.0	0.0	0.0	89.9	0.0	0.0	422.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	79.4	0.0
CA12	HsT18816	ENSG00000074410	"Carbonic anhydrase 12"	O43570	15	63321378-63382161	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"		Lyase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 103.5"	"Cell type enhanced"	"Detected in many"	9	"Basal keratinocytes: 155.1;Enterocytes: 240.0;Paneth cells: 157.9;Suprabasal keratinocytes: 220.4"	"Cancer enhanced"	"Detected in all"		"renal cancer: 109.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"A549: 39.0;ASC TERT1: 41.1;RT4: 41.3;SK-BR-3: 33.1;T-47d: 53.4;U-138 MG: 57.0;U-87 MG: 68.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA008773, CAB025181, CAB062549, CAB068179"	Enhanced					NA	NA		29000			"CAB025181: , CAB062549: AB_2665617, CAB068179: AB_2665616, HPA008773: AB_1078394"	"unprognostic (2.01e-1)"	"unprognostic (8.38e-3)"	"unprognostic (3.47e-1)"	"unprognostic (3.25e-3)"	"unprognostic (2.73e-2)"	"unprognostic (2.47e-2)"	"unprognostic (7.48e-2)"	"unprognostic (3.43e-3)"	"unprognostic (2.29e-1)"	"unprognostic (4.67e-2)"	"prognostic unfavorable (3.80e-6)"	"unprognostic (2.59e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.38e-1)"	"unprognostic (6.56e-2)"	"unprognostic (7.26e-2)"	"unprognostic (1.21e-1)"	3.7	0.3	4.7	15.0	27.4	0.3	14.5	3.7	2.3	15.7	32.0	2.6	5.0	0.4	9.8	12.3	42.8	8.5	2.6	1.6	4.9	1.4	103.5	0.3	1.2	0.3	1.8	0.2	2.1	43.8	0.3	3.9	5.9	16.9	3.8	30.3	8.5	8.2	17.9	0.5	44.1	2.4	18.1	0.1	0.4	2.2	1.3	6.7	0.0	1.7	18.4	25.9	10.6	14.5	0.3	0.2	0.6	0.7	0.3	0.2	0.0	0.0	39.0	0.6	0.1	5.2	41.1	2.1	2.8	2.5	0.4	0.7	0.2	0.1	0.0	9.6	2.3	15.4	0.2	0.0	1.9	1.1	0.0	1.4	0.0	2.6	0.0	0.1	0.0	0.0	15.5	2.1	11.9	3.8	0.0	0.5	0.0	0.0	0.0	0.5	22.4	0.0	0.0	0.6	0.0	6.1	0.0	0.0	0.0	0.0	41.3	0.3	0.0	0.1	33.1	0.0	0.4	53.4	0.0	0.0	57.0	3.0	1.8	0.0	0.0	0.0	0.0	68.4	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.1	0.2	0.6	0.3	0.7	0.2	0.1	0.0	4.7	27.4	3.7	1.3	4.9	1.4	1.8	0.2	16.9	6.7	0.0	5.8	1.5	18.6	155.1	0.0	0.6	0.0	2.7	3.4	38.4	0.0	0.4	46.4	14.9	12.0	0.0	240.0	0.0	48.3	1.7	5.1	14.8	1.1	0.0	0.6	0.0	8.1	0.0	0.0	3.0	0.0	2.2	21.9	0.0	92.2	2.5	15.0	157.9	0.0	59.0	0.2	0.0	3.9	0.0	0.0	220.4	1.5	0.0	95.7	16.3
CA14		ENSG00000118298	"Carbonic anhydrase 14"	Q9ULX7	1	150257159-150265078	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 20.9;retina: 29.4;seminal vesicle: 16.5;skeletal muscle: 24.1"	"Group enriched"	"Detected in some"	16	"Cardiomyocytes: 44.5;Melanocytes: 50.6;Muller glia cells: 123.0"	"Group enriched"	"Detected in many"	7	"glioma: 4.9;melanoma: 23.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"AF22: 28.7;AN3-CA: 17.0;NTERA-2: 22.3;SK-MEL-30: 57.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008482	Approved		Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA008482: AB_1078395"	"unprognostic (3.06e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.10e-2)"	"unprognostic (3.25e-2)"	"prognostic favorable (8.47e-4)"	"unprognostic (7.28e-2)"	"unprognostic (4.48e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.47e-1)"	"unprognostic (5.46e-2)"	"unprognostic (1.73e-1)"	"unprognostic (5.89e-3)"	"unprognostic (1.91e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.22e-1)"	"unprognostic (5.80e-2)"	0.1	0.3	4.6	0.2	5.2	0.9	0.3	1.4	6.8	0.1	1.7	10.8	0.1	0.3	0.1	0.5	1.6	1.3	0.7	4.4	6.4	4.1	0.3	6.3	0.2	0.2	11.3	3.2	1.4	0.3	0.8	0.1	0.3	4.4	3.2	0.7	29.4	0.6	16.5	24.1	3.7	0.6	0.5	20.9	0.3	0.8	0.5	2.7	0.1	0.9	0.1	0.1	0.2	0.1	2.8	2.2	2.1	2.0	0.2	1.6	0.2	0.2	0.0	28.7	17.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.1	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.2	0.0	0.1	22.3	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.8	0.4	0.0	0.1	57.1	4.1	0.2	0.1	0.0	0.0	0.0	0.0	0.1	0.2	1.3	0.1	0.1	0.1	0.0	0.0	0.9	1.3	1.6	2.0	0.6	2.0	1.0	1.2	0.2	2.8	1.2	1.3	2.1	0.2	0.5	2.2	0.0	0.2	4.6	5.2	1.4	4.7	6.4	4.1	11.3	3.2	4.4	2.7	3.0	0.3	0.0	0.2	1.9	1.4	44.5	0.0	0.0	1.2	0.0	0.0	0.4	0.0	0.4	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.1	0.0	3.8	0.1	0.0	0.0	0.0	0.3	0.0	0.9	0.0	50.6	0.0	0.0	123.0	1.2	0.0	3.2	0.0	4.5	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.1	0.4
CA2	"CA-II, CAII, Car2"	ENSG00000104267	"Carbonic anhydrase 2"	P00918	8	85463852-85481493	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Lyase	"Disease mutation, FDA approved drug targets, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 108.1;stomach 1: 171.5"	"Cell type enhanced"	"Detected in many"	14	"Enterocytes: 870.3;Erythroid cells: 2055.8;Muller glia cells: 1176.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 20.3"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HaCaT: 33.8;HEK 293: 142.4;THP-1: 59.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA001550, CAB010102"	Enhanced					NA	Yes		790000000			"CAB010102: AB_626796, HPA001550: AB_1078393"	"unprognostic (6.78e-2)"	"unprognostic (3.06e-2)"	"unprognostic (1.05e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.59e-1)"	"unprognostic (9.24e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.72e-2)"	"unprognostic (1.07e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.57e-1)"	"unprognostic (9.89e-2)"	"prognostic favorable (5.57e-6)"	"unprognostic (2.45e-1)"	"unprognostic (2.03e-1)"	"unprognostic (1.32e-1)"	"unprognostic (6.49e-3)"	1.6	2.2	24.4	21.5	32.6	32.4	6.9	4.3	23.2	1.3	108.1	28.9	42.0	46.9	0.9	2.2	5.6	0.9	33.0	4.3	29.1	14.5	53.5	43.0	10.2	1.3	49.0	14.2	0.5	9.1	3.1	2.0	3.5	65.0	0.8	105.6	7.0	14.0	54.2	9.2	13.3	7.6	6.0	27.5	2.5	171.5	5.1	58.3	0.0	3.8	2.4	1.1	1.0	1.4	1.9	8.0	20.3	8.2	0.0	4.4	17.5	0.5	0.3	1.6	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	2.0	0.1	0.0	1.2	0.0	0.0	33.8	4.9	1.7	0.0	0.0	142.4	4.4	2.5	0.0	0.0	3.1	0.6	0.0	8.6	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.4	11.2	0.0	2.7	0.1	0.0	0.5	1.1	0.0	0.0	0.7	0.0	0.0	1.3	0.0	59.7	0.0	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	20.3	3.1	4.4	0.1	8.2	4.4	0.6	0.0	0.4	8.0	1.9	0.0	0.0	6.8	0.0	7.1	0.8	0.0	17.5	24.4	32.6	4.3	23.2	29.1	14.5	49.0	14.2	65.0	58.3	14.9	56.8	27.3	1.0	80.5	23.5	18.5	400.0	0.0	1.2	153.5	60.9	10.7	295.1	50.5	65.5	14.6	870.3	2055.8	9.9	311.4	6.4	1.1	16.1	101.2	34.8	12.7	29.2	1.8	8.2	179.8	3.1	46.0	70.9	1.0	94.2	1176.2	10.3	374.2	2.1	304.9	61.5	0.0	7.3	1.7	2.3	97.6	14.3	5.7	229.3	0.3
CA3	"CAIII, Car3"	ENSG00000164879	"Carbonic anhydrase 3"	P07451	8	85373436-85449040	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"skeletal muscle: 347.5"	"Cell type enriched"	"Detected in some"	14	"Erythroid cells: 280.4"	"Group enriched"	"Detected in many"	7	"glioma: 23.1;prostate cancer: 9.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.8"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	9	"HEL: 23.8;RH-30: 40.1"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"CAB004967, HPA021775, HPA026700"	Enhanced					NA	NA		31000000			"CAB004967: AB_437014, HPA021775: AB_1845990, HPA026700: AB_1845991"	"prognostic favorable (4.24e-6)"	"unprognostic (1.40e-1)"	"unprognostic (1.50e-2)"	"unprognostic (2.22e-3)"	"unprognostic (4.71e-2)"	"unprognostic (8.43e-3)"	"unprognostic (3.56e-2)"	"unprognostic (4.04e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.68e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.54e-1)"	"unprognostic (3.19e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.96e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.19e-1)"	18.0	0.4	0.2	0.1	0.2	0.5	0.6	0.2	0.1	0.5	0.3	0.0	0.1	0.1	0.6	29.0	9.5	1.0	0.2	1.3	0.2	0.1	0.2	0.2	4.1	0.0	0.1	0.0	0.1	0.1	0.0	0.3	0.0	0.0	6.6	0.0	0.0	5.5	0.2	347.5	0.3	0.4	1.4	0.1	0.1	0.3	0.5	0.0	0.0	0.3	14.1	3.4	0.7	0.5	0.5	1.8	0.0	0.0	0.0	0.8	0.2	0.9	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.1	23.8	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	40.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.9	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.0	1.8	0.0	0.2	0.2	0.2	0.2	0.1	0.2	0.1	0.1	0.0	0.0	0.0	3.0	3.4	0.0	0.9	0.5	0.0	0.8	7.6	0.0	0.0	0.0	5.9	0.6	0.0	0.7	20.2	0.0	0.7	280.4	0.2	0.0	0.6	0.5	0.0	0.0	0.4	0.0	0.0	1.8	0.3	4.7	0.3	0.0	0.0	0.0	0.3	16.0	0.2	1.7	0.0	0.5	1.4	0.0	0.1	0.5	0.9	0.9	1.4	0.0	0.6	0.3
CA4	"CAIV, Car4, RP17"	ENSG00000167434	"Carbonic anhydrase 4"	P22748	17	60149936-60170899	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Lyase	"Disease mutation, FDA approved drug targets, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 81.7"	"Cell type enriched"	"Detected in many"	43	"Paneth cells: 2128.8"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	4	"cerebellum: 50.1"	"Cell type enriched"	"Detected in some"	7	"neutrophil: 37.0"	"Lineage enriched"	"Detected in single"	370	"granulocytes: 37.0"	"Cell line enhanced"	"Detected in some"		"HUVEC TERT2: 1.5;NTERA-2: 3.4;OE19: 3.9;RPTEC TERT1: 1.9;SuSa: 2.6"	"Region enriched"	"Detected in all"	5	"cerebellum: 336.9"	"Low region specificity"	"Detected in many"			"HPA011089, HPA017258"	Enhanced					NA	NA		190000			"HPA011089: AB_1845996, HPA017258: AB_1845997"	"unprognostic (2.07e-2)"	"unprognostic (7.85e-2)"	"unprognostic (1.55e-2)"	"unprognostic (7.78e-3)"	"unprognostic (8.42e-2)"	"unprognostic (1.19e-1)"	"unprognostic (3.19e-2)"	"unprognostic (5.84e-2)"	"unprognostic (7.76e-2)"	"unprognostic (9.74e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.71e-2)"	"unprognostic (2.68e-3)"	"unprognostic (8.59e-2)"	"unprognostic (1.43e-1)"	"unprognostic (2.45e-1)"	"unprognostic (4.57e-2)"	32.2	0.9	3.4	9.8	4.4	5.7	46.4	50.1	11.8	2.3	81.7	2.0	31.5	1.4	2.3	17.4	0.9	1.7	12.2	8.8	4.7	2.6	12.0	0.3	33.3	2.4	3.5	5.2	1.9	9.5	3.3	5.1	3.2	3.0	2.4	54.9	20.3	4.8	24.0	10.0	1.0	3.2	1.1	2.1	4.9	2.5	1.2	0.3	0.2	23.1	5.0	0.2	1.7	7.9	0.0	0.0	37.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.1	0.3	0.0	0.0	0.0	0.5	0.8	0.1	0.0	0.3	0.0	0.0	0.3	1.3	0.0	0.0	0.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	3.4	3.9	0.0	0.0	0.2	1.3	1.9	0.0	0.7	0.3	0.2	0.0	0.0	2.6	0.0	0.6	0.0	0.2	0.7	0.4	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.0	0.0	0.0	0.0	0.0	0.0	3.4	4.4	50.1	11.8	4.7	2.6	3.5	5.2	3.0	0.3	0.0	3.7	0.0	0.2	1.3	0.0	9.2	0.0	1.4	1.2	14.0	0.0	0.0	28.2	3.1	0.2	15.8	49.7	0.0	0.2	0.0	1.5	0.1	11.5	0.0	0.5	0.0	18.6	1.8	0.0	0.0	0.6	0.8	0.0	0.0	27.9	0.0	0.1	2128.8	0.0	18.6	0.0	6.5	17.9	0.0	0.0	1.0	0.0	0.0	32.8	0.3
CA7		ENSG00000168748	"Carbonic anhydrase 7"	P43166	16	66844379-66854153	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	5	"intestine: 37.2"	"Cell type enriched"	"Detected in some"	58	"Paneth cells: 2512.0"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 0.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 1.3;HAP1: 1.8;NTERA-2: 1.6;REH: 3.4;SCLC-21H: 2.7;THP-1: 5.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA047237	Uncertain					NA	NA					"HPA047237: AB_2679994"	"unprognostic (8.77e-4)"	"unprognostic (5.23e-4)"	"unprognostic (1.57e-1)"	"unprognostic (1.96e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.16e-2)"		"unprognostic (7.90e-2)"	"unprognostic (1.59e-1)"	"unprognostic (1.84e-2)"	"unprognostic (9.62e-2)"	"unprognostic (1.69e-2)"	"unprognostic (7.12e-3)"	"unprognostic (8.47e-2)"	"unprognostic (5.20e-1)"	"unprognostic (1.90e-2)"	"unprognostic (6.46e-2)"	0.2	0.2	3.2	0.4	7.5	0.2	0.2	3.9	7.7	0.2	37.2	0.3	0.0	4.8	0.3	0.9	0.3	0.2	0.2	0.2	6.3	0.5	0.2	0.2	0.2	0.2	0.7	2.9	0.2	0.2	0.2	0.0	0.2	1.8	0.2	32.0	0.0	1.1	0.4	0.2	0.2	22.8	1.0	0.1	0.2	0.2	0.5	1.3	0.1	0.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.2	0.0	0.4	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.9	3.4	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	7.5	3.9	7.7	6.3	0.5	0.7	2.9	1.8	1.3	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	43.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	15.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.1	0.0	0.0	2512.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	25.5	0.0
CACNA1A	"APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6"	ENSG00000141837	"Calcium voltage-gated channel subunit alpha1 A"	O00555	19	13206442-13633025	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"brain: 77.9"	"Group enriched"	"Detected in many"	8	"Bipolar cells: 68.3;Horizontal cells: 235.2;Intestinal endocrine cells: 205.4"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in all"	4	"cerebellum: 77.9"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"SCLC-21H: 31.2;U-87 MG: 17.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA064258, HPA068138, HPA071902"	Enhanced	Supported	Uncertain	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA064258: AB_2685229, HPA068138: , HPA071902: "	"unprognostic (1.09e-1)"	"unprognostic (3.73e-3)"	"unprognostic (2.27e-1)"	"unprognostic (2.78e-4)"	"unprognostic (4.00e-2)"	"unprognostic (2.29e-3)"	"unprognostic (5.47e-2)"	"unprognostic (3.13e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.14e-2)"	"prognostic favorable (4.32e-4)"	"unprognostic (5.31e-3)"	"unprognostic (5.03e-6)"	"unprognostic (6.29e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.61e-2)"	"unprognostic (6.25e-2)"	2.2	5.3	7.6	1.0	12.2	0.7	0.9	77.9	19.7	0.8	1.5	1.8	0.0	3.9	1.2	2.8	0.7	2.2	0.8	1.1	5.7	5.1	0.7	0.5	0.7	1.3	3.9	7.3	1.1	3.0	0.7	1.5	0.6	7.2	0.8	1.7	1.2	0.9	0.8	1.3	0.7	2.8	0.9	3.3	1.3	7.7	1.9	2.8	0.0	0.7	0.0	1.0	0.8	0.3	2.8	0.8	1.9	1.1	0.8	0.8	0.4	0.0	0.1	0.0	3.9	0.1	0.3	0.0	1.6	1.6	0.2	0.0	0.0	0.0	0.1	0.0	0.1	3.4	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	2.1	0.0	1.3	0.0	0.0	0.0	0.0	0.0	4.6	0.1	0.0	0.0	0.1	0.9	0.0	0.2	0.4	0.0	0.1	0.0	0.1	31.2	0.0	0.0	0.0	0.2	0.1	0.0	1.2	0.1	0.1	0.7	0.1	0.0	0.0	0.0	0.0	17.6	0.0	0.4	1.9	0.4	0.7	0.5	0.5	0.8	2.8	0.5	0.3	0.4	1.7	0.6	0.7	1.6	0.8	1.1	0.8	0.6	0.4	7.6	12.2	77.9	17.4	5.7	5.1	3.9	7.3	7.2	2.8	6.0	2.7	1.3	1.4	0.6	68.3	2.2	0.0	6.7	2.3	1.8	15.7	0.0	0.0	0.6	22.1	4.2	0.0	0.0	0.3	0.1	2.1	0.8	1.1	0.0	0.5	235.2	205.4	1.8	1.3	17.9	1.1	2.1	0.0	1.0	1.1	2.9	1.9	0.0	0.4	2.0	6.2	0.0	4.2	4.1	5.1	0.1	0.2	4.3	0.8	0.9
CACNA1B	"CACNL1A5, CACNN, Cav2.2"	ENSG00000148408	"Calcium voltage-gated channel subunit alpha1 B"	Q00975	9	137877789-138124624	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 6.2;brain: 18.9;fallopian tube: 6.6;pituitary gland: 4.8;testis: 8.1"	"Cell type enhanced"	"Detected in some"	11	"Bipolar cells: 5.9;Horizontal cells: 6.4;Late spermatids: 3.6;Spermatocytes: 5.1;Spermatogonia: 9.3"	"Cancer enhanced"	"Detected in some"		"testis cancer: 2.2"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"SCLC-21H: 21.2"	"Low region specificity"	"Detected in all"							"HPA022919, HPA044347"	Uncertain		Approved	Mitochondria		NA	NA			Mitochondria		"HPA022919: , HPA044347: AB_10960837"	"unprognostic (1.34e-3)"	"unprognostic (2.70e-2)"	"unprognostic (8.08e-2)"	"unprognostic (2.51e-7)"	"unprognostic (8.10e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.10e-1)"	"unprognostic (2.50e-1)"	"unprognostic (2.36e-2)"	"unprognostic (9.73e-4)"	"unprognostic (5.98e-2)"	"unprognostic (6.63e-6)"	"unprognostic (4.25e-2)"	"unprognostic (4.72e-1)"	"unprognostic (7.77e-3)"	"unprognostic (8.69e-2)"	0.5	6.2	5.7	0.7	8.7	0.5	0.5	18.7	18.9	1.2	0.8	0.2	0.0	0.6	0.6	1.7	0.4	6.6	1.4	1.0	4.5	7.3	0.4	1.2	0.5	0.5	2.9	9.1	0.5	1.2	0.4	4.8	0.4	3.6	1.6	0.8	0.4	0.4	1.3	0.4	0.9	0.7	0.8	4.5	0.6	0.6	8.1	1.4	0.0	0.9	0.0	0.4	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	21.2	4.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	8.7	18.7	10.9	4.5	7.3	2.9	9.1	3.6	1.4	0.0	0.0	0.0	0.0	0.0	5.9	3.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	6.4	0.0	0.0	0.0	3.6	0.0	0.0	0.0	1.0	0.0	2.4	0.0	0.0	0.4	0.0	1.5	0.0	0.0	5.1	9.3	0.0	0.0	0.0	0.0	0.0
CACNA1C	"CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS"	ENSG00000151067	"Calcium voltage-gated channel subunit alpha1 C"	Q13936	12	1970786-2697950	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Host-virus interaction, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel"	"Autism, Autism spectrum disorder, Brugada syndrome, Disease mutation, FDA approved drug targets, Long QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 32.5"	"Cell type enriched"	"Detected in many"	4	"Horizontal cells: 284.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"NK-cell: 4.2"	"Group enriched"	"Detected in many"	19	"NK-cells: 4.2;T-cells: 1.2"	"Cell line enriched"	"Detected in some"	17	"HDLM-2: 47.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039796, CAB079031"	Enhanced	Approved				NA	NA					"CAB079031: , HPA039796: AB_10673019"	"unprognostic (1.76e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.29e-2)"	"unprognostic (9.35e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.60e-2)"	"unprognostic (4.68e-2)"	"unprognostic (7.99e-2)"	"unprognostic (3.07e-2)"	"unprognostic (1.03e-5)"	"unprognostic (1.93e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.02e-7)"	"unprognostic (8.85e-2)"	"unprognostic (3.60e-2)"	"unprognostic (6.90e-2)"	"unprognostic (3.39e-2)"	3.8	2.5	8.6	6.0	7.7	1.4	2.4	7.1	11.7	11.2	26.5	1.3	7.4	2.4	29.7	4.5	5.2	4.3	7.1	32.5	5.5	4.0	2.7	1.4	4.7	2.0	2.4	6.6	2.7	3.2	1.5	8.1	5.1	3.9	7.9	3.8	6.5	2.4	8.1	2.3	1.7	5.2	28.8	1.9	3.5	7.2	11.3	1.7	0.0	2.0	1.1	1.7	12.6	5.4	0.0	0.1	0.0	0.1	4.2	1.2	0.2	0.0	0.0	0.0	0.0	1.6	1.1	0.1	1.7	2.0	1.1	0.8	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.5	47.6	0.4	0.6	0.0	0.0	1.2	0.0	0.0	2.7	0.0	0.6	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	2.7	0.3	2.6	0.0	0.0	0.0	0.0	2.2	0.1	0.6	0.0	0.0	0.0	0.6	0.0	1.2	0.0	0.5	0.7	0.0	0.0	0.9	0.7	0.0	4.2	0.1	0.1	0.4	0.2	8.6	7.7	7.1	11.7	5.5	4.0	2.4	6.6	3.9	1.7	0.0	0.0	0.0	1.2	0.6	15.3	42.8	0.0	0.0	0.0	0.0	2.0	0.1	0.0	0.0	27.5	2.9	0.0	0.0	0.0	0.2	2.5	1.4	0.0	0.0	0.2	284.4	35.2	2.5	0.0	64.7	0.9	0.0	0.0	0.0	0.6	6.1	0.3	0.2	3.9	0.0	1.2	12.9	17.5	2.6	5.8	0.1	0.1	0.0	0.4	2.4
CACNA1D	"CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2"	ENSG00000157388	"Calcium voltage-gated channel subunit alpha1 D"	Q01668	3	53328963-53813733	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Cancer-related genes, Deafness, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 2: 45.9;Cone photoreceptor cells: 33.4;Intestinal endocrine cells: 57.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	9	"basophil: 7.2"	"Lineage enriched"	"Detected in single"	20	"granulocytes: 7.2"	"Cell line enhanced"	"Detected in some"		"HMC-1: 14.4;RPMI-8226: 33.6;SK-BR-3: 6.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA020215	Uncertain		Approved	"Nuclear membrane"		NA	NA			"Nuclear membrane"		"HPA020215: AB_1845860"	"unprognostic (5.85e-2)"	"unprognostic (4.90e-3)"	"unprognostic (5.09e-2)"	"unprognostic (2.24e-2)"	"unprognostic (7.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.32e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.42e-2)"	"unprognostic (3.90e-3)"	"unprognostic (1.53e-1)"	"prognostic favorable (8.34e-8)"	"unprognostic (1.14e-1)"	"unprognostic (3.05e-2)"	"unprognostic (8.09e-3)"	"unprognostic (6.70e-3)"	0.6	13.4	10.0	0.8	12.6	1.4	3.6	12.2	16.5	11.2	2.8	3.7	0.1	3.3	6.8	13.2	1.2	14.9	6.2	1.8	5.3	3.5	4.2	3.0	9.0	0.5	2.5	9.6	1.2	5.3	3.0	13.6	1.4	8.7	5.7	3.1	10.1	1.1	3.5	0.6	1.5	4.2	1.7	2.2	4.4	1.8	3.0	1.6	0.0	5.2	0.0	0.6	2.3	0.6	0.1	0.3	7.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	1.6	1.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	14.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.2	0.5	0.0	0.0	0.1	33.6	0.3	2.2	3.1	1.3	0.2	6.3	0.7	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	7.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	10.0	12.6	12.2	16.5	5.3	3.5	2.5	9.6	8.7	1.6	3.0	45.9	0.0	0.6	0.8	23.0	1.2	12.7	14.7	14.8	1.8	33.4	0.6	0.0	5.5	3.6	0.5	3.3	0.0	2.0	0.1	1.0	2.6	11.6	2.4	0.2	7.9	57.1	0.0	1.0	4.9	4.0	0.3	5.0	0.0	2.7	2.5	2.6	3.5	25.5	1.6	13.0	0.0	2.8	1.1	2.5	0.9	0.2	1.3	4.5	0.6
CACNA1E	"BII, CACH6, CACNL1A6, Cav2.3"	ENSG00000198216	"Calcium voltage-gated channel subunit alpha1 E"	Q15878	1	181317690-181808084	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"brain: 30.8"	"Cell type enhanced"	"Detected in single"	15	"Cardiomyocytes: 1.4"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	8	"neutrophil: 1.8"	"Lineage enriched"	"Detected in single"	8	"granulocytes: 1.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 4.0;NB-4: 2.5;NTERA-2: 2.9;SCLC-21H: 2.3;U-266/70: 7.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042515, CAB079032"		Approved	Approved	"Plasma membrane,Actin filaments,Cytosol"		NA	NA			"Plasma membrane"	"Actin filaments, Cytosol"	"CAB079032: , HPA042515: "	"unprognostic (3.96e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.05e-2)"	"unprognostic (1.54e-5)"	"unprognostic (6.56e-2)"	"unprognostic (3.16e-2)"	"unprognostic (4.30e-3)"	"unprognostic (1.18e-1)"	"unprognostic (2.40e-1)"	"unprognostic (9.48e-3)"	"unprognostic (1.04e-1)"	"unprognostic (2.06e-1)"	"unprognostic (9.85e-7)"	"unprognostic (1.74e-2)"	"unprognostic (2.07e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.75e-2)"	0.6	3.0	17.9	2.1	19.7	3.1	0.5	3.9	22.5	0.6	0.8	1.3	0.0	0.6	0.6	4.4	1.1	2.3	0.6	0.6	30.8	5.8	3.8	0.6	0.6	1.4	2.4	10.6	0.5	0.6	0.5	0.2	0.8	4.2	0.5	0.8	0.5	0.5	0.5	0.6	0.5	1.1	1.0	5.2	0.9	0.8	2.8	2.4	0.0	0.6	0.0	1.0	0.6	0.1	0.2	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	1.5	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.9	0.1	0.0	0.0	0.0	1.1	1.4	0.0	2.3	0.1	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.1	0.1	0.0	0.0	7.1	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	17.9	19.7	3.9	22.5	30.8	5.8	2.4	10.6	4.2	2.4	0.0	0.0	0.0	0.0	0.1	0.8	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0
CACNA1F	"AIED, Cav1.4, CORDX3, CSNB2, CSNB2A, CSNBX2, JM8, JMC8, OA2"	ENSG00000102001	"Calcium voltage-gated channel subunit alpha1 F"	O60840	X	49205063-49233371	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Sensory transduction, Transport, Vision"	"Calcium channel, Ion channel, Voltage-gated channel"	"Cone-rod dystrophy, Congenital stationary night blindness, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	10	"retina: 55.8"	"Group enriched"	"Detected in some"	15	"Bipolar cells: 66.5;Cone photoreceptor cells: 125.7;Rod photoreceptor cells: 91.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 4.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"MCF7: 2.8;U-266/70: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA068379	Enhanced					NA	NA					"HPA068379: AB_2732782"	"unprognostic (1.20e-3)"	"unprognostic (8.62e-2)"	"unprognostic (4.25e-3)"	"unprognostic (1.56e-2)"	"unprognostic (8.46e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.23e-1)"	"unprognostic (9.04e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.59e-1)"	"unprognostic (6.08e-7)"	"unprognostic (8.03e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.65e-2)"	"unprognostic (3.77e-3)"	0.7	0.8	1.8	0.7	1.5	4.0	1.8	5.3	2.0	0.7	1.0	0.7	0.7	1.9	0.7	2.7	0.7	1.0	0.7	0.7	0.8	0.6	0.7	0.7	1.4	2.7	0.7	0.7	0.7	1.4	0.0	0.7	0.7	0.7	0.7	1.5	55.8	1.2	0.9	0.7	2.4	3.7	0.7	0.7	1.8	1.0	0.7	0.7	0.7	1.2	0.7	0.9	0.7	0.7	1.4	4.6	2.0	0.9	0.5	1.0	0.2	0.2	2.5	0.2	0.0	0.6	0.0	2.5	0.4	0.2	0.0	0.0	0.1	0.9	1.4	0.5	0.5	0.0	0.1	0.4	0.0	0.0	0.1	0.0	0.7	0.0	0.5	0.6	0.1	0.8	0.6	0.0	0.4	0.0	0.2	0.8	0.8	1.0	0.3	0.0	2.8	1.3	1.5	1.1	1.9	0.0	0.1	0.0	0.5	0.4	1.5	0.6	0.0	0.0	0.1	0.0	0.9	0.9	1.5	1.0	0.2	0.3	0.3	0.1	4.6	1.6	0.1	0.8	0.4	0.0	0.9	0.7	0.6	0.6	0.5	0.5	0.7	0.8	0.4	0.8	1.4	0.5	1.0	2.0	0.5	0.9	4.6	0.7	0.2	1.8	1.5	5.3	2.0	0.8	0.6	0.7	0.7	0.7	0.7	0.0	0.3	0.0	0.1	0.0	66.5	1.2	0.0	0.0	0.0	1.8	125.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.2	6.4	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.3	5.5	0.0	0.0	0.4	0.0	91.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.1
CACNA1G	"Cav3.1, NBR13"	ENSG00000006283	"Calcium voltage-gated channel subunit alpha1 G"	O43497	17	50561068-50627474	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 22.8;cervix, uterine: 13.6"	"Cell type enriched"	"Detected in some"	26	"Bipolar cells: 147.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A549: 13.4;GAMG: 5.0;HeLa: 4.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004714	Uncertain					NA	NA					"HPA004714: AB_1078368"	"unprognostic (1.90e-2)"	"unprognostic (5.83e-2)"	"unprognostic (2.85e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.00e-1)"	"unprognostic (9.89e-2)"	"unprognostic (1.47e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.02e-4)"	"unprognostic (1.47e-2)"	"unprognostic (2.16e-2)"	"unprognostic (9.76e-2)"	"unprognostic (4.87e-12)"	"unprognostic (3.34e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.56e-3)"	"unprognostic (6.63e-2)"	1.7	1.0	3.5	0.9	5.2	1.3	2.1	22.8	17.1	13.6	1.0	2.7	0.0	0.9	7.4	1.0	1.6	5.7	1.2	3.8	2.4	8.8	0.7	1.1	0.9	1.2	5.3	7.9	7.1	0.6	0.6	0.4	1.4	6.1	2.5	0.8	4.3	1.1	1.6	0.8	3.9	0.8	2.1	5.9	0.9	0.9	1.7	2.3	0.0	1.2	0.0	1.0	1.0	3.9	1.3	1.3	2.7	0.8	0.7	1.4	0.0	0.0	13.4	3.1	3.5	0.9	0.1	0.2	0.1	0.0	0.1	0.2	2.8	0.5	0.0	1.0	0.1	5.0	0.5	1.6	0.0	0.3	1.8	0.6	0.9	4.6	0.7	0.1	0.2	0.3	0.1	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.2	0.1	0.7	0.0	0.0	1.2	1.0	0.8	1.4	1.1	0.0	0.0	0.2	4.1	1.8	2.8	0.1	0.0	2.4	0.2	0.1	0.3	1.4	3.9	0.5	0.1	1.0	0.1	0.0	0.6	0.1	0.5	0.5	0.8	0.6	1.4	0.4	0.7	0.8	0.7	0.8	0.2	1.3	0.9	1.0	2.7	0.7	0.4	1.3	0.5	0.0	3.5	5.2	22.8	17.1	2.4	8.8	5.3	7.9	6.1	2.3	0.0	0.0	0.0	0.1	1.6	147.6	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.3	3.6	0.4	0.0	0.0	0.4	4.8	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	1.8	0.0	0.0	0.0	0.0	5.7	0.0	3.6	0.3	0.2	2.5	0.1	0.0	0.0	0.0
CACNA1H	Cav3.2	ENSG00000196557	"Calcium voltage-gated channel subunit alpha1 H"	O95180	16	1153121-1221772	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 49.5"	"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 16.2;Late spermatids: 13.2;Peritubular cells: 24.4;Sertoli cells: 25.8;Smooth muscle cells: 16.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 10.9;AN3-CA: 15.7;MCF7: 28.9;OE19: 9.6;T-47d: 8.6"	"Low region specificity"	"Detected in many"							HPA039125	Approved		Approved	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"HPA039125: AB_10795578"	"unprognostic (1.66e-3)"	"unprognostic (2.10e-1)"	"unprognostic (4.07e-2)"	"unprognostic (1.21e-3)"	"unprognostic (1.37e-2)"	"unprognostic (2.15e-1)"	"unprognostic (4.39e-2)"	"unprognostic (2.38e-2)"	"unprognostic (1.06e-1)"	"unprognostic (3.30e-2)"	"prognostic favorable (3.12e-5)"	"unprognostic (1.66e-2)"	"prognostic unfavorable (1.78e-5)"	"unprognostic (1.93e-2)"	"unprognostic (4.65e-2)"	"unprognostic (1.70e-2)"	"unprognostic (5.55e-2)"	5.0	6.8	5.1	4.2	12.0	0.3	3.3	0.3	4.3	17.5	28.1	1.6	10.2	5.4	25.7	5.9	16.3	11.7	26.0	2.2	2.5	2.1	4.7	5.5	3.5	0.7	1.0	2.8	31.8	2.1	6.6	14.8	1.9	2.0	21.0	2.2	4.2	1.7	24.9	2.9	4.8	8.5	49.5	1.1	0.5	9.7	11.7	2.1	0.0	5.2	1.4	0.5	34.6	20.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	10.9	1.9	15.7	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	6.4	0.0	0.0	6.5	1.9	0.0	2.8	0.2	0.0	0.0	0.0	0.0	0.0	1.9	2.9	0.0	0.0	28.9	0.0	0.0	5.9	9.6	2.2	0.0	0.0	0.1	2.9	0.0	0.0	0.0	0.0	0.0	0.5	0.7	8.6	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	12.0	0.3	4.3	2.5	2.1	1.0	2.8	2.0	2.1	0.0	0.0	0.0	0.0	1.3	16.2	1.8	2.5	0.0	0.0	0.0	0.0	0.0	0.0	3.1	5.0	1.2	0.0	0.0	0.0	0.0	0.2	3.3	4.6	8.1	0.1	0.0	10.4	0.6	0.0	13.2	7.8	0.0	0.0	0.0	0.3	0.8	0.7	0.0	24.4	0.8	1.0	25.8	16.5	1.8	4.5	3.0	0.0	0.0	0.0	0.5
CACNA1I	Cav3.3	ENSG00000100346	"Calcium voltage-gated channel subunit alpha1 I"	Q9P0X4	22	39570753-39689737	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"adrenal gland: 4.6;brain: 8.1;lymphoid tissue: 4.3;thyroid gland: 4.1"	"Cell type enriched"	"Detected in some"	6	"Bipolar cells: 18.4"	"Cancer enhanced"	"Detected in single"		"thyroid cancer: 2.1"					"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 1.9"	"Lineage enriched"	"Detected in single"	20	"T-cells: 1.9"	"Cell line enhanced"	"Detected in some"		"JURKAT: 1.2;SK-BR-3: 6.1;T-47d: 3.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.97e-2)"	"unprognostic (1.42e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.60e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.19e-1)"	"unprognostic (2.63e-1)"	"unprognostic (7.21e-2)"	"unprognostic (5.20e-3)"	"unprognostic (1.64e-2)"	"unprognostic (8.64e-2)"	"unprognostic (1.62e-2)"	"unprognostic (6.14e-3)"	"unprognostic (1.57e-1)"	"unprognostic (3.78e-2)"	"unprognostic (8.27e-4)"	0.0	4.6	3.4	1.9	5.8	1.3	0.2	8.1	7.5	0.0	0.2			0.2	0.0	0.0	0.1	0.0	0.4	0.0	5.0	3.6	0.0	0.0	0.2	4.3	0.7		0.0	0.0	0.0	0.0	0.0		0.0	0.1		0.0	0.0	0.0	0.1	0.9	0.0	0.4	1.3	0.5	1.1			4.1		1.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.8	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.3	0.0	0.1	0.2	0.0	0.0	6.1	0.0	0.4	3.6	0.0	0.0	0.0	0.8	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.2	0.5	0.0	0.0	1.9	0.7	0.0	0.0	0.0	0.0	0.8	0.1											0.0	0.0	0.0	0.0	0.0	18.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
CACNA1S	"CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5"	ENSG00000081248	"Calcium voltage-gated channel subunit alpha1 S"	Q13698	1	201039512-201112566	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Ion channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"skeletal muscle: 83.1"	"Cell type enhanced"	"Detected in some"	21	"Cardiomyocytes: 1.4;Cone photoreceptor cells: 5.9;Early spermatids: 1.4;Late spermatids: 3.3;Rod photoreceptor cells: 1.2"	"Cancer enhanced"	"Detected in single"		"head and neck cancer: 0.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	20	"BEWO: 5.5;HSkMC: 7.1"	"Low region specificity"	"Detected in single"			"Region enriched"	"Detected in single"	13	"olfactory region: 5.3"	"CAB009507, HPA048892, HPA056815"	Enhanced					NA	NA					"CAB009507: AB_2069576, HPA048892: AB_2680548, HPA056815: AB_2683242"	"unprognostic (2.14e-2)"		"unprognostic (1.38e-1)"	"unprognostic (1.12e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.52e-3)"	"unprognostic (4.53e-2)"	"unprognostic (2.84e-1)"		"unprognostic (2.23e-1)"	"unprognostic (2.53e-2)"	"unprognostic (1.51e-1)"	"unprognostic (4.72e-3)"	"unprognostic (1.12e-1)"	"unprognostic (5.28e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.57e-1)"	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.9	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.4	0.6	0.0	83.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	10.6	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.4	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
CACNA2D1	"CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3"	ENSG00000153956	"Calcium voltage-gated channel auxiliary subunit alpha2delta 1"	P54289	7	81946444-82443798	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 59.0"	"Cell type enhanced"	"Detected in many"	11	"Cardiomyocytes: 89.3;Early spermatids: 53.8;Intestinal endocrine cells: 37.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 49.0;HUVEC TERT2: 20.6;SH-SY5Y: 23.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008213, HPA008621"	Enhanced				"Intracellular and membrane"	NA	NA		310000000			"HPA008213: AB_1233654, HPA008621: AB_1845863"	"unprognostic (5.07e-3)"	"unprognostic (2.21e-1)"	"unprognostic (4.27e-3)"	"unprognostic (2.92e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.70e-1)"	"unprognostic (3.22e-1)"	"unprognostic (3.76e-1)"	"unprognostic (2.05e-1)"	"unprognostic (6.24e-3)"	"unprognostic (2.23e-2)"	"prognostic unfavorable (1.16e-4)"	"unprognostic (4.28e-3)"	"unprognostic (2.13e-1)"	"unprognostic (9.18e-2)"	"unprognostic (1.03e-4)"	9.9	13.4	15.7	4.2	18.1	0.7	4.3	8.8	20.8	5.7	11.3	7.3	1.0	5.0	7.1	2.9	5.4	4.1	6.3	25.8	12.7	14.9	8.0	1.8	3.6	2.2	6.3	15.6	7.8	2.0	1.9	8.3	4.2	8.6	12.8	5.3	1.9	3.3	6.6	59.0	4.7	3.5	13.0	5.6	4.3	5.5	3.7	8.0	0.0	16.9	14.6	3.3	6.8	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	4.0	0.0	7.1	9.0	0.0	8.7	5.6	4.3	4.3	0.0	1.3	0.0	0.0	7.5	5.4	0.0	4.2	0.0	5.7	0.0	5.6	0.2	5.6	0.0	4.6	1.9	0.0	5.3	0.0	15.1	0.0	49.0	20.6	0.0	0.0	0.0	9.7	0.0	0.0	0.0	4.7	0.0	1.8	0.8	0.8	0.0	0.3	0.3	8.0	23.9	1.7	0.0	0.0	4.4	0.0	0.0	14.7	7.7	5.8	7.6	0.0	0.0	0.0	0.0	6.5	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.7	18.1	8.8	20.8	12.7	14.9	6.3	15.6	8.6	8.0	0.0	1.7	0.0	4.0	5.0	30.7	89.3	0.0	1.4	2.3	7.0	17.7	0.0	0.0	0.0	53.8	9.0	0.0	0.0	0.0	0.0	11.0	11.4	24.3	0.0	0.2	23.8	37.2	1.3	0.0	25.0	9.5	0.4	1.7	1.0	0.2	5.8	0.6	0.0	5.6	9.9	6.0	6.5	17.6	1.0	2.3	5.6	0.1	0.0	0.0	1.4
CACNA2D2	KIAA0558	ENSG00000007402	"Calcium voltage-gated channel auxiliary subunit alpha2delta 2"	Q9NY47	3	50362799-50504244	"FDA approved drug targets, Predicted intracellular proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"lung: 86.1"	"Group enriched"	"Detected in many"	6	"Alveolar cells type 1: 71.5;Alveolar cells type 2: 145.9"	"Cancer enhanced"	"Detected in many"		"testis cancer: 20.4"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	8	"SH-SY5Y: 66.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA034771, HPA071829"	Enhanced		Approved	Vesicles		NA	NA		1000000	Vesicles		"HPA034771: AB_10603555, HPA071829: AB_2686454"	"unprognostic (2.06e-1)"	"unprognostic (2.37e-1)"	"unprognostic (1.72e-2)"	"prognostic unfavorable (7.62e-5)"	"unprognostic (6.59e-2)"	"unprognostic (6.37e-2)"	"unprognostic (6.91e-2)"	"unprognostic (6.57e-3)"	"unprognostic (4.39e-2)"	"unprognostic (1.17e-1)"	"prognostic favorable (1.21e-4)"	"unprognostic (2.71e-2)"	"unprognostic (1.57e-4)"	"unprognostic (3.03e-1)"	"unprognostic (4.14e-2)"	"unprognostic (3.55e-1)"	"unprognostic (4.22e-2)"	1.0	0.9	1.6	1.3	11.1	1.1	1.4	14.9	6.5	1.1	1.7	0.9	0.6	1.4	1.7	1.2	0.9	1.1	0.9	7.6	1.7	9.1	1.6	0.5	86.1	1.3	3.9	3.2	2.2	4.0	3.8	6.0	1.9	6.1	3.0	2.0	6.1	1.5	1.4	1.7	2.6	1.7	1.4	1.4	1.5	4.1	5.8	2.5	0.2	2.3	0.1	0.7	0.7	0.7	1.8	0.3	0.7	0.1	2.3	3.6	1.1	0.0	0.0	1.0	2.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	8.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.3	0.0	0.0	2.7	0.0	0.2	0.0	0.0	0.2	0.0	0.0	6.4	66.5	0.2	0.1	0.0	2.0	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	2.2	0.0	2.7	1.8	2.6	2.0	0.0	1.3	3.6	2.2	0.0	2.3	0.1	0.3	3.2	1.1	1.6	11.1	14.9	6.5	1.7	9.1	3.9	3.2	6.1	2.5	71.5	145.9	0.0	0.3	1.3	7.2	3.0	0.0	4.0	4.5	1.8	19.6	0.0	0.0	0.0	0.5	0.3	0.0	0.0	0.0	0.0	1.1	0.7	19.7	0.0	0.1	0.0	1.2	0.6	0.0	2.3	0.3	0.0	0.0	0.0	3.5	4.0	0.6	0.0	1.8	0.4	10.0	12.9	0.8	1.6	11.1	0.5	0.2	1.0	0.4	0.3
CACNB1	CACNLB1	ENSG00000067191	"Calcium voltage-gated channel auxiliary subunit beta 1"	Q02641	17	39173456-39197703	"FDA approved drug targets, Predicted intracellular proteins"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"skeletal muscle: 130.9"	"Cell type enhanced"	"Detected in many"	7	"Melanocytes: 5.0;Muller glia cells: 8.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023343	Approved					NA	NA					"HPA023343: AB_1845866"	"unprognostic (3.44e-2)"	"unprognostic (1.89e-2)"	"unprognostic (1.69e-3)"	"prognostic unfavorable (3.80e-4)"	"unprognostic (3.99e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.37e-2)"	"unprognostic (2.80e-3)"	"unprognostic (4.43e-1)"	"unprognostic (1.04e-3)"	"unprognostic (5.98e-2)"	"unprognostic (3.38e-1)"	"unprognostic (1.94e-11)"	"unprognostic (7.62e-2)"	"unprognostic (2.30e-1)"	"unprognostic (1.34e-2)"	"unprognostic (7.44e-3)"	2.0	2.4	7.8	2.2	14.9	1.6	2.0	5.4	22.0	3.3	2.3	2.0	6.0	1.7	2.3	3.7	4.2	2.3	2.0	2.8	8.6	6.4	1.3	1.1	3.0	2.1	3.3	11.0	2.6	1.4	1.6	2.0	1.8	7.6	3.6	2.2	0.8	3.4	5.7	130.9	5.8	1.7	2.4	1.9	2.0	1.8	2.3	2.1	1.7	2.0	7.3	1.8	1.8	1.6	0.1	3.1	0.1	1.2	1.8	3.2	0.8	6.0	2.7	3.4	7.9	3.9	4.7	0.1	3.7	4.5	3.5	4.3	2.0	6.2	10.5	3.8	5.4	4.9	5.7	3.3	6.0	2.6	5.0	3.8	1.5	6.5	0.8	7.9	0.3	1.0	5.2	2.0	7.2	8.2	4.5	2.4	6.6	0.9	9.2	3.6	1.7	7.5	2.7	2.4	0.9	2.0	5.1	11.4	4.6	1.4	2.0	8.6	5.3	2.1	11.6	3.5	1.3	8.2	4.1	3.4	6.2	7.2	4.6	3.6	4.3	1.4	1.7	5.1	0.0	2.5	0.0	1.2	0.0	2.0	0.6	3.2	0.1	1.9	2.6	0.5	0.1	0.6	1.2	0.1	1.8	0.3	3.1	0.5	0.8	7.8	14.9	5.4	22.0	8.6	6.4	3.3	11.0	7.6	2.1	3.0	2.7	0.0	0.5	2.6	2.4	1.4	0.0	0.0	2.3	0.0	0.0	0.1	0.0	0.5	2.4	1.0	0.0	0.0	0.8	0.1	2.5	1.2	0.0	0.0	0.9	0.0	0.0	0.6	0.6	1.7	1.7	1.0	5.0	0.0	1.0	8.3	1.2	0.0	1.1	0.0	1.1	0.0	2.5	1.0	1.1	2.6	0.1	1.0	0.6	0.7
CACNB2	"CACNLB2, MYSB"	ENSG00000165995	"Calcium voltage-gated channel auxiliary subunit beta 2"	Q08289	10	18140677-18543557	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Brugada syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	15	"Bipolar cells: 30.8;Cone photoreceptor cells: 102.1;Intestinal endocrine cells: 35.6;Rod photoreceptor cells: 76.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HAP1: 10.7;HSkMC: 13.5;SCLC-21H: 5.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA035326	Enhanced					NA	NA					"HPA035326: AB_10669903"	"unprognostic (3.03e-3)"	"unprognostic (3.04e-1)"	"unprognostic (1.49e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.58e-3)"	"unprognostic (4.67e-4)"	"unprognostic (8.03e-2)"	"unprognostic (3.76e-2)"	"unprognostic (8.10e-2)"	"unprognostic (1.70e-1)"	"unprognostic (7.78e-4)"	"unprognostic (1.40e-1)"	"prognostic favorable (3.56e-5)"	"unprognostic (3.48e-2)"	"unprognostic (5.72e-2)"	"unprognostic (1.03e-1)"	"unprognostic (8.16e-2)"	2.7	15.6	10.5	4.2	16.4	2.1	2.8	27.0	25.8	7.0	11.6	1.9	7.4	3.4	9.6	5.8	9.7	7.8	4.6	15.8	8.8	9.7	4.6	4.0	2.7	1.8	4.3	11.8	18.1	8.6	2.7	16.9	1.3	9.2	9.7	8.7	10.0	7.1	18.0	2.1	5.6	9.4	31.1	2.4	1.7	6.5	2.0	3.2	0.1	2.5	0.0	1.0	13.4	12.8	1.9	0.8	4.0	0.7	1.0	3.7	0.2	0.2	1.4	1.0	0.7	0.7	0.5	0.6	0.4	0.0	0.1	0.4	0.6	0.6	1.1	0.3	0.3	0.5	0.9	10.7	0.0	0.0	0.4	3.3	1.0	1.8	2.0	2.8	0.8	1.9	13.5	0.0	0.0	0.0	0.4	0.0	1.8	1.1	2.2	0.0	0.8	1.1	1.3	3.8	0.0	0.1	0.9	1.0	1.0	0.0	1.1	5.4	1.6	0.1	0.1	0.5	1.2	0.2	1.1	0.2	0.8	2.4	0.4	0.7	2.5	2.4	2.2	0.3	1.5	0.5	4.0	0.5	0.6	1.0	0.7	1.4	1.3	1.1	0.5	0.1	1.9	1.8	2.6	0.7	1.0	0.7	0.8	3.7	0.2	10.5	16.4	27.0	18.3	8.8	9.7	4.3	11.8	9.2	3.2	0.0	1.1	0.0	1.1	3.0	30.8	16.2	0.0	0.0	0.0	0.0	102.1	0.2	1.7	0.3	0.7	0.3	3.8	0.0	0.2	0.0	1.3	2.0	0.0	0.9	0.1	7.9	35.6	0.0	0.0	0.6	0.9	0.5	1.7	0.0	6.9	14.8	0.3	3.1	4.2	0.0	76.6	6.5	9.2	0.1	0.0	3.6	0.2	0.0	5.2	0.7
CACNB3	CACNLB3	ENSG00000167535	"Calcium voltage-gated channel auxiliary subunit beta 3"	P54284	12	48813794-48828941	"FDA approved drug targets, Predicted intracellular proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 42.9"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.7"	"Lineage enriched"	"Detected in single"	9	"T-cells: 4.7"	"Cell line enhanced"	"Detected in many"		"U-937: 44.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA059515			Approved	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"HPA059515: AB_2684047"	"unprognostic (1.77e-2)"	"unprognostic (4.84e-2)"	"unprognostic (2.16e-3)"	"unprognostic (2.12e-2)"	"unprognostic (8.76e-2)"	"unprognostic (2.68e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.60e-2)"	"unprognostic (3.27e-2)"	"unprognostic (2.24e-1)"	"unprognostic (5.67e-3)"	"unprognostic (1.04e-1)"	"unprognostic (5.44e-3)"	"unprognostic (6.31e-3)"	"unprognostic (6.58e-2)"	"unprognostic (1.98e-1)"	"unprognostic (2.78e-3)"	3.8	3.7	27.4	2.9	22.4	1.2	4.2	18.5	42.9	11.9	9.1	1.5	3.0	3.8	22.6	8.1	11.6	16.1	6.7	2.6	16.4	12.2	3.9	1.3	6.1	1.7	10.0	14.5	24.1	2.1	2.8	4.2	5.3	4.4	5.7	7.8	3.4	4.5	9.1	2.1	7.8	5.8	20.4	2.4	2.2	4.7	4.7	2.3	4.6	6.1	3.4	3.6	7.5	6.9	0.2	0.5	0.0	0.3	0.0	4.7	0.5	6.6	5.3	8.9	18.2	10.9	7.7	5.4	6.8	14.5	10.2	6.0	1.7	5.5	0.8	9.0	11.5	1.7	7.1	8.1	7.5	3.8	7.8	2.4	3.5	4.3	0.2	4.3	0.6	3.9	4.9	4.5	4.2	2.1	28.4	11.6	7.4	0.4	2.8	6.5	16.6	8.3	0.9	5.5	6.9	4.5	9.5	2.0	2.6	7.4	12.6	12.7	12.5	2.1	15.2	5.0	7.5	10.4	2.9	11.0	6.5	9.2	3.1	3.7	3.3	1.3	0.2	5.4	44.2	2.0	0.0	0.3	0.0	0.9	0.1	0.4	0.2	1.8	1.8	0.5	0.0	0.4	0.2	0.0	0.0	0.0	0.4	4.7	0.5	27.4	22.4	18.5	42.9	16.4	12.2	10.0	14.5	4.4	2.3	3.0	7.0	0.0	3.1	2.6	1.0	2.4	0.0	2.7	2.3	1.8	3.9	0.5	1.7	8.6	0.7	3.1	8.4	0.0	3.7	9.3	6.6	2.8	1.1	0.0	1.5	0.0	9.8	3.1	0.6	1.8	12.4	2.3	1.7	5.4	9.1	0.9	8.5	5.8	10.3	0.6	1.0	0.0	10.8	0.5	5.9	4.4	0.9	4.4	11.7	1.4
CACNB4	EJM4	ENSG00000182389	"Calcium voltage-gated channel auxiliary subunit beta 4"	O00305	2	151832768-152099475	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 35.7"	"Cell type enhanced"	"Detected in many"	10	"Alveolar cells type 2: 38.2;Glandular cells: 25.1;Horizontal cells: 19.1"	"Low cancer specificity"	"Detected in single"			"Group enriched"	"Detected in all"	4	"basal ganglia: 28.0;cerebellum: 35.7;cerebral cortex: 21.7;olfactory region: 10.9;pons and medulla: 9.8"	"Cell type enriched"	"Detected in some"	5	"neutrophil: 7.0"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 7.0"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 21.2"									HPA015601	Approved					NA	NA					"HPA015601: AB_1845873"	"unprognostic (2.92e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.49e-2)"	"unprognostic (3.70e-1)"	"unprognostic (9.42e-4)"	"unprognostic (1.23e-1)"	"unprognostic (1.98e-1)"	"unprognostic (1.05e-3)"	"unprognostic (2.02e-1)"	"unprognostic (1.55e-2)"	"unprognostic (7.26e-3)"	"unprognostic (3.93e-2)"	"unprognostic (9.55e-3)"	"unprognostic (2.45e-1)"	1.6	1.7	5.2	1.3	28.0	1.7	3.2	35.7	28.0	1.4	1.2	2.6	0.0	1.2	1.4	1.7	3.1	1.1	2.1	1.1	4.5	4.4	2.8	0.9	3.9	1.1	4.3	10.9	1.3	1.2	1.0	3.8	2.1	9.8	3.9	1.4	0.9	2.1	3.9	0.8	11.7	1.1	4.2	3.0	1.2	1.6	4.1	3.4	0.0	3.1	0.0	2.2	3.5	0.8	0.4	1.3	7.0	0.6	0.2	0.1	0.1	0.0	0.0	0.7	0.7	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.9	0.0	2.0	0.0	0.1	0.3	3.3	0.0	0.2	4.1	0.0	0.2	21.2	0.2	0.1	0.4	0.0	1.6	0.0	0.8	0.0	0.5	0.2	0.0	0.2	0.3	0.5	0.1	0.6	1.8	0.2	0.6	1.2	0.6	1.4	0.8	0.0	0.0	0.0	0.1	3.4	0.9	0.0	1.9	2.2	0.7	0.4	0.4	0.0	0.0	0.5	4.9	0.1	1.2	0.6	0.0	0.1	0.0	0.1	0.1	0.0	0.0	1.3	0.4	0.1	0.1	7.0	0.2	0.0	1.3	0.0	0.1	5.2	28.0	35.7	21.7	4.5	4.4	4.3	10.9	9.8	3.4	11.9	38.2	0.8	10.5	11.0	3.1	0.9	0.0	1.4	5.7	3.5	3.9	0.1	3.3	0.3	0.8	0.6	0.0	0.0	1.3	0.0	3.9	25.1	0.0	0.0	2.6	19.1	0.0	0.6	0.8	1.7	3.1	2.4	1.7	0.0	0.0	1.9	1.2	0.0	4.2	0.6	3.3	0.0	0.7	0.5	0.0	7.2	0.0	0.7	0.0	12.2
CACNG1	CACNLG	ENSG00000108878	"Calcium voltage-gated channel auxiliary subunit gamma 1"	Q06432	17	67044590-67056797	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"skeletal muscle: 126.7"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in some"		"head and neck cancer: 1.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HSkMC: 8.3;SH-SY5Y: 2.6"	"Region enriched"	"Detected in single"	6	"basal ganglia: 3.0"	"Not detected"	"Not detected"									NA	NA						"unprognostic (1.76e-1)"	"unprognostic (9.83e-3)"		"unprognostic (1.75e-5)"	"unprognostic (2.60e-1)"	"unprognostic (6.72e-3)"	"unprognostic (2.85e-1)"	"unprognostic (1.44e-2)"		"unprognostic (4.84e-3)"	"unprognostic (1.07e-1)"	"unprognostic (4.20e-2)"		"unprognostic (1.60e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.03e-1)"	"unprognostic (1.94e-1)"	5.7	0.4	0.3	0.0	0.6	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	5.3	1.6	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.9	0.0	126.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.7	25.0	1.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	8.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	2.6	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CALY	"CALCYON, DRD1IP, NSG3"	ENSG00000130643	"Calcyon neuron specific vesicular protein"	Q9NYX4	10	133324072-133336935	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Endocytosis		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	9	"adrenal gland: 26.5;brain: 98.9;pituitary gland: 47.7"	"Cell type enhanced"	"Detected in some"	19	"Bipolar cells: 84.4;Horizontal cells: 68.3;Intestinal endocrine cells: 18.7;Rod photoreceptor cells: 31.1"	"Group enriched"	"Detected in some"	14	"glioma: 1.7;pancreatic cancer: 7.7"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 1.3;naive CD4 T-cell: 1.0"	"Lineage enriched"	"Detected in single"	14	"T-cells: 1.3"	"Cell line enhanced"	"Detected in some"		"SH-SY5Y: 2.7;U-266/70: 2.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042283	Enhanced					NA	NA					"HPA042283: AB_10794417"	"unprognostic (1.43e-2)"	"unprognostic (7.84e-2)"	"unprognostic (3.77e-3)"	"unprognostic (1.41e-2)"	"unprognostic (7.32e-2)"	"unprognostic (9.81e-3)"	"unprognostic (2.56e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.18e-1)"	"prognostic favorable (3.54e-4)"	"unprognostic (1.23e-2)"	"unprognostic (4.19e-10)"	"unprognostic (8.04e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.60e-1)"	"unprognostic (1.63e-1)"	1.8	26.5	27.1	2.7	57.4	1.8	1.8	12.7	67.1	1.7	2.6	3.6	0.0	5.0	1.7	1.9	1.8	2.0	1.8	1.7	31.8	98.9	1.7	1.7	1.9	2.0	25.1	39.8	1.7	6.3	1.7	47.7	1.7	33.9	1.8	2.4	0.7	2.1	2.0	1.7	1.9	3.8	2.1	14.3	1.9	4.1	4.3	4.8	0.0	1.9	0.0	1.9	1.7	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.6	0.1	0.8	0.3	0.0	0.0	0.0	0.3	0.6	0.6	0.0	0.0	0.0	0.0	0.5	0.5	0.0	0.0	0.2	0.3	0.0	0.0	0.3	0.0	0.1	0.0	0.8	1.1	0.0	1.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.1	1.0	0.0	1.1	0.0	0.0	0.3	0.3	0.0	0.0	0.4	0.1	0.0	0.0	0.0	2.7	0.0	0.0	0.9	0.1	0.1	0.0	0.0	0.0	0.3	0.0	0.1	2.7	0.0	0.0	0.3	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.3	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	27.1	57.4	12.7	45.9	31.8	98.9	25.1	39.8	33.9	4.8	0.0	0.0	0.0	0.0	0.2	84.4	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.1	68.3	18.7	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	8.1	0.9	0.0	0.4	0.2	31.1	0.0	0.8	1.4	2.6	0.0	0.2	0.0	0.0	0.0
CAMLG	"CAML, GET2"	ENSG00000164615	"Calcium modulating ligand"	P49069	5	134738501-134752160	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"Early spermatids: 658.5;Late spermatids: 1206.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA052636, HPA056472"	Approved		Approved	Nucleoplasm,Nucleoli,Vesicles		NA	NA			Vesicles	"Nucleoplasm, Nucleoli"	"HPA052636: AB_2681893, HPA056472: AB_2683143"	"unprognostic (9.23e-2)"	"unprognostic (8.54e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.21e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.07e-2)"	"unprognostic (3.68e-2)"	"unprognostic (5.41e-3)"	"unprognostic (3.07e-1)"	"unprognostic (8.54e-2)"	"unprognostic (5.34e-3)"	"unprognostic (4.58e-2)"	"prognostic unfavorable (1.09e-5)"	"unprognostic (3.26e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.19e-1)"	"unprognostic (3.16e-1)"	24.2	29.0	37.6	14.3	32.4	22.7	29.3	28.2	39.3	33.3	32.7	15.5	20.2	26.1	31.7	45.2	21.4	23.0	21.8	22.3	32.4	38.3	20.1	19.7	18.9	18.4	36.2	22.7	53.0	25.7	14.8	21.9	14.0	22.4	27.5	14.3	21.7	15.9	26.2	32.5	19.7	22.2	30.4	26.0	15.1	17.7	36.6	14.0	21.1	21.6	18.5	19.3	40.3	20.0	25.0	16.1	32.1	23.3	16.6	28.6	17.4	9.6	7.5	12.8	23.8	28.5	44.2	5.8	13.7	19.9	10.2	19.4	13.7	14.7	39.3	20.1	9.5	15.9	12.5	10.5	16.7	14.6	18.3	19.5	10.4	13.6	11.1	21.0	5.5	33.0	35.8	18.2	12.6	21.7	33.9	19.3	17.4	6.6	18.3	15.2	10.7	14.5	23.3	6.6	12.0	7.6	16.4	17.0	15.1	17.5	9.4	19.0	13.3	9.8	6.3	32.7	17.2	17.3	11.5	18.4	10.0	6.2	15.2	12.4	17.2	18.6	15.0	16.8	17.4	5.4	32.1	15.2	32.1	18.3	17.3	24.6	25.0	26.4	22.9	16.1	22.4	27.8	26.8	27.6	16.6	23.3	14.7	28.6	17.4	37.6	32.4	28.2	39.3	32.4	38.3	36.2	22.7	22.4	14.0	35.7	31.3	84.3	104.0	148.5	76.2	38.6	76.5	32.1	48.9	40.1	23.6	43.8	77.9	53.1	658.5	74.5	44.2	0.0	78.9	53.3	107.2	105.7	119.1	66.0	62.6	52.4	60.0	81.6	102.8	1206.3	155.6	92.2	91.1	124.4	64.9	79.0	61.6	59.6	124.5	149.1	63.7	97.0	161.7	114.4	74.5	176.2	61.2	108.0	83.2	90.1
CARTPT	CART	ENSG00000164326	"CART prepropeptide"	Q16568	5	71719163-71721048	"FDA approved drug targets, Predicted secreted proteins"		"Neuropeptide, Neurotransmitter"	"FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	10	"adrenal gland: 67.5;brain: 101.4"	"Cell type enhanced"	"Detected in some"	12	"Bipolar cells: 5.8;Cone photoreceptor cells: 7.9;Early spermatids: 12.3;Glandular cells: 4.8;Intestinal endocrine cells: 6.8;Rod photoreceptor cells: 7.6"	"Cancer enriched"	"Detected in many"	9	"breast cancer: 117.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"NB-4: 1.1;SH-SY5Y: 3.5"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"hippocampal formation: 179.9"	"CAB025515, HPA046278, CAB079776"	Enhanced	Supported			"Secreted to blood"	NA	NA					"CAB025515: , CAB079776: , HPA046278: AB_10961570"			"unprognostic (1.37e-1)"		"unprognostic (1.43e-1)"					"unprognostic (2.27e-1)"	"unprognostic (3.45e-2)"	"unprognostic (6.67e-2)"		"prognostic unfavorable (4.36e-4)"		"unprognostic (1.14e-1)"		1.6	67.5	8.0	2.8	22.3	0.5	5.8	0.1	29.0	0.5	3.4	2.1	0.0	3.5	0.6	0.9	3.5	0.7	0.6	0.5	31.1	101.4	0.5	0.5	0.5	0.5	1.0	4.5	0.5	5.3	0.5	1.7	0.5	54.1	3.3	3.1	1.6	0.5	0.5	0.5	0.5	1.4	8.1	8.6	0.5	3.4	1.9	9.7	0.0	3.4	0.0	0.5	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.0	22.3	0.1	29.0	31.1	101.4	1.0	4.5	54.1	9.7	0.0	0.0	0.0	0.3	0.0	5.8	0.0	0.0	0.0	0.0	0.0	7.9	0.0	0.0	0.0	12.3	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	6.8	0.0	0.0	2.7	0.6	0.0	0.0	0.0	0.0	2.3	0.0	0.0	1.1	0.0	7.6	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.1
CASR	"FHH, GPRC2A, HHC, HHC1, NSHPT"	ENSG00000036828	"Calcium sensing receptor"	P41180	3	122183683-122291629	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	7	"parathyroid gland: 155.3"	"Group enriched"	"Detected in some"	5	"Alveolar cells type 1: 23.8;Alveolar cells type 2: 13.2;Cholangiocytes: 33.1;Ciliated cells: 28.1;Club cells: 10.3;Distal tubular cells: 11.6;Intestinal endocrine cells: 11.1"	"Cancer enriched"	"Detected in some"	7	"pancreatic cancer: 5.5"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"RPTEC TERT1: 4.0"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA039686, HPA050335"	Enhanced					NA	NA					"HPA039686: AB_10673536, HPA050335: AB_2681092"		"unprognostic (1.97e-2)"	"unprognostic (7.40e-2)"	"unprognostic (8.20e-4)"	"unprognostic (3.15e-1)"	"unprognostic (8.55e-4)"	"unprognostic (1.58e-1)"	"unprognostic (7.32e-2)"		"unprognostic (7.67e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.91e-5)"	"unprognostic (2.72e-1)"	"unprognostic (2.26e-1)"		"unprognostic (1.24e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.8	0.4	0.0	0.1	0.0	0.0	0.0	0.0	21.0	0.0	0.1	0.2	18.1	0.5	0.0	0.0	0.1	0.0	0.6	12.1	155.3	0.6	0.0	0.2	0.0	0.0	0.6	0.5	0.0	0.0	0.0	0.6	0.3	0.2	0.2	0.5	0.3	0.0	0.1	1.6	0.0	0.1	0.7	0.0	1.4	0.5	1.1	0.3	0.8	1.1	0.2	0.6	1.3	0.7	1.1	0.3	0.3	0.7	0.7	0.0	0.0	0.1	0.6	0.9	1.1	0.9	0.4	0.8	0.5	0.2	0.2	0.3	0.8	0.1	1.4	1.1	1.1	0.0	0.7	0.8	0.4	0.4	0.5	0.2	0.5	0.2	1.1	0.6	2.0	0.3	0.7	0.5	0.9	1.4	0.8	0.7	0.6	0.5	0.6	4.0	1.5	0.6	0.8	0.9	0.5	0.3	1.7	1.0	0.3	1.3	1.0	1.9	1.0	0.3	1.7	1.1	0.5	0.7	0.6	1.0	1.0	0.3	0.1	0.9	0.2	0.9	0.7	0.9	0.9	0.1	1.4	0.7	0.6	1.1	0.8	0.2	0.5	1.1	0.2	0.0	0.0	0.0	0.6	0.1	0.2	0.1	0.0	0.2	0.0	23.8	13.2	0.0	0.0	0.0	0.0	0.8	33.1	28.1	10.3	3.5	0.0	0.0	11.6	3.7	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.1	0.0	0.1	0.0	11.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.9	0.0	0.4	0.2	1.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0
CAT		ENSG00000121691	Catalase	P04040	11	34438925-34472062	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Hydrogen peroxide"	"Mitogen, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 258.3;liver: 184.8"	"Cell type enhanced"	"Detected in many"	5	"Erythroid cells: 350.4;Hepatocytes: 400.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in all"	13	"eosinophil: 258.3"	"Lineage enriched"	"Detected in all"	13	"granulocytes: 258.3"	"Cell line enhanced"	"Detected in many"		"HL-60: 76.4;THP-1: 63.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001515, HPA051282, HPA055838"	Enhanced		Enhanced	Vesicles		NA	NA		960000000	Vesicles		"CAB001515: AB_384710, HPA051282: AB_2681419, HPA055838: AB_2682937"	"unprognostic (3.62e-2)"	"unprognostic (2.72e-1)"	"unprognostic (3.59e-3)"	"unprognostic (5.43e-2)"	"unprognostic (4.44e-2)"	"unprognostic (5.80e-3)"	"prognostic favorable (9.67e-4)"	"unprognostic (9.95e-3)"	"unprognostic (3.22e-1)"	"unprognostic (7.23e-2)"	"unprognostic (3.34e-2)"	"unprognostic (9.77e-2)"	"prognostic favorable (1.96e-8)"	"unprognostic (1.01e-1)"	"unprognostic (7.31e-2)"	"unprognostic (4.77e-2)"	"unprognostic (6.59e-3)"	70.0	33.0	9.4	10.1	9.6	54.2	36.1	3.1	7.7	15.3	26.6	18.6	15.7	22.2	13.5	9.5	14.8	14.2	19.0	22.4	10.7	5.2	50.4	184.8	26.1	21.3	14.5	6.0	11.0	24.7	7.1	5.0	16.4	10.2	23.2	11.3	11.4	14.5	13.2	27.8	19.7	29.2	11.6	11.3	17.9	15.9	6.2	11.6	23.4	41.7	14.9	11.5	20.4	24.9	7.6	19.9	258.3	17.5	5.5	5.0	17.8	6.2	6.9	5.1	8.0	49.2	21.4	10.8	8.0	10.1	8.9	9.8	3.9	6.3	15.4	7.7	15.7	13.2	14.9	8.5	8.6	9.9	13.5	7.8	13.0	7.4	22.2	5.8	76.4	6.5	11.5	6.0	2.7	1.1	12.6	10.8	9.4	26.9	6.4	11.2	5.9	15.6	13.6	0.0	29.4	16.8	11.1	24.2	12.6	24.5	23.7	2.6	4.1	8.9	14.4	11.8	0.0	20.7	63.8	7.6	5.4	5.2	13.4	4.7	5.2	2.9	3.3	10.6	52.6	3.9	12.5	17.5	258.3	3.2	14.7	3.8	7.6	3.8	3.6	19.9	6.8	3.8	4.0	17.1	5.5	15.5	13.4	5.0	17.8	9.4	9.6	3.1	7.7	10.7	5.2	14.5	6.0	10.2	11.6	211.4	229.6	40.9	69.6	25.6	11.8	38.0	73.9	89.7	77.3	69.8	25.5	60.5	190.6	26.7	2.1	31.6	91.9	350.4	23.0	26.6	50.3	53.0	22.1	400.0	121.0	0.0	46.1	49.7	114.9	3.8	72.5	85.2	25.3	295.8	48.0	21.2	16.4	52.6	72.9	233.4	17.7	77.6	65.1	4.1	9.6	23.7	33.9	35.5	72.9	69.8
CCKAR		ENSG00000163394	"Cholecystokinin A receptor"	P32238	4	26481400-26490462	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"gallbladder: 47.5;stomach 1: 14.0"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 4.3;RH-30: 1.3;U-2 OS: 1.3"	"Region enhanced"	"Detected in some"		"hypothalamus: 8.3"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (7.48e-2)"				"unprognostic (3.70e-2)"	"unprognostic (7.13e-2)"					"unprognostic (3.08e-2)"	"unprognostic (3.36e-1)"		"unprognostic (3.79e-1)"				0.0	0.0	0.4	0.0	0.5	0.0	0.2	0.0	0.1	0.1	0.6	0.0	0.0	1.3	0.3	0.0	1.3	0.0	47.5	0.1	0.1	1.3	0.1	0.0	0.0	0.0	1.0	0.0	0.0	0.8	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.6	0.0	14.0	0.2	0.1	0.2	0.0	1.0	7.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.5	0.0	0.1	0.1	1.3	1.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CCKBR		ENSG00000110148	"Cholecystokinin B receptor"	P32239	11	6259736-6272127	"Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	24	"brain: 12.9;pancreas: 34.7;stomach 1: 21.4"	"Cell type enhanced"	"Detected in some"	13	"Ciliated cells: 1.4;Exocrine glandular cells: 1.2;Spermatogonia: 1.1"	"Cancer enriched"	"Detected in some"	8	"testis cancer: 9.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"NTERA-2: 39.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.82e-1)"			"unprognostic (4.62e-2)"	"unprognostic (1.79e-3)"	"unprognostic (2.19e-1)"		"unprognostic (1.95e-1)"	"unprognostic (6.34e-4)"	"unprognostic (8.01e-2)"	"unprognostic (3.01e-2)"	"unprognostic (9.00e-2)"	"unprognostic (3.30e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.92e-1)"	"unprognostic (1.30e-2)"		0.3	0.4	6.5	0.3	5.6	0.3	0.3	10.8	12.9	0.3	0.3	0.0	0.0	0.6	0.4	0.3	0.3	0.6	0.4	0.3	3.3	0.8	0.3	0.3	0.3	0.3	1.0	6.9	0.3	34.7	0.3	0.4	0.4	2.1	0.9	0.3	0.3	0.3	0.4	0.4	0.8	0.3	0.3	0.3	0.3	21.4	0.6	0.0	0.0	0.6	0.0	0.3	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	39.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	6.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.5	5.6	10.8	12.9	3.3	0.8	1.0	6.9	2.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.1	0.0	0.2	0.0	0.0	0.0
CCL2	"GDCF-2, HC11, MCAF, MCP-1, MCP1, MGC9434, SCYA2, SMC-CF"	ENSG00000108691	"C-C motif chemokine ligand 2"	P13500	17	34255218-34257203	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Chemotaxis, Inflammatory response"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	14	"Ductal cells: 3138.5;Pancreatic endocrine cells: 1040.3;Smooth muscle cells: 1844.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"classical monocyte: 10.3;eosinophil: 3.9"	"Group enriched"	"Detected in many"	6	"granulocytes: 3.9;monocytes: 10.3"	"Group enriched"	"Detected in many"	4	"BJ hTERT+: 163.0;HMC-1: 212.4"					"Low region specificity"	"Detected in many"			"CAB013676, HPA019163"	Approved		Approved	"Golgi apparatus,Vesicles"	"Secreted to blood"	NA	NA	323000		"Golgi apparatus"	Vesicles	"CAB013676: , HPA019163: AB_1846179"	"unprognostic (6.43e-2)"	"unprognostic (4.14e-2)"	"unprognostic (4.78e-2)"	"unprognostic (5.57e-2)"	"unprognostic (2.37e-3)"	"unprognostic (8.64e-2)"	"unprognostic (2.78e-2)"	"unprognostic (7.53e-2)"	"unprognostic (2.90e-1)"	"unprognostic (1.19e-1)"	"unprognostic (9.33e-2)"	"unprognostic (2.65e-1)"	"prognostic unfavorable (4.51e-4)"	"unprognostic (1.33e-1)"	"unprognostic (2.50e-2)"	"unprognostic (1.81e-1)"	"unprognostic (4.92e-2)"	78.1	31.2	10.3	52.3	50.6	19.1	19.0	1.5	23.3	9.7	41.9	28.6	3.0	9.4	7.2	7.6	14.4	25.8	62.0	76.9	45.1	6.7	32.5	38.4	105.2	16.9	16.0	2.0	28.6	32.8	15.2	17.3	22.8	63.6	42.0	25.3	22.3	13.5	13.4	17.8	10.5	16.7	34.6	85.4	16.1	30.2	4.6	8.6	4.8	20.8	21.6	19.1	27.2	9.0	0.0	1.1	3.9	10.3	0.0	0.1	2.3	0.0	1.3	3.5	0.0	9.8	8.4	0.0	9.9	163.0	21.2	45.5	0.6	0.0	0.0	7.9	2.3	0.3	5.5	0.3	0.0	10.8	0.0	0.0	0.0	1.2	0.0	0.3	0.0	212.4	9.4	0.0	4.4	0.2	14.2	9.6	0.0	0.5	1.7	0.0	0.0	0.0	1.6	0.5	0.0	0.0	0.0	0.2	1.7	30.3	0.0	0.0	0.7	0.0	0.5	0.2	9.9	0.4	0.2	0.5	11.3	0.5	0.3	0.0	0.1	0.0	0.0	6.6	3.1	7.2	0.0	10.3	3.9	0.0	0.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.1	0.7	0.0	0.0	0.3	0.0	2.3	10.3	50.6	1.5	23.3	45.1	6.7	16.0	2.0	63.6	8.6	169.7	145.0	2.7	681.4	505.1	0.0	10.8	91.7	41.5	131.9	130.9	0.0	2.4	0.0	3138.5	0.0	322.6	0.0	0.0	773.5	3.2	475.0	113.8	329.6	0.0	387.1	0.0	0.0	58.3	3.5	0.0	11.2	253.5	202.4	63.1	0.0	6.0	1040.3	0.0	1.4	11.5	0.2	129.4	1844.0	0.0	0.1	194.7	3.8	4.3	0.0	39.4
CCND1	"BCL1, D11S287E, PRAD1, U21B31"	ENSG00000110092	"Cyclin D1"	P24385	11	69641087-69654474	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Cell cycle, Cell division, DNA damage, Transcription, Transcription regulation"	"Cyclin, Repressor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Ductal cells: 534.1;Pancreatic endocrine cells: 367.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 3.0;myeloid DC: 3.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"U-266/70: 96.3;WM-115: 134.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000024, HPA027802"	Uncertain		Supported	Nucleoplasm		Yes	No			Nucleoplasm		"CAB000024: AB_563678, HPA027802: AB_2672390"	"unprognostic (4.90e-2)"	"unprognostic (1.54e-1)"	"unprognostic (7.62e-2)"	"unprognostic (1.39e-2)"	"unprognostic (2.18e-1)"	"prognostic unfavorable (5.51e-4)"	"unprognostic (1.38e-1)"	"unprognostic (2.53e-2)"	"unprognostic (9.46e-2)"	"unprognostic (4.84e-3)"	"prognostic unfavorable (1.96e-4)"	"unprognostic (4.39e-2)"	"unprognostic (2.61e-3)"	"unprognostic (4.38e-3)"	"unprognostic (1.16e-1)"	"unprognostic (6.40e-3)"	"unprognostic (2.57e-1)"	52.0	11.6	9.7	6.0	9.7	0.7	22.8	3.4	7.7	15.4	8.9	15.4	19.9	8.4	18.8	23.1	37.7	11.8	31.0	23.9	10.8	8.8	14.5	68.1	22.2	3.7	12.4	5.6	6.5	31.5	83.2	16.6	38.1	10.0	30.7	6.8	24.8	25.6	21.7	2.0	43.6	10.4	16.5	12.6	12.9	19.2	4.0	7.5	9.0	17.1	23.1	23.6	21.4	22.1	3.0	3.4	0.8	0.0	0.0	0.9	0.3	48.7	19.5	6.5	0.2	20.0	21.1	14.0	77.2	28.8	9.0	5.3	21.9	37.8	0.0	35.1	40.1	15.1	35.7	0.7	21.0	16.2	0.1	3.9	0.0	4.8	22.2	4.8	0.3	0.7	11.9	4.1	12.7	4.9	21.3	15.4	0.0	0.0	0.1	71.0	20.6	0.0	2.8	11.9	20.2	21.5	0.1	20.6	1.1	41.9	30.1	1.1	25.5	0.9	18.3	48.0	16.5	11.1	1.0	64.4	44.3	12.3	19.2	52.4	96.3	57.5	0.1	37.9	0.6	134.1	0.8	0.0	0.0	0.9	0.0	0.1	3.0	0.4	0.2	3.4	2.5	0.8	0.2	0.2	0.0	0.0	0.0	0.0	0.3	9.7	9.7	3.4	7.7	10.8	8.8	12.4	5.6	10.0	7.5	169.7	99.5	5.9	202.5	179.8	2.2	68.0	124.9	78.9	155.8	118.7	2.0	6.4	26.6	534.1	0.2	134.5	22.2	0.0	128.5	1.1	63.9	195.1	27.8	148.1	60.6	0.0	54.3	108.1	18.0	0.9	3.7	17.9	49.0	3.6	40.4	66.7	367.2	54.7	54.1	42.3	2.0	129.4	220.1	0.2	19.0	306.9	2.1	7.0	62.1	326.2
CCR5	"CC-CKR-5, CD195, CKR-5, CKR5, CMKBR5, IDDM22"	ENSG00000160791	"C-C motif chemokine receptor 5 (gene/pseudogene)"	P51681	3	46370854-46376206	"CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Diabetes mellitus, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.5"	"Cell type enhanced"	"Detected in some"	17	"Hofbauer cells: 4.9;Kupffer cells: 4.1;Macrophages: 16.2;T-cells: 13.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 24.5"	"Lineage enriched"	"Detected in many"	4	"T-cells: 24.5"	"Cell line enhanced"	"Detected in some"		"JURKAT: 2.5;Karpas-707: 12.0;U-266/84: 5.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.32e-3)"	"unprognostic (1.94e-3)"	"unprognostic (1.89e-3)"	"prognostic favorable (7.42e-5)"	"unprognostic (1.80e-2)"	"prognostic favorable (9.33e-5)"	"unprognostic (3.38e-3)"	"unprognostic (9.90e-3)"	"unprognostic (7.65e-2)"	"unprognostic (6.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (5.34e-2)"	"unprognostic (1.14e-3)"	"unprognostic (8.34e-2)"	"unprognostic (4.69e-2)"	"unprognostic (3.14e-2)"	"unprognostic (2.42e-2)"	7.1	2.3	3.4	13.8	6.1	0.8	2.1	0.8	2.5	2.3	3.0	3.0	0.8	3.8	3.7	4.0	2.6	2.6	5.0	3.6	1.6	2.0	2.7	3.0	9.3	11.9	8.1	0.5	3.0	2.1	0.4	1.9	1.2	4.0	2.8	3.8	3.5	4.4	2.5	0.8	1.1	7.2	2.9	6.1	14.6	6.0	0.9	5.9	2.0	2.6	1.5	13.9	5.7	2.0	0.3	5.5	5.6	2.1	3.2	24.5	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	12.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.2	0.0	0.0	0.0	0.0	0.4	5.1	0.0	0.0	0.3	0.0	5.6	1.1	0.0	6.7	2.1	24.5	0.3	2.9	9.7	5.5	0.0	0.3	2.6	0.3	3.2	0.0	5.2	4.5	1.5	3.4	6.1	0.8	2.5	1.6	2.0	8.1	0.5	4.0	5.9	0.0	1.7	0.9	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.2	4.9	0.0	0.0	1.3	4.1	0.0	0.0	16.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	13.1	0.0	0.0
CD19		ENSG00000177455	"CD19 molecule"	P15391	16	28931939-28939346	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"blood: 47.6;intestine: 16.7;lymphoid tissue: 40.3"	"Cell type enriched"	"Detected in some"	6	"B-cells: 94.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	93	"memory B-cell: 36.0;naive B-cell: 47.6"	"Lineage enriched"	"Detected in single"	106	"B-cells: 47.6"	"Cell line enhanced"	"Detected in some"		"Daudi: 53.4;REH: 28.3;U-698: 12.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB016110	Enhanced					NA	NA					"CAB016110: AB_626952"	"unprognostic (3.27e-3)"	"unprognostic (1.19e-3)"	"unprognostic (6.63e-2)"	"unprognostic (1.09e-2)"	"unprognostic (8.68e-3)"	"unprognostic (3.11e-5)"	"unprognostic (2.61e-1)"	"unprognostic (6.96e-3)"	"unprognostic (1.29e-2)"	"unprognostic (4.29e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.30e-1)"	"unprognostic (5.41e-6)"	"unprognostic (2.06e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.07e-1)"	0.4	0.2	0.2	37.0	0.2	2.3	0.2	0.1	0.2	0.2	0.9	0.1	0.0	0.2	0.2	0.1	1.4	0.3	0.2	0.2	0.2	0.2	0.7	0.3	1.4	32.0	0.2	0.0	0.3	0.2	0.0	0.2	0.0	0.0	0.4	0.5	0.1	5.9	0.0	0.1	0.1	16.7	0.0	0.2	40.3	1.3	1.9	0.0	2.4	0.7	0.2	38.7	1.8	0.3	47.6	0.0	0.4	0.1	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	28.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.1	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	36.0	0.0	0.0	0.0	47.6	0.1	0.0	0.3	0.0	0.1	0.0	0.0	1.8	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	1.1	94.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	16.9	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	1.4	0.0	0.0	1.8	0.6	3.6	0.3	0.4	3.3	0.0	0.0	0.3	0.2	0.0	0.7	0.0	0.0	0.0	0.0	6.1	3.0	0.0	0.6	0.0	0.4	0.0
CD2	SRBC	ENSG00000116824	"CD2 molecule"	P06729	1	116754385-116769228	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"blood: 101.7;lymphoid tissue: 164.4"	"Cell type enriched"	"Detected in many"	11	"T-cells: 299.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in many"	6	"gdT-cell: 44.4;MAIT T-cell: 42.5;memory CD4 T-cell: 65.3;memory CD8 T-cell: 74.2;naive CD4 T-cell: 34.2;naive CD8 T-cell: 52.4;NK-cell: 101.7;T-reg: 62.3"	"Group enriched"	"Detected in many"	9	"NK-cells: 101.7;T-cells: 74.2"	"Group enriched"	"Detected in some"	24	"HDLM-2: 58.9;JURKAT: 39.9;MOLT-4: 43.3"	"Region enhanced"	"Detected in single"		"basal ganglia: 0.3"	"Low region specificity"	"Detected in some"			"CAB002430, HPA003883"	Enhanced					NA	NA					"CAB002430: AB_442057, HPA003883: AB_1846263"	"prognostic favorable (4.36e-4)"	"prognostic favorable (1.47e-4)"	"unprognostic (3.34e-3)"	"prognostic favorable (1.69e-5)"	"unprognostic (1.52e-1)"	"prognostic favorable (7.46e-5)"	"unprognostic (9.32e-3)"	"unprognostic (1.61e-2)"	"prognostic favorable (3.97e-5)"	"prognostic favorable (7.72e-4)"	"unprognostic (4.18e-2)"	"unprognostic (3.31e-1)"	"prognostic unfavorable (4.82e-6)"	"unprognostic (6.16e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.73e-2)"	"unprognostic (7.63e-3)"	3.0	1.1	0.6	14.5	0.5	2.4	1.7	0.5	0.6	2.9	6.0	0.6	0.6	4.8	1.7	2.1	3.8	3.1	4.8	1.4	0.6	0.6	3.3	2.5	8.1	33.0	1.2	0.6	1.9	1.6	0.0	1.0	1.0	1.0	2.9	4.7	2.3	4.1	1.3	1.0	1.2	18.8	0.9	1.8	28.8	6.5	1.1	0.8	164.4	3.5	3.4	30.8	7.7	2.7	0.3	9.3	1.4	0.5	101.7	74.2	45.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.9	0.0	0.1	0.0	0.0	0.0	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.0	39.9	0.0	0.1	0.0	0.0	43.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.7	0.5	0.1	44.4	0.3	42.5	0.3	65.3	74.2	9.3	0.2	34.2	52.4	1.4	101.7	0.2	2.0	62.3	45.9	0.6	0.5	0.5	0.6	0.6	0.6	1.2	0.6	1.0	0.8	3.0	27.0	1.5	0.4	4.4	0.0	0.8	0.0	0.0	4.5	3.5	0.0	0.0	0.0	0.0	13.2	2.4	0.0	0.0	0.0	0.0	2.1	0.1	4.7	0.9	0.7	0.0	2.9	9.8	7.0	4.0	0.6	8.7	1.7	0.0	0.0	0.0	0.0	0.0	0.4	1.3	0.0	0.0	4.7	0.2	0.2	3.1	0.0	299.5	0.1	0.1
CD22	"SIGLEC-2, SIGLEC2"	ENSG00000012124	"CD22 molecule"	P20273	19	35319261-35347355	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 39.3;lymphoid tissue: 77.8;ovary: 35.4"	"Group enriched"	"Detected in some"	12	"B-cells: 68.1;granulocytes: 94.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	25	"memory B-cell: 29.8;naive B-cell: 39.3"	"Lineage enriched"	"Detected in many"	28	"B-cells: 39.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 69.8;REH: 20.6;U-698: 55.5;WM-115: 12.7"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB002418, HPA024353"	Enhanced					NA	NA					"CAB002418: AB_563529, HPA024353: AB_10600695"	"unprognostic (2.80e-3)"	"unprognostic (3.99e-2)"	"unprognostic (6.79e-3)"	"unprognostic (9.17e-2)"	"unprognostic (3.07e-1)"	"unprognostic (6.45e-3)"	"unprognostic (3.79e-1)"	"unprognostic (3.32e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.47e-1)"	"unprognostic (1.75e-3)"	"unprognostic (1.98e-2)"	"unprognostic (1.48e-2)"	"unprognostic (9.05e-2)"	"unprognostic (3.04e-1)"	"unprognostic (2.35e-2)"	"unprognostic (1.48e-1)"	2.1	1.0	5.5	57.9	6.8	3.1	0.5	0.7	3.2	1.4	1.0	0.9	0.5	0.4	1.4	0.9	4.4	7.9	2.9	0.8	9.9	4.2	1.4	0.6	5.5	52.6	9.8	0.5	35.4	0.5	0.0	0.7	1.0	0.9	2.8	1.5	1.1	5.9	1.1	0.5	0.0	11.6	2.0	13.5	64.1	1.4	1.2	0.6	5.0	1.1	2.3	77.8	4.3	0.9	39.3	1.3	0.3	0.3	0.0	0.0	1.4	0.2	0.4	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.0	1.3	69.8	1.4	0.0	3.9	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.5	0.0	0.0	3.2	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.3	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.1	20.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.7	0.0	0.1	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	55.5	0.5	0.2	12.7	0.0	0.0	0.0	0.0	0.3	0.0	29.8	0.0	0.0	1.3	39.3	0.0	0.0	0.3	0.0	0.2	1.1	0.0	1.4	5.5	6.8	0.7	3.2	9.9	4.2	9.8	0.5	0.9	0.6	3.0	4.8	68.1	0.4	0.2	0.0	0.6	0.0	0.0	1.2	0.0	0.0	0.1	0.0	0.0	0.3	0.5	0.0	0.0	0.2	0.4	0.6	0.4	94.6	0.0	7.0	0.0	0.0	1.8	6.4	0.0	3.4	2.3	1.7	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.9	0.4	0.1	0.5	0.0	0.0
CD247	"CD3H, CD3Q, CD3Z"	ENSG00000198821	"CD247 molecule"	P20963	1	167430640-167518610	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 62.8;lymphoid tissue: 129.5"	"Cell type enriched"	"Detected in many"	10	"T-cells: 248.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	26	"gdT-cell: 62.8;MAIT T-cell: 35.4;memory CD4 T-cell: 32.4;memory CD8 T-cell: 36.7;naive CD4 T-cell: 41.3;naive CD8 T-cell: 33.5;NK-cell: 33.4;T-reg: 39.0"	"Group enriched"	"Detected in many"	31	"NK-cells: 33.4;T-cells: 62.8"	"Group enriched"	"Detected in some"	25	"HDLM-2: 46.4;JURKAT: 34.6;MOLT-4: 48.9"	"Region enhanced"	"Detected in single"		"thalamus: 0.7"	"Low region specificity"	"Detected in all"			"CAB004651, HPA008750"	Enhanced					NA	NA					"CAB004651: AB_425347, HPA008750: AB_1857863"	"prognostic favorable (9.12e-4)"	"unprognostic (3.21e-3)"	"unprognostic (7.09e-3)"	"prognostic favorable (8.63e-6)"	"unprognostic (1.99e-2)"	"prognostic favorable (3.98e-4)"	"unprognostic (1.79e-2)"	"unprognostic (1.11e-2)"	"unprognostic (5.46e-3)"	"unprognostic (9.73e-3)"	"unprognostic (1.33e-2)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (9.94e-6)"	"unprognostic (1.60e-1)"	"unprognostic (5.33e-2)"	"unprognostic (4.02e-2)"	"unprognostic (5.94e-3)"	2.3	0.5	0.9	13.5	2.1	17.8	1.3	1.2	1.1	1.4	4.4	0.7	0.7	2.9	1.5	1.6	1.4	1.2	2.9	1.0	0.8	1.4	1.9	3.2	7.3	24.3	1.0	0.5	1.0	0.5	0.0	0.6	1.3	0.7	2.0	1.8	1.7	3.3	0.4	1.4	0.6	9.8	0.8	0.9	28.6	2.7	0.9	0.5	129.5	1.8	0.9	18.1	3.5	1.4	1.5	0.4	1.4	0.2	33.4	62.8	31.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	46.4	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	34.6	0.0	0.0	0.0	0.0	48.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	1.0	0.1	0.0	62.8	0.2	35.4	1.5	32.4	36.7	0.2	0.5	41.3	33.5	1.4	33.4	0.1	0.4	39.0	31.4	0.9	2.1	1.2	1.1	0.8	1.4	1.0	0.5	0.7	0.5	3.0	26.0	2.2	0.1	1.3	0.2	0.4	2.5	4.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	1.6	0.0	0.0	0.0	0.1	0.7	0.1	5.8	0.6	0.3	3.2	0.0	5.5	5.9	0.0	0.0	1.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.3	0.1	1.5	0.5	0.1	248.3	0.0	0.0
CD274	"B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1"	ENSG00000120217	"CD274 molecule"	Q9NZQ7	9	5450503-5470566	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lung: 23.9;placenta: 56.0"	"Cell type enhanced"	"Detected in many"	14	"granulocytes: 26.7;monocytes: 73.9;Syncytiotrophoblasts: 37.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"basophil: 8.4"	"Group enriched"	"Detected in many"	6	"granulocytes: 8.4;T-cells: 2.4"	"Cell line enhanced"	"Detected in many"		"HDLM-2: 34.2;HHSteC: 22.8;U-251 MG: 37.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003528, CAB076385"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane, Actin filaments"	Nucleoplasm	"CAB076385: AB_2687655, HPA003528: "	"prognostic favorable (8.89e-4)"	"unprognostic (4.54e-2)"	"prognostic favorable (1.64e-5)"	"unprognostic (1.27e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.08e-1)"	"unprognostic (4.61e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.68e-2)"	"unprognostic (5.67e-4)"	"unprognostic (7.39e-3)"	"unprognostic (1.69e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.67e-1)"	"unprognostic (9.02e-2)"	3.4	2.1	1.7	10.8	3.2	1.4	2.2	2.5	3.3	2.0	2.3	2.5	2.8	2.6	1.7	2.4	3.0	1.9	4.3	9.5	1.4	3.7	3.0	3.6	23.9	6.4	2.3	0.7	1.7	2.7	3.8	7.4	56.0	3.2	2.9	2.2	3.3	1.7	1.6	4.3	1.3	2.7	2.3	2.4	12.8	1.9	1.2	1.0	11.6	3.7	2.1	5.8	3.1	1.9	0.9	0.0	8.4	0.1	0.4	2.4	0.7	5.9	0.1	0.0	0.2	0.0	0.0	0.0	11.9	10.1	3.0	4.2	0.0	1.9	0.0	0.2	0.3	1.5	0.2	0.0	5.2	9.9	34.2	0.0	3.4	0.1	0.0	22.8	0.0	0.0	0.2	0.0	6.3	9.3	3.1	5.9	0.3	0.0	1.1	9.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	1.7	0.3	0.6	0.1	0.0	0.1	0.1	0.9	0.7	0.9	0.0	0.1	10.9	6.5	2.0	0.2	37.9	0.2	0.1	0.1	2.1	0.1	0.0	8.4	0.1	0.3	1.2	0.1	2.1	0.9	2.4	1.8	0.0	0.2	1.3	0.7	5.7	0.4	0.0	0.0	1.1	0.7	1.7	3.2	2.5	3.3	1.4	3.7	2.3	0.7	3.2	1.0	11.9	10.7	0.5	1.2	4.0	1.4	6.5	0.0	4.0	3.4	0.0	0.0	4.9	0.0	6.4	0.2	6.3	0.8	0.0	3.7	20.2	1.9	0.9	26.7	1.0	4.9	0.0	0.0	10.4	1.9	0.0	0.3	7.7	3.3	73.9	0.1	0.6	12.0	0.0	0.4	0.4	0.1	0.0	0.9	0.5	0.7	2.3	37.2	1.3	0.2	2.2
CD33	"FLJ00391, p67, SIGLEC-3, SIGLEC3"	ENSG00000105383	"CD33 molecule"	P20138	19	51225064-51243860	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Cell adhesion"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 49.3;lymphoid tissue: 45.4"	"Group enriched"	"Detected in many"	7	"granulocytes: 73.9;Hofbauer cells: 67.4;Kupffer cells: 119.1;Macrophages: 56.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"classical monocyte: 37.6;intermediate monocyte: 27.3;myeloid DC: 49.3;non-classical monocyte: 12.6"	"Group enriched"	"Detected in many"	9	"dendritic cells: 49.3;monocytes: 37.6"	"Cell line enhanced"	"Detected in some"		"HEL: 28.5;HL-60: 37.9;HMC-1: 28.4;NB-4: 18.1;RPMI-8226: 20.5;THP-1: 22.2;U-937: 28.0"									"CAB011442, HPA035832, HPA064807"	Approved		Approved	"Nucleoplasm,Plasma membrane"		NA	NA		1400000	"Nucleoplasm, Plasma membrane"		"CAB011442: , HPA035832: AB_2674808, HPA064807: AB_2685356"	"unprognostic (1.18e-2)"	"unprognostic (1.45e-2)"	"unprognostic (2.80e-2)"	"unprognostic (7.14e-2)"	"unprognostic (3.71e-1)"	"unprognostic (9.43e-2)"	"unprognostic (2.59e-1)"	"unprognostic (5.90e-3)"	"unprognostic (1.76e-1)"	"unprognostic (1.56e-1)"	"unprognostic (2.53e-1)"	"unprognostic (6.28e-2)"	"unprognostic (6.88e-4)"	"unprognostic (7.79e-2)"	"unprognostic (3.35e-2)"	"unprognostic (6.49e-2)"	"unprognostic (1.67e-1)"	10.2	4.3	3.6	8.4	6.0	23.0	6.5	0.8	3.5	2.6	2.7	4.4	0.3	2.5	2.3	5.2	1.7	3.9	5.3	7.5	3.1	2.5	4.1	6.4	11.6	45.4	6.4	1.8	1.9	1.9	0.5	1.7	5.4	5.2	2.6	3.4	2.6	2.9	2.1	1.2	2.5	4.0	5.6	9.9	31.6	2.8	1.5	5.8	2.5	1.7	0.2	2.7	4.7	2.3	0.1	49.3	4.6	37.6	3.3	0.2	14.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	1.7	0.1	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	28.5	0.1	0.0	0.0	37.9	28.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	5.2	7.2	0.0	0.0	0.0	18.1	0.0	0.0	8.7	0.0	1.5	20.5	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.2	0.2	4.9	0.4	0.6	0.0	0.1	2.4	0.0	3.3	28.0	0.1	3.3	37.6	2.3	0.0	27.3	0.1	0.0	0.0	0.1	49.3	0.1	0.0	0.0	4.6	3.3	12.6	1.4	0.2	14.7	3.6	6.0	0.8	3.5	3.1	2.5	6.4	1.8	5.2	5.8	0.0	10.7	1.4	0.5	1.5	0.1	0.6	0.0	1.4	1.2	0.0	0.0	0.7	0.0	0.0	0.4	1.5	0.0	0.0	0.0	0.4	1.5	0.3	73.9	0.8	67.4	0.0	0.0	8.6	119.1	1.3	0.3	56.4	1.7	2.8	0.0	0.2	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.7	0.5	0.9	0.7	1.7	0.0	0.3
CD3D	T3D	ENSG00000167286	"CD3d molecule"	P04234	11	118338954-118342744	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 108.7;lymphoid tissue: 181.4"	"Cell type enriched"	"Detected in many"	12	"T-cells: 532.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	53	"gdT-cell: 105.6;MAIT T-cell: 68.6;memory CD4 T-cell: 88.1;memory CD8 T-cell: 97.6;naive CD4 T-cell: 78.8;naive CD8 T-cell: 98.6;T-reg: 108.7"	"Lineage enriched"	"Detected in many"	63	"T-cells: 108.7"	"Cell line enhanced"	"Detected in some"		"JURKAT: 69.9;MOLT-4: 149.5;NB-4: 27.9"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"CAB013055, HPA071778"	Enhanced		Uncertain	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB013055: , HPA071778: "	"prognostic favorable (3.00e-4)"	"prognostic favorable (8.46e-5)"	"unprognostic (1.05e-2)"	"prognostic favorable (1.73e-7)"	"unprognostic (6.00e-2)"	"prognostic favorable (1.70e-4)"	"unprognostic (3.82e-1)"	"unprognostic (2.40e-2)"	"unprognostic (2.24e-3)"	"unprognostic (1.01e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.55e-1)"	"prognostic unfavorable (3.07e-5)"	"unprognostic (9.00e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.66e-2)"	"prognostic favorable (6.16e-4)"	2.6	0.8	0.5	17.4	0.7	4.8	1.7	0.5	0.7	1.3	4.1	0.7	0.8	4.1	1.2	1.6	3.2	1.9	2.9	1.0	0.7	0.4	2.6	1.9	6.1	40.8	0.9	0.5	1.0	1.2	0.0	0.7	0.8	0.7	2.2	4.3	1.1	9.0	0.8	0.7	1.3	19.3	1.0	1.5	28.6	4.4	0.8	0.5	181.4	2.7	2.8	32.6	5.7	2.4	0.5	0.3	1.7	0.3	0.2	108.7	64.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	69.9	5.7	0.0	0.0	0.0	149.5	27.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.5	0.3	0.2	105.6	0.2	68.6	0.5	88.1	97.6	0.3	0.2	78.8	98.6	1.7	0.2	0.3	0.3	108.7	64.9	0.5	0.7	0.5	0.7	0.7	0.4	0.9	0.5	0.7	0.5	6.0	45.4	3.0	0.3	13.6	0.0	2.5	0.0	2.7	4.5	3.5	0.0	0.2	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	5.1	0.1	11.6	2.0	0.6	0.0	1.2	9.8	7.6	0.4	0.0	6.1	11.8	0.0	0.0	0.0	0.1	0.0	0.0	2.2	0.0	0.0	5.6	0.0	0.0	10.3	0.2	532.0	0.3	0.0
CD3E		ENSG00000198851	"CD3e molecule"	P07766	11	118304545-118316175	"CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 294.2"	"Cell type enriched"	"Detected in some"	31	"T-cells: 377.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	36	"gdT-cell: 59.5;MAIT T-cell: 50.2;memory CD4 T-cell: 50.7;memory CD8 T-cell: 55.7;naive CD4 T-cell: 61.3;naive CD8 T-cell: 62.0;NK-cell: 21.8;T-reg: 46.8"	"Group enriched"	"Detected in many"	29	"NK-cells: 21.8;T-cells: 62.0"	"Group enriched"	"Detected in some"	67	"JURKAT: 80.1;MOLT-4: 108.8"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB000010, HPA040957, HPA043955, CAB072863, CAB072864"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane"		NA	NA			"Endoplasmic reticulum, Plasma membrane"		"CAB000010: AB_2631163, CAB072863: AB_2665707, CAB072864: AB_2665708, HPA040957: AB_2677222, HPA043955: AB_2678747"	"prognostic favorable (1.72e-4)"	"prognostic favorable (1.62e-4)"	"unprognostic (1.51e-2)"	"prognostic favorable (2.30e-6)"	"unprognostic (4.31e-2)"	"prognostic favorable (1.32e-4)"	"unprognostic (3.60e-3)"	"unprognostic (3.85e-2)"	"prognostic favorable (1.18e-4)"	"unprognostic (6.11e-3)"	"unprognostic (1.59e-1)"	"unprognostic (3.59e-1)"	"prognostic unfavorable (1.12e-5)"	"unprognostic (5.46e-2)"	"unprognostic (9.28e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.12e-2)"	3.9	1.0	0.5	16.7	0.7	6.8	1.9	0.5	0.7	2.1	4.7	0.9	0.7	4.4	2.0	1.4	3.3	3.0	4.0	1.4	0.5	0.5	3.3	2.6	7.3	40.9	1.3	0.6	1.5	1.3	0.0	0.9	1.2	0.9	2.6	3.9	1.9	6.4	1.1	0.8	1.3	21.1	1.1	1.9	34.5	4.6	1.2	0.5	294.2	3.4	2.1	37.8	6.3	3.0	0.2	0.9	1.4	0.2	21.8	62.0	32.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	80.1	0.1	0.3	0.0	0.0	108.8	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.1	1.4	0.0	0.1	0.0	1.3	0.2	0.2	59.5	0.1	50.2	0.1	50.7	55.7	0.1	0.2	61.3	62.0	1.4	21.8	0.2	0.9	46.8	32.9	0.5	0.7	0.5	0.7	0.5	0.5	1.3	0.6	0.9	0.5	0.0	11.3	4.5	0.3	4.6	0.0	0.2	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.1	6.5	0.2	0.0	0.0	0.0	0.0	1.0	0.1	7.0	0.8	0.3	0.0	0.0	12.3	7.3	0.0	0.0	2.5	11.8	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.5	0.0	0.0	4.6	0.2	377.3	0.2	0.3
CD3G		ENSG00000160654	"CD3g molecule"	P09693	11	118344344-118355161	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 187.6"	"Cell type enriched"	"Detected in some"	18	"T-cells: 153.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	30	"gdT-cell: 43.5;MAIT T-cell: 25.6;memory CD4 T-cell: 36.1;memory CD8 T-cell: 37.1;naive CD4 T-cell: 37.6;naive CD8 T-cell: 46.7;T-reg: 34.2"	"Lineage enriched"	"Detected in many"	37	"T-cells: 46.7"	"Group enriched"	"Detected in some"	53	"JURKAT: 24.1;MOLT-4: 64.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB017520, HPA038494"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB017520: AB_831094, HPA038494: AB_2676044"	"prognostic favorable (6.33e-4)"	"prognostic favorable (2.61e-4)"	"unprognostic (4.58e-3)"	"unprognostic (3.12e-5)"	"unprognostic (6.30e-2)"	"prognostic favorable (3.00e-4)"	"unprognostic (1.98e-2)"	"unprognostic (1.54e-2)"	"unprognostic (8.25e-3)"	"unprognostic (1.08e-3)"	"unprognostic (1.54e-2)"	"unprognostic (2.19e-1)"	"prognostic unfavorable (9.33e-5)"	"unprognostic (1.60e-1)"	"unprognostic (2.37e-2)"	"unprognostic (4.13e-2)"	"unprognostic (2.10e-3)"	1.1	0.6	0.4	7.1	0.4	0.5	0.8	0.3	0.3	0.7	2.3	0.4	0.4	2.0	0.9	0.6	1.5	1.1	1.9	0.6	0.4	0.4	1.2	0.9	2.4	17.2	0.5	0.2	0.7	0.7	0.0	0.5	0.4	0.3	1.0	1.6	0.9	2.9	0.3	5.9	0.6	8.1	0.2	0.8	11.5	2.4	0.5	0.2	187.6	1.4	1.7	19.2	2.5	1.1	0.1	0.2	1.2	0.2	0.2	46.7	14.1	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	24.1	0.8	0.2	0.0	0.2	64.5	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.2	0.1	0.1	0.1	0.0	0.6	0.2	0.2	43.5	0.1	25.6	0.1	36.1	37.1	0.1	0.1	37.6	46.7	1.2	0.2	0.1	0.2	34.2	14.1	0.4	0.4	0.3	0.3	0.4	0.4	0.5	0.2	0.3	0.2	3.0	8.6	0.8	0.0	2.1	0.1	0.4	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.8	0.0	5.8	1.3	0.1	0.0	0.0	6.2	2.8	0.4	0.0	2.8	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.6	0.0	0.3	0.2	0.0	2.0	0.2	153.8	0.0	0.0
CD4		ENSG00000010610	"CD4 molecule"	P01730	12	6786858-6820808	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 111.5;parathyroid gland: 78.4"	"Cell type enhanced"	"Detected in many"	19	"Hofbauer cells: 121.3;Ito cells: 382.4;Kupffer cells: 192.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	17	"classical monocyte: 42.2;intermediate monocyte: 42.5;memory CD4 T-cell: 29.1;myeloid DC: 29.3;naive CD4 T-cell: 24.8;non-classical monocyte: 33.3;plasmacytoid DC: 46.7;T-reg: 26.4"	"Group enriched"	"Detected in many"	20	"dendritic cells: 46.7;monocytes: 42.5;T-cells: 29.1"	"Group enriched"	"Detected in some"	6	"HEL: 34.3;HL-60: 13.8;NB-4: 19.7;THP-1: 39.0;U-937: 36.7"	"Region enriched"	"Detected in single"	15	"basal ganglia: 41.4"	"Not detected"	"Not detected"			"CAB000011, HPA004252, HPA004472, CAB068180"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000011: AB_442062, CAB068180: AB_2665653, HPA004252: AB_1078466, HPA004472: AB_1078465"	"unprognostic (1.39e-2)"	"unprognostic (1.12e-2)"	"unprognostic (2.75e-2)"	"prognostic favorable (2.16e-4)"	"unprognostic (7.76e-2)"	"unprognostic (4.82e-3)"	"unprognostic (3.70e-2)"	"unprognostic (2.74e-2)"	"unprognostic (7.04e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.92e-1)"	"prognostic unfavorable (7.45e-4)"	"unprognostic (1.06e-1)"	"unprognostic (4.65e-3)"	"unprognostic (9.08e-3)"	"unprognostic (2.95e-1)"	13.8	5.4	6.1	16.0	5.8	4.4	5.6	1.2	4.3	4.5	5.1	8.6	1.8	3.6	3.5	8.3	3.0	5.5	7.3	5.4	4.9	4.4	6.1	32.2	24.0	30.8	6.3	3.1	3.0	3.1	78.4	3.4	10.9	6.2	4.1	6.5	5.7	5.4	3.9	1.9	3.5	9.5	5.2	10.2	49.1	3.9	2.8	5.7	111.5	3.9	4.1	18.6	8.6	3.2	0.1	46.7	1.9	42.5	0.3	29.1	33.6	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	34.3	0.0	0.2	3.8	13.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	19.7	0.3	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	39.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.7	0.0	0.1	42.2	0.3	0.3	42.5	1.1	0.0	29.1	0.1	29.3	0.1	24.8	0.1	1.9	0.3	33.3	46.7	26.4	33.6	6.1	5.8	1.2	4.3	4.9	4.4	6.3	3.1	6.2	5.7	0.0	6.9	8.2	0.2	3.1	1.5	1.6	15.3	26.8	3.4	3.5	0.0	0.8	5.0	0.0	0.0	2.8	0.0	0.0	0.3	0.9	5.4	0.1	7.0	7.8	121.3	4.8	0.0	382.4	192.9	0.0	15.5	72.7	5.0	39.7	0.0	14.3	0.0	0.0	14.2	1.1	0.1	12.9	4.2	0.0	0.1	1.9	1.0	28.4	0.0	0.3
CD44	"CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1"	ENSG00000026508	"CD44 molecule (Indian blood group)"	P16070	11	35138870-35232402	"Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Blood group antigen, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	4	"Basal keratinocytes: 888.0;Ductal cells: 858.7;Suprabasal keratinocytes: 895.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 139.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB000112, CAB000316, HPA005785"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"	"Secreted - unknown location"	NA	NA		2400000000	"Plasma membrane"	"Golgi apparatus"	"CAB000112: , CAB000316: AB_2076596, HPA005785: AB_1078467"	"unprognostic (5.33e-2)"	"unprognostic (1.85e-1)"	"unprognostic (4.97e-2)"	"unprognostic (9.90e-3)"	"unprognostic (3.50e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.56e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.57e-1)"	"unprognostic (4.18e-2)"	"unprognostic (1.51e-3)"	"unprognostic (4.63e-2)"	"prognostic unfavorable (1.78e-8)"	"unprognostic (6.41e-2)"	"unprognostic (4.14e-2)"	"unprognostic (3.93e-2)"	"unprognostic (7.98e-2)"	45.5	9.0	10.5	42.5	21.7	53.0	35.6	4.7	13.4	43.2	19.5	26.3	8.3	10.6	80.5	20.3	66.5	18.6	48.0	11.7	14.9	9.3	12.4	9.1	43.4	48.4	31.5	6.1	12.8	83.9	0.8	3.8	19.4	40.7	30.1	24.5	30.2	148.2	22.4	15.9	107.7	18.9	44.5	100.5	30.9	19.9	7.2	20.3	17.9	20.6	53.9	53.7	55.0	54.2	22.7	41.0	19.1	65.2	54.6	53.1	59.9	39.7	35.9	0.3	0.0	21.7	60.0	0.1	77.9	60.9	43.4	24.2	2.4	12.5	0.0	10.4	110.3	89.3	68.5	0.8	84.7	59.6	8.5	0.4	1.4	17.7	0.0	21.4	20.2	93.5	27.0	66.8	58.3	47.4	139.4	15.1	0.0	0.3	13.0	41.6	0.2	1.8	13.3	0.7	0.7	10.6	0.1	7.4	0.6	63.6	11.5	0.1	0.1	14.7	0.4	35.2	3.4	2.1	1.2	43.5	54.1	9.8	66.3	80.0	22.5	24.3	0.2	82.1	11.4	78.6	19.1	65.2	6.0	26.2	45.7	37.0	22.7	39.8	34.9	41.0	16.2	34.5	28.7	16.4	54.6	59.3	14.2	53.1	59.9	10.5	21.7	4.7	13.4	14.9	9.3	31.5	6.1	40.7	20.3	89.3	339.9	168.9	263.7	888.0	0.0	4.0	25.5	18.7	135.4	19.2	2.0	4.0	1.7	858.7	30.1	53.0	5.0	23.3	741.5	3.7	143.9	293.1	733.4	2.5	234.7	0.0	96.2	20.3	427.0	13.8	20.8	611.7	573.6	514.0	84.8	26.6	787.6	8.6	0.4	0.6	1.6	155.2	254.2	0.4	0.4	895.8	15.0	244.8	66.1	304.0
CD52	"CDW52, EDDM5, HE5"	ENSG00000169442	"CD52 molecule"	P31358	1	26317957-26320523	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins"			"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"blood: 495.7;epididymis: 978.9"	"Cell type enhanced"	"Detected in many"	13	"B-cells: 1214.9;granulocytes: 550.2;Hofbauer cells: 593.7;Macrophages: 676.6;T-cells: 760.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"Daudi: 76.1;REH: 111.3;U-266/84: 111.2;U-698: 123.2"															NA	NA						"prognostic favorable (1.85e-5)"	"unprognostic (3.28e-3)"	"unprognostic (1.93e-2)"	"prognostic favorable (2.06e-4)"	"unprognostic (4.18e-2)"	"prognostic favorable (4.45e-4)"	"unprognostic (9.11e-2)"	"unprognostic (2.98e-2)"	"unprognostic (7.73e-3)"	"unprognostic (6.27e-2)"	"unprognostic (4.58e-1)"	"unprognostic (1.70e-1)"	"prognostic unfavorable (5.85e-4)"	"unprognostic (3.64e-1)"	"unprognostic (6.14e-2)"	"unprognostic (7.95e-2)"	"unprognostic (1.26e-1)"	9.5	0.9	0.8	23.0	1.4	5.7	4.7	0.3	0.8	0.9	3.7	0.3	93.2	1.0	1.1	978.9	2.9	1.5	2.2	1.5	0.6	0.2	3.5	3.2	43.4	54.6	0.8	0.6	0.8	1.0	0.0	0.7	0.7	0.7	1.7	2.5	1.3	5.7	2.9	0.4	1.9	39.6	1.1	1.2	98.7	2.7	5.3	0.4	24.7	3.2	2.1	30.4	4.3	1.7	292.0	87.6	258.4	194.6	94.3	308.1	495.7	0.2	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.1	0.0	0.0	0.0	0.0	76.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.1	0.0	0.7	11.9	0.0	0.0	0.0	0.0	0.0	0.0	4.9	2.5	0.1	0.0	0.5	0.8	6.8	0.3	0.0	0.0	111.3	0.1	1.7	0.0	0.0	0.2	1.0	0.0	0.1	0.1	1.0	0.0	1.3	0.1	0.0	0.2	0.0	0.1	0.3	111.2	123.2	0.0	1.9	0.0	12.4	126.8	258.4	194.7	194.6	155.1	292.0	244.1	190.3	87.6	273.7	166.6	171.2	9.6	94.3	167.6	28.6	308.1	495.7	0.8	1.4	0.3	0.8	0.6	0.2	0.8	0.6	0.7	0.4	62.5	287.6	1214.9	0.7	40.3	0.0	6.0	2.5	32.1	92.1	47.1	0.0	2.7	0.0	0.2	0.7	22.7	0.7	0.0	0.2	4.3	18.8	0.4	550.2	1.5	593.7	0.0	0.0	17.8	203.9	1.3	0.0	676.6	101.3	2.8	1.9	0.0	0.1	2.9	0.0	7.6	0.0	0.0	3.3	0.2	0.2	27.5	4.7	760.6	0.2	0.8
CD80	"B7-1, B7.1, CD28LG, CD28LG1"	ENSG00000121594	"CD80 molecule"	P33681	3	119524293-119559602	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 17.5"	"Cell type enriched"	"Detected in some"	22	"monocytes: 113.6"	"Low cancer specificity"	"Detected in some"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"memory B-cell: 4.3;non-classical monocyte: 1.1;T-reg: 3.3"	"Group enriched"	"Detected in many"	24	"B-cells: 4.3;monocytes: 1.1;T-cells: 3.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 8.2;HDLM-2: 29.0;Karpas-707: 12.1;U-266/70: 5.2"					"Low region specificity"	"Detected in all"			"CAB025368, HPA050092"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB025368: , HPA050092: AB_2681012"	"unprognostic (2.36e-1)"	"unprognostic (1.55e-2)"	"unprognostic (5.91e-2)"	"unprognostic (1.24e-1)"	"unprognostic (3.14e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.86e-2)"	"unprognostic (4.14e-3)"	"unprognostic (1.02e-2)"	"unprognostic (4.96e-3)"	"unprognostic (1.16e-2)"	"unprognostic (1.15e-1)"	"unprognostic (9.03e-8)"	"unprognostic (3.20e-1)"	"unprognostic (3.65e-2)"	"unprognostic (7.81e-3)"	"unprognostic (1.94e-2)"	0.7	0.6	0.4	11.7	0.3	1.5	1.2	0.3	0.3	0.6	0.7	0.3	0.7	1.3	0.4	0.6	0.7	0.3	1.0	0.5	0.9	0.3	0.7	2.0	6.2	7.4	0.4	0.0	0.3	0.9	0.0	1.1	0.7	0.6	0.6	1.7	0.8	3.9	0.2	0.5	0.4	2.4	0.2	0.8	17.5	0.6	0.4	0.0	5.6	1.6	0.8	17.2	1.8	0.4	4.3	0.1	0.0	1.1	0.0	3.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	12.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	5.2	0.2	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	4.3	0.5	0.3	0.1	0.6	0.0	0.0	0.0	0.0	1.1	0.0	3.3	0.2	0.4	0.3	0.3	0.3	0.9	0.3	0.4	0.0	0.6	0.0	0.0	1.0	0.5	0.0	0.6	0.0	0.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	0.0	0.0	3.9	0.0	0.0	5.2	0.0	113.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	0.0	0.0	0.0
CD86	"B7-2, B7.2, CD28LG2"	ENSG00000114013	"CD86 molecule"	P42081	3	122055366-122121139	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Host-virus interaction, Immunity"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 27.0;brain: 26.1"	"Cell type enriched"	"Detected in many"	5	"monocytes: 760.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	8	"classical monocyte: 25.6;intermediate monocyte: 26.4;memory B-cell: 13.6;myeloid DC: 25.9;naive B-cell: 8.0;non-classical monocyte: 27.0"	"Group enriched"	"Detected in many"	17	"B-cells: 13.6;dendritic cells: 25.9;monocytes: 27.0"	"Cell line enriched"	"Detected in some"	7	"HDLM-2: 80.7"					"Low region specificity"	"Detected in all"			"CAB004319, HPA026802"	Approved		Supported	"Plasma membrane"		NA	NA		220000	"Plasma membrane"		"CAB004319: AB_627200, HPA026802: "	"unprognostic (1.81e-1)"	"unprognostic (3.78e-3)"	"unprognostic (3.04e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.36e-1)"	"unprognostic (2.79e-1)"	"unprognostic (1.15e-1)"	"unprognostic (8.56e-2)"	"unprognostic (7.72e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.98e-1)"	"prognostic unfavorable (9.83e-5)"	"unprognostic (9.72e-2)"	"unprognostic (1.70e-2)"	"unprognostic (9.78e-2)"	"unprognostic (8.67e-2)"	10.5	4.7	7.1	23.6	9.5	6.0	3.6	1.5	6.3	2.9	4.3	9.8	0.6	2.5	2.6	5.2	2.8	3.3	10.4	3.5	7.3	6.0	4.0	7.8	13.0	17.8	11.7	3.0	2.5	2.3	2.1	2.6	10.3	8.1	3.1	5.6	3.0	3.6	1.8	1.3	2.4	6.9	5.1	26.1	22.5	3.4	2.4	10.3	7.7	2.3	2.1	15.0	9.2	2.2	13.6	25.9	0.3	27.0	1.2	0.4	9.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	80.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	4.3	0.1	9.6	0.0	0.2	0.0	0.0	25.6	0.2	0.0	26.4	0.0	13.6	0.1	0.1	25.9	8.0	0.0	0.0	0.3	1.2	27.0	2.6	0.4	9.3	7.1	9.5	1.5	6.3	7.3	6.0	11.7	3.0	8.1	10.3	0.0	10.6	25.1	0.0	3.2	0.0	0.2	0.0	0.0	4.5	1.8	0.0	1.6	0.0	0.2	3.0	0.2	0.0	0.0	2.9	0.5	1.7	0.3	2.3	0.8	106.9	0.0	0.0	1.8	111.1	1.3	0.0	155.5	6.8	760.2	0.0	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.1	3.4	1.6	0.0	0.0	0.3
CDK4	PSK-J3	ENSG00000135446	"Cyclin dependent kinase 4"	P11802	12	57747727-57756013	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in all"	10	"HBEC3-KT: 128.1;LHCN-M2: 141.4;RH-30: 445.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006024, CAB013116, CAB069405"	Supported		Supported	"Nucleoplasm,Nuclear membrane,Nucleoli,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Nuclear membrane, Nucleoli"	"CAB013116: AB_2536376, CAB069405: AB_1613464, HPA006024: AB_2667497"	"unprognostic (8.88e-2)"	"unprognostic (2.53e-1)"	"unprognostic (5.27e-2)"	"unprognostic (9.01e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (2.09e-7)"	"unprognostic (7.39e-2)"	"unprognostic (3.23e-3)"	"unprognostic (2.93e-2)"	"unprognostic (3.19e-2)"	"unprognostic (9.10e-2)"	"prognostic unfavorable (3.15e-5)"	"unprognostic (3.32e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.57e-2)"	32.2	43.1	13.8	22.2	15.7	24.0	45.0	13.1	17.9	36.3	28.2	20.1	22.8	15.2	51.4	28.1	29.9	31.0	32.3	27.4	14.5	12.1	24.0	36.9	26.8	26.4	18.3	13.7	61.4	54.4	18.9	34.2	25.0	16.0	37.2	26.9	26.2	29.3	24.1	27.8	25.6	20.7	34.1	13.5	27.2	23.9	24.6	17.5	29.2	54.3	32.1	27.5	33.6	30.9	29.6	25.5	2.6	19.9	15.8	32.1	22.2	9.5	11.1	14.6	13.0	13.4	11.8	9.8	5.5	18.0	24.4	20.2	15.8	9.1	13.9	10.0	8.6	14.4	7.4	20.2	128.1	18.5	6.8	9.3	13.0	7.5	11.1	15.7	14.7	9.0	11.6	9.4	14.9	17.2	16.6	15.6	13.3	13.8	12.0	141.4	13.9	14.1	12.0	17.2	10.0	11.2	12.6	445.0	12.9	7.6	15.1	13.3	12.4	9.8	7.4	14.7	10.5	9.8	17.9	7.1	11.4	10.8	12.9	11.1	6.0	9.7	21.4	10.5	13.7	13.7	1.7	14.3	2.6	26.2	19.9	27.0	29.6	23.1	23.7	21.0	28.1	32.1	28.5	1.2	15.8	12.0	25.5	16.6	22.2	13.8	15.7	13.1	17.9	14.5	12.1	18.3	13.7	16.0	17.5	20.8	25.0	32.0	62.9	79.7	15.3	0.5	48.4	4.0	23.9	45.4	9.8	64.6	59.7	71.7	10.1	44.2	11.3	23.3	53.6	108.9	77.4	41.8	68.1	32.1	111.7	17.5	43.8	34.4	23.2	6.8	59.2	34.0	50.6	54.1	33.5	51.3	55.4	7.0	59.4	66.3	15.3	32.3	54.2	25.9	40.3	75.3	39.1	34.1	78.3	32.5
CDK6	PLSTIRE	ENSG00000105810	"Cyclin dependent kinase 6"	Q00534	7	92604921-92836594	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cell cycle, Cell division, Differentiation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary microcephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 74.6"	"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 219.8;Late spermatids: 186.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"MOLT-4: 93.5;REH: 45.7"					"Low region specificity"	"Detected in all"			"HPA002637, CAB004363"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB004363: AB_627242, HPA002637: AB_1846432"	"unprognostic (1.29e-1)"	"unprognostic (5.98e-3)"	"unprognostic (9.07e-2)"	"unprognostic (2.78e-3)"	"unprognostic (2.56e-2)"	"unprognostic (3.24e-2)"	"unprognostic (3.39e-1)"	"unprognostic (2.42e-3)"	"unprognostic (7.19e-2)"	"unprognostic (7.78e-3)"	"prognostic unfavorable (3.86e-6)"	"unprognostic (4.06e-2)"	"unprognostic (4.09e-3)"	"unprognostic (1.09e-1)"	"unprognostic (7.88e-2)"	"unprognostic (1.93e-1)"	"prognostic unfavorable (2.33e-5)"	6.6	11.3	6.0	9.1	7.5	22.5	5.9	2.4	6.0	7.8	10.0	9.6	5.7	7.5	6.0	5.9	8.5	4.6	7.8	6.6	6.9	4.2	6.5	7.5	7.3	7.4	7.0	5.2	5.0	10.0	25.7	4.2	20.5	7.5	6.1	9.2	4.4	10.9	6.1	2.0	11.6	9.4	9.8	7.5	6.3	10.8	5.4	8.0	74.6	4.3	9.2	10.3	6.7	9.0	3.6	5.6	6.5	4.8	3.9	7.1	2.3	6.2	2.9	8.0	5.1	2.3	2.6	1.7	6.4	4.0	3.2	3.0	7.8	4.8	4.8	3.7	4.3	2.0	3.8	4.4	9.2	7.6	10.5	3.1	12.0	5.5	7.5	1.4	7.4	0.6	2.6	5.0	4.3	20.4	3.0	1.2	19.6	11.5	13.3	5.7	1.2	93.5	0.8	2.5	7.9	2.6	45.7	28.1	8.1	4.4	0.1	4.2	27.3	0.7	2.2	3.7	6.1	0.1	12.3	4.7	10.5	16.5	4.1	12.9	7.1	0.1	6.4	1.5	25.5	13.9	4.9	1.9	6.5	5.2	3.9	5.9	2.0	5.5	5.6	4.0	3.6	7.1	4.0	1.1	3.9	4.8	5.6	2.8	2.3	6.0	7.5	2.4	6.0	6.9	4.2	7.0	5.2	7.5	8.0	23.8	3.0	11.9	19.5	53.5	0.2	14.8	25.5	4.0	27.3	21.0	0.0	42.7	8.3	31.7	219.8	24.1	11.0	0.0	20.1	3.4	21.6	18.1	24.3	18.4	15.0	0.0	16.1	7.4	23.4	186.0	4.6	21.9	18.6	20.8	46.7	0.5	63.1	14.0	3.2	5.1	0.0	6.5	22.1	2.6	46.4	44.2	14.8	20.3	68.3	23.3
CES1	"CEH, CES1A1, CES1A2, CES2, HMSE, HMSE1, SES1"	ENSG00000198848	"Carboxylesterase 1"	P23141	16	55802851-55833337	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Hydrolase, Serine esterase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"liver: 355.0"	"Group enriched"	"Detected in many"	7	"Cholangiocytes: 565.6;Hepatocytes: 2145.0"	"Cancer enriched"	"Detected in all"	6	"liver cancer: 711.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	18	"classical monocyte: 32.6;myeloid DC: 32.9"	"Group enriched"	"Detected in many"	20	"dendritic cells: 32.9;monocytes: 32.6"	"Group enriched"	"Detected in some"	5	"Hep G2: 96.2;THP-1: 103.6"	"Not detected"	"Not detected"							"HPA012023, HPA046717"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	No	NA		40000000	"Endoplasmic reticulum"		"HPA012023: AB_1846554, HPA046717: AB_2679770"	"unprognostic (1.04e-2)"	"unprognostic (9.85e-2)"	"unprognostic (2.94e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.55e-3)"	"unprognostic (7.46e-3)"	"unprognostic (1.51e-1)"	"unprognostic (1.42e-1)"	"unprognostic (3.51e-1)"	"unprognostic (5.74e-2)"	"unprognostic (4.62e-2)"	"unprognostic (3.29e-2)"	"unprognostic (1.91e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.92e-1)"	"unprognostic (2.87e-1)"	"prognostic unfavorable (9.92e-4)"	27.1	1.7	0.3	0.5	0.4	2.1	24.7	0.4	0.6	3.1	8.9	0.5	1.5	2.4	7.3	2.1	4.5	6.7	57.7	8.1	0.3	0.0	0.7	355.0	19.8	2.3	0.3	0.6	3.9	1.3	0.0	0.8	1.1	0.6	11.2	1.0	3.8	3.9	4.0	1.6	1.4	3.5	10.2	0.7	4.4	7.0	1.0	0.3	0.4	1.7	2.3	1.5	8.2	16.1	0.2	32.9	0.2	32.6	0.1	1.6	12.1	0.0	0.6	0.0	0.0	14.4	0.0	0.4	0.0	0.0	0.0	0.0	6.7	0.0	0.0	2.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	103.6	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	20.8	0.0	0.0	32.6	0.1	1.3	1.8	0.5	0.2	0.2	1.6	32.9	0.2	0.2	0.4	0.2	0.1	0.4	1.7	0.1	12.1	0.3	0.4	0.4	0.6	0.3	0.0	0.3	0.6	0.6	0.3	14.9	74.9	21.0	2.5	14.8	0.0	0.6	565.6	202.1	28.4	15.7	0.0	0.4	0.0	16.2	77.2	1.5	0.0	70.0	17.2	0.8	45.8	1.1	5.8	2145.0	18.9	0.0	36.2	43.0	88.2	134.3	17.3	20.4	37.1	0.0	0.0	8.3	0.9	0.2	93.0	0.5	0.5	0.0	7.2	0.9	1.0	10.2	0.7	20.3	0.0	1.7
CFTR	"ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR"	ENSG00000001626	"Cystic fibrosis transmembrane conductance regulator"	P13569	7	117465784-117715971	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Isomerase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"pancreas: 103.0"	"Cell type enriched"	"Detected in many"	5	"Ductal cells: 325.5"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 23.9;pancreatic cancer: 28.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	22	"CACO-2: 12.8;MOLT-4: 48.1;U-266/70: 26.3"	"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in single"	5	"olfactory region: 6.3"	"CAB001951, HPA021939, HPA079652"	Enhanced					NA	NA					"CAB001951: , HPA021939: AB_1846578, HPA079652: "	"unprognostic (6.38e-3)"	"unprognostic (9.55e-2)"	"unprognostic (1.77e-2)"	"unprognostic (1.44e-2)"	"unprognostic (8.74e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavorable (9.44e-4)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-1)"	"unprognostic (8.89e-2)"	"unprognostic (1.55e-2)"	"unprognostic (2.14e-2)"	"unprognostic (4.78e-3)"	"unprognostic (1.24e-1)"	"unprognostic (2.58e-1)"	"unprognostic (9.08e-2)"	"unprognostic (6.64e-2)"	0.4	0.2	0.4	10.5	0.4	0.0	0.3	0.3	0.3	2.5	19.8	0.1	0.8	10.5	0.6	2.1	0.4	0.4	15.8	0.3	0.4	0.3	1.1	1.4	5.7	0.1	0.5	0.1	0.3	103.0	0.0	0.3	0.1	0.1	1.5	12.5	0.1	22.4	0.1	0.3	1.1	24.2	0.3	0.7	0.3	0.6	0.9	0.1	0.1	0.3	0.2	0.3	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.8	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	48.1	0.0	0.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	26.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.3	0.3	0.4	0.3	0.5	0.1	0.1	0.1	6.0	48.7	0.0	1.7	0.0	0.4	1.2	43.3	9.4	23.9	0.0	0.0	0.0	0.0	325.5	2.9	0.0	19.4	0.0	3.7	0.0	0.1	3.6	1.1	0.2	0.0	0.0	6.9	0.0	0.0	1.6	0.3	0.0	0.0	11.8	11.5	0.6	21.5	37.7	0.0	0.0	0.0	0.0	0.3	1.8	0.4	0.0	0.0	0.0	64.4	3.9
CHD1		ENSG00000153922	"Chromodomain helicase DNA binding protein 1"	O14646	5	98853985-98928957	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Helicase, Hydrolase"	"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 70.1"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA022236	Approved		Approved	"Nucleoplasm,Nucleoli fibrillar center"		NA	NA			"Nucleoplasm, Nucleoli fibrillar center"		"HPA022236: AB_2670915"	"unprognostic (2.63e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.09e-2)"	"unprognostic (4.11e-2)"	"unprognostic (7.79e-2)"	"unprognostic (7.15e-2)"	"unprognostic (6.50e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.88e-1)"	"unprognostic (4.94e-2)"	"unprognostic (3.15e-1)"	"prognostic unfavorable (7.25e-6)"	"unprognostic (2.69e-1)"	"unprognostic (3.33e-1)"	"unprognostic (1.52e-1)"	"unprognostic (1.17e-1)"	13.0	7.4	5.5	15.8	7.5	41.7	10.2	14.9	5.5	9.4	9.3	4.7	7.9	6.6	11.3	7.5	7.6	10.8	10.6	6.8	4.9	3.1	7.3	10.1	12.1	8.8	8.8	3.2	18.1	8.3	9.3	12.0	11.1	6.4	7.7	7.4	5.6	8.1	11.5	13.2	8.2	12.3	8.3	7.2	17.2	8.6	12.0	7.4	70.1	8.1	5.5	9.3	10.4	11.3	10.1	7.1	16.7	8.2	8.1	8.4	2.2	11.0	10.2	23.9	16.2	8.1	8.4	20.9	11.5	7.5	9.3	12.2	12.6	8.6	9.4	11.2	6.6	15.2	9.2	18.7	12.6	19.5	14.7	14.1	16.6	12.1	9.6	8.9	15.9	12.9	7.2	5.2	16.2	16.4	6.3	11.2	30.8	20.0	14.5	9.3	8.9	31.6	6.9	16.0	3.5	12.4	26.9	16.7	14.0	8.2	10.6	11.2	9.6	14.7	7.7	18.6	13.0	7.5	11.0	12.7	20.1	10.8	12.5	20.2	10.1	10.6	19.9	11.0	16.0	12.0	11.4	8.2	10.7	6.5	7.5	8.2	10.1	6.1	6.1	7.1	9.4	8.4	6.6	16.7	8.1	7.1	5.2	6.3	2.2	5.5	7.5	14.9	5.5	4.9	3.1	8.8	3.2	6.4	7.4	44.7	61.6	41.0	98.1	138.2	37.4	25.7	20.4	61.6	79.6	34.9	41.2	44.3	6.6	31.7	85.6	50.1	37.2	0.0	27.6	32.9	75.7	63.5	85.6	26.0	30.8	31.8	30.5	36.2	71.6	14.8	30.0	68.0	64.1	52.3	28.7	17.0	29.9	35.1	18.0	11.0	50.1	45.3	96.8	51.7	52.7	164.7	75.5	54.3	26.9	58.2
CHRM1		ENSG00000168539	"Cholinergic receptor muscarinic 1"	P11229	11	62908679-62921807	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	8	"brain: 34.7;prostate: 28.2;salivary gland: 25.3"	"Group enriched"	"Detected in some"	6	"Glandular cells: 2.0;Melanocytes: 3.3;Mucus-secreting cells: 2.1"	"Cancer enriched"	"Detected in some"	16	"prostate cancer: 27.9"	"Group enriched"	"Detected in many"	10	"amygdala: 13.2;basal ganglia: 22.0;cerebral cortex: 34.7;hippocampal formation: 14.2;olfactory region: 14.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"MCF7: 4.9;OE19: 15.2"	"Group enriched"	"Detected in many"	9	"amygdala: 74.1;basal ganglia: 65.6;cerebral cortex: 83.5;hippocampal formation: 100.4;olfactory region: 36.8"					"HPA014101, CAB022366"	Enhanced	Supported	Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB022366: , HPA014101: AB_1854210"	"unprognostic (3.19e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.25e-1)"	"unprognostic (1.31e-2)"	"unprognostic (7.94e-2)"	"unprognostic (2.29e-1)"		"unprognostic (1.16e-2)"	"unprognostic (2.89e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.76e-1)"	"unprognostic (2.08e-1)"	"unprognostic (8.57e-4)"	"unprognostic (4.88e-1)"	"unprognostic (6.43e-2)"	"unprognostic (1.75e-1)"		0.5	3.7	13.2	0.8	22.0	0.5	3.2	0.2	34.7	0.6	1.3	0.5	0.0	1.0	0.7	0.6	0.8	0.8	0.7	0.6	14.2	1.7	0.7	0.6	2.9	0.6	1.4	14.0	0.5	1.2	1.0	0.1	0.8	0.1	28.2	1.3	1.3	25.3	0.6	0.6	2.6	1.3	0.6	0.3	0.6	1.9	0.6	1.8	0.0	0.8	0.0	0.7	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.1	0.1	15.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.4	0.4	0.1	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.2	22.0	0.2	34.7	14.2	1.7	1.4	14.0	0.1	1.8	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1
CHRM2		ENSG00000181072	"Cholinergic receptor muscarinic 2"	P08172	7	136868669-137020255	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 25.5;heart muscle: 35.0;smooth muscle: 32.8"	"Cell type enriched"	"Detected in some"	6	"Cardiomyocytes: 45.4"	"Cancer enhanced"	"Detected in single"		"stomach cancer: 0.8"	"Region enhanced"	"Detected in many"		"pons and medulla: 15.7"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	5	"fHDF/TERT166: 44.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB022338, HPA029795"	Approved					NA	NA					"CAB022338: , HPA029795: AB_10601357"			"unprognostic (3.51e-2)"	"unprognostic (3.73e-4)"	"unprognostic (5.77e-2)"			"unprognostic (1.78e-2)"		"unprognostic (1.97e-1)"	"unprognostic (4.00e-1)"	"unprognostic (2.69e-1)"		"unprognostic (1.43e-2)"	"unprognostic (1.80e-1)"		"unprognostic (1.35e-3)"	0.8	0.9	3.6	7.2	1.9	0.3	0.8	0.8	6.0	0.9	8.9	0.0	0.0	0.9	0.8	0.3	0.8	0.8	25.5	35.0	0.9	0.9	0.8	1.2	1.0	0.2	0.9	2.2	0.8	0.8	0.2	0.9	1.7	15.7	5.4	3.9	0.0	0.8	0.2	0.8	0.8	3.7	32.8	5.0	0.8	2.7	2.3	1.5	0.0	0.8	0.0	0.2	14.0	1.8	0.0	0.2	1.3	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.2	9.2	0.1	0.0	0.0	0.0	0.0	0.0	44.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.7	0.2	0.0	0.0	3.6	1.9	0.8	6.0	0.9	0.9	0.9	2.2	15.7	1.5	0.0	0.0	0.0	0.0	0.0	4.9	45.4	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.5	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0
CHRM3		ENSG00000133019	"Cholinergic receptor muscarinic 3"	P20309	1	239386565-239915452	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"retina: 39.8"	"Cell type enhanced"	"Detected in many"	9	"Bipolar cells: 17.2;Early spermatids: 14.2;Exocrine glandular cells: 14.9;Paneth cells: 23.2"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"cerebral cortex: 8.7"	"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.3"	"Group enriched"	"Detected in many"	18	"monocytes: 1.2;T-cells: 2.3"	"Cell line enhanced"	"Detected in some"		"RPMI-8226: 10.2;SH-SY5Y: 32.5;U-266/70: 13.5;U-266/84: 9.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA024106, HPA048036"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA024106: AB_1854211, HPA048036: AB_2680238"	"unprognostic (1.63e-1)"	"unprognostic (4.82e-2)"	"unprognostic (1.05e-1)"	"unprognostic (4.11e-3)"	"unprognostic (3.48e-3)"	"unprognostic (5.81e-2)"	"unprognostic (2.30e-3)"	"unprognostic (5.18e-2)"	"unprognostic (1.71e-1)"	"unprognostic (1.27e-1)"	"unprognostic (6.29e-2)"	"unprognostic (6.44e-2)"	"unprognostic (5.34e-4)"	"unprognostic (3.04e-2)"	"unprognostic (2.67e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.88e-2)"	0.8	0.0	2.1	1.4	1.8	0.0	0.8	0.8	8.7	0.8	5.9	0.8	0.8	0.8	1.4	0.8	6.6	0.3	0.8	0.8	2.5	1.8	0.8	0.8	1.5	0.8	0.8	1.1	4.3	8.7	0.2	0.8	0.8	0.8	3.8	2.2	39.8	13.7	2.5	0.8	0.7	1.2	3.3	0.8	1.0	4.8	1.7	0.8	1.3	1.3	0.8	1.6	7.1	0.8	0.0	0.0	0.0	1.2	0.0	2.3	0.2	0.0	0.0	0.2	0.2	0.0	0.0	0.5	0.3	0.0	0.2	0.0	0.0	0.0	0.0	1.4	0.0	0.0	3.5	0.3	2.3	1.6	0.0	2.2	0.3	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.6	5.6	0.5	0.8	0.0	0.0	2.9	2.7	5.1	0.0	0.7	10.2	0.4	0.5	0.0	32.5	0.0	0.1	0.1	2.7	1.1	0.0	0.0	1.3	0.5	0.1	0.3	13.5	9.6	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.3	1.2	0.7	0.0	0.5	0.4	0.0	0.0	2.3	0.7	0.0	0.0	0.7	0.0	0.5	0.2	2.1	1.8	0.8	8.7	2.5	1.8	0.8	1.1	0.8	0.8	0.0	3.0	0.0	1.4	0.0	17.2	0.8	0.0	2.7	1.2	0.0	0.0	2.6	1.7	0.3	14.2	1.1	2.6	0.0	14.9	0.8	0.5	2.3	1.1	0.0	0.4	0.0	3.4	1.3	0.0	2.6	0.0	0.0	6.8	0.0	2.4	0.2	3.7	23.2	0.4	0.7	0.4	0.0	0.3	5.2	2.0	0.0	0.5	0.0	6.6	0.1
CHRM4		ENSG00000180720	"Cholinergic receptor muscarinic 4"	P08173	11	46385098-46386608	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 11.7;intestine: 8.0;lymphoid tissue: 17.2"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in single"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"RH-30: 5.0;SCLC-21H: 14.5;U-2 OS: 4.2"	"Group enriched"	"Detected in many"	6	"amygdala: 26.8;basal ganglia: 65.9;cerebral cortex: 30.5;hippocampal formation: 26.4;olfactory region: 36.4"	"Group enriched"	"Detected in many"	7	"amygdala: 5.5;basal ganglia: 15.3;cerebral cortex: 8.6;hippocampal formation: 7.6;olfactory region: 20.1"	"CAB022444, HPA072083"	Enhanced		Uncertain	"Nucleoplasm,Golgi apparatus"		NA	NA			"Golgi apparatus"	Nucleoplasm	"CAB022444: , HPA072083: "	"unprognostic (7.11e-2)"	"unprognostic (3.79e-1)"	"unprognostic (5.31e-2)"	"unprognostic (7.38e-2)"	"unprognostic (8.63e-3)"	"unprognostic (1.38e-1)"	"unprognostic (6.02e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.96e-3)"	"unprognostic (4.08e-3)"	"unprognostic (5.02e-2)"	"unprognostic (3.83e-2)"	"unprognostic (3.64e-1)"	"unprognostic (1.71e-1)"	"unprognostic (3.56e-1)"	"unprognostic (5.08e-2)"	0.0	0.5	1.1	0.2	11.7	1.6	0.0	0.0	6.0	0.0	0.6			3.7	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.6	0.0	0.0	0.2	0.0	0.2		0.0	0.2	0.0	0.5	0.0		0.0	0.1		0.0	0.0	0.0	1.2	8.0	0.1	0.0	17.2	0.8	4.1			0.0		0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.7	0.3	0.1	0.2	0.0	3.0	0.0	0.1	0.2	0.1	1.5	0.2	0.3	0.3	0.0	2.6	0.1	1.8	0.1	0.0	2.2	0.3	0.5	0.2	0.0	0.2	0.5	0.6	0.0	0.0	0.1	0.1	0.2	0.1	0.0	0.6	0.2	0.0	1.1	0.2	0.2	0.6	0.1	0.2	0.0	5.0	0.0	0.0	0.1	14.5	0.4	0.4	0.1	0.1	0.3	0.1	2.4	0.0	0.4	4.2	0.0	0.1	0.8	0.6	0.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2											0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CHRM5		ENSG00000184984	"Cholinergic receptor muscarinic 5"	P08912	15	33968720-34067457	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	4	"brain: 22.8"	"Cell type enhanced"	"Detected in some"	21	"Bipolar cells: 3.0;Early spermatids: 5.2;Extravillous trophoblasts: 13.6;Late spermatids: 3.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.8"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 4.8"	"Group enriched"	"Detected in some"	5	"BEWO: 5.5;HMC-1: 19.3"	"Region enhanced"	"Detected in many"		"hypothalamus: 15.4"	"Low region specificity"	"Detected in many"			HPA013172	Uncertain					NA	NA					"HPA013172: AB_1854212"	"unprognostic (8.19e-2)"	"unprognostic (2.13e-1)"	"unprognostic (7.67e-2)"	"unprognostic (4.32e-1)"	"unprognostic (3.05e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.49e-2)"	"unprognostic (2.79e-1)"	"unprognostic (3.02e-1)"	"unprognostic (1.27e-2)"	"unprognostic (4.61e-4)"	"unprognostic (7.95e-2)"	"unprognostic (1.33e-6)"	"unprognostic (1.42e-1)"	"unprognostic (4.53e-2)"	"unprognostic (1.38e-1)"	"unprognostic (9.07e-2)"	0.3	0.5	1.2	0.9	15.7	1.3	2.1	0.8	6.9	0.3	0.4	5.1	0.0	1.1	0.5	0.8	0.5	0.3	0.6	0.3	6.8	4.4	0.6	0.9	0.4	1.0	5.8	4.5	0.5	1.0	0.1	0.5	4.8	17.8	0.6	0.3	0.0	0.5	0.1	0.7	1.8	1.8	0.2	22.8	0.7	0.6	5.2	0.0	0.0	2.3	0.0	0.3	0.4	0.3	0.3	0.9	4.8	0.3	0.2	0.3	0.0	0.1	0.2	0.8	0.3	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.5	0.1	0.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.5	0.2	0.7	0.3	0.2	0.0	0.5	19.3	0.4	0.0	0.2	0.1	0.2	0.0	0.5	0.6	1.2	0.1	0.2	0.2	2.2	0.2	0.2	0.3	0.1	0.3	0.2	0.0	0.4	0.4	0.3	0.3	0.7	0.2	0.2	0.2	1.2	0.2	0.2	0.2	0.2	0.1	0.9	0.3	0.4	0.1	0.2	0.3	1.5	0.3	0.2	0.3	0.1	0.3	0.2	0.2	0.2	0.1	0.3	0.1	0.2	4.8	0.2	0.1	0.9	0.2	0.0	1.2	15.7	0.8	6.9	6.8	4.4	5.8	4.5	17.8	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.6	0.0	0.0	0.0	0.0	0.0	1.2	1.7	0.0	5.2	0.0	0.0	0.0	0.0	13.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.1	0.7	0.0	0.7	0.0	0.0	0.0
CHRNA10		ENSG00000129749	"Cholinergic receptor nicotinic alpha 10 subunit"	Q9GZZ6	11	3665587-3671384	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	15	"skeletal muscle: 33.6"	"Cell type enhanced"	"Detected in some"	5	"Ciliated cells: 2.7"	"Low cancer specificity"	"Detected in some"							"Cell type enhanced"	"Detected in some"		"neutrophil: 2.2"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Region enriched"	"Detected in single"	6	"olfactory region: 8.9"	"Not detected"	"Not detected"									NA	NA						"unprognostic (3.04e-1)"	"unprognostic (2.23e-1)"	"unprognostic (4.04e-2)"	"unprognostic (1.11e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.71e-2)"	"unprognostic (8.22e-2)"	"unprognostic (1.50e-1)"	"unprognostic (3.79e-2)"	"unprognostic (2.74e-1)"	"unprognostic (6.90e-5)"	"unprognostic (4.35e-2)"	"unprognostic (1.06e-5)"	"unprognostic (5.60e-2)"	"unprognostic (1.70e-2)"	"unprognostic (2.32e-1)"	"unprognostic (4.39e-3)"	0.2	0.2	0.2	0.4	0.3	0.2	0.1	1.1	0.1	0.2	0.2			0.4	0.2	0.2	0.4	0.3	0.1	0.2	0.2	0.2	0.3	0.6	0.4	0.3	0.1		0.3	0.1	0.0	0.7	0.1		0.7	0.1		0.3	0.1	33.6	0.4	0.2	0.1	0.0	1.0	0.2	0.3			0.5		0.1	0.1	0.0	0.3	0.3	2.2	0.6	0.2	1.0	0.2	1.4	1.5	2.1	2.8	0.9	0.3	1.4	1.7	0.4	1.3	1.3	1.1	2.5	2.5	1.0	0.8	1.1	3.1	1.6	0.9	1.1	1.6	5.2	0.7	3.9	0.5	1.2	0.6	2.7	0.9	1.0	0.9	0.3	0.5	0.8	3.1	2.0	0.6	1.0	0.4	1.5	4.1	2.9	2.6	2.0	2.8	0.9	0.4	1.0	2.0	1.9	0.8	0.9	0.9	1.5	1.8	0.6	3.2	0.7	1.8	2.3	1.3	2.1	0.7	1.7	1.3	0.9	1.3	1.2	0.0	0.4	0.4	1.0	0.0	0.3	0.0	0.8	0.2	0.1	0.3	0.4	0.5	2.2	0.2	0.6	0.3	0.6	0.2											0.0	0.3	0.0	0.6	1.5	1.6	0.8	0.0	2.7	0.0	0.0	0.0	0.3	0.0	0.2	1.2	0.6	0.7	0.0	0.4	0.2	0.3	0.6	0.0	0.8	0.5	1.6	0.0	1.3	0.8	0.4	0.3	0.0	1.7	1.0	0.7	1.3	0.2	0.0	0.4	0.0	0.7	0.0	0.9	0.2	0.4	1.0	0.2	0.0	0.8	0.6
CHRNA2		ENSG00000120903	"Cholinergic receptor nicotinic alpha 2 subunit"	Q15822	8	27459761-27479883	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	9	"brain: 11.6;prostate: 33.5"	"Cell type enhanced"	"Detected in single"	22	"Glandular cells: 1.6"	"Cancer enriched"	"Detected in single"	421	"prostate cancer: 30.2"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"eosinophil: 1.8;plasmacytoid DC: 1.0"	"Group enriched"	"Detected in many"	14	"dendritic cells: 1.0;granulocytes: 1.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.4;SiHa: 2.0;U-2197: 1.8;U-266/84: 1.2"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.10e-2)"	"unprognostic (1.47e-1)"			"unprognostic (2.23e-2)"	"unprognostic (3.19e-1)"	"unprognostic (6.19e-2)"	"unprognostic (6.29e-3)"			"unprognostic (1.19e-2)"	"unprognostic (2.13e-1)"	"unprognostic (1.91e-1)"	"unprognostic (7.60e-2)"	"unprognostic (1.70e-1)"	"unprognostic (1.47e-1)"		0.3	0.8	1.2	0.6	2.0	1.2	2.1	2.0	11.6	0.3	0.3	11.3	0.0	0.6	0.3	1.4	0.3	0.4	0.4	0.4	1.6	2.9	0.3	0.4	0.6	0.4	1.6	0.6	0.3	0.6	0.4	0.5	0.3	7.0	33.5	0.3	2.4	0.3	0.4	0.4	0.5	0.6	0.3	0.8	0.4	0.4	0.4	1.0	2.4	0.4	0.0	0.4	0.4	0.1	0.0	1.0	1.8	0.0	0.0	0.1	1.8	0.0	0.0	0.1	0.5	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.5	0.9	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.0	0.7	0.0	0.0	0.3	0.4	0.0	0.3	0.0	0.0	0.0	0.4	0.0	0.1	0.6	0.5	2.0	0.7	0.0	0.0	0.0	0.0	0.0	0.5	0.7	1.8	0.2	0.0	1.2	0.0	0.0	0.0	0.5	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	1.0	0.0	1.8	1.2	2.0	2.0	11.6	1.6	2.9	1.6	0.6	7.0	1.0	0.0	0.0	0.0	0.0	0.0	1.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
CHRNA3		ENSG00000080644	"Cholinergic receptor nicotinic alpha 3 subunit"	P32297	15	78593052-78621295	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 33.6;lymphoid tissue: 57.2;retina: 74.1"	"Cell type enriched"	"Detected in some"	18	"Cone photoreceptor cells: 155.1"	"Low cancer specificity"	"Detected in some"			"Region enhanced"	"Detected in some"		"cerebellum: 6.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"SH-SY5Y: 86.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA029430	Enhanced					NA	NA					"HPA029430: AB_10603785"	"unprognostic (2.28e-1)"	"unprognostic (3.45e-1)"	"unprognostic (2.58e-2)"	"unprognostic (2.36e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.12e-1)"	"unprognostic (9.16e-3)"	"unprognostic (1.97e-1)"	"unprognostic (4.28e-2)"	"unprognostic (7.20e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.86e-4)"	"unprognostic (2.65e-3)"	"unprognostic (2.76e-1)"	"unprognostic (1.53e-1)"	"unprognostic (4.48e-1)"	0.4	33.6	0.8	4.0	2.4	0.1	0.3	6.0	0.4	0.5	8.2	0.7	0.2	1.2	0.5	0.1	0.5	0.1	0.8	0.4	0.2	0.8	0.1	0.1	0.3	2.8	0.4	0.0	0.1	0.2	0.1	1.5	0.2	1.2	0.6	3.4	74.1	0.2	0.6	0.1	0.6	2.9	2.8	0.2	0.2	3.6	0.9	0.5	57.2	0.2	0.2	0.7	0.8	0.6	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.1	0.0	0.0	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	1.5	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.1	16.4	86.4	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	2.4	6.0	0.4	0.2	0.8	0.4	0.0	1.2	0.5	0.0	0.0	0.0	0.0	0.0	4.2	0.6	0.0	0.0	0.0	0.0	155.1	0.0	1.7	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.6	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	2.7	2.5	0.1	0.0	0.0	0.0	8.5	0.0	0.0	0.2	1.9	0.0	0.0	0.0	0.0	0.1
CHRNA4	"BFNC, EBN, EBN1"	ENSG00000101204	"Cholinergic receptor nicotinic alpha 4 subunit"	P43681	20	63343223-63378401	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	4	"brain: 16.4;liver: 38.8;parathyroid gland: 21.6"	"Cell type enriched"	"Detected in some"	5	"Horizontal cells: 131.9"	"Cancer enhanced"	"Detected in some"		"liver cancer: 1.4"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"U-2 OS: 7.6"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"midbrain: 22.6;pons and medulla: 19.3;thalamus: 29.6"	CAB034064	Uncertain					NA	NA					"CAB034064: AB_2080535"	"unprognostic (3.40e-1)"	"unprognostic (1.71e-1)"		"unprognostic (2.87e-2)"	"unprognostic (3.98e-1)"	"unprognostic (8.03e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.74e-1)"	"unprognostic (2.10e-3)"	"unprognostic (5.72e-4)"	"unprognostic (9.02e-3)"	"unprognostic (9.79e-4)"	"unprognostic (6.77e-2)"	"unprognostic (1.08e-1)"	"unprognostic (3.81e-2)"		0.6	0.8	5.2	0.6	8.7	0.6	0.6	3.1	14.5	0.6	0.6	11.0	0.0	0.6	0.6	0.6	0.6	2.0	0.6	0.6	5.1	6.8	2.1	38.8	0.7	0.6	11.3	8.2	0.7	0.6	21.6	1.0	0.6	16.4	1.3	0.6	5.7	0.6	0.6	0.6	0.6	0.6	0.6	3.9	4.8	0.6	1.9	3.9	0.0	1.2	0.0	0.6	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	8.7	3.1	14.5	5.1	6.8	11.3	8.2	16.4	3.9	0.0	0.0	0.0	0.0	0.0	20.2	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.2	0.0	131.9	0.0	0.0	1.0	1.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	2.8	2.3	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0
CHRNA7		ENSG00000175344	"Cholinergic receptor nicotinic alpha 7 subunit"	P36544	15	31923438-32173018	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"intestine: 27.2"	"Cell type enhanced"	"Detected in some"	14	"Cholangiocytes: 5.1;Enterocytes: 7.1;Horizontal cells: 15.9;Spermatogonia: 7.9"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 6.3;RT4: 12.2;SH-SY5Y: 6.9;SK-BR-3: 13.5;U-2 OS: 11.1"	"Low region specificity"	"Detected in all"							"HPA029422, CAB033624"	Enhanced					NA	NA					"CAB033624: AB_784835, HPA029422: AB_10600863"	"unprognostic (3.43e-2)"	"unprognostic (8.44e-2)"	"unprognostic (2.02e-1)"	"unprognostic (4.61e-4)"	"unprognostic (6.19e-2)"	"unprognostic (1.31e-1)"	"unprognostic (2.14e-2)"	"unprognostic (5.08e-2)"	"unprognostic (1.63e-1)"	"unprognostic (4.31e-2)"	"unprognostic (3.22e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.40e-2)"	"unprognostic (4.36e-3)"	"unprognostic (5.44e-2)"	"unprognostic (7.41e-3)"	"unprognostic (2.43e-1)"	0.8	12.9	4.4	1.5	3.4	2.3	2.0	0.9	8.4	1.1	12.2	1.0	1.1	7.9	1.4	0.8	0.8	0.7	4.6	1.2	2.5	5.6	0.9	0.4	1.2	2.0	3.8	2.7	2.9	4.9	1.8	2.0	0.4	11.8	2.2	4.0	11.7	2.1	1.2	0.8	0.7	27.2	0.9	3.1	5.2	11.2	5.1	0.6	0.1	4.3	0.9	1.4	3.1	2.0	0.3	1.2	3.1	1.1	1.8	0.7	0.4	0.0	1.4	2.3	6.3	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.4	0.0	2.9	0.0	0.0	0.0	1.8	0.4	0.0	1.9	0.0	0.3	0.6	0.0	0.0	0.1	0.0	0.1	0.1	2.5	0.0	0.2	0.0	0.2	0.0	0.2	1.1	3.5	0.0	0.0	3.8	0.2	0.2	12.2	0.5	6.9	0.2	13.5	0.0	0.7	0.0	0.0	0.7	0.0	11.1	0.2	0.0	0.0	0.0	0.3	0.0	0.3	0.0	1.5	1.1	3.1	0.7	0.4	0.2	0.3	0.4	0.1	1.2	0.2	0.2	0.3	0.7	1.8	0.6	0.7	0.5	0.4	4.4	3.4	0.9	8.4	2.5	5.6	3.8	2.7	11.8	0.6	0.0	0.0	0.0	2.2	0.2	1.7	1.0	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	7.1	0.0	2.2	0.0	0.0	0.5	1.1	0.0	0.1	15.9	2.9	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.6	0.0	1.5	1.1	0.0	0.0	0.0	0.0	0.4	0.2	7.9	0.0	0.0	0.0	1.5	0.9
CHRNB2		ENSG00000160716	"Cholinergic receptor nicotinic beta 2 subunit"	P17787	1	154567781-154580026	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"brain: 28.4"	"Cell type enhanced"	"Detected in some"	22	"Bipolar cells: 12.2;Cone photoreceptor cells: 13.7;Horizontal cells: 39.7;Late spermatids: 8.0;Rod photoreceptor cells: 7.6"	"Cancer enhanced"	"Detected in some"		"glioma: 1.9"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.2"	"Group enriched"	"Detected in some"	6	"SCLC-21H: 20.7;SH-SY5Y: 20.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.13e-1)"	"unprognostic (6.33e-2)"	"unprognostic (8.15e-3)"	"unprognostic (3.32e-1)"	"unprognostic (4.37e-3)"	"unprognostic (2.25e-1)"	"unprognostic (3.51e-1)"	"unprognostic (1.28e-1)"	"unprognostic (3.65e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.24e-3)"	"unprognostic (1.83e-1)"	"unprognostic (4.36e-1)"	"unprognostic (2.32e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.84e-1)"	0.9	3.2	7.8	1.2	16.4	1.0	1.8	8.1	28.4	0.9	1.1	1.6	0.0	1.4	1.0	0.9	1.1	1.0	0.9	0.9	9.4	8.9	0.9	0.9	0.9	0.9	7.9	9.8	1.0	2.1	0.9	3.3	0.9	15.4	0.9	1.2	3.1	1.0	0.9	0.9	1.3	1.2	1.1	1.4	0.9	1.6	2.0	1.7	0.0	0.9	0.0	0.9	0.9	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.5	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	3.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	20.7	20.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	7.8	16.4	8.1	22.1	9.4	8.9	7.9	9.8	15.4	1.7	0.0	0.0	0.0	0.0	0.1	12.2	1.6	0.0	0.0	0.0	0.0	13.7	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	39.7	3.5	0.0	0.0	8.0	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	7.6	0.0	0.0	0.9	0.3	0.3	0.0	0.0	0.0	0.0
CHRNB4		ENSG00000117971	"Cholinergic receptor nicotinic beta 4 subunit"	P30926	15	78624119-78727754	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"adrenal gland: 6.6;lymphoid tissue: 18.5;retina: 10.6;testis: 10.7"	"Group enriched"	"Detected in some"	21	"Early spermatids: 41.7;Late spermatids: 39.8"	"Cancer enhanced"	"Detected in some"		"testis cancer: 2.0"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	16	"SCLC-21H: 20.7;SH-SY5Y: 26.9"	"Group enriched"	"Detected in some"	5	"olfactory region: 6.5;pons and medulla: 1.4;thalamus: 4.6"	"Low region specificity"	"Detected in many"			HPA059484			Approved	"Endoplasmic reticulum,Cell Junctions"		NA	NA			"Endoplasmic reticulum"	"Cell Junctions"	"HPA059484: "	"unprognostic (4.74e-2)"	"unprognostic (4.54e-1)"	"unprognostic (1.26e-2)"	"unprognostic (8.77e-5)"	"unprognostic (8.15e-2)"	"unprognostic (6.43e-3)"	"unprognostic (1.10e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.09e-1)"	"unprognostic (3.19e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.45e-4)"	"unprognostic (7.00e-3)"	"unprognostic (2.58e-1)"	"unprognostic (8.50e-2)"	"unprognostic (7.76e-2)"	0.2	6.6	2.7	3.9	0.8	0.7	0.2	0.5	0.4	0.6	2.3	0.2	0.0	0.2	0.8	0.7	1.4	0.1	0.1	0.8	1.0	0.3	0.5	0.1	0.1	2.9	0.2	0.0	0.3	0.2	0.0	1.6	0.0	1.3	0.2	1.1	10.6	2.2	2.4	0.6	0.3	1.0	0.9	1.0	1.0	0.8	10.7	0.1	18.5	0.4	0.3	1.1	0.5	0.5	1.5	0.4	1.4	0.8	1.0	0.8	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.4	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.7	26.9	0.1	0.3	0.1	0.2	0.0	0.0	0.0	0.1	0.3	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	1.4	0.8	0.3	0.5	0.2	0.6	0.9	0.5	0.6	0.2	1.5	0.8	0.8	1.4	1.0	0.4	0.4	0.3	0.0	2.7	0.8	0.5	0.4	1.0	0.3	0.2	0.0	1.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	41.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	39.8	0.0	0.0	0.0	1.0	0.0	0.3	0.2	0.0	0.4	0.1	0.0	0.0	0.0	1.6	1.9	0.0	0.0	0.0	0.0	0.1
CKB	CKBB	ENSG00000166165	"Creatine kinase B"	P12277	14	103519659-103523111	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 158.5"	"Cell type enhanced"	"Detected in many"	9	"Bipolar cells: 2313.9;Horizontal cells: 4762.4;Muller glia cells: 3352.8;Rod photoreceptor cells: 2841.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	10	"non-classical monocyte: 50.0"	"Lineage enriched"	"Detected in many"	17	"monocytes: 50.0"	"Cell line enhanced"	"Detected in many"		"CACO-2: 54.3;HEK 293: 138.1;SCLC-21H: 78.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001254, CAB047313"	Enhanced		Supported	Cytosol		No	No		50000000	Cytosol		"CAB047313: , HPA001254: AB_1078528"	"unprognostic (9.97e-2)"	"unprognostic (1.33e-3)"	"unprognostic (4.25e-3)"	"unprognostic (1.10e-1)"	"unprognostic (7.63e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.30e-1)"	"unprognostic (4.24e-1)"	"unprognostic (4.60e-2)"	"unprognostic (2.68e-3)"	"unprognostic (9.89e-3)"	"prognostic favorable (4.02e-8)"	"unprognostic (2.62e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.13e-1)"	32.4	27.3	75.4	10.4	114.6	3.1	5.3	94.3	158.5	29.1	121.5	51.4	23.8	17.6	37.3	8.9	28.6	35.7	17.8	36.4	60.7	43.2	26.7	3.4	12.8	3.6	63.4	93.3	15.8	10.2	20.3	9.7	3.7	63.3	107.5	55.0	43.9	18.3	92.1	19.1	14.4	17.5	53.2	31.9	3.6	66.7	22.1	50.9	0.0	19.8	7.8	3.9	43.0	13.0	0.0	2.9	1.4	50.0	0.0	0.1	0.9	0.3	6.8	27.5	1.4	0.2	0.2	0.5	2.9	0.0	0.3	0.1	54.3	0.8	0.0	3.3	2.1	1.1	6.0	7.9	0.1	0.0	1.2	138.1	10.2	30.3	18.6	1.2	0.0	8.4	1.1	0.0	0.2	0.1	0.4	0.0	0.6	17.8	0.4	0.4	2.3	0.2	0.3	10.7	4.6	21.4	1.8	0.5	28.2	5.0	0.2	78.6	32.3	5.8	1.0	2.1	2.0	2.5	4.2	0.1	0.1	5.3	0.5	12.9	1.3	0.3	0.9	0.7	0.2	1.0	0.3	0.1	1.4	0.0	5.1	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.1	0.0	50.0	0.0	0.1	0.9	75.4	114.6	94.3	152.7	60.7	43.2	63.4	93.3	63.3	50.9	181.7	96.3	15.9	251.5	136.6	2313.9	490.2	117.2	301.2	83.0	108.2	1798.5	3.2	1933.1	99.3	397.5	36.5	717.3	0.0	37.5	9.9	100.2	316.9	28.8	6.8	6.9	4762.4	449.5	67.5	3.0	120.4	281.6	32.2	172.1	122.6	614.3	3352.8	99.2	2059.7	1024.0	69.5	2841.9	58.2	193.9	161.4	92.5	153.2	34.8	12.1	562.9	194.5
CKM	CKMM	ENSG00000104879	"Creatine kinase, M-type"	P06732	19	45306414-45322977	"Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"skeletal muscle: 1374.7;tongue: 354.9"	"Cell type enriched"	"Detected in some"	137	"Cardiomyocytes: 5083.5"	"Group enriched"	"Detected in many"	33	"head and neck cancer: 64.4;prostate cancer: 14.3"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"classical monocyte: 2.8;intermediate monocyte: 1.1;myeloid DC: 2.1"	"Group enriched"	"Detected in many"	25	"dendritic cells: 2.1;monocytes: 2.8"	"Cell line enriched"	"Detected in some"	4	"SCLC-21H: 37.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA047859	Enhanced					NA	NA		190000000			"HPA047859: AB_2680186"	"unprognostic (3.51e-1)"	"unprognostic (7.63e-2)"	"unprognostic (2.61e-2)"	"unprognostic (4.14e-1)"	"unprognostic (7.68e-3)"	"unprognostic (4.04e-3)"	"unprognostic (1.85e-2)"	"unprognostic (4.23e-2)"	"unprognostic (5.19e-2)"	"unprognostic (1.81e-1)"	"unprognostic (5.00e-1)"	"unprognostic (9.46e-3)"	"unprognostic (9.67e-8)"	"unprognostic (3.23e-1)"	"unprognostic (1.73e-1)"	"unprognostic (2.33e-1)"	"unprognostic (1.95e-1)"	13.9	0.1	0.2	0.1	0.2	0.1	0.4	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.1	23.5	21.1	0.1	0.1	187.9	0.2	0.1	0.2	0.2	0.2	0.1	0.2	0.0	0.1	0.2	0.1	0.1	0.1	0.0	2.8	0.1	0.8	17.6	0.2	1374.7	0.2	0.2	0.2	0.3	0.1	0.5	0.3	0.0	0.0	11.1	354.9	24.8	0.2	0.1	0.0	2.1	0.0	2.8	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	3.0	0.0	0.1	8.9	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	3.3	0.1	0.1	0.0	0.0	37.6	0.0	0.0	0.0	0.0	0.0	0.0	8.6	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	1.1	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.0	0.2	0.2	0.1	0.1	0.2	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5083.5	0.0	0.0	0.0	0.0	0.0	0.3	10.0	0.0	12.4	0.0	0.0	0.0	0.0	0.7	0.0	0.0	1.1	0.0	5.5	0.0	0.0	0.6	1.9	37.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.3	15.2	1.8	0.1	0.2	0.0	0.0	0.1
CKMT1A	CKMT1	ENSG00000223572	"Creatine kinase, mitochondrial 1A"	P12532	15	43692886-43699222	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 17.2;esophagus: 19.9;intestine: 25.5"	"Cell type enhanced"	"Detected in many"	7	"Cytotrophoblasts: 64.4;Enterocytes: 82.9;Paneth cells: 55.7;Syncytiotrophoblasts: 78.6;Undifferentiated cells: 74.1"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HaCaT: 39.8;hTCEpi: 18.1;OE19: 43.7;SK-BR-3: 31.3;T-47d: 27.9"									HPA043491	Uncertain				"Intracellular and membrane"	NA	NA		2100000			"HPA043491: AB_2678510"	"unprognostic (2.04e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.02e-3)"	"unprognostic (3.80e-1)"	"unprognostic (7.44e-2)"	"unprognostic (2.21e-1)"	"unprognostic (3.10e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.72e-1)"	"unprognostic (2.51e-2)"	"unprognostic (3.78e-9)"	"unprognostic (3.52e-2)"	"unprognostic (1.03e-1)"	"unprognostic (7.37e-2)"	"unprognostic (1.73e-3)"	0.0	0.7	4.8	1.9	6.3	0.0	2.1	17.2	12.6	1.8	25.5			24.7	0.0	0.0	19.9	0.4	3.0	0.0	5.6	7.9	0.9	0.0	0.0	0.0	5.0		0.0	0.1	2.1	1.4	2.5		0.5	24.1		7.2	0.0	0.0	13.0	21.7	0.9	1.1	0.0	7.8	0.0			0.6		4.4	1.4	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.2	0.0	0.3	0.0	9.9	0.0	0.0	0.0	0.0	2.1	6.9	0.0	0.4	0.0	0.6	39.8	5.7	11.7	0.0	0.0	4.3	0.0	0.6	0.1	0.0	0.0	1.8	0.0	18.1	0.0	3.1	0.0	0.0	1.4	1.7	0.0	0.0	9.2	0.0	0.0	2.8	43.7	2.1	0.0	0.0	1.8	1.9	1.4	14.1	5.5	0.0	31.3	2.0	0.8	27.9	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	8.2	15.8	5.9	0.4	12.7	1.4	5.7	1.8	19.6	64.4	23.2	3.4	0.0	0.1	82.9	0.0	18.3	17.8	0.6	2.2	9.2	0.0	4.0	6.4	17.2	0.0	0.0	0.0	0.0	0.0	5.0	0.0	34.6	1.5	9.9	55.7	0.0	0.3	8.7	0.0	0.3	0.0	0.0	16.2	78.6	0.0	74.1	11.5
CKMT1B	"CKMT, CKMT1, UMTCK"	ENSG00000237289	"Creatine kinase, mitochondrial 1B"	P12532	15	43593054-43604901	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 52.7;intestine: 28.1"	"Cell type enhanced"	"Detected in many"	7	"Cytotrophoblasts: 111.7;Enterocytes: 108.3;Paneth cells: 69.6;Syncytiotrophoblasts: 115.3;Undifferentiated cells: 90.6"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HaCaT: 38.6;hTCEpi: 19.9;OE19: 42.8;SK-BR-3: 47.5;T-47d: 27.7"									HPA043491	Uncertain				"Intracellular and membrane"	NA	NA		2100000			"HPA043491: AB_2678510"	"unprognostic (3.47e-2)"	"unprognostic (9.73e-3)"	"unprognostic (3.10e-1)"	"prognostic unfavorable (2.55e-5)"	"unprognostic (1.29e-1)"	"unprognostic (1.96e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.84e-1)"	"unprognostic (3.64e-1)"	"unprognostic (5.75e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.15e-2)"	"unprognostic (2.26e-8)"	"unprognostic (1.71e-2)"	"unprognostic (1.69e-1)"	"unprognostic (4.43e-2)"	"unprognostic (4.36e-2)"	0.0	0.3	5.4	1.6	8.8	0.0	1.6	52.7	13.6	0.7	28.1			22.4	0.0	0.0	13.8	0.2	2.8	0.0	6.8	7.4	0.9	0.0	0.0	0.0	5.4		0.0	0.2	1.4	1.3	3.7		0.6	23.1		4.8	0.0	0.0	7.6	16.2	1.2	1.8	0.0	10.0	0.0			1.7		4.1	1.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.1	0.0	9.4	0.0	0.0	0.0	0.0	2.2	6.6	0.0	0.3	0.0	1.9	38.6	7.7	14.8	0.0	0.1	4.5	0.0	0.9	0.9	0.0	0.0	2.2	0.0	19.9	0.0	1.7	0.0	0.0	1.5	2.5	0.0	0.0	9.4	0.0	0.0	3.1	42.8	4.1	0.0	0.0	0.2	0.7	1.0	14.9	5.3	0.2	47.5	2.8	0.6	27.7	0.0	0.0	0.0	0.5	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.3	0.0	8.5	22.2	7.6	0.3	7.6	4.0	1.2	5.2	17.7	111.7	18.3	3.4	0.0	0.1	108.3	0.0	25.5	16.9	0.5	1.7	0.0	0.0	8.1	6.4	20.2	0.0	0.0	0.0	0.0	0.0	3.3	0.0	49.2	2.3	12.5	69.6	0.0	0.5	7.5	0.0	0.2	0.0	0.0	21.7	115.3	0.0	90.6	15.9
CKMT2	SMTCK	ENSG00000131730	"Creatine kinase, mitochondrial 2"	P17540	5	81233285-81266397	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	13	"heart muscle: 153.2;skeletal muscle: 182.4;tongue: 103.6"	"Cell type enriched"	"Detected in some"	25	"Cardiomyocytes: 792.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	9	"NK-cell: 3.8"	"Lineage enriched"	"Detected in single"	9	"NK-cells: 3.8"	"Cell line enhanced"	"Detected in some"		"ASC diff: 3.7;BEWO: 6.0;Hep G2: 5.2;HHSteC: 4.0;T-47d: 9.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA051880	Enhanced					NA	NA		3200000			"HPA051880: AB_2681650"	"unprognostic (3.64e-3)"	"unprognostic (1.15e-1)"	"unprognostic (2.82e-3)"	"unprognostic (1.88e-2)"	"unprognostic (1.21e-2)"	"unprognostic (2.41e-2)"	"unprognostic (1.73e-2)"	"unprognostic (3.57e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.03e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.60e-2)"	"unprognostic (5.34e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.75e-3)"	2.5	5.0	1.3	0.3	1.9	0.2	0.8	0.4	1.2	1.2	0.5	1.2	2.5	0.3	1.3	11.5	3.0	1.2	1.5	153.2	1.5	0.9	2.7	0.3	0.4	0.3	2.3	1.4	1.6	1.3	1.1	0.7	0.3	4.1	2.0	0.3	2.5	9.1	2.1	182.4	0.5	0.6	1.4	2.8	0.4	2.1	0.9	1.5	0.0	3.3	103.6	2.9	1.0	0.6	0.4	0.1	0.0	0.4	3.8	0.3	0.0	0.1	0.9	0.0	0.9	3.7	0.8	6.0	0.1	0.0	0.0	0.0	0.3	0.3	0.7	0.4	0.0	0.9	0.1	0.0	0.0	0.0	0.5	3.2	0.0	0.7	5.2	4.0	0.5	0.2	1.4	0.0	0.0	0.0	0.5	0.0	0.8	0.0	0.6	0.0	0.7	0.2	0.1	0.8	0.0	0.4	0.8	0.9	0.0	0.0	0.1	0.7	0.7	0.5	0.4	0.9	2.3	9.7	0.4	0.8	0.5	0.9	0.5	0.3	0.1	0.1	0.8	0.4	0.5	0.9	0.0	0.2	0.0	0.1	0.4	0.0	0.1	0.3	0.0	0.0	0.4	0.1	0.2	0.0	3.8	0.0	0.1	0.2	0.0	1.3	1.9	0.4	1.2	1.5	0.9	2.3	1.4	4.1	1.5	0.0	0.3	0.0	0.4	0.1	0.7	792.8	7.6	1.4	1.2	12.2	0.0	0.1	31.5	1.6	16.2	5.3	0.0	0.0	0.5	0.4	0.6	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.8	6.6	0.0	3.3	0.0	0.0	1.3	0.2	0.0	14.2	0.6	0.9	0.0	5.9	0.2	0.4	0.1	0.2	0.0	0.2	0.1
CLCN2	"ClC-2, CLC2, EJM6"	ENSG00000114859	"Chloride voltage-gated channel 2"	P51788	3	184346185-184361651	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 21.0;intestine: 20.2"	"Cell type enhanced"	"Detected in many"	13	"Cholangiocytes: 10.2;Enterocytes: 30.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009397, HPA014545, HPA024108"	Approved		Approved	Cytosol		NA	NA			Cytosol		"CAB009397: AB_2079256, HPA014545: AB_1846881, HPA024108: AB_1846883"	"unprognostic (1.13e-1)"	"unprognostic (4.01e-2)"	"unprognostic (6.48e-2)"	"unprognostic (5.11e-3)"	"unprognostic (1.15e-1)"	"unprognostic (2.53e-2)"	"prognostic unfavorable (4.67e-8)"	"unprognostic (1.72e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.50e-3)"	"unprognostic (1.19e-1)"	"unprognostic (4.40e-2)"	"unprognostic (5.88e-2)"	"unprognostic (4.60e-2)"	"unprognostic (1.35e-1)"	1.6	5.4	4.9	2.6	8.3	1.3	1.6	8.8	6.3	2.8	20.2	16.9	5.1	11.6	4.5	5.0	1.7	2.8	21.0	1.5	6.3	3.1	3.7	1.8	1.3	1.0	15.3	4.1	6.1	5.9	4.4	4.0	1.5	8.9	2.6	14.0	15.6	3.7	9.0	1.2	2.2	11.8	2.4	10.8	1.6	2.7	11.9	9.8	0.1	3.2	1.3	1.3	2.2	2.2	0.0	0.0	0.0	0.4	0.0	0.1	0.0	8.0	2.8	2.3	6.2	2.1	1.8	5.4	2.9	1.6	2.9	1.8	15.1	2.7	2.8	8.0	1.4	7.5	14.0	3.3	3.1	0.9	2.5	4.0	2.5	5.8	6.4	1.3	1.0	2.5	3.4	2.5	2.5	2.9	1.3	2.7	3.0	1.0	1.4	1.0	4.4	0.8	1.3	3.5	6.7	4.4	5.0	2.2	9.6	3.5	6.1	3.9	2.3	3.0	10.5	4.7	1.6	8.5	1.1	1.3	1.5	4.4	7.1	7.0	3.8	4.8	1.7	2.6	4.8	6.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	8.3	8.8	6.3	6.3	3.1	15.3	4.1	8.9	9.8	3.0	2.6	0.0	0.7	0.9	2.2	1.1	10.2	4.0	1.2	0.0	0.0	0.9	0.0	3.5	2.4	0.5	30.8	0.0	1.8	0.4	1.0	0.6	1.1	0.4	0.5	1.6	2.9	1.8	0.0	1.3	4.9	0.4	0.0	1.0	3.6	1.8	1.8	7.8	4.6	2.2	2.6	0.0	0.8	3.3	1.6	0.4	1.3	0.0	6.5	0.3
CNR1	"CANN6, CB-R, CB1, CB1A, CB1K5, CNR"	ENSG00000118432	"Cannabinoid receptor 1"	P21554	6	88139864-88166359	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 30.5"	"Cell type enriched"	"Detected in some"	14	"Sertoli cells: 97.0"	"Cancer enriched"	"Detected in many"	13	"glioma: 12.5"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"memory B-cell: 2.9;naive B-cell: 2.1"	"Lineage enriched"	"Detected in single"	6	"B-cells: 2.9"	"Group enriched"	"Detected in some"	7	"ASC diff: 40.3;HSkMC: 26.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA042256, HPA069945"	Enhanced	Supported	Supported	"Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane"	"Actin filaments"	"HPA042256: AB_2677917, HPA069945: "	"unprognostic (1.28e-1)"	"unprognostic (7.04e-2)"	"unprognostic (4.61e-2)"	"unprognostic (4.08e-3)"	"unprognostic (1.21e-1)"	"unprognostic (1.07e-3)"	"unprognostic (1.37e-1)"	"unprognostic (2.07e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.16e-2)"	"unprognostic (2.74e-2)"	"unprognostic (2.68e-1)"	"unprognostic (1.70e-1)"	"unprognostic (5.59e-3)"	"unprognostic (2.68e-3)"	"unprognostic (5.88e-2)"	"unprognostic (7.00e-2)"	19.4	6.4	18.0	5.2	15.8	1.5	14.9	13.8	30.5	3.9	5.5	0.8	0.8	2.3	3.1	4.7	3.7	5.5	3.6	1.4	17.6	7.7	0.9	0.7	6.4	6.5	2.3	14.7	4.1	1.8	1.3	18.3	5.2	4.2	1.5	5.1	0.0	4.3	4.0	1.7	2.4	4.2	5.8	3.2	2.3	2.3	2.7	2.8	0.0	2.6	0.0	9.9	2.7	3.1	2.9	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	40.3	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.1	0.9	1.4	0.0	2.6	0.0	0.0	26.6	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.2	0.0	3.3	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.6	2.3	0.0	0.0	0.0	0.0	0.0	0.7	3.3	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	2.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	18.0	15.8	13.8	21.4	17.6	7.7	2.3	14.7	4.2	2.8	0.0	7.2	2.7	0.4	0.6	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	97.0	2.3	0.0	0.1	0.1	0.1	0.0	0.0	0.7
CNR2	CB2	ENSG00000188822	"Cannabinoid receptor 2"	P34972	1	23870526-23913362	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Inflammatory response"	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"blood: 19.2;lymphoid tissue: 31.1"	"Cell type enhanced"	"Detected in some"	17	"Alveolar cells type 2: 4.6;B-cells: 16.4;T-cells: 5.7"	"Cancer enriched"	"Detected in single"	6	"testis cancer: 2.5"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	7	"basophil: 19.2;eosinophil: 16.2;memory B-cell: 14.9;naive B-cell: 15.1;NK-cell: 8.7"	"Group enriched"	"Detected in many"	7	"B-cells: 15.1;granulocytes: 19.2;NK-cells: 8.7"	"Cell line enhanced"	"Detected in some"		"Daudi: 5.0;HEL: 4.2;HMC-1: 19.4;U-698: 13.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB009719	Uncertain					NA	NA					"CAB009719: AB_2082784"	"unprognostic (9.45e-4)"	"unprognostic (5.40e-3)"	"unprognostic (8.50e-3)"	"unprognostic (8.19e-3)"	"unprognostic (3.55e-3)"	"unprognostic (9.34e-6)"	"unprognostic (5.58e-3)"	"unprognostic (6.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (7.87e-2)"	"unprognostic (1.53e-1)"	"unprognostic (4.93e-2)"	"unprognostic (1.04e-3)"	"unprognostic (3.67e-1)"	"unprognostic (1.80e-1)"	"unprognostic (3.75e-2)"	"unprognostic (4.91e-2)"	0.3	0.2	0.2	18.5	0.2	1.8	0.2	0.2	0.2	0.2	0.4	0.0	0.0	0.1	0.2	0.1	1.8	0.2	0.3	0.3	0.2	0.2	0.4	0.3	0.6	27.7	0.2	0.0	0.2	0.2	0.0	0.2	0.0	0.0	0.4	0.3	0.3	3.1	0.0	1.8	0.2	5.5	0.0	0.2	29.7	0.4	0.4	0.0	3.0	0.6	0.6	31.1	1.5	0.3	15.1	0.8	19.2	0.1	8.7	2.0	0.9	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.2	0.1	0.0	0.0	0.0	19.4	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	13.0	0.0	0.1	0.0	19.2	0.1	16.2	1.7	0.0	2.0	14.9	0.1	1.5	0.2	15.1	0.1	0.9	0.6	8.7	0.1	0.8	0.1	0.9	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	3.0	4.6	16.4	0.7	0.6	0.7	0.3	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.9	0.3	3.5	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.1	2.5	0.0	0.0	0.8	0.0	0.3	0.3	0.2	0.3	0.2	5.7	0.0	0.6
COL1A1	OI4	ENSG00000108821	"Collagen type I alpha 1 chain"	P02452	17	50183289-50201632	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"			"Cancer-related genes, Disease mutation, Dwarfism, Ehlers-Danlos syndrome, FDA approved drug targets, Osteogenesis imperfecta"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 415.7"	"Cell type enhanced"	"Detected in many"	22	"Fibroblasts: 2038.6;Ito cells: 615.0;Leydig cells: 514.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 91.8;BJ: 176.2;fHDF/TERT166: 266.1;HHSteC: 71.8;HSkMC: 134.8;U-138 MG: 143.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA011795, HPA012111"	Approved		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"	NA	NA		58000000	"Endoplasmic reticulum, Vesicles"		"HPA011795: AB_1847088, HPA012111: "	"unprognostic (1.61e-1)"	"unprognostic (3.60e-3)"	"unprognostic (8.29e-2)"	"unprognostic (5.52e-2)"	"unprognostic (7.74e-2)"	"unprognostic (2.22e-1)"	"unprognostic (6.01e-2)"	"prognostic unfavorable (4.43e-4)"	"unprognostic (1.23e-2)"	"unprognostic (2.55e-2)"	"unprognostic (8.53e-2)"	"unprognostic (9.90e-2)"	"prognostic unfavorable (7.19e-12)"	"unprognostic (2.74e-2)"	"unprognostic (4.73e-2)"	"unprognostic (7.26e-2)"	"unprognostic (3.87e-3)"	30.2	5.7	0.7	28.2	4.0	0.1	31.7	0.6	0.9	415.7	25.7	1.6	23.9	3.0	121.8	70.9	17.4	33.0	110.3	43.9	0.7	0.1	7.5	4.6	18.8	38.5	0.7	1.2	73.6	10.5	1.0	10.7	89.1	2.2	31.5	4.0	9.2	9.1	21.0	11.0	35.5	10.6	88.0	1.3	13.7	15.0	44.6	0.7	7.7	6.7	15.5	8.7	67.3	49.7	0.2	0.0	0.0	0.0	0.0	1.1	0.0	0.3	0.2	0.9	0.1	37.7	91.8	1.6	176.2	47.9	43.9	27.6	3.5	0.8	0.0	0.4	266.1	0.3	0.5	0.4	0.1	7.9	0.2	0.3	0.0	4.4	0.2	71.8	0.0	0.0	134.8	2.6	53.7	0.2	7.3	0.0	0.2	0.1	0.0	22.1	0.4	0.0	0.0	0.9	0.6	0.5	0.3	0.1	0.1	0.2	0.0	0.1	0.5	0.3	0.2	0.0	13.7	2.2	0.0	0.0	143.2	31.3	21.4	0.8	0.1	0.3	0.0	10.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	4.0	0.6	0.9	0.7	0.1	0.7	1.2	2.2	0.7	8.9	14.4	0.5	11.0	166.9	0.0	4.8	0.0	5.3	12.5	7.0	0.0	29.5	0.0	11.2	0.9	5.1	0.0	0.0	3.7	26.1	2038.6	12.1	2.3	1.9	59.9	0.0	2.9	615.0	0.8	4.5	514.8	7.7	178.8	0.0	2.2	2.8	25.7	0.0	252.1	0.5	0.1	77.6	273.4	4.2	1.7	142.9	93.5	0.5	1.3	7.5
COMT		ENSG00000093010	Catechol-O-methyltransferase	P21964	22	19941607-19969975	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Catecholamine metabolism, Neurotransmitter degradation"	"Methyltransferase, Transferase"	"FDA approved drug targets, Schizophrenia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 139.3"	"Cell type enhanced"	"Detected in many"	6	"Cytotrophoblasts: 779.9;Syncytiotrophoblasts: 542.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"MCF7: 118.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001169, CAB011233"	Enhanced		Enhanced	"Endoplasmic reticulum,Vesicles"		NA	NA		560000	Vesicles	"Endoplasmic reticulum"	"CAB011233: , HPA001169: AB_1078402"	"unprognostic (5.20e-2)"	"unprognostic (2.73e-2)"	"unprognostic (3.08e-2)"	"prognostic favorable (3.68e-4)"	"unprognostic (2.99e-2)"	"unprognostic (2.32e-3)"	"unprognostic (5.54e-3)"	"unprognostic (9.14e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.14e-3)"	"prognostic favorable (5.67e-4)"	"prognostic unfavorable (9.76e-4)"	"unprognostic (2.27e-1)"	"unprognostic (7.09e-2)"	"unprognostic (3.97e-1)"	"unprognostic (1.07e-2)"	18.6	49.0	29.4	14.3	28.8	24.3	27.8	19.6	32.9	22.4	23.4	42.4	36.1	21.0	19.8	33.8	58.1	19.4	36.8	28.1	28.9	22.3	31.1	139.3	30.9	17.0	29.0	18.4	36.3	27.2	14.1	12.7	59.0	23.3	25.7	8.9	24.9	67.3	30.9	21.5	27.7	28.6	15.5	41.0	17.8	24.8	18.2	23.7	11.5	19.2	44.0	32.0	36.3	28.0	11.2	55.1	10.9	60.0	12.9	15.6	28.0	19.1	19.7	2.3	19.5	22.2	19.8	0.8	21.8	27.4	18.7	21.4	16.7	22.4	7.7	9.7	31.1	7.4	26.3	3.7	23.3	5.0	16.7	24.9	13.8	10.5	39.0	41.5	23.0	5.5	25.2	28.9	16.2	16.1	18.0	17.5	12.5	55.7	16.5	15.0	118.8	9.0	41.3	4.8	52.7	6.7	13.6	19.5	10.6	19.7	60.8	9.5	8.4	7.2	61.7	18.0	1.3	13.3	64.7	20.9	33.4	12.8	10.9	16.3	6.1	2.6	6.3	36.0	31.0	23.0	10.2	60.0	10.9	15.6	39.9	12.8	11.2	10.8	12.6	47.7	10.7	9.6	10.6	2.4	12.9	26.6	55.1	13.3	28.0	29.4	28.8	19.6	32.9	28.9	22.3	29.0	18.4	23.3	23.7	116.1	64.8	45.5	189.7	90.7	68.3	29.9	109.5	88.3	85.3	144.8	9.8	779.9	271.9	173.4	3.6	68.7	98.5	0.0	167.1	75.3	99.4	123.4	70.4	231.9	281.1	23.8	81.1	74.9	149.0	7.4	124.3	142.1	227.7	154.1	89.3	151.7	163.3	110.1	169.0	60.7	34.5	135.8	91.5	4.4	5.3	107.9	542.4	36.6	110.1	180.5
CPB2	"CPU, PCPB, TAFI"	ENSG00000080618	"Carboxypeptidase B2"	Q96IY4	13	46053195-46105033	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"	"Carboxypeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	82	"liver: 246.8"	"Cell type enriched"	"Detected in some"	8	"Hepatocytes: 1070.7"	"Cancer enriched"	"Detected in some"	112	"liver cancer: 268.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	76	"Hep G2: 62.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA004146	Approved				"Secreted to blood"	NA	NA		14000000000			"HPA004146: AB_1078397"	"unprognostic (3.44e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.89e-2)"	"unprognostic (7.69e-2)"	"unprognostic (1.17e-2)"	"prognostic favorable (2.06e-4)"	"unprognostic (1.89e-1)"	"unprognostic (2.74e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.17e-2)"	"unprognostic (4.83e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.34e-1)"	"unprognostic (7.10e-2)"	"unprognostic (3.34e-2)"	"unprognostic (9.61e-2)"	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.7	0.0	0.0	0.0	0.0	246.8	3.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.5	0.5	0.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	62.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.6	0.0	0.0	0.4	0.2	0.1	0.0	0.0	0.4	0.2	0.5	0.4	0.5	0.2	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	24.8	0.0	0.0	0.0	0.0	0.0	127.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1070.7	0.1	0.0	0.0	16.0	15.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0
CPS1		ENSG00000021826	"Carbamoyl-phosphate synthase 1"	P31327	2	210477682-210679107	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Urea cycle"	"Allosteric enzyme, Ligase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"liver: 298.3"	"Cell type enriched"	"Detected in many"	72	"Hepatocytes: 1670.2"	"Cancer enriched"	"Detected in many"	8	"liver cancer: 136.1"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HeLa: 90.5;SK-BR-3: 27.3"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"CAB003781, HPA021400"	Enhanced		Supported	"Nucleoli,Nucleoli rim"		NA	NA		2100000	"Nucleoli, Nucleoli rim"		"CAB003781: , HPA021400: AB_1847197"	"unprognostic (1.67e-2)"	"unprognostic (3.72e-2)"	"unprognostic (4.02e-2)"	"unprognostic (7.21e-7)"	"unprognostic (3.81e-2)"	"unprognostic (2.52e-1)"	"prognostic favorable (6.93e-5)"	"unprognostic (1.23e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.35e-2)"	"unprognostic (5.38e-2)"	"unprognostic (1.94e-3)"	"unprognostic (2.38e-4)"	"unprognostic (5.90e-2)"	"unprognostic (1.13e-1)"	"unprognostic (3.14e-2)"	"unprognostic (3.74e-2)"	0.4	0.1	0.5	0.3	1.6	0.0	0.8	0.3	0.7	0.4	0.2	0.7	0.3	31.5	0.3	0.7	0.5	0.2	0.4	0.3	0.5	0.4	0.6	298.3	0.2	0.3	1.5	0.8	0.7	0.2	0.0	0.4	1.1	1.4	0.3	0.0	0.6	0.2	0.2	0.3	0.3	17.2	0.4	2.3	0.3	0.2	1.3	0.5	0.0	0.4	0.4	0.1	0.2	0.4	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.3	2.4	6.3	4.3	4.2	7.4	6.7	2.3	2.7	2.7	4.2	0.6	0.0	1.0	0.1	2.5	3.8	1.1	0.2	3.8	6.8	0.0	1.9	4.0	90.5	5.6	1.4	2.1	0.0	3.8	2.8	5.3	5.4	6.9	0.3	1.7	4.0	0.3	4.4	1.1	0.1	0.2	2.4	0.0	0.6	0.2	5.8	0.5	5.7	0.0	0.1	0.4	15.8	27.3	3.0	8.5	0.0	0.7	3.0	7.0	2.1	2.1	4.9	0.0	0.3	0.0	4.6	4.4	4.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.6	0.3	0.7	0.5	0.4	1.5	0.8	1.4	0.5	11.9	9.6	20.7	0.5	1.9	1.1	0.7	15.3	1.4	6.8	1.8	7.9	0.3	0.0	0.1	23.2	1.4	0.3	23.3	0.2	0.4	2.5	1.2	3.5	1670.2	0.2	0.0	0.0	16.5	22.7	3.6	2.3	1.8	1.7	0.0	0.1	1.4	0.0	0.0	1.1	0.7	2.2	0.0	2.5	0.3	1.1	1.6	17.4	5.0	0.1	0.4
CPT1A	"CPT1, CPT1-L, L-CPT1"	ENSG00000110090	"Carnitine palmitoyltransferase 1A"	P50416	11	68754620-68844410	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Fatty acid metabolism, Lipid metabolism, Transport"	"Acyltransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA008835	Supported		Supported	Mitochondria		NA	NA		790000	Mitochondria		"HPA008835: AB_1078563"	"prognostic unfavorable (3.84e-4)"	"unprognostic (1.38e-3)"	"unprognostic (3.04e-3)"	"unprognostic (2.46e-2)"	"unprognostic (1.45e-1)"	"unprognostic (7.25e-2)"	"unprognostic (2.17e-1)"	"unprognostic (4.99e-2)"	"unprognostic (2.72e-1)"	"unprognostic (1.47e-2)"	"unprognostic (2.92e-2)"	"unprognostic (2.34e-1)"	"prognostic favorable (2.67e-7)"	"unprognostic (9.76e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.46e-3)"	18.0	18.3	9.9	9.9	12.1	15.8	24.4	7.0	10.3	12.8	31.9	8.2	14.1	33.7	17.0	7.2	11.2	12.8	14.7	14.6	12.0	6.6	30.6	62.0	13.1	10.1	10.5	8.6	17.0	24.4	16.9	13.8	8.7	10.8	15.6	22.0	19.7	12.9	11.4	6.9	10.3	33.4	16.9	8.7	18.9	16.8	10.4	9.0	17.9	13.2	7.5	7.6	11.3	30.2	2.5	11.9	10.6	8.6	5.7	8.8	2.5	8.1	14.5	2.1	14.2	9.3	8.4	0.6	6.5	5.4	5.2	1.0	0.5	27.6	0.0	24.2	17.2	18.2	26.9	18.4	3.9	1.5	13.0	1.8	20.1	15.8	6.7	13.9	11.6	24.3	8.7	1.9	10.4	6.3	7.1	18.3	8.1	2.1	16.5	4.7	23.4	9.4	20.6	0.2	42.2	15.4	26.5	0.3	35.6	12.2	20.4	0.2	9.3	18.0	34.9	5.7	1.4	31.1	11.3	18.4	11.3	0.2	22.6	9.4	12.9	16.4	8.3	11.9	8.6	12.3	9.2	7.8	10.6	8.8	8.6	5.1	2.3	5.5	5.3	5.0	2.5	3.4	7.0	3.8	5.7	7.2	11.9	2.9	2.5	9.9	12.1	7.0	10.3	12.0	6.6	10.5	8.6	10.8	9.0	35.7	36.9	11.5	7.7	8.4	4.9	22.1	28.1	32.1	22.7	22.7	60.9	12.9	16.6	11.2	9.2	25.4	82.1	0.0	8.1	4.1	13.9	7.4	27.8	79.0	14.6	1.6	15.5	37.4	42.3	15.7	8.9	13.5	0.0	11.8	44.9	12.9	9.7	40.3	30.1	9.4	41.0	38.8	16.0	12.1	8.8	6.8	6.5	16.6	59.0	6.4
CPT2	"CPT1, CPTASE"	ENSG00000157184	"Carnitine palmitoyltransferase 2"	P23786	1	53196429-53214197	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Fatty acid metabolism, Lipid metabolism, Transport"	"Acyltransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 69.0"	"Cell type enhanced"	"Detected in many"	6	"Cytotrophoblasts: 64.6;Hepatocytes: 80.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA028201, HPA028202, HPA028214"	Enhanced		Approved	Nucleoplasm,Nucleoli,Mitochondria		Yes	No			"Nucleoplasm, Mitochondria"	Nucleoli	"HPA028201: AB_10599177, HPA028202: AB_10599942, HPA028214: AB_10601958"	"unprognostic (2.43e-1)"	"unprognostic (2.27e-1)"	"prognostic favorable (5.27e-4)"	"unprognostic (6.48e-2)"	"unprognostic (1.88e-1)"	"unprognostic (9.34e-2)"	"unprognostic (6.48e-2)"	"unprognostic (1.75e-2)"	"unprognostic (2.86e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.00e-2)"	"unprognostic (8.97e-2)"	"prognostic favorable (1.46e-12)"	"unprognostic (4.00e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.79e-2)"	"unprognostic (2.95e-2)"	7.5	15.5	5.3	6.8	6.1	2.3	6.5	4.0	7.2	5.1	15.4	9.4	10.7	16.6	5.1	7.6	10.5	5.4	11.3	21.4	4.3	4.5	19.8	69.0	6.9	8.3	5.7	3.7	5.3	15.9	10.7	11.5	18.1	6.4	6.0	15.6	13.8	11.8	12.2	13.6	6.0	18.9	5.5	5.2	10.3	10.1	11.2	4.7	9.7	8.3	7.2	10.3	8.0	4.9	5.9	12.4	10.0	13.1	4.8	8.0	6.5	7.7	3.2	7.5	7.3	6.5	3.8	8.5	4.8	4.9	6.9	6.4	1.6	6.5	13.2	7.3	2.2	7.8	7.7	14.0	11.0	5.9	7.3	8.2	7.5	4.3	1.3	9.5	7.1	7.3	8.2	9.4	5.0	4.2	7.7	4.7	11.7	9.6	4.7	4.2	4.5	5.5	5.8	14.0	14.4	8.6	6.4	7.2	13.9	8.6	7.2	11.2	7.6	9.6	12.2	18.1	18.1	14.2	15.2	4.5	3.9	3.1	6.8	3.9	14.5	8.9	8.1	5.0	8.2	5.7	4.1	8.4	10.0	5.1	12.6	6.2	4.5	4.9	5.9	12.4	5.9	8.0	5.5	5.1	4.8	13.1	6.4	7.0	6.5	5.3	6.1	4.0	7.2	4.3	4.5	5.7	3.7	6.4	4.7	11.9	20.8	8.9	5.1	1.5	3.1	12.4	15.3	4.0	3.4	10.4	13.7	64.6	21.6	10.7	1.1	3.6	39.8	0.0	9.3	16.0	2.8	4.8	2.3	80.0	23.6	14.3	13.9	6.7	13.5	2.1	6.4	8.2	6.8	26.2	26.9	10.5	9.8	21.0	4.9	28.3	9.9	6.5	3.2	29.8	16.3	2.3	45.7	7.1	25.3	4.6
CRBN	"MRT2, MRT2A"	ENSG00000113851	Cereblon	Q96SW2	3	3144628-3179727	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Ubl conjugation pathway"		"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA045910	Approved					NA	NA					"HPA045910: AB_10960409"	"unprognostic (1.26e-1)"	"unprognostic (4.14e-2)"	"unprognostic (4.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (1.85e-2)"	"unprognostic (3.31e-2)"	"unprognostic (1.21e-1)"	"unprognostic (6.40e-3)"	"unprognostic (2.15e-1)"	"unprognostic (2.38e-1)"	"unprognostic (1.23e-1)"	"unprognostic (4.79e-2)"	"unprognostic (2.17e-3)"	"unprognostic (1.70e-1)"	"unprognostic (5.95e-2)"	"unprognostic (2.28e-2)"	"unprognostic (1.47e-2)"	22.9	17.3	30.9	12.4	29.0	28.1	26.2	41.8	36.6	19.1	19.1	15.3	15.8	15.9	19.7	18.5	15.4	16.8	15.5	22.0	27.6	27.1	23.1	25.6	18.3	18.8	31.4	25.2	25.0	17.3	20.4	23.4	21.4	38.6	20.7	17.7	9.5	27.4	18.9	31.8	17.9	20.3	24.7	37.1	21.2	16.6	33.5	33.1	18.3	24.0	12.9	15.3	20.2	17.9	13.0	10.9	65.3	14.3	26.2	25.5	26.1	7.2	6.1	19.2	8.3	23.2	23.1	8.0	8.2	14.0	10.9	14.8	8.9	10.8	7.9	12.2	10.2	13.3	7.1	11.6	13.7	12.0	13.9	18.5	20.3	12.1	11.1	15.8	18.2	13.3	17.6	18.4	11.8	9.0	21.5	14.6	17.3	11.8	17.2	9.5	10.6	15.9	18.2	15.9	10.0	15.1	14.6	11.5	18.7	12.8	11.5	8.4	14.1	9.1	12.6	19.7	15.0	16.8	13.6	9.3	11.1	5.9	15.9	10.6	19.7	31.9	19.9	17.4	16.8	13.5	65.3	12.6	25.9	18.1	14.2	19.2	13.0	24.4	19.3	10.9	10.1	25.5	21.0	7.2	26.2	14.3	5.7	16.7	26.1	30.9	29.0	41.8	36.6	27.6	27.1	31.4	25.2	38.6	33.1	41.7	33.7	28.3	31.7	32.1	54.5	62.4	35.7	33.5	34.2	36.6	25.5	45.4	61.3	28.7	136.1	69.7	24.8	23.3	18.7	30.4	35.8	22.7	134.3	31.0	31.4	41.3	15.0	47.9	45.5	37.6	58.1	40.7	32.1	46.9	26.5	64.8	20.5	28.5	62.6	57.5	63.0	58.2	39.2	114.7	88.4	33.6	42.0	72.2	28.7	17.6
CRHR1	"CRF-R, CRF1, CRHR"	ENSG00000120088	"Corticotropin releasing hormone receptor 1"	P34998	17	45784280-45835828	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	7	"brain: 23.2;pituitary gland: 16.5"	"Group enriched"	"Detected in some"	13	"Early spermatids: 37.9;Late spermatids: 37.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"RT4: 8.1;SH-SY5Y: 5.0"									CAB025251	Enhanced				"Intracellular and membrane"	NA	NA					"CAB025251: "	"unprognostic (4.59e-2)"	"unprognostic (1.43e-2)"		"unprognostic (2.59e-7)"	"unprognostic (1.76e-1)"	"unprognostic (2.71e-1)"		"unprognostic (3.94e-2)"	"unprognostic (2.48e-1)"	"unprognostic (4.55e-4)"	"unprognostic (1.65e-2)"	"unprognostic (2.21e-1)"	"unprognostic (3.33e-4)"	"unprognostic (2.07e-5)"	"unprognostic (3.26e-1)"	"unprognostic (1.49e-1)"	"unprognostic (1.59e-1)"	0.8	0.6	14.7	0.5	5.1	0.5	1.5	23.2	11.5	1.4	0.6	1.1	0.0	0.8	2.7	1.1	0.5	1.6	0.7	0.5	3.2	2.2	0.6	0.5	0.6	0.5	1.8	5.2	0.6	0.5	0.6	16.5	0.6	2.9	1.3	0.6	1.9	1.2	2.5	0.6	1.4	1.0	1.2	1.0	0.5	0.5	1.0	2.8	0.0	0.9	0.0	0.5	1.4	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1	1.6	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.7	5.1	23.2	11.5	3.2	2.2	1.8	5.2	2.9	2.8	0.0	0.0	0.0	1.1	1.0	0.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.9	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.3	0.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.0	0.5	0.0	0.1	2.3	1.5	2.9	0.0	0.0	0.0	0.5
CSF1R	"C-FMS, CD115, CSFR, FMS"	ENSG00000182578	"Colony stimulating factor 1 receptor"	P07333	5	150053291-150113372	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Immunity, Inflammatory response, Innate immunity"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 82.5;lymphoid tissue: 82.6"	"Group enriched"	"Detected in many"	8	"Extravillous trophoblasts: 97.9;Hofbauer cells: 277.3;Kupffer cells: 200.7;Macrophages: 125.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 60.7;non-classical monocyte: 82.5"	"Lineage enriched"	"Detected in many"	4	"monocytes: 82.5"	"Group enriched"	"Detected in some"	5	"BEWO: 51.8;SK-BR-3: 19.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008970, HPA012323"	Uncertain		Supported	"Vesicles,Plasma membrane"	"Intracellular and membrane"	NA	NA		1500000000	"Vesicles, Plasma membrane"		"CAB008970: , HPA012323: AB_1848977"	"unprognostic (3.82e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.86e-3)"	"unprognostic (9.83e-2)"	"unprognostic (1.20e-1)"	"unprognostic (7.33e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.45e-1)"	"unprognostic (9.37e-2)"	"unprognostic (1.11e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.65e-1)"	"prognostic unfavorable (1.08e-4)"	"unprognostic (3.67e-2)"	"prognostic unfavorable (4.92e-4)"	"unprognostic (1.72e-2)"	"unprognostic (4.61e-2)"	20.9	12.4	18.2	28.1	18.9	1.8	7.7	2.8	13.5	9.3	8.3	25.4	1.1	9.2	5.9	13.1	8.4	7.9	16.1	8.7	16.4	13.7	7.8	15.1	13.7	25.4	21.3	6.0	5.3	5.2	5.9	6.4	52.1	17.1	8.5	8.4	16.8	8.0	8.7	3.0	5.8	14.5	16.2	25.8	82.6	9.0	4.9	23.0	3.1	4.2	2.9	8.2	16.4	4.7	0.0	19.1	2.9	82.5	0.0	0.1	13.9	1.7	0.0	0.0	0.0	0.8	0.2	51.8	0.1	0.0	0.0	0.0	1.5	0.0	2.4	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	1.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.1	0.0	19.8	0.0	0.8	0.0	7.4	0.0	0.3	0.0	0.0	1.3	0.0	0.1	0.0	2.6	0.9	0.0	0.4	18.1	0.5	0.1	60.7	0.0	0.0	0.0	0.0	19.1	0.0	0.0	0.0	2.9	0.0	82.5	1.4	0.0	13.9	18.2	18.9	2.8	13.4	16.4	13.7	21.3	6.0	17.1	23.0	0.0	6.7	0.5	0.0	2.5	0.0	2.8	5.1	1.4	0.0	0.0	0.0	2.9	0.0	0.0	3.7	2.2	0.0	0.0	0.0	97.9	3.3	0.0	2.3	0.8	277.3	0.0	0.0	4.9	200.7	3.5	1.7	125.7	3.3	1.8	0.0	0.0	0.1	0.0	0.0	0.0	0.4	12.9	1.3	0.5	0.2	1.1	22.1	2.2	0.0	0.0
CSF2RA	"alphaGMR, CD116, CSF2R"	ENSG00000198223	"Colony stimulating factor 2 receptor alpha subunit"	P15509	X	1268800-1310381	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 60.2;placenta: 79.5"	"Cell type enhanced"	"Detected in many"	26	"Cytotrophoblasts: 215.8;monocytes: 954.0;Syncytiotrophoblasts: 261.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 30.0;eosinophil: 36.0;intermediate monocyte: 17.7;myeloid DC: 31.9;neutrophil: 60.2;plasmacytoid DC: 30.5"	"Group enriched"	"Detected in many"	28	"dendritic cells: 31.9;granulocytes: 60.2;monocytes: 30.0"	"Group enriched"	"Detected in some"	7	"BEWO: 60.4;HMC-1: 18.2;SK-MEL-30: 42.3"									CAB016148	Uncertain				"Secreted to blood"	NA	NA		9400000			"CAB016148: AB_626868"	"unprognostic (4.19e-2)"	"prognostic favorable (2.38e-5)"	"unprognostic (5.47e-2)"	"unprognostic (4.33e-2)"	"unprognostic (4.88e-2)"	"prognostic favorable (2.81e-4)"	"unprognostic (8.24e-2)"	"unprognostic (2.17e-1)"	"unprognostic (5.55e-2)"	"unprognostic (8.48e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.80e-1)"	"unprognostic (2.89e-2)"	"unprognostic (8.91e-3)"	"prognostic unfavorable (5.53e-4)"	"unprognostic (3.60e-1)"	"unprognostic (9.44e-2)"	8.7	2.3	11.8	11.1	11.1	8.9	17.7	3.4	9.6	3.1	2.2	0.6	0.6	2.2	4.4	0.6	2.1	2.2	5.7	3.7	15.0	4.7	2.4	1.7	11.2	8.3	18.8	6.5	3.5	1.0	0.2	2.1	79.5	13.2	1.5	3.3	0.6	3.1	1.0	0.6	1.8	3.3	2.9	25.5	12.6	1.7	0.6	16.3	0.6	2.5	0.6	10.4	4.2	1.5	0.3	31.9	60.2	30.0	1.4	0.2	10.1	0.1	3.5	0.2	0.0	0.0	0.0	60.4	0.0	0.1	0.1	0.0	1.2	0.3	0.0	3.9	0.0	3.3	0.0	0.0	0.0	0.0	1.1	0.0	0.0	2.4	0.0	0.0	1.3	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.1	5.6	0.5	0.5	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	1.0	0.0	42.3	5.0	2.8	5.0	0.0	0.0	1.7	0.3	0.0	0.1	0.1	0.1	0.0	5.5	0.0	2.4	30.0	36.0	0.0	17.7	0.2	0.3	0.0	0.0	31.9	0.1	0.0	0.0	60.2	1.4	8.4	30.5	0.1	10.1	11.8	11.1	3.4	9.6	15.0	4.7	18.8	6.5	13.2	16.3	0.0	8.2	11.1	1.0	6.9	0.6	1.1	5.1	4.0	5.7	1.8	0.0	215.8	0.0	0.2	0.5	1.4	0.0	0.0	1.5	101.6	5.3	0.5	9.3	0.0	66.0	0.0	0.0	1.3	66.8	0.0	0.9	146.7	8.5	954.0	0.0	0.5	0.3	0.0	0.4	0.0	1.1	6.5	2.1	0.2	0.4	4.5	261.3	0.0	0.0	2.1
CSF2RB	"betaGMR, CD131, IL3RB, IL5RB"	ENSG00000100368	"Colony stimulating factor 2 receptor beta common subunit"	P32927	22	36913628-36940449	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 53.1;placenta: 73.6"	"Cell type enhanced"	"Detected in many"	12	"Extravillous trophoblasts: 32.6;granulocytes: 87.9;Macrophages: 41.6;monocytes: 29.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"basophil: 53.1;neutrophil: 20.1"	"Lineage enriched"	"Detected in many"	14	"granulocytes: 53.1"	"Group enriched"	"Detected in some"	6	"HEL: 27.0;HMC-1: 84.6"					"Low region specificity"	"Detected in all"			HPA078677			Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA078677: AB_2732389"	"unprognostic (1.67e-2)"	"unprognostic (9.44e-3)"	"unprognostic (1.03e-2)"	"unprognostic (6.66e-3)"	"unprognostic (1.51e-1)"	"prognostic favorable (7.47e-5)"	"unprognostic (1.86e-1)"	"unprognostic (1.94e-2)"	"unprognostic (4.38e-1)"	"unprognostic (9.57e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.21e-1)"	"unprognostic (1.82e-3)"	"unprognostic (5.76e-2)"	"unprognostic (3.65e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.52e-2)"	8.5	1.8	1.5	28.9	1.5	21.7	6.0	0.6	1.0	3.0	5.9	2.0	0.4	4.5	2.2	2.8	4.0	3.6	5.5	4.2	1.4	1.4	2.4	3.5	12.6	34.1	2.9	0.2	2.5	1.9	0.3	1.2	73.6	2.4	3.5	3.8	2.8	9.7	1.0	2.6	3.8	10.2	3.0	2.9	25.2	3.9	2.1	1.9	8.2	3.4	4.8	30.5	8.2	4.3	0.4	3.8	53.1	2.1	0.0	0.6	1.8	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	0.0	27.0	0.0	0.0	0.0	0.4	84.6	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	3.2	0.0	0.0	0.0	2.8	0.0	0.0	0.0	2.7	0.0	10.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	2.4	0.1	0.2	0.0	0.0	0.0	0.4	0.2	1.7	0.0	3.9	0.0	53.1	1.9	5.8	0.0	2.1	0.0	0.4	0.0	0.0	1.2	0.3	0.0	0.0	20.1	0.0	1.7	3.8	0.6	1.8	1.5	1.5	0.6	1.0	1.4	1.4	2.9	0.2	2.4	1.9	0.0	14.5	8.2	0.0	6.4	0.0	0.8	5.1	5.3	3.4	0.0	0.0	2.2	0.0	0.0	11.1	9.0	0.0	0.0	0.2	32.6	4.1	0.0	87.9	0.0	16.8	0.0	0.0	4.3	26.0	26.5	0.0	41.6	11.8	29.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	5.5	13.8	1.3	0.0	0.0
CSF3R	"CD114, GCSFR"	ENSG00000119535	"Colony stimulating factor 3 receptor"	Q99062	1	36466043-36483278	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 167.3;bone marrow: 88.9;lymphoid tissue: 71.4;placenta: 152.7"	"Cell type enhanced"	"Detected in many"	27	"Alveolar cells type 2: 228.0;Cytotrophoblasts: 271.6;Syncytiotrophoblasts: 999.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 167.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 167.3"	"Group enriched"	"Detected in some"	18	"BEWO: 34.9;NB-4: 9.4;THP-1: 22.9;U-937: 22.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB017116, HPA048086"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB017116: , HPA048086: AB_2680257"	"unprognostic (5.57e-3)"	"unprognostic (8.05e-2)"	"unprognostic (7.23e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.88e-1)"	"unprognostic (2.92e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.83e-1)"	"unprognostic (5.65e-2)"	"unprognostic (2.47e-1)"	"unprognostic (3.44e-1)"	"prognostic unfavorable (5.72e-4)"	"unprognostic (6.33e-2)"	"prognostic unfavorable (3.79e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.31e-2)"	8.5	1.5	2.9	39.5	3.2	88.9	2.4	0.7	2.9	1.1	1.1	4.2	0.4	0.6	0.7	1.1	1.2	6.9	4.3	5.6	2.6	2.0	1.7	4.5	26.9	27.5	7.2	1.1	1.1	1.3	0.3	1.1	152.7	3.8	1.3	0.5	2.1	1.6	0.5	0.6	0.3	1.6	3.1	7.1	71.4	2.2	1.4	3.3	1.1	1.0	0.4	0.9	4.6	3.9	0.0	8.2	167.3	22.1	0.2	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	34.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.9	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	9.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.7	0.0	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	22.1	0.0	0.0	22.1	0.6	0.0	4.8	0.0	0.0	0.0	0.0	8.2	0.0	0.0	0.0	167.3	0.2	1.8	0.2	0.0	10.3	2.9	3.2	0.7	2.9	2.6	2.0	7.2	1.1	3.8	3.3	23.8	228.0	2.4	0.6	0.9	0.0	1.4	0.0	12.0	18.2	0.0	0.0	271.6	0.0	0.0	0.4	1.9	0.0	0.0	0.0	49.1	3.0	0.2	17.4	0.8	60.8	0.0	0.0	3.7	146.3	0.4	0.3	62.6	0.0	3.6	0.0	0.2	0.1	0.0	0.0	0.4	0.2	0.0	0.3	0.0	0.2	0.1	999.2	0.5	0.0	2.2
CTLA4	"CD, CD152, CELIAC3, GSE, IDDM12"	ENSG00000163599	"Cytotoxic T-lymphocyte associated protein 4"	P16410	2	203867786-203873960	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"		"Diabetes mellitus, Disease mutation, FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 24.8;lymphoid tissue: 31.2"	"Cell type enhanced"	"Detected in some"	22	"Alveolar cells type 2: 5.6;granulocytes: 1.1;T-cells: 1.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in some"	6	"T-reg: 24.8"	"Lineage enriched"	"Detected in single"	248	"T-cells: 24.8"	"Cell line enhanced"	"Detected in some"		"SK-MEL-30: 3.9;U-266/70: 5.9;U-266/84: 16.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Intracellular and membrane"	NA	NA						"unprognostic (1.92e-2)"	"unprognostic (9.13e-3)"	"unprognostic (1.47e-3)"	"unprognostic (9.89e-6)"	"unprognostic (1.86e-1)"	"prognostic favorable (4.48e-5)"	"unprognostic (1.02e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.84e-3)"	"unprognostic (2.65e-3)"	"unprognostic (2.77e-1)"	"unprognostic (3.76e-1)"	"unprognostic (9.86e-10)"	"unprognostic (4.13e-2)"	"unprognostic (7.45e-2)"	"unprognostic (4.94e-2)"	"unprognostic (1.19e-2)"	1.6	0.2	0.2	24.1	0.3	2.9	1.3	0.2	0.6	0.8	1.6	0.1	0.6	0.2	1.1	0.1	2.0	1.2	3.6	0.5	0.3	0.5	1.6	0.6	5.8	27.9	0.3	0.3	0.7	0.3	0.1	0.6	0.1	1.7	1.1	1.7	0.8	1.4	0.6	0.2	1.0	10.3	0.3	1.5	6.7	1.2	1.7	0.1	14.2	1.9	3.3	31.2	4.6	1.3	0.0	0.0	0.0	0.0	0.0	24.8	0.4	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.3	0.0	0.5	0.1	0.3	0.0	5.9	16.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	4.0	0.4	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	24.8	0.4	0.2	0.3	0.2	0.6	0.3	0.5	0.3	0.3	1.7	0.1	0.0	5.6	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	1.1	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.7	0.6	0.1	1.9	0.0	0.0
CXCR4	"CD184, D2S201E, fusin, HM89, HSY3RR, LESTR, NPY3R, NPYR, NPYY3R"	ENSG00000121966	"C-X-C motif chemokine receptor 4"	P61073	2	136114349-136118165	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 149.9;lymphoid tissue: 186.3"	"Cell type enhanced"	"Detected in many"	14	"B-cells: 772.9;Macrophages: 299.5;monocytes: 255.1;T-cells: 588.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 76.4;JURKAT: 43.5;Karpas-707: 41.0;MOLT-4: 69.2;REH: 36.7;U-266/70: 88.9;U-698: 89.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.19e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.69e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.12e-2)"	"unprognostic (4.99e-2)"	"unprognostic (9.25e-2)"	"unprognostic (6.06e-2)"	"prognostic favorable (2.05e-4)"	"unprognostic (1.23e-1)"	"unprognostic (2.66e-1)"	"prognostic unfavorable (1.41e-7)"	"prognostic unfavorable (5.67e-4)"	"unprognostic (1.57e-1)"	"unprognostic (3.47e-2)"	"unprognostic (9.33e-2)"	15.4	26.5	3.0	39.1	3.4	149.9	9.7	0.8	2.1	7.7	8.7	6.8	1.5	1.6	8.3	3.8	16.4	9.1	12.0	5.4	4.1	4.7	8.2	7.1	29.3	94.5	6.5	1.3	6.3	3.1	0.7	8.1	7.8	6.1	6.8	7.0	10.0	10.6	2.2	3.2	2.3	57.8	3.8	22.9	82.4	8.0	7.2	3.4	186.3	9.2	4.6	97.5	50.0	6.6	47.3	16.8	37.8	7.2	4.0	32.0	11.9	0.1	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	76.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	3.8	0.9	4.6	12.1	0.0	0.0	10.5	8.3	0.0	0.0	0.0	0.0	0.0	7.3	43.5	0.1	41.0	0.0	0.2	69.2	9.4	1.2	5.9	0.4	36.7	8.5	13.3	0.6	0.0	4.2	3.5	0.0	0.2	0.0	0.4	0.0	20.7	1.0	0.0	0.2	0.0	0.0	88.9	15.0	89.4	0.0	17.4	0.0	17.9	7.2	29.6	22.9	3.8	18.7	30.1	21.1	21.7	6.6	47.3	32.0	30.1	37.8	4.0	2.1	16.8	18.9	11.9	3.0	3.4	0.8	2.1	4.1	4.7	6.5	1.3	6.1	3.4	14.9	64.2	772.9	4.0	36.5	4.4	3.6	2.5	4.0	6.8	3.5	0.0	1.4	11.6	3.6	0.9	19.0	0.0	46.7	0.8	2.2	30.2	4.8	11.6	5.5	168.4	0.0	1.7	22.7	175.5	1.7	1.4	299.5	108.0	255.1	0.1	1.0	1.6	0.0	2.5	2.1	0.6	45.3	16.3	0.5	5.5	31.1	5.3	588.4	0.4	3.2
CYP11A1	"CYP11A, P450SCC"	ENSG00000140459	"Cytochrome P450 family 11 subfamily A member 1"	P05108	15	74337759-74367740	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Steroidogenesis, Sterol metabolism"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"adrenal gland: 145.3;placenta: 157.2"	"Group enriched"	"Detected in some"	5	"Extravillous trophoblasts: 305.6;Syncytiotrophoblasts: 1214.3"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in single"	36	"basal ganglia: 14.8"	"Cell type enriched"	"Detected in single"	37	"basophil: 15.8"	"Lineage enriched"	"Detected in single"	37	"granulocytes: 15.8"	"Group enriched"	"Detected in some"	4	"BEWO: 44.0;HEL: 35.0"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA016436	Enhanced					NA	NA					"HPA016436: AB_1847423"	"unprognostic (8.89e-2)"	"unprognostic (6.96e-2)"	"unprognostic (4.95e-3)"	"unprognostic (9.31e-2)"	"unprognostic (9.42e-4)"	"unprognostic (1.90e-1)"	"unprognostic (1.55e-3)"	"unprognostic (8.06e-2)"	"unprognostic (3.04e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.77e-2)"	"unprognostic (5.45e-2)"	"unprognostic (9.66e-4)"	"unprognostic (2.40e-2)"	"unprognostic (2.74e-1)"	"unprognostic (3.04e-2)"	"unprognostic (7.95e-2)"	0.4	145.3	0.4	0.1	14.8	0.0	0.4	0.3	0.3	0.2	0.2	7.6	0.1	0.0	0.3	0.5	1.5	0.3	0.0	0.3	0.3	0.2	0.1	0.7	0.1	0.0	0.3	0.2	9.2	0.1	0.0	0.4	157.2	0.2	0.2	0.0	0.3	0.1	0.6	0.3	0.1	0.1	0.3	0.3	5.7	0.1	20.4	0.1	0.0	0.1	0.3	0.7	0.2	0.2	0.0	0.0	15.8	0.0	0.4	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.3	44.0	0.1	0.0	0.3	0.1	0.0	0.0	0.0	1.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.1	35.0	1.0	0.3	0.2	0.0	0.2	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	8.9	0.0	0.0	6.9	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.1	0.0	0.0	0.1	0.0	0.0	15.8	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.4	14.8	0.3	0.3	0.3	0.2	0.3	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.4	2.5	0.0	0.0	0.0	0.0	139.8	1.7	0.0	1.4	0.0	0.0	0.0	0.0	305.6	0.6	0.1	0.0	3.4	19.4	0.0	0.0	0.0	0.0	2.9	45.1	0.0	0.0	1.0	0.0	5.1	0.2	0.0	163.4	0.0	0.0	0.0	0.0	3.2	3.1	0.0	1214.3	0.0	0.0	0.0
CYP11B1	"CPN1, CYP11B, FHI, P450C11"	ENSG00000160882	"Cytochrome P450 family 11 subfamily B member 1"	P15538	8	142872356-142879846	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroidogenesis"	"Monooxygenase, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	781	"adrenal gland: 224.9"	"Group enriched"	"Detected in some"	119	"Early spermatids: 41.1;Late spermatids: 67.4"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"SCLC-21H: 3.1;SH-SY5Y: 1.3"									"HPA049171, HPA056348, HPA057752"	Supported					NA	NA					"HPA049171: AB_2680661, HPA056348: AB_2683104, HPA057752: AB_2683516"																		0.0	224.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	41.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0
CYP17A1	"CPT7, CYP17, P450C17, S17AH"	ENSG00000148795	"Cytochrome P450 family 17 subfamily A member 1"	P05093	10	102830531-102837533	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	Steroidogenesis	"Lyase, Monooxygenase, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"adrenal gland: 425.4"	"Cell type enhanced"	"Detected in some"	17	"Distal tubular cells: 18.3;Early spermatids: 40.8;Proximal tubular cells: 39.5"	"Cancer enriched"	"Detected in many"	5	"liver cancer: 22.7"	"Region enriched"	"Detected in single"	103	"basal ganglia: 19.7"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.2"	"Group enriched"	"Detected in some"	4	"HMC-1: 8.0;SCLC-21H: 3.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA048533	Enhanced				"Intracellular and membrane"	NA	NA					"HPA048533: AB_2680432"	"unprognostic (1.07e-2)"	"unprognostic (8.84e-2)"	"unprognostic (3.01e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.91e-1)"	"unprognostic (6.29e-2)"	"unprognostic (2.92e-3)"	"unprognostic (2.39e-4)"	"unprognostic (8.26e-2)"	"unprognostic (2.35e-1)"	"unprognostic (5.92e-3)"	"unprognostic (1.13e-1)"	"prognostic favorable (5.43e-7)"	"unprognostic (1.07e-1)"	"unprognostic (5.56e-2)"	"unprognostic (1.66e-2)"	"unprognostic (2.94e-4)"	0.0	425.4	0.0	0.1	19.7	0.0	0.0	0.1	0.1	0.1	0.0	78.5	0.0	0.0	0.1	0.3	0.1	0.1	0.0	0.1	0.0	0.0	6.4	1.7	0.1	0.0	0.0	0.0	3.2	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	82.3	0.0	0.1	2.2	0.0	0.0	0.1	0.0	0.0	0.0	1.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	8.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.3	0.0	0.0	0.0	0.0	0.1	0.1	3.1	1.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.2	0.0	0.0	0.0	0.0	19.7	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.3	0.1	0.6	0.6	0.0	0.0	0.0	1.8	0.0	0.3	18.3	0.0	40.8	0.0	0.0	0.0	0.2	0.0	0.2	0.2	0.0	3.2	0.1	1.6	0.0	0.0	0.0	8.3	1.7	0.2	0.0	0.0	0.0	0.2	1.2	0.0	0.0	39.5	1.3	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.1
CYP19A1	"ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM"	ENSG00000137869	"Cytochrome P450 family 19 subfamily A member 1"	P11511	15	51208057-51338610	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		"Monooxygenase, Oxidoreductase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	49	"placenta: 440.1"	"Cell type enriched"	"Detected in some"	36	"Syncytiotrophoblasts: 1678.9"	"Low cancer specificity"	"Detected in single"			"Region enriched"	"Detected in single"	8	"basal ganglia: 5.9"	"Cell type enriched"	"Detected in single"	17	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 1.7"	"Cell line enhanced"	"Detected in some"		"ASC TERT1: 45.7;HDLM-2: 7.9;HSkMC: 15.3;SuSa: 8.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000355, HPA051194"	Enhanced		Uncertain	Mitochondria		NA	NA			Mitochondria		"CAB000355: , HPA051194: AB_2681381"	"unprognostic (9.41e-2)"	"unprognostic (7.44e-2)"	"unprognostic (9.52e-5)"	"unprognostic (6.81e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.25e-4)"	"unprognostic (5.18e-5)"	"unprognostic (1.54e-3)"	"unprognostic (2.38e-2)"	"unprognostic (2.52e-1)"	"unprognostic (1.97e-1)"	"unprognostic (5.37e-2)"	"unprognostic (1.54e-5)"	"unprognostic (2.52e-3)"	"unprognostic (2.11e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.11e-1)"	9.0	4.6	0.2	0.2	5.9	0.1	2.1	0.2	0.3	0.9	0.3	0.3	0.2	0.4	0.2	0.3	0.3	0.2	0.3	1.3	0.2	0.7	0.3	0.2	0.6	0.2	0.2	0.2	4.4	0.6	0.1	0.2	440.1	0.2	0.5	0.1	0.2	0.9	1.4	0.8	2.3	0.2	0.7	0.5	0.5	0.1	3.0	0.2	0.3	3.0	0.2	0.2	1.2	0.5	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	45.7	2.8	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.0	0.0	7.9	0.0	0.3	0.1	3.7	0.3	0.0	0.0	15.3	0.0	0.1	1.9	0.1	0.0	0.0	0.0	0.3	0.1	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	8.1	0.0	0.2	0.0	0.1	0.0	0.1	0.0	1.4	0.6	0.0	0.3	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.2	5.9	0.2	0.3	0.2	0.7	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	46.8	0.0	0.0	2.2	0.0	0.0	0.0	0.0	6.9	1.4	0.0	0.0	0.0	13.4	0.0	0.0	0.0	1.6	4.5	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	6.5	0.3	7.7	0.2	0.0	1678.9	0.0	0.0	0.0
CYP51A1	"CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1"	ENSG00000001630	"Cytochrome P450 family 51 subfamily A member 1"	Q16850	7	92112151-92142952	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism"	"Monooxygenase, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 80.9"	"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 1: 62.5;Alveolar cells type 2: 133.7;Club cells: 77.3;Early spermatids: 70.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"GAMG: 96.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041325, HPA043508"	Enhanced		Enhanced	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA041325: AB_2677411, HPA043508: AB_2678520"	"unprognostic (6.68e-2)"	"prognostic unfavorable (6.12e-4)"	"unprognostic (3.48e-2)"	"unprognostic (1.18e-2)"	"unprognostic (7.82e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.97e-1)"	"unprognostic (9.84e-2)"	"unprognostic (1.36e-1)"	"unprognostic (9.75e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.59e-9)"	"unprognostic (1.82e-1)"	"unprognostic (2.73e-1)"	"unprognostic (5.13e-2)"	"unprognostic (1.09e-3)"	10.3	27.0	16.7	8.1	22.1	10.5	15.5	13.3	32.0	11.8	21.1	32.9	6.3	33.1	9.1	15.3	23.4	7.1	10.3	9.9	18.6	20.8	18.6	80.9	22.2	5.0	17.2	13.7	21.0	20.2	32.4	11.9	8.8	47.1	18.2	16.9	17.1	11.0	7.7	4.3	12.8	28.8	8.3	43.7	7.3	18.1	35.7	19.5	2.3	14.1	18.7	10.0	9.0	13.2	14.2	14.1	3.5	13.9	6.7	10.7	7.1	21.4	10.5	26.6	17.0	18.7	30.7	3.8	7.3	22.1	9.5	26.0	25.3	39.3	18.7	11.6	12.6	96.2	18.8	23.1	46.1	11.1	7.8	16.4	5.4	11.2	19.0	25.6	11.0	8.1	22.2	21.0	37.1	39.0	8.4	9.7	3.8	20.2	43.2	11.1	22.0	2.3	10.2	19.8	8.8	10.5	7.6	5.5	42.2	43.0	36.4	18.7	12.5	15.5	30.9	22.6	12.6	11.2	13.2	11.5	13.0	14.6	18.8	9.5	14.7	13.1	17.1	10.0	14.6	16.6	1.8	9.7	3.5	10.7	13.9	7.1	14.2	7.6	8.4	14.1	10.7	7.2	9.2	1.5	6.7	8.3	12.4	5.8	7.1	16.7	22.1	13.3	32.0	18.6	20.8	17.2	13.7	47.1	19.5	62.5	133.7	7.5	1.0	2.3	2.1	1.2	7.6	28.1	77.3	1.8	2.0	1.3	1.7	9.2	70.7	2.1	14.4	23.3	17.0	0.8	1.8	1.3	27.7	4.2	1.3	0.0	10.4	8.6	6.6	27.7	3.4	2.1	0.0	1.0	12.0	1.9	12.3	10.4	1.4	1.7	1.8	0.0	2.8	3.2	1.5	4.6	3.7	1.0	11.5	2.1
CYSLTR1	"CysLT(1), CysLT1, CYSLT1R"	ENSG00000173198	"Cysteinyl leukotriene receptor 1"	Q9Y271	X	78271464-78327691	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.9;esophagus: 24.6"	"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 1: 62.5;Alveolar cells type 2: 54.8;Ciliated cells: 65.6;Club cells: 67.1;granulocytes: 76.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"eosinophil: 33.9"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HL-60: 11.6;Karpas-707: 7.5;NB-4: 16.2;RPMI-8226: 24.7;THP-1: 15.2;U-937: 16.8"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			HPA010546	Approved					NA	NA					"HPA010546: AB_1078268"	"unprognostic (9.48e-2)"	"unprognostic (6.01e-5)"	"unprognostic (4.72e-3)"	"unprognostic (3.04e-1)"	"unprognostic (6.30e-2)"	"unprognostic (2.80e-3)"	"unprognostic (2.52e-1)"	"unprognostic (8.19e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.53e-2)"	"unprognostic (4.55e-1)"	"unprognostic (2.43e-1)"	"unprognostic (4.41e-4)"	"unprognostic (5.82e-2)"	"unprognostic (3.56e-2)"	"unprognostic (9.87e-2)"	"unprognostic (8.94e-2)"	7.3	2.0	1.7	7.8	1.7	2.8	5.4	0.8	2.2	3.0	3.3	1.7	2.9	2.2	2.3	4.4	24.6	2.3	5.6	3.1	2.3	1.9	4.8	2.7	6.9	19.5	3.8	0.8	1.7	2.0	1.7	1.5	3.3	2.9	3.7	4.8	3.1	5.4	0.8	1.7	3.1	7.1	4.2	5.1	22.8	5.2	2.3	4.0	4.7	4.5	4.8	11.3	9.8	3.5	8.1	7.4	33.9	11.9	4.1	3.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	11.6	4.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.0	0.0	0.0	16.2	0.0	0.0	0.0	3.3	0.0	24.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	15.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	16.8	0.0	5.8	6.3	33.9	0.0	10.9	0.0	8.1	2.4	0.1	4.8	5.8	3.7	0.0	18.4	4.1	11.9	7.4	0.5	2.8	1.7	1.7	0.8	2.2	2.3	1.9	3.8	0.8	2.9	4.0	62.5	54.8	40.4	3.9	3.3	2.9	0.6	0.0	65.6	67.1	0.0	5.9	0.3	0.0	0.1	0.0	9.0	0.0	0.0	0.2	0.2	1.4	1.2	76.2	0.0	23.3	0.0	0.0	3.7	30.2	0.0	0.6	32.2	6.8	0.0	0.0	0.5	0.2	0.0	0.0	0.0	0.6	0.0	1.4	0.0	0.2	3.1	0.7	17.5	0.5	1.4
CYSLTR2	"CysLT(2), CYSLT2R"	ENSG00000152207	"Cysteinyl leukotriene receptor 2"	Q9NS75	13	48653711-48711226	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 37.2;ductus deferens: 25.1;placenta: 22.6;seminal vesicle: 22.4"	"Cell type enhanced"	"Detected in some"	12	"Macrophages: 4.3;Melanocytes: 5.0;Sertoli cells: 12.9;Smooth muscle cells: 5.1"	"Group enriched"	"Detected in many"	6	"melanoma: 1.8;renal cancer: 6.6;thyroid cancer: 7.7"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	12	"eosinophil: 37.2"	"Lineage enriched"	"Detected in many"	12	"granulocytes: 37.2"	"Cell line enriched"	"Detected in some"	43	"HDLM-2: 44.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			HPA046528	Approved					NA	NA					"HPA046528: AB_2679687"	"unprognostic (9.83e-3)"	"unprognostic (2.72e-3)"	"unprognostic (1.05e-2)"	"unprognostic (6.81e-2)"	"unprognostic (2.94e-2)"	"unprognostic (3.11e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.41e-3)"	"unprognostic (8.33e-2)"	"unprognostic (1.83e-1)"	"unprognostic (5.44e-2)"	"unprognostic (5.93e-2)"	"unprognostic (1.88e-3)"	"unprognostic (3.79e-2)"	"unprognostic (4.44e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.18e-2)"	2.0	11.4	3.4	3.9	4.2	0.7	1.0	1.6	8.0	0.9	1.0	1.1	25.1	2.1	1.3	1.7	0.7	3.4	1.6	11.5	4.1	3.4	1.8	1.0	1.5	4.4	3.3	1.5	5.4	0.5	0.7	2.3	22.6	3.7	3.4	1.1	2.9	0.7	22.4	0.5	1.3	2.5	0.7	2.3	6.9	1.1	1.0	2.9	1.0	1.1	0.5	1.5	1.0	1.2	0.0	0.9	37.2	3.2	0.4	0.5	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.7	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	1.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.2	1.0	37.2	0.2	3.2	0.0	0.0	0.4	0.0	0.9	0.0	0.5	0.1	0.1	0.4	2.0	0.0	0.3	0.4	3.4	4.2	1.6	8.0	4.1	3.4	3.3	1.5	3.7	2.9	0.0	1.4	0.5	0.1	0.5	0.0	0.8	0.0	0.0	0.0	3.5	0.0	0.3	0.0	0.0	0.2	0.8	0.0	0.0	0.0	1.0	4.1	0.0	1.1	0.0	0.6	0.0	0.0	3.1	2.1	0.0	0.3	4.3	5.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	5.1	0.0	0.1	0.0	2.4	1.9	0.0	0.0
DBH	DBM	ENSG00000123454	"Dopamine beta-hydroxylase"	P09172	9	133636360-133659344	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	9	"adrenal gland: 86.6;brain: 36.2;liver: 35.6"	"Cell type enriched"	"Detected in single"	43	"Ito cells: 17.2"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	45	"pons and medulla: 36.2"	"Cell type enhanced"	"Detected in single"		"naive CD4 T-cell: 2.0"	"Lineage enriched"	"Detected in single"	21	"T-cells: 2.0"	"Cell line enriched"	"Detected in single"	340	"SH-SY5Y: 206.1"	"Region enriched"	"Detected in some"	6	"pons and medulla: 23.2"	"Region enriched"	"Detected in single"	38	"pons and medulla: 25.1"	"HPA002130, HPA005960, HPA070789"	Enhanced		Supported	"Endoplasmic reticulum,Vesicles"	"Intracellular and membrane"	NA	NA		2000000000	Vesicles	"Endoplasmic reticulum"	"HPA002130: AB_2666554, HPA005960: AB_1078628, HPA070789: AB_2686312"	"unprognostic (1.93e-3)"	"unprognostic (7.52e-3)"	"unprognostic (8.53e-2)"	"unprognostic (2.10e-2)"	"unprognostic (2.18e-3)"	"unprognostic (3.38e-3)"	"unprognostic (3.39e-3)"	"unprognostic (3.97e-2)"	"unprognostic (1.71e-1)"	"unprognostic (8.99e-2)"	"unprognostic (5.80e-2)"	"unprognostic (7.69e-2)"	"unprognostic (2.81e-7)"	"unprognostic (9.31e-2)"	"unprognostic (6.77e-2)"	"unprognostic (1.49e-2)"	"unprognostic (5.06e-3)"	0.7	86.6	0.1	0.3	0.1	0.0	0.0	0.1	0.8	0.3	0.0	1.9	0.7	0.1	0.1	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.5	35.6	0.3	0.6	0.0	0.0	0.1	1.3	0.0	0.6	0.4	36.2	0.8	0.0	1.0	0.2	5.9	0.0	0.0	0.2	0.0	1.4	0.4	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.8	0.5	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	0.2	206.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.8	0.0	0.1	0.0	0.0	36.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DCK		ENSG00000156136	"Deoxycytidine kinase"	P27707	4	70992538-71030914	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 80.9"	"Cell type enhanced"	"Detected in many"	9	"Erythroid cells: 186.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Daudi: 60.9;U-698: 49.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA059609, HPA062773"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA059609: AB_2684082, HPA062773: AB_2684865"	"unprognostic (9.16e-2)"	"unprognostic (2.44e-1)"	"unprognostic (5.24e-3)"	"unprognostic (4.77e-2)"	"unprognostic (3.95e-1)"	"unprognostic (6.45e-2)"	"prognostic unfavorable (6.90e-7)"	"unprognostic (3.04e-2)"	"unprognostic (7.19e-2)"	"unprognostic (8.28e-2)"	"unprognostic (4.51e-1)"	"unprognostic (1.33e-1)"	"unprognostic (3.37e-2)"	"unprognostic (4.47e-2)"	"unprognostic (6.82e-2)"	"unprognostic (1.33e-1)"	"unprognostic (2.27e-2)"	8.0	8.3	11.9	30.9	16.8	17.2	6.9	11.4	14.8	5.6	8.6	10.4	2.6	7.6	7.5	4.4	8.8	5.5	6.1	5.5	12.3	13.1	5.8	4.8	9.7	42.8	11.7	10.3	6.0	5.0	3.6	4.2	7.9	11.1	5.9	10.4	6.4	6.3	4.0	6.8	7.9	12.4	7.5	17.6	17.5	8.2	5.6	8.6	80.9	8.3	3.8	39.9	9.5	6.5	27.9	34.2	17.5	12.7	18.5	24.9	25.1	6.7	4.5	9.9	5.9	3.1	5.5	5.7	17.5	6.5	13.9	11.6	2.9	14.8	60.9	7.6	7.2	8.1	3.9	8.8	5.5	18.8	12.9	5.4	12.6	5.2	4.6	3.2	25.1	16.3	2.7	6.7	8.4	5.1	6.8	7.9	17.3	5.0	23.2	15.8	3.9	31.0	9.9	4.7	11.5	5.5	26.4	20.1	4.8	6.9	4.7	8.8	9.4	6.6	12.9	7.7	4.7	5.8	13.2	6.3	15.7	11.8	13.1	9.4	8.8	5.8	49.4	10.9	15.7	11.6	13.1	10.7	17.5	16.2	12.7	20.3	27.9	21.8	20.0	14.3	26.4	23.4	23.5	5.4	18.5	12.1	34.2	24.9	25.1	11.9	16.8	11.4	14.8	12.3	13.1	11.7	10.3	11.1	8.6	0.0	11.3	75.5	8.0	38.1	13.6	4.6	7.6	1.4	3.4	12.2	5.9	9.8	24.9	17.7	0.4	14.3	9.0	186.9	5.6	16.0	12.9	9.5	23.0	5.3	33.7	17.5	20.2	21.5	48.3	1.1	7.8	41.6	43.9	68.5	17.2	14.3	8.9	7.0	9.6	6.1	8.2	6.5	20.6	34.4	28.8	37.9	3.8	61.7	14.3	6.2
DDC	AADC	ENSG00000132437	"Dopa decarboxylase"	P20711	7	50458436-50565457	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Catecholamine biosynthesis"	"Decarboxylase, Lyase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"intestine: 90.1;kidney: 68.1"	"Group enriched"	"Detected in many"	5	"Intestinal endocrine cells: 394.4;Proximal tubular cells: 366.2;Rod photoreceptor cells: 456.4"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"midbrain: 7.9;pons and medulla: 3.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"CACO-2: 17.2;Hep G2: 15.1;OE19: 26.4;SCLC-21H: 43.6;SH-SY5Y: 45.3"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	10	"midbrain: 90.4;pons and medulla: 40.7"	HPA017742	Enhanced		Approved	"Actin filaments"		NA	NA		380000	"Actin filaments"		"HPA017742: AB_1847832"	"unprognostic (1.04e-1)"	"unprognostic (3.68e-2)"	"unprognostic (2.57e-2)"	"unprognostic (3.49e-5)"	"unprognostic (1.17e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.28e-1)"	"unprognostic (5.15e-2)"	"unprognostic (4.69e-2)"	"unprognostic (5.44e-2)"	"unprognostic (9.36e-3)"	"unprognostic (5.24e-2)"	"unprognostic (1.76e-3)"	"unprognostic (1.60e-1)"	"unprognostic (3.55e-1)"	"unprognostic (7.65e-2)"	"unprognostic (1.16e-1)"	0.3	10.9	0.3	3.0	0.7	0.0	0.3	0.3	0.4	0.3	36.7	0.4	0.3	33.5	0.3	1.8	0.3	0.0	0.7	0.3	0.3	1.3	68.1	11.7	0.7	0.3	7.9	0.3	0.4	9.8	0.0	0.3	0.3	3.4	0.4	8.1	0.4	0.3	0.3	0.3	0.1	90.1	0.3	0.3	0.3	4.3	0.6	0.5	0.3	0.3	0.4	0.3	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	17.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.1	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	26.4	0.0	0.0	0.0	0.2	0.4	0.0	43.6	45.3	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.7	0.3	0.4	0.3	1.3	7.9	0.3	3.4	0.5	0.0	9.8	0.8	0.0	0.0	81.1	0.4	5.1	0.0	1.2	3.5	39.3	0.0	21.6	0.0	3.6	0.0	72.8	0.0	0.7	0.1	0.0	0.4	0.0	58.7	0.1	3.2	394.4	1.3	1.3	4.3	0.0	0.0	0.0	0.0	30.4	24.1	0.2	26.6	0.0	366.2	456.4	0.0	0.0	3.6	0.4	0.0	0.1	0.0	46.0	0.0
DDR2	"NTRKR3, TKT, TYRO10"	ENSG00000162733	"Discoidin domain receptor tyrosine kinase 2"	Q16832	1	162631373-162787400	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Osteogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Fibroblasts: 84.7;Leydig cells: 58.4;Peritubular cells: 83.1;Smooth muscle cells: 68.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 1.1;MAIT T-cell: 1.3"	"Lineage enriched"	"Detected in single"	5	"T-cells: 1.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 61.7;ASC TERT1: 61.0;BJ hTERT+: 45.1;fHDF/TERT166: 32.3;HSkMC: 43.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA070112			Supported	"Plasma membrane,Actin filaments"		Yes	No		850000	"Plasma membrane, Actin filaments"		"HPA070112: AB_2686229"	"unprognostic (4.12e-2)"	"unprognostic (2.73e-1)"	"unprognostic (6.97e-3)"	"unprognostic (4.52e-2)"	"unprognostic (1.17e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.19e-1)"	"unprognostic (6.62e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.15e-1)"	"prognostic unfavorable (1.73e-7)"	"unprognostic (1.56e-3)"	"unprognostic (8.26e-3)"	"unprognostic (7.57e-2)"	"unprognostic (4.10e-3)"	42.1	43.5	4.7	10.9	6.9	0.2	15.6	7.9	7.1	30.3	30.4	9.0	18.6	3.3	24.2	17.7	25.0	13.4	16.6	15.4	7.9	4.7	4.0	3.3	8.9	5.1	12.9	3.4	26.4	2.2	2.1	4.0	6.6	12.7	21.8	9.1	30.7	6.4	19.3	5.2	6.1	10.1	34.3	19.7	3.4	14.1	8.3	7.5	0.0	8.6	12.8	4.1	29.0	18.3	0.1	0.2	0.0	0.0	0.2	1.3	0.0	0.1	0.0	0.0	16.3	61.7	61.0	0.2	24.0	45.1	10.5	15.1	0.0	0.0	0.0	0.0	32.3	2.1	0.0	0.0	0.1	14.4	12.9	0.1	0.0	0.1	0.0	26.8	0.0	0.0	43.3	0.1	18.5	0.5	17.0	12.1	0.1	0.1	5.1	9.6	0.0	0.0	0.0	0.1	0.0	0.1	0.0	6.9	0.1	0.0	0.0	0.0	9.9	0.0	0.0	0.8	0.9	0.0	0.0	0.6	16.8	3.7	8.5	3.3	0.7	1.3	0.0	15.2	0.0	17.0	0.0	0.0	0.0	1.1	0.0	1.3	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	4.7	6.9	7.9	7.1	7.9	4.7	12.9	3.4	12.7	7.5	3.0	2.9	0.0	2.4	11.2	3.1	23.3	2.5	4.0	1.2	0.0	0.0	0.5	0.0	0.5	6.9	21.3	2.0	0.0	1.5	0.4	84.7	4.1	1.1	3.0	1.1	0.0	1.2	24.5	2.1	4.0	58.4	1.5	21.9	0.0	0.7	19.0	1.5	1.7	83.1	0.9	2.9	38.8	68.4	0.9	0.9	7.5	0.8	1.3	0.6	3.3
DHFR		ENSG00000228716	"Dihydrofolate reductase"	P00374	5	80626228-80654983	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Methotrexate resistance, One-carbon metabolism"	"Oxidoreductase, RNA-binding"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	10	"Erythroid cells: 163.5;Spermatocytes: 92.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB037129, HPA051465"	Uncertain		Approved	Mitochondria		NA	Yes			Mitochondria		"CAB037129: AB_439683, HPA051465: AB_2681494"	"unprognostic (1.44e-2)"	"unprognostic (1.03e-2)"	"unprognostic (2.24e-3)"	"unprognostic (2.91e-3)"	"unprognostic (3.27e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.83e-2)"	"unprognostic (2.35e-2)"	"unprognostic (2.02e-2)"	"unprognostic (4.19e-3)"	"unprognostic (1.83e-2)"	"unprognostic (2.55e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.82e-2)"	"unprognostic (2.49e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.09e-1)"	17.7	6.1	16.0	11.6	13.9	28.3	10.9	10.2	14.0	7.5	12.6	18.1	11.7	14.5	5.9	9.0	9.8	4.7	6.9	9.7	17.3	14.4	13.1	35.5	8.6	23.2	18.9	9.4	7.5	4.9	9.6	7.2	8.5	13.0	5.9	15.5	8.6	8.0	8.4	10.4	5.9	14.5	7.3	25.3	9.1	7.4	10.5	11.5	13.4	9.2	2.3	22.8	7.9	6.1	2.4	3.3	3.5	2.6	2.1	4.0	2.1	19.8	13.8	35.1	25.9	6.6	7.0	12.9	15.9	12.2	27.8	32.1	13.1	24.0	40.4	7.0	9.2	22.7	14.0	45.1	20.5	45.0	17.9	27.8	19.3	23.0	12.1	1.4	22.5	8.6	4.8	2.1	24.9	2.8	4.7	13.4	29.7	21.7	31.1	28.1	19.9	55.4	9.1	17.7	9.9	8.1	36.0	68.9	40.0	16.0	12.7	28.7	20.0	22.5	10.5	11.4	18.6	20.8	22.3	8.0	8.8	13.4	24.6	30.4	14.6	29.2	43.7	19.7	45.8	22.6	0.8	1.2	1.1	2.3	2.6	1.1	2.1	2.7	3.2	1.9	2.4	2.1	2.7	3.5	2.1	1.7	3.3	4.0	2.1	16.0	13.9	10.2	14.0	17.3	14.4	18.9	9.4	13.0	11.5	6.0	9.4	21.6	5.3	6.2	3.7	13.2	7.6	8.1	6.8	14.0	2.0	13.0	8.3	6.6	4.3	3.6	20.0	163.5	3.3	35.4	9.5	2.1	2.3	41.2	36.1	3.2	4.7	9.2	13.2	4.6	13.0	8.3	0.0	2.8	11.1	10.0	4.3	5.8	15.2	33.5	3.4	12.9	9.0	92.4	48.0	4.8	11.1	10.1	21.0	3.7
DHODH		ENSG00000102967	"Dihydroorotate dehydrogenase (quinone)"	Q02127	16	72008588-72027664	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Pyrimidine biosynthesis"	Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"liver: 72.4"	"Cell type enriched"	"Detected in many"	5	"Hepatocytes: 106.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA010123, HPA011942"	Approved		Enhanced	Nucleoplasm,Mitochondria,Cytosol		NA	NA			Mitochondria	"Nucleoplasm, Cytosol"	"HPA010123: AB_1847648, HPA011942: AB_1847649"	"unprognostic (4.88e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.12e-2)"	"unprognostic (1.41e-3)"	"unprognostic (2.10e-1)"	"unprognostic (4.27e-2)"	"unprognostic (1.31e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.68e-1)"	"unprognostic (2.14e-1)"	"unprognostic (6.40e-2)"	"unprognostic (9.26e-3)"	"unprognostic (1.98e-1)"	"unprognostic (1.97e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.81e-1)"	5.9	4.2	4.7	8.8	5.1	2.9	5.0	2.7	5.0	5.9	4.4	6.1	1.4	3.4	6.6	2.3	5.1	5.2	2.3	11.5	4.3	3.0	6.6	72.4	3.4	5.5	4.8	2.7	6.2	9.9	7.1	4.0	2.6	5.2	3.9	4.8	5.9	6.0	4.4	11.7	4.0	3.0	7.5	4.0	3.5	3.4	4.3	5.4	4.0	3.6	7.1	5.1	3.5	3.3	11.2	13.4	3.9	8.1	9.3	12.9	6.8	7.4	15.5	4.5	7.5	2.4	3.2	8.6	6.4	2.6	9.7	7.5	12.2	6.8	16.8	8.7	3.5	5.4	7.9	8.9	6.9	11.5	3.8	8.4	9.2	7.5	12.0	6.8	12.7	6.8	3.1	7.1	11.7	12.3	3.1	7.0	11.4	14.0	3.1	5.9	19.8	12.0	12.2	10.2	12.7	6.1	15.2	5.9	17.7	5.8	4.9	5.4	6.3	8.6	9.2	4.2	5.8	8.2	6.4	3.0	8.9	5.5	8.4	9.3	5.9	10.9	28.4	4.6	14.0	8.1	3.9	8.1	0.9	9.3	7.7	12.7	11.2	8.9	9.0	13.3	10.6	12.4	12.9	2.1	9.3	5.6	13.4	7.1	6.8	4.7	5.1	2.7	5.0	4.3	3.0	4.8	2.7	5.2	5.4	3.0	9.6	9.5	6.4	4.9	5.7	12.1	7.6	9.4	1.2	7.0	3.9	12.0	5.0	6.6	2.1	6.7	0.7	0.0	4.4	9.6	6.0	5.0	8.1	106.1	6.9	3.2	1.2	2.5	5.3	2.3	2.6	3.4	11.8	3.6	4.4	4.8	5.2	2.9	2.1	20.1	4.2	0.0	9.9	7.9	8.0	3.3	2.4	5.0	6.2	4.1
DIO3	TXDI3	ENSG00000197406	"Iodothyronine deiodinase 3"	P55073	14	101561351-101563452	"Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Thyroid hormones biosynthesis"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 40.9;placenta: 17.6"	"Group enriched"	"Detected in some"	4	"Fibroblasts: 8.0;Leydig cells: 10.0;Muller glia cells: 6.6;Peritubular cells: 7.1;Syncytiotrophoblasts: 23.7"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"basal ganglia: 1.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	10	"AF22: 35.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA073684			Supported	Vesicles		NA	NA			Vesicles		"HPA073684: "	"unprognostic (4.52e-3)"	"unprognostic (1.80e-1)"	"unprognostic (3.04e-3)"	"unprognostic (3.48e-1)"	"unprognostic (5.16e-2)"	"unprognostic (1.50e-1)"	"unprognostic (4.24e-2)"	"unprognostic (8.11e-2)"	"unprognostic (2.58e-1)"	"unprognostic (6.24e-2)"	"unprognostic (2.34e-1)"	"unprognostic (2.52e-1)"	"unprognostic (7.46e-5)"	"unprognostic (4.82e-3)"	"unprognostic (2.43e-1)"	"unprognostic (1.11e-4)"	"unprognostic (9.80e-3)"	4.5	0.2	0.2	1.7	1.8	0.0	3.5	0.1	0.8	40.9	1.6	0.1	1.0	0.0	3.4	2.2	1.9	3.5	2.9	1.6	0.7	0.0	0.9	2.7	1.4	7.1	0.1	0.1	9.2	4.1	0.0	0.6	17.6	0.3	1.6	0.4	12.6	0.8	2.5	2.2	1.9	0.7	0.9	0.1	2.5	0.7	1.0	0.1	0.1	3.6	1.1	0.4	6.9	8.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	35.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.6	0.9	0.5	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.8	0.1	0.6	0.7	0.0	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.5	0.1	0.0	0.9	0.0	0.0	2.1	8.0	0.3	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	1.0	0.0	6.6	0.6	0.0	7.1	0.0	0.1	0.0	1.2	0.0	0.0	0.1	23.7	0.0	0.0	0.1
DNMT1	"CXXC9, DNMT, MCMT"	ENSG00000130816	"DNA methyltransferase 1"	P26358	19	10133345-10231286	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, Chromatin regulator, DNA-binding, Methyltransferase, Repressor, Transferase"	"Deafness, Disease mutation, FDA approved drug targets, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	7	"Cytotrophoblasts: 329.4;Spermatocytes: 249.6;Syncytiotrophoblasts: 270.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002694, CAB005876"	Enhanced		Supported	Nucleoplasm		NA	Yes			Nucleoplasm		"CAB005876: AB_731983, HPA002694: AB_1847810"	"unprognostic (3.51e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.26e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.62e-1)"	"unprognostic (7.59e-3)"	"prognostic unfavorable (1.46e-4)"	"unprognostic (2.90e-1)"	"unprognostic (4.23e-3)"	"unprognostic (1.10e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.28e-3)"	"unprognostic (7.81e-3)"	"unprognostic (1.73e-1)"	"unprognostic (8.11e-2)"	"unprognostic (1.46e-1)"	12.1	7.6	9.8	20.2	10.8	31.9	11.5	27.1	14.4	12.0	8.6	10.0	4.3	8.1	12.1	8.0	12.0	11.5	7.8	8.0	9.3	8.1	6.9	9.2	11.8	29.7	12.5	7.9	11.1	6.2	10.2	8.8	32.5	8.7	8.3	10.7	7.8	9.3	6.5	6.8	10.8	11.3	11.2	9.1	11.0	9.0	19.9	12.6	31.4	9.5	8.8	28.8	11.4	9.7	12.6	19.0	10.2	13.4	25.0	18.2	6.8	24.3	15.4	19.7	16.7	7.3	7.5	42.3	16.5	13.1	23.8	23.9	14.9	13.3	40.8	10.4	10.1	12.0	16.1	21.7	12.9	24.4	16.0	32.3	59.1	13.8	7.7	3.2	24.0	24.0	5.0	2.5	20.8	8.2	7.2	12.9	12.6	23.4	25.2	17.7	16.2	35.1	32.8	25.9	11.0	22.5	35.6	20.7	22.4	7.5	15.4	21.0	16.3	20.0	9.0	6.4	12.6	9.4	12.2	9.7	40.0	13.7	24.2	24.4	20.6	21.5	48.3	11.6	22.4	31.0	10.2	13.4	3.3	18.2	13.2	15.9	7.9	14.6	12.5	11.3	12.6	16.6	12.3	3.1	25.0	7.9	19.0	12.9	6.8	9.8	10.8	27.1	14.4	9.3	8.1	12.5	7.9	8.7	12.6	6.0	24.5	38.8	19.1	26.3	66.8	11.9	7.6	48.2	29.6	21.0	53.0	329.4	11.6	20.3	42.9	33.0	4.7	93.5	12.4	56.3	25.7	12.5	34.8	12.1	68.9	62.0	15.1	24.5	28.2	38.6	25.9	51.5	13.5	45.1	16.3	39.9	15.7	11.5	26.9	7.6	50.4	12.9	22.0	249.6	179.2	19.6	270.7	54.2	37.6	14.1
DPEP1		ENSG00000015413	"Dipeptidase 1"	P16444	16	89613308-89638456	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Lipid metabolism"	"Dipeptidase, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	11	"intestine: 161.7;kidney: 52.2;pancreas: 100.5"	"Cell type enhanced"	"Detected in many"	26	"Leydig cells: 268.4;Peritubular cells: 1144.5;Proximal tubular cells: 391.6"	"Cancer enriched"	"Detected in many"	8	"colorectal cancer: 107.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 5.2;Hep G2: 20.3;HHSteC: 9.2;U-937: 28.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA009426, HPA012783"	Enhanced		Approved	"Nucleoplasm,Cell Junctions"	"Intracellular and membrane"	NA	NA		270000	"Nucleoplasm, Cell Junctions"		"HPA009426: AB_1847842, HPA012783: AB_1847843"	"unprognostic (3.31e-2)"	"unprognostic (3.86e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.95e-2)"	"unprognostic (1.91e-2)"	"unprognostic (4.93e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.89e-1)"	"unprognostic (3.45e-2)"	"unprognostic (5.18e-1)"	"unprognostic (8.68e-2)"	"unprognostic (1.27e-1)"	"prognostic favorable (6.84e-4)"	"unprognostic (6.12e-3)"	"unprognostic (1.92e-1)"	"unprognostic (5.23e-2)"	"unprognostic (3.93e-2)"	0.1	0.4	0.1	0.9	0.1	0.0	0.1	0.1	0.1	1.5	53.6	0.1	0.4	16.1	0.2	3.4	0.3	0.1	0.9	0.1	0.1	0.1	52.2	0.1	0.3	0.9	0.1	0.1	0.2	100.5	0.0	0.2	0.1	0.2	0.1	0.0	0.2	0.3	0.4	0.1	0.4	161.7	0.1	0.1	0.9	0.2	9.8	0.1	0.2	0.1	0.1	0.5	0.6	0.3	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.1	0.0	1.1	0.1	2.8	0.0	0.0	0.0	0.0	5.2	0.1	0.0	1.9	0.0	0.0	0.0	0.1	0.0	0.0	1.3	0.4	0.0	0.0	20.3	9.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.6	0.7	2.1	0.0	0.0	0.0	1.8	0.0	0.0	0.6	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.9	0.0	0.0	0.1	0.1	0.0	28.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	3.0	2.6	14.9	0.0	0.5	3.3	0.3	0.0	0.0	1.2	22.7	0.0	0.1	48.0	0.3	10.3	0.1	4.2	0.0	171.7	0.3	4.5	0.0	1.1	0.0	0.5	0.0	8.5	1.8	0.0	29.1	268.4	1.7	5.0	1.8	1.9	0.0	43.8	11.5	1144.5	391.6	0.1	6.5	0.3	15.6	2.9	0.3	0.3	0.5	1.2	0.0
DPP4	"ADCP2, CD26, DPPIV"	ENSG00000197635	"Dipeptidyl peptidase 4"	P27487	2	161992241-162074542	"CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Aminopeptidase, Hydrolase, Protease, Receptor, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 133.1;parathyroid gland: 75.5"	"Cell type enhanced"	"Detected in many"	9	"Cytotrophoblasts: 134.1;Proximal tubular cells: 80.1;Syncytiotrophoblasts: 143.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 26.7"	"Lineage enriched"	"Detected in many"	10	"T-cells: 26.7"	"Cell line enhanced"	"Detected in many"		"ASC diff: 42.8;ASC TERT1: 43.4;BJ hTERT+: 39.8;RPTEC TERT1: 58.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB045970, HPA068778, HPA071236"	Enhanced				"Secreted in other tissues"	NA	NA		170000000			"CAB045970: AB_11140529, HPA068778: , HPA071236: "	"unprognostic (4.47e-2)"	"unprognostic (4.47e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.36e-1)"	"unprognostic (7.25e-2)"	"unprognostic (5.40e-2)"	"unprognostic (2.78e-1)"	"unprognostic (3.54e-2)"	"unprognostic (3.58e-1)"	"unprognostic (4.73e-1)"	"unprognostic (2.36e-1)"	"prognostic unfavorable (1.98e-4)"	"prognostic favorable (1.35e-6)"	"unprognostic (4.68e-2)"	"unprognostic (6.33e-2)"	"prognostic favorable (4.99e-4)"	"unprognostic (1.21e-2)"	9.5	2.9	0.3	3.2	0.5	0.0	5.0	0.3	1.4	2.2	50.0	0.2	36.9	19.1	2.2	3.5	1.2	1.2	5.2	2.1	0.4	0.3	29.1	12.2	5.4	2.1	0.4	0.2	2.7	1.8	75.5	0.3	24.0	0.2	21.1	2.8	0.6	46.9	38.8	2.4	4.4	133.1	0.9	0.8	5.0	1.2	0.6	0.1	6.2	1.0	1.4	1.1	1.0	2.6	0.1	2.1	0.3	0.0	2.6	26.7	2.5	0.0	0.0	0.1	0.0	42.8	43.4	0.1	7.9	39.8	2.2	7.7	8.0	0.2	0.0	3.0	13.7	7.4	0.2	0.1	0.0	1.3	2.5	0.1	0.0	0.0	11.9	17.4	0.0	0.0	4.9	0.0	13.4	0.1	2.0	1.3	0.1	0.0	0.0	0.7	0.0	0.7	0.1	0.4	0.3	16.4	0.0	0.0	0.1	58.0	0.0	0.0	0.1	0.0	0.0	0.0	0.9	0.0	0.0	7.1	4.6	0.2	0.2	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	3.2	0.0	26.7	0.1	8.3	5.2	0.6	0.0	8.3	3.3	0.3	2.6	0.0	2.1	0.9	2.5	0.3	0.5	0.3	1.4	0.4	0.3	0.4	0.2	0.2	0.1	6.0	17.5	0.0	0.3	3.7	1.7	4.0	12.7	4.0	4.5	14.0	9.8	134.1	1.7	3.1	13.0	3.9	21.3	0.0	0.0	52.7	45.7	38.3	12.8	39.9	12.7	0.0	53.0	12.3	1.6	6.2	0.0	4.6	5.0	1.0	11.0	0.0	0.9	11.4	0.0	80.1	0.0	0.0	1.0	2.1	0.8	3.6	143.8	11.4	12.8	0.3
DPYD	DPD	ENSG00000188641	"Dihydropyrimidine dehydrogenase"	Q12882	1	97077743-97995000	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	11	"Hepatocytes: 50.8;Kupffer cells: 129.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033241, HPA045210"	Uncertain					NA	NA		1300000			"CAB033241: AB_2094323, HPA045210: AB_2679256"	"unprognostic (2.33e-2)"	"unprognostic (1.69e-1)"	"unprognostic (9.82e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.13e-2)"	"unprognostic (8.81e-2)"	"unprognostic (2.86e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.56e-1)"	"unprognostic (9.29e-2)"	"prognostic unfavorable (6.27e-4)"	"unprognostic (6.54e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.43e-2)"	"unprognostic (3.71e-1)"	"unprognostic (2.25e-1)"	24.9	15.4	8.8	17.0	20.9	7.4	18.4	2.0	11.2	17.9	15.6	20.3	6.4	17.0	13.7	10.8	19.0	13.5	20.5	13.3	8.3	6.1	10.5	52.2	26.0	25.7	25.3	7.1	20.4	9.7	15.5	18.4	8.0	13.9	11.6	8.4	6.2	16.7	11.6	6.7	7.7	22.4	15.5	15.0	27.7	12.0	6.0	22.2	27.4	13.5	10.0	10.4	16.3	19.6	2.6	14.3	28.3	28.1	5.7	7.3	8.0	7.7	2.2	2.8	0.0	15.9	27.4	0.0	12.7	11.6	11.8	8.8	0.0	3.3	4.1	18.7	11.7	1.8	1.9	0.0	2.9	21.8	4.0	2.6	3.5	4.2	0.0	7.1	1.5	0.2	21.6	1.1	9.4	10.8	25.1	9.6	2.4	0.1	13.2	6.1	0.0	8.1	2.2	0.3	0.0	2.7	0.0	13.6	6.4	14.5	0.0	4.1	3.2	10.8	0.9	0.1	0.3	0.0	3.5	11.0	25.7	1.8	20.6	25.0	1.1	0.0	0.0	3.7	4.5	20.3	6.3	28.1	1.7	5.5	13.0	7.3	0.9	6.5	5.3	14.3	2.6	6.2	5.4	28.3	5.7	10.7	0.4	7.0	8.0	8.8	20.9	2.0	11.2	8.3	6.1	25.3	7.1	13.9	22.2	14.9	33.7	3.0	8.0	6.8	1.9	3.1	30.6	6.7	12.5	7.0	0.0	0.2	5.0	2.1	5.8	11.7	4.0	0.0	5.5	0.1	11.7	5.8	9.2	50.8	17.3	0.0	2.9	17.8	129.0	2.0	31.1	44.1	3.3	10.0	3.7	4.8	3.9	2.3	17.7	5.6	0.0	12.9	9.5	1.2	1.7	4.8	0.1	10.8	3.0	8.8
DRD1		ENSG00000184845	"Dopamine receptor D1"	P21728	5	175440039-175444208	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	12	"brain: 34.5"	"Group enriched"	"Detected in some"	13	"Bipolar cells: 40.8;Horizontal cells: 31.8"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"basal ganglia: 34.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"RT4: 24.2"	"Region enriched"	"Detected in many"	9	"basal ganglia: 147.4"	"Region enriched"	"Detected in many"	13	"basal ganglia: 95.6"	"HPA013393, HPA017304"		Supported	Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	Cytosol	"HPA013393: AB_1847833, HPA017304: "	"unprognostic (2.74e-2)"	"unprognostic (6.36e-3)"	"unprognostic (2.02e-1)"	"unprognostic (1.07e-1)"	"unprognostic (7.63e-3)"	"unprognostic (1.28e-1)"	"unprognostic (1.15e-6)"	"unprognostic (6.69e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.74e-2)"	"unprognostic (8.60e-4)"	"unprognostic (5.86e-2)"	"unprognostic (5.43e-1)"	"unprognostic (6.00e-3)"	"unprognostic (1.10e-2)"	0.7	1.5	1.9	0.2	34.5	0.0	0.1	0.1	12.0	0.7	0.7	0.4	0.0	0.5	0.4	0.7	0.7	0.6	1.1	0.3	1.0	0.6	0.7	2.6	1.8	0.1	0.5	1.6	0.3	0.0	0.0	0.1	2.5	0.3	2.7	0.9	2.1	0.1	1.2	0.1	0.1	0.3	0.4	0.1	0.4	0.4	0.1	6.8	0.1	0.1	0.0	0.4	1.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	24.2	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	34.5	0.1	5.3	1.0	0.6	0.5	1.6	0.3	6.8	0.0	0.0	0.0	0.0	0.1	40.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	31.8	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.2	0.0	0.0	0.0	2.9	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DRD2		ENSG00000149295	"Dopamine receptor D2"	P14416	11	113409615-113475691	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	8	"adrenal gland: 17.3;brain: 52.0;pituitary gland: 51.6"	"Cell type enriched"	"Detected in some"	12	"Horizontal cells: 57.2"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"basal ganglia: 52.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	9	"SCLC-21H: 45.2"	"Region enriched"	"Detected in many"	10	"basal ganglia: 183.8"	"Group enriched"	"Detected in many"	8	"basal ganglia: 126.7;midbrain: 41.7"	"HPA015139, HPA015691"	Supported	Supported				NA	NA					"HPA015139: , HPA015691: AB_1847834"	"unprognostic (8.49e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.29e-4)"	"unprognostic (2.32e-2)"	"unprognostic (1.15e-1)"		"unprognostic (1.97e-2)"	"unprognostic (5.89e-2)"	"unprognostic (4.40e-2)"	"unprognostic (8.33e-4)"	"unprognostic (1.10e-1)"	"unprognostic (6.65e-3)"	"unprognostic (2.29e-1)"	"unprognostic (1.71e-1)"	"unprognostic (4.82e-2)"	"unprognostic (8.49e-3)"	0.6	17.3	0.9	0.5	52.0	0.2	2.1	0.2	3.3	1.3	0.6	1.5	0.0	0.3	2.3	0.4	0.9	2.1	0.6	0.5	0.3	4.1	0.3	0.2	0.6	0.2	9.9	0.2	0.3	0.4	0.3	51.6	0.2	2.4	1.5	0.9	3.9	5.1	1.7	1.7	0.3	0.5	3.2	0.2	0.2	0.5	1.6	9.5	0.0	0.2	0.0	0.3	0.3	0.3	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.1	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.8	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.5	0.2	0.0	0.0	0.5	0.0	0.0	0.0	4.8	0.0	0.0	0.0	45.2	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.9	52.0	0.2	3.3	0.3	4.1	9.9	0.2	2.4	9.5	0.0	0.0	0.0	0.0	0.0	4.9	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	57.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
DRD3		ENSG00000151577	"Dopamine receptor D3"	P35462	3	114128652-114199407	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets, Schizophrenia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 2.0;brain: 8.3;testis: 4.2"	"Group enriched"	"Detected in some"	39	"Early spermatids: 5.5;Late spermatids: 12.5"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.0;T-reg: 1.4"	"Lineage enriched"	"Detected in single"	6	"T-cells: 2.0"	"Cell line enhanced"	"Detected in single"		"HAP1: 1.0"	"Region enriched"	"Detected in some"	5	"basal ganglia: 7.5"	"Region enriched"	"Detected in many"	12	"basal ganglia: 25.2"							NA	NA										"unprognostic (2.32e-1)"													0.0	0.0	0.0	0.1	8.3	0.0	0.0	0.0	0.1	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.2			0.0		0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	2.0	0.6	0.0	0.0	0.0	1.0	0.3	0.0	0.0	0.0	1.4	0.2											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
DRD4		ENSG00000069696	"Dopamine receptor D4"	P21917	11	637293-640706	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	"Biological rhythms"	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"retina: 86.1"	"Group enriched"	"Detected in some"	7	"Bipolar cells: 115.9;Cone photoreceptor cells: 82.5;Rod photoreceptor cells: 193.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	14	"plasmacytoid DC: 3.2"	"Lineage enriched"	"Detected in single"	14	"dendritic cells: 3.2"	"Cell line enhanced"	"Detected in some"		"HaCaT: 2.7;Hep G2: 2.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (8.83e-2)"	"unprognostic (2.99e-2)"	"unprognostic (4.98e-4)"	"unprognostic (3.81e-2)"	"unprognostic (7.52e-2)"	"unprognostic (7.89e-3)"	"unprognostic (3.14e-2)"	"unprognostic (2.96e-1)"	"unprognostic (8.45e-2)"	"unprognostic (5.07e-2)"	"unprognostic (3.28e-1)"	"unprognostic (8.59e-2)"	"unprognostic (1.05e-4)"	"unprognostic (1.26e-2)"	"unprognostic (8.21e-2)"	"unprognostic (2.36e-2)"	"unprognostic (1.85e-1)"	0.9	0.6	1.8	0.5	1.9	1.2	0.7	3.5	1.6	1.2	1.4	4.3	0.5	1.5	1.5	0.5	0.5	1.5	0.6	0.7	2.3	2.0	1.0	0.7	1.1	1.4	1.0	1.1	3.4	1.4	0.5	4.2	1.1	7.3	1.6	0.5	86.1	1.6	0.5	10.2	3.5	2.8	0.8	1.2	1.0	0.6	1.8	0.7	0.7	1.3	0.5	1.0	0.5	1.2	0.0	3.2	0.2	0.0	0.0	0.0	0.0	1.2	0.6	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.1	0.0	2.7	0.0	0.1	0.0	0.3	1.3	0.2	0.4	2.7	0.0	0.7	0.3	0.0	0.3	0.0	0.3	0.0	0.0	0.1	1.0	0.0	0.0	0.8	0.6	0.1	0.6	0.2	0.0	0.2	0.3	0.0	0.0	0.3	0.0	1.0	0.5	0.3	0.1	0.0	0.3	1.0	0.0	0.7	0.7	0.1	0.9	1.0	0.9	0.1	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.2	0.0	0.0	1.8	1.9	3.5	1.6	2.3	2.0	1.0	1.1	7.3	0.7	0.0	0.3	0.0	0.3	0.0	115.9	1.1	0.0	0.0	0.0	1.8	82.5	0.4	0.0	0.1	0.4	0.0	1.3	0.0	0.3	0.2	0.4	0.7	0.0	0.0	0.2	6.4	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	1.1	19.0	0.3	0.0	0.7	1.2	193.4	0.0	0.3	0.2	1.0	0.4	0.1	0.0	1.1	0.3
DRD5	"DRD1B, DRD1L2"	ENSG00000169676	"Dopamine receptor D5"	P21918	4	9781680-9784009	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Dystonia, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	6	"brain: 8.4;lymphoid tissue: 3.5;stomach 1: 10.9"	"Cell type enhanced"	"Detected in single"	41	"Horizontal cells: 1.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"REH: 3.6;THP-1: 2.0;U-2 OS: 1.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA048930	Supported					NA	NA					"HPA048930: AB_2680562"		"unprognostic (2.03e-2)"			"unprognostic (2.63e-1)"	"unprognostic (9.73e-2)"		"unprognostic (4.27e-2)"		"unprognostic (4.44e-3)"	"unprognostic (1.98e-2)"	"unprognostic (1.32e-4)"	"unprognostic (5.09e-4)"	"unprognostic (6.51e-2)"	"unprognostic (1.46e-1)"		"unprognostic (7.36e-3)"	0.2	0.2	2.8	3.5	4.1	0.1	0.2	0.0	8.4	0.1	0.9	0.0	0.0	0.9	0.1	0.1	0.3	0.3	0.1	0.1	3.2	3.2	0.2	0.1	0.4	0.2	1.9	0.8	0.1	0.2	0.1	1.0	0.1	7.4	0.6	0.2	0.4	0.2	0.2	0.1	0.2	0.2	0.2	0.6	0.1	10.9	1.3	1.0	0.0	0.2	0.0	0.2	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.8	0.0	0.0	3.6	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.4	0.0	2.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	4.1	0.0	8.4	3.2	3.2	1.9	0.8	7.4	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EDNRA		ENSG00000151617	"Endothelin receptor type A"	P25101	4	147480917-147544954	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 62.6;seminal vesicle: 52.3"	"Cell type enhanced"	"Detected in some"	14	"Leydig cells: 40.6;Peritubular cells: 64.0;Sertoli cells: 51.8;Smooth muscle cells: 84.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 7.3;ASC TERT1: 14.5;HHSteC: 7.4;LHCN-M2: 17.2;SH-SY5Y: 13.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013774, CAB018957"	Uncertain		Uncertain	"Plasma membrane,Cytosol"		NA	NA			Cytosol	"Plasma membrane"	"CAB018957: AB_2039838, HPA013774: AB_1847994"	"unprognostic (3.08e-2)"	"unprognostic (6.28e-2)"	"unprognostic (1.78e-1)"	"unprognostic (3.42e-1)"	"unprognostic (1.07e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.20e-2)"	"unprognostic (7.20e-2)"	"unprognostic (2.75e-3)"	"unprognostic (1.47e-2)"	"unprognostic (1.34e-3)"	"unprognostic (2.88e-1)"	"prognostic unfavorable (1.50e-7)"	"prognostic unfavorable (3.93e-4)"	"unprognostic (6.20e-3)"	"unprognostic (3.11e-2)"	"unprognostic (2.53e-3)"	7.6	2.6	1.3	1.4	1.8	0.0	7.2	0.6	2.4	62.6	2.6	1.0	21.7	1.5	37.3	14.2	4.7	13.3	7.3	15.1	1.3	1.3	3.1	1.4	12.7	2.0	1.8	1.0	23.5	0.9	1.9	2.2	5.9	2.7	21.5	1.5	10.3	4.1	52.3	4.8	3.2	1.8	19.4	1.6	11.5	4.4	9.1	1.4	2.9	5.0	6.0	2.6	14.7	18.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	4.2	0.0	7.3	14.5	0.0	2.2	2.9	0.4	0.1	0.2	0.0	0.0	0.0	0.7	0.5	0.0	0.3	0.6	0.2	0.0	1.5	0.0	2.5	0.0	7.4	0.0	0.0	5.6	0.5	0.4	0.0	2.7	0.0	0.0	0.0	1.1	17.2	0.2	0.0	0.1	1.2	0.0	0.9	0.0	0.7	0.1	1.1	0.8	0.0	13.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	2.9	0.6	0.0	0.0	1.1	0.3	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	1.8	0.6	2.4	1.3	1.3	1.8	1.0	2.7	1.4	3.0	4.0	0.0	0.6	2.7	0.0	17.1	0.0	0.0	7.9	0.0	0.0	0.2	0.0	0.0	2.0	2.7	0.0	0.0	0.0	0.1	11.8	1.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.1	40.6	0.3	3.3	0.0	0.0	0.0	0.2	0.0	64.0	0.0	0.0	51.8	84.6	0.6	0.6	2.4	0.1	0.0	0.0	0.2
EDNRB	"ETB, HSCR, HSCR2"	ENSG00000136160	"Endothelin receptor type B"	P24530	13	77895481-77975529	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Albinism, Deafness, Disease mutation, FDA approved drug targets, Hirschsprung disease, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 67.5"	"Cell type enhanced"	"Detected in many"	10	"Endothelial cells: 97.7;Ito cells: 106.8;Melanocytes: 104.6;Muller glia cells: 142.7;Sertoli cells: 213.4;Smooth muscle cells: 110.2"	"Group enriched"	"Detected in all"	7	"glioma: 41.1;melanoma: 127.7;renal cancer: 28.2"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	21	"classical monocyte: 2.0;intermediate monocyte: 2.1"	"Lineage enriched"	"Detected in single"	21	"monocytes: 2.1"	"Cell line enhanced"	"Detected in some"		"AF22: 25.2;ASC diff: 19.2;SK-MEL-30: 23.1;U-266/70: 15.1;WM-115: 48.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017842, HPA027546"	Approved		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	Cytosol	"CAB017842: , HPA027546: AB_2672327"	"unprognostic (7.75e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.41e-3)"	"unprognostic (2.59e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.45e-3)"	"unprognostic (4.17e-3)"	"unprognostic (5.43e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.38e-2)"	"unprognostic (3.40e-2)"	"unprognostic (3.01e-2)"	"prognostic favorable (7.20e-5)"	"unprognostic (1.59e-2)"	"unprognostic (3.86e-2)"	"unprognostic (4.58e-2)"	"unprognostic (6.77e-3)"	25.4	23.2	22.2	10.3	29.8	0.8	23.1	10.3	30.7	8.1	7.2	13.6	2.3	10.9	7.7	3.6	4.9	6.0	8.5	23.7	16.7	16.4	22.3	26.5	28.4	15.6	24.2	8.1	4.9	6.4	7.7	6.3	67.5	33.2	14.9	7.7	51.0	13.4	4.4	6.7	5.1	11.9	7.4	33.4	16.0	5.8	3.1	12.4	0.0	17.6	2.0	2.9	10.9	8.2	0.0	0.0	0.0	2.1	0.0	0.0	0.4	2.0	0.0	25.2	0.0	19.2	0.7	0.3	0.0	0.0	0.0	0.0	9.3	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	1.3	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	23.1	3.4	0.0	0.1	0.1	0.2	0.0	0.0	0.1	15.1	8.5	0.0	0.4	0.0	48.1	0.0	2.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	22.2	29.8	10.3	11.9	16.7	16.4	24.2	8.1	33.2	12.4	11.9	38.2	0.0	1.0	13.2	3.2	7.3	0.0	2.7	4.5	0.0	5.9	14.3	0.0	0.0	2.4	97.7	0.0	0.0	0.0	10.2	27.8	2.5	5.8	0.5	10.9	0.0	0.0	106.8	21.3	1.8	73.9	9.2	104.6	0.0	0.0	142.7	0.1	0.0	2.5	0.0	3.4	213.4	110.2	0.3	1.4	6.4	4.8	0.0	0.0	1.4
EGF		ENSG00000138798	"Epidermal growth factor"	P01133	4	109912884-110012266	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Growth factor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"kidney: 48.4;pancreas: 41.2;skeletal muscle: 19.8"	"Cell type enriched"	"Detected in some"	6	"Muller glia cells: 38.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 1.7"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 1.7"	"Cell line enhanced"	"Detected in some"		"EFO-21: 8.2;SK-BR-3: 14.9;U-251 MG: 4.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"									NA	NA	209000	25000				"unprognostic (2.83e-2)"	"unprognostic (1.02e-2)"	"unprognostic (8.50e-3)"	"unprognostic (1.88e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.64e-3)"	"unprognostic (5.06e-4)"	"unprognostic (8.30e-2)"	"unprognostic (2.21e-3)"	"unprognostic (4.25e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.95e-1)"	"unprognostic (7.72e-3)"	"unprognostic (4.64e-5)"	"unprognostic (2.63e-1)"	"unprognostic (9.80e-5)"	"unprognostic (3.92e-3)"	0.8	0.1	0.4	0.0	0.4	0.0	5.9	0.1	0.9	0.2	0.2	0.3	0.3	0.0	0.3	2.6	0.9	0.2	0.3	2.3	0.8	0.3	48.4	0.0	0.6	0.0	1.2	0.7	0.0	41.2	0.0	0.4	0.0	1.4	0.6	0.4	3.9	8.4	0.1	19.8	0.5	0.2	1.9	0.6	0.2	0.0	0.2	0.2	0.0	1.2	4.5	0.4	0.4	0.5	0.0	0.4	1.7	0.0	0.0	0.0	2.6	0.2	0.3	2.4	0.1	0.0	0.1	0.0	0.6	1.5	0.8	0.5	0.1	0.1	0.0	8.2	0.8	2.1	0.0	0.3	0.0	0.6	0.1	0.4	0.1	0.9	1.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.8	0.0	0.0	1.6	0.2	0.8	0.1	0.0	0.0	2.9	0.0	0.6	0.2	0.1	0.7	0.7	0.2	0.0	0.0	0.0	14.9	0.5	1.8	3.5	0.0	0.0	1.3	2.0	0.0	4.7	0.0	0.0	0.0	1.4	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.4	0.0	2.6	0.4	0.4	0.1	0.9	0.8	0.3	1.2	0.7	1.4	0.2	0.0	0.0	0.0	0.1	0.9	0.6	6.2	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.2	2.2	0.0	0.4	0.0	4.9	0.0	0.0	1.5	0.0	0.0	0.1	1.6	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	38.3	1.6	0.0	0.0	1.2	1.1	0.0	0.0	0.5	0.3	1.3	0.0	0.0	1.6	0.1
EGFR	"ERBB, ERBB1"	ENSG00000146648	"Epidermal growth factor receptor"	P00533	7	55019021-55211628	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Host-virus interaction"	"Developmental protein, Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 102.3"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 207.2;Syncytiotrophoblasts: 315.1"	"Cancer enhanced"	"Detected in all"		"glioma: 136.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in many"	12	"A-431: 345.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000035, HPA001200, HPA018530, CAB068186, CAB073534"	Enhanced		Enhanced	"Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA	4740000	93000000	"Plasma membrane, Cell Junctions"		"CAB000035: , CAB068186: AB_2665679, CAB073534: , HPA001200: AB_1078723, HPA018530: AB_1848044"	"unprognostic (2.62e-2)"	"unprognostic (9.56e-3)"	"unprognostic (1.59e-1)"	"unprognostic (7.51e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.27e-2)"	"unprognostic (6.11e-2)"	"unprognostic (4.88e-2)"	"unprognostic (2.85e-2)"	"unprognostic (3.30e-3)"	"unprognostic (1.78e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.93e-3)"	"unprognostic (6.98e-3)"	"unprognostic (1.72e-1)"	"unprognostic (6.62e-2)"	"prognostic unfavorable (2.04e-5)"	16.2	8.4	4.9	7.5	6.8	0.1	39.8	5.1	8.5	13.8	7.8	3.3	10.7	3.6	8.2	11.7	15.6	8.8	8.5	4.8	6.8	2.7	7.6	23.5	14.2	2.3	4.1	3.9	10.4	10.1	1.8	2.1	102.3	5.6	10.9	6.7	9.2	15.4	12.9	10.7	32.5	6.3	15.5	3.5	3.3	7.8	5.5	5.9	3.2	12.8	15.5	8.0	10.2	28.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	345.9	4.4	1.1	1.5	7.1	4.4	1.2	3.4	4.6	2.1	1.6	0.8	3.7	0.2	0.8	2.9	9.0	13.9	0.0	15.3	2.5	0.1	0.2	0.0	1.9	0.2	1.8	0.0	0.0	2.1	14.0	5.3	28.6	3.1	0.2	0.0	0.0	0.0	4.5	0.2	0.0	0.0	0.3	1.3	2.2	0.0	0.6	0.0	2.6	3.7	0.0	1.3	2.9	3.5	0.7	1.2	0.3	0.8	1.0	1.9	0.5	14.9	3.2	0.0	0.3	0.2	2.6	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	6.8	5.1	6.6	6.8	2.7	4.1	3.9	5.6	5.9	89.3	37.5	4.2	67.7	76.2	1.5	7.3	53.5	16.0	59.1	21.0	5.9	207.2	0.0	30.6	4.6	10.9	15.9	23.3	21.0	36.6	45.3	37.8	0.0	77.4	24.2	0.0	4.1	6.7	7.0	2.2	118.8	1.3	16.9	2.8	25.3	106.1	41.7	17.3	125.5	14.0	2.3	77.6	23.1	1.6	2.7	78.5	315.1	0.0	20.0	46.4
ELANE	"ELA2, HLE, HNE, NE"	ENSG00000197561	"Elastase, neutrophil expressed"	P08246	19	851014-856247	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"bone marrow: 244.3"	"Cell type enhanced"	"Detected in some"	9	"Basal keratinocytes: 7.7;Fibroblasts: 5.7;Kupffer cells: 5.6;Leydig cells: 5.8;Melanocytes: 6.8;Suprabasal keratinocytes: 6.5"	"Group enriched"	"Detected in some"	7	"pancreatic cancer: 3.5;stomach cancer: 3.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"classical monocyte: 3.2;neutrophil: 6.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 6.9;monocytes: 3.2"	"Cell line enriched"	"Detected in some"	65	"THP-1: 197.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB015409, HPA066836"	Enhanced				"Secreted to blood"	NA	NA		59000			"CAB015409: AB_831596, HPA066836: AB_2685733"	"unprognostic (3.46e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.42e-3)"	"unprognostic (2.09e-2)"	"unprognostic (1.80e-3)"	"unprognostic (3.43e-2)"	"unprognostic (3.92e-1)"	"unprognostic (6.38e-3)"	"unprognostic (5.80e-1)"	"unprognostic (2.54e-2)"	"unprognostic (4.06e-2)"	"unprognostic (3.48e-2)"	"unprognostic (1.19e-10)"	"unprognostic (6.27e-3)"	"unprognostic (4.00e-2)"	"unprognostic (2.76e-2)"	"unprognostic (4.75e-3)"	1.5	0.3	0.1	0.3	0.1	244.3	1.6	0.2	0.6	0.3	0.6	0.7	0.0	0.3	0.3	0.7	0.5	0.6	0.8	31.2	0.0	0.0	0.3	1.5	17.8	1.6	0.0	0.0	0.3	1.8	0.3	0.4	4.7	0.5	1.4	0.3	1.0	0.7	0.3	1.1	2.1	0.5	0.5	0.0	22.5	0.5	0.3	0.0	23.0	2.3	0.9	0.3	1.0	0.2	0.0	0.0	6.9	3.2	0.0	0.5	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	197.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.2	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	0.0	11.2	0.1	0.1	0.2	0.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	7.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	5.7	0.0	0.0	0.5	0.2	0.0	0.0	0.0	5.6	0.0	5.8	0.0	6.8	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	1.7	0.2	0.0	6.5	0.0	0.0	0.0	0.0
EPCAM	"17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1"	ENSG00000119888	"Epithelial cell adhesion molecule"	P16422	2	47345158-47387601	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Tumor antigen"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary nonpolyposis colorectal cancer"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 303.2"	"Cell type enhanced"	"Detected in many"	10	"Enterocytes: 1952.6;Mucus-secreting cells: 1256.8;Paneth cells: 2168.3;Undifferentiated cells: 1330.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.9"	"Lineage enriched"	"Detected in single"	5	"dendritic cells: 1.9"	"Cell line enhanced"	"Detected in many"		"A-431: 55.5;CACO-2: 71.9;CAPAN-2: 101.2;OE19: 96.3;RPTEC TERT1: 43.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"CAB003809, HPA026761, CAB030012, CAB055098, HPA067463"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB003809: AB_562285, CAB030012: AB_756075, CAB055098: AB_2335685, HPA026761: AB_1848198, HPA067463: AB_2685846"	"unprognostic (6.79e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.49e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.61e-2)"	"unprognostic (3.40e-1)"	"prognostic favorable (3.30e-4)"	"unprognostic (5.27e-2)"	"unprognostic (3.28e-2)"	"prognostic favorable (1.04e-6)"	"unprognostic (6.38e-3)"	"unprognostic (1.28e-1)"	"unprognostic (6.45e-3)"	"unprognostic (6.08e-2)"	0.4	2.1	1.8	49.8	3.0	0.2	8.9	0.6	1.0	10.8	155.8	0.7	31.5	66.8	4.4	35.2	2.8	10.2	41.6	0.4	1.7	2.7	60.2	1.2	22.6	0.4	1.2	0.4	3.8	54.1	19.8	38.7	2.2	0.9	9.0	70.5	0.7	47.2	25.0	0.5	2.0	303.2	1.7	1.4	0.5	15.3	5.5	0.9	1.7	83.6	4.2	4.1	4.1	2.1	0.2	1.9	0.4	0.2	0.0	0.0	0.6	55.5	0.6	0.0	0.1	0.0	0.0	35.2	0.0	0.0	0.0	0.0	71.9	101.2	0.0	15.6	0.1	0.0	26.2	0.5	6.6	0.2	0.0	6.4	0.0	0.3	28.2	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.1	0.0	16.6	0.0	0.0	28.3	0.0	2.6	18.2	96.3	3.6	0.0	0.0	14.1	43.2	24.5	39.1	0.3	0.4	20.7	0.0	15.5	17.4	0.1	0.0	0.0	0.7	0.2	0.1	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	1.9	0.0	0.6	1.8	3.0	0.6	1.0	1.7	2.7	1.2	0.4	0.9	0.9	288.8	113.7	7.2	161.4	8.2	0.1	1.7	236.9	180.7	188.8	425.7	0.0	14.0	64.6	814.0	5.0	2.3	1952.6	0.0	356.0	2.6	1.9	182.8	33.3	0.4	2.4	0.0	478.4	0.0	0.0	3.2	19.0	5.0	33.7	19.8	1256.8	11.8	505.0	2168.3	17.7	160.0	0.7	12.9	0.4	67.3	135.0	9.2	5.0	2.5	1330.8	202.8
EPHA2	ECK	ENSG00000142627	"EPH receptor A2"	P29317	1	16124337-16156087	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Apoptosis, Cell adhesion, Differentiation, Host-virus interaction"	"Host cell receptor for virus entry, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 51.2"	"Cell type enhanced"	"Detected in many"	8	"Basal keratinocytes: 179.7;Suprabasal keratinocytes: 217.2;Urothelial cells: 155.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	115	"plasmacytoid DC: 11.4"	"Lineage enriched"	"Detected in single"	115	"dendritic cells: 11.4"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 42.4;EFO-21: 40.9;PC-3: 48.6;U-251 MG: 49.8;WM-115: 54.6"					"Low region specificity"	"Detected in all"			CAB010464			Supported	"Nuclear speckles,Golgi apparatus,Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane, Cell Junctions"	"Nuclear speckles, Golgi apparatus"	"CAB010464: AB_631436"	"unprognostic (9.41e-2)"	"unprognostic (1.67e-1)"	"unprognostic (4.13e-2)"	"unprognostic (1.67e-2)"	"unprognostic (6.22e-2)"	"unprognostic (9.12e-2)"	"unprognostic (5.24e-2)"	"unprognostic (1.29e-3)"	"unprognostic (2.52e-2)"	"unprognostic (7.05e-3)"	"unprognostic (1.52e-3)"	"unprognostic (2.77e-1)"	"unprognostic (2.65e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.73e-1)"	"unprognostic (4.77e-3)"	"unprognostic (4.40e-2)"	6.7	3.4	1.3	3.1	2.6	0.0	5.2	0.5	2.1	12.1	4.9	1.6	1.9	4.3	7.8	3.8	51.2	4.6	16.7	6.4	1.1	0.8	5.7	8.2	6.6	4.7	2.7	1.3	4.5	10.2	2.2	2.8	8.9	3.4	5.8	2.6	5.4	31.0	2.8	3.4	12.7	13.1	2.7	3.0	2.8	6.8	2.4	1.2	1.2	5.7	21.8	25.5	15.2	18.5	0.0	11.4	0.0	0.0	0.0	0.0	0.0	15.6	31.7	8.8	4.2	0.6	0.7	5.2	9.5	13.4	17.2	10.9	13.2	42.4	0.0	40.9	5.4	21.3	6.4	2.1	21.9	6.0	0.0	1.4	0.0	9.2	8.4	11.3	0.0	0.0	1.0	8.2	9.3	20.7	27.0	18.3	0.0	0.0	0.0	10.9	5.0	0.0	0.0	4.2	11.8	48.6	0.0	8.0	0.0	18.2	8.1	0.0	1.3	18.4	4.5	1.2	4.8	0.6	0.1	22.6	6.1	16.5	0.4	49.8	0.0	0.1	0.1	4.7	0.0	54.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	1.3	2.6	0.5	2.1	1.1	0.8	2.7	1.3	3.4	1.2	50.6	28.9	0.5	100.5	179.7	0.6	5.8	40.8	37.5	33.0	8.7	3.9	8.1	0.0	31.3	5.4	17.5	57.1	0.0	12.5	0.9	7.0	56.8	5.7	19.8	1.6	0.0	2.9	32.5	2.8	0.0	3.1	4.6	25.3	1.8	19.6	5.8	62.9	20.1	0.0	1.4	2.0	32.3	17.6	0.0	0.7	217.2	6.3	0.0	17.7	155.0
EPOR		ENSG00000187266	"Erythropoietin receptor"	P19235	19	11377205-11384342	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins"		Receptor	"Cancer-related genes, Congenital erythrocytosis, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Erythroid cells: 70.0;Ito cells: 78.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA077654			Supported	"Nuclear speckles,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	"Nuclear speckles"	"HPA077654: "	"unprognostic (9.13e-2)"	"unprognostic (7.14e-2)"	"unprognostic (1.45e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.70e-1)"	"unprognostic (1.50e-2)"	"unprognostic (5.60e-2)"	"unprognostic (9.00e-2)"	"prognostic favorable (3.17e-5)"	"unprognostic (6.37e-3)"	"unprognostic (1.59e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.00e-1)"	"unprognostic (7.48e-2)"	"unprognostic (1.01e-3)"	5.5	8.6	2.1	1.1	2.9	14.7	2.6	1.3	1.7	3.9	3.3	2.8	13.3	1.0	3.6	11.6	2.4	3.2	1.8	11.2	1.9	1.4	12.1	8.4	8.5	6.9	1.9	1.6	1.9	9.2	28.1	5.2	12.7	2.3	3.1	1.4	3.3	8.7	18.3	2.0	1.1	1.7	1.5	4.0	8.0	3.7	2.2	1.0	1.6	21.5	1.0	1.5	1.9	2.1	2.6	2.5	12.2	7.7	0.9	4.8	2.9	3.5	1.2	3.5	4.1	5.4	3.4	2.1	2.2	6.8	3.6	4.6	1.2	1.3	2.4	3.9	4.0	5.0	0.9	2.7	1.4	4.2	2.0	1.6	13.1	1.1	2.0	3.8	2.7	5.5	2.5	0.5	4.8	3.3	8.4	8.3	5.1	11.6	11.7	4.0	3.1	2.5	3.3	1.9	1.9	9.4	6.7	6.0	5.3	3.3	1.8	1.4	11.0	1.4	2.0	6.1	3.9	3.6	4.7	3.4	1.9	2.7	6.5	2.0	6.0	4.3	2.6	10.5	2.7	2.0	8.1	4.2	3.3	2.1	5.1	4.5	2.6	4.2	3.1	2.5	1.6	4.8	2.8	12.2	0.9	7.7	0.1	3.7	2.9	2.1	2.9	1.3	1.7	1.9	1.4	1.9	1.6	2.3	1.0	17.9	16.8	5.3	3.5	2.1	2.5	5.1	7.6	2.7	4.5	19.2	0.0	1.8	3.3	2.0	0.7	6.5	0.3	70.0	2.9	11.5	7.6	2.4	26.5	1.9	32.5	1.6	8.1	78.5	15.6	0.0	2.6	3.1	8.5	1.0	2.3	11.1	3.8	0.0	3.9	0.8	2.2	19.4	20.8	3.3	6.4	0.9	2.5	8.7	1.4	1.1
ERBB2	"CD340, HER-2, HER2, NEU, NGL"	ENSG00000141736	"Erb-b2 receptor tyrosine kinase 2"	P04626	17	39687914-39730426	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Transcription, Transcription regulation"	"Activator, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Collecting duct cells: 129.1;Enterocytes: 93.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 8.8"	"Lineage enriched"	"Detected in many"	4	"T-cells: 8.8"	"Group enriched"	"Detected in many"	41	"OE19: 366.2;SK-BR-3: 179.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		NA	NA		430000	"Plasma membrane"	Cytosol	"CAB000043: AB_2335701, CAB020416: AB_442047, CAB062555: AB_2665610, HPA001060: AB_2666185, HPA001338: AB_2666279, HPA001383: AB_1078500"	"unprognostic (1.97e-1)"	"unprognostic (6.60e-3)"	"unprognostic (6.21e-2)"	"prognostic unfavorable (8.99e-8)"	"unprognostic (2.96e-2)"	"unprognostic (1.40e-2)"	"unprognostic (1.97e-2)"	"unprognostic (9.04e-2)"	"unprognostic (1.79e-2)"	"unprognostic (1.20e-3)"	"prognostic unfavorable (9.17e-4)"	"unprognostic (3.92e-1)"	"prognostic favorable (2.41e-14)"	"unprognostic (9.29e-2)"	"unprognostic (1.40e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.96e-1)"	5.8	2.4	5.2	10.4	7.0	0.1	20.1	4.2	7.0	19.1	46.5	9.1	55.2	21.6	14.9	18.7	40.9	22.7	26.6	24.8	6.3	3.1	37.5	21.5	17.6	3.7	5.1	5.6	19.3	16.2	27.7	8.1	60.8	7.5	23.6	16.6	15.9	28.7	58.1	8.9	35.3	47.2	10.9	4.5	4.0	17.1	6.5	3.7	2.8	35.7	20.8	22.9	19.7	20.3	1.3	0.3	2.1	0.4	0.9	8.8	2.2	2.1	2.5	2.9	1.8	3.5	2.4	3.9	1.5	2.5	3.3	2.8	1.9	5.8	0.1	3.1	3.5	1.8	6.7	0.1	3.4	1.5	0.2	2.2	0.1	2.0	3.1	2.0	0.0	0.0	2.4	3.2	2.0	1.2	3.2	1.3	0.1	0.3	0.1	2.4	3.3	0.3	0.1	5.2	366.2	0.6	0.2	1.1	0.3	3.4	6.7	0.5	0.1	2.9	179.8	0.9	3.7	5.0	0.1	0.1	1.7	2.2	2.1	0.9	0.3	0.1	0.1	0.1	0.0	5.6	1.6	0.4	0.8	8.8	0.3	0.7	0.9	0.5	2.5	0.3	1.3	1.0	2.5	2.1	0.9	0.2	0.2	0.4	2.2	5.2	7.0	4.2	7.0	6.3	3.1	5.1	5.6	7.5	3.7	38.7	34.4	1.3	21.0	12.5	4.3	13.5	30.6	10.7	15.9	129.1	11.8	9.7	6.6	27.1	0.3	4.6	93.2	0.0	22.3	75.4	11.0	33.4	0.0	10.4	3.5	6.4	15.0	12.3	2.4	0.7	17.0	1.8	10.1	1.0	56.6	30.9	26.2	42.1	21.5	20.7	5.9	0.0	10.3	7.1	5.3	16.6	19.0	2.2	63.0	28.1
ERBB4	"ALS19, HER4"	ENSG00000178568	"Erb-b2 receptor tyrosine kinase 4"	Q15303	2	211375717-212538841	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Lactation, Transcription, Transcription regulation"	"Activator, Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Amyotrophic lateral sclerosis, Cancer-related genes, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"fallopian tube: 24.5"	"Cell type enhanced"	"Detected in many"	10	"Bipolar cells: 11.2;Cardiomyocytes: 15.3;Ciliated cells: 26.8;Club cells: 17.0;Collecting duct cells: 12.2;Muller glia cells: 12.4"	"Cancer enhanced"	"Detected in many"		"breast cancer: 4.1"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 9.6;EFO-21: 7.2;HEK 293: 5.3;RPTEC TERT1: 7.8;SCLC-21H: 4.4;T-47d: 7.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000276, HPA012016, CAB025522"	Enhanced					NA	NA		140000			"CAB000276: , CAB025522: , HPA012016: AB_1846541"	"unprognostic (1.48e-1)"	"unprognostic (3.28e-1)"	"unprognostic (4.31e-3)"	"unprognostic (1.76e-3)"	"unprognostic (3.59e-1)"	"unprognostic (2.75e-1)"	"unprognostic (2.88e-1)"	"unprognostic (9.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.67e-3)"	"unprognostic (1.07e-1)"	"unprognostic (3.61e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.49e-3)"	"unprognostic (1.41e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.11e-2)"	1.6	1.9	15.1	1.2	15.0	1.0	13.4	18.6	14.1	7.8	1.1	7.6	8.8	1.1	1.5	1.2	1.3	24.5	1.2	7.0	14.3	6.5	11.9	1.1	2.9	1.2	7.8	10.7	1.3	2.4	10.8	5.1	1.3	8.8	1.7	1.1	2.0	9.7	18.1	3.8	1.8	1.2	1.1	7.3	1.2	1.5	7.6	12.0	0.0	4.5	1.1	1.2	1.4	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	9.6	0.2	0.0	0.0	0.0	0.0	0.3	0.5	0.1	0.0	0.0	0.0	7.2	1.0	0.0	0.4	0.2	0.0	0.0	0.1	5.3	0.0	1.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	2.8	0.0	0.0	0.5	0.0	7.8	0.4	4.4	0.2	0.0	0.1	0.1	0.1	7.1	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.1	15.0	18.6	14.1	14.3	6.5	7.8	10.7	8.8	12.0	0.0	9.3	0.0	0.8	0.6	11.2	15.3	0.0	26.8	17.0	12.2	0.0	0.0	5.0	0.4	4.1	0.1	0.0	0.0	0.4	0.1	0.2	2.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.3	1.7	0.0	3.3	0.0	0.0	12.4	0.0	0.0	0.4	0.0	1.4	6.5	3.1	1.9	1.5	1.1	0.0	0.0	0.0	1.0
ESR1	"ER-alpha, Era, ESR, NR3A1"	ENSG00000091831	"Estrogen receptor 1"	P03372	6	151656691-152129619	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"cervix, uterine: 64.5;endometrium 1: 68.9"	"Group enriched"	"Detected in many"	6	"Early spermatids: 36.0;Hepatocytes: 48.4;Horizontal cells: 58.8"	"Group enriched"	"Detected in many"	9	"breast cancer: 40.2;endometrial cancer: 24.3;ovarian cancer: 8.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.5"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"MCF7: 24.9;T-47d: 32.2"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB000037, HPA000449, HPA000450, CAB055099, CAB072858"	Enhanced		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"CAB000037: AB_563706, CAB055099: AB_2101946, CAB072858: AB_2665701, HPA000449: AB_1078753, HPA000450: AB_1078754"	"unprognostic (8.28e-2)"	"unprognostic (3.02e-2)"	"unprognostic (1.43e-2)"	"prognostic favorable (5.47e-7)"	"unprognostic (4.79e-1)"	"unprognostic (2.43e-3)"	"unprognostic (4.10e-5)"	"unprognostic (9.92e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.17e-2)"	"unprognostic (7.35e-2)"	"unprognostic (3.45e-1)"	"unprognostic (1.20e-2)"	"unprognostic (7.91e-3)"	"unprognostic (6.45e-2)"	"unprognostic (1.25e-1)"	"unprognostic (1.52e-1)"	3.0	0.9	0.5	1.6	0.5	0.2	16.2	0.8	0.4	64.5	1.5	0.2	2.2	0.1	68.9	27.7	1.1	26.7	1.9	1.1	0.5	0.8	1.5	6.6	3.6	1.6	0.4	0.1	14.2	0.4	0.0	9.3	0.9	0.6	3.6	0.1	2.6	1.6	4.1	2.0	0.6	0.5	20.8	0.4	1.6	0.3	1.9	0.4	1.9	1.3	2.2	2.5	3.8	23.7	0.6	1.0	0.0	0.8	0.3	2.5	1.0	0.3	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.1	0.4	0.0	0.0	0.0	0.6	0.0	24.9	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	1.8	0.0	0.0	0.0	0.3	0.0	0.1	32.2	0.0	0.0	0.1	0.1	0.3	0.0	3.0	0.5	0.0	0.1	0.3	0.0	0.0	0.8	0.0	0.3	0.2	1.0	0.6	1.3	0.4	1.0	0.4	2.5	0.9	0.0	0.3	0.0	0.0	0.3	1.0	0.5	0.5	0.8	0.4	0.5	0.8	0.4	0.1	0.6	0.4	0.0	0.6	0.0	1.4	0.9	3.8	4.5	0.0	1.4	1.2	0.0	7.9	0.1	1.7	0.0	36.0	0.6	0.0	0.0	0.2	0.1	4.7	0.6	2.3	48.4	0.9	58.8	1.7	6.7	4.7	6.9	3.7	2.4	1.7	0.0	0.0	2.7	0.2	0.0	2.1	3.3	4.0	0.0	1.4	1.6	1.2	1.5	0.1	0.0	0.0	8.4
ESR2	"ER-beta, Erb, NR3A2"	ENSG00000140009	"Estrogen receptor 2"	Q92731	14	64084232-64338112	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"ovary: 19.1;testis: 30.2;vagina: 14.3"	"Group enriched"	"Detected in many"	9	"Early spermatids: 48.9;Late spermatids: 62.8;Rod photoreceptor cells: 41.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 4.1;U-266/70: 10.8;U-698: 17.6"	"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in many"	5	"cerebellum: 17.8"	CAB079300	Enhanced					NA	NA					"CAB079300: "	"unprognostic (7.63e-3)"	"unprognostic (2.28e-3)"	"unprognostic (8.27e-3)"	"unprognostic (5.41e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.06e-1)"	"unprognostic (1.80e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.95e-1)"	"unprognostic (8.75e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.03e-5)"	"unprognostic (1.57e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.21e-2)"	"unprognostic (5.89e-2)"	2.1	9.4	0.2	2.3	0.8	1.0	3.7	0.8	0.6	1.3	2.9	0.6	0.2	1.4	1.7	0.7	1.7	1.1	0.6	1.0	1.1	0.4	1.4	0.7	1.3	2.8	0.2	0.2	19.1	2.5	0.0	1.6	0.7	1.4	2.2	1.5	0.5	1.5	0.9	1.4	1.2	1.5	0.6	1.0	3.0	1.3	30.2	0.6	5.0	0.6	0.2	2.9	1.8	14.3	2.4	4.0	1.1	0.3	0.4	1.3	0.2	0.7	0.3	0.7	0.7	0.0	0.1	1.3	0.1	0.0	0.1	0.1	0.2	0.8	2.9	0.1	0.0	0.3	1.0	0.9	0.0	0.1	0.7	0.3	0.3	0.7	0.1	0.1	0.1	0.2	0.0	0.0	0.1	0.2	0.2	0.3	1.2	0.6	4.1	0.2	0.7	0.4	0.2	0.7	0.6	0.4	0.5	0.4	0.3	0.1	1.4	2.5	0.7	0.5	0.2	1.1	0.4	0.8	0.0	0.4	0.5	1.0	0.2	0.1	10.8	3.2	17.6	0.2	0.1	0.7	0.3	0.3	1.0	0.8	0.2	0.6	1.7	0.6	1.1	0.1	2.4	1.3	1.0	1.1	0.4	0.2	4.0	0.5	0.2	0.2	0.8	0.8	0.6	1.1	0.4	0.2	0.2	1.4	0.6	6.0	0.0	2.7	2.5	0.2	1.4	0.8	0.0	2.7	1.2	0.0	5.9	0.6	0.0	0.1	48.9	0.6	0.0	0.0	0.6	0.4	0.3	0.9	1.1	0.0	0.1	0.0	0.0	0.0	0.0	62.8	0.9	0.0	1.7	0.0	0.6	1.6	0.4	0.0	1.1	0.0	41.7	0.0	0.8	6.0	0.8	0.1	0.9	0.5	0.4	1.7
ESRRG	NR3B3	ENSG00000196482	"Estrogen related receptor gamma"	P62508	1	216503246-217137755	"FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 49.5;parathyroid gland: 37.2;placenta: 40.8"	"Cell type enhanced"	"Detected in many"	15	"Cone photoreceptor cells: 55.0;Syncytiotrophoblasts: 179.8"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	5	"pons and medulla: 49.5"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.5"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	4	"RPMI-8226: 15.4;SH-SY5Y: 29.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044678	Uncertain		Approved	Nucleoplasm		No	NA			Nucleoplasm		"HPA044678: AB_10963215"	"unprognostic (6.48e-2)"	"unprognostic (1.11e-1)"	"unprognostic (7.06e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.34e-1)"	"unprognostic (5.48e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.13e-1)"	"unprognostic (4.55e-2)"	"unprognostic (2.88e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.79e-2)"	"prognostic favorable (1.13e-11)"	"unprognostic (3.04e-1)"	"unprognostic (2.55e-1)"	"unprognostic (3.65e-4)"	"unprognostic (2.05e-1)"	0.5	5.1	2.8	0.4	3.3	0.2	2.9	6.9	10.3	1.4	0.7	0.7	2.2	4.0	0.5	1.5	1.4	2.1	0.8	8.3	3.2	2.6	22.0	0.8	0.7	0.4	6.8	1.7	0.8	4.4	37.2	9.9	40.8	49.5	2.6	0.4	10.7	11.0	2.4	6.3	1.5	3.7	0.9	2.6	1.0	22.2	1.0	1.5	0.0	4.6	7.2	0.4	1.0	0.7	0.4	0.2	1.5	0.0	0.2	0.1	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.0	0.1	0.0	0.0	15.4	2.4	1.7	5.5	29.5	0.0	0.2	0.0	1.8	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.4	0.1	0.1	1.5	0.2	0.0	0.2	0.0	0.0	2.8	3.3	6.9	10.3	3.2	2.6	6.8	1.7	49.5	1.5	0.0	2.6	0.0	3.3	0.2	26.3	45.0	7.6	18.7	1.2	22.7	55.0	29.1	46.4	3.1	4.5	0.3	0.0	0.0	2.1	3.1	1.5	8.3	0.0	0.8	3.8	46.1	7.9	0.6	0.8	4.6	0.3	0.0	8.5	0.0	0.7	12.3	0.6	0.2	0.7	23.0	34.7	0.0	1.0	1.4	0.1	0.3	179.8	0.0	0.2	1.4
F10		ENSG00000126218	"Coagulation factor X"	P00742	13	113122814-113149529	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"liver: 116.7"	"Cell type enhanced"	"Detected in many"	12	"Hepatocytes: 174.9;Leydig cells: 199.9;Peritubular cells: 222.0"	"Cancer enriched"	"Detected in many"	11	"liver cancer: 95.4"	"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in single"		"MAIT T-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BJ: 8.5;BJ hTERT+: 6.8;CACO-2: 7.2;fHDF/TERT166: 7.6;Hep G2: 33.5;HHSteC: 7.0;SH-SY5Y: 16.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Secreted to blood"	NA	NA		16000000000				"unprognostic (4.18e-2)"	"unprognostic (1.07e-1)"	"unprognostic (7.62e-2)"	"unprognostic (9.88e-2)"	"unprognostic (9.44e-2)"	"unprognostic (1.15e-2)"	"unprognostic (4.90e-2)"	"unprognostic (1.02e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (1.82e-5)"	"unprognostic (6.39e-2)"	"prognostic unfavorable (5.14e-5)"	"unprognostic (6.60e-2)"	"unprognostic (1.21e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.23e-3)"	8.1	3.7	0.3	2.9	0.7	0.0	5.4	0.4	0.8	20.3	5.9	0.6	7.6	4.5	12.6	21.4	4.5	9.9	10.0	18.4	0.5	0.5	2.3	116.7	4.9	1.6	0.5	0.7	18.2	3.0	0.0	1.7	3.6	1.0	18.1	0.7	6.9	2.0	6.1	2.6	7.8	7.6	11.7	0.6	1.3	3.2	9.5	0.6	0.6	3.1	5.6	1.8	7.8	10.3	0.0	0.0	0.0	0.0	0.9	1.0	0.3	0.0	0.0	1.5	0.2	4.9	5.0	0.0	8.5	6.8	0.5	0.2	7.2	0.0	0.0	0.3	7.6	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	33.5	7.0	0.0	0.2	4.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.8	0.1	0.0	0.1	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.1	0.6	16.6	0.0	0.3	0.0	0.3	0.3	0.1	0.0	0.0	0.4	0.1	0.0	0.1	0.0	0.0	0.1	0.1	0.3	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.9	0.0	0.0	0.0	0.3	0.3	0.7	0.4	0.8	0.5	0.5	0.5	0.7	1.0	0.6	0.0	0.0	0.0	0.0	14.0	1.0	4.8	7.6	0.0	0.0	1.8	0.0	0.6	0.0	0.0	2.6	2.1	0.3	0.0	0.0	0.6	66.0	0.1	1.1	174.9	1.2	6.4	17.1	9.8	4.5	5.6	199.9	0.3	18.6	1.0	1.4	3.8	0.5	2.9	222.0	5.6	1.1	51.8	54.2	2.1	1.1	13.4	0.9	2.5	0.9	0.2
F11	FXI	ENSG00000088926	"Coagulation factor XI"	P03951	4	186265945-186288806	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Heparin-binding, Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 88.9"	"Cell type enhanced"	"Detected in some"	27	"Alveolar cells type 2: 19.3;Distal tubular cells: 10.0;Hepatocytes: 59.9"	"Cancer enriched"	"Detected in some"	13	"liver cancer: 16.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	11	"Hep G2: 14.0"	"Not detected"	"Not detected"							HPA039808			Approved	Vesicles	"Secreted to blood"	NA	NA		4400000000	Vesicles		"HPA039808: AB_2676693"			"unprognostic (1.28e-1)"		"unprognostic (3.15e-1)"		"prognostic favorable (3.29e-5)"	"unprognostic (1.88e-1)"			"unprognostic (2.08e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.85e-3)"	"unprognostic (2.91e-2)"	"unprognostic (7.65e-2)"			0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.3	2.7	0.1	0.1	5.5	0.2	0.3	0.1	0.1	4.8	0.1	0.1	0.1	10.2	88.9	2.8	0.1	0.1	0.1	0.1	19.0	0.0	0.2	0.1	0.3	0.1	0.0	0.4	0.1	0.1	0.1	0.1	6.1	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	14.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.1	0.4	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.0	19.3	0.0	0.0	0.0	0.0	0.3	2.5	0.0	4.5	1.8	0.0	0.0	10.0	0.8	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	59.9	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.3	0.0	0.0	4.7	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
F12		ENSG00000131187	"Coagulation factor XII"	P00748	5	177402140-177409576	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	26	"liver: 180.1"	"Cell type enriched"	"Detected in many"	8	"Hepatocytes: 391.6"	"Cancer enriched"	"Detected in many"	21	"liver cancer: 171.0"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"classical monocyte: 2.5;eosinophil: 6.9"	"Group enriched"	"Detected in many"	5	"granulocytes: 6.9;monocytes: 2.5"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 8.7;MCF7: 11.1;PC-3: 8.2;SH-SY5Y: 5.6;U-937: 5.8"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			HPA003825	Approved				"Secreted to blood"	NA	NA	1040000	6600000000			"HPA003825: AB_1078790"	"unprognostic (9.75e-2)"	"unprognostic (1.71e-1)"	"unprognostic (2.93e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.01e-1)"	"unprognostic (2.32e-1)"	"prognostic favorable (4.63e-5)"	"unprognostic (6.97e-2)"	"unprognostic (1.26e-2)"	"unprognostic (3.96e-2)"	"unprognostic (4.41e-1)"	"unprognostic (6.54e-2)"	"prognostic unfavorable (7.09e-4)"	"unprognostic (4.11e-2)"	"unprognostic (3.69e-1)"	"unprognostic (3.40e-6)"	"unprognostic (6.48e-2)"	0.1	0.0	0.1	0.1	0.1	0.7	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.1	0.1	0.1	0.1	0.2	180.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.5	1.0	6.9	2.5	0.7	0.3	1.0	0.8	2.0	0.0	0.6	0.0	0.0	0.2	0.0	0.1	0.0	0.0	2.3	1.4	0.0	0.4	0.0	0.3	1.4	0.7	0.4	0.0	8.7	1.9	1.4	0.3	0.9	0.2	0.7	3.1	0.2	1.3	0.1	0.4	0.1	0.2	2.1	0.4	3.3	0.0	11.1	0.1	2.6	0.0	2.6	8.2	0.6	0.2	1.9	1.1	0.0	2.6	5.6	0.3	1.0	0.7	0.0	0.4	0.0	0.0	0.2	1.1	0.0	0.3	0.5	0.0	0.1	0.1	5.8	0.6	0.0	2.5	6.9	0.3	0.1	0.2	0.5	0.3	0.2	0.1	0.2	0.0	0.1	0.9	0.7	0.9	1.0	0.0	1.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	8.5	7.4	29.5	0.4	0.8	17.8	0.0	0.0	1.8	3.9	0.0	0.0	6.1	19.4	0.7	34.8	0.0	3.5	0.2	0.9	2.0	0.0	391.6	0.5	0.0	9.9	17.8	13.2	32.7	0.6	1.8	8.5	1.0	5.5	0.2	9.4	20.1	0.0	9.1	0.5	0.0	0.7	13.0	12.8	47.4	0.1	0.7	30.8	5.8
F13A1	F13A	ENSG00000124491	"Coagulation factor XIII A chain"	P00488	6	6144085-6321013	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Acyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 110.1"	"Cell type enriched"	"Detected in many"	6	"Hofbauer cells: 646.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 27.6;myeloid DC: 33.7"	"Group enriched"	"Detected in many"	5	"dendritic cells: 33.7;monocytes: 27.6"	"Cell line enhanced"	"Detected in some"		"AF22: 15.7;LHCN-M2: 5.8;RH-30: 29.5"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA001804, CAB002155"	Enhanced				"Secreted to blood"	NA	NA		1400000000			"CAB002155: AB_564077, HPA001804: AB_1078792"	"unprognostic (4.44e-1)"	"unprognostic (5.90e-2)"	"unprognostic (2.65e-2)"	"unprognostic (3.93e-2)"	"unprognostic (5.02e-2)"	"unprognostic (3.75e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.68e-2)"	"unprognostic (6.84e-3)"	"unprognostic (4.96e-2)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (6.61e-6)"	"unprognostic (2.79e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.57e-1)"	"unprognostic (2.54e-3)"	56.6	19.4	2.2	11.4	6.5	3.1	57.9	2.2	1.8	13.3	21.8	2.6	2.5	2.2	4.7	35.6	13.4	16.8	12.6	55.4	2.0	2.2	17.5	1.3	14.5	52.7	5.8	1.4	10.2	8.9	5.3	9.3	110.1	7.5	16.4	15.1	11.6	11.5	3.3	18.5	10.4	10.6	20.1	5.0	5.1	11.5	16.7	2.5	2.7	22.4	8.3	6.1	23.7	6.5	0.0	33.7	6.6	27.6	0.0	0.1	63.5	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	5.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	29.5	0.5	0.0	0.0	0.2	0.2	0.1	0.0	0.0	0.1	0.0	2.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.7	27.6	0.2	0.1	4.9	0.1	0.0	0.0	0.0	33.7	0.0	0.0	0.0	6.6	0.0	0.1	2.4	0.0	63.5	2.2	6.5	2.2	1.8	2.0	2.2	5.8	1.4	7.5	2.5	0.0	3.4	0.8	0.0	16.7	0.0	7.5	10.2	4.0	0.0	0.0	0.0	4.0	0.0	0.0	3.8	4.7	0.0	0.0	0.0	3.4	16.5	0.0	1.1	0.8	646.4	0.0	0.0	4.3	113.2	4.2	4.0	57.6	18.6	1.0	0.0	0.7	0.1	0.0	0.7	3.1	4.1	58.2	9.2	1.4	1.0	13.2	8.5	0.0	0.0	0.0
F2		ENSG00000180210	"Coagulation factor II, thrombin"	P00734	11	46719180-46739506	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	593	"liver: 324.8"	"Cell type enriched"	"Detected in some"	37	"Hepatocytes: 904.6"	"Cancer enriched"	"Detected in some"	110	"liver cancer: 508.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	21	"Hep G2: 78.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB016780, HPA051476, HPA054698"	Enhanced				"Secreted to blood"	NA	NA	108000000000	43000000000			"CAB016780: , HPA051476: AB_2681498, HPA054698: AB_2682578"	"unprognostic (1.98e-1)"	"unprognostic (2.52e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.85e-1)"	"unprognostic (2.29e-1)"	"unprognostic (2.81e-1)"	"unprognostic (2.23e-2)"	"unprognostic (3.94e-2)"		"unprognostic (5.79e-2)"	"unprognostic (8.29e-2)"	"unprognostic (4.46e-2)"	"prognostic unfavorable (6.75e-12)"	"unprognostic (5.65e-3)"	"unprognostic (5.80e-2)"		"unprognostic (1.54e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	324.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	78.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.5	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.6	22.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	904.6	0.0	0.0	0.0	24.5	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0
F2R	"CF2R, PAR-1, PAR1, TR"	ENSG00000181104	"Coagulation factor II thrombin receptor"	P25116	5	76716043-76735781	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 67.5"	"Cell type enriched"	"Detected in many"	9	"Ito cells: 323.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"gdT-cell: 17.6"	"Lineage enriched"	"Detected in many"	4	"T-cells: 17.6"	"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 39.1;HUVEC TERT2: 71.3;WM-115: 67.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB008973, CAB012962"	Approved					NA	NA					"CAB008973: , CAB012962: AB_2533198"	"unprognostic (3.03e-1)"	"unprognostic (7.76e-2)"	"unprognostic (5.55e-2)"	"unprognostic (7.76e-2)"	"unprognostic (7.14e-2)"	"unprognostic (3.46e-1)"	"unprognostic (2.51e-1)"	"unprognostic (3.75e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.36e-1)"	"unprognostic (2.22e-1)"	"prognostic unfavorable (2.21e-7)"	"unprognostic (2.72e-3)"	"unprognostic (1.30e-1)"	"unprognostic (1.12e-1)"	"unprognostic (6.74e-3)"	12.3	11.2	1.5	7.5	2.2	1.1	8.9	0.8	3.5	11.7	14.0	3.3	20.1	5.9	17.6	8.6	9.3	3.5	20.8	19.2	1.4	1.7	19.5	22.6	24.4	10.4	1.5	1.8	6.2	4.0	1.6	4.7	32.0	2.5	9.6	5.1	9.6	26.4	14.0	7.2	23.7	15.5	8.4	3.5	67.5	4.5	16.6	1.4	4.0	9.1	11.4	13.5	10.7	4.7	0.4	0.2	0.8	0.3	4.2	17.6	6.4	1.0	3.3	10.5	1.7	19.8	34.7	0.5	5.8	20.0	3.8	13.9	0.7	9.1	0.0	9.9	2.5	17.4	2.5	4.5	3.5	7.3	0.8	3.7	22.8	0.7	2.8	29.9	0.1	0.9	19.5	11.9	7.3	2.0	39.1	71.3	4.1	4.2	4.3	7.8	0.4	1.7	0.0	3.3	0.0	18.2	3.2	6.3	0.8	18.1	0.1	1.2	5.7	1.7	0.0	8.5	9.9	0.1	0.2	32.6	24.3	5.4	0.2	10.8	11.7	3.4	0.0	6.4	0.4	67.2	0.5	0.2	0.3	17.6	0.3	4.4	0.4	4.1	12.1	0.0	0.1	0.7	9.1	0.8	4.2	0.1	0.2	0.4	6.4	1.5	2.2	0.8	2.1	1.4	1.7	1.5	1.8	2.5	1.4	0.0	11.6	1.5	0.5	15.2	2.5	2.0	10.2	4.0	3.4	7.0	0.0	0.1	0.0	1.9	8.8	22.6	0.2	0.0	1.9	0.3	28.8	1.2	5.8	2.5	1.6	0.0	6.3	323.5	25.7	3.6	0.9	1.3	11.8	0.0	3.2	0.0	6.7	0.0	9.9	2.2	1.6	0.0	17.5	6.7	4.1	35.0	0.2	30.2	1.0	0.4
F3	"CD142, TF"	ENSG00000117525	"Coagulation factor III, tissue factor"	P13726	1	94529225-94541800	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Basal glandular cells: 636.0;Exocrine glandular cells: 410.4;Muller glia cells: 389.7;Pancreatic endocrine cells: 1078.7;Peritubular cells: 498.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.8"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 117.4;HaCaT: 55.6;HBEC3-KT: 144.4;U-2197: 54.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009438, HPA049292, HPA069132"	Uncertain		Approved	Vesicles	"Secreted to blood"	NA	NA	603000		Vesicles		"CAB009438: AB_668005, HPA049292: AB_2680701, HPA069132: AB_2686092"	"unprognostic (3.86e-2)"	"unprognostic (1.19e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.69e-2)"	"unprognostic (1.23e-3)"	"unprognostic (4.93e-2)"	"unprognostic (8.00e-2)"	"unprognostic (5.88e-1)"	"unprognostic (1.35e-1)"	"prognostic unfavorable (1.07e-4)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (2.02e-8)"	"unprognostic (4.84e-2)"	"unprognostic (4.08e-1)"	"unprognostic (1.23e-1)"	"unprognostic (1.08e-1)"	45.5	9.8	27.0	14.1	42.9	2.1	55.1	3.4	27.9	14.8	18.7	20.9	18.7	18.3	30.5	23.7	21.3	25.4	30.9	18.8	26.9	14.5	6.6	2.8	31.4	5.8	14.1	20.3	41.6	35.0	6.1	28.8	65.4	39.2	29.7	22.2	49.9	29.2	33.0	2.4	17.7	19.2	5.9	46.3	2.9	18.2	16.4	16.0	0.0	21.8	17.3	11.9	24.7	22.3	0.5	0.9	2.8	0.8	0.7	0.4	0.2	117.4	0.2	0.2	0.0	12.8	6.3	6.6	16.7	10.0	18.1	19.7	2.1	25.2	0.0	8.6	20.7	3.9	55.6	1.5	144.4	29.9	0.1	0.1	0.0	3.6	0.3	4.2	0.0	0.0	10.9	3.2	8.5	41.9	34.4	0.1	0.1	0.1	0.1	12.6	0.2	0.1	2.4	1.1	0.7	0.2	0.1	1.2	0.0	2.2	0.3	0.1	0.3	13.3	5.5	0.4	3.6	0.1	1.6	0.0	11.0	0.3	54.8	5.0	0.1	0.1	0.1	8.4	0.6	0.4	1.7	0.8	0.1	0.3	0.3	0.4	0.2	0.3	0.2	0.2	0.5	0.3	0.3	2.8	0.7	0.2	0.9	0.2	0.2	27.0	42.9	3.4	27.1	26.9	14.5	14.1	20.3	39.2	16.0	122.1	188.9	0.5	636.0	14.4	1.5	21.1	7.6	72.3	238.8	14.0	0.0	13.6	0.0	120.9	5.6	10.5	10.3	0.0	410.4	4.8	48.3	85.3	2.3	0.6	5.4	3.2	12.6	12.3	4.0	9.8	260.4	4.9	3.3	3.6	40.9	389.7	1078.7	11.0	498.9	0.3	13.3	6.5	7.2	1.1	3.4	6.6	6.4	0.8	9.5	358.5
F5		ENSG00000198734	"Coagulation factor V"	P12259	1	169514166-169586588	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"		"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.9;liver: 88.8;placenta: 32.2"	"Cell type enhanced"	"Detected in many"	22	"Cholangiocytes: 79.0;Cytotrophoblasts: 65.0;Hepatocytes: 221.3;Syncytiotrophoblasts: 49.8"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 69.6"	"Region enriched"	"Detected in many"	11	"pons and medulla: 27.9"	"Cell type enhanced"	"Detected in some"		"eosinophil: 8.7;neutrophil: 8.0"	"Group enriched"	"Detected in many"	13	"granulocytes: 8.7;monocytes: 4.2;T-cells: 7.0"	"Group enriched"	"Detected in some"	23	"Hep G2: 13.8;OE19: 52.9"	"Group enriched"	"Detected in many"	5	"basal ganglia: 2.8;hippocampal formation: 7.4;pons and medulla: 4.6;thalamus: 5.8"	"Group enriched"	"Detected in many"	7	"amygdala: 59.9;basal ganglia: 33.8;cerebral cortex: 88.3;hippocampal formation: 79.2;olfactory region: 58.9"	HPA002036			Approved	"Golgi apparatus"	"Secreted to blood"	NA	NA	7670000000	13000000000	"Golgi apparatus"		"HPA002036: AB_1078787"	"unprognostic (3.67e-2)"	"unprognostic (2.77e-4)"	"unprognostic (5.42e-2)"	"unprognostic (2.56e-4)"	"unprognostic (2.03e-1)"	"unprognostic (2.39e-4)"	"unprognostic (3.46e-3)"	"unprognostic (9.25e-3)"	"unprognostic (2.02e-1)"	"unprognostic (8.99e-3)"	"unprognostic (6.55e-3)"	"unprognostic (1.32e-1)"	"unprognostic (2.01e-2)"	"prognostic unfavorable (3.39e-4)"	"unprognostic (7.15e-2)"	"unprognostic (3.41e-1)"	"unprognostic (4.31e-1)"	1.1	0.4	0.4	1.4	0.5	1.5	0.8	1.0	0.4	0.4	0.4	6.7	0.0	0.5	0.4	2.2	0.4	1.6	14.1	13.9	2.5	0.5	1.2	88.8	1.1	1.1	1.4	0.1	0.4	1.3	0.1	2.0	32.2	27.9	1.0	0.4	17.8	4.4	0.1	0.4	1.3	0.5	0.5	2.6	1.9	2.2	0.7	1.1	0.0	0.7	0.2	2.6	1.5	0.4	0.0	0.5	8.7	4.2	0.0	7.0	1.1	0.0	0.2	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.8	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	52.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	4.2	8.7	0.0	0.2	0.0	0.0	1.7	0.2	0.5	0.0	0.3	0.0	8.0	0.0	0.0	0.0	7.0	1.1	0.4	0.5	1.0	0.4	2.5	0.5	1.4	0.1	27.9	1.1	3.0	1.1	0.0	4.4	0.1	0.1	8.6	79.0	5.3	3.4	0.0	2.0	65.0	0.0	1.6	0.7	1.0	0.0	0.0	0.2	1.6	7.7	0.3	0.0	221.3	4.7	0.0	24.2	3.1	18.7	0.0	0.0	0.2	3.3	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	49.8	1.3	0.0	9.0
F7		ENSG00000057593	"Coagulation factor VII"	P08709	13	113105788-113120681	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	39	"liver: 68.0"	"Cell type enriched"	"Detected in some"	6	"Hepatocytes: 131.2"	"Cancer enriched"	"Detected in some"	17	"liver cancer: 41.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	15	"gdT-cell: 1.7;MAIT T-cell: 1.2;memory CD8 T-cell: 1.6"	"Lineage enriched"	"Detected in single"	17	"T-cells: 1.7"	"Group enriched"	"Detected in some"	9	"CACO-2: 16.6;Hep G2: 10.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA004826			Approved	Mitochondria	"Secreted to blood"	NA	NA	351000000	1500000000	Mitochondria		"HPA004826: AB_10602805"	"unprognostic (2.06e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.34e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.50e-3)"	"unprognostic (3.81e-1)"	"unprognostic (4.36e-3)"	"unprognostic (1.16e-1)"	"unprognostic (4.19e-3)"	"unprognostic (1.15e-1)"	"unprognostic (1.35e-3)"	"unprognostic (3.36e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.86e-1)"	"unprognostic (1.47e-1)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.2	0.4	0.2	0.1	0.1	0.1	0.3	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.1	0.1	68.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.0	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	1.7	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	16.6	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	10.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	1.2	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.2	0.4	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	2.4	0.0	0.0	0.6	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.2	0.0	0.5	0.0	0.0	131.2	0.1	0.0	0.0	3.7	3.1	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.1	0.1	0.0	0.1	0.1	0.9	0.1	0.1	0.5	0.0	0.0
F8	"DXS1253E, F8C, FVIII, HEMA"	ENSG00000185010	"Coagulation factor VIII"	P00451	X	154835788-155026940	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Blood coagulation, Hemostasis"		"Disease mutation, FDA approved drug targets, Hemophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	11	"Ito cells: 376.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-2197: 15.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB018777	Enhanced				"Secreted to blood"	NA	NA		6400000			"CAB018777: AB_640320"	"unprognostic (2.09e-1)"	"unprognostic (5.66e-4)"	"unprognostic (4.94e-2)"	"unprognostic (8.32e-5)"	"unprognostic (1.26e-1)"	"unprognostic (5.05e-2)"	"unprognostic (6.05e-2)"	"unprognostic (8.27e-2)"	"unprognostic (6.58e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.67e-2)"	"unprognostic (5.58e-2)"	"unprognostic (1.24e-2)"	"unprognostic (2.16e-3)"	"unprognostic (1.69e-1)"	"unprognostic (1.17e-2)"	"unprognostic (4.44e-2)"	48.9	9.4	6.8	3.1	7.2	1.5	32.2	1.5	8.6	11.9	10.3	2.2	6.1	2.3	11.1	8.5	18.4	5.4	4.4	38.0	4.9	4.4	17.1	31.3	24.4	25.6	5.6	1.2	18.8	7.2	6.0	14.0	2.8	5.1	20.5	3.5	8.8	4.0	7.1	30.3	2.0	4.3	12.8	3.3	39.0	3.2	17.2	1.8	1.1	15.8	15.0	3.0	17.5	20.2	2.3	3.0	5.2	3.3	4.0	12.9	2.7	4.8	3.9	0.8	1.8	6.1	9.6	0.2	2.6	1.7	1.9	3.1	0.1	5.8	10.4	7.3	2.7	4.2	0.5	0.9	0.9	1.7	4.2	1.5	2.2	2.0	0.0	2.9	1.7	5.0	6.8	0.5	1.6	2.2	3.3	1.1	5.1	0.8	8.0	9.1	2.3	1.4	1.6	1.2	1.5	4.0	1.2	1.3	1.4	1.7	1.1	3.2	2.4	6.3	0.6	3.3	1.0	1.4	4.3	1.1	9.5	4.8	15.0	2.8	4.7	3.9	5.0	8.7	10.8	5.0	3.7	3.3	0.5	6.5	2.8	12.9	2.3	3.9	6.8	3.0	1.6	2.0	5.1	5.2	4.0	2.6	0.4	5.2	2.7	6.8	7.2	1.5	8.6	4.9	4.4	5.6	1.2	5.1	1.8	0.0	4.6	2.2	1.5	1.5	7.9	14.6	12.7	2.7	2.3	3.5	2.0	0.9	6.6	2.3	0.9	33.2	0.5	0.0	0.6	0.7	2.8	1.7	1.1	9.2	2.9	6.4	0.0	376.3	25.4	1.9	10.6	3.2	0.0	1.8	0.7	6.5	6.9	0.0	4.9	8.4	3.3	6.5	3.3	1.6	2.5	1.0	0.1	4.9	0.4	0.9
F9	FIX	ENSG00000101981	"Coagulation factor IX"	P00740	X	139530758-139563458	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets, Hemophilia, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	2334	"liver: 233.6"	"Cell type enriched"	"Detected in some"	20	"Hepatocytes: 475.1"	"Cancer enriched"	"Detected in single"	1354	"liver cancer: 67.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HL-60: 1.8;RH-30: 2.0;SiHa: 1.6;U-698: 1.1"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"								"Secreted to blood"	NA	NA		11000000000										"prognostic favorable (6.69e-4)"											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	233.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.8	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.2	17.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.0	0.0	0.0	0.0	0.0	475.1	0.0	0.0	0.0	15.4	17.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FADS1	"D5D, FADS6, FADSD5, LLCDL1, TU12"	ENSG00000149485	"Fatty acid desaturase 1"	O60427	11	61799625-61829318	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Muller glia cells: 82.0;Rod photoreceptor cells: 89.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 99.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA042705	Approved					NA	NA					"HPA042705: AB_10795709"	"unprognostic (8.28e-2)"	"unprognostic (3.54e-1)"	"unprognostic (1.29e-1)"	"unprognostic (1.99e-1)"	"unprognostic (8.17e-3)"	"unprognostic (1.40e-1)"	"unprognostic (1.99e-2)"	"unprognostic (3.23e-3)"	"unprognostic (7.88e-2)"	"unprognostic (1.94e-2)"	"unprognostic (4.10e-2)"	"unprognostic (2.00e-1)"	"prognostic unfavorable (1.95e-9)"	"unprognostic (2.29e-2)"	"unprognostic (3.59e-2)"	"prognostic unfavorable (2.79e-4)"	"prognostic unfavorable (1.33e-4)"	15.1	51.6	26.7	14.4	21.8	6.6	7.6	12.5	41.4	9.6	4.8	46.1	12.9	4.6	14.8	5.6	4.6	8.5	11.1	16.6	23.2	21.8	6.5	38.3	14.9	11.5	16.2	25.4	23.2	7.8	34.4	11.3	15.3	27.1	15.2	4.3	23.0	4.9	13.5	8.9	7.7	3.8	15.4	18.6	6.1	5.7	9.0	21.8	3.3	4.5	1.9	6.9	8.7	7.8	4.2	14.9	3.8	21.1	3.6	6.6	7.3	11.8	31.1	29.7	7.4	58.5	99.0	8.7	7.5	36.6	13.0	21.8	9.5	26.4	0.4	8.2	11.0	32.6	15.5	23.8	20.9	9.6	2.1	3.4	18.6	35.7	17.0	31.4	4.1	1.9	44.5	6.9	29.0	14.1	13.5	11.6	19.2	10.2	22.0	12.8	3.2	13.9	4.1	17.2	0.9	11.5	15.4	29.3	41.2	14.9	5.3	15.1	16.7	18.9	0.3	16.4	11.1	7.0	17.9	10.9	13.5	13.7	13.5	9.0	21.1	19.0	9.5	8.0	19.2	11.0	3.8	18.0	3.2	6.6	21.1	1.4	1.3	2.3	2.7	14.9	4.2	1.3	3.2	1.4	3.6	8.9	12.5	1.4	7.3	26.7	21.8	12.5	25.5	23.2	21.8	16.2	25.4	27.1	21.8	6.0	65.1	11.5	1.6	2.4	73.3	30.9	5.1	5.3	22.7	12.2	25.5	4.8	0.0	12.9	6.7	9.5	0.0	0.0	29.6	42.1	29.7	6.9	35.9	30.1	30.3	65.2	9.4	8.0	17.1	11.3	27.6	19.4	30.4	41.5	0.2	82.0	7.9	0.0	20.1	0.9	89.8	0.0	23.3	7.0	10.4	1.3	7.8	6.4	0.4	1.0
FADS2	"D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13"	ENSG00000134824	"Fatty acid desaturase 2"	O95864	11	61792980-61867354	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Transport"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"ductus deferens: 204.5;seminal vesicle: 98.8"	"Cell type enhanced"	"Detected in many"	5	"monocytes: 34.3;Muller glia cells: 29.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 151.3;HBEC3-KT: 90.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA006741	Approved					NA	NA					"HPA006741: AB_1078796"	"unprognostic (2.37e-2)"	"unprognostic (1.02e-1)"	"unprognostic (8.34e-2)"	"unprognostic (4.33e-3)"	"unprognostic (4.63e-2)"	"unprognostic (2.42e-2)"	"unprognostic (4.51e-2)"	"unprognostic (4.35e-3)"	"unprognostic (2.01e-1)"	"unprognostic (4.21e-2)"	"unprognostic (8.95e-3)"	"unprognostic (7.80e-2)"	"prognostic unfavorable (1.00e-7)"	"unprognostic (6.19e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.41e-2)"	"prognostic unfavorable (3.42e-4)"	7.1	85.9	34.3	10.0	31.7	7.5	20.2	10.1	48.5	23.7	4.9	28.6	204.5	9.3	19.9	10.3	3.2	8.9	6.6	8.2	24.4	29.9	3.8	38.0	9.7	6.7	28.1	20.1	8.6	3.1	41.5	11.8	12.8	26.4	32.0	4.3	16.7	5.0	98.8	3.0	26.1	3.6	39.3	17.9	3.3	3.6	10.4	24.0	8.4	2.5	3.2	9.2	10.6	6.5	3.5	13.3	6.9	9.0	6.3	9.4	3.8	1.4	53.2	79.1	43.7	72.0	151.3	20.6	8.9	80.5	13.1	35.8	3.3	17.8	0.3	1.2	19.6	19.9	1.5	51.7	90.4	5.6	0.6	1.1	30.2	10.6	7.8	56.8	1.8	1.7	56.8	2.7	47.6	4.3	19.6	38.7	28.4	1.7	24.5	6.0	1.3	17.0	10.0	34.5	0.0	14.0	23.0	1.4	74.4	52.0	0.4	23.5	28.6	5.8	0.1	2.3	19.5	2.2	22.3	15.6	1.4	14.2	0.9	1.2	11.4	10.0	4.0	1.4	10.1	16.0	4.5	5.7	6.9	9.4	9.0	2.2	1.6	3.5	5.0	10.5	3.5	2.0	4.4	3.1	6.3	7.5	13.3	3.0	3.8	34.3	31.7	10.1	25.2	24.4	29.9	28.1	20.1	26.4	24.0	8.9	13.1	0.0	1.0	1.4	6.9	3.6	2.5	0.0	6.8	3.5	3.9	1.6	0.0	5.8	1.5	2.9	0.0	0.0	15.7	18.4	8.5	18.5	4.7	12.9	16.1	4.8	5.2	3.1	3.2	3.5	23.9	3.8	8.5	34.3	0.0	29.9	4.9	0.0	22.3	0.2	13.0	0.0	10.8	0.9	0.5	0.5	2.6	4.4	0.6	0.7
FASN	"FAS, SDR27X1"	ENSG00000169710	"Fatty acid synthase"	P49327	17	82078333-82098332	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism"	"Hydrolase, Lyase, Multifunctional enzyme, Oxidoreductase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adipose tissue: 147.6"	"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 2: 103.0;Hepatocytes: 169.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"SK-BR-3: 155.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005192, HPA006461, CAB015417, HPA056108"	Enhanced		Enhanced	"Plasma membrane,Cytosol"		No	No		1600000	"Plasma membrane, Cytosol"		"CAB005192: AB_2101095, CAB015417: AB_2231427, HPA006461: AB_1848437, HPA056108: AB_2683039"	"unprognostic (3.35e-2)"	"prognostic unfavorable (1.42e-5)"	"unprognostic (9.69e-3)"	"unprognostic (4.09e-2)"	"unprognostic (3.46e-3)"	"unprognostic (1.55e-2)"	"unprognostic (3.09e-2)"	"unprognostic (4.74e-3)"	"unprognostic (3.15e-1)"	"unprognostic (3.15e-1)"	"unprognostic (2.87e-3)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (7.16e-5)"	"unprognostic (4.50e-2)"	"unprognostic (9.62e-2)"	"unprognostic (1.35e-2)"	"unprognostic (7.03e-3)"	147.6	7.8	8.2	14.2	11.5	11.1	57.5	19.1	23.0	6.6	27.7	17.0	14.1	8.2	4.7	14.2	17.1	4.3	19.4	6.3	7.9	6.7	3.7	30.8	26.8	9.8	7.3	11.5	6.4	10.4	6.7	15.3	8.4	21.7	28.8	3.4	7.6	16.9	10.8	7.5	17.2	6.5	4.6	8.4	5.1	11.9	6.6	8.8	1.9	5.1	10.7	5.4	8.0	6.6	0.5	1.4	0.0	0.8	0.2	1.9	0.8	23.6	24.8	11.5	7.9	18.7	12.7	24.7	4.7	6.1	5.0	9.2	25.9	16.1	7.9	3.9	3.6	14.0	19.7	11.1	21.7	0.9	3.7	48.3	16.3	18.5	34.6	5.3	8.8	2.5	12.1	5.7	12.7	3.0	1.7	5.6	7.4	24.6	7.0	1.7	40.9	9.5	14.0	22.4	3.7	14.4	8.5	6.5	15.6	5.6	30.3	28.7	16.0	6.9	155.8	12.6	4.4	27.8	16.8	9.7	7.3	15.1	6.0	11.3	9.5	2.1	8.1	4.4	9.6	10.8	0.0	0.8	0.0	1.2	0.5	0.7	0.5	1.9	1.4	1.4	0.2	0.7	0.6	0.0	0.2	0.4	1.1	0.6	0.8	8.2	11.5	19.1	23.0	7.9	6.7	7.3	11.5	21.7	8.8	23.8	103.0	0.8	10.3	6.9	24.9	4.8	25.5	6.7	10.3	10.4	5.9	28.9	3.3	18.9	1.2	4.5	20.8	23.3	24.9	65.8	10.4	65.5	12.7	169.2	11.7	28.6	17.4	11.1	6.9	1.3	15.3	5.0	16.9	8.2	18.9	12.3	16.1	17.5	10.6	5.5	9.5	0.0	9.6	1.9	13.9	12.0	24.7	10.7	18.3	17.5
FCER1A	FCE1A	ENSG00000179639	"Fc fragment of IgE receptor Ia"	P12319	1	159289714-159308224	"FDA approved drug targets, Predicted membrane proteins"		"IgE-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	18	"blood: 494.6"	"Group enriched"	"Detected in some"	4	"granulocytes: 258.2;Macrophages: 206.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	7	"basophil: 494.6"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 494.6"	"Cell line enriched"	"Detected in some"	94	"HEL: 100.1"					"Low region specificity"	"Detected in all"			"CAB022102, HPA036051, CAB055526"	Approved					NA	NA					"CAB022102: , CAB055526: , HPA036051: AB_2674919"	"unprognostic (1.78e-2)"	"unprognostic (2.26e-2)"	"unprognostic (7.32e-2)"	"unprognostic (7.51e-2)"	"unprognostic (1.32e-2)"	"unprognostic (1.44e-3)"	"unprognostic (7.19e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.44e-1)"	"unprognostic (7.20e-2)"	"unprognostic (8.54e-2)"	"unprognostic (2.74e-1)"	"prognostic favorable (1.20e-4)"	"unprognostic (1.68e-2)"	"unprognostic (1.18e-1)"	"unprognostic (2.70e-1)"	"unprognostic (3.39e-2)"	5.8	1.4	1.6	3.6	0.8	6.0	9.2	0.9	1.3	8.0	3.4	1.1	3.4	3.2	10.6	5.6	12.1	2.0	25.4	4.1	4.3	1.3	3.6	2.4	27.8	0.6	1.0	5.3	1.5	2.6	0.5	1.9	0.5	2.7	9.4	5.4	6.5	5.9	4.7	1.2	17.9	4.1	6.0	2.8	3.5	2.3	1.5	6.8	2.4	2.5	19.7	16.2	3.8	4.9	0.0	75.4	494.6	0.3	0.4	0.1	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	100.1	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	494.6	0.3	0.9	0.0	0.1	0.1	0.0	0.1	0.0	75.4	0.0	0.0	0.1	0.4	0.4	0.2	10.4	0.0	3.0	1.6	0.8	0.9	1.3	4.3	1.3	1.0	5.3	2.7	6.8	6.0	53.5	20.1	0.0	33.5	0.0	0.2	0.0	2.7	3.4	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.0	7.2	0.0	258.2	0.0	6.6	0.0	0.0	0.0	2.5	0.6	0.0	206.7	43.9	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.9	0.6	0.0	0.2	29.7	0.0	0.0	0.0	0.0
FCER1G		ENSG00000158869	"Fc fragment of IgE receptor Ig"	P30273	1	161215234-161220699	"FDA approved drug targets, Predicted membrane proteins"	"Immunity, Innate immunity"	"IgE-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 262.7;lymphoid tissue: 176.3"	"Group enriched"	"Detected in many"	6	"granulocytes: 677.9;Hofbauer cells: 2071.1;Kupffer cells: 1979.2;Macrophages: 2000.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 262.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HEL: 17.5;HMC-1: 71.6;THP-1: 63.0;U-266/84: 19.4;U-937: 19.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022108, HPA026872"	Supported					NA	NA		9800000			"CAB022108: , HPA026872: AB_1848473"	"unprognostic (3.71e-2)"	"unprognostic (2.52e-2)"	"unprognostic (2.40e-2)"	"unprognostic (8.73e-3)"	"unprognostic (1.46e-1)"	"unprognostic (4.28e-2)"	"unprognostic (3.10e-3)"	"unprognostic (1.84e-1)"	"unprognostic (3.25e-1)"	"unprognostic (9.63e-2)"	"unprognostic (2.28e-2)"	"unprognostic (5.67e-2)"	"prognostic unfavorable (1.83e-6)"	"unprognostic (1.99e-1)"	"unprognostic (6.28e-2)"	"unprognostic (2.04e-2)"	"unprognostic (7.87e-2)"	62.6	20.5	12.1	49.5	22.4	71.5	17.6	2.4	10.8	10.6	14.6	14.1	1.3	8.0	7.2	15.9	6.9	20.5	18.8	21.2	15.3	11.2	18.9	35.9	71.2	124.8	23.4	4.5	11.4	7.4	2.9	7.9	38.1	17.0	9.7	21.3	9.7	12.8	7.4	11.9	5.7	13.6	28.5	33.3	176.3	10.9	11.6	16.0	6.5	11.5	6.7	14.7	22.4	10.5	0.9	135.4	73.5	262.7	66.6	2.0	132.1	0.0	0.0	0.1	0.3	0.4	0.1	0.0	0.1	0.0	0.1	0.2	0.5	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.3	17.5	0.1	3.3	0.0	3.6	71.6	1.4	0.7	0.5	0.0	0.1	0.1	0.4	0.0	1.7	0.5	0.1	0.3	8.5	0.3	0.0	0.0	0.0	1.5	0.1	0.1	0.0	0.0	0.2	0.1	0.0	0.6	0.3	0.0	63.0	0.1	0.4	0.1	0.2	0.2	0.7	19.4	0.2	0.4	19.7	0.1	64.3	129.8	12.1	0.5	210.3	0.6	0.9	0.4	0.4	97.1	0.3	0.7	2.0	73.5	66.6	262.7	135.4	0.8	132.1	12.1	22.4	2.4	10.8	15.3	11.2	23.4	4.5	17.0	16.0	80.4	219.7	81.8	1.4	35.1	0.0	4.0	20.4	28.1	50.0	17.4	0.0	11.9	0.0	0.5	1.4	15.7	0.6	46.7	0.8	13.5	26.5	1.8	677.9	7.6	2071.1	0.0	1.7	49.7	1979.2	4.7	4.9	2000.4	75.9	55.9	0.0	0.2	0.7	0.9	1.1	3.9	2.6	71.1	23.6	0.9	2.6	31.5	19.8	270.2	0.2	1.6
FCGR1A	"CD64, CD64A"	ENSG00000150337	"Fc fragment of IgG receptor Ia"	P12314	1	149782671-149792518	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Innate immunity"	"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 35.6;epididymis: 33.2"	"Cell type enhanced"	"Detected in many"	21	"Hofbauer cells: 235.7;Kupffer cells: 121.8;Late spermatids: 48.6;Macrophages: 101.0"	"Cancer enhanced"	"Detected in many"		"glioma: 10.3"					"Group enriched"	"Detected in some"	7	"classical monocyte: 35.6;intermediate monocyte: 14.0;myeloid DC: 9.5;neutrophil: 25.5"	"Group enriched"	"Detected in many"	80	"dendritic cells: 9.5;granulocytes: 25.5;monocytes: 35.6"	"Cell line enriched"	"Detected in some"	5	"THP-1: 61.0"									HPA026910			Uncertain	"Golgi apparatus,Vesicles,Plasma membrane"		NA	NA			Vesicles	"Golgi apparatus, Plasma membrane"	"HPA026910: "	"unprognostic (5.27e-2)"	"unprognostic (2.89e-2)"	"unprognostic (2.34e-2)"	"unprognostic (7.97e-2)"	"unprognostic (8.44e-3)"	"unprognostic (1.73e-1)"	"unprognostic (7.69e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.72e-1)"	"unprognostic (1.98e-2)"	"unprognostic (6.18e-2)"	"prognostic unfavorable (4.83e-8)"	"unprognostic (1.28e-1)"	"unprognostic (4.51e-2)"	"unprognostic (9.99e-2)"	"unprognostic (9.03e-2)"	3.9	2.4	6.7	14.1	4.4	5.0	0.7	0.3	3.5	1.1	0.3			0.0	0.1	33.2	0.3	0.7	2.4	0.7	5.3	4.9	1.0	1.1	8.9	3.4	10.1		0.3	1.0	0.5	1.2	10.8		0.4	0.3		0.7	0.2	0.0	0.0	0.1	5.5	14.3	7.0	0.3	0.9			0.3		0.0	3.3	0.0	0.2	9.5	25.5	35.6	0.0	0.2	11.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	12.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.4	61.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.5	35.6	0.4	0.0	14.0	0.2	0.2	0.0	0.1	9.5	0.0	0.0	0.0	25.5	0.0	2.8	0.2	0.1	11.2											0.0	1.9	3.5	0.0	0.1	1.5	1.2	2.5	1.4	2.3	0.0	2.0	2.1	0.0	0.0	28.2	0.1	0.0	0.0	0.0	1.1	0.6	0.0	0.0	0.0	235.7	0.0	0.0	1.3	121.8	48.6	0.3	101.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	0.7	6.5	0.0	0.7	0.4	0.0	3.4	0.0	0.0	0.0
FCGR1B	CD64b	ENSG00000198019	"Fc fragment of IgG receptor Ib"	Q92637	1	121087345-121096310	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity"	"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 21.8;epididymis: 36.9"	"Group enriched"	"Detected in some"	5	"Hofbauer cells: 68.7;Kupffer cells: 38.3;Macrophages: 36.3;Sertoli cells: 19.4"	"Cancer enhanced"	"Detected in single"		"glioma: 1.6"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 19.2;neutrophil: 21.8"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"NB-4: 10.7;THP-1: 40.9"									HPA026910			Uncertain	"Golgi apparatus,Vesicles,Plasma membrane"	"Intracellular and membrane"	NA	NA			Vesicles	"Golgi apparatus, Plasma membrane"	"HPA026910: "	"unprognostic (3.21e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.13e-2)"	"unprognostic (2.84e-1)"	"unprognostic (1.85e-1)"	"unprognostic (9.60e-2)"	"unprognostic (1.56e-2)"	"unprognostic (6.42e-2)"	"unprognostic (3.10e-2)"	"unprognostic (8.17e-2)"	"unprognostic (1.91e-1)"	"unprognostic (3.65e-1)"	"unprognostic (3.24e-10)"	"unprognostic (8.99e-2)"	"unprognostic (2.85e-2)"	"unprognostic (7.86e-3)"	"unprognostic (8.93e-2)"	4.2	2.3	6.6	13.2	6.2	3.9	1.3	0.8	3.2	0.8	0.5	3.0	0.2	0.5	0.9	36.9	0.5	0.8	1.5	7.4	5.0	4.2	1.0	1.1	4.8	7.9	8.9	0.2	1.1	1.9	0.4	1.5	8.1	6.4	0.6	0.6	0.4	1.3	0.5	0.2	0.0	0.4	4.2	11.3	6.8	0.5	0.5	6.2	0.4	1.8	0.2	0.4	1.5	0.2	0.0	5.2	21.8	19.2	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.1	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	10.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	40.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	19.2	0.2	0.0	11.3	0.0	0.0	0.0	0.0	5.2	0.0	0.0	0.0	21.8	0.0	6.2	0.1	0.0	5.3	6.6	6.2	0.8	3.0	5.0	4.2	8.9	0.2	6.4	6.2	0.0	1.3	0.8	0.0	0.0	0.8	2.0	0.0	0.0	1.2	0.0	2.0	0.5	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	68.7	3.2	0.0	0.0	38.3	8.2	1.1	36.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	19.4	0.0	0.4	0.2	0.0	0.3	0.0	0.0	0.0
FCGR2A	"CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2"	ENSG00000143226	"Fc fragment of IgG receptor IIa"	P12318	1	161505430-161524013	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 182.8"	"Cell type enhanced"	"Detected in many"	17	"Hofbauer cells: 145.9;Kupffer cells: 155.0;Macrophages: 311.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"neutrophil: 182.8"	"Lineage enriched"	"Detected in many"	7	"granulocytes: 182.8"	"Cell line enhanced"	"Detected in some"		"HEL: 14.3;HMC-1: 28.9;K-562: 8.4;NB-4: 8.1;THP-1: 30.7;U-937: 13.2"									"HPA010718, HPA010776, HPA014730"	Enhanced		Supported	"Golgi apparatus,Plasma membrane"		NA	NA		55000000	"Plasma membrane"	"Golgi apparatus"	"HPA010718: AB_1078463, HPA010776: , HPA014730: AB_2669074"	"unprognostic (2.57e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.48e-2)"	"unprognostic (4.12e-2)"	"unprognostic (5.89e-2)"	"unprognostic (6.17e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.17e-1)"	"unprognostic (7.63e-2)"	"unprognostic (1.17e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.91e-1)"	"prognostic unfavorable (6.49e-7)"	"unprognostic (8.85e-3)"	"unprognostic (6.47e-3)"	"unprognostic (1.54e-1)"	"unprognostic (3.42e-2)"	36.8	12.6	13.2	44.6	19.2	18.6	8.2	2.2	10.1	9.1	7.1	10.0	0.0	3.8	4.7	6.6	5.5	11.6	17.0	11.3	17.0	8.9	11.5	7.1	44.1	50.0	25.9	1.7	8.0	5.8	2.8	6.1	47.5	19.6	7.0	9.9	10.8	8.3	4.8	7.3	3.0	7.3	17.6	30.9	43.4	5.9	4.8	19.2	3.2	6.3	2.5	4.4	19.3	4.5	0.2	7.0	182.8	27.2	0.0	0.0	10.6	0.0	0.0	0.0	1.2	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.2	0.0	0.3	4.1	28.9	0.3	0.0	0.0	0.0	0.4	0.0	0.0	8.4	0.2	0.0	0.0	0.2	8.1	0.0	0.0	0.6	0.1	0.6	3.9	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	30.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	13.2	3.6	0.1	27.2	31.6	0.0	20.7	0.0	0.2	0.0	0.0	7.0	0.1	0.0	0.0	182.8	0.0	16.7	0.2	0.0	10.6	13.2	19.2	2.2	10.1	17.0	8.9	25.9	1.7	19.6	19.2	20.8	63.3	13.7	0.4	7.7	0.0	1.2	5.1	6.7	21.6	0.0	0.0	0.8	8.3	0.2	37.5	2.6	0.0	0.0	0.5	1.1	5.8	0.3	29.0	0.8	145.9	0.0	0.0	4.3	155.0	35.2	1.4	311.2	16.9	1.8	0.0	0.3	0.7	0.0	0.0	7.9	0.1	6.5	5.8	0.3	0.4	6.8	1.4	4.1	0.0	0.3
FCGR2B	"CD32, CD32B, FCG2, FCGR2"	ENSG00000072694	"Fc fragment of IgG receptor IIb"	P31994	1	161663147-161678654	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Host-virus interaction"	"IgG-binding protein, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 53.3;placenta: 83.2"	"Group enriched"	"Detected in many"	5	"Ito cells: 479.4;Macrophages: 138.2"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"basophil: 53.3;memory B-cell: 42.2"	"Group enriched"	"Detected in many"	18	"B-cells: 42.2;dendritic cells: 14.5;granulocytes: 53.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.7;HMC-1: 23.5;NB-4: 5.2;RPMI-8226: 8.4"									"CAB007796, HPA014730"	Enhanced					NA	NA					"CAB007796: AB_562288, HPA014730: AB_2669074"	"unprognostic (1.58e-1)"	"unprognostic (5.14e-2)"	"unprognostic (3.32e-3)"	"unprognostic (3.12e-2)"	"unprognostic (6.79e-3)"	"unprognostic (4.05e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.65e-3)"	"unprognostic (1.91e-1)"	"unprognostic (4.72e-2)"	"unprognostic (2.89e-2)"	"unprognostic (3.49e-1)"	"prognostic unfavorable (8.82e-4)"	"unprognostic (3.51e-2)"	"unprognostic (6.36e-2)"	"unprognostic (4.31e-1)"	"unprognostic (3.37e-1)"	11.3	2.4	0.0	2.0	0.2	0.0	4.1	0.0	0.0	1.9	3.4			0.2	0.9	0.2	2.1	2.1	2.3	3.7	0.0	0.2	2.0	9.5	5.6	2.5	0.5		0.8	0.6	0.0	0.3	83.2		0.3	2.0		3.3	0.2	0.5	2.0	4.6	3.1	4.7	6.7	1.5	0.1			1.7		5.6	3.3	1.2	42.2	14.5	53.3	1.9	0.1	0.3	2.4	0.0	0.1	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	5.2	0.1	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.1	0.1	0.0	0.0	1.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	2.2	0.0	53.3	1.8	5.4	0.3	1.9	0.1	42.2	0.1	0.2	14.5	34.3	0.0	0.3	11.2	0.1	1.7	0.0	0.0	2.4											0.0	4.6	57.3	0.0	4.7	0.0	1.9	5.1	0.0	2.3	0.0	0.0	0.2	0.0	0.0	4.2	1.4	0.0	23.3	0.0	0.2	2.7	0.0	2.3	2.5	7.6	0.0	0.0	479.4	63.3	2.3	0.6	138.2	21.9	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.3	0.2	2.8	0.3	4.9	0.0	0.0
FCGR3A	"CD16, CD16a, FCG3, FCGR3"	ENSG00000203747	"Fc fragment of IgG receptor IIIa"	P08637	1	161541759-161550737	"CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 223.6;lymphoid tissue: 60.8"	"Cell type enhanced"	"Detected in many"	22	"Hofbauer cells: 191.4;Kupffer cells: 556.1;Macrophages: 266.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 109.4;non-classical monocyte: 223.6"	"Group enriched"	"Detected in many"	4	"granulocytes: 73.0;monocytes: 223.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.0;HaCaT: 1.7;SH-SY5Y: 1.3;U-2197: 1.1;U-266/70: 1.8"									"CAB032435, HPA055431"	Supported				"Secreted to blood"	NA	NA		2500000000			"CAB032435: AB_626925, HPA055431: AB_2682815"	"unprognostic (5.27e-2)"	"unprognostic (9.95e-2)"	"unprognostic (2.37e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.39e-1)"	"unprognostic (1.82e-1)"	"unprognostic (2.24e-2)"	"unprognostic (6.06e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.64e-1)"	"unprognostic (1.98e-2)"	"unprognostic (7.52e-2)"	"prognostic unfavorable (3.22e-6)"	"unprognostic (1.14e-1)"	"unprognostic (4.66e-2)"	"unprognostic (1.03e-2)"	"unprognostic (7.51e-2)"	11.9	9.7	7.5	20.5	12.4	4.4	4.1	1.6	7.0	1.9	2.1	5.5	0.8	0.8	1.1	2.4	1.0	2.4	5.1	6.4	6.3	7.3	2.6	22.5	43.2	8.0	12.7	1.9	1.4	2.9	1.8	3.9	14.6	6.8	2.6	2.3	2.2	2.7	1.3	1.3	0.3	1.2	14.3	25.7	60.8	1.3	1.2	8.0	1.4	1.8	1.3	1.3	6.3	2.3	0.1	11.7	73.0	223.6	7.9	33.9	35.8	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.5	1.7	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.8	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.3	0.5	0.5	0.0	0.0	0.8	0.5	0.4	0.0	0.0	0.5	1.3	0.4	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.1	1.1	0.0	1.8	0.0	0.4	0.0	0.0	0.0	0.3	1.6	0.5	33.9	109.4	0.3	0.1	0.3	13.2	11.7	0.0	0.2	12.2	73.0	7.9	223.6	0.2	0.1	35.8	7.5	12.4	1.6	7.0	6.3	7.3	12.7	1.9	6.8	8.0	20.8	30.6	13.0	0.0	0.5	0.1	0.4	7.6	10.7	19.4	3.5	2.0	1.1	0.0	0.0	0.9	0.8	0.0	0.0	0.0	1.1	0.3	0.0	17.4	3.4	191.4	0.0	0.0	9.2	556.1	1.5	0.3	266.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.6	1.3	19.4	0.0	0.0	0.5	0.0	1.7	99.7	0.0	0.1
FCGR3B	"CD16, CD16b, FCG3, FCGR3"	ENSG00000162747	"Fc fragment of IgG receptor IIIb"	O75015	1	161623196-161631963	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		"IgG-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	8	"blood: 334.5"	"Cell type enhanced"	"Detected in some"	19	"Alveolar cells type 1: 3.0;Alveolar cells type 2: 11.1;Ciliated cells: 4.0;Club cells: 5.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	95	"neutrophil: 334.5"	"Lineage enriched"	"Detected in many"	95	"granulocytes: 334.5"	"Cell line enhanced"	"Detected in single"		"K-562: 1.5"														"Secreted to blood"	NA	NA						"unprognostic (1.60e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.59e-3)"	"unprognostic (4.16e-2)"	"unprognostic (1.15e-1)"	"unprognostic (6.52e-2)"	"unprognostic (3.97e-2)"	"unprognostic (6.96e-3)"	"unprognostic (2.53e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.67e-2)"	"unprognostic (5.16e-2)"	"unprognostic (1.35e-1)"	"unprognostic (8.37e-3)"	"unprognostic (2.28e-1)"	"unprognostic (9.24e-2)"	9.9	0.8	1.8	30.8	1.5	13.8	1.5	0.9	1.8	0.9	0.8	0.5	0.2	0.0	0.4	0.5	1.7	2.8	6.8	4.6	1.2	0.9	0.9	2.9	15.2	16.9	5.0	0.5	1.2	1.2	0.0	0.6	4.5	1.9	1.5	0.0	1.3	0.9	0.9	0.8	1.4	0.8	2.0	4.0	44.3	1.3	1.5	0.9	0.6	0.8	0.2	0.9	11.1	4.7	0.0	0.1	334.5	3.5	0.1	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.5	0.5	1.2	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	334.5	0.1	3.5	0.0	0.0	0.5	1.8	1.5	0.9	1.8	1.2	0.9	5.0	0.5	1.9	0.9	3.0	11.1	0.0	0.0	0.0	0.0	0.3	0.0	4.0	5.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.8	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.0
FDPS		ENSG00000160752	"Farnesyl diphosphate synthase"	P14324	1	155308748-155320666	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Cholesterol biosynthesis, Cholesterol metabolism, Host-virus interaction, Isoprene biosynthesis, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism"	Transferase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HBEC3-KT: 149.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028200	Approved		Approved	Nucleoplasm,Cytosol		NA	NA		2000000	Cytosol	Nucleoplasm	"HPA028200: AB_10612109"	"unprognostic (1.23e-1)"	"unprognostic (8.46e-3)"	"unprognostic (2.47e-2)"	"unprognostic (6.57e-2)"	"unprognostic (4.58e-2)"	"unprognostic (2.84e-2)"	"prognostic unfavorable (7.35e-4)"	"unprognostic (4.21e-2)"	"unprognostic (6.78e-3)"	"unprognostic (1.64e-3)"	"unprognostic (7.19e-2)"	"unprognostic (2.25e-2)"	"unprognostic (1.11e-2)"	"unprognostic (8.25e-2)"	"unprognostic (2.07e-1)"	"unprognostic (5.65e-2)"	"unprognostic (8.44e-2)"	21.0	57.8	19.3	17.6	26.5	16.5	19.8	12.8	32.2	19.0	25.0	22.6	14.5	45.9	18.0	21.7	41.4	16.7	18.8	19.6	18.6	23.4	23.7	100.8	25.7	19.2	19.5	24.3	15.2	27.5	15.6	12.3	20.2	47.3	16.5	29.7	20.5	29.2	12.9	15.7	29.3	32.3	18.9	23.0	17.7	23.4	15.1	16.5	25.1	19.5	41.7	27.3	13.7	20.8	41.1	39.7	49.4	37.1	45.3	45.5	48.3	36.0	19.6	72.1	26.0	16.9	62.0	25.7	17.2	34.1	27.5	44.8	31.7	85.9	27.5	41.9	15.0	65.7	40.3	42.9	149.6	25.8	15.0	30.7	15.9	35.0	38.3	27.8	25.8	18.3	44.1	23.7	43.7	22.0	12.5	47.9	40.8	28.5	74.2	28.6	38.7	33.0	25.1	43.3	26.8	28.7	28.5	31.3	76.3	72.5	24.1	28.1	24.0	17.7	32.3	29.7	42.9	23.3	70.2	34.8	15.4	18.9	9.5	31.4	31.5	24.2	49.1	15.0	27.6	24.2	30.5	36.0	49.4	39.4	37.1	35.0	41.1	34.8	39.8	39.7	34.2	31.5	39.3	16.5	45.3	27.2	31.4	45.5	48.3	19.3	26.5	12.8	32.2	18.6	23.4	19.5	24.3	47.3	16.5	68.5	144.0	64.8	78.5	32.6	65.5	1.4	107.0	85.6	83.0	50.6	58.9	177.4	116.0	154.2	171.3	113.0	197.2	93.5	286.2	162.6	57.3	89.5	62.2	111.9	95.6	52.4	68.5	133.8	57.6	52.3	56.4	56.4	91.1	217.4	74.5	75.0	194.9	143.8	66.1	113.5	78.0	71.1	63.8	41.9	15.5	52.2	120.0	77.8	106.3	110.3
FFAR1	"FFA1R, GPR40"	ENSG00000126266	"Free fatty acid receptor 1"	O14842	19	35351552-35353862	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"bone marrow: 5.7;brain: 4.1;ovary: 4.8;pancreas: 9.6"	"Group enriched"	"Detected in some"	4	"granulocytes: 1.1;Intestinal endocrine cells: 1.7"	"Cancer enriched"	"Detected in single"	13	"pancreatic cancer: 2.2"					"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 2.9;HMC-1: 1.4;U-698: 5.5;WM-115: 2.1"	"Not detected"	"Not detected"													NA	NA						"unprognostic (9.49e-2)"				"unprognostic (2.08e-1)"			"unprognostic (1.59e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.51e-2)"		"unprognostic (1.03e-2)"	"unprognostic (4.46e-2)"	"unprognostic (6.19e-2)"	"unprognostic (9.56e-3)"		0.0	0.0	1.2	0.2	1.6	5.7	0.0	0.0	0.6	0.0	0.0			0.8	0.1	0.0	0.0	0.8	0.0	0.0	1.9	0.9	0.0	0.0	0.1	0.7	1.7		4.8	9.6	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.1	0.2	0.5	0.0	4.1	0.3	1.6	0.1			0.0		0.2	0.0	0.0	1.2	0.5	1.9	0.3	0.7	0.4	0.0	0.0	0.0	0.3	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	2.9	0.4	0.1	0.2	0.4	0.0	0.0	0.1	0.3	0.3	0.9	0.2	0.0	0.1	0.4	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.1	0.0	0.1	0.7	0.1	0.1	0.0	1.1	0.2	0.0	0.0	0.3	0.1	0.4	0.1	0.0	0.8	0.1	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.0	5.5	0.1	0.2	2.1	1.6	0.3	0.7	0.4	0.2	0.4	0.3	0.3	0.2	0.0	1.2	0.3	0.4	1.9	0.7	0.2	0.5	0.2	0.0											0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	1.7	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0
FGA		ENSG00000171560	"Fibrinogen alpha chain"	P02671	4	154583126-154590766	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	740	"liver: 2009.3"	"Cell type enriched"	"Detected in many"	40	"Hepatocytes: 16694.6"	"Cancer enriched"	"Detected in many"	43	"liver cancer: 2431.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	15	"Hep G2: 96.9"	"Not detected"	"Not detected"							"CAB016776, HPA051370, HPA064755"	Supported		Approved	"Endoplasmic reticulum"	"Secreted to blood"	NA	NA	407000000	170000000000	"Endoplasmic reticulum"		"CAB016776: , HPA051370: AB_2681458, HPA064755: AB_2685345"		"unprognostic (5.95e-2)"	"unprognostic (6.25e-2)"	"unprognostic (2.02e-1)"		"unprognostic (5.68e-2)"	"prognostic favorable (7.33e-4)"	"unprognostic (1.29e-3)"			"unprognostic (1.84e-1)"		"prognostic unfavorable (4.23e-6)"	"unprognostic (4.20e-1)"	"unprognostic (1.41e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	2.7	2009.3	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	96.9	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	1.4	0.0	0.0	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	24.4	83.9	0.0	0.0	0.0	0.4	420.4	17.4	5.7	0.0	0.0	0.0	1.7	5.5	23.9	0.0	0.0	256.9	1.5	0.0	0.0	0.0	0.0	16694.6	0.1	0.0	0.0	255.3	257.1	29.3	0.6	0.0	0.0	0.0	0.0	0.0	31.5	0.0	1.1	1.0	0.0	0.0	0.0	14.4	0.6	0.0	0.1	4.3	0.0	0.0
FGB		ENSG00000171564	"Fibrinogen beta chain"	P02675	4	154562956-154571086	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Adaptive immunity, Blood coagulation, Hemostasis, Immunity, Innate immunity"		"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	189	"liver: 1908.6"	"Cell type enriched"	"Detected in some"	33	"Hepatocytes: 15347.2"	"Cancer enriched"	"Detected in many"	42	"liver cancer: 2262.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	12	"Hep G2: 77.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001900, HPA001901, CAB008624"	Enhanced		Enhanced	"Endoplasmic reticulum"	"Secreted to blood"	NA	NA		120000000000	"Endoplasmic reticulum"		"CAB008624: AB_1615610, HPA001900: AB_1078865, HPA001901: AB_1078864"	"unprognostic (1.16e-1)"	"unprognostic (3.89e-2)"	"unprognostic (4.65e-2)"	"unprognostic (3.44e-1)"			"unprognostic (2.20e-3)"	"unprognostic (1.42e-2)"			"unprognostic (1.79e-1)"		"prognostic unfavorable (5.72e-5)"	"unprognostic (2.48e-2)"	"unprognostic (7.91e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	10.1	1908.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.7	0.0	77.7	0.0	1.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.2	0.0	0.7	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	153.8	0.0	0.0	0.0	0.4	257.4	0.0	0.0	3.5	0.0	0.0	1.7	3.0	0.4	0.0	0.0	467.2	3.2	0.1	0.0	0.0	0.0	15347.2	0.3	0.0	1.7	349.9	342.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.8	0.0	0.0
FGF1	"AFGF, ECGF, ECGF-beta, ECGFA, ECGFB, FGF-alpha, FGFA, GLIO703, HBGF1"	ENSG00000113578	"Fibroblast growth factor 1"	P05230	5	142592178-142698070	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 65.0;heart muscle: 35.5;kidney: 41.5"	"Cell type enhanced"	"Detected in some"	18	"Cardiomyocytes: 49.6;Collecting duct cells: 19.2;Cone photoreceptor cells: 15.7;Muller glia cells: 68.6"	"Cancer enriched"	"Detected in many"	12	"glioma: 33.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ: 19.8;BJ hTERT+: 14.8;BJ hTERT+ SV40 Large T+: 16.3;BJ hTERT+ SV40 Large T+ RasG12V: 20.6;HBF TERT88: 29.5;hTEC/SVTERT24-B: 20.6;LHCN-M2: 13.7;U-2 OS: 14.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003265, CAB017519"	Enhanced		Supported	Nucleoplasm	"Secreted in other tissues"	NA	NA			Nucleoplasm		"CAB017519: AB_629473, HPA003265: AB_1848522"	"unprognostic (1.25e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.06e-1)"	"unprognostic (3.41e-3)"	"unprognostic (2.55e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.39e-1)"	"unprognostic (3.63e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.54e-1)"	"prognostic favorable (2.59e-5)"	"unprognostic (3.72e-4)"	"unprognostic (2.49e-1)"	"prognostic favorable (3.45e-5)"	"unprognostic (3.01e-4)"	7.3	3.5	44.2	2.0	43.1	1.5	9.7	10.5	59.9	1.8	1.7	65.0	0.0	1.6	3.1	8.7	2.3	2.1	2.7	35.5	47.4	33.0	41.5	2.0	2.9	1.4	62.6	13.8	1.5	1.4	3.4	1.6	2.3	36.3	2.2	1.8	0.8	5.8	2.6	2.3	2.0	1.7	2.6	57.7	5.5	1.1	2.2	48.6	0.0	4.9	0.8	2.2	1.7	0.4	1.2	1.0	1.8	0.6	0.1	2.3	0.2	2.4	0.1	0.1	0.7	0.5	1.5	0.8	19.8	14.8	16.3	20.6	0.1	0.1	0.5	1.4	6.8	0.9	0.3	0.0	1.5	29.5	0.1	0.0	0.0	0.3	0.1	0.3	0.0	0.2	0.7	0.5	20.6	1.2	4.4	0.0	0.1	0.0	0.7	13.7	0.3	0.0	0.4	0.6	0.0	0.6	0.1	0.7	0.2	0.6	0.1	0.5	1.0	0.0	0.4	0.2	3.9	0.0	0.1	0.4	2.6	14.7	0.3	9.3	0.3	0.1	0.1	3.7	0.1	0.7	0.3	0.3	1.8	2.3	0.1	1.8	0.4	0.8	0.9	0.2	1.2	0.9	1.9	1.7	0.1	0.6	1.0	0.5	0.2	44.2	43.1	10.5	22.6	47.4	33.0	62.6	13.8	36.3	48.6	0.0	0.0	0.0	3.4	0.3	1.6	49.6	0.0	0.0	3.4	19.2	15.7	0.5	0.0	0.6	0.3	0.0	0.0	0.0	0.0	0.4	1.8	1.4	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.4	0.0	0.0	3.3	0.0	0.0	68.6	0.7	0.0	0.4	0.0	9.6	6.5	4.7	0.0	0.1	0.0	0.7	0.0	0.0	0.3
FGF2	FGFB	ENSG00000138685	"Fibroblast growth factor 2"	P09038	4	122826708-122898236	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins, Transporters"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Fibroblasts: 12.4;Smooth muscle cells: 15.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"BJ: 57.4;BJ hTERT+: 33.7;fHDF/TERT166: 62.3;hTERT-HME1: 34.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000125, HPA065502"	Enhanced		Supported	"Nucleoplasm,Nuclear bodies"	"Secreted in other tissues"	NA	NA	92500		"Nucleoplasm, Nuclear bodies"		"CAB000125: , HPA065502: "	"unprognostic (1.53e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.08e-1)"	"unprognostic (7.42e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.33e-1)"	"unprognostic (6.98e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.79e-1)"	"prognostic unfavorable (9.85e-4)"	"unprognostic (3.37e-1)"	"unprognostic (4.61e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.81e-1)"	"unprognostic (4.45e-2)"	"unprognostic (3.45e-3)"	28.1	3.8	19.4	6.9	21.3	0.7	12.1	6.5	15.3	10.2	14.2	10.3	1.9	2.6	17.9	6.3	6.4	10.1	9.4	5.6	17.1	11.0	5.5	2.9	8.3	2.5	9.9	10.7	16.8	2.4	10.1	4.0	8.1	18.6	10.3	5.6	7.5	4.6	11.9	2.0	2.3	4.1	16.2	17.3	1.9	7.6	3.0	12.3	0.0	3.1	3.8	2.7	7.5	14.5	0.8	0.8	0.5	0.5	0.3	1.0	0.0	1.2	3.1	1.8	6.9	4.4	7.4	0.0	57.4	33.7	24.1	14.0	0.0	0.1	0.0	6.7	62.3	19.0	0.2	1.8	0.1	24.3	4.5	0.8	0.0	6.5	0.0	13.0	0.3	0.0	3.9	0.4	23.8	34.4	12.1	2.6	0.0	1.7	1.9	6.2	0.0	0.0	0.0	5.2	0.0	1.4	0.0	0.9	0.0	7.6	0.0	1.0	0.9	11.1	0.0	0.4	10.8	0.0	0.1	2.4	20.0	3.9	7.4	4.9	3.4	3.6	0.0	5.7	0.0	2.1	0.5	0.5	0.4	0.3	0.4	0.2	0.4	0.5	0.4	0.2	0.8	0.7	1.0	0.4	0.3	0.4	0.8	0.7	0.0	19.4	21.3	6.5	15.3	17.1	11.0	9.9	10.7	18.6	12.3	6.0	0.0	0.0	1.5	1.4	3.5	3.9	0.0	0.0	2.3	7.0	0.0	1.8	3.3	6.9	8.7	5.8	0.0	0.0	0.8	0.0	12.4	5.2	0.0	0.4	0.4	0.0	1.7	7.4	0.0	2.5	9.2	0.9	5.0	1.0	0.0	8.4	6.7	0.0	7.8	0.4	1.8	0.0	15.5	3.1	0.2	1.1	4.0	0.0	0.0	0.3
FGFR1	"BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM"	ENSG00000077782	"Fibroblast growth factor receptor 1"	P11362	8	38411138-38468834	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Transcription, Transcription regulation"	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Dwarfism, FDA approved drug targets, Holoprosencephaly, Hypogonadotropic hypogonadism, Kallmann syndrome, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Leydig cells: 177.8;Muller glia cells: 106.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 111.2;BJ hTERT+: 50.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB033614, HPA056402"	Approved					NA	NA		120000000			"CAB033614: AB_783377, HPA056402: AB_2683118"	"unprognostic (9.53e-2)"	"unprognostic (7.33e-2)"	"unprognostic (2.44e-1)"	"unprognostic (1.35e-2)"	"unprognostic (4.23e-3)"	"unprognostic (7.02e-2)"	"unprognostic (6.59e-2)"	"unprognostic (2.77e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.99e-2)"	"unprognostic (7.97e-3)"	"unprognostic (4.59e-2)"	"unprognostic (7.69e-2)"	"unprognostic (6.87e-3)"	"unprognostic (5.60e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.05e-3)"	41.1	8.6	12.5	14.5	12.2	7.2	39.5	45.0	10.5	36.0	31.5	10.1	11.6	5.5	29.3	20.6	22.9	29.4	32.4	31.7	12.8	10.1	11.8	5.4	18.6	9.7	11.4	14.3	42.0	51.2	11.5	22.3	28.4	20.0	28.2	10.8	35.8	14.0	31.6	12.0	12.9	14.4	52.4	15.6	4.5	16.4	16.4	8.5	11.3	12.6	13.0	9.8	39.6	41.2	1.6	0.7	1.8	1.1	0.8	5.7	0.7	2.4	9.4	41.1	111.2	25.5	18.2	27.1	25.3	50.7	17.6	18.4	6.1	1.4	0.3	7.0	24.2	22.6	0.0	19.4	1.2	20.4	6.6	4.3	0.0	1.6	6.0	14.4	5.9	0.1	16.5	0.1	14.3	2.9	9.5	16.9	1.4	2.3	0.1	8.3	2.9	17.4	2.0	28.9	0.3	3.9	16.0	4.3	0.0	8.5	0.0	1.6	3.6	4.5	0.2	1.0	21.5	2.3	1.1	10.6	11.5	6.4	31.8	6.0	0.4	0.8	0.0	13.6	0.3	6.0	1.4	1.1	0.4	5.7	0.3	3.9	0.7	2.7	3.7	0.1	1.6	1.5	4.1	1.8	0.8	0.5	0.7	2.2	0.7	12.5	12.2	45.0	10.5	12.8	10.1	11.4	14.3	20.0	8.5	3.0	12.0	0.0	68.4	27.9	1.3	48.2	17.8	1.4	9.1	8.7	3.9	6.5	0.0	23.4	14.2	57.3	0.0	0.0	56.3	69.1	85.6	80.3	8.1	0.9	19.7	20.6	24.0	47.3	3.2	9.3	177.8	7.5	32.1	2.8	0.0	106.2	29.8	0.0	93.7	8.0	2.4	12.9	68.0	1.4	11.3	17.2	8.7	6.4	0.4	8.4
FGFR2	"BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25"	ENSG00000066468	"Fibroblast growth factor receptor 2"	P21802	10	121478334-121598458	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Apoptosis	"Heparin-binding, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome, Mental retardation, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 74.8"	"Cell type enhanced"	"Detected in many"	16	"Cholangiocytes: 191.1;Club cells: 52.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	15	"basophil: 10.8;eosinophil: 4.6"	"Lineage enriched"	"Detected in single"	35	"granulocytes: 10.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 58.9;BEWO: 19.8;CACO-2: 15.4;HaCaT: 17.8;HAP1: 19.1;NTERA-2: 18.9;T-47d: 15.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010886, HPA035305"	Uncertain		Supported	"Nucleoplasm,Vesicles,Cell Junctions"	"Secreted - unknown location"	NA	NA		500000	"Cell Junctions"	"Nucleoplasm, Vesicles"	"CAB010886: AB_259379, HPA035305: AB_10672862"	"unprognostic (5.53e-2)"	"prognostic favorable (8.79e-4)"	"unprognostic (1.08e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.73e-1)"	"prognostic favorable (9.32e-4)"	"unprognostic (1.53e-1)"	"unprognostic (4.96e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.01e-1)"	"unprognostic (6.11e-2)"	"unprognostic (2.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (2.25e-1)"	2.1	8.8	16.4	3.0	30.3	0.0	9.9	15.8	21.3	6.8	14.1	55.7	5.6	4.2	22.0	6.6	10.2	12.5	12.5	1.4	20.6	11.1	11.4	16.1	13.1	1.0	41.2	13.3	7.4	12.8	25.5	2.5	6.2	30.2	11.7	8.7	16.4	23.8	24.3	0.4	45.4	4.7	18.3	74.8	0.5	9.3	2.9	32.1	0.8	23.4	1.6	3.4	6.9	8.5	0.1	0.1	10.8	0.1	0.1	0.3	0.0	2.2	0.1	9.2	58.9	0.0	0.0	19.8	0.1	0.0	0.0	0.0	15.4	0.3	0.0	4.2	0.9	0.0	17.8	19.1	4.0	0.0	0.0	4.1	0.0	0.0	0.3	0.4	0.0	3.8	0.0	8.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	18.9	2.7	0.0	0.0	0.0	2.3	5.7	5.0	0.1	0.1	0.1	10.8	0.0	11.5	15.8	0.0	0.0	0.1	2.9	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	10.8	0.1	4.6	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.0	0.0	16.4	30.3	15.8	21.3	20.6	11.1	41.2	13.3	30.2	32.1	17.9	31.8	0.0	29.5	35.6	0.0	2.7	191.1	18.7	52.4	34.9	0.0	12.6	0.0	4.0	2.9	0.5	2.6	0.0	0.2	2.7	17.5	9.8	0.0	4.3	2.0	0.0	2.4	3.1	0.3	6.5	1.1	1.3	5.0	1.0	32.0	1.6	0.6	1.4	5.6	11.5	0.1	0.0	2.1	0.9	7.7	24.2	3.3	1.5	3.0	27.7
FGFR3	"ACH, CD333, CEK2, JTK4"	ENSG00000068078	"Fibroblast growth factor receptor 3"	P22607	4	1793293-1808872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Apoptosis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Craniosynostosis, Deafness, Disease mutation, Dwarfism, Ectodermal dysplasia, FDA approved drug targets, Lacrimo-auriculo-dento-digital syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"skin 1: 131.7"	"Cell type enhanced"	"Detected in many"	9	"Basal keratinocytes: 92.2;Cholangiocytes: 94.3;Suprabasal keratinocytes: 77.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"CACO-2: 19.3;HaCaT: 15.1;Hep G2: 32.5;NTERA-2: 15.8;RT4: 19.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004231, HPA067204"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA		670000	"Endoplasmic reticulum"		"CAB004231: AB_627596, HPA067204: AB_2685804"	"unprognostic (1.34e-1)"	"unprognostic (5.29e-3)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (3.77e-4)"	"unprognostic (5.90e-2)"	"unprognostic (1.24e-3)"	"unprognostic (7.22e-2)"	"unprognostic (2.54e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.17e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.30e-1)"	"unprognostic (9.11e-3)"	"unprognostic (1.98e-1)"	"unprognostic (4.74e-2)"	"unprognostic (1.97e-1)"	1.5	1.5	24.7	1.7	30.3	1.6	4.2	10.2	22.0	4.1	4.9	15.8	3.4	9.9	1.8	2.7	26.9	2.0	5.0	2.0	21.6	11.7	9.6	7.4	4.5	1.3	17.6	21.5	1.1	23.0	1.2	3.0	5.6	15.1	3.7	3.8	1.7	3.8	9.0	1.7	131.7	7.4	1.3	9.0	2.1	4.9	8.1	10.6	0.1	1.3	8.5	7.3	8.5	10.1	0.1	0.6	0.1	0.1	0.2	0.3	0.0	0.0	1.5	9.2	2.6	0.0	0.1	9.4	1.1	0.1	0.4	0.2	19.3	0.4	0.0	7.7	0.3	0.4	15.1	2.6	0.1	0.1	0.1	9.7	6.0	1.5	32.5	0.0	0.0	0.2	0.0	5.1	0.1	0.0	0.0	0.0	0.9	6.5	0.0	0.0	9.6	0.4	0.2	15.8	8.8	0.0	0.5	0.5	0.1	1.3	19.3	2.7	0.7	0.8	1.6	0.0	11.1	9.0	1.1	0.4	0.0	0.9	0.2	0.6	0.0	0.0	0.0	0.1	0.7	0.5	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.2	0.0	0.6	0.1	0.0	24.7	30.3	10.2	22.0	21.6	11.7	17.6	21.5	15.1	10.6	0.0	23.8	2.4	3.6	92.2	0.0	2.0	94.3	0.0	21.6	14.0	0.0	0.4	0.0	4.8	5.4	0.9	20.6	0.0	0.6	9.2	7.0	3.3	0.0	27.0	0.5	0.0	4.1	14.7	1.2	0.4	0.6	1.2	11.8	1.0	20.7	0.2	0.4	17.3	0.4	7.5	0.6	0.0	2.8	0.4	17.9	77.5	0.7	0.0	13.0	11.8
FGFR4	"CD334, JTK2"	ENSG00000160867	"Fibroblast growth factor receptor 4"	P22455	5	177086886-177098144	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 33.6;kidney: 37.7;liver: 45.3"	"Cell type enhanced"	"Detected in many"	11	"Cholangiocytes: 50.9;Hepatocytes: 23.7;Proximal tubular cells: 19.5;Sertoli cells: 19.4;Undifferentiated cells: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"neutrophil: 3.0"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"CACO-2: 43.0;Hep G2: 43.0;RH-30: 69.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB005196, HPA027273, HPA027369, HPA028251"	Approved				"Intracellular and membrane"	NA	NA		4300000			"CAB005196: AB_631512, HPA027273: AB_10600212, HPA027369: AB_10599427, HPA028251: AB_10601221"	"unprognostic (1.96e-1)"	"unprognostic (2.10e-2)"	"unprognostic (1.12e-1)"	"unprognostic (9.06e-3)"	"unprognostic (2.87e-1)"	"unprognostic (1.95e-2)"	"unprognostic (7.85e-3)"	"unprognostic (9.19e-2)"	"unprognostic (4.25e-1)"	"unprognostic (4.46e-2)"	"unprognostic (1.16e-1)"	"unprognostic (3.48e-2)"	"unprognostic (1.78e-1)"	"unprognostic (1.71e-3)"	"unprognostic (2.41e-1)"	"unprognostic (5.75e-2)"	"unprognostic (4.68e-2)"	0.5	5.7	0.7	14.3	0.6	0.1	1.6	2.6	0.5	2.8	10.4	0.9	0.7	13.5	0.9	4.8	1.6	1.7	33.6	0.7	0.8	0.3	37.7	45.3	25.3	2.5	0.7	1.0	13.6	26.0	0.0	0.7	1.3	0.8	4.0	3.7	2.0	1.6	0.3	4.3	0.5	17.3	1.6	0.8	11.2	5.4	2.9	0.4	0.3	0.8	2.3	0.7	1.9	3.6	1.1	0.9	3.0	1.1	0.4	0.4	0.0	0.7	12.1	0.2	2.9	0.0	0.0	5.9	0.0	0.0	0.0	0.0	43.0	1.6	1.3	5.6	0.0	0.6	0.6	2.4	0.4	0.0	0.7	2.8	0.1	0.6	43.0	1.3	0.1	1.0	0.2	0.0	2.1	0.0	0.0	0.0	0.8	4.0	0.1	0.9	9.8	0.0	0.8	7.3	7.6	1.0	1.9	69.1	7.2	5.8	0.1	0.4	0.7	0.4	3.1	1.4	1.6	2.9	0.6	0.2	0.0	5.8	0.0	0.1	0.4	0.4	0.7	0.0	0.2	0.5	1.5	1.1	0.4	0.4	0.3	0.3	1.1	0.4	0.0	0.1	0.6	0.4	0.4	3.0	0.4	0.3	0.9	0.2	0.0	0.7	0.6	2.6	0.5	0.8	0.3	0.7	1.0	0.8	0.4	0.0	0.0	0.8	0.6	0.6	0.4	0.8	50.9	0.0	0.0	3.5	0.0	1.1	3.3	8.4	0.1	0.1	10.6	0.0	4.4	3.2	1.7	0.3	0.0	23.7	0.3	0.0	4.1	2.5	0.8	0.0	0.6	0.0	0.0	1.0	5.2	0.9	3.6	2.9	1.4	19.5	0.1	19.4	0.5	1.6	12.8	0.4	7.3	0.0	33.6	0.6
FKBP1A	"FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE"	ENSG00000088832	"FK506 binding protein 1A"	P62942	20	1368978-1393172	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"Isomerase, Rotamase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"dendritic cells: 63.6;granulocytes: 88.4;monocytes: 94.3"	"Cell line enhanced"	"Detected in all"		"HUVEC TERT2: 152.2;TIME: 176.4"									"CAB004639, HPA051798"	Uncertain					NA	NA		16000000			"CAB004639: AB_425434, HPA051798: AB_2681615"	"unprognostic (4.09e-2)"	"unprognostic (2.29e-1)"	"unprognostic (5.22e-3)"	"unprognostic (1.28e-2)"	"unprognostic (2.66e-1)"	"unprognostic (7.18e-3)"	"prognostic unfavorable (3.44e-7)"	"unprognostic (7.05e-3)"	"unprognostic (2.76e-1)"	"unprognostic (8.81e-2)"	"unprognostic (5.12e-3)"	"unprognostic (6.65e-2)"	"prognostic unfavorable (6.69e-5)"	"unprognostic (1.97e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.47e-1)"	106.0	42.4	67.3	55.0	114.8	44.4	63.5	15.8	55.8	33.2	39.7	22.1	33.8	32.7	45.5	45.9	42.7	33.8	32.0	36.4	51.7	30.6	41.9	41.7	59.2	84.1	26.0	36.5	41.7	57.7	20.6	21.7	65.0	22.5	34.4	49.4	21.4	30.8	40.6	38.9	31.5	37.1	56.0	23.3	68.0	33.0	21.1	28.4	47.4	62.2	39.7	48.3	48.1	37.0	13.3	63.6	88.4	94.3	14.5	18.6	84.3	71.4	19.8	15.8	22.8	53.5	67.2	20.8	45.4	30.8	36.4	33.8	19.8	27.8	29.3	14.6	42.3	52.9	32.9	20.4	83.1	47.9	8.4	22.1	30.0	9.3	37.6	32.9	34.8	16.7	39.0	26.5	33.7	34.8	42.5	152.2	33.0	27.4	15.1	42.8	8.9	34.0	48.0	33.9	25.3	38.8	29.2	27.6	35.4	47.0	18.1	26.3	19.9	22.4	45.3	75.2	22.1	17.7	29.7	176.4	135.4	22.7	28.8	33.5	7.5	16.3	30.6	23.3	35.4	29.9	23.9	79.4	88.4	11.5	94.3	10.2	12.8	13.9	13.2	63.6	13.3	14.8	14.2	77.9	14.5	90.3	31.6	18.6	84.3	67.3	114.8	15.8	55.8	51.7	30.6	26.0	36.5	22.5	28.4	80.4	70.6	192.2	178.9	233.8	16.6	52.9	173.3	66.9	58.0	164.0	0.0	249.8	202.2	393.2	31.1	486.6	196.8	23.3	297.3	496.2	197.8	189.6	142.9	99.4	651.5	33.4	317.5	445.0	487.0	41.0	185.2	363.6	229.5	390.5	244.5	40.1	382.3	768.7	153.1	245.7	11.0	135.8	189.1	153.9	133.6	261.7	193.6	124.6	263.1	202.2
FLT1	"FLT, VEGFR1"	ENSG00000102755	"Fms related tyrosine kinase 1"	P17948	13	28300344-28495145	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Chemotaxis, Differentiation"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	8	"placenta: 155.3"	"Cell type enhanced"	"Detected in many"	16	"Extravillous trophoblasts: 778.4;Ito cells: 284.2;Syncytiotrophoblasts: 942.6"	"Cancer enhanced"	"Detected in all"		"renal cancer: 28.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	4	"memory B-cell: 1.1;naive B-cell: 3.7;neutrophil: 2.1"	"Group enriched"	"Detected in many"	5	"B-cells: 3.7;granulocytes: 2.1"	"Cell line enhanced"	"Detected in some"		"BJ: 17.4;BJ hTERT+: 13.8;HMC-1: 86.4;HUVEC TERT2: 15.6;WM-115: 31.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011740, HPA014290, CAB068189, CAB068190"	Enhanced		Supported	"Plasma membrane,Actin filaments"	"Secreted to blood"	NA	NA	876000	54000	"Plasma membrane"	"Actin filaments"	"CAB068189: AB_2665636, CAB068190: AB_2665637, HPA011740: AB_1858737, HPA014290: AB_1858738"	"unprognostic (3.33e-2)"	"unprognostic (3.52e-3)"	"unprognostic (1.13e-3)"	"unprognostic (5.02e-2)"	"unprognostic (3.65e-1)"	"unprognostic (5.03e-2)"	"unprognostic (8.25e-2)"	"unprognostic (2.27e-3)"	"unprognostic (9.91e-2)"	"unprognostic (6.61e-2)"	"unprognostic (2.33e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (2.19e-4)"	"unprognostic (4.20e-2)"	"unprognostic (6.00e-2)"	"unprognostic (1.57e-1)"	"unprognostic (6.32e-2)"	18.9	4.0	9.9	4.0	14.3	1.2	13.5	8.0	15.9	7.1	4.6	3.5	1.7	3.5	7.2	2.2	3.4	4.0	6.9	18.3	11.4	7.3	10.3	7.6	12.3	2.5	10.3	3.2	5.1	5.4	13.4	3.7	155.3	13.8	5.1	3.1	9.1	3.0	5.0	12.5	2.6	3.4	7.3	9.6	7.2	4.6	6.8	10.2	0.0	19.1	3.8	2.8	7.6	9.2	3.7	0.5	2.1	0.1	0.2	0.4	0.2	0.0	0.0	0.0	0.1	0.1	0.2	0.0	17.4	13.8	6.3	3.7	0.0	0.0	0.0	0.0	2.2	0.0	0.0	1.6	0.0	11.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	86.4	0.1	0.0	0.0	0.2	0.0	15.6	1.4	0.4	0.0	0.0	0.0	1.0	0.8	9.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.0	0.1	0.0	0.0	0.0	11.4	0.0	0.0	1.5	0.0	0.3	0.0	0.0	0.5	0.2	0.0	0.1	0.0	31.0	0.2	0.1	0.1	0.1	0.1	0.0	1.1	0.1	0.1	0.0	3.7	0.4	0.4	2.1	0.2	0.1	0.5	0.2	0.2	9.9	14.3	8.0	15.9	11.4	7.3	10.3	3.2	13.8	10.2	0.0	8.9	2.2	0.5	3.7	5.9	12.6	5.1	2.7	1.2	0.0	3.9	155.4	1.7	0.0	116.6	192.1	0.0	0.0	0.0	778.4	17.5	1.1	1.1	2.1	28.1	1.6	0.0	284.2	16.1	130.7	17.3	5.3	0.0	0.0	0.0	172.0	0.0	0.0	45.6	0.0	7.3	90.5	6.6	12.9	2.8	4.3	942.6	2.9	0.0	0.5
FLT3	"CD135, FLK2, STK1"	ENSG00000122025	"Fms related tyrosine kinase 3"	P36888	13	28003274-28100592	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 29.9;brain: 19.3;lymphoid tissue: 15.0"	"Cell type enhanced"	"Detected in some"	25	"Kupffer cells: 29.6;Macrophages: 12.4;monocytes: 55.9"	"Cancer enhanced"	"Detected in some"		"breast cancer: 1.8"	"Region enhanced"	"Detected in many"		"cerebellum: 19.3"	"Group enriched"	"Detected in some"	11	"myeloid DC: 29.9;plasmacytoid DC: 12.1"	"Lineage enriched"	"Detected in many"	16	"dendritic cells: 29.9"	"Group enriched"	"Detected in some"	11	"REH: 28.5;THP-1: 17.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA047539			Approved	"Endoplasmic reticulum"		NA	NA		180000	"Endoplasmic reticulum"		"HPA047539: AB_2680080"	"unprognostic (2.19e-3)"	"unprognostic (3.16e-3)"	"unprognostic (6.54e-3)"	"unprognostic (9.96e-2)"	"unprognostic (3.88e-1)"	"unprognostic (3.96e-7)"	"unprognostic (7.99e-3)"	"unprognostic (1.65e-2)"	"unprognostic (5.37e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.03e-1)"	"unprognostic (4.56e-2)"	"unprognostic (3.65e-1)"	"unprognostic (3.91e-2)"	"unprognostic (2.51e-1)"	"unprognostic (2.22e-1)"	0.9	0.6	0.6	7.2	1.1	7.5	2.6	19.3	3.5	0.9	1.2	0.1	0.1	0.4	0.8	0.8	1.0	1.2	4.6	0.5	0.9	1.7	2.8	0.7	2.7	15.0	1.8	1.1	0.5	5.7	0.0	0.4	0.0	7.4	0.6	1.4	0.1	2.3	0.6	0.4	1.2	3.0	1.3	4.4	8.8	0.9	1.2	0.0	8.2	0.6	0.0	5.8	2.4	0.7	0.1	29.9	1.4	1.8	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	2.1	0.5	0.0	0.0	28.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	17.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.8	1.4	0.0	0.3	0.0	0.1	0.0	0.0	29.9	0.0	0.0	0.0	0.0	0.8	0.0	12.1	0.0	1.2	0.6	1.1	19.3	3.5	0.9	1.7	1.8	1.1	7.4	0.0	0.0	0.0	0.8	0.0	0.2	0.0	0.3	2.5	0.0	0.0	0.0	0.0	0.0	0.0	2.2	3.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.0	1.3	29.6	1.6	0.0	12.4	1.7	55.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.5	0.0	0.0	0.0	0.0
FLT4	"PCL, VEGFR3"	ENSG00000037280	"Fms related tyrosine kinase 4"	P35916	5	180601506-180649624	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 56.3"	"Group enriched"	"Detected in some"	5	"Extravillous trophoblasts: 31.7;Ito cells: 65.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	5	"MAIT T-cell: 7.7"	"Lineage enriched"	"Detected in single"	35	"T-cells: 7.7"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 8.3;BEWO: 10.1;HEK 293: 12.5;HUVEC TERT2: 8.1;JURKAT: 10.0;T-47d: 11.9;TIME: 12.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB000099, HPA046519, HPA067906, HPA074389"	Approved		Supported	"Nuclear speckles,Plasma membrane,Cell Junctions"	"Secreted to blood"	NA	NA		270000000	"Nuclear speckles, Plasma membrane"	"Cell Junctions"	"CAB000099: , HPA046519: AB_2732527, HPA067906: AB_2732775, HPA074389: "	"unprognostic (7.35e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.45e-3)"	"unprognostic (3.81e-1)"	"unprognostic (9.26e-2)"	"unprognostic (3.20e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.80e-2)"	"unprognostic (2.19e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.13e-2)"	"unprognostic (3.69e-1)"	"unprognostic (1.88e-2)"	"unprognostic (9.41e-3)"	"unprognostic (1.83e-1)"	"unprognostic (8.26e-2)"	"unprognostic (1.32e-1)"	14.8	7.1	1.6	4.9	6.0	0.7	28.5	1.3	2.7	6.3	7.3	1.9	2.1	3.1	7.3	6.2	5.7	9.2	5.3	6.4	1.7	0.9	11.7	10.2	14.1	23.6	2.0	0.8	5.8	2.3	2.3	6.2	56.3	2.1	4.9	1.4	6.7	3.3	4.4	4.8	2.8	4.7	4.7	1.5	14.5	2.4	3.5	2.0	0.3	19.4	4.4	2.3	6.1	14.7	0.0	0.1	0.2	0.0	0.0	7.7	0.2	0.1	2.0	2.7	8.3	0.0	0.0	10.1	0.2	0.1	0.0	0.0	0.3	0.3	0.2	0.8	0.1	0.5	0.3	2.8	0.1	0.2	0.1	12.5	1.0	0.4	0.4	0.1	7.4	0.2	0.2	0.0	0.1	0.3	0.3	8.1	10.0	0.3	0.3	1.7	4.5	0.1	0.4	5.8	0.2	0.5	6.5	0.0	0.1	0.1	0.2	0.2	0.9	0.1	0.2	0.0	2.7	11.9	0.2	12.6	0.1	5.9	0.2	0.1	0.2	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.9	0.0	7.7	0.0	0.4	1.6	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.2	1.6	6.0	1.3	2.7	1.7	0.9	2.0	0.8	2.1	2.0	0.0	1.7	0.9	0.2	0.8	0.0	4.5	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.2	9.2	0.0	0.0	0.0	31.7	0.6	0.2	2.3	0.4	1.1	0.0	0.0	65.1	5.7	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	4.3	1.0	0.8	0.7	0.0	0.1
FN1	"CIG, FINC, GFND2, LETS, MSF"	ENSG00000115414	"Fibronectin 1"	P02751	2	215360440-215436172	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase, Angiogenesis, Cell adhesion, Cell shape"	Heparin-binding	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 235.4;placenta: 433.0"	"Cell type enhanced"	"Detected in many"	19	"Extravillous trophoblasts: 2156.8;Fibroblasts: 526.4;Hepatocytes: 963.3"	"Cancer enhanced"	"Detected in all"		"thyroid cancer: 833.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC TERT1: 845.3;HSkMC: 395.4;hTERT-HME1: 232.5;hTERT-RPE1: 257.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB000126, HPA027066"	Enhanced				"Secreted to blood"	NA	NA		47000000000			"CAB000126: , HPA027066: AB_10602500"	"unprognostic (8.08e-2)"	"unprognostic (1.09e-3)"	"unprognostic (2.20e-2)"	"unprognostic (3.45e-3)"	"unprognostic (1.82e-2)"	"unprognostic (3.47e-3)"	"unprognostic (3.36e-2)"	"unprognostic (5.91e-3)"	"unprognostic (2.96e-2)"	"unprognostic (2.91e-3)"	"unprognostic (1.41e-2)"	"unprognostic (2.84e-1)"	"prognostic unfavorable (3.44e-8)"	"prognostic unfavorable (8.82e-5)"	"unprognostic (7.88e-2)"	"unprognostic (7.74e-2)"	"prognostic unfavorable (3.33e-4)"	20.2	4.5	3.1	13.0	5.2	0.2	13.1	2.2	4.3	21.9	57.1	4.4	235.4	3.5	25.1	27.5	37.4	26.5	20.9	57.3	3.9	2.9	5.8	166.3	81.5	7.9	4.6	5.0	16.9	3.3	1.7	3.5	433.0	6.1	17.1	25.1	5.1	10.4	141.2	9.8	7.0	13.5	114.9	4.6	1.9	21.8	9.0	2.7	9.4	5.4	17.4	2.6	64.7	16.9	0.2	0.8	0.0	0.6	0.0	0.3	0.0	0.2	1.9	2.6	0.5	107.3	845.3	0.1	43.6	29.1	44.2	31.4	26.4	1.0	0.0	0.2	144.9	1.2	4.5	0.4	99.3	23.8	0.0	0.1	0.0	0.6	82.3	77.6	0.0	0.1	395.4	0.6	104.4	232.5	257.3	51.2	0.0	0.1	0.1	88.0	0.3	0.0	0.0	1.3	0.0	0.3	0.0	0.0	0.1	1.1	0.3	0.1	0.6	5.2	2.7	28.3	119.4	0.4	0.0	98.1	63.9	6.8	70.0	8.0	0.1	0.0	0.0	76.0	0.0	16.6	0.0	0.6	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.0	0.0	0.8	0.0	0.0	3.1	5.2	2.2	4.3	3.9	2.9	4.6	5.0	6.1	2.7	62.5	83.1	7.8	3.5	48.9	5.1	27.2	35.7	24.1	28.4	15.7	0.0	51.6	0.0	4.9	1.5	166.7	0.0	0.0	8.1	2156.8	526.4	18.4	17.4	963.3	368.5	1.6	20.2	165.1	27.1	2.6	172.6	39.4	104.6	1.8	4.3	1.4	19.0	0.0	83.1	0.6	9.7	71.1	163.2	1.1	4.5	32.6	172.1	0.9	3.7	1.6
FOLH1	"FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA"	ENSG00000086205	"Folate hydrolase 1"	Q04609	11	49146635-49208670	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Carboxypeptidase, Dipeptidase, Hydrolase, Metalloprotease, Multifunctional enzyme, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 37.7;intestine: 111.2;prostate: 33.8"	"Cell type enhanced"	"Detected in some"	16	"Glandular cells: 41.1;Hepatocytes: 24.1;Muller glia cells: 17.3;Proximal tubular cells: 22.6"	"Cancer enriched"	"Detected in many"	27	"prostate cancer: 142.7"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HAP1: 5.4;RPMI-8226: 3.8;SK-BR-3: 4.5;TIME: 2.9;U-2 OS: 2.7;WM-115: 5.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001451, HPA010593"	Enhanced					NA	NA					"CAB001451: AB_563979, HPA010593: AB_1079685"	"unprognostic (1.33e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (5.24e-5)"	"unprognostic (2.55e-1)"	"unprognostic (8.31e-2)"	"prognostic favorable (4.25e-4)"	"unprognostic (1.32e-1)"	"unprognostic (2.09e-2)"	"unprognostic (2.67e-3)"	"unprognostic (2.13e-2)"	"unprognostic (2.72e-1)"	"prognostic unfavorable (1.30e-6)"	"unprognostic (4.81e-2)"	"unprognostic (7.27e-2)"	"unprognostic (4.74e-3)"	"unprognostic (4.04e-1)"	1.2	1.0	10.4	0.9	16.4	0.8	2.5	1.4	12.7	1.4	67.6	37.7	0.0	111.2	1.3	0.8	1.2	2.1	5.0	0.7	16.9	8.7	6.1	15.7	1.1	0.9	19.0	9.1	1.0	0.7	0.7	0.4	0.7	17.7	33.8	0.8	0.6	20.7	0.8	0.6	1.2	61.1	1.0	33.0	1.5	1.0	0.9	16.2	0.0	1.0	0.0	0.8	1.2	0.5	0.9	0.1	0.3	0.8	1.4	1.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	2.7	0.3	0.0	0.0	0.0	0.0	0.9	0.2	0.7	0.0	0.2	0.2	5.4	0.5	0.0	1.3	1.0	0.0	0.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.2	0.0	1.1	0.0	0.0	0.0	1.1	1.0	0.2	0.0	0.4	0.3	3.8	0.0	0.0	0.4	1.7	0.0	4.5	1.0	0.6	1.0	0.0	2.9	0.2	2.7	0.4	0.3	0.1	0.5	0.1	0.0	0.9	5.4	0.1	0.8	0.3	0.9	0.6	0.2	0.6	1.2	0.5	0.0	0.9	0.7	0.3	0.2	1.4	0.5	0.1	0.4	0.0	10.4	16.4	1.4	12.7	16.9	8.7	19.0	9.1	17.7	16.2	0.0	1.1	0.0	0.8	0.2	0.0	0.1	0.0	0.0	2.3	0.0	0.0	0.0	6.6	0.0	3.5	0.3	0.0	0.0	0.0	0.0	0.4	41.1	0.0	24.1	0.1	0.0	0.0	3.1	0.0	1.0	1.4	0.0	3.3	0.0	0.0	17.3	0.0	0.0	0.4	22.6	0.2	0.0	0.3	0.2	1.6	0.6	0.0	0.0	0.0	0.5
FRK	"GTK, PTK5, RAK"	ENSG00000111816	"Fyn related Src family tyrosine kinase"	P42685	6	115931149-116060758	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"FDA approved drug targets, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 41.4"	"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 73.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"OE19: 19.0;RT4: 8.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"CAB025217, HPA030479, HPA072590"	Approved		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB025217: , HPA030479: AB_2732457, HPA072590: "	"unprognostic (7.70e-3)"	"unprognostic (1.99e-2)"	"unprognostic (1.11e-1)"	"unprognostic (4.68e-3)"	"unprognostic (1.96e-1)"	"unprognostic (3.49e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.58e-1)"	"unprognostic (4.23e-2)"	"unprognostic (5.82e-3)"	"unprognostic (1.45e-1)"	"unprognostic (7.54e-2)"	"prognostic favorable (9.66e-7)"	"unprognostic (1.52e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.10e-1)"	1.5	2.2	0.8	3.0	1.3	1.3	2.6	0.5	0.8	6.4	21.4	0.2	10.2	6.8	1.6	9.0	10.5	2.8	7.3	3.3	1.2	0.8	23.7	19.6	5.6	0.6	1.5	0.5	2.4	5.9	0.3	3.8	2.7	0.8	4.1	5.5	0.8	9.2	6.1	2.9	2.0	41.4	2.5	2.4	1.0	5.5	1.8	0.5	1.2	1.0	5.2	7.4	5.0	3.6	2.2	1.2	3.8	1.2	1.4	2.3	0.3	2.5	4.2	0.7	1.0	0.3	0.3	0.8	0.6	0.2	0.0	0.1	3.3	4.1	1.1	3.9	0.6	0.6	6.1	0.3	1.2	0.1	3.5	0.4	1.4	3.6	2.8	0.2	1.0	0.9	0.3	1.7	0.4	0.4	0.5	0.2	0.7	0.7	2.6	1.0	1.4	0.8	0.6	1.1	19.0	0.7	1.2	3.7	1.3	5.2	8.0	0.9	1.0	0.9	5.4	0.5	1.1	1.6	0.8	1.0	1.2	1.2	0.9	0.6	4.0	2.8	1.8	1.2	0.7	0.8	3.2	1.0	1.0	1.9	0.6	2.3	1.1	1.4	1.7	0.4	2.2	1.1	1.4	3.8	1.4	1.2	1.2	1.0	0.3	0.8	1.3	0.5	0.7	1.2	0.8	1.5	0.5	0.8	0.5	0.0	10.1	0.0	15.3	2.4	0.7	8.4	12.7	22.7	15.9	22.7	0.0	4.3	10.0	16.5	73.1	0.3	35.5	0.0	14.3	3.8	3.5	20.3	3.5	19.2	0.8	6.4	19.0	1.8	0.6	17.7	0.6	0.5	0.0	1.8	13.0	0.3	19.1	20.1	1.1	22.5	0.0	12.9	7.5	1.4	0.7	2.8	0.7	0.5	16.1	34.6
FSHR	"FSHRO, LGR1, ODG1"	ENSG00000170820	"Follicle stimulating hormone receptor"	P23945	2	48962157-49154537	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"gallbladder: 5.3;ovary: 6.5;testis: 16.3"	"Group enriched"	"Detected in some"	24	"Early spermatids: 1.6;Late spermatids: 4.9"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"basal ganglia: 1.5;cerebral cortex: 2.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	11	"SuSa: 3.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"								"Intracellular and membrane"	NA	NA															"unprognostic (5.94e-2)"			"unprognostic (4.06e-3)"		"unprognostic (5.78e-2)"			0.1	0.1	0.1	0.0	1.5	0.1	0.1	0.1	2.9	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.3	5.3	1.0	0.1	0.4	0.3	0.1	0.1	0.0	0.1	0.1	6.5	0.1	0.0	0.1	0.0	0.5	0.1	0.0	0.3	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	16.3	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.0	0.3	0.0	3.6	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	1.5	0.1	2.9	0.1	0.4	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
FTH1	"FHC, FTH, FTHL6, PIG15, PLIF"	ENSG00000167996	"Ferritin heavy chain 1"	P02794	11	61959718-61967660	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Iron storage"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 756.2"	"Cell type enhanced"	"Detected in all"	9	"monocytes: 52379.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 756.2"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 555.5;HHSteC: 578.8"	"Low region specificity"	"Detected in all"							CAB008623	Approved		Approved	Microtubules		NA	NA		9000000	Microtubules		"CAB008623: "	"unprognostic (7.15e-2)"	"unprognostic (1.52e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.00e-2)"	"unprognostic (2.53e-1)"	"prognostic unfavorable (7.56e-5)"	"prognostic unfavorable (6.18e-4)"	"unprognostic (3.08e-2)"	"unprognostic (2.48e-2)"	"unprognostic (6.65e-2)"	"unprognostic (2.44e-2)"	"unprognostic (8.13e-2)"	"prognostic unfavorable (5.20e-5)"	"unprognostic (2.99e-1)"	"unprognostic (4.89e-2)"	"unprognostic (3.44e-1)"	"unprognostic (5.83e-2)"	155.1	118.0	177.6	138.9	92.6	162.0	302.9	38.5	163.7	104.2	142.4	97.8	72.0	72.2	81.6	102.4	88.8	70.6	83.5	236.1	124.7	91.2	113.5	128.2	297.3	394.0	118.5	110.6	81.7	150.8	49.7	46.7	70.1	77.5	60.9	138.5	79.5	180.5	65.1	124.1	42.5	110.0	140.0	182.1	84.4	81.0	67.8	88.2	58.5	100.3	64.1	48.9	106.7	94.0	69.5	163.3	756.2	424.5	30.7	69.2	284.2	65.4	183.8	28.0	74.1	555.5	269.1	154.7	60.1	258.0	61.3	61.9	22.2	90.9	7.6	381.6	172.8	234.7	112.1	25.0	49.7	39.8	31.2	12.3	38.1	254.7	145.1	578.8	17.8	59.9	364.4	244.0	122.3	230.1	194.4	76.7	44.1	56.7	87.4	214.0	88.5	20.0	29.2	47.9	229.9	310.8	19.9	34.6	54.5	313.4	178.2	23.8	30.2	206.4	22.7	97.7	96.5	40.4	24.1	85.4	191.7	45.9	84.8	37.7	15.1	52.0	23.4	261.3	8.0	45.6	401.9	297.7	247.4	40.8	367.6	40.2	68.6	58.3	40.4	163.3	69.5	49.3	38.2	756.2	30.7	424.5	121.2	69.2	284.2	177.6	92.6	38.5	163.7	124.7	91.2	118.5	110.6	77.5	88.2	1223.8	3688.2	1741.3	6882.7	4581.6	811.0	10.8	4076.4	2049.0	1899.5	1819.7	540.0	3704.8	9226.3	8116.7	214.1	3238.4	10084.1	4345.2	9486.9	4714.1	4023.6	8092.3	6278.5	3801.3	17699.0	697.6	2425.9	2794.1	10131.9	335.0	4320.5	19898.9	6750.0	52379.0	4287.5	3515.6	10476.1	8248.3	3589.2	14886.0	2120.1	2050.2	6618.7	591.9	960.7	3108.0	3865.9	1625.8	5251.4	8218.4
FTL	"MGC71996, NBIA3"	ENSG00000087086	"Ferritin light chain"	P02792	19	48965301-48966878	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Iron storage"		"Cancer-related genes, Cataract, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 1149.4"	"Cell type enhanced"	"Detected in all"	10	"Hofbauer cells: 67925.7;Kupffer cells: 48067.7;Proximal tubular cells: 39652.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"granulocytes: 1149.4;monocytes: 890.5"	"Cell line enhanced"	"Detected in all"		"HHSteC: 575.7;HSkMC: 481.6"									"CAB020769, HPA041602"	Enhanced		Approved	Cytosol		NA	NA		240000000	Cytosol		"CAB020769: , HPA041602: AB_2677575"	"unprognostic (2.95e-1)"	"unprognostic (2.64e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.56e-3)"	"unprognostic (7.48e-2)"	"unprognostic (5.28e-2)"	"unprognostic (2.16e-3)"	"unprognostic (6.17e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.08e-1)"	"unprognostic (2.66e-1)"	"unprognostic (2.96e-1)"	"prognostic unfavorable (4.40e-5)"	"unprognostic (1.32e-1)"	"unprognostic (2.43e-2)"	"unprognostic (2.30e-2)"	"unprognostic (1.87e-2)"	326.0	111.3	147.1	113.6	130.9	179.8	321.8	25.8	101.3	105.7	107.5	134.7	58.2	120.5	54.9	85.4	85.0	71.3	214.6	140.8	111.7	88.2	295.2	526.9	391.6	444.6	139.4	49.6	126.8	108.0	27.0	63.6	166.3	89.0	108.0	92.3	114.4	59.4	75.4	75.6	48.3	159.4	149.2	194.5	317.9	105.2	53.9	74.5	45.1	130.0	57.5	67.5	159.8	172.1	147.8	231.2	1149.4	890.5	41.5	86.1	674.1	18.7	285.4	21.4	32.7	370.5	384.5	38.3	48.6	286.4	70.1	158.0	62.5	76.1	14.3	93.6	290.5	153.7	11.2	17.5	28.8	63.3	192.3	11.3	37.8	74.5	408.6	575.7	88.8	127.3	481.6	39.1	119.3	52.5	104.8	101.5	17.2	69.9	29.9	138.3	4.5	24.5	51.9	38.8	330.4	29.2	20.5	14.5	147.1	44.5	11.9	27.4	15.9	127.8	7.0	26.6	121.4	4.1	185.8	75.9	76.8	40.4	98.5	66.5	129.3	285.0	13.3	81.5	93.7	134.3	488.0	642.5	675.8	63.9	890.5	72.6	147.8	71.3	68.3	231.2	132.2	86.1	74.8	1149.4	41.5	768.3	97.2	83.8	674.1	147.1	130.9	25.8	101.3	111.7	88.2	139.4	49.6	89.0	74.5	1045.2	3325.0	4263.9	4805.4	2481.8	468.5	679.4	4145.2	769.6	1043.0	1917.5	166.9	816.1	9070.4	3524.4	247.8	2245.5	2735.4	2149.2	5208.6	1016.5	4146.4	6478.0	2236.8	16333.4	67925.7	503.7	1551.5	4087.4	48067.7	879.3	3866.6	17106.8	4823.4	23991.6	2116.7	1184.6	7872.5	3673.3	1890.2	39652.4	496.5	1319.4	4074.7	56.3	327.7	1946.3	1256.7	2296.9	2288.6	7488.3
FXYD2	"ATP1G1, HOMG2, MGC12372"	ENSG00000137731	"FXYD domain containing ion transport regulator 2"	P54710	11	117800844-117828698	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Sodium/potassium transport, Transport"		"Disease mutation, FDA approved drug targets, Primary hypomagnesemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"kidney: 258.1;pancreas: 68.9;salivary gland: 91.7"	"Group enriched"	"Detected in many"	5	"Cholangiocytes: 1434.4;Distal tubular cells: 2501.8;Proximal tubular cells: 3101.2"	"Cancer enriched"	"Detected in some"	8	"renal cancer: 49.9"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"memory CD8 T-cell: 14.1"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	25	"MOLT-4: 141.0;RPTEC TERT1: 323.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA064218, HPA068838"	Supported		Approved	Mitochondria		NA	NA		26000	Mitochondria		"HPA064218: AB_2685214, HPA068838: AB_2686047"	"unprognostic (4.11e-4)"	"unprognostic (1.14e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.36e-3)"	"unprognostic (1.09e-3)"	"unprognostic (2.30e-2)"	"unprognostic (3.65e-2)"	"unprognostic (4.62e-1)"	"unprognostic (4.01e-2)"	"unprognostic (4.91e-2)"	"unprognostic (1.24e-2)"	"unprognostic (2.64e-1)"	"prognostic favorable (3.23e-9)"	"unprognostic (3.22e-3)"	"unprognostic (4.38e-2)"	"unprognostic (4.62e-1)"	"unprognostic (3.00e-2)"	0.3	0.2	0.2	0.2	0.1	0.0	0.7	0.2	0.2	0.2	0.2	0.1	0.0	0.0	0.3	2.8	0.3	0.3	54.7	0.2	0.1	0.2	258.1	2.2	0.2	0.6	0.1	0.0	0.4	68.9	0.0	0.3	0.6	0.1	0.3	0.0	0.1	91.7	0.1	0.1	0.2	0.3	0.1	0.1	0.4	0.2	0.2	0.0	9.5	0.2	0.3	0.4	0.2	0.6	0.4	3.2	0.0	1.1	8.4	14.1	2.0	0.0	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	9.2	0.0	0.0	0.0	0.0	141.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	323.5	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.0	0.0	1.1	0.2	1.8	14.1	0.2	0.4	5.1	4.1	0.0	8.4	0.0	3.2	1.6	2.0	0.2	0.1	0.2	0.2	0.1	0.2	0.1	0.0	0.1	0.0	0.0	1.1	0.0	0.0	1.0	0.1	0.8	1434.4	0.0	0.0	413.5	0.0	0.1	2501.8	465.3	14.4	1.3	0.0	0.0	8.3	0.1	1.1	0.1	0.0	2.4	2.9	0.0	14.6	5.5	4.3	15.4	8.6	2.6	0.0	14.4	0.0	0.5	33.3	0.0	7.1	3101.2	3.5	6.5	3.9	0.4	0.2	0.6	0.2	0.0	0.0	0.0
GAA		ENSG00000171298	"Glucosidase alpha, acid"	P10253	17	80101556-80119879	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Glycosidase, Hydrolase"	"Disease mutation, FDA approved drug targets, Glycogen storage disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Extravillous trophoblasts: 125.7;Syncytiotrophoblasts: 139.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"classical monocyte: 23.8;eosinophil: 8.4;intermediate monocyte: 20.0;myeloid DC: 15.6;neutrophil: 10.8;non-classical monocyte: 24.7"	"Group enriched"	"Detected in all"	9	"dendritic cells: 15.6;granulocytes: 10.8;monocytes: 24.7"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026970, HPA029126"	Enhanced		Approved	Vesicles		NA	NA		3000000	Vesicles		"HPA026970: AB_2672065, HPA029126: AB_2672918"	"unprognostic (1.13e-1)"	"unprognostic (1.11e-1)"	"prognostic unfavorable (7.66e-4)"	"unprognostic (2.94e-2)"	"unprognostic (1.14e-2)"	"unprognostic (7.96e-2)"	"unprognostic (2.05e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.90e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.46e-1)"	"unprognostic (7.02e-2)"	"unprognostic (2.38e-1)"	"unprognostic (1.78e-2)"	"unprognostic (1.18e-1)"	27.5	19.6	13.8	17.0	14.8	11.3	18.6	14.3	23.0	14.9	16.5	23.4	21.7	19.4	20.1	50.9	13.9	18.2	23.5	21.4	13.5	17.6	27.9	44.2	34.0	30.2	18.1	16.1	14.6	29.4	28.8	24.7	84.1	14.9	22.3	7.2	21.9	27.5	22.1	26.3	18.3	15.4	17.2	16.6	35.8	17.4	30.7	14.6	13.9	21.9	14.9	13.5	24.0	13.4	1.4	15.6	10.8	24.7	1.1	1.8	9.8	11.4	22.4	4.4	14.5	13.9	14.0	28.9	7.2	13.3	5.5	4.5	6.6	18.7	4.1	19.2	5.6	4.7	4.9	1.4	8.3	1.3	5.3	16.7	0.0	3.8	23.7	24.2	0.5	13.7	30.1	12.0	10.3	3.6	11.2	9.7	11.2	4.1	17.3	4.1	26.5	1.9	2.7	9.2	2.8	15.7	10.0	15.2	7.0	4.4	12.0	5.1	14.7	9.4	10.5	12.9	2.8	30.0	16.4	6.2	20.4	11.0	14.7	2.6	41.4	11.5	1.2	6.5	10.7	12.8	0.1	23.8	8.4	1.5	20.0	1.8	1.3	1.2	1.6	15.6	1.4	1.4	0.9	10.8	1.1	24.7	3.8	0.8	9.8	13.8	14.8	14.3	23.0	13.5	17.6	18.1	16.1	14.9	14.6	17.9	45.3	3.9	14.4	10.0	15.6	14.3	30.6	5.3	17.0	14.0	7.9	106.8	5.0	23.0	42.5	17.4	18.6	0.0	13.8	125.7	30.3	19.9	8.1	23.1	92.2	11.1	5.8	29.4	107.0	25.5	22.2	64.5	23.6	31.5	14.3	28.7	9.4	17.5	18.0	18.2	16.5	6.5	10.3	18.4	26.8	7.3	139.0	7.7	15.5	10.8
GABBR1	"GPRC3A, hGB1a"	ENSG00000204681	"Gamma-aminobutyric acid type B receptor subunit 1"	Q9UBS5	6	29555629-29633976	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 53.8"	"Cell type enhanced"	"Detected in many"	4	"Ito cells: 28.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 1.8;plasmacytoid DC: 1.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 8.1;HEL: 7.9;U-2 OS: 8.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA050483, HPA058459"	Uncertain		Approved	Centrosome	"Intracellular and membrane"	NA	NA			Centrosome		"HPA050483: AB_2681140, HPA058459: "	"unprognostic (1.01e-1)"	"unprognostic (2.07e-3)"	"unprognostic (3.22e-3)"	"unprognostic (2.93e-3)"	"unprognostic (3.37e-1)"	"unprognostic (2.65e-1)"	"unprognostic (7.95e-4)"	"unprognostic (5.44e-2)"	"unprognostic (4.24e-2)"	"unprognostic (1.14e-1)"	"prognostic favorable (2.54e-5)"	"unprognostic (1.23e-3)"	"prognostic unfavorable (3.77e-10)"	"unprognostic (3.82e-2)"	"unprognostic (2.26e-1)"	"unprognostic (3.87e-2)"	"unprognostic (2.55e-2)"	14.0	7.4	33.6	7.0	47.2	8.2	4.2	29.1	53.8	6.9	5.6	17.3	3.0	2.3	18.1	1.9	2.9	7.9	4.1	4.6	24.8	21.4	2.9	2.0	6.9	6.6	15.6	33.7	7.8	5.1	1.8	5.8	5.0	22.3	12.8	3.2	4.4	13.0	13.3	8.5	18.3	6.1	5.5	14.9	24.2	6.1	4.3	15.4	0.0	3.9	0.1	5.2	4.0	5.9	1.8	1.7	0.0	0.5	0.0	0.4	0.3	3.0	0.0	1.9	8.1	0.9	2.1	2.1	2.0	0.9	1.8	0.5	2.4	0.1	1.4	2.0	0.0	0.5	2.5	0.9	0.0	0.0	7.3	3.4	7.9	3.5	0.0	1.2	0.3	4.0	0.0	0.0	1.6	0.0	2.3	1.0	4.3	6.7	0.0	0.3	2.0	0.8	0.1	0.6	0.0	1.1	3.5	0.7	0.1	0.3	0.0	0.5	1.3	0.5	0.0	3.3	0.6	1.5	1.2	4.6	3.3	8.4	0.3	3.8	7.1	0.8	0.0	1.8	3.6	0.9	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.4	0.3	1.8	0.0	0.0	0.0	0.0	0.5	1.7	0.0	0.3	33.6	47.2	29.1	53.8	24.8	21.4	15.6	33.7	22.3	15.4	11.9	19.8	5.2	6.1	10.5	22.1	8.9	2.5	1.4	18.2	3.5	0.0	0.4	0.0	1.2	2.4	11.9	0.0	0.0	0.7	0.2	9.6	5.4	7.0	0.0	1.1	22.3	6.9	28.8	7.2	1.7	14.1	10.5	0.0	5.4	3.8	9.7	2.2	1.5	24.1	0.7	13.8	12.9	15.5	1.1	1.5	9.7	0.5	1.0	1.2	1.8
GABBR2	"GABABR2, GPR51, GPRC3B, HG20"	ENSG00000136928	"Gamma-aminobutyric acid type B receptor subunit 2"	O75899	9	98288082-98709197	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"brain: 52.7"	"Group enriched"	"Detected in some"	11	"Bipolar cells: 87.5;Early spermatids: 83.9;Late spermatids: 26.5"	"Group enriched"	"Detected in many"	10	"glioma: 7.2;thyroid cancer: 11.6;urothelial cancer: 3.9"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BJ: 11.1;fHDF/TERT166: 5.5;HUVEC TERT2: 23.0;U-138 MG: 9.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013820, HPA031684, CAB079065"	Enhanced	Approved				NA	NA					"CAB079065: , HPA013820: AB_1849364, HPA031684: AB_2673993"	"unprognostic (2.00e-1)"	"unprognostic (7.56e-2)"	"unprognostic (3.75e-1)"	"unprognostic (3.09e-5)"	"unprognostic (2.52e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.42e-1)"	"unprognostic (2.66e-1)"	"unprognostic (4.43e-2)"	"unprognostic (1.43e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.52e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.68e-2)"	"unprognostic (3.45e-2)"	0.9	4.4	13.6	1.0	14.6	0.8	0.9	19.7	52.7	0.8	0.9	2.1	0.0	0.8	1.1	1.1	0.9	0.8	0.9	0.9	14.6	11.1	0.9	0.9	1.0	0.9	7.6	17.6	0.8	0.8	0.9	0.3	0.9	10.3	0.9	0.8	0.6	0.9	0.9	3.2	0.9	0.8	1.0	2.2	0.9	1.0	1.3	0.2	0.0	2.3	0.0	1.1	1.5	0.1	0.7	0.7	1.7	1.1	1.7	1.0	0.4	0.0	0.0	0.0	0.0	0.1	0.1	1.0	11.1	2.2	2.4	4.3	0.0	0.1	0.0	0.7	5.5	0.5	0.0	0.1	0.2	0.8	0.0	0.4	0.0	0.0	0.0	1.1	0.0	0.0	0.3	0.0	0.8	0.2	0.0	23.0	0.0	0.2	0.1	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.6	3.1	0.0	0.0	2.8	0.0	0.0	0.0	0.1	1.0	9.0	0.6	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.2	1.7	0.4	0.8	0.6	0.7	1.0	0.7	0.7	0.7	0.4	0.6	0.8	0.9	1.2	1.7	1.1	0.7	1.0	0.4	13.6	14.6	19.7	35.0	14.6	11.1	7.6	17.6	10.3	0.2	0.0	0.0	0.0	0.0	0.1	87.5	1.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	83.9	0.0	0.0	0.0	0.2	0.9	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	26.5	0.3	0.0	1.7	0.0	0.0	1.9	0.0	0.0	0.0	0.0	5.8	0.0	0.5	0.6	0.7	0.1	0.3	0.0	0.0	0.0
GABRA1	EJM5	ENSG00000022355	"Gamma-aminobutyric acid type A receptor alpha1 subunit"	P14867	5	161847063-161899981	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	22	"brain: 58.6"	"Cell type enriched"	"Detected in some"	24	"Bipolar cells: 209.5"	"Cancer enriched"	"Detected in single"	5	"glioma: 1.1"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEL: 3.7;SCLC-21H: 1.1;U-2 OS: 1.6;U-87 MG: 2.3;WM-115: 1.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022502, HPA029363, HPA055746"	Enhanced	Supported	Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"CAB022502: , HPA029363: , HPA055746: AB_2682904"					"unprognostic (2.58e-2)"						"unprognostic (4.78e-3)"	"unprognostic (1.84e-1)"		"unprognostic (3.31e-1)"		"unprognostic (2.43e-1)"		1.0	2.6	8.5	1.0	21.9	1.0	1.0	35.2	58.6	1.0	1.0	1.8	0.0	1.1	1.0	1.0	1.0	1.0	1.0	1.0	10.5	8.8	1.0	1.0	1.0	1.0	6.7	22.0	1.0	1.0	1.0	0.1	1.0	7.4	1.2	1.0	0.2	1.0	1.1	1.0	1.0	1.0	1.0	1.3	1.1	1.5	1.1	0.0	0.0	1.0	0.0	1.3	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	3.7	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.1	0.0	0.0	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.5	21.9	35.2	49.8	10.5	8.8	6.7	22.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	209.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	7.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GABRA2		ENSG00000151834	"Gamma-aminobutyric acid type A receptor alpha2 subunit"	P47869	4	46248427-46475230	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 52.6"	"Group enriched"	"Detected in some"	4	"Collecting duct cells: 38.4;Enterocytes: 16.9;Intestinal endocrine cells: 30.6"	"Cancer enhanced"	"Detected in some"		"glioma: 0.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"U-2 OS: 9.6;U-87 MG: 4.5;WM-115: 5.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029363, CAB079061"		Supported	Uncertain	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	Nucleoplasm	"CAB079061: , HPA029363: "	"unprognostic (2.03e-2)"		"unprognostic (2.77e-1)"	"unprognostic (2.45e-4)"	"unprognostic (6.87e-3)"	"unprognostic (2.65e-1)"		"unprognostic (2.08e-1)"	"unprognostic (1.01e-1)"	"unprognostic (4.09e-1)"	"unprognostic (6.90e-3)"	"unprognostic (8.83e-2)"	"unprognostic (2.22e-5)"	"unprognostic (1.75e-1)"	"unprognostic (1.15e-1)"	"unprognostic (2.67e-1)"	"unprognostic (3.04e-2)"	2.2	1.3	38.5	1.4	34.4	1.2	1.9	10.4	52.6	1.7	4.5	4.9	0.0	2.0	1.4	11.7	1.7	1.0	1.6	1.0	38.9	7.7	8.8	1.4	1.0	1.4	3.7	31.0	1.9	1.0	0.9	0.6	1.5	10.5	1.0	3.5	0.0	1.2	1.9	1.0	1.3	7.7	1.3	6.9	2.3	1.6	1.5	7.1	0.0	1.1	0.0	1.4	1.2	0.8	0.2	0.3	1.0	0.1	0.1	0.1	0.0	0.5	0.5	0.1	0.6	0.0	0.0	0.5	0.3	0.0	0.0	0.0	2.1	0.6	0.2	0.5	0.0	0.1	0.8	0.0	0.0	0.2	0.5	0.5	0.1	0.7	0.3	0.8	0.1	0.2	0.0	0.0	0.2	0.2	0.0	0.0	0.2	0.8	0.2	0.0	0.4	0.0	0.3	0.9	1.8	0.1	0.0	0.6	0.4	0.1	0.6	0.2	0.0	0.1	0.3	0.0	0.6	0.4	0.4	0.1	0.5	9.6	0.5	0.1	0.8	1.2	0.2	4.5	0.4	5.1	1.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.9	0.1	0.1	0.3	0.0	0.0	38.5	34.4	10.4	31.4	38.9	7.7	3.7	31.0	10.5	7.1	0.0	0.0	0.0	0.0	0.1	1.5	0.4	0.0	0.0	0.0	38.4	3.9	0.0	3.3	0.0	6.4	0.2	16.9	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	30.6	0.0	0.0	6.9	0.6	0.0	1.7	0.0	1.9	0.3	0.0	0.9	0.0	0.0	1.1	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.6	0.0
GABRA3		ENSG00000011677	"Gamma-aminobutyric acid type A receptor alpha3 subunit"	P34903	X	152166234-152451358	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"brain: 30.1"	"Cell type enriched"	"Detected in some"	4	"Hofbauer cells: 12.1"	"Cancer enriched"	"Detected in many"	7	"testis cancer: 16.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 1.5"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"GAMG: 9.1;HMC-1: 7.7;Karpas-707: 13.0;PC-3: 7.6;U-266/70: 7.0;U-266/84: 11.6;U-87 MG: 7.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000839, HPA029363"	Approved	Supported	Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA000839: AB_1078929, HPA029363: "	"unprognostic (9.63e-3)"	"unprognostic (2.04e-1)"	"unprognostic (2.02e-1)"	"unprognostic (1.18e-2)"	"unprognostic (7.07e-2)"	"unprognostic (5.42e-2)"	"unprognostic (2.34e-6)"	"unprognostic (1.24e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.39e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.73e-1)"	"unprognostic (7.29e-6)"	"unprognostic (7.42e-3)"	"unprognostic (6.20e-2)"		"unprognostic (8.13e-2)"	0.7	0.7	7.7	0.6	15.2	0.7	0.7	1.3	30.1	2.2	0.8	3.3	0.0	0.8	1.2	0.8	1.3	0.7	0.7	0.7	10.9	15.9	0.7	0.7	0.7	0.7	4.7	10.5	0.6	0.7	0.6	0.9	5.2	6.2	0.8	0.8	0.4	0.7	1.8	0.8	1.1	0.9	0.8	2.1	0.7	0.7	1.8	1.1	0.0	0.7	0.0	0.9	1.8	0.4	0.0	0.1	1.5	0.3	0.3	0.2	0.0	0.0	0.8	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	9.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.0	0.0	0.0	0.0	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	13.0	0.0	0.0	0.0	0.0	2.4	5.5	7.6	0.0	0.0	0.0	0.0	0.0	0.2	4.7	0.0	4.8	0.4	0.3	0.1	1.2	0.0	4.9	6.5	0.3	1.4	7.0	11.6	0.0	7.7	0.0	4.9	1.5	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.3	0.3	0.1	0.2	0.0	7.7	15.2	1.3	28.4	10.9	15.9	4.7	10.5	6.2	1.1	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.0	3.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	12.1	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.9	0.0	1.6	0.0	0.0	0.3
GABRA4		ENSG00000109158	"Gamma-aminobutyric acid type A receptor alpha4 subunit"	P48169	4	46918900-46994407	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"brain: 16.1"	"Group enriched"	"Detected in some"	5	"Cardiomyocytes: 11.0;Muller glia cells: 5.0"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	177	"REH: 17.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA								"unprognostic (2.78e-2)"		"unprognostic (6.57e-3)"	"unprognostic (2.46e-1)"			"unprognostic (2.23e-1)"		"unprognostic (3.17e-1)"			"unprognostic (1.11e-1)"	"unprognostic (6.91e-2)"			0.0	0.1	2.7	0.1	8.9	0.0	0.0	0.3	16.1	0.1	0.1			0.6	0.0	0.0	0.2	0.0	0.1	4.0	1.9	1.4	0.1	0.0	0.0	0.0	1.0		0.0	0.0	0.0	0.2	0.3		0.0	0.1		0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.1	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.5	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.2	1.7	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0
GABRA5		ENSG00000186297	"Gamma-aminobutyric acid type A receptor alpha5 subunit"	P31644	15	26866363-26949207	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	21	"brain: 52.6"	"Cell type enhanced"	"Detected in single"	18	"Spermatogonia: 1.5"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	10	"A549: 26.4;HAP1: 9.1;NTERA-2: 10.9;U-2 OS: 9.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA029363, HPA077031, CAB079022"		Supported	Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"CAB079022: , HPA029363: , HPA077031: AB_2686825"	"unprognostic (6.33e-2)"			"unprognostic (8.94e-3)"	"unprognostic (1.04e-1)"			"unprognostic (2.50e-1)"	"unprognostic (1.81e-1)"	"unprognostic (3.75e-1)"	"unprognostic (9.50e-3)"	"unprognostic (2.57e-1)"		"unprognostic (7.63e-2)"	"unprognostic (8.50e-2)"	"unprognostic (1.44e-2)"		0.8	0.8	12.0	0.8	48.2	0.8	0.8	0.1	52.6	0.8	0.8	0.8	0.0	0.8	0.8	0.7	2.5	0.8	1.5	0.9	20.9	6.0	0.9	0.8	0.8	0.8	2.3	15.2	0.7	0.7	0.7	0.1	0.8	1.0	1.0	0.7	0.0	0.7	0.9	0.7	0.8	0.7	1.4	0.3	0.8	1.1	1.4	2.0	1.3	0.9	0.0	1.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	26.4	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	9.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	10.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.4	0.0	0.0	0.1	1.3	0.0	0.0	0.0	0.0	9.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.0	48.2	0.1	26.0	20.9	6.0	2.3	15.2	1.0	2.0	0.0	0.0	0.0	0.0	0.0	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.5	0.0	0.1	0.0	0.0	0.0
GABRA6		ENSG00000145863	"Gamma-aminobutyric acid type A receptor alpha6 subunit"	Q16445	5	161547063-161702593	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	23	"brain: 96.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in some"	36	"cerebellum: 96.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"AF22: 1.0;PC-3: 1.5;TIME: 1.1;U-266/70: 2.5"	"Region enriched"	"Detected in some"	40	"cerebellum: 1204.9"	"Region enriched"	"Detected in some"	44	"cerebellum: 189.6"	CAB022462	Approved					NA	NA					"CAB022462: "																"unprognostic (3.79e-2)"		0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.4	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	96.4	0.1	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GABRB1		ENSG00000163288	"Gamma-aminobutyric acid type A receptor beta1 subunit"	P18505	4	46993723-47426444	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 34.5;pituitary gland: 14.7"	"Cell type enriched"	"Detected in some"	25	"Muller glia cells: 39.0"	"Cancer enhanced"	"Detected in single"		"glioma: 0.7"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 2.4;REH: 4.2;SCLC-21H: 1.1;U-87 MG: 6.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.11e-2)"		"unprognostic (7.56e-3)"		"unprognostic (5.10e-2)"	"unprognostic (1.83e-1)"			"unprognostic (1.11e-1)"		"unprognostic (4.98e-3)"		"unprognostic (8.16e-3)"	"unprognostic (6.22e-2)"	"unprognostic (2.72e-2)"	"unprognostic (2.34e-1)"		1.0	1.3	19.9	1.0	34.5	0.9	1.0	14.7	27.9	1.0	1.2	2.7	0.0	1.6	1.2	1.0	1.0	1.2	1.2	6.0	16.3	4.2	1.8	1.1	1.1	0.9	2.8	18.5	1.1	0.9	0.9	14.7	1.3	5.6	1.0	1.2	0.0	0.9	0.9	0.9	0.9	1.3	1.0	3.4	1.0	1.0	1.1	6.7	0.0	1.3	0.0	0.9	0.9	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.7	0.0	0.0	0.0	6.8	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.9	34.5	14.7	16.6	16.3	4.2	2.8	18.5	5.6	6.7	0.0	0.0	0.0	0.0	0.0	0.6	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	39.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.3	1.4	0.0	0.1	0.0	0.0	0.0
GABRB2		ENSG00000145864	"Gamma-aminobutyric acid type A receptor beta2 subunit"	P47870	5	161288429-161549044	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"brain: 48.7"	"Cell type enhanced"	"Detected in some"	17	"Bipolar cells: 17.4;Cone photoreceptor cells: 25.5;Rod photoreceptor cells: 9.0"	"Cancer enriched"	"Detected in some"	20	"thyroid cancer: 10.2"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	10	"SCLC-21H: 23.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001964, HPA067632"	Enhanced					NA	NA					"CAB001964: , HPA067632: AB_2685874"	"unprognostic (5.46e-2)"	"unprognostic (1.03e-1)"	"unprognostic (3.29e-1)"	"unprognostic (2.26e-6)"	"unprognostic (2.33e-2)"	"unprognostic (6.65e-2)"	"unprognostic (3.58e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.01e-2)"	"unprognostic (1.22e-1)"	"unprognostic (5.19e-3)"	"unprognostic (2.24e-4)"	"unprognostic (1.22e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.58e-1)"	"unprognostic (7.18e-3)"	"unprognostic (1.04e-2)"	1.2	3.6	7.7	0.8	19.2	0.7	0.9	48.7	45.4	1.3	1.5	0.9	0.0	2.0	0.9	5.8	0.8	1.2	0.8	0.9	8.1	4.6	2.8	0.7	1.8	0.8	3.7	16.3	0.9	0.9	0.8	0.5	1.0	4.3	0.9	2.2	0.1	1.3	1.5	0.8	0.8	1.4	0.9	1.1	3.4	1.2	1.5	1.8	0.0	1.3	0.0	0.8	0.8	0.3	0.4	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	1.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	23.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	2.2	0.1	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	7.7	19.2	48.7	34.1	8.1	4.6	3.7	16.3	4.3	1.8	0.0	0.0	0.0	0.0	0.2	17.4	1.6	0.0	0.0	0.0	0.0	25.5	0.0	5.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.1	0.0	1.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.9	1.4	0.0	0.0	0.4	2.6	9.0	0.0	0.4	2.7	1.5	0.4	0.0	0.0	3.0	0.0
GABRB3		ENSG00000166206	"Gamma-aminobutyric acid type A receptor beta3 subunit"	P28472	15	26543546-26939539	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 48.6"	"Cell type enhanced"	"Detected in many"	16	"Bipolar cells: 136.2;Cone photoreceptor cells: 37.3;Horizontal cells: 71.5;Rod photoreceptor cells: 48.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 32.3;HAP1: 13.3;NTERA-2: 23.2;OE19: 10.0;SCLC-21H: 21.5;U-2 OS: 8.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.72e-1)"	"unprognostic (4.91e-2)"	"unprognostic (3.20e-2)"	"unprognostic (4.25e-2)"	"unprognostic (1.66e-1)"	"unprognostic (7.07e-2)"	"unprognostic (1.00e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.44e-1)"	"unprognostic (1.44e-2)"	"unprognostic (3.62e-1)"	"unprognostic (3.56e-3)"	"unprognostic (2.99e-2)"	"unprognostic (1.49e-1)"	"unprognostic (3.33e-2)"	"unprognostic (4.05e-1)"	1.2	6.2	16.8	1.1	22.6	0.7	1.5	12.7	48.6	3.0	1.8	1.6	0.1	1.4	2.4	1.6	1.9	3.0	13.9	7.4	14.3	11.7	7.8	1.5	1.5	0.7	4.6	13.7	2.5	5.2	1.2	12.2	0.7	3.7	5.7	1.6	3.2	1.2	1.9	0.7	1.3	1.2	2.0	2.5	1.2	6.0	4.4	3.4	0.0	9.1	0.0	0.9	1.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	32.3	5.1	0.0	0.0	0.0	1.2	0.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	13.3	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	2.6	1.6	0.0	0.0	0.0	0.0	0.0	7.0	0.9	0.0	0.0	0.0	2.2	0.0	23.2	10.0	1.6	0.0	0.0	0.0	2.3	0.0	21.5	8.1	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	16.8	22.6	12.7	25.7	14.3	11.7	4.6	13.7	3.7	3.4	11.9	2.2	0.0	1.0	0.0	136.2	8.9	17.8	18.7	2.3	5.2	37.3	0.4	0.0	3.3	9.0	1.3	0.5	0.0	0.4	0.0	0.2	3.6	0.0	0.5	0.0	71.5	9.9	1.3	0.0	4.9	1.7	0.0	0.0	0.0	1.8	6.7	1.4	0.0	3.2	6.3	48.7	0.0	0.9	5.1	15.1	0.1	0.2	0.0	0.4	0.3
GABRD		ENSG00000187730	"Gamma-aminobutyric acid type A receptor delta subunit"	O14764	1	2019298-2030758	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	25	"brain: 87.0"	"Cell type enhanced"	"Detected in some"	9	"Bipolar cells: 9.3;Ciliated cells: 8.1;Club cells: 11.4;Horizontal cells: 12.7;Spermatogonia: 13.5"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 87.0"	"Cell type enriched"	"Detected in single"	5	"plasmacytoid DC: 1.2"	"Lineage enriched"	"Detected in single"	5	"dendritic cells: 1.2"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.9;HMC-1: 2.5;MCF7: 8.3;NB-4: 5.3;NTERA-2: 2.1;SH-SY5Y: 3.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA044371	Enhanced		Uncertain	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"HPA044371: AB_2678916"	"unprognostic (4.28e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.95e-8)"	"unprognostic (6.34e-3)"	"unprognostic (2.66e-3)"	"unprognostic (1.04e-2)"	"unprognostic (3.44e-3)"	"unprognostic (2.14e-1)"	"unprognostic (4.53e-2)"	"unprognostic (1.12e-1)"	"unprognostic (3.77e-2)"	"unprognostic (1.99e-1)"	"prognostic unfavorable (4.12e-8)"	"unprognostic (1.72e-1)"	"unprognostic (1.76e-1)"	"unprognostic (2.77e-1)"	"unprognostic (5.16e-2)"	1.2	3.4	8.8	0.9	16.8	1.0	1.0	87.0	40.0	1.0	1.2	1.7	0.0	0.9	1.3	1.2	1.3	1.0	1.5	1.7	6.0	1.7	1.1	0.9	1.4	1.3	3.3	11.1	0.9	0.9	1.4	0.7	1.2	17.1	1.0	1.0	0.0	1.1	0.9	1.3	1.4	1.0	1.4	1.4	1.0	1.0	3.3	1.5	0.0	1.6	0.0	1.0	1.2	0.1	0.0	1.2	0.2	0.1	0.0	0.0	0.8	0.0	0.7	0.0	1.8	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.9	0.0	0.3	0.0	1.4	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.3	0.0	5.3	2.1	1.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	3.1	0.1	0.0	0.0	0.0	1.1	1.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.2	0.0	0.8	8.8	16.8	87.0	40.0	6.0	1.7	3.3	11.1	17.1	1.5	3.0	5.1	0.0	0.0	0.5	9.3	0.8	0.0	8.1	11.4	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	0.0	0.2	0.0	0.1	2.3	0.0	0.1	12.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	1.7	0.0	3.1	0.1	13.5	0.0	0.2	0.0	0.0	0.0
GABRE		ENSG00000102287	"Gamma-aminobutyric acid type A receptor epsilon subunit"	P78334	X	151953124-151974680	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"placenta: 36.4;vagina: 27.7"	"Cell type enhanced"	"Detected in many"	9	"Syncytiotrophoblasts: 51.4;Urothelial cells: 32.0"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	5	"hypothalamus: 21.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC diff: 4.4;EFO-21: 14.9;HeLa: 6.7;SiHa: 7.0"					"Low region specificity"	"Detected in many"			HPA045918	Uncertain					NA	NA					"HPA045918: AB_10961281"	"unprognostic (1.33e-2)"	"unprognostic (6.75e-2)"	"unprognostic (3.50e-3)"	"unprognostic (1.39e-3)"	"unprognostic (2.43e-1)"	"unprognostic (7.52e-2)"	"unprognostic (5.06e-3)"	"unprognostic (1.27e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.44e-2)"	"unprognostic (6.73e-2)"	"prognostic unfavorable (4.05e-11)"	"unprognostic (1.96e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.29e-2)"	"unprognostic (5.28e-2)"	14.8	1.0	1.5	2.2	2.8	0.3	16.5	1.0	1.6	8.9	5.8	0.0	2.2	1.4	6.0	4.1	5.0	1.5	4.2	16.3	1.0	21.8	1.1	0.9	2.3	0.7	1.1	0.6	1.6	2.5	0.4	4.1	36.4	4.5	5.9	0.8	3.8	2.0	6.3	0.9	5.6	10.1	2.5	1.1	0.9	1.0	0.9	0.4	0.0	2.5	5.9	3.5	2.9	27.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	4.4	0.0	0.0	0.6	0.0	1.1	0.5	2.3	0.8	0.0	14.9	3.1	0.0	2.4	0.0	0.8	0.7	0.0	0.5	1.7	6.7	0.9	0.2	0.0	0.2	1.0	0.7	1.2	0.3	1.4	0.6	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	7.0	1.0	0.0	1.0	0.0	0.0	1.3	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	2.8	1.0	1.3	1.0	21.8	1.1	0.6	4.5	0.4	14.9	5.7	0.0	20.6	15.2	0.0	6.4	12.7	2.7	14.8	1.8	0.0	17.3	0.0	3.6	1.7	7.9	9.3	0.0	0.3	2.0	9.7	14.0	0.0	0.8	2.7	0.0	1.7	4.3	0.6	1.8	1.4	0.2	1.7	0.0	1.8	0.5	3.7	8.6	2.1	0.0	0.3	0.0	4.7	1.1	1.7	9.5	51.4	0.5	2.3	32.0
GABRG1		ENSG00000163285	"Gamma-aminobutyric acid type A receptor gamma1 subunit"	Q8N1C3	4	46035769-46124081	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in many"	9	"brain: 35.7"	"Group enriched"	"Detected in some"	5	"Early spermatids: 5.9;Muller glia cells: 15.1;Sertoli cells: 6.5"	"Cancer enriched"	"Detected in single"	8	"glioma: 0.6"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 1.3;THP-1: 2.6;U-2 OS: 1.8;U-266/70: 5.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035622, HPA058102"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA035622: AB_10603669, HPA058102: "	"unprognostic (2.50e-1)"				"unprognostic (2.20e-1)"		"unprognostic (6.06e-2)"			"unprognostic (1.46e-2)"	"unprognostic (7.39e-4)"		"unprognostic (1.23e-1)"		"unprognostic (1.28e-1)"	"unprognostic (1.99e-1)"		1.5	1.5	20.3	1.2	25.9	1.2	1.3	26.4	35.7	1.3	1.3	12.2	0.0	1.4	1.4	1.3	1.3	1.7	1.3	1.2	26.0	14.6	1.4	1.4	1.2	1.3	10.2	14.0	3.9	1.2	1.3	1.6	1.2	17.9	1.2	1.3	0.0	1.2	1.3	1.2	1.2	1.4	1.4	17.8	1.4	1.3	1.8	17.8	0.0	1.5	0.0	1.2	1.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.6	0.0	0.3	1.8	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	20.3	25.9	26.4	18.5	26.0	14.6	10.2	14.0	17.9	17.8	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	15.1	0.0	0.0	0.0	0.0	1.8	6.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
GABRG2		ENSG00000113327	"Gamma-aminobutyric acid type A receptor gamma2 subunit"	P18507	5	162000057-162162977	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 47.1"	"Cell type enriched"	"Detected in some"	4	"Bipolar cells: 81.7"	"Cancer enhanced"	"Detected in single"		"glioma: 1.4"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.3"	"Group enriched"	"Detected in many"	5	"B-cells: 2.9;granulocytes: 7.3;T-cells: 3.2"	"Cell line enhanced"	"Detected in many"		"CACO-2: 10.6;RPMI-8226: 10.2;SuSa: 11.4;U-266/70: 17.8;U-266/84: 14.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB079060		Supported				NA	NA					"CAB079060: "					"unprognostic (2.88e-2)"			"unprognostic (1.56e-2)"			"unprognostic (6.31e-3)"			"unprognostic (3.07e-3)"	"unprognostic (1.52e-1)"			1.1	5.7	9.7	1.2	28.8	3.3	0.9	21.7	47.1	0.7	1.5	1.1	0.0	2.2	1.2	1.3	1.3	1.3	3.8	1.6	10.6	19.6	1.0	1.2	1.9	1.2	7.5	19.1	1.5	1.0	0.8	5.3	2.9	17.6	1.0	1.3	0.6	1.3	0.8	1.2	3.3	1.9	1.6	2.6	1.2	3.3	1.7	1.8	0.0	1.8	0.0	1.3	1.5	0.3	2.9	0.7	7.3	0.3	0.9	3.2	0.2	3.6	1.7	1.9	0.3	0.0	0.0	2.0	0.6	0.0	0.0	0.0	10.6	4.7	0.7	5.2	0.0	0.4	1.6	1.2	0.0	0.0	0.8	1.1	0.0	2.1	1.3	0.0	0.2	0.5	0.3	0.0	0.0	0.0	0.5	0.0	1.0	1.8	8.5	0.0	2.5	0.4	0.1	6.1	3.4	2.9	0.4	0.1	10.2	0.0	3.4	0.9	0.8	0.3	0.6	3.4	11.4	5.6	5.7	0.2	0.3	4.5	0.3	0.5	17.8	14.1	0.5	0.2	0.4	0.4	7.3	0.3	0.6	0.4	0.3	2.7	2.9	0.7	0.6	0.0	2.5	3.2	0.7	1.6	0.9	0.2	0.7	0.6	0.2	9.7	28.8	21.7	38.1	10.6	19.6	7.5	19.1	17.6	1.8	17.9	19.7	0.0	0.0	0.0	81.7	0.2	0.0	12.0	19.4	0.0	11.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1	0.0	0.1	15.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.0	0.0	8.4	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0
GABRG3		ENSG00000182256	"Gamma-aminobutyric acid type A receptor gamma3 subunit"	Q99928	15	26971282-27541991	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"brain: 15.3;prostate: 13.5;testis: 16.6"	"Group enriched"	"Detected in some"	36	"Early spermatids: 81.6;Late spermatids: 207.6;Muller glia cells: 241.7"	"Cancer enhanced"	"Detected in single"		"prostate cancer: 1.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"K-562: 5.0;PC-3: 6.5;SK-MEL-30: 4.2;U-2 OS: 3.0;U-266/70: 3.8;U-87 MG: 17.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA054010	Approved					NA	NA					"HPA054010: AB_2682342"	"unprognostic (1.23e-1)"	"unprognostic (1.67e-1)"		"unprognostic (1.02e-2)"	"unprognostic (3.50e-2)"	"unprognostic (2.61e-1)"	"unprognostic (2.33e-3)"	"unprognostic (1.30e-1)"	"unprognostic (2.39e-2)"	"unprognostic (5.15e-2)"	"unprognostic (2.95e-1)"	"unprognostic (4.41e-1)"	"unprognostic (1.43e-5)"	"unprognostic (1.52e-1)"	"unprognostic (1.32e-1)"	"unprognostic (2.03e-2)"	"unprognostic (1.83e-1)"	0.5	1.3	2.2	0.8	10.4	0.5	1.2	3.1	15.3	2.2	0.5	0.8	0.0	0.4	0.7	4.4	0.5	1.3	0.5	0.4	3.0	5.8	1.0	0.6	0.5	1.5	1.0	7.8	0.5	0.4	0.4	6.4	0.5	2.7	13.5	0.5	4.0	1.5	3.4	0.5	0.9	0.4	0.6	0.8	2.3	0.4	16.6	0.5	0.3	3.3	0.0	1.9	0.4	0.7	0.8	0.3	0.9	0.4	0.3	0.3	0.0	0.0	0.1	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.5	0.4	0.0	6.5	0.0	0.0	1.2	0.0	0.0	0.1	1.1	0.0	0.0	4.2	0.1	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.8	0.0	0.0	17.1	0.1	0.0	0.4	0.4	0.1	0.1	0.1	0.2	0.3	0.1	0.1	0.0	0.8	0.3	0.1	0.9	0.3	0.1	0.3	0.1	0.0	2.2	10.4	3.1	15.3	3.0	5.8	1.0	7.8	2.7	0.5	0.0	0.0	0.0	0.1	0.0	3.0	0.8	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	81.6	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	207.6	0.9	0.0	0.0	0.0	0.0	241.7	0.0	0.0	0.7	0.2	2.6	0.0	0.0	1.4	4.9	0.0	0.0	0.0	0.0	0.1
GABRP		ENSG00000094755	"Gamma-aminobutyric acid type A receptor pi subunit"	O00591	5	170763350-170814047	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 37.0;lymphoid tissue: 57.7"	"Cell type enhanced"	"Detected in some"	23	"Cholangiocytes: 48.4;Pancreatic endocrine cells: 33.1;Urothelial cells: 141.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"basophil: 10.1"	"Group enriched"	"Detected in many"	6	"granulocytes: 10.1;monocytes: 6.1"	"Cell line enhanced"	"Detected in many"		"A-431: 39.5;EFO-21: 46.1;HeLa: 27.7;PC-3: 63.2;SuSa: 85.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB014883	Uncertain					NA	NA					"CAB014883: "	"unprognostic (3.98e-3)"	"prognostic favorable (3.37e-4)"	"unprognostic (8.34e-2)"	"unprognostic (1.57e-1)"	"unprognostic (8.90e-2)"	"unprognostic (1.27e-1)"	"unprognostic (7.89e-2)"	"unprognostic (4.97e-3)"	"unprognostic (3.72e-1)"	"unprognostic (4.93e-3)"	"unprognostic (1.30e-3)"	"unprognostic (2.30e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.82e-1)"	"unprognostic (5.92e-3)"	"unprognostic (6.52e-3)"	1.5	0.5	0.5	1.3	0.5	1.1	31.6	0.5	1.1	18.5	1.7	0.6	2.6	2.6	30.4	9.9	37.0	2.2	8.6	1.0	0.5	0.4	6.9	3.8	2.5	0.5	0.5	0.5	1.1	4.3	0.0	2.4	5.5	0.6	6.8	0.4	0.8	25.5	3.2	2.0	10.0	3.9	0.5	0.5	0.8	5.0	1.0	0.5	2.5	0.6	3.1	57.7	1.2	20.0	0.9	1.1	10.1	6.1	0.2	1.3	3.1	39.5	1.8	1.9	1.3	0.1	0.8	4.6	0.7	0.2	0.1	0.1	7.1	4.5	0.6	46.1	0.2	0.4	14.3	1.2	0.0	0.1	0.6	1.4	2.6	27.7	1.0	0.1	0.9	2.2	0.3	0.5	0.5	0.3	1.5	0.2	2.5	10.6	5.0	0.0	1.2	1.7	0.8	16.2	0.7	63.2	2.5	1.2	1.5	2.6	2.2	1.6	0.7	14.6	0.7	0.4	85.1	0.8	0.4	1.6	3.7	13.5	3.0	2.9	1.9	1.2	1.1	0.5	2.6	0.5	10.1	2.3	6.8	0.5	1.7	1.3	0.3	0.5	0.4	0.7	0.9	0.7	0.6	5.4	0.2	6.1	1.1	0.7	3.1	0.5	0.5	0.5	0.6	0.5	0.4	0.5	0.5	0.6	0.5	3.0	1.1	0.0	14.6	0.0	0.0	0.4	48.4	12.0	15.9	1.8	0.0	3.6	0.0	0.8	0.0	0.0	0.0	0.0	12.6	0.1	0.8	15.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	33.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.8	0.0	0.4	141.9
GABRQ	THETA	ENSG00000268089	"Gamma-aminobutyric acid type A receptor theta subunit"	Q9UN88	X	152638183-152657534	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"brain: 28.9;cervix, uterine: 16.2"	"Cell type enhanced"	"Detected in some"	20	"Basal keratinocytes: 3.5;Spermatogonia: 1.1;Suprabasal keratinocytes: 1.6"	"Cancer enhanced"	"Detected in many"		"testis cancer: 6.6"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 9.0;SiHa: 8.7;SuSa: 4.1;U-87 MG: 28.8"	"Region enriched"	"Detected in many"	5	"hypothalamus: 61.6"	"Region enhanced"	"Detected in many"		"midbrain: 24.9"							NA	NA						"unprognostic (3.68e-3)"	"unprognostic (7.78e-2)"	"unprognostic (9.16e-2)"	"unprognostic (1.17e-4)"	"unprognostic (3.38e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.45e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.84e-1)"	"unprognostic (1.41e-1)"	"unprognostic (3.73e-1)"	"unprognostic (3.76e-2)"	"unprognostic (3.10e-5)"	"unprognostic (3.43e-3)"	"unprognostic (1.84e-1)"	"unprognostic (6.42e-2)"	"unprognostic (7.70e-2)"	0.2	4.4	10.5	0.2	5.7	0.1	0.1	0.0	7.5	16.2	0.2	1.5	1.0	0.2	2.6	0.5	1.1	0.3	0.1	0.2	23.4		0.2	0.1	0.1	0.2	0.0	13.6	0.1	0.1	0.1	0.0	0.3	28.9	0.9	0.2	0.0	0.1	1.7	0.1	0.7	0.5	1.6	7.2	0.2	0.1	4.7	1.0	0.0	0.3	1.5	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.2	0.2	9.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.7	0.0	2.2	0.0	0.0	0.0	0.0	1.2	8.7	1.6	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.1	3.5	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.2	1.1	1.6	0.7	0.0	0.0	0.3
GABRR1		ENSG00000146276	"Gamma-aminobutyric acid type A receptor rho1 subunit"	P24046	6	89177501-89231278	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in some"		"retina: 12.3;testis: 4.6"	"Cell type enriched"	"Detected in some"	11	"Bipolar cells: 53.4"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	6	"amygdala: 2.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"NTERA-2: 3.3;OE19: 6.7;SuSa: 4.6"	"Not detected"	"Not detected"													NA	NA						"unprognostic (5.75e-2)"	"unprognostic (3.92e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.90e-2)"	"unprognostic (5.78e-2)"	"unprognostic (4.90e-2)"		"unprognostic (8.32e-3)"	"unprognostic (2.52e-3)"	"unprognostic (1.74e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.62e-5)"	"unprognostic (1.18e-1)"	"unprognostic (9.90e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.29e-1)"	0.4	0.0	2.2	0.1	0.1	0.0	0.2	0.3	0.1	0.2	0.3	0.1	0.1	0.1	0.1	0.2	1.0	0.1	0.1	0.1	0.1	0.2	0.4	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.0	0.2	1.0	0.3	0.2	0.1	12.3	0.2	0.1	0.7	0.6	0.7	0.1	0.1	0.1	0.0	4.6	0.1	0.1	0.1	0.1	0.2	0.6	0.2	0.0	0.1	0.2	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.3	6.7	0.0	0.0	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	4.6	0.0	1.0	0.0	0.1	0.2	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	2.2	0.1	0.3	0.1	0.1	0.2	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.2	53.4	0.3	0.0	0.0	0.0	0.0	3.9	0.3	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	3.8	0.0	0.3	0.0	0.2	0.0	0.2	0.0	0.0	0.1
GABRR2		ENSG00000111886	"Gamma-aminobutyric acid type A receptor rho2 subunit"	P28476	6	89257208-89315299	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	12	"retina: 18.8"	"Cell type enriched"	"Detected in some"	13	"Bipolar cells: 19.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.0"	"Lineage enhanced"	"Detected in single"		"dendritic cells: 1.0"	"Cell line enhanced"	"Detected in some"		"U-266/70: 4.4;U-266/84: 1.6"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (2.05e-2)"	"unprognostic (1.47e-4)"	"unprognostic (1.56e-1)"	"unprognostic (1.88e-4)"	"unprognostic (4.19e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.24e-2)"	"unprognostic (9.13e-2)"	"unprognostic (2.87e-1)"	"unprognostic (1.10e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.54e-6)"	"unprognostic (3.69e-2)"	"unprognostic (7.81e-2)"	"unprognostic (5.79e-2)"	"unprognostic (7.15e-3)"	0.2	0.6	0.2	0.5	0.4	0.3	0.1	0.3	0.4	0.1	0.1	0.1	0.1	0.0	0.7	0.5	0.2	0.1	0.4	0.2	0.3	0.2	0.3	0.4	0.1	0.9	0.3	0.1	0.1	0.8	0.0	0.2	0.1	0.1	0.3	0.0	18.8	0.6	0.2	1.5	0.5	0.1	0.1	0.2	0.4	0.1	0.6	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.3	1.0	0.0	0.0	0.0	0.1	0.1	0.0	0.6	0.0	0.4	0.5	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.3	0.6	0.3	0.2	0.1	0.1	0.0	0.0	0.1	0.0	0.4	0.3	0.0	0.0	0.2	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.6	0.0	0.2	0.2	0.0	0.0	0.0	0.2	0.9	0.4	0.0	0.3	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	1.0	0.0	0.4	0.0	0.0	0.0	4.4	1.6	0.0	0.5	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.1	0.2	0.4	0.3	0.3	0.3	0.2	0.3	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	19.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GABRR3		ENSG00000183185	"Gamma-aminobutyric acid type A receptor rho3 subunit (gene/pseudogene)"	A8MPY1	3	97986673-98035304	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Chloride channel, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"No human protein/transcript evidence"	"No human protein/transcript evidence"		"Tissue enriched"	"Detected in some"	7	"retina: 18.2"	"Group enriched"	"Detected in some"	5	"Bipolar cells: 10.5;Rod photoreceptor cells: 11.0"	"Not detected"	"Not detected"							"Cell type enriched"	"Detected in single"	25	"plasmacytoid DC: 2.4"	"Lineage enriched"	"Detected in single"	25	"dendritic cells: 2.4"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 1.1;U-266/70: 2.0;U-698: 4.7"	"Not detected"	"Not detected"													NA	NA										"unprognostic (3.22e-2)"		"unprognostic (2.06e-3)"							"unprognostic (5.65e-2)"	"unprognostic (2.82e-1)"	"unprognostic (1.43e-4)"	"unprognostic (2.84e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	18.2	0.0	0.2	0.4	0.0	0.0	0.1	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0											0.0	0.0	0.0	0.0	0.0	10.5	0.2	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	11.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GALNT8	GALNAC-T8	ENSG00000130035	"Polypeptide N-acetylgalactosaminyltransferase 8"	"Q9NY28, P17658"	12	4720341-4851927	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Glycosyltransferase, Ion channel, Potassium channel, Transferase, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"brain: 12.7;intestine: 33.2;testis: 18.5"	"Group enriched"	"Detected in some"	6	"Early spermatids: 74.9;Late spermatids: 88.4;Mucus-secreting cells: 32.6"	"Cancer enhanced"	"Detected in some"		"testis cancer: 2.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 3.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 26.1;NTERA-2: 9.3;SuSa: 11.2;U-266/84: 7.5"					"Not detected"	"Not detected"			"HPA012638, HPA073461"	Enhanced		Approved	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	Yes	No			"Golgi apparatus, Vesicles"		"HPA012638: AB_2294503, HPA073461: AB_2686604"	"unprognostic (2.36e-2)"	"unprognostic (1.95e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.75e-2)"	"unprognostic (6.24e-2)"	"unprognostic (2.87e-1)"	"unprognostic (2.59e-2)"	"unprognostic (3.79e-1)"	"unprognostic (2.72e-1)"	"unprognostic (5.76e-2)"	"unprognostic (8.06e-5)"	"unprognostic (1.16e-2)"	"unprognostic (6.67e-5)"	"unprognostic (5.18e-2)"	"unprognostic (2.59e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.33e-2)"	1.1	2.2	5.3	2.2	6.5	0.5	3.1	1.4	12.7	1.0	15.5	9.4	0.0	7.2	0.9	0.4	0.7	1.2	1.1	3.7	8.0	1.7	1.2	0.8	0.9	1.0	5.7	9.6	1.6	0.9	0.2	3.7	0.5	6.0	1.1	33.2	0.1	1.0	0.9	0.7	0.9	14.7	2.1	3.5	1.2	1.3	18.5	11.5	0.0	0.8	0.5	0.9	1.2	0.9	1.0	0.7	0.1	0.1	0.9	3.0	0.0	0.0	0.0	1.4	0.1	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	0.7	0.0	0.0	0.2	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.0	26.1	0.0	0.0	0.2	0.1	9.3	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	11.2	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.3	7.5	0.7	0.0	0.0	0.0	0.0	0.1	0.0	1.8	0.0	0.4	0.3	0.7	1.2	0.0	1.0	0.0	0.1	0.1	0.9	0.0	0.7	3.0	0.0	5.3	6.5	1.4	12.7	8.0	1.7	5.7	9.6	6.0	11.5	6.0	0.3	0.0	0.0	0.0	1.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	74.9	0.0	0.9	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.1	0.0	6.3	0.0	0.0	88.4	1.4	0.0	0.0	0.0	32.6	0.1	0.3	0.0	2.5	1.0	0.3	6.5	0.0	11.6	3.6	0.0	0.0	0.0	1.8	0.0
GAMT	"PIG2, TP53I2"	ENSG00000130005	"Guanidinoacetate N-methyltransferase"	Q14353	19	1397026-1401570	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Methyltransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 73.0;skeletal muscle: 222.2"	"Cell type enhanced"	"Detected in many"	14	"Hepatocytes: 641.0;Proximal tubular cells: 334.2"	"Cancer enriched"	"Detected in all"	5	"liver cancer: 173.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Hep G2: 52.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA051806	Approved					NA	NA		38000			"HPA051806: AB_2681619"	"unprognostic (3.25e-1)"	"unprognostic (7.74e-3)"	"unprognostic (3.22e-2)"	"unprognostic (6.32e-2)"	"unprognostic (4.35e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.92e-2)"	"unprognostic (2.80e-2)"	"unprognostic (1.14e-1)"	"unprognostic (2.27e-1)"	"unprognostic (3.41e-2)"	"unprognostic (7.10e-2)"	"unprognostic (6.36e-2)"	"prognostic unfavorable (6.57e-4)"	"unprognostic (1.78e-1)"	"unprognostic (1.82e-1)"	"unprognostic (1.54e-2)"	5.1	4.6	9.1	1.5	8.7	2.2	3.2	5.1	11.4	2.3	1.4	15.1	5.1	1.3	2.0	31.3	5.3	3.8	2.6	10.8	9.2	7.7	8.0	73.0	1.5	2.0	8.7	5.2	3.8	47.0	5.4	4.9	1.6	5.9	5.6	1.1	4.5	9.1	4.7	222.2	6.0	1.4	2.1	8.8	2.1	3.2	7.7	4.5	5.6	3.3	26.7	2.8	1.9	1.7	15.7	23.0	6.9	2.6	8.0	21.6	7.7	6.3	7.2	7.8	17.5	9.8	11.9	10.6	7.6	12.6	9.9	9.0	16.3	4.6	3.4	5.3	9.0	1.2	2.7	12.2	4.7	2.6	24.1	13.9	10.4	6.0	52.0	5.8	0.2	3.6	13.2	1.7	10.5	0.0	13.7	2.1	13.1	14.7	8.2	16.0	6.5	30.3	3.5	8.8	3.2	22.9	30.4	6.9	24.1	11.6	5.9	2.6	18.2	0.6	4.4	9.4	5.2	20.1	14.4	3.7	10.8	11.2	0.6	3.4	36.9	7.1	5.7	10.0	13.7	12.4	1.6	1.2	6.9	9.9	1.6	13.9	10.6	13.7	12.2	5.4	15.7	21.6	16.1	0.8	8.0	2.6	23.0	7.5	7.7	9.1	8.7	5.1	11.4	9.2	7.7	8.7	5.2	5.9	4.5	0.0	7.4	17.2	31.8	52.3	38.7	89.3	129.9	1.4	3.4	15.7	53.0	28.0	77.9	26.6	4.1	7.8	0.0	23.3	29.0	35.1	26.0	27.5	4.6	641.0	61.9	17.5	6.9	21.5	25.6	12.0	77.6	9.9	30.4	6.4	1.1	39.8	21.8	0.0	131.2	334.2	60.1	32.3	40.1	2.7	29.6	37.5	10.1	20.0	0.8	11.1
GANAB	"G2AN, GIIA, GluII, KIAA0088"	ENSG00000089597	"Glucosidase II alpha subunit"	Q14697	11	62624826-62646726	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Glycosidase, Hydrolase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026874, HPA061426"	Enhanced		Approved	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA		37000000	"Endoplasmic reticulum"		"HPA026874: AB_1849745, HPA061426: AB_2684516"	"unprognostic (2.12e-1)"	"unprognostic (5.95e-3)"	"unprognostic (4.35e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.65e-2)"	"prognostic unfavorable (1.27e-5)"	"unprognostic (5.80e-3)"	"unprognostic (1.09e-1)"	"unprognostic (1.79e-1)"	"unprognostic (1.68e-3)"	"unprognostic (5.91e-2)"	"unprognostic (1.01e-3)"	"unprognostic (3.81e-2)"	"unprognostic (1.82e-2)"	"unprognostic (1.39e-1)"	"prognostic unfavorable (9.54e-4)"	33.6	34.6	16.2	23.3	20.7	17.9	30.1	19.9	31.0	38.9	31.5	29.8	43.4	26.0	44.0	38.6	29.2	34.2	33.8	32.6	17.2	16.5	35.9	91.5	31.4	30.2	21.7	19.5	49.0	51.4	56.6	27.3	61.1	20.0	29.4	32.6	33.7	43.5	40.7	28.2	24.5	39.8	37.4	19.5	37.4	31.2	27.7	20.2	41.8	45.6	25.2	34.0	36.0	29.4	14.6	17.5	16.5	18.8	22.5	20.0	17.6	42.5	37.3	46.7	84.6	72.1	63.1	50.6	48.0	72.1	66.5	57.5	31.1	79.2	29.2	97.1	84.8	52.9	58.2	56.3	53.9	68.9	23.5	24.3	28.8	51.2	12.9	53.3	44.6	36.3	61.2	35.0	66.1	69.4	84.2	61.6	30.0	40.8	52.7	59.7	37.4	23.2	14.5	39.5	35.0	30.3	31.0	56.0	73.3	32.6	34.8	24.7	33.5	68.6	44.5	51.1	52.5	58.3	38.1	46.3	66.6	42.6	52.2	44.6	52.9	61.2	22.3	73.1	24.0	64.7	16.5	15.0	14.4	20.0	18.8	20.0	14.6	13.8	15.9	17.5	13.1	17.9	16.3	7.0	22.5	16.4	11.6	13.0	17.6	16.2	20.7	19.9	31.0	17.2	16.5	21.7	19.5	20.0	20.2	11.9	26.8	19.7	22.3	25.1	29.5	6.5	61.1	10.7	7.9	64.6	56.9	71.8	5.0	43.0	15.3	31.5	35.1	0.0	36.9	114.6	43.7	31.3	10.5	80.2	51.7	33.4	30.6	51.5	41.2	11.0	54.1	24.9	33.7	36.9	50.5	40.2	38.3	25.9	64.0	24.2	33.9	32.3	26.7	18.4	48.6	27.4	67.1	24.2	55.2	26.0
GANC		ENSG00000214013	"Glucosidase alpha, neutral C"	Q8TET4	15	42273233-42356935	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Glycosidase, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Alveolar cells type 2: 36.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016949, HPA051522"	Approved		Approved	Cytosol		NA	NA			Cytosol		"HPA016949: AB_1849465, HPA051522: "	"unprognostic (8.83e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.24e-1)"	"unprognostic (3.04e-3)"	"unprognostic (2.51e-2)"	"unprognostic (9.85e-2)"	"unprognostic (2.49e-2)"	"prognostic favorable (9.76e-4)"	"unprognostic (1.73e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.66e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.14e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.14e-1)"	"unprognostic (1.55e-2)"	"unprognostic (3.74e-2)"	13.3	14.0	12.5	17.3	20.7	17.6	14.4	16.6	14.2	15.8	14.3	25.6	15.4	11.7	17.9	26.0	20.7	12.9	13.0	12.4	13.4	10.4	13.5	18.0	30.5	13.8	25.0	13.7	18.8	13.1	17.4	20.5	10.8	19.8	13.1	17.8	18.3	20.4	13.7	23.9	13.9	15.4	15.9	25.1	15.5	13.1	24.5	22.6	17.4	16.8	12.3	18.3	16.2	16.3	17.6	12.2	9.3	10.1	4.0	7.4	4.7	6.2	3.2	7.9	8.6	9.6	13.6	5.0	13.7	14.8	15.1	12.7	4.7	4.4	3.4	7.5	13.8	10.5	13.0	9.5	14.6	10.5	8.5	4.4	8.5	8.6	9.2	8.1	8.2	7.4	9.2	8.7	6.1	10.5	8.5	10.2	8.7	8.8	9.6	11.9	1.3	5.5	9.1	4.9	2.7	4.2	10.6	9.3	11.8	11.4	5.8	6.0	8.5	7.7	6.7	4.8	4.5	2.5	19.4	9.2	15.9	4.2	13.1	8.2	10.4	13.7	6.9	7.5	15.1	8.7	9.3	9.3	7.4	3.7	10.1	5.0	16.2	5.7	6.9	12.2	17.6	7.4	4.4	5.0	4.0	8.1	9.6	5.5	4.7	12.5	20.7	16.6	14.2	13.4	10.4	25.0	13.7	19.8	22.6	17.9	36.3	8.3	15.1	9.3	5.1	6.9	2.5	12.0	10.3	1.8	9.8	4.4	5.0	4.3	9.0	4.0	8.4	0.0	3.3	4.2	4.5	6.5	10.4	9.0	6.0	3.2	4.1	7.4	11.6	3.0	6.6	10.3	13.5	11.8	5.5	10.4	5.0	16.5	6.0	6.3	6.5	12.9	5.2	14.2	14.4	4.5	2.4	5.0	7.5	21.3
GAPDH	GAPD	ENSG00000111640	"Glyceraldehyde-3-phosphate dehydrogenase"	P04406	12	6533927-6538374	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Glycolysis, Translation regulation"	"Oxidoreductase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"skeletal muscle: 1236.8"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB005197, CAB016392, HPA040067, HPA061280"	Supported		Supported	"Nuclear membrane,Vesicles,Plasma membrane,Cytosol"		No	No		2200000000	"Plasma membrane, Cytosol"	"Nuclear membrane, Vesicles"	"CAB005197: AB_641107, CAB016392: AB_627678, HPA040067: AB_10965903, HPA061280: AB_2684463"	"unprognostic (3.03e-1)"	"unprognostic (2.62e-3)"	"unprognostic (3.58e-2)"	"unprognostic (4.20e-1)"	"unprognostic (9.73e-3)"	"unprognostic (1.77e-3)"	"prognostic unfavorable (1.79e-6)"	"unprognostic (2.89e-3)"	"unprognostic (2.86e-1)"	"unprognostic (2.06e-2)"	"unprognostic (9.50e-3)"	"unprognostic (4.52e-1)"	"prognostic unfavorable (6.25e-10)"	"unprognostic (2.33e-1)"	"unprognostic (4.28e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.26e-2)"	50.0	59.4	104.1	57.6	101.0	195.5	38.4	58.0	151.3	49.4	73.3	80.7	24.0	75.8	37.3	46.8	146.9	50.2	58.0	215.1	95.0	95.5	88.4	221.0	41.3	90.1	111.8	58.0	62.0	27.0	66.1	46.1	98.2	115.9	48.3	76.7	74.5	60.8	63.2	1236.8	54.4	74.4	68.0	95.6	50.7	41.1	36.4	35.9	101.9	38.3	238.7	105.3	89.5	50.5	57.9	171.0	110.0	201.6	60.5	108.8	271.9	188.4	332.6	95.9	149.5	93.6	154.4	209.1	143.2	204.0	209.6	218.8	234.7	129.4	220.4	28.3	168.8	159.1	107.3	89.1	332.2	145.5	193.2	96.8	121.9	208.7	199.3	126.2	197.0	98.1	129.1	108.5	206.0	232.8	501.3	230.7	161.2	65.4	46.4	238.1	376.0	224.4	103.7	354.5	226.1	110.8	182.6	170.9	104.9	238.5	230.6	68.0	109.1	126.4	329.8	190.3	285.1	51.5	139.2	143.9	163.6	197.8	84.4	247.4	105.5	76.7	284.0	346.8	124.9	256.0	110.0	201.6	37.0	74.1	103.2	65.3	57.9	77.9	74.4	171.0	32.2	44.1	51.2	106.5	60.5	92.3	25.2	108.8	271.9	104.1	101.0	58.0	151.3	95.0	95.5	111.8	58.0	115.9	35.9	220.3	245.0	821.1	1485.4	1615.7	992.1	33.2	1355.4	275.7	444.7	970.1	392.7	4082.4	2934.5	4447.1	583.7	1564.4	2836.9	443.9	3299.5	7140.5	1484.6	1124.2	551.6	1346.2	3470.6	2218.3	1273.2	1144.2	2599.6	1556.8	823.5	2367.4	4003.5	3613.2	2061.2	5234.8	4742.6	2687.7	965.3	5345.0	1026.0	1131.8	2133.1	429.6	390.5	1399.2	3925.6	1271.1	3009.6	2464.1
GART	"GARS-AIRS-GART, PGFT, PRGS"	ENSG00000159131	"Phosphoribosylglycinamide formyltransferase, phosphoribosylglycinamide synthetase, phosphoribosylaminoimidazole synthetase"	P22102	21	33503931-33543491	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Purine biosynthesis"	"Ligase, Multifunctional enzyme, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002119, HPA005779"	Approved		Approved	Mitochondria,Cytosol		NA	NA		1300000	Cytosol	Mitochondria	"HPA002119: AB_1849482, HPA005779: AB_1849484"	"unprognostic (3.77e-2)"	"unprognostic (2.25e-2)"	"unprognostic (4.51e-3)"	"unprognostic (1.72e-2)"	"unprognostic (2.30e-2)"	"prognostic unfavorable (5.05e-5)"	"prognostic unfavorable (9.82e-5)"	"unprognostic (2.50e-2)"	"unprognostic (2.76e-3)"	"unprognostic (2.92e-1)"	"prognostic unfavorable (2.19e-4)"	"unprognostic (1.98e-3)"	"prognostic unfavorable (3.95e-6)"	"unprognostic (1.36e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.28e-1)"	"unprognostic (1.57e-1)"	24.9	24.7	16.0	20.0	22.3	14.2	22.2	14.5	20.3	16.2	20.1	20.5	13.3	18.9	21.7	15.9	28.1	19.9	14.3	19.3	16.4	14.9	19.2	33.6	18.3	24.4	21.9	14.6	21.0	30.6	21.6	22.9	23.1	21.0	16.4	26.9	19.5	18.6	16.1	33.2	17.6	19.1	23.5	17.9	21.4	21.9	47.0	21.7	40.8	20.0	19.4	32.8	21.6	17.6	18.7	19.5	9.7	20.9	27.1	21.1	13.3	30.2	14.4	21.3	23.6	15.7	16.2	24.0	19.6	16.7	23.0	24.4	27.3	25.7	40.3	11.7	13.1	30.1	16.0	44.7	30.8	33.6	21.1	26.6	60.8	17.2	17.8	21.5	33.7	16.0	14.3	21.6	27.1	39.9	11.7	21.7	32.6	70.6	25.9	20.7	14.5	35.6	22.6	46.6	44.2	17.0	29.7	39.8	57.0	18.4	16.2	22.7	20.5	27.2	21.4	25.4	20.6	27.2	21.7	15.9	15.6	18.7	13.5	21.0	25.8	35.6	44.0	16.4	39.7	23.1	5.3	15.2	9.7	17.3	20.9	21.1	18.7	16.9	17.9	19.5	14.4	17.7	17.4	7.0	27.1	17.7	14.7	20.6	13.3	16.0	22.3	14.5	20.3	16.4	14.9	21.9	14.6	21.0	21.7	17.9	17.5	28.9	32.0	40.9	17.7	16.9	2.5	14.7	26.1	14.0	33.4	35.3	19.9	22.6	9.1	20.1	11.8	0.0	20.8	29.3	16.6	18.9	7.0	17.1	21.0	4.8	12.6	16.5	18.7	2.2	16.1	16.9	11.8	17.2	15.1	12.9	24.5	10.5	17.0	11.3	25.4	12.9	25.0	50.8	27.2	40.1	21.4	17.5	20.8	38.9
GCGR	GGR	ENSG00000215644	"Glucagon receptor"	P47871	17	81804132-81814013	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Diabetes mellitus, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"liver: 68.8"	"Cell type enriched"	"Detected in some"	7	"Hepatocytes: 60.2"	"Cancer enhanced"	"Detected in many"		"liver cancer: 10.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 3.9;MCF7: 6.1;SK-BR-3: 5.3;U-87 MG: 6.1"	"Region enriched"	"Detected in single"	5	"cerebellum: 0.9"	"Not detected"	"Not detected"			HPA071228			Uncertain	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA071228: AB_2686368"	"unprognostic (3.28e-4)"	"unprognostic (9.30e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.53e-4)"	"unprognostic (1.11e-1)"	"unprognostic (2.30e-3)"	"unprognostic (4.38e-2)"	"unprognostic (1.79e-3)"	"unprognostic (2.18e-1)"	"unprognostic (2.77e-1)"	"unprognostic (3.09e-1)"	"unprognostic (2.61e-1)"	"unprognostic (6.42e-2)"	"unprognostic (5.99e-3)"	"unprognostic (1.71e-1)"	"unprognostic (1.17e-3)"	"unprognostic (8.36e-3)"	0.2	3.9	0.1	0.6	0.3	0.0	0.1	0.1	0.3	0.2	0.2	0.1	0.1	0.2	0.1	0.2	0.2	0.0	0.1	0.1	0.1	0.0	11.4	68.8	0.1	0.1	0.1	0.1	0.1	0.5	3.9	0.1	0.1	0.5	0.2	0.0	1.4	0.3	0.1	0.1	0.9	0.2	0.1	0.1	0.1	0.0	0.2	0.1	0.2	0.2	0.6	0.1	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.0	3.9	0.2	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	1.6	0.0	5.3	0.0	0.0	0.0	0.6	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.3	0.1	0.0	0.1	0.1	0.5	0.1	0.0	0.0	0.0	0.0	0.8	0.2	0.6	0.0	0.0	0.0	3.5	2.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	60.2	0.1	0.0	0.0	1.3	3.7	0.0	0.0	0.0	0.0	0.0	0.0	8.3	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.2	0.4	0.0	0.0	0.0	0.0
GGCX	VKCFD1	ENSG00000115486	"Gamma-glutamyl carboxylase"	P38435	2	85544723-85561547	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"		Lyase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	5	"liver: 74.8"	"Cell type enhanced"	"Detected in all"	6	"Hepatocytes: 132.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA018284	Enhanced					NA	NA					"HPA018284: AB_1849641"	"unprognostic (4.88e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.22e-2)"	"prognostic unfavorable (1.82e-6)"	"unprognostic (5.67e-2)"	"unprognostic (1.85e-3)"	"unprognostic (2.96e-2)"	"unprognostic (3.77e-2)"	"unprognostic (5.64e-2)"	"unprognostic (2.18e-2)"	"unprognostic (6.45e-3)"	"unprognostic (5.23e-2)"	"unprognostic (8.17e-3)"	"unprognostic (7.85e-2)"	"unprognostic (2.59e-1)"	"unprognostic (7.63e-3)"	"unprognostic (9.38e-2)"	7.1	7.8	4.8	4.2	6.3	1.6	10.8	6.3	6.6	6.4	4.9	5.4	8.3	4.0	6.3	8.1	6.5	5.9	7.0	6.8	5.4	3.6	9.0	74.8	8.1	5.4	5.4	5.0	7.0	11.4	15.1	5.6	13.8	5.9	6.3	5.5	5.8	7.4	7.9	6.8	4.9	5.5	7.2	5.1	4.5	6.0	3.6	5.7	3.4	8.5	5.3	5.4	7.3	6.0	0.9	4.9	6.0	7.2	2.2	3.2	3.2	6.8	11.2	8.0	8.9	40.4	11.5	17.8	12.3	14.6	9.1	13.0	19.3	8.5	2.5	12.6	20.2	11.4	11.3	5.7	15.5	10.1	4.4	7.8	4.5	7.5	18.2	15.0	2.8	4.2	14.3	9.2	18.5	12.6	15.1	12.9	4.4	5.3	3.6	26.4	9.0	1.4	2.1	3.7	19.4	9.7	2.6	18.8	6.2	12.7	13.3	3.0	5.1	11.0	21.9	11.4	14.2	10.7	2.7	11.8	11.7	10.3	11.4	8.4	2.9	7.9	2.1	11.3	2.9	16.4	6.0	7.2	3.6	3.2	7.2	3.0	0.7	1.3	1.2	4.9	0.9	3.2	3.0	3.2	2.2	4.4	4.0	1.9	3.2	4.8	6.3	6.3	6.6	5.4	3.6	5.4	5.0	5.9	5.7	26.8	38.9	20.9	16.3	16.7	19.1	20.2	35.7	14.7	17.0	27.9	15.7	51.8	6.6	24.1	3.2	18.0	14.4	23.3	34.3	40.8	26.7	15.3	15.1	132.3	27.6	7.9	13.8	24.5	21.6	1.3	18.7	22.6	20.3	28.9	15.2	19.0	23.2	12.4	19.1	21.4	28.4	6.5	16.5	16.9	8.1	13.2	45.0	14.9	15.8	18.8
GGPS1	GGPPS1	ENSG00000152904	"Geranylgeranyl diphosphate synthase 1"	O95749	1	235327350-235344532	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Isoprene biosynthesis"	Transferase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Early spermatids: 164.1;Late spermatids: 214.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029472	Enhanced					NA	NA					"HPA029472: AB_10696206"	"unprognostic (7.45e-2)"	"unprognostic (3.18e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.10e-3)"	"prognostic unfavorable (6.69e-4)"	"unprognostic (4.50e-2)"	"unprognostic (3.66e-2)"	"unprognostic (3.77e-3)"	"unprognostic (2.66e-2)"	"unprognostic (8.77e-3)"	"unprognostic (1.95e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.35e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.70e-2)"	24.5	24.8	26.8	16.2	25.7	6.8	33.4	30.1	28.7	24.9	23.1	19.9	21.8	19.8	22.8	30.3	24.1	20.9	19.2	21.8	25.4	25.8	26.4	20.0	18.9	18.3	24.4	22.0	23.5	16.0	19.0	29.3	24.2	25.8	29.0	23.2	15.9	27.8	21.9	26.8	19.0	20.6	24.9	28.3	20.4	20.1	42.5	25.6	22.6	27.9	21.2	20.0	26.9	17.9	28.5	22.2	33.9	35.9	22.1	31.3	26.0	16.6	9.0	22.7	17.0	17.7	25.6	8.9	14.9	20.8	9.8	13.9	7.0	26.6	11.3	21.6	16.3	16.0	13.6	12.0	15.3	13.1	11.5	22.4	9.6	8.6	11.8	20.0	11.8	8.2	16.6	27.6	13.3	18.0	17.4	17.4	19.1	22.9	10.2	12.9	9.8	14.6	14.1	19.4	44.2	4.7	9.0	7.1	12.8	27.4	9.0	18.2	25.2	11.1	25.6	21.3	8.7	31.9	18.8	14.7	11.8	8.9	19.9	13.9	17.8	21.5	13.8	14.9	13.3	21.1	26.6	22.8	33.9	24.8	26.8	24.9	28.5	31.3	26.4	22.2	23.4	29.2	26.5	20.6	22.1	35.9	18.4	30.0	26.0	26.8	25.7	30.1	28.7	25.4	25.8	24.4	22.0	25.8	25.6	29.8	37.5	16.7	58.0	35.4	29.3	20.4	20.4	17.4	15.9	19.2	41.2	26.1	61.3	31.7	164.1	29.1	23.6	0.0	25.0	30.3	35.7	57.0	23.2	12.4	23.9	46.1	16.7	28.3	22.2	214.2	33.1	33.8	64.1	33.3	21.8	38.1	25.9	24.1	32.9	45.5	48.9	25.8	42.4	62.3	46.6	35.5	39.4	32.6	20.4	46.7
GHR	GHBP	ENSG00000112964	"Growth hormone receptor"	P10912	5	42423777-42721878	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	Endocytosis	Receptor	"Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adipose tissue: 44.4;breast: 31.5;liver: 82.4;skeletal muscle: 23.4"	"Cell type enhanced"	"Detected in many"	19	"Hepatocytes: 103.6;Syncytiotrophoblasts: 33.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"HSkMC: 13.6;T-47d: 34.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA045339, HPA057705"	Enhanced		Supported	"Plasma membrane,Cytosol,Cytoplasmic bodies"	"Secreted to blood"	NA	NA	2200000	21000000	"Plasma membrane, Cytosol, Cytoplasmic bodies"		"HPA045339: AB_2679294, HPA057705: AB_2683507"	"unprognostic (2.18e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.96e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.57e-1)"	"prognostic favorable (2.73e-6)"	"unprognostic (1.06e-1)"	"unprognostic (3.92e-2)"	"unprognostic (3.73e-2)"	"unprognostic (6.15e-3)"	"unprognostic (2.67e-2)"	"unprognostic (1.67e-3)"	"unprognostic (4.29e-4)"	"unprognostic (7.82e-2)"	"unprognostic (7.33e-4)"	"unprognostic (8.35e-6)"	44.4	2.8	0.7	5.4	1.3	0.3	31.5	0.4	1.4	4.0	6.9	0.5	1.7	0.6	5.7	3.9	2.4	2.5	3.9	6.0	1.3	1.6	5.3	82.4	2.3	2.2	1.2	1.4	5.0	1.3	3.6	2.0	4.0	2.0	8.7	2.5	2.4	2.3	7.4	23.4	3.0	2.4	5.2	1.0	2.6	3.5	1.6	0.2	0.1	2.9	4.3	0.5	3.8	8.4	0.6	0.3	1.8	0.5	0.4	0.3	0.1	0.0	0.0	0.3	3.1	2.1	0.5	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.1	2.6	0.0	0.0	1.6	0.0	0.0	0.0	0.4	0.0	0.0	13.6	4.4	0.0	0.6	0.1	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.2	0.0	0.5	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.1	0.0	2.1	0.4	34.7	0.0	1.8	3.0	1.3	1.6	0.3	0.3	0.0	0.0	0.3	0.0	1.6	1.8	0.3	0.4	0.2	0.2	0.1	0.3	0.2	0.1	0.1	0.6	0.2	0.3	1.7	0.4	0.5	0.3	0.2	0.1	0.7	1.3	0.4	1.4	1.3	1.6	1.2	1.4	2.0	0.2	0.0	0.3	0.0	2.8	4.1	0.6	13.6	2.5	0.0	0.0	1.8	0.0	8.6	1.7	0.0	3.3	2.9	0.0	0.0	0.2	0.9	9.3	3.5	0.0	103.6	1.6	0.0	2.9	4.9	1.9	1.8	17.3	0.3	1.7	0.0	2.0	0.8	0.2	0.0	11.3	8.8	0.2	12.9	4.4	0.0	0.3	3.1	33.6	0.0	1.5	0.9
GHRHR		ENSG00000106128	"Growth hormone releasing hormone receptor"	Q02643	7	30938669-30993254	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	36	"pituitary gland: 108.9"	"Cell type enhanced"	"Detected in single"	31	"Spermatogonia: 2.4"	"Cancer enhanced"	"Detected in single"		"liver cancer: 0.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"SCLC-21H: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Intracellular and membrane"	NA	NA						"unprognostic (8.32e-2)"		"unprognostic (1.45e-1)"	"unprognostic (9.30e-2)"	"unprognostic (1.39e-1)"		"unprognostic (7.23e-2)"	"unprognostic (4.15e-1)"		"unprognostic (2.28e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.43e-2)"	"unprognostic (1.47e-1)"	"unprognostic (5.87e-3)"		0.4	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.0	0.0	0.0	0.0	1.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	108.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	2.4	0.0	0.0	0.0	0.0	0.0
GLP1R	GLP-1R	ENSG00000112164	"Glucagon like peptide 1 receptor"	P43220	6	39048798-39087743	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"pancreas: 19.0"	"Cell type enhanced"	"Detected in single"	37	"Cardiomyocytes: 2.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 1.6;HAP1: 1.3;HMC-1: 1.5;NTERA-2: 3.3;SCLC-21H: 8.1;SH-SY5Y: 1.8"	"Group enriched"	"Detected in some"	5	"basal ganglia: 16.1;hypothalamus: 4.8"	"Low region specificity"	"Detected in some"									NA	NA						"unprognostic (4.06e-3)"			"unprognostic (5.38e-6)"	"unprognostic (1.80e-2)"	"unprognostic (4.16e-2)"	"unprognostic (4.98e-2)"	"unprognostic (3.55e-1)"	"unprognostic (2.11e-1)"	"unprognostic (1.38e-1)"	"unprognostic (9.76e-2)"	"unprognostic (3.29e-1)"	"unprognostic (1.73e-1)"	"unprognostic (8.60e-3)"	"unprognostic (2.47e-1)"	"unprognostic (1.15e-2)"	"unprognostic (1.42e-2)"	0.2	0.1	0.1	0.0	1.8	0.0	0.9	0.1	2.2	0.1	0.1	0.8	0.0	2.4	0.1	0.6	0.1	0.0	3.5	4.8	1.4	1.4	0.1	0.0	0.5	1.0	0.1	2.3	0.0	19.0	0.0	0.1	0.0	2.0	0.1	0.0	0.0	4.1	0.0	0.4	0.3	0.1	0.0	1.4	0.1	1.8	0.4	0.0	0.4	0.8	0.4	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.4	3.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	8.1	1.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	1.8	0.1	0.7	1.4	1.4	0.1	2.3	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GLP2R		ENSG00000065325	"Glucagon like peptide 2 receptor"	O95838	17	9822206-9892102	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"gallbladder: 32.7"	"Cell type enriched"	"Detected in some"	6	"Rod photoreceptor cells: 24.5"	"Cancer enhanced"	"Detected in single"		"pancreatic cancer: 1.1"	"Group enriched"	"Detected in some"	4	"basal ganglia: 2.9;cerebral cortex: 4.1;olfactory region: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	5	"HeLa: 42.8"	"Group enriched"	"Detected in some"	6	"cerebral cortex: 2.1;hippocampal formation: 2.6"	"Low region specificity"	"Detected in some"			"CAB022690, HPA049244"	Supported		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB022690: , HPA049244: AB_2680690"	"unprognostic (2.14e-1)"	"unprognostic (2.45e-3)"	"unprognostic (2.66e-3)"	"unprognostic (2.21e-2)"	"unprognostic (3.81e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.39e-2)"	"unprognostic (5.15e-2)"	"unprognostic (7.63e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.19e-1)"	"unprognostic (6.16e-3)"	"unprognostic (3.40e-8)"	"unprognostic (9.53e-5)"	"unprognostic (5.51e-2)"	"unprognostic (3.92e-1)"	"unprognostic (6.48e-3)"	7.9	0.7	0.6	2.0	2.9	0.0	2.6	0.3	4.3	6.6	14.5	0.0	1.7	12.4	1.9	0.4	5.3	1.4	32.7	0.9	0.6	0.5	0.4	3.2	1.4	0.7	0.6	1.6	0.8	2.1	0.0	0.3	1.5	0.5	8.4	7.5	0.8	0.4	0.2	0.3	0.3	15.4	15.6	0.6	0.3	4.9	1.1	0.2	0.0	0.5	0.1	0.4	13.5	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.7	0.0	0.0	0.4	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	42.8	0.3	0.5	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	2.9	0.3	4.1	0.6	0.5	0.6	1.6	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.4	0.0	24.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GLRA1	STHE	ENSG00000145888	"Glycine receptor alpha 1"	P23415	5	151822513-151924842	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	10	"brain: 31.7"	"Cell type enhanced"	"Detected in some"	26	"Basal glandular cells: 1.1;Bipolar cells: 4.9;Horizontal cells: 1.6"	"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	10	"pons and medulla: 31.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HeLa: 1.4"	"Group enriched"	"Detected in many"	4	"hypothalamus: 11.0;midbrain: 18.1;pons and medulla: 27.6"	"Region enhanced"	"Detected in all"		"pons and medulla: 54.9"	CAB079042		Supported				NA	NA					"CAB079042: "					"unprognostic (3.17e-1)"						"unprognostic (2.47e-1)"		"unprognostic (3.85e-7)"	"unprognostic (8.24e-2)"		"unprognostic (9.45e-3)"		0.3	3.2	1.2	0.1	0.7	0.2	0.1	3.2	0.9	0.1	0.2	0.0	0.0	0.5	0.1	0.1	0.1	0.1	0.1	0.3	0.1	2.7	0.2	0.1	0.1	0.1	2.7	0.0	0.1	2.2	0.1	0.1	0.2	31.7	0.1	0.1	1.6	0.1	0.1	0.6	0.1	0.1	0.1	12.6	0.1	0.1	0.2	0.0	0.0	0.2	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	1.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.7	3.2	0.9	0.1	2.7	2.7	0.0	31.7	0.0	0.0	0.0	0.0	1.1	0.1	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.6
GLRA2	GLR	ENSG00000101958	"Glycine receptor alpha 2"	P23416	X	14529298-14731812	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	14	"brain: 21.0;intestine: 11.1"	"Cell type enhanced"	"Detected in some"	16	"Cardiomyocytes: 1.2;Horizontal cells: 1.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	33	"AN3-CA: 20.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB070422	Approved					NA	NA					"CAB070422: AB_11153055"	"unprognostic (2.52e-1)"	"unprognostic (3.13e-1)"	"unprognostic (5.52e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.74e-2)"			"unprognostic (1.81e-2)"	"unprognostic (3.39e-1)"	"unprognostic (5.82e-2)"	"unprognostic (7.95e-3)"		"unprognostic (1.13e-1)"	"unprognostic (2.76e-1)"	"unprognostic (6.69e-2)"			0.4	0.5	14.5	0.7	13.2	0.7	0.5	21.0	10.8	0.4	4.1	0.1	0.0	0.7	0.5	0.5	0.4	0.8	0.7	0.4	3.6	13.9	0.5	0.5	0.4	0.5	1.6	8.4	0.9	0.5	0.4	0.5	0.8	10.1	0.4	11.1	1.1	0.8	0.5	0.5	0.8	0.9	0.7	6.5	0.5	0.5	0.9	0.8	0.0	0.5	0.0	0.4	0.4	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	20.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.5	13.2	21.0	10.4	3.6	13.9	1.6	8.4	10.1	0.8	0.0	0.0	0.0	0.0	0.1	0.2	1.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.4	0.0
GLRA3		ENSG00000145451	"Glycine receptor alpha 3"	O75311	4	174636914-174829314	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	4	"brain: 15.2;breast: 6.1;pituitary gland: 12.5"	"Group enriched"	"Detected in some"	9	"Early spermatids: 18.4;Late spermatids: 13.2"	"Cancer enhanced"	"Detected in single"		"breast cancer: 1.2"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 2.7"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"HEL: 2.7;Karpas-707: 6.3;U-698: 2.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (2.75e-3)"	"unprognostic (3.14e-1)"	"unprognostic (1.78e-2)"		"unprognostic (1.36e-1)"	"unprognostic (9.02e-2)"		"unprognostic (3.82e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.12e-2)"	"unprognostic (4.26e-2)"	"unprognostic (1.64e-5)"	"unprognostic (4.61e-4)"	"unprognostic (2.24e-1)"		"unprognostic (1.15e-2)"	0.5	2.6	13.3	0.6	7.3	0.6	6.1	0.7	15.2	0.5	0.5	0.3	0.0	0.5	0.7	0.5	0.5	0.4	0.6	0.4	2.7	7.4	0.5	0.4	0.5	0.9	4.6	8.7	0.4	1.4	0.5	12.5	0.5	4.4	0.5	0.5	0.0	0.5	0.5	0.4	0.7	0.5	0.8	2.1	0.6	0.5	1.7	0.0	0.0	0.5	0.0	0.9	0.4	0.2	2.7	0.1	1.1	0.0	0.3	0.5	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	2.7	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.6	0.0	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.1	0.0	0.6	0.0	0.7	0.6	0.0	0.1	0.0	0.1	0.1	0.0	0.2	0.0	2.3	0.1	0.1	0.1	0.6	0.0	0.4	0.1	0.0	0.5	2.7	0.2	0.1	0.0	0.5	0.2	0.2	1.1	0.3	0.0	0.1	0.1	0.0	13.3	7.3	0.7	14.5	2.7	7.4	4.6	8.7	4.4	0.0	0.0	1.1	0.0	1.0	0.0	0.7	1.7	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	18.4	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.1	0.0	0.0	0.0	0.0	0.0	0.0	13.2	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.6	0.0	0.4	0.2	1.5	0.1	0.0	0.0	0.0	0.3
GLRB		ENSG00000109738	"Glycine receptor beta"	P48167	4	157076057-157172090	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Chloride channel, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 43.1;parathyroid gland: 37.0"	"Cell type enhanced"	"Detected in many"	7	"Cardiomyocytes: 12.6;Cholangiocytes: 7.6;Ciliated cells: 8.1;Muller glia cells: 11.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	18	"plasmacytoid DC: 1.7"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 1.7"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 17.5;hTERT-RPE1: 23.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA052363	Approved					NA	NA					"HPA052363: AB_2681800"	"unprognostic (7.36e-2)"	"unprognostic (6.53e-2)"	"unprognostic (1.44e-1)"	"unprognostic (2.59e-3)"	"unprognostic (5.65e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.47e-2)"	"unprognostic (1.52e-1)"	"unprognostic (1.19e-2)"	"unprognostic (2.99e-2)"	"unprognostic (6.81e-2)"	"unprognostic (1.48e-1)"	"prognostic favorable (4.89e-4)"	"unprognostic (4.32e-3)"	"unprognostic (1.85e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.66e-2)"	4.5	7.2	12.6	1.5	20.9	0.7	10.3	15.9	43.1	9.4	2.3	2.8	0.1	1.1	3.3	5.4	1.5	7.4	3.5	9.9	18.3	17.3	4.1	1.6	3.4	0.8	11.1	21.3	1.8	14.2	37.0	6.7	2.9	16.5	6.5	1.4	0.7	16.7	5.2	3.3	1.5	1.2	4.0	6.1	0.6	2.2	1.9	4.5	0.0	1.5	0.5	0.7	1.9	1.4	0.0	1.7	0.0	0.0	0.0	0.0	0.0	4.8	2.0	5.8	17.5	11.3	4.6	0.0	9.6	6.2	4.7	8.9	0.0	14.8	0.0	2.3	9.7	5.8	0.0	4.4	1.5	8.9	0.0	5.8	2.9	2.2	0.2	5.2	3.7	0.0	4.1	1.3	8.2	1.2	23.3	4.2	3.1	0.0	0.0	8.5	0.0	0.4	0.0	0.3	0.0	1.3	0.0	7.9	0.0	12.7	0.8	6.3	3.8	0.0	4.5	0.7	0.9	4.1	0.9	6.2	2.8	8.3	4.7	9.3	0.0	0.0	0.0	6.7	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	12.6	20.9	15.9	43.1	18.3	17.3	11.1	21.3	16.5	4.5	0.0	0.6	0.0	0.7	1.0	6.9	12.6	7.6	8.1	3.4	0.0	2.0	0.3	0.0	6.9	0.2	1.0	0.0	0.0	1.5	0.0	2.6	0.6	1.1	0.0	0.1	1.6	0.0	1.8	0.0	0.0	0.3	0.0	3.3	1.0	0.0	11.6	1.9	0.0	3.2	0.4	1.6	0.0	1.1	1.1	3.0	0.3	0.1	0.0	0.0	0.1
GNRHR	"GRHR, LHRHR"	ENSG00000109163	"Gonadotropin releasing hormone receptor"	P30968	4	67739328-67754360	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets, Hypogonadotropic hypogonadism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	14	"pituitary gland: 56.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"K-562: 3.0"	"Not detected"	"Not detected"							HPA013424	Enhanced					NA	NA					"HPA013424: AB_2668840"	"unprognostic (2.77e-1)"	"unprognostic (1.58e-1)"	"unprognostic (4.05e-1)"	"unprognostic (1.78e-1)"	"unprognostic (4.65e-1)"	"unprognostic (8.75e-3)"	"unprognostic (3.09e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.01e-1)"	"unprognostic (6.84e-2)"	"unprognostic (1.63e-1)"	"unprognostic (9.03e-2)"	"unprognostic (3.23e-2)"	"unprognostic (9.67e-2)"	"unprognostic (1.22e-3)"	"unprognostic (3.99e-2)"	0.1	3.9	0.1	0.4	0.2	0.2	0.1	0.3	1.7	0.3	0.1	0.1	0.1	0.7	0.1	0.1	1.6	0.0	0.2	0.2	0.2	0.2	0.1	0.1	0.1	1.1	0.1	0.1	0.2	0.3	0.0	56.6	0.1	0.5	0.2	0.0	0.1	0.3	0.1	0.2	0.9	0.1	0.1	0.1	0.2	0.3	0.3	0.1	0.2	1.0	0.1	0.4	0.1	0.5	1.3	0.2	0.0	0.0	0.4	0.3	0.0	0.2	1.5	1.5	1.6	0.0	0.0	0.6	0.3	0.0	0.0	0.0	0.5	1.7	1.3	0.2	0.0	0.6	0.5	0.0	0.0	0.0	0.3	0.5	0.3	0.3	0.7	0.0	1.1	0.4	0.0	0.0	0.0	0.0	0.7	0.0	1.2	3.0	0.0	0.0	0.8	0.6	0.4	1.0	0.5	0.0	0.6	1.3	0.6	0.0	0.0	0.9	2.1	0.0	0.3	0.0	0.3	0.3	0.2	1.0	0.1	0.2	0.6	0.2	1.2	0.3	0.6	1.4	0.8	0.9	0.0	0.0	0.0	0.2	0.0	0.2	0.5	0.1	0.0	0.0	1.3	0.1	0.3	0.0	0.4	0.0	0.2	0.0	0.0	0.1	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GRIA1	"GluA1, GLUR1, GLURA"	ENSG00000155511	"Glutamate ionotropic receptor AMPA type subunit 1"	P42261	5	153489615-153813869	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 52.6"	"Group enriched"	"Detected in some"	7	"Bipolar cells: 34.6;Muller glia cells: 48.7"	"Cancer enriched"	"Detected in some"	15	"glioma: 9.9"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 13.7;ASC diff: 4.2;BJ: 6.5;BJ hTERT+: 3.4;LHCN-M2: 9.7;U-266/70: 6.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA035202	Enhanced					NA	NA					"HPA035202: AB_2674516"	"unprognostic (2.51e-1)"	"unprognostic (4.76e-3)"	"unprognostic (1.97e-1)"	"unprognostic (4.20e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.61e-1)"	"unprognostic (1.18e-2)"	"unprognostic (2.04e-1)"	"unprognostic (2.35e-2)"	"unprognostic (5.14e-4)"	"unprognostic (7.97e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.70e-1)"	"unprognostic (2.80e-1)"	"unprognostic (7.61e-2)"	1.8	1.6	44.9	1.2	23.1	1.0	1.5	23.6	52.6	1.4	1.2	3.7	0.0	1.3	1.2	2.0	1.2	1.2	1.1	2.0	50.4	13.4	1.1	1.1	9.5	1.0	4.8	20.0	1.3	1.4	1.2	0.5	1.1	4.6	1.1	1.2	0.7	1.1	1.7	1.1	1.1	1.3	2.3	2.3	1.1	1.2	2.1	5.2	0.0	1.1	0.0	1.1	1.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.7	0.0	4.2	2.9	0.0	6.5	3.4	0.4	0.1	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	9.7	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	44.9	23.1	23.6	24.3	50.4	13.4	4.8	20.0	4.6	5.2	0.0	0.0	0.0	0.0	0.0	34.6	0.8	0.0	0.0	0.0	0.0	5.9	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	48.7	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
GRIK1	"GluK1, GLUR5"	ENSG00000171189	"Glutamate ionotropic receptor kainate type subunit 1"	P39086	21	29536933-29940033	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 23.7;brain: 44.2;retina: 12.0"	"Cell type enhanced"	"Detected in some"	12	"Bipolar cells: 6.8;Early spermatids: 4.6;Late spermatids: 7.9;Melanocytes: 3.3;Rod photoreceptor cells: 4.8"	"Group enriched"	"Detected in some"	7	"glioma: 4.5;prostate cancer: 0.9"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Daudi: 4.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA014623	Uncertain					NA	NA					"HPA014623: AB_1850305"	"unprognostic (1.39e-1)"	"unprognostic (6.54e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.03e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.12e-3)"	"unprognostic (1.25e-1)"	"unprognostic (8.77e-2)"	"unprognostic (4.89e-3)"	"unprognostic (1.20e-3)"	"unprognostic (1.47e-8)"	"unprognostic (2.09e-1)"	"unprognostic (2.68e-1)"	"unprognostic (1.09e-1)"	"unprognostic (3.15e-3)"	0.8	23.7	9.8	0.9	10.2	0.7	4.1	6.6	18.3	1.2	1.2	2.9	0.0	0.7	0.7	4.3	1.2	0.7	0.8	0.6	10.0	13.4	0.6	0.8	0.8	0.9	7.1	7.6	1.1	0.6	0.6	0.3	1.3	44.2	5.3	1.5	12.0	0.7	0.8	0.8	2.1	1.3	0.8	2.6	0.8	0.7	1.4	2.7	0.0	0.7	0.0	0.6	1.0	0.6	0.4	0.3	1.6	1.1	0.2	0.4	0.0	0.2	0.5	0.8	0.3	0.0	0.0	0.4	0.5	0.0	0.0	0.0	0.2	0.7	4.4	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.8	0.4	1.3	1.0	0.2	0.0	1.0	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.9	1.8	0.0	0.0	0.4	1.0	1.1	0.1	0.3	0.2	1.2	0.3	0.0	0.4	0.1	0.3	0.1	1.0	0.1	0.6	0.5	1.0	0.4	0.6	1.0	0.2	0.2	0.5	0.9	0.2	0.8	0.8	1.8	0.0	1.1	0.6	0.1	0.8	0.0	0.2	0.1	0.0	0.3	0.4	0.3	0.1	1.6	0.2	0.5	0.1	0.4	0.0	9.8	10.2	6.6	18.3	10.0	13.4	7.1	7.6	44.2	2.7	0.0	0.0	0.0	0.0	0.2	6.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	1.6	0.0	0.0	0.0	7.9	0.3	0.0	3.3	0.0	0.0	2.3	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
GRIN1	"GluN1, NMDAR1"	ENSG00000176884	"Glutamate ionotropic receptor NMDA type subunit 1"	Q05586	9	137138390-137168762	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	38	"brain: 97.5"	"Cell type enhanced"	"Detected in some"	10	"Bipolar cells: 5.6;Cardiomyocytes: 2.4;monocytes: 3.6;Rod photoreceptor cells: 5.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"OE19: 2.6;REH: 3.1;RPMI-8226: 4.3;SCLC-21H: 10.0;SH-SY5Y: 6.9;T-47d: 2.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA067773	Enhanced					NA	NA					"HPA067773: "	"unprognostic (3.58e-2)"	"unprognostic (4.51e-1)"	"unprognostic (2.68e-2)"	"unprognostic (5.48e-4)"	"unprognostic (5.20e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.34e-2)"	"unprognostic (2.81e-2)"	"unprognostic (6.46e-3)"	"unprognostic (1.51e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.21e-3)"	"unprognostic (4.47e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.56e-3)"	"unprognostic (4.72e-2)"	1.7	2.0	23.6	2.0	47.5	1.7	1.8	28.1	97.5	1.8	2.0	3.2	0.0	2.2	1.7	1.8	1.7	1.7	1.7	1.7	29.1	26.4	1.8	1.7	1.8	1.8	15.4	37.9	1.7	1.8	1.8	0.0	1.7	22.0	2.2	1.8	0.7	2.5	1.8	1.7	1.8	2.2	1.8	4.7	1.8	1.8	1.9	6.3	0.0	1.7	0.0	1.8	1.8	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.7	0.0	0.1	0.0	0.0	0.4	1.0	0.0	0.1	0.0	0.0	1.2	0.0	0.0	0.0	1.5	0.1	0.0	0.2	0.2	0.0	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.9	0.0	0.0	0.1	2.6	0.0	3.1	0.0	4.3	0.0	0.0	10.0	6.9	0.1	0.6	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	23.6	47.5	28.1	87.9	29.1	26.4	15.4	37.9	22.0	6.3	0.0	0.0	0.0	0.4	0.0	5.6	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.1	1.6	1.7	0.0	0.0	0.4	0.0	0.0	0.0	3.6	1.7	1.6	0.3	0.0	0.0	0.0	5.7	0.0	0.0	0.2	1.3	0.0	0.0	0.0	0.0	0.3
GRIN2A	"GluN2A, NMDAR2A"	ENSG00000183454	"Glutamate ionotropic receptor NMDA type subunit 2A"	Q12879	16	9753404-10182754	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"brain: 25.2"	"Cell type enhanced"	"Detected in some"	9	"Cardiomyocytes: 14.9;Early spermatids: 13.4;Late spermatids: 13.0;Muller glia cells: 17.7;Rod photoreceptor cells: 12.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"fHDF/TERT166: 7.8;hTERT-RPE1: 3.4;RPMI-8226: 2.9;U-138 MG: 8.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB022725	Enhanced					NA	NA					"CAB022725: "	"unprognostic (6.43e-2)"	"unprognostic (2.47e-1)"	"unprognostic (5.97e-2)"	"unprognostic (3.21e-2)"	"unprognostic (3.13e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.10e-1)"	"unprognostic (2.08e-1)"	"unprognostic (5.39e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.69e-1)"	"unprognostic (3.75e-3)"	"unprognostic (4.79e-3)"	"unprognostic (2.05e-1)"	"unprognostic (3.92e-3)"	"unprognostic (3.33e-2)"	0.9	1.0	5.4	0.5	5.9	0.4	0.6	8.5	25.2	0.6	0.7	1.5	0.0	0.9	0.8	4.5	2.1	4.1	0.5	4.0	8.0	1.9	0.9	0.4	1.0	0.5	1.7	10.3	0.5	0.6	0.4	0.3	0.4	1.4	0.5	0.7	1.4	0.7	1.0	0.5	1.2	0.7	0.9	1.2	0.4	1.1	5.2	0.8	0.0	0.8	0.0	0.7	0.6	0.5	0.6	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	1.9	0.6	1.4	0.0	0.1	0.0	0.0	7.8	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.3	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	8.5	0.8	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	5.4	5.9	8.5	17.9	8.0	1.9	1.7	10.3	1.4	0.8	0.0	0.0	0.0	1.9	1.6	3.6	14.9	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.6	13.4	0.1	0.0	0.0	0.2	0.0	0.2	0.4	0.0	0.0	0.1	1.6	0.0	0.0	0.0	13.0	0.9	0.0	0.0	0.0	0.0	17.7	1.2	0.0	0.0	0.0	12.1	0.0	4.2	3.2	3.8	0.4	0.0	0.0	0.0	0.3
GRIN2B	"GluN2B, NMDAR2B"	ENSG00000273079	"Glutamate ionotropic receptor NMDA type subunit 2B"	Q13224	12	13437942-13981957	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	19	"brain: 36.5"	"Group enriched"	"Detected in some"	10	"Early spermatids: 36.4;Late spermatids: 25.3"	"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"amygdala: 19.5;basal ganglia: 26.0;cerebral cortex: 36.5;hippocampal formation: 19.6;olfactory region: 15.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 1.4;AF22: 3.4;CACO-2: 3.9;Daudi: 1.6;NTERA-2: 4.9;RPTEC TERT1: 4.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA069762	Approved					NA	NA					"HPA069762: AB_2686192"	"unprognostic (2.01e-2)"	"unprognostic (4.07e-2)"	"unprognostic (7.89e-2)"	"unprognostic (3.77e-3)"	"unprognostic (3.39e-3)"	"unprognostic (9.36e-2)"	"unprognostic (5.92e-2)"	"unprognostic (1.77e-2)"	"unprognostic (6.85e-2)"	"unprognostic (2.24e-1)"	"unprognostic (4.68e-2)"	"unprognostic (4.12e-2)"	"unprognostic (4.48e-5)"	"unprognostic (2.43e-1)"	"unprognostic (8.76e-2)"	"unprognostic (1.63e-1)"	"unprognostic (2.37e-1)"	1.9	0.9	19.5	0.8	26.0	0.8	0.9	0.9	36.5	0.8	1.9	1.9	0.0	0.8	0.8	0.8	0.9	0.8	0.8	0.8	19.6	3.5	1.0	1.6	0.8	1.4	1.8	15.0	0.9	0.8	0.8	0.4	0.9	2.6	0.8	1.2	0.0	0.8	0.8	0.8	0.8	1.8	0.8	0.8	0.9	1.0	1.5	3.6	0.0	0.8	0.0	1.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.5	26.0	0.9	36.5	19.6	3.5	1.8	15.0	2.6	3.6	0.0	0.0	0.0	0.0	0.0	0.8	3.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	36.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	25.3	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.4	0.0	1.6	0.0	0.0	0.9	0.9	0.0	0.0	0.0	0.4	0.0
GRIN2C	"GluN2C, NMDAR2C"	ENSG00000161509	"Glutamate ionotropic receptor NMDA type subunit 2C"	Q14957	17	74842023-74861504	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"brain: 43.6;heart muscle: 13.2;salivary gland: 14.2;thyroid gland: 12.4"	"Cell type enhanced"	"Detected in some"	13	"Cardiomyocytes: 15.9;Hofbauer cells: 9.4;Muller glia cells: 18.3"	"Cancer enhanced"	"Detected in some"		"thyroid cancer: 2.3"	"Region enriched"	"Detected in many"	5	"cerebellum: 43.6"	"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BEWO: 11.3;RPMI-8226: 4.0;SCLC-21H: 5.2"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in some"	13	"cerebellum: 65.6"							NA	NA						"unprognostic (7.21e-3)"	"unprognostic (4.68e-2)"	"unprognostic (9.38e-3)"	"unprognostic (2.24e-5)"	"unprognostic (3.42e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.84e-1)"	"unprognostic (1.82e-2)"	"unprognostic (1.78e-1)"	"unprognostic (2.95e-2)"	"unprognostic (3.31e-3)"	"unprognostic (3.25e-1)"	"unprognostic (1.14e-3)"	"unprognostic (4.20e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.51e-2)"	"unprognostic (1.14e-1)"	1.0	1.4	7.8	0.5	9.1	1.0	0.5	43.6	8.9	0.5	0.5	2.4	0.0	0.5	0.5	0.5	0.4	0.6	0.6	13.2	4.5	1.4	0.3	0.2	0.3	0.3	3.2	4.5	0.4	0.2	0.5	0.0	2.7	4.2	0.3	0.4	0.3	14.2	0.5	0.6	0.4	0.6	0.5	1.0	0.4	0.3	2.7	0.9	0.0	12.4	0.0	0.3	0.4	0.0	0.2	1.3	0.3	0.1	0.2	0.7	0.0	0.0	0.4	0.4	0.1	0.1	0.0	11.3	0.0	0.0	0.0	0.0	1.4	0.2	0.5	0.1	0.0	0.1	0.4	0.1	0.0	0.0	1.0	0.3	0.2	0.3	0.3	0.0	0.8	0.9	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.4	0.3	0.0	1.7	0.1	0.1	0.1	0.1	0.1	0.3	0.9	4.0	0.0	0.3	5.2	0.4	2.2	0.2	0.8	0.8	0.7	0.1	0.2	0.4	2.0	0.5	0.2	1.1	0.1	0.2	0.5	0.7	0.2	0.1	0.1	0.3	0.7	0.1	0.1	0.0	0.1	0.3	0.1	0.2	0.3	0.2	0.3	0.2	0.0	1.3	0.2	0.0	7.8	9.1	43.6	6.3	4.5	1.4	3.2	4.5	4.2	0.9	0.0	0.0	0.0	0.0	0.1	2.5	15.9	2.5	0.0	0.0	1.8	0.0	0.2	0.0	0.0	0.8	0.3	0.0	0.0	0.2	0.1	0.0	0.2	0.0	0.0	9.4	1.6	0.0	1.3	0.3	4.3	0.0	0.0	1.7	0.0	0.0	18.3	0.0	0.0	0.4	0.0	2.4	0.0	1.0	3.0	2.5	0.0	0.6	0.0	0.0	0.0
GRIN2D	"EB11, GluN2D, NMDAR2D, NR2D"	ENSG00000105464	"Glutamate ionotropic receptor NMDA type subunit 2D"	O15399	19	48394875-48444931	"Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 6.9"	"Cell type enhanced"	"Detected in some"	8	"Cardiomyocytes: 2.8;Extravillous trophoblasts: 3.1;Ito cells: 3.1"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in single"		"classical monocyte: 1.2"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A549: 12.9;EFO-21: 8.9;HMC-1: 22.0;NB-4: 12.9;SK-BR-3: 11.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009006	Approved					NA	NA					"CAB009006: AB_2279191"	"unprognostic (9.96e-2)"	"unprognostic (6.98e-2)"	"unprognostic (1.17e-1)"	"unprognostic (5.08e-3)"	"unprognostic (1.46e-1)"	"unprognostic (4.17e-1)"	"unprognostic (1.43e-4)"	"unprognostic (7.84e-2)"	"unprognostic (2.72e-1)"	"unprognostic (2.23e-3)"	"unprognostic (1.57e-1)"	"unprognostic (1.80e-1)"	"unprognostic (6.66e-13)"	"unprognostic (2.15e-2)"	"unprognostic (1.92e-2)"	"unprognostic (1.26e-3)"	"unprognostic (1.14e-1)"	0.5	0.1	4.1	1.1	1.7	0.1	0.1	2.0	5.0	0.1	0.6			1.8	0.0	0.1	0.0	0.2	1.1	0.3	2.4	6.9	0.0	0.0	0.4	0.3	3.1		0.0	0.0	1.4	0.0	3.2		0.8	0.0		0.5	0.1	0.1	1.0	2.8	0.4	1.1	0.4	0.7	1.6			1.0		0.1	0.5	0.1	0.0	0.8	0.0	1.2	0.0	0.0	0.0	1.0	12.9	0.3	0.0	1.0	2.8	7.6	1.6	0.0	0.4	0.1	0.9	7.6	0.3	8.9	0.8	0.0	0.1	0.1	0.1	0.2	1.3	0.3	3.9	0.2	1.6	1.5	0.3	22.0	1.0	0.0	0.8	0.0	0.1	0.3	0.1	7.2	0.4	0.1	2.3	0.0	12.9	0.4	6.4	0.2	0.0	0.0	0.1	0.2	0.0	1.3	1.2	0.5	11.5	0.1	0.2	0.0	4.9	4.3	0.0	0.1	0.0	0.0	2.0	2.4	0.0	0.0	1.5	0.1	0.0	1.2	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.6	2.8	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.8	0.1	0.0	0.0	0.2	3.1	1.3	0.2	0.0	0.0	1.2	0.0	0.0	3.1	0.3	1.3	0.6	0.5	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	1.1	0.0	0.0	0.3	0.2	0.0	1.5	0.0	0.0	0.0
GRIN3A	GluN3A	ENSG00000198785	"Glutamate ionotropic receptor NMDA type subunit 3A"	Q8TCU5	9	101569353-101738580	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 17.3"	"Cell type enhanced"	"Detected in some"	21	"Cone photoreceptor cells: 3.9;Early spermatids: 1.4;Sertoli cells: 6.5"	"Cancer enriched"	"Detected in single"	7	"prostate cancer: 3.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"intermediate monocyte: 3.3;non-classical monocyte: 2.5"	"Lineage enriched"	"Detected in single"	7	"monocytes: 3.3"	"Cell line enriched"	"Detected in some"	5	"SCLC-21H: 6.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.29e-1)"	"unprognostic (7.10e-3)"	"unprognostic (3.01e-5)"	"unprognostic (3.39e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.06e-4)"	"unprognostic (1.74e-1)"	"unprognostic (2.59e-1)"	"unprognostic (7.56e-2)"	"unprognostic (7.34e-3)"	"unprognostic (1.16e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.42e-1)"	"unprognostic (4.87e-1)"	"unprognostic (9.41e-2)"	0.6	0.6	7.4	0.8	4.2	0.5	0.7	0.4	17.3	4.1	1.0	2.6	0.0	0.6	1.0	1.0	0.5	0.6	0.5	1.2	6.8	6.4	0.6	0.6	0.7	1.1	3.8	12.4	2.4	0.5	0.4	0.4	0.4	4.6	1.8	0.8	2.7	0.6	2.6	0.7	1.0	0.7	0.7	3.0	1.8	0.6	1.0	2.3	0.0	0.5	0.0	0.8	0.5	0.6	0.0	0.4	0.1	3.3	0.0	0.4	0.2	0.0	0.2	0.2	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.1	0.0	0.5	0.2	0.0	0.0	0.2	0.5	0.0	0.0	0.6	0.1	0.0	0.1	0.2	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.5	0.0	0.0	0.2	0.3	0.7	0.1	0.5	0.3	0.4	0.1	0.0	0.3	6.4	0.7	0.2	0.2	0.2	0.6	0.2	0.3	0.3	0.4	0.1	0.7	0.3	0.6	1.0	0.3	0.7	0.3	1.2	0.0	0.6	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.1	0.0	2.5	0.0	0.4	0.2	7.4	4.2	0.4	13.4	6.8	6.4	3.8	12.4	4.6	2.3	0.0	0.0	0.0	0.0	0.3	0.0	0.8	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.8	0.0	0.0	0.0	0.6	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0
GRIN3B	GluN3B	ENSG00000116032	"Glutamate ionotropic receptor NMDA type subunit 3B"	O60391	19	1000419-1009732	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in some"		"fallopian tube: 8.7"	"Cell type enhanced"	"Detected in some"	22	"Ciliated cells: 2.7;Early spermatids: 2.6;Spermatogonia: 9.0"	"Low cancer specificity"	"Detected in some"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"U-266/70: 8.4"	"Region enhanced"	"Detected in single"		"pons and medulla: 1.6"	"Low region specificity"	"Detected in some"									NA	NA						"unprognostic (7.86e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.61e-2)"	"unprognostic (3.43e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.20e-2)"	"unprognostic (1.49e-1)"	"unprognostic (3.78e-3)"	"unprognostic (9.35e-3)"	"unprognostic (3.62e-2)"	"unprognostic (3.34e-5)"	"unprognostic (1.94e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.72e-1)"	"unprognostic (1.33e-1)"	0.3	0.5	0.1	0.4	0.4	0.2	0.1	0.6	0.1	2.0	0.0			0.7	0.3	0.0	0.1	8.7	0.0	0.0	0.3	0.4	1.0	0.0	2.2	1.1	0.0		0.2	0.6	0.0	0.7	0.2		0.2	0.0		0.5	0.0	0.4	1.6	0.4	0.0	0.2	3.0	0.4	0.7			0.6		0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	1.0	0.7	0.3	0.3	1.5	2.6	1.3	0.2	0.0	0.0	0.1	0.2	1.2	1.7	0.0	0.7	0.8	0.0	0.2	0.0	0.5	2.6	0.5	0.6	0.3	0.1	0.2	1.9	0.1	0.1	0.0	0.0	0.1	0.1	0.5	0.5	1.2	0.0	0.8	0.4	0.3	0.4	0.1	0.1	2.7	0.3	1.0	0.1	0.1	0.0	0.6	0.0	0.1	0.0	0.2	0.4	1.0	1.1	0.3	0.7	0.8	0.1	8.4	2.0	0.2	0.1	2.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0											0.0	1.1	0.0	0.0	0.1	0.0	1.4	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.1	9.0	0.0	0.0	0.0	0.0	0.0
GRM5	"GPRC1E, mGlu5, MGLUR5, PPP1R86"	ENSG00000168959	"Glutamate metabotropic receptor 5"	P41594	11	88504576-89065945	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"brain: 27.7"	"Group enriched"	"Detected in some"	9	"Bipolar cells: 27.0;Early spermatids: 14.2;Late spermatids: 15.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 1.6"	"Lineage enriched"	"Detected in single"	9	"granulocytes: 1.6"	"Cell line enhanced"	"Detected in some"		"Hep G2: 2.2;U-266/70: 1.5;U-937: 1.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA						"unprognostic (1.94e-1)"			"unprognostic (9.62e-2)"	"unprognostic (9.57e-2)"	"unprognostic (2.79e-2)"		"unprognostic (1.80e-1)"	"unprognostic (2.62e-1)"	"unprognostic (1.26e-1)"	"unprognostic (7.16e-2)"		"unprognostic (8.15e-4)"	"unprognostic (3.43e-2)"				0.5	0.5	11.4	0.5	11.0	0.6	0.5	2.6	27.7	0.6	0.5	1.0	0.0	0.5	0.5	0.5	0.5	0.7	0.7	0.5	6.0	3.2	0.7	0.5	0.7	0.5	2.1	10.0	0.5	0.5	0.5	0.8	0.6	1.5	0.5	0.5	0.0	0.5	0.5	0.6	1.1	0.5	0.5	1.2	0.6	0.5	3.1	1.5	0.0	0.5	0.0	0.5	0.5	0.2	0.0	0.1	1.6	0.0	0.0	0.1	0.0	0.7	0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.8	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.9	0.6	0.2	0.0	0.0	1.5	0.0	0.2	0.1	1.1	0.8	1.6	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	11.4	11.0	2.6	13.2	6.0	3.2	2.1	10.0	1.5	1.5	0.0	0.0	0.0	0.0	0.0	27.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.6	0.0	0.0	0.0	15.3	0.3	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	2.0	0.0	0.0	1.2	0.1	0.0	0.0	0.0	0.0	0.0
GSR		ENSG00000104687	"Glutathione-disulfide reductase"	P00390	8	30678061-30727999	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Enterocytes: 61.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001538, CAB008632, HPA064806"	Approved		Supported	Cytosol		NA	NA		110000000	Cytosol		"CAB008632: AB_1616690, HPA001538: AB_1078986, HPA064806: "	"unprognostic (1.23e-1)"	"prognostic favorable (3.37e-4)"	"prognostic favorable (4.08e-5)"	"unprognostic (2.89e-3)"	"unprognostic (1.62e-1)"	"unprognostic (3.50e-1)"	"prognostic unfavorable (3.26e-5)"	"unprognostic (3.61e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.15e-2)"	"unprognostic (2.83e-2)"	"unprognostic (6.92e-3)"	"prognostic favorable (1.80e-4)"	"unprognostic (2.31e-3)"	"unprognostic (2.26e-1)"	"unprognostic (1.01e-1)"	"unprognostic (1.29e-1)"	8.9	14.4	6.8	10.7	9.1	7.9	6.2	9.1	11.8	18.6	18.7	7.1	18.4	20.4	13.2	12.0	19.4	8.8	17.3	11.9	5.0	5.7	27.9	17.8	10.8	9.7	4.9	6.0	11.8	17.6	22.9	7.2	8.9	6.8	16.4	17.2	10.9	12.0	17.4	14.7	6.5	31.8	9.3	4.5	13.6	17.7	7.9	4.2	17.0	9.2	11.8	12.0	23.9	14.5	2.5	4.7	19.0	5.7	2.6	7.3	2.1	11.6	49.4	8.0	6.2	8.6	9.7	7.7	5.2	11.5	7.4	10.0	14.5	6.2	22.8	25.8	6.7	22.0	13.1	12.1	11.3	8.2	5.9	11.2	23.0	17.1	48.5	23.2	7.0	37.0	16.1	7.1	11.1	4.5	8.1	10.5	14.5	19.0	10.1	16.7	10.6	24.7	8.2	14.2	48.3	8.8	9.4	9.2	11.0	14.8	29.6	6.1	7.8	7.2	16.8	12.5	11.2	7.2	8.0	14.3	3.1	8.6	7.3	7.7	5.6	6.2	14.7	9.9	9.9	10.1	19.0	4.6	11.5	4.2	4.2	7.3	2.5	3.8	4.6	4.7	2.0	2.4	3.1	6.5	2.6	5.7	2.9	3.2	2.1	6.8	9.1	9.1	11.8	5.0	5.7	4.9	6.0	6.8	4.2	3.0	21.0	15.2	10.5	3.8	6.1	21.4	30.6	9.4	14.8	12.2	15.7	11.8	8.3	9.6	6.9	8.0	61.3	0.0	17.1	5.3	5.4	23.6	5.8	37.6	15.4	3.2	32.7	15.4	38.4	14.1	6.6	12.8	8.5	5.4	52.8	11.8	14.3	34.0	10.3	14.4	7.5	6.5	6.2	1.2	4.4	4.6	5.4	11.3	38.8	23.0
GSS		ENSG00000100983	"Glutathione synthetase"	P48637	20	34928433-34956027	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Glutathione biosynthesis"	Ligase	"Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054508, HPA059315"	Enhanced		Supported	Nucleoplasm		NA	NA		23000000	Nucleoplasm		"HPA054508: AB_2682509, HPA059315: AB_2683976"	"unprognostic (5.80e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.14e-1)"	"unprognostic (7.21e-2)"	"unprognostic (3.63e-2)"	"unprognostic (5.68e-2)"	"prognostic unfavorable (7.21e-5)"	"unprognostic (2.90e-2)"	"unprognostic (8.52e-2)"	"unprognostic (3.64e-1)"	"unprognostic (6.49e-2)"	"unprognostic (1.50e-1)"	"prognostic favorable (7.31e-6)"	"unprognostic (3.35e-3)"	"unprognostic (1.96e-1)"	"unprognostic (1.42e-3)"	"unprognostic (1.52e-1)"	12.9	29.8	14.7	13.2	21.0	16.0	16.2	9.2	27.6	12.7	26.9	17.2	28.9	20.0	11.5	47.5	25.6	18.5	18.3	14.6	15.0	15.9	30.5	30.9	12.1	11.7	15.1	15.1	11.6	10.3	17.5	15.6	27.2	15.3	18.6	27.6	15.4	19.1	19.4	10.7	19.1	21.4	12.9	13.3	13.3	15.7	16.8	9.2	17.0	18.0	12.0	21.0	14.4	13.9	7.3	24.3	7.9	21.3	15.2	18.3	14.9	18.2	22.2	10.9	15.3	12.7	13.2	15.5	15.6	14.4	24.6	20.4	40.7	22.3	12.9	20.8	16.0	23.8	17.4	15.9	39.7	20.8	6.0	9.0	51.0	14.1	40.4	17.9	12.8	18.0	13.9	42.5	23.1	39.1	11.0	17.4	17.6	24.6	10.6	29.8	20.1	20.4	18.2	6.4	24.1	28.7	18.8	21.9	30.7	35.2	18.7	21.4	12.5	27.5	25.8	20.5	6.2	31.7	11.7	13.7	28.3	16.1	18.6	13.4	10.8	10.0	14.2	24.1	14.1	16.8	7.9	20.3	4.6	18.0	21.3	16.1	7.3	14.5	18.3	24.3	5.2	16.9	14.3	5.3	15.2	19.0	13.5	17.5	14.9	14.7	21.0	9.2	27.6	15.0	15.9	15.1	15.1	15.3	9.2	17.9	8.0	10.4	28.7	23.4	20.6	14.0	30.6	8.1	12.5	24.4	9.8	69.5	21.6	40.0	44.5	14.6	44.5	0.0	41.7	42.0	15.3	18.9	17.3	23.3	52.3	33.4	22.5	5.5	16.2	108.3	9.5	20.4	15.1	40.5	44.4	26.6	32.4	28.8	17.3	95.3	15.4	25.8	12.2	16.4	14.7	21.1	41.0	20.3	70.9	22.9
GUCY1A2	"GC-SA2, GUC1A2"	ENSG00000152402	"Guanylate cyclase 1 soluble subunit alpha 2"	P33402	11	106674012-107018524	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"cGMP biosynthesis"	Lyase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"endometrium 1: 23.0;placenta: 23.6"	"Cell type enhanced"	"Detected in many"	16	"Muller glia cells: 27.1;Sertoli cells: 103.5;Smooth muscle cells: 57.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 12.5;BJ hTERT+ SV40 Large T+ RasG12V: 14.6;HBF TERT88: 7.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB009534	Uncertain					NA	NA					"CAB009534: AB_2279509"	"unprognostic (7.53e-2)"	"unprognostic (6.67e-2)"	"unprognostic (7.99e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.22e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.24e-1)"	"unprognostic (6.53e-3)"	"unprognostic (9.70e-3)"	"unprognostic (8.00e-2)"	"unprognostic (2.03e-1)"	"prognostic unfavorable (3.02e-5)"	"unprognostic (2.48e-4)"	"unprognostic (1.62e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.09e-2)"	5.5	3.3	4.6	1.3	10.9	0.6	3.9	4.3	10.7	19.2	1.5	1.2	1.1	0.9	23.0	5.0	1.3	8.4	2.6	3.8	4.6	4.0	3.2	2.8	11.8	1.6	3.7	5.3	3.9	6.2	1.8	1.5	23.6	5.5	3.2	1.3	1.4	1.4	10.1	4.1	1.4	1.2	18.0	2.4	7.9	1.0	2.8	5.4	0.0	2.4	3.0	1.0	2.2	5.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	4.3	0.0	0.2	2.6	2.4	0.3	12.5	1.6	14.6	0.0	0.0	0.0	0.0	0.9	0.4	0.0	0.2	0.0	7.8	0.0	1.2	0.0	0.1	0.0	0.2	0.0	1.7	0.7	0.0	1.9	0.2	0.0	0.9	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	0.5	3.8	0.0	0.8	0.5	0.9	0.2	4.8	4.0	3.3	0.9	1.3	0.0	0.0	0.0	0.1	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	10.9	4.3	9.9	4.6	4.0	3.7	5.3	5.5	5.4	0.0	0.3	0.0	1.4	1.4	23.1	5.9	0.0	0.0	0.0	3.5	11.8	0.1	0.0	3.2	2.2	3.9	0.0	0.0	0.2	0.0	6.1	1.1	0.0	0.0	0.3	17.5	0.0	2.5	0.6	4.9	22.7	0.0	3.3	0.0	0.0	27.1	0.5	0.0	23.7	0.0	4.0	103.5	57.5	0.9	1.5	1.0	0.2	0.0	0.0	1.2
GUCY2C	"GUC2C, STAR"	ENSG00000070019	"Guanylate cyclase 2C"	P25092	12	14612632-14696585	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"cGMP biosynthesis"	"Lyase, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	19	"intestine: 85.1"	"Cell type enhanced"	"Detected in some"	21	"Enterocytes: 37.2;Intestinal endocrine cells: 169.6;Mucus-secreting cells: 61.9;Paneth cells: 99.3;Undifferentiated cells: 41.2"	"Group enriched"	"Detected in many"	5	"colorectal cancer: 23.9;stomach cancer: 9.1"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"memory B-cell: 4.3"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 3.7;BEWO: 2.2;CACO-2: 3.2;CAPAN-2: 4.6;SiHa: 4.2"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA037655, HPA073759"	Uncertain		Uncertain	Vesicles		NA	NA			Vesicles		"HPA037655: AB_10672388, HPA073759: "	"unprognostic (1.08e-1)"	"unprognostic (2.12e-1)"	"unprognostic (3.58e-2)"	"unprognostic (2.11e-2)"	"unprognostic (1.60e-2)"	"unprognostic (5.67e-3)"	"prognostic unfavorable (1.37e-5)"	"unprognostic (9.14e-2)"	"unprognostic (1.49e-2)"	"unprognostic (2.95e-1)"	"unprognostic (1.58e-1)"	"unprognostic (5.40e-2)"	"unprognostic (2.35e-4)"	"unprognostic (8.02e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.98e-1)"	0.2	0.1	0.2	3.4	0.2	0.0	0.2	0.2	0.2	0.2	38.8	0.2	0.2	28.0	0.3	0.2	0.4	0.2	0.3	0.4	0.2	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.5	0.0	0.2	0.2	0.2	0.2	17.5	0.2	0.5	0.2	0.2	1.0	85.1	0.3	0.2	0.2	0.5	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.3	4.3	0.7	2.7	1.7	0.0	0.0	0.6	1.1	0.1	0.0	3.7	0.0	0.0	2.2	0.2	0.0	0.0	0.0	3.2	4.6	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.7	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.5	0.1	0.6	0.0	0.6	4.2	0.3	0.0	1.1	0.4	0.1	0.0	0.0	0.0	0.9	0.1	1.3	0.8	1.3	0.0	0.0	0.1	0.0	1.7	0.0	0.0	0.5	0.0	4.3	0.0	0.0	0.7	2.3	0.0	0.0	2.7	0.0	0.0	0.7	0.0	0.6	0.2	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.2	0.0	0.0	1.5	0.0	0.5	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	37.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	169.6	0.0	0.8	0.0	0.0	0.0	0.0	0.0	61.9	0.0	0.3	99.3	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	41.2	0.0
HBA1	HBA-T3	ENSG00000206172	"Hemoglobin subunit alpha 1"	P69905	16	176680-177522	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Oxygen transport, Transport"		"Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"bone marrow: 1020.7"	"Cell type enriched"	"Detected in many"	24	"Erythroid cells: 99681.0"	"Cancer enhanced"	"Detected in many"		"glioma: 6.3"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 11.7;plasmacytoid DC: 7.4"	"Group enriched"	"Detected in many"	4	"dendritic cells: 7.4;granulocytes: 11.7"	"Group enriched"	"Detected in some"	37	"HEL: 248.9;K-562: 175.4"									"CAB032534, HPA043780"	Enhanced					NA	NA		17000000000			"CAB032534: AB_2294993, HPA043780: AB_2678667"	"unprognostic (1.16e-1)"	"unprognostic (1.45e-2)"	"unprognostic (8.87e-2)"	"unprognostic (9.78e-3)"	"unprognostic (3.02e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.35e-1)"	"unprognostic (6.21e-3)"	"unprognostic (1.92e-2)"	"unprognostic (1.64e-1)"	"unprognostic (1.02e-2)"	"unprognostic (3.59e-2)"	"unprognostic (3.79e-1)"	"unprognostic (6.61e-2)"	"unprognostic (2.67e-2)"	"unprognostic (9.56e-2)"	12.6	8.8	7.1	5.0	6.6	1020.7	5.0	7.9	10.0	2.2	3.2	3.0	2.2	1.3	2.2	4.1	2.8	4.8	4.0	16.9	5.2	5.1	20.6	15.7	30.3	8.1	10.1	5.8	4.9	2.2	0.9	7.5	104.1	3.3	4.8	1.4	4.5	6.7	3.3	9.4	1.9	2.2	5.1	7.9	101.4	1.6	6.7	2.2	2.2	9.3	2.2	2.2	3.4	9.4	0.6	7.4	11.7	0.5	0.9	2.1	186.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.4	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	248.9	0.0	2.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	175.4	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	5.8	0.0	0.0	0.5	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	3.3	1.9	0.0	0.0	0.6	0.2	0.7	0.7	0.4	0.7	2.1	11.7	0.9	0.0	7.4	0.0	186.1	7.1	6.6	7.9	10.0	5.2	5.1	10.1	5.8	3.3	2.2	0.0	0.0	18.2	0.0	9.4	0.2	0.8	2.5	0.0	0.0	0.0	0.0	0.0	6.6	0.0	4.6	0.5	0.7	99681.0	0.0	0.0	0.0	0.1	0.0	30.9	0.0	0.0	1.2	17.2	53.0	11.2	0.0	0.0	4114.8	0.0	0.9	0.3	0.1	1.7	0.4	3.7	14.8	0.0	179.2	0.1	5.1	11.5	0.0	21.3	1.4	0.0
HBA2	HBA-T2	ENSG00000188536	"Hemoglobin subunit alpha 2"	P69905	16	172876-173710	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Oxygen transport, Transport"		"Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 427.1;bone marrow: 1094.2"	"Cell type enriched"	"Detected in many"	20	"Erythroid cells: 168432.0"	"Cancer enhanced"	"Detected in all"		"glioma: 59.7"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"eosinophil: 9.8;neutrophil: 33.6;plasmacytoid DC: 15.7"	"Group enriched"	"Detected in many"	8	"dendritic cells: 15.7;granulocytes: 33.6"	"Group enriched"	"Detected in some"	18	"HEL: 161.2;K-562: 43.2"									"CAB038417, HPA043780"	Enhanced					NA	NA		17000000000			"CAB038417: , HPA043780: AB_2678667"	"unprognostic (1.57e-1)"	"unprognostic (7.02e-2)"	"unprognostic (2.59e-2)"	"unprognostic (2.13e-1)"	"unprognostic (3.59e-1)"	"unprognostic (3.18e-1)"	"unprognostic (3.39e-2)"	"unprognostic (2.12e-1)"	"unprognostic (4.99e-2)"	"unprognostic (4.43e-1)"	"unprognostic (1.09e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.72e-3)"	"unprognostic (1.36e-1)"	"unprognostic (2.11e-1)"	"unprognostic (4.73e-2)"	"unprognostic (8.92e-2)"	15.4	11.8	7.2	6.9	7.3	1094.2	7.6	4.1	4.1	4.1	4.1	4.1	4.1	1.1	4.1	4.1	4.1	7.7	5.8	19.5	5.8	6.2	24.3	17.7	38.4	4.1	11.2	4.1	4.1	4.1	0.5	8.9	128.7	4.1	4.1	1.3	4.1	9.2	5.6	17.7	0.9	4.1	4.1	9.3	98.3	1.9	4.1	4.1	4.1	12.5	4.1	4.1	4.1	20.1	1.4	15.7	33.6	0.9	1.5	3.0	427.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	161.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	43.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	0.1	1.6	1.3	0.1	0.0	0.0	0.0	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.9	9.8	3.0	0.0	0.1	1.4	0.3	0.2	1.4	0.8	0.8	2.6	33.6	1.5	0.0	15.7	0.0	427.1	7.2	7.3	4.1	4.1	5.8	6.2	11.2	4.1	4.1	4.1	3.0	1.0	72.9	0.1	39.4	1.2	4.0	12.7	4.0	1.2	0.0	0.0	0.0	46.4	0.0	2.6	9.0	1.0	168432.0	0.0	0.0	2.1	0.2	1.1	54.4	0.0	0.0	2.9	39.9	114.1	9.4	0.0	1.1	8337.5	0.0	1.3	1.3	0.0	3.7	0.0	12.3	41.0	0.0	364.9	0.2	6.6	39.0	0.0	20.8	0.7	0.0
HBB	"beta-globin, CD113t-C"	ENSG00000244734	"Hemoglobin subunit beta"	P68871	11	5225464-5229395	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Oxygen transport, Transport"	"Hypotensive agent, Vasoactive"	"Congenital dyserythropoietic anemia, Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in all"	7	"bone marrow: 3646.7"	"Cell type enriched"	"Detected in many"	16	"Erythroid cells: 407904.6"	"Cancer enhanced"	"Detected in all"		"glioma: 244.6"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	7	"neutrophil: 19.3;plasmacytoid DC: 9.9"	"Group enriched"	"Detected in many"	12	"dendritic cells: 9.9;granulocytes: 19.3"	"Cell line enhanced"	"Detected in some"		"HEL: 5.5;SCLC-21H: 4.8;SH-SY5Y: 6.1;U-266/70: 22.3;U-266/84: 3.7"									"CAB009526, HPA043234"	Enhanced					NA	NA		15000000000			"CAB009526: AB_2143058, HPA043234: AB_2678378"	"unprognostic (2.41e-1)"	"unprognostic (8.55e-2)"	"unprognostic (2.40e-1)"	"unprognostic (4.40e-2)"	"unprognostic (1.14e-1)"	"unprognostic (3.22e-1)"	"unprognostic (4.88e-2)"	"unprognostic (7.46e-2)"	"unprognostic (2.91e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.91e-1)"	"unprognostic (8.11e-3)"	"unprognostic (2.40e-2)"	"unprognostic (5.81e-2)"	"unprognostic (1.42e-1)"	"unprognostic (8.87e-3)"	"unprognostic (6.41e-2)"	32.7	20.0	20.9	10.1	21.0	3646.7	43.4	6.5	10.7	9.2	11.3	7.2	3.4	3.2	7.3	11.1	36.6	28.4	30.4	38.9	17.9	17.4	45.0	37.6	305.8	7.0	31.6	10.8	82.6	28.4	2.9	18.6	236.8	23.7	23.1	7.5	32.0	17.4	12.8	29.5	3.8	3.9	12.0	26.5	216.8	4.0	9.3	3.8	5.6	46.4	20.2	7.6	124.5	256.7	0.6	9.9	19.3	0.6	1.2	1.1	523.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	2.1	0.0	0.0	0.0	0.8	0.2	0.4	0.0	0.0	0.4	0.3	0.0	0.0	4.8	6.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	22.3	3.7	0.0	0.0	0.0	0.0	2.2	0.6	1.9	0.9	0.0	0.1	0.6	0.2	0.0	0.9	0.4	0.4	1.1	19.3	1.2	0.1	9.9	0.0	523.2	20.9	21.0	6.5	10.7	17.9	17.4	31.6	10.8	23.7	3.8	3.0	5.9	120.0	0.0	139.4	3.4	2.0	28.1	49.5	2.3	7.0	3.9	1.1	43.1	0.0	0.0	20.2	1.0	407904.6	0.0	2.3	16.4	0.0	0.0	226.1	6.6	3.2	3.5	92.1	289.2	0.0	0.0	2.3	25972.5	0.0	3.8	6.2	0.1	2.9	0.0	79.6	86.7	0.0	737.5	0.0	0.0	220.7	1.8	46.8	0.6	0.0
HCAR2	"GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG"	ENSG00000182782	"Hydroxycarboxylic acid receptor 2"	Q8TDS4	12	122701293-122703343	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	Apoptosis	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 50.9"	"Cell type enhanced"	"Detected in many"	11	"Basal glandular cells: 69.6;Basal keratinocytes: 83.9;Suprabasal keratinocytes: 92.8"	"Group enriched"	"Detected in many"	8	"cervical cancer: 12.6;head and neck cancer: 16.1;lung cancer: 6.4;urothelial cancer: 9.2"	"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in some"	6	"neutrophil: 50.9"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 50.9"	"Cell line enriched"	"Detected in some"	6	"HaCaT: 52.0"									HPA028660	Approved		Supported	"Cell Junctions"		NA	NA			"Cell Junctions"		"HPA028660: AB_10602139"	"unprognostic (5.43e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.05e-1)"	"unprognostic (6.65e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.33e-3)"	"unprognostic (7.26e-2)"	"unprognostic (2.17e-1)"	"unprognostic (1.77e-2)"	"unprognostic (7.10e-2)"	"unprognostic (7.33e-2)"	"unprognostic (4.83e-4)"	"unprognostic (5.76e-2)"	"unprognostic (5.07e-2)"	"unprognostic (1.54e-1)"	"unprognostic (4.63e-2)"	16.1	0.2	0.4	6.4	0.5	13.2	8.3	0.2	0.7	5.8	3.6	0.3	6.2	0.4	0.8	1.6	26.0	0.4	1.1	1.2	0.8	0.2	1.9	1.8	11.3	0.7	3.3	0.2	1.2	0.2	4.4	0.9	8.2	1.0	8.6	0.0	0.3	9.7	10.7	0.7	17.8	0.7	0.4	0.9	16.5	0.8	2.8	1.1	1.1	0.4	13.5	21.5	3.5	8.3	0.0	0.5	50.9	6.6	0.0	0.0	0.3	1.9	0.1	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	52.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	1.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	8.5	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	9.0	0.6	0.6	0.0	1.5	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	50.9	0.0	6.6	0.0	0.0	0.3	0.4	0.5	0.2	0.7	0.8	0.2	3.3	0.2	1.0	1.1	0.0	7.0	0.0	69.6	83.9	0.4	0.0	0.0	6.7	33.0	0.0	0.0	0.4	0.0	0.0	21.5	0.4	0.0	0.0	0.0	22.6	2.3	8.9	2.3	0.0	3.8	0.0	0.0	0.0	4.1	2.3	0.0	30.0	8.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	92.8	2.2	0.0	0.0	18.6
HCAR3	"GPR109B, HCA3, HM74"	ENSG00000255398	"Hydroxycarboxylic acid receptor 3"	P49019	12	122714756-122716892	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"blood: 47.7"	"Cell type enhanced"	"Detected in many"	11	"Basal glandular cells: 75.5;Basal keratinocytes: 83.9;Suprabasal keratinocytes: 93.0;Urothelial cells: 41.6"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	5	"midbrain: 3.5"	"Group enriched"	"Detected in some"	6	"basophil: 12.1;neutrophil: 47.7;non-classical monocyte: 21.3"	"Group enriched"	"Detected in many"	49	"granulocytes: 47.7;monocytes: 21.3"	"Group enriched"	"Detected in some"	5	"HaCaT: 7.2;RT4: 27.9"									HPA028660	Approved		Approved	"Cell Junctions"		NA	NA			"Cell Junctions"		"HPA028660: AB_10602139"	"unprognostic (2.32e-1)"	"unprognostic (5.82e-2)"	"unprognostic (8.23e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.17e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.64e-3)"	"unprognostic (1.60e-1)"	"unprognostic (6.29e-2)"	"unprognostic (9.87e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.80e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.30e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.16e-1)"	"unprognostic (9.28e-2)"	4.8	0.2	0.6	7.9	0.3	20.8	4.0	0.4	0.5	2.3	0.9	0.2	2.2	0.1	0.4	0.4	18.2	0.5	0.5	1.0	0.3	0.3	0.9	2.5	10.2	3.5	3.5	0.0	1.6	0.2	6.6	1.1	3.0	0.7	4.2	0.0	0.3	2.9	4.3	0.6	13.9	0.3	0.4	1.2	21.6	0.5	1.6	0.4	0.3	0.5	12.0	14.9	5.7	7.2	0.0	0.7	47.7	21.3	0.0	0.0	0.6	0.6	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	7.2	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	27.9	0.1	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.1	12.1	0.5	0.2	0.0	4.4	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	47.7	0.0	21.3	0.0	0.0	0.6	0.6	0.3	0.4	0.5	0.3	0.3	3.5	0.0	0.7	0.4	3.0	10.7	0.0	75.5	83.9	0.0	0.0	0.0	0.0	19.4	0.0	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.0	0.0	19.1	2.0	5.3	3.5	0.0	6.1	0.0	0.0	0.0	7.3	0.0	0.0	22.1	8.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	93.0	11.6	0.0	0.0	41.6
HCRTR1	OX1R	ENSG00000121764	"Hypocretin receptor 1"	O43613	1	31617686-31632518	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 8.0"	"Cell type enhanced"	"Detected in some"	27	"Early spermatids: 1.1;Late spermatids: 2.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HeLa: 1.7;HUVEC TERT2: 3.0;TIME: 1.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA014018	Approved					NA	NA					"HPA014018: AB_1854810"	"unprognostic (2.96e-2)"	"unprognostic (2.34e-2)"	"unprognostic (7.86e-3)"	"unprognostic (3.72e-3)"	"unprognostic (2.42e-1)"	"unprognostic (3.45e-3)"	"unprognostic (2.54e-5)"	"unprognostic (3.58e-2)"	"unprognostic (4.17e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.28e-1)"	"unprognostic (2.93e-1)"	"unprognostic (3.77e-3)"	"unprognostic (2.16e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.07e-1)"	3.3	4.3	0.9	0.3	1.4	1.6	2.7	0.7	4.5	0.1	0.3	0.0	0.0	0.2	0.6	0.3	0.7	0.5	0.8	1.8	0.8	4.6	0.5	0.1	0.2	0.6	1.1	0.0	0.5	0.3	0.0	1.7	2.3	8.0	0.5	0.2	0.7	0.5	0.0	2.4	1.1	0.5	0.0	0.5	0.6	0.4	0.4	0.0	0.0	2.9	0.8	0.2	0.6	0.1	1.1	0.2	0.0	0.2	0.2	0.5	0.1	0.4	0.0	0.4	0.1	0.0	0.0	0.7	0.5	0.0	0.0	0.0	0.0	0.6	0.6	0.2	0.3	0.5	0.0	0.0	0.0	0.0	0.0	0.4	0.3	1.7	0.0	0.0	1.0	0.4	0.0	0.0	0.5	0.0	0.5	3.0	0.5	0.4	0.2	0.0	0.5	0.1	0.1	0.1	0.0	0.0	1.1	0.1	0.0	0.0	0.7	0.1	0.4	0.3	0.2	0.0	0.8	0.2	0.0	1.7	0.1	0.2	0.3	0.4	0.5	0.1	0.2	0.0	0.6	1.0	0.0	0.2	0.0	0.5	0.2	0.0	0.1	0.2	0.0	0.1	1.1	0.1	0.1	0.0	0.2	0.1	0.2	0.0	0.1	0.9	1.4	0.7	4.5	0.8	4.6	1.1	0.0	8.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0
HCRTR2	OX2R	ENSG00000137252	"Hypocretin receptor 2"	O43614	6	55106460-55282620	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	5	"brain: 17.4"	"Cell type enhanced"	"Detected in some"	24	"Distal tubular cells: 1.7;Peritubular cells: 3.5"	"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	4	"pons and medulla: 17.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"AF22: 4.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA054516	Enhanced					NA	NA					"HPA054516: AB_2682513"						"unprognostic (4.86e-1)"		"unprognostic (2.69e-2)"		"unprognostic (1.86e-2)"	"unprognostic (2.32e-1)"			"unprognostic (7.45e-2)"	"unprognostic (7.39e-2)"			0.1	0.2	1.7	0.0	1.3	0.0	0.1	0.6	2.2	0.1	0.1	0.3	0.0	0.0	0.1	0.5	0.0	0.1	0.1	1.1	0.9	4.2	3.7	0.1	0.4	0.1	2.6	1.7	1.7	0.0	0.0	0.3	2.2	17.4	0.0	0.1	0.5	0.0	0.0	0.0	0.1	0.2	0.1	0.5	0.0	0.0	1.5	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.3	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.7	1.3	0.6	2.2	0.9	4.2	2.6	1.7	17.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.0
HDAC1	"GON-10, HD1, RPD3L1"	ENSG00000116478	"Histone deacetylase 1"	Q13547	1	32292086-32333635	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"CAB005017, HPA029693, CAB068191"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB005017: AB_2248344, CAB068191: AB_2665664, HPA029693: AB_10601659"	"unprognostic (2.51e-2)"	"unprognostic (9.10e-2)"	"unprognostic (2.92e-1)"	"unprognostic (2.98e-1)"	"unprognostic (9.15e-2)"	"unprognostic (3.57e-3)"	"prognostic unfavorable (5.76e-7)"	"unprognostic (9.57e-2)"	"unprognostic (5.02e-2)"	"unprognostic (3.47e-2)"	"unprognostic (7.06e-2)"	"unprognostic (4.44e-2)"	"prognostic unfavorable (1.04e-5)"	"unprognostic (6.86e-2)"	"unprognostic (3.78e-1)"	"unprognostic (7.16e-2)"	"unprognostic (1.72e-1)"	13.8	22.8	12.8	33.5	14.8	15.0	21.1	5.1	13.0	21.9	35.7	16.0	34.8	22.2	24.6	17.5	40.6	21.0	43.8	12.4	12.5	8.5	21.1	21.5	17.2	33.3	14.7	8.6	27.7	20.5	17.2	27.1	24.4	12.2	25.2	33.9	18.0	27.8	31.3	6.6	16.9	32.7	22.1	13.3	32.6	27.8	20.0	16.7	59.4	36.8	21.2	51.1	26.0	25.1	47.7	32.1	59.8	44.6	42.4	49.2	54.7	29.4	18.0	11.6	23.0	6.8	8.1	24.1	20.9	23.4	28.0	25.9	32.9	53.1	45.4	38.8	23.0	28.5	34.4	35.5	28.4	31.1	42.4	35.3	31.3	21.6	25.2	16.0	55.4	45.4	14.6	15.6	21.7	14.4	22.0	21.2	59.5	41.0	18.1	12.3	22.4	63.1	31.2	26.8	35.2	46.1	43.6	27.5	20.2	30.3	42.6	9.1	11.5	34.8	23.5	43.8	47.7	27.7	43.1	24.5	18.7	21.9	5.7	50.8	11.0	23.7	62.3	15.4	46.0	24.2	37.0	27.7	59.8	43.2	35.5	35.4	47.7	42.4	46.1	32.1	44.3	49.2	45.7	19.9	42.4	44.6	20.1	42.5	54.7	12.8	14.8	5.1	13.0	12.5	8.5	14.7	8.6	12.2	16.7	23.8	38.4	50.1	48.1	22.0	15.5	18.2	56.0	80.3	48.9	64.6	15.7	81.3	81.2	57.2	10.0	40.9	97.1	0.0	65.1	93.0	21.5	29.1	29.0	28.2	38.0	11.1	82.9	63.8	40.8	5.9	38.0	31.0	27.0	42.3	101.3	32.1	65.7	108.7	41.8	25.9	13.9	58.2	37.7	45.1	76.2	22.2	78.1	50.7	115.8	49.8
HDAC10	DKFZP761B039	ENSG00000100429	"Histone deacetylase 10"	Q969S8	22	50245183-50251405	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Autophagy, DNA damage, DNA recombination, DNA repair"	Hydrolase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HMC-1: 19.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB045977	Supported					NA	NA					"CAB045977: AB_11124034"	"unprognostic (1.53e-1)"	"prognostic favorable (4.46e-4)"	"unprognostic (1.43e-2)"	"prognostic favorable (2.45e-5)"	"unprognostic (2.71e-2)"	"unprognostic (3.70e-2)"	"unprognostic (6.15e-3)"	"unprognostic (5.48e-2)"	"unprognostic (3.28e-1)"	"unprognostic (2.56e-2)"	"prognostic favorable (9.25e-4)"	"unprognostic (4.93e-2)"	"prognostic unfavorable (4.74e-11)"	"unprognostic (2.21e-2)"	"unprognostic (2.52e-2)"	"unprognostic (1.43e-2)"	"unprognostic (1.38e-3)"	8.9	9.3	10.1	14.7	10.3	16.9	6.8	10.9	8.8	8.6	13.9	4.7	14.6	12.9	7.7	13.5	10.2	7.9	13.1	4.0	8.4	6.1	11.4	15.1	8.2	12.5	4.9	8.8	7.8	15.0	6.4	13.2	7.0	6.1	10.2	3.7	8.8	18.6	12.9	9.2	12.1	14.2	7.1	4.4	17.1	14.2	2.4	4.7	16.1	9.3	7.6	19.2	8.2	7.7	1.1	3.1	5.4	4.2	1.1	1.9	2.5	4.2	2.4	0.6	3.5	3.0	2.4	7.8	2.8	2.4	1.6	0.9	4.4	4.6	2.7	4.0	2.1	1.5	7.0	1.5	4.2	0.3	3.5	3.9	5.9	6.2	7.3	5.3	6.9	19.3	5.0	3.1	1.5	0.9	3.2	3.0	5.6	4.1	4.2	1.4	13.0	3.8	17.3	1.4	4.5	5.2	9.2	2.3	17.0	2.5	7.1	1.9	4.6	2.9	1.0	4.9	0.8	8.0	11.2	4.7	2.8	4.0	4.7	1.7	5.2	1.8	2.3	4.5	4.4	2.1	0.8	4.0	5.4	1.9	4.2	1.6	1.0	0.9	1.2	3.1	1.1	0.8	1.0	2.0	1.1	2.3	2.7	1.6	2.5	10.1	10.3	10.9	8.8	8.4	6.1	4.9	8.8	6.1	4.7	0.0	4.3	9.8	4.4	7.7	5.4	0.6	7.6	4.0	2.3	14.0	15.7	9.3	6.6	5.7	1.8	5.6	25.6	0.0	3.4	13.2	8.5	3.2	4.7	6.7	18.7	0.0	20.1	9.2	21.1	6.3	10.3	10.8	8.5	17.2	14.6	2.6	5.7	17.0	7.4	13.3	6.8	0.0	3.7	0.9	2.3	8.3	8.6	30.6	14.4	3.1
HDAC11		ENSG00000163517	"Histone deacetylase 11"	Q96DB2	3	13479724-13506424	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"Early spermatids: 300.6;Late spermatids: 525.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"SK-BR-3: 27.9;T-47d: 24.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (5.22e-2)"	"unprognostic (3.58e-2)"	"unprognostic (1.83e-1)"	"unprognostic (5.69e-3)"	"unprognostic (1.76e-1)"	"unprognostic (4.71e-2)"	"prognostic unfavorable (1.20e-5)"	"unprognostic (4.50e-2)"	"unprognostic (5.67e-3)"	"unprognostic (1.78e-2)"	"unprognostic (9.87e-2)"	"unprognostic (3.94e-1)"	"prognostic favorable (7.88e-10)"	"unprognostic (3.63e-2)"	"unprognostic (1.65e-1)"	"unprognostic (1.46e-1)"	"unprognostic (1.39e-3)"	4.8	7.6	24.6	3.2	31.7	0.7	5.8	7.6	30.6	8.8	7.1	29.2	3.8	8.9	6.5	5.1	9.5	10.1	6.5	19.6	24.4	19.0	9.9	2.1	6.4	3.0	25.4	20.7	12.5	18.8	10.4	7.7	3.4	16.5	8.2	5.1	6.6	12.8	9.7	35.1	13.2	9.6	5.4	19.9	3.0	4.9	24.0	20.3	1.5	9.9	4.9	3.7	4.4	6.6	1.4	2.3	7.5	3.3	11.4	4.5	2.3	6.9	4.5	4.8	3.9	7.1	6.2	3.6	4.6	3.2	4.6	3.1	2.2	5.8	0.5	5.5	6.4	7.3	5.3	2.8	8.3	3.0	3.0	2.6	1.3	1.9	6.3	8.0	0.1	2.5	5.2	15.6	5.1	3.9	8.6	3.3	4.3	2.7	1.3	4.3	7.0	0.8	0.9	1.3	4.5	12.0	0.9	6.9	2.0	9.6	5.1	0.8	3.6	6.6	27.9	13.2	4.1	24.6	1.6	3.1	3.9	7.9	7.7	2.7	0.9	2.5	0.1	1.2	1.0	2.2	0.2	3.3	7.5	4.5	1.8	3.1	1.4	4.1	3.5	2.3	0.6	4.1	2.7	1.4	11.4	0.7	2.3	3.3	2.3	24.6	31.7	7.6	23.0	24.4	19.0	25.4	20.7	16.5	20.3	8.9	5.3	0.0	7.4	10.2	8.7	71.4	10.2	9.4	3.4	10.4	0.0	15.7	16.6	11.3	300.6	4.5	28.8	0.0	10.0	2.1	7.6	4.5	1.1	2.6	5.2	9.5	8.5	7.4	4.3	525.1	15.0	3.1	8.5	6.4	14.8	17.7	10.6	16.9	14.5	14.2	5.8	0.0	6.9	10.2	6.0	9.3	4.8	4.3	18.5	5.0
HDAC2	"RPD3, YAF1"	ENSG00000196591	"Histone deacetylase 2"	Q92769	6	113933028-114011308	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005054, HPA011727"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB005054: AB_562295, HPA011727: AB_1850540"	"prognostic unfavorable (7.07e-4)"	"unprognostic (1.44e-1)"	"unprognostic (2.67e-1)"	"unprognostic (2.56e-2)"	"unprognostic (2.61e-2)"	"unprognostic (1.89e-2)"	"prognostic unfavorable (5.39e-10)"	"unprognostic (2.03e-1)"	"unprognostic (2.63e-2)"	"unprognostic (9.00e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.92e-1)"	"unprognostic (1.84e-2)"	"unprognostic (1.96e-1)"	"unprognostic (2.42e-1)"	"unprognostic (9.80e-2)"	"unprognostic (3.51e-1)"	25.8	33.8	25.8	30.1	31.3	34.9	58.7	32.8	36.5	32.1	30.7	25.6	32.2	22.0	38.7	36.7	36.3	32.7	23.3	27.6	26.5	26.9	31.6	22.2	29.9	41.5	29.6	26.5	39.2	31.5	31.7	45.1	38.1	27.9	32.1	36.1	17.5	29.3	39.0	33.9	30.8	26.1	36.1	31.1	30.7	29.9	47.4	27.4	64.0	35.1	31.3	32.5	33.1	47.3	27.0	35.7	28.2	32.6	26.3	32.6	24.3	24.6	17.0	79.6	45.7	20.5	23.5	33.3	29.5	24.1	34.8	41.7	45.1	18.2	20.4	24.6	26.5	35.8	19.4	54.0	29.8	58.7	29.0	37.3	49.1	22.1	26.0	27.4	49.8	22.2	18.9	20.1	37.0	34.8	34.1	40.5	36.1	63.1	20.7	57.6	20.7	44.6	45.1	45.0	26.4	23.5	30.3	39.7	18.7	35.9	29.8	53.3	45.2	23.3	22.0	24.5	50.0	16.0	58.1	32.7	22.2	25.5	23.2	48.8	16.5	21.7	48.8	18.8	48.0	37.6	23.1	27.6	28.2	21.1	26.6	28.1	27.0	25.9	22.7	35.7	22.3	32.6	29.7	16.3	26.3	32.6	30.9	24.5	24.3	25.8	31.3	32.8	36.5	26.5	26.9	29.6	26.5	27.9	27.4	53.6	49.8	31.2	71.8	170.6	26.7	56.1	33.1	81.7	79.6	50.6	3.9	139.9	36.5	140.8	72.3	70.5	33.4	140.2	91.3	114.1	97.6	61.7	53.2	30.8	91.5	14.3	96.4	47.9	63.7	84.2	76.8	67.2	79.2	128.0	68.7	30.1	115.2	49.1	63.3	52.8	23.5	38.8	84.5	123.0	166.8	168.8	173.7	50.7	90.3	79.6
HDAC3	"HD3, RPD3, RPD3-2"	ENSG00000171720	"Histone deacetylase 3"	O15379	5	141620876-141636870	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Biological rhythms, Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005583, HPA052052, CAB072336"	Supported		Supported	"Nucleoplasm,Golgi apparatus"		NA	NA			Nucleoplasm	"Golgi apparatus"	"CAB005583: AB_562296, CAB072336: , HPA052052: AB_2681708"	"unprognostic (6.65e-2)"	"unprognostic (1.96e-1)"	"prognostic favorable (3.39e-4)"	"unprognostic (1.17e-1)"	"unprognostic (1.24e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.19e-2)"	"unprognostic (3.16e-1)"	"unprognostic (5.56e-2)"	"unprognostic (2.45e-2)"	"prognostic favorable (3.95e-4)"	"unprognostic (1.12e-1)"	"prognostic unfavorable (2.65e-6)"	"unprognostic (1.85e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.28e-3)"	"unprognostic (2.17e-1)"	15.9	28.8	19.6	12.2	17.6	18.1	18.6	22.6	20.8	15.6	14.1	11.2	13.1	10.6	17.3	17.6	22.8	16.3	14.0	16.8	18.0	8.9	14.5	23.3	24.4	36.4	13.4	14.2	17.3	24.7	20.9	17.3	14.3	18.8	13.6	14.4	13.6	17.5	13.7	24.5	26.7	15.2	17.2	10.8	20.1	15.5	11.9	12.6	18.5	14.4	9.6	23.7	17.5	17.0	22.1	46.7	16.4	22.6	14.1	23.1	16.9	21.3	14.5	27.0	40.9	26.1	20.8	17.5	15.6	34.3	35.4	50.8	31.0	18.3	31.1	20.2	20.2	25.2	18.6	27.1	36.5	43.9	26.5	29.1	24.3	13.3	17.6	18.4	29.2	22.3	17.7	23.5	20.5	26.8	18.4	22.8	28.1	23.7	16.6	22.3	20.2	32.4	25.3	23.8	13.3	11.5	23.5	28.2	22.4	18.9	21.5	22.6	18.3	20.6	21.4	25.7	17.9	22.8	18.5	11.5	22.0	13.8	16.8	25.5	13.5	16.6	29.3	18.5	27.8	18.8	13.2	22.4	16.4	15.9	22.6	20.8	22.1	19.8	19.2	46.7	20.1	21.7	18.0	9.5	14.1	19.0	23.9	23.1	16.9	19.6	17.6	22.6	20.8	18.0	8.9	13.4	14.2	18.8	12.6	8.9	10.4	32.3	23.0	39.3	30.6	12.3	15.3	5.3	11.4	12.2	56.9	47.2	18.3	28.5	7.6	20.2	15.4	0.0	31.4	44.3	29.3	18.8	18.4	14.8	34.9	47.7	17.2	20.9	15.4	3.4	20.8	33.0	30.4	66.7	17.7	27.7	27.2	14.0	20.8	15.7	30.4	25.8	24.0	22.3	24.5	44.9	51.1	31.9	22.7	26.5
HDAC4	"BDMR, HA6116, HD4, HDAC-4, HDAC-A, HDACA, KIAA0288"	ENSG00000068024	"Histone deacetylase 4"	P56524	2	239048168-239401654	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Autism spectrum disorder, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 54.6"	"Cell type enhanced"	"Detected in many"	10	"Early spermatids: 73.9;Late spermatids: 47.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"basophil: 10.5;classical monocyte: 7.4;neutrophil: 28.3"	"Group enriched"	"Detected in many"	8	"granulocytes: 28.3;monocytes: 7.4"	"Cell line enhanced"	"Detected in many"		"JURKAT: 30.4;MOLT-4: 28.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA048723, HPA071448"	Approved		Supported	"Nucleoplasm,Nuclear speckles,Cytosol"		NA	NA			"Nuclear speckles"	"Nucleoplasm, Cytosol"	"HPA048723: AB_2680501, HPA071448: "	"unprognostic (1.54e-1)"	"unprognostic (1.76e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.18e-3)"	"unprognostic (2.43e-2)"	"unprognostic (2.39e-3)"	"unprognostic (3.06e-4)"	"unprognostic (1.00e-1)"	"unprognostic (1.24e-1)"	"prognostic unfavorable (6.33e-4)"	"prognostic favorable (1.13e-4)"	"unprognostic (1.40e-1)"	"unprognostic (4.82e-3)"	"unprognostic (2.40e-1)"	"unprognostic (3.26e-2)"	"unprognostic (1.32e-2)"	"unprognostic (6.04e-2)"	7.9	6.8	6.1	6.8	5.2	17.1	4.6	6.4	12.3	11.3	21.4	4.6	4.3	2.5	10.2	6.4	8.8	9.0	24.6	5.2	5.0	6.0	3.2	3.1	4.2	4.3	6.1	5.4	8.5	5.8	4.9	8.3	2.5	5.2	7.5	4.8	8.3	3.7	7.3	54.6	6.9	6.5	15.8	4.2	5.4	7.0	8.1	4.3	6.5	4.8	13.2	5.6	10.2	4.6	0.5	1.7	28.3	7.4	2.1	1.2	0.4	3.8	3.8	4.9	5.9	2.8	4.7	5.8	4.0	2.7	3.2	3.1	1.7	7.0	1.8	1.6	3.4	4.6	3.8	3.4	1.6	1.6	10.6	1.8	2.8	4.7	5.6	3.7	4.3	2.6	3.2	4.1	5.9	4.7	1.6	3.4	30.4	4.0	4.1	1.5	4.7	28.1	5.9	3.8	4.8	2.0	7.3	9.2	2.8	3.7	4.9	3.9	6.9	5.6	2.5	9.8	2.9	1.3	11.9	5.4	3.7	0.3	6.4	5.4	2.9	2.7	3.5	5.4	6.0	7.4	10.5	7.4	1.1	0.9	2.4	1.1	0.5	0.9	0.8	0.8	0.5	0.5	1.0	28.3	2.1	1.0	1.7	1.2	0.4	6.1	5.2	6.4	7.5	5.0	6.0	6.1	5.4	5.2	4.3	3.0	9.0	3.7	2.2	7.0	11.5	10.1	7.6	0.0	3.4	10.4	2.0	1.2	0.0	2.4	73.9	5.8	4.5	0.0	1.8	1.5	8.0	5.0	2.3	5.8	2.9	15.9	5.8	13.5	22.7	47.3	10.9	5.5	5.0	0.0	5.5	10.1	1.7	0.0	11.7	1.2	7.1	0.0	5.6	2.2	2.1	8.4	1.1	8.7	5.7	2.2
HDAC5	"FLJ90614, KIAA0600, NY-CO-9"	ENSG00000108840	"Histone deacetylase 5"	Q9UQL6	17	44076746-44123702	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Cone photoreceptor cells: 111.9;Syncytiotrophoblasts: 182.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB019400, HPA030991"	Approved		Supported	"Nuclear speckles,Golgi apparatus,Cytosol"		NA	NA			"Nuclear speckles"	"Golgi apparatus, Cytosol"	"CAB019400: AB_2116626, HPA030991: AB_10795286"	"unprognostic (1.30e-2)"	"prognostic favorable (6.14e-4)"	"unprognostic (6.65e-2)"	"unprognostic (8.06e-2)"	"unprognostic (3.49e-1)"	"unprognostic (3.52e-2)"	"prognostic unfavorable (3.12e-5)"	"unprognostic (8.80e-3)"	"unprognostic (3.80e-2)"	"unprognostic (2.37e-2)"	"unprognostic (4.91e-3)"	"unprognostic (4.30e-1)"	"prognostic favorable (3.30e-5)"	"unprognostic (1.51e-2)"	"unprognostic (3.11e-1)"	"unprognostic (6.00e-2)"	"unprognostic (1.76e-2)"	15.6	17.6	24.9	7.9	15.8	13.2	18.1	35.9	25.8	16.5	8.8	19.6	9.5	8.4	15.0	11.9	20.1	16.9	11.3	24.4	22.1	24.2	8.6	6.3	13.6	8.8	24.7	22.1	24.5	16.1	28.2	17.5	23.0	19.3	13.6	5.5	11.7	14.2	11.9	42.6	34.0	9.7	12.4	20.5	13.8	9.3	10.3	18.1	7.6	15.0	9.8	8.2	14.9	20.4	7.6	9.4	17.9	13.6	3.5	4.9	5.0	3.6	2.4	6.5	1.5	12.7	9.8	23.6	9.8	24.4	4.9	8.0	5.2	3.9	5.7	3.9	23.2	7.3	2.9	7.6	4.2	2.1	8.8	12.4	11.1	7.8	12.0	5.4	3.6	15.7	13.9	7.2	5.6	7.0	8.4	4.0	4.6	8.2	11.6	28.3	2.8	5.9	10.9	7.1	2.8	5.6	22.9	18.2	14.7	0.5	1.6	17.0	8.9	2.8	12.0	13.3	10.1	17.1	21.0	2.2	12.3	7.9	2.8	4.9	19.2	16.0	6.8	7.1	4.5	5.8	7.1	7.3	7.7	4.9	11.6	3.5	6.6	3.9	4.9	9.4	7.6	4.1	3.5	17.9	3.5	13.6	8.3	3.5	5.0	24.9	15.8	35.9	25.8	22.1	24.2	24.7	22.1	19.3	18.1	11.9	13.6	10.4	30.2	26.0	84.0	21.0	12.7	5.3	7.9	19.2	111.9	12.7	18.3	13.6	17.9	18.3	11.2	0.0	7.5	47.4	24.1	34.1	11.6	9.0	19.6	77.9	44.2	20.3	12.1	8.7	44.8	13.6	13.5	9.0	13.7	17.3	12.1	15.8	41.1	6.4	58.6	64.7	41.8	2.3	33.8	28.7	182.4	17.5	11.2	18.5
HDAC6	"FLJ16239, HD6, JM21, KIAA0901, PPP1R90"	ENSG00000094631	"Histone deacetylase 6"	Q9UBN7	X	48801377-48824982	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Autophagy, Transcription, Transcription regulation"	"Actin-binding, Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003714, CAB004236, HPA026321"	Supported		Supported	Nucleoplasm		NA	NA		39000	Nucleoplasm		"CAB004236: AB_627708, HPA003714: AB_1850544, HPA026321: AB_1850546"	"unprognostic (9.53e-2)"	"unprognostic (1.59e-1)"	"unprognostic (2.66e-2)"	"unprognostic (2.42e-2)"	"unprognostic (2.82e-2)"	"unprognostic (4.11e-3)"	"unprognostic (2.17e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.68e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.16e-3)"	"unprognostic (2.33e-2)"	"unprognostic (6.10e-2)"	"unprognostic (1.47e-1)"	"unprognostic (6.60e-2)"	"unprognostic (2.34e-1)"	"prognostic favorable (3.34e-4)"	14.6	13.7	23.4	12.8	29.8	19.0	14.4	34.2	30.1	12.7	14.1	24.4	14.9	16.9	16.0	14.7	13.1	15.7	11.7	11.9	21.7	24.8	32.8	43.3	15.1	13.9	27.2	22.4	18.7	15.5	26.7	24.4	15.1	27.0	12.3	15.9	15.1	12.2	15.3	18.2	11.3	16.1	15.0	20.9	15.3	14.2	24.7	22.4	19.0	15.7	9.5	14.0	11.7	12.1	5.7	9.7	6.3	12.4	4.0	5.8	5.0	15.1	12.9	25.3	9.6	10.2	9.3	17.1	7.2	6.2	14.0	13.8	12.4	13.0	14.6	7.0	8.2	17.9	10.8	15.3	7.7	12.1	13.6	9.7	20.0	15.4	12.7	9.6	9.2	31.0	13.5	12.6	10.9	13.2	12.5	11.6	18.5	21.9	16.2	8.8	5.3	13.0	14.4	9.4	6.9	12.3	11.2	27.2	15.0	8.0	6.6	13.0	12.8	14.6	4.4	8.7	34.3	18.3	8.6	9.4	10.9	14.1	14.9	6.9	14.9	14.8	10.6	11.1	11.9	10.8	0.0	5.8	6.3	5.8	9.7	4.1	4.3	4.0	4.2	8.6	5.7	3.9	3.7	2.9	4.0	12.4	9.7	4.4	5.0	23.4	29.8	34.2	30.1	21.7	24.8	27.2	22.4	27.0	22.4	17.9	30.9	11.7	10.4	6.6	37.4	9.5	12.7	9.4	20.5	17.4	47.1	9.6	16.6	6.3	37.4	7.7	17.6	0.0	6.4	10.4	8.4	7.6	5.8	45.7	9.7	38.1	13.8	11.6	10.0	14.2	13.0	9.2	5.0	15.4	11.6	26.8	6.8	11.5	10.6	39.4	33.8	12.9	8.0	31.5	13.0	5.1	8.1	6.7	13.6	6.4
HDAC7	"DKFZP586J0917, HDAC7A"	ENSG00000061273	"Histone deacetylase 7"	Q8WUI4	12	47782722-47833132	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 85.8"	"Cell type enhanced"	"Detected in many"	4	"Ito cells: 87.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 10.5"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 10.5"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA004775			Supported	Cytosol		NA	NA			Cytosol		"HPA004775: AB_1850548"	"unprognostic (3.83e-1)"	"unprognostic (9.49e-3)"	"unprognostic (1.37e-2)"	"unprognostic (4.46e-2)"	"unprognostic (6.56e-3)"	"unprognostic (2.22e-2)"	"unprognostic (2.50e-3)"	"unprognostic (1.26e-1)"	"prognostic unfavorable (5.16e-4)"	"unprognostic (1.28e-1)"	"unprognostic (2.07e-1)"	"unprognostic (2.38e-2)"	"prognostic unfavorable (8.25e-4)"	"unprognostic (6.24e-2)"	"unprognostic (4.38e-2)"	"unprognostic (9.69e-2)"	"prognostic favorable (4.65e-4)"	26.0	21.6	8.2	22.7	10.8	17.3	24.4	8.4	10.7	28.2	20.7	8.7	15.4	8.0	27.9	21.5	19.2	25.2	22.1	16.5	10.3	4.3	17.7	5.1	27.6	21.1	8.2	8.0	25.4	8.9	23.7	11.5	17.5	10.0	20.1	4.1	17.6	16.3	18.9	12.5	19.7	13.9	24.9	10.3	23.1	14.9	9.5	11.5	85.8	20.9	12.9	21.0	24.8	25.0	1.4	0.6	10.5	1.9	1.7	1.5	1.8	14.2	9.7	10.1	16.5	7.9	22.1	9.1	14.0	10.9	10.2	6.7	12.9	13.5	28.6	46.8	12.7	5.0	13.2	2.3	10.9	3.7	13.4	4.8	9.8	9.5	3.0	8.6	3.0	0.4	14.4	3.8	10.1	5.5	18.4	21.0	16.4	10.3	11.7	6.4	6.2	28.1	7.5	14.1	3.1	10.8	21.7	5.4	10.3	4.3	9.3	2.9	6.9	10.7	5.0	5.1	6.8	4.7	4.1	23.8	20.9	22.7	17.0	9.9	26.5	19.2	22.7	8.6	14.5	6.8	0.0	1.9	0.0	1.5	0.8	1.5	1.4	1.3	1.1	0.6	1.1	1.5	1.0	10.5	1.7	0.7	0.5	0.6	1.8	8.2	10.8	8.4	10.7	10.3	4.3	8.2	8.0	10.0	11.5	38.7	36.7	31.8	21.0	12.2	18.0	11.5	30.6	5.3	22.7	34.9	0.0	3.9	1.7	29.4	13.4	71.6	1.1	0.0	19.7	2.5	28.8	40.0	8.1	0.4	13.7	27.0	7.0	87.8	29.5	4.9	50.9	11.5	13.5	12.6	9.7	13.6	47.3	9.7	31.1	2.9	3.2	25.8	20.6	0.9	3.1	18.9	2.4	26.6	7.6	38.2
HDAC8	"HDACL1, MRXS6, RPD3, WTS"	ENSG00000147099	"Histone deacetylase 8"	Q9BY41	X	72329516-72573103	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"Disease mutation, FDA approved drug targets, Mental retardation, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA048560	Supported		Approved	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA048560: AB_2680442"	"unprognostic (1.42e-1)"	"unprognostic (6.62e-3)"	"unprognostic (3.20e-2)"	"unprognostic (9.24e-3)"	"unprognostic (1.10e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.64e-2)"	"unprognostic (6.03e-2)"	"unprognostic (1.58e-1)"	"unprognostic (2.81e-2)"	"unprognostic (3.17e-2)"	"unprognostic (9.68e-2)"	"unprognostic (8.42e-2)"	"unprognostic (2.33e-3)"	"unprognostic (9.10e-2)"	"unprognostic (7.15e-3)"	"unprognostic (2.12e-3)"	9.6	22.5	14.7	9.9	16.2	10.2	12.4	31.4	20.6	12.6	10.4	13.9	11.5	8.6	12.3	28.2	11.0	9.4	9.4	12.6	15.0	15.2	16.8	18.6	10.2	9.6	14.9	9.4	12.8	15.9	13.6	22.0	11.2	19.3	13.3	12.8	14.3	12.2	10.3	10.4	9.3	8.4	13.1	12.2	9.5	10.7	3.6	14.0	8.0	15.0	8.2	11.9	10.4	10.1	9.4	12.8	19.7	13.2	7.7	11.4	7.7	12.5	17.1	12.6	17.4	17.3	12.9	8.7	7.3	14.1	11.2	12.7	12.4	12.9	8.7	23.0	10.0	17.5	9.2	23.5	14.2	14.9	14.3	16.7	11.5	22.0	14.4	9.5	19.1	20.4	13.5	10.4	13.7	10.3	15.9	17.2	11.7	12.8	24.4	14.9	15.8	8.9	25.1	17.5	19.3	24.8	12.2	16.2	15.6	19.5	13.2	9.0	19.7	17.1	13.7	17.5	16.4	6.9	16.3	12.9	9.2	13.3	13.2	8.1	9.4	15.0	11.1	12.5	21.1	11.9	7.2	13.2	19.7	8.8	11.8	6.9	9.4	9.5	7.3	12.8	9.1	7.6	7.1	0.7	7.7	10.5	4.8	11.4	7.7	14.7	16.2	31.4	20.6	15.0	15.2	14.9	9.4	19.3	14.0	3.0	18.8	8.1	10.0	5.5	16.0	10.8	12.7	13.4	10.3	7.0	41.2	14.3	8.3	11.9	0.5	10.5	8.1	0.0	10.7	11.6	8.6	13.3	11.5	9.7	13.8	22.3	8.7	11.6	7.8	1.3	10.9	10.6	6.8	6.4	9.1	10.8	10.1	2.9	9.9	17.8	16.8	25.8	9.5	5.1	0.7	5.5	11.3	11.4	9.7	10.9
HDAC9	"HD7, HDAC, HDAC7B, KIAA0744, MITR"	ENSG00000048052	"Histone deacetylase 9"	Q9UKV0	7	18086949-19002416	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Transcription, Transcription regulation"	"Chromatin regulator, Hydrolase, Repressor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	16	"Early spermatids: 197.2;Late spermatids: 49.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"myeloid DC: 29.5"	"Group enriched"	"Detected in many"	9	"B-cells: 21.8;dendritic cells: 29.5;monocytes: 9.7"	"Cell line enhanced"	"Detected in many"		"HAP1: 55.1;hTERT-HME1: 26.4;SH-SY5Y: 22.0;U-698: 21.8;WM-115: 22.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA028926	Uncertain		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA028926: AB_10602327"	"unprognostic (2.06e-2)"	"unprognostic (2.67e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.17e-1)"	"unprognostic (2.74e-1)"	"unprognostic (5.54e-2)"	"unprognostic (2.20e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.21e-1)"	"unprognostic (2.45e-1)"	"unprognostic (5.01e-1)"	"unprognostic (7.58e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.94e-2)"	"unprognostic (1.32e-1)"	"unprognostic (1.02e-1)"	"unprognostic (6.87e-3)"	10.7	13.5	12.6	10.7	16.2	5.9	8.4	19.1	16.9	11.6	7.4	11.3	7.5	3.8	17.8	6.7	4.7	10.5	7.5	14.9	13.1	12.0	3.9	3.1	5.7	18.9	13.9	14.9	3.0	2.7	3.0	17.7	6.8	11.2	12.5	6.2	9.7	6.9	16.5	15.5	3.8	8.4	14.4	17.6	17.4	9.1	8.7	18.2	2.9	5.5	5.4	19.3	7.1	9.6	21.8	29.5	0.5	9.7	2.0	2.1	4.5	12.5	0.0	2.1	0.0	0.3	2.8	0.0	0.7	7.4	3.1	5.3	0.1	4.1	5.4	13.9	8.3	17.1	1.9	55.1	1.0	8.1	0.0	0.3	0.0	0.0	0.0	0.0	1.1	0.0	1.0	1.0	9.8	26.4	2.7	0.1	0.8	0.0	8.4	4.3	0.0	0.5	1.1	6.7	0.0	1.2	1.5	0.8	3.1	1.7	3.3	3.9	22.0	0.1	0.1	4.0	3.3	0.2	4.9	0.5	11.4	3.6	0.6	7.1	9.7	4.1	21.8	3.0	0.5	22.5	0.1	9.7	0.0	1.7	6.7	1.7	21.8	0.6	0.8	29.5	16.3	0.0	0.9	0.5	2.0	3.8	6.4	2.1	4.5	12.6	16.2	19.1	16.9	13.1	12.0	13.9	14.9	11.2	18.2	6.0	3.2	26.4	0.4	2.2	32.0	12.1	0.0	1.4	4.5	0.0	15.7	0.1	3.3	6.6	197.2	11.1	0.0	0.0	0.6	0.1	5.7	1.4	1.1	0.8	10.5	19.1	6.9	13.5	45.7	49.8	1.4	31.1	15.1	0.0	0.4	5.0	7.0	0.2	0.7	0.0	27.3	6.5	6.9	10.3	8.8	1.8	0.1	8.7	0.0	2.0
HMGCR		ENSG00000113161	"3-hydroxy-3-methylglutaryl-CoA reductase"	P04035	5	75336329-75362104	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cholesterol biosynthesis, Cholesterol metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Suprabasal keratinocytes: 80.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA008338, CAB016797"	Approved					NA	NA					"CAB016797: , HPA008338: AB_10960401"	"unprognostic (5.07e-2)"	"unprognostic (1.65e-2)"	"unprognostic (3.65e-3)"	"unprognostic (1.02e-2)"	"unprognostic (1.65e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.45e-1)"	"unprognostic (4.41e-2)"	"unprognostic (5.45e-2)"	"unprognostic (1.90e-2)"	"unprognostic (1.41e-1)"	"unprognostic (3.99e-2)"	"prognostic favorable (9.42e-6)"	"unprognostic (2.44e-1)"	"unprognostic (2.55e-2)"	"unprognostic (3.64e-3)"	"unprognostic (4.37e-2)"	5.6	28.9	12.4	8.7	31.1	12.1	16.4	14.4	36.3	13.9	23.0	10.9	7.1	18.9	9.0	14.4	35.0	6.5	8.2	4.0	21.8	16.5	12.1	53.5	12.1	7.0	9.8	19.4	15.2	8.4	16.2	11.4	9.2	29.6	12.4	19.7	7.8	12.4	4.5	3.4	36.1	19.0	6.8	17.0	7.9	14.6	14.0	8.8	13.9	12.5	23.2	12.4	6.2	18.1	4.3	12.5	23.2	11.0	9.5	6.5	5.1	15.3	6.0	61.4	21.1	13.0	25.2	15.4	4.4	12.4	9.0	20.1	22.6	37.8	13.7	16.1	7.1	58.9	19.4	31.9	51.8	9.6	4.6	11.7	10.5	9.1	17.5	19.2	8.7	7.7	16.3	30.5	31.5	15.6	4.5	7.2	19.7	11.2	21.0	14.2	10.0	16.0	8.8	26.2	3.9	4.5	11.3	18.4	19.6	37.1	35.8	21.3	9.7	9.7	10.1	8.8	22.1	10.0	22.9	8.4	4.9	7.3	5.2	7.5	6.7	8.5	18.9	7.1	17.1	10.1	6.7	11.0	6.3	6.1	6.9	5.1	4.3	4.6	6.4	12.5	4.2	4.5	6.2	23.2	9.5	7.4	3.9	6.5	5.1	12.4	31.1	14.4	36.3	21.8	16.5	9.8	19.4	29.6	8.8	17.9	33.4	7.5	8.5	36.9	20.9	5.7	12.7	32.1	22.7	26.2	17.7	16.3	3.3	12.1	38.1	7.6	33.8	0.0	18.8	21.6	10.5	13.9	24.2	22.5	11.5	38.1	41.2	9.8	19.3	19.5	8.6	12.3	15.1	2.8	50.6	10.3	11.9	20.1	5.6	6.3	13.1	12.9	8.2	21.0	14.0	80.0	39.0	8.7	20.2	17.3
HMMR	"CD168, RHAMM"	ENSG00000072571	"Hyaluronan mediated motility receptor"	O75330	5	163460203-163491945	"CD markers, FDA approved drug targets, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 54.5;testis: 16.7"	"Cell type enhanced"	"Detected in many"	21	"Early spermatids: 60.3;Erythroid cells: 256.9;Extravillous trophoblasts: 50.4;Spermatocytes: 80.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB002433, HPA040025, HPA043926, HPA061524"	Enhanced		Enhanced	Microtubules,Centrosome,Cytosol		Yes	Yes			Microtubules	"Centrosome, Cytosol"	"CAB002433: AB_564080, HPA040025: AB_2676805, HPA043926: , HPA061524: AB_2684551"	"unprognostic (3.53e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.38e-3)"	"unprognostic (8.88e-3)"	"unprognostic (2.12e-1)"	"prognostic unfavorable (5.52e-4)"	"prognostic unfavorable (1.93e-7)"	"prognostic unfavorable (1.09e-4)"	"unprognostic (5.68e-2)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (3.71e-5)"	"unprognostic (1.02e-1)"	"unprognostic (0.00e+0)"	"unprognostic (1.65e-2)"	"unprognostic (4.98e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.77e-2)"	1.6	1.4	0.6	13.4	0.6	11.4	2.4	0.4	0.9	1.7	5.0	0.6	0.6	4.5	0.6	2.3	6.4	0.5	0.9	1.6	0.8	0.7	1.4	1.8	2.5	10.9	1.0	0.4	0.6	1.1	0.6	0.5	6.9	1.1	0.7	5.6	0.4	1.6	0.2	1.4	2.3	4.8	1.4	1.9	8.6	2.6	16.7	0.3	54.5	0.7	5.6	10.8	1.8	2.1	1.2	1.8	0.6	0.7	1.5	4.8	0.8	21.1	13.3	27.2	14.5	1.4	2.7	20.3	20.1	9.8	25.2	22.9	27.0	40.9	35.2	19.2	6.2	34.4	24.5	31.4	19.1	43.1	31.9	9.7	21.0	9.5	13.2	0.4	18.6	19.4	0.7	1.1	23.7	18.6	4.2	14.3	24.2	19.9	28.8	26.2	7.7	19.6	10.6	23.4	14.2	14.6	21.4	36.4	17.6	9.8	5.7	22.7	12.6	29.9	9.4	11.4	13.5	27.7	15.0	9.3	18.1	15.4	14.5	26.9	15.5	25.9	28.4	12.0	28.9	17.4	0.5	0.7	0.0	0.5	0.3	0.9	1.2	1.0	0.6	0.9	0.9	0.4	0.7	0.6	1.5	0.0	1.8	4.8	0.8	0.6	0.6	0.4	0.9	0.8	0.7	1.0	0.4	1.1	0.3	0.0	0.6	15.5	0.8	2.3	0.6	1.7	7.6	4.0	4.5	0.0	0.0	5.1	0.0	0.6	60.3	0.1	1.3	256.9	0.2	50.4	2.4	0.8	0.0	1.7	17.7	0.0	1.2	3.1	3.5	44.1	2.0	4.3	0.0	3.6	1.6	0.0	0.1	0.0	0.7	2.4	0.7	6.5	0.0	80.6	18.5	1.3	3.8	1.0	4.2	0.9
HPD	"4-HPPD, 4HPPD, GLOD3, PPD"	ENSG00000158104	"4-hydroxyphenylpyruvate dioxygenase"	P32754	12	121839527-121863596	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Phenylalanine catabolism, Tyrosine catabolism"	"Dioxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 267.5"	"Group enriched"	"Detected in some"	9	"Hepatocytes: 1077.2;Proximal tubular cells: 1892.6"	"Cancer enriched"	"Detected in many"	100	"liver cancer: 540.9"	"Region enriched"	"Detected in single"	29	"pons and medulla: 13.7"	"Group enriched"	"Detected in many"	4	"eosinophil: 9.8;neutrophil: 4.8;plasmacytoid DC: 5.0"	"Group enriched"	"Detected in many"	5	"dendritic cells: 5.0;granulocytes: 9.8"	"Cell line enriched"	"Detected in some"	30	"Hep G2: 107.2"	"Region enriched"	"Detected in single"	8	"amygdala: 0.4"	"Not detected"	"Not detected"			"HPA038321, HPA038322"	Enhanced		Uncertain	"Nuclear speckles"		NA	NA		23000000	"Nuclear speckles"		"HPA038321: AB_2675957, HPA038322: AB_10670778"	"unprognostic (3.01e-2)"	"unprognostic (2.30e-1)"	"unprognostic (4.81e-3)"	"unprognostic (1.42e-3)"	"unprognostic (1.10e-2)"	"unprognostic (9.08e-2)"	"unprognostic (1.13e-2)"	"unprognostic (8.84e-2)"	"unprognostic (5.58e-2)"	"unprognostic (6.14e-3)"	"unprognostic (9.72e-3)"	"unprognostic (8.61e-3)"	"unprognostic (7.16e-2)"	"unprognostic (1.97e-1)"	"unprognostic (4.12e-1)"	"unprognostic (3.06e-2)"	"unprognostic (2.34e-1)"	0.1	0.5	0.0	0.1	0.1	0.0	0.4	0.1	0.3	0.2	0.1	2.1	0.3	0.0	0.3	0.4	0.1	0.7	0.2	0.3	0.4	0.0	51.3	267.5	0.2	0.4	0.1	0.0	0.7	0.7	0.0	0.1	0.0	13.7	0.5	0.0	3.8	0.0	0.8	0.2	0.0	0.1	0.4	0.2	0.2	0.1	0.8	0.1	0.0	0.1	0.1	0.1	0.6	0.2	0.1	5.0	9.8	1.4	0.0	0.3	0.3	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	1.1	107.2	2.5	0.3	3.5	0.8	0.0	0.0	0.0	0.3	0.0	0.1	0.1	0.0	0.2	0.2	0.0	0.1	2.1	0.0	0.0	0.0	0.3	0.1	0.0	0.3	0.0	0.0	0.3	0.0	0.0	1.5	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.0	0.0	0.8	9.8	0.0	1.0	0.1	0.1	0.1	0.1	1.3	0.1	0.3	0.2	4.8	0.0	1.4	5.0	0.0	0.3	0.0	0.1	0.1	0.3	0.4	0.0	0.1	0.0	13.7	0.1	0.0	0.0	18.3	0.0	0.0	0.0	0.3	48.4	0.0	0.0	87.2	0.0	0.6	164.2	0.3	33.1	0.0	0.0	0.0	14.8	0.2	0.0	0.0	0.0	1077.2	0.3	0.0	0.0	33.2	23.4	97.3	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.9	1892.6	0.0	0.0	0.0	1.7	1.1	0.0	0.9	0.0	0.0	0.0
HPRT1	"HGPRT, HPRT"	ENSG00000165704	"Hypoxanthine phosphoribosyltransferase 1"	P00492	X	134460153-134520513	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Purine salvage"	"Glycosyltransferase, Transferase"	"Disease mutation, FDA approved drug targets, Gout"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Distal tubular cells: 192.3;monocytes: 181.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"HPA006360, CAB012200"	Enhanced		Supported	Cytosol		NA	NA		15000000	Cytosol		"CAB012200: AB_297217, HPA006360: AB_1079082"	"unprognostic (2.02e-1)"	"unprognostic (2.18e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.32e-3)"	"unprognostic (8.55e-2)"	"prognostic unfavorable (1.35e-5)"	"unprognostic (1.58e-2)"	"unprognostic (4.77e-3)"	"unprognostic (4.93e-2)"	"unprognostic (2.02e-2)"	"unprognostic (7.05e-2)"	"unprognostic (1.38e-3)"	"unprognostic (6.00e-2)"	"unprognostic (2.12e-1)"	"unprognostic (2.04e-1)"	"unprognostic (2.70e-2)"	"unprognostic (1.51e-1)"	7.9	14.9	31.0	12.6	30.2	25.3	11.3	24.2	49.8	7.5	13.7	5.8	9.8	11.0	7.9	36.2	10.3	9.4	8.1	12.8	27.6	37.3	18.4	24.7	7.3	15.9	23.5	28.9	9.8	20.2	9.9	18.6	8.8	34.4	8.8	13.2	9.7	7.1	9.5	10.7	8.0	14.2	9.5	9.8	8.7	17.1	39.7	4.9	13.7	12.3	8.6	15.9	10.8	7.5	13.5	19.7	10.1	18.5	19.9	29.3	12.6	31.4	15.1	4.3	8.8	9.6	13.9	13.0	16.8	16.2	21.5	28.4	13.6	20.2	35.6	38.3	10.9	25.7	19.3	27.7	23.0	37.2	29.5	51.9	19.3	21.5	13.8	9.5	41.5	17.8	10.2	8.7	19.2	30.6	11.9	24.8	21.2	14.8	0.9	16.8	32.1	32.0	36.0	8.8	37.1	40.8	19.2	21.8	36.5	25.9	15.3	27.2	14.8	12.1	9.9	11.4	12.2	8.4	17.4	12.2	14.6	11.0	41.9	41.7	13.6	23.5	0.2	18.0	46.1	8.0	2.2	11.6	10.1	11.6	18.5	16.7	12.3	17.3	15.3	19.7	13.5	14.3	15.1	2.9	19.9	17.2	8.2	29.3	12.6	31.0	30.2	24.2	49.8	27.6	37.3	23.5	28.9	34.4	4.9	17.9	8.0	31.0	44.7	35.1	39.0	20.7	33.1	24.1	15.9	54.1	3.9	12.2	192.3	35.3	6.9	29.4	17.7	0.0	28.2	23.6	24.0	37.5	34.6	18.1	62.7	23.8	26.4	15.4	61.4	18.0	37.7	64.9	52.3	181.3	22.6	23.4	31.4	22.6	25.1	21.6	59.2	51.8	47.2	74.7	143.7	33.9	5.0	61.0	37.4	39.6
HRH1		ENSG00000196639	"Histamine receptor H1"	P35367	3	11137093-11263557	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Basal keratinocytes: 41.0;Club cells: 30.7;Enterocytes: 29.3;Suprabasal keratinocytes: 36.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"T-reg: 3.5"	"Group enriched"	"Detected in many"	7	"granulocytes: 1.2;T-cells: 3.5"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 17.5;hTEC/SVTERT24-B: 17.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029740	Uncertain		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	Cytosol	"HPA029740: AB_10601578"	"unprognostic (4.60e-3)"	"unprognostic (3.41e-2)"	"unprognostic (6.37e-3)"	"unprognostic (9.55e-2)"	"unprognostic (3.32e-2)"	"unprognostic (1.07e-2)"	"unprognostic (9.60e-3)"	"unprognostic (4.00e-3)"	"unprognostic (7.54e-2)"	"unprognostic (4.98e-2)"	"prognostic unfavorable (1.27e-5)"	"unprognostic (1.43e-1)"	"unprognostic (1.70e-2)"	"unprognostic (1.66e-1)"	"unprognostic (3.13e-2)"	"unprognostic (7.19e-2)"	"unprognostic (1.20e-1)"	9.1	4.4	7.3	4.6	4.4	0.2	9.6	0.5	10.6	8.0	13.5	1.3	2.4	3.8	6.2	7.2	5.7	10.6	9.9	7.0	5.1	4.0	3.3	1.1	8.2	1.8	2.2	2.1	8.7	2.1	1.7	1.2	5.5	3.2	7.2	7.2	2.0	3.4	6.1	3.0	8.0	10.5	9.2	8.6	1.4	3.3	2.4	2.0	0.1	2.5	7.2	3.1	11.2	16.2	0.1	0.3	1.2	0.2	0.1	3.5	0.1	1.5	3.5	0.0	0.0	1.6	17.5	2.4	2.6	8.8	7.8	5.3	0.6	12.6	0.0	7.8	6.1	8.0	9.9	0.0	3.6	10.7	5.5	0.0	0.8	5.7	0.0	5.3	2.4	1.4	6.1	2.2	17.7	6.2	10.9	10.9	0.1	0.0	0.0	3.5	0.0	0.0	1.1	0.0	1.5	3.2	0.2	0.9	0.3	14.0	2.0	0.1	0.0	3.7	2.7	0.0	0.1	0.0	2.0	16.2	8.8	5.5	9.0	13.1	0.0	0.9	0.0	13.5	2.2	7.6	0.4	0.2	0.0	0.1	0.2	0.0	0.0	1.3	0.5	0.3	0.1	0.1	0.1	1.2	0.1	0.0	0.1	3.5	0.1	7.3	4.4	0.5	8.4	5.1	4.0	2.2	2.1	3.2	2.0	6.0	1.4	0.0	7.7	41.0	0.0	0.4	0.0	2.7	30.7	1.8	0.0	0.2	0.0	0.4	0.3	9.3	29.3	0.0	0.6	1.0	6.7	3.9	2.3	0.0	21.0	0.0	3.4	0.6	6.9	0.0	3.4	5.7	0.0	0.0	8.0	0.0	8.3	11.4	0.0	0.3	0.1	0.0	2.3	2.3	2.8	36.3	0.5	0.0	8.8	18.2
HRH2		ENSG00000113749	"Histamine receptor H2"	P25021	5	175658030-175710756	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"blood: 45.7;bone marrow: 30.1"	"Cell type enhanced"	"Detected in some"	15	"Cardiomyocytes: 21.0;Kupffer cells: 24.0;Macrophages: 14.4;Smooth muscle cells: 45.1"	"Cancer enhanced"	"Detected in many"		"renal cancer: 4.6"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 45.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 45.7;monocytes: 13.1"	"Group enriched"	"Detected in some"	4	"RPMI-8226: 36.2;SK-MEL-30: 10.8;THP-1: 10.0;U-937: 12.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA013770	Approved					NA	NA					"HPA013770: AB_1851086"	"unprognostic (8.56e-3)"	"unprognostic (1.62e-1)"	"unprognostic (6.66e-2)"	"unprognostic (5.96e-2)"	"unprognostic (3.49e-2)"	"unprognostic (1.80e-1)"	"unprognostic (1.20e-1)"	"unprognostic (4.77e-2)"	"unprognostic (9.93e-2)"	"unprognostic (5.76e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.35e-1)"	"unprognostic (3.71e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.97e-2)"	"unprognostic (1.97e-3)"	"unprognostic (1.77e-2)"	7.9	1.5	5.9	11.1	11.6	30.1	2.8	1.0	12.1	3.9	2.8	0.9	0.5	5.9	2.3	1.3	1.6	2.7	2.6	18.6	3.4	1.7	2.4	1.2	5.4	12.3	2.3	4.9	1.6	1.6	0.3	1.3	9.5	2.4	3.0	1.3	0.6	1.7	4.8	1.2	2.1	7.2	3.5	4.4	9.9	10.3	1.2	5.6	9.9	1.8	0.2	3.0	2.8	2.0	0.0	6.4	45.7	13.1	0.6	2.3	3.7	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.8	1.7	0.0	0.0	3.9	0.0	36.2	0.0	0.2	0.2	0.0	0.0	0.0	10.8	1.0	0.0	10.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	12.1	2.4	28.9	12.9	13.6	0.0	12.0	0.1	0.0	1.1	0.2	6.4	0.0	2.3	1.4	45.7	0.6	13.1	5.0	0.8	3.7	5.9	11.6	1.0	12.1	3.4	1.7	2.3	4.9	2.4	5.6	0.0	4.5	0.5	0.1	0.7	4.5	21.0	0.0	1.4	4.5	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.0	0.0	2.2	0.1	5.2	0.1	2.3	0.0	10.1	1.6	0.0	0.0	24.0	0.7	0.0	14.4	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.1	0.0	0.0	45.1	0.2	1.1	0.3	0.0	2.5	0.0	0.0
HRH3	GPCR97	ENSG00000101180	"Histamine receptor H3"	Q9Y5N1	20	62214970-62220267	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	22	"brain: 50.1"	"Group enriched"	"Detected in some"	5	"Bipolar cells: 4.2;Horizontal cells: 3.2"	"Low cancer specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"SCLC-21H: 19.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.56e-1)"	"unprognostic (3.22e-1)"		"unprognostic (4.15e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.77e-2)"			"unprognostic (1.62e-2)"	"unprognostic (7.30e-2)"	"unprognostic (3.17e-4)"	"unprognostic (2.40e-1)"		"unprognostic (3.66e-3)"	"unprognostic (3.30e-1)"		"unprognostic (3.59e-2)"	1.0	2.3	5.7	0.8	50.1	0.9	0.9	16.7	20.6	0.8	0.9	2.8	0.0	1.0	0.8	0.8	0.9	0.8	0.8	0.8	5.1	16.5	0.9	0.9	0.9	0.9	2.7	8.7	0.8	0.8	0.8	0.7	0.8	2.6	1.4	0.9	0.0	1.1	0.8	0.8	1.6	0.9	0.9	1.0	0.8	0.9	1.6	10.5	0.0	0.8	0.0	0.9	2.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	3.0	0.0	0.0	0.0	0.0	1.3	0.0	0.1	19.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	5.7	50.1	16.7	15.1	5.1	16.5	2.7	8.7	2.6	10.5	0.0	0.0	0.0	0.0	0.0	4.2	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0
HSD3B1	"HSD3B, HSDB3, SDR11E1"	ENSG00000203857	"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1"	P14060	1	119507198-119515054	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Lipid metabolism, Steroid metabolism, Steroidogenesis"	"Isomerase, Multifunctional enzyme, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	19	"placenta: 231.4"	"Group enriched"	"Detected in some"	23	"Extravillous trophoblasts: 115.9;Syncytiotrophoblasts: 419.8"	"Cancer enhanced"	"Detected in single"		"urothelial cancer: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	6	"CACO-2: 36.4;SuSa: 16.3"									"HPA043261, HPA043264, HPA044028"	Supported		Approved	"Nucleoli,Endoplasmic reticulum,Cytokinetic bridge"		NA	NA			"Nucleoli, Endoplasmic reticulum"	"Cytokinetic bridge"	"HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781"			"unprognostic (1.53e-1)"				"unprognostic (7.11e-2)"					"unprognostic (1.15e-1)"		"unprognostic (1.04e-1)"			"prognostic favorable (4.59e-5)"	0.1	0.6	0.0	0.0	0.3	0.0	0.7	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.5	0.0	0.0	231.4	0.1	0.0	0.1	0.0	0.0	0.0	0.0	4.5	11.9	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.0	0.0	36.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	4.0	0.4	0.5	16.3	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	115.9	0.0	0.0	0.0	0.0	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	419.8	0.0	0.0	0.0
HSD3B2	SDR11E2	ENSG00000203859	"Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2"	P26439	1	119414931-119423035	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	Steroidogenesis	"Isomerase, Multifunctional enzyme, Oxidoreductase"	"Congenital adrenal hyperplasia, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"adrenal gland: 223.2"	"Cell type enhanced"	"Detected in some"	17	"Enterocytes: 1.6;Exocrine glandular cells: 1.1;Peritubular cells: 2.5"	"Cancer enhanced"	"Detected in single"		"testis cancer: 0.6"	"Region enriched"	"Detected in single"	198	"basal ganglia: 19.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"SCLC-21H: 1.5;SH-SY5Y: 1.4;SK-MEL-30: 5.1;SuSa: 1.9;TIME: 1.2;WM-115: 3.2"									"HPA043261, HPA043264, HPA044028"	Supported		Uncertain	"Nucleoli,Endoplasmic reticulum,Cytokinetic bridge"		NA	NA			"Nucleoli, Endoplasmic reticulum"	"Cytokinetic bridge"	"HPA043261: AB_2630368, HPA043264: AB_2678398, HPA044028: AB_2678781"	"unprognostic (3.56e-1)"		"unprognostic (1.85e-1)"		"unprognostic (2.80e-1)"		"unprognostic (2.72e-2)"		"unprognostic (8.87e-2)"	"unprognostic (3.91e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.94e-1)"	"unprognostic (6.51e-2)"	"unprognostic (1.97e-2)"	"unprognostic (1.55e-1)"			0.0	223.2	0.0	0.8	19.8	0.0	0.0	0.0	0.0	0.0	0.5	43.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	3.6	0.2	0.0	0.0	0.0	1.9	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.5	1.4	0.0	0.0	5.1	1.9	0.0	0.0	1.2	0.2	0.1	0.1	0.7	0.0	0.0	0.0	0.8	0.0	3.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.6	0.0	1.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.5	0.0	2.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0
HTR1A	"5-HT1A, ADRB2RL1, ADRBRL1"	ENSG00000178394	"5-hydroxytryptamine receptor 1A"	P08908	5	63960356-63962507	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	24	"brain: 21.5;ovary: 10.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"amygdala: 14.7;cerebral cortex: 10.7;hippocampal formation: 21.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	32	"NTERA-2: 5.4;SCLC-21H: 4.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA018073	Uncertain					NA	NA					"HPA018073: AB_1856704"					"unprognostic (1.81e-1)"													0.2	0.4	14.7	0.2	1.0	0.2	0.2	0.1	10.7	0.2	0.2	0.0	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.5	21.5	2.4	0.2	0.2	0.3	0.2	0.7	2.7	10.4	0.2	0.2	0.1	0.2	0.9	0.3	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.5	0.2	0.2	0.6	0.0	0.0	0.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.7	1.0	0.1	10.7	21.5	2.4	0.7	2.7	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR1B	"5-HT1B, 5-HT1DB, HTR1D2, S12"	ENSG00000135312	"5-hydroxytryptamine receptor 1B"	P28222	6	77461753-77463773	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 11.8;placenta: 14.2;stomach 1: 10.2"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in some"			"Region enhanced"	"Detected in many"		"basal ganglia: 11.8"	"Cell type enriched"	"Detected in single"	17	"basophil: 1.6"	"Lineage enriched"	"Detected in single"	17	"granulocytes: 1.6"	"Group enriched"	"Detected in some"	15	"HUVEC TERT2: 41.8;TIME: 18.4"	"Region enriched"	"Detected in many"	4	"basal ganglia: 34.5"					HPA028808	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA028808: AB_2672782"	"unprognostic (3.86e-2)"	"unprognostic (3.56e-1)"	"unprognostic (7.68e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.88e-1)"	"unprognostic (1.18e-2)"	"unprognostic (2.67e-1)"	"unprognostic (2.11e-1)"	"unprognostic (8.96e-2)"	"unprognostic (4.03e-1)"	"unprognostic (1.77e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.10e-3)"	"unprognostic (3.08e-2)"	"unprognostic (2.81e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.02e-1)"	2.2	1.5	1.3	1.1	11.8	0.3	2.4	0.4	3.7	2.9	0.6	0.1	0.0	0.6	1.1	1.0	1.4	0.8	2.8	0.4	1.0	2.1	0.9	0.3	1.1	0.3	1.2	0.9	1.1	0.5	0.3	0.5	14.2	3.0	1.6	0.4	0.3	1.3	1.2	0.9	0.5	0.4	4.1	0.6	0.4	10.2	1.5	0.6	0.0	0.5	0.0	0.3	2.6	1.4	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	1.9	1.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.1	0.4	1.1	0.8	41.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	11.8	0.4	3.7	1.0	2.1	1.2	0.9	3.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR1D	"5-HT1D, HT1DA, HTRL, RDC4"	ENSG00000179546	"5-hydroxytryptamine receptor 1D"	P28221	1	23191895-23194729	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 3.9;intestine: 12.2"	"Cell type enriched"	"Detected in single"	12	"Cholangiocytes: 7.6"	"Low cancer specificity"	"Detected in many"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A549: 8.5;hTERT-RPE1: 8.2;OE19: 11.4;TIME: 21.3;U-2 OS: 7.2"	"Region enhanced"	"Detected in some"		"basal ganglia: 7.6"	"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (1.73e-2)"	"unprognostic (8.69e-3)"	"unprognostic (8.86e-3)"	"unprognostic (2.03e-1)"	"unprognostic (2.65e-2)"	"unprognostic (5.97e-4)"	"prognostic unfavorable (1.86e-4)"	"unprognostic (3.87e-3)"	"unprognostic (8.88e-2)"	"unprognostic (4.00e-2)"	"prognostic unfavorable (5.30e-4)"	"unprognostic (3.17e-2)"	"unprognostic (3.28e-6)"	"unprognostic (9.14e-2)"	"unprognostic (2.27e-1)"	"unprognostic (2.45e-1)"	"unprognostic (8.02e-3)"	0.0	0.0	0.3	0.0	3.9	0.1	0.0	0.0	0.2	0.0	0.1			12.2	0.0	0.0	0.0	0.5	1.9	0.0	0.2	0.4	0.0	0.0	0.2	0.0	0.2		0.0	0.1	0.0	0.1	0.0		0.1	0.1		0.0	0.0	0.0	0.1	10.4	0.0	0.2	0.0	0.0	0.4			0.0		0.0	0.5	0.0	1.0	0.7	2.2	1.2	1.2	0.9	0.2	2.5	8.5	0.0	0.0	0.0	0.2	0.7	0.0	0.6	0.3	0.3	0.5	6.1	0.0	2.5	0.3	4.3	1.8	1.7	0.0	0.4	0.0	0.7	0.0	5.0	0.1	0.3	0.0	0.0	0.1	0.1	1.0	0.3	8.2	5.0	0.1	0.0	0.0	0.2	1.0	0.0	0.0	2.0	11.4	0.1	0.0	0.0	0.0	0.2	0.0	2.1	0.0	5.7	0.3	0.1	0.7	0.1	0.0	21.3	0.0	7.2	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.1	1.7	1.2	0.5	0.6	0.8	0.4	1.0	0.9	0.6	0.4	1.0	0.6	0.6	2.2	1.2	1.0	0.7	0.4	0.2											0.0	0.0	0.0	0.2	0.0	0.0	0.3	7.6	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.4	0.0	0.3	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5
HTR1E	5-HT1E	ENSG00000168830	"5-hydroxytryptamine receptor 1E"	P28566	6	86937306-87016683	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 16.4;ovary: 13.3"	"Cell type enriched"	"Detected in some"	4	"Early spermatids: 6.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	11	"PC-3: 2.9;SH-SY5Y: 11.6"					"Low region specificity"	"Detected in many"			HPA004931	Approved					NA	NA					"HPA004931: AB_1856706"					"unprognostic (2.25e-2)"					"unprognostic (1.32e-1)"		"unprognostic (6.29e-2)"			"unprognostic (4.52e-2)"	"unprognostic (1.25e-1)"		0.5	0.6	8.9	0.6	13.3	0.5	0.5	5.4	16.4	1.6	0.5	0.0	0.0	0.5	5.1	1.1	0.6	0.5	0.8	0.5	4.1	2.8	0.5	0.5	0.5	0.5	1.8	11.4	13.3	0.8	0.5	0.3	0.5	2.2	1.1	0.5	0.0	0.5	1.2	0.5	0.5	0.5	2.9	0.6	0.5	3.6	1.4	1.5	0.0	2.7	0.0	0.5	0.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.3	11.6	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.9	13.3	5.4	16.4	4.1	2.8	1.8	11.4	2.2	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0
HTR1F	"5-HT1F, HTR1EL"	ENSG00000179097	"5-hydroxytryptamine receptor 1F"	P30939	3	87990696-87993835	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"placenta: 5.7"	"Group enriched"	"Detected in some"	10	"Muller glia cells: 19.5;Sertoli cells: 19.4;Smooth muscle cells: 11.2"	"Not detected"	"Not detected"							"Cell type enriched"	"Detected in single"	16	"basophil: 3.2"	"Lineage enriched"	"Detected in single"	16	"granulocytes: 3.2"	"Group enriched"	"Detected in some"	6	"A549: 1.2;K-562: 4.5;LHCN-M2: 4.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA005555	Uncertain					NA	NA					"HPA005555: AB_1856708"	"unprognostic (1.66e-1)"	"unprognostic (2.62e-1)"	"unprognostic (2.58e-1)"	"unprognostic (9.03e-2)"	"unprognostic (1.09e-1)"	"unprognostic (1.01e-2)"	"unprognostic (4.78e-1)"	"unprognostic (1.58e-1)"	"unprognostic (2.77e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.33e-1)"	"unprognostic (9.80e-2)"	"unprognostic (2.67e-6)"	"unprognostic (1.25e-4)"	"unprognostic (1.55e-2)"	"unprognostic (3.33e-2)"	"unprognostic (3.31e-2)"	2.8	0.5	0.7	0.0	0.6	1.5	1.6	0.0	1.8	1.4	0.0			0.0	1.2	0.3	0.1	0.4	0.1	0.3	0.6	0.4	0.6	0.0	0.9	0.1	0.8		0.4	0.7	0.3	1.4	5.7		0.4	0.0		0.1	1.0	0.6	0.4	0.0	1.3	0.3	1.7	0.0	0.3			1.5		0.5	0.6	0.7	0.1	0.2	3.2	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	4.5	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	1.7	0.0	0.0	19.5	0.1	0.0	0.0	0.0	1.0	19.4	11.2	0.0	1.1	0.0	0.0	0.0	0.0	0.0
HTR2A	"5-HT2A, HTR2"	ENSG00000102468	"5-hydroxytryptamine receptor 2A"	P28223	13	46831550-46897076	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	"Behavior, Host-virus interaction"	"G-protein coupled receptor, Host cell receptor for virus entry, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	7	"brain: 30.4"	"Cell type enhanced"	"Detected in some"	19	"Early spermatids: 1.3;Late spermatids: 1.4;Muller glia cells: 4.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"neutrophil: 1.2;plasmacytoid DC: 1.2"	"Group enriched"	"Detected in many"	8	"dendritic cells: 1.2;granulocytes: 1.2"	"Cell line enhanced"	"Detected in some"		"ASC diff: 3.8;ASC TERT1: 9.3;BEWO: 2.9;HEL: 2.8;U-138 MG: 4.7;U-2 OS: 3.0;U-87 MG: 2.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA014011	Enhanced					NA	NA					"HPA014011: AB_1856709"	"unprognostic (8.01e-2)"	"unprognostic (2.71e-2)"	"unprognostic (9.49e-2)"	"unprognostic (7.40e-2)"	"unprognostic (2.78e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.70e-2)"	"unprognostic (4.31e-2)"	"unprognostic (5.27e-2)"	"unprognostic (3.97e-2)"	"unprognostic (2.61e-1)"	"unprognostic (2.90e-1)"	"unprognostic (9.94e-5)"	"unprognostic (4.78e-3)"	"unprognostic (2.54e-1)"	"unprognostic (2.91e-2)"	"unprognostic (8.28e-2)"	1.9	1.0	9.5	1.7	13.5	0.6	1.3	0.6	30.4	1.6	1.2	1.2	0.0	1.1	1.6	0.6	1.4	1.1	2.9	1.5	3.8	5.1	0.7	0.6	1.0	0.6	3.3	13.3	1.0	0.6	0.6	0.5	0.6	1.8	0.9	1.6	2.0	0.6	1.5	0.9	0.7	1.1	4.4	1.2	0.6	1.0	1.5	0.7	0.0	0.7	0.0	0.8	1.9	1.5	0.1	1.2	1.2	0.0	0.0	0.1	1.5	0.0	0.0	0.0	0.0	3.8	9.3	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.1	0.1	0.8	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.1	1.0	0.1	4.7	3.0	0.0	0.2	0.1	0.0	0.0	2.2	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	1.2	0.0	0.0	1.2	0.0	1.5	9.5	13.5	0.6	26.4	3.8	5.1	3.3	13.3	1.8	0.7	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	1.4	0.9	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.4	0.0	0.2	0.0	0.8	0.0	0.1	0.1	0.0	0.0	0.0	0.0
HTR2B	"5-HT(2B), 5-HT2B"	ENSG00000135914	"5-hydroxytryptamine receptor 2B"	P41595	2	231108230-231125118	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"placenta: 26.0"	"Cell type enhanced"	"Detected in some"	14	"Cone photoreceptor cells: 3.9;Ito cells: 5.5;monocytes: 10.8;Peritubular cells: 4.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	12	"basophil: 3.8;T-reg: 2.9"	"Group enriched"	"Detected in many"	29	"granulocytes: 3.8;T-cells: 2.9"	"Group enriched"	"Detected in some"	4	"HHSteC: 7.0;HSkMC: 13.3;SK-MEL-30: 24.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA012867, HPA063658"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA012867: AB_1856710, HPA063658: AB_2685079"	"unprognostic (1.86e-1)"	"unprognostic (3.55e-2)"	"unprognostic (1.20e-3)"	"unprognostic (1.45e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.16e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.15e-4)"	"unprognostic (3.59e-1)"	"unprognostic (2.17e-2)"	"unprognostic (1.42e-3)"	"unprognostic (7.44e-4)"	"unprognostic (1.81e-1)"	"unprognostic (1.17e-1)"	"unprognostic (1.14e-2)"	2.3	17.9	0.2	5.8	0.3	0.7	4.1	0.3	0.6	17.8	7.3	0.2	1.7	1.0	14.9	9.5	5.7	1.9	0.8	4.6	0.3	0.3	5.6	2.5	1.8	0.5	0.3	0.4	4.3	0.3	0.3	0.4	26.0	0.9	2.6	1.5	1.8	0.5	1.0	0.2	0.2	6.3	12.8	0.3	0.4	5.2	3.3	0.3	2.4	6.8	1.0	0.4	4.9	0.8	0.0	0.1	3.8	0.0	0.0	2.9	0.0	0.1	0.2	0.0	0.1	0.4	3.6	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	7.0	0.1	0.3	13.3	0.0	0.0	0.0	0.0	2.5	1.1	0.1	0.0	0.0	0.1	0.0	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.0	0.1	24.4	0.0	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.8	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.1	2.9	0.0	0.2	0.3	0.3	0.6	0.3	0.3	0.3	0.4	0.9	0.3	0.0	0.0	0.0	0.0	0.1	0.5	0.3	0.0	2.7	0.0	0.0	3.9	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.6	0.1	0.3	0.0	0.0	0.9	2.6	1.6	0.0	5.5	1.2	0.0	0.6	0.0	0.0	10.8	0.0	0.0	0.1	0.0	4.9	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1
HTR2C	"5-HT2C, 5HTR2C, HTR1C"	ENSG00000147246	"5-hydroxytryptamine receptor 2C"	P28335	X	114584078-114910061	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	20	"brain: 45.3"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"testis cancer: 0.9"	"Region enhanced"	"Detected in many"		"basal ganglia: 45.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"EFO-21: 5.0;RPMI-8226: 2.4;U-266/70: 8.9;U-266/84: 7.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"									NA	NA										"unprognostic (2.14e-1)"	"unprognostic (6.09e-3)"		"unprognostic (9.54e-2)"	"unprognostic (3.47e-2)"	"unprognostic (2.89e-2)"		"unprognostic (3.42e-2)"		"unprognostic (9.22e-4)"	"unprognostic (1.37e-1)"		"unprognostic (6.84e-2)"	0.5	0.5	2.4	0.4	45.3	0.5	0.5	0.0	9.4	2.3	0.4	8.5	0.0	0.4	0.5	0.6	0.4	0.4	0.5	0.4	2.4	9.8	0.5	0.5	0.5	0.4	2.0	1.2	0.4	0.4	0.4	0.3	1.0	29.7	0.9	0.4	0.8	0.4	1.1	0.4	0.4	0.4	0.4	1.7	0.4	0.4	0.6	2.4	0.0	0.4	0.0	0.4	0.5	0.2	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.3	0.0	0.0	0.3	1.2	0.0	0.0	0.0	2.4	0.0	1.4	0.0	0.0	0.1	0.0	0.7	0.6	0.1	0.0	0.0	0.0	0.9	0.0	0.0	8.9	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	2.4	45.3	0.0	4.6	2.4	9.8	2.0	1.2	29.7	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR3A	"5-HT3A, 5-HT3R, HTR3"	ENSG00000166736	"5-hydroxytryptamine receptor 3A"	P46098	11	113974881-113990313	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 11.1;lymphoid tissue: 12.0;salivary gland: 8.6"	"Group enriched"	"Detected in some"	11	"Ductal cells: 14.6;Exocrine glandular cells: 44.3;Pancreatic endocrine cells: 54.7"	"Cancer enriched"	"Detected in many"	7	"ovarian cancer: 15.2"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	13	"memory B-cell: 4.1;naive B-cell: 9.7;plasmacytoid DC: 11.1"	"Group enriched"	"Detected in many"	104	"B-cells: 9.7;dendritic cells: 11.1"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 6.3;Daudi: 6.0;NTERA-2: 3.8;SCLC-21H: 20.0"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	15	"amygdala: 3.3;cerebral cortex: 4.0;hippocampal formation: 4.2"	HPA069442	Supported					NA	NA					"HPA069442: AB_2732132"	"unprognostic (6.46e-3)"	"prognostic favorable (6.26e-4)"	"unprognostic (1.09e-1)"	"prognostic unfavorable (1.26e-4)"	"unprognostic (3.36e-3)"	"unprognostic (8.36e-3)"	"unprognostic (1.65e-5)"	"unprognostic (1.46e-2)"	"unprognostic (8.87e-2)"	"unprognostic (6.21e-2)"	"unprognostic (6.80e-3)"	"unprognostic (3.00e-2)"	"unprognostic (1.65e-2)"	"unprognostic (8.72e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.79e-1)"	"unprognostic (3.40e-2)"	0.3	0.5	2.2	4.4	3.9	0.0	0.3	0.3	0.9	0.3	2.5	0.3	0.3	1.0	0.3	0.3	0.8	0.0	0.3	0.3	2.1	0.0	0.3	0.3	0.3	9.7	0.3	0.3	0.3	3.7	0.0	0.3	0.3	0.3	0.3	0.6	0.3	8.6	0.3	0.3	0.6	2.0	1.0	0.3	3.0	0.9	0.3	0.3	0.7	0.3	0.3	12.0	0.3	0.3	9.7	11.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	6.0	0.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.7	0.0	0.0	0.0	20.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.6	9.7	0.0	0.0	0.0	0.0	0.0	11.1	0.0	0.2	2.2	3.9	0.3	0.9	2.1	0.0	0.3	0.3	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	14.6	0.0	0.0	0.0	0.0	44.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	54.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR3B	5-HT3B	ENSG00000149305	"5-hydroxytryptamine receptor 3B"	O95264	11	113904677-113946565	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 8.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	4	"cerebral cortex: 8.7"	"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"hypothalamus: 0.4"	"Not detected"	"Not detected"			HPA039559	Approved					NA	NA					"HPA039559: AB_10672779"					"unprognostic (1.60e-2)"	"unprognostic (8.37e-2)"			"unprognostic (2.84e-1)"	"unprognostic (3.28e-1)"				"unprognostic (1.71e-1)"	"unprognostic (2.46e-1)"			0.2	0.2	1.0	0.8	2.1	2.4	0.2	0.4	8.7	0.3	0.4	0.2	0.0	0.3	0.5	1.6	2.6	0.2	0.2	0.2	1.2	0.7	1.0	0.2	0.2	0.5	0.8	1.4	0.3	0.3	0.1	0.2	0.2	0.0	0.2	0.5	0.0	0.5	0.1	0.5	1.2	0.5	0.1	0.7	0.5	0.3	1.5	0.0	0.0	0.5	0.0	0.5	0.3	0.6	1.6	1.3	2.9	0.9	1.9	0.9	0.1	0.5	1.4	0.8	0.8	1.6	0.9	1.2	0.1	0.2	0.2	0.2	1.0	0.9	1.9	0.5	0.5	0.7	0.5	0.6	0.6	0.8	0.5	0.8	0.6	1.9	1.8	0.3	1.6	1.4	1.1	0.5	0.2	0.0	0.6	0.2	1.0	0.8	1.5	0.3	0.2	0.9	1.6	0.4	0.7	0.2	0.8	1.4	0.9	0.9	0.7	0.7	2.8	0.5	1.6	1.1	1.3	0.6	0.4	1.8	1.5	1.1	1.5	1.1	1.1	0.7	1.4	0.9	0.6	0.8	1.6	0.9	0.3	0.9	0.5	0.7	1.3	0.8	0.6	0.5	1.6	0.9	0.9	2.9	1.9	0.3	1.3	0.7	0.1	1.0	2.1	0.4	8.7	1.2	0.7	0.8	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR3C		ENSG00000178084	"5-hydroxytryptamine receptor 3C"	Q8WXA8	3	184053047-184060671	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	4	"lung: 6.8"	"Cell type enriched"	"Detected in single"	7	"Intestinal endocrine cells: 1.7"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	5	"GAMG: 3.8"					"Not detected"	"Not detected"									NA	NA									"unprognostic (4.56e-2)"		"unprognostic (2.01e-1)"		"unprognostic (1.39e-1)"		"unprognostic (1.61e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.68e-2)"		"unprognostic (8.72e-2)"	"unprognostic (1.75e-1)"		"unprognostic (3.88e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3			1.5	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	6.8	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.1	0.2		0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1			0.2		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.6	0.1	0.0	0.3	0.0	0.1	0.2	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1
HTR3D		ENSG00000186090	"5-hydroxytryptamine receptor 3D"	Q70Z44	3	184031544-184039369	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"No human protein/transcript evidence"	"Evidence at protein level"	"Evidence at protein level"		"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"RPTEC TERT1: 1.8"					"Low region specificity"	"Detected in many"									NA	NA															"unprognostic (3.08e-1)"								0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0			0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.1		0.0	0.0	0.0	0.2	0.0		0.2	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.8			0.3		0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR3E		ENSG00000186038	"5-hydroxytryptamine receptor 3E"	A5X5Y0	3	184097064-184106995	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	6	"intestine: 7.0"	"Cell type enriched"	"Detected in single"	24	"Intestinal endocrine cells: 3.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"RH-30: 5.5"									HPA049764	Enhanced					NA	NA					"HPA049764: AB_2680869"		"unprognostic (4.12e-2)"	"unprognostic (5.86e-2)"	"unprognostic (2.15e-1)"		"unprognostic (4.57e-4)"		"unprognostic (3.61e-3)"		"unprognostic (1.15e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.47e-1)"		"unprognostic (3.32e-1)"	"unprognostic (2.67e-1)"		"unprognostic (4.16e-2)"	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	5.7	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	7.0	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1
HTR4	5-HT4	ENSG00000164270	"5-hydroxytryptamine receptor 4"	Q13639	5	148451032-148677235	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"brain: 18.1;heart muscle: 7.2;intestine: 14.6;pituitary gland: 5.9"	"Cell type enhanced"	"Detected in some"	18	"Cardiomyocytes: 4.3;Enterocytes: 2.8;Undifferentiated cells: 3.5"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"basal ganglia: 18.1"	"Cell type enriched"	"Detected in single"	8	"T-reg: 1.5"	"Lineage enriched"	"Detected in single"	15	"T-cells: 1.5"	"Cell line enriched"	"Detected in single"	5	"Karpas-707: 2.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA040591	Enhanced					NA	NA					"HPA040591: AB_2677028"	"unprognostic (1.12e-1)"	"unprognostic (4.60e-2)"	"unprognostic (7.74e-2)"		"unprognostic (2.37e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.77e-2)"	"unprognostic (4.68e-2)"			"unprognostic (1.10e-2)"	"unprognostic (1.13e-1)"	"unprognostic (1.46e-1)"	"unprognostic (3.40e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.49e-2)"	"unprognostic (8.83e-5)"	0.4	1.4	1.9	1.1	18.1	0.1	0.2	0.1	3.2	0.6	4.3	0.0	0.0	8.0	0.3	0.1	0.3	0.4	1.5	7.2	5.2	0.6	0.1	0.2	0.3	0.2	0.5	1.3	0.2	0.1	0.1	5.9	0.1	0.1	0.1	4.9	0.0	0.2	0.2	0.2	0.2	14.6	1.1	0.3	0.2	0.2	0.2	2.4	0.0	0.2	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.5	0.0	1.9	18.1	0.1	3.2	5.2	0.6	0.5	1.3	0.1	2.4	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0
HTR6	"5-HT6, 5-HT6R"	ENSG00000158748	"5-hydroxytryptamine receptor 6"	P50406	1	19665287-19679562	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	9	"brain: 24.6"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"renal cancer: 0.6"	"Group enriched"	"Detected in many"	5	"basal ganglia: 24.6;cerebral cortex: 6.6"	"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 1.4;naive CD4 T-cell: 1.1"	"Lineage enriched"	"Detected in single"	14	"T-cells: 1.4"	"Cell line enhanced"	"Detected in some"		"MCF7: 1.2;NTERA-2: 2.4;SH-SY5Y: 6.7"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 9.5"	HPA068165	Uncertain					NA	NA					"HPA068165: "	"unprognostic (2.34e-2)"	"unprognostic (1.84e-1)"	"unprognostic (7.19e-3)"	"unprognostic (3.84e-5)"	"unprognostic (1.38e-4)"	"unprognostic (2.69e-2)"		"unprognostic (1.36e-1)"	"unprognostic (2.80e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.33e-3)"	"unprognostic (8.63e-2)"	"unprognostic (5.47e-4)"	"unprognostic (1.28e-1)"	"unprognostic (2.49e-1)"	"unprognostic (6.13e-3)"	"unprognostic (2.02e-1)"	0.4	0.5	1.2	1.4	24.6	0.4	0.4	0.2	6.6	0.6	0.4	0.0	0.0	0.6	0.6	0.5	0.5	0.6	0.5	0.4	1.4	1.0	0.3	0.3	0.3	1.4	0.5	2.2	0.3	0.3	0.3	0.4	0.3	0.4	0.4	0.3	0.0	0.5	0.3	0.3	0.8	0.5	0.5	0.2	0.4	0.5	0.8	3.2	0.0	0.3	0.0	2.7	0.6	0.2	0.0	0.0	0.0	0.0	0.0	1.4	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.0	2.4	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	1.4	0.0	1.0	0.5	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.2	24.6	0.2	6.6	1.4	1.0	0.5	2.2	0.4	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
HTR7	5-HT7	ENSG00000148680	"5-hydroxytryptamine receptor 7"	P34969	10	90740823-90857698	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"parathyroid gland: 30.8;testis: 14.3"	"Cell type enhanced"	"Detected in some"	17	"Early spermatids: 4.8;Hofbauer cells: 1.3;Kupffer cells: 1.5;Late spermatids: 2.0;Spermatocytes: 1.4"	"Group enriched"	"Detected in some"	5	"cervical cancer: 0.9;head and neck cancer: 3.3;lung cancer: 0.9;urothelial cancer: 1.3"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	12	"myeloid DC: 4.6"	"Lineage enriched"	"Detected in single"	12	"dendritic cells: 4.6"	"Cell line enhanced"	"Detected in some"		"HBEC3-KT: 8.2;hTCEpi: 7.5;hTERT-HME1: 25.0;LHCN-M2: 10.0;U-87 MG: 7.7;WM-115: 9.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB022708, HPA073617"	Approved	Supported	Supported	"Nuclear speckles,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nuclear speckles, Cytosol"	"CAB022708: , HPA073617: AB_2732228"	"unprognostic (1.17e-1)"	"unprognostic (1.24e-2)"	"unprognostic (4.72e-2)"	"unprognostic (1.33e-1)"	"unprognostic (5.51e-3)"	"unprognostic (1.71e-2)"	"unprognostic (1.89e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.15e-1)"	"unprognostic (4.58e-3)"	"unprognostic (3.32e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.89e-1)"	"unprognostic (1.23e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.84e-2)"	"unprognostic (6.49e-2)"	1.0	0.5	2.4	1.1	2.5	0.5	0.7	0.3	4.3	0.6	0.8	1.7	1.2	0.8	0.4	0.3	1.0	0.4	1.3	0.6	9.9	5.1	0.3	0.6	0.5	0.7	1.7	1.8	0.4	1.4	30.8	0.2	0.5	3.1	1.0	1.2	0.4	0.6	0.3	1.7	0.9	2.2	3.6	1.5	1.3	1.5	14.3	1.0	0.0	0.3	0.1	0.6	3.5	2.1	0.0	4.6	0.0	0.3	0.0	0.2	0.1	0.2	0.0	0.0	0.0	0.1	0.7	0.0	0.5	0.2	0.5	0.8	0.0	0.9	0.0	0.0	0.1	1.5	3.4	0.9	8.2	2.1	0.0	0.1	0.0	0.0	0.0	3.9	0.0	0.4	5.9	7.5	2.5	25.0	4.7	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.1	0.9	0.0	1.2	0.7	0.1	0.0	0.0	0.9	0.3	0.0	0.3	0.0	3.9	0.4	0.0	0.2	0.2	4.6	0.0	0.0	6.9	0.0	0.0	0.0	7.7	0.0	9.5	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.1	0.1	4.6	0.0	0.2	0.2	0.0	0.0	0.3	0.0	0.1	0.1	2.4	2.5	0.3	4.3	9.9	5.1	1.7	1.8	3.1	1.0	0.0	0.0	0.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.3	0.0	0.0	0.6	1.5	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.0	0.1	0.1	0.0	0.0	0.2
ICAM1	"BB2, CD54"	ENSG00000090339	"Intercellular adhesion molecule 1"	P05362	19	10270835-10286615	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 68.3;lung: 91.3"	"Cell type enhanced"	"Detected in many"	9	"Alveolar cells type 1: 568.7;Alveolar cells type 2: 522.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HHSteC: 31.6;Karpas-707: 90.1;RPMI-8226: 28.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA002126, CAB002142, HPA004877"	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA	87900000	3100000000	"Plasma membrane, Cytosol"		"CAB002142: AB_563596, HPA002126: AB_1078470, HPA004877: AB_1846317"	"prognostic favorable (7.09e-4)"	"unprognostic (1.88e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.63e-2)"	"unprognostic (3.25e-3)"	"unprognostic (3.05e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.48e-1)"	"unprognostic (3.18e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.49e-2)"	"unprognostic (1.79e-1)"	"prognostic unfavorable (1.32e-6)"	"unprognostic (2.77e-1)"	"unprognostic (2.16e-2)"	"unprognostic (2.25e-1)"	"unprognostic (3.70e-3)"	26.1	8.6	4.0	41.0	4.1	36.5	15.0	1.0	4.5	5.6	10.0	2.7	1.6	6.1	8.5	7.7	7.9	10.7	19.8	16.3	2.6	2.1	10.9	68.3	91.3	32.8	5.4	1.7	12.4	7.2	2.5	4.0	9.3	6.8	10.4	6.6	10.6	7.2	3.6	13.9	6.9	7.9	8.0	7.8	42.2	7.3	6.5	3.6	8.3	11.6	13.7	13.4	14.8	17.1	2.2	13.3	22.2	14.2	7.9	5.6	8.9	8.4	0.1	1.5	0.0	0.4	0.9	2.1	1.7	18.8	4.2	12.7	2.8	9.5	7.7	26.2	0.7	19.3	1.7	0.3	0.0	8.9	23.1	0.0	0.7	0.2	11.5	31.6	0.2	4.5	11.1	0.7	2.6	4.1	0.4	2.1	0.9	2.9	90.1	0.3	0.6	0.1	6.5	0.5	0.1	4.8	0.2	0.0	28.6	7.2	0.0	0.0	0.2	11.6	0.6	18.4	0.7	1.4	0.5	6.5	4.3	0.4	2.4	0.1	27.5	28.3	4.8	7.0	4.9	6.3	2.2	13.9	2.6	3.0	14.2	5.6	2.2	2.4	3.6	13.3	0.9	1.0	2.2	22.2	7.9	7.9	7.5	3.4	8.9	4.0	4.1	1.0	4.5	2.6	2.1	5.4	1.7	6.8	3.6	568.7	522.3	12.0	22.9	75.8	0.0	0.8	20.4	80.3	159.3	3.5	0.0	1.0	0.0	152.6	1.9	139.3	0.5	0.0	84.4	2.5	171.6	19.1	133.1	12.9	75.0	0.0	2.4	56.4	41.3	1.1	4.4	160.6	72.6	168.7	0.3	2.3	107.4	0.0	1.4	9.4	0.3	6.5	95.4	0.5	1.7	60.6	1.0	12.7	0.5	10.0
IDE		ENSG00000119912	"Insulin degrading enzyme"	P14735	10	92451684-92574076	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Allosteric enzyme, Host cell receptor for virus entry, Hydrolase, Metalloprotease, Protease, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Cone photoreceptor cells: 45.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA063478	Approved				"Intracellular and membrane"	NA	NA		140000			"HPA063478: AB_2685020"	"unprognostic (1.70e-1)"	"unprognostic (6.40e-2)"	"prognostic favorable (3.69e-4)"	"prognostic favorable (3.53e-4)"	"unprognostic (2.54e-1)"	"unprognostic (1.78e-1)"	"unprognostic (2.51e-1)"	"unprognostic (3.79e-1)"	"unprognostic (8.88e-2)"	"unprognostic (2.57e-1)"	"unprognostic (6.58e-2)"	"unprognostic (7.79e-2)"	"unprognostic (6.81e-2)"	"unprognostic (9.24e-3)"	"unprognostic (6.13e-2)"	"unprognostic (3.89e-2)"	"unprognostic (3.91e-1)"	9.8	13.1	6.9	11.7	8.8	6.0	19.8	8.6	9.4	10.5	9.9	6.5	17.5	7.4	10.2	15.9	13.0	8.4	9.6	13.6	5.8	5.3	13.3	21.3	7.9	9.2	8.9	5.1	7.7	15.7	19.4	11.1	9.4	7.6	11.6	10.0	10.5	11.0	17.2	31.1	45.2	10.7	14.3	8.8	9.9	10.3	18.1	7.5	13.5	12.0	13.9	10.7	11.5	9.8	7.4	11.3	3.8	13.7	7.7	10.6	5.5	12.3	18.4	14.4	29.4	14.0	11.8	7.9	11.0	26.1	11.6	9.9	18.7	14.8	17.5	16.3	16.0	10.9	16.0	18.9	12.1	7.6	21.0	11.6	8.7	15.4	16.4	12.3	26.6	13.8	8.3	11.8	13.6	19.7	16.4	19.5	7.4	16.2	12.5	13.1	8.3	8.8	10.5	11.4	13.8	7.3	12.3	13.4	11.2	17.1	23.3	6.7	9.3	14.8	10.6	9.7	15.6	15.2	7.5	18.1	7.5	8.5	7.8	14.2	11.4	14.3	18.8	10.9	21.3	5.2	2.3	8.2	3.8	6.7	11.4	5.9	7.4	7.9	6.5	11.3	5.3	6.0	6.4	0.5	7.7	13.7	4.4	10.6	5.5	6.9	8.8	8.6	9.4	5.8	5.3	8.9	5.1	7.6	7.5	8.9	10.2	2.2	5.3	4.6	14.0	39.2	7.6	24.1	6.8	7.0	45.2	9.9	1.7	11.7	31.2	8.0	10.7	0.0	17.4	4.7	5.5	10.9	1.1	22.4	10.4	6.4	10.4	14.7	18.1	7.7	6.1	8.6	8.5	1.8	11.4	7.5	14.5	5.8	9.6	8.8	26.3	6.5	7.5	18.0	10.8	14.3	3.2	4.3	8.3	7.8
IDH2		ENSG00000182054	"Isocitrate dehydrogenase (NADP(+)) 2, mitochondrial"	P48735	15	90083045-90102504	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Glyoxylate bypass, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 126.2;skeletal muscle: 190.7"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 682.3;Distal tubular cells: 989.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MOLT-4: 69.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA007831	Enhanced		Supported	Mitochondria		NA	NA		53000000	Mitochondria		"HPA007831: AB_1851397"	"unprognostic (2.45e-2)"	"prognostic favorable (5.15e-5)"	"unprognostic (2.92e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.53e-1)"	"unprognostic (8.46e-2)"	"unprognostic (3.83e-2)"	"unprognostic (2.55e-3)"	"unprognostic (1.86e-2)"	"unprognostic (1.89e-2)"	"unprognostic (2.76e-1)"	"unprognostic (4.90e-2)"	"unprognostic (2.19e-3)"	"unprognostic (3.92e-3)"	"unprognostic (4.46e-1)"	"unprognostic (1.30e-2)"	"unprognostic (2.58e-2)"	5.4	2.0	14.9	10.1	16.6	22.6	8.8	4.9	19.1	6.4	16.2	13.8	12.4	16.1	5.9	15.3	23.7	6.0	9.4	126.2	10.2	9.3	25.0	93.2	6.9	15.8	14.4	12.0	3.0	25.1	8.4	3.3	15.1	11.9	13.3	14.5	6.0	28.0	21.9	190.7	11.0	13.9	15.8	11.0	7.5	27.9	1.2	7.6	28.2	3.4	69.0	13.6	11.0	8.6	16.8	32.8	17.2	56.3	22.2	29.5	31.2	10.3	5.9	30.6	30.3	4.3	5.2	26.0	13.0	19.8	12.3	13.2	2.8	9.0	12.3	3.7	10.7	11.7	3.6	4.4	3.9	5.8	24.2	2.9	21.0	2.2	20.6	5.2	14.4	21.3	11.0	2.2	2.9	2.3	14.9	25.1	43.6	3.1	10.6	9.4	30.2	69.1	22.4	9.1	14.2	2.4	58.6	21.9	36.7	18.9	12.5	44.1	22.4	16.1	64.4	5.2	17.8	51.9	44.5	6.0	21.9	3.2	2.8	6.0	17.5	3.2	1.4	7.0	30.3	12.6	9.0	26.4	17.2	26.1	48.0	12.4	16.8	18.7	29.5	32.8	9.8	10.2	18.2	5.1	22.2	56.3	17.8	15.9	31.2	14.9	16.6	4.9	19.1	10.2	9.3	14.4	12.0	11.9	7.6	6.0	21.8	67.0	66.5	35.4	5.3	402.1	104.4	56.2	21.6	71.5	9.8	682.3	989.8	188.2	4.7	25.3	53.5	23.3	255.6	386.0	36.6	189.5	30.1	240.4	229.9	9.5	59.3	41.1	60.4	2.5	13.0	70.5	55.6	96.4	122.1	17.5	127.7	132.1	33.2	128.5	5.1	12.9	38.3	0.5	4.5	58.6	479.2	123.2	268.2	90.1
IDH3A		ENSG00000166411	"Isocitrate dehydrogenase 3 (NAD(+)) alpha"	P50213	15	78131498-78171949	"Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Tricarboxylic acid cycle"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"plasmacytoid DC: 47.2"	"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA041465, HPA062971"	Supported		Enhanced	Mitochondria		No	No		2000000	Mitochondria		"HPA041465: AB_10794377, HPA062971: AB_2684913"	"unprognostic (2.33e-1)"	"unprognostic (1.21e-1)"	"unprognostic (5.76e-3)"	"unprognostic (2.26e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.01e-1)"	"unprognostic (2.29e-1)"	"unprognostic (6.47e-2)"	"unprognostic (1.69e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.05e-1)"	"unprognostic (1.42e-1)"	"prognostic favorable (6.49e-8)"	"unprognostic (1.40e-1)"	"unprognostic (3.08e-2)"	"unprognostic (4.49e-2)"	"unprognostic (3.39e-2)"	14.6	18.1	18.0	13.0	25.3	6.5	7.7	16.1	29.5	9.9	17.6	11.9	6.1	24.5	11.2	5.9	12.0	8.4	6.5	41.5	16.6	16.8	15.2	10.4	8.8	11.0	20.6	18.1	8.0	9.2	18.5	12.4	8.4	29.0	10.1	18.8	10.4	11.2	11.9	47.7	11.1	23.8	11.9	18.1	10.1	8.9	11.5	13.8	16.2	8.1	26.5	16.4	11.1	10.3	10.1	47.2	6.1	17.0	5.5	6.0	7.4	16.0	22.0	4.0	14.0	10.0	10.3	8.7	19.1	9.3	15.7	11.9	15.7	9.8	34.2	14.2	11.2	23.2	24.3	37.2	14.8	14.5	15.0	12.3	13.2	23.9	7.1	8.6	25.6	18.9	7.8	9.1	15.2	16.0	7.5	9.8	12.2	16.9	14.1	9.9	15.3	18.7	6.8	4.9	9.3	8.3	10.9	17.2	10.6	13.0	21.9	16.0	6.2	21.9	31.4	17.8	7.7	12.5	13.9	10.0	18.5	17.1	24.3	30.8	16.1	35.8	18.2	13.0	24.5	14.4	4.2	9.4	2.7	5.3	17.0	5.7	9.2	5.2	4.8	14.2	10.1	5.6	6.0	6.1	5.5	16.6	47.2	5.6	7.4	18.0	25.3	16.1	29.5	16.6	16.8	20.6	18.1	29.0	13.8	8.9	13.9	26.8	49.8	49.7	32.4	15.3	10.2	40.2	11.4	24.4	35.3	35.1	69.6	20.4	40.5	16.4	42.3	0.0	15.5	32.0	20.6	24.1	26.5	21.2	23.7	25.4	18.5	11.1	22.8	17.5	19.2	26.5	25.3	6.4	36.6	24.2	18.9	28.8	22.3	37.6	27.3	12.9	34.3	41.4	22.6	36.0	57.2	20.3	49.2	35.8
IFNAR1	"IFNAR, IFRC"	ENSG00000142166	"Interferon alpha and beta receptor subunit 1"	P17181	21	33324477-33359862	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 50.8"					"Low region specificity"	"Detected in all"			HPA029226	Approved					NA	NA		100000			"HPA029226: AB_2672954"	"unprognostic (2.42e-3)"	"unprognostic (2.95e-1)"	"unprognostic (3.01e-1)"	"unprognostic (1.15e-1)"	"unprognostic (4.93e-2)"	"unprognostic (2.22e-1)"	"unprognostic (1.01e-1)"	"unprognostic (3.02e-1)"	"unprognostic (4.69e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.31e-2)"	"unprognostic (2.38e-1)"	"unprognostic (9.38e-3)"	"unprognostic (5.93e-2)"	"unprognostic (2.01e-1)"	"unprognostic (8.45e-2)"	"unprognostic (3.06e-2)"	27.2	16.4	18.5	16.8	18.7	14.8	15.9	18.1	22.9	14.2	16.8	15.1	10.0	12.3	15.7	10.9	15.8	13.5	16.2	14.5	16.9	15.8	17.5	56.4	16.6	15.0	19.7	13.8	16.6	18.3	30.6	17.9	23.2	18.3	14.7	12.2	12.1	17.6	12.6	17.3	10.6	15.8	13.7	22.2	29.8	18.8	10.3	16.7	26.9	21.4	9.1	13.1	18.7	18.1	20.5	17.8	64.5	23.1	7.3	12.1	10.7	13.3	12.2	5.2	5.9	17.2	17.5	6.0	14.4	15.5	6.7	6.8	13.1	15.3	10.3	11.7	9.9	8.4	8.0	4.9	8.5	7.1	11.7	9.8	15.4	11.8	7.7	7.3	11.3	11.0	14.5	7.5	11.0	6.6	8.8	12.7	11.8	17.6	50.8	10.9	11.1	8.4	4.6	5.6	8.9	7.8	8.3	18.3	17.6	7.3	17.6	6.2	5.6	14.5	10.3	9.2	3.6	15.9	8.3	20.2	13.4	7.3	17.6	8.0	33.9	46.6	11.9	18.0	16.0	14.3	18.9	16.8	9.7	8.0	19.7	7.5	18.5	10.6	9.0	11.3	20.5	12.1	9.4	64.5	7.3	23.1	17.8	12.0	10.7	18.5	18.7	18.1	22.9	16.9	15.8	19.7	13.8	18.3	16.7	101.3	37.9	45.4	49.1	40.6	49.3	32.2	25.5	61.6	71.7	41.8	27.5	23.5	18.3	64.6	10.8	66.9	25.8	23.3	78.0	78.5	32.8	57.7	37.1	71.7	60.0	55.6	25.8	50.3	69.5	7.7	30.2	70.9	35.4	83.0	28.9	32.2	57.6	24.6	29.0	21.4	25.6	19.4	33.4	26.3	12.1	39.3	16.8	29.3	26.0	69.1
IFNAR2	IFNABR	ENSG00000159110	"Interferon alpha and beta receptor subunit 2"	P48551	21	33229901-33265675	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"Karpas-707: 52.3;U-266/70: 66.4;U-266/84: 34.4"														"Secreted to blood"	NA	NA		610000				"unprognostic (2.00e-2)"	"unprognostic (7.83e-3)"	"unprognostic (4.98e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.50e-3)"	"unprognostic (8.05e-2)"	"unprognostic (4.17e-2)"	"unprognostic (2.11e-2)"	"unprognostic (7.65e-2)"	"unprognostic (4.42e-1)"	"prognostic unfavorable (7.54e-7)"	"unprognostic (9.70e-3)"	"unprognostic (2.39e-1)"	"unprognostic (5.12e-3)"	"unprognostic (1.85e-2)"	16.9	8.7	9.9	28.1	11.3	19.1	18.3	10.7	13.0	10.2	12.2	10.6	9.6	12.8	12.0	10.1	8.1	11.1	15.5	13.6	10.3	9.7	13.4	20.5	21.6	41.7	13.3	8.3	11.9	10.2	11.2	10.9	15.7	10.2	9.9	13.2	7.9	14.4	11.6	6.6	6.6	14.1	13.0	13.2	40.9	9.9	4.6	12.1	34.7	11.3	6.6	25.3	24.2	10.7	9.9	37.6	37.1	25.3	12.2	23.7	14.2	4.1	4.7	2.5	5.7	3.0	7.1	4.1	4.2	11.2	3.6	3.8	6.3	4.7	6.5	3.1	6.5	5.5	2.6	3.5	2.3	3.5	4.1	5.3	23.8	5.2	5.8	4.4	4.0	8.9	5.0	2.2	4.0	4.9	6.4	11.4	10.2	7.5	52.3	3.5	2.4	10.3	4.9	4.5	5.5	3.1	3.5	12.9	12.8	7.6	8.3	6.5	3.7	7.2	6.4	6.1	2.7	1.1	7.6	7.5	3.7	2.2	2.9	2.3	66.4	34.4	16.1	5.3	14.4	8.6	13.7	14.5	22.7	12.2	23.7	12.8	9.9	15.2	11.5	13.6	6.7	11.2	12.3	37.1	12.2	25.3	37.6	23.7	14.2	9.9	11.3	10.7	13.0	10.3	9.7	13.3	8.3	10.2	12.1	56.6	17.3	28.9	40.1	6.1	5.2	2.5	25.5	28.1	20.5	10.4	5.9	24.6	3.3	61.4	2.4	32.2	8.1	0.0	54.3	61.5	11.8	37.0	31.1	17.4	40.5	19.1	2.9	38.6	68.7	2.4	6.9	46.3	18.6	33.3	3.7	5.7	58.2	3.6	8.5	8.4	5.4	0.0	13.3	2.9	22.4	5.0	19.7	40.3	3.8	62.9
IFNG		ENSG00000111537	"Interferon gamma"	P01579	12	68154768-68159747	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Antiviral defense, Growth regulation"	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.4;lung: 14.5"	"Cell type enriched"	"Detected in some"	14	"T-cells: 93.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	5	"gdT-cell: 7.3;memory CD4 T-cell: 3.3;memory CD8 T-cell: 8.6;naive CD8 T-cell: 5.2"	"Lineage enriched"	"Detected in many"	7	"T-cells: 8.6"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 2.3;U-266/70: 2.3;U-698: 1.2"					"Low region specificity"	"Detected in some"			CAB010344	Approved				"Secreted to blood"	NA	NA	1470				"CAB010344: AB_2123447"	"unprognostic (2.16e-4)"	"unprognostic (1.93e-3)"	"unprognostic (9.21e-2)"	"unprognostic (1.04e-4)"	"unprognostic (5.14e-1)"	"unprognostic (3.96e-3)"	"unprognostic (1.33e-1)"	"unprognostic (3.17e-4)"	"unprognostic (7.79e-2)"	"unprognostic (7.97e-3)"	"unprognostic (1.63e-2)"	"unprognostic (5.36e-2)"	"unprognostic (7.62e-9)"	"unprognostic (3.54e-2)"	"unprognostic (5.36e-1)"	"unprognostic (6.32e-2)"	"unprognostic (7.38e-3)"	2.4	0.9	0.3	4.5	0.3	14.4	0.5	0.1	1.0	1.4	0.9	0.5	0.0	0.2	0.6	1.4	1.3	0.2	0.6	1.0	0.3	0.3	0.7	4.1	14.5	8.5	1.5	0.4	0.4	0.2	0.0	0.5	0.8	0.6	1.2	0.4	1.1	1.4	0.2	1.7	0.3	0.7	0.7	1.3	4.1	0.8	0.2	0.0	0.8	1.3	3.1	4.7	2.2	0.6	0.5	0.0	0.2	0.0	1.2	8.6	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	3.3	8.6	0.0	0.5	0.8	5.2	0.2	1.2	0.0	0.0	0.2	1.1	0.3	0.3	0.1	1.0	0.3	0.3	1.5	0.4	0.6	0.0	0.0	0.0	0.5	0.4	2.9	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.8	0.1	0.0	0.0	1.3	3.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.4	0.0	93.0	0.1	0.1
IFNGR1	"CD119, IFNGR"	ENSG00000027697	"Interferon gamma receptor 1"	P15260	6	137197484-137219449	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 258.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTCEpi: 57.1"					"Low region specificity"	"Detected in all"			"CAB025889, HPA029213, HPA063871"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB025889: , HPA029213: AB_10601023, HPA063871: AB_2685138"	"unprognostic (1.73e-1)"	"unprognostic (8.86e-2)"	"unprognostic (9.85e-3)"	"unprognostic (1.71e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.25e-1)"	"unprognostic (4.05e-1)"	"unprognostic (6.97e-2)"	"unprognostic (9.86e-2)"	"unprognostic (1.57e-2)"	"unprognostic (4.09e-2)"	"unprognostic (2.85e-1)"	"prognostic unfavorable (5.48e-4)"	"unprognostic (1.58e-1)"	"unprognostic (2.87e-2)"	"unprognostic (1.81e-2)"	"unprognostic (5.38e-3)"	69.5	22.2	17.4	36.9	23.5	37.7	65.3	8.4	18.5	23.6	27.1	27.8	13.8	28.0	19.2	21.2	23.0	20.3	25.9	53.7	20.6	17.4	19.3	66.4	58.7	86.9	33.8	13.2	19.2	17.5	9.2	12.8	47.0	29.9	20.1	22.8	11.6	24.5	18.0	25.3	24.0	46.7	22.5	45.7	69.1	20.3	14.1	26.3	14.5	22.8	19.7	38.2	25.0	22.3	12.2	39.4	92.3	65.4	5.4	29.7	52.3	4.8	4.7	6.2	8.0	40.8	21.5	5.2	13.9	20.7	9.1	12.3	30.5	9.5	4.8	22.3	8.0	13.2	30.3	5.4	14.1	12.7	10.4	7.5	7.6	5.8	45.1	23.1	23.7	11.4	47.5	57.1	7.6	12.3	8.4	11.4	7.0	6.4	8.3	6.8	5.5	3.8	10.9	5.1	44.4	3.8	11.7	6.5	7.3	15.8	23.0	6.2	9.6	17.2	10.1	12.6	12.3	3.6	15.7	15.8	8.9	6.5	11.5	7.3	6.1	5.7	5.4	4.6	15.8	8.6	16.5	65.4	43.3	14.1	63.0	29.7	10.9	8.0	11.8	39.4	12.2	5.2	5.8	92.3	5.4	44.1	10.1	5.6	52.3	17.4	23.5	8.4	18.5	20.6	17.4	33.8	13.2	29.9	26.3	74.5	64.2	57.6	146.1	113.3	14.2	38.0	33.1	83.0	77.3	26.2	11.8	63.2	6.6	61.6	3.2	106.4	70.3	0.0	88.3	59.0	70.9	89.3	61.2	50.3	132.8	9.5	12.6	63.8	258.9	4.3	40.9	249.4	47.2	88.4	19.2	19.7	74.0	28.1	46.3	15.1	20.6	12.9	65.2	8.4	20.4	99.0	175.5	67.8	27.9	144.7
IFNGR2	"AF-1, IFNGT1"	ENSG00000159128	"Interferon gamma receptor 2"	P38484	21	33402896-33479348	"Disease related genes, FDA approved drug targets, Predicted membrane proteins"		Receptor	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Glandular cells: 309.5;Urothelial cells: 502.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 55.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 20.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001535	Approved		Approved	"Nucleoplasm,Golgi apparatus"		NA	NA			"Nucleoplasm, Golgi apparatus"		"HPA001535: AB_1078432"	"unprognostic (9.58e-2)"	"unprognostic (5.18e-3)"	"unprognostic (1.53e-1)"	"unprognostic (5.03e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavorable (3.25e-4)"	"unprognostic (3.29e-1)"	"unprognostic (1.54e-1)"	"unprognostic (3.53e-2)"	"unprognostic (3.25e-2)"	"unprognostic (9.49e-2)"	"prognostic unfavorable (1.13e-10)"	"unprognostic (6.74e-3)"	"unprognostic (2.49e-1)"	"unprognostic (8.02e-2)"	"unprognostic (2.15e-3)"	27.2	13.4	11.9	20.8	12.6	45.1	64.4	4.6	18.0	12.5	21.6	5.7	13.0	18.5	10.6	14.1	21.9	11.5	15.2	17.7	11.1	10.1	14.6	20.2	26.3	46.3	8.7	9.4	13.0	21.7	7.1	12.6	20.5	12.2	14.9	11.7	12.1	21.9	11.7	13.1	16.7	20.0	15.3	18.1	27.4	30.3	14.1	7.2	7.9	18.1	19.4	18.9	14.8	26.8	13.2	7.7	55.1	22.8	0.3	3.3	13.8	3.0	2.6	1.3	2.7	3.8	6.5	4.3	8.8	6.4	2.0	3.3	3.1	1.7	5.3	4.9	5.3	5.9	2.3	2.8	6.1	1.1	20.4	17.2	1.5	1.1	2.7	2.6	7.6	4.8	4.9	4.0	3.5	3.5	3.8	5.2	2.6	8.0	2.6	2.8	0.9	1.8	5.2	4.9	3.6	16.7	4.5	4.2	4.4	2.2	4.1	1.9	4.7	4.4	0.5	8.4	0.7	1.6	4.9	8.8	2.5	5.5	2.1	2.1	5.6	7.6	6.8	2.2	6.8	12.0	12.9	22.2	14.8	0.1	22.0	0.1	11.5	1.3	0.1	7.7	13.2	3.3	1.4	55.1	0.3	22.8	2.4	1.4	13.8	11.9	12.6	4.6	18.0	11.1	10.1	8.7	9.4	12.2	7.2	38.7	25.1	76.3	178.2	64.0	8.7	16.6	43.3	13.4	19.4	26.2	7.9	28.1	23.2	100.9	35.4	41.3	130.0	0.0	48.9	66.1	81.2	309.5	59.9	24.9	150.7	14.3	49.5	36.8	129.5	44.6	38.9	162.5	54.0	211.0	45.2	7.8	102.1	105.2	30.8	39.8	7.2	12.9	30.1	3.9	1.7	61.2	14.5	13.8	35.8	502.7
IGF1R	"CD221, IGFIR, IGFR, JTK13, MGC18216"	ENSG00000140443	"Insulin like growth factor 1 receptor"	P08069	15	98648971-98964530	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 7.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 7.7;T-cells: 2.9"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							"CAB010268, HPA045563"	Approved					NA	NA		36000			"CAB010268: AB_671792, HPA045563: AB_2679368"	"unprognostic (1.30e-3)"	"unprognostic (5.81e-3)"	"unprognostic (1.53e-1)"	"unprognostic (3.34e-2)"	"unprognostic (2.65e-1)"	"unprognostic (2.05e-2)"	"unprognostic (1.29e-2)"	"unprognostic (6.87e-2)"	"unprognostic (2.64e-2)"	"unprognostic (2.87e-2)"	"unprognostic (8.56e-2)"	"unprognostic (1.62e-1)"	"prognostic favorable (3.75e-7)"	"unprognostic (1.57e-1)"	"unprognostic (3.59e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.06e-1)"	8.4	12.7	11.5	5.9	13.5	16.3	18.5	23.0	15.7	15.3	13.4	10.4	22.7	4.2	15.3	16.3	9.2	18.9	7.7	11.6	11.7	7.3	17.0	2.0	11.0	4.9	8.0	11.8	23.2	22.5	4.7	13.8	17.5	9.5	21.7	7.2	16.7	12.5	23.2	9.1	13.0	7.5	18.1	8.0	7.3	10.7	12.0	11.5	10.7	16.1	7.0	5.6	12.8	21.6	1.0	0.4	7.7	0.6	1.0	2.9	0.7	3.2	16.3	11.4	0.2	5.7	4.2	7.6	3.6	7.3	1.2	1.0	7.0	8.6	0.8	10.6	7.1	8.0	15.5	5.1	14.8	1.0	0.0	5.1	12.3	18.2	14.0	5.0	6.5	1.3	6.5	7.0	2.1	10.0	4.3	4.0	1.3	0.6	2.9	5.6	23.0	2.5	4.4	10.6	5.4	0.9	4.0	8.9	2.9	3.4	20.0	3.8	17.1	26.2	1.5	14.1	25.7	8.0	3.0	11.1	1.1	14.7	2.9	5.7	1.0	4.4	2.7	2.2	4.8	2.7	4.0	0.6	1.8	0.9	0.6	0.6	0.4	0.8	0.3	0.4	1.0	2.9	1.0	7.7	1.0	0.5	0.3	0.0	0.7	11.5	13.5	23.0	15.7	11.7	7.3	8.0	11.8	9.5	11.5	26.8	11.2	0.0	25.0	29.1	51.6	25.7	10.2	38.8	31.8	21.0	86.4	26.8	1.7	13.8	23.0	23.2	5.1	0.0	9.4	16.8	24.2	51.2	0.0	0.4	5.8	71.5	33.7	38.1	7.0	38.8	16.7	5.0	20.3	2.8	21.9	47.2	25.3	10.5	12.7	18.6	32.3	0.0	17.6	3.3	13.6	28.0	23.0	3.2	20.4	39.1
IKBKB	"IKK-beta, IKK2, IKKB, NFKBIKB"	ENSG00000104365	"Inhibitor of nuclear factor kappa B kinase subunit beta"	O14920	8	42271302-42332653	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Host-virus interaction"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cone photoreceptor cells: 127.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001249, CAB004447"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB004447: AB_627785, HPA001249: AB_1079126"	"unprognostic (1.04e-1)"	"unprognostic (2.30e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.73e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.27e-3)"	"unprognostic (1.95e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.75e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.27e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.20e-2)"	"unprognostic (1.89e-2)"	"unprognostic (9.20e-2)"	"unprognostic (3.02e-1)"	"prognostic favorable (1.46e-6)"	9.1	10.8	10.9	17.0	16.7	9.3	10.0	26.1	16.9	10.3	10.3	12.4	11.4	4.7	15.3	13.2	17.9	16.4	14.9	7.9	13.1	6.9	12.4	9.9	14.9	12.2	20.3	7.9	9.6	13.3	18.0	13.6	11.2	11.9	14.0	10.9	10.5	11.4	9.7	17.6	22.2	9.8	16.4	10.5	18.7	10.8	8.3	18.6	12.9	14.3	8.4	17.1	18.1	12.8	12.6	14.8	14.1	9.6	11.9	11.2	5.8	3.6	12.9	3.7	6.3	14.3	12.4	4.7	3.2	11.3	9.5	8.4	2.9	6.7	7.1	5.5	8.8	9.0	4.1	5.0	12.7	12.3	6.9	5.7	9.9	6.0	2.3	10.9	1.9	10.4	8.2	9.7	9.1	14.2	18.7	14.0	4.7	8.4	3.5	20.8	4.1	6.9	3.1	3.6	11.8	4.1	7.1	6.3	4.1	10.7	3.3	1.1	2.1	2.0	3.6	5.2	6.9	4.8	8.3	7.2	6.7	3.5	5.2	2.3	2.1	2.1	5.0	7.9	4.7	7.6	14.1	9.6	10.4	10.1	7.6	10.3	9.4	10.5	11.2	8.9	12.6	10.2	10.4	11.4	11.9	9.0	14.8	9.9	5.8	10.9	16.7	26.1	16.9	13.1	6.9	20.3	7.9	11.9	18.6	11.9	24.0	17.7	29.3	21.6	11.3	4.5	15.3	14.7	13.6	15.7	127.6	8.6	1.7	11.4	2.0	27.7	11.8	0.0	11.8	4.6	9.8	23.2	36.9	10.2	15.8	17.5	10.9	15.4	26.9	3.0	15.3	17.7	18.6	13.6	15.1	11.6	13.3	14.4	12.0	4.8	52.3	6.5	6.4	2.6	6.4	25.5	12.7	20.3	13.6	25.7
IL11RA		ENSG00000137070	"Interleukin 11 receptor subunit alpha"	Q14626	9	34650702-34661892	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Craniosynostosis, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Fibroblasts: 55.3;Late spermatids: 74.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 21.7;HSkMC: 23.5"					"Low region specificity"	"Detected in all"			"HPA013162, CAB032830, HPA036652"	Supported					NA	NA					"CAB032830: AB_2123745, HPA013162: AB_2668790, HPA036652: AB_2675229"	"unprognostic (7.76e-2)"	"unprognostic (7.63e-2)"	"unprognostic (1.05e-1)"	"unprognostic (6.76e-3)"	"unprognostic (1.67e-1)"	"unprognostic (1.39e-2)"	"unprognostic (9.91e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.89e-2)"	"unprognostic (4.02e-1)"	"unprognostic (1.28e-3)"	"unprognostic (1.96e-1)"	"prognostic unfavorable (6.56e-4)"	"unprognostic (2.14e-1)"	"unprognostic (1.51e-1)"	"unprognostic (2.93e-2)"	"unprognostic (8.71e-2)"	9.6	4.4	6.8	8.5	10.1	5.2	9.4	13.0	8.7	24.4	15.6	23.2	3.4	9.8	14.2	9.2	8.8	12.6	17.7	38.2	7.1	5.9	6.1	14.1	8.6	13.4	9.7	12.7	11.5	3.7	18.6	6.3	8.2	9.8	12.4	5.1	30.9	11.9	7.8	12.6	28.5	9.9	23.6	6.6	9.9	7.9	9.2	11.9	3.4	14.5	18.1	9.5	13.6	10.7	2.5	2.7	3.4	2.7	1.9	6.0	3.3	1.4	3.3	7.2	7.2	10.2	18.3	3.3	8.1	11.2	5.3	7.5	1.1	2.7	1.4	2.2	21.7	2.0	2.9	2.0	2.9	2.4	13.3	5.4	4.5	11.6	0.6	5.1	1.5	2.5	23.5	3.6	2.9	1.0	7.1	3.3	9.5	1.8	3.3	6.7	0.9	2.0	10.6	1.5	1.3	2.0	3.1	1.6	1.5	1.7	1.3	2.1	7.3	1.0	2.2	3.0	4.0	5.7	5.9	3.1	2.5	5.7	1.9	0.0	2.2	1.4	0.6	6.6	1.7	11.9	3.4	2.2	0.0	3.2	2.7	4.4	1.9	6.0	4.7	2.7	2.5	5.9	3.8	0.6	1.9	0.6	1.1	3.2	3.3	6.8	10.1	13.0	8.7	7.1	5.9	9.7	12.7	9.8	11.9	3.0	14.7	0.0	6.7	15.5	18.5	32.2	2.5	1.4	4.5	3.5	13.7	9.5	0.0	1.9	16.6	11.1	4.2	0.0	0.6	3.1	55.3	3.0	0.0	24.5	4.0	22.3	8.7	11.6	2.8	74.5	10.3	5.5	30.4	0.0	3.1	15.3	0.2	3.5	5.3	2.4	9.1	0.0	4.6	4.1	17.8	12.3	10.4	4.9	4.8	0.9
IL12B	"CLMF, CLMF2, IL-12B, NKSF, NKSF2"	ENSG00000113302	"Interleukin 12B"	P29460	5	159314783-159330887	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Cytokine	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 10.8"	"Cell type enriched"	"Detected in single"	60	"monocytes: 11.8"	"Cancer enriched"	"Detected in single"	20	"testis cancer: 3.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"neutrophil: 2.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"Karpas-707: 3.0;NB-4: 2.7;SCLC-21H: 3.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA040970	Supported				"Secreted to blood"	NA	NA	140000				"HPA040970: AB_10796234"	"unprognostic (5.96e-5)"	"unprognostic (4.59e-5)"	"unprognostic (1.05e-1)"	"unprognostic (3.40e-1)"		"unprognostic (9.13e-4)"	"unprognostic (6.89e-2)"	"unprognostic (2.58e-4)"	"unprognostic (6.69e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.50e-2)"	"unprognostic (2.53e-1)"	"unprognostic (7.15e-3)"	"unprognostic (9.25e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.02e-2)"	0.2	0.2	0.2	0.7	0.2	1.4	0.2	0.4	0.2	0.3	0.2	0.2	0.2	0.2	0.2	1.2	0.4	0.2	0.7	0.2	0.2	0.2	0.6	0.3	0.9	1.8	0.2	0.2	0.2	0.2	0.0	2.4	0.2	0.2	0.2	0.6	0.2	0.7	0.2	0.2	1.3	0.5	0.2	0.2	1.8	0.9	0.5	0.2	10.8	0.4	0.2	0.9	0.3	0.2	1.1	0.3	2.9	0.5	1.0	0.2	0.0	0.3	0.4	0.6	0.7	0.1	0.0	0.2	0.5	0.0	0.0	0.5	0.6	0.9	0.5	0.1	0.1	0.2	0.4	0.1	0.1	0.0	0.5	0.9	0.1	1.5	0.2	0.1	0.4	1.1	0.3	0.3	0.1	0.0	0.7	0.1	0.4	0.2	3.0	0.0	0.2	0.5	2.7	0.6	0.1	0.4	0.6	0.8	1.8	0.0	0.2	3.7	0.2	0.3	0.3	0.0	0.8	0.4	0.4	0.4	0.5	0.2	0.2	0.2	0.2	0.1	0.3	0.7	0.5	0.2	1.7	0.5	0.2	0.2	0.1	0.1	1.1	0.2	0.1	0.1	0.3	0.2	0.2	2.9	1.0	0.1	0.3	0.1	0.0	0.2	0.2	0.4	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IL17A	"CTLA8, IL-17, IL-17A, IL17"	ENSG00000112115	"Interleukin 17A"	Q16552	6	52186387-52190638	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"lymphoid tissue: 7.6;tongue: 12.2;urinary bladder: 4.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	37	"Karpas-707: 7.3;U-266/84: 4.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA052258	Uncertain				"Secreted to blood"	NA	NA	9920				"HPA052258: "		"unprognostic (5.55e-1)"	"unprognostic (2.18e-4)"			"unprognostic (3.05e-4)"		"unprognostic (1.41e-2)"						"unprognostic (2.22e-2)"				0.2	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.4	0.3	0.0	0.0	0.4	0.0	0.0	1.3	0.5	0.6	0.0	0.1	0.0	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.1	0.0	0.1	0.1	1.0	0.1	0.0	0.1	0.3	0.1	0.0	0.0	0.0	12.2	7.6	4.4	0.5	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
IL1B	"IL-1B, IL1-BETA, IL1F2"	ENSG00000125538	"Interleukin 1 beta"	P01584	2	112829751-112836903	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Cytokine, Mitogen, Pyrogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 62.3;lymphoid tissue: 35.4"	"Cell type enriched"	"Detected in many"	7	"Macrophages: 764.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"neutrophil: 34.4"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 34.4"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 93.2;HBEC3-KT: 42.4;HMC-1: 34.6;hTEC/SVTERT24-B: 46.6;hTERT-RPE1: 40.3;U-87 MG: 85.2"	"Low region specificity"	"Detected in some"												"Secreted to blood"	NA	NA	2330					"unprognostic (1.55e-3)"	"prognostic unfavorable (1.31e-4)"	"unprognostic (2.75e-2)"	"unprognostic (5.71e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.12e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.61e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.63e-3)"	"unprognostic (3.72e-2)"	"unprognostic (5.57e-2)"	"prognostic unfavorable (7.49e-5)"	"unprognostic (1.29e-2)"	"unprognostic (4.42e-2)"	"unprognostic (5.09e-2)"	"unprognostic (4.01e-2)"	19.6	3.3	4.2	20.4	15.3	62.3	0.8	1.1	10.8	1.6	3.2	12.7	0.2	1.2	3.0	1.5	3.5	3.4	7.5	3.7	19.0	3.6	1.7	4.0	17.3	5.0	5.9	0.3	3.4	2.4	2.4	3.0	10.3	24.9	2.6	2.6	1.0	2.2	0.8	0.4	0.9	3.7	3.5	29.7	35.4	20.9	1.6	5.8	0.8	1.1	13.5	14.0	10.4	1.2	0.0	6.9	34.4	7.0	0.0	0.0	1.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	93.2	0.4	1.0	0.0	0.0	0.0	2.6	0.0	1.6	2.1	0.0	42.4	5.8	0.0	0.0	4.1	0.0	0.0	0.3	0.0	34.6	0.1	1.3	46.6	15.7	40.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.1	3.5	0.1	0.0	0.0	0.0	5.6	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.4	0.0	2.2	0.0	0.1	0.0	0.0	0.0	0.0	85.2	1.9	3.2	0.5	4.2	1.5	0.0	7.0	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.0	34.4	0.0	2.7	0.0	0.0	1.0	4.2	15.3	1.1	10.8	19.0	3.6	5.9	0.3	24.9	5.8	8.9	45.3	1.4	4.6	27.4	0.0	4.3	0.0	13.4	7.9	1.8	0.0	1.2	0.0	12.2	0.1	2.2	0.3	0.0	0.5	2.1	9.9	2.3	39.4	0.0	109.6	0.0	0.0	1.3	54.0	0.0	0.0	764.6	21.9	0.0	2.2	0.0	3.6	6.2	0.0	0.5	0.2	0.0	4.3	0.0	0.2	17.8	3.7	2.2	0.0	4.6
IL1R1	"CD121A, D2S1473, IL1R, IL1RA"	ENSG00000115594	"Interleukin 1 receptor type 1"	P14778	2	102064544-102179874	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters"	"Inflammatory response"	"Hydrolase, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Club cells: 93.3;Ito cells: 139.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 4.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"ASC diff: 95.6;ASC TERT1: 42.7;HHSteC: 30.0;HSkMC: 117.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA001237, HPA005823, CAB007779, HPA029560"	Approved		Approved	"Nucleoplasm,Vesicles,Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA		1000000	"Nucleoplasm, Vesicles"	"Plasma membrane, Cytosol"	"CAB007779: AB_562073, HPA001237: , HPA005823: AB_2667445, HPA029560: AB_2673094"	"unprognostic (6.16e-3)"	"unprognostic (3.55e-2)"	"unprognostic (3.33e-1)"	"unprognostic (1.22e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.10e-2)"	"unprognostic (2.01e-1)"	"unprognostic (3.36e-2)"	"unprognostic (1.44e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.26e-2)"	"unprognostic (7.77e-2)"	"prognostic unfavorable (6.92e-6)"	"unprognostic (2.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (4.83e-2)"	"unprognostic (7.73e-2)"	48.6	25.2	2.6	18.2	5.2	4.0	92.4	2.4	3.9	47.8	21.0	2.5	34.3	5.2	15.2	30.2	18.2	17.1	25.8	27.0	4.2	2.5	23.7	74.8	40.5	28.0	5.6	1.1	25.1	17.1	16.9	7.3	66.2	10.9	26.0	8.4	8.6	12.7	36.4	15.5	13.5	13.0	15.1	10.0	19.2	15.6	13.4	2.8	3.5	33.6	9.0	9.6	32.0	36.4	0.1	0.1	4.0	0.5	0.8	1.8	0.2	0.2	1.8	0.0	1.5	95.6	42.7	0.6	4.0	18.2	2.8	4.3	0.8	0.5	0.0	2.9	8.0	5.0	0.8	0.0	0.3	2.4	7.9	0.0	0.1	0.4	4.4	30.0	0.0	0.0	117.7	0.3	3.2	0.7	1.2	1.2	0.0	0.5	0.1	4.1	0.8	0.0	0.1	0.1	0.8	0.1	0.0	0.3	0.0	2.7	1.9	0.0	0.0	1.8	1.1	0.0	0.5	1.6	0.1	0.0	8.2	0.5	13.7	0.3	0.0	0.0	0.0	3.2	0.0	0.5	0.6	0.5	0.1	0.0	0.0	0.7	0.1	1.1	0.0	0.1	0.1	0.0	0.1	4.0	0.8	0.0	0.1	1.8	0.2	2.6	5.2	2.4	3.9	4.2	2.5	5.6	1.1	10.9	2.8	23.8	55.6	3.7	27.6	27.6	0.0	3.9	28.1	40.2	93.3	5.2	0.0	5.3	3.3	21.6	6.4	58.3	0.0	0.0	18.7	76.6	77.2	84.5	1.1	43.2	5.1	0.0	1.2	139.3	12.4	9.4	25.9	21.6	18.6	9.0	0.7	7.3	15.4	0.0	1.4	6.2	1.0	6.5	23.1	0.7	0.9	33.8	20.0	2.6	0.9	19.6
IL23A	"IL-23, IL-23A, IL23P19, P19, SGRF"	ENSG00000110944	"Interleukin 23 subunit alpha"	Q9NPF7	12	56334174-56340410	"FDA approved drug targets, Predicted secreted proteins"	"Antiviral defense, Immunity, Inflammatory response, Innate immunity, Tissue remodeling"	Cytokine	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 17.0;lymphoid tissue: 15.2;testis: 12.1"	"Cell type enhanced"	"Detected in many"	10	"Ductal cells: 26.3;monocytes: 58.7;Pancreatic endocrine cells: 46.8;Spermatocytes: 41.1"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"MAIT T-cell: 8.4;memory B-cell: 10.6;memory CD4 T-cell: 15.5;memory CD8 T-cell: 7.4;naive B-cell: 10.6;naive CD4 T-cell: 17.0;naive CD8 T-cell: 10.6;T-reg: 8.4"	"Group enriched"	"Detected in many"	14	"B-cells: 10.6;T-cells: 17.0"	"Cell line enhanced"	"Detected in some"		"A-431: 9.4;CAPAN-2: 16.5;U-266/70: 27.6;U-266/84: 12.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in some"			HPA001554	Approved		Approved	Cytosol	"Secreted to blood"	NA	NA	11000		Cytosol		"HPA001554: AB_1079135"	"unprognostic (2.34e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.06e-1)"	"unprognostic (5.24e-2)"	"unprognostic (4.01e-3)"	"unprognostic (4.40e-1)"	"unprognostic (1.43e-3)"	"unprognostic (1.30e-1)"	"unprognostic (6.79e-2)"	"unprognostic (3.38e-2)"	"unprognostic (4.16e-2)"	"unprognostic (3.03e-10)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.83e-1)"	"unprognostic (4.50e-3)"	0.7	0.5	0.4	3.9	0.5	3.6	0.4	0.3	0.3	0.5	0.6	0.3	0.3	0.0	1.3	0.8	6.0	0.5	2.0	0.3	0.4	0.5	1.3	1.4	1.2	7.5	0.4	0.3	0.3	1.1	0.0	1.1	0.6	0.3	1.0	0.2	0.3	1.8	0.3	0.3	0.8	2.5	1.0	0.4	2.8	0.7	12.1	0.3	12.9	0.6	10.4	15.2	7.4	0.6	10.6	0.5	0.1	0.2	1.0	17.0	5.9	9.4	0.2	0.3	0.3	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.4	16.5	0.5	4.9	0.0	0.5	0.9	0.0	1.6	0.0	0.6	0.3	0.3	0.1	0.7	0.0	0.2	0.6	0.1	0.0	0.0	0.4	2.1	0.0	2.2	0.4	4.1	0.0	0.4	0.3	0.5	1.4	0.2	0.3	0.2	0.1	0.4	5.7	4.7	0.3	0.4	0.2	0.2	0.8	1.4	0.1	4.4	0.3	0.3	0.3	0.3	1.1	27.6	12.4	1.2	0.3	2.4	0.2	0.0	0.2	0.0	1.7	0.0	8.4	10.6	15.5	7.4	0.5	10.6	17.0	10.6	0.1	1.0	0.0	0.0	8.4	5.9	0.4	0.5	0.3	0.3	0.4	0.5	0.4	0.3	0.3	0.3	3.0	2.1	14.5	10.2	3.2	0.0	0.3	0.0	2.7	5.7	1.8	0.0	0.3	1.7	26.3	4.7	0.6	0.3	0.0	6.4	0.3	1.4	5.0	0.0	0.6	2.4	0.0	0.0	0.0	0.0	3.2	0.3	8.1	8.5	58.7	0.0	0.1	46.8	0.0	0.7	0.5	0.1	0.0	1.9	41.1	5.3	3.4	0.0	10.2	0.0	13.9
IL2RA	"CD25, IDDM10, IL2R"	ENSG00000134460	"Interleukin 2 receptor subunit alpha"	P01589	10	6010689-6062370	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Immunity	Receptor	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"adipose tissue: 16.5;blood: 55.4;lymphoid tissue: 56.7"	"Cell type enriched"	"Detected in some"	4	"monocytes: 309.2"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in single"		"pons and medulla: 2.4"	"Group enriched"	"Detected in many"	6	"basophil: 30.3;T-reg: 55.4"	"Group enriched"	"Detected in many"	12	"granulocytes: 30.3;T-cells: 55.4"	"Cell line enriched"	"Detected in some"	59	"HDLM-2: 157.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"CAB002419, HPA054622"	Enhanced					NA	NA		110000			"CAB002419: AB_563538, HPA054622: AB_2682546"	"unprognostic (2.82e-1)"	"unprognostic (8.10e-3)"	"unprognostic (1.75e-2)"	"unprognostic (5.86e-2)"	"unprognostic (1.50e-1)"	"unprognostic (1.45e-3)"	"unprognostic (2.78e-2)"	"unprognostic (2.73e-1)"	"unprognostic (5.03e-2)"	"unprognostic (6.32e-2)"	"unprognostic (7.21e-2)"	"unprognostic (2.07e-1)"	"prognostic unfavorable (2.08e-9)"	"unprognostic (2.10e-2)"	"unprognostic (4.66e-2)"	"unprognostic (2.22e-1)"	"unprognostic (5.10e-2)"	16.5	2.5	0.3	10.9	0.6	0.1	1.4	0.3	0.3	0.6	3.1	0.1	0.0	1.3	0.8	4.9	1.9	0.8	2.2	1.9	0.4	0.5	2.6	1.3	4.0	50.4	0.5	0.0	0.6	1.0	0.0	1.8	1.8	2.4	1.1	1.6	3.4	2.2	0.5	0.8	0.6	10.3	3.5	2.2	56.7	1.4	0.4	0.0	4.5	4.2	2.0	16.8	5.0	0.6	3.6	0.0	30.3	0.0	2.9	55.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	157.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.6	0.0	0.0	0.0	30.3	0.0	4.5	0.1	0.0	0.5	3.6	6.8	0.7	0.0	1.5	0.5	0.0	0.2	2.9	0.0	0.0	55.4	0.7	0.3	0.6	0.3	0.3	0.4	0.5	0.5	0.0	2.4	0.0	0.0	2.6	7.5	0.1	0.8	0.0	0.4	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.2	74.4	0.0	0.3	0.0	0.0	0.6	5.6	0.0	0.0	3.7	3.3	309.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.5	0.0	7.7	0.0	0.1
IL2RB	"CD122, IL15RB"	ENSG00000100385	"Interleukin 2 receptor subunit beta"	P14784	22	37125838-37175054	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 51.6;lymphoid tissue: 35.0;placenta: 58.5"	"Group enriched"	"Detected in many"	8	"Extravillous trophoblasts: 80.1;T-cells: 97.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	4	"gdT-cell: 14.7;NK-cell: 51.6"	"Group enriched"	"Detected in many"	32	"NK-cells: 51.6;T-cells: 14.7"	"Cell line enriched"	"Detected in some"	8	"HDLM-2: 106.6"	"Region enriched"	"Detected in single"	7	"basal ganglia: 1.6"	"Low region specificity"	"Detected in single"			HPA062657	Enhanced					NA	NA					"HPA062657: AB_2684822"	"unprognostic (3.38e-3)"	"unprognostic (1.21e-2)"	"prognostic favorable (6.76e-4)"	"prognostic favorable (3.18e-5)"	"unprognostic (2.44e-2)"	"unprognostic (9.69e-3)"	"unprognostic (2.60e-1)"	"unprognostic (5.22e-2)"	"unprognostic (1.03e-3)"	"unprognostic (5.37e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.74e-1)"	"prognostic unfavorable (3.50e-7)"	"unprognostic (4.63e-2)"	"unprognostic (7.96e-2)"	"unprognostic (3.94e-3)"	"unprognostic (2.46e-2)"	2.2	1.0	0.8	20.5	0.8	12.3	1.6	0.6	0.7	1.3	5.5	0.6	1.4	1.8	4.3	2.8	2.6	1.8	5.8	3.7	0.7	0.8	1.9	6.0	7.4	20.8	0.8	0.2	1.5	1.0	0.0	1.1	58.5	0.7	3.5	1.8	2.9	3.7	2.1	0.9	4.0	7.3	0.6	1.1	35.0	2.3	1.1	0.2	21.0	2.1	1.8	28.7	4.0	1.5	0.3	0.0	1.0	0.1	51.6	14.7	7.9	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	106.6	0.1	0.2	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.8	0.7	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.2	0.0	0.0	2.8	0.0	0.1	7.7	13.2	0.0	0.1	0.0	0.1	1.0	0.0	0.1	14.7	0.1	8.1	0.1	3.3	8.2	0.0	0.3	1.1	4.3	0.3	51.6	0.1	0.0	6.8	7.9	0.8	0.8	0.6	0.7	0.7	0.8	0.8	0.2	0.7	0.2	3.0	11.6	1.5	0.8	2.9	0.0	1.1	0.0	1.4	1.2	1.8	0.0	0.4	0.0	0.0	1.7	0.0	0.0	0.0	0.2	80.1	1.1	0.1	9.3	1.0	2.1	0.0	0.0	8.6	1.6	0.9	0.3	0.5	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.4	1.0	97.0	0.0	0.0
IL2RG	"CD132, CIDX, IMD4, SCIDX1"	ENSG00000147168	"Interleukin 2 receptor subunit gamma"	P31785	X	71107404-71112108	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Host-virus interaction"	Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 115.3;lymphoid tissue: 169.3"	"Cell type enhanced"	"Detected in many"	12	"B-cells: 121.6;Enterocytes: 82.5;monocytes: 130.8;T-cells: 235.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	6	"Karpas-707: 225.6"									"HPA046641, HPA049691"	Enhanced		Approved	Vesicles		NA	NA			Vesicles		"HPA046641: AB_2679733, HPA049691: AB_2680851"	"unprognostic (2.97e-3)"	"unprognostic (4.24e-2)"	"unprognostic (1.23e-1)"	"prognostic favorable (1.73e-4)"	"unprognostic (8.25e-2)"	"unprognostic (1.93e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.53e-1)"	"unprognostic (1.91e-3)"	"unprognostic (1.23e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.45e-1)"	"prognostic unfavorable (2.28e-7)"	"unprognostic (1.73e-1)"	"unprognostic (4.69e-2)"	"unprognostic (4.89e-2)"	"unprognostic (9.54e-2)"	5.8	1.3	1.4	39.5	1.4	12.8	3.6	0.8	0.9	2.9	16.6	0.9	0.9	8.2	3.0	2.1	5.3	3.1	5.3	2.6	1.4	1.5	3.7	4.7	13.6	70.4	1.8	0.6	2.9	1.5	0.0	1.2	5.3	1.5	3.2	20.8	2.9	10.4	1.8	1.6	2.7	28.6	1.5	2.9	58.7	6.0	2.0	0.9	169.3	3.3	4.2	61.4	7.6	3.1	51.9	30.6	65.6	19.7	94.6	115.3	99.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.8	17.6	1.3	0.0	0.0	0.1	0.0	0.0	0.0	14.8	0.0	2.3	0.0	0.0	0.0	9.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	21.0	3.9	225.6	0.0	0.0	32.6	17.8	0.0	0.0	0.0	7.5	0.0	1.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	12.9	22.7	11.3	0.2	37.8	0.0	35.2	8.5	13.4	107.2	19.7	105.6	51.9	97.7	110.4	20.3	51.6	68.0	84.9	65.6	94.6	13.5	30.6	115.3	99.0	1.4	1.4	0.8	0.9	1.4	1.5	1.8	0.6	1.5	0.9	3.0	15.7	121.6	6.6	7.2	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.3	0.0	1.0	0.0	4.5	82.5	0.0	2.0	0.2	3.3	3.6	38.1	1.5	32.3	0.0	74.7	6.7	21.7	0.0	0.0	41.4	40.5	130.8	19.5	0.0	16.5	58.8	0.4	1.1	0.2	0.0	4.1	0.0	0.0	5.9	0.2	235.1	18.0	6.8
IL3RA	CD123	ENSG00000185291	"Interleukin 3 receptor subunit alpha"	P26951	X	1336616-1382689	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 163.1;breast: 50.7;vagina: 65.4"	"Group enriched"	"Detected in many"	5	"Endothelial cells: 40.7;Macrophages: 35.6;monocytes: 120.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	16	"basophil: 163.1;plasmacytoid DC: 49.1"	"Group enriched"	"Detected in many"	33	"dendritic cells: 49.1;granulocytes: 163.1"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 49.0;NB-4: 9.4;RPMI-8226: 20.0"									"HPA003539, CAB018374"	Uncertain					NA	NA					"CAB018374: AB_2233620, HPA003539: AB_1078438"	"prognostic favorable (9.78e-4)"	"prognostic favorable (4.27e-4)"	"unprognostic (8.13e-2)"	"unprognostic (9.32e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.29e-3)"	"unprognostic (1.32e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.38e-1)"	"unprognostic (3.73e-2)"	"unprognostic (5.77e-3)"	"unprognostic (1.43e-1)"	"unprognostic (1.50e-3)"	"unprognostic (9.41e-2)"	"unprognostic (2.85e-3)"	"unprognostic (2.49e-1)"	"unprognostic (1.46e-1)"	14.9	1.2	7.8	7.7	7.8	12.1	50.7	5.0	10.1	9.7	4.6	1.5	1.5	2.4	13.8	1.5	2.8	4.2	5.6	9.2	11.1	2.4	5.4	1.5	15.9	12.3	8.5	3.9	7.6	2.6	0.6	3.7	9.3	10.9	4.4	3.1	1.5	5.6	1.5	5.7	6.8	5.4	6.1	7.6	5.3	4.2	1.5	7.9	1.5	7.0	1.5	6.4	6.8	65.4	0.7	49.1	163.1	3.2	1.1	0.0	0.7	0.1	4.0	1.5	0.5	0.0	0.0	0.5	0.5	0.1	0.0	0.0	0.4	0.6	0.5	2.8	0.0	0.2	3.9	0.0	0.0	0.0	49.0	1.6	0.2	0.7	0.1	0.0	0.3	6.7	0.0	0.0	0.0	0.0	1.7	3.2	0.4	0.1	2.5	0.0	0.6	0.2	9.4	1.2	0.3	0.2	0.6	1.8	20.0	0.0	0.5	0.2	0.2	0.2	0.1	1.1	0.7	0.5	7.5	0.1	0.2	0.6	0.2	0.1	5.3	1.5	0.4	4.4	1.1	0.0	163.1	0.4	6.7	0.0	2.4	0.0	0.2	0.0	0.0	1.1	0.7	0.0	0.0	0.3	1.1	3.2	49.1	0.0	0.7	7.8	7.8	5.0	10.1	11.1	2.4	8.5	3.9	10.9	7.9	3.0	2.6	7.7	0.5	5.3	2.7	2.4	2.5	0.0	1.2	0.0	9.8	0.0	0.0	0.3	0.0	40.7	0.4	0.0	0.2	0.1	2.8	0.4	11.5	0.0	4.4	0.0	0.0	14.1	3.5	0.0	0.3	35.6	8.5	120.0	1.3	0.8	0.1	3.4	0.7	0.0	2.2	0.0	4.1	0.0	0.2	4.8	0.2	0.0	0.2	1.8
IL4R	CD124	ENSG00000077238	"Interleukin 4 receptor"	P24394	16	27313668-27364778	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"granulocytes: 107.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 34.4"	"Group enriched"	"Detected in all"	6	"B-cells: 34.4;granulocytes: 11.9"	"Cell line enhanced"	"Detected in many"		"Daudi: 36.5;HBEC3-KT: 35.1;U-698: 34.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004451, HPA050124, HPA070380"	Enhanced		Approved	"Nucleoplasm,Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA		49000	"Nucleoplasm, Plasma membrane"	"Centriolar satellite"	"CAB004451: AB_626889, HPA050124: AB_2681026, HPA070380: "	"unprognostic (6.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (2.84e-1)"	"prognostic favorable (6.43e-4)"	"unprognostic (1.12e-1)"	"unprognostic (1.14e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.95e-3)"	"unprognostic (1.34e-1)"	"unprognostic (1.54e-1)"	"unprognostic (2.41e-1)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (1.23e-5)"	"unprognostic (1.49e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.58e-2)"	20.7	14.8	8.7	31.6	10.6	36.9	12.0	4.4	7.7	20.8	30.3	5.9	11.5	10.9	18.0	12.8	24.7	13.6	25.1	12.3	6.7	4.4	13.3	39.1	40.9	44.8	10.8	1.7	14.7	11.3	3.8	5.5	16.1	10.1	18.8	15.1	12.3	7.7	11.5	7.2	9.9	18.6	39.6	13.6	31.8	21.1	10.4	9.8	9.1	8.6	13.7	38.4	31.6	15.4	34.4	1.6	11.9	2.6	3.3	4.0	1.8	11.5	3.0	2.0	3.9	1.0	4.6	4.2	7.3	8.5	2.9	2.4	6.2	32.0	36.5	9.1	11.5	5.7	12.3	2.1	35.1	2.5	31.6	1.0	6.8	1.8	9.5	13.2	1.8	19.4	7.0	14.2	13.5	8.0	15.5	15.7	2.1	2.9	3.1	4.7	5.1	0.1	5.5	2.4	10.4	2.7	0.1	15.2	2.9	13.6	13.2	0.6	0.3	1.0	7.0	1.6	5.3	2.7	7.0	23.5	6.7	3.0	5.9	5.1	1.8	0.5	34.0	0.7	6.1	0.0	0.5	2.6	4.7	1.7	1.1	1.3	7.7	2.6	1.7	1.6	34.4	4.0	1.9	11.9	3.3	0.6	1.6	1.8	1.8	8.7	10.6	4.4	7.7	6.7	4.4	10.8	1.7	10.1	9.8	26.8	51.7	49.6	35.5	11.7	0.0	2.2	20.4	17.4	30.7	1.8	0.0	15.0	0.0	31.7	0.1	31.5	27.6	0.0	28.2	3.5	13.9	27.2	107.5	47.4	22.9	0.0	22.4	54.6	31.1	0.2	0.3	21.3	13.5	40.5	32.8	0.0	35.6	22.1	0.0	1.1	0.0	38.8	27.4	0.5	1.9	13.0	20.8	20.3	15.0	38.2
IL5	"EDF, IL-5, TRF"	ENSG00000113525	"Interleukin 5"	P05113	5	132541444-132556838	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"blood: 3.8;testis: 10.6"	"Cell type enriched"	"Detected in some"	9	"Spermatocytes: 24.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"Cell type enriched"	"Detected in single"	6	"memory B-cell: 3.8"	"Lineage enriched"	"Detected in single"	6	"B-cells: 3.8"	"Cell line enhanced"	"Detected in some"		"CACO-2: 2.5;HEK 293: 2.2;Hep G2: 7.2;TIME: 3.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB010304	Approved				"Secreted to blood"	NA	NA	4130				"CAB010304: AB_2296159"	"unprognostic (1.66e-1)"	"unprognostic (4.76e-2)"	"unprognostic (5.30e-3)"	"unprognostic (2.35e-1)"	"unprognostic (9.07e-2)"		"unprognostic (7.98e-2)"	"unprognostic (2.03e-2)"		"unprognostic (3.51e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.44e-2)"	"unprognostic (1.53e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.27e-2)"	"unprognostic (5.84e-3)"	"unprognostic (1.91e-1)"	0.1	0.1	0.3	0.3	1.0	0.0	0.1	0.3	1.3	0.2	0.1	0.0	0.0	1.0	0.5	0.0	0.1	0.7	1.1	0.4	1.0	0.3	0.1	0.3	0.1	0.0	0.3	0.0	0.2	0.1	0.0	2.0	0.0	0.9	0.1	0.3	0.0	0.1	0.0	0.1	0.1	1.8	0.1	0.3	0.1	0.3	10.6	0.0	0.4	0.7	0.0	0.2	0.2	0.2	3.8	0.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.8	0.0	0.6	0.0	1.0	0.0	0.0	0.0	0.0	0.1	2.2	0.0	0.2	7.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.9	0.6	0.8	0.0	0.0	0.0	0.0	0.2	1.0	0.0	0.5	0.1	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.3	0.0	0.4	0.9	0.4	0.8	0.0	0.2	0.8	0.0	0.0	0.0	0.5	0.0	0.0	3.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	1.0	0.3	1.3	1.0	0.3	0.3	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.2	1.1	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	1.6	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	0.7	0.1	0.0	0.0	0.0	0.0
IL5RA	"CD125, CDw125, IL5R"	ENSG00000091181	"Interleukin 5 receptor subunit alpha"	Q01344	3	3066326-3126613	"CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 70.1;fallopian tube: 18.6"	"Cell type enhanced"	"Detected in some"	18	"Ciliated cells: 21.4;granulocytes: 18.5;Melanocytes: 5.0"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.4"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	196	"basophil: 31.4;eosinophil: 70.1"	"Lineage enriched"	"Detected in single"	308	"granulocytes: 70.1"	"Cell line enriched"	"Detected in some"	30	"HMC-1: 42.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Intracellular and membrane"	NA	NA		92000				"unprognostic (1.38e-3)"	"unprognostic (2.26e-2)"	"unprognostic (2.66e-1)"	"unprognostic (6.13e-3)"	"unprognostic (2.66e-1)"	"unprognostic (1.54e-3)"	"unprognostic (7.79e-3)"	"unprognostic (8.42e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.67e-1)"	"unprognostic (9.84e-4)"	"unprognostic (4.32e-3)"	"unprognostic (3.08e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.20e-1)"	"unprognostic (7.49e-2)"	"unprognostic (4.93e-2)"	0.5	0.2	6.7	0.6	6.2	0.7	1.3	0.2	0.3	1.8	0.9	1.8	0.0	2.2	0.6	8.2	0.6	18.6	2.0	2.4	2.3	2.1	0.6	1.3	7.9	1.2	0.1	0.0	3.8	0.5	0.1	7.5	0.1	11.8	2.6	1.4	0.5	2.2	0.1	0.3	0.4	2.1	0.6	0.6	4.6	1.3	1.6	0.7	1.1	0.4	1.1	1.9	4.2	0.4	0.1	0.0	70.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.4	42.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	31.4	0.0	70.1	0.2	0.0	0.0	0.1	0.2	0.1	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	6.7	6.2	0.2	0.3	2.3	2.1	0.1	0.0	11.8	0.7	0.0	4.5	0.0	0.0	0.1	0.0	2.4	0.0	21.4	2.3	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.9	18.5	0.0	0.1	0.0	0.0	0.0	0.0	4.7	0.0	0.0	5.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0
IL6	"BSF2, HGF, HSF, IFNB2, IL-6"	ENSG00000136244	"Interleukin 6"	P05231	7	22725884-22732002	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Acute phase"	"Cytokine, Growth factor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 60.1;lymphoid tissue: 48.0"	"Cell type enriched"	"Detected in many"	9	"Smooth muscle cells: 589.1"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in many"	4	"basal ganglia: 10.0;cerebral cortex: 4.4;hippocampal formation: 3.9;pons and medulla: 12.8"	"Group enriched"	"Detected in some"	70	"memory B-cell: 6.1;naive B-cell: 7.7"	"Lineage enriched"	"Detected in single"	77	"B-cells: 7.7"	"Group enriched"	"Detected in some"	4	"BJ hTERT+: 208.4;GAMG: 141.1"					"Low region specificity"	"Detected in single"			"CAB023406, CAB072821"	Supported		Approved	Vesicles	"Secreted to blood"	NA	NA	5700		Vesicles		"CAB023406: AB_617317, CAB072821: "	"unprognostic (1.13e-1)"	"unprognostic (1.55e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (3.59e-2)"	"unprognostic (9.88e-3)"	"unprognostic (1.35e-1)"	"unprognostic (3.07e-3)"	"unprognostic (3.25e-1)"	"unprognostic (2.17e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.57e-2)"	"prognostic unfavorable (1.10e-11)"	"unprognostic (2.45e-3)"	"unprognostic (2.10e-1)"	"unprognostic (4.31e-2)"	"unprognostic (7.80e-2)"	60.1	5.6	1.4	48.0	10.0	15.3	11.5	0.7	4.4	2.9	8.1	1.2	0.4	0.7	2.1	4.6	14.3	7.8	16.1	21.6	3.9	1.5	1.3	5.2	34.9	3.0	1.8	0.2	5.3	8.3	5.7	14.2	4.5	12.8	6.5	7.5	3.3	3.1	0.8	6.9	2.8	4.5	8.2	7.0	3.5	6.5	3.2	1.2	0.1	4.5	12.7	3.5	34.9	8.4	7.7	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.8	208.4	3.9	13.4	0.0	0.0	0.0	6.8	1.3	141.1	0.1	0.0	0.0	5.3	8.2	0.0	0.0	0.3	0.0	4.4	0.0	0.0	0.5	0.0	39.8	5.7	3.8	1.4	0.0	0.8	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	10.4	0.0	0.0	0.0	13.5	0.0	0.0	0.7	0.0	0.0	1.2	1.3	0.1	2.4	0.4	0.0	2.3	0.0	9.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.1	0.0	0.0	0.0	7.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.4	10.0	0.7	4.4	3.9	1.5	1.8	0.2	12.8	1.2	6.0	27.2	7.2	1.9	39.6	0.0	0.9	0.0	13.4	20.5	3.5	0.0	0.5	0.0	5.8	0.3	40.7	0.0	0.0	2.4	3.1	63.9	7.3	5.8	0.0	4.2	0.0	0.0	3.1	6.1	0.0	0.0	46.2	38.8	7.2	0.0	0.0	4.8	0.0	0.0	0.0	0.0	0.0	589.1	0.0	0.0	29.2	1.1	0.0	0.0	9.0
IL6R	CD126	ENSG00000160712	"Interleukin 6 receptor"	P08887	1	154405193-154469450	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"skeletal muscle: 59.6"	"Cell type enhanced"	"Detected in many"	5	"Alveolar cells type 1: 107.2;Hepatocytes: 81.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 35.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"THP-1: 55.9;U-266/84: 65.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA	24800000	22000000				"unprognostic (1.19e-1)"	"unprognostic (3.97e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.95e-1)"	"unprognostic (4.47e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.05e-2)"	"unprognostic (3.27e-1)"	"unprognostic (6.42e-2)"	"prognostic favorable (1.65e-4)"	"unprognostic (7.94e-2)"	"unprognostic (1.05e-1)"	"unprognostic (7.75e-2)"	"unprognostic (1.51e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.07e-1)"	8.4	4.0	4.7	14.8	5.1	9.0	6.5	1.4	6.3	6.1	16.9	4.8	1.2	9.6	6.3	4.7	5.2	7.9	6.9	5.0	5.2	2.9	8.9	38.1	20.8	15.4	7.2	2.2	5.7	5.3	0.0	7.7	3.7	7.8	4.5	6.0	3.6	5.4	1.7	59.6	4.7	12.6	5.3	5.0	11.3	6.6	3.7	5.0	4.2	2.5	6.1	13.3	6.3	4.8	0.6	14.3	35.0	11.7	0.5	8.0	5.5	0.8	1.5	0.1	0.1	0.9	1.3	0.1	0.8	0.6	0.5	0.2	0.1	1.0	0.0	1.9	1.0	3.1	0.4	0.3	4.5	0.4	15.1	0.5	0.2	0.6	3.4	0.1	2.4	1.3	0.8	2.7	0.4	6.8	0.1	0.6	0.0	0.1	6.2	0.1	0.3	0.0	3.9	0.4	0.2	3.4	0.0	0.0	13.0	2.8	1.1	0.1	0.0	0.2	9.2	15.1	1.2	0.8	55.9	0.6	0.9	0.9	0.8	0.5	10.7	65.8	0.1	1.1	15.2	1.4	2.8	11.7	10.4	0.2	7.1	0.6	0.6	6.4	0.7	14.3	0.2	6.4	2.2	35.0	0.5	3.0	5.1	8.0	5.5	4.7	5.1	1.4	6.3	5.2	2.9	7.2	2.2	7.8	5.0	107.2	76.2	9.0	41.2	33.7	0.0	8.5	25.5	37.5	59.1	1.8	0.0	0.4	0.0	3.5	35.4	7.1	43.2	0.0	1.0	0.9	20.1	71.1	57.9	81.0	36.1	0.0	7.5	3.1	36.2	9.6	0.3	29.9	23.6	39.7	5.7	5.6	4.9	5.3	0.4	12.6	0.2	0.0	27.0	0.2	0.9	26.0	0.8	4.4	11.5	12.5
IMPDH1	"LCA11, RP10, sWSS2608"	ENSG00000106348	"Inosine monophosphate dehydrogenase 1"	P20839	7	128392277-128410252	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"GMP biosynthesis, Purine biosynthesis"	"DNA-binding, Oxidoreductase, RNA-binding"	"Disease mutation, FDA approved drug targets, Leber congenital amaurosis, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 172.4;Cone photoreceptor cells: 133.5;Horizontal cells: 114.4;Rod photoreceptor cells: 184.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in all"	4	"classical monocyte: 21.6;eosinophil: 20.2;intermediate monocyte: 26.2;myeloid DC: 15.1;neutrophil: 49.9;non-classical monocyte: 31.0"	"Group enriched"	"Detected in all"	5	"dendritic cells: 15.1;granulocytes: 49.9;monocytes: 31.0"	"Cell line enhanced"	"Detected in all"		"SK-BR-3: 89.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001400	Approved		Supported	"Cytosol,Rods & Rings"		NA	NA			Cytosol	"Rods & Rings"	"HPA001400: AB_1079139"	"unprognostic (2.84e-1)"	"prognostic unfavorable (3.87e-4)"	"unprognostic (2.23e-2)"	"unprognostic (6.45e-2)"	"prognostic unfavorable (7.31e-5)"	"unprognostic (6.03e-2)"	"prognostic unfavorable (1.12e-7)"	"unprognostic (1.24e-1)"	"unprognostic (7.45e-3)"	"unprognostic (1.03e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.50e-1)"	"prognostic unfavorable (1.78e-12)"	"unprognostic (1.65e-1)"	"unprognostic (1.19e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (3.72e-5)"	26.0	7.4	7.5	20.7	8.5	24.5	37.1	7.7	10.2	11.3	10.9	3.6	12.4	5.2	8.5	6.5	14.6	9.1	7.6	12.6	7.6	5.0	7.5	3.5	14.8	31.2	5.1	5.8	10.7	20.3	5.2	12.0	7.2	9.9	12.1	6.3	19.5	20.6	11.4	3.5	11.9	8.8	12.3	6.4	25.1	20.6	7.1	5.6	3.9	5.5	11.2	9.7	14.2	9.9	4.1	15.1	49.9	31.0	2.8	6.4	11.7	25.5	22.0	3.3	24.5	13.9	10.1	9.4	17.5	11.1	15.0	9.8	16.0	8.2	16.3	6.0	26.0	15.6	19.6	18.5	24.6	7.5	5.9	20.7	10.7	16.3	11.3	12.7	14.1	5.1	12.0	11.8	15.2	15.2	7.1	17.7	9.9	10.6	12.3	5.0	17.5	9.9	38.0	18.6	20.3	25.8	11.9	6.1	33.7	6.6	8.2	13.2	13.3	11.3	89.8	15.8	2.1	10.2	27.4	16.2	25.3	9.2	13.2	12.4	9.2	8.5	20.9	12.9	31.3	15.3	2.3	21.6	20.2	5.9	26.2	6.4	4.1	4.7	5.1	15.1	2.4	2.8	3.4	49.9	2.8	31.0	1.5	5.2	11.7	7.5	8.5	7.7	10.2	7.6	5.0	5.1	5.8	9.9	5.6	0.0	12.8	13.7	7.5	7.8	172.4	4.5	0.0	6.7	6.8	5.2	133.5	2.2	5.0	6.6	0.5	14.0	1.7	0.0	15.6	18.1	11.6	17.1	20.7	0.4	41.4	114.4	9.2	12.9	59.2	1.3	4.4	34.4	15.1	56.9	8.9	17.6	11.7	0.0	6.3	1.3	184.8	0.0	13.3	3.1	18.8	6.5	1.9	14.9	11.9	8.5
IMPDH2		ENSG00000178035	"Inosine monophosphate dehydrogenase 2"	P12268	3	49024325-49029408	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"GMP biosynthesis, Purine biosynthesis"	"DNA-binding, Oxidoreductase, RNA-binding"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001400, CAB020717"	Approved		Supported	"Cytosol,Rods & Rings"		NA	NA		19000	Cytosol	"Rods & Rings"	"CAB020717: , HPA001400: AB_1079139"	"unprognostic (2.09e-2)"	"unprognostic (2.91e-1)"	"unprognostic (5.96e-2)"	"unprognostic (1.20e-1)"	"unprognostic (7.31e-3)"	"unprognostic (1.56e-1)"	"prognostic unfavorable (3.22e-4)"	"unprognostic (1.30e-1)"	"unprognostic (2.65e-1)"	"unprognostic (2.17e-1)"	"unprognostic (5.44e-2)"	"unprognostic (4.24e-2)"	"unprognostic (1.30e-1)"	"unprognostic (3.85e-1)"	"unprognostic (5.80e-2)"	"unprognostic (2.24e-1)"	"unprognostic (4.47e-2)"	25.0	21.5	16.1	25.7	15.4	23.9	47.0	9.7	21.1	34.7	24.9	15.1	19.1	18.9	29.5	19.8	40.1	51.9	33.3	29.3	13.0	11.2	21.4	29.4	19.9	52.5	18.1	13.0	89.0	88.8	19.1	16.6	23.2	15.6	33.2	31.7	10.8	22.1	22.2	61.4	40.7	17.8	34.1	15.2	23.7	22.2	15.3	15.4	31.2	29.8	51.3	33.4	30.3	32.1	31.6	18.8	6.2	16.8	21.6	34.8	16.0	40.1	23.2	32.2	33.3	48.2	88.1	31.3	27.9	45.2	67.3	57.4	40.3	36.3	73.4	20.0	33.6	19.1	28.0	66.5	56.6	59.0	19.2	22.2	54.4	34.3	36.9	41.4	57.5	22.4	78.2	62.4	64.3	116.9	51.6	47.2	52.0	32.5	41.6	54.1	32.7	48.7	40.1	41.8	38.4	46.9	21.2	33.9	72.0	38.3	26.0	20.9	20.6	30.3	34.3	50.4	27.9	42.4	25.7	23.7	29.5	54.8	71.6	71.5	40.3	29.1	35.2	34.1	64.3	28.8	6.2	10.1	4.0	17.0	16.8	31.7	31.6	23.3	19.6	18.8	31.1	34.8	28.6	4.4	21.6	13.9	14.5	15.5	16.0	16.1	15.4	9.7	21.1	13.0	11.2	18.1	13.0	15.6	15.4	59.6	51.7	94.7	205.9	180.0	15.2	31.5	58.6	44.2	79.6	34.9	13.7	273.1	68.0	75.3	1.3	60.9	35.9	0.0	160.1	214.5	119.3	96.3	66.7	22.1	86.0	14.3	58.3	51.0	42.7	4.7	114.2	60.0	84.4	76.7	112.2	22.9	107.0	31.6	66.8	71.0	14.2	38.8	124.9	26.3	53.7	171.0	262.6	46.8	265.0	109.1
INSR	CD220	ENSG00000171105	"Insulin receptor"	P06213	19	7112255-7294034	"CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Carbohydrate metabolism"	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"pancreas: 64.5"	"Cell type enhanced"	"Detected in many"	4	"Peritubular cells: 230.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"dendritic cells: 8.8;granulocytes: 5.1;monocytes: 10.5"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 31.3;U-266/70: 23.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA036302, HPA036303"	Uncertain		Approved	"Vesicles,Plasma membrane"		NA	NA		72000	Vesicles	"Plasma membrane"	"HPA036302: AB_2675048, HPA036303: "	"unprognostic (4.64e-2)"	"unprognostic (2.42e-1)"	"unprognostic (9.65e-3)"	"unprognostic (9.70e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.15e-2)"	"unprognostic (2.58e-1)"	"unprognostic (5.09e-2)"	"unprognostic (1.97e-1)"	"unprognostic (3.05e-1)"	"unprognostic (9.29e-2)"	"unprognostic (1.86e-1)"	"unprognostic (6.33e-2)"	"unprognostic (3.45e-3)"	"unprognostic (2.43e-1)"	"unprognostic (2.75e-1)"	"unprognostic (8.82e-2)"	13.9	14.7	7.1	3.5	8.2	4.5	12.0	12.0	8.2	10.3	15.2	11.7	10.6	8.4	15.5	6.1	4.7	13.1	7.7	17.7	6.4	5.8	18.7	32.5	5.3	2.2	10.1	4.9	28.3	64.5	11.6	11.6	26.2	8.0	10.5	8.9	11.0	12.0	10.6	15.1	7.3	16.0	10.6	6.8	47.3	8.7	6.9	9.7	2.2	17.1	5.0	3.2	11.3	16.0	1.1	8.8	5.1	10.5	0.8	0.7	1.3	3.8	2.1	2.0	3.0	10.9	3.8	6.5	2.2	2.0	1.2	1.2	5.4	4.4	4.8	5.4	3.9	2.6	1.0	4.7	1.0	0.7	0.0	3.8	0.0	1.5	11.8	4.7	2.2	3.9	5.9	2.4	0.1	2.8	2.4	2.2	2.7	5.9	31.3	0.9	1.7	1.7	3.9	1.8	2.0	3.4	16.7	1.1	4.2	0.1	15.8	3.7	2.9	3.9	2.1	2.1	3.7	1.0	11.0	2.0	2.3	1.4	4.9	2.8	23.1	12.6	11.2	2.6	3.9	0.0	2.0	8.2	5.1	0.2	7.8	0.3	0.8	0.3	0.1	8.8	1.1	0.7	0.1	1.7	0.8	10.5	7.4	0.0	1.3	7.1	8.2	12.0	8.2	6.4	5.8	10.1	4.9	8.0	9.7	44.7	26.7	8.2	54.6	57.7	38.7	85.3	107.0	41.5	50.0	59.3	74.6	15.8	13.3	41.1	2.9	52.3	87.1	0.0	68.2	39.2	29.8	84.0	3.5	214.7	8.6	36.5	157.1	201.3	47.7	3.6	89.2	26.7	49.0	8.2	103.9	26.9	67.8	56.1	230.5	116.2	22.2	58.2	42.3	6.2	1.2	60.1	32.0	6.4	56.3	113.2
ITGA2B	"CD41, CD41B, GP2B, PPP1R93"	ENSG00000005961	"Integrin subunit alpha 2b"	P08514	17	44372180-44389505	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.5;epididymis: 25.2;lymphoid tissue: 22.8"	"Cell type enhanced"	"Detected in some"	11	"Cone photoreceptor cells: 7.9;Early spermatids: 14.4;granulocytes: 18.4;Late spermatids: 20.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	10	"basophil: 28.5"	"Lineage enriched"	"Detected in single"	54	"granulocytes: 28.5"	"Group enriched"	"Detected in some"	13	"HEL: 71.0;HMC-1: 121.4"	"Low region specificity"	"Detected in single"							"CAB018611, HPA031168, HPA031169, HPA031170, HPA031171"	Enhanced		Approved	"Plasma membrane"		NA	NA		1100000000	"Plasma membrane"		"CAB018611: AB_2265153, HPA031168: AB_10664706, HPA031169: AB_10669671, HPA031170: AB_10696214, HPA031171: AB_10669773"	"unprognostic (6.11e-2)"	"unprognostic (3.23e-2)"	"unprognostic (1.23e-1)"	"unprognostic (4.85e-2)"	"unprognostic (1.59e-2)"	"unprognostic (3.98e-3)"	"unprognostic (4.23e-5)"	"unprognostic (1.25e-1)"	"unprognostic (1.33e-2)"	"unprognostic (7.22e-2)"	"unprognostic (2.97e-3)"	"unprognostic (1.30e-1)"	"unprognostic (8.83e-9)"	"unprognostic (7.82e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.25e-1)"	0.7	0.2	1.4	0.4	1.0	15.2	0.6	3.8	2.4	1.2	0.9	0.4	0.4	0.1	1.1	25.2	0.7	1.9	1.4	10.6	0.9	1.6	1.0	0.4	6.5	0.5	0.7	0.8	2.1	2.5	0.1	2.5	1.9	1.1	0.6	0.3	0.6	0.4	1.6	0.8	0.1	0.6	0.4	0.8	22.8	0.2	3.0	0.4	0.4	5.2	1.0	0.6	0.7	1.9	0.0	0.5	28.5	0.2	0.0	0.2	11.1	0.0	0.1	0.7	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.4	71.0	0.1	0.7	0.0	0.0	121.4	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.3	0.0	7.3	0.1	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.7	0.6	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	28.5	0.2	2.1	0.1	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.8	0.0	0.0	0.5	0.0	11.1	1.4	1.0	3.8	2.4	0.9	1.6	0.7	0.8	1.1	0.4	0.0	1.0	0.0	0.5	0.2	4.5	1.2	0.0	0.0	2.3	5.2	7.9	0.5	0.0	0.0	14.4	0.6	0.0	0.0	0.0	1.1	0.8	0.3	18.4	0.0	0.2	3.2	0.0	0.6	0.3	20.0	1.7	0.0	0.0	0.0	0.0	1.9	0.1	0.0	1.8	0.0	3.1	0.0	0.0	0.7	3.4	0.0	0.6	0.0	0.0	0.1
ITGA4	CD49d	ENSG00000115232	"Integrin subunit alpha 4"	P13612	2	181457202-181536187	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 38.4;lymphoid tissue: 101.6"	"Cell type enhanced"	"Detected in many"	11	"B-cells: 42.0;Erythroid cells: 70.0;monocytes: 36.1;T-cells: 59.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"fHDF/TERT166: 39.1;HEL: 62.0;JURKAT: 32.6;MOLT-4: 72.3"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in many"	7	"cerebellum: 26.0"	HPA074961			Approved	"Plasma membrane"	"Intracellular and membrane"	NA	NA		100000	"Plasma membrane"		"HPA074961: AB_2732273"	"unprognostic (5.31e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.99e-2)"	"unprognostic (3.94e-2)"	"unprognostic (3.76e-1)"	"prognostic favorable (8.29e-4)"	"unprognostic (1.27e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.67e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.94e-1)"	"prognostic unfavorable (3.08e-5)"	"unprognostic (2.26e-2)"	"unprognostic (8.64e-3)"	"unprognostic (2.49e-1)"	"unprognostic (2.57e-2)"	3.8	1.7	1.3	39.7	1.1	19.2	3.2	2.4	1.9	6.7	4.8	0.5	1.1	3.8	3.0	3.1	2.9	2.1	6.9	1.7	2.9	1.3	3.0	2.5	13.6	33.7	1.2	0.5	1.8	1.6	0.0	1.3	7.1	0.9	3.8	4.9	2.9	7.5	2.0	1.0	1.5	11.6	2.4	1.6	36.0	4.4	1.2	0.2	101.6	2.6	1.5	14.3	6.0	4.1	11.0	19.1	38.4	38.3	8.8	15.9	16.2	0.0	0.2	1.0	0.0	9.2	13.9	0.0	9.0	11.3	4.8	10.2	0.0	0.0	7.2	0.0	39.1	4.2	5.3	3.2	0.1	5.8	0.0	0.7	62.0	0.2	0.0	0.9	27.4	1.5	9.9	0.0	0.3	0.0	4.7	0.5	32.6	0.0	10.5	3.0	0.0	72.3	19.2	0.8	0.0	0.0	15.9	4.5	1.0	0.0	0.0	1.6	0.6	0.0	0.0	0.3	0.4	0.0	18.1	4.9	1.5	0.9	0.1	1.8	20.5	15.2	4.1	0.8	13.6	20.8	6.7	16.2	38.4	12.9	38.3	9.7	11.0	14.6	15.9	19.1	10.0	8.5	10.4	2.1	8.8	37.5	5.0	3.7	16.2	1.3	1.1	2.4	1.9	2.9	1.3	1.2	0.5	0.9	0.2	0.0	7.9	42.0	0.2	0.2	2.4	0.8	5.1	1.4	3.4	0.0	5.9	0.1	0.0	0.0	0.0	0.0	0.0	70.0	0.0	0.2	2.9	0.3	17.4	0.0	5.8	0.0	0.0	1.8	21.0	0.0	0.6	22.7	0.0	36.1	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	1.6	0.4	0.9	0.5	0.3	59.7	0.0	0.2
ITGAL	"CD11A, LFA-1"	ENSG00000005844	"Integrin subunit alpha L"	P20701	16	30472658-30523185	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction, Phagocytosis"	"Integrin, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 36.7;lymphoid tissue: 74.6"	"Cell type enhanced"	"Detected in some"	19	"Alveolar cells type 2: 14.6;Hofbauer cells: 17.3;Kupffer cells: 16.8;T-cells: 66.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	4	"HMC-1: 121.9"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB025011	Enhanced				"Intracellular and membrane"	NA	NA		1100000			"CAB025011: "	"unprognostic (1.10e-2)"	"unprognostic (4.26e-3)"	"unprognostic (3.72e-3)"	"prognostic favorable (5.63e-5)"	"unprognostic (2.88e-1)"	"prognostic favorable (3.34e-4)"	"unprognostic (1.63e-1)"	"unprognostic (5.69e-3)"	"prognostic favorable (5.57e-4)"	"unprognostic (3.37e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.84e-1)"	"prognostic unfavorable (2.69e-5)"	"unprognostic (2.89e-1)"	"unprognostic (3.05e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.71e-2)"	2.8	1.1	1.8	29.8	2.0	15.1	1.8	0.6	1.5	1.3	3.0	2.7	0.5	2.4	1.7	1.4	2.2	2.6	4.9	1.4	1.3	1.3	2.6	6.7	16.2	29.0	3.1	1.4	1.4	1.2	0.0	1.4	1.7	1.7	2.0	3.4	1.9	6.6	0.7	0.8	1.0	12.7	1.4	4.7	44.1	3.5	0.8	2.7	74.6	2.8	2.0	41.8	4.4	1.9	2.1	7.5	7.2	36.7	9.5	22.5	11.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.2	121.9	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	27.3	0.0	0.0	8.1	0.7	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.4	4.3	0.0	0.0	0.0	0.0	0.0	7.7	2.6	0.0	0.1	0.8	0.0	3.1	8.4	6.5	22.5	16.9	11.2	2.1	8.8	16.2	7.5	1.3	4.9	11.4	7.2	9.5	36.7	3.0	6.3	11.5	1.8	2.0	0.6	1.5	1.3	1.3	3.1	1.4	1.7	2.7	6.0	14.6	8.2	0.2	0.7	0.0	1.1	0.0	12.0	3.4	1.8	0.0	0.2	0.0	0.0	0.2	0.7	0.4	0.0	0.0	0.4	0.8	0.1	4.7	3.2	17.3	0.0	0.0	4.3	16.8	0.4	0.0	5.4	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.7	0.0	0.4	0.1	0.2	0.3	0.6	66.0	0.0	0.1
ITGAV	"CD51, MSK8, VNRA, VTNR"	ENSG00000138448	"Integrin subunit alpha V"	P06756	2	186590065-186680901	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.7"	"Group enriched"	"Detected in many"	4	"granulocytes: 7.7;monocytes: 2.3"	"Cell line enhanced"	"Detected in many"		"RT4: 71.7;SuSa: 62.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002499, HPA004856"	Supported		Approved	"Focal adhesion sites,Cytosol"		NA	NA		750000	"Focal adhesion sites, Cytosol"		"CAB002499: AB_563594, HPA004856: AB_1846316"	"unprognostic (4.03e-2)"	"unprognostic (5.17e-3)"	"unprognostic (1.22e-2)"	"unprognostic (5.22e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.18e-1)"	"prognostic unfavorable (2.08e-4)"	"unprognostic (1.48e-2)"	"unprognostic (6.95e-2)"	"unprognostic (2.89e-1)"	"prognostic unfavorable (5.07e-4)"	"unprognostic (5.84e-2)"	"unprognostic (2.67e-2)"	"prognostic unfavorable (1.05e-6)"	"unprognostic (2.61e-1)"	"unprognostic (9.11e-2)"	"unprognostic (8.07e-2)"	23.2	22.1	17.9	18.3	21.8	3.1	25.8	16.7	23.1	22.9	13.6	23.4	11.6	8.4	26.0	11.4	14.2	14.5	25.2	40.7	16.8	12.3	51.5	9.5	20.6	7.6	24.2	11.6	35.4	18.7	65.0	11.0	29.6	22.1	16.5	11.9	83.4	17.9	15.9	13.1	21.5	10.1	29.6	33.0	12.1	17.3	11.2	17.0	7.8	33.1	10.9	11.1	17.6	17.9	0.3	0.9	7.7	2.3	0.4	1.1	0.5	9.3	11.1	7.4	23.7	27.3	18.5	28.3	18.3	14.8	6.5	6.5	9.7	32.2	0.0	36.1	20.6	22.7	11.7	3.8	17.2	9.4	1.8	3.4	2.2	14.6	13.3	10.8	1.5	1.4	13.4	8.2	14.4	12.3	39.0	15.4	1.1	2.1	4.7	17.2	3.7	0.9	1.3	5.6	5.6	5.6	0.0	15.2	1.2	16.8	71.7	1.5	4.6	21.1	6.5	7.7	62.1	5.1	4.3	46.8	40.2	12.6	8.2	15.4	1.1	1.9	1.0	16.2	0.6	19.8	7.7	1.1	1.6	1.0	2.3	0.7	0.3	0.5	0.8	0.9	0.1	0.5	0.5	0.5	0.4	1.2	0.4	1.1	0.5	17.9	21.8	16.7	17.3	16.8	12.3	24.2	11.6	22.1	17.0	26.8	18.5	2.4	54.8	114.0	118.2	124.7	73.9	12.0	20.5	73.3	72.6	46.9	1.7	78.4	0.5	50.4	13.2	0.0	89.0	21.8	61.3	83.9	49.5	15.8	26.1	14.3	7.0	34.4	33.9	1.6	17.8	18.2	43.9	20.8	18.9	82.5	120.4	18.2	24.4	16.5	54.8	32.3	47.2	0.7	1.4	90.7	33.2	6.9	11.4	48.6
ITGB1	"CD29, FNRB, GPIIA, MDF2, MSK12"	ENSG00000150093	"Integrin subunit beta 1"	P05556	10	32900319-33005792	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Ductal cells: 1163.1;Pancreatic endocrine cells: 917.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"hTERT-RPE1: 196.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003434, HPA059297, HPA069003"	Enhanced		Supported	"Endoplasmic reticulum,Plasma membrane,Focal adhesion sites"		NA	NA		540000000	"Plasma membrane, Focal adhesion sites"	"Endoplasmic reticulum"	"CAB003434: AB_303570, HPA059297: AB_2732634, HPA069003: AB_2732125"	"unprognostic (3.07e-2)"	"prognostic unfavorable (5.01e-4)"	"unprognostic (8.67e-2)"	"unprognostic (4.36e-1)"	"unprognostic (1.20e-2)"	"unprognostic (3.87e-2)"	"unprognostic (1.60e-2)"	"prognostic unfavorable (3.36e-6)"	"unprognostic (3.22e-1)"	"unprognostic (2.36e-3)"	"unprognostic (3.68e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.02e-3)"	"unprognostic (1.25e-2)"	"unprognostic (2.23e-1)"	"unprognostic (2.48e-1)"	"unprognostic (3.08e-2)"	95.2	30.6	13.7	32.1	19.7	9.7	107.7	6.5	14.8	55.1	61.3	17.0	80.2	20.2	84.2	56.2	59.9	45.0	49.8	68.7	15.0	14.4	47.3	85.8	55.4	34.5	23.0	11.1	47.4	37.4	17.6	35.2	83.3	19.5	53.1	32.2	18.6	30.3	76.2	58.0	19.5	42.3	109.3	30.1	59.8	45.4	26.9	18.8	12.7	36.8	27.6	19.4	92.7	47.4	31.3	9.1	4.3	27.1	21.9	68.4	26.2	45.6	67.0	36.2	40.1	87.3	75.2	31.6	153.5	89.0	73.1	66.9	15.0	106.9	12.3	27.8	128.7	48.0	31.9	10.9	87.3	81.6	12.1	8.8	14.8	31.9	17.5	61.5	3.3	14.7	76.2	47.8	76.9	31.3	196.1	89.8	6.1	10.2	5.4	120.5	7.5	5.7	3.3	8.0	13.9	34.0	3.7	26.8	2.2	104.2	13.2	8.6	21.4	47.8	8.1	34.4	61.5	10.9	11.9	100.4	94.2	54.7	66.9	51.1	5.0	1.1	6.9	69.4	14.1	36.9	1.6	9.8	4.3	25.5	17.8	6.0	31.3	54.6	37.5	9.1	8.6	7.1	19.1	2.3	21.9	27.1	3.7	68.4	26.2	13.7	19.7	6.5	14.8	15.0	14.4	23.0	11.1	19.5	18.8	318.6	128.6	76.4	295.7	485.6	32.6	175.3	242.0	164.6	252.5	214.6	29.5	156.7	11.6	1163.1	4.3	314.7	83.6	70.0	355.7	460.3	265.1	177.2	86.6	221.3	161.3	36.5	185.6	387.9	152.7	9.7	235.6	174.3	325.6	83.0	81.4	76.8	917.0	113.2	565.7	64.3	45.2	627.3	497.4	10.0	63.7	149.1	183.8	106.6	98.8	257.2
ITGB3	"CD61, GP3A, GPIIIa"	ENSG00000259207	"Integrin subunit beta 3"	P05106	17	47253846-47311816	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Host-virus interaction"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"thyroid gland: 36.6"	"Cell type enhanced"	"Detected in some"	10	"Late spermatids: 4.1;Proximal tubular cells: 3.5;Sertoli cells: 6.5"	"Group enriched"	"Detected in many"	6	"melanoma: 7.5;renal cancer: 3.6;thyroid cancer: 11.5"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	19	"basophil: 2.8;neutrophil: 2.8"	"Lineage enriched"	"Detected in single"	19	"granulocytes: 2.8"	"Cell line enhanced"	"Detected in many"		"EFO-21: 46.6;HEL: 41.2;RPTEC TERT1: 26.8;U-87 MG: 21.1;WM-115: 67.2"									HPA027852	Approved		Supported	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	NA	NA		710000000	"Plasma membrane"	Nucleoplasm	"HPA027852: AB_10601760"	"unprognostic (1.13e-2)"	"unprognostic (1.97e-3)"	"unprognostic (2.47e-1)"	"unprognostic (3.00e-2)"	"unprognostic (1.91e-2)"	"unprognostic (6.04e-3)"	"unprognostic (3.70e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.85e-1)"	"unprognostic (6.35e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.72e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.17e-3)"	10.0	0.6	1.0	6.2	2.5	2.7	7.0	0.4	1.6	4.6	13.6	0.9	2.4	2.2	9.7	5.7	6.4	6.4	2.8	8.5	0.7	0.6	16.0	3.7	5.2	1.2	2.3	0.1	4.6	0.6	0.7	1.6	23.5	1.6	6.4	4.8	1.8	2.5	11.5	4.9	2.4	5.0	17.0	1.8	9.5	3.6	2.6	0.6	0.2	36.6	1.9	0.9	11.0	7.8	0.1	0.0	2.8	0.1	0.0	0.0	9.5	0.0	0.4	0.1	0.0	2.4	1.0	0.0	1.2	6.1	2.6	2.4	0.0	0.0	0.1	46.6	0.3	3.6	0.0	0.0	0.0	3.4	0.9	0.0	41.2	0.1	0.0	2.0	0.0	0.0	1.0	0.0	15.6	0.4	1.8	11.6	0.6	0.1	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.1	0.0	1.1	0.0	26.8	0.0	0.0	0.1	1.5	0.0	8.4	2.4	0.0	0.0	12.6	0.5	0.7	0.3	2.8	0.0	0.0	0.3	21.1	0.0	67.2	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	9.5	1.0	2.5	0.4	1.6	0.7	0.6	2.3	0.1	1.6	0.6	0.0	0.0	0.0	0.1	0.1	0.0	0.8	0.0	0.0	1.2	0.0	0.0	0.0	0.0	1.1	2.7	1.4	0.0	0.0	0.4	0.0	0.8	0.1	0.0	0.8	0.8	0.0	0.0	1.8	0.0	4.1	0.3	0.3	0.0	0.0	0.0	0.0	1.0	0.0	1.1	3.5	0.0	6.5	1.9	0.0	2.3	0.4	1.0	0.0	0.0	0.1
ITGB7		ENSG00000139626	"Integrin subunit beta 7"	P26010	12	53191318-53207307	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Host cell receptor for virus entry, Integrin, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 31.3;lymphoid tissue: 37.6"	"Cell type enhanced"	"Detected in many"	10	"B-cells: 35.7;granulocytes: 29.9;T-cells: 27.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Group enriched"	"Detected in some"	99	"Karpas-707: 295.2;RPMI-8226: 230.5"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA042277			Approved	"Nucleoplasm,Nuclear membrane,Vesicles,Plasma membrane,Cytosol"		NA	NA		42000	"Plasma membrane, Cytosol"	"Nucleoplasm, Nuclear membrane, Vesicles"	"HPA042277: AB_10793877"	"unprognostic (5.34e-2)"	"unprognostic (4.47e-2)"	"unprognostic (2.80e-3)"	"unprognostic (1.40e-2)"	"unprognostic (6.57e-4)"	"unprognostic (3.51e-5)"	"unprognostic (3.11e-3)"	"unprognostic (1.37e-2)"	"unprognostic (3.58e-1)"	"unprognostic (2.18e-1)"	"unprognostic (9.63e-3)"	"unprognostic (3.36e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.16e-1)"	"unprognostic (6.95e-2)"	"unprognostic (9.34e-2)"	"unprognostic (2.47e-4)"	1.8	1.4	1.4	29.1	1.8	7.5	1.5	0.6	1.2	1.8	8.7	2.9	0.8	6.7	2.3	2.8	6.6	2.0	5.6	1.4	1.5	1.0	5.4	5.1	4.9	26.4	1.9	1.0	1.1	1.3	0.7	1.7	1.8	2.4	2.7	5.6	2.1	10.7	2.2	1.0	6.4	15.1	1.5	2.0	26.7	4.3	0.9	2.0	7.8	3.6	4.4	37.6	4.6	3.0	10.1	15.4	31.3	1.9	7.5	23.0	5.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.6	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	295.2	0.0	0.0	0.0	0.4	0.0	2.4	0.0	0.1	0.0	230.5	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.5	1.0	0.2	0.2	0.1	0.1	22.6	1.9	31.3	19.3	0.5	14.3	10.1	19.4	23.0	15.4	8.3	16.3	17.1	0.5	7.5	0.1	4.2	22.7	5.2	1.4	1.8	0.6	1.2	1.5	1.0	1.9	1.0	2.4	2.0	3.0	8.5	35.7	0.3	1.9	0.0	0.4	2.5	0.0	0.0	7.0	3.9	0.1	6.6	0.2	0.0	0.1	0.0	0.0	0.5	0.1	1.0	0.1	29.9	1.6	13.8	0.0	0.0	0.6	3.0	0.0	0.0	7.0	6.8	7.2	0.3	6.6	0.6	0.0	0.0	4.4	0.7	0.0	0.4	0.2	1.1	3.1	0.1	27.7	0.9	1.3
JAK1	"JAK1A, JAK1B, JTK3"	ENSG00000162434	"Janus kinase 1"	P23458	1	64833229-64966504	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"ASC diff: 70.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB013088	Approved					NA	NA					"CAB013088: "	"prognostic favorable (9.63e-4)"	"unprognostic (1.24e-1)"	"prognostic favorable (2.81e-4)"	"unprognostic (5.10e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.21e-2)"	"unprognostic (1.53e-1)"	"unprognostic (7.00e-3)"	"unprognostic (8.40e-2)"	"unprognostic (7.88e-3)"	"unprognostic (1.66e-2)"	"unprognostic (8.84e-2)"	"prognostic favorable (2.67e-4)"	"unprognostic (2.35e-1)"	"unprognostic (2.04e-1)"	"unprognostic (7.30e-2)"	"unprognostic (3.51e-1)"	46.7	20.4	15.5	31.1	16.5	21.2	56.6	24.3	20.4	27.3	27.1	16.3	16.5	13.8	28.2	22.0	27.0	20.7	27.7	27.3	15.3	16.5	31.4	38.3	36.5	61.4	15.6	14.1	33.3	29.1	28.3	39.8	22.9	25.1	26.0	22.2	18.1	19.8	21.3	45.1	29.7	29.3	30.7	16.3	52.7	20.9	17.3	15.0	62.7	29.0	17.9	42.5	37.2	29.3	20.2	15.4	34.9	17.1	68.1	27.5	25.8	11.2	14.6	6.1	0.6	70.7	40.1	7.9	17.5	25.9	14.6	17.2	4.8	6.2	17.1	13.6	31.1	27.2	6.3	4.1	13.5	20.8	22.5	6.6	23.1	7.7	10.4	26.1	8.8	16.1	35.1	18.8	22.0	23.0	17.4	45.4	8.5	8.4	18.3	16.1	6.4	4.8	5.9	4.2	12.9	8.8	6.9	17.6	6.3	37.6	19.8	4.3	12.9	24.0	11.3	10.3	12.7	24.0	5.5	41.2	17.5	7.8	39.6	9.3	11.5	5.2	13.5	16.3	11.7	7.9	31.2	10.9	31.5	22.8	15.2	27.5	20.2	22.0	25.7	15.4	16.1	24.3	20.7	34.9	68.1	17.1	10.5	26.5	25.8	15.5	16.5	24.3	20.4	15.3	16.5	15.6	14.1	25.1	15.0	47.6	79.3	120.3	114.0	103.6	35.7	98.8	79.0	41.5	63.7	106.4	21.6	5.5	36.5	152.3	100.2	130.9	49.5	23.3	184.7	94.8	76.6	173.3	55.4	77.3	52.1	20.6	63.8	178.0	138.0	72.8	88.9	109.3	47.2	252.5	54.9	54.4	180.7	49.2	79.5	61.6	35.1	161.7	144.2	30.5	50.9	145.2	10.2	159.2	38.1	188.3
JAK2	JTK10	ENSG00000096968	"Janus kinase 2"	O60674	9	4984390-5128183	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Chromatin regulator, Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Kupffer cells: 36.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 40.8"	"Lineage enriched"	"Detected in all"	4	"granulocytes: 40.8"	"Group enriched"	"Detected in many"	5	"ASC diff: 19.4;HDLM-2: 27.4;HEL: 56.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013089, HPA040820, HPA043870"	Approved		Supported	"Nucleoplasm,Plasma membrane,Focal adhesion sites"		No	No			Nucleoplasm	"Plasma membrane, Focal adhesion sites"	"CAB013089: AB_2533647, HPA040820: AB_2677151, HPA043870: AB_2678708"	"unprognostic (2.24e-3)"	"unprognostic (2.76e-2)"	"unprognostic (1.50e-2)"	"unprognostic (7.67e-2)"	"unprognostic (5.50e-2)"	"unprognostic (3.09e-2)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.58e-1)"	"unprognostic (1.72e-2)"	"unprognostic (3.85e-1)"	"unprognostic (4.53e-2)"	"unprognostic (3.43e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.37e-3)"	19.8	8.8	11.5	19.0	10.5	19.0	17.7	14.7	14.4	17.8	10.6	7.0	10.3	7.2	14.8	13.6	12.4	13.4	14.6	27.6	10.3	6.7	7.7	5.6	16.1	19.4	7.0	10.5	15.9	6.7	10.1	7.5	12.0	10.0	12.0	7.4	9.4	7.2	7.4	14.4	19.0	12.3	10.4	11.7	21.5	14.1	10.1	9.0	13.6	8.6	6.5	13.5	13.9	15.6	2.1	9.6	40.8	7.5	3.4	2.1	2.5	2.5	1.5	1.5	2.5	19.4	5.0	0.4	3.5	3.0	2.7	1.8	0.1	0.8	0.1	0.8	2.1	2.2	0.9	1.6	2.1	2.0	27.4	0.5	56.1	3.0	0.7	4.0	3.8	2.9	4.1	0.9	1.1	1.8	3.3	2.5	2.0	4.0	6.5	4.8	0.9	0.9	5.4	1.3	1.3	1.7	1.9	2.8	0.8	2.0	1.3	1.7	0.9	1.0	1.5	1.1	1.6	0.8	6.7	5.1	4.1	1.4	4.2	2.4	1.2	2.3	0.5	5.3	1.9	2.0	40.8	7.5	13.4	2.1	7.3	1.7	2.1	1.6	1.2	9.6	1.9	0.9	1.1	7.1	3.4	5.8	3.6	1.6	2.5	11.5	10.5	14.7	14.4	10.3	6.7	7.0	10.5	10.0	9.0	14.9	6.4	6.9	2.8	8.7	7.4	22.0	0.0	5.3	7.9	7.0	7.9	1.8	1.7	3.0	7.4	8.7	3.9	23.3	3.4	0.8	7.0	1.7	13.9	1.6	11.9	7.9	2.9	4.9	36.0	5.3	21.9	27.7	5.0	16.2	4.2	12.2	5.4	14.4	31.5	2.5	11.1	0.0	5.0	14.9	5.7	7.3	2.9	5.0	3.3	4.1
JAK3	"JAK-3, JAK3_HUMAN, JAKL, L-JAK, LJAK"	ENSG00000105639	"Janus kinase 3"	P52333	19	17824780-17848071	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Adaptive immunity, Immunity, Innate immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, SCID"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 68.3"	"Cell type enhanced"	"Detected in many"	7	"B-cells: 18.2;Ito cells: 14.1;Peritubular cells: 13.8;T-cells: 24.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 20.6;HEL: 9.2;HMC-1: 9.4;Karpas-707: 24.0;U-266/70: 9.3;U-266/84: 13.8;U-937: 14.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA070314	Enhanced		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA070314: AB_2686251"	"unprognostic (5.59e-3)"	"prognostic favorable (6.42e-5)"	"unprognostic (5.71e-2)"	"unprognostic (2.34e-1)"	"unprognostic (6.13e-3)"	"unprognostic (1.11e-3)"	"unprognostic (4.21e-2)"	"unprognostic (2.60e-1)"	"unprognostic (2.38e-2)"	"unprognostic (2.36e-1)"	"unprognostic (3.58e-2)"	"unprognostic (1.94e-1)"	"prognostic unfavorable (2.89e-14)"	"unprognostic (2.28e-1)"	"unprognostic (2.21e-2)"	"unprognostic (4.43e-2)"	"unprognostic (7.61e-2)"	6.8	1.7	4.0	24.5	8.5	12.0	2.7	2.4	3.1	1.9	2.3	1.0	0.0	2.2	1.7	2.0	2.5	3.5	3.6	4.3	2.7	2.8	3.8	2.0	8.4	68.3	7.5	0.0	11.0	2.0	0.4	2.3	4.1	5.3	3.0	2.4	1.6	6.1	1.5	0.7	1.3	9.5	2.5	8.4	36.1	3.2	1.8	5.8	20.9	3.4	1.7	28.8	5.3	2.4	7.4	4.5	16.9	9.6	8.4	15.0	6.8	0.1	0.3	0.3	1.1	0.4	1.5	0.2	0.5	0.0	0.0	0.1	0.0	0.9	0.4	2.0	0.4	0.3	0.1	0.0	0.2	0.0	20.6	0.0	9.2	0.0	0.8	0.7	0.0	9.4	5.1	0.2	0.0	0.0	0.0	0.2	2.1	0.0	24.0	0.0	0.4	3.6	0.0	0.2	0.5	0.7	4.7	0.0	0.4	0.5	0.0	0.0	0.3	0.1	0.2	0.0	0.1	2.0	1.4	0.4	0.0	0.4	0.0	0.0	9.3	13.8	2.5	0.1	14.0	0.2	1.2	4.9	0.2	12.6	9.6	14.5	6.5	15.0	13.1	4.5	7.4	14.9	13.0	16.9	8.4	8.8	3.7	11.8	6.8	4.0	8.5	2.4	3.1	2.7	2.8	7.5	0.0	5.3	5.8	0.0	5.8	18.2	0.5	0.7	0.3	1.4	0.0	0.0	1.2	1.8	0.0	0.9	0.0	0.6	1.0	5.8	0.0	0.0	0.3	0.7	2.3	0.2	4.7	0.0	11.5	0.0	0.0	14.1	10.8	0.9	11.5	3.5	3.3	12.6	0.0	0.8	0.4	0.0	13.8	0.1	0.5	6.5	2.1	0.3	0.7	0.9	1.1	24.5	0.0	0.5
JUN	"AP-1, c-Jun"	ENSG00000177606	"Jun proto-oncogene, AP-1 transcription factor subunit"	P05412	1	58780788-58784327	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RH-30: 71.6"	"Low region specificity"	"Detected in all"							"CAB003801, CAB007780, HPA031174, HPA059474"	Enhanced		Enhanced	Nucleoplasm		Yes	No			Nucleoplasm		"CAB003801: AB_365485, CAB007780: AB_562268, HPA031174: , HPA059474: AB_2684030"	"unprognostic (2.06e-2)"	"unprognostic (1.76e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.85e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.11e-2)"	"unprognostic (5.21e-2)"	"unprognostic (1.24e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.14e-1)"	"unprognostic (2.82e-1)"	"unprognostic (5.15e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.81e-3)"	64.5	29.4	26.7	33.7	17.2	68.4	61.7	19.5	20.6	60.0	32.7	30.8	28.4	13.3	40.5	21.8	34.1	72.6	48.5	31.3	20.2	12.4	21.2	39.3	55.1	14.3	15.3	12.0	49.8	48.7	15.0	16.7	21.6	24.1	48.6	16.7	40.5	59.4	39.3	32.2	51.3	28.6	40.7	17.6	22.9	47.0	18.2	18.1	9.0	61.0	35.2	23.3	41.5	33.1	7.4	1.3	4.0	5.1	3.2	2.5	1.2	16.1	2.3	5.2	1.0	8.3	9.5	0.1	20.6	7.5	14.6	8.9	4.2	1.2	0.6	9.9	12.8	31.6	5.6	0.4	6.7	9.3	12.8	37.5	0.2	0.9	4.7	6.9	1.1	3.7	10.2	17.3	18.8	7.9	6.6	10.9	0.7	5.7	9.4	5.6	3.0	1.0	9.0	4.2	7.8	14.7	0.4	71.6	3.2	13.7	1.5	14.5	4.2	14.3	15.0	6.0	5.9	5.3	0.6	19.1	33.3	15.1	12.0	25.8	20.9	3.3	1.2	34.8	2.1	9.5	1.2	5.1	2.0	2.4	1.1	1.3	4.1	1.2	2.5	1.3	7.4	0.3	1.7	4.0	3.2	0.4	0.2	0.9	1.2	26.7	17.2	19.5	20.6	20.2	12.4	15.3	12.0	24.1	18.1	500.2	627.8	505.0	717.3	1097.5	107.5	1349.5	494.3	76.3	282.1	99.5	247.4	529.1	43.1	569.2	40.2	960.8	1411.6	46.7	449.9	86.5	867.7	1920.0	529.9	118.4	560.4	82.6	1440.1	352.4	430.2	18.1	1136.5	481.3	718.7	237.2	1907.1	688.6	543.7	1520.1	243.3	25.0	400.6	1513.4	1714.3	15.6	13.8	843.0	347.6	518.9	938.7	449.9
KCNA1	"AEMK, HUK1, Kv1.1, MBK1, RBK1"	ENSG00000111262	"Potassium voltage-gated channel subfamily A member 1"	Q09470	12	4909893-4918256	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"brain: 24.1"	"Group enriched"	"Detected in some"	6	"Bipolar cells: 10.8;Ciliated cells: 6.7"	"Not detected"	"Not detected"			"Group enriched"	"Detected in all"	4	"basal ganglia: 13.7;cerebellum: 23.8;cerebral cortex: 21.1;pons and medulla: 24.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	11	"LHCN-M2: 2.4;NTERA-2: 2.1;SCLC-21H: 3.9;U-2 OS: 3.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA074471	Approved					NA	NA					"HPA074471: "	"unprognostic (6.39e-3)"	"unprognostic (2.64e-1)"			"unprognostic (1.09e-1)"	"unprognostic (8.44e-2)"		"unprognostic (1.33e-1)"		"unprognostic (1.79e-2)"	"unprognostic (4.69e-3)"	"unprognostic (2.48e-1)"		"unprognostic (8.77e-5)"	"unprognostic (6.30e-2)"	"unprognostic (1.08e-4)"		0.8	0.7	1.5	0.7	13.7	0.7	1.3	23.8	21.1	1.6	0.9	0.9	0.0	0.9	1.0	0.7	0.7	0.7	0.9	0.7	4.6	1.1	0.7	0.7	0.8	0.7	2.2	3.5	0.7	0.7	4.0	0.6	0.7	24.1	0.7	0.9	0.0	1.9	0.8	0.7	0.8	0.8	1.1	1.1	0.7	1.0	0.7	1.4	0.2	2.0	0.0	0.7	0.9	0.4	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	13.7	23.8	21.1	4.6	1.1	2.2	3.5	24.1	1.4	0.0	0.0	0.0	0.0	0.3	10.8	1.4	0.0	6.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNA10	Kv1.8	ENSG00000143105	"Potassium voltage-gated channel subfamily A member 10"	Q16322	1	110517217-110519175	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in single"		"testis: 3.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"U-2 OS: 1.4;U-87 MG: 1.2"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	4	"basal ganglia: 0.2"	"HPA015061, CAB022564"			Uncertain	Nucleoplasm,Cytosol		No	NA			"Nucleoplasm, Cytosol"		"CAB022564: , HPA015061: AB_1855573"														"unprognostic (2.96e-2)"				0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0			0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.1	3.2			0.0		0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.4	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNA2	"HK4, Kv1.2"	ENSG00000177301	"Potassium voltage-gated channel subfamily A member 2"	P16389	1	110519837-110631474	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 28.0"	"Cell type enriched"	"Detected in some"	5	"Muller glia cells: 24.2"	"Cancer enhanced"	"Detected in some"		"glioma: 1.2"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.1"	"Lineage enriched"	"Detected in single"	8	"T-cells: 4.1"	"Cell line enhanced"	"Detected in some"		"Karpas-707: 10.9;SCLC-21H: 2.8;U-2 OS: 2.4;U-266/70: 3.6;U-266/84: 5.4;WM-115: 2.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB001976	Enhanced					NA	NA					"CAB001976: "	"unprognostic (1.84e-2)"	"unprognostic (9.70e-3)"	"unprognostic (1.97e-1)"	"unprognostic (2.98e-1)"	"unprognostic (7.17e-3)"	"unprognostic (6.68e-3)"		"unprognostic (5.05e-3)"	"unprognostic (2.02e-1)"	"unprognostic (1.29e-1)"	"unprognostic (4.50e-3)"	"unprognostic (3.08e-3)"	"unprognostic (2.93e-4)"	"unprognostic (2.15e-1)"	"unprognostic (3.55e-1)"	"unprognostic (6.41e-2)"	"unprognostic (2.83e-1)"	3.2	1.4	7.1	2.2	13.1	0.8	1.2	17.2	28.0	1.2	1.6	3.1	0.0	1.4	1.0	1.3	1.7	1.1	1.6	1.6	7.2	6.1	0.9	0.9	1.0	1.9	7.2	14.5	1.1	1.9	0.8	1.4	0.7	21.1	1.8	2.0	1.4	1.8	2.4	2.1	1.6	1.6	1.6	2.8	1.3	1.3	2.5	3.8	0.3	5.3	0.0	3.5	1.4	0.5	0.5	0.0	0.0	0.0	0.0	4.1	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	10.9	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.5	0.0	1.4	0.0	0.0	2.8	0.0	0.0	0.0	1.2	0.6	0.0	0.0	0.0	0.1	2.4	0.0	0.0	3.6	5.4	0.2	0.1	0.0	2.9	0.0	0.0	0.0	0.4	0.0	0.3	0.5	1.8	1.3	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	4.1	0.1	7.1	13.1	17.2	26.3	7.2	6.1	7.2	14.5	21.1	3.8	0.0	0.0	0.0	0.0	0.0	3.7	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	24.2	0.0	0.0	4.9	0.0	2.9	0.0	0.5	0.0	1.4	0.0	0.0	0.0	0.0	0.0
KCNA3	"HLK3, HPCN3, Kv1.3, MK3"	ENSG00000177272	"Potassium voltage-gated channel subfamily A member 3"	P22001	1	110672465-110675033	"FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"lymphoid tissue: 59.4"	"Cell type enhanced"	"Detected in some"	12	"Alveolar cells type 2: 3.4;Melanocytes: 3.3;Sertoli cells: 6.5;T-cells: 8.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	7	"B-cells: 3.3;T-cells: 11.5"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 12.7;Karpas-707: 26.1;U-266/70: 18.9;U-266/84: 16.9"	"Low region specificity"	"Detected in all"							HPA016625	Approved					NA	NA					"HPA016625: AB_2669407"	"unprognostic (2.17e-2)"	"unprognostic (5.07e-3)"	"unprognostic (3.92e-3)"	"unprognostic (1.20e-2)"	"unprognostic (2.35e-1)"	"unprognostic (1.76e-5)"	"unprognostic (1.70e-4)"	"unprognostic (8.48e-2)"	"unprognostic (1.49e-2)"	"unprognostic (5.92e-4)"	"unprognostic (1.81e-2)"	"unprognostic (3.96e-2)"	"unprognostic (1.39e-1)"	"unprognostic (3.13e-2)"	"unprognostic (2.99e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.40e-1)"	1.9	1.3	4.0	7.8	5.7	5.6	1.3	5.0	5.6	1.7	3.1	0.5	0.0	3.2	1.1	0.4	1.1	1.3	2.3	1.4	3.5	4.3	1.5	1.3	7.8	14.5	1.5	3.1	1.3	0.9	0.4	1.8	0.9	3.1	1.1	2.6	0.5	3.7	0.3	0.5	0.8	5.9	0.7	1.9	7.7	5.3	1.4	1.5	59.4	2.1	0.3	10.9	5.8	1.3	3.3	1.0	0.0	0.7	0.9	11.5	2.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.7	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.8	0.0	26.1	0.0	0.0	5.4	0.0	0.5	0.0	0.0	0.0	0.0	5.2	0.0	0.0	3.6	0.3	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.4	0.0	0.0	18.9	16.9	6.5	0.0	1.5	0.0	0.0	0.7	0.0	7.2	0.0	8.2	2.3	10.8	11.5	1.0	3.3	8.5	6.4	0.0	0.9	0.1	0.5	9.5	2.9	4.0	5.7	5.0	5.6	3.5	4.3	1.5	3.1	3.1	1.5	0.0	3.4	2.2	0.0	0.3	1.3	0.4	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	2.5	0.6	0.0	0.0	1.6	3.3	2.8	0.0	0.2	0.0	0.0	0.0	0.0	0.1	6.5	0.0	0.9	0.2	0.5	0.0	8.7	0.0	0.0
KCNA4	"HK1, HPCN2, KCNA4L, Kv1.4"	ENSG00000182255	"Potassium voltage-gated channel subfamily A member 4"	P22459	11	30009741-30017023	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Cataract, Disease mutation, Dystonia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"adrenal gland: 16.5;brain: 39.0"	"Group enriched"	"Detected in some"	5	"Bipolar cells: 9.6;Horizontal cells: 12.7;Muller glia cells: 6.7"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"basal ganglia: 39.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"U-2 OS: 1.6;WM-115: 2.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB001977, HPA016422"	Approved					NA	NA					"CAB001977: , HPA016422: AB_1855574"				"unprognostic (1.12e-2)"	"unprognostic (1.80e-2)"			"unprognostic (1.31e-2)"	"unprognostic (2.73e-2)"	"unprognostic (1.00e-1)"	"unprognostic (4.09e-3)"	"unprognostic (2.24e-1)"	"unprognostic (1.15e-2)"	"unprognostic (6.71e-2)"	"unprognostic (1.17e-1)"			2.2	16.5	9.8	0.6	39.0	0.6	0.6	0.2	12.2	0.6	0.6	0.8	1.8	0.7	1.1	0.9	0.6	0.8	0.6	5.9	6.1	2.7	1.2	0.6	2.4	0.6	1.6	6.2	0.6	0.6	0.6	2.8	1.2	10.5	0.6	0.6	0.0	0.6	1.7	0.6	0.8	0.6	0.8	0.6	0.6	1.0	0.7	5.9	0.0	0.6	0.0	0.6	0.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.1	0.0	0.0	0.6	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.8	39.0	0.2	12.2	6.1	2.7	1.6	6.2	10.5	5.9	0.0	0.0	0.0	0.0	0.0	9.6	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.7	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	6.7	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNA5	"HK2, HPCN1, Kv1.5"	ENSG00000130037	"Potassium voltage-gated channel subfamily A member 5"	P22460	12	5043989-5046788	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Atrial fibrillation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 33.0"	"Cell type enriched"	"Detected in some"	8	"Bipolar cells: 153.4"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	134	"plasmacytoid DC: 13.3"	"Lineage enriched"	"Detected in single"	134	"dendritic cells: 13.3"	"Cell line enriched"	"Detected in single"	12	"NTERA-2: 10.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA021516, CAB022562"	Approved					NA	NA					"CAB022562: , HPA021516: AB_2670732"	"unprognostic (3.87e-1)"	"unprognostic (9.91e-3)"	"unprognostic (1.94e-1)"	"unprognostic (3.23e-1)"	"unprognostic (2.64e-1)"	"unprognostic (7.06e-3)"	"unprognostic (1.20e-1)"	"unprognostic (4.61e-3)"	"unprognostic (1.34e-1)"	"unprognostic (2.14e-1)"	"unprognostic (2.37e-2)"	"unprognostic (5.08e-3)"	"unprognostic (6.73e-4)"	"unprognostic (1.92e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.86e-2)"	"unprognostic (3.08e-2)"	3.4	1.4	1.9	0.9	8.6	0.7	1.2	0.4	2.3	1.6	3.3	7.2	0.0	1.1	1.7	2.6	7.6	2.1	2.3	33.0	3.5	5.8	1.9	0.8	2.3	0.9	2.3	2.2	3.2	2.4	0.6	7.5	3.4	8.8	3.7	1.3	7.2	0.9	2.0	5.3	0.6	1.1	3.0	3.9	1.2	3.3	0.8	4.9	0.0	1.1	3.4	1.2	4.5	3.4	0.0	13.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.3	0.0	0.0	1.9	8.6	0.4	2.3	3.5	5.8	2.3	2.2	8.8	4.9	0.0	0.0	0.0	0.0	0.8	153.4	8.6	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.1	0.0	0.4	0.0	3.4	12.9	19.1	0.0	0.0	0.3	0.1	0.0	0.0	0.0
KCNA6	"HBK2, Kv1.6, PPP1R96"	ENSG00000151079	"Potassium voltage-gated channel subfamily A member 6"	P17658	12	4809176-4813412	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 9.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Daudi: 3.4;JURKAT: 4.5;TIME: 1.0;U-698: 2.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA																							0.7	0.8	3.8	2.7	4.7	0.8	2.0	0.7	9.6	1.0	0.7	6.8	0.0	2.2	0.8	0.6	0.8	0.8	0.6	0.7	5.8	0.7	0.8	0.9	0.9	2.1	3.9	7.2	0.9	0.8	0.6	2.0	0.7	4.3	0.8	0.6	0.0	0.8	0.6	1.2	0.7	0.8	0.7	1.7	1.5	0.8	2.0	8.4	0.0	0.8	0.0	0.6	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.5	0.0	0.0	0.0	0.0	2.8	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	4.7	0.7	9.6	5.8	0.7	3.9	7.2	4.3	8.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNA7	"HAK6, Kv1.7"	ENSG00000104848	"Potassium voltage-gated channel subfamily A member 7"	Q96RP8	19	49067418-49072941	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	9	"skeletal muscle: 40.6"	"Cell type enriched"	"Detected in some"	4	"Alveolar cells type 2: 25.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HMC-1: 4.0;U-251 MG: 4.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (2.00e-1)"	"unprognostic (2.10e-2)"		"unprognostic (1.19e-1)"	"unprognostic (2.72e-1)"	"unprognostic (1.68e-1)"		"unprognostic (4.31e-2)"	"unprognostic (3.17e-2)"	"unprognostic (6.97e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.26e-1)"	"unprognostic (2.21e-8)"	"unprognostic (1.70e-1)"	"unprognostic (2.62e-1)"	"unprognostic (5.80e-2)"	"unprognostic (5.29e-2)"	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	40.6	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	4.6	0.3	0.0	0.0	1.1	0.9	3.3	0.8	0.9	0.8	0.2	0.7	0.3	0.4	2.0	0.0	0.2	0.7	0.4	0.0	0.1	0.0	0.5	0.9	0.4	0.2	0.2	0.7	1.3	0.1	0.2	0.0	0.4	0.6	0.2	1.5	0.4	0.2	0.6	4.0	0.1	0.3	0.1	0.1	0.4	0.0	0.4	0.5	1.1	0.1	0.5	0.3	0.7	0.5	0.3	0.3	0.4	0.2	0.5	0.2	0.5	0.4	0.4	1.5	0.3	0.1	0.6	0.5	1.1	0.7	1.4	0.5	0.9	4.0	0.7	0.3	0.3	0.6	0.4	0.5	3.3	0.8	0.7	0.8	0.4	0.5	0.5	0.7	0.7	0.2	1.1	0.7	0.8	2.6	0.9	0.7	0.9	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	25.9	0.0	1.2	0.3	0.4	3.1	0.0	1.4	5.7	0.0	5.9	0.0	0.0	0.0	0.2	0.3	0.0	0.0	0.2	0.1	0.4	0.5	3.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	2.2	0.0	0.0	0.0	1.6	0.0	0.1	0.1	0.7	0.3	0.9	0.0	0.0	0.3
KCNB1	Kv2.1	ENSG00000158445	"Potassium voltage-gated channel subfamily B member 1"	Q14721	20	49293394-49484297	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Exocytosis, Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.9;retina: 22.4"	"Group enriched"	"Detected in some"	7	"Bipolar cells: 119.5;Cone photoreceptor cells: 200.3;Rod photoreceptor cells: 366.4"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"ASC diff: 3.6;CACO-2: 5.1;hTCEpi: 3.2;U-2 OS: 4.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001979, HPA042434"	Enhanced					NA	NA					"CAB001979: , HPA042434: AB_2677996"	"unprognostic (4.51e-1)"	"unprognostic (1.72e-1)"	"unprognostic (6.54e-3)"	"unprognostic (4.87e-2)"	"unprognostic (1.94e-1)"	"unprognostic (1.82e-1)"	"unprognostic (8.09e-2)"	"unprognostic (6.22e-2)"	"unprognostic (5.31e-1)"	"unprognostic (8.32e-2)"	"unprognostic (1.87e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.31e-2)"	"unprognostic (2.07e-3)"	"unprognostic (8.17e-2)"	"unprognostic (9.35e-2)"	"unprognostic (5.25e-4)"	16.9	3.6	11.4	1.3	14.6	0.8	2.4	8.1	25.9	2.3	5.1	1.8	0.7	1.2	6.8	2.3	3.9	9.0	1.9	1.9	6.6	5.3	1.3	3.5	1.2	0.8	3.3	12.5	1.2	1.2	0.9	2.5	1.0	2.5	4.8	1.9	22.4	1.7	6.5	6.2	1.1	1.8	9.6	1.2	1.2	3.9	1.5	2.4	0.0	1.0	0.1	0.8	4.0	0.9	0.4	0.3	1.2	0.2	0.3	0.7	0.0	0.0	0.1	0.8	0.0	3.6	0.3	0.1	0.0	0.4	0.4	0.0	5.1	0.0	0.0	0.0	0.1	1.3	0.1	0.0	0.1	0.3	0.1	0.2	0.0	0.1	0.0	0.0	2.6	0.0	0.6	3.2	0.0	0.1	0.2	0.0	0.0	0.0	1.9	1.2	0.3	0.0	2.4	0.1	0.0	0.9	0.0	1.0	0.0	0.0	0.0	2.3	1.9	1.6	2.3	0.0	0.0	1.7	0.0	0.0	2.2	4.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.3	0.2	0.0	0.1	0.1	0.3	0.2	0.0	0.4	0.7	0.2	1.2	0.3	0.1	0.3	0.1	0.0	11.4	14.6	8.1	25.9	6.6	5.3	3.3	12.5	2.5	2.4	0.0	2.1	0.0	0.1	0.7	119.5	1.2	2.5	5.3	1.2	0.0	200.3	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.4	0.1	3.5	4.7	0.1	17.5	0.0	0.0	0.0	0.4	4.0	0.1	0.0	0.0	0.0	26.9	0.1	0.0	32.5	0.0	366.4	0.0	3.4	0.2	0.3	0.3	0.1	0.0	0.0	0.0
KCNB2	Kv2.2	ENSG00000182674	"Potassium voltage-gated channel subfamily B member 2"	Q92953	8	72537391-72938349	"FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 9.7;lymphoid tissue: 8.6;pituitary gland: 9.2"	"Cell type enriched"	"Detected in some"	15	"Cone photoreceptor cells: 249.4"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"HaCaT: 3.2;HDLM-2: 3.1;HEK 293: 7.6;SCLC-21H: 6.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA065970			Approved	"Nucleoli,Plasma membrane,Midbody"		Yes	NA			"Plasma membrane"	"Nucleoli, Midbody"	"HPA065970: AB_2685591"	"unprognostic (9.87e-3)"	"unprognostic (1.71e-1)"	"unprognostic (7.57e-2)"	"unprognostic (1.10e-3)"	"unprognostic (1.22e-1)"	"unprognostic (1.34e-1)"		"unprognostic (1.44e-2)"		"unprognostic (2.72e-1)"	"unprognostic (6.93e-5)"	"unprognostic (5.53e-3)"	"unprognostic (3.30e-2)"	"unprognostic (1.62e-1)"	"unprognostic (3.35e-2)"	"unprognostic (3.26e-1)"		0.8	1.9	3.8	0.6	5.3	0.4	0.7	0.3	9.7	0.5	0.7	0.0	0.0	1.2	0.4	0.4	1.1	2.1	0.5	0.4	7.1	3.1	0.5	0.4	0.6	0.5	0.9	7.8	0.4	2.4	0.4	9.2	0.5	3.2	0.7	0.7	4.2	0.5	0.5	0.4	0.4	1.6	0.5	1.6	8.6	2.4	1.7	0.4	0.9	0.4	0.0	0.9	0.6	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	3.1	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	5.3	0.3	9.7	7.1	3.1	0.9	7.8	3.2	0.4	0.0	0.0	0.0	0.0	0.0	12.9	0.2	0.0	0.0	0.0	1.8	249.4	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	17.1	0.0	0.0	5.0	1.1	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.4	0.0	2.4	0.0	0.0	0.4	0.7	0.0	0.0	0.0	0.0	0.0
KCNC1	Kv3.1	ENSG00000129159	"Potassium voltage-gated channel subfamily C member 1"	P48547	11	17734774-17856804	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	12	"brain: 67.5"	"Cell type enriched"	"Detected in some"	4	"Bipolar cells: 36.6"	"Cancer enhanced"	"Detected in some"		"glioma: 1.1"	"Region enhanced"	"Detected in all"		"cerebellum: 67.5"	"Cell type enhanced"	"Detected in some"		"basophil: 5.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"RH-30: 7.5;SCLC-21H: 7.1;SH-SY5Y: 4.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047634, HPA048249"	Enhanced		Approved	"Nucleoplasm,Nuclear membrane,Vesicles,Cytosol"		NA	NA			"Nucleoplasm, Nuclear membrane"	"Vesicles, Cytosol"	"HPA047634: AB_2680109, HPA048249: "	"unprognostic (1.79e-2)"	"unprognostic (2.68e-1)"	"unprognostic (1.33e-1)"	"unprognostic (4.09e-3)"	"unprognostic (1.12e-1)"	"unprognostic (8.02e-2)"	"unprognostic (2.40e-1)"	"unprognostic (1.27e-1)"	"unprognostic (8.37e-2)"	"unprognostic (2.14e-1)"	"unprognostic (7.04e-5)"	"unprognostic (5.89e-2)"	"unprognostic (7.32e-4)"	"unprognostic (1.29e-1)"	"unprognostic (5.44e-2)"	"unprognostic (1.05e-2)"	"unprognostic (7.83e-2)"	0.7	2.3	8.2	1.0	10.0	2.9	0.9	67.5	33.3	3.0	1.0	1.0	0.0	1.4	1.5	0.6	1.1	0.9	1.3	0.6	5.6	4.9	0.9	1.1	1.0	1.2	3.3	12.6	1.1	0.9	0.6	1.4	0.7	19.5	1.2	0.8	0.7	1.2	0.7	1.7	1.8	1.2	0.8	1.9	1.0	1.3	2.9	2.0	0.0	1.5	0.0	0.8	2.4	0.5	1.7	0.8	5.8	0.8	0.7	1.1	0.3	0.4	0.1	3.1	1.2	0.5	0.0	0.1	0.0	0.0	0.1	0.0	0.2	1.0	0.0	0.2	0.0	0.9	1.1	1.8	0.0	0.3	0.3	2.1	0.6	3.0	0.2	0.4	0.5	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.8	0.5	1.4	0.0	0.5	0.5	1.2	1.5	0.0	0.0	0.8	7.5	0.9	0.0	0.4	7.1	4.4	0.4	0.5	0.0	0.4	0.6	0.5	0.1	0.2	2.3	0.3	0.3	0.5	0.6	1.0	0.5	0.3	1.0	5.8	0.7	1.1	1.1	0.7	0.7	0.7	0.9	0.5	0.2	1.7	0.7	0.8	3.8	0.7	0.8	0.8	0.4	0.3	8.2	10.0	67.5	33.3	5.6	4.9	3.3	12.6	19.5	2.0	0.0	0.0	0.0	0.0	0.0	36.6	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	7.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.6	7.5	0.0	0.0	8.4	0.3	0.0	0.0	1.0	0.0	1.5	0.2	0.0	0.0	0.1	7.4	0.0	0.4	5.4	4.5	0.0	0.0	0.0	0.0	0.0
KCNC2	Kv3.2	ENSG00000166006	"Potassium voltage-gated channel subfamily C member 2"	Q96PR1	12	75040077-75209868	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"brain: 39.3"	"Group enriched"	"Detected in some"	12	"Basal glandular cells: 1.9;Bipolar cells: 5.0;Glandular cells: 1.6;Muller glia cells: 1.9;Rod photoreceptor cells: 5.9"	"Group enriched"	"Detected in some"	8	"breast cancer: 1.5;prostate cancer: 4.6"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"Karpas-707: 1.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA019664, CAB022571"	Uncertain					NA	NA					"CAB022571: , HPA019664: AB_1855578"	"unprognostic (2.01e-1)"				"unprognostic (1.14e-1)"		"unprognostic (2.68e-1)"				"unprognostic (5.58e-3)"	"unprognostic (4.46e-2)"		"unprognostic (3.39e-2)"				0.7	0.7	8.7	0.7	12.9	0.7	3.3	0.4	39.3	0.7	0.8	1.9	0.0	0.7	0.9	0.9	0.7	0.7	0.7	0.7	7.4	10.4	0.7	0.9	0.7	0.7	4.7	13.5	0.7	0.7	0.7	6.0	0.7	19.1	4.4	0.8	1.3	1.1	0.7	0.7	0.7	0.8	0.7	1.0	0.7	0.7	1.0	0.6	0.0	0.7	0.0	0.7	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.4	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	8.7	12.9	0.4	27.3	7.4	10.4	4.7	13.5	19.1	0.6	0.0	0.0	0.0	1.9	0.0	5.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.2	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNC3	"Kv3.3, SCA13"	ENSG00000131398	"Potassium voltage-gated channel subfamily C member 3"	Q14003	19	50311937-50333515	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 32.1;parathyroid gland: 31.1;thyroid gland: 23.9"	"Cell type enhanced"	"Detected in many"	11	"Bipolar cells: 9.8;Collecting duct cells: 19.2;Cone photoreceptor cells: 7.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"CACO-2: 8.9;CAPAN-2: 7.8;HDLM-2: 8.0;HMC-1: 21.4;K-562: 7.9;SK-BR-3: 14.5;T-47d: 13.8;U-2 OS: 9.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA018041	Approved					NA	NA					"HPA018041: AB_1855579"	"unprognostic (8.05e-2)"	"unprognostic (2.34e-2)"	"unprognostic (3.01e-4)"	"unprognostic (4.41e-2)"	"unprognostic (3.84e-2)"	"unprognostic (1.91e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.59e-1)"	"unprognostic (3.94e-3)"	"unprognostic (2.10e-5)"	"prognostic unfavorable (1.23e-4)"	"unprognostic (1.68e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.85e-2)"	"unprognostic (1.19e-1)"	1.4	2.2	7.2	5.4	9.4	1.4	2.3	32.1	31.2	3.1	1.1	3.4	3.0	1.8	4.5	5.8	1.1	12.8	1.4	1.7	6.9	4.2	10.6	2.5	4.5	4.7	4.0	6.6	0.6	3.7	31.1	9.7	2.4	15.6	2.4	1.4	3.0	2.3	15.1	1.2	2.1	1.8	1.7	3.8	6.5	2.1	2.4	2.9	1.1	23.9	0.0	3.4	1.8	1.0	0.4	1.1	0.0	0.8	0.0	0.0	0.0	0.0	0.4	0.0	1.5	0.0	0.0	4.2	0.0	0.0	0.0	0.0	8.9	7.8	0.7	1.0	0.0	0.5	1.2	0.2	0.0	0.0	8.0	1.8	0.0	0.0	1.7	0.0	0.0	21.4	0.1	0.0	0.0	0.0	0.0	0.1	0.3	7.9	0.0	0.0	2.8	0.1	0.0	1.1	0.9	3.3	0.0	0.1	0.0	0.5	0.2	0.0	1.4	1.7	14.5	0.0	0.2	13.8	2.2	0.2	0.0	9.5	0.0	0.0	0.1	0.1	0.5	0.3	1.8	0.0	0.0	0.4	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.0	0.0	0.1	1.1	0.0	0.0	7.2	9.4	32.1	31.2	6.9	4.2	4.0	6.6	15.6	2.9	0.0	0.3	0.0	0.8	0.7	9.8	2.6	0.0	1.4	1.2	19.2	7.9	1.9	0.0	1.2	0.3	0.0	0.0	0.0	1.2	0.7	0.2	1.1	0.0	1.5	2.8	1.6	4.1	0.6	5.3	0.0	0.6	2.3	0.0	2.8	0.0	0.7	0.2	0.0	0.0	2.3	6.3	0.0	1.0	0.9	1.1	0.5	1.9	0.0	0.0	0.9
KCND1	Kv4.1	ENSG00000102057	"Potassium voltage-gated channel subfamily D member 1"	Q9NSA2	X	48961378-48971569	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 16.8"	"Cell type enhanced"	"Detected in some"	8	"Collecting duct cells: 1.8;Distal tubular cells: 1.7;Intestinal endocrine cells: 3.4;Leydig cells: 1.7;Peritubular cells: 3.5;Rod photoreceptor cells: 2.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"neutrophil: 1.4"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HSkMC: 13.2;NB-4: 10.5;SuSa: 10.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA000524, HPA001066"	Supported		Uncertain	Nucleoplasm		Yes	No			Nucleoplasm		"HPA000524: AB_2666013, HPA001066: AB_1079662"	"unprognostic (6.00e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.01e-4)"	"unprognostic (2.19e-4)"	"unprognostic (1.41e-1)"	"unprognostic (3.79e-2)"	"unprognostic (2.79e-1)"	"unprognostic (8.13e-3)"	"unprognostic (1.13e-2)"	"unprognostic (2.41e-3)"	"prognostic favorable (2.66e-6)"	"unprognostic (2.61e-1)"	"unprognostic (4.30e-11)"	"unprognostic (3.13e-2)"	"unprognostic (3.49e-1)"	"unprognostic (7.64e-2)"	"unprognostic (2.22e-3)"	4.9	2.4	4.2	3.4	4.7	6.0	2.2	16.8	7.8	5.1	2.2	6.3	1.9	2.0	5.0	3.8	1.4	7.4	6.3	2.9	6.9	2.5	2.5	1.8	3.0	3.1	3.1	3.5	4.6	1.4	1.8	3.0	2.5	10.4	3.3	2.1	2.6	1.2	6.0	0.7	1.6	2.6	6.6	6.5	4.2	2.5	3.0	2.7	1.1	2.3	0.5	3.6	3.0	3.0	0.6	1.3	1.4	0.1	0.0	0.8	0.1	0.4	1.9	0.8	4.7	6.4	5.1	1.6	1.0	4.0	2.8	1.9	1.2	0.6	1.6	3.4	3.1	0.8	0.6	0.8	0.4	2.7	2.6	3.1	1.4	1.9	0.1	2.4	0.4	2.9	13.2	1.8	5.2	0.6	4.7	0.9	2.2	1.1	3.6	2.0	3.5	0.4	10.5	2.5	0.3	0.7	1.3	0.9	1.5	3.1	1.5	0.5	2.1	0.9	0.0	2.1	10.2	2.0	1.5	2.4	0.6	2.6	0.6	0.2	2.9	3.8	3.8	1.7	3.7	2.1	0.0	0.1	0.0	0.5	0.0	0.3	0.6	0.2	0.8	0.0	0.1	0.2	0.0	1.4	0.0	0.0	1.3	0.0	0.1	4.2	4.7	16.8	7.8	6.9	2.5	3.1	3.5	10.4	2.7	0.0	1.4	0.0	0.0	0.7	0.2	0.4	0.0	0.0	0.0	1.8	0.0	0.0	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.0	0.0	0.1	0.0	3.4	0.6	0.8	0.0	1.7	0.0	0.0	0.0	0.2	0.3	0.1	0.0	3.5	0.0	2.8	0.0	0.4	0.2	0.0	0.0	0.1	0.0	0.0	0.1
KCND2	"KIAA1044, Kv4.2, RK5"	ENSG00000184408	"Potassium voltage-gated channel subfamily D member 2"	Q9NZV8	7	120273668-120750331	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 41.1"	"Cell type enhanced"	"Detected in some"	9	"Bipolar cells: 2.9;Cholangiocytes: 5.1;Ductal cells: 2.5;Leydig cells: 3.4;Spermatocytes: 4.2;Spermatogonia: 3.3"	"Cancer enhanced"	"Detected in many"		"glioma: 6.2"	"Region enhanced"	"Detected in all"		"cerebellum: 41.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 6.5;HSkMC: 4.1;NTERA-2: 3.2;RT4: 3.3;SCLC-21H: 16.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029068	Enhanced					NA	NA					"HPA029068: AB_10601436"	"unprognostic (4.22e-1)"	"unprognostic (2.79e-4)"	"unprognostic (3.79e-2)"	"unprognostic (3.40e-1)"	"unprognostic (1.23e-1)"	"unprognostic (3.91e-2)"	"unprognostic (4.98e-3)"	"unprognostic (9.07e-3)"	"unprognostic (1.03e-1)"	"unprognostic (1.14e-1)"	"unprognostic (9.77e-3)"	"unprognostic (1.51e-1)"	"unprognostic (4.51e-4)"	"unprognostic (4.07e-5)"	"unprognostic (2.71e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.83e-3)"	2.9	1.0	3.9	1.0	6.7	0.3	1.9	41.1	20.6	2.4	0.7	1.5	0.0	0.7	5.6	0.5	0.5	1.7	7.0	0.5	3.7	5.4	0.3	0.4	0.6	0.5	4.2	3.6	5.9	0.6	2.5	6.6	0.8	12.1	0.5	0.6	0.0	0.7	1.7	0.5	0.3	0.5	3.7	3.7	0.3	0.5	2.9	4.5	0.0	0.8	1.1	0.3	2.2	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	1.7	6.5	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.1	2.6	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.7	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.2	0.0	0.0	0.0	3.2	0.0	0.2	0.0	0.0	0.0	0.0	3.3	16.6	0.0	0.0	0.0	0.0	0.2	0.2	0.8	0.0	0.5	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	6.7	41.1	5.3	3.7	5.4	4.2	3.6	12.1	4.5	0.0	0.0	0.0	0.0	0.0	2.9	1.2	5.1	0.0	0.0	0.0	0.0	0.0	0.0	2.5	2.3	0.1	0.0	0.0	0.2	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.4	3.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.5	0.0	0.4	4.2	3.3	0.1	0.0	0.0	0.0	0.1
KCND3	"KSHIVB, Kv4.3, SCA19, SCA22"	ENSG00000171385	"Potassium voltage-gated channel subfamily D member 3"	Q9UK17	1	111770662-111989155	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Brugada syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 25.9"	"Cell type enhanced"	"Detected in many"	6	"Bipolar cells: 38.5;Cardiomyocytes: 34.4;Early spermatids: 29.0;Horizontal cells: 28.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"OE19: 6.6;SCLC-21H: 15.9;U-2 OS: 2.4;WM-115: 3.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA029452	Approved					NA	NA					"HPA029452: AB_10602239"	"unprognostic (1.11e-2)"	"unprognostic (1.73e-3)"	"unprognostic (1.71e-1)"	"unprognostic (2.60e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.41e-1)"	"unprognostic (9.48e-2)"	"unprognostic (1.15e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.86e-2)"	"unprognostic (1.40e-1)"	"unprognostic (7.44e-2)"	"unprognostic (3.64e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.51e-3)"	"unprognostic (6.64e-3)"	3.3	0.8	6.8	3.1	6.9	0.0	2.1	25.9	11.9	1.3	2.5	1.3	1.3	0.3	4.1	9.6	3.2	3.4	4.2	5.5	5.6	5.6	1.3	11.6	1.3	1.3	8.9	5.7	1.3	2.2	4.1	1.5	1.3	1.6	9.2	1.6	1.9	1.3	10.0	2.8	5.1	1.3	7.7	1.3	2.0	1.7	1.3	1.3	1.3	1.3	2.3	1.3	3.7	1.3	0.5	0.4	1.2	0.3	0.9	0.3	0.7	0.0	0.0	0.3	0.0	0.5	0.1	0.1	0.4	0.0	0.0	0.0	0.8	0.1	0.0	1.6	0.6	0.0	0.5	0.6	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.0	1.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.2	0.0	0.2	0.3	6.6	0.0	0.0	0.1	0.0	0.0	0.3	15.9	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.5	0.2	0.1	0.3	0.1	0.1	0.1	0.1	0.3	0.4	0.5	0.3	0.2	1.2	0.9	0.3	0.3	0.1	0.7	6.8	6.9	25.9	9.3	5.6	5.6	8.9	5.7	1.6	1.3	0.0	9.4	0.0	10.7	6.6	38.5	34.4	0.0	0.0	1.2	0.0	3.9	0.1	0.0	0.7	29.0	1.8	0.0	0.0	21.1	0.1	1.4	14.3	0.0	23.7	0.2	28.6	0.0	1.8	0.6	20.3	16.7	0.0	3.3	0.0	0.2	6.1	4.4	0.3	1.8	0.2	4.2	0.0	3.1	1.1	0.7	5.8	0.0	0.0	0.0	12.3
KCNE1	"ISK, JLNS2, LQT5, minK"	ENSG00000180509	"Potassium voltage-gated channel subfamily E regulatory subunit 1"	P15382	21	34446688-34512275	"Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Deafness, Disease mutation, FDA approved drug targets, Long QT syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"fallopian tube: 17.6"	"Group enriched"	"Detected in many"	7	"Ciliated cells: 32.1;Cone photoreceptor cells: 23.6;Kupffer cells: 26.3;Macrophages: 15.3"	"Not detected"	"Not detected"			"Region enriched"	"Detected in some"	6	"pons and medulla: 10.6"	"Cell type enhanced"	"Detected in some"		"eosinophil: 6.8"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 6.8"	"Cell line enhanced"	"Detected in some"		"BJ hTERT+ SV40 Large T+: 3.0;CACO-2: 9.2;HBF TERT88: 2.3"															NA	NA						"unprognostic (8.24e-3)"	"unprognostic (9.14e-3)"	"unprognostic (1.26e-1)"	"unprognostic (2.71e-3)"	"unprognostic (1.01e-3)"	"unprognostic (2.98e-2)"	"unprognostic (2.45e-2)"	"unprognostic (1.47e-2)"	"unprognostic (2.58e-1)"	"unprognostic (2.06e-1)"	"unprognostic (9.30e-2)"	"unprognostic (7.90e-3)"	"unprognostic (1.41e-2)"	"unprognostic (3.27e-2)"	"unprognostic (2.34e-2)"	"unprognostic (1.30e-1)"	"unprognostic (4.40e-2)"	9.3	0.4	0.7	1.3	0.9	1.6	4.8	0.1	0.5	1.8	3.2	2.7	0.0	0.4	0.8	4.0	0.7	17.6	0.4	9.2	1.3	0.8	3.4	4.3	12.0	10.6	1.7	0.0	2.9	0.2	1.0	1.3	3.5	10.6	1.0	0.4	0.5	0.8	0.3	0.2	0.4	0.6	0.7	0.5	7.3	0.5	4.8	0.3	0.2	0.7	0.1	0.3	1.6	14.8	0.0	0.5	6.8	1.5	0.0	0.0	0.4	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.5	1.1	3.0	1.0	9.2	0.1	0.0	0.0	0.3	0.0	0.1	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.4	0.2	0.0	0.1	0.1	0.0	0.1	0.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	1.3	0.6	0.1	0.2	0.0	0.0	0.0	0.0	0.3	0.3	0.0	0.0	0.0	0.3	0.1	0.1	1.3	6.8	0.0	1.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	3.0	0.0	1.5	0.0	0.0	0.4	0.7	0.9	0.1	0.5	1.3	0.8	1.7	0.0	10.6	0.3	3.0	2.6	0.0	0.6	0.7	1.4	3.1	0.0	32.1	1.2	0.0	23.6	0.0	0.0	0.6	3.1	1.8	0.0	0.0	0.3	0.3	0.6	0.3	0.0	3.4	3.7	0.0	0.0	1.8	26.3	1.8	0.3	15.3	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.6	0.0	0.6	0.9	0.0	0.3	0.0	0.0	0.0	0.8
KCNH2	"erg1, HERG, Kv11.1, LQT2"	ENSG00000055118	"Potassium voltage-gated channel subfamily H member 2"	Q12809	7	150944961-150978315	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Deafness, Disease mutation, FDA approved drug targets, Long QT syndrome, Short QT syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 37.9"	"Group enriched"	"Detected in many"	5	"Bipolar cells: 199.1;Cardiomyocytes: 76.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"eosinophil: 2.0"	"Lineage enriched"	"Detected in single"	10	"granulocytes: 2.0"	"Group enriched"	"Detected in some"	7	"K-562: 59.8;NB-4: 29.8;SH-SY5Y: 25.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.22e-1)"	"unprognostic (1.75e-2)"	"unprognostic (1.06e-2)"	"prognostic unfavorable (6.06e-5)"	"unprognostic (9.79e-3)"	"unprognostic (1.95e-2)"	"unprognostic (3.40e-2)"	"unprognostic (3.84e-2)"	"unprognostic (3.53e-2)"	"unprognostic (3.52e-1)"	"prognostic favorable (5.61e-4)"	"unprognostic (6.08e-2)"	"unprognostic (2.26e-2)"	"unprognostic (4.90e-2)"	"unprognostic (2.83e-1)"	"unprognostic (6.24e-2)"	"unprognostic (3.02e-2)"	1.1	4.9	5.0	3.2	8.3	37.9	0.7	19.3	8.0	4.3	17.3	2.8	3.1	3.5	9.3	4.6	3.4	4.1	28.5	24.9	4.8	9.3	0.8	0.7	1.7	0.9	4.7	3.9	6.6	5.1	10.5	23.8	2.2	14.1	6.8	1.8	8.0	1.8	10.2	0.8	0.7	6.9	9.4	2.2	1.6	6.8	18.0	1.6	0.1	0.7	0.0	0.7	7.5	2.4	0.1	0.0	2.0	0.0	0.0	0.1	0.0	0.0	0.1	0.3	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.5	0.9	0.0	0.0	0.0	1.1	0.0	0.0	0.2	0.1	5.7	0.0	0.0	0.1	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	59.8	0.0	0.0	0.3	0.5	29.8	0.4	0.0	0.0	0.0	0.0	3.0	0.0	0.0	1.2	25.0	0.0	0.0	0.0	0.3	0.0	0.5	0.2	0.0	0.5	0.0	0.0	1.7	0.0	0.6	0.0	3.7	0.0	0.8	0.0	2.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	8.3	19.3	8.0	4.8	9.3	4.7	3.9	14.1	1.6	0.0	0.0	0.0	0.1	0.0	199.1	76.1	0.0	0.0	0.0	0.0	3.9	0.1	0.0	1.8	0.8	0.0	0.0	23.3	0.2	1.0	0.9	0.1	26.4	0.0	0.3	15.9	15.6	2.5	0.0	2.5	2.3	0.0	0.0	0.0	0.7	2.7	0.5	0.0	12.4	0.0	9.6	0.0	1.9	0.7	2.6	0.0	0.2	0.0	0.2	0.3
KCNJ1	"Kir1.1, ROMK1"	ENSG00000151704	"Potassium voltage-gated channel subfamily J member 1"	P48048	11	128836315-128867373	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"Bartter syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	51	"kidney: 123.2"	"Cell type enriched"	"Detected in some"	5	"Distal tubular cells: 165.8"	"Cancer enriched"	"Detected in some"	7	"renal cancer: 3.4"	"Region enriched"	"Detected in single"	4	"basal ganglia: 2.3"	"Cell type enhanced"	"Detected in single"		"memory B-cell: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	40	"RPTEC TERT1: 51.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA026962	Enhanced					NA	NA					"HPA026962: AB_10601934"	"unprognostic (1.75e-1)"	"unprognostic (4.38e-2)"	"unprognostic (1.14e-1)"	"unprognostic (3.19e-1)"	"unprognostic (7.55e-2)"	"unprognostic (1.29e-1)"	"unprognostic (3.01e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.46e-1)"	"unprognostic (2.44e-2)"	"unprognostic (6.47e-2)"	"unprognostic (2.78e-1)"	"unprognostic (6.05e-2)"	"unprognostic (4.99e-2)"	"unprognostic (1.61e-1)"	"unprognostic (1.28e-1)"	"unprognostic (7.81e-3)"	0.1	0.0	0.5	0.2	2.3	0.0	0.1	0.1	0.1	0.4	0.1	0.1	0.1	0.0	0.1	0.5	0.1	0.0	0.1	0.1	0.1	0.0	123.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.3	0.1	0.3	0.1	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.1	1.3	0.0	0.0	0.4	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	51.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.3	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.4	0.9	1.3	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	2.3	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.0	0.0	36.6	0.0	0.0	165.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0
KCNJ11	"BIR, Kir6.2"	ENSG00000187486	"Potassium voltage-gated channel subfamily J member 11"	Q14654	11	17385859-17389331	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"Diabetes mellitus, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	5	"skeletal muscle: 63.1"	"Cell type enhanced"	"Detected in some"	17	"Cardiomyocytes: 11.3;Collecting duct cells: 5.2;Intestinal endocrine cells: 4.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"Daudi: 7.1;HEK 293: 13.5;MCF7: 10.8;SCLC-21H: 9.2"	"Low region specificity"	"Detected in all"							HPA048891	Approved					NA	NA					"HPA048891: AB_2680547"	"unprognostic (1.95e-2)"	"unprognostic (6.18e-3)"	"unprognostic (7.79e-2)"	"unprognostic (2.26e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.25e-1)"	"unprognostic (4.81e-5)"	"unprognostic (1.83e-3)"	"unprognostic (5.45e-2)"	"unprognostic (8.09e-3)"	"unprognostic (3.72e-3)"	"unprognostic (9.23e-3)"	"prognostic favorable (1.56e-4)"	"unprognostic (4.05e-2)"	"unprognostic (2.10e-2)"	"unprognostic (1.67e-1)"	"unprognostic (4.75e-2)"	2.5	1.1	2.9	1.0	7.8	0.8	2.7	13.6	7.8	1.0	1.1	0.7	4.9	1.4	1.1	2.1	1.7	1.1	1.1	6.2	3.5	2.4	1.3	0.9	1.3	1.2	2.7	5.2	0.8	8.7	2.7	3.3	0.7	3.5	2.5	1.0	0.1	1.2	7.6	63.1	1.0	1.1	0.8	1.7	1.0	4.6	0.8	1.9	0.0	4.1	4.5	1.0	0.9	1.1	0.8	0.4	1.4	0.3	0.8	0.4	0.4	1.5	2.4	0.3	4.0	0.0	0.0	1.6	0.0	0.0	0.0	0.1	2.5	0.2	7.1	0.2	0.0	0.3	0.3	4.8	0.1	0.3	1.7	13.5	3.7	0.9	0.8	0.1	0.4	0.3	0.1	0.3	0.0	0.1	0.1	0.0	6.1	3.8	3.8	0.0	10.8	0.7	0.1	1.0	4.2	0.3	1.4	1.7	2.1	0.4	0.9	9.2	0.8	0.0	3.6	0.0	0.0	4.7	0.2	0.0	0.0	1.2	0.0	0.1	0.2	6.0	0.9	0.0	1.0	0.0	1.4	0.3	0.2	0.4	0.3	0.3	0.7	0.4	0.4	0.1	0.8	0.4	0.4	1.3	0.8	0.1	0.4	0.3	0.4	2.9	7.8	13.6	7.8	3.5	2.4	2.7	5.2	3.5	1.9	0.0	2.4	0.0	0.1	0.0	2.4	11.3	0.0	0.0	1.2	5.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	1.0	0.1	0.0	4.1	0.6	0.6	0.0	0.0	0.0	0.0	0.0	0.8	0.5	0.2	0.0	0.0	0.0	0.7	0.0	0.1	0.2	0.2	0.0	0.0	0.0	0.2	0.1
KCNJ12	"hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v"	ENSG00000184185	"Potassium voltage-gated channel subfamily J member 12"	Q14500	17	21376197-21419872	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in many"	4	"brain: 39.4;skeletal muscle: 47.8"	"Cell type enriched"	"Detected in some"	7	"Horizontal cells: 84.2"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	7	"cerebellum: 39.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 3.6;HeLa: 5.9;PC-3: 6.3;SCLC-21H: 7.3;SiHa: 3.7;SuSa: 8.0;U-2197: 6.3"	"Low region specificity"	"Detected in all"							HPA027021	Approved		Uncertain	"Nucleoplasm,Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	"Nucleoplasm, Cytosol"	"HPA027021: AB_10602912"	"unprognostic (3.81e-3)"	"unprognostic (2.69e-2)"	"unprognostic (8.60e-2)"	"prognostic unfavorable (7.84e-5)"	"unprognostic (2.29e-1)"	"unprognostic (1.73e-2)"	"unprognostic (3.80e-2)"	"unprognostic (1.54e-2)"	"unprognostic (4.39e-2)"	"unprognostic (4.91e-2)"	"unprognostic (8.12e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.22e-2)"	"unprognostic (2.23e-1)"	"unprognostic (1.51e-1)"	"unprognostic (5.90e-2)"	"unprognostic (9.70e-3)"	1.2	1.3	1.9	0.9	2.9	0.7	0.9	39.4	5.8	1.2	0.8	1.1	0.5	0.5	0.8	1.4	1.5	2.1	0.7	5.1	0.9	1.4	1.2	0.5	1.3	0.4	1.3	3.4	0.7	0.5	10.6	0.7	0.7	4.0	0.9	0.6	1.7	0.6	0.9	47.8	6.0	0.6	1.0	0.9	1.3	0.9	1.3	0.9	0.0	1.0	7.5	1.1	0.8	1.5	0.0	0.9	0.0	0.5	0.0	0.1	0.0	0.0	1.1	0.4	2.2	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.0	0.0	3.6	0.1	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.2	5.9	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.1	0.1	0.0	1.5	0.0	6.3	0.0	1.0	1.6	0.0	0.0	7.3	0.4	3.7	0.0	1.5	8.0	0.0	0.0	2.8	0.0	0.5	6.3	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.9	0.1	0.0	1.9	2.9	39.4	5.8	0.9	1.4	1.3	3.4	4.0	0.9	0.0	0.0	0.0	0.0	1.3	0.8	12.5	0.0	0.0	0.0	1.8	0.0	0.0	1.7	0.0	0.4	1.4	0.0	0.0	0.0	0.0	2.1	0.2	0.0	0.0	0.2	84.2	1.2	5.5	0.0	0.2	6.9	0.0	0.0	0.0	0.4	11.2	0.0	0.0	3.9	0.6	1.4	0.0	0.5	0.5	1.3	1.9	0.1	0.0	0.6	0.0
KCNJ8	Kir6.1	ENSG00000121361	"Potassium voltage-gated channel subfamily J member 8"	Q15842	12	21764955-21775581	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 60.1;pancreas: 47.6"	"Group enriched"	"Detected in many"	5	"Sertoli cells: 194.1;Smooth muscle cells: 65.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	12	"eosinophil: 4.5"	"Lineage enriched"	"Detected in single"	45	"granulocytes: 4.5"	"Cell line enhanced"	"Detected in some"		"CACO-2: 42.5;HSkMC: 8.6;SH-SY5Y: 14.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031066	Uncertain					NA	NA					"HPA031066: AB_10602240"	"unprognostic (8.12e-3)"	"unprognostic (1.89e-1)"	"prognostic unfavorable (9.29e-4)"	"unprognostic (7.81e-2)"	"unprognostic (8.71e-2)"	"unprognostic (2.34e-1)"	"unprognostic (3.15e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.36e-2)"	"unprognostic (3.90e-2)"	"unprognostic (3.66e-3)"	"unprognostic (2.88e-2)"	"prognostic unfavorable (1.62e-6)"	"unprognostic (4.70e-3)"	"unprognostic (9.61e-2)"	"unprognostic (1.73e-2)"	"unprognostic (3.54e-3)"	14.6	12.9	3.2	2.7	3.4	0.0	14.7	1.7	5.1	7.7	6.6	2.3	3.6	2.0	10.6	4.5	6.7	5.9	6.3	60.1	2.2	1.7	6.4	29.7	12.4	3.5	2.9	3.0	12.4	47.6	1.7	3.8	4.9	3.7	10.6	1.6	8.8	2.9	15.7	15.0	2.4	3.8	13.2	2.6	3.8	6.5	3.4	2.8	0.9	8.4	7.0	1.2	11.4	5.6	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.2	1.4	0.0	5.2	3.4	0.0	5.7	4.6	6.6	3.4	42.5	0.0	0.0	0.0	0.1	0.7	0.0	0.2	0.0	1.9	0.0	2.1	1.3	0.0	0.0	0.2	0.0	0.0	8.6	0.0	2.5	0.0	0.6	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.8	0.0	0.0	0.0	4.2	0.0	0.0	0.0	4.2	1.9	0.0	1.7	0.1	0.0	0.0	0.1	0.0	0.1	0.3	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	3.4	1.7	5.1	2.2	1.7	2.9	3.0	3.7	2.8	3.0	19.8	0.0	0.4	1.1	0.0	24.3	0.0	0.0	1.2	1.8	0.0	0.1	0.0	0.0	0.0	2.4	0.0	0.0	1.1	0.0	6.6	0.3	0.0	22.1	0.2	0.0	1.2	1.8	1.5	0.0	0.3	0.0	1.7	0.0	0.0	12.2	2.0	0.0	0.7	0.0	1.1	194.1	65.3	0.0	0.4	0.6	0.2	0.0	0.0	0.1
KCNK2	"K2p2.1, TREK-1"	ENSG00000082482	"Potassium two pore domain channel subfamily K member 2"	O95069	1	215005775-215237093	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"adrenal gland: 49.1"	"Cell type enhanced"	"Detected in some"	18	"Early spermatids: 1.1;Fibroblasts: 1.4;Melanocytes: 3.3;Suprabasal keratinocytes: 1.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"ASC TERT1: 31.4;fHDF/TERT166: 27.6;hTERT-RPE1: 18.9;T-47d: 42.0;U-2197: 15.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.43e-2)"	"unprognostic (1.02e-1)"	"unprognostic (6.91e-2)"	"unprognostic (3.81e-4)"	"unprognostic (2.58e-1)"	"unprognostic (3.58e-2)"	"unprognostic (3.48e-3)"	"unprognostic (1.26e-1)"	"unprognostic (1.49e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.98e-6)"	"unprognostic (1.63e-2)"	"unprognostic (4.37e-2)"	"unprognostic (7.69e-3)"	"unprognostic (7.46e-3)"	2.9	49.1	4.8	1.1	7.4	0.5	6.1	1.1	6.2	2.3	1.1	2.5	0.0	0.6	0.8	2.6	1.2	1.0	1.6	0.5	5.1	4.3	1.2	0.5	0.7	0.5	2.3	7.3	3.5	2.0	0.5	0.5	0.5	3.3	1.2	1.6	0.0	0.8	3.7	1.2	3.4	2.3	1.5	4.5	0.4	3.7	1.5	3.3	0.0	8.9	2.7	0.4	2.6	3.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	0.0	7.9	31.4	0.0	11.0	7.3	3.5	8.3	0.0	0.4	0.0	0.0	27.6	0.0	0.0	4.9	0.0	6.1	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	8.1	0.0	8.4	0.8	18.9	0.0	0.0	0.0	0.0	4.0	0.0	0.1	0.0	0.9	1.5	0.2	0.0	0.0	0.0	0.0	0.0	2.7	0.0	1.8	0.2	0.1	0.0	42.0	0.0	0.0	6.1	0.2	15.0	0.6	0.6	1.4	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	4.8	7.4	1.1	6.2	5.1	4.3	2.3	7.3	3.3	3.3	0.0	0.0	0.0	0.0	0.6	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.1	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.4	0.0	0.2	1.3	0.0	0.0	0.0	0.0
KCNK3	"K2p3.1, TASK, TASK-1"	ENSG00000171303	"Potassium two pore domain channel subfamily K member 3"	O14649	2	26692690-26733420	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 69.2"	"Cell type enhanced"	"Detected in many"	17	"Collecting duct cells: 97.7;Exocrine glandular cells: 82.2;Pancreatic endocrine cells: 31.4"	"Cancer enhanced"	"Detected in many"		"renal cancer: 9.7"	"Group enriched"	"Detected in many"	4	"basal ganglia: 4.0;cerebellum: 4.7;cerebral cortex: 6.2;hypothalamus: 4.0;pons and medulla: 13.4"	"Cell type enhanced"	"Detected in some"		"neutrophil: 2.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 4.7;EFO-21: 10.0;HeLa: 3.4;SCLC-21H: 23.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.16e-3)"	"unprognostic (7.13e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.67e-4)"	"unprognostic (2.08e-1)"	"unprognostic (2.91e-1)"	"unprognostic (5.01e-2)"	"unprognostic (2.16e-1)"	"unprognostic (3.31e-1)"	"unprognostic (5.48e-2)"	"unprognostic (3.77e-2)"	"unprognostic (1.48e-2)"	"prognostic unfavorable (2.37e-7)"	"unprognostic (3.09e-2)"	"unprognostic (7.45e-2)"	"unprognostic (1.44e-2)"	"unprognostic (9.24e-3)"	2.4	69.2	1.3	1.9	4.0	0.6	8.3	4.7	6.2	3.5	4.0	0.8	5.7	1.3	2.4	5.6	1.9	2.0	2.3	10.3	1.0	4.0	1.8	0.7	10.0	0.6	1.5	1.5	4.6	24.7	0.7	3.6	16.6	13.4	8.2	1.1	1.9	0.6	7.7	0.6	0.6	2.6	4.7	1.1	0.9	2.2	0.9	0.0	0.0	2.1	0.0	0.5	3.2	2.3	0.7	0.5	2.5	0.4	1.2	0.4	0.0	0.0	0.6	0.2	0.0	4.7	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.0	10.0	0.0	1.5	0.0	0.0	0.0	0.0	1.8	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	1.3	0.0	23.5	2.1	0.2	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.2	0.1	0.0	0.0	0.0	0.2	0.0	0.0	1.0	0.4	0.3	0.4	0.2	0.4	0.3	0.3	0.3	0.2	0.7	0.4	0.4	2.5	1.2	0.2	0.5	0.2	0.0	1.3	4.0	4.7	6.2	1.0	4.0	1.5	1.5	13.4	0.0	0.0	3.2	0.0	0.2	0.0	11.5	10.0	0.0	0.0	0.0	97.7	0.0	0.2	0.0	0.8	0.4	1.0	0.0	0.0	82.2	0.2	1.9	1.6	0.0	0.0	0.3	1.6	22.5	0.6	0.0	1.3	0.9	0.0	0.0	1.0	0.4	1.2	31.4	0.0	0.0	0.0	3.9	6.5	3.1	0.0	1.3	0.1	0.5	0.0	0.0	0.3
KCNK9	"K2p9.1, TASK-3, TASK3"	ENSG00000169427	"Potassium two pore domain channel subfamily K member 9"	Q9NPC2	8	139600838-139703056	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel"	"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"adrenal gland: 9.4;brain: 15.4"	"Cell type enhanced"	"Detected in some"	18	"Collecting duct cells: 1.8;Distal tubular cells: 1.7;Exocrine glandular cells: 2.2;Late spermatids: 4.6"	"Low cancer specificity"	"Detected in some"			"Region enhanced"	"Detected in many"		"cerebellum: 15.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"PC-3: 6.6;SCLC-21H: 2.9;SH-SY5Y: 2.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA075842			Approved	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA075842: "	"unprognostic (1.84e-2)"	"unprognostic (2.57e-1)"	"unprognostic (1.58e-1)"	"unprognostic (8.96e-8)"	"unprognostic (1.91e-1)"	"unprognostic (8.17e-3)"	"unprognostic (2.19e-3)"	"unprognostic (1.65e-1)"	"unprognostic (3.87e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.00e-2)"	"unprognostic (3.21e-1)"	"unprognostic (5.12e-6)"	"unprognostic (2.94e-2)"	"unprognostic (1.64e-1)"	"unprognostic (9.99e-3)"	"unprognostic (1.76e-1)"	0.2	9.4	0.5	0.5	1.0	0.1	0.1	15.4	7.7	1.3	0.5	0.0	0.0	0.1	0.3	0.1	0.2	0.3	0.1	0.2	1.6	1.4	0.1	0.1	0.1	0.1	0.7	1.7	0.1	0.1	0.1	1.1	0.2	6.6	0.1	0.2	0.2	0.1	0.1	1.4	0.1	0.1	0.6	0.6	0.1	0.3	0.5	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.1	6.6	0.0	0.0	0.0	0.0	0.0	2.9	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	1.0	15.4	3.7	1.6	1.4	0.7	1.7	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	1.8	0.0	0.0	1.7	0.2	1.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0
KCNMA1	"KCa1.1, mSLO1, SLO"	ENSG00000156113	"Potassium calcium-activated channel subfamily M alpha 1"	Q12791	10	76869601-77638369	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	7	"Bipolar cells: 372.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	5	"intermediate monocyte: 5.5;memory B-cell: 1.7;non-classical monocyte: 3.7"	"Group enriched"	"Detected in many"	5	"B-cells: 1.7;monocytes: 5.5"	"Cell line enhanced"	"Detected in many"		"BJ: 27.4;hTERT-HME1: 32.2;PC-3: 43.8;U-138 MG: 31.6;U-87 MG: 30.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA054648	Approved					NA	NA					"HPA054648: AB_2682556"	"unprognostic (1.25e-1)"	"unprognostic (2.23e-2)"	"unprognostic (1.86e-2)"	"unprognostic (5.29e-2)"	"unprognostic (9.43e-2)"	"unprognostic (2.25e-1)"	"unprognostic (1.77e-1)"	"unprognostic (2.81e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.34e-1)"	"unprognostic (4.12e-3)"	"unprognostic (1.20e-1)"	"unprognostic (2.26e-2)"	"unprognostic (1.42e-2)"	"unprognostic (5.19e-2)"	"unprognostic (1.42e-2)"	"unprognostic (3.99e-3)"	6.0	8.1	12.5	8.8	13.6	1.1	7.1	8.2	18.5	36.3	39.0	5.7	27.9	4.8	54.0	19.7	20.7	18.3	15.6	2.7	10.8	8.2	2.0	6.6	4.0	6.2	7.4	16.5	7.0	4.1	0.7	10.1	3.3	10.1	30.1	13.2	6.6	24.0	47.6	37.1	1.8	8.6	55.1	6.8	10.4	14.8	2.6	4.9	0.4	1.4	2.7	2.5	21.7	12.6	1.7	0.6	0.3	5.5	0.0	0.0	0.3	0.0	8.2	0.0	0.1	1.3	7.1	0.1	27.4	24.5	6.6	3.3	1.8	0.1	0.0	0.2	20.4	15.8	0.0	0.0	16.0	4.1	16.2	0.1	0.0	0.0	0.0	12.8	0.0	0.1	4.9	2.9	10.6	32.2	23.5	2.6	0.1	0.0	0.0	11.6	0.3	0.5	0.0	0.5	0.0	43.8	0.0	1.0	0.0	4.2	0.0	2.5	0.3	0.0	0.7	0.0	3.4	3.3	0.0	17.7	31.6	3.5	5.6	24.2	0.0	0.0	0.0	30.8	0.0	12.3	0.0	0.2	0.0	0.0	5.5	0.0	1.7	0.0	0.0	0.6	0.3	0.0	0.0	0.3	0.0	3.7	0.0	0.0	0.3	12.5	13.6	8.2	18.5	10.8	8.2	7.4	16.5	10.1	4.9	0.0	7.0	2.7	41.2	1.8	372.4	2.5	2.5	0.0	6.8	1.8	56.9	0.3	24.9	2.9	55.5	0.9	1.5	0.0	9.7	0.1	4.1	44.9	0.0	23.7	11.3	6.4	4.7	2.5	53.8	46.9	3.4	19.8	45.5	4.6	52.9	48.0	11.6	0.8	1.1	0.8	15.2	6.5	17.9	1.4	1.6	0.3	0.2	0.7	1.1	1.4
KCNMB1	hslo-beta	ENSG00000145936	"Potassium calcium-activated channel subfamily M regulatory beta subunit 1"	Q16558	5	170374671-170389677	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 55.5"	"Cell type enriched"	"Detected in many"	6	"Peritubular cells: 333.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"dendritic cells: 7.0;monocytes: 7.1"	"Cell line enhanced"	"Detected in some"		"REH: 13.0;SK-BR-3: 3.2;U-937: 5.4"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in single"									NA	NA						"unprognostic (2.06e-2)"	"unprognostic (2.70e-4)"	"unprognostic (1.69e-2)"	"unprognostic (1.27e-1)"	"unprognostic (3.37e-2)"	"unprognostic (8.88e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.46e-1)"	"unprognostic (2.28e-1)"	"unprognostic (4.68e-2)"	"unprognostic (5.37e-1)"	"unprognostic (1.00e-1)"	"prognostic unfavorable (4.13e-6)"	"unprognostic (1.08e-1)"	"unprognostic (2.49e-1)"	"unprognostic (4.31e-2)"	"unprognostic (1.04e-2)"	3.2	1.0	0.6	7.7	0.5	0.7	4.2	0.4	0.6	26.8	34.7	0.8	12.6	2.2	31.3	10.6	29.8	10.9	32.4	2.6	0.6	0.7	1.9	0.4	2.2	1.3	1.1	0.9	8.7	0.5	0.1	0.5	0.9	2.2	29.4	5.0	5.6	5.3	29.3	0.9	1.6	11.4	55.5	1.5	1.1	13.4	8.0	0.6	0.3	1.0	1.5	1.6	43.4	6.4	0.5	7.0	1.4	7.1	0.6	0.3	1.0	0.1	0.2	2.3	0.6	0.2	0.0	0.4	0.3	0.1	0.1	0.1	0.5	0.4	0.2	1.6	0.1	0.6	0.2	0.1	0.1	0.1	0.5	0.1	1.5	0.8	0.3	0.0	0.6	0.4	0.4	0.0	0.2	0.4	0.2	0.2	0.7	0.5	1.1	0.1	1.0	0.0	1.4	0.4	0.1	0.2	13.0	0.1	0.3	0.1	0.4	0.5	0.3	0.1	3.2	0.0	1.1	0.2	1.4	0.8	0.3	0.5	0.5	0.1	0.8	0.3	0.2	0.2	5.4	0.2	1.3	4.3	0.4	0.2	7.1	0.1	0.2	0.3	0.2	7.0	0.5	0.2	0.2	1.4	0.6	6.0	2.6	0.2	1.0	0.6	0.5	0.4	0.5	0.6	0.7	1.1	0.9	2.2	0.6	0.0	7.5	1.3	1.0	1.8	1.5	2.6	2.5	8.1	7.9	1.8	5.9	0.5	0.0	0.1	0.5	2.7	0.0	0.0	0.4	0.6	14.4	1.0	19.6	0.0	7.7	1.6	0.0	1.8	9.1	1.6	35.6	21.4	3.3	29.7	0.0	1.1	0.0	0.0	333.0	0.0	1.8	45.3	59.8	0.7	0.9	1.5	0.5	0.0	0.0	0.5
KCNMB2		ENSG00000197584	"Potassium calcium-activated channel subfamily M regulatory beta subunit 2"	Q9Y691	3	178272932-178844429	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"epididymis: 36.8"	"Group enriched"	"Detected in some"	4	"Ciliated cells: 14.7;Intestinal endocrine cells: 13.3"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 6.5;fHDF/TERT166: 2.6;RPMI-8226: 1.8;SCLC-21H: 8.5"									CAB022649	Uncertain					NA	NA					"CAB022649: "	"unprognostic (9.52e-2)"	"unprognostic (1.13e-1)"	"unprognostic (6.82e-2)"	"unprognostic (2.07e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.04e-2)"	"unprognostic (2.43e-2)"	"unprognostic (6.97e-2)"	"unprognostic (6.74e-2)"	"unprognostic (2.15e-1)"	"unprognostic (3.58e-3)"	"unprognostic (3.57e-2)"	"unprognostic (1.71e-2)"	"unprognostic (2.07e-1)"	"unprognostic (1.68e-1)"	"unprognostic (6.89e-4)"	"unprognostic (7.85e-2)"	0.7	6.3	7.8	0.5	6.2	0.4	1.3	1.8	11.2	2.5	1.9	2.2	4.4	1.0	7.2	36.8	0.9	14.3	0.9	7.4	13.2	4.5	4.1	0.6	1.6	0.4	4.7	4.9	16.3	4.5	0.4	10.2	0.5	6.2	1.1	0.9	0.5	0.6	1.9	0.6	0.7	0.9	3.0	3.2	1.9	3.6	0.6	3.2	0.0	1.1	0.0	0.4	0.6	1.5	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	6.5	0.0	0.0	0.4	0.0	0.0	1.4	2.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.1	0.0	0.0	0.7	0.1	0.0	0.0	0.0	1.8	0.0	1.0	8.5	0.0	0.0	0.5	0.0	0.6	1.4	0.0	0.3	0.0	0.1	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.8	6.2	1.8	11.2	13.2	4.5	4.7	4.9	6.2	3.2	0.0	0.0	0.0	0.0	0.0	0.4	2.8	0.0	14.7	1.2	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	13.3	2.5	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
KCNMB3	"KCNMB2, KCNMBL"	ENSG00000171121	"Potassium calcium-activated channel subfamily M regulatory beta subunit 3"	Q9NPA1	3	179236691-179267002	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Cone photoreceptor cells: 13.7;Late spermatids: 10.9"	"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HEL: 11.2;NB-4: 7.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA015665, HPA019185"	Approved		Approved	Nucleoplasm,Mitochondria		NA	NA			Nucleoplasm	Mitochondria	"HPA015665: AB_1852142, HPA019185: AB_1852144"	"unprognostic (2.50e-1)"	"unprognostic (1.32e-1)"	"unprognostic (6.76e-5)"	"unprognostic (2.65e-2)"	"unprognostic (2.22e-2)"	"unprognostic (2.08e-1)"	"unprognostic (4.59e-3)"	"unprognostic (1.14e-1)"	"unprognostic (9.15e-3)"	"unprognostic (5.09e-2)"	"unprognostic (1.87e-2)"	"unprognostic (1.95e-5)"	"unprognostic (5.93e-10)"	"unprognostic (7.22e-2)"	"unprognostic (4.72e-1)"	"unprognostic (8.69e-2)"	"unprognostic (3.49e-2)"	3.0	2.0	0.7	2.9	0.7	1.2	3.3	0.2	0.6	1.8	2.0			1.9	2.0	2.3	0.7	1.0	2.4	1.8	1.0	0.9	2.2	4.0	1.2	2.9	1.1		1.6	5.3	3.7	2.1	6.6		2.9	2.2		2.7	1.4	0.5	0.6	2.2	1.9	1.5	5.9	2.6	4.5			2.4		2.6	1.9	1.5	3.5	0.3	2.3	0.4	3.6	1.0	0.0	3.0	0.7	1.2	0.0	1.4	1.1	1.9	0.8	0.5	1.3	0.6	6.5	2.6	0.1	3.0	0.6	2.7	1.1	0.0	0.2	1.5	3.8	0.4	11.2	2.9	2.5	1.2	0.2	3.7	1.9	0.6	0.9	0.0	1.0	1.1	0.1	0.4	0.1	1.5	1.8	0.1	7.6	0.0	1.2	2.3	3.3	0.0	0.1	1.0	2.1	1.5	0.4	1.0	1.2	0.7	1.1	3.1	6.1	0.7	0.6	1.1	0.3	0.9	1.0	0.4	3.6	0.6	4.3	0.8	2.3	0.4	0.5	1.0	0.3	0.6	3.5	0.6	0.8	0.1	2.1	0.4	0.7	1.9	3.6	0.1	0.3	0.9	0.0											0.0	2.2	0.8	1.8	0.2	2.3	0.6	2.5	1.4	2.3	0.0	13.7	1.0	0.0	4.3	8.0	2.7	1.5	0.0	3.1	1.0	1.2	1.6	2.3	1.5	1.0	0.0	4.7	1.8	1.6	10.9	2.6	0.8	0.0	1.0	1.3	1.9	2.7	0.0	2.8	0.0	5.3	6.5	1.4	1.6	1.4	0.1	1.0	0.0	1.1	0.7
KCNMB4		ENSG00000135643	"Potassium calcium-activated channel subfamily M regulatory beta subunit 4"	Q86W47	12	70366276-70434292	"FDA approved drug targets, Predicted membrane proteins"	"Ion transport, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"adrenal gland: 24.4;brain: 37.7"	"Cell type enhanced"	"Detected in many"	9	"Bipolar cells: 16.9;Collecting duct cells: 22.7;Ito cells: 24.5;Peritubular cells: 17.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive CD8 T-cell: 2.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 8.9;RH-30: 9.5;RT4: 10.4;SuSa: 8.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA072287	Enhanced	Approved	Approved	Cytosol		NA	NA			Cytosol		"HPA072287: AB_2686507"	"unprognostic (3.90e-1)"	"unprognostic (1.72e-2)"	"unprognostic (2.69e-2)"	"unprognostic (2.62e-2)"	"unprognostic (6.98e-2)"	"unprognostic (1.13e-3)"	"unprognostic (1.85e-1)"	"unprognostic (2.48e-2)"	"unprognostic (3.50e-1)"	"unprognostic (2.95e-2)"	"unprognostic (3.75e-1)"	"unprognostic (2.47e-2)"	"unprognostic (2.19e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.78e-1)"	"unprognostic (4.62e-2)"	"unprognostic (1.05e-2)"	4.4	24.4	19.8	2.6	24.6	1.3	2.6	13.8	37.7	3.5	5.0	28.4	1.0	2.5	3.2	2.8	2.6	3.3	3.2	5.9	25.9	10.4	5.8	1.8	4.6	2.8	28.6	19.3	5.4	1.5	1.3	1.4	4.9	11.6	2.9	2.9	2.0	3.8	4.5	4.2	4.9	3.0	2.8	15.2	2.8	1.8	3.8	26.0	0.8	3.3	0.0	2.6	2.4	2.1	1.7	0.6	0.3	0.3	0.2	2.8	0.5	0.0	0.3	5.6	3.1	0.3	0.3	0.6	0.6	1.0	0.3	0.9	0.2	2.1	2.7	0.3	0.0	1.2	0.1	6.0	0.9	0.2	1.3	3.5	1.4	1.3	3.2	0.0	0.1	0.1	1.6	0.1	0.0	0.0	0.6	0.2	4.0	0.0	0.0	1.1	0.7	1.9	0.4	8.9	0.1	6.4	2.8	9.5	0.2	0.2	10.4	2.7	3.4	0.8	1.1	0.1	8.9	3.1	0.1	0.1	0.4	1.5	0.1	0.3	2.0	0.0	2.8	0.5	0.0	0.9	0.3	0.3	0.0	0.3	0.3	0.3	0.6	0.6	0.6	0.6	1.7	2.2	2.8	0.3	0.2	0.1	0.2	0.6	0.5	19.8	24.6	13.8	19.1	25.9	10.4	28.6	19.3	11.6	26.0	0.0	1.1	0.0	0.1	2.9	16.9	3.1	0.0	0.0	0.0	22.7	0.0	0.2	0.0	0.0	0.9	6.0	0.0	0.0	0.0	0.2	2.2	0.4	0.0	0.2	1.1	0.0	0.0	24.5	9.5	1.8	6.1	2.0	1.7	0.0	0.0	0.4	0.0	0.0	17.0	7.8	2.7	0.0	1.7	1.5	4.9	4.8	0.2	0.5	0.0	0.0
KCNN1	"hSK1, KCa2.1"	ENSG00000105642	"Potassium calcium-activated channel subfamily N member 1"	Q92952	19	17951293-18000080	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in many"	12	"brain: 32.5"	"Cell type enhanced"	"Detected in some"	6	"Melanocytes: 5.0;monocytes: 3.6;Spermatogonia: 4.3"	"Cancer enhanced"	"Detected in some"		"testis cancer: 3.5"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"basophil: 2.3"	"Lineage enriched"	"Detected in single"	9	"granulocytes: 2.3"	"Cell line enriched"	"Detected in some"	12	"REH: 58.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA065938			Approved	"Actin filaments,Cytosol"		Yes	No			"Actin filaments, Cytosol"		"HPA065938: AB_2685582"	"unprognostic (7.55e-2)"	"unprognostic (4.03e-2)"	"unprognostic (1.82e-1)"	"unprognostic (7.80e-2)"	"unprognostic (1.90e-1)"	"unprognostic (8.94e-5)"	"unprognostic (3.92e-3)"	"unprognostic (1.01e-1)"	"unprognostic (8.42e-2)"	"unprognostic (3.59e-1)"	"unprognostic (2.71e-3)"	"unprognostic (3.38e-1)"	"unprognostic (5.21e-3)"	"unprognostic (2.70e-2)"	"unprognostic (1.14e-1)"	"unprognostic (7.24e-3)"	"unprognostic (3.24e-1)"	0.8	0.9	25.8	1.5	11.3	0.9	0.8	3.3	27.0	1.6	1.0	0.5	0.1	1.0	1.7	1.0	1.0	0.9	1.0	1.3	32.5	3.3	0.9	0.8	0.8	1.0	5.0	8.7	2.6	0.9	0.7	0.2	0.8	4.1	1.2	0.8	0.0	1.5	1.3	1.0	0.9	1.2	0.9	1.2	0.9	0.9	2.8	1.6	0.0	0.9	0.0	1.0	0.9	0.0	0.2	0.2	2.3	0.1	0.1	0.2	0.0	0.0	0.2	0.1	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.2	0.0	2.1	0.0	0.1	0.1	0.9	1.9	0.1	0.0	0.0	0.0	5.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.7	0.0	0.0	58.8	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	2.3	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.1	0.2	0.5	0.1	0.0	0.2	0.0	0.0	25.8	11.3	3.3	22.4	32.5	3.3	5.0	8.7	4.1	1.6	0.0	0.0	0.0	2.5	2.3	2.2	0.8	0.0	0.0	1.2	0.0	2.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	1.0	2.3	0.0	0.0	0.1	0.0	0.0	0.6	0.3	0.0	0.9	0.9	5.0	3.6	0.0	1.3	0.2	0.0	1.8	0.0	0.9	0.0	1.9	0.4	4.3	3.3	0.1	0.7	0.0	1.4
KCNN2	"hSK2, KCa2.2"	ENSG00000080709	"Potassium calcium-activated channel subfamily N member 2"	Q9H2S1	5	114360945-114496500	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 25.3;brain: 23.1;liver: 33.2"	"Cell type enhanced"	"Detected in some"	12	"Cardiomyocytes: 10.8;Hepatocytes: 14.7;Melanocytes: 20.3;Rod photoreceptor cells: 7.2"	"Group enriched"	"Detected in some"	7	"glioma: 3.5;melanoma: 3.2;prostate cancer: 12.6"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 15.0;NTERA-2: 5.7;SK-MEL-30: 10.6;THP-1: 18.7;U-937: 6.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA038221	Uncertain		Uncertain	"Nucleoplasm,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"		"HPA038221: AB_10673044"	"unprognostic (9.22e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.04e-1)"	"unprognostic (5.65e-2)"	"unprognostic (1.43e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.94e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.11e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.15e-1)"	"unprognostic (1.66e-1)"	"unprognostic (1.23e-2)"	"unprognostic (4.61e-1)"	"unprognostic (3.16e-1)"	"unprognostic (4.25e-1)"	0.8	25.3	12.6	0.8	7.3	0.6	1.1	21.7	15.0	1.7	1.2	9.5	0.0	0.9	3.9	0.9	0.8	1.0	1.0	7.7	23.1	3.6	4.8	33.2	2.5	0.9	4.5	16.9	1.4	3.8	1.0	16.0	0.6	9.1	11.7	1.3	4.2	1.1	5.4	9.9	2.1	0.9	2.8	8.4	1.1	1.1	3.8	6.5	0.0	0.9	0.0	0.8	2.4	1.1	0.3	0.3	0.8	0.3	0.1	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.8	15.0	2.3	0.3	0.1	0.0	0.2	0.0	0.5	0.0	2.0	0.0	2.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	3.3	0.0	0.1	0.0	0.2	0.0	1.2	5.7	0.0	0.0	0.1	0.0	0.7	0.3	0.1	1.8	0.0	0.0	0.2	10.6	0.3	0.2	18.7	0.2	0.0	0.4	1.7	0.0	0.1	0.0	0.1	1.8	6.7	0.5	0.5	0.0	0.1	0.1	0.0	0.1	0.0	0.2	0.1	0.3	0.3	0.1	0.3	0.8	0.1	0.3	0.3	0.1	0.0	12.6	7.3	21.7	15.0	23.1	3.6	4.5	16.9	9.1	6.5	0.0	0.6	0.0	0.1	0.2	6.8	10.8	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.7	5.2	0.0	0.0	0.8	0.0	0.9	4.5	0.0	14.7	0.0	0.0	0.0	6.2	1.0	0.0	0.0	0.0	20.3	0.0	0.5	0.3	1.4	0.0	0.0	0.5	7.2	0.0	0.5	0.5	3.2	0.3	0.0	0.0	0.4	0.1
KCNN3	"hSK3, KCa2.3, SKCA3"	ENSG00000143603	"Potassium calcium-activated channel subfamily N member 3"	Q9UGI6	1	154697455-154870280	"FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 26.7"	"Cell type enhanced"	"Detected in many"	16	"Alveolar cells type 1: 11.9;Ciliated cells: 32.1;Endothelial cells: 16.9"	"Cancer enhanced"	"Detected in many"		"glioma: 5.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.8;memory B-cell: 4.8"	"Group enriched"	"Detected in many"	9	"B-cells: 4.8;granulocytes: 5.8;monocytes: 2.7"	"Cell line enhanced"	"Detected in some"		"Daudi: 18.1;HMC-1: 12.5;Karpas-707: 31.0;RPMI-8226: 8.4;U-266/70: 29.9;U-698: 10.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA057127	Enhanced		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA057127: AB_2683345"	"unprognostic (2.09e-1)"	"unprognostic (2.91e-2)"	"unprognostic (3.41e-2)"	"unprognostic (1.04e-1)"	"unprognostic (7.22e-2)"	"unprognostic (4.06e-2)"	"unprognostic (2.19e-2)"	"unprognostic (2.03e-1)"	"unprognostic (3.43e-2)"	"unprognostic (9.51e-2)"	"unprognostic (4.07e-3)"	"unprognostic (4.89e-2)"	"prognostic unfavorable (1.97e-4)"	"unprognostic (1.71e-2)"	"unprognostic (1.54e-1)"	"unprognostic (6.93e-2)"	"unprognostic (1.80e-2)"	1.7	2.5	20.6	6.5	21.7	1.0	1.8	5.7	26.7	9.3	9.1	12.4	1.1	5.4	12.6	1.7	3.5	10.3	3.1	4.0	21.6	8.0	3.5	1.0	3.1	5.8	12.0	10.9	2.1	1.0	1.5	2.6	0.7	13.3	3.4	4.6	0.1	2.7	2.7	8.5	1.1	3.9	10.6	8.1	5.0	4.4	1.3	15.5	0.2	3.7	3.5	9.2	8.3	4.9	4.8	0.4	5.8	2.7	0.0	0.0	0.4	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.1	1.4	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	12.5	0.2	0.0	0.1	0.0	0.0	0.4	0.0	0.0	31.0	0.3	0.0	0.1	0.0	0.4	0.0	1.2	0.0	7.7	8.4	0.0	0.0	0.4	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.5	0.5	0.0	0.0	0.0	29.9	3.9	10.0	0.3	0.0	2.9	5.8	0.0	0.0	0.0	0.2	0.0	4.8	0.0	0.0	0.4	1.1	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.4	20.6	21.7	5.7	10.3	21.6	8.0	12.0	10.9	13.3	15.5	11.9	2.4	0.0	0.5	1.1	0.2	2.2	0.0	32.1	3.4	0.0	2.0	0.0	3.3	0.2	2.6	16.9	0.0	0.0	0.2	0.0	2.3	0.4	0.0	0.0	0.4	0.0	4.1	5.5	0.0	6.2	0.3	0.8	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.3	0.0	1.0	0.5	0.1	1.5	0.0	0.0	0.0	0.1
KCNN4	"hIKCa1, hKCa4, hSK4, IK, KCa3.1"	ENSG00000104783	"Potassium calcium-activated channel subfamily N member 4"	O15554	19	43766533-43781257	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Immunity, Ion transport, Transport"	"Calmodulin-binding, Ion channel"	"Disease mutation, FDA approved drug targets, Hereditary hemolytic anemia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 45.7;salivary gland: 82.3"	"Group enriched"	"Detected in many"	6	"Cytotrophoblasts: 196.8;Syncytiotrophoblasts: 638.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"CAPAN-2: 27.8;hTERT-RPE1: 24.5;SK-BR-3: 27.5;WM-115: 70.6"	"Region enhanced"	"Detected in single"		"olfactory region: 2.3"	"Not detected"	"Not detected"			"HPA053841, HPA059622"	Approved					NA	NA					"HPA053841: AB_2682278, HPA059622: AB_2684085"	"unprognostic (1.23e-2)"	"unprognostic (3.22e-2)"	"unprognostic (4.29e-1)"	"unprognostic (3.74e-3)"	"prognostic unfavorable (2.68e-4)"	"unprognostic (1.98e-2)"	"unprognostic (7.33e-2)"	"unprognostic (1.42e-2)"	"unprognostic (2.48e-3)"	"unprognostic (4.12e-2)"	"prognostic unfavorable (4.56e-4)"	"unprognostic (9.96e-3)"	"prognostic unfavorable (1.05e-14)"	"unprognostic (3.70e-2)"	"unprognostic (2.17e-2)"	"unprognostic (7.50e-2)"	"prognostic favorable (1.75e-4)"	3.0	0.1	0.5	12.2	2.5	6.5	5.6	0.4	0.5	8.0	5.7	0.7	6.4	2.0	0.9	2.9	2.6	2.6	8.8	0.6	1.4	0.5	0.8	0.3	2.6	5.7	1.7	0.6	1.3	0.3	0.0	0.3	45.7	1.5	11.0	3.8	0.8	82.3	6.8	0.7	10.8	10.0	2.0	1.1	8.4	13.6	0.9	1.0	9.1	0.7	3.6	17.3	10.3	2.4	18.7	14.4	1.9	15.8	0.0	6.9	5.2	5.1	9.6	0.0	0.0	0.0	0.8	13.5	0.2	0.7	0.5	0.1	0.1	27.8	1.5	2.2	0.2	3.2	4.1	0.0	9.8	1.4	9.3	0.0	6.8	12.5	0.2	0.0	0.0	0.1	0.0	1.2	0.6	4.4	24.5	0.0	0.0	1.5	0.8	0.1	5.0	1.5	5.2	0.0	21.9	10.3	4.6	0.1	5.1	8.5	14.4	0.0	0.0	13.8	27.5	8.1	0.6	0.0	5.5	0.3	3.8	19.7	0.1	11.1	0.0	0.3	0.6	13.1	1.2	70.6	1.9	10.2	0.0	0.3	15.8	0.4	18.7	5.1	2.6	14.4	9.4	3.4	3.2	0.5	0.0	8.6	0.4	6.9	5.2	0.5	2.5	0.4	0.5	1.4	0.5	1.7	0.6	1.5	1.0	0.0	3.4	27.2	43.3	2.5	0.1	0.4	7.6	0.0	6.8	1.8	3.9	196.8	0.0	3.0	0.7	2.8	4.2	23.3	3.5	6.8	2.8	66.7	0.0	0.0	43.0	0.0	0.0	0.0	7.5	0.0	0.0	28.3	20.3	0.0	5.9	0.0	37.2	16.9	0.0	0.0	0.3	0.0	1.0	0.0	1.3	1.9	638.3	6.5	43.7	53.5
KCNQ1	"JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1"	ENSG00000053918	"Potassium voltage-gated channel subfamily Q member 1"	P51787	11	2444684-2849110	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Calmodulin-binding, Ion channel, Potassium channel, Voltage-gated channel"	"Atrial fibrillation, Deafness, Diabetes mellitus, Disease mutation, FDA approved drug targets, Long QT syndrome, Short QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 78.2;ductus deferens: 88.1;seminal vesicle: 83.6"	"Cell type enhanced"	"Detected in many"	6	"Enterocytes: 32.7;Undifferentiated cells: 44.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HMC-1: 19.9;OE19: 24.0;RPMI-8226: 13.4;U-266/70: 7.9;U-937: 7.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB018656, HPA048553"	Enhanced					NA	NA					"CAB018656: AB_2131551, HPA048553: AB_2680438"	"unprognostic (6.02e-2)"	"unprognostic (2.48e-1)"	"unprognostic (6.39e-3)"	"unprognostic (4.38e-1)"	"unprognostic (1.86e-1)"	"unprognostic (1.83e-1)"	"unprognostic (3.46e-2)"	"unprognostic (7.36e-2)"	"unprognostic (8.07e-2)"	"unprognostic (8.81e-2)"	"unprognostic (1.58e-1)"	"unprognostic (5.39e-2)"	"unprognostic (2.46e-3)"	"prognostic favorable (9.85e-4)"	"unprognostic (3.99e-2)"	"unprognostic (4.19e-2)"	"unprognostic (5.27e-2)"	3.0	78.2	1.0	5.1	1.0	3.4	3.1	0.6	1.2	5.0	13.7	4.1	88.1	14.2	1.9	15.9	1.5	2.1	12.2	10.7	1.5	1.0	13.8	1.0	11.4	5.8	1.2	0.8	1.6	25.6	5.6	2.7	1.8	1.8	7.5	4.6	2.5	9.5	83.6	0.8	1.0	18.4	1.5	1.4	5.5	31.2	3.6	1.5	1.6	36.2	0.9	4.8	5.5	3.6	1.2	5.6	5.3	4.7	0.0	1.7	1.4	0.0	0.1	0.0	3.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	1.4	0.9	3.3	0.0	0.2	0.1	0.4	0.0	0.0	0.2	0.9	0.0	2.4	0.2	0.2	0.0	19.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.4	0.0	0.4	0.7	24.0	0.1	0.1	0.0	13.4	5.0	1.6	0.4	3.7	0.4	0.0	0.0	0.3	0.1	5.1	0.0	0.0	0.1	0.1	0.0	7.9	0.0	0.0	0.0	7.8	0.0	1.6	4.7	4.7	0.0	2.6	0.1	1.2	0.6	0.1	5.6	0.6	1.7	1.7	5.3	0.0	3.7	1.9	0.5	1.4	1.0	1.0	0.6	1.2	1.5	1.0	1.2	0.8	1.8	1.5	3.0	11.7	6.7	6.7	0.6	0.0	15.9	17.8	2.7	5.7	27.9	0.0	1.0	13.3	16.6	1.1	2.9	32.7	0.0	18.8	1.1	1.0	6.2	19.6	0.2	13.9	0.0	6.3	9.2	24.1	0.6	0.3	10.1	1.7	1.8	21.3	0.6	17.8	17.5	0.0	1.6	0.2	6.5	1.0	0.2	0.1	0.9	1.7	1.3	44.9	14.7
KCNQ2	"BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2"	ENSG00000075043	"Potassium voltage-gated channel subfamily Q member 2"	O43526	20	63400210-63472677	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 50.8"	"Group enriched"	"Detected in some"	5	"Early spermatids: 10.8;Horizontal cells: 12.7;Late spermatids: 5.7;Spermatocytes: 6.6;Spermatogonia: 17.0"	"Cancer enriched"	"Detected in some"	9	"glioma: 8.7"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.2;T-reg: 1.5"	"Lineage enriched"	"Detected in single"	22	"T-cells: 2.2"	"Cell line enhanced"	"Detected in some"		"AF22: 8.5;AN3-CA: 14.0;NTERA-2: 7.8;SCLC-21H: 27.5;SH-SY5Y: 48.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA016642, HPA057112"	Enhanced		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA016642: AB_1855555, HPA057112: AB_2683339"	"unprognostic (2.35e-1)"	"unprognostic (1.41e-1)"	"unprognostic (2.22e-4)"	"unprognostic (8.21e-6)"	"unprognostic (6.18e-2)"	"unprognostic (7.58e-2)"	"unprognostic (6.06e-2)"	"unprognostic (3.16e-1)"	"unprognostic (1.73e-1)"	"unprognostic (1.92e-1)"	"unprognostic (9.96e-2)"	"unprognostic (9.39e-2)"	"unprognostic (1.43e-5)"	"unprognostic (4.36e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.81e-1)"	"unprognostic (2.70e-2)"	1.2	10.0	18.7	1.3	21.4	1.2	1.2	24.1	50.8	1.2	1.3	2.4	0.0	1.3	1.2	1.3	1.2	1.7	1.7	1.2	15.4	10.0	1.2	1.2	1.2	1.2	8.4	14.1	1.2	1.9	1.2	9.2	1.2	8.9	2.8	1.2	0.0	1.2	1.2	1.2	1.2	1.3	1.2	2.6	1.2	1.3	6.9	4.2	0.0	1.2	0.0	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	8.5	14.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	3.3	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	7.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	27.5	48.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.8	0.9	0.0	0.0	0.0	0.0	1.5	0.0	18.7	21.4	24.1	31.2	15.4	10.0	8.4	14.1	8.9	4.2	0.0	0.0	0.0	0.0	0.1	1.5	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.8	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0	12.7	0.0	0.0	0.0	5.7	0.6	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.4	0.0	2.1	0.0	0.0	6.6	17.0	0.0	0.0	0.0	0.0	0.0
KCNQ3	"EBN2, Kv7.3"	ENSG00000184156	"Potassium voltage-gated channel subfamily Q member 3"	O43525	8	132120858-132481019	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Potassium transport, Transport"	"Ion channel, Potassium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	9	"brain: 29.5"	"Cell type enhanced"	"Detected in some"	11	"Alveolar cells type 2: 9.4;Bipolar cells: 5.7;Cardiomyocytes: 4.5;Exocrine glandular cells: 5.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"hTERT-HME1: 10.1;JURKAT: 5.6;RPMI-8226: 4.1;U-2 OS: 6.6;U-87 MG: 5.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.90e-1)"	"unprognostic (1.26e-3)"	"unprognostic (1.45e-2)"	"unprognostic (3.65e-5)"	"unprognostic (2.32e-1)"	"unprognostic (4.60e-2)"	"unprognostic (5.57e-6)"	"unprognostic (5.82e-2)"	"unprognostic (7.32e-2)"	"unprognostic (6.09e-2)"	"unprognostic (7.09e-2)"	"unprognostic (3.22e-1)"	"unprognostic (2.71e-4)"	"unprognostic (1.14e-3)"	"unprognostic (3.52e-1)"	"unprognostic (7.92e-2)"	"unprognostic (2.50e-2)"	1.8	3.3	10.6	1.5	13.1	0.7	1.4	0.9	29.5	1.4	1.0	1.7	0.0	1.0	1.0	0.9	0.8	1.2	1.3	1.8	8.0	7.3	1.8	0.7	2.0	0.9	7.4	11.5	0.8	1.2	1.2	1.4	1.0	6.5	1.4	1.0	0.0	1.0	1.8	0.7	1.3	1.7	1.6	2.1	1.3	0.9	1.0	4.7	0.0	1.2	0.0	1.0	1.1	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.1	0.0	0.0	0.5	1.6	0.0	0.5	1.6	0.0	0.0	0.0	1.5	0.0	1.8	2.3	3.8	0.0	0.0	3.7	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.6	0.0	2.6	10.1	0.1	0.0	5.6	0.0	0.2	1.3	0.0	0.0	0.0	0.7	0.0	0.3	0.0	0.0	4.1	2.4	0.0	1.9	1.7	0.7	0.0	0.0	0.3	0.0	1.4	0.0	0.0	6.6	0.2	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	13.1	0.9	13.3	8.0	7.3	7.4	11.5	6.5	4.7	0.0	9.4	0.0	0.0	0.2	5.7	4.5	0.0	1.4	2.3	0.0	0.0	0.0	0.0	2.9	1.5	0.6	0.0	0.0	5.1	0.0	0.2	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.3	0.0	1.2	0.0	1.0	0.0	0.2	2.8	0.0	0.0	0.4	0.4	0.0	1.7	0.0	0.2	0.1	0.0	0.0	0.0	0.0
KDR	"CD309, FLK1, VEGFR, VEGFR2"	ENSG00000128052	"Kinase insert domain receptor"	P35968	4	55078259-55125595	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"Endothelial cells: 100.3;Ito cells: 200.7;Muller glia cells: 229.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	9	"HUVEC TERT2: 32.5;TIME: 36.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			CAB004028	Enhanced		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		7400000	"Plasma membrane"		"CAB004028: AB_2212507"	"unprognostic (1.61e-1)"	"unprognostic (2.03e-1)"	"unprognostic (9.65e-2)"	"unprognostic (1.97e-1)"	"unprognostic (9.63e-2)"	"unprognostic (1.22e-2)"	"unprognostic (1.78e-3)"	"unprognostic (2.59e-2)"	"unprognostic (1.19e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.79e-3)"	"unprognostic (1.34e-1)"	"prognostic unfavorable (7.26e-4)"	"unprognostic (4.00e-2)"	"unprognostic (2.30e-1)"	"unprognostic (3.22e-1)"	"unprognostic (1.86e-1)"	19.7	6.2	1.8	4.4	3.1	0.4	20.5	1.1	2.2	11.4	6.0	1.8	11.5	2.3	28.8	10.2	5.2	9.5	6.2	12.1	2.3	1.7	7.8	10.4	13.2	14.1	3.1	2.9	6.0	8.1	8.0	6.8	34.5	3.9	9.5	1.4	27.6	7.1	10.3	5.3	3.0	3.8	7.7	2.6	4.4	4.2	5.3	1.2	0.5	20.0	5.3	3.0	4.4	12.0	0.1	0.1	0.7	0.0	0.2	0.2	0.1	0.0	0.0	1.7	0.0	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	3.8	0.0	0.0	0.3	0.0	0.0	0.2	0.2	32.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	36.7	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.7	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.1	0.0	0.1	1.8	3.1	1.1	2.2	2.3	1.7	3.1	2.9	3.9	1.2	0.0	8.2	7.5	0.4	2.3	7.4	4.8	0.0	6.7	30.7	0.0	0.0	0.1	0.0	0.5	0.8	100.3	0.0	0.0	0.0	0.1	1.9	0.4	2.3	1.3	0.4	0.0	0.0	200.7	14.5	0.6	0.0	1.0	6.8	0.0	0.0	229.2	0.3	0.0	0.4	0.0	6.0	0.0	1.4	0.2	0.2	2.4	0.1	0.0	0.0	0.4
KEAP1	"INrf2, KIAA0132, KLHL19, MGC10630, MGC1114, MGC20887, MGC4407, MGC9454"	ENSG00000079999	"Kelch like ECH associated protein 1"	Q14145	19	10486120-10503741	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction, Ubl conjugation pathway"		"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA005558, CAB025337"	Approved		Supported	"Nucleoplasm,Centriolar satellite,Cytosol"		NA	NA			"Nucleoplasm, Centriolar satellite"	Cytosol	"CAB025337: , HPA005558: AB_1079175"	"unprognostic (1.98e-1)"	"prognostic favorable (3.28e-4)"	"unprognostic (1.61e-1)"	"unprognostic (1.02e-1)"	"unprognostic (1.42e-1)"	"unprognostic (1.63e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.46e-1)"	"unprognostic (1.48e-1)"	"unprognostic (5.22e-3)"	"unprognostic (2.04e-1)"	"unprognostic (9.99e-2)"	"unprognostic (1.29e-1)"	"unprognostic (7.71e-3)"	"unprognostic (5.06e-1)"	"unprognostic (8.18e-2)"	"unprognostic (1.60e-2)"	16.0	13.7	13.5	10.4	14.3	9.1	12.4	13.2	15.1	13.1	15.7	15.4	13.8	13.6	11.0	12.7	26.3	15.1	12.7	19.7	13.9	13.7	13.2	22.0	10.8	15.5	16.7	7.4	11.8	14.3	11.1	10.2	11.5	14.3	13.9	8.8	11.8	11.3	13.9	63.9	16.8	13.8	11.6	16.5	11.3	10.6	12.2	13.8	13.1	14.5	29.1	16.1	14.5	11.2	14.6	23.7	21.3	19.8	21.0	30.8	19.6	17.3	31.8	8.8	11.7	18.2	15.5	9.4	14.8	11.0	15.2	13.6	22.6	17.5	24.7	39.0	16.4	11.3	15.6	17.5	11.5	7.5	23.9	19.2	37.3	9.5	26.7	17.6	19.5	20.3	16.0	15.6	17.1	8.0	12.7	14.4	7.4	22.8	45.8	13.2	24.0	14.1	53.6	25.7	16.6	26.8	25.7	11.0	28.9	9.8	20.8	24.3	12.7	20.6	13.8	12.8	8.1	11.9	26.1	17.7	24.5	13.2	27.4	17.9	26.7	33.4	24.2	18.9	23.3	17.9	16.1	19.8	21.3	30.8	17.0	29.3	14.6	21.5	28.3	23.7	5.7	13.5	19.1	10.9	21.0	16.6	16.3	25.4	19.6	13.5	14.3	13.2	12.8	13.9	13.7	16.7	7.4	14.3	13.8	26.8	17.3	19.6	22.6	19.5	21.5	20.3	20.4	13.4	17.0	10.4	7.9	22.5	11.6	29.0	22.3	24.1	31.5	0.0	31.3	21.0	19.7	21.7	11.5	28.8	25.7	25.4	25.8	27.0	14.8	34.6	27.0	14.9	10.1	57.7	20.6	39.6	26.7	21.0	24.4	19.1	11.1	12.9	15.6	19.5	17.3	19.3	22.4	22.4	27.9	21.7
KIT	"C-Kit, CD117, PBT, SCFR"	ENSG00000157404	"KIT proto-oncogene receptor tyrosine kinase"	P10721	4	54657918-54740715	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"breast: 65.5"	"Group enriched"	"Detected in many"	10	"granulocytes: 496.5;Melanocytes: 200.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"basophil: 12.7;eosinophil: 10.0;NK-cell: 9.7"	"Group enriched"	"Detected in many"	6	"granulocytes: 12.7;NK-cells: 9.7"	"Group enriched"	"Detected in some"	13	"HEL: 48.8;HMC-1: 102.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003288, HPA004471, CAB068253, CAB072867, HPA073252"	Enhanced	Supported	Supported	"Plasma membrane"		NA	NA		48000000	"Plasma membrane"		"CAB003288: AB_2335702, CAB068253: AB_2665717, CAB072867: AB_2665718, HPA004471: AB_1078431, HPA073252: AB_2686589"	"unprognostic (1.55e-2)"	"unprognostic (1.91e-1)"	"unprognostic (4.04e-2)"	"unprognostic (8.19e-2)"	"unprognostic (3.96e-2)"	"unprognostic (2.18e-2)"	"unprognostic (2.33e-2)"	"unprognostic (1.97e-2)"	"unprognostic (3.60e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.92e-2)"	"prognostic favorable (5.63e-4)"	"unprognostic (1.34e-3)"	"unprognostic (1.87e-1)"	"unprognostic (1.29e-2)"	"unprognostic (2.30e-1)"	8.1	1.6	9.5	6.6	11.8	3.7	65.5	18.3	12.0	12.1	10.3	6.5	10.2	5.8	8.9	4.2	9.9	2.5	15.5	2.4	36.0	4.4	9.4	1.1	13.8	3.8	3.6	6.0	28.5	2.1	1.3	2.3	6.2	5.7	9.6	10.4	20.7	12.9	6.9	1.3	14.6	8.9	10.2	3.9	3.2	12.8	4.0	4.5	0.4	28.9	4.3	4.9	9.8	12.5	0.0	1.8	12.7	0.9	9.7	1.9	0.1	0.0	0.0	0.8	0.0	0.1	0.0	0.0	0.6	0.9	2.6	3.2	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.5	0.0	2.2	0.0	1.2	48.8	0.0	0.0	0.0	0.0	102.6	0.0	0.0	0.0	0.0	0.0	5.7	0.8	0.6	0.1	0.0	0.0	0.2	0.4	1.4	0.0	0.0	0.1	0.0	0.0	0.0	4.8	1.2	0.4	0.0	0.0	0.0	3.0	0.0	0.5	0.0	0.1	0.0	1.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	12.7	0.0	10.0	0.1	0.0	1.9	0.0	0.3	0.7	1.8	0.0	0.0	0.0	0.8	9.7	0.9	0.0	0.0	0.1	9.5	11.8	18.3	12.0	36.0	4.4	3.6	6.0	5.7	4.5	6.0	34.8	1.4	1.1	12.7	0.0	0.4	5.1	0.0	5.7	3.5	0.0	0.0	3.3	0.8	0.0	2.4	0.0	0.0	0.0	0.1	1.3	0.5	496.5	0.0	0.3	0.0	5.2	1.8	0.3	0.0	1.1	3.1	200.8	0.0	0.3	2.4	0.0	0.0	0.0	0.6	0.3	0.0	0.5	0.0	8.2	3.3	0.2	2.2	0.3	0.3
KLK1	Klk6	ENSG00000167748	"Kallikrein 1"	P06870	19	50819148-50823787	"Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Protease, Serine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	56	"pancreas: 742.6;salivary gland: 473.0"	"Cell type enhanced"	"Detected in many"	19	"Exocrine glandular cells: 663.7;Mucus-secreting cells: 890.7;Pancreatic endocrine cells: 205.3"	"Group enriched"	"Detected in many"	6	"colorectal cancer: 20.0;pancreatic cancer: 50.9;renal cancer: 84.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	10	"memory B-cell: 10.9;naive B-cell: 3.8"	"Lineage enriched"	"Detected in single"	14	"B-cells: 10.9"	"Cell line enriched"	"Detected in some"	4	"RPMI-8226: 29.2"														"Secreted to digestive system"	NA	NA		4300000				"unprognostic (1.51e-3)"	"unprognostic (1.23e-2)"	"unprognostic (4.20e-1)"	"unprognostic (1.73e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.92e-2)"	"unprognostic (7.47e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.49e-2)"	"unprognostic (8.06e-2)"	"unprognostic (2.12e-1)"	"unprognostic (1.42e-2)"	"unprognostic (2.55e-1)"	"unprognostic (6.49e-2)"	"unprognostic (2.10e-1)"	"unprognostic (6.23e-2)"	0.1	0.2	0.1	0.3	0.1	0.0	0.1	0.1	0.1	0.2	2.5	0.1	0.1	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	3.8	0.1	0.1	0.1	0.1	0.1	0.1	742.6	0.0	0.1	0.1	0.1	0.2	1.9	0.1	473.0	0.1	0.1	1.8	0.6	0.1	0.1	0.3	0.1	0.1	0.1	0.1	1.2	0.2	0.2	0.1	0.1	10.9	0.7	0.1	0.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.3	0.2	0.2	0.3	1.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.0	0.3	0.1	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.0	0.0	0.0	29.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.3	0.0	10.9	0.0	0.0	0.2	3.8	0.0	0.0	0.1	0.0	0.2	0.7	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	1.1	17.9	1.4	17.3	0.0	0.3	0.0	0.0	1.2	0.0	0.0	0.0	38.1	2.8	0.4	0.1	46.5	0.0	663.7	0.0	1.6	15.7	9.2	0.0	0.6	0.0	112.7	0.0	0.8	0.0	5.8	2.9	5.0	9.0	890.7	0.0	205.3	113.2	0.0	0.2	0.0	0.0	0.1	0.3	0.7	47.2	0.0	0.0	128.7	3.4
KLKB1	KLK3	ENSG00000164344	"Kallikrein B1"	P03952	4	186208979-186258471	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Inflammatory response"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	76	"liver: 102.9"	"Cell type enriched"	"Detected in some"	11	"Hepatocytes: 203.0"	"Cancer enriched"	"Detected in some"	17	"liver cancer: 27.6"	"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	7	"gdT-cell: 1.3"	"Lineage enriched"	"Detected in single"	8	"T-cells: 1.3"	"Cell line enhanced"	"Detected in some"		"NTERA-2: 7.3;SCLC-21H: 5.0;SK-MEL-30: 2.2;U-937: 2.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"								"Secreted to blood"	NA	NA	28900000000	4900000000				"unprognostic (4.80e-2)"	"unprognostic (4.53e-3)"	"unprognostic (4.36e-2)"	"unprognostic (4.17e-2)"	"unprognostic (5.93e-2)"	"unprognostic (1.90e-2)"	"unprognostic (1.15e-2)"	"unprognostic (2.83e-1)"	"unprognostic (8.14e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.38e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.45e-2)"	"unprognostic (6.01e-2)"	"unprognostic (7.30e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.59e-2)"	0.3	0.3	0.8	0.3	1.2	0.0	0.3	0.7	0.5	0.3	0.4	0.3	0.3	0.7	0.4	0.4	0.3	0.2	0.7	0.5	0.6	0.5	1.3	102.9	0.3	0.3	0.5	0.5	0.3	1.3	0.5	1.0	0.4	0.4	0.3	0.3	0.5	0.3	0.3	0.5	0.1	0.6	0.3	0.3	0.5	0.0	0.3	0.3	0.4	0.3	0.3	0.4	0.3	0.3	0.1	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.2	0.8	0.2	0.0	0.0	0.0	0.2	0.0	0.4	0.3	0.3	0.0	0.2	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.2	0.2	0.2	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.2	0.0	0.0	0.4	0.0	7.3	0.1	0.0	0.1	0.0	0.2	1.3	0.0	5.0	0.4	0.2	0.0	2.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.8	1.2	0.7	0.5	0.6	0.5	0.5	0.5	0.4	0.3	0.0	0.0	0.0	0.0	0.0	4.2	3.9	17.8	1.4	0.0	1.8	15.7	0.0	0.0	1.1	2.2	0.4	0.2	0.0	0.5	0.0	0.0	0.0	0.0	203.0	0.2	0.0	2.9	5.5	3.2	0.8	0.6	0.0	0.0	0.0	0.3	14.6	0.7	0.3	0.0	0.9	3.6	0.0	0.2	1.4	0.9	0.0	0.0	0.0	0.4	0.0
KRT12	K12	ENSG00000187242	"Keratin 12"	Q99456	17	40861303-40867210	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Corneal dystrophy, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 3.3;retina: 3.6;skin 1: 1.9"	"Cell type enriched"	"Detected in some"	5	"Paneth cells: 7.0"	"Low cancer specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	6	"HeLa: 3.8"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA055217, HPA055835"	Enhanced					NA	NA					"HPA055217: AB_2682742, HPA055835: AB_2682935"	"unprognostic (1.89e-1)"	"unprognostic (2.40e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.82e-1)"	"unprognostic (2.19e-1)"	"unprognostic (2.04e-1)"	"unprognostic (1.74e-2)"	"unprognostic (5.52e-2)"	"unprognostic (9.41e-3)"	"unprognostic (3.49e-1)"	"unprognostic (1.73e-1)"		"unprognostic (3.94e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.27e-1)"	"unprognostic (2.60e-4)"	"unprognostic (6.31e-3)"	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	0.9	0.1	3.3	0.1	0.1	1.3	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	1.0	3.6	0.1	0.1	0.1	1.9	3.3	0.1	0.1	0.1	0.4	0.7	0.1	1.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.1	0.1	3.8	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.3	0.2	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.9	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0
KRT2	"KRT2A, KRTE"	ENSG00000172867	"Keratin 2"	P35908	12	52644558-52652164	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Disease mutation, FDA approved drug targets, Ichthyosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	15	"skin 1: 289.9"	"Cell type enriched"	"Detected in some"	15	"Suprabasal keratinocytes: 232.0"	"Group enriched"	"Detected in some"	35	"head and neck cancer: 4.7;melanoma: 23.4"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"naive CD4 T-cell: 4.4;naive CD8 T-cell: 2.1"	"Lineage enriched"	"Detected in single"	45	"T-cells: 4.4"	"Group enriched"	"Detected in some"	4	"HEL: 6.3;HMC-1: 2.7;JURKAT: 2.4;OE19: 2.9"	"Group enriched"	"Detected in some"	6	"amygdala: 1.8;hippocampal formation: 2.9"	"Not detected"	"Not detected"			"HPA006299, CAB037321"	Enhanced		Approved	"Golgi apparatus,Intermediate filaments,Cytosol"		NA	NA		14000000000	"Intermediate filaments, Cytosol"	"Golgi apparatus"	"CAB037321: , HPA006299: AB_1079180"	"unprognostic (1.22e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.34e-1)"	"unprognostic (2.56e-1)"	"unprognostic (8.47e-3)"	"unprognostic (1.69e-2)"		"unprognostic (1.84e-1)"	"unprognostic (3.59e-1)"		"unprognostic (2.12e-1)"	"unprognostic (4.76e-2)"	"unprognostic (3.56e-7)"	"unprognostic (6.43e-2)"	"unprognostic (5.98e-3)"	"unprognostic (6.69e-2)"	"unprognostic (3.46e-1)"	0.1	0.0	0.1	0.1	0.1	0.0	9.5	0.1	0.1	18.3	0.1	0.1	0.1	0.0	2.0	0.1	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	4.4	289.9	0.1	0.1	0.1	0.1	0.0	0.1	0.1	6.8	0.1	19.2	1.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	4.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	6.3	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.4	0.0	0.0	4.4	2.1	0.0	0.0	0.0	0.0	0.0	0.8	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	15.9	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	1.2	0.6	0.8	0.0	0.0	0.0	8.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	232.0	0.1	0.0	0.1	0.0
LCK		ENSG00000182866	"LCK proto-oncogene, Src family tyrosine kinase"	P06239	1	32251239-32286165	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Host-virus interaction"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"blood: 112.2;lymphoid tissue: 153.0"	"Cell type enriched"	"Detected in many"	10	"T-cells: 207.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	14	"gdT-cell: 83.4;MAIT T-cell: 77.5;memory CD4 T-cell: 86.1;memory CD8 T-cell: 90.2;naive CD4 T-cell: 97.0;naive CD8 T-cell: 91.3;NK-cell: 42.8;T-reg: 112.2"	"Group enriched"	"Detected in many"	13	"NK-cells: 42.8;T-cells: 112.2"	"Group enriched"	"Detected in some"	6	"JURKAT: 66.9;MOLT-4: 93.9;U-698: 54.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA003494, CAB003816"	Enhanced		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"CAB003816: AB_562158, HPA003494: AB_1852751"	"unprognostic (6.38e-3)"	"unprognostic (5.45e-3)"	"unprognostic (8.39e-2)"	"prognostic favorable (2.96e-6)"	"unprognostic (2.20e-2)"	"prognostic favorable (2.91e-4)"	"unprognostic (4.78e-3)"	"unprognostic (1.33e-2)"	"prognostic favorable (5.65e-5)"	"unprognostic (3.07e-2)"	"unprognostic (3.80e-2)"	"unprognostic (2.83e-1)"	"prognostic unfavorable (2.60e-5)"	"unprognostic (8.15e-2)"	"unprognostic (4.05e-2)"	"unprognostic (7.39e-2)"	"unprognostic (1.17e-2)"	2.6	0.7	0.4	28.2	0.5	3.8	1.3	0.3	0.5	1.7	3.9	0.5	0.9	2.2	1.1	4.5	2.3	1.6	3.8	1.0	0.4	0.4	3.0	2.3	6.6	34.9	0.9	0.5	1.2	0.8	0.0	0.8	0.7	0.6	2.2	1.9	1.3	8.4	1.3	0.9	1.0	16.5	0.7	1.0	28.9	3.5	0.7	0.5	153.0	2.9	1.5	27.1	5.8	2.1	6.1	0.5	2.5	0.3	42.8	112.2	109.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	11.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.9	0.0	0.0	0.0	0.0	93.9	0.0	1.0	0.8	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	54.1	0.0	0.0	0.0	0.6	0.3	0.4	83.4	0.3	77.5	4.0	86.1	90.2	0.3	6.1	97.0	91.3	2.5	42.8	0.3	0.5	112.2	109.3	0.4	0.5	0.3	0.5	0.4	0.4	0.9	0.5	0.6	0.5	0.0	16.0	20.4	0.9	4.0	0.0	1.1	2.5	2.7	2.3	3.5	0.0	0.2	0.0	0.3	0.1	1.6	0.0	0.0	0.4	0.1	2.0	0.8	4.7	1.0	0.3	0.0	2.4	3.7	4.9	0.0	0.0	0.6	3.3	0.0	0.0	0.0	2.7	0.0	0.4	1.1	0.0	0.0	0.9	3.7	1.9	2.8	0.3	207.5	0.4	1.0
LDHA		ENSG00000134333	"Lactate dehydrogenase A"	P00338	11	18394388-18408425	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glycogen storage disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 249.1"	"Cell type enhanced"	"Detected in many"	4	"Basal keratinocytes: 1952.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"CAB015336, CAB069404"	Uncertain		Supported	Vesicles,Cytosol		NA	NA		300000000	Cytosol	Vesicles	"CAB015336: AB_2134947, CAB069404: "	"unprognostic (8.83e-2)"	"prognostic unfavorable (2.78e-5)"	"unprognostic (3.81e-2)"	"unprognostic (1.73e-1)"	"unprognostic (3.43e-3)"	"unprognostic (4.66e-3)"	"prognostic unfavorable (3.26e-8)"	"prognostic unfavorable (2.27e-6)"	"unprognostic (1.08e-1)"	"unprognostic (1.88e-2)"	"prognostic unfavorable (8.09e-6)"	"unprognostic (1.76e-2)"	"prognostic unfavorable (9.69e-9)"	"unprognostic (4.15e-2)"	"unprognostic (1.89e-1)"	"unprognostic (3.07e-1)"	"unprognostic (1.05e-2)"	84.2	56.4	24.5	52.6	32.5	64.0	56.0	22.3	40.2	38.1	53.5	13.5	9.1	60.5	24.9	36.2	77.7	29.0	31.6	59.4	24.4	33.0	100.1	249.1	37.1	59.4	29.7	25.7	49.7	34.1	10.5	16.4	49.7	44.3	33.3	51.2	45.9	46.3	37.0	199.6	70.2	128.3	50.7	35.5	45.0	31.2	25.9	23.9	45.0	56.4	90.6	60.1	81.9	44.8	27.6	76.5	29.1	61.2	32.8	52.2	72.1	131.7	82.0	3.1	46.2	72.2	49.3	44.0	127.5	135.5	112.0	166.7	36.6	21.7	99.7	41.9	128.8	80.8	106.6	82.0	195.4	242.9	34.0	48.5	34.5	74.9	62.8	17.8	85.1	25.9	49.2	90.1	44.0	44.1	189.0	66.1	31.6	48.6	48.0	131.1	34.9	70.0	53.9	19.8	43.8	102.6	45.4	32.7	83.5	178.0	30.6	24.6	30.4	69.1	57.0	23.6	50.2	26.8	20.3	59.5	140.3	50.9	122.1	1.5	38.2	55.9	95.9	200.8	44.1	47.2	28.9	53.1	29.1	38.1	61.2	42.6	27.6	50.2	40.1	76.5	19.2	32.8	33.3	18.1	32.8	59.5	25.8	52.2	72.1	24.5	32.5	22.3	40.2	24.4	33.0	29.7	25.7	44.3	23.9	68.5	191.6	171.4	331.5	1952.6	415.5	222.7	142.7	85.6	187.7	293.1	137.4	475.1	368.1	1059.9	147.3	475.2	671.1	0.0	1350.8	1780.5	725.6	281.3	256.4	438.3	607.6	486.3	43.8	182.3	215.4	106.3	266.3	427.9	1116.8	1462.6	176.8	316.6	1380.9	487.5	192.7	408.8	354.8	187.5	1239.9	102.9	38.5	1506.3	419.6	213.6	251.8	384.9
LDHB		ENSG00000111716	"Lactate dehydrogenase B"	P07195	12	21635342-21757857	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 255.8;kidney: 233.1"	"Cell type enhanced"	"Detected in all"	7	"Cardiomyocytes: 2212.6;Distal tubular cells: 2801.9;Proximal tubular cells: 2766.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Lineage enriched"	"Detected in all"	4	"T-cells: 145.1"	"Cell line enhanced"	"Detected in many"		"RPTEC TERT1: 316.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004641, HPA019007"	Enhanced		Supported	Cytosol		No	No		780000000	Cytosol		"CAB004641: AB_425525, HPA019007: AB_2670008"	"unprognostic (2.93e-1)"	"unprognostic (9.20e-3)"	"unprognostic (6.10e-2)"	"unprognostic (1.11e-1)"	"unprognostic (5.39e-3)"	"unprognostic (1.36e-3)"	"unprognostic (1.61e-2)"	"unprognostic (1.72e-2)"	"unprognostic (5.34e-2)"	"unprognostic (8.40e-2)"	"unprognostic (2.91e-1)"	"unprognostic (6.41e-2)"	"prognostic favorable (2.51e-4)"	"unprognostic (1.31e-1)"	"unprognostic (1.71e-1)"	"unprognostic (2.55e-1)"	"unprognostic (9.32e-2)"	70.9	60.2	79.5	33.3	79.6	40.8	33.4	52.4	80.1	24.9	31.8	30.6	13.2	11.8	38.7	27.3	25.6	34.4	32.3	255.8	58.8	69.9	233.1	9.8	27.7	52.3	91.6	62.3	68.0	54.8	41.8	19.4	40.1	84.9	34.9	39.4	26.8	21.8	42.2	29.7	8.6	18.0	42.9	52.9	23.8	47.5	16.4	47.6	59.1	48.5	56.3	58.7	49.7	21.8	28.1	32.9	33.0	15.3	33.7	145.1	93.2	32.6	87.5	77.0	50.6	55.2	61.5	89.5	45.6	45.6	63.8	63.2	138.5	0.1	115.5	29.9	30.7	62.2	16.4	105.9	84.5	81.3	29.6	73.7	118.8	83.7	0.1	52.8	110.9	51.4	70.3	30.3	55.9	76.1	75.5	72.7	83.7	64.9	17.4	70.1	0.1	94.2	134.3	222.1	53.5	38.0	85.1	107.5	93.1	316.6	145.6	24.8	57.4	20.9	32.5	78.6	213.4	0.2	87.0	28.3	43.0	56.4	30.5	85.8	15.4	20.8	151.7	47.6	53.2	51.0	33.0	15.3	1.8	28.5	9.4	47.5	28.1	110.7	59.4	28.3	17.7	145.1	92.2	2.5	33.7	6.7	32.9	105.4	93.2	79.5	79.6	52.4	80.1	58.8	69.9	91.6	62.3	84.9	47.6	131.0	259.8	264.1	356.5	64.9	144.4	2212.6	252.3	329.2	235.4	450.1	64.8	1548.4	2801.9	8.8	8.2	201.1	10.6	163.5	278.5	675.2	313.9	183.2	261.1	6.8	514.5	133.5	88.8	124.0	155.9	19.6	254.3	185.3	170.4	154.1	114.8	173.5	149.2	14.4	390.3	2766.7	85.3	232.8	418.6	17.7	95.7	56.1	1371.1	274.1	316.8	307.0
LEPR	"CD295, OBR"	ENSG00000116678	"Leptin receptor"	P48357	1	65420652-65641559	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"		Receptor	"Cancer-related genes, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 82.8"	"Cell type enhanced"	"Detected in many"	18	"Endothelial cells: 59.1;Hepatocytes: 196.4"	"Cancer enriched"	"Detected in many"	7	"liver cancer: 13.1"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 6.9"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 15.7;K-562: 46.5;RPTEC TERT1: 22.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA030899	Approved	Supported			"Secreted to blood"	NA	NA	8240000	8300000			"HPA030899: AB_10610003"	"unprognostic (1.59e-2)"	"unprognostic (1.09e-3)"	"unprognostic (3.09e-1)"	"unprognostic (8.95e-2)"	"unprognostic (2.32e-1)"	"unprognostic (2.64e-1)"	"unprognostic (2.58e-1)"	"unprognostic (2.30e-1)"	"unprognostic (1.78e-1)"	"unprognostic (6.59e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.41e-1)"	"unprognostic (7.53e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.27e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.73e-1)"	15.9	5.5	3.8	3.7	4.3	3.3	23.5	2.5	3.9	15.0	9.2	5.6	5.4	3.2	20.6	7.3	10.9	11.7	10.1	9.2	4.3	4.9	14.6	82.8	20.3	9.0	4.9	3.3	18.4	16.7	3.9	13.1	12.8	8.2	10.8	4.1	18.1	12.0	5.7	5.6	10.2	7.3	12.9	7.0	6.4	11.9	6.6	3.1	1.9	13.1	11.2	6.9	13.6	8.6	0.6	1.8	6.9	1.9	1.1	2.3	1.8	1.3	0.8	1.1	1.2	5.0	4.7	3.9	5.9	3.4	2.0	1.9	0.6	3.2	0.5	4.4	7.5	0.5	1.1	0.9	5.2	5.5	7.0	1.5	7.7	3.6	0.1	3.0	0.5	0.6	13.2	3.0	1.2	4.7	15.7	5.9	0.6	46.5	0.9	9.5	0.3	0.6	0.1	1.8	0.8	0.1	0.1	0.9	0.3	22.5	0.6	0.7	11.4	1.4	0.6	1.6	6.7	2.1	2.1	2.2	2.1	4.4	0.4	3.2	1.3	0.9	0.2	4.5	2.2	2.0	6.9	1.9	2.8	1.3	1.5	1.3	0.6	1.1	1.1	1.8	0.3	0.9	1.5	1.1	1.1	1.7	1.2	2.3	1.8	3.8	4.3	2.5	3.9	4.3	4.9	4.9	3.3	8.2	3.1	0.0	16.5	3.0	1.9	31.4	4.9	3.5	10.2	2.7	4.5	8.7	0.0	1.2	3.3	1.5	1.0	59.1	0.4	0.0	0.9	2.3	20.2	3.3	1.1	196.4	1.9	1.6	0.0	27.6	6.5	1.5	31.9	5.8	33.7	2.8	0.9	0.0	1.6	1.7	7.1	6.8	0.9	0.0	17.7	1.1	0.6	25.7	2.2	0.5	0.8	1.4
LHCGR	"HHG, LCGR, LGR2, LHR, ULG5"	ENSG00000138039	"Luteinizing hormone/choriogonadotropin receptor"	P22888	2	48686775-48755730	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"brain: 10.3;testis: 18.8"	"Cell type enhanced"	"Detected in some"	13	"Basal keratinocytes: 1.1;Leydig cells: 1.1;Suprabasal keratinocytes: 1.3"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in some"		"basal ganglia: 6.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 2.8;HSkMC: 1.0;NTERA-2: 1.6;SuSa: 1.0"									CAB009814	Uncertain					NA	NA					"CAB009814: AB_2135467"	"unprognostic (8.57e-2)"				"unprognostic (1.08e-1)"			"unprognostic (1.54e-1)"		"unprognostic (1.41e-1)"			"unprognostic (3.14e-2)"	"unprognostic (2.97e-2)"	"unprognostic (2.24e-2)"	"unprognostic (5.22e-2)"		3.6	2.9	0.3	1.4	6.1	0.0	1.6	0.3	0.4	0.2	0.5	0.2	0.0	0.2	0.4	0.3	2.1	0.2	1.8	0.6	0.7	0.4	0.9	0.1	0.4	0.1	2.6	0.0	5.0	0.1	0.0	2.7	0.1	1.4	0.4	0.2	0.3	1.0	0.1	0.2	0.6	0.3	1.0	10.3	0.1	0.6	18.8	0.0	0.4	2.2	0.1	0.1	0.4	0.8	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.3	0.0	0.0	1.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.3	6.1	0.3	0.4	0.7	0.4	2.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0
LIPF	"HGL, HLAL"	ENSG00000182333	"Lipase F, gastric type"	P07098	10	88664441-88678814	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	24	"stomach 1: 762.9"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in some"	75	"stomach cancer: 278.5"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.9"	"Cell type enriched"	"Detected in single"	16	"eosinophil: 1.5"	"Lineage enriched"	"Detected in single"	16	"granulocytes: 1.5"	"Cell line enhanced"	"Detected in some"		"HMC-1: 6.4;MOLT-4: 5.0;NTERA-2: 5.3;REH: 3.1;THP-1: 10.0;U-2 OS: 3.6;U-266/70: 4.9"	"Region enriched"	"Detected in single"	51	"olfactory region: 9.9"					HPA045930	Enhanced				"Secreted to digestive system"	NA	NA					"HPA045930: AB_10959518"										"unprognostic (1.53e-1)"				"unprognostic (1.83e-1)"				0.1	0.0	0.1	0.1	0.5	0.0	0.1	0.1	1.9	0.1	0.2	28.2	0.1	8.2	0.1	0.1	31.6	0.1	0.6	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.0	0.1	9.9	0.1	0.1	0.0	0.1	0.1	0.1	0.1	762.9	0.1	0.1	0.2	0.1	1.1	0.1	0.1	0.1	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.1	5.3	0.0	0.0	3.1	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.0	0.0	0.0	3.6	0.0	0.0	4.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.1	1.9	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0
LPL	LIPD	ENSG00000175445	"Lipoprotein lipase"	P06858	8	19901717-19967258	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	"Heparin-binding, Hydrolase"	"Disease mutation, FDA approved drug targets, Hyperlipidemia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 178.6;breast: 146.2;heart muscle: 121.4"	"Cell type enhanced"	"Detected in many"	20	"Cardiomyocytes: 482.3;Hofbauer cells: 114.1;Horizontal cells: 195.5;Sertoli cells: 232.8"	"Cancer enhanced"	"Detected in all"		"glioma: 39.2"	"Region enhanced"	"Detected in many"		"basal ganglia: 16.3"	"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 7.1"	"Lineage enriched"	"Detected in many"	5	"monocytes: 7.1"	"Cell line enriched"	"Detected in some"	5	"AF22: 91.4"	"Region enhanced"	"Detected in many"		"basal ganglia: 40.6"	"Region enriched"	"Detected in many"	4	"basal ganglia: 64.0"	HPA048749			Supported	Vesicles	"Secreted to blood"	NA	NA		880000	Vesicles		"HPA048749: AB_2680511"	"unprognostic (5.52e-2)"	"unprognostic (3.16e-1)"	"unprognostic (6.41e-2)"	"unprognostic (3.03e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.01e-2)"	"unprognostic (1.88e-4)"	"unprognostic (1.05e-1)"	"unprognostic (6.78e-2)"	"unprognostic (8.20e-2)"	"unprognostic (2.54e-2)"	"unprognostic (5.28e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.20e-3)"	"unprognostic (4.16e-3)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (6.07e-4)"	178.6	4.3	2.0	11.4	16.3	0.6	146.2	3.9	8.0	1.0	16.9	0.3	27.3	0.8	1.3	1.1	1.1	0.7	8.2	121.4	2.8	2.3	4.8	0.6	20.7	7.0	4.5	0.7	2.7	1.8	32.6	0.9	7.1	1.7	0.9	1.8	8.4	9.2	85.1	53.8	1.8	3.1	1.3	2.8	0.8	1.8	0.7	3.4	0.0	2.7	9.7	1.0	3.2	6.1	0.0	0.7	1.3	7.1	0.0	0.1	0.4	0.0	0.0	91.4	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	18.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	2.2	0.0	0.0	0.0	0.0	14.5	0.0	0.0	1.8	0.0	0.0	0.0	0.0	3.5	0.0	0.4	0.0	0.0	1.8	0.0	0.7	0.0	0.0	0.0	0.0	0.0	7.4	0.0	1.6	1.3	0.0	2.8	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.4	2.0	16.3	3.9	2.3	2.8	2.3	4.5	0.7	1.7	3.4	11.9	93.6	0.0	0.1	1.3	1.0	482.3	0.0	5.3	1.2	0.0	2.0	0.3	13.3	0.0	0.6	5.4	0.0	0.0	0.0	0.6	3.1	0.3	5.8	0.0	114.1	195.5	0.0	4.3	13.4	1.0	1.1	23.8	13.5	2.8	0.0	1.7	0.0	0.0	0.0	0.0	2.2	232.8	19.1	0.3	0.2	0.5	0.3	0.0	0.0	0.1
M6PR	"CD-M6PR, CD-MPR"	ENSG00000003056	"Mannose-6-phosphate receptor, cation dependent"	P20645	12	8940363-8949955	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	4	"Hofbauer cells: 214.9;monocytes: 227.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HDLM-2: 127.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034464, HPA040445"	Approved					NA	NA		280000			"CAB034464: AB_2139108, HPA040445: AB_2676989"	"unprognostic (2.43e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.74e-2)"	"unprognostic (1.54e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.89e-2)"	"prognostic unfavorable (3.89e-4)"	"unprognostic (1.76e-1)"	"unprognostic (2.84e-1)"	"unprognostic (5.82e-3)"	"unprognostic (1.44e-2)"	"unprognostic (6.82e-2)"	"unprognostic (4.53e-3)"	"unprognostic (3.79e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.64e-1)"	"unprognostic (3.98e-1)"	37.9	40.5	24.7	40.7	27.6	34.8	32.3	21.8	39.6	25.6	28.3	26.3	27.9	20.8	37.4	26.2	30.0	29.2	28.0	36.5	23.3	22.8	37.2	50.6	42.8	46.8	27.4	23.0	30.1	40.0	31.3	24.8	34.0	24.2	27.8	35.2	26.1	37.0	29.4	32.3	27.7	36.9	31.7	26.5	56.1	31.6	33.9	25.2	43.1	46.9	24.4	44.8	34.3	27.2	17.6	47.4	75.4	74.6	22.1	30.4	57.5	14.7	23.0	15.4	17.3	27.2	13.1	46.4	19.4	22.6	26.7	29.4	24.5	36.0	25.8	7.1	20.4	58.1	22.3	21.8	19.4	30.9	127.9	12.0	45.0	19.3	18.3	32.3	48.9	85.5	19.7	23.0	28.6	36.3	26.5	14.5	18.9	12.7	17.1	23.1	14.4	17.5	16.3	53.7	26.7	9.8	16.9	33.9	14.2	20.6	37.4	3.5	15.8	21.4	20.4	25.6	57.2	5.1	31.3	14.6	22.1	26.4	26.6	28.5	21.6	37.7	29.4	25.6	29.8	16.2	75.4	40.3	42.9	26.9	64.5	29.7	17.6	30.4	28.0	47.4	14.5	22.5	25.4	5.9	22.1	74.6	28.2	23.9	57.5	24.7	27.6	21.8	39.6	23.3	22.8	27.4	23.0	24.2	25.2	53.6	53.6	73.6	61.1	39.2	43.5	8.7	17.8	60.2	69.4	29.6	21.6	56.3	16.6	78.0	6.0	32.2	18.8	23.3	58.0	58.9	32.0	49.1	127.2	22.7	214.9	52.4	36.8	31.9	110.8	5.2	32.5	120.2	64.1	227.2	29.6	31.8	48.3	24.6	30.1	33.8	31.4	25.8	44.8	102.2	45.3	35.4	44.4	78.7	41.7	55.7
MAOA		ENSG00000189221	"Monoamine oxidase A"	P21397	X	43654907-43746824	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Catecholamine metabolism, Neurotransmitter degradation"	Oxidoreductase	"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Enterocytes: 358.2;Proximal tubular cells: 497.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.0;MAIT T-cell: 1.3"	"Group enriched"	"Detected in many"	10	"monocytes: 1.0;T-cells: 1.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 40.4;HHSteC: 75.9;HSkMC: 19.1;hTCEpi: 21.4;RT4: 31.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009437, HPA054807, HPA059299"	Enhanced		Enhanced	Mitochondria,Cytosol		No	No			Mitochondria	Cytosol	"CAB009437: AB_2137260, HPA054807: AB_2682607, HPA059299: AB_2683970"	"unprognostic (9.54e-3)"	"unprognostic (1.63e-1)"	"unprognostic (7.99e-2)"	"unprognostic (3.07e-1)"	"unprognostic (6.75e-2)"	"unprognostic (3.32e-1)"	"unprognostic (9.51e-2)"	"unprognostic (6.89e-3)"	"unprognostic (2.21e-1)"	"unprognostic (4.29e-2)"	"unprognostic (3.94e-1)"	"unprognostic (3.54e-1)"	"unprognostic (1.45e-3)"	"unprognostic (1.16e-2)"	"unprognostic (1.47e-1)"	"unprognostic (4.04e-2)"	"unprognostic (2.98e-3)"	72.3	11.0	8.2	10.2	7.8	0.3	35.2	3.3	6.1	12.4	85.7	2.8	10.7	53.6	12.5	6.2	36.6	12.0	14.7	37.8	6.7	8.3	77.8	45.9	34.4	5.2	11.1	6.1	14.2	24.4	9.6	1.5	79.8	8.7	26.2	39.9	6.2	49.1	12.9	12.5	11.2	90.1	23.6	3.4	2.1	19.3	5.5	4.7	0.0	68.6	9.7	3.9	35.3	35.1	0.0	0.0	0.1	1.0	0.0	1.3	0.1	0.0	0.8	0.1	2.4	40.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.1	4.1	1.5	5.4	0.0	0.0	0.6	1.6	0.1	4.3	75.9	0.0	4.1	19.1	21.4	0.0	11.2	0.0	4.8	0.0	0.0	0.1	1.4	0.6	0.0	0.1	0.4	4.9	1.2	0.0	0.0	0.1	5.5	31.3	0.7	1.9	0.0	0.0	0.0	0.1	0.1	0.0	2.1	0.0	2.0	0.1	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.3	0.0	0.1	0.3	0.0	0.0	0.1	0.6	0.1	0.0	0.0	0.0	0.0	0.1	8.2	7.8	3.3	6.1	6.7	8.3	11.1	6.1	8.7	4.7	65.5	115.2	10.9	141.7	9.7	4.4	90.1	91.7	34.8	50.0	57.6	21.6	9.7	102.8	29.5	19.6	35.3	358.2	0.0	12.0	17.7	14.2	55.4	5.7	169.3	6.2	3.2	36.6	36.8	14.9	22.5	5.2	4.0	10.1	29.7	119.4	23.2	31.4	140.8	0.0	497.3	21.7	6.5	15.1	1.1	0.4	12.5	173.1	3.1	215.1	89.9
MAOB		ENSG00000069535	"Monoamine oxidase B"	P27338	X	43766611-43882447	"Enzymes, FDA approved drug targets, Predicted membrane proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 104.9"	"Cell type enhanced"	"Detected in many"	10	"Cardiomyocytes: 111.3;granulocytes: 138.1;Hepatocytes: 197.3;Peritubular cells: 89.5;Proximal tubular cells: 130.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	5	"naive CD8 T-cell: 1.0"	"Lineage enriched"	"Detected in single"	6	"T-cells: 1.0"	"Group enriched"	"Detected in some"	7	"Hep G2: 20.6;SiHa: 39.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002328, CAB037200"	Enhanced					NA	NA		3600000			"CAB037200: AB_1841012, HPA002328: AB_1854062"	"unprognostic (1.19e-2)"	"unprognostic (1.36e-1)"	"unprognostic (5.16e-2)"	"unprognostic (1.85e-2)"	"unprognostic (4.39e-2)"	"unprognostic (2.69e-2)"	"unprognostic (5.61e-2)"	"unprognostic (4.37e-2)"	"unprognostic (1.56e-1)"	"unprognostic (1.04e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.54e-2)"	"unprognostic (9.74e-2)"	"unprognostic (5.35e-3)"	"unprognostic (1.48e-2)"	"unprognostic (3.53e-1)"	"unprognostic (1.90e-3)"	25.0	18.2	24.8	3.9	34.8	0.5	16.5	5.5	24.5	12.0	18.9	20.3	15.6	24.9	38.0	20.0	11.4	34.9	15.4	32.4	21.2	46.9	41.8	104.9	10.9	2.3	24.4	19.9	56.0	4.1	15.6	8.9	9.4	26.8	30.1	6.3	3.0	38.0	55.9	34.8	3.0	30.5	35.9	39.1	1.3	8.4	5.2	21.3	0.2	1.8	8.2	2.8	12.1	8.5	0.0	0.0	0.0	0.1	0.0	1.0	1.2	0.0	0.5	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	2.7	2.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	4.5	20.6	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.2	2.1	0.0	0.0	0.6	39.9	0.0	0.3	0.3	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	1.2	24.8	34.8	5.5	24.5	21.2	46.9	24.4	19.9	26.8	21.3	0.0	5.5	0.0	0.4	4.8	1.0	111.3	38.2	21.4	3.4	5.2	3.9	0.3	53.0	15.6	0.1	11.3	8.0	0.0	2.5	0.7	11.2	0.6	138.1	197.3	1.4	14.3	0.0	4.9	4.7	0.4	42.6	1.3	6.8	0.0	2.9	25.5	4.7	8.0	89.5	130.3	0.7	12.9	15.6	0.0	0.1	3.4	0.3	4.3	3.9	0.3
MAP1A	MAP1L	ENSG00000166963	"Microtubule associated protein 1A"	P78559	15	43510958-43531620	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"brain: 103.6"	"Cell type enhanced"	"Detected in many"	17	"Ciliated cells: 71.0;Horizontal cells: 282.9;Peritubular cells: 71.8"	"Cancer enhanced"	"Detected in many"		"glioma: 18.1"	"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	74	"plasmacytoid DC: 12.3"	"Lineage enriched"	"Detected in single"	74	"dendritic cells: 12.3"	"Cell line enhanced"	"Detected in many"		"ASC diff: 21.8;BJ hTERT+: 21.4;fHDF/TERT166: 32.0;hTEC/SVTERT24-B: 20.4;U-87 MG: 43.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA039063, HPA039064, HPA066488"	Enhanced		Approved	Cytosol		No	No			Cytosol		"HPA039063: AB_2676327, HPA039064: AB_10673302, HPA066488: AB_2685676"	"unprognostic (1.60e-1)"	"unprognostic (1.31e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.86e-3)"	"unprognostic (4.45e-2)"	"unprognostic (3.58e-2)"	"unprognostic (5.66e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.13e-3)"	"unprognostic (8.36e-3)"	"unprognostic (3.45e-3)"	"prognostic unfavorable (6.59e-5)"	"unprognostic (5.83e-2)"	"unprognostic (2.53e-1)"	"prognostic unfavorable (1.09e-5)"	"prognostic unfavorable (1.66e-5)"	5.2	7.9	43.6	5.4	42.8	2.5	4.3	24.5	103.6	10.5	5.4	18.3	1.0	3.0	5.6	4.3	4.8	9.1	5.9	14.8	40.9	30.2	2.8	1.9	3.4	2.7	34.7	31.3	7.1	2.7	4.1	4.4	4.4	56.2	6.7	5.3	3.1	2.5	9.6	4.5	3.1	3.2	14.5	21.4	2.6	2.7	5.4	12.6	6.5	3.7	0.1	2.7	6.3	2.8	0.0	12.3	0.0	0.0	0.0	0.1	0.2	0.1	0.8	3.9	2.2	21.8	15.0	0.0	12.5	21.4	3.7	3.6	1.5	0.0	0.0	5.4	32.0	1.1	0.1	5.2	0.0	2.1	1.8	0.5	4.8	1.2	0.1	2.1	0.1	2.0	11.2	0.0	20.4	0.1	5.6	2.7	14.2	7.9	0.1	14.8	0.1	8.7	0.2	2.8	0.0	0.3	2.4	11.3	0.0	0.0	0.0	12.2	3.7	0.4	0.0	0.1	5.4	0.8	0.2	0.5	11.9	4.0	3.9	0.1	0.0	0.5	1.7	43.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	12.3	0.1	0.2	43.6	42.8	24.5	63.1	40.9	30.2	34.7	31.3	56.2	12.6	3.0	0.6	0.0	1.1	4.8	35.3	48.5	0.0	71.0	12.5	3.5	23.6	0.3	0.0	0.4	10.6	4.3	0.0	0.0	0.0	0.6	30.1	0.7	6.9	0.0	1.9	282.9	10.9	4.9	0.8	5.2	47.2	1.4	8.5	0.0	0.0	15.3	1.2	0.0	71.8	0.3	20.6	32.3	49.5	9.2	27.3	3.6	0.9	0.7	0.0	0.5
MAP2	"MAP2A, MAP2B, MAP2C"	ENSG00000078018	"Microtubule associated protein 2"	P11137	2	209424058-209734118	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Calmodulin-binding	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"brain: 122.3"	"Group enriched"	"Detected in many"	5	"Cone photoreceptor cells: 824.7;Rod photoreceptor cells: 453.2"	"Cancer enhanced"	"Detected in many"		"glioma: 30.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	13	"memory B-cell: 2.6;naive B-cell: 3.4"	"Lineage enriched"	"Detected in single"	15	"B-cells: 3.4"	"Cell line enhanced"	"Detected in some"		"AF22: 76.3;NTERA-2: 27.3;SCLC-21H: 38.4;SH-SY5Y: 21.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB001984, HPA008273, HPA012558, HPA012828"	Enhanced	Supported	Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB001984: , HPA008273: AB_1853945, HPA012558: , HPA012828: AB_1853946"	"unprognostic (2.47e-2)"	"unprognostic (2.81e-1)"	"unprognostic (2.58e-2)"	"prognostic unfavorable (1.98e-6)"	"unprognostic (2.29e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.13e-2)"	"unprognostic (6.06e-2)"	"unprognostic (1.31e-1)"	"unprognostic (9.84e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.69e-3)"	"unprognostic (2.54e-1)"	"unprognostic (7.28e-2)"	"unprognostic (4.10e-5)"	4.6	9.2	62.1	2.1	63.1	1.5	4.9	24.7	122.3	4.4	2.5	3.8	0.0	2.0	2.9	4.0	5.6	2.8	6.3	6.2	73.6	53.8	3.9	3.7	9.3	2.4	31.0	48.8	6.4	8.2	12.5	14.7	1.9	35.4	6.5	2.5	7.6	4.9	4.7	2.2	12.1	2.0	3.2	19.9	2.4	2.6	5.4	11.4	0.0	12.2	0.4	2.9	2.8	1.5	3.4	0.1	0.0	0.0	0.0	0.2	0.3	0.6	0.1	76.3	0.0	1.0	0.5	0.0	0.4	0.5	0.1	0.5	0.0	4.0	0.0	0.4	0.9	3.6	1.0	5.9	0.4	0.2	0.0	0.3	0.2	2.4	0.0	9.7	0.0	0.0	0.8	2.4	0.0	1.5	4.4	2.0	0.0	0.0	0.8	0.0	0.2	0.0	0.0	27.3	0.1	0.1	0.0	0.1	0.0	1.0	0.0	38.4	21.5	1.6	0.2	0.9	9.4	2.1	0.0	0.0	0.0	0.4	0.0	1.0	0.5	0.0	0.0	4.0	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	2.6	0.1	0.0	0.0	3.4	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.3	62.1	63.1	24.7	79.6	73.6	53.8	31.0	48.8	35.4	11.4	89.3	2.7	0.0	3.1	5.3	111.0	3.6	30.6	1.4	4.5	5.2	824.7	0.3	3.3	19.1	16.8	7.1	0.0	0.0	9.4	0.0	1.9	10.4	1.1	0.0	0.5	31.8	31.2	16.0	3.0	7.5	26.4	0.8	18.6	0.0	0.0	125.4	13.7	0.0	14.5	0.4	453.2	32.3	17.6	3.3	19.9	5.6	0.2	0.0	0.0	0.6
MAP2K1	"MAPKK1, MEK1, PRKMK1"	ENSG00000169032	"Mitogen-activated protein kinase kinase 1"	Q02750	15	66386817-66492312	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003834, HPA026430"	Approved		Enhanced	"Plasma membrane,Cytosol"		NA	NA		62000	"Plasma membrane, Cytosol"		"CAB003834: AB_562310, HPA026430: AB_1853742"	"unprognostic (4.05e-2)"	"unprognostic (1.23e-2)"	"unprognostic (2.07e-1)"	"unprognostic (4.92e-2)"	"prognostic unfavorable (1.95e-4)"	"unprognostic (1.81e-3)"	"unprognostic (5.78e-2)"	"unprognostic (9.91e-3)"	"unprognostic (1.11e-1)"	"unprognostic (1.77e-1)"	"unprognostic (1.45e-1)"	"unprognostic (7.62e-3)"	"unprognostic (1.20e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.96e-1)"	"unprognostic (1.15e-1)"	"unprognostic (9.40e-3)"	28.6	16.9	33.9	19.1	54.1	29.0	23.6	32.5	48.4	12.5	12.1	8.4	10.2	10.0	11.8	16.5	22.0	10.6	14.4	19.1	49.2	26.4	15.3	53.1	16.4	23.3	17.6	31.2	13.5	11.7	23.4	12.0	15.4	17.2	14.4	12.9	9.1	13.2	12.4	39.5	12.3	10.9	16.9	17.4	14.5	10.8	7.8	12.6	12.6	12.3	9.7	27.9	13.6	18.7	4.6	16.2	5.5	8.2	8.4	7.9	2.7	33.6	15.9	31.9	13.3	19.3	14.5	18.5	24.4	20.9	26.5	23.7	23.8	27.7	30.9	30.3	20.1	20.2	30.0	29.8	35.7	31.3	24.9	17.8	9.9	16.6	12.9	15.6	13.0	14.8	11.2	22.1	19.2	28.5	28.3	20.7	15.8	17.5	39.6	38.7	13.0	10.5	17.1	16.3	31.2	13.9	11.9	19.7	27.5	25.7	14.5	19.7	11.0	19.8	15.5	20.5	26.9	14.0	11.2	28.5	34.6	21.2	24.4	36.2	24.5	43.6	19.7	36.5	23.1	16.1	3.2	8.2	5.5	7.4	8.2	6.7	3.0	6.6	6.9	8.3	4.6	7.9	4.9	3.9	8.4	7.3	16.2	4.9	2.7	33.9	54.1	32.5	46.9	49.2	26.4	17.6	31.2	17.2	12.6	26.8	21.9	30.2	40.5	73.6	8.5	16.9	38.2	6.7	13.6	24.4	13.7	40.9	39.7	65.3	10.2	19.0	20.0	46.7	20.4	39.4	31.3	59.4	9.2	116.5	44.9	9.5	20.8	17.2	91.3	18.3	20.8	67.7	50.6	88.4	17.0	33.9	70.1	21.0	20.5	28.5	5.6	6.5	53.6	16.3	44.5	58.8	43.3	40.5	16.8	65.5
MAP2K2	"MEK2, PRKMK2"	ENSG00000126934	"Mitogen-activated protein kinase kinase 2"	P36507	19	4090321-4124129	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Cardiomyopathy, Disease mutation, Ectodermal dysplasia, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Late spermatids: 596.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"CAB003835, HPA051993"	Supported		Supported	Cytosol		NA	NA			Cytosol		"CAB003835: AB_562312, HPA051993: AB_2681685"	"unprognostic (4.39e-1)"	"prognostic favorable (3.72e-4)"	"unprognostic (4.24e-1)"	"unprognostic (1.26e-3)"	"unprognostic (2.58e-1)"	"prognostic favorable (7.98e-4)"	"unprognostic (2.08e-3)"	"unprognostic (2.11e-1)"	"unprognostic (2.65e-1)"	"unprognostic (1.06e-1)"	"unprognostic (7.45e-3)"	"unprognostic (4.95e-2)"	"unprognostic (1.32e-1)"	"prognostic favorable (5.43e-5)"	"unprognostic (2.91e-2)"	"unprognostic (2.25e-1)"	"unprognostic (4.90e-2)"	23.9	33.0	35.6	27.6	36.1	46.7	30.2	31.2	43.4	22.6	38.8	24.6	27.0	70.9	21.8	23.2	32.8	21.7	27.9	41.4	33.1	31.0	22.7	42.0	24.1	44.5	34.4	29.2	30.8	46.0	18.9	29.7	21.3	26.1	25.7	24.3	21.7	41.5	24.0	134.9	27.4	56.7	19.0	25.2	25.9	28.3	42.0	20.9	44.1	26.2	42.2	29.1	20.0	26.9	11.4	10.7	28.3	10.6	11.3	12.1	4.5	36.8	40.7	22.3	31.3	30.9	37.3	22.3	24.3	32.6	33.3	30.2	35.2	20.0	31.6	23.0	27.7	26.8	26.6	17.4	26.0	25.8	26.8	21.2	11.5	22.2	38.9	47.3	21.1	24.3	41.1	25.3	23.4	31.2	44.6	29.4	28.8	22.0	62.4	28.0	46.3	41.8	29.7	25.5	27.2	29.6	32.0	14.7	36.1	29.1	23.7	30.3	30.2	22.3	30.9	75.8	26.9	23.8	36.4	25.9	27.3	23.8	69.8	37.4	62.8	38.0	22.1	42.4	38.2	46.8	15.2	9.1	28.3	11.9	10.6	9.7	8.9	9.7	12.1	10.7	11.4	8.9	11.6	14.4	11.3	8.7	6.0	9.2	4.5	35.6	36.1	31.2	43.4	33.1	31.0	34.4	29.2	26.1	20.9	8.9	38.8	57.0	73.8	31.5	79.0	54.9	17.8	10.7	19.4	38.4	39.3	23.7	124.3	17.7	223.1	33.7	242.0	0.0	38.5	28.5	33.0	88.2	19.6	43.1	46.2	114.4	60.6	34.4	35.6	596.7	33.1	29.7	40.5	12.6	77.6	82.3	41.7	90.9	21.5	75.0	82.4	25.8	32.5	25.9	14.5	55.8	29.7	45.4	69.4	97.8
MAP4		ENSG00000047849	"Microtubule associated protein 4"	P27816	3	47850690-48089272	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 131.5;skeletal muscle: 197.9"	"Group enriched"	"Detected in many"	6	"Bipolar cells: 398.9;Cardiomyocytes: 855.4;Cone photoreceptor cells: 589.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA038149, HPA038150"	Enhanced		Enhanced	"Plasma membrane,Microtubules,Cytosol"		NA	NA		120000	"Plasma membrane, Microtubules, Cytosol"		"HPA038149: AB_10672471, HPA038150: AB_10672505"	"unprognostic (2.51e-1)"	"unprognostic (4.48e-1)"	"unprognostic (2.72e-1)"	"unprognostic (1.95e-2)"	"unprognostic (3.36e-1)"	"unprognostic (4.57e-1)"	"prognostic unfavorable (1.82e-4)"	"unprognostic (6.82e-2)"	"unprognostic (1.46e-2)"	"unprognostic (5.02e-2)"	"unprognostic (2.23e-2)"	"unprognostic (1.30e-2)"	"unprognostic (2.25e-2)"	"unprognostic (8.89e-2)"	"unprognostic (6.45e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.21e-3)"	39.3	14.8	60.5	18.2	50.9	6.3	16.4	29.3	56.0	26.9	26.4	80.8	15.8	13.6	25.8	27.4	27.0	24.6	20.1	110.2	63.7	57.5	20.8	13.8	22.7	12.4	86.8	26.1	26.8	18.9	14.6	9.3	24.0	59.5	21.8	18.8	25.2	14.0	34.9	197.9	25.1	15.2	35.0	131.5	18.3	16.2	21.2	41.8	7.3	15.4	31.3	14.2	24.3	18.1	9.9	8.9	6.3	19.7	10.7	13.4	6.7	22.2	17.9	22.4	17.0	33.1	59.1	9.5	41.8	45.7	35.4	39.8	15.0	14.0	18.9	9.8	63.0	33.3	14.9	28.6	37.9	39.8	27.2	12.1	12.7	20.0	19.4	45.0	8.8	10.4	49.4	47.4	43.0	52.7	32.3	46.4	13.3	16.4	22.0	27.8	12.6	12.5	10.8	13.5	11.0	37.0	6.7	21.1	23.4	22.7	18.7	8.9	13.9	32.1	13.0	22.1	32.8	9.5	8.2	62.6	33.5	25.9	35.0	26.7	15.4	11.9	8.9	43.1	10.9	31.6	6.3	5.3	2.8	13.4	9.0	6.5	9.9	9.0	10.9	5.7	9.4	4.3	6.7	2.2	10.7	19.7	8.9	10.2	6.7	60.5	50.9	29.3	51.8	63.7	57.5	86.8	26.1	59.5	41.8	65.5	44.5	28.6	38.3	66.4	398.9	855.4	48.4	45.5	70.5	76.8	589.0	27.7	23.2	85.7	90.1	78.7	34.2	0.0	56.1	64.5	84.5	58.1	26.6	49.9	34.2	44.5	27.6	41.1	23.5	28.8	71.4	40.8	74.2	101.8	29.5	77.6	76.7	23.0	96.9	27.0	86.7	71.1	108.8	53.1	49.0	60.9	18.8	48.4	33.0	40.0
MAPK1	"ERK, ERK2, MAPK2, p41mapk, PRKM1, PRKM2"	ENSG00000100030	"Mitogen-activated protein kinase 1"	P28482	22	21754500-21867680	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Cell cycle, Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Kinase, Repressor, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 80.3"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"K-562: 81.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003995, CAB004229, HPA005700, HPA030069"	Approved					NA	NA		250000			"CAB004229: AB_627547, HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035"	"unprognostic (9.41e-3)"	"unprognostic (2.68e-1)"	"unprognostic (2.50e-3)"	"unprognostic (4.17e-1)"	"unprognostic (4.44e-3)"	"unprognostic (1.72e-1)"	"prognostic unfavorable (4.95e-4)"	"unprognostic (2.29e-1)"	"unprognostic (1.67e-1)"	"unprognostic (1.58e-1)"	"unprognostic (8.43e-3)"	"unprognostic (1.04e-1)"	"unprognostic (1.35e-2)"	"unprognostic (2.08e-1)"	"unprognostic (1.94e-1)"	"unprognostic (1.41e-1)"	"unprognostic (6.49e-2)"	16.1	21.1	32.9	18.3	80.3	20.2	13.6	31.0	54.5	18.6	18.5	23.2	9.6	13.7	17.4	10.6	25.7	16.9	14.9	22.8	32.4	23.4	21.7	16.4	19.9	16.6	18.4	23.6	16.0	19.8	27.4	10.9	17.2	27.6	16.4	19.9	14.2	15.8	17.8	28.2	17.5	15.1	22.8	20.4	19.8	17.2	24.2	21.5	19.5	23.0	11.1	21.4	17.7	15.3	2.5	3.2	13.5	4.9	7.0	13.7	2.5	19.7	12.5	16.1	9.2	19.1	19.2	6.1	21.8	20.4	19.6	19.0	9.9	10.5	10.9	10.9	29.2	18.0	18.8	18.9	17.4	25.6	44.0	17.7	19.8	11.7	11.6	15.7	27.8	20.6	14.3	14.0	23.7	21.9	15.4	26.7	11.9	81.1	12.5	23.9	8.1	18.0	6.1	6.1	26.8	12.3	19.8	39.7	2.9	11.2	16.2	13.1	7.3	23.6	14.2	12.7	16.7	10.7	9.4	23.3	16.4	21.4	18.8	13.8	12.0	14.6	17.0	15.5	13.6	17.7	1.0	4.0	5.8	13.7	4.6	3.9	2.0	2.9	4.9	3.2	2.5	2.8	5.1	13.5	7.0	4.9	3.2	2.7	2.5	32.9	80.3	31.0	54.5	32.4	23.4	18.4	23.6	27.6	21.5	44.7	30.2	28.0	22.1	53.3	23.8	34.6	63.7	21.4	33.0	48.8	51.1	18.0	16.6	24.0	33.2	31.2	46.6	23.3	33.6	18.2	31.5	37.5	93.2	59.4	47.7	27.0	57.3	57.7	88.6	9.9	30.2	59.7	38.8	15.4	44.2	32.3	39.5	28.8	41.8	37.6	21.0	32.3	32.2	70.0	47.7	54.1	16.0	95.8	30.7	34.8
MAPK11	"p38-2, p38Beta, PRKM11, SAPK2"	ENSG00000185386	"Mitogen-activated protein kinase 11"	Q15759	22	50263713-50270767	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Stress response, Transcription, Transcription regulation"	"Kinase, Serine/threonine-protein kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Endothelial cells: 13.2;Ito cells: 14.7;Rod photoreceptor cells: 10.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"memory B-cell: 1.1"	"Low lineage specificity"	"Detected in single"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB012961, HPA045069"	Approved		Approved	Mitochondria		NA	NA			Mitochondria		"CAB012961: AB_2533144, HPA045069: AB_2679207"	"unprognostic (1.11e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.49e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.18e-2)"	"unprognostic (1.64e-3)"	"unprognostic (1.02e-1)"	"unprognostic (5.84e-2)"	"unprognostic (5.89e-2)"	"unprognostic (2.46e-1)"	"unprognostic (4.96e-3)"	"unprognostic (2.18e-1)"	"prognostic unfavorable (6.02e-6)"	"unprognostic (9.84e-2)"	"unprognostic (4.25e-2)"	"unprognostic (9.16e-2)"	"unprognostic (2.10e-2)"	20.4	5.7	14.2	7.5	17.3	0.8	8.2	22.0	23.7	6.6	2.7	2.8	1.0	1.9	8.2	6.2	5.3	7.0	8.8	8.8	11.7	9.1	5.0	1.5	8.5	8.5	7.2	19.9	5.3	3.1	6.4	10.9	8.4	6.6	7.2	2.7	4.1	5.7	8.0	5.0	6.4	2.6	9.8	5.5	7.3	4.6	3.1	4.1	0.9	4.5	5.3	6.1	6.0	4.4	1.1	0.0	0.0	0.3	0.0	0.9	0.0	1.7	4.2	4.7	17.6	6.2	9.4	0.1	6.6	4.7	4.4	1.7	1.7	3.2	0.0	5.9	6.1	7.3	4.3	3.1	2.6	0.3	9.1	2.1	6.2	5.6	0.4	7.1	1.5	9.7	13.0	7.8	1.2	0.5	4.9	9.6	6.7	5.0	17.0	4.3	7.5	0.3	5.7	0.4	5.2	4.9	17.0	0.1	6.0	6.6	0.0	4.4	11.8	5.6	2.3	4.6	0.6	7.7	4.9	15.0	13.2	11.0	0.9	2.4	0.7	2.0	7.2	6.7	1.8	11.0	0.0	0.0	0.0	0.0	0.3	0.0	1.1	0.4	0.2	0.0	0.5	0.0	0.6	0.0	0.0	0.0	0.0	0.9	0.0	14.2	17.3	22.0	23.7	11.7	9.1	7.2	19.9	6.6	4.1	0.0	1.4	1.3	1.1	1.6	2.6	2.8	0.0	0.0	0.0	0.0	5.9	0.0	1.7	0.8	3.7	13.2	0.0	0.0	0.2	0.3	1.7	3.3	0.0	1.0	0.2	0.0	0.0	14.7	2.6	5.7	2.8	0.0	5.0	0.0	0.0	5.6	0.7	0.0	2.1	1.4	10.9	0.0	1.0	1.2	2.1	1.1	0.0	1.0	0.0	0.9
MAPK3	"ERK1, p44erk1, p44mapk, PRKM3"	ENSG00000102882	"Mitogen-activated protein kinase 3"	P27361	16	30114105-30123506	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Apoptosis, Cell cycle, Host-virus interaction"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 255.2;Enterocytes: 275.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"eosinophil: 25.1;neutrophil: 11.3"	"Lineage enriched"	"Detected in many"	8	"granulocytes: 25.1"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002683, HPA003995, HPA005700, HPA030069"	Approved		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB002683: , HPA003995: AB_1078751, HPA005700: AB_1078750, HPA030069: AB_10602035"	"unprognostic (5.03e-2)"	"unprognostic (4.62e-2)"	"unprognostic (3.46e-2)"	"unprognostic (1.60e-1)"	"unprognostic (4.70e-3)"	"unprognostic (2.75e-1)"	"prognostic unfavorable (1.11e-4)"	"unprognostic (2.09e-2)"	"unprognostic (3.59e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.51e-2)"	"unprognostic (8.78e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.01e-2)"	"unprognostic (2.38e-1)"	"unprognostic (1.19e-2)"	24.9	18.5	63.3	15.3	43.2	15.6	21.1	24.8	52.0	21.3	45.1	30.4	6.3	39.7	24.2	11.4	44.1	28.7	25.6	21.2	37.1	34.0	13.4	8.8	23.3	13.1	33.8	27.4	32.7	13.0	26.1	15.2	27.6	27.6	20.1	36.7	26.2	17.1	18.3	13.9	18.7	49.2	24.0	27.8	15.9	33.7	11.6	19.5	8.4	20.5	18.7	26.0	18.2	22.2	1.4	1.5	25.1	2.7	0.8	3.1	1.4	14.0	7.7	16.4	9.2	41.2	54.6	9.2	10.5	26.0	16.6	19.9	9.1	28.2	14.1	10.4	29.3	19.2	5.2	13.7	12.3	16.3	26.7	15.9	4.3	8.5	15.3	41.4	3.2	12.1	33.7	7.2	19.0	8.6	25.3	42.2	15.5	5.9	18.2	22.0	36.8	14.5	5.0	4.3	28.6	6.7	17.2	9.7	31.7	15.2	8.9	14.5	10.3	6.0	21.1	6.1	13.8	13.8	7.7	29.9	11.0	9.5	12.5	3.6	20.7	9.4	7.2	22.0	6.8	7.7	2.4	2.7	25.1	0.9	1.9	1.4	1.3	2.1	1.6	1.4	1.4	1.5	1.6	11.3	0.8	1.0	1.5	3.1	1.4	63.3	43.2	24.8	52.0	37.1	34.0	33.8	27.4	27.6	19.5	20.8	20.3	9.0	19.0	8.8	28.0	12.7	15.3	20.1	7.9	8.7	21.6	66.6	19.9	31.0	255.2	49.5	275.3	0.0	54.5	107.4	25.7	11.8	2.3	6.4	38.5	7.9	52.6	52.8	25.3	107.0	30.0	18.9	21.9	27.9	135.6	38.1	77.0	98.1	25.8	18.2	32.7	19.4	18.6	10.5	17.5	11.5	28.3	13.1	63.5	18.0
MAPT	"DDPAC, FLJ31424, FTDP-17, MAPTL, MGC138549, MSTD, MTBT1, MTBT2, PPND, PPP1R103, tau"	ENSG00000186868	"Microtubule associated protein tau"	P10636	17	45894382-46028334	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Alzheimer disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 89.9;skeletal muscle: 43.7"	"Cell type enhanced"	"Detected in many"	13	"Bipolar cells: 300.5;Early spermatids: 153.8;Horizontal cells: 341.7;Late spermatids: 194.8;Muller glia cells: 139.1"	"Group enriched"	"Detected in many"	11	"breast cancer: 9.5;glioma: 13.3;prostate cancer: 3.0;renal cancer: 4.7"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 1.7"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 27.9;SCLC-21H: 10.1;T-47d: 12.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000151, HPA048895, HPA069524, HPA069570, CAB072344"	Enhanced		Supported	"Nuclear speckles,Plasma membrane"		NA	NA			"Plasma membrane"	"Nuclear speckles"	"CAB000151: , CAB072344: , HPA048895: AB_2680550, HPA069524: AB_2686145, HPA069570: AB_2686155"	"unprognostic (1.78e-3)"	"unprognostic (7.51e-2)"	"unprognostic (3.71e-2)"	"unprognostic (8.40e-5)"	"unprognostic (1.40e-1)"	"unprognostic (1.31e-2)"	"unprognostic (4.06e-5)"	"unprognostic (6.04e-2)"	"unprognostic (2.19e-2)"	"unprognostic (3.49e-2)"	"unprognostic (3.88e-3)"	"unprognostic (2.65e-1)"	"unprognostic (1.72e-3)"	"unprognostic (6.53e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.85e-2)"	"unprognostic (5.47e-2)"	3.8	7.1	28.9	2.4	31.2	2.1	8.8	40.1	89.9	2.4	2.7	21.4	1.7	2.5	2.6	2.3	6.4	2.5	2.8	6.5	28.7	29.7	15.3	2.2	2.4	2.3	22.6	35.2	2.3	2.8	8.5	8.8	5.2	29.1	5.1	2.5	2.2	8.1	5.3	43.7	4.6	2.8	2.5	13.6	2.2	2.3	6.5	27.7	0.0	2.3	3.1	2.3	3.2	0.8	0.0	0.0	0.3	0.1	0.5	1.7	0.1	0.8	0.3	0.2	2.6	0.0	0.5	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.3	0.0	1.3	0.1	0.0	27.9	1.4	0.0	0.0	2.6	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.0	1.6	0.2	1.4	0.0	4.2	0.5	0.1	0.0	0.4	1.1	0.0	2.3	2.8	0.0	3.6	10.1	4.7	1.0	0.0	1.0	0.6	12.7	0.0	0.0	0.2	0.3	0.6	0.1	0.5	0.2	0.0	0.2	0.5	0.3	0.0	0.1	0.3	0.8	0.0	0.6	0.0	0.4	1.2	0.0	0.0	0.9	0.9	0.0	0.5	0.1	0.0	1.7	0.1	28.9	31.2	40.1	46.3	28.7	29.7	22.6	35.2	29.1	27.7	0.0	9.8	0.8	1.1	0.9	300.5	32.3	0.0	0.0	0.0	1.8	60.9	0.1	6.6	0.4	153.8	1.3	0.0	0.0	0.4	8.0	1.9	2.9	4.6	0.5	0.3	341.7	0.0	0.6	0.3	194.8	2.6	1.3	5.0	1.0	0.0	139.1	0.6	0.0	2.5	44.6	24.8	0.0	4.1	11.4	5.9	2.9	0.2	0.0	0.1	0.5
MC2R	ACTHR	ENSG00000185231	"Melanocortin 2 receptor"	Q01718	18	13882044-13915707	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	8	"adrenal gland: 31.7;pituitary gland: 14.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"basophil: 1.3"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 1.3"	"Cell line enhanced"	"Detected in some"		"HeLa: 1.7;MCF7: 3.6;SuSa: 1.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA079148	Enhanced					NA	NA					"HPA079148: "											"unprognostic (2.09e-1)"			"unprognostic (3.63e-2)"	"unprognostic (1.85e-2)"			0.0	31.7	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.0	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	14.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.2	0.1	0.0	0.0	0.3	0.0	0.1	0.1	1.3	0.3	0.1	0.1	0.0	0.2	0.0	0.1	0.3	0.1	0.3	1.1	0.2	0.0	0.1	0.3	0.1	0.2	0.0	0.0	0.4	0.1	0.3	0.1	0.9	0.1	0.0	0.5	0.0	1.7	0.2	0.0	0.2	0.0	0.0	0.9	0.0	0.6	0.2	0.0	0.2	0.1	0.4	0.0	3.6	0.0	0.0	0.6	0.0	0.1	0.2	0.5	0.0	0.3	0.1	0.1	0.0	0.0	0.0	0.1	1.8	0.1	0.3	0.0	0.2	0.3	0.5	0.0	0.2	0.2	0.0	0.1	0.4	0.0	1.3	0.1	0.0	0.1	0.3	0.1	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.5	0.1	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MDH2		ENSG00000146701	"Malate dehydrogenase 2"	P40926	7	76048051-76067508	"Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Tricarboxylic acid cycle"	Oxidoreductase	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 175.8"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019714, HPA019716, HPA019848, HPA026720"	Enhanced		Enhanced	Mitochondria		No	No		47000000	Mitochondria		"HPA019714: AB_1853678, HPA019716: AB_1853680, HPA019848: AB_1853683, HPA026720: AB_1853685"	"unprognostic (3.20e-2)"	"unprognostic (2.85e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.43e-2)"	"unprognostic (5.55e-3)"	"unprognostic (8.94e-2)"	"unprognostic (6.45e-2)"	"unprognostic (3.77e-2)"	"unprognostic (3.60e-1)"	"unprognostic (2.02e-2)"	"unprognostic (1.40e-1)"	"unprognostic (9.70e-2)"	"prognostic favorable (1.49e-5)"	"unprognostic (8.57e-2)"	"unprognostic (9.64e-2)"	"unprognostic (5.68e-2)"	"unprognostic (2.66e-1)"	18.1	39.1	17.4	15.4	20.6	18.3	22.2	15.3	34.4	14.9	27.0	13.5	16.9	32.5	16.6	13.5	31.8	19.4	17.6	103.1	17.1	18.8	29.1	101.9	13.8	26.6	17.4	21.9	17.3	35.5	16.8	16.9	17.5	20.5	17.9	24.3	15.0	26.8	21.5	175.8	24.6	26.7	21.9	12.8	21.1	22.3	17.6	9.5	22.4	20.1	76.2	23.8	19.9	17.8	37.1	52.8	22.1	45.3	30.1	45.6	44.7	29.0	47.7	17.3	43.2	19.7	21.7	29.7	19.5	25.2	28.0	25.4	41.9	35.0	44.0	8.8	25.7	30.3	29.7	44.3	29.2	20.0	31.3	64.1	24.4	25.6	38.6	24.3	38.0	25.3	27.4	26.1	27.2	40.6	22.0	26.0	27.4	76.9	25.7	25.9	65.8	32.9	67.0	38.5	51.5	60.2	26.9	21.3	63.2	26.2	38.4	43.3	39.4	19.6	98.1	40.3	23.0	55.7	42.9	20.1	28.1	26.6	30.5	38.8	28.9	23.8	48.7	24.4	48.7	42.7	22.1	38.9	18.2	32.7	43.5	34.2	37.1	36.9	35.3	52.8	32.1	36.0	33.1	10.2	30.1	45.3	47.1	45.6	44.7	17.4	20.6	15.3	34.4	17.1	18.8	17.4	21.9	20.5	9.5	47.6	54.0	113.9	144.7	120.7	61.8	448.3	122.3	80.3	48.9	109.9	17.7	283.1	379.7	210.0	208.8	86.2	316.5	0.0	291.5	257.6	93.5	138.9	53.1	240.8	220.1	68.3	162.9	73.1	117.9	127.9	92.0	117.1	172.1	171.3	226.5	63.6	223.7	228.0	93.3	301.0	48.8	84.1	129.5	71.9	69.5	145.2	246.6	109.1	306.4	194.4
MET	"DFNB97, HGFR, RCCP2"	ENSG00000105976	"MET proto-oncogene, receptor tyrosine kinase"	P08581	7	116672390-116798386	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"		"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 2: 78.1;Club cells: 116.0;Urothelial cells: 88.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"A-431: 45.3;CAPAN-2: 49.5"	"Group enriched"	"Detected in many"	5	"amygdala: 3.5;basal ganglia: 9.9;cerebral cortex: 7.6;hippocampal formation: 8.0;olfactory region: 9.1"	"Low region specificity"	"Detected in many"			"CAB005282, CAB018577, HPA055607"	Approved		Approved	"Plasma membrane,Cytosol"	"Secreted to blood"	NA	NA	179000000	70000000	"Plasma membrane, Cytosol"		"CAB005282: AB_631940, CAB018577: AB_649068, HPA055607: AB_2682860"	"unprognostic (1.60e-2)"	"unprognostic (7.71e-2)"	"unprognostic (2.53e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.57e-3)"	"prognostic unfavorable (6.75e-4)"	"unprognostic (1.68e-1)"	"unprognostic (3.22e-2)"	"unprognostic (3.81e-2)"	"unprognostic (2.52e-2)"	"prognostic unfavorable (1.21e-7)"	"unprognostic (1.86e-1)"	"unprognostic (1.25e-1)"	"unprognostic (5.53e-2)"	"unprognostic (8.88e-2)"	"unprognostic (2.01e-2)"	"unprognostic (2.20e-1)"	16.2	1.1	1.8	4.5	2.3	4.3	11.2	0.9	15.2	9.9	6.5	2.4	2.4	4.4	7.5	5.2	5.1	4.6	12.3	5.4	5.7	1.8	20.1	30.2	15.6	1.4	3.6	2.1	2.0	9.3	0.7	8.1	24.4	2.6	8.0	6.6	34.1	12.2	8.4	12.8	7.2	8.6	4.0	2.3	5.7	10.6	2.7	2.4	0.5	21.4	7.0	2.1	10.1	15.0	0.2	0.3	1.2	0.2	0.3	0.4	0.0	45.3	26.1	0.0	0.1	2.0	2.0	1.8	25.9	10.5	14.0	11.8	5.4	49.5	2.0	43.2	16.2	37.7	12.0	4.4	24.7	28.6	0.1	5.6	0.0	27.1	4.7	0.3	0.0	0.0	2.6	9.8	9.1	30.0	25.3	9.6	0.0	0.9	0.2	25.9	1.0	0.0	0.0	3.9	7.2	26.6	0.0	22.0	0.0	24.5	5.2	3.8	0.0	10.6	3.4	10.1	4.7	0.0	0.2	17.6	20.9	7.4	11.0	20.0	0.5	4.0	0.2	22.9	0.0	2.9	1.1	0.2	0.4	0.4	0.1	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.2	1.2	0.3	0.1	0.3	0.1	0.0	1.8	2.3	0.9	15.2	5.7	1.8	3.6	2.1	2.6	2.4	26.8	78.1	2.4	56.1	34.7	0.9	10.0	15.3	22.7	116.0	29.6	0.0	57.9	0.0	28.0	0.0	11.7	11.2	0.0	39.8	5.0	4.0	55.8	0.0	26.0	6.1	0.0	6.9	1.3	1.0	0.0	0.6	2.0	3.3	1.8	19.7	7.4	69.4	7.0	0.0	13.5	0.3	0.0	2.3	0.0	0.6	15.6	18.2	0.0	12.7	88.5
METAP2	"MAP2, MNPEP, p67"	ENSG00000111142	"Methionyl aminopeptidase 2"	P50579	12	95473520-95515839	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Aminopeptidase, Hydrolase, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013025, HPA019095"	Enhanced		Supported	"Plasma membrane,Cytosol"		NA	NA		22000	"Plasma membrane, Cytosol"		"CAB013025: AB_2533993, HPA019095: AB_1853823"	"unprognostic (1.91e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.44e-1)"	"unprognostic (3.27e-2)"	"unprognostic (2.57e-2)"	"prognostic unfavorable (4.51e-6)"	"unprognostic (1.25e-1)"	"unprognostic (2.28e-2)"	"unprognostic (1.40e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.49e-1)"	"unprognostic (2.51e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.95e-2)"	"unprognostic (1.03e-1)"	24.2	36.4	25.8	49.9	33.7	39.1	25.1	25.9	32.3	23.9	26.2	16.3	102.5	16.6	28.7	25.4	30.1	22.5	21.7	30.7	29.6	24.0	26.0	46.8	22.1	32.6	29.1	23.4	29.4	31.9	21.0	36.1	25.1	42.9	24.2	24.0	10.1	22.1	140.7	94.4	28.7	19.7	26.1	48.2	25.2	22.2	26.3	27.7	32.1	24.1	29.0	55.2	33.4	37.3	39.4	31.8	21.3	27.1	25.7	32.0	16.2	33.9	28.6	30.6	23.8	18.7	30.0	23.6	33.5	23.4	33.0	23.5	41.5	16.3	98.8	21.1	23.9	19.2	21.9	34.4	25.6	38.0	23.5	29.7	44.2	21.8	29.2	19.9	54.7	21.7	25.9	27.4	31.2	30.6	39.6	35.1	34.1	57.2	11.2	24.4	22.3	40.5	37.4	37.5	19.6	42.8	31.9	26.5	32.4	22.6	36.0	23.8	31.3	29.7	24.3	29.3	27.6	29.3	26.0	30.1	19.0	18.4	21.2	35.3	16.2	42.1	105.9	10.8	30.9	23.8	21.3	27.1	11.1	23.8	19.1	29.2	39.4	26.7	26.6	24.4	37.6	32.0	29.7	1.2	25.7	22.3	31.8	25.3	16.2	25.8	33.7	25.9	32.3	29.6	24.0	29.1	23.4	42.9	27.7	262.0	228.6	96.8	102.9	207.2	62.7	117.4	91.7	104.4	160.3	275.7	62.8	125.5	139.3	94.7	135.8	104.6	80.2	256.9	126.2	136.4	102.7	68.6	119.0	278.9	86.9	71.5	88.0	102.5	122.4	83.3	92.9	93.2	87.7	80.2	109.6	67.6	105.7	83.4	100.4	81.6	68.7	97.0	97.6	340.7	217.0	187.9	143.8	93.5	118.5	90.7
MGAM	MGA	ENSG00000257335	Maltase-glucoamylase	O43451	7	141907813-142106747	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"		"Glycosidase, Hydrolase, Multifunctional enzyme"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"intestine: 155.5"	"Cell type enhanced"	"Detected in some"	24	"Early spermatids: 50.7;Late spermatids: 90.5;Proximal tubular cells: 18.9"	"Cancer enriched"	"Detected in some"	7	"renal cancer: 4.9"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	8	"neutrophil: 14.1"	"Lineage enriched"	"Detected in single"	104	"granulocytes: 14.1"	"Cell line enhanced"	"Detected in some"		"A549: 3.7;BJ hTERT+: 3.3;HL-60: 5.5;U-937: 8.7;WM-115: 2.1"	"Region enriched"	"Detected in single"	12	"olfactory region: 3.1"					HPA002270	Enhanced					NA	NA		68000			"HPA002270: AB_1079366"	"unprognostic (1.02e-2)"	"unprognostic (1.45e-1)"	"unprognostic (1.13e-1)"	"unprognostic (6.95e-3)"	"unprognostic (2.80e-1)"	"unprognostic (7.81e-2)"	"unprognostic (7.32e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.97e-1)"	"unprognostic (2.17e-2)"	"unprognostic (6.86e-2)"	"unprognostic (1.99e-1)"	"prognostic favorable (6.16e-5)"	"unprognostic (1.82e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.34e-3)"	"unprognostic (3.03e-1)"	0.9	0.2	0.3	0.8	0.2	6.9	0.3	0.2	0.2	0.2	59.4	0.1	7.6	25.2	0.2	36.0	0.2	1.0	0.1	0.3	0.2	0.2	8.7	0.4	2.1	0.1	0.3	0.1	0.2	0.2	0.0	0.2	0.1	0.1	0.6	0.0	0.1	0.2	3.2	0.2	0.1	155.5	0.1	0.3	8.3	0.7	4.3	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.0	0.0	14.1	0.1	0.0	0.0	0.0	0.0	3.7	0.2	0.1	0.0	0.0	0.5	0.1	3.3	0.3	0.2	0.1	0.0	0.0	0.1	0.0	0.3	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	5.5	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.5	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.3	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.3	1.0	0.4	0.1	0.3	0.0	0.1	0.0	8.7	2.1	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.1	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.2	0.2	0.2	0.2	0.3	0.1	0.1	0.1	0.0	4.5	0.0	0.0	0.0	0.0	1.1	0.0	2.7	2.3	12.2	0.0	0.0	1.7	0.0	50.7	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.0	90.5	0.6	1.8	0.0	0.0	0.4	0.5	0.2	0.0	0.4	18.9	0.0	0.0	0.0	1.6	1.2	0.0	0.0	0.0	0.2	0.2
MME	"CALLA, CD10, NEP"	ENSG00000196549	"Membrane metalloendopeptidase"	P08473	3	155024124-155183729	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy, Spinocerebellar ataxia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 61.1;intestine: 136.0;kidney: 64.9"	"Cell type enhanced"	"Detected in many"	8	"Basal glandular cells: 62.4;Cytotrophoblasts: 71.6;Proximal tubular cells: 101.6;Syncytiotrophoblasts: 105.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	129	"neutrophil: 61.1"	"Lineage enriched"	"Detected in single"	129	"granulocytes: 61.1"	"Cell line enhanced"	"Detected in many"		"ASC TERT1: 97.1;BJ hTERT+: 146.1;HSkMC: 94.2"	"Low region specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"basal ganglia: 26.8"	"CAB000013, HPA052583, HPA056072"	Enhanced					NA	NA		99000			"CAB000013: AB_563478, HPA052583: AB_2681872, HPA056072: AB_2683027"	"unprognostic (1.36e-1)"	"unprognostic (1.02e-3)"	"unprognostic (8.52e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.78e-2)"	"unprognostic (6.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.67e-2)"	"unprognostic (8.67e-2)"	"unprognostic (1.96e-1)"	"unprognostic (7.30e-3)"	"unprognostic (1.31e-1)"	"unprognostic (2.71e-3)"	"unprognostic (1.50e-1)"	"unprognostic (7.29e-2)"	"unprognostic (1.06e-2)"	"unprognostic (1.37e-2)"	26.5	0.4	0.4	3.4	7.4	1.9	14.7	0.4	0.7	4.8	65.6	0.1	18.4	74.0	2.8	8.1	0.7	0.9	8.5	1.8	0.3	0.4	64.9	11.5	13.7	3.0	2.1	0.2	0.9	0.6	0.0	0.6	35.0	8.6	18.3	0.4	1.3	3.7	11.3	11.7	1.4	136.0	0.6	0.9	2.7	0.7	1.0	1.2	13.2	1.0	5.3	2.3	3.4	4.9	0.1	0.4	61.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	39.4	97.1	0.2	21.7	146.1	11.1	28.7	0.0	0.0	23.9	0.0	19.2	15.1	0.0	0.7	0.8	26.7	0.0	0.1	0.0	0.0	0.0	31.6	0.0	0.0	94.2	0.1	5.9	42.5	12.3	8.4	0.0	0.0	0.0	17.7	0.1	0.0	0.1	0.9	0.0	0.1	39.7	18.7	0.1	0.6	0.2	0.0	0.2	0.0	0.0	4.2	8.9	0.0	0.0	23.8	47.7	0.1	16.3	3.7	0.0	0.0	31.5	5.7	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	61.1	0.0	0.0	0.4	0.0	0.0	0.4	7.4	0.4	0.7	0.3	0.4	2.1	0.2	8.6	1.2	8.9	18.3	0.9	62.4	0.7	0.0	1.1	17.8	2.7	19.4	21.0	0.0	71.6	8.3	0.1	0.3	0.6	0.0	0.0	0.0	48.9	19.2	29.2	2.3	48.9	8.1	0.0	0.0	3.1	1.8	0.2	3.7	2.7	0.0	0.0	0.2	0.0	0.3	0.0	1.1	101.6	0.0	0.0	3.1	0.2	0.4	0.3	105.4	0.0	0.0	29.2
MMP1	CLG	ENSG00000196611	"Matrix metallopeptidase 1"	P03956	11	102789920-102798160	"Cancer-related genes, Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation, Host-virus interaction"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 62.4;stomach 1: 27.2"	"Cell type enriched"	"Detected in some"	7	"Pancreatic endocrine cells: 1303.6"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 344.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ hTERT+: 90.2;HBF TERT88: 89.3;HUVEC TERT2: 234.8;WM-115: 115.7"									HPA004920			Approved	Vesicles	"Secreted to extracellular matrix"	NA	NA	7730000	430000	Vesicles		"HPA004920: AB_2667293"	"unprognostic (4.11e-3)"	"prognostic unfavorable (4.66e-4)"	"unprognostic (4.20e-3)"	"unprognostic (1.19e-3)"	"unprognostic (6.46e-2)"	"unprognostic (6.50e-2)"	"prognostic unfavorable (4.22e-6)"	"unprognostic (7.83e-3)"	"unprognostic (2.94e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.11e-3)"	"unprognostic (1.75e-1)"	"prognostic unfavorable (9.86e-10)"	"unprognostic (1.67e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.26e-2)"	"unprognostic (5.11e-2)"	0.2	0.1	0.3	12.3	0.3	0.0	0.9	0.3	0.3	0.3	2.7	0.3	0.2	3.2	4.8	0.2	3.3	0.1	62.4	0.4	0.2	0.1	0.7	1.3	4.7	0.2	0.2	0.2	0.2	1.6	0.0	0.2	8.6	0.5	0.7	3.0	0.3	2.0	0.2	0.2	0.3	8.8	0.2	0.4	1.8	27.2	2.2	0.2	0.4	0.3	1.3	0.9	11.0	0.2	0.0	0.0	0.6	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.8	90.2	36.9	9.6	0.7	0.0	0.0	0.4	21.6	14.2	0.3	0.0	12.6	89.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	37.9	3.2	0.0	234.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	14.7	1.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	12.1	30.6	0.0	1.3	0.1	0.0	0.0	0.0	0.7	0.0	115.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.9	0.3	0.3	0.3	0.3	0.2	0.1	0.2	0.2	0.5	0.2	3.0	1.6	0.0	14.4	2.1	0.0	0.0	35.7	0.0	23.9	3.5	0.0	0.0	0.0	3.5	0.0	0.1	0.0	0.0	184.0	0.0	0.2	5.4	0.0	0.0	0.3	0.0	0.0	0.0	1.9	0.0	0.0	0.2	0.0	7.2	0.0	0.0	1303.6	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.1	0.0	0.0	25.0
MMP10	STMY2	ENSG00000166670	"Matrix metallopeptidase 10"	P09238	11	102770503-102780628	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"endometrium 1: 89.4"	"Cell type enhanced"	"Detected in some"	14	"Basal glandular cells: 38.9;Club cells: 70.5;Collecting duct cells: 27.9;Pancreatic endocrine cells: 62.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 102.2"	"Region enriched"	"Detected in single"	9	"pons and medulla: 2.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 12.6;HUVEC TERT2: 16.2;SCLC-21H: 5.2"	"Not detected"	"Not detected"							CAB002159	Uncertain		Approved	"Plasma membrane,Cytosol"	"Secreted to extracellular matrix"	NA	NA	765000		Cytosol	"Plasma membrane"	"CAB002159: AB_564103"	"unprognostic (8.76e-2)"	"unprognostic (3.38e-1)"	"unprognostic (1.98e-3)"	"unprognostic (2.72e-3)"	"unprognostic (7.17e-3)"	"unprognostic (1.52e-2)"	"unprognostic (5.67e-8)"	"unprognostic (2.08e-3)"	"unprognostic (2.20e-1)"	"unprognostic (1.75e-1)"	"unprognostic (1.67e-2)"	"unprognostic (2.67e-1)"	"unprognostic (6.99e-5)"	"unprognostic (2.66e-2)"	"unprognostic (7.98e-2)"	"unprognostic (5.46e-2)"	"prognostic favorable (7.12e-4)"	0.1	0.1	0.0	2.6	0.2	0.1	0.1	0.0	0.3	1.7	0.5	0.0	0.0	0.4	89.4	0.1	0.2	0.1	0.5	0.1	0.0	0.1	0.1	3.6	11.0	0.1	0.0	0.0	0.5	0.3	0.1	0.9	19.8	2.8	3.2	0.2	0.0	2.9	0.1	0.1	0.1	0.7	0.1	0.0	0.2	3.3	0.5	0.0	1.2	0.1	0.0	1.9	0.6	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.8	0.2	0.0	0.0	0.2	12.6	0.7	0.1	0.1	0.3	0.0	0.0	3.7	1.9	0.2	2.9	0.0	1.4	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.6	0.0	16.2	0.0	0.7	0.0	0.0	0.0	0.0	0.3	3.0	0.5	1.7	0.0	0.0	0.0	0.0	0.7	5.2	0.0	2.5	0.0	0.0	0.9	0.0	0.0	2.0	3.9	1.3	0.4	0.5	0.0	0.0	0.0	0.6	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.1	0.0	0.0	2.8	0.0	0.0	0.0	0.0	38.9	0.7	0.0	0.0	0.0	5.3	70.5	27.9	0.0	0.0	0.0	9.8	5.0	0.0	0.0	0.0	12.9	0.0	0.2	5.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.2	0.0	2.8	0.0	0.0	62.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.1	0.0	0.0	0.0	7.4
MMP11	STMY3	ENSG00000099953	"Matrix metallopeptidase 11"	P24347	22	23768226-23784316	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"endometrium 1: 44.1;placenta: 119.6"	"Cell type enhanced"	"Detected in many"	15	"Extravillous trophoblasts: 34.6;Syncytiotrophoblasts: 15.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 7.8"	"Group enriched"	"Detected in many"	5	"B-cells: 2.4;dendritic cells: 7.8"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 18.7;hTERT-RPE1: 9.7;REH: 7.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB002593, HPA068864"	Approved				"Secreted to extracellular matrix"	NA	NA					"CAB002593: , HPA068864: AB_2686051"	"unprognostic (1.06e-1)"	"unprognostic (3.08e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.84e-3)"	"unprognostic (2.77e-2)"	"unprognostic (6.73e-2)"	"unprognostic (2.14e-2)"	"unprognostic (5.15e-1)"	"unprognostic (2.73e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.89e-3)"	"unprognostic (7.04e-2)"	"prognostic unfavorable (2.62e-4)"	"unprognostic (8.05e-2)"	"unprognostic (6.78e-2)"	"unprognostic (1.10e-1)"	"unprognostic (1.68e-2)"	1.7	0.6	0.2	1.0	0.6	0.1	1.6	1.0	0.5	13.4	1.8	0.4	0.4	1.9	44.1	1.1	0.8	2.2	2.0	3.1	0.5	0.0	1.7	0.5	0.7	1.8	0.4	0.2	7.7	1.1	0.2	0.3	119.6	0.5	1.4	1.0	0.8	2.5	0.4	0.5	2.0	4.0	2.7	0.3	0.9	0.7	3.4	0.2	2.6	0.5	0.6	0.9	1.6	2.1	2.4	7.8	0.0	0.0	0.0	1.0	0.1	0.1	0.0	2.3	18.7	2.8	4.2	0.0	0.2	5.0	0.6	0.4	0.0	0.6	0.6	3.5	1.3	0.9	0.1	1.0	0.0	0.2	0.0	0.3	0.0	0.0	1.0	2.1	0.0	0.0	2.7	0.4	0.5	0.0	9.7	2.9	0.2	0.3	0.0	0.6	0.1	0.0	0.0	0.6	0.5	0.1	7.8	0.0	0.2	0.3	0.0	2.9	5.0	1.9	0.3	0.0	3.0	1.7	0.0	1.3	0.3	0.0	0.7	0.0	0.1	0.0	2.5	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	2.4	1.0	0.3	0.0	0.0	0.0	7.8	0.0	0.1	0.2	0.6	1.0	0.5	0.5	0.0	0.4	0.2	0.5	0.2	0.0	4.5	0.8	0.8	0.9	0.4	4.3	2.5	1.4	0.0	0.0	0.0	0.3	1.7	5.9	6.6	0.2	0.0	0.0	0.6	34.6	5.7	0.4	1.1	0.0	0.7	0.0	1.7	1.3	0.0	8.0	0.6	0.0	1.7	0.0	0.8	0.5	1.6	0.0	0.4	2.2	0.6	0.0	2.0	1.1	2.7	0.5	15.6	0.0	0.8	0.3
MMP12	HME	ENSG00000262406	"Matrix metallopeptidase 12"	P39900	11	102862736-102875034	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 42.4;urinary bladder: 13.2"	"Cell type enriched"	"Detected in some"	5	"Extravillous trophoblasts: 80.4"	"Low cancer specificity"	"Detected in all"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	12	"BJ: 4.2;fHDF/TERT166: 14.6;hTEC/SVTERT24-B: 8.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (7.33e-2)"	"unprognostic (3.20e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.74e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavorable (1.42e-4)"	"unprognostic (1.69e-2)"	"unprognostic (7.31e-2)"	"unprognostic (1.52e-2)"	"unprognostic (1.52e-3)"	"unprognostic (5.45e-2)"	"unprognostic (3.05e-6)"	"unprognostic (1.08e-2)"	"unprognostic (4.66e-2)"	"unprognostic (1.73e-1)"	"unprognostic (6.92e-2)"	2.7	0.0	0.0	21.2	0.0	0.0	0.0	0.0	0.0	0.3	6.9	0.0	0.0	3.3	0.0	5.9	0.0	0.0	1.0	0.0	0.0		0.0	0.4	0.6	18.9	0.0	0.0	0.1	0.0	0.0	0.0	9.7	0.0	0.3	8.4	0.0	0.9	0.0	0.0	0.0	3.8	4.6	0.0	42.4	1.3	0.1	0.0	5.5	0.0	1.5	9.9	13.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.4	0.2	0.0	0.1	0.0	0.0	0.0	14.6	0.1	0.5	0.0	0.0	0.4	0.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.5	0.6	0.2	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.0	0.0	0.0	0.0	0.0	17.0	80.4	0.0	0.0	0.0	0.0	15.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	1.4
MMP13	CLG3	ENSG00000137745	"Matrix metallopeptidase 13"	P45452	11	102942995-102955734	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"lung: 12.6;vagina: 10.8"	"Group enriched"	"Detected in some"	8	"Club cells: 30.7;Urothelial cells: 14.0"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 70.9"	"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"HaCaT: 19.5;PC-3: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			CAB002742	Supported				"Secreted to extracellular matrix"	NA	NA					"CAB002742: "	"unprognostic (8.98e-3)"	"unprognostic (1.54e-1)"	"unprognostic (4.75e-2)"	"unprognostic (4.57e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.59e-3)"		"unprognostic (1.32e-1)"	"unprognostic (6.35e-3)"	"unprognostic (1.69e-1)"	"unprognostic (7.55e-3)"	"unprognostic (2.24e-1)"	"unprognostic (1.73e-8)"	"unprognostic (2.12e-2)"	"unprognostic (3.14e-1)"	"unprognostic (4.14e-2)"	"unprognostic (4.33e-2)"	0.5	0.1	0.0	0.8	0.0	1.3	0.4	0.0	0.2	1.3	0.1	0.0	0.0	0.6	0.1	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.2	0.1	12.6	0.1	0.0	0.0	0.1	0.0	0.0	3.1	0.1	0.1	1.2	0.0	0.0	0.6	0.0	0.0	1.0	0.5	0.0	0.0	0.1	0.1	1.9	0.0	1.4	0.0	0.0	0.1	4.6	10.8	1.0	0.7	2.7	0.5	1.9	1.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.1	19.5	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.1	0.0	0.0	0.0	7.4	0.0	0.0	0.1	0.0	1.9	0.0	0.1	0.1	2.3	0.0	0.0	0.0	0.0	0.0	2.8	1.5	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	2.7	0.5	0.6	1.3	0.4	1.0	0.5	0.7	0.8	0.3	1.0	0.6	1.1	1.9	1.9	0.3	0.7	0.4	0.5	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.1	0.0	2.7	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.0
MMP14	MT1-MMP	ENSG00000157227	"Matrix metallopeptidase 14"	P50281	14	22836557-22849027	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Extravillous trophoblasts: 216.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 96.4;HHSteC: 91.2;HSkMC: 92.7;hTERT-RPE1: 91.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009918, HPA051432"	Approved		Approved	"Intermediate filaments,Cytosol"		No	No		570000	Cytosol	"Intermediate filaments"	"CAB009918: AB_2250767, HPA051432: AB_2681484"	"unprognostic (1.34e-1)"	"unprognostic (1.37e-1)"	"unprognostic (1.11e-2)"	"unprognostic (2.81e-1)"	"unprognostic (4.28e-2)"	"unprognostic (1.12e-2)"	"unprognostic (3.05e-3)"	"unprognostic (5.91e-3)"	"unprognostic (1.95e-1)"	"prognostic unfavorable (9.48e-4)"	"unprognostic (3.82e-3)"	"unprognostic (7.31e-2)"	"prognostic unfavorable (1.34e-4)"	"unprognostic (5.02e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.00e-2)"	"unprognostic (3.41e-3)"	60.9	10.5	2.4	16.6	4.7	0.2	64.2	2.2	3.2	56.3	35.0	8.2	12.7	12.0	53.1	24.1	47.0	21.9	39.6	17.5	3.4	1.8	16.8	9.0	29.8	16.9	5.8	2.9	39.3	11.2	34.4	4.7	73.5	16.4	39.1	11.3	27.1	24.4	16.7	20.4	37.0	22.9	28.5	20.7	22.5	18.2	26.3	4.6	5.4	22.3	14.6	16.7	52.5	53.9	0.1	0.7	0.0	0.7	0.0	0.0	0.1	7.8	0.1	2.4	0.1	96.4	61.3	44.3	24.7	49.8	7.5	13.4	2.3	29.4	0.1	13.8	26.0	2.3	20.0	0.0	25.7	9.6	0.1	0.1	3.6	0.1	0.5	91.2	0.0	0.1	92.7	15.5	31.2	26.8	91.6	45.3	0.1	0.0	0.2	17.6	0.1	0.0	8.8	1.4	1.7	4.3	0.3	8.5	0.0	6.8	13.5	0.0	0.0	16.1	0.0	53.5	10.8	0.1	7.9	40.0	60.9	5.2	17.7	28.1	0.1	0.1	0.1	37.1	0.0	35.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	4.7	2.2	3.2	3.4	1.8	5.8	2.9	16.4	4.6	11.9	4.8	3.7	19.4	30.2	0.0	3.6	53.5	2.7	3.4	7.0	0.0	83.6	10.0	61.2	0.4	13.5	16.8	0.0	24.9	216.8	65.7	13.9	3.5	2.9	79.3	0.0	7.5	41.1	18.3	0.7	66.7	26.5	35.4	34.3	32.5	17.1	102.2	28.5	51.6	13.0	0.8	38.8	34.8	0.9	0.7	29.9	102.6	1.0	17.1	28.7
MMP15	"MT2-MMP, MTMMP2, SMCP-2"	ENSG00000102996	"Matrix metallopeptidase 15"	P51511	16	58025566-58046901	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 43.2"	"Cell type enhanced"	"Detected in many"	7	"Cholangiocytes: 56.0;Enterocytes: 81.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	30	"plasmacytoid DC: 2.9"	"Lineage enriched"	"Detected in single"	30	"dendritic cells: 2.9"	"Cell line enhanced"	"Detected in many"		"BEWO: 37.1;Hep G2: 19.3;SK-BR-3: 18.6;WM-115: 30.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002611, HPA040390"	Uncertain		Approved	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"	Nucleoplasm	"CAB002611: , HPA040390: AB_2676956"	"unprognostic (1.76e-2)"	"unprognostic (7.32e-2)"	"unprognostic (2.69e-1)"	"unprognostic (6.85e-2)"	"unprognostic (3.09e-1)"	"unprognostic (1.68e-1)"	"unprognostic (6.88e-3)"	"unprognostic (1.40e-1)"	"unprognostic (3.02e-2)"	"unprognostic (1.24e-2)"	"unprognostic (4.81e-2)"	"unprognostic (1.81e-1)"	"prognostic favorable (8.54e-8)"	"unprognostic (3.63e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.28e-1)"	"prognostic favorable (3.08e-4)"	5.9	2.3	2.0	5.5	3.0	0.1	7.7	3.7	7.2	3.3	19.5	4.2	16.3	22.6	2.9	1.7	2.5	3.6	15.9	17.6	2.3	3.7	8.4	26.4	6.1	2.0	2.5	2.2	2.1	10.3	7.3	5.2	28.5	10.4	3.6	8.2	9.5	4.7	14.7	3.4	2.3	43.2	3.4	3.4	5.2	14.7	28.0	2.1	1.1	26.8	2.5	2.2	3.3	4.2	0.0	2.9	0.0	0.0	0.0	0.0	0.0	5.7	4.4	2.3	11.9	2.4	0.1	37.1	0.5	0.3	2.1	0.5	3.5	14.9	0.0	7.0	0.6	1.6	8.1	2.0	1.7	0.6	0.0	3.9	0.0	1.9	19.3	3.1	0.1	7.7	1.2	3.1	0.3	0.9	3.3	1.4	3.3	4.8	0.0	0.7	2.9	0.2	0.9	6.8	17.0	1.2	2.9	0.3	3.1	6.5	2.1	0.6	4.1	7.7	18.6	3.5	5.5	2.0	3.1	1.3	0.1	3.7	1.4	0.5	0.0	0.0	0.1	0.7	0.9	30.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	2.0	3.0	3.7	7.2	2.3	3.7	2.5	2.2	10.4	2.1	17.9	11.8	0.9	1.0	2.3	1.9	19.3	56.0	5.3	9.1	17.4	15.7	33.4	1.7	33.5	2.2	6.0	81.1	0.0	10.5	19.6	2.8	1.6	0.0	29.0	10.2	1.6	10.9	19.6	3.5	4.8	0.9	0.1	1.7	0.0	31.8	1.7	13.5	40.7	3.2	5.4	1.4	0.0	0.8	0.9	4.9	1.9	40.5	1.5	28.3	1.4
MMP16	"C8orf57, DKFZp761D112, MT3-MMP"	ENSG00000156103	"Matrix metallopeptidase 16"	P51512	8	88032009-88328025	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 15.9"	"Cell type enhanced"	"Detected in some"	11	"Bipolar cells: 3.9;Early spermatids: 4.9;Fibroblasts: 9.9;Late spermatids: 4.7"	"Cancer enhanced"	"Detected in many"		"glioma: 4.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AN3-CA: 20.4;HUVEC TERT2: 8.8;SH-SY5Y: 11.4;U-138 MG: 9.7;WM-115: 20.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023693	Uncertain		Approved	Vesicles,Cytosol	"Secreted to extracellular matrix"	NA	NA			Cytosol	Vesicles	"HPA023693: AB_1854025"	"unprognostic (2.58e-1)"	"unprognostic (2.42e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.87e-1)"	"unprognostic (7.09e-2)"	"unprognostic (3.31e-2)"	"unprognostic (2.39e-3)"	"unprognostic (1.45e-3)"	"unprognostic (2.46e-1)"	"unprognostic (2.61e-1)"	"unprognostic (9.42e-2)"	"unprognostic (2.92e-1)"	"unprognostic (2.09e-8)"	"unprognostic (6.90e-3)"	"unprognostic (1.16e-1)"	"unprognostic (3.62e-1)"	"unprognostic (2.19e-3)"	2.4	1.3	11.0	1.4	6.8	0.5	4.9	8.3	15.9	5.3	2.2	2.9	0.7	0.8	4.9	2.1	1.7	2.1	7.3	2.7	8.7	6.9	0.8	0.9	1.0	1.0	5.5	9.1	3.3	2.1	1.5	1.7	3.0	6.3	3.2	1.7	0.6	1.2	2.4	0.7	1.1	1.3	4.0	4.6	1.5	1.4	1.5	5.5	0.0	3.2	0.7	1.0	2.6	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	5.5	20.4	0.7	1.4	0.0	7.5	1.1	2.1	1.3	0.0	0.0	0.0	0.0	3.3	1.2	0.0	4.0	0.0	2.6	0.0	2.4	0.0	0.0	0.0	1.7	0.0	0.3	1.0	0.0	3.1	0.9	3.8	8.8	0.0	0.0	0.7	1.1	0.0	0.0	0.0	1.2	0.0	2.0	0.2	0.4	0.0	0.4	0.0	0.1	11.4	0.0	0.0	0.1	1.6	0.8	0.0	4.9	9.7	5.5	0.1	2.8	0.0	0.0	0.0	3.9	0.0	20.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	11.0	6.8	8.3	14.1	8.7	6.9	5.5	9.1	6.3	5.5	0.0	0.0	0.0	0.0	1.0	3.9	0.6	0.0	0.0	0.0	0.0	2.0	0.0	1.7	0.0	4.9	2.9	0.0	0.0	0.0	0.0	9.9	0.0	0.0	0.0	0.3	1.6	0.0	0.6	0.0	4.7	0.9	0.6	1.7	0.0	0.0	3.2	0.2	0.0	1.1	0.0	0.3	0.0	1.3	0.0	0.9	0.1	0.0	0.0	0.0	0.0
MMP17	MT4-MMP	ENSG00000198598	"Matrix metallopeptidase 17"	Q9ULZ9	12	131828393-131851783	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 23.3"	"Cell type enriched"	"Detected in some"	7	"Melanocytes: 27.0"	"Cancer enriched"	"Detected in many"	10	"melanoma: 29.9"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	9	"classical monocyte: 2.2;intermediate monocyte: 2.1;memory B-cell: 1.4;myeloid DC: 1.2;naive B-cell: 1.7;non-classical monocyte: 2.7"	"Group enriched"	"Detected in many"	9	"B-cells: 1.7;dendritic cells: 1.2;monocytes: 2.7"	"Group enriched"	"Detected in many"	4	"REH: 17.3;SK-MEL-30: 42.1;WM-115: 62.3"	"Group enriched"	"Detected in many"	5	"amygdala: 51.6;basal ganglia: 52.2;cerebral cortex: 70.8;hippocampal formation: 73.1;hypothalamus: 21.6"	"Low region specificity"	"Detected in all"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (9.11e-2)"	"unprognostic (1.27e-2)"	"unprognostic (1.69e-2)"	"unprognostic (3.71e-3)"	"unprognostic (5.62e-2)"	"unprognostic (1.85e-2)"	"unprognostic (8.90e-3)"	"unprognostic (2.14e-2)"	"unprognostic (2.60e-1)"	"unprognostic (2.66e-4)"	"unprognostic (7.68e-2)"	"unprognostic (5.88e-2)"	"unprognostic (9.26e-10)"	"unprognostic (1.15e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.21e-3)"	"unprognostic (2.81e-2)"	4.6	2.0	12.6	3.0	23.3	6.2	2.5	1.4	21.5	5.6	3.0	3.1	0.0	1.4	4.2	0.9	2.1	2.1	7.0	1.1	22.5	10.1	0.5	0.5	1.8	5.5	3.7	7.6	9.0	5.0	3.1	0.7	1.1	2.2	1.6	0.8	1.6	8.5	2.5	1.6	9.7	1.9	1.7	1.6	4.8	1.4	2.9	3.5	0.0	0.8	1.5	1.6	2.8	2.8	1.7	1.2	0.2	2.7	0.1	0.0	1.1	0.1	5.3	0.2	0.5	4.3	1.7	0.1	2.7	6.7	2.6	2.7	0.0	1.5	0.0	2.2	4.2	1.6	2.3	2.2	2.5	0.5	0.0	0.3	0.9	1.9	0.0	5.3	0.0	3.8	2.6	0.7	3.7	0.9	1.0	3.5	0.0	1.0	0.1	3.3	4.7	0.1	4.0	2.4	1.6	3.2	17.3	0.0	2.0	0.0	0.0	2.3	0.7	0.3	0.9	42.1	0.7	4.9	10.0	2.7	0.7	0.7	3.8	0.3	0.0	0.0	0.0	1.4	0.5	62.3	0.1	2.2	0.0	0.0	2.1	0.0	1.4	0.0	0.0	1.2	1.7	0.0	0.0	0.2	0.1	2.7	0.0	0.0	1.1	12.6	23.3	1.4	17.9	22.5	10.1	3.7	7.6	2.2	3.5	0.0	0.0	0.0	0.1	2.3	0.5	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.1	1.0	0.2	0.0	0.0	0.6	3.2	0.0	1.3	4.0	0.0	0.9	0.4	27.0	0.0	0.0	0.2	0.0	0.0	1.8	0.3	0.0	0.0	1.0	0.5	0.4	1.0	0.0	0.0	0.0	0.1
MMP19	"MMP18, RASI-1"	ENSG00000123342	"Matrix metallopeptidase 19"	Q99542	12	55835433-55842966	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Angiogenesis, Collagen degradation, Differentiation"	"Developmental protein, Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 60.7"	"Cell type enhanced"	"Detected in many"	8	"Extravillous trophoblasts: 42.0;Hofbauer cells: 31.2;Kupffer cells: 30.5;Macrophages: 48.2;monocytes: 38.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	16	"classical monocyte: 3.2;myeloid DC: 1.0"	"Group enriched"	"Detected in many"	16	"dendritic cells: 1.0;monocytes: 3.2"	"Cell line enriched"	"Detected in many"	6	"BEWO: 57.2"	"Region enriched"	"Detected in single"	6	"olfactory region: 8.8"	"Low region specificity"	"Detected in all"			HPA070804			Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to extracellular matrix"	NA	NA		800000	"Endoplasmic reticulum, Vesicles"		"HPA070804: AB_2686315"	"unprognostic (2.61e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.28e-2)"	"unprognostic (2.42e-1)"	"unprognostic (4.77e-3)"	"unprognostic (4.77e-3)"	"unprognostic (2.01e-2)"	"unprognostic (4.03e-2)"	"unprognostic (2.85e-2)"	"unprognostic (4.30e-2)"	"unprognostic (2.37e-1)"	"unprognostic (2.09e-1)"	"prognostic unfavorable (8.56e-9)"	"unprognostic (5.06e-3)"	"unprognostic (1.28e-3)"	"unprognostic (2.73e-2)"	"unprognostic (4.00e-2)"	60.7	1.9	0.2	10.9	0.7	0.0	9.9	0.2	0.5	7.6	3.9	0.4	1.4	0.8	12.7	6.0	3.6	11.8	30.3	4.7	0.6	0.1	4.1	3.0	14.0	15.5	0.5	0.2	7.4	8.1	0.0	0.5	24.5	1.0	2.9	2.8	3.1	2.0	3.5	2.1	2.7	4.1	7.7	0.8	27.4	5.0	2.9	0.2	2.7	3.3	1.8	7.1	5.9	3.5	0.0	1.0	0.1	3.2	0.0	0.0	0.6	0.8	0.0	0.0	0.0	6.3	8.1	57.2	6.0	7.1	2.5	2.9	0.3	0.2	0.0	0.0	8.4	0.1	0.0	0.0	1.8	3.4	0.3	0.0	0.0	0.0	0.1	5.2	0.0	0.2	8.4	0.2	1.5	1.6	3.0	0.4	0.0	0.1	0.0	8.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	1.4	0.0	1.1	2.9	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.1	9.7	1.5	3.3	0.0	0.2	0.0	0.0	0.0	4.5	0.0	0.0	0.0	3.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.2	0.7	0.2	0.5	0.6	0.1	0.5	0.2	1.0	0.2	0.0	5.8	0.9	0.2	6.4	0.5	0.6	5.1	2.7	5.7	0.0	3.9	14.4	0.0	0.3	0.4	2.1	0.0	0.0	0.4	42.0	24.0	0.4	2.3	0.5	31.2	0.0	0.0	4.9	30.5	0.4	5.5	48.2	11.8	38.7	0.0	0.3	0.1	0.0	4.9	0.0	1.7	0.0	9.6	0.0	0.2	3.8	15.7	0.0	0.0	0.1
MMP2	"CLG4, CLG4A, TBE-1"	ENSG00000087245	"Matrix metallopeptidase 2"	P08253	16	55389700-55506691	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Angiogenesis, Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Extravillous trophoblasts: 217.4;Fibroblasts: 249.9;Leydig cells: 315.0;Peritubular cells: 393.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"ASC diff: 292.5;ASC TERT1: 85.2;hTERT-RPE1: 329.2;U-87 MG: 93.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA001939, CAB002788"	Approved		Approved	Vesicles	"Secreted to extracellular matrix"	NA	NA	1600000000	160000000	Vesicles		"CAB002788: , HPA001939: AB_1079395"	"unprognostic (7.26e-2)"	"unprognostic (1.36e-3)"	"unprognostic (1.66e-1)"	"unprognostic (2.14e-3)"	"unprognostic (5.03e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.74e-1)"	"unprognostic (9.36e-3)"	"unprognostic (4.81e-3)"	"unprognostic (3.79e-2)"	"unprognostic (4.59e-3)"	"unprognostic (6.12e-2)"	"unprognostic (1.28e-3)"	"unprognostic (1.59e-2)"	"unprognostic (8.00e-2)"	"unprognostic (8.98e-2)"	"unprognostic (4.63e-2)"	197.5	9.0	1.2	13.2	1.6	0.0	136.4	0.8	1.4	74.3	74.4	2.4	36.9	5.6	85.0	123.0	52.3	25.7	115.4	54.0	0.9	0.5	9.4	3.5	38.9	3.9	1.5	1.1	71.0	6.5	0.7	2.2	58.9	2.2	66.8	18.7	36.4	18.6	20.4	68.6	68.2	22.6	57.1	1.8	12.4	20.5	57.0	1.1	1.3	20.6	31.8	9.1	84.1	105.3	0.0	0.0	0.9	0.7	0.0	0.0	0.0	0.3	0.1	9.7	0.1	292.5	85.2	15.9	25.0	57.5	5.0	4.0	0.0	0.1	0.0	20.1	44.1	1.9	2.7	0.0	0.2	2.9	0.0	0.0	0.0	0.6	0.1	27.7	0.0	0.7	72.6	0.0	26.0	0.2	329.2	32.7	0.0	0.0	0.1	16.8	0.0	0.0	0.3	7.7	0.0	0.0	0.0	2.3	0.0	0.8	0.3	0.1	17.6	4.6	0.0	0.1	45.4	0.0	1.7	45.9	79.6	7.6	15.2	3.2	0.0	0.0	0.0	93.1	1.3	14.5	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.2	0.0	0.0	0.0	1.2	1.6	0.8	1.4	0.9	0.5	1.5	1.1	2.2	1.1	0.0	0.3	0.0	13.0	108.4	5.2	3.1	0.0	0.0	3.4	10.4	0.0	5.4	0.0	1.7	11.5	11.9	0.0	0.0	0.3	217.4	249.9	2.7	0.0	0.0	25.6	1.6	27.1	15.4	0.0	26.9	315.0	5.3	121.4	0.0	0.0	5.0	6.9	0.0	393.8	0.0	1.8	12.9	70.0	1.2	2.1	89.5	14.4	0.0	0.0	3.8
MMP20		ENSG00000137674	"Matrix metallopeptidase 20"	O60882	11	102576835-102625332	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"Amelogenesis imperfecta, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 1.0;testis: 3.5"	"Cell type enriched"	"Detected in some"	10	"Early spermatids: 66.1"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"OE19: 7.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"								"Secreted to extracellular matrix"	NA	NA						"unprognostic (4.62e-3)"		"unprognostic (2.61e-2)"	"unprognostic (1.68e-3)"		"unprognostic (1.75e-1)"		"unprognostic (2.13e-1)"		"unprognostic (3.06e-1)"	"unprognostic (2.97e-2)"	"unprognostic (6.75e-2)"	"unprognostic (9.58e-5)"	"unprognostic (6.10e-2)"		"unprognostic (2.35e-1)"		0.0	0.0	0.0	0.3	0.0	0.0	0.8	0.0	0.0	0.0	0.0			0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.2	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5			0.0		1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	66.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	6.5	0.0	0.0	0.3	0.0	0.5	0.0	0.0	0.5
MMP21		ENSG00000154485	"Matrix metallopeptidase 21"	Q8N119	10	125766453-125775821	"Disease related genes, Enzymes, FDA approved drug targets, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets, Heterotaxy"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	13	"epididymis: 37.6"	"Cell type enhanced"	"Detected in single"	32	"Distal tubular cells: 1.7"	"Not detected"	"Not detected"							"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.1"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BEWO: 1.1;NB-4: 1.2;U-266/70: 2.1;U-266/84: 1.8"	"Not detected"	"Not detected"												"Secreted to extracellular matrix"	NA	NA						"unprognostic (1.32e-2)"	"unprognostic (1.28e-1)"	"unprognostic (8.51e-2)"	"unprognostic (2.19e-2)"	"unprognostic (4.02e-2)"	"unprognostic (2.21e-2)"	"unprognostic (4.22e-3)"	"unprognostic (1.01e-1)"	"unprognostic (2.12e-1)"	"unprognostic (1.48e-1)"	"unprognostic (2.89e-2)"	"unprognostic (3.62e-2)"	"unprognostic (9.70e-8)"	"unprognostic (1.30e-2)"	"unprognostic (7.69e-2)"	"unprognostic (7.00e-2)"	"unprognostic (2.18e-1)"	0.2	0.1	0.1	0.1	0.4	0.1	0.3	0.7	0.0	0.1	0.2			0.1	0.1	37.6	0.1	0.4	0.2	0.9	0.0	0.4	0.1	1.0	0.1	0.1	0.0		2.8	0.8	0.0	0.3	0.0		0.6	0.1		0.5	0.1	0.0	0.1	0.5	0.1	0.0	0.7	0.2	0.1			0.6		0.1	0.2	0.0	1.1	0.0	0.0	0.1	0.5	0.6	0.0	0.1	0.0	0.0	0.8	0.3	0.0	1.1	0.2	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.7	0.7	0.5	0.0	0.0	0.2	0.2	0.1	0.0	0.3	0.0	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.1	0.1	0.2	0.3	0.0	0.1	0.0	0.1	0.0	0.0	0.3	0.7	0.0	2.1	1.8	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.6	0.0	0.0	1.1	0.0	0.4	0.0	0.5	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP23B	"MIFR, MIFR-1, MMP22"	ENSG00000189409	"Matrix metallopeptidase 23B"	O75900	1	1632095-1635263	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 51.8"	"Group enriched"	"Detected in many"	6	"Fibroblasts: 124.0;Leydig cells: 90.9;Peritubular cells: 167.3"	"Cancer enhanced"	"Detected in single"		"ovarian cancer: 0.8"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"plasmacytoid DC: 12.3"	"Lineage enriched"	"Detected in many"	5	"dendritic cells: 12.3"	"Cell line enhanced"	"Detected in some"		"AN3-CA: 3.4;HHSteC: 8.3;NTERA-2: 3.6;PC-3: 3.6;U-266/70: 6.5"	"Region enriched"	"Detected in some"	5	"cerebellum: 8.7"	"Not detected"	"Not detected"									NA	NA						"unprognostic (2.19e-2)"	"unprognostic (6.31e-2)"	"unprognostic (6.70e-3)"	"unprognostic (1.29e-1)"	"unprognostic (3.99e-2)"	"unprognostic (9.31e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.20e-1)"	"unprognostic (8.06e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.22e-1)"	"unprognostic (2.33e-1)"	"unprognostic (2.26e-11)"	"unprognostic (1.60e-3)"	"unprognostic (1.36e-1)"	"unprognostic (2.44e-2)"	"unprognostic (6.66e-2)"	4.7	2.4	0.3	3.9	0.3	2.1	2.3	0.5	0.4	19.6	3.2	0.1	4.2	3.9	17.3	20.1	4.7	6.4	28.5	14.4	0.2	0.3	3.6	2.3	11.0	3.3	0.1	0.0	51.8	0.7	0.0	3.1	10.5	0.1	32.1	0.2	1.2	1.4	6.3	0.9	2.5	2.7	11.7	0.2	4.1	4.3	13.5	0.0	0.4	1.2	0.9	2.8	13.9	7.0	0.2	12.3	0.1	0.2	2.2	1.8	1.3	1.0	0.0	0.3	3.4	0.0	0.0	1.7	0.0	0.0	0.2	0.0	0.7	1.0	0.2	0.8	0.0	0.0	0.1	0.0	0.0	0.0	0.7	2.6	1.0	0.3	2.2	8.3	0.4	0.5	0.2	0.0	0.0	0.0	0.1	0.0	0.4	0.3	0.3	0.0	0.9	0.0	0.6	3.6	0.0	3.6	1.3	0.1	1.6	0.0	0.1	0.6	0.2	0.5	0.0	0.2	0.1	1.0	0.0	0.7	0.5	0.3	0.7	0.0	6.5	0.3	1.1	0.1	0.4	0.3	0.0	0.2	0.0	1.8	0.0	1.1	0.0	0.4	1.1	0.0	0.2	0.1	0.9	0.1	2.2	0.1	12.3	0.2	1.3	0.3	0.3	0.5	0.4	0.2	0.3	0.1	0.0	0.1	0.0	0.0	0.3	0.0	0.9	11.8	1.1	9.0	2.5	0.0	0.0	1.8	0.0	2.7	0.0	0.8	0.8	1.5	1.7	0.0	0.5	1.6	124.0	0.4	0.0	1.0	5.1	3.2	2.9	20.9	1.5	3.2	90.9	1.0	18.6	1.0	1.7	0.8	3.4	0.0	167.3	0.6	5.7	0.0	8.2	1.6	10.7	13.8	8.6	9.2	1.2	0.7
MMP24	MT5-MMP	ENSG00000125966	"Matrix metallopeptidase 24"	Q9Y5R2	20	35226654-35277000	"Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins"	"Cell adhesion"	"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 38.5"	"Cell type enhanced"	"Detected in some"	10	"Alveolar cells type 1: 14.9;Cholangiocytes: 12.7;Ductal cells: 7.5;Horizontal cells: 14.3;Proximal tubular cells: 7.3"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in all"	5	"cerebellum: 38.5"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"A549: 20.1;CACO-2: 30.6;EFO-21: 9.0;RPTEC TERT1: 13.8;U-2 OS: 10.4"	"Low region specificity"	"Detected in all"			"Region enriched"	"Detected in all"	4	"cerebellum: 91.3"	"HPA049280, HPA078816"	Approved		Approved	"Nucleoli,Plasma membrane"	"Secreted to extracellular matrix"	Yes	No			"Nucleoli, Plasma membrane"		"HPA049280: , HPA078816: "	"unprognostic (1.52e-3)"	"unprognostic (1.36e-1)"	"unprognostic (1.18e-1)"	"unprognostic (4.51e-4)"	"unprognostic (2.47e-2)"	"unprognostic (7.61e-3)"	"unprognostic (1.22e-1)"	"unprognostic (4.59e-2)"	"unprognostic (2.32e-2)"	"unprognostic (8.82e-2)"	"unprognostic (9.20e-3)"	"unprognostic (7.12e-2)"	"prognostic favorable (8.17e-11)"	"unprognostic (3.32e-2)"	"unprognostic (5.63e-2)"	"unprognostic (1.69e-2)"	"unprognostic (9.90e-4)"	1.6	1.3	4.0	0.4	7.8	0.6	0.4	38.5	8.9	0.7	0.3	1.3	0.2	2.8	1.6	0.9	0.2	2.8	0.6	1.0	2.7	3.2	8.6	0.9	6.1	0.3	1.8	1.5	0.9	8.0	0.0	3.8	0.6	1.7	2.2	0.1	0.5	0.4	6.0	0.2	1.5	1.7	2.5	0.9	0.6	0.7	0.4	1.4	0.2	0.8	0.2	0.2	0.5	0.2	0.8	0.4	2.2	0.8	0.6	1.2	0.3	0.3	20.1	0.0	0.1	0.1	0.0	0.6	1.1	1.3	2.1	1.1	30.6	5.4	0.0	9.0	1.4	0.7	0.3	4.7	0.0	0.9	0.1	0.2	1.1	0.6	0.3	0.0	0.0	0.2	0.1	0.1	0.1	0.0	0.6	0.0	0.1	0.0	0.3	0.2	0.2	0.1	0.1	7.7	0.0	1.4	0.0	0.1	0.0	13.8	0.1	8.0	5.5	1.4	0.5	0.2	1.8	0.3	0.1	0.3	4.3	10.4	1.0	0.4	0.1	0.1	0.0	0.9	0.1	0.6	1.0	0.6	0.1	1.0	0.7	1.2	0.6	0.7	0.8	0.4	0.8	0.6	0.6	2.2	0.6	0.8	0.2	0.0	0.3	4.0	7.8	38.5	5.3	2.7	3.2	1.8	1.5	1.7	1.4	14.9	1.0	0.0	0.1	0.1	3.6	0.6	12.7	0.0	2.3	1.8	0.0	0.0	5.0	7.5	0.6	0.7	0.3	0.0	0.8	0.1	0.2	0.4	0.0	0.2	0.0	14.3	0.0	0.0	0.3	0.0	0.3	0.0	1.7	0.0	0.0	0.2	2.1	0.0	0.0	7.3	0.3	0.0	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0
MMP25	"MMP20, MMPL1, MT6-MMP"	ENSG00000008516	"Matrix metallopeptidase 25"	Q9NPA2	16	3046681-3060726	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 17.6;bone marrow: 25.6;lymphoid tissue: 54.1"	"Group enriched"	"Detected in some"	4	"Alveolar cells type 2: 10.7;Kupffer cells: 5.9;monocytes: 23.4"	"Cancer enhanced"	"Detected in many"		"testis cancer: 7.1"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	6	"basophil: 10.2;eosinophil: 6.0;neutrophil: 17.6"	"Lineage enriched"	"Detected in many"	10	"granulocytes: 17.6"	"Cell line enriched"	"Detected in some"	12	"HMC-1: 50.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"CAB025177, HPA055640"	Uncertain		Supported	"Plasma membrane"	"Secreted to blood"	NA	NA			"Plasma membrane"		"CAB025177: , HPA055640: "	"unprognostic (4.51e-3)"	"unprognostic (9.28e-3)"	"unprognostic (7.57e-2)"	"unprognostic (2.95e-3)"	"unprognostic (2.26e-1)"	"prognostic favorable (1.09e-5)"	"unprognostic (1.36e-1)"	"unprognostic (7.39e-3)"	"unprognostic (7.63e-3)"	"unprognostic (2.29e-2)"	"unprognostic (1.51e-1)"	"unprognostic (2.53e-2)"	"unprognostic (2.37e-3)"	"unprognostic (1.17e-2)"	"unprognostic (8.30e-2)"	"unprognostic (4.01e-1)"	"unprognostic (2.02e-1)"	4.0	0.3	0.6	12.3	0.4	25.6	0.8	0.5	0.6	0.8	1.1	0.2	0.0	1.0	0.4	0.5	0.8	3.8	1.1	2.8	0.5	0.4	0.7	2.5	10.7	54.1	1.8	0.0	0.6	0.8	0.0	0.5	2.0	1.1	0.6	1.0	1.0	0.9	0.0	2.4	0.6	1.8	0.5	0.4	43.9	1.1	0.7	0.5	4.1	0.7	0.9	4.2	1.5	2.5	0.0	0.3	17.6	0.2	1.7	0.5	0.1	0.2	0.1	0.7	1.5	0.0	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.0	0.3	0.6	0.3	0.0	0.0	4.0	0.8	0.1	0.1	0.0	0.0	0.1	50.5	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.3	0.0	0.5	0.2	3.0	1.4	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.1	0.3	3.6	0.1	0.1	0.4	0.1	0.0	1.2	0.1	0.1	0.0	1.0	0.1	10.2	0.2	6.0	0.3	0.0	0.5	0.0	0.2	0.2	0.0	0.0	0.3	0.2	17.6	1.7	0.0	0.3	0.3	0.1	0.6	0.4	0.5	0.6	0.5	0.4	1.8	0.0	1.1	0.5	3.0	10.7	0.0	0.2	0.3	0.6	0.4	0.0	0.0	1.2	1.8	0.0	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.5	0.1	0.2	0.5	1.1	0.0	0.1	0.0	0.0	0.0	5.9	0.0	0.0	2.0	0.0	23.4	0.0	0.1	1.1	0.0	0.7	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	3.1	0.1	0.1
MMP26	"endometase, MGC126590, MGC126592"	ENSG00000167346	"Matrix metallopeptidase 26"	Q9NRE1	11	4704927-4992429	"Enzymes, FDA approved drug targets, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	13	"endometrium 1: 19.1"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	20	"endometrial cancer: 8.8;prostate cancer: 2.0"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"																"Secreted to extracellular matrix"	NA	NA									"unprognostic (4.21e-3)"								"unprognostic (2.63e-1)"						0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	19.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		1.4	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP27		ENSG00000137675	"Matrix metallopeptidase 27"	Q9H306	11	102691487-102705806	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"breast: 10.4;tongue: 10.0"	"Cell type enriched"	"Detected in single"	5	"Suprabasal keratinocytes: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	7	"neutrophil: 1.0"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 1.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA069097	Approved				"Intracellular and membrane"	NA	NA					"HPA069097: AB_2686085"	"unprognostic (3.99e-2)"	"unprognostic (2.37e-4)"				"unprognostic (1.25e-3)"			"unprognostic (1.63e-1)"					"unprognostic (4.60e-1)"				3.2	0.0	0.0	0.0	0.5	2.4	10.4	0.0	0.0	1.5	0.8	0.0	0.0	0.3	0.9	4.7	0.8	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.6	0.0	5.1	0.0	0.8	5.4	2.6	2.0	0.0	0.1	0.4	0.4	0.0	0.9	0.1	10.0	2.2	0.4	0.3	0.0	0.0	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.1	0.0	0.0	0.0	0.0
MMP28	"EPILYSIN, MM28, MMP-25, MMP-28"	ENSG00000271447	"Matrix metallopeptidase 28"	Q9H239	17	35756249-35795707	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		"Hydrolase, Metalloprotease, Protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 34.2;Enterocytes: 39.1;Mucus-secreting cells: 31.9;Paneth cells: 47.6;Urothelial cells: 34.5"	"Low cancer specificity"	"Detected in many"							"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 7.2;naive CD8 T-cell: 5.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 7.2"	"Cell line enriched"	"Detected in some"	7	"HaCaT: 28.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA057288, HPA057890"			Approved	"Nucleoplasm,Focal adhesion sites"	"Secreted to extracellular matrix"	NA	NA			Nucleoplasm	"Focal adhesion sites"	"HPA057288: , HPA057890: "	"unprognostic (7.99e-3)"	"unprognostic (3.27e-1)"	"unprognostic (2.20e-1)"	"unprognostic (1.01e-1)"	"unprognostic (7.52e-2)"	"unprognostic (1.63e-1)"	"unprognostic (6.90e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.99e-1)"	"prognostic unfavorable (6.28e-6)"	"unprognostic (9.37e-2)"	"unprognostic (1.31e-1)"	"unprognostic (8.87e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.76e-2)"	"unprognostic (3.27e-3)"	8.0	1.6	1.8	2.7	3.7	0.5	4.3	0.0	5.1	1.7	7.3	1.6	1.4	3.0	3.2	4.8	4.3	1.5	12.3	0.5	2.8		0.8	0.2	10.3	0.4	0.0	2.9	0.1	1.3	0.5	0.0	0.7	1.3	2.9	4.1	2.7	0.1	2.1	0.6	4.5	9.3	4.3	0.2	0.6	7.2	13.4	0.2	0.0	4.2	4.4	2.5	5.5	2.2	1.1	1.5	0.1	0.2	1.3	7.2	0.9	0.1	0.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.1	0.7	0.0	0.1	28.7	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.0	2.6	0.0	0.1	0.0	0.2	0.2	0.0	0.1	0.0	0.2	0.1	0.2	0.0	3.9	0.2	0.6	0.0	0.0	0.0	1.6	0.2	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.1	2.0	1.1	0.4	1.7	0.1	0.9	7.2	5.9	0.1	1.3	0.2	1.5	0.0	0.9											26.8	20.8	0.0	5.1	34.2	0.4	1.0	2.5	5.3	5.7	7.0	0.0	0.0	0.0	0.1	5.0	8.1	39.1	0.0	0.3	0.0	1.6	1.8	0.0	0.0	0.1	1.6	3.5	6.2	0.0	7.1	1.1	0.9	3.3	0.0	31.9	9.1	9.7	47.6	2.8	0.7	0.5	6.5	2.0	0.5	2.5	29.0	0.0	0.7	18.5	34.5
MMP3	"STMY, STMY1"	ENSG00000149968	"Matrix metallopeptidase 3"	P08254	11	102835801-102843803	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"epididymis: 177.5;salivary gland: 73.4"	"Cell type enhanced"	"Detected in some"	10	"Basal glandular cells: 11.5;Basal keratinocytes: 7.4;Club cells: 11.4;Early spermatids: 14.6"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 59.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	17	"BJ: 101.3;BJ hTERT+: 275.6;fHDF/TERT166: 119.3"					"Low region specificity"	"Detected in many"			HPA007875	Uncertain		Supported	Vesicles	"Secreted to extracellular matrix"	NA	NA	2540000	170000	Vesicles		"HPA007875: AB_1079396"	"unprognostic (2.27e-1)"	"prognostic unfavorable (9.73e-4)"	"unprognostic (1.63e-3)"	"unprognostic (5.11e-3)"	"unprognostic (3.78e-1)"	"unprognostic (5.11e-2)"	"unprognostic (5.26e-6)"	"unprognostic (3.46e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.87e-1)"	"prognostic unfavorable (4.09e-4)"	"unprognostic (3.26e-2)"	"unprognostic (1.22e-15)"	"unprognostic (3.17e-1)"	"unprognostic (1.55e-1)"	"unprognostic (3.43e-2)"	"unprognostic (2.34e-1)"	19.1	0.0	0.2	14.4	0.3	0.0	6.9	0.2	0.5	0.2	1.5	0.3	0.2	1.8	28.3	177.5	0.2	0.0	1.4	0.2	0.2	0.0	0.3	0.5	0.4	0.2	0.2	0.2	0.3	0.2	0.0	0.2	0.2	0.2	1.2	1.7	0.2	73.4	1.5	7.3	12.6	0.7	5.9	0.2	0.2	2.8	1.4	0.2	0.2	0.6	1.5	0.9	7.5	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	101.3	275.6	1.8	0.5	0.0	0.0	0.0	0.0	119.3	6.8	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	8.1	0.4	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	9.4	0.8	0.1	0.0	0.0	0.0	0.0	3.9	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.3	0.2	0.5	0.2	0.0	0.2	0.2	0.2	0.2	3.0	0.0	0.0	11.5	7.4	0.0	0.2	5.1	0.0	11.4	0.0	0.0	0.1	0.0	0.7	14.6	0.0	0.0	0.0	1.2	2.2	1.3	0.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	2.3	0.6	0.0	0.0	0.0	0.0	1.0	0.0	0.9	3.0	0.2	0.0	0.1	5.2
MMP7	"MPSL1, PUMP-1"	ENSG00000137673	"Matrix metallopeptidase 7"	P09237	11	102520508-102530753	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 93.0;kidney: 129.5;salivary gland: 79.3"	"Cell type enriched"	"Detected in many"	6	"Ductal cells: 5335.6"	"Cancer enhanced"	"Detected in all"		"pancreatic cancer: 352.1"	"Region enriched"	"Detected in single"	5	"pons and medulla: 1.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 23.2;CAPAN-2: 129.5;EFO-21: 30.7;RPTEC TERT1: 56.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB025869, HPA051358"	Supported		Approved	Nucleoplasm,Vesicles	"Secreted to extracellular matrix"	NA	NA	2810000		"Nucleoplasm, Vesicles"		"CAB025869: , HPA051358: AB_2681452"	"unprognostic (1.06e-3)"	"unprognostic (9.51e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.38e-1)"	"unprognostic (7.70e-3)"	"unprognostic (7.28e-2)"	"prognostic unfavorable (2.53e-4)"	"prognostic unfavorable (3.38e-4)"	"unprognostic (3.96e-2)"	"unprognostic (5.63e-2)"	"unprognostic (6.59e-3)"	"unprognostic (1.51e-1)"	"unprognostic (6.36e-3)"	"unprognostic (1.42e-2)"	"unprognostic (5.54e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.46e-1)"	6.8	0.2	0.2	1.2	0.2	0.0	28.8	0.2	0.2	5.2	0.2	0.2	2.1	0.0	17.2	12.3	3.3	16.4	93.0	0.2	0.2	0.2	129.5	1.4	5.0	0.9	0.2	0.2	3.9	23.5	0.0	0.7	2.7	1.3	42.0	0.0	0.2	79.3	6.7	0.2	7.8	0.3	0.5	0.2	0.2	0.9	9.4	0.2	1.2	0.3	1.4	4.5	19.9	0.8	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	23.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	129.5	0.0	30.7	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	56.0	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.1	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	1.3	0.2	80.4	30.5	0.0	310.5	0.9	0.0	0.6	119.8	113.8	646.0	964.8	0.0	0.3	0.0	5335.6	3.9	0.3	0.0	0.0	184.1	0.2	0.4	323.2	2.3	0.0	103.8	0.0	0.0	0.0	0.0	6.5	10.9	7.3	0.0	113.6	0.0	0.0	723.2	0.0	0.0	6.0	0.0	0.0	0.4	0.0	0.1	2.0	0.7	0.0	0.0	640.3
MMP8	CLG1	ENSG00000118113	"Matrix metallopeptidase 8"	P22894	11	102711795-102727050	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"bone marrow: 119.3"	"Cell type enriched"	"Detected in single"	32	"Hofbauer cells: 4.3"	"Cancer enriched"	"Detected in single"	17	"melanoma: 5.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.7"	"Group enriched"	"Detected in some"	32	"neutrophil: 1.4;non-classical monocyte: 4.9"	"Group enriched"	"Detected in many"	32	"granulocytes: 1.4;monocytes: 4.9"	"Cell line enriched"	"Detected in some"	8	"WM-115: 40.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA021221, HPA022935"	Enhanced				"Secreted to extracellular matrix"	NA	NA		83000			"HPA021221: AB_1854043, HPA022935: AB_1854044"	"unprognostic (3.03e-1)"	"unprognostic (8.49e-5)"	"unprognostic (1.08e-2)"	"unprognostic (3.95e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.01e-2)"		"unprognostic (7.68e-3)"	"unprognostic (1.27e-1)"	"unprognostic (4.92e-2)"	"unprognostic (6.64e-3)"		"unprognostic (2.45e-6)"	"unprognostic (2.33e-4)"	"unprognostic (1.33e-1)"	"unprognostic (4.97e-1)"	"unprognostic (2.30e-2)"	1.9	0.1	0.2	0.2	0.4	119.3	0.3	0.1	1.7	0.1	0.2	0.0	0.0	0.1	0.6	0.1	0.1	0.1	0.1	9.0	0.2	0.3	0.4	0.8	12.6	2.6	0.3	0.0	0.9	0.9	0.1	0.6	1.4	0.2	0.1	0.1	0.1	0.3	0.1	0.6	0.3	0.1	0.2	0.3	18.7	0.2	0.1	0.1	5.2	1.9	0.0	0.1	0.2	7.6	0.0	0.0	1.4	4.9	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	40.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	4.9	0.0	0.0	1.7	0.2	0.4	0.1	1.7	0.2	0.3	0.3	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MMP9	CLG4B	ENSG00000100985	"Matrix metallopeptidase 9"	P14780	20	46008908-46016561	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Collagen degradation"	"Hydrolase, Metalloprotease, Protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"adipose tissue: 64.0;blood: 63.2;bone marrow: 89.4;lymphoid tissue: 80.1"	"Cell type enhanced"	"Detected in many"	25	"Hofbauer cells: 273.8;Macrophages: 115.1;Melanocytes: 54.0"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	141	"neutrophil: 63.2"	"Lineage enriched"	"Detected in single"	339	"granulocytes: 63.2"	"Cell line enriched"	"Detected in some"	12	"NB-4: 89.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000348, HPA001238, HPA063909, CAB068199, CAB068200, CAB068201"	Enhanced		Approved	Cytosol	"Secreted to blood"	NA	NA	43300000	57000000	Cytosol		"CAB000348: , CAB068199: AB_2665675, CAB068200: AB_2665676, CAB068201: AB_2665677, HPA001238: AB_1079398, HPA063909: AB_2685150"	"unprognostic (4.62e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.85e-2)"	"prognostic favorable (2.55e-4)"	"unprognostic (6.65e-3)"	"unprognostic (2.82e-1)"	"prognostic unfavorable (7.19e-4)"	"unprognostic (1.54e-1)"	"unprognostic (8.57e-2)"	"unprognostic (3.21e-2)"	"unprognostic (4.15e-2)"	"unprognostic (1.96e-1)"	"prognostic unfavorable (4.05e-5)"	"unprognostic (4.65e-1)"	"unprognostic (9.85e-3)"	"unprognostic (2.48e-2)"	"unprognostic (2.17e-3)"	64.0	0.5	0.6	38.6	0.7	89.4	4.3	0.4	0.6	0.8	1.2	0.1	0.0	2.8	0.6	0.2	0.9	1.5	0.6	4.0	0.5	0.6	1.4	2.0	13.3	80.1	0.6	0.0	2.7	1.4	0.0	0.8	2.6	0.5	0.6	0.8	0.5	12.5	0.0	1.3	1.3	4.2	0.3	0.5	53.7	2.5	2.7	0.0	23.6	1.3	2.3	44.5	4.5	2.9	0.0	0.0	63.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.8	0.0	7.5	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.9	0.0	89.4	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.0	1.0	0.0	0.3	0.0	2.7	2.8	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	63.2	0.0	0.0	0.0	0.0	0.0	0.6	0.7	0.4	0.6	0.5	0.6	0.6	0.0	0.5	0.0	0.0	8.5	0.0	0.0	30.5	1.6	0.4	0.0	0.0	0.0	0.0	7.9	0.9	0.0	0.8	0.6	0.5	0.0	0.0	1.5	2.0	1.7	0.1	1.1	0.0	273.8	3.2	0.0	0.0	1.9	0.0	0.0	115.1	54.0	3.6	0.0	0.5	1.6	0.0	0.0	0.3	4.3	0.0	12.3	5.4	5.5	24.6	1.6	0.0	0.0	0.0
MPL	"CD110, TPOR"	ENSG00000117400	"MPL proto-oncogene, thrombopoietin receptor"	P40238	1	43337849-43352772	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lymphoid tissue: 8.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Cell type enriched"	"Detected in single"	5	"neutrophil: 1.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.6"	"Cell line enriched"	"Detected in single"	78	"HEL: 41.7"	"Region enhanced"	"Detected in single"		"cerebral cortex: 1.4"	"Low region specificity"	"Detected in all"			HPA007619			Supported	"Nuclear membrane,Plasma membrane"		NA	NA			"Plasma membrane"	"Nuclear membrane"	"HPA007619: AB_1854080"	"unprognostic (2.74e-1)"	"unprognostic (6.56e-2)"	"unprognostic (2.95e-1)"	"unprognostic (8.71e-2)"	"unprognostic (1.37e-2)"	"unprognostic (1.06e-3)"	"unprognostic (1.19e-1)"	"unprognostic (1.22e-2)"	"unprognostic (5.83e-2)"	"unprognostic (1.03e-1)"	"unprognostic (5.94e-4)"	"unprognostic (1.51e-1)"	"unprognostic (1.19e-4)"	"unprognostic (2.39e-1)"	"unprognostic (3.26e-1)"	"unprognostic (1.03e-4)"	"unprognostic (1.42e-1)"	1.1	0.3	0.9	0.5	0.8	2.0	0.9	0.5	2.2	0.6	0.6	0.5	0.5	0.3	0.9	1.7	0.9	2.1	0.5	3.9	0.8	0.6	0.5	0.5	2.0	0.5	0.9	0.5	6.6	1.1	0.6	0.6	2.2	0.5	1.5	0.7	0.5	0.5	0.7	0.6	0.4	1.2	2.1	2.5	8.6	0.5	2.1	0.5	0.5	2.2	2.4	0.5	0.9	0.5	0.0	0.0	1.6	0.3	0.0	0.0	4.0	0.1	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.5	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	41.7	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.1	0.4	0.2	0.2	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	4.0	0.9	0.8	0.5	2.2	0.8	0.6	0.9	0.5	0.5	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MR1	HLALS	ENSG00000153029	"Major histocompatibility complex, class I-related"	Q95460	1	181033425-181061938	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Innate immunity"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA048304			Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"		"HPA048304: AB_2680347"	"unprognostic (6.89e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.31e-2)"	"unprognostic (1.96e-1)"	"unprognostic (8.66e-3)"	"unprognostic (4.37e-2)"	"unprognostic (1.96e-1)"	"unprognostic (1.36e-2)"	"unprognostic (2.03e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.49e-2)"	"unprognostic (6.41e-2)"	"unprognostic (1.05e-2)"	"unprognostic (7.40e-3)"	"unprognostic (4.69e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.07e-2)"	10.5	13.8	5.3	10.2	7.1	7.7	8.3	1.7	5.5	8.6	8.2	5.3	6.8	5.3	10.4	10.9	12.6	8.6	13.2	8.9	5.2	3.1	10.5	10.7	16.6	16.2	5.9	5.0	13.9	5.1	12.4	17.6	11.5	5.1	13.2	6.3	12.3	8.1	8.6	3.8	10.1	7.8	9.6	6.1	14.9	6.7	5.5	6.2	23.2	13.6	7.1	18.4	16.4	9.6	12.9	15.6	24.0	22.2	14.9	14.3	11.1	3.7	2.6	0.1	2.2	16.0	19.5	6.8	7.4	20.4	6.2	10.6	1.0	15.2	4.5	15.5	13.3	4.9	9.9	0.3	8.7	5.4	13.7	2.4	6.6	3.0	4.5	5.4	5.3	19.9	12.7	24.3	9.2	10.0	11.6	0.6	8.5	12.2	12.4	12.0	4.1	5.6	3.8	0.0	0.0	0.4	6.4	0.1	12.6	6.7	11.0	0.1	0.2	3.9	7.2	5.2	3.1	7.6	11.5	3.8	6.1	0.8	10.6	3.6	20.6	6.9	8.5	5.7	7.2	0.6	24.0	17.9	18.1	14.3	22.2	12.7	12.1	13.0	12.7	15.6	12.9	9.7	14.3	13.4	14.9	18.7	8.4	13.6	11.1	5.3	7.1	1.7	5.5	5.2	3.1	5.9	5.0	5.1	6.2	17.9	25.9	17.9	7.5	4.4	0.8	3.9	10.2	10.7	11.4	14.0	0.0	13.9	5.0	7.7	0.2	4.4	1.4	23.3	5.6	7.4	9.3	6.2	16.2	9.0	24.5	0.0	2.4	1.8	22.5	0.0	10.0	17.1	6.8	25.2	3.2	4.5	6.1	5.5	11.3	2.1	0.4	0.0	6.6	0.3	1.1	4.6	20.5	15.2	4.0	12.7
MRC1	"bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1"	ENSG00000260314	"Mannose receptor C-type 1"	P22897	10	17809344-17911170	"CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Endocytosis, Host-virus interaction"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 44.8;lymphoid tissue: 37.8"	"Group enriched"	"Detected in many"	6	"Hofbauer cells: 135.5;Ito cells: 511.3;Kupffer cells: 324.4;Macrophages: 182.8"	"Low cancer specificity"	"Detected in all"							"Cell type enriched"	"Detected in single"	15	"myeloid DC: 8.2"	"Lineage enriched"	"Detected in single"	15	"dendritic cells: 8.2"	"Group enriched"	"Detected in some"	19	"MOLT-4: 17.7;TIME: 16.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA004114, HPA045134, CAB068203"	Enhanced					NA	NA		130000000			"CAB068203: AB_2665652, HPA004114: AB_1846270, HPA045134: AB_2679228"	"unprognostic (2.20e-1)"	"unprognostic (2.07e-1)"	"unprognostic (1.03e-2)"	"unprognostic (2.58e-1)"	"unprognostic (5.62e-2)"	"unprognostic (4.30e-1)"	"unprognostic (6.36e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.05e-2)"	"unprognostic (6.05e-2)"	"unprognostic (5.61e-2)"	"unprognostic (4.12e-1)"	"unprognostic (2.94e-2)"	"unprognostic (4.97e-2)"	"unprognostic (3.05e-2)"	"unprognostic (1.74e-2)"	"unprognostic (7.02e-2)"	34.8	8.3	0.3	6.2	1.2	0.0	19.8	0.7	0.6	5.2	11.2	0.6	0.9	2.2	4.5	10.4	4.2	1.3	7.9	13.4	0.9		12.4	16.4	44.8	37.8	1.0	0.0	3.6	5.1	1.8	2.4	15.4	3.1	5.5	5.1	7.0	0.7	1.9	5.1	0.0	6.5	8.2	1.4	30.6	2.2	7.1	0.8	0.8	6.5	3.5	0.7	7.5	5.1	0.0	8.2	0.1	0.5	0.0	0.4	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	17.7	0.0	0.2	0.0	0.0	0.1	0.3	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	16.4	0.0	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.1	0.0	8.2	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.4	0.2											29.8	47.4	11.5	0.0	0.3	0.0	3.6	5.1	10.7	13.6	0.0	0.0	0.8	0.0	0.0	26.7	4.8	1.3	0.0	0.3	1.1	1.0	0.0	12.8	2.5	135.5	0.0	0.0	511.3	324.4	7.9	1.4	182.8	0.0	0.0	0.4	0.0	0.1	1.1	0.0	0.0	0.0	32.3	0.0	0.3	1.2	0.4	1.7	4.9	0.8	0.0
MS4A1	"B1, Bp35, CD20, MS4A2"	ENSG00000156738	"Membrane spanning 4-domains A1"	P11836	11	60455752-60470760	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"B-cell activation"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"blood: 77.7;intestine: 46.1;lymphoid tissue: 134.1"	"Cell type enriched"	"Detected in some"	61	"B-cells: 527.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	105	"memory B-cell: 77.7;naive B-cell: 77.7"	"Lineage enriched"	"Detected in single"	105	"B-cells: 77.7"	"Group enriched"	"Detected in some"	25	"Daudi: 122.9;U-698: 61.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000015, HPA014341, HPA014391"	Enhanced		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000015: AB_2282030, HPA014341: AB_1846265, HPA014391: AB_1846264"	"prognostic favorable (4.34e-5)"	"unprognostic (4.45e-4)"	"unprognostic (1.19e-4)"	"unprognostic (2.04e-3)"	"unprognostic (1.06e-1)"	"unprognostic (5.53e-7)"	"unprognostic (2.46e-3)"	"unprognostic (1.85e-3)"	"unprognostic (3.06e-2)"	"unprognostic (2.89e-4)"	"unprognostic (6.96e-2)"	"unprognostic (2.84e-2)"	"unprognostic (3.96e-5)"	"unprognostic (2.23e-1)"	"unprognostic (8.04e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.30e-1)"	1.6	0.3	0.3	79.0	0.3	3.6	0.6	0.3	0.3	0.5	2.0	0.0	0.0	0.2	0.4	0.5	7.0	0.4	1.3	0.7	0.3	0.3	2.0	0.9	2.7	81.2	0.3	0.1	0.3	0.4	0.0	0.4	0.4	0.1	1.1	1.7	0.6	14.5	0.2	0.3	0.3	46.1	0.1	0.4	90.7	2.6	0.6	0.0	15.7	2.5	2.7	134.1	6.4	0.8	77.7	0.0	0.2	0.0	0.7	0.6	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	122.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	61.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	77.7	0.3	0.6	0.0	77.7	0.0	0.2	0.2	0.7	0.0	0.0	0.0	3.5	0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.1	0.1	0.0	0.0	6.7	527.8	0.0	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.1	0.0	0.0	0.0	0.6	1.8	0.0	0.0	6.8	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	8.7	0.0	0.0
MS4A2	"APY, FCER1B, IGER, MS4A1"	ENSG00000149534	"Membrane spanning 4-domains A2"	Q01362	11	60088261-60098466	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"IgE-binding protein, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 72.0"	"Cell type enriched"	"Detected in some"	18	"granulocytes: 912.4"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	720	"basophil: 72.0"	"Lineage enriched"	"Detected in single"	720	"granulocytes: 72.0"	"Cell line enhanced"	"Detected in some"		"HEL: 7.1;NB-4: 2.6;THP-1: 4.2;U-937: 1.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA059967	Enhanced					NA	NA					"HPA059967: AB_2684183"	"unprognostic (7.28e-2)"	"unprognostic (9.21e-2)"	"unprognostic (2.50e-4)"	"unprognostic (4.97e-2)"	"unprognostic (4.47e-1)"	"unprognostic (2.40e-6)"	"unprognostic (1.88e-2)"	"unprognostic (6.21e-3)"	"unprognostic (3.96e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.41e-1)"	"unprognostic (6.63e-3)"	"unprognostic (6.49e-3)"	"unprognostic (9.95e-2)"	"unprognostic (4.03e-2)"	"unprognostic (1.57e-1)"	"unprognostic (1.74e-1)"	4.9	0.5	0.4	5.1	0.4	0.2	2.1	0.4	0.4	11.9	4.6	0.1	4.5	4.7	14.3	11.2	5.9	1.1	14.6	2.1	0.4	0.4	1.5	0.9	12.9	0.5	0.4	0.1	1.1	1.2	0.2	0.6	0.6	0.1	17.5	5.6	4.5	3.2	5.4	1.5	4.3	7.4	15.9	0.4	0.6	4.5	2.7	0.2	1.2	0.6	6.7	3.4	5.1	4.1	0.0	0.0	72.0	0.0	0.0	0.0	0.0	0.1	0.2	0.1	0.3	0.2	0.0	0.3	0.0	0.0	0.1	0.3	0.2	0.4	0.1	0.1	0.0	0.0	0.2	0.0	0.1	0.1	0.3	0.0	7.1	0.5	0.2	0.3	0.9	0.4	0.1	0.2	0.0	0.1	0.0	0.1	0.1	0.9	0.3	0.0	0.1	0.0	2.6	0.1	0.0	0.1	0.1	0.0	0.2	0.0	1.0	0.2	0.1	0.1	0.2	0.0	0.0	0.3	4.2	0.0	0.1	0.1	0.3	0.1	0.1	0.0	0.1	0.2	1.9	0.2	72.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.4	0.4	0.4	0.4	0.4	0.4	0.1	0.1	0.2	0.0	51.4	0.0	0.6	0.0	0.4	0.4	0.0	1.4	12.5	0.0	0.0	0.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.5	912.4	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1
MTNR1A	MEL-1A-R	ENSG00000168412	"Melatonin receptor 1A"	P48039	4	186533655-186555567	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 3.8;intestine: 3.1;kidney: 5.7;testis: 2.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A549: 2.8;EFO-21: 2.0;HEK 293: 2.1;NTERA-2: 1.8;SCLC-21H: 1.6;SH-SY5Y: 3.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"									NA	NA								"unprognostic (7.99e-2)"			"unprognostic (2.27e-1)"		"unprognostic (2.16e-1)"		"unprognostic (3.67e-1)"	"unprognostic (2.14e-1)"	"unprognostic (9.88e-2)"	"unprognostic (9.20e-2)"	"unprognostic (8.81e-2)"				0.0	0.0	0.1	1.2	0.1	0.0	0.0	3.8	0.2	0.0	3.1			0.3	0.0	0.0	0.0	0.4	0.6	0.0	0.1	0.1	5.7	0.0	0.0	0.0	0.0		0.0	1.6	0.0	0.0	0.0		0.0	2.4		0.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	2.5			0.0		0.1	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.1	0.3	0.5	0.0	2.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.1	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
MTNR1B		ENSG00000134640	"Melatonin receptor 1B"	P49286	11	92969720-92985066	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 3.0;lymphoid tissue: 1.9;placenta: 4.5;testis: 2.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	20	"GAMG: 10.6;SuSa: 2.9"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"midbrain: 0.8;pons and medulla: 1.2"	HPA074024	Supported					NA	NA					"HPA074024: "					"unprognostic (3.61e-1)"												"unprognostic (1.43e-1)"	0.1	0.0	0.3	0.0	3.0	0.0	0.0	0.1	0.6	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.0	0.0	0.0	0.2	0.1		0.0	0.0	0.0	0.0	4.5		0.0	0.0		0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	2.0			0.0		1.9	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
MTOR	"FLJ44809, FRAP, FRAP1, FRAP2, RAFT1, RAPT1"	ENSG00000198793	"Mechanistic target of rapamycin kinase"	P42345	1	11106535-11262507	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Sertoli cells: 38.8;Spermatocytes: 48.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB069425, HPA071227"	Approved		Approved	Vesicles,Cytosol		NA	NA			"Vesicles, Cytosol"		"CAB069425: , HPA071227: AB_2686367"	"unprognostic (3.18e-1)"	"unprognostic (1.50e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.45e-3)"	"unprognostic (5.50e-2)"	"unprognostic (2.55e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.68e-1)"	"unprognostic (1.18e-1)"	"unprognostic (8.24e-3)"	"unprognostic (3.48e-2)"	"unprognostic (1.88e-1)"	"prognostic favorable (1.49e-5)"	"unprognostic (1.27e-1)"	"unprognostic (2.45e-1)"	"unprognostic (6.60e-2)"	"unprognostic (7.55e-2)"	11.3	13.9	18.7	13.0	22.5	12.3	14.9	25.2	25.2	11.3	14.5	18.2	10.4	11.2	13.8	23.6	13.1	10.5	15.7	14.2	14.5	13.6	15.8	19.4	10.8	14.3	14.0	14.4	10.7	16.6	26.5	16.0	12.5	15.5	15.2	17.1	14.4	14.2	15.2	24.6	16.5	13.6	15.2	10.4	15.4	13.1	38.6	13.1	16.6	13.2	9.9	15.7	11.7	10.2	3.9	4.0	3.0	6.4	2.6	5.6	2.3	15.2	13.9	18.7	14.2	22.7	10.8	9.4	12.9	12.4	17.3	17.0	14.2	14.1	17.0	11.1	15.2	10.7	18.2	25.3	19.8	22.4	13.5	18.5	22.6	28.7	17.9	14.2	21.9	16.8	13.8	15.1	24.7	25.1	8.2	21.8	16.4	25.2	14.6	12.0	17.4	15.1	16.8	14.2	16.0	13.1	15.2	22.1	11.4	15.3	13.9	18.9	13.9	27.6	15.0	16.9	21.5	12.2	13.0	23.3	15.1	13.7	11.5	17.3	14.4	13.4	33.4	10.9	23.8	15.9	0.7	2.9	3.0	5.2	6.4	4.3	3.9	3.0	2.7	4.0	3.4	3.6	3.1	2.0	2.6	3.3	3.1	5.6	2.3	18.7	22.5	25.2	25.2	14.5	13.6	14.0	14.4	15.5	13.1	14.9	10.2	5.2	4.5	3.1	0.0	25.7	2.5	2.7	10.3	8.7	0.0	6.5	1.7	6.3	31.2	7.8	7.9	0.0	5.4	5.9	5.1	7.5	12.7	13.0	6.1	0.0	9.9	5.5	7.3	29.3	7.2	6.0	8.5	5.4	6.8	0.0	8.6	3.5	7.8	4.3	0.0	38.8	6.9	48.4	31.3	5.0	8.2	6.5	9.5	5.5
MTR	cblG	ENSG00000116984	"5-methyltetrahydrofolate-homocysteine methyltransferase"	Q99707	1	236795281-236903981	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Amino-acid biosynthesis, Methionine biosynthesis"	"Methyltransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cardiomyocytes: 84.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA044474, HPA054915"	Approved		Supported	Cytosol		NA	NA			Cytosol		"HPA044474: AB_10966696, HPA054915: AB_2732589"	"unprognostic (2.12e-1)"	"unprognostic (1.03e-1)"	"unprognostic (6.96e-2)"	"unprognostic (1.99e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.76e-1)"	"unprognostic (4.87e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.48e-2)"	"unprognostic (3.34e-1)"	"unprognostic (5.73e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.67e-2)"	"unprognostic (8.84e-3)"	"unprognostic (1.88e-1)"	"prognostic unfavorable (5.75e-4)"	"unprognostic (8.10e-2)"	14.5	11.4	9.9	13.2	13.5	7.6	13.6	14.8	14.4	16.9	16.4	16.2	16.0	7.5	18.1	27.3	10.4	18.4	16.3	21.9	9.4	9.8	21.2	9.5	11.7	14.3	12.6	12.8	24.7	20.8	27.4	12.4	17.5	13.0	14.0	8.9	17.7	11.1	17.3	27.0	15.4	11.7	23.3	12.1	13.9	14.9	20.1	12.1	20.8	22.4	11.1	13.2	18.4	14.4	3.3	1.6	3.0	2.0	2.3	5.8	2.1	9.9	6.7	8.3	6.8	15.4	14.2	9.8	8.8	7.8	9.7	10.1	6.4	7.7	22.3	8.1	9.8	5.2	6.9	10.7	7.8	11.6	10.3	9.2	13.1	9.0	11.7	10.3	20.7	8.2	20.2	4.9	12.8	12.3	7.6	12.8	12.1	18.8	10.5	8.1	6.9	10.8	6.7	11.1	8.2	3.6	11.8	14.7	14.3	7.0	11.6	6.8	18.9	9.9	7.2	8.8	6.1	10.3	8.5	16.6	16.0	6.1	12.2	11.3	22.7	7.0	13.0	10.4	13.1	15.8	2.7	1.6	3.0	3.2	2.0	5.8	2.7	4.2	4.5	1.5	3.3	5.0	4.0	0.1	2.3	1.5	1.6	2.9	2.1	9.9	13.5	14.8	14.4	9.4	9.8	12.6	12.8	13.0	12.1	53.6	31.2	20.1	6.8	7.2	0.0	84.0	20.4	20.1	13.6	38.4	0.0	19.3	1.7	11.9	5.3	12.8	6.3	0.0	12.8	7.8	17.5	8.3	29.0	9.6	12.6	0.0	8.1	15.4	16.5	4.2	22.2	10.4	10.1	10.8	7.3	0.0	11.7	10.5	31.1	5.7	0.0	6.5	15.5	14.9	19.7	4.4	18.9	11.7	12.1	4.8
MTTP	"ABL, MTP"	ENSG00000138823	"Microsomal triglyceride transfer protein"	P55157	4	99563761-99623999	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Lipid transport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	49	"intestine: 211.4;liver: 60.8"	"Cell type enriched"	"Detected in some"	8	"Hepatocytes: 201.1"	"Cancer enriched"	"Detected in many"	13	"liver cancer: 28.7"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.0"	"Lineage enriched"	"Detected in single"	10	"B-cells: 1.0"	"Group enriched"	"Detected in some"	6	"AF22: 12.8;Hep G2: 14.0"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA051170, HPA054862"	Uncertain		Uncertain	Cytosol	"Intracellular and membrane"	NA	NA		450000	Cytosol		"HPA051170: , HPA054862: AB_2682628"	"unprognostic (1.66e-2)"	"unprognostic (1.14e-1)"	"unprognostic (5.64e-2)"	"unprognostic (5.33e-2)"	"unprognostic (3.49e-3)"	"unprognostic (7.38e-2)"	"unprognostic (1.05e-1)"	"unprognostic (2.74e-2)"	"unprognostic (1.08e-1)"	"unprognostic (3.66e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.62e-1)"	"unprognostic (1.27e-3)"	"unprognostic (2.02e-2)"	"unprognostic (3.64e-1)"	"unprognostic (1.53e-2)"	"unprognostic (1.31e-1)"	0.1	0.1	0.3	0.0	0.3	0.0	0.1	0.1	0.2	0.0	53.2	0.2	0.1	53.4	0.0	0.0	0.2	0.2	0.4	0.4	0.3	0.4	2.7	60.8	0.1	0.0	0.4	0.1	1.1	0.1	0.0	0.3	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.1	0.1	211.4	0.7	0.4	0.1	0.2	1.8	0.2	0.1	0.1	0.1	0.0	0.3	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	12.8	0.0	0.0	0.1	1.1	0.1	0.0	0.0	0.3	0.5	0.0	0.4	0.2	0.0	0.1	0.0	0.1	0.0	0.0	2.3	0.2	0.3	0.1	14.0	0.0	0.1	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.1	0.7	0.6	0.0	0.3	0.3	0.2	1.3	0.0	0.0	0.8	1.0	0.2	0.1	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.4	0.1	0.1	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.1	0.2	0.3	0.4	0.4	0.1	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.5	7.6	0.0	0.0	1.8	0.0	0.1	0.0	0.0	25.5	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	201.1	0.1	0.0	0.0	5.5	3.3	7.9	0.9	0.0	0.0	1.0	0.0	0.0	0.3	0.0	0.4	18.6	0.0	6.5	0.0	21.9	1.5	0.0	0.0	0.0	0.0	0.0
MUT		ENSG00000146085	"Methylmalonyl-CoA mutase"	P22033	6	49430360-49463191	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Isomerase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 96.5"	"Cell type enhanced"	"Detected in many"	6	"Hepatocytes: 117.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA035971, HPA035972"	Enhanced		Approved	Mitochondria,Cytosol		NA	NA		110000	Cytosol	Mitochondria	"HPA035971: AB_10696648, HPA035972: AB_2674895"	"unprognostic (1.34e-2)"	"unprognostic (1.12e-1)"	"unprognostic (1.17e-2)"	"unprognostic (3.72e-2)"	"unprognostic (3.18e-3)"	"unprognostic (1.20e-1)"	"unprognostic (1.16e-2)"	"unprognostic (1.16e-2)"	"unprognostic (3.62e-2)"	"unprognostic (1.89e-2)"	"unprognostic (6.57e-2)"	"unprognostic (9.89e-2)"	"prognostic favorable (8.71e-13)"	"unprognostic (5.38e-2)"	"unprognostic (3.78e-1)"	"unprognostic (6.01e-3)"	"unprognostic (1.91e-1)"	10.7	14.3	10.9	5.7	13.4	4.1	9.7	10.0	12.1	8.9	12.7	8.6	9.0	13.6	8.7	8.6	13.2	8.4	7.5	16.6	10.1	10.0	25.5	96.5	7.8	5.7	11.8	9.5	13.1	15.7	15.8	13.5	7.5	12.0	11.2	11.2	8.0	9.3	9.2	13.7	9.0	14.7	11.8	9.7	6.4	10.9	9.1	9.9	8.2	11.2	9.1	5.8	12.8	8.1	9.4	8.9	14.0	15.2	14.2	12.0	6.7	13.4	4.8	14.5	16.9	28.9	27.5	8.0	12.1	16.0	12.8	19.0	5.5	7.0	12.5	9.7	12.9	19.4	7.7	16.1	8.6	18.1	10.6	11.7	6.6	11.0	14.4	21.1	8.5	6.4	16.6	12.8	13.0	15.2	11.5	12.3	13.6	12.0	15.0	15.0	8.4	9.9	8.4	6.2	14.2	3.5	8.9	18.2	17.2	14.8	12.9	13.5	9.4	13.3	9.6	20.0	15.9	8.3	13.6	8.8	11.9	8.8	16.1	16.3	5.9	6.7	10.7	16.8	10.0	10.4	14.0	7.5	12.5	7.9	9.9	9.9	9.4	9.5	9.9	8.9	8.3	12.0	9.0	4.3	14.2	15.2	6.3	11.9	6.7	10.9	13.4	10.0	12.1	10.1	10.0	11.8	9.5	12.0	9.9	17.9	17.4	10.4	16.2	17.7	16.5	60.2	22.9	18.7	21.6	31.4	2.0	21.2	24.9	14.4	5.7	10.0	27.4	0.0	12.8	11.2	13.8	13.3	10.4	117.7	10.8	19.1	50.0	14.1	10.0	2.1	22.2	9.4	8.5	2.8	23.1	28.2	10.5	23.0	26.2	34.2	15.2	32.3	12.2	18.6	14.3	17.6	27.9	7.9	21.2	11.5
NDUFV3	CI-10k	ENSG00000160194	"NADH:ubiquinone oxidoreductase subunit V3"	P56181	21	42879644-42913304	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Respiratory chain, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 129.5"	"Cell type enhanced"	"Detected in all"	9	"Cardiomyocytes: 701.2;Late spermatids: 1042.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"							"Low region specificity"	"Detected in all"			"HPA019791, HPA020463, HPA030427, CAB034142"	Enhanced		Enhanced	Mitochondria		NA	NA			Mitochondria		"CAB034142: AB_2298212, HPA019791: AB_1854357, HPA020463: AB_1854358, HPA030427: AB_10603024"	"unprognostic (1.62e-1)"	"unprognostic (2.17e-3)"	"unprognostic (1.31e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.11e-2)"	"unprognostic (4.69e-1)"	"unprognostic (2.97e-2)"	"unprognostic (1.05e-1)"	"unprognostic (3.13e-1)"	"unprognostic (3.85e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.45e-1)"	"unprognostic (6.56e-2)"	"unprognostic (9.30e-3)"	"unprognostic (2.14e-1)"	"unprognostic (1.94e-1)"	18.1	14.1	16.9	11.1	17.2	15.8	14.6	11.8	23.2	12.0	15.9	11.9	14.6	15.2	15.1	15.7	15.6	12.7	15.4	54.9	14.2	11.0	15.1	24.3	10.8	12.5	14.0	18.6	16.0	17.7	13.2	13.1	11.6	19.2	13.6	11.4	12.2	19.4	21.8	129.5	15.4	13.5	16.9	16.0	13.3	14.3	20.3	13.3	6.6	11.6	18.5	10.6	13.3	11.8	9.9	22.9	16.0	22.8	10.5	8.8	10.3	9.6	11.4	11.0	18.0	13.6	11.9	13.6	19.2	11.0	11.5	9.6	20.7	11.9	10.7	15.2	7.2	15.6	10.5	12.8	16.9	7.5	6.1	15.5	35.3	13.3	16.2	21.4	12.0	18.5	13.3	14.7	11.6	18.4	10.4	14.4	7.4	27.9	14.0	13.1	18.9	8.0	18.2	14.4	21.5	22.4	13.9	8.0	33.4	15.4	12.8	8.1	8.4	19.3	22.8	12.7	6.2	19.6	15.9	16.9	10.8	7.5	13.8	13.6	20.8	13.7	12.2	14.1	21.6	16.2	3.7	21.4	16.0	8.0	22.8	8.1	8.1	7.6	6.7	22.9	9.9	8.8	7.7	3.8	10.5	19.6	11.3	8.8	10.3	16.9	17.2	11.8	23.2	14.2	11.0	14.0	18.6	19.2	13.3	50.6	37.7	43.0	46.0	17.6	69.1	701.2	89.2	92.3	27.3	85.5	64.8	46.1	195.6	69.0	416.9	34.9	128.4	140.2	87.3	49.8	41.1	75.6	30.1	285.4	97.8	54.0	75.1	62.0	81.5	1042.9	61.5	68.7	35.4	67.7	73.4	56.3	83.6	77.2	58.7	265.4	102.6	71.1	47.2	216.7	86.2	20.6	75.2	34.6	82.9	49.3
NFKB1	"KBF1, NF-kappaB, NF-kB1, NFkappaB, NFKB-p50, p105, p50"	ENSG00000109320	"Nuclear factor kappa B subunit 1"	P19838	4	102501329-102617302	"Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins, Transcription factors"	"Apoptosis, Transcription, Transcription regulation"	"Activator, DNA-binding"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"monocytes: 303.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004031, HPA027305"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB004031: AB_330564, HPA027305: AB_1854429"	"unprognostic (1.06e-1)"	"unprognostic (1.61e-2)"	"unprognostic (4.37e-2)"	"unprognostic (2.38e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.20e-1)"	"unprognostic (2.04e-2)"	"unprognostic (8.98e-2)"	"unprognostic (1.96e-1)"	"unprognostic (9.03e-3)"	"unprognostic (2.28e-1)"	"unprognostic (2.71e-1)"	"prognostic favorable (1.76e-4)"	"unprognostic (1.84e-2)"	"unprognostic (6.75e-3)"	"unprognostic (1.74e-1)"	"unprognostic (6.92e-3)"	19.8	14.7	8.2	37.7	12.0	44.5	26.6	12.4	10.3	18.2	17.1	10.4	10.4	10.7	17.5	11.2	20.5	16.4	20.3	14.5	7.5	5.1	13.2	15.8	26.9	46.0	11.4	4.8	17.5	14.3	10.2	8.7	13.7	10.0	18.8	14.6	10.8	17.7	13.5	17.1	19.6	16.7	16.0	10.1	30.0	14.6	9.3	12.5	37.5	14.7	16.3	26.7	18.4	22.7	5.8	10.4	5.5	7.1	14.3	10.6	3.5	17.1	9.7	5.2	7.9	16.2	14.6	6.4	9.9	29.1	12.3	12.5	10.7	24.6	28.1	8.9	15.5	17.8	13.7	10.3	17.2	16.9	25.3	6.1	11.9	7.8	11.5	15.1	21.2	25.4	12.0	12.1	11.9	16.6	8.9	15.4	9.4	11.6	20.6	8.8	12.1	1.8	11.7	3.1	12.7	8.9	15.0	12.4	12.7	11.5	24.2	3.6	5.9	18.1	25.3	9.9	5.2	5.1	15.9	19.7	16.7	8.7	9.0	13.8	9.1	6.3	27.3	10.7	10.9	23.6	5.2	5.4	4.9	3.4	7.1	6.0	5.6	8.4	5.6	10.4	5.8	10.6	8.9	5.5	14.3	5.9	7.4	4.5	3.5	8.2	12.0	12.4	10.3	7.5	5.1	11.4	4.8	10.0	12.5	38.7	46.7	27.4	82.1	147.0	6.7	16.5	12.7	24.1	36.4	19.2	5.9	12.5	3.3	25.5	3.8	30.8	32.3	0.0	31.9	14.4	46.3	57.3	111.6	20.3	23.2	19.1	32.2	22.7	57.1	0.9	22.2	56.9	52.3	303.0	36.5	10.3	40.0	26.9	32.5	21.4	6.5	0.0	61.7	2.1	6.6	131.4	11.9	22.4	32.1	74.8
NISCH	"I-1, IRAS, KIAA0975"	ENSG00000010322	Nischarin	Q9Y2I1	3	52455118-52493071	"FDA approved drug targets, Predicted intracellular proteins"	Apoptosis	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Intestinal endocrine cells: 162.6;Peritubular cells: 231.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA023189	Approved		Approved	"Nucleoplasm,Vesicles,Microtubules,Cytokinetic bridge,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Vesicles, Microtubules, Cytokinetic bridge"	"HPA023189: AB_1854495"	"unprognostic (6.66e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.59e-3)"	"unprognostic (4.11e-3)"	"unprognostic (1.64e-1)"	"unprognostic (8.08e-3)"	"unprognostic (1.60e-2)"	"unprognostic (6.56e-3)"	"unprognostic (4.96e-2)"	"unprognostic (8.33e-3)"	"prognostic favorable (1.91e-4)"	"unprognostic (1.40e-2)"	"unprognostic (5.10e-2)"	"unprognostic (1.19e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.47e-1)"	"unprognostic (7.05e-3)"	16.5	24.9	29.7	14.3	36.1	18.1	16.7	84.5	47.5	24.1	16.4	21.4	22.1	12.9	24.4	19.5	14.1	20.9	16.4	14.1	24.7	18.8	14.9	11.8	17.1	15.9	13.2	35.6	30.7	21.8	23.3	55.3	21.0	20.8	29.8	11.4	27.0	26.5	30.2	12.2	42.5	14.8	20.9	13.3	16.8	14.8	27.3	13.9	16.3	17.1	7.8	12.6	21.9	19.5	5.8	6.6	6.5	8.3	6.1	8.1	6.4	7.4	7.9	24.6	20.0	18.4	20.4	20.2	16.2	10.7	13.0	13.3	11.8	11.3	10.5	4.5	22.4	10.7	10.1	13.0	17.6	7.7	10.6	14.0	18.9	27.5	11.4	16.8	11.1	17.0	32.0	14.2	14.0	12.0	27.5	20.9	21.1	10.0	11.7	12.1	10.7	19.8	24.6	15.0	9.6	13.5	11.8	6.7	12.2	14.8	15.0	10.4	18.2	17.5	4.6	11.2	22.4	14.5	18.7	22.8	18.3	17.6	18.5	11.5	19.5	11.1	13.3	12.6	18.1	11.1	6.3	8.3	6.5	6.4	7.6	6.3	4.7	5.4	8.1	4.5	5.8	6.5	6.5	2.9	6.1	1.1	6.6	5.8	6.4	29.7	36.1	84.5	47.5	24.7	18.8	13.2	35.6	20.8	13.9	23.8	28.8	12.0	14.1	24.5	39.6	18.2	7.6	10.7	18.2	14.0	7.9	26.9	8.3	11.4	7.2	20.2	15.8	0.0	8.2	11.6	19.3	13.0	24.3	12.4	25.4	27.0	162.6	52.2	62.2	16.8	81.7	22.2	18.6	5.4	16.3	10.6	9.2	13.9	231.3	11.0	23.3	25.8	23.1	31.1	15.6	19.4	20.3	13.8	15.0	10.8
NNMT		ENSG00000166741	"Nicotinamide N-methyltransferase"	P40261	11	114257787-114313285	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Methyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 97.7"	"Cell type enriched"	"Detected in many"	9	"Hepatocytes: 3284.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"HSkMC: 68.8;LHCN-M2: 40.9;RPTEC TERT1: 105.9"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA059180	Approved		Approved	"Golgi apparatus,Cytosol"		NA	NA		15000	"Golgi apparatus"	Cytosol	"HPA059180: AB_2683940"	"unprognostic (1.62e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.61e-2)"	"unprognostic (6.14e-2)"	"unprognostic (3.51e-1)"	"prognostic unfavorable (2.07e-4)"	"unprognostic (1.76e-1)"	"unprognostic (5.84e-2)"	"unprognostic (2.71e-2)"	"unprognostic (2.48e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.69e-2)"	"prognostic unfavorable (1.02e-6)"	"prognostic unfavorable (1.75e-4)"	"unprognostic (1.11e-1)"	"unprognostic (3.37e-3)"	"unprognostic (2.77e-2)"	23.7	1.4	0.6	8.8	0.9	0.1	14.6	0.6	1.7	13.1	8.5	0.7	4.9	0.5	15.8	8.7	12.0	8.3	15.3	8.2	1.6	0.0	4.7	97.7	10.0	3.4	1.1	0.6	11.2	2.0	0.6	2.6	8.6	3.3	9.6	3.3	1.6	3.6	6.7	18.3	8.2	4.3	12.4	1.5	5.8	5.1	7.3	0.6	1.3	5.3	2.2	3.1	10.9	35.3	0.6	0.1	0.7	0.2	0.0	0.9	0.0	0.0	4.8	0.0	4.3	24.8	32.2	0.0	6.1	16.3	9.8	19.5	0.0	6.6	0.0	21.8	12.5	1.3	0.0	0.0	2.2	9.9	0.0	0.0	0.0	7.6	0.0	33.8	0.0	0.0	68.8	23.8	6.9	10.3	8.2	13.5	0.0	0.0	0.0	40.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	27.4	0.0	105.9	0.0	0.0	0.0	30.7	0.0	0.0	1.5	0.0	0.0	9.5	5.6	22.6	8.7	1.0	0.0	0.0	0.0	1.7	0.0	0.4	0.0	0.2	0.0	0.2	0.1	0.9	0.2	0.0	0.2	0.1	0.6	0.0	0.2	0.7	0.0	0.0	0.1	0.0	0.0	0.6	0.9	0.6	1.7	1.6	0.0	1.1	0.6	3.3	0.6	41.7	380.8	30.2	10.6	92.0	0.5	4.0	76.5	18.7	20.5	76.8	0.0	0.9	8.3	207.6	0.2	191.1	0.0	163.5	133.3	1.9	375.3	11.6	12.8	3284.1	21.8	0.0	5.1	176.1	103.2	1.0	68.7	12.7	91.1	10.0	0.0	0.0	366.0	0.0	12.4	27.9	0.1	0.0	113.1	0.3	0.4	80.5	1.8	46.0	0.0	2.4
NNT		ENSG00000112992	"Nicotinamide nucleotide transhydrogenase"	Q13423	5	43602692-43707405	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Translocase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 100.0"	"Group enriched"	"Detected in many"	6	"Cardiomyocytes: 303.5;Hepatocytes: 274.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			"HPA004829, CAB004975"	Enhanced		Approved	Mitochondria,Cytosol		NA	NA		1100000	Mitochondria	Cytosol	"CAB004975: AB_425908, HPA004829: AB_1079495"	"unprognostic (1.51e-1)"	"unprognostic (1.07e-1)"	"unprognostic (3.33e-2)"	"unprognostic (4.81e-2)"	"unprognostic (5.02e-2)"	"unprognostic (1.81e-1)"	"unprognostic (4.04e-2)"	"unprognostic (1.96e-3)"	"unprognostic (2.20e-2)"	"unprognostic (3.98e-2)"	"unprognostic (1.65e-1)"	"unprognostic (8.33e-2)"	"prognostic favorable (1.22e-15)"	"unprognostic (8.24e-2)"	"unprognostic (1.11e-1)"	"unprognostic (2.76e-2)"	"unprognostic (2.58e-1)"	10.8	10.5	11.7	8.3	14.0	7.3	9.1	8.3	19.0	7.6	11.2	7.3	8.8	9.2	7.1	8.8	7.9	5.4	7.1	62.1	10.8	8.2	26.0	48.5	7.2	9.6	9.2	10.3	5.8	12.2	15.6	6.2	5.8	10.0	8.5	12.1	6.7	14.4	7.8	100.0	6.0	8.9	14.7	6.1	6.5	13.6	4.2	6.1	14.0	14.0	32.6	8.7	10.9	6.2	11.4	25.5	13.1	18.5	18.2	19.1	13.5	8.3	6.2	14.3	26.6	16.7	18.6	4.5	8.4	14.4	10.4	9.4	7.1	13.9	8.6	10.5	16.0	11.0	8.0	56.7	2.0	11.0	13.6	15.3	12.4	33.3	8.7	9.6	20.7	18.5	16.0	6.3	5.9	8.5	18.2	20.5	12.5	8.9	34.4	24.7	5.7	22.3	11.2	2.8	0.0	5.6	25.1	33.8	30.8	19.7	7.4	21.1	17.6	30.9	0.4	19.1	3.1	21.6	20.9	11.2	15.2	14.8	6.3	4.1	18.5	19.0	13.2	3.1	27.7	9.8	9.3	14.2	13.1	14.4	18.4	14.8	11.4	15.6	14.5	25.5	10.3	14.6	13.3	2.4	18.2	18.5	9.2	19.1	13.5	11.7	14.0	8.3	19.0	10.8	8.2	9.2	10.3	10.0	6.1	50.6	27.8	20.7	7.7	10.2	17.5	303.5	28.1	24.1	31.8	26.2	33.4	7.2	23.2	10.7	12.2	12.6	17.2	23.3	9.3	2.1	17.9	10.5	23.3	274.2	21.7	6.4	19.1	20.3	31.4	3.4	13.8	18.2	13.5	10.8	24.6	13.2	9.5	11.5	18.0	21.1	11.9	0.0	15.1	2.1	1.2	7.0	1.7	27.7	25.8	7.6
NOD2	"BLAU, CARD15, CD, CLR16.3, IBD1, NLRC2, PSORAS1"	ENSG00000167207	"Nucleotide binding oligomerization domain containing 2"	Q9HC29	16	50693588-50734041	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"Immunity, Innate immunity"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"Alveolar cells type 2: 5.9;Basal keratinocytes: 5.3;Kupffer cells: 9.7;Macrophages: 13.7;Suprabasal keratinocytes: 13.6"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"classical monocyte: 15.3;eosinophil: 3.9;intermediate monocyte: 9.1;myeloid DC: 15.5;neutrophil: 6.3;non-classical monocyte: 5.8"	"Group enriched"	"Detected in many"	6	"dendritic cells: 15.5;granulocytes: 6.3;monocytes: 15.3"	"Cell line enhanced"	"Detected in some"		"HMC-1: 11.9;T-47d: 5.7;THP-1: 6.8;U-266/70: 15.7;U-266/84: 6.7"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"HPA041985, HPA054494"	Enhanced		Approved	"Golgi apparatus,Cytosol"		No	NA			"Golgi apparatus, Cytosol"		"HPA041985: AB_2677780, HPA054494: AB_2682505"	"unprognostic (1.01e-1)"	"unprognostic (4.38e-1)"	"unprognostic (1.07e-1)"	"unprognostic (1.02e-3)"	"unprognostic (9.91e-3)"	"unprognostic (5.84e-2)"	"unprognostic (5.90e-3)"	"unprognostic (1.23e-1)"	"unprognostic (4.17e-1)"	"unprognostic (3.88e-2)"	"unprognostic (6.94e-3)"	"unprognostic (1.48e-2)"	"unprognostic (2.31e-9)"	"unprognostic (4.38e-2)"	"unprognostic (1.08e-2)"	"unprognostic (1.53e-1)"	"unprognostic (1.13e-1)"	2.6	0.6	0.9	6.2	0.5	13.2	1.7	0.5	1.5	5.7	1.0	0.7	0.9	1.5	1.8	2.6	12.6	1.1	3.7	3.2	1.2	0.5	0.8	1.9	7.6	8.0	1.6	0.0	1.4	0.4	0.0	1.0	2.6	1.4	1.8	1.0	1.2	5.5	0.4	1.4	14.2	1.3	1.9	3.2	4.7	1.4	2.2	0.9	1.0	0.9	12.1	8.3	4.0	10.6	0.0	15.5	6.3	15.3	1.9	1.0	6.8	0.5	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.2	0.0	11.9	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	2.1	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.1	0.0	1.4	0.0	0.0	5.7	6.8	0.0	0.0	0.0	0.0	0.0	15.7	6.7	0.0	0.2	0.1	0.0	2.0	15.3	3.9	0.2	9.1	0.5	0.0	1.0	0.9	15.5	0.0	0.1	0.3	6.3	1.9	5.8	0.6	0.6	6.8	0.9	0.5	0.5	1.5	1.2	0.5	1.6	0.0	1.4	0.9	0.0	5.9	0.0	0.3	5.3	0.0	0.4	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.3	1.1	0.0	2.4	0.0	1.2	0.0	9.7	0.0	0.0	13.7	1.7	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	13.6	0.2	0.7	0.0	0.3
NOS1	"nNOS, NOS"	ENSG00000089250	"Nitric oxide synthase 1"	P29475	12	117208142-117452170	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"brain: 13.4;skeletal muscle: 36.3"	"Cell type enhanced"	"Detected in some"	12	"Basal glandular cells: 7.9;Basal keratinocytes: 3.4;Glandular cells: 2.8;Ito cells: 8.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HaCaT: 6.3;RH-30: 13.1;RPTEC TERT1: 8.2;U-2 OS: 2.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002167, HPA058312, HPA069509"	Enhanced		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"CAB002167: AB_564073, HPA058312: AB_2683676, HPA069509: "	"unprognostic (1.63e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.18e-2)"	"unprognostic (6.64e-3)"	"unprognostic (4.91e-2)"	"unprognostic (2.74e-1)"	"unprognostic (2.54e-1)"	"unprognostic (9.12e-3)"	"unprognostic (2.51e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.07e-1)"	"unprognostic (7.56e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.73e-2)"	"unprognostic (1.34e-1)"	"unprognostic (5.97e-4)"	"unprognostic (1.87e-1)"	0.5	0.6	3.8	3.5	13.4	0.7	0.6	4.4	4.8	0.7	2.0	1.1	0.0	0.5	0.6	0.7	1.3	0.8	0.5	0.5	2.8	4.4	1.9	0.5	1.4	0.6	2.4	1.6	0.5	1.9	0.4	0.8	0.4	5.9	1.6	0.9	0.6	3.8	0.6	36.3	2.2	0.6	0.8	1.2	0.5	0.5	0.9	3.0	0.0	0.6	0.0	0.5	0.9	0.6	0.9	0.6	2.1	0.5	0.8	0.5	0.0	0.0	0.4	0.1	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.3	0.0	0.0	6.3	0.0	0.0	0.0	0.1	0.0	0.1	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.2	0.0	1.5	0.0	13.1	0.1	8.2	0.1	0.3	1.3	0.0	0.0	0.0	0.1	0.1	0.0	0.1	0.1	2.5	0.0	0.0	0.1	0.0	0.1	0.4	0.1	0.0	2.1	0.5	0.5	0.5	0.4	0.4	0.7	0.4	0.3	0.2	0.9	0.5	0.5	1.9	0.8	0.5	0.6	0.3	0.0	3.8	13.4	4.4	4.8	2.8	4.4	2.4	1.6	5.9	3.0	0.0	0.0	0.0	7.9	3.4	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	1.9	0.4	0.0	0.0	0.0	0.0	0.1	2.8	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.2	0.3	0.2	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.9	0.5	0.0	0.0	0.0	1.0
NOS2	"HEP-NOS, iNOS, NOS, NOS2A"	ENSG00000007171	"Nitric oxide synthase 2"	P35228	17	27756766-27800499	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 20.8;lymphoid tissue: 15.6"	"Group enriched"	"Detected in some"	6	"Extravillous trophoblasts: 22.7;Undifferentiated cells: 6.6"	"Cancer enhanced"	"Detected in many"		"colorectal cancer: 16.0"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"CACO-2: 17.0;SCLC-21H: 13.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB002014	Enhanced					NA	NA					"CAB002014: "	"unprognostic (1.95e-3)"	"unprognostic (3.08e-3)"	"unprognostic (4.75e-3)"	"unprognostic (4.42e-3)"	"unprognostic (3.49e-1)"	"unprognostic (2.13e-2)"	"unprognostic (5.61e-2)"	"unprognostic (5.09e-2)"	"unprognostic (9.91e-3)"	"unprognostic (1.93e-1)"	"unprognostic (2.39e-2)"	"unprognostic (1.34e-1)"	"unprognostic (6.04e-2)"	"unprognostic (8.02e-2)"	"unprognostic (3.68e-1)"	"unprognostic (8.69e-2)"	"unprognostic (4.03e-2)"	1.0	0.7	1.6	15.6	1.6	0.0	0.5	1.5	7.3	0.4	6.8	0.0	0.0	11.8	0.4	0.0	1.0	0.5	0.4	0.7	1.3	1.1	1.7	0.2	3.8	1.8	1.0	2.2	1.0	0.3	0.1	2.1	3.4	0.4	0.9	9.0	1.2	0.2	0.2	0.7	0.4	20.8	1.7	0.8	0.2	0.3	0.4	0.2	0.2	0.5	5.3	1.7	5.4	0.3	0.4	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.1	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	17.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	13.9	1.0	0.0	0.1	0.1	0.8	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.6	1.6	1.5	7.3	1.3	1.1	1.0	2.2	0.4	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.3	0.0	0.0	22.7	0.0	0.6	0.0	0.0	0.5	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	1.4	0.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.5	0.0	6.6	0.3
NOS3	"ECNOS, eNOS"	ENSG00000164867	"Nitric oxide synthase 3"	P29474	7	150990995-151014588	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Oxidoreductase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 70.6"	"Cell type enhanced"	"Detected in many"	18	"Early spermatids: 62.0;Endothelial cells: 23.5;Ito cells: 30.1;Late spermatids: 21.4"	"Low cancer specificity"	"Detected in all"			"Group enriched"	"Detected in all"	5	"basal ganglia: 32.4;cerebral cortex: 12.4;hippocampal formation: 18.8;pons and medulla: 35.3"	"Low cell type specificity"	"Detected in many"			"Lineage enriched"	"Detected in many"	5	"T-cells: 5.3"	"Cell line enhanced"	"Detected in some"		"BEWO: 11.4;HUVEC TERT2: 22.1;K-562: 7.8;TIME: 40.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB002168	Enhanced					NA	NA					"CAB002168: AB_564072"	"unprognostic (6.53e-2)"	"unprognostic (3.36e-1)"	"unprognostic (1.63e-2)"	"unprognostic (8.46e-2)"	"unprognostic (2.96e-2)"	"unprognostic (1.47e-1)"	"unprognostic (1.35e-1)"	"unprognostic (1.36e-1)"	"unprognostic (6.97e-2)"	"unprognostic (2.56e-1)"	"unprognostic (9.40e-2)"	"unprognostic (2.36e-1)"	"prognostic unfavorable (3.63e-4)"	"unprognostic (1.25e-2)"	"unprognostic (6.63e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.01e-1)"	11.4	4.5	3.1	7.5	32.4	1.9	25.6	1.8	12.4	4.6	3.2	1.7	1.0	4.0	8.3	2.5	4.7	5.0	6.6	35.2	18.8	3.4	5.5	5.4	14.0	10.3	4.7	1.7	4.5	4.1	2.7	4.8	11.5	35.3	5.2	2.5	5.2	3.0	3.2	6.0	4.9	4.0	5.4	25.9	70.6	3.6	4.5	1.6	0.0	5.9	2.1	2.4	5.1	7.3	1.1	0.5	0.7	0.4	0.5	5.3	1.2	0.2	0.0	0.6	2.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	0.1	1.0	0.2	1.0	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.2	1.0	0.1	3.0	0.3	0.2	5.1	0.0	0.1	0.0	0.0	0.0	22.1	2.5	7.8	1.8	0.0	0.0	0.1	0.2	0.8	0.3	0.0	1.4	0.0	0.8	0.0	0.1	0.2	0.2	0.1	0.7	0.0	0.2	0.1	0.7	40.2	0.1	0.4	0.2	0.0	1.2	4.1	1.0	0.0	3.6	0.0	0.3	0.3	0.2	2.5	0.4	1.5	0.8	3.9	2.2	0.5	1.1	5.3	2.1	0.7	0.5	0.4	0.5	4.4	1.2	3.1	32.4	1.8	12.4	18.8	3.4	4.7	1.7	35.3	1.6	8.9	2.1	0.0	0.0	0.8	0.0	2.0	0.0	1.4	1.2	0.0	0.0	0.2	0.0	0.5	62.0	23.5	0.0	0.0	0.0	0.1	3.1	0.2	5.7	0.0	0.3	0.0	0.0	30.1	0.6	21.4	0.9	0.4	0.0	0.0	0.0	0.0	1.0	0.0	1.1	0.1	0.3	0.0	1.0	3.7	2.5	0.5	3.0	0.0	0.0	0.2
NOXO1	"P41NOXA, P41NOXB, P41NOXC, SH3PXD5, SNX28"	ENSG00000196408	"NADPH oxidase organizer 1"	Q8NFA2	16	1978917-1984192	"FDA approved drug targets, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 7.0;intestine: 10.5;lymphoid tissue: 10.6"	"Cell type enhanced"	"Detected in many"	11	"Enterocytes: 20.0;Mucus-secreting cells: 25.4;Paneth cells: 19.0;Undifferentiated cells: 31.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 5.6;HaCaT: 3.2;OE19: 8.7"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA071540	Enhanced					NA	NA					"HPA071540: AB_2686415"			"unprognostic (3.74e-1)"							"unprognostic (1.10e-1)"				"unprognostic (1.73e-2)"				0.5	0.0	1.1	10.6	3.1	0.3	0.5	7.0	2.0	0.9	10.5	0.5	0.5	4.6	0.5	1.5	2.2	0.2	2.8	0.5	1.0	0.9	0.5	2.2	1.0	0.5	0.6	0.5	0.5	0.5	0.3	0.8	0.5	0.5	0.5	8.6	0.5	4.9	0.5	0.5	0.6	4.2	0.6	0.5	0.5	0.3	4.8	0.5	1.4	0.5	0.5	4.1	1.1	0.5	0.7	0.2	1.3	0.0	0.0	0.3	0.0	0.3	0.9	0.9	0.2	0.5	0.0	0.0	0.1	0.2	0.8	0.5	0.7	5.6	0.5	0.4	0.0	0.0	3.2	0.0	0.2	0.0	1.0	0.0	0.0	1.6	0.0	0.1	0.0	0.5	0.9	0.2	0.9	0.3	0.9	0.0	1.4	0.2	0.0	0.0	0.2	2.8	0.0	0.0	8.7	0.0	0.4	0.8	0.1	0.6	0.0	2.9	0.0	1.2	1.1	0.1	0.2	2.2	0.9	0.0	0.6	0.1	0.0	1.4	0.1	0.5	1.3	0.5	0.1	0.4	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	1.3	0.0	0.0	0.2	0.0	0.0	1.1	3.1	7.0	2.0	1.0	0.9	0.6	0.5	0.5	0.5	0.0	0.0	0.0	1.3	0.2	0.0	0.0	2.5	0.0	0.0	5.2	0.0	0.6	0.0	0.8	5.8	0.0	20.0	0.0	1.7	2.6	0.0	3.2	0.0	0.2	0.2	0.0	6.3	0.0	0.3	1.0	0.6	0.0	0.0	1.0	25.4	0.3	1.1	19.0	0.4	0.8	0.0	0.0	0.0	2.7	2.8	0.4	1.3	0.0	31.2	4.3
NPC1L1	SLC65A2	ENSG00000015520	"NPC1 like intracellular cholesterol transporter 1"	Q9UHC9	7	44512535-44541315	"FDA approved drug targets, Predicted membrane proteins"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	5	"intestine: 77.0;liver: 29.8"	"Group enriched"	"Detected in some"	9	"Cholangiocytes: 10.2;Early spermatids: 13.1;Hepatocytes: 27.0"	"Group enriched"	"Detected in many"	5	"liver cancer: 8.5;pancreatic cancer: 7.8;stomach cancer: 4.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"CACO-2: 6.9;Hep G2: 17.2;SCLC-21H: 14.8"	"Region enhanced"	"Detected in single"		"cerebral cortex: 0.7"	"Low region specificity"	"Detected in all"			"CAB070127, CAB070128"	Enhanced					NA	NA					"CAB070127: AB_10002744, CAB070128: AB_10000815"	"unprognostic (2.96e-2)"	"unprognostic (2.23e-1)"	"unprognostic (7.57e-3)"	"unprognostic (8.43e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.07e-1)"	"unprognostic (9.40e-2)"	"unprognostic (6.75e-2)"	"unprognostic (1.44e-1)"	"unprognostic (1.96e-2)"	"unprognostic (4.51e-2)"	"unprognostic (7.59e-2)"	"unprognostic (8.08e-10)"	"unprognostic (1.64e-2)"	"unprognostic (2.83e-1)"	"unprognostic (3.62e-2)"	"unprognostic (5.83e-2)"	0.5	0.1	0.1	0.0	0.2	0.0	0.4	0.5	0.2	0.3	42.0	0.0	0.0	30.5	0.4	0.3	0.3	0.3	11.4	0.1	0.1	0.1	0.7	29.8	0.2	0.0	0.1	0.0	0.5	1.4	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.1	0.2	77.0	0.0	0.1	0.1	0.8	0.7	0.0	0.0	0.1	0.0	0.0	0.3	0.5	0.2	0.0	0.6	0.2	0.4	0.5	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.2	0.0	0.0	0.0	0.0	6.9	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	17.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	14.8	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.2	0.0	0.5	0.0	0.0	0.1	0.1	0.1	0.0	0.2	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.1	0.2	0.5	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.8	10.2	0.0	0.0	1.8	0.0	0.0	0.0	0.2	13.1	0.0	0.0	0.0	0.4	0.0	0.3	0.2	0.0	27.0	0.0	0.0	1.7	1.8	1.0	1.9	0.3	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.0	0.0
NPR1	"ANPa, ANPRA, GUCY2A, NPRA"	ENSG00000169418	"Natriuretic peptide receptor 1"	P16066	1	153678637-153693992	"Enzymes, FDA approved drug targets, Predicted membrane proteins"	"cGMP biosynthesis"	"Lyase, Receptor, Vasoactive"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"breast: 98.4"	"Cell type enriched"	"Detected in many"	10	"Ito cells: 136.2"	"Cancer enhanced"	"Detected in all"		"ovarian cancer: 39.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	6	"ASC diff: 60.5"	"Region enriched"	"Detected in many"	5	"olfactory region: 23.0"	"Region enhanced"	"Detected in single"		"olfactory region: 11.1"	HPA031087			Approved	"Nucleoplasm,Nucleoli,Plasma membrane"		NA	NA			Nucleoli	"Nucleoplasm, Plasma membrane"	"HPA031087: AB_10601975"	"unprognostic (2.54e-1)"	"unprognostic (3.03e-3)"	"unprognostic (6.31e-2)"	"prognostic unfavorable (3.97e-4)"	"unprognostic (1.55e-1)"	"unprognostic (6.60e-2)"	"unprognostic (1.54e-2)"	"unprognostic (2.03e-1)"	"unprognostic (2.46e-1)"	"unprognostic (3.27e-2)"	"prognostic favorable (2.49e-4)"	"unprognostic (1.27e-1)"	"unprognostic (6.69e-2)"	"unprognostic (1.16e-2)"	"unprognostic (1.09e-1)"	"unprognostic (4.06e-1)"	"unprognostic (1.74e-2)"	41.1	4.3	0.5	5.9	0.9	0.1	98.4	0.5	0.8	8.1	8.2	0.3	7.3	1.2	16.8	11.1	8.7	25.0	9.3	19.6	0.9	0.5	28.7	3.7	34.8	8.6	0.7	0.0	19.5	4.2	7.8	4.5	11.8	2.5	4.9	1.5	2.0	2.0	9.0	6.9	3.4	4.6	15.6	2.2	1.2	5.0	6.4	0.2	0.8	7.6	5.1	1.1	11.6	26.5	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	60.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	10.0	0.0	7.2	0.0	0.0	0.1	0.0	0.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	5.7	0.0	0.0	0.8	0.0	0.0	0.0	0.6	0.0	2.0	0.4	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.9	0.5	0.8	0.9	0.5	0.7	0.0	2.5	0.2	0.0	5.8	0.0	0.4	1.3	0.0	4.8	5.1	0.0	0.0	14.0	0.0	0.1	0.0	0.6	8.0	14.2	0.0	0.0	0.0	0.9	3.9	0.4	0.0	1.5	0.2	0.0	0.0	136.2	6.0	7.9	9.5	0.0	0.0	9.0	0.0	0.0	0.7	0.0	3.9	2.8	0.0	0.0	0.9	0.2	0.1	0.9	0.6	0.0	0.0	0.0
NPR2	"AMDM, ANPb, ANPRB, GUCY2B, NPRB"	ENSG00000159899	"Natriuretic peptide receptor 2"	P20594	9	35792154-35809732	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"cGMP biosynthesis, Osteogenesis"	"Lyase, Receptor"	"Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 32.7"	"Cell type enhanced"	"Detected in many"	5	"Leydig cells: 8.6;Muller glia cells: 8.2;Peritubular cells: 7.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"plasmacytoid DC: 3.1"	"Group enriched"	"Detected in many"	6	"dendritic cells: 3.1;T-cells: 2.1"	"Cell line enhanced"	"Detected in many"		"ASC diff: 27.6;ASC TERT1: 20.6;BJ hTERT+: 16.8;HSkMC: 20.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.93e-2)"	"unprognostic (8.22e-3)"	"unprognostic (9.25e-3)"	"unprognostic (3.59e-2)"	"unprognostic (6.13e-2)"	"unprognostic (2.63e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.56e-1)"	"unprognostic (2.40e-1)"	"unprognostic (3.06e-1)"	"unprognostic (1.49e-1)"	"unprognostic (3.99e-2)"	"unprognostic (6.99e-3)"	"unprognostic (7.10e-2)"	"unprognostic (3.24e-1)"	"unprognostic (7.86e-2)"	9.0	4.8	3.8	1.9	6.4	0.0	7.2	32.7	11.2	29.2	7.8	1.8	4.4	1.8	22.6	9.8	5.3	7.6	5.7	7.6	3.7	4.2	3.7	8.4	4.7	2.3	2.5	5.1	8.0	1.3	2.7	7.9	7.1	11.8	8.3	4.0	8.3	3.3	9.5	7.7	6.2	3.7	17.1	3.9	2.6	4.5	5.5	4.0	0.9	3.2	2.4	2.0	6.2	8.9	0.4	3.1	0.0	0.0	0.1	2.1	0.1	0.0	1.6	1.9	0.0	27.6	20.6	1.2	7.7	16.8	6.2	6.7	4.0	2.7	1.1	2.0	15.0	11.6	0.7	2.3	0.2	5.6	1.3	0.7	1.0	1.8	2.0	15.0	0.1	0.0	20.4	1.1	6.9	0.5	6.1	10.1	1.7	0.5	0.1	11.6	0.5	0.3	0.4	2.6	0.8	2.8	1.3	0.1	0.5	1.0	0.8	0.5	0.6	0.2	0.0	0.3	3.1	0.1	0.0	6.5	6.6	5.1	2.1	0.7	0.2	0.3	3.0	8.4	0.3	3.7	0.0	0.0	0.0	1.1	0.0	0.0	0.4	1.2	0.6	0.0	0.0	0.5	0.4	0.0	0.1	0.0	3.1	2.1	0.1	3.8	6.4	32.7	11.2	3.7	4.2	2.5	5.1	11.8	4.0	3.0	4.3	0.0	0.6	1.0	4.0	0.6	0.0	1.4	0.0	0.0	2.0	0.3	0.0	0.4	0.1	2.3	0.1	0.0	0.7	0.1	5.7	1.7	1.1	5.7	0.3	3.2	0.0	2.5	0.3	0.0	8.6	0.0	0.0	0.0	0.9	8.2	0.5	3.1	7.4	0.6	2.1	0.0	1.9	2.8	2.0	1.4	0.2	0.0	1.0	0.3
NR1H4	"FXR, HRR-1, HRR1, RIP14"	ENSG00000012504	"Nuclear receptor subfamily 1 group H member 4"	Q96RI1	12	100473708-100564413	"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters"	"Immunity, Inflammatory response, Innate immunity, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor, Repressor"	"Disease mutation, FDA approved drug targets, Intrahepatic cholestasis"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"liver: 109.4"	"Cell type enhanced"	"Detected in some"	15	"Cholangiocytes: 79.0;Distal tubular cells: 36.5;Hepatocytes: 90.4;Proximal tubular cells: 116.5"	"Group enriched"	"Detected in some"	11	"liver cancer: 18.7;renal cancer: 12.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	32	"Hep G2: 18.4;HHSteC: 11.1;RPTEC TERT1: 29.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA047699			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA047699: AB_10965320"			"unprognostic (1.78e-1)"		"unprognostic (1.81e-1)"		"unprognostic (6.68e-2)"	"unprognostic (2.49e-1)"		"unprognostic (1.60e-1)"	"unprognostic (9.39e-2)"	"unprognostic (2.01e-1)"	"unprognostic (1.88e-2)"	"unprognostic (1.16e-1)"	"unprognostic (2.43e-1)"		"unprognostic (3.77e-3)"	0.1	11.3	0.1	1.4	0.4	0.0	0.2	0.1	0.2	0.2	5.8	0.4	0.1	11.3	0.1	0.4	0.1	0.1	7.0	0.1	0.1	0.0	25.0	109.4	0.6	2.4	0.1	0.1	7.7	2.7	0.0	2.9	0.2	0.3	0.5	0.4	0.6	0.1	0.1	0.1	0.0	19.5	0.3	0.1	0.2	0.1	0.2	0.1	0.1	0.1	0.3	0.3	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.4	11.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.7	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.2	0.1	0.0	0.1	0.1	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.3	79.0	0.0	0.0	21.0	0.0	0.0	36.5	6.3	0.2	0.0	25.7	0.0	0.0	0.0	0.0	0.0	0.0	90.4	0.0	0.0	0.0	14.7	1.9	1.3	0.9	0.0	0.0	0.0	0.1	0.0	0.6	2.9	0.0	116.5	0.0	0.0	0.1	0.5	0.7	0.0	0.0	0.0	0.3	0.9
NR1I2	"BXR, ONR1, PAR2, PXR, SXR"	ENSG00000144852	"Nuclear receptor subfamily 1 group I member 2"	O75469	3	119780484-119818485	"FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"blood: 7.1;intestine: 15.4;liver: 22.2"	"Group enriched"	"Detected in some"	4	"Enterocytes: 29.0;Hepatocytes: 28.7"	"Group enriched"	"Detected in some"	24	"colorectal cancer: 9.0;liver cancer: 5.7;pancreatic cancer: 2.6;stomach cancer: 2.7"					"Cell type enriched"	"Detected in single"	18	"NK-cell: 7.1"	"Lineage enriched"	"Detected in single"	18	"NK-cells: 7.1"	"Cell line enriched"	"Detected in some"	4	"Hep G2: 17.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA029309, HPA055121, HPA073926"			Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"HPA029309: AB_2672990, HPA055121: AB_2682703, HPA073926: AB_2686643"	"unprognostic (6.76e-3)"	"unprognostic (2.25e-1)"	"unprognostic (5.84e-2)"	"unprognostic (1.24e-4)"	"unprognostic (4.51e-2)"	"unprognostic (4.52e-2)"	"unprognostic (4.03e-3)"	"unprognostic (3.97e-2)"	"unprognostic (5.78e-2)"	"unprognostic (5.05e-2)"	"unprognostic (5.21e-2)"	"unprognostic (3.60e-2)"	"unprognostic (5.51e-6)"	"unprognostic (4.86e-1)"	"unprognostic (6.95e-2)"	"unprognostic (3.13e-1)"	"unprognostic (6.12e-3)"	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	5.6			15.4	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.3	0.0	22.2	0.0	0.0	0.0		0.0	0.1	0.0	0.0	0.0		0.0	5.5		0.0	0.0	0.0	0.0	15.1	0.0	0.0	0.1	0.7	0.0			0.0		0.0	0.0	0.0	0.3	0.0	0.0	0.0	7.1	0.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	17.7	0.1	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	1.7	0.5	0.0	0.0	0.0	0.0	0.4	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.3	0.1											0.0	0.0	0.5	0.0	0.0	0.0	0.8	2.5	0.0	0.0	1.8	0.0	0.0	1.7	0.0	0.0	0.0	29.0	0.0	0.2	0.0	0.0	0.0	0.0	28.7	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	5.1	0.0	0.6	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0
NR3C1	"GR, GRL"	ENSG00000113580	"Nuclear receptor subfamily 3 group C member 1"	P04150	5	143277931-143435512	"Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Apoptosis, Cell cycle, Cell division, Chromosome partition, Mitosis, Transcription, Transcription regulation"	"Chromatin regulator, DNA-binding, Receptor, RNA-binding"	"Disease mutation, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004248, CAB010435"	Supported		Supported	Nucleoplasm,Mitochondria,Cytosol		NA	NA			"Nucleoplasm, Cytosol"	Mitochondria	"CAB010435: AB_2155784, HPA004248: AB_1078976"	"unprognostic (1.38e-1)"	"unprognostic (1.93e-1)"	"unprognostic (1.17e-1)"	"prognostic unfavorable (3.64e-5)"	"unprognostic (1.43e-2)"	"unprognostic (2.74e-1)"	"unprognostic (4.19e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.46e-2)"	"unprognostic (3.87e-2)"	"unprognostic (2.15e-1)"	"unprognostic (6.85e-2)"	"prognostic unfavorable (1.72e-6)"	"unprognostic (9.06e-3)"	"unprognostic (1.02e-1)"	"unprognostic (2.43e-3)"	"unprognostic (2.45e-2)"	27.7	8.6	13.5	26.1	14.9	29.6	23.5	30.1	19.2	14.9	14.2	17.0	10.5	13.0	14.7	12.9	18.2	13.7	14.7	17.4	13.4	14.1	13.5	27.3	22.0	16.1	18.3	12.8	15.5	12.5	21.9	18.9	31.9	13.6	14.3	10.3	14.2	12.0	15.2	40.4	18.3	14.8	16.8	17.2	17.5	13.4	7.3	18.2	37.1	18.0	15.1	18.2	14.8	32.2	11.1	13.6	33.7	11.8	10.9	9.6	7.3	10.1	20.7	1.5	0.0	13.6	15.2	1.8	15.9	19.1	13.8	15.9	1.5	13.6	9.0	7.3	23.3	16.1	9.6	0.1	12.5	17.1	5.0	7.1	2.3	28.0	4.5	12.8	9.3	7.2	11.0	16.2	22.6	22.1	17.2	5.1	4.1	3.3	34.3	12.1	3.6	5.4	6.6	4.1	1.7	4.4	1.9	14.4	19.1	4.0	0.7	2.7	2.1	27.8	4.0	6.6	1.8	1.8	13.4	12.2	33.4	6.6	15.9	12.0	6.9	6.3	14.1	17.5	9.6	11.6	25.4	9.8	17.9	9.3	11.8	7.7	7.6	9.6	8.9	13.6	11.1	9.2	8.9	33.7	10.9	10.5	12.4	5.8	7.3	13.5	14.9	30.1	19.2	13.4	14.1	18.3	12.8	13.6	18.2	62.5	66.3	52.2	35.5	52.2	11.3	38.3	43.3	45.5	46.6	24.4	15.7	34.4	14.9	27.4	129.9	67.3	15.8	0.0	28.6	30.5	63.9	36.5	86.6	160.0	47.2	35.0	27.0	55.3	56.4	113.7	58.4	78.4	50.6	53.3	2.3	41.2	29.3	21.0	67.1	50.1	55.0	148.8	81.5	18.0	35.6	49.2	30.6	85.5	12.0	12.3
NR3C2	"MLR, MR"	ENSG00000151623	"Nuclear receptor subfamily 3 group C member 2"	P08235	4	148078762-148444698	"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 47.2;Mucus-secreting cells: 43.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 4.8"	"Lineage enriched"	"Detected in single"	6	"T-cells: 4.8"	"Cell line enhanced"	"Detected in some"		"hTERT-RPE1: 11.1;HUVEC TERT2: 6.8;Karpas-707: 7.3;PC-3: 6.8;RPTEC TERT1: 9.1;TIME: 8.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009155, HPA074979"	Enhanced		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB009155: AB_2155949, HPA074979: AB_2686724"	"unprognostic (2.75e-3)"	"unprognostic (2.63e-2)"	"unprognostic (6.70e-3)"	"unprognostic (1.52e-1)"	"unprognostic (4.09e-1)"	"unprognostic (7.82e-3)"	"unprognostic (1.04e-2)"	"unprognostic (1.11e-2)"	"unprognostic (1.14e-1)"	"unprognostic (4.35e-2)"	"unprognostic (4.97e-2)"	"unprognostic (2.39e-1)"	"prognostic favorable (3.10e-11)"	"unprognostic (1.42e-1)"	"unprognostic (1.87e-1)"	"unprognostic (1.57e-1)"	"unprognostic (1.27e-1)"	7.0	5.6	9.0	12.9	9.5	1.5	7.2	16.8	14.5	8.2	23.4	8.2	6.5	9.7	7.2	4.8	3.8	7.1	10.2	9.7	12.7	6.5	13.8	9.6	8.2	4.2	7.5	7.7	17.0	8.6	22.5	16.7	2.4	5.7	5.9	28.4	12.1	16.9	9.6	12.1	4.6	26.5	8.6	6.5	5.7	9.0	4.8	6.5	2.2	21.7	7.6	5.0	10.7	5.6	0.8	0.0	0.0	0.4	0.1	4.8	0.4	0.0	0.0	0.0	0.0	0.5	0.4	0.4	0.0	0.1	0.0	0.5	0.0	0.1	1.5	2.9	1.1	0.2	0.0	1.6	0.8	0.1	0.3	2.8	0.3	0.7	0.0	0.0	1.8	0.4	0.1	0.0	0.1	0.0	11.1	6.8	1.1	0.0	7.3	2.3	0.0	0.0	0.0	0.1	1.3	6.8	0.6	0.0	0.1	9.1	0.1	0.1	0.1	0.0	1.6	0.7	0.1	0.8	0.0	8.9	4.8	2.8	0.2	0.9	0.0	0.0	0.1	1.6	0.6	1.2	0.0	0.0	0.0	1.5	0.0	4.8	0.4	1.8	1.2	0.0	0.8	2.9	2.9	0.0	0.1	0.4	0.0	0.5	0.4	9.0	9.5	16.8	14.5	12.7	6.5	7.5	7.7	5.7	6.5	26.8	11.5	3.5	1.7	1.8	8.9	17.5	10.2	5.3	10.3	10.4	17.7	0.7	8.3	3.1	47.2	4.9	35.4	0.0	5.1	0.2	3.1	1.8	5.7	4.0	0.5	12.7	17.3	6.2	3.7	30.6	4.0	0.9	6.8	1.0	43.5	7.3	3.7	23.4	3.5	1.7	9.3	0.0	3.1	1.2	4.9	1.5	0.1	0.0	20.3	1.8
NTRK1	"MTC, TRK, TRKA"	ENSG00000198400	"Neurotrophic receptor tyrosine kinase 1"	P04629	1	156815640-156881850	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins"	"Differentiation, Neurogenesis"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	8	"adrenal gland: 15.8;blood: 32.3;brain: 28.3"	"Group enriched"	"Detected in some"	8	"granulocytes: 56.4;Horizontal cells: 54.0"	"Cancer enhanced"	"Detected in some"		"glioma: 1.3"	"Region enriched"	"Detected in many"	5	"pons and medulla: 28.3"	"Cell type enriched"	"Detected in single"	127	"basophil: 32.3"	"Lineage enriched"	"Detected in single"	323	"granulocytes: 32.3"	"Cell line enriched"	"Detected in some"	4	"HMC-1: 42.1"	"Region enhanced"	"Detected in some"		"basal ganglia: 8.2"	"Low region specificity"	"Detected in all"			"CAB004606, HPA035799, HPA076570"	Approved		Approved	Vesicles,Cytosol		NA	NA		140000	"Vesicles, Cytosol"		"CAB004606: AB_628397, HPA035799: AB_2674788, HPA076570: "	"unprognostic (5.89e-3)"	"unprognostic (7.56e-2)"	"unprognostic (2.74e-2)"	"unprognostic (5.99e-3)"	"unprognostic (7.26e-2)"	"unprognostic (1.43e-3)"	"unprognostic (1.56e-1)"	"unprognostic (7.42e-3)"	"unprognostic (7.63e-2)"	"unprognostic (1.35e-1)"	"unprognostic (6.73e-2)"	"unprognostic (2.29e-2)"	"unprognostic (3.18e-11)"	"unprognostic (2.18e-3)"	"unprognostic (3.79e-2)"	"unprognostic (1.07e-1)"	"unprognostic (4.89e-1)"	1.0	15.8	0.5	0.8	6.0	0.9	0.4	0.0	0.7	0.9	1.1	0.1	0.0	0.8	1.6	2.0	0.7	0.6	2.1	1.5	0.0	1.2	2.9	0.2	1.9	0.3	2.1	0.6	0.3	0.3	0.3	1.1	0.5	28.3	2.2	0.2	3.1	1.2	0.5	0.7	0.2	0.4	1.1	1.2	0.2	1.0	2.4	1.5	0.4	0.3	0.0	0.4	0.7	0.8	0.0	0.0	32.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	5.7	0.0	6.8	0.0	0.0	0.0	0.0	42.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.8	0.0	0.0	0.0	1.2	0.0	0.0	0.6	1.2	0.0	0.1	0.0	0.0	0.8	9.6	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.6	0.0	0.0	1.6	0.2	0.0	0.0	0.0	0.0	32.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.0	0.0	0.6	0.0	1.2	2.1	0.6	28.3	1.5	0.0	2.2	0.0	0.0	0.0	6.8	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	56.4	0.0	0.1	54.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.2	2.5	0.1	0.0	0.0	0.0	0.0
NTSR2	NTR2	ENSG00000169006	"Neurotensin receptor 2"	O95665	2	11658178-11670164	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in many"	12	"brain: 33.4"	"Not detected"	"Not detected"			"Cancer enriched"	"Detected in single"	15	"glioma: 6.7"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEK 293: 1.0;NTERA-2: 1.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (5.40e-2)"	"unprognostic (2.30e-2)"			"unprognostic (2.36e-2)"	"unprognostic (5.32e-2)"			"unprognostic (2.23e-1)"	"unprognostic (1.80e-1)"		"unprognostic (2.75e-1)"		"unprognostic (4.98e-1)"	"unprognostic (1.64e-1)"			1.3	1.8	22.3	1.1	30.7	1.1	1.1	2.1	33.4	1.1	1.1	11.9	0.0	1.1	1.1	1.2	1.1	1.1	1.1	1.1	13.4	15.6	1.1	1.1	1.1	1.1	26.8	13.8	2.8	1.7	1.1	0.0	1.1	10.6	1.1	1.1	0.0	1.1	1.1	1.2	1.1	1.1	1.1	4.3	1.1	1.1	1.5	8.7	0.0	1.1	0.0	1.1	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.3	30.7	2.1	14.5	13.4	15.6	26.8	13.8	10.6	8.7	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0
ODC1	ODC	ENSG00000115758	"Ornithine decarboxylase 1"	P11926	2	10439968-10448504	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Polyamine biosynthesis"	"Decarboxylase, Lyase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 459.5;Late spermatids: 626.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001536, CAB035996"	Approved		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"CAB035996: , HPA001536: AB_1079521"	"unprognostic (2.33e-1)"	"unprognostic (3.41e-1)"	"unprognostic (7.25e-3)"	"unprognostic (5.21e-3)"	"unprognostic (4.22e-2)"	"unprognostic (2.70e-1)"	"prognostic unfavorable (3.07e-5)"	"unprognostic (3.06e-2)"	"unprognostic (4.18e-2)"	"unprognostic (6.27e-2)"	"unprognostic (3.04e-1)"	"unprognostic (6.65e-2)"	"unprognostic (1.67e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.05e-1)"	"unprognostic (2.26e-2)"	"unprognostic (5.86e-2)"	13.2	8.2	11.6	33.5	11.1	41.8	9.1	7.2	11.8	11.7	17.4	11.5	33.8	8.6	22.9	21.6	16.5	16.5	30.0	33.8	9.7	10.6	31.5	48.7	14.2	42.3	11.3	6.5	29.2	48.7	13.4	35.4	6.9	11.2	26.3	20.7	18.2	11.0	27.2	64.2	9.6	14.9	26.2	10.2	20.4	19.2	54.6	6.3	31.0	16.4	19.8	39.6	16.1	14.6	13.4	10.8	2.4	2.4	1.2	4.4	3.0	19.0	15.3	21.3	25.2	3.8	11.4	49.4	27.6	13.6	26.1	12.1	81.2	8.9	100.7	13.8	16.8	25.2	3.5	65.2	31.3	31.8	38.3	27.2	46.0	26.3	49.5	30.9	77.6	11.0	7.6	8.5	59.0	74.1	13.5	20.9	28.1	76.4	32.8	14.4	12.5	76.8	30.6	38.8	26.5	49.9	54.9	66.9	67.9	15.8	14.0	29.8	25.3	34.6	10.6	13.9	17.1	7.1	34.8	14.6	21.2	43.7	27.3	59.1	15.3	46.3	91.6	19.0	51.5	13.0	0.0	1.3	2.4	2.7	2.4	3.2	13.4	3.8	4.4	3.0	11.0	2.7	4.3	0.5	1.2	1.5	10.8	3.8	3.0	11.6	11.1	7.2	11.8	9.7	10.6	11.3	6.5	11.2	6.3	41.7	217.2	112.6	112.8	51.5	34.5	48.8	71.4	25.4	36.4	38.4	29.5	1.0	61.3	55.5	459.5	35.3	38.6	0.0	23.5	53.1	21.2	276.8	57.7	46.1	43.4	6.4	260.2	11.6	30.9	626.4	14.4	29.0	21.9	12.6	143.2	85.1	24.6	48.9	10.6	101.8	62.6	0.0	40.8	91.4	74.0	76.5	2.9	37.6	120.9	94.9
OGDH	E1k	ENSG00000105953	"Oxoglutarate dehydrogenase"	Q02218	7	44606572-44709066	"Citric acid cycle related proteins, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	Glycolysis	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 99.3"	"Cell type enhanced"	"Detected in many"	4	"Cardiomyocytes: 100.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019514, HPA020347"	Supported		Enhanced	Mitochondria		No	No		53000	Mitochondria		"HPA019514: AB_1854772, HPA020347: AB_1854773"	"unprognostic (1.96e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.39e-1)"	"unprognostic (5.64e-3)"	"unprognostic (3.02e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.45e-1)"	"unprognostic (7.58e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.52e-2)"	"unprognostic (3.38e-1)"	"unprognostic (3.30e-2)"	"prognostic favorable (2.22e-14)"	"unprognostic (1.53e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.23e-2)"	"unprognostic (5.88e-3)"	18.9	20.8	12.3	14.5	18.5	8.7	11.0	14.3	23.7	10.1	19.4	15.9	13.5	29.0	16.2	11.1	19.5	11.1	11.8	73.9	11.3	12.8	28.8	14.8	13.0	11.1	14.2	11.7	9.8	13.0	25.5	11.0	14.5	22.2	12.3	13.3	22.3	23.7	15.9	99.3	15.6	35.5	16.4	10.1	12.1	14.9	11.3	11.0	11.3	17.8	39.8	15.8	13.0	10.8	7.2	13.4	7.5	20.4	11.2	25.7	11.6	10.8	22.8	13.7	20.8	21.2	23.3	13.3	17.0	16.6	19.3	16.9	20.7	22.5	47.8	20.2	24.7	39.0	33.8	27.0	25.4	18.9	27.9	7.1	14.5	46.1	10.2	10.8	17.9	16.3	21.6	19.3	27.4	19.7	14.2	26.2	16.0	16.7	14.3	20.4	15.3	17.7	10.3	12.6	30.2	25.7	17.0	9.6	53.6	22.2	32.4	23.4	11.2	24.5	34.1	10.6	25.9	20.2	18.0	20.6	13.9	12.6	24.2	19.6	13.0	24.9	26.4	25.3	20.3	25.3	4.8	12.1	7.3	11.7	17.7	12.8	7.2	13.5	11.7	13.4	5.9	5.8	7.0	7.5	11.2	20.4	6.6	25.7	11.6	12.3	18.5	14.3	23.7	11.3	12.8	14.2	11.7	22.2	11.0	6.0	22.7	20.4	11.1	17.3	20.1	100.7	15.3	12.0	9.1	45.4	17.7	19.4	26.6	13.2	43.1	14.2	61.4	0.0	14.8	14.3	16.4	14.4	20.8	17.5	29.3	58.8	22.4	14.1	22.4	20.0	10.9	21.9	20.3	21.6	29.2	15.4	16.7	21.0	16.3	38.9	22.2	19.4	18.2	9.1	20.0	23.1	30.7	13.8	27.6	14.2
OPRD1		ENSG00000116329	"Opioid receptor delta 1"	P41143	1	28812142-28871267	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 8.7"	"Cell type enhanced"	"Detected in some"	20	"Bipolar cells: 3.4;Urothelial cells: 1.1"	"Cancer enhanced"	"Detected in single"		"melanoma: 1.0"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	12	"RH-30: 14.9;SCLC-21H: 5.9;SH-SY5Y: 5.9;WM-115: 19.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA070831	Approved					NA	NA					"HPA070831: AB_2732167"	"unprognostic (1.44e-1)"	"unprognostic (4.07e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.89e-2)"	"unprognostic (2.68e-1)"	"unprognostic (5.84e-3)"	"unprognostic (6.28e-3)"	"unprognostic (5.92e-2)"	"unprognostic (1.82e-2)"	"unprognostic (5.95e-3)"	"unprognostic (4.28e-3)"	"unprognostic (2.98e-1)"	"unprognostic (1.52e-7)"	"unprognostic (1.44e-2)"	"unprognostic (1.28e-1)"	"unprognostic (1.26e-1)"	"unprognostic (2.18e-3)"	0.4	2.4	5.5	0.6	3.9	1.9	0.4	0.4	8.7	0.4	0.6	0.0	0.0	0.5	0.4	0.4	0.4	0.4	0.6	0.4	3.0	1.3	0.4	0.4	0.5	0.7	0.6	5.9	0.5	1.3	0.2	0.5	0.5	4.7	0.4	0.5	0.1	1.0	0.2	3.2	1.0	0.6	0.4	0.4	0.7	0.8	0.8	0.2	0.0	0.6	0.0	0.2	0.4	0.4	1.2	1.1	3.1	0.5	1.1	0.7	0.1	0.0	0.1	0.3	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.5	0.2	0.2	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.3	0.1	0.1	0.0	0.2	0.9	0.0	0.0	0.0	14.9	0.1	0.0	0.0	5.9	5.9	0.0	0.1	1.0	0.3	0.1	0.1	0.0	0.1	0.3	0.2	0.0	0.2	0.0	0.2	0.1	0.3	19.8	3.1	0.5	0.6	0.6	0.3	0.4	0.6	0.6	0.5	0.1	1.2	0.6	0.7	2.5	1.1	0.3	1.1	0.3	0.1	5.5	3.9	0.4	8.7	3.0	1.3	0.6	5.9	4.7	0.2	0.0	0.0	0.0	0.8	0.0	3.4	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	1.1
OPRK1	"KOR, OPRK"	ENSG00000082556	"Opioid receptor kappa 1"	P41145	8	53225716-53251697	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	Behavior	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"brain: 18.0;prostate: 6.7"	"Group enriched"	"Detected in some"	8	"Extravillous trophoblasts: 7.3;Leydig cells: 4.4"	"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"basophil: 1.2"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in some"	5	"U-937: 22.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA067549	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	"Nucleoplasm, Cytosol"	"HPA067549: AB_2732770"	"unprognostic (1.01e-1)"	"unprognostic (1.17e-2)"		"unprognostic (8.70e-3)"	"unprognostic (3.73e-2)"	"unprognostic (6.74e-2)"		"unprognostic (2.22e-3)"		"unprognostic (8.09e-2)"	"unprognostic (9.71e-2)"	"unprognostic (4.28e-3)"		"unprognostic (3.29e-1)"	"unprognostic (3.35e-2)"	"unprognostic (9.54e-4)"	"unprognostic (1.61e-1)"	0.7	0.7	15.9	0.3	18.0	0.4	0.3	2.2	8.8	0.4	0.4	0.3	0.0	0.4	0.4	0.6	0.5	0.7	0.4	0.8	4.5	6.2	0.3	0.5	0.8	0.4	1.7	5.8	0.4	0.3	0.4	0.8	2.8	3.1	6.7	0.4	0.0	0.3	0.4	3.8	0.4	0.5	0.5	0.5	0.6	0.3	2.8	1.6	0.2	0.9	0.0	0.3	0.3	0.1	0.2	0.8	1.2	0.2	0.1	0.4	0.0	0.0	0.0	4.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.3	22.1	0.1	1.2	0.2	0.1	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.4	0.1	0.1	0.8	0.0	0.0	15.9	18.0	2.2	8.8	4.5	6.2	1.7	5.8	3.1	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.0	0.0	0.0	7.3	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0
OPRM1	MOR1	ENSG00000112038	"Opioid receptor mu 1"	P35372	6	154010496-154246867	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enriched"	"Detected in some"	5	"brain: 37.9"	"Group enriched"	"Detected in some"	33	"Early spermatids: 24.0;Late spermatids: 23.1"	"Not detected"	"Not detected"			"Region enhanced"	"Detected in many"		"cerebellum: 37.9"	"Cell type enhanced"	"Detected in single"		"neutrophil: 2.1"	"Low lineage specificity"	"Detected in single"			"Cell line enriched"	"Detected in single"	24	"SH-SY5Y: 13.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA014509, HPA067435"	Enhanced	Supported				NA	NA					"HPA014509: AB_1854801, HPA067435: "											"unprognostic (7.34e-2)"			"unprognostic (6.91e-2)"				0.5	3.4	7.0	0.6	17.5	1.8	0.9	37.9	7.6	0.5	0.6	0.8	0.0	0.6	0.7	1.4	3.7	0.5	1.0	0.5	2.6	2.3	0.5	0.5	0.5	0.9	0.6	9.3	0.8	0.7	0.4	0.6	0.5	5.2	0.7	0.4	0.0	0.6	0.2	0.9	1.8	0.5	0.3	1.9	0.6	1.0	8.0	0.5	0.0	1.0	0.0	0.3	0.5	0.5	0.5	0.2	2.1	0.1	0.1	0.7	0.0	0.1	0.0	0.2	0.4	0.0	0.2	0.2	0.2	0.0	0.1	0.0	0.2	0.4	0.4	0.1	0.0	0.5	0.3	0.3	0.2	0.1	0.3	0.1	0.1	0.4	0.1	0.0	0.3	0.5	0.1	0.5	0.0	0.1	0.0	0.1	0.2	0.1	0.3	0.3	0.2	0.1	0.0	0.1	0.0	0.0	0.2	0.2	0.0	0.1	0.1	0.3	13.1	0.0	0.1	0.3	0.4	0.3	0.1	0.3	0.4	0.1	0.3	0.1	0.4	0.2	0.1	0.3	0.1	0.0	0.2	0.1	0.6	0.6	0.0	0.7	0.2	0.3	0.5	0.1	0.5	0.4	0.1	2.1	0.1	0.0	0.2	0.3	0.0	7.0	17.5	37.9	7.6	2.6	2.3	0.6	9.3	5.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.5	0.0	0.1
OXTR		ENSG00000180914	"Oxytocin receptor"	P30559	3	8750408-8769628	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"breast: 42.5"	"Cell type enriched"	"Detected in some"	8	"Ciliated cells: 93.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.6"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.6"	"Cell line enhanced"	"Detected in some"		"BJ: 81.2;BJ hTERT+: 24.9;BJ hTERT+ SV40 Large T+: 23.6;fHDF/TERT166: 81.3;HBF TERT88: 18.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.18e-1)"	"unprognostic (7.94e-2)"	"unprognostic (4.76e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.02e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.56e-3)"	"unprognostic (2.12e-1)"	"unprognostic (3.42e-1)"	"unprognostic (2.76e-1)"	"unprognostic (3.80e-2)"	"unprognostic (4.24e-4)"	"unprognostic (8.25e-2)"	"unprognostic (4.60e-2)"	"unprognostic (2.71e-1)"	"unprognostic (1.84e-1)"	0.5	0.4	1.8	0.3	6.5	0.6	42.5	0.9	2.2	0.5	0.3	0.1	0.0	0.3	2.8	0.5	1.1	2.7	1.0	0.6	1.8	4.0	0.6	0.4	1.0	0.4	8.6	0.8	2.8	0.3	0.3	0.3	1.3	3.7	0.9	0.3	1.6	0.4	0.9	0.3	0.4	0.4	0.6	2.5	0.5	0.3	0.5	1.2	0.1	0.4	0.0	0.4	0.4	0.0	0.0	0.2	1.6	0.1	0.1	0.3	1.0	0.2	0.8	0.4	0.1	0.1	0.2	0.1	81.2	24.9	23.6	12.6	0.1	2.1	0.0	0.1	81.3	0.3	0.1	0.3	0.1	18.4	0.7	0.4	0.2	0.3	0.1	0.4	0.1	0.2	0.1	0.1	0.3	0.1	7.1	0.0	0.2	0.0	0.1	13.1	0.0	0.1	0.6	0.5	0.2	3.6	0.1	0.3	4.8	0.9	0.0	0.1	0.1	0.1	0.1	0.0	1.6	0.0	0.1	0.1	1.1	0.3	0.2	0.2	0.1	0.2	0.0	0.1	0.2	0.2	0.5	0.0	0.1	0.2	0.1	0.2	0.0	0.2	0.2	0.2	0.0	0.2	0.3	1.6	0.1	0.0	0.1	0.1	1.0	1.8	6.5	0.9	2.2	1.8	4.0	8.6	0.8	3.7	1.2	8.9	1.4	0.0	0.4	0.3	0.2	1.2	0.0	93.7	11.4	0.0	0.0	0.0	0.0	2.6	0.9	0.0	0.0	0.0	0.0	0.1	0.5	1.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.5	0.0	0.2	0.0	0.0	0.0	5.8	1.0	0.0	0.4	0.0	0.0	0.0	0.5	0.7	1.3	0.1	0.0	0.0	0.0	0.1
P2RX4	P2X4	ENSG00000135124	"Purinergic receptor P2X 4"	Q99571	12	121209857-121234106	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"	"Ion channel, Ligand-gated ion channel, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cytotrophoblasts: 110.0;Hofbauer cells: 116.1;Syncytiotrophoblasts: 130.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA039494	Enhanced					NA	NA					"HPA039494: AB_10969132"	"unprognostic (4.02e-3)"	"unprognostic (1.06e-1)"	"unprognostic (5.43e-2)"	"prognostic favorable (6.30e-10)"	"unprognostic (2.98e-2)"	"unprognostic (2.52e-1)"	"unprognostic (2.06e-3)"	"unprognostic (1.68e-1)"	"unprognostic (1.21e-1)"	"unprognostic (5.42e-2)"	"unprognostic (7.71e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.81e-2)"	"unprognostic (1.13e-1)"	"unprognostic (6.06e-2)"	"unprognostic (1.42e-2)"	"unprognostic (4.76e-3)"	14.1	7.8	4.9	6.5	4.7	4.8	13.8	24.0	8.1	11.3	16.3	8.8	5.5	13.4	6.3	5.5	5.6	8.4	8.6	6.1	3.9	3.4	10.2	13.2	11.6	16.1	6.0	3.5	9.9	22.7	15.7	8.4	25.9	5.8	7.7	13.9	7.0	15.7	9.5	2.3	4.1	17.6	8.4	6.8	11.5	11.2	4.2	5.0	4.2	7.1	2.8	7.1	7.8	5.8	2.7	6.1	17.1	14.2	5.6	6.1	7.2	2.2	6.2	0.1	7.7	4.0	3.7	19.3	2.3	12.4	3.2	5.6	3.6	9.1	1.6	7.0	7.5	20.0	0.9	2.1	1.2	1.5	7.7	4.5	1.0	0.1	3.2	9.7	2.8	16.7	4.6	2.5	3.2	4.2	7.8	11.1	2.5	2.8	5.8	2.4	11.6	1.5	1.9	2.0	11.3	5.0	1.6	11.2	11.9	1.1	3.8	1.9	3.7	5.4	3.2	20.9	2.2	15.6	5.2	0.6	4.5	3.7	0.4	1.3	8.3	9.4	1.5	9.0	3.4	4.3	17.1	13.0	2.1	4.2	14.2	4.2	2.7	6.1	3.4	6.1	1.5	4.5	2.2	0.1	5.6	12.2	1.4	3.9	7.2	4.9	4.7	24.0	8.1	3.9	3.4	6.0	3.5	5.8	5.0	6.0	19.2	9.8	7.8	3.4	11.5	2.7	17.8	9.4	14.8	19.2	2.0	110.0	0.0	52.0	12.4	8.8	73.4	0.0	31.1	62.5	11.8	13.0	12.8	8.5	116.1	14.3	20.6	27.0	43.8	19.4	8.1	37.9	10.1	84.8	75.8	6.3	36.8	55.1	9.2	18.9	7.4	19.4	9.2	5.1	4.9	3.4	130.2	15.2	22.5	8.0
P2RY12	"HORK3, P2Y12, SP1999"	ENSG00000169313	"Purinergic receptor P2Y12"	Q9H244	3	151337380-151384812	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"	"Blood coagulation, Hemostasis"	"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 46.0"	"Cell type enhanced"	"Detected in some"	27	"granulocytes: 1.1;Kupffer cells: 2.9"	"Cancer enriched"	"Detected in many"	14	"glioma: 17.3"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 12.4"	"Group enriched"	"Detected in many"	13	"dendritic cells: 5.0;monocytes: 12.4"	"Cell line enhanced"	"Detected in some"		"HSkMC: 1.7;JURKAT: 1.1;Karpas-707: 1.1;REH: 1.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013796, HPA014518"	Enhanced					NA	NA					"HPA013796: AB_1854884, HPA014518: AB_2669027"	"unprognostic (2.39e-2)"	"unprognostic (1.60e-3)"	"unprognostic (5.93e-2)"	"unprognostic (1.77e-1)"	"unprognostic (2.41e-2)"	"unprognostic (2.52e-2)"	"unprognostic (8.09e-2)"	"unprognostic (1.72e-3)"	"unprognostic (6.46e-2)"	"unprognostic (8.64e-4)"	"unprognostic (4.84e-2)"	"unprognostic (5.96e-2)"	"unprognostic (2.03e-1)"	"unprognostic (8.92e-2)"	"unprognostic (1.65e-1)"	"unprognostic (3.52e-2)"	"unprognostic (4.04e-1)"	7.4	4.3	15.3	2.2	14.2	0.8	4.3	2.3	46.0	2.0	2.0	13.4	0.0	1.6	1.1	1.1	1.7	3.2	2.7	1.8	14.3	11.6	1.1	2.7	2.9	9.2	21.1	10.0	2.2	0.9	2.0	0.9	2.7	16.8	1.4	1.8	0.2	3.1	2.9	0.6	0.8	3.1	2.1	24.9	5.3	1.5	0.6	18.8	0.0	0.9	0.0	8.6	1.9	0.9	0.6	5.0	0.3	12.4	0.0	0.0	2.0	0.0	0.0	0.2	0.2	0.0	0.3	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.2	0.0	0.3	1.7	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.1	0.0	0.0	0.3	0.0	0.1	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.2	0.3	0.3	0.3	0.0	2.9	0.0	0.0	12.4	0.0	0.6	0.0	0.0	5.0	0.6	0.0	0.0	0.3	0.0	3.3	0.5	0.0	2.0	15.3	14.2	2.3	14.6	14.3	11.6	21.1	10.0	16.8	18.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	1.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
P2RY2	P2U	ENSG00000175591	"Purinergic receptor P2Y2"	P41231	11	73218298-73236352	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 28.1;skeletal muscle: 29.5"	"Cell type enhanced"	"Detected in many"	5	"Cytotrophoblasts: 14.0;Enterocytes: 12.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"eosinophil: 28.1"	"Group enriched"	"Detected in many"	12	"granulocytes: 28.1;monocytes: 10.4"	"Cell line enhanced"	"Detected in many"		"HaCaT: 16.4;HL-60: 15.5;MCF7: 12.4;NB-4: 12.6;PC-3: 12.9;SK-BR-3: 14.3;THP-1: 36.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			CAB022642	Uncertain		Uncertain	Cytosol		NA	NA			Cytosol		"CAB022642: "	"unprognostic (1.24e-1)"	"unprognostic (1.13e-1)"	"unprognostic (6.36e-2)"	"unprognostic (7.97e-3)"	"unprognostic (6.50e-4)"	"unprognostic (2.04e-2)"	"unprognostic (4.66e-3)"	"unprognostic (8.93e-2)"	"unprognostic (2.87e-1)"	"unprognostic (4.17e-2)"	"prognostic unfavorable (2.19e-5)"	"unprognostic (9.69e-2)"	"unprognostic (4.92e-4)"	"unprognostic (1.34e-1)"	"unprognostic (2.82e-1)"	"unprognostic (1.05e-1)"	"unprognostic (8.57e-3)"	0.4	2.3	0.9	1.4	1.2	10.8	1.3	0.3	1.1	5.5	3.1	1.1	0.3	2.2	1.3	2.3	20.0	1.2	2.8	11.7	0.6	0.3	0.9	2.6	2.9	1.5	1.2	0.6	1.7	1.7	6.1	1.1	10.3	1.0	1.7	2.4	3.3	4.0	1.6	29.5	3.4	10.8	0.4	0.4	6.6	0.6	0.7	0.6	0.6	20.2	20.6	12.8	2.1	10.9	0.0	1.6	28.1	10.4	0.0	0.0	1.2	3.6	3.4	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	8.4	2.8	0.0	5.6	0.2	0.0	16.4	0.4	7.7	0.0	0.0	0.3	1.2	0.2	1.5	0.0	15.5	0.0	0.0	3.6	1.2	0.2	0.0	0.7	0.0	0.7	0.0	0.0	12.4	0.0	12.6	0.2	3.3	12.9	0.0	0.0	0.5	1.2	8.8	0.0	0.0	0.2	14.3	0.0	0.1	6.6	36.3	5.3	0.0	0.1	0.0	0.0	0.5	0.2	0.0	0.0	2.8	0.0	0.2	3.4	28.1	0.0	10.4	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.1	0.0	6.2	0.0	0.0	1.2	0.9	1.2	0.3	1.1	0.6	0.3	1.2	0.6	1.0	0.6	3.0	0.3	0.0	6.8	3.3	0.5	5.3	7.6	0.0	4.5	0.0	0.0	14.0	1.7	5.0	5.3	0.5	12.9	0.0	5.6	0.5	0.4	1.1	0.0	4.5	2.3	0.0	0.0	0.0	2.7	6.7	0.0	0.9	0.0	0.0	2.9	5.2	11.6	10.5	0.0	0.3	0.2	0.0	0.2	0.0	0.0	6.4	9.2	0.0	2.3	11.1
PAH	PH	ENSG00000171759	"Phenylalanine hydroxylase"	P00439	12	102836885-102958410	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Phenylalanine catabolism"	"Allosteric enzyme, Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets, Phenylketonuria"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"kidney: 65.1;liver: 220.0"	"Group enriched"	"Detected in some"	8	"Cholangiocytes: 226.7;Hepatocytes: 723.9;Proximal tubular cells: 215.9"	"Cancer enriched"	"Detected in some"	17	"liver cancer: 94.7"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	31	"Hep G2: 72.8"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in single"			"HPA028407, HPA031642"	Enhanced		Approved	"Endoplasmic reticulum,Vesicles"		No	NA			"Endoplasmic reticulum, Vesicles"		"HPA028407: AB_10601241, HPA031642: AB_2673974"	"unprognostic (1.16e-1)"	"unprognostic (1.52e-1)"	"unprognostic (4.47e-2)"	"unprognostic (9.13e-3)"	"unprognostic (5.19e-2)"	"unprognostic (5.99e-2)"	"prognostic favorable (4.30e-4)"	"unprognostic (1.27e-1)"	"unprognostic (6.60e-2)"	"unprognostic (4.45e-3)"	"unprognostic (1.94e-3)"	"unprognostic (1.83e-1)"	"unprognostic (1.10e-2)"	"unprognostic (3.51e-1)"	"unprognostic (1.64e-1)"	"unprognostic (3.96e-2)"	"unprognostic (1.68e-2)"	0.1	1.3	0.5	0.0	0.5	0.0	0.1	0.2	1.0	0.0	0.1	0.6	0.0	0.0	0.0	0.1	0.0	0.1	20.3	0.1	0.8	0.3	65.1	220.0	0.0	0.0	0.3	0.7	0.1	1.7	0.0	1.6	0.0	0.8	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.8	0.1	0.0	2.8	0.4	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	72.8	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.5	0.2	1.0	0.8	0.3	0.3	0.7	0.8	0.4	0.0	0.0	16.2	0.0	0.0	0.0	0.4	226.7	0.0	0.0	5.2	0.0	0.0	18.3	2.0	50.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	723.9	0.0	3.2	1.7	14.1	22.2	13.1	0.6	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.1	215.9	0.1	0.0	0.0	0.7	0.4	0.0	0.0	5.0	0.0	0.0
PARP1	"ADPRT, PARP, PPOL"	ENSG00000143799	"Poly(ADP-ribose) polymerase 1"	P09874	1	226360691-226408079	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, Transcription, Transcription regulation"	"DNA-binding, Glycosyltransferase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Cytotrophoblasts: 400.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000147, CAB003839, CAB003840, HPA045168, CAB075726, CAB075727"	Supported	Supported	Enhanced	Nucleoplasm,Nucleoli		NA	NA		39000	Nucleoplasm	Nucleoli	"CAB000147: AB_430876, CAB003839: AB_365493, CAB003840: AB_562187, CAB075726: AB_2665732, CAB075727: AB_2665733, HPA045168: AB_2679240"	"unprognostic (2.02e-1)"	"unprognostic (9.40e-2)"	"unprognostic (7.44e-3)"	"unprognostic (1.32e-1)"	"unprognostic (4.29e-1)"	"unprognostic (9.22e-2)"	"prognostic unfavorable (3.40e-4)"	"unprognostic (2.20e-1)"	"unprognostic (3.62e-2)"	"unprognostic (1.39e-1)"	"unprognostic (2.13e-1)"	"unprognostic (1.66e-1)"	"prognostic unfavorable (1.35e-5)"	"unprognostic (2.38e-2)"	"unprognostic (1.82e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.64e-1)"	17.3	16.6	31.2	35.7	31.2	14.3	15.3	21.1	29.2	14.3	21.8	37.4	10.3	15.0	18.2	13.0	18.1	15.0	10.8	24.2	27.8	21.9	13.4	24.8	14.1	56.3	40.7	21.8	14.6	28.1	62.6	22.9	28.7	30.4	22.0	19.2	16.3	17.0	24.7	47.3	11.7	19.6	25.5	49.1	32.7	15.9	22.5	34.8	29.5	14.5	16.5	70.2	19.9	13.7	53.0	16.5	9.0	17.5	11.1	21.8	11.5	28.9	15.5	43.2	30.6	11.3	9.4	24.6	19.2	17.1	26.1	21.5	24.7	14.2	84.4	28.7	11.6	11.5	21.8	59.4	18.8	23.1	35.4	82.9	32.6	20.7	16.1	6.8	54.2	15.8	9.2	7.5	21.0	14.9	7.3	20.3	19.6	51.9	43.1	13.5	13.8	17.3	19.6	79.5	40.9	30.8	52.5	74.0	78.0	12.2	20.7	43.5	38.1	25.0	28.0	15.7	31.8	23.5	34.0	15.4	13.9	23.0	18.7	35.9	17.6	29.4	72.5	11.6	18.3	31.1	9.0	6.7	6.9	18.3	11.3	21.6	46.8	19.4	18.0	14.3	53.0	15.2	16.4	1.0	11.1	17.5	16.5	21.8	11.5	31.2	31.2	21.1	28.4	27.8	21.9	40.7	21.8	30.4	34.8	50.6	68.3	130.2	75.6	64.2	94.4	106.4	43.3	75.0	97.8	54.1	133.5	400.4	61.3	77.0	28.3	54.0	16.8	23.3	91.9	75.6	55.5	70.8	116.9	65.7	117.1	85.8	72.1	31.9	42.2	16.3	37.2	45.7	59.1	93.8	46.5	78.6	54.3	24.6	32.9	36.1	102.8	45.3	47.4	92.8	211.4	42.0	115.1	74.0	57.9	42.9
PARP2	ADPRTL2	ENSG00000129484	"Poly(ADP-ribose) polymerase 2"	Q9UGN5	14	20343582-20357905	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"DNA-binding, Glycosyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA052003	Approved		Supported	Nucleoplasm,Nucleoli		NA	NA			Nucleoplasm	Nucleoli	"HPA052003: AB_2681689"	"unprognostic (3.93e-1)"	"unprognostic (7.92e-2)"	"unprognostic (4.12e-1)"	"unprognostic (1.24e-1)"	"unprognostic (3.40e-2)"	"unprognostic (7.30e-2)"	"prognostic unfavorable (6.48e-4)"	"unprognostic (1.97e-2)"	"unprognostic (4.43e-2)"	"unprognostic (9.35e-3)"	"unprognostic (1.44e-2)"	"unprognostic (1.42e-2)"	"unprognostic (3.37e-3)"	"unprognostic (2.83e-1)"	"unprognostic (9.19e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.89e-2)"	11.5	16.6	23.6	8.9	28.5	20.9	15.2	36.7	31.3	12.0	11.7	16.8	9.3	11.2	18.8	16.8	10.7	14.7	8.9	14.0	19.2	17.8	14.0	15.0	12.0	11.8	16.6	30.8	20.2	11.8	11.6	14.6	11.3	22.1	11.3	12.9	10.8	10.5	12.9	25.9	15.1	10.8	14.6	13.9	11.4	11.6	20.4	17.4	6.0	11.7	13.9	15.2	9.3	10.4	6.7	5.6	1.8	5.0	6.9	12.3	4.9	20.3	14.9	23.0	17.2	7.6	7.3	16.7	22.7	12.4	28.9	35.8	14.1	19.5	15.1	10.3	7.1	25.8	19.2	30.6	10.4	34.2	12.1	14.9	13.8	18.1	23.5	6.8	28.6	7.9	5.0	8.9	18.0	19.9	8.0	14.8	18.5	14.6	20.7	19.8	12.6	14.6	12.3	12.6	23.2	23.3	18.3	31.3	9.8	11.5	10.6	16.0	11.0	25.3	14.1	6.6	15.3	13.0	9.7	10.1	17.6	26.7	12.1	18.4	19.4	24.7	20.1	7.3	12.7	19.5	1.8	5.0	0.5	9.5	4.5	12.3	6.7	8.9	8.3	5.4	4.6	9.6	9.3	0.1	6.9	2.5	5.6	5.2	4.9	23.6	28.5	36.7	31.3	19.2	17.8	16.6	30.8	22.1	17.4	23.8	6.2	10.4	9.3	5.8	26.8	12.3	5.1	36.1	21.6	7.0	11.8	19.1	6.6	10.5	7.3	10.0	3.4	23.3	7.7	17.9	8.4	3.7	8.1	9.6	10.2	28.6	4.6	6.2	4.9	7.3	10.6	6.4	8.5	4.6	4.2	21.9	8.0	5.5	15.9	5.6	21.7	6.5	9.5	17.7	33.3	4.3	12.5	4.4	5.2	4.6
PARP3	"ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3"	ENSG00000041880	"Poly(ADP-ribose) polymerase family member 3"	Q9Y6F1	3	51942345-51948867	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"DNA damage, DNA repair"	"Glycosyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020984, HPA067657"	Supported		Supported	"Nucleoplasm,Nuclear bodies"		Yes	No			"Nucleoplasm, Nuclear bodies"		"HPA020984: , HPA067657: AB_2685881"	"prognostic favorable (6.39e-5)"	"unprognostic (1.25e-1)"	"unprognostic (1.54e-2)"	"unprognostic (2.85e-2)"	"unprognostic (7.31e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.13e-1)"	"unprognostic (3.53e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.01e-1)"	"unprognostic (7.44e-3)"	"unprognostic (4.30e-1)"	"prognostic favorable (1.25e-8)"	"unprognostic (5.63e-2)"	"unprognostic (1.77e-1)"	"unprognostic (1.40e-2)"	"unprognostic (4.65e-3)"	15.2	29.2	11.2	14.6	17.1	2.8	13.6	5.7	18.8	7.5	17.3	10.6	14.3	26.9	10.3	14.1	10.8	12.1	16.2	12.4	11.6	12.3	17.3	22.3	13.3	9.7	12.0	14.2	8.2	3.9	34.2	9.8	6.2	12.2	12.1	10.7	13.2	14.0	18.1	14.6	6.1	26.3	18.9	8.7	12.8	15.8	4.5	10.2	2.9	17.0	9.6	10.3	15.1	8.9	9.0	2.9	1.7	4.1	6.6	4.9	2.3	5.9	3.3	0.9	9.0	8.7	16.5	2.5	9.8	15.8	12.1	13.6	1.9	15.8	8.1	2.6	16.1	7.0	0.9	2.5	8.8	5.9	19.9	0.6	4.1	6.7	6.3	9.4	2.5	5.7	13.0	5.5	7.7	5.2	18.6	6.0	5.1	1.7	7.7	9.3	1.5	2.2	6.3	1.2	2.0	9.5	3.5	1.5	7.0	7.4	6.5	1.0	3.4	9.9	2.8	5.2	0.7	3.4	2.8	13.6	24.4	5.1	3.6	5.9	11.8	14.3	3.5	15.7	7.4	7.6	0.0	2.6	1.7	3.6	4.1	3.4	9.0	4.2	2.8	2.9	4.3	4.9	4.9	0.1	6.6	2.0	1.2	4.3	2.3	11.2	17.1	5.7	18.8	11.6	12.3	12.0	14.2	12.2	10.2	6.0	10.6	10.1	10.0	2.4	1.7	5.9	12.7	9.4	7.9	0.0	0.0	0.4	6.6	8.8	5.9	3.0	15.8	0.0	5.7	0.3	4.5	3.4	4.6	8.5	3.4	0.0	2.9	1.8	2.2	8.4	4.4	2.9	6.8	6.4	11.0	4.0	7.9	3.5	1.4	16.1	2.1	6.5	6.2	3.2	1.8	1.3	0.5	5.3	11.2	6.4
PCSK9	"FH3, HCHOLA3, NARC-1"	ENSG00000169174	"Proprotein convertase subtilisin/kexin type 9"	Q8NBP7	1	55039548-55064852	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Apoptosis, Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Hydrolase, Protease, Serine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"liver: 47.1;lung: 14.6"	"Cell type enhanced"	"Detected in some"	13	"Alveolar cells type 1: 14.9;Alveolar cells type 2: 15.3;Hepatocytes: 17.0"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"cerebellum: 6.9;pons and medulla: 2.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 29.1;CACO-2: 13.5;HaCaT: 38.9;HeLa: 33.9;RPTEC TERT1: 19.2"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"								"Secreted to blood"	NA	NA	143000000	300000000				"unprognostic (1.28e-3)"	"unprognostic (6.93e-2)"	"unprognostic (4.02e-1)"	"unprognostic (2.19e-2)"	"unprognostic (7.30e-2)"	"unprognostic (1.82e-1)"	"unprognostic (1.20e-3)"	"unprognostic (1.14e-2)"	"unprognostic (5.44e-3)"	"unprognostic (1.22e-2)"	"unprognostic (2.09e-3)"	"unprognostic (3.70e-2)"	"unprognostic (2.45e-4)"	"unprognostic (1.49e-1)"	"unprognostic (1.86e-1)"	"unprognostic (2.13e-1)"	"prognostic unfavorable (2.40e-4)"	0.2	0.1	0.0	6.1	0.5	0.4	0.0	6.9	0.2	0.6	4.4	0.0	0.0	3.9	0.2	0.7	5.2	0.4	2.6	0.0	0.0	0.0	0.1	47.1	14.6	0.0	0.1	0.0	0.1	11.0	0.0	0.0	0.0	2.6	0.0	1.9	0.1	0.3	0.3	0.0	0.8	5.1	0.8	0.1	0.2	1.0	0.4	0.0	0.0	0.0	6.1	0.9	0.6	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.1	6.5	0.9	0.0	2.1	1.5	0.1	0.0	0.0	0.0	0.0	13.5	4.6	0.0	5.3	2.5	0.1	38.9	1.1	11.8	0.0	0.0	0.0	0.0	33.9	9.4	0.7	0.0	0.0	2.3	8.8	8.5	6.2	0.0	0.0	0.0	3.7	0.0	0.0	0.0	0.0	0.0	5.5	0.5	0.7	0.0	0.0	0.3	19.2	0.0	0.5	0.0	3.8	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	6.9	0.2	0.0	0.0	0.1	0.0	2.6	0.0	14.9	15.3	0.0	0.0	0.5	0.0	0.6	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.5	0.0	1.3	0.0	0.4	0.1	0.0	17.0	0.1	0.0	4.1	1.8	1.6	0.2	0.0	0.0	1.7	0.0	2.2	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	0.5	0.0	0.0	2.9	0.2
PDCD1	"CD279, hSLE1, PD-1, PD1, SLEB2"	ENSG00000188389	"Programmed cell death 1"	Q15116	2	241849881-241858908	"CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Apoptosis, Immunity"		"FDA approved drug targets, Systemic lupus erythematosus"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 11.6;lymphoid tissue: 21.5"	"Cell type enriched"	"Detected in some"	9	"T-cells: 15.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	5	"gdT-cell: 4.1;MAIT T-cell: 3.9;memory CD4 T-cell: 6.8;memory CD8 T-cell: 11.6;T-reg: 3.5"	"Lineage enriched"	"Detected in single"	93	"T-cells: 11.6"	"Group enriched"	"Detected in some"	7	"MOLT-4: 9.5;RPMI-8226: 9.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA035981, CAB038418, CAB076386"	Enhanced					NA	NA					"CAB038418: AB_1160824, CAB076386: AB_881954, HPA035981: AB_10669664"	"unprognostic (2.90e-3)"	"unprognostic (4.50e-3)"	"unprognostic (7.78e-2)"	"prognostic favorable (9.44e-5)"	"unprognostic (7.18e-3)"	"unprognostic (1.31e-3)"	"unprognostic (3.83e-2)"	"unprognostic (7.33e-2)"	"unprognostic (5.82e-3)"	"unprognostic (3.75e-2)"	"unprognostic (6.57e-2)"	"unprognostic (3.94e-1)"	"prognostic unfavorable (3.48e-7)"	"unprognostic (1.20e-2)"	"unprognostic (3.10e-1)"	"unprognostic (5.35e-2)"	"unprognostic (5.06e-3)"	1.4	0.4	0.0	21.5	0.7	3.0	0.5	0.1	0.3	1.2	1.9	0.0	0.0	0.4	0.5	1.6	2.0	0.8	1.7	9.2	0.2	0.5	1.3	0.5	5.6	16.6	0.1	0.3	0.7	1.0	0.2	1.9	0.3	0.4	1.3	0.2	1.2	3.0	0.5	0.2	0.2	4.9	0.4	0.3	9.5	1.9	0.4	0.2	16.6	1.9	3.0	20.1	1.3	0.8	0.1	0.0	0.0	0.0	0.0	11.6	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.2	0.0	0.0	0.5	9.5	0.0	0.0	0.0	0.0	0.0	0.1	9.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.1	0.0	3.9	0.1	6.8	11.6	0.0	0.0	0.5	1.2	0.0	0.0	0.0	0.0	3.5	1.5	0.0	0.7	0.1	0.1	0.2	0.5	0.1	0.3	0.4	0.2	0.0	1.1	0.0	0.2	0.3	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	15.9	0.0	0.0
PDE10A		ENSG00000112541	"Phosphodiesterase 10A"	Q9Y233	6	165327287-165986603	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Hydrolase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 36.8"	"Cell type enhanced"	"Detected in many"	7	"Horizontal cells: 15.9;Muller glia cells: 21.0"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in all"		"basal ganglia: 36.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HeLa: 7.7;LHCN-M2: 14.0;RH-30: 8.2;RT4: 8.5;SH-SY5Y: 8.6;TIME: 14.5;U-2 OS: 7.9"	"Region enriched"	"Detected in many"	11	"basal ganglia: 307.0"	"Group enriched"	"Detected in all"	4	"basal ganglia: 155.2;cerebellum: 80.7"	"CAB045998, HPA047200"	Supported					NA	NA					"CAB045998: AB_2162589, HPA047200: AB_2679981"	"unprognostic (1.02e-1)"	"unprognostic (3.63e-2)"	"unprognostic (3.58e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.20e-1)"	"unprognostic (1.25e-1)"	"unprognostic (1.76e-1)"	"unprognostic (1.23e-1)"	"unprognostic (9.36e-2)"	"unprognostic (6.03e-2)"	"unprognostic (3.79e-2)"	"unprognostic (9.24e-2)"	"prognostic unfavorable (4.44e-7)"	"unprognostic (3.59e-3)"	"unprognostic (2.37e-2)"	"unprognostic (3.44e-2)"	"unprognostic (5.90e-3)"	3.1	1.9	1.7	1.0	36.8	0.0	3.4	4.5	6.9	2.2	1.0	1.1	4.3	0.8	2.9	7.5	0.7	3.1	3.2	3.6	2.6	2.1	8.8	0.9	4.3	1.4	2.7	1.1	3.4	0.8	1.2	2.5	5.3	1.7	2.6	0.5	0.6	0.7	4.9	0.9	0.6	0.8	4.3	1.1	2.5	1.2	8.7	16.0	0.0	12.2	1.0	0.8	7.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.7	6.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.3	0.8	0.0	0.0	0.0	5.0	0.0	2.8	0.0	0.0	0.0	3.4	0.0	7.7	0.0	0.5	0.0	0.0	0.1	0.0	0.6	0.0	0.0	7.5	0.0	0.0	0.0	14.0	0.1	1.1	0.0	1.5	0.0	5.6	1.7	8.2	0.0	7.4	8.5	2.2	8.6	0.0	0.0	0.4	0.6	0.0	0.0	14.5	0.0	7.9	0.0	0.0	0.0	0.0	0.0	0.1	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	36.8	4.5	6.9	2.6	2.1	2.7	1.1	1.7	16.0	0.0	0.0	0.0	2.8	0.3	8.8	6.9	0.0	1.4	1.2	5.2	2.0	6.0	3.3	1.7	8.9	10.3	0.0	0.0	0.0	5.2	2.0	11.7	1.1	0.0	0.7	15.9	0.0	9.8	0.0	11.8	0.0	0.0	1.7	0.0	0.0	21.0	0.2	0.0	0.4	6.5	0.6	0.0	2.1	6.6	0.5	0.3	2.4	0.0	0.0	2.2
PDE11A		ENSG00000128655	"Phosphodiesterase 11A"	Q9HCR9	2	177623252-178072755	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Hydrolase"	"Cushing syndrome, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"prostate: 20.8"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in some"		"prostate cancer: 1.7"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"CAPAN-2: 3.8;fHDF/TERT166: 5.6;HAP1: 3.2;Hep G2: 6.4"									HPA034560	Approved				"Intracellular and membrane"	NA	NA					"HPA034560: AB_10602140"	"unprognostic (1.02e-1)"	"unprognostic (4.73e-2)"	"unprognostic (1.02e-1)"	"unprognostic (9.61e-3)"	"unprognostic (2.34e-2)"	"unprognostic (1.43e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.28e-2)"	"unprognostic (2.23e-1)"	"unprognostic (3.91e-1)"	"unprognostic (9.95e-2)"	"unprognostic (2.80e-2)"	"unprognostic (5.06e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.75e-1)"	"unprognostic (4.11e-4)"	"unprognostic (1.64e-3)"	2.9	0.5	1.3	0.7	1.0	0.2	2.5	0.2	0.8	4.2	3.1	0.1	0.0	1.2	1.9	1.5	0.3	0.4	5.4	2.6	1.6	2.0	4.0	11.8	0.5	0.0	3.3	0.0	0.5	7.8	9.8	13.6	0.0	1.2	20.8	0.5	5.6	8.5	1.2	7.5	0.3	7.6	1.7	5.6	0.1	0.4	3.8	0.0	0.1	13.2	0.7	0.1	0.6	0.3	1.0	0.8	2.2	0.9	0.9	0.7	0.2	0.1	1.0	0.5	0.2	0.2	0.0	0.2	2.5	0.4	0.1	0.9	0.5	3.8	0.1	1.6	5.6	0.6	0.2	3.2	0.1	0.1	0.0	2.0	2.4	0.2	6.4	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.3	0.0	2.1	0.1	0.4	0.6	0.9	0.3	1.3	0.1	0.7	0.5	0.1	0.5	0.0	1.1	0.1	0.7	1.7	0.0	0.2	0.4	0.5	0.3	0.0	0.0	0.3	0.6	0.2	0.3	0.5	0.0	0.0	1.0	0.1	0.2	1.6	0.7	1.1	0.7	0.6	0.5	0.7	0.6	0.7	0.4	1.0	0.6	0.7	2.2	0.9	0.9	0.8	0.7	0.2	1.3	1.0	0.2	0.7	1.6	2.0	3.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0
PDE1A		ENSG00000115252	"Phosphodiesterase 1A"	P54750	2	182140036-182523192	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Calmodulin-binding, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 66.0;kidney: 37.1"	"Group enriched"	"Detected in many"	6	"Distal tubular cells: 157.5;Early spermatids: 314.8;Late spermatids: 455.7"	"Cancer enhanced"	"Detected in many"		"thyroid cancer: 13.0"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"myeloid DC: 1.4"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"ASC diff: 22.8;HHSteC: 13.5;HSkMC: 28.9"	"Group enriched"	"Detected in many"	6	"amygdala: 118.0;basal ganglia: 76.2;cerebral cortex: 161.5;hippocampal formation: 155.8;hypothalamus: 47.8"	"Low region specificity"	"Detected in all"			HPA022151	Approved		Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA022151: AB_1855118"	"unprognostic (3.63e-1)"	"unprognostic (7.21e-2)"	"unprognostic (1.32e-1)"	"unprognostic (8.61e-2)"	"unprognostic (1.58e-1)"	"unprognostic (3.02e-1)"	"unprognostic (3.84e-1)"	"unprognostic (3.82e-1)"	"unprognostic (1.02e-1)"	"unprognostic (5.38e-2)"	"unprognostic (2.78e-1)"	"unprognostic (2.86e-1)"	"unprognostic (5.55e-3)"	"unprognostic (2.50e-3)"	"unprognostic (5.96e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.40e-3)"	7.6	3.9	13.8	3.6	11.5	0.5	4.1	66.0	25.3	11.5	8.8	6.2	1.7	2.6	7.3	6.7	4.7	7.4	18.2	11.8	12.6	4.1	37.1	3.2	3.1	1.8	7.1	15.7	9.2	2.0	1.3	2.3	1.3	6.9	3.8	5.6	3.0	1.8	4.8	2.4	2.1	4.6	11.8	10.1	2.6	4.6	24.6	9.0	0.0	35.1	2.6	1.1	8.3	9.0	0.0	1.4	0.8	0.2	0.0	0.0	0.0	0.0	0.1	2.3	0.0	22.8	1.9	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	3.2	0.0	13.5	0.0	0.0	28.9	0.0	0.0	0.0	0.3	0.0	0.0	0.0	4.4	0.6	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.2	0.0	3.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	13.8	11.5	66.0	25.3	12.6	4.1	7.1	15.7	6.9	9.0	0.0	1.6	0.0	2.2	1.1	12.6	3.6	0.0	0.0	2.3	26.2	0.0	0.1	157.5	0.3	314.8	5.8	0.0	0.0	0.3	0.0	1.9	2.0	0.0	0.0	0.1	0.0	0.0	8.0	0.0	455.7	13.8	0.2	0.0	0.0	0.6	0.2	0.2	0.0	7.8	1.4	1.1	51.8	47.4	4.4	3.9	1.1	0.0	0.0	0.0	0.7
PDE1B	PDES1B	ENSG00000123360	"Phosphodiesterase 1B"	Q01064	12	54549350-54579239	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Calmodulin-binding, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 52.6"	"Cell type enhanced"	"Detected in many"	11	"Erythroid cells: 23.3;Kupffer cells: 11.5;Sertoli cells: 12.9;Smooth muscle cells: 9.5"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in all"		"basal ganglia: 52.6"	"Cell type enriched"	"Detected in single"	4	"naive CD4 T-cell: 1.6"	"Lineage enriched"	"Detected in single"	4	"T-cells: 1.6"	"Cell line enhanced"	"Detected in some"		"HDLM-2: 11.5;HL-60: 6.4;HMC-1: 12.3;NB-4: 8.1;THP-1: 7.8;U-937: 6.5"	"Region enriched"	"Detected in all"	6	"basal ganglia: 895.2"	"Region enriched"	"Detected in all"	7	"basal ganglia: 253.8"	HPA018492	Enhanced					NA	NA					"HPA018492: AB_1855119"	"unprognostic (2.90e-1)"	"unprognostic (1.51e-1)"	"unprognostic (7.67e-4)"	"unprognostic (5.63e-3)"	"unprognostic (7.02e-2)"	"unprognostic (7.51e-2)"	"unprognostic (1.97e-1)"	"unprognostic (9.39e-2)"	"unprognostic (1.14e-1)"	"unprognostic (5.11e-2)"	"unprognostic (3.84e-3)"	"unprognostic (2.70e-2)"	"prognostic unfavorable (4.77e-6)"	"unprognostic (6.64e-4)"	"unprognostic (2.14e-1)"	"unprognostic (3.09e-1)"	"unprognostic (2.83e-2)"	12.3	1.4	9.9	4.6	52.6	5.6	2.7	3.1	19.4	2.6	3.7	1.4	0.0	1.2	3.9	2.5	1.7	2.4	2.9	1.9	3.7	3.8	1.3	1.6	2.9	1.6	3.0	9.3	12.5	0.6	11.0	0.5	0.5	5.8	1.0	1.7	0.5	1.3	2.1	0.7	1.0	2.6	4.9	1.2	4.8	2.5	1.1	7.7	0.0	2.7	0.0	1.1	2.8	1.1	0.2	0.3	0.1	0.3	0.1	1.6	0.4	0.0	0.0	0.5	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	3.1	0.1	0.0	0.0	0.0	1.8	0.0	0.0	11.5	0.3	4.7	0.0	0.0	0.0	6.4	12.3	0.7	0.0	0.0	0.0	0.0	0.0	4.6	0.0	1.9	0.0	0.0	0.7	8.1	3.4	0.0	0.0	2.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	7.8	0.0	0.0	0.2	0.0	0.0	0.0	0.1	2.4	0.0	6.5	1.3	0.0	0.3	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.3	0.2	1.6	0.0	0.1	0.1	0.0	0.0	0.0	0.4	9.9	52.6	3.1	19.4	3.7	3.8	3.0	9.3	5.8	7.7	0.0	0.6	0.0	0.2	0.9	0.1	3.1	0.0	0.0	1.2	3.5	0.0	0.0	0.0	0.0	4.8	0.3	0.0	23.3	0.0	0.0	0.4	0.3	0.0	0.0	7.3	4.8	1.7	0.0	11.5	3.4	2.0	5.2	0.0	1.8	0.0	0.0	0.0	0.0	2.8	0.0	0.1	12.9	9.5	0.9	0.5	0.4	0.2	1.5	0.0	0.1
PDE1C	Hcam3	ENSG00000154678	"Phosphodiesterase 1C"	Q14123	7	31751179-32299329	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Calmodulin-binding, Hydrolase"	"Deafness, Disease mutation, FDA approved drug targets, Non-syndromic deafness"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 33.6;heart muscle: 56.2"	"Group enriched"	"Detected in some"	7	"Bipolar cells: 55.0;Cardiomyocytes: 112.6;Cone photoreceptor cells: 49.1;Early spermatids: 40.4;Late spermatids: 38.3"	"Cancer enhanced"	"Detected in some"		"glioma: 1.7"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 15.2;fHDF/TERT166: 49.0;hTERT-RPE1: 15.0;U-251 MG: 26.5;WM-115: 35.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA052375			Approved	Nucleoplasm		NA	NA			Nucleoplasm		"HPA052375: AB_2681802"	"unprognostic (1.29e-2)"	"unprognostic (2.20e-5)"	"unprognostic (1.68e-2)"	"unprognostic (1.20e-3)"	"unprognostic (2.29e-1)"	"unprognostic (5.65e-2)"	"unprognostic (4.06e-3)"	"unprognostic (2.75e-1)"	"unprognostic (6.79e-3)"	"unprognostic (6.49e-2)"	"unprognostic (3.88e-5)"	"unprognostic (7.03e-2)"	"unprognostic (3.09e-3)"	"unprognostic (5.76e-2)"	"unprognostic (5.80e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.06e-3)"	2.9	2.7	10.6	3.2	27.7	0.9	5.1	2.4	17.1	1.2	2.7	30.1	0.0	2.3	3.1	6.8	7.4	8.4	2.4	56.2	14.8	7.5	4.0	1.0	5.0	1.4	31.1	12.0	4.9	2.7	1.3	1.3	4.0	16.3	2.9	2.7	7.9	2.6	4.2	1.4	0.9	2.8	10.4	17.1	1.4	3.8	4.2	33.6	0.0	3.9	0.2	1.0	7.6	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	5.2	0.0	0.2	0.1	0.0	15.2	6.2	7.2	5.9	0.0	0.0	0.0	0.0	49.0	0.0	0.4	0.0	0.0	9.3	0.0	0.0	0.4	0.4	0.0	0.0	0.0	10.9	0.6	0.0	1.5	0.1	15.0	2.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	7.4	0.0	2.3	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.0	8.1	3.0	0.1	26.5	0.0	0.0	0.0	0.7	0.1	35.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	27.7	2.4	17.1	14.8	7.5	31.1	12.0	16.3	33.6	0.0	0.0	0.0	0.8	0.0	55.0	112.6	0.0	4.0	1.2	1.8	49.1	0.0	0.0	5.6	40.4	2.9	0.0	0.0	0.4	0.0	0.0	0.2	8.1	0.0	0.1	3.2	0.0	0.0	0.0	38.3	0.3	0.0	0.0	0.0	0.0	0.9	0.2	0.0	0.4	0.0	4.4	0.0	2.1	1.1	0.7	0.0	0.0	0.0	0.0	0.0
PDE2A		ENSG00000186642	"Phosphodiesterase 2A"	O00408	11	72576141-72674591	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 48.0;lymphoid tissue: 65.4"	"Group enriched"	"Detected in some"	6	"Endothelial cells: 33.1;Intestinal endocrine cells: 33.1;Ito cells: 118.4"	"Low cancer specificity"	"Detected in many"			"Group enriched"	"Detected in all"	4	"amygdala: 30.4;basal ganglia: 34.2;cerebral cortex: 48.0;hippocampal formation: 18.0;olfactory region: 27.0"	"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"B-cells: 3.7;T-cells: 9.6"	"Cell line enriched"	"Detected in some"	8	"HeLa: 107.5"					"Group enriched"	"Detected in all"	5	"amygdala: 111.5;basal ganglia: 166.3;cerebral cortex: 98.9;hippocampal formation: 120.9"	"CAB009752, HPA031192"	Enhanced		Supported	Cytosol		NA	NA			Cytosol		"CAB009752: AB_2268159, HPA031192: AB_2673781"	"unprognostic (1.92e-1)"	"unprognostic (1.52e-3)"	"unprognostic (4.58e-2)"	"unprognostic (1.49e-1)"	"unprognostic (1.26e-1)"	"unprognostic (2.50e-1)"	"prognostic favorable (1.76e-6)"	"unprognostic (3.06e-2)"	"unprognostic (1.35e-1)"	"unprognostic (3.01e-3)"	"unprognostic (3.13e-3)"	"unprognostic (1.50e-2)"	"unprognostic (1.77e-2)"	"unprognostic (2.85e-3)"	"unprognostic (6.31e-2)"	"unprognostic (7.72e-2)"	"unprognostic (7.96e-4)"	27.8	18.4	30.4	3.0	34.2	2.5	25.4	1.0	48.0	8.9	7.7	3.8	1.9	3.5	9.4	4.9	10.2	11.6	12.0	11.3	18.0	6.1	7.0	10.4	5.1	3.8	3.8	27.0	3.4	2.4	4.4	3.4	6.6	6.7	4.8	5.2	3.0	2.3	6.3	6.6	4.8	4.2	10.3	2.1	65.4	4.2	2.9	7.4	0.1	7.0	3.9	2.2	8.3	11.2	3.7	1.2	0.2	1.0	0.1	9.6	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	2.6	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.0	107.5	0.1	0.2	0.0	1.6	0.0	0.2	0.5	4.4	0.2	2.4	0.1	0.1	0.1	0.0	0.0	0.0	0.0	1.6	0.0	2.9	0.0	0.0	0.2	0.0	0.0	9.6	0.5	0.0	0.0	0.4	0.1	0.0	0.0	13.7	0.0	2.0	0.7	0.0	0.0	0.0	0.0	0.8	0.0	0.1	0.0	0.8	0.0	9.6	1.0	5.6	3.7	5.7	5.6	1.2	2.5	3.7	3.0	0.2	0.1	0.5	0.0	2.3	1.9	30.4	34.2	1.0	48.0	18.0	6.1	3.8	27.0	6.7	7.4	0.0	0.3	0.0	0.0	2.3	2.7	6.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	33.1	0.0	0.0	0.0	0.2	0.9	0.1	1.1	0.9	0.5	1.6	33.1	118.4	10.0	1.5	0.3	1.0	1.7	0.0	0.6	0.0	0.1	0.0	0.4	0.0	0.4	0.0	4.3	1.4	0.8	2.5	0.0	0.0	0.0	0.3
PDE3A	CGI-PDE	ENSG00000172572	"Phosphodiesterase 3A"	Q14432	12	20369245-20684381	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"		Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 62.2"	"Cell type enhanced"	"Detected in many"	15	"Bipolar cells: 41.0;Cardiomyocytes: 107.8;Horizontal cells: 49.3;Smooth muscle cells: 51.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 7.9;HEL: 14.6;HeLa: 39.5;HUVEC TERT2: 7.1;SH-SY5Y: 14.8;U-138 MG: 11.4"	"Low region specificity"	"Detected in some"			"Region enhanced"	"Detected in many"		"cerebellum: 35.4"	"HPA014492, HPA074258"	Approved		Approved	"Plasma membrane"		NA	NA		23000	"Plasma membrane"		"HPA014492: AB_1855120, HPA074258: "	"unprognostic (2.59e-2)"	"unprognostic (2.94e-2)"	"unprognostic (1.25e-1)"	"unprognostic (3.23e-1)"	"unprognostic (2.27e-1)"	"unprognostic (1.21e-1)"	"unprognostic (3.50e-2)"	"unprognostic (1.67e-2)"	"unprognostic (8.14e-2)"	"unprognostic (1.49e-1)"	"unprognostic (4.25e-1)"	"unprognostic (3.37e-1)"	"prognostic unfavorable (1.72e-6)"	"unprognostic (5.58e-2)"	"unprognostic (5.94e-2)"	"unprognostic (4.28e-2)"	"unprognostic (2.76e-4)"	7.1	1.0	1.7	4.7	2.0	0.0	3.8	3.5	1.4	7.8	15.9	1.0	2.0	2.1	7.8	3.5	9.1	4.9	5.5	62.2	1.6	1.4	3.7	1.8	3.9	3.3	1.9	1.1	7.1	6.5	1.0	2.8	13.8	2.7	6.3	9.0	12.0	7.8	4.2	2.0	1.4	21.4	6.0	1.8	2.1	5.5	2.3	0.7	0.0	2.8	1.9	0.9	4.0	3.7	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	7.9	0.0	1.8	1.3	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	14.6	39.5	0.2	0.6	0.0	0.0	1.8	0.0	0.4	0.1	0.1	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	1.1	0.0	0.0	0.0	2.2	0.0	0.1	14.8	0.0	0.0	0.0	3.5	0.0	0.0	0.2	11.4	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	1.7	2.0	3.5	1.4	1.6	1.4	1.9	1.1	2.7	0.7	0.0	0.0	0.0	0.1	0.2	41.0	107.8	5.1	0.0	1.2	0.0	0.0	0.0	0.0	3.7	0.2	2.2	24.6	0.0	0.4	0.0	3.5	0.5	16.2	0.0	0.5	49.3	4.1	0.6	0.0	0.0	1.4	0.0	1.7	0.0	7.4	2.5	0.5	24.6	0.7	2.6	2.2	6.5	51.8	0.2	0.4	0.3	0.0	0.0	13.9	0.2
PDE3B	HcGIP1	ENSG00000152270	"Phosphodiesterase 3B"	Q13370	11	14643723-14872044	"Enzymes, FDA approved drug targets, Predicted membrane proteins"	Angiogenesis	Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 42.6"	"Cell type enhanced"	"Detected in many"	7	"granulocytes: 34.7;Hepatocytes: 50.5;Spermatocytes: 45.1"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in many"	6	"cerebellum: 19.2"	"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"granulocytes: 5.0;T-cells: 8.7"	"Cell line enhanced"	"Detected in many"		"HL-60: 13.6;Karpas-707: 15.7;THP-1: 16.7;U-266/70: 17.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA056111			Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA056111: AB_2683041"	"unprognostic (1.05e-1)"	"unprognostic (2.86e-2)"	"unprognostic (4.12e-2)"	"unprognostic (2.76e-3)"	"unprognostic (4.25e-1)"	"unprognostic (1.84e-3)"	"unprognostic (3.40e-2)"	"unprognostic (3.24e-2)"	"unprognostic (5.39e-2)"	"unprognostic (1.20e-1)"	"prognostic favorable (7.91e-4)"	"unprognostic (1.77e-1)"	"unprognostic (2.33e-2)"	"unprognostic (1.39e-2)"	"unprognostic (3.42e-1)"	"unprognostic (2.47e-1)"	"unprognostic (9.03e-3)"	42.6	1.0	2.3	12.6	2.2	6.7	17.0	19.2	3.0	2.9	21.8	0.9	0.8	2.2	0.9	1.4	2.6	1.0	6.9	4.7	2.2	2.1	2.4	18.2	10.2	14.1	1.6	1.6	0.9	7.3	0.3	5.1	5.5	1.5	10.7	8.1	1.9	16.5	1.3	0.8	0.9	6.3	9.7	2.1	8.7	3.0	12.5	0.8	7.8	1.2	2.3	7.1	10.5	4.5	0.3	0.4	5.0	1.2	0.1	8.7	1.8	0.0	1.5	3.4	5.5	6.8	0.0	1.3	0.4	0.0	0.0	0.0	5.0	0.0	0.0	0.0	0.0	1.6	0.0	5.1	0.0	0.0	0.1	11.3	0.1	8.3	10.2	2.4	13.6	0.0	0.5	0.0	0.0	0.3	0.0	0.0	4.0	11.9	15.7	0.0	0.1	2.7	6.6	4.6	1.8	2.5	6.5	1.5	10.3	0.0	1.1	5.2	9.7	1.3	8.8	3.0	1.6	0.0	16.7	0.0	0.0	0.8	0.0	0.0	17.7	5.4	0.4	0.1	2.3	1.0	0.0	0.7	2.9	1.4	0.7	2.9	0.3	4.2	3.2	0.4	0.2	8.7	7.5	5.0	0.1	1.2	0.1	4.2	1.8	2.3	2.2	19.2	3.0	2.2	2.1	1.6	1.6	1.5	0.8	14.9	9.9	1.9	0.8	0.2	0.4	8.2	0.0	6.7	11.4	1.8	0.0	1.0	1.7	0.0	12.4	2.2	2.6	23.3	4.3	1.9	8.5	3.4	34.7	50.5	6.3	0.0	1.2	7.4	14.0	10.1	1.4	12.3	0.0	1.0	13.1	4.5	2.9	17.5	8.5	1.9	0.3	0.0	0.1	45.1	11.1	0.1	2.1	11.7	9.7	0.9
PDE4A	DPDE2	ENSG00000065989	"Phosphodiesterase 4A"	P27815	19	10416773-10469631	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 38.5;testis: 31.8"	"Cell type enhanced"	"Detected in many"	13	"Late spermatids: 164.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HMC-1: 22.0;NB-4: 25.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB017632, HPA043310, HPA076091"	Uncertain		Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"CAB017632: AB_1127109, HPA043310: AB_2678419, HPA076091: AB_2686775"	"unprognostic (1.29e-2)"	"unprognostic (3.98e-2)"	"unprognostic (8.91e-2)"	"unprognostic (1.82e-1)"	"unprognostic (7.00e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.54e-2)"	"unprognostic (4.39e-2)"	"unprognostic (7.91e-2)"	"unprognostic (1.52e-2)"	"unprognostic (6.90e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.27e-2)"	"unprognostic (1.64e-2)"	"unprognostic (2.57e-2)"	"unprognostic (1.67e-1)"	"unprognostic (2.15e-1)"	6.4	2.5	9.0	4.2	13.9	3.4	6.3	15.0	38.5	8.4	4.3	3.2	0.4	2.0	4.4	1.1	3.1	4.8	5.0	4.1	12.4	6.9	2.8	1.9	7.7	2.0	5.3	19.4	1.7	9.8	17.3	2.3	4.9	34.7	3.7	3.0	3.1	7.1	4.0	26.1	2.2	2.7	4.7	3.6	4.1	6.1	31.8	4.5	0.0	5.4	1.0	1.9	4.6	3.5	0.2	3.3	5.9	4.4	5.3	2.0	1.3	0.0	1.4	0.3	3.9	11.6	6.9	2.2	3.3	6.6	0.4	1.1	3.5	3.2	1.5	9.7	8.5	0.2	0.3	2.3	0.4	0.2	3.8	3.3	13.6	4.7	3.8	7.5	2.2	22.0	5.1	0.4	3.7	0.0	0.4	3.1	1.2	10.7	3.3	2.3	1.0	1.3	25.3	1.8	3.9	2.8	8.9	2.2	11.7	0.6	0.8	2.5	0.9	0.2	0.1	3.6	0.6	0.5	4.5	6.6	5.0	6.5	3.4	2.1	6.5	0.5	7.2	2.1	0.1	4.0	5.9	2.6	5.1	1.5	4.4	0.8	0.2	0.5	2.0	3.3	0.1	0.1	0.7	0.2	5.3	4.4	0.2	1.2	1.3	9.0	13.9	15.0	38.5	12.4	6.9	5.3	19.4	34.7	4.5	3.0	15.2	8.0	2.7	9.0	23.9	5.8	12.7	10.7	7.9	8.7	0.0	0.3	0.0	2.8	44.2	10.9	1.3	0.0	11.1	4.3	13.4	3.1	32.2	0.8	9.8	52.4	0.0	11.6	18.3	164.4	16.1	37.2	13.5	14.4	6.2	1.3	10.6	0.0	17.0	0.0	2.6	6.5	8.1	7.7	7.8	7.0	0.3	16.0	6.8	1.4
PDE4B	DPDE4	ENSG00000184588	"Phosphodiesterase 4B"	Q07343	1	65792514-66374579	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 48.2"	"Cell type enhanced"	"Detected in many"	7	"Glandular cells: 81.5;Horizontal cells: 108.1;monocytes: 104.6"	"Cancer enhanced"	"Detected in all"		"glioma: 18.9"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 36.6"	"Group enriched"	"Detected in all"	5	"B-cells: 16.1;granulocytes: 36.6;T-cells: 13.3"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 24.4;HUVEC TERT2: 36.6;NTERA-2: 22.2;SK-MEL-30: 22.0;TIME: 20.4;U-266/84: 19.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA003005	Uncertain		Approved	"Golgi apparatus,Cytosol"		NA	NA			"Golgi apparatus"	Cytosol	"HPA003005: AB_1079587"	"unprognostic (7.86e-2)"	"unprognostic (3.13e-1)"	"unprognostic (4.62e-2)"	"unprognostic (2.90e-1)"	"unprognostic (3.21e-1)"	"unprognostic (3.33e-3)"	"unprognostic (1.35e-1)"	"unprognostic (1.15e-3)"	"unprognostic (1.04e-2)"	"unprognostic (6.10e-2)"	"unprognostic (8.78e-2)"	"unprognostic (4.24e-2)"	"prognostic unfavorable (5.04e-4)"	"unprognostic (2.89e-2)"	"unprognostic (3.54e-1)"	"unprognostic (9.04e-3)"	"unprognostic (8.33e-3)"	14.9	2.9	21.5	28.4	29.0	48.2	15.0	12.7	31.9	6.4	6.6	39.2	0.7	3.9	6.7	2.1	3.9	3.5	8.1	16.1	20.7	18.8	3.7	8.7	10.0	15.9	36.3	14.2	2.0	1.7	1.7	3.4	13.1	32.2	18.3	8.6	6.6	15.9	10.3	28.2	6.2	8.5	9.5	37.4	18.5	4.2	3.2	36.9	2.3	5.5	5.5	14.7	16.1	3.9	16.1	2.6	36.6	2.8	4.4	13.3	3.7	0.1	7.0	13.8	24.4	0.7	0.7	0.0	4.5	5.3	4.2	5.6	0.0	0.0	2.0	0.1	8.4	0.1	0.0	0.1	0.0	4.2	5.9	0.0	0.1	2.0	0.0	0.5	4.9	0.0	1.4	0.2	2.1	0.1	0.6	36.6	0.0	0.0	1.3	1.8	0.1	0.0	2.8	22.2	0.0	0.3	1.0	2.4	1.3	3.4	0.0	0.1	10.6	0.0	1.2	22.0	1.2	0.1	1.7	20.4	3.3	0.8	1.8	0.7	0.6	19.1	7.5	3.4	5.1	1.4	2.7	2.8	8.4	4.4	2.4	8.4	15.4	8.3	6.2	2.4	16.1	9.4	6.5	36.6	4.4	2.1	2.6	13.3	3.7	21.5	29.0	12.7	24.6	20.7	18.8	36.3	14.2	32.2	36.9	8.9	16.4	50.2	24.5	18.0	35.4	29.1	0.0	2.7	12.5	5.2	0.0	5.2	0.0	0.5	7.9	23.2	0.0	0.0	0.8	1.6	9.3	81.5	14.0	1.6	12.6	108.1	4.1	12.3	25.8	5.6	0.3	42.5	49.0	104.6	1.2	12.2	0.1	0.0	2.5	1.6	3.3	0.0	10.3	0.1	0.7	7.0	4.7	36.2	1.1	5.7
PDE4C	DPDE1	ENSG00000105650	"Phosphodiesterase 4C"	Q08493	19	18208652-18248200	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"tongue: 28.6"	"Cell type enhanced"	"Detected in many"	14	"Enterocytes: 141.8;Paneth cells: 179.9;Undifferentiated cells: 66.4"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"BEWO: 6.0;Hep G2: 4.0;U-87 MG: 9.0"									"HPA048975, HPA054218"	Approved		Approved	"Midbody ring,Centrosome,Cytosol"		NA	NA			"Centrosome, Cytosol"	"Midbody ring"	"HPA048975: AB_2680581, HPA054218: "	"unprognostic (4.20e-2)"	"unprognostic (4.02e-2)"	"unprognostic (1.20e-1)"	"unprognostic (1.27e-1)"	"unprognostic (5.22e-4)"	"unprognostic (1.44e-2)"	"unprognostic (7.70e-2)"	"unprognostic (1.15e-1)"	"unprognostic (4.01e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.50e-3)"	"unprognostic (2.21e-1)"	"unprognostic (7.25e-10)"	"unprognostic (2.73e-2)"	"unprognostic (2.65e-1)"	"unprognostic (9.21e-2)"	"unprognostic (2.45e-2)"	2.0	1.3	1.8	1.5	2.8	1.0	2.0	0.8	6.1	4.1	4.4	1.5	3.1	1.5	6.4	6.8	1.3	4.2	5.6	4.2	1.6	1.9	4.1	2.0	4.1	0.5	1.7	5.1	2.0	0.8	0.3	3.5	7.0	2.8	5.8	1.3	2.5	1.3	5.4	13.4	0.6	4.1	3.4	0.7	2.3	5.2	2.6	1.1	0.4	1.2	28.6	0.7	1.8	3.3	1.3	0.6	3.5	0.7	1.0	0.7	0.2	0.1	0.3	0.2	0.3	0.1	0.3	6.0	0.1	0.0	0.2	0.3	1.2	0.2	0.2	0.6	0.1	0.4	0.1	0.0	0.0	0.0	0.1	0.2	0.3	0.4	4.0	0.2	0.2	0.6	0.7	0.1	2.6	0.0	0.5	0.0	0.3	0.9	2.1	0.1	0.4	0.2	0.3	0.2	0.4	0.2	0.2	0.3	0.4	0.1	0.2	0.2	0.8	0.3	0.5	0.0	1.6	0.5	0.3	0.0	0.4	0.2	0.7	0.1	1.3	0.6	0.2	9.0	0.2	0.3	3.4	0.7	1.0	0.6	0.4	0.5	0.5	0.5	0.4	0.2	1.3	0.5	0.7	3.5	1.0	0.4	0.6	0.3	0.2	1.8	2.8	0.8	6.1	1.6	1.9	1.7	5.1	2.8	1.1	3.0	8.8	0.0	2.2	4.8	3.0	28.1	5.1	0.0	1.2	0.0	5.9	1.9	0.0	0.0	29.1	3.6	141.8	0.0	0.0	3.5	4.2	1.8	4.6	0.0	0.4	0.0	6.9	1.3	2.2	26.0	0.6	1.1	1.7	0.0	34.4	2.7	0.0	179.9	3.9	0.0	3.3	45.3	13.4	1.9	1.9	3.3	0.9	0.0	66.4	18.4
PDE4D	DPDE3	ENSG00000113448	"Phosphodiesterase 4D"	Q08499	5	58969038-60522120	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 60.0"	"Cell type enhanced"	"Detected in many"	4	"Alveolar cells type 2: 76.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	5	"eosinophil: 28.1"	"Lineage enriched"	"Detected in many"	5	"granulocytes: 28.1"	"Cell line enhanced"	"Detected in many"		"A549: 25.3;AN3-CA: 29.1;HeLa: 41.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA045895	Uncertain		Supported	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane"	Cytosol	"HPA045895: AB_10960275"	"unprognostic (1.14e-1)"	"unprognostic (8.73e-3)"	"unprognostic (4.35e-2)"	"unprognostic (7.87e-2)"	"unprognostic (5.97e-2)"	"unprognostic (2.03e-1)"	"unprognostic (8.10e-4)"	"unprognostic (1.17e-1)"	"unprognostic (6.59e-2)"	"unprognostic (1.84e-1)"	"unprognostic (2.71e-1)"	"unprognostic (2.65e-1)"	"prognostic favorable (4.00e-5)"	"unprognostic (1.51e-1)"	"unprognostic (8.20e-2)"	"unprognostic (1.77e-2)"	"unprognostic (2.56e-2)"	8.2	1.9	4.4	6.8	8.6	46.2	5.3	4.2	13.0	13.5	18.6	1.4	14.7	4.1	17.1	14.0	10.3	6.6	12.7	15.5	4.5	5.8	12.8	3.4	11.1	3.7	5.2	6.6	5.3	2.9	7.0	9.0	11.8	2.7	18.2	11.2	8.6	24.4	16.5	60.0	5.1	7.5	35.8	5.0	3.8	10.2	2.6	2.8	4.4	6.2	11.3	9.5	20.0	11.2	6.1	0.7	28.1	1.1	0.1	0.8	0.5	0.0	25.3	5.3	29.1	1.0	1.9	4.2	0.6	0.7	1.4	2.1	9.9	0.8	1.9	0.1	0.2	4.3	4.3	0.0	1.1	2.5	1.1	2.9	3.7	41.9	2.1	3.9	1.7	0.2	3.9	0.9	4.0	0.7	0.4	3.0	0.1	0.0	0.6	2.4	1.8	1.4	4.1	1.0	0.7	1.3	0.4	6.7	4.2	6.6	9.5	0.9	3.3	6.7	11.3	5.7	5.0	0.8	3.7	3.4	0.3	0.1	5.0	1.3	1.4	0.0	0.2	4.3	7.0	1.1	2.0	1.1	28.1	0.8	0.0	0.8	6.1	0.7	0.3	0.7	6.1	0.5	0.4	1.5	0.1	0.1	0.0	0.4	0.5	4.4	8.6	4.2	13.0	4.5	5.8	5.2	6.6	2.7	2.8	29.8	76.9	9.1	30.5	9.4	13.6	32.7	10.2	22.7	48.9	40.1	68.7	9.2	10.0	0.5	16.6	12.4	16.7	0.0	1.6	14.8	13.1	46.1	21.9	0.8	4.3	1.6	32.0	14.1	6.0	29.3	1.4	9.4	10.1	4.6	18.4	16.1	5.4	10.5	4.6	17.7	52.1	0.0	5.3	0.5	7.1	7.8	2.6	37.3	10.1	21.1
PDE5A		ENSG00000138735	"Phosphodiesterase 5A"	O76074	4	119494395-119628991	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Allosteric enzyme, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Peritubular cells: 98.6;Smooth muscle cells: 79.9"	"Cancer enhanced"	"Detected in all"		"thyroid cancer: 27.3"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ hTERT+: 24.6;HHSteC: 35.4;hTERT-RPE1: 12.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA004729, HPA012873"	Approved		Approved	Cytosol		NA	NA		3100000	Cytosol		"HPA004729: AB_1079588, HPA012873: AB_1855124"	"unprognostic (6.95e-2)"	"prognostic favorable (5.20e-4)"	"unprognostic (1.28e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.25e-1)"	"unprognostic (3.66e-2)"	"unprognostic (7.36e-2)"	"unprognostic (2.58e-2)"	"unprognostic (2.29e-2)"	"unprognostic (6.97e-2)"	"unprognostic (2.05e-2)"	"unprognostic (2.54e-1)"	"unprognostic (2.16e-2)"	"unprognostic (1.52e-2)"	"unprognostic (8.98e-2)"	"unprognostic (8.71e-3)"	"prognostic unfavorable (1.17e-4)"	12.3	4.9	2.0	28.2	2.3	0.4	8.1	3.0	2.3	21.3	28.0	1.7	20.1	6.5	17.3	21.4	30.7	10.7	13.3	5.3	2.0	2.8	3.8	1.2	11.4	4.1	2.4	3.4	10.0	7.8	5.1	3.4	8.9	4.4	31.8	11.7	20.2	8.5	23.7	6.8	4.2	15.6	45.6	2.0	2.1	9.1	7.6	1.2	0.9	9.1	8.1	2.2	25.9	15.9	1.5	0.5	1.4	0.4	0.6	2.1	4.2	8.1	0.4	5.7	0.6	2.0	3.0	1.0	5.5	24.6	0.2	0.5	0.5	0.7	0.8	0.2	6.8	1.5	3.0	1.8	0.8	0.7	0.2	3.7	9.1	1.4	0.4	35.4	1.9	0.9	3.3	1.7	0.6	0.0	12.9	0.7	1.9	1.0	1.5	0.8	0.4	2.4	0.3	1.2	0.9	1.4	0.3	2.9	2.1	2.1	2.5	2.2	4.6	6.3	8.0	0.6	4.4	1.4	1.0	1.2	3.2	2.8	1.7	0.7	2.1	1.0	0.7	3.1	0.5	0.4	0.0	0.3	0.0	0.6	0.1	2.1	1.5	1.3	0.4	0.2	1.0	0.6	0.9	1.4	0.6	0.4	0.5	0.4	4.2	2.0	2.3	3.0	2.3	2.0	2.8	2.4	3.4	4.4	1.2	6.0	4.6	0.0	2.3	3.1	8.1	3.5	12.7	1.4	5.7	1.8	13.7	0.2	0.0	12.0	25.6	3.3	6.3	0.0	2.5	0.2	3.8	2.4	1.1	1.0	0.2	4.8	2.4	1.3	0.0	9.4	19.2	0.7	5.0	0.0	10.1	28.4	4.2	9.1	98.6	0.5	5.9	19.4	79.9	2.9	5.5	2.0	0.2	0.0	8.6	1.6
PDE6A	"PDEA, RP43"	ENSG00000132915	"Phosphodiesterase 6A"	P16499	5	149857955-149944793	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Sensory transduction, Vision"	Hydrolase	"Disease mutation, FDA approved drug targets, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	8	"retina: 153.4"	"Cell type enriched"	"Detected in many"	12	"Rod photoreceptor cells: 2864.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	4	"CACO-2: 7.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA016970, HPA074677"	Enhanced					NA	NA					"HPA016970: AB_1855125, HPA074677: AB_2732264"	"unprognostic (6.85e-2)"	"unprognostic (8.84e-2)"	"unprognostic (1.70e-2)"	"unprognostic (4.11e-2)"	"unprognostic (1.12e-2)"	"unprognostic (5.72e-2)"	"unprognostic (4.39e-3)"	"unprognostic (8.83e-2)"	"unprognostic (6.54e-2)"	"unprognostic (5.91e-3)"	"unprognostic (1.77e-2)"	"unprognostic (9.21e-2)"	"unprognostic (7.57e-5)"	"unprognostic (9.93e-2)"	"unprognostic (3.08e-1)"	"unprognostic (1.31e-1)"	"unprognostic (2.26e-2)"	0.2	2.3	0.2	0.2	0.2	0.9	0.2	0.3	0.2	0.2	1.8	0.2	0.3	0.2	0.2	20.1	2.4	0.1	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.2	4.6	0.2	0.2	0.2	1.0	153.4	1.4	0.2	0.2	1.6	0.2	0.2	0.2	0.2	0.1	3.1	0.2	0.2	0.4	0.3	0.5	0.2	0.2	1.5	0.8	3.3	0.8	1.2	0.8	0.1	0.4	0.8	0.6	0.6	0.3	0.3	0.6	0.3	0.1	0.4	0.1	7.6	0.8	0.9	1.4	0.2	1.4	0.7	0.2	0.4	0.5	0.6	0.3	1.0	1.1	0.6	0.2	0.8	0.6	0.3	1.1	0.9	0.6	0.6	0.2	0.4	0.3	1.4	1.5	0.4	0.5	0.9	0.5	0.2	0.5	0.3	0.8	0.7	0.5	1.0	0.8	1.1	0.0	0.7	0.2	0.6	1.0	0.5	1.4	0.8	1.7	0.8	0.5	0.6	0.4	0.5	0.8	0.8	0.6	3.3	0.8	0.5	0.6	0.4	0.5	0.7	0.6	0.5	0.2	1.5	0.7	0.8	2.8	1.2	0.5	0.8	0.4	0.1	0.2	0.2	0.3	0.2	0.2	0.0	0.2	0.2	0.2	0.2	0.0	7.2	0.0	0.5	1.0	117.9	3.6	0.0	5.3	4.5	0.0	229.7	0.9	0.0	0.0	7.0	0.6	3.9	0.0	0.2	1.9	0.6	0.3	3.5	0.8	0.3	71.5	0.0	2.5	0.3	4.0	1.1	0.5	0.0	1.0	0.2	162.2	0.1	2.9	0.4	0.0	2864.0	0.0	1.0	1.1	0.9	0.5	2.4	0.5	0.9	0.1
PDE6B	"CSNB3, CSNBAD2, PDEB, rd1, RP40"	ENSG00000133256	"Phosphodiesterase 6B"	P35913	4	625584-670782	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Sensory transduction, Vision"	Hydrolase	"Congenital stationary night blindness, Disease mutation, FDA approved drug targets, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 30.2;retina: 64.2"	"Cell type enriched"	"Detected in many"	6	"Rod photoreceptor cells: 453.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"EFO-21: 8.0;JURKAT: 11.8;MOLT-4: 20.5;REH: 11.1;SCLC-21H: 14.0;SH-SY5Y: 8.2;U-266/84: 15.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA054148, HPA059929"	Enhanced		Approved	Cytosol		NA	NA			Cytosol		"HPA054148: AB_2682401, HPA059929: AB_2684166"	"unprognostic (2.43e-2)"	"unprognostic (1.33e-4)"	"unprognostic (2.45e-4)"	"unprognostic (7.18e-3)"	"unprognostic (1.88e-2)"	"unprognostic (5.04e-3)"	"unprognostic (7.32e-3)"	"prognostic favorable (5.34e-4)"	"unprognostic (9.70e-2)"	"unprognostic (1.14e-1)"	"unprognostic (1.37e-2)"	"unprognostic (2.33e-2)"	"unprognostic (4.09e-2)"	"unprognostic (1.67e-2)"	"unprognostic (2.26e-1)"	"unprognostic (2.41e-3)"	"unprognostic (1.85e-1)"	1.6	1.9	12.1	4.6	19.1	6.7	3.8	2.3	13.2	2.3	1.3	30.2	1.5	0.8	2.5	3.9	1.4	9.6	3.2	5.2	18.1	10.2	4.6	0.7	4.2	12.0	29.6	9.8	2.6	1.4	9.1	3.2	2.6	14.5	2.5	1.0	64.2	3.5	2.9	0.7	1.8	2.2	2.1	20.2	8.7	2.5	3.6	22.4	4.3	11.4	0.2	8.3	4.1	1.1	16.5	14.1	11.2	5.8	10.2	13.1	7.1	0.0	0.2	0.8	0.4	0.2	0.3	0.2	0.0	0.0	0.5	1.4	0.0	0.1	0.2	8.0	0.2	0.7	0.1	1.7	0.4	0.0	0.1	0.0	0.6	0.2	0.0	4.1	0.1	0.3	0.5	0.1	2.4	0.0	0.5	0.7	11.8	0.1	0.6	0.0	0.2	20.5	0.2	6.5	0.4	0.2	11.1	0.2	0.4	1.4	0.9	14.0	8.2	0.0	0.3	0.1	3.3	0.4	0.0	0.2	0.1	0.8	0.1	0.3	5.4	15.2	0.2	0.2	0.2	0.1	11.2	4.2	0.6	11.5	5.8	10.5	10.0	7.7	7.9	6.6	16.5	12.2	13.1	1.1	10.2	5.6	14.1	11.4	7.1	12.1	19.1	2.3	10.0	18.1	10.2	29.6	9.8	14.5	22.4	3.0	5.3	4.5	1.2	0.3	18.2	3.7	0.0	16.0	5.7	0.0	78.5	0.1	1.7	5.1	0.4	1.8	0.0	0.0	0.6	0.2	0.8	0.9	3.5	0.0	9.2	11.1	1.7	2.5	3.9	0.0	1.4	3.4	3.3	7.2	0.2	20.9	0.7	0.0	1.4	6.7	453.5	0.0	0.2	3.9	2.7	0.3	0.2	7.0	0.1	0.6
PDE6C	"ACHM5, COD4, PDEA2"	ENSG00000095464	"Phosphodiesterase 6C"	P51160	10	93612588-93666010	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Sensory transduction, Vision"	Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"retina: 12.8"	"Cell type enriched"	"Detected in some"	18	"Cone photoreceptor cells: 53.0"	"Not detected"	"Not detected"			"Region enriched"	"Detected in single"	7	"cerebellum: 3.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"Hep G2: 2.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (1.39e-3)"	"unprognostic (7.41e-3)"	"unprognostic (2.61e-2)"	"unprognostic (2.24e-1)"	"unprognostic (3.17e-2)"	"unprognostic (5.23e-3)"	"unprognostic (2.46e-3)"	"unprognostic (2.81e-3)"	"unprognostic (9.68e-2)"	"unprognostic (2.64e-1)"	"unprognostic (1.51e-2)"	"unprognostic (2.96e-3)"	"unprognostic (2.19e-7)"	"unprognostic (1.19e-1)"	"unprognostic (6.61e-2)"	"unprognostic (1.81e-1)"	"unprognostic (1.80e-3)"	0.4	0.6	0.3	0.4	0.4	1.3	0.4	3.0	0.7	0.8	0.3	0.3	0.3	0.4	0.5	0.3	0.3	0.5	0.3	0.3	0.3	0.2	0.3	0.5	0.5	1.0	0.3	0.3	1.0	0.3	0.0	0.8	0.3	0.3	0.7	0.0	12.8	0.8	0.3	3.1	3.1	0.7	0.3	0.3	0.9	0.6	0.7	0.3	0.3	0.6	0.3	0.3	0.4	0.7	0.2	0.1	0.2	0.2	0.3	0.6	0.0	0.2	0.7	0.4	1.4	0.0	0.1	1.0	0.8	0.0	0.0	0.0	0.8	1.0	0.6	0.2	0.0	0.1	0.4	0.0	0.0	0.0	0.1	0.6	0.5	1.4	2.4	0.1	0.5	0.3	0.0	0.0	0.0	0.0	0.3	0.0	0.7	0.3	0.8	0.0	0.2	1.0	1.6	0.8	0.1	0.4	0.6	0.0	0.1	0.0	0.2	1.2	0.1	0.2	0.0	0.1	0.5	0.5	0.3	0.2	0.0	0.4	0.0	0.2	0.7	0.6	0.6	0.6	0.4	0.2	0.0	0.2	0.0	0.5	0.0	0.0	0.1	0.2	0.1	0.1	0.2	0.6	0.5	0.2	0.3	0.2	0.1	0.0	0.0	0.3	0.4	3.0	0.3	0.3	0.2	0.3	0.3	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.7	0.3	0.0	0.0	0.0	0.0	53.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PDE7A	HCP1	ENSG00000205268	"Phosphodiesterase 7A"	Q13946	8	65717510-65842322	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 87.5;skeletal muscle: 48.3"	"Cell type enhanced"	"Detected in many"	5	"B-cells: 80.1;Rod photoreceptor cells: 69.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Karpas-707: 32.0;MOLT-4: 53.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB018770, HPA027340"	Approved					NA	NA					"CAB018770: AB_677329, HPA027340: AB_1855127"	"unprognostic (2.76e-1)"	"unprognostic (2.94e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.17e-2)"	"unprognostic (2.15e-1)"	"unprognostic (7.11e-2)"	"prognostic unfavorable (5.64e-4)"	"unprognostic (1.44e-2)"	"unprognostic (6.94e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.76e-2)"	"unprognostic (1.56e-1)"	"prognostic unfavorable (1.35e-4)"	"unprognostic (3.08e-2)"	"unprognostic (1.26e-1)"	"unprognostic (5.06e-2)"	"unprognostic (2.03e-2)"	6.9	1.4	4.4	22.7	4.6	12.3	10.0	7.3	4.3	7.1	4.1	5.8	5.9	5.6	3.6	8.2	3.6	3.8	6.1	21.0	4.3	3.6	13.4	2.7	10.1	27.7	4.3	2.7	3.4	9.2	1.4	7.5	4.0	4.6	7.3	5.0	3.3	11.7	12.6	48.3	4.3	13.6	4.0	3.4	16.3	6.2	4.8	5.5	87.5	13.0	25.4	22.4	5.4	4.7	7.7	2.2	5.3	0.7	2.1	12.6	1.8	4.0	3.6	15.8	7.4	2.3	2.0	6.7	3.0	2.6	3.8	3.7	4.4	2.7	11.4	0.7	1.9	3.4	4.5	5.8	6.4	4.1	13.3	3.0	8.2	5.7	3.1	1.1	6.5	3.3	2.9	10.8	2.5	7.6	3.3	3.8	27.9	6.1	32.0	2.6	2.3	53.3	8.2	16.8	3.2	1.6	19.9	2.4	2.9	2.6	8.1	7.9	9.0	3.2	1.6	1.6	11.4	8.7	17.1	2.4	5.4	6.7	3.8	2.4	15.6	6.7	19.8	5.5	13.9	2.9	0.2	0.7	5.3	3.7	0.6	6.0	6.7	5.7	3.7	1.5	7.7	12.6	9.6	2.6	2.1	0.1	2.2	4.5	1.8	4.4	4.6	7.3	4.3	4.3	3.6	4.3	2.7	4.6	5.5	17.9	17.7	80.1	11.5	16.1	26.4	35.0	17.8	26.8	25.0	3.5	53.0	11.4	0.0	6.7	20.3	9.0	4.2	0.0	4.6	7.2	18.3	16.5	9.2	3.9	9.2	17.5	9.2	8.0	14.5	10.3	6.9	15.6	15.1	10.0	6.4	11.4	5.1	5.8	7.1	15.4	69.6	0.0	10.3	10.0	11.5	16.4	7.2	50.7	6.0	8.1
PDE7B		ENSG00000171408	"Phosphodiesterase 7B"	Q9NP56	6	135851696-136195574	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	10	"Collecting duct cells: 21.0;Endothelial cells: 18.2;Ito cells: 35.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"naive B-cell: 4.3"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 7.3;ASC TERT1: 8.6;EFO-21: 13.4;HeLa: 7.8;HSkMC: 18.7;HUVEC TERT2: 8.7;U-2197: 9.3"	"Region enriched"	"Detected in all"	5	"basal ganglia: 112.3"	"Low region specificity"	"Detected in all"			HPA023967	Uncertain		Approved	Nucleoplasm		No	NA			Nucleoplasm		"HPA023967: AB_1855128"	"unprognostic (3.18e-1)"	"unprognostic (3.47e-1)"	"unprognostic (2.34e-1)"	"unprognostic (1.79e-3)"	"unprognostic (3.34e-1)"	"unprognostic (3.22e-4)"	"unprognostic (1.37e-2)"	"unprognostic (3.00e-1)"	"unprognostic (2.80e-1)"	"unprognostic (6.73e-3)"	"unprognostic (1.11e-2)"	"unprognostic (7.85e-2)"	"prognostic favorable (1.59e-4)"	"unprognostic (3.14e-3)"	"unprognostic (2.68e-2)"	"unprognostic (1.43e-1)"	"unprognostic (3.34e-2)"	5.8	4.3	7.3	4.0	21.9	0.8	3.6	1.6	12.8	6.2	4.0	2.3	25.2	3.6	14.2	4.9	2.8	4.2	6.1	7.9	5.1	7.4	9.6	6.4	3.3	2.8	6.4	4.2	22.7	1.6	3.7	8.7	2.2	5.9	6.8	5.0	5.4	5.0	28.5	7.2	1.5	3.7	13.5	5.3	2.3	5.2	2.9	7.1	7.7	8.3	6.1	1.9	10.6	5.1	4.3	2.6	0.6	0.9	0.7	1.8	0.3	0.0	4.5	0.1	0.0	7.3	8.6	0.0	0.4	2.3	1.7	0.9	0.0	0.0	0.0	13.4	2.9	0.0	0.0	0.0	0.0	0.6	0.0	0.1	0.0	7.8	0.0	3.1	0.1	0.0	18.7	0.0	3.4	0.0	0.7	8.7	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	3.0	0.5	3.2	3.0	0.1	0.1	0.0	0.0	1.5	0.0	1.9	0.0	9.3	0.0	0.1	0.0	0.0	0.5	0.0	0.7	0.2	0.9	0.6	0.2	0.2	0.1	1.5	0.4	0.2	2.6	4.3	1.8	1.0	0.3	0.7	0.1	0.2	0.2	0.3	7.3	21.9	1.6	12.8	5.1	7.4	6.4	4.2	5.9	7.1	0.0	0.3	3.0	0.2	0.3	2.3	8.5	2.5	0.0	0.0	21.0	0.0	0.1	0.0	0.1	0.4	18.2	0.0	0.0	1.5	0.0	3.3	0.3	10.3	4.7	0.3	6.4	7.0	35.0	1.5	0.0	11.2	0.5	0.0	0.0	0.0	13.8	0.1	0.0	7.4	1.2	0.7	12.9	3.1	0.1	0.2	1.3	0.0	0.0	0.0	0.1
PDE8A	HsT19550	ENSG00000073417	"Phosphodiesterase 8A"	O60658	15	84980440-85139145	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"RT4: 40.2"	"Low region specificity"	"Detected in all"							HPA007722	Approved		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"HPA007722: AB_1855130"	"unprognostic (1.68e-1)"	"unprognostic (2.83e-2)"	"unprognostic (4.81e-2)"	"unprognostic (4.97e-2)"	"unprognostic (6.25e-2)"	"unprognostic (3.47e-2)"	"unprognostic (2.97e-2)"	"unprognostic (3.94e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.45e-1)"	"unprognostic (8.99e-3)"	"unprognostic (2.75e-2)"	"unprognostic (3.42e-1)"	"unprognostic (3.72e-1)"	"unprognostic (4.26e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.94e-2)"	14.3	16.6	14.0	8.5	18.7	2.6	9.8	2.6	14.8	11.4	21.0	35.5	9.1	13.2	9.0	8.2	5.9	8.8	14.3	7.8	17.2	9.8	21.7	26.2	10.5	5.4	23.3	12.1	12.0	12.7	17.6	7.1	10.1	20.1	6.9	19.8	12.6	8.2	9.2	5.6	6.2	11.7	10.7	17.6	6.7	10.8	10.6	25.5	2.2	11.2	4.8	5.0	11.9	10.6	1.3	1.7	1.7	4.5	0.6	3.2	0.6	12.8	21.5	3.7	2.5	15.5	8.2	4.4	8.6	9.6	7.7	8.9	4.8	7.7	2.5	6.8	11.6	9.2	9.1	15.6	6.8	10.4	4.7	9.3	3.4	13.9	6.9	11.2	2.0	5.2	8.2	4.2	9.0	8.7	6.7	9.9	2.9	6.8	8.4	7.0	10.8	1.1	1.9	1.7	4.2	4.0	1.5	3.0	3.6	6.1	40.2	8.5	6.5	8.5	9.4	25.0	4.2	3.0	3.9	7.7	18.1	6.3	6.4	14.1	4.1	7.2	2.8	12.3	8.1	5.1	0.0	2.4	1.7	1.1	2.2	2.1	0.8	1.8	1.9	1.7	1.3	2.2	0.9	0.2	0.6	4.5	0.0	3.2	0.6	14.0	18.7	2.6	14.8	17.2	9.8	23.3	12.1	20.1	25.5	6.0	31.1	9.3	10.7	10.1	13.4	5.2	30.6	10.7	15.9	7.0	11.8	6.3	6.6	8.7	5.6	17.9	20.8	0.0	8.2	5.8	13.3	17.2	20.9	20.8	9.7	9.5	13.9	16.5	12.5	4.1	10.0	16.1	10.1	6.4	17.5	2.5	11.6	31.7	10.6	15.7	32.2	38.8	14.1	22.4	14.5	9.2	3.8	4.8	22.9	22.5
PDE8B		ENSG00000113231	"Phosphodiesterase 8B"	O95263	5	77210449-77429807	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"Cushing syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"thyroid gland: 67.7"	"Group enriched"	"Detected in many"	4	"Cardiomyocytes: 26.4;Cone photoreceptor cells: 51.1;Glandular cells: 41.8;Horizontal cells: 65.2;Muller glia cells: 77.6"	"Cancer enriched"	"Detected in many"	6	"thyroid cancer: 35.7"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"BJ hTERT+: 12.4;HeLa: 28.4;SK-BR-3: 7.6"									"HPA036911, HPA036912"	Supported		Approved	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"HPA036911: AB_2675378, HPA036912: AB_10670377"	"unprognostic (1.30e-1)"	"unprognostic (7.95e-2)"	"unprognostic (3.35e-2)"	"unprognostic (7.61e-4)"	"unprognostic (1.59e-2)"	"unprognostic (1.41e-1)"	"unprognostic (2.66e-2)"	"unprognostic (4.48e-2)"	"unprognostic (1.71e-1)"	"unprognostic (3.26e-2)"	"unprognostic (3.98e-2)"	"unprognostic (2.44e-1)"	"unprognostic (9.04e-3)"	"unprognostic (3.40e-2)"	"unprognostic (3.76e-2)"	"unprognostic (1.98e-1)"	"unprognostic (3.19e-2)"	6.8	2.5	9.9	0.7	14.2	0.4	3.8	1.1	16.3	6.3	1.2	2.3	0.3	1.2	11.3	3.2	1.1	10.1	2.1	7.9	8.2	9.2	3.1	1.2	2.2	0.7	5.4	8.3	1.9	4.2	0.3	3.8	13.1	8.6	10.5	0.8	2.0	5.3	7.1	0.4	0.7	1.3	10.3	2.3	0.4	1.5	1.5	5.7	0.3	67.7	0.3	0.7	0.8	1.4	0.2	0.8	1.4	2.3	0.4	0.4	0.1	0.3	3.4	1.4	0.4	1.2	0.0	0.5	1.1	12.4	0.2	0.1	1.4	0.2	0.5	0.2	0.1	0.3	0.9	0.1	0.0	0.2	0.2	1.1	0.7	28.4	0.3	0.0	0.5	0.6	0.5	0.0	0.0	0.0	0.6	0.0	0.6	0.2	0.3	0.0	0.2	0.6	0.7	0.8	0.3	0.1	0.8	1.4	0.7	0.0	0.3	3.8	1.1	1.7	7.6	0.8	1.1	1.6	1.1	0.6	0.4	0.2	0.2	0.6	0.9	0.5	0.6	1.6	0.7	0.4	0.0	0.3	1.4	0.3	2.2	0.1	0.2	0.2	0.3	0.8	0.2	0.4	0.0	0.3	0.4	2.3	0.5	0.1	0.1	9.9	14.2	1.1	16.3	8.2	9.2	5.4	8.3	8.6	5.7	3.0	3.2	0.0	1.6	0.3	11.8	26.4	0.0	0.0	2.3	1.8	51.1	0.0	0.0	1.8	3.6	0.7	0.0	0.0	0.0	0.0	2.3	41.8	1.1	0.0	0.3	65.2	4.7	4.3	0.6	3.0	5.5	0.0	1.7	0.0	0.6	77.6	0.2	0.0	0.0	0.8	4.6	6.5	8.2	0.6	2.1	1.0	0.0	0.0	0.5	2.4
PDE9A		ENSG00000160191	"Phosphodiesterase 9A"	O76083	21	42653636-42775509	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	15	"Enterocytes: 168.7;Paneth cells: 77.2"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 31.5"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 6.8"	"Group enriched"	"Detected in many"	4	"NK-cells: 1.7;T-cells: 6.8"	"Cell line enhanced"	"Detected in many"		"AF22: 16.3;EFO-21: 16.5;MCF7: 12.2;NB-4: 18.2;NTERA-2: 22.5;SCLC-21H: 12.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA011380, HPA011978"	Enhanced		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			Cytosol	"Nucleoplasm, Plasma membrane"	"HPA011380: AB_1855132, HPA011978: "	"unprognostic (5.75e-2)"	"unprognostic (9.92e-3)"	"unprognostic (3.50e-1)"	"unprognostic (1.08e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.40e-1)"	"unprognostic (5.06e-2)"	"unprognostic (3.99e-2)"	"unprognostic (6.02e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.25e-2)"	"unprognostic (5.01e-2)"	"unprognostic (1.90e-2)"	"unprognostic (4.01e-3)"	"unprognostic (1.97e-1)"	"unprognostic (6.55e-2)"	"unprognostic (1.79e-1)"	6.1	6.6	9.9	6.8	15.2	0.8	9.4	13.7	9.0	3.7	37.1	11.9	14.0	3.0	5.7	18.8	6.1	10.3	7.7	3.5	6.2	7.7	13.2	2.5	4.7	4.6	10.0	4.9	4.1	4.0	4.7	6.0	9.6	6.9	33.2	15.8	9.7	8.8	15.9	2.3	3.8	26.1	22.3	8.0	15.9	8.4	1.5	8.9	4.9	5.2	2.1	4.1	12.6	4.0	0.5	0.9	1.0	0.1	1.7	6.8	0.5	0.0	1.5	16.3	2.0	0.0	0.6	0.3	0.0	0.0	0.0	0.0	1.8	9.8	0.0	16.5	0.0	1.1	0.0	1.4	5.3	0.0	0.0	5.6	0.0	0.0	3.3	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.2	0.0	0.0	12.2	0.8	18.2	22.5	8.0	0.0	0.0	0.0	0.6	11.2	4.5	12.5	7.4	2.8	0.0	0.2	4.0	0.1	10.1	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.1	0.0	0.0	0.0	0.8	0.1	0.0	0.0	2.1	0.6	0.2	0.5	6.8	1.7	1.0	1.7	0.1	0.9	2.2	0.5	9.9	15.2	13.7	6.7	6.2	7.7	10.0	4.9	6.9	8.9	3.0	5.3	0.0	8.5	0.9	21.0	1.4	5.1	1.4	0.0	17.4	0.0	0.0	24.9	6.2	0.3	6.7	168.7	0.0	2.1	0.1	3.1	27.6	1.1	0.8	5.6	33.4	12.6	3.7	0.6	1.7	10.9	1.0	27.0	1.8	19.3	9.4	5.1	77.2	5.6	7.6	2.7	12.9	5.9	0.4	0.7	0.5	0.3	2.1	22.2	13.1
PDGFRA	"CD140a, GAS9, PDGFR2"	ENSG00000134853	"Platelet derived growth factor receptor alpha"	P16234	4	54229097-54298247	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Host-virus interaction"	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ovary: 81.5"	"Group enriched"	"Detected in many"	9	"Fibroblasts: 171.4;Leydig cells: 416.6;Peritubular cells: 384.4"	"Cancer enhanced"	"Detected in all"		"glioma: 30.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"ASC diff: 82.8;ASC TERT1: 38.8;BJ hTERT+: 48.0;fHDF/TERT166: 33.4;HHSteC: 28.0;HSkMC: 70.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004947, CAB018143"	Supported		Approved	"Nucleoplasm,Plasma membrane,Cell Junctions"	"Intracellular and membrane"	NA	NA		150000	"Nucleoplasm, Plasma membrane, Cell Junctions"		"CAB018143: AB_2162351, HPA004947: AB_2732399"	"unprognostic (1.67e-1)"	"unprognostic (9.35e-2)"	"unprognostic (4.59e-3)"	"unprognostic (1.60e-1)"	"unprognostic (8.92e-2)"	"prognostic favorable (9.33e-4)"	"unprognostic (1.24e-1)"	"unprognostic (2.00e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.18e-2)"	"unprognostic (2.18e-1)"	"unprognostic (7.01e-2)"	"prognostic unfavorable (9.79e-6)"	"unprognostic (9.58e-3)"	"unprognostic (9.87e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.72e-3)"	35.0	12.4	12.6	16.1	7.6	0.9	17.2	2.4	20.1	33.2	19.1	9.2	6.4	9.6	27.6	14.6	21.9	22.5	16.2	15.3	8.9	7.4	22.8	8.4	24.1	26.9	9.2	4.0	81.5	6.8	1.6	2.1	25.1	7.2	18.6	15.2	19.2	8.5	8.3	11.9	7.0	17.4	19.7	8.8	51.6	13.6	19.0	9.3	0.5	11.3	12.8	4.3	35.9	24.6	0.9	0.4	2.5	0.4	0.3	0.8	0.3	0.0	0.0	0.2	0.1	82.8	38.8	0.1	4.3	48.0	0.0	0.1	11.5	0.0	0.1	0.1	33.4	0.1	0.1	3.3	0.0	0.0	0.4	0.1	0.1	0.1	0.2	28.0	0.0	0.0	70.4	0.0	5.5	0.0	0.9	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.2	0.6	0.0	0.1	0.1	0.0	0.0	0.0	0.3	0.1	6.7	0.0	0.1	0.0	0.3	0.1	0.0	0.1	15.2	0.5	16.6	0.0	0.0	0.0	0.1	0.4	0.0	0.3	2.5	0.4	0.2	0.5	0.2	0.2	0.6	0.8	0.4	0.0	0.9	0.7	0.4	2.3	0.3	0.3	0.4	0.2	0.3	12.6	7.6	2.4	7.3	8.9	7.4	9.2	4.0	7.2	9.3	0.0	0.3	0.9	0.3	15.1	0.7	4.0	0.0	0.0	0.0	0.0	0.0	1.3	1.7	2.9	1.6	3.3	0.0	0.0	5.8	1.2	171.4	0.4	0.0	0.8	2.8	0.0	0.0	38.1	0.6	3.7	416.6	1.6	21.9	8.2	0.0	18.3	12.2	0.0	384.4	0.0	0.4	0.0	13.2	1.1	3.5	13.8	1.1	0.0	0.0	0.8
PDGFRB	"CD140b, JTK12, PDGFR, PDGFR1"	ENSG00000113721	"Platelet derived growth factor receptor beta"	P09619	5	150113837-150155872	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	Chemotaxis	"Developmental protein, Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enriched"	"Detected in many"	5	"Sertoli cells: 1267.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"gdT-cell: 2.9;non-classical monocyte: 4.1"	"Group enriched"	"Detected in many"	8	"monocytes: 4.1;T-cells: 2.9"	"Group enriched"	"Detected in some"	4	"ASC diff: 173.0;ASC TERT1: 59.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003842, CAB018144, HPA028499"	Enhanced		Supported	"Golgi apparatus,Vesicles"		NA	NA		35000000	Vesicles	"Golgi apparatus"	"CAB003842: AB_562328, CAB018144: AB_2162497, HPA028499: AB_10602018"	"unprognostic (4.75e-2)"	"unprognostic (2.48e-1)"	"unprognostic (5.21e-2)"	"unprognostic (3.60e-2)"	"unprognostic (3.27e-1)"	"unprognostic (5.61e-2)"	"unprognostic (1.02e-1)"	"unprognostic (3.36e-2)"	"unprognostic (2.12e-2)"	"unprognostic (2.57e-3)"	"unprognostic (6.72e-2)"	"unprognostic (1.25e-1)"	"prognostic unfavorable (5.87e-8)"	"unprognostic (3.13e-3)"	"unprognostic (1.25e-2)"	"unprognostic (5.47e-2)"	"prognostic unfavorable (8.11e-4)"	61.8	10.4	8.3	11.0	9.1	0.5	66.1	4.6	10.4	73.1	15.7	6.7	6.9	5.1	44.3	17.3	21.7	26.1	51.7	24.2	8.2	3.9	17.0	4.6	28.9	21.5	7.9	8.1	46.5	7.5	10.4	7.7	46.4	7.7	24.2	6.3	22.9	11.2	19.3	29.8	20.3	11.2	29.8	5.0	19.6	9.2	21.5	6.7	1.4	21.4	16.0	7.3	23.6	35.1	0.4	0.1	0.0	4.1	0.0	2.9	0.6	0.0	0.0	1.0	0.0	173.0	59.9	0.4	6.0	25.1	4.2	7.1	0.6	0.0	0.0	0.8	17.3	2.4	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.4	0.4	24.5	0.0	0.0	27.0	0.0	5.8	0.0	13.5	0.0	0.0	0.0	0.6	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.4	0.3	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	5.0	0.0	0.0	0.0	6.8	2.2	2.9	0.3	0.0	0.0	0.0	4.2	0.0	0.1	0.0	0.0	0.0	2.9	0.6	0.0	0.4	0.1	0.8	0.1	0.1	0.0	1.3	0.0	0.0	4.1	0.0	0.0	0.6	8.3	9.1	4.6	10.4	8.2	3.9	7.9	8.1	7.7	6.7	0.0	0.6	0.0	0.5	21.3	5.0	13.4	0.0	1.4	0.0	1.8	3.9	0.6	0.0	0.0	0.8	16.2	0.0	0.0	0.0	1.0	68.8	0.6	0.0	1.5	1.4	0.0	0.0	6.7	0.0	4.7	153.1	2.2	23.6	1.0	0.0	74.9	0.1	0.0	191.6	0.0	1.1	1267.6	273.4	1.1	1.5	13.4	0.7	1.0	0.4	0.9
PDK1		ENSG00000152256	"Pyruvate dehydrogenase kinase 1"	Q15118	2	172555373-172608669	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Carbohydrate metabolism, Glucose metabolism"	"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 96.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in all"	5	"B-cells: 5.9;granulocytes: 16.0;T-cells: 15.8"	"Cell line enhanced"	"Detected in many"		"U-266/70: 32.0;U-87 MG: 32.7"	"Low region specificity"	"Detected in all"							"CAB017554, HPA027376"	Approved					NA	NA		22000			"CAB017554: AB_2161138, HPA027376: AB_1855139"	"unprognostic (2.14e-1)"	"prognostic unfavorable (7.30e-5)"	"unprognostic (1.21e-1)"	"unprognostic (3.94e-2)"	"unprognostic (6.47e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.02e-2)"	"unprognostic (1.45e-1)"	"unprognostic (9.69e-3)"	"unprognostic (6.44e-2)"	"unprognostic (5.44e-3)"	"unprognostic (1.55e-1)"	"prognostic unfavorable (1.10e-8)"	"unprognostic (1.82e-1)"	"unprognostic (1.94e-1)"	"unprognostic (2.56e-2)"	"unprognostic (5.34e-2)"	9.9	16.2	6.8	11.0	10.5	13.4	16.7	7.1	15.6	7.3	15.3	3.3	2.9	15.5	5.4	8.0	11.2	4.4	5.8	27.6	6.9	5.2	6.8	14.2	6.1	21.4	7.2	5.2	19.5	7.2	3.4	7.5	7.9	7.2	6.5	13.1	7.6	14.1	7.6	9.6	24.7	8.4	5.2	10.7	14.2	12.5	11.0	6.7	10.3	5.1	5.0	20.8	18.0	9.8	5.9	2.3	16.0	2.2	1.4	15.8	6.2	14.4	0.6	3.7	9.3	1.5	2.3	5.3	12.7	10.3	6.4	13.7	3.7	3.1	13.7	7.0	3.9	5.3	6.3	2.5	7.9	20.5	2.7	5.1	16.7	3.4	4.3	2.7	8.3	6.2	3.0	2.9	4.4	7.5	8.9	3.4	7.3	3.5	9.5	8.4	1.5	5.2	10.4	9.1	2.9	4.0	5.5	6.1	22.1	3.3	4.6	7.0	8.0	3.3	3.9	4.8	3.3	2.5	3.4	3.9	10.2	3.3	5.3	3.4	32.0	18.5	11.3	32.7	6.0	2.0	12.2	2.2	16.0	2.5	1.5	3.0	4.7	4.2	2.8	2.3	5.9	15.8	9.6	8.5	1.4	1.9	0.4	8.0	6.2	6.8	10.5	7.1	15.6	6.9	5.2	7.2	5.2	7.2	6.7	3.0	5.3	32.2	5.4	44.5	26.8	32.3	5.1	1.4	2.3	3.5	45.2	9.1	5.0	7.7	96.0	8.9	6.0	0.0	3.3	9.6	8.4	5.5	5.7	11.9	8.7	52.4	7.5	23.9	12.9	34.3	3.1	8.8	28.7	5.4	5.2	7.6	9.0	14.0	3.5	1.5	18.9	6.5	12.3	6.3	7.7	37.9	3.4	12.5	6.0	2.1
PDXK	"C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79"	ENSG00000160209	"Pyridoxal kinase"	O00764	21	43719094-43762307	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase"	"Charcot-Marie-Tooth disease, Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 68.9"	"Group enriched"	"Detected in all"	7	"Early spermatids: 1421.5;Late spermatids: 3146.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA030196, HPA030197, HPA030198, CAB033918"	Enhanced		Enhanced	Nucleoplasm		NA	NA		870000	Nucleoplasm		"CAB033918: AB_2162502, HPA030196: AB_10599735, HPA030197: AB_10601792, HPA030198: AB_10603570"	"unprognostic (1.01e-1)"	"unprognostic (1.99e-1)"	"unprognostic (5.88e-2)"	"unprognostic (1.87e-1)"	"unprognostic (8.29e-2)"	"unprognostic (4.31e-3)"	"unprognostic (3.64e-3)"	"unprognostic (1.32e-1)"	"unprognostic (8.66e-2)"	"unprognostic (9.34e-2)"	"unprognostic (2.10e-1)"	"unprognostic (3.54e-1)"	"unprognostic (3.70e-2)"	"unprognostic (1.31e-3)"	"unprognostic (1.10e-1)"	"unprognostic (4.78e-2)"	"unprognostic (1.51e-3)"	28.1	13.2	37.4	8.7	36.6	13.3	13.3	21.9	38.5	9.7	13.8	11.0	15.7	16.7	9.0	13.2	11.0	12.9	8.8	11.4	26.1	30.4	22.8	17.4	20.4	9.5	24.1	22.7	16.4	17.6	25.7	20.7	12.6	20.3	10.6	11.8	7.8	18.3	13.9	5.8	14.3	22.1	8.8	10.1	7.8	15.2	68.9	10.7	3.9	13.6	7.0	11.0	9.7	8.6	2.7	2.5	1.3	7.7	1.9	3.3	2.4	17.4	21.4	3.4	6.5	8.4	11.9	4.2	6.3	9.9	6.1	5.2	17.4	27.3	5.9	6.7	9.0	8.5	13.2	6.6	17.9	4.1	6.6	5.7	6.0	23.4	12.8	16.5	5.6	8.7	16.8	17.2	6.4	7.2	10.0	2.9	2.6	10.4	13.6	5.8	11.8	0.8	10.1	9.3	17.0	8.2	6.7	2.0	16.3	26.6	21.4	3.3	3.9	26.1	24.2	9.3	1.5	8.0	7.9	5.1	4.5	8.8	6.0	5.8	8.3	3.9	3.4	18.4	16.2	4.3	1.3	4.8	0.2	1.7	4.4	3.3	1.4	1.7	1.9	2.5	2.7	2.0	1.4	1.3	1.9	7.7	1.2	1.5	2.4	37.4	36.6	21.9	38.5	26.1	30.4	24.1	22.7	20.3	10.7	74.5	71.3	17.5	132.2	25.2	41.8	39.3	25.5	21.4	31.8	96.0	21.6	37.3	152.5	146.7	1421.5	25.3	96.0	46.7	174.9	62.9	26.6	143.6	32.2	46.0	193.8	49.3	28.9	18.4	44.0	3146.3	46.3	89.3	40.5	27.1	42.8	10.9	164.5	30.9	50.9	69.5	40.4	6.5	25.8	332.6	27.9	24.8	103.8	22.4	42.8	203.8
PGF	"D12S1900, PGFL, PIGF, PLGF, PlGF-2, SHGC-10760"	ENSG00000119630	"Placental growth factor"	P49763	14	74941834-74955784	"Cancer-related genes, Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	7	"placenta: 177.3"	"Group enriched"	"Detected in many"	16	"Extravillous trophoblasts: 1478.5;Syncytiotrophoblasts: 1775.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	6	"BEWO: 93.4;HUVEC TERT2: 44.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			HPA041624			Approved	Nucleoplasm,Mitochondria,Cytosol	"Secreted to blood"	No	No	20800		Nucleoplasm	"Mitochondria, Cytosol"	"HPA041624: AB_10794522"	"unprognostic (1.67e-2)"	"unprognostic (4.62e-2)"	"unprognostic (9.25e-3)"	"unprognostic (1.34e-3)"	"unprognostic (8.67e-3)"	"unprognostic (2.41e-1)"	"prognostic unfavorable (1.40e-4)"	"unprognostic (7.26e-2)"	"unprognostic (1.48e-1)"	"unprognostic (4.45e-1)"	"unprognostic (1.45e-2)"	"unprognostic (3.51e-3)"	"prognostic unfavorable (1.33e-6)"	"unprognostic (2.52e-3)"	"unprognostic (1.20e-1)"	"unprognostic (3.49e-2)"	"unprognostic (1.14e-1)"	4.3	2.7	1.9	4.4	2.4	0.0	4.3	1.6	3.5	13.1	2.3	2.3	4.0	1.3	2.9	6.3	3.9	9.2	3.4	5.1	2.4	4.1	3.1	2.6	3.6	4.9	2.9	2.0	3.8	1.9	5.4	2.0	177.3	4.6	7.5	1.1	3.5	3.8	6.7	3.3	6.0	4.3	4.6	1.7	1.2	1.7	3.3	2.0	1.4	24.2	4.4	2.9	5.1	5.9	0.7	0.7	1.1	1.0	0.0	2.4	0.2	0.3	0.3	0.3	0.3	0.4	0.0	93.4	0.8	0.8	0.4	0.5	2.2	0.1	0.0	2.0	0.6	0.0	0.1	0.4	4.2	0.3	0.0	0.5	0.0	0.0	2.2	0.3	0.0	2.4	1.1	1.0	1.7	0.4	0.1	44.0	0.0	0.0	0.0	12.4	0.1	0.0	0.1	0.4	0.0	0.7	0.0	11.6	0.0	0.1	0.2	7.0	3.8	0.0	0.1	1.6	5.9	0.0	0.1	8.9	0.0	2.3	0.0	3.7	0.0	0.0	0.1	1.4	0.1	0.1	0.0	0.2	1.1	2.4	1.0	0.0	0.7	0.3	0.7	0.3	0.3	0.6	1.0	0.0	0.0	0.8	0.7	0.5	0.2	1.9	2.4	1.6	2.2	2.4	4.1	2.9	2.0	4.6	2.0	8.9	5.8	0.8	13.0	21.9	0.8	2.8	0.0	1.4	7.9	0.0	13.7	75.1	0.0	0.9	0.1	15.8	0.5	0.0	0.4	1478.5	42.9	3.3	5.8	0.0	33.1	0.0	6.8	7.4	0.3	0.6	12.0	4.5	20.3	0.0	1.1	1.9	0.6	0.2	18.4	0.4	7.5	103.5	62.6	0.2	3.4	17.1	1775.1	0.9	1.7	4.7
PGR	"NR3C3, PR"	ENSG00000082175	"Progesterone receptor"	P06401	11	101029624-101130524	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"cervix, uterine: 50.7;endometrium 1: 116.4;smooth muscle: 31.2"	"Cell type enhanced"	"Detected in some"	15	"Cardiomyocytes: 14.5;Early spermatids: 47.8;Late spermatids: 35.6;Leydig cells: 13.6"	"Group enriched"	"Detected in some"	13	"breast cancer: 10.1;endometrial cancer: 11.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	349	"T-47d: 62.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"CAB000068, HPA004751, HPA008428, HPA017176, CAB055100"	Enhanced					NA	NA					"CAB000068: AB_442124, CAB055100: AB_2532076, HPA004751: AB_1079681, HPA008428: AB_1079680, HPA017176: AB_1855728"	"unprognostic (2.59e-2)"	"unprognostic (9.80e-3)"	"unprognostic (5.23e-3)"	"prognostic favorable (5.76e-8)"	"unprognostic (2.81e-2)"	"unprognostic (1.56e-1)"	"unprognostic (4.11e-1)"	"unprognostic (1.64e-1)"	"unprognostic (2.08e-1)"	"unprognostic (2.50e-1)"	"unprognostic (3.29e-2)"	"unprognostic (1.77e-1)"	"unprognostic (7.71e-3)"	"unprognostic (1.90e-2)"	"unprognostic (2.35e-2)"	"unprognostic (1.15e-1)"	"unprognostic (5.44e-3)"	0.8	0.7	0.2	0.3	0.6	0.0	5.0	0.2	0.7	50.7	1.3	0.2	0.4	0.0	116.4	6.1	0.5	13.2	0.4	2.0	0.5	0.6	0.4	0.1	1.2	0.3	0.4	0.1	10.6	0.8	0.0	2.8	1.8	0.8	3.8	0.1	0.7	3.5	5.5	0.3	0.3	1.2	31.2	0.9	0.5	0.4	1.5	0.3	0.1	0.3	0.8	0.2	1.1	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	62.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.2	0.7	0.5	0.6	0.4	0.1	0.8	0.3	3.0	0.0	0.0	0.7	0.1	1.6	14.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	47.8	2.1	0.0	0.0	0.0	0.1	6.7	0.3	0.0	0.0	0.1	0.0	0.0	4.3	0.0	35.6	13.6	0.3	0.0	0.0	0.0	0.0	0.1	0.0	9.9	0.0	0.0	6.5	7.6	0.7	1.5	0.5	0.0	0.0	0.0	0.8
PIK3CA	PI3K	ENSG00000121879	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha"	P42336	3	179148114-179240093	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Angiogenesis, Phagocytosis"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009985, CAB017804"	Approved		Supported	Mitochondria,Cytosol		NA	NA			Cytosol	Mitochondria	"CAB017804: , HPA009985: AB_1079610"	"unprognostic (1.81e-1)"	"unprognostic (2.77e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.69e-3)"	"unprognostic (6.49e-3)"	"unprognostic (1.43e-1)"	"unprognostic (2.65e-2)"	"unprognostic (1.00e-2)"	"unprognostic (1.03e-1)"	"unprognostic (2.37e-1)"	"unprognostic (2.57e-3)"	"unprognostic (5.21e-2)"	"unprognostic (4.50e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.48e-1)"	"unprognostic (9.74e-2)"	"unprognostic (3.82e-2)"	20.1	12.3	13.7	11.5	13.4	25.7	22.4	17.1	24.5	12.9	14.0	5.2	5.7	6.5	15.3	7.9	11.6	11.1	13.2	14.2	18.4	9.7	11.7	10.8	13.2	13.8	9.8	15.7	15.4	9.2	24.7	11.6	16.5	16.3	10.7	8.9	7.2	10.9	10.9	15.2	12.0	10.5	12.8	14.4	16.2	10.6	9.3	9.8	29.6	11.0	7.3	13.9	15.1	15.7	6.2	2.6	7.8	3.8	2.4	5.0	1.1	14.6	5.0	8.0	7.4	19.0	22.2	5.9	9.4	12.7	9.3	14.7	4.3	10.9	13.4	16.1	11.2	13.2	6.0	6.6	8.1	13.5	22.4	5.8	18.4	5.5	3.8	9.1	10.3	10.5	14.0	8.6	10.2	11.7	10.4	13.3	9.7	9.1	15.0	13.3	5.8	7.9	9.3	6.4	7.3	6.8	12.0	8.1	16.1	7.3	9.0	4.5	7.7	10.2	9.1	12.2	7.3	15.2	8.9	14.0	8.7	5.7	13.7	9.3	7.3	10.3	24.1	7.9	7.8	5.1	2.1	3.8	1.6	5.0	2.9	3.9	5.8	4.2	2.8	2.2	6.2	4.6	3.8	7.8	2.4	3.0	2.6	4.1	1.1	13.7	13.4	17.1	24.5	18.4	9.7	9.8	15.7	16.3	9.8	29.8	23.2	13.7	15.2	13.1	26.3	15.4	7.6	18.7	17.0	7.0	29.5	8.1	1.7	9.8	1.7	21.4	4.9	0.0	11.9	5.0	18.3	27.3	30.1	17.4	9.5	36.5	2.4	29.4	21.2	1.6	30.2	16.4	13.5	16.2	9.6	15.6	13.1	12.7	37.1	11.2	26.2	25.8	22.1	9.6	7.6	13.0	7.3	14.0	9.2	27.6
PIK3CD	p110D	ENSG00000171608	"Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta"	O00329	1	9651732-9729114	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Adaptive immunity, Chemotaxis, Differentiation, Immunity, Inflammatory response, Innate immunity"	"Kinase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 35.0;bone marrow: 32.8;lymphoid tissue: 40.3"	"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 2: 20.7;granulocytes: 24.3;Kupffer cells: 28.8;T-cells: 30.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 51.7;NB-4: 22.4;REH: 23.3;THP-1: 22.5;U-937: 26.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB015420, HPA044953"	Enhanced		Approved	"Vesicles,Cytokinetic bridge"		Yes	No			Vesicles	"Cytokinetic bridge"	"CAB015420: AB_831654, HPA044953: AB_2679153"	"unprognostic (5.73e-3)"	"unprognostic (2.75e-3)"	"unprognostic (8.93e-2)"	"unprognostic (4.05e-2)"	"unprognostic (4.71e-2)"	"unprognostic (1.40e-2)"	"unprognostic (2.13e-1)"	"unprognostic (7.42e-2)"	"unprognostic (2.78e-2)"	"unprognostic (1.54e-2)"	"unprognostic (3.46e-2)"	"unprognostic (6.75e-2)"	"unprognostic (8.65e-3)"	"unprognostic (2.09e-1)"	"unprognostic (1.34e-1)"	"unprognostic (2.04e-1)"	"unprognostic (6.78e-2)"	4.5	2.1	3.4	34.8	7.1	32.8	2.9	3.3	4.3	3.2	3.3	5.5	0.7	3.1	3.7	3.4	3.5	4.0	6.5	2.9	4.2	3.1	4.6	3.3	8.2	40.3	7.4	1.8	5.3	2.2	2.3	2.2	3.3	4.6	3.2	2.1	3.1	11.2	1.8	0.9	2.0	11.4	2.9	5.3	35.5	3.3	3.0	5.7	23.5	4.1	2.3	36.0	5.8	3.6	8.4	14.5	35.0	15.0	14.5	13.7	16.6	2.7	1.8	0.1	0.5	0.4	0.4	0.2	4.2	8.6	9.2	7.6	0.1	1.1	7.3	1.7	3.3	4.4	0.8	0.7	3.8	5.8	51.7	0.1	0.8	0.4	3.0	1.8	18.8	6.6	1.5	1.6	10.3	3.5	4.0	1.3	5.2	2.6	0.0	5.2	0.2	1.8	22.4	0.8	0.1	0.5	23.3	4.6	0.2	3.9	0.0	0.6	0.5	0.9	1.7	4.1	2.5	0.3	22.5	3.4	2.7	2.8	0.0	3.9	1.7	1.6	10.2	5.9	26.9	1.5	9.6	11.8	21.1	12.9	13.1	13.7	7.8	9.8	11.8	12.5	8.4	12.9	13.4	35.0	14.5	15.0	14.5	7.4	16.6	3.4	7.1	3.3	4.3	4.2	3.1	7.4	1.8	4.6	5.7	8.9	20.7	7.8	1.8	1.3	0.4	2.7	0.0	1.4	1.2	0.0	2.0	0.1	1.7	3.1	2.0	1.6	0.0	0.0	1.8	0.3	1.4	2.5	24.3	0.0	12.5	0.0	0.0	3.7	28.8	1.7	1.1	13.4	3.3	1.0	0.0	2.5	7.7	0.0	1.4	2.9	1.6	6.5	3.8	1.1	2.1	1.0	0.2	30.5	0.1	2.0
PLA2G1B	"PLA2, PLA2A, PPLA2"	ENSG00000170890	"Phospholipase A2 group IB"	P04054	12	120322111-120327789	"Candidate cardiovascular disease genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Lipid metabolism, Phospholipid metabolism"	Hydrolase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	933	"pancreas: 2360.6"	"Cell type enriched"	"Detected in many"	10	"Exocrine glandular cells: 17927.2"	"Cancer enriched"	"Detected in many"	185	"pancreatic cancer: 763.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 2.5"	"Group enriched"	"Detected in many"	19	"NK-cells: 1.3;T-cells: 2.5"	"Cell line enhanced"	"Detected in some"		"EFO-21: 2.2;Hep G2: 6.4;U-2 OS: 4.7"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"HPA047822, HPA060803"	Enhanced				"Secreted to digestive system"	NA	NA		3900000			"HPA047822: AB_2680169, HPA060803: AB_2684369"	"unprognostic (1.28e-4)"	"unprognostic (6.02e-2)"	"unprognostic (1.84e-2)"	"unprognostic (2.86e-2)"	"unprognostic (2.74e-2)"	"unprognostic (2.41e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.63e-2)"	"unprognostic (3.61e-2)"	"unprognostic (1.27e-1)"	"unprognostic (1.03e-1)"	"unprognostic (2.80e-4)"	"unprognostic (2.15e-1)"	"unprognostic (1.97e-1)"	"unprognostic (3.60e-1)"	"unprognostic (8.61e-4)"	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.0	0.1	0.1	1.1	0.1	0.1	0.1	1.1	2360.6	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.2	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	1.3	2.5	0.9	0.2	0.0	1.2	0.2	0.0	0.0	0.0	0.0	0.0	0.3	1.6	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.3	0.0	0.0	1.4	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.8	0.2	0.0	0.0	0.0	0.7	0.4	0.0	0.0	0.0	0.5	0.0	0.3	1.3	0.3	1.6	0.0	0.0	0.3	0.0	0.1	0.6	0.0	1.0	0.2	4.7	0.6	0.6	0.0	1.2	0.4	0.0	0.6	0.0	0.0	0.0	0.0	0.9	0.0	1.7	0.0	0.0	0.3	0.0	0.0	2.5	0.9	0.0	1.3	0.0	0.0	0.0	0.9	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	11.9	65.5	0.0	0.1	0.0	0.0	0.3	0.0	1.4	1.2	0.0	0.0	0.0	1.7	16.1	7.5	0.0	0.7	0.0	17927.2	0.0	0.0	0.2	0.0	1.6	0.0	0.0	1.2	0.0	0.0	27.8	2.8	0.3	0.0	76.7	1.0	0.0	1839.8	1.1	3.2	2.1	0.0	0.0	0.0	0.2	0.2	0.1	0.0	0.7	1.2	0.0
PLA2G2A	"PLA2B, PLA2L"	ENSG00000188257	"Phospholipase A2 group IIA"	P14555	1	19975431-19980416	"Enzymes, FDA approved drug targets, Predicted secreted proteins, RAS pathway related proteins"	"Inflammatory response, Lipid metabolism, Phospholipid metabolism"	"Antimicrobial, Bacteriolytic enzyme, Hydrolase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 377.9"	"Cell type enhanced"	"Detected in many"	11	"Enterocytes: 366.3;Exocrine glandular cells: 945.9;Glandular cells: 937.5;Paneth cells: 354.3;Undifferentiated cells: 591.0"	"Cancer enhanced"	"Detected in all"		"prostate cancer: 875.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	23	"Hep G2: 23.4;OE19: 64.1;RT4: 21.5"					"Not detected"	"Not detected"			HPA015236	Enhanced				"Secreted to blood"	NA	NA	1000000	290000			"HPA015236: AB_10601047"	"unprognostic (2.33e-2)"	"unprognostic (1.28e-1)"	"unprognostic (2.79e-2)"	"unprognostic (7.85e-3)"	"unprognostic (8.71e-2)"	"unprognostic (9.27e-2)"	"unprognostic (2.02e-1)"	"unprognostic (1.80e-1)"	"prognostic favorable (1.49e-4)"	"unprognostic (1.68e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.58e-2)"	"unprognostic (3.77e-15)"	"unprognostic (2.72e-2)"	"unprognostic (9.14e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.51e-1)"	25.2	1.0	0.0	13.1	0.0	0.6	14.0	0.0	0.6	1.4	63.9	0.0	0.1	35.0	0.7	22.7	31.5	11.7	2.4	105.4	0.0	0.0	1.6	377.9	3.0	6.5	0.0	0.0	35.6	2.4	0.6	0.5	15.5	0.0	27.1	68.2	6.1	9.5	1.0	30.6	5.0	99.0	39.7	0.0	0.6	4.0	9.8	0.0	0.0	16.0	8.9	19.3	39.0	72.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	64.1	0.0	0.0	0.0	0.6	0.0	21.5	0.0	0.2	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	1.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.0	4.1	6.7	10.0	12.4	0.0	7.2	5.1	2.7	6.8	0.0	0.0	2.8	1.7	0.0	3.0	8.4	366.3	0.0	945.9	3.3	308.9	937.5	4.6	51.6	8.2	0.0	59.8	35.0	6.0	7.5	158.5	4.9	13.5	0.0	270.5	0.0	3.6	354.3	1.1	0.0	0.0	0.0	11.3	0.5	0.1	14.6	5.7	8.4	591.0	9.1
PLA2G4A	"cPLA2-alpha, PLA2G4"	ENSG00000116711	"Phospholipase A2 group IVA"	P47712	1	186828953-186988981	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Glycerol metabolism, Leukotriene biosynthesis, Lipid biosynthesis, Lipid degradation, Lipid metabolism, Phospholipid degradation, Phospholipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"ductus deferens: 52.6;parathyroid gland: 63.5;seminal vesicle: 56.1"	"Cell type enhanced"	"Detected in many"	7	"Basal keratinocytes: 19.1;Peritubular cells: 13.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	6	"classical monocyte: 7.1;eosinophil: 7.7;intermediate monocyte: 8.4;myeloid DC: 7.8;non-classical monocyte: 3.9;plasmacytoid DC: 3.2"	"Group enriched"	"Detected in many"	7	"dendritic cells: 7.8;granulocytes: 7.7;monocytes: 8.4"	"Cell line enhanced"	"Detected in many"		"HeLa: 23.0;OE19: 33.2;RPMI-8226: 28.5;U-2197: 27.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB010050, HPA050062, HPA054206"	Approved		Supported	Vesicles,Cytosol		NA	NA		78000	Cytosol	Vesicles	"CAB010050: AB_631312, HPA050062: AB_2681002, HPA054206: AB_2682417"	"prognostic favorable (9.07e-4)"	"unprognostic (1.18e-1)"	"unprognostic (2.03e-1)"	"prognostic favorable (2.85e-4)"	"unprognostic (5.55e-2)"	"unprognostic (1.51e-3)"	"unprognostic (2.67e-2)"	"unprognostic (2.43e-1)"	"unprognostic (2.63e-1)"	"unprognostic (7.14e-3)"	"unprognostic (1.50e-1)"	"unprognostic (1.68e-1)"	"unprognostic (2.96e-2)"	"unprognostic (8.07e-2)"	"unprognostic (1.58e-1)"	"unprognostic (1.90e-2)"	"unprognostic (4.26e-2)"	6.0	8.6	3.4	3.5	5.3	2.2	3.8	1.5	4.7	8.5	10.9	2.9	52.6	5.4	7.7	7.4	7.0	12.3	4.2	6.6	3.3	2.5	6.7	1.1	4.9	5.2	6.5	1.4	5.1	3.8	63.5	2.7	2.9	5.6	10.9	4.2	2.9	5.8	56.1	0.6	6.1	10.3	14.6	7.5	4.2	5.1	2.7	5.3	0.4	2.7	5.9	2.3	19.4	9.4	0.0	7.8	7.7	8.4	1.1	0.2	1.5	0.0	15.8	0.0	0.0	9.9	4.0	0.0	0.6	6.1	0.7	1.3	0.1	6.2	0.0	0.0	0.0	2.8	1.1	9.9	2.9	0.3	4.8	0.2	2.9	23.0	0.0	6.1	4.3	1.5	2.2	2.0	7.9	1.6	1.0	6.6	1.3	6.4	2.3	0.0	0.0	0.0	0.0	0.8	33.2	2.1	0.0	0.0	28.5	0.0	2.1	0.0	0.0	2.3	0.8	2.8	0.3	0.3	5.8	1.3	5.9	0.8	27.0	1.2	0.9	0.0	0.0	2.1	12.8	8.3	0.1	7.1	7.7	0.0	8.4	0.2	0.0	0.0	0.0	7.8	0.0	0.0	0.0	0.6	1.1	3.9	3.2	0.0	1.5	3.4	5.3	1.5	4.7	3.3	2.5	6.5	1.4	5.6	5.3	0.0	0.6	0.0	2.8	19.1	0.0	0.8	0.0	1.4	1.2	0.0	0.0	0.1	1.7	1.6	0.7	6.0	1.3	0.0	0.0	0.0	4.3	1.7	10.4	0.0	5.5	0.0	1.2	1.3	8.8	0.6	9.8	6.0	5.0	1.0	1.7	0.0	1.1	2.8	13.8	0.1	0.2	0.0	3.4	0.5	0.1	7.9	0.0	0.0	2.9	10.5
PLA2G6	"iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9"	ENSG00000184381	"Phospholipase A2 group VI"	O60733	22	38111495-38205690	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins"	"Chemotaxis, Lipid metabolism, Phospholipid metabolism"	"Calmodulin-binding, Hydrolase"	"Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Spermatocytes: 23.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HEL: 31.8;HMC-1: 20.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA001171	Approved		Approved	"Centriolar satellite,Cytosol"		NA	NA			"Centriolar satellite, Cytosol"		"HPA001171: AB_1079145"	"unprognostic (5.26e-2)"	"prognostic favorable (7.29e-4)"	"unprognostic (8.74e-2)"	"unprognostic (6.27e-2)"	"unprognostic (3.83e-1)"	"unprognostic (3.70e-3)"	"unprognostic (8.67e-3)"	"unprognostic (9.55e-2)"	"unprognostic (3.48e-1)"	"unprognostic (1.91e-1)"	"unprognostic (2.37e-3)"	"unprognostic (4.95e-2)"	"unprognostic (1.94e-3)"	"unprognostic (1.01e-1)"	"unprognostic (3.00e-1)"	"unprognostic (1.48e-1)"	"prognostic favorable (1.55e-4)"	16.2	17.7	15.6	8.5	20.5	13.1	15.6	15.9	26.3	14.8	7.9	36.9	18.5	9.8	16.3	20.5	8.7	21.6	25.3	6.3	19.7	7.2	18.1	8.6	9.0	12.4	19.3	16.7	21.3	12.8	24.2	12.7	6.8	19.5	17.6	6.3	12.9	20.2	17.4	7.4	18.1	8.7	7.8	14.9	12.1	9.5	30.0	23.2	16.3	45.7	4.1	11.3	12.1	11.2	1.8	5.4	4.1	0.9	8.8	5.7	1.9	0.7	2.8	3.0	7.8	10.1	5.0	8.2	0.9	1.0	0.8	1.1	3.1	1.8	5.9	6.6	2.3	1.3	3.6	3.5	1.9	1.0	9.0	13.2	31.8	3.9	3.6	2.8	3.5	20.3	16.3	4.3	2.8	4.5	8.2	1.0	13.0	5.2	10.7	1.5	4.6	6.6	2.1	2.6	2.1	1.8	4.9	1.2	4.5	2.9	7.0	5.8	2.4	1.3	3.1	7.2	4.5	3.3	2.5	1.3	2.6	4.5	1.1	0.6	17.6	3.1	3.1	3.7	4.1	1.6	4.1	0.9	0.4	3.8	0.3	1.9	1.8	3.1	5.7	1.5	1.5	1.4	3.9	3.3	8.8	0.6	5.4	3.7	1.9	15.6	20.5	15.9	26.3	19.7	7.2	19.3	16.7	19.5	23.2	3.0	2.4	4.4	3.6	2.7	9.4	1.5	2.5	5.3	5.7	12.2	3.9	2.5	0.0	1.4	16.1	1.9	11.0	0.0	0.9	2.4	2.1	4.2	0.0	3.4	1.4	14.3	10.9	3.7	1.5	13.7	5.5	1.0	1.7	3.6	6.9	4.5	1.4	11.5	3.5	0.8	7.0	6.5	1.7	23.8	7.5	3.0	4.1	6.9	6.9	1.3
PLAT		ENSG00000104368	"Plasminogen activator, tissue type"	P00750	8	42175233-42207724	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 132.2"	"Cell type enhanced"	"Detected in many"	22	"Basal glandular cells: 379.6;Glandular cells: 176.4;granulocytes: 158.4;Urothelial cells: 792.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 2.1;T-reg: 2.3"	"Group enriched"	"Detected in many"	7	"granulocytes: 1.6;T-cells: 2.3"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 85.9;HMC-1: 55.1;hTERT-RPE1: 61.0;LHCN-M2: 55.7;U-2197: 58.1;WM-115: 115.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA003412, CAB009335"	Supported		Approved	"Actin filaments"	"Secreted to blood"	NA	NA	9900000	12000	"Actin filaments"		"CAB009335: AB_2237146, HPA003412: AB_1858205"	"prognostic favorable (7.57e-4)"	"unprognostic (2.23e-1)"	"unprognostic (4.08e-1)"	"unprognostic (3.39e-1)"	"unprognostic (4.88e-3)"	"unprognostic (9.39e-2)"	"unprognostic (4.65e-3)"	"unprognostic (5.78e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.75e-1)"	"unprognostic (2.98e-3)"	"unprognostic (2.46e-1)"	"prognostic unfavorable (4.95e-4)"	"unprognostic (8.72e-3)"	"unprognostic (1.37e-2)"	"unprognostic (2.63e-2)"	"unprognostic (6.09e-2)"	19.3	14.9	5.2	12.9	6.8	0.4	13.3	2.2	6.2	24.5	17.1	9.1	19.0	11.2	35.5	28.1	18.1	19.1	18.5	7.3	6.0	5.9	67.6	2.8	15.9	1.9	8.2	3.6	18.4	5.8	132.2	5.1	15.5	9.4	27.4	12.2	39.4	6.1	12.7	5.8	2.0	31.7	23.0	7.0	1.0	14.6	12.2	3.8	0.6	11.2	14.7	7.4	47.9	13.7	0.3	0.1	1.6	0.0	0.0	2.3	0.3	0.5	0.2	4.2	1.0	7.7	10.5	0.1	18.1	32.0	7.7	6.6	0.2	85.9	0.0	0.6	2.3	3.7	1.4	0.0	4.0	15.9	7.9	1.4	0.1	0.1	0.1	37.9	0.0	55.1	10.5	0.0	18.8	0.7	61.0	14.4	0.0	0.5	0.1	55.7	0.0	0.0	0.0	5.6	0.0	7.6	0.0	15.6	0.0	2.5	0.0	0.0	0.9	0.0	0.1	24.6	8.2	0.1	0.0	27.5	1.5	5.7	58.1	1.8	0.0	0.1	0.0	1.2	0.0	115.5	1.6	0.0	0.0	0.3	0.0	1.0	0.3	2.1	0.5	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	2.3	0.3	5.2	6.8	2.2	6.2	6.0	5.9	8.2	3.6	9.4	3.8	0.0	20.2	2.4	379.6	9.6	4.1	7.6	0.0	5.3	11.4	0.0	3.9	0.5	0.0	0.6	0.8	82.6	0.0	0.0	0.6	1.1	19.9	176.4	158.4	1.0	1.5	1.6	0.0	36.8	0.6	0.8	3.4	7.8	21.9	2.8	0.0	2.0	30.5	0.0	2.5	0.1	3.7	12.9	17.6	0.7	0.4	11.8	0.6	3.8	0.4	792.4
PLAU	"UPA, URK"	ENSG00000122861	"Plasminogen activator, urokinase"	P00749	10	73909177-73917497	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Plasminogen activation"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"placenta: 48.4"	"Cell type enhanced"	"Detected in many"	17	"Basal glandular cells: 550.8;Pancreatic endocrine cells: 366.2;Urothelial cells: 779.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	9	"myeloid DC: 2.4;neutrophil: 4.5;plasmacytoid DC: 4.5"	"Group enriched"	"Detected in many"	11	"dendritic cells: 4.5;granulocytes: 4.5"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 70.3;LHCN-M2: 67.8;RPTEC TERT1: 257.8;U-251 MG: 69.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA070796	Supported				"Secreted to blood"	NA	NA	647000	58000			"HPA070796: "	"unprognostic (1.96e-2)"	"unprognostic (2.99e-2)"	"unprognostic (7.40e-2)"	"prognostic favorable (3.38e-4)"	"unprognostic (4.73e-2)"	"prognostic unfavorable (2.70e-4)"	"unprognostic (1.39e-2)"	"prognostic unfavorable (4.04e-4)"	"unprognostic (2.26e-1)"	"unprognostic (6.58e-2)"	"prognostic unfavorable (1.32e-4)"	"unprognostic (1.61e-1)"	"prognostic unfavorable (3.51e-4)"	"unprognostic (2.83e-1)"	"unprognostic (3.37e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.77e-2)"	26.7	2.4	1.0	15.5	2.1	11.3	9.7	1.6	1.5	6.9	5.8	2.9	4.9	3.8	10.7	21.2	9.1	6.5	10.7	14.3	1.3	1.0	23.3	2.3	23.4	5.5	1.6	1.5	6.8	3.7	3.6	1.8	48.4	3.1	7.5	6.7	4.5	10.6	5.0	12.2	9.0	8.1	8.4	2.5	23.8	7.8	5.8	1.3	4.8	10.9	11.6	8.2	16.3	9.3	0.1	4.5	4.5	0.4	0.0	0.0	0.3	13.3	7.1	3.0	0.1	0.2	5.1	0.1	8.1	37.9	3.3	5.2	0.1	70.3	0.0	15.0	1.1	35.0	9.2	0.0	13.5	3.8	0.7	0.0	0.0	0.3	0.1	6.2	1.2	2.6	13.5	1.6	22.6	8.7	37.6	9.4	0.0	0.0	0.0	67.8	0.0	0.0	1.7	0.8	0.0	18.7	0.0	9.2	0.0	257.8	10.5	0.0	0.0	0.0	0.3	0.2	2.2	0.0	1.8	23.8	0.2	1.7	1.7	69.2	0.0	0.1	0.1	18.2	2.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.1	0.0	0.0	2.4	0.0	0.0	0.0	4.5	0.0	0.0	4.5	0.0	0.3	1.0	2.1	1.6	1.5	1.3	1.0	1.6	1.5	3.1	1.3	3.0	5.8	0.5	550.8	33.2	0.0	2.4	0.0	1.4	10.3	27.9	0.0	17.1	58.0	65.4	0.5	11.7	0.0	0.0	18.1	16.5	18.1	169.7	31.1	0.0	38.5	0.0	3.4	6.2	3.9	0.0	2.3	31.5	6.8	41.5	0.0	0.0	366.2	0.0	0.0	0.7	0.0	6.5	25.9	0.0	0.1	25.7	14.6	0.5	0.9	779.6
PLAUR	"CD87, UPAR, URKR"	ENSG00000011422	"Plasminogen activator, urokinase receptor"	Q03405	19	43646095-43670547	"Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 118.0;bone marrow: 165.0"	"Cell type enhanced"	"Detected in many"	17	"Basal glandular cells: 664.4;Macrophages: 801.6;Urothelial cells: 2343.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 118.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"hTEC/SVTERT24-B: 50.2;U-251 MG: 71.3;U-87 MG: 62.2;WM-115: 60.6"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"HPA050843, CAB073533"	Uncertain		Supported	"Plasma membrane"	"Intracellular and membrane"	NA	NA		760000	"Plasma membrane"		"CAB073533: , HPA050843: AB_2681255"	"unprognostic (9.28e-2)"	"unprognostic (9.65e-3)"	"unprognostic (1.39e-1)"	"unprognostic (1.29e-3)"	"unprognostic (3.59e-3)"	"unprognostic (1.50e-2)"	"unprognostic (2.18e-3)"	"prognostic unfavorable (2.33e-5)"	"unprognostic (8.08e-3)"	"unprognostic (4.30e-2)"	"unprognostic (2.29e-3)"	"unprognostic (5.30e-2)"	"prognostic unfavorable (7.83e-9)"	"unprognostic (4.99e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.45e-2)"	"unprognostic (9.33e-2)"	25.2	3.6	3.0	23.6	4.8	165.0	6.3	2.2	6.1	10.7	7.5	4.4	1.8	3.3	9.5	6.0	8.6	10.6	23.0	11.5	4.5	3.2	5.1	6.1	39.4	8.1	6.0	1.1	11.9	4.3	2.5	4.4	12.2	6.9	6.1	6.0	4.6	11.0	3.7	7.9	3.5	7.3	7.2	7.1	12.6	12.0	6.3	6.3	2.5	4.4	7.7	7.0	22.7	14.9	0.2	21.3	118.0	50.5	0.6	0.9	21.0	14.3	5.0	4.5	0.3	4.1	14.6	2.8	30.0	30.5	19.0	23.8	0.4	16.9	0.5	7.6	18.5	11.0	6.1	1.2	7.4	21.2	0.9	0.9	2.7	7.5	0.6	5.2	3.2	34.9	15.0	1.5	50.2	7.5	27.8	20.9	3.3	2.7	0.6	18.2	1.0	3.4	8.6	1.5	25.7	10.8	4.0	3.0	1.0	5.9	0.7	0.2	3.9	13.4	3.1	3.9	2.3	0.6	10.0	21.4	41.9	21.5	19.1	71.3	0.6	1.4	0.1	62.2	5.8	60.6	7.2	48.9	72.4	0.7	41.5	0.8	0.2	0.9	0.6	21.3	0.1	0.3	0.4	118.0	0.6	50.5	6.8	0.3	21.0	3.0	4.8	2.2	6.1	4.5	3.2	6.0	1.1	6.9	6.3	68.5	114.1	4.7	664.4	93.4	0.4	3.5	15.3	20.1	44.3	19.2	0.0	4.1	1.7	219.5	0.8	49.2	68.8	0.0	94.2	28.2	110.9	445.0	294.8	1.3	440.8	9.5	14.3	18.4	142.0	0.9	6.4	801.6	69.2	13.6	15.1	1.2	350.1	4.9	3.9	2.4	0.6	6.5	151.4	0.9	3.2	55.2	11.0	9.6	5.0	2343.3
PLCL1	"PLC-L, PLCE, PLCL, PPP1R127, PRIP"	ENSG00000115896	"Phospholipase C like 1 (inactive)"	Q15111	2	197804702-198572581	"FDA approved drug targets, Predicted intracellular proteins"		Transducer	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 34.9"	"Cell type enhanced"	"Detected in many"	16	"Cardiomyocytes: 128.1;Distal tubular cells: 49.7;Proximal tubular cells: 34.2;Sertoli cells: 32.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"T-reg: 4.1"	"Lineage enriched"	"Detected in single"	6	"T-cells: 4.1"	"Cell line enhanced"	"Detected in some"		"HUVEC TERT2: 8.8;K-562: 14.7;Karpas-707: 11.1;MOLT-4: 10.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA031849	Enhanced					NA	NA					"HPA031849: AB_10602192"	"unprognostic (7.77e-3)"	"unprognostic (2.57e-1)"	"unprognostic (2.09e-1)"	"unprognostic (5.18e-3)"	"unprognostic (4.40e-2)"	"unprognostic (7.14e-2)"	"unprognostic (2.05e-1)"	"unprognostic (4.42e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.32e-1)"	"unprognostic (3.02e-2)"	"unprognostic (7.42e-2)"	"prognostic favorable (3.91e-7)"	"unprognostic (1.07e-4)"	"unprognostic (6.74e-2)"	"unprognostic (1.68e-1)"	"unprognostic (3.20e-2)"	4.4	5.2	11.1	3.3	26.0	2.2	4.4	3.4	16.3	5.3	4.5	21.2	3.4	1.3	15.4	3.9	4.3	4.1	3.7	32.8	14.9	10.9	32.8	1.3	3.9	4.4	34.9	8.8	8.1	2.2	20.7	3.0	8.4	19.9	11.8	2.1	4.8	2.9	8.2	28.4	1.8	2.5	6.7	23.0	2.5	3.1	2.3	26.9	22.1	4.0	3.2	3.2	5.3	2.9	0.0	0.1	0.6	0.1	0.0	4.1	0.2	0.0	0.0	0.1	0.0	1.7	0.4	0.0	0.4	0.2	0.1	0.1	0.0	0.1	0.0	0.1	2.0	0.0	0.0	0.0	0.0	0.0	0.3	0.8	0.0	1.5	0.0	0.2	0.2	1.9	4.3	0.0	0.0	0.0	0.0	8.8	2.9	14.7	11.1	0.1	0.4	10.3	0.0	0.1	0.0	0.0	0.0	0.0	4.5	0.3	0.0	1.7	1.0	1.8	0.0	2.6	0.8	0.3	0.0	0.7	0.2	0.0	0.0	0.1	4.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.3	0.0	2.5	0.0	1.8	0.0	0.1	0.0	1.3	0.4	0.6	0.0	0.1	0.0	4.1	0.2	11.1	26.0	3.4	16.3	14.9	10.9	34.9	8.8	19.9	26.9	17.9	4.1	0.0	0.7	1.1	18.7	128.1	0.0	4.0	3.4	14.0	0.0	0.0	49.7	0.5	10.5	1.4	0.3	0.0	0.3	0.0	3.1	1.0	5.8	0.0	2.5	14.3	1.7	0.0	4.1	3.0	1.7	2.6	0.0	2.8	0.0	2.3	0.3	0.0	7.4	34.2	1.1	32.3	13.7	0.7	1.8	1.1	0.1	3.8	0.0	0.3
PLG		ENSG00000122194	Plasminogen	P00747	6	160702238-160753315	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis, Tissue remodeling"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	11	"liver: 269.9"	"Cell type enriched"	"Detected in some"	7	"Hepatocytes: 1391.0"	"Cancer enriched"	"Detected in some"	84	"liver cancer: 180.7"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HEL: 1.2;HL-60: 3.6;RH-30: 4.0;U-698: 2.0;U-937: 1.6"									"CAB000668, CAB016678, HPA021602, HPA048823"	Supported				"Secreted to blood"	NA	NA	140000000000	41000000000			"CAB000668: , CAB016678: AB_1621208, HPA021602: AB_1855453, HPA048823: AB_2680532"		"unprognostic (1.70e-1)"		"unprognostic (2.16e-3)"	"unprognostic (2.44e-1)"		"unprognostic (8.54e-3)"	"unprognostic (1.41e-1)"		"unprognostic (1.76e-3)"	"unprognostic (6.28e-2)"	"unprognostic (7.25e-2)"	"prognostic favorable (4.22e-4)"	"unprognostic (3.97e-3)"	"unprognostic (5.21e-2)"		"unprognostic (2.33e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.0	269.9	0.0	0.0	0.0		0.0	0.0	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0		0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.5	0.0	3.6	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.4	0.0	0.0	0.3	0.2	0.9	0.0	0.0	0.4	4.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.0	1.0	0.0	2.0	0.0	1.6	0.0	0.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	2.2	0.0	0.0	0.0	0.6	28.1	2.7	0.0	1.8	0.0	0.0	16.6	0.0	0.1	0.0	0.0	23.3	0.0	0.0	0.0	0.0	1.1	1391.0	0.1	0.0	0.0	26.4	26.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	203.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	4.9	0.0	0.0
PLIN3	"M6PRBP1, PP17, TIP47"	ENSG00000105355	"Perilipin 3"	O60664	19	4838341-4867768	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	Transport		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA006427, HPA066538"	Uncertain		Enhanced	"Lipid droplets"		NA	Yes		9300000	"Lipid droplets"		"HPA006427: AB_1079289, HPA066538: AB_2685687"	"unprognostic (1.18e-1)"	"unprognostic (4.86e-2)"	"unprognostic (1.55e-2)"	"prognostic favorable (2.62e-4)"	"unprognostic (2.94e-1)"	"unprognostic (1.56e-1)"	"prognostic unfavorable (3.27e-5)"	"prognostic unfavorable (7.67e-6)"	"unprognostic (2.27e-1)"	"unprognostic (1.28e-1)"	"unprognostic (4.34e-2)"	"unprognostic (8.24e-2)"	"prognostic unfavorable (9.15e-7)"	"unprognostic (2.62e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.39e-2)"	13.2	28.9	7.4	16.9	16.3	25.5	12.7	2.8	10.8	17.8	17.5	37.9	4.2	29.1	9.3	12.6	46.9	9.5	14.8	12.4	9.2	7.0	10.4	19.6	9.9	13.6	32.4	8.3	23.4	8.1	3.1	3.9	28.3	17.8	11.0	8.9	6.7	18.1	9.7	40.0	31.8	38.6	11.1	26.7	13.1	11.1	13.6	25.1	20.0	13.1	35.8	29.1	14.1	19.7	12.5	28.9	45.9	37.5	9.4	8.4	19.0	28.2	16.7	11.7	10.6	12.9	42.1	5.1	41.2	38.4	33.3	30.8	10.9	25.8	14.6	9.4	51.7	17.6	13.0	5.3	23.2	19.6	16.7	7.6	15.9	9.5	19.9	9.3	11.3	24.2	32.9	9.7	23.5	5.1	19.0	17.3	4.7	24.1	6.5	40.2	11.6	16.1	15.3	8.8	12.9	27.1	27.7	15.7	8.2	28.3	6.5	0.5	5.5	12.8	11.6	10.1	9.9	14.9	25.7	25.7	17.7	17.5	70.7	21.2	9.2	11.7	10.1	53.3	16.1	20.4	28.3	37.5	16.1	3.8	26.2	3.8	12.5	6.7	4.3	28.9	9.3	5.4	3.4	45.9	9.4	18.0	21.4	8.4	19.0	7.4	16.3	2.8	10.8	9.2	7.0	32.4	8.3	17.8	25.1	17.9	24.6	17.5	48.4	126.4	0.2	2.5	10.2	64.3	42.1	10.4	2.0	124.8	31.5	90.9	8.1	25.3	190.9	0.0	74.9	62.3	89.7	37.6	54.3	14.4	92.9	0.0	39.0	29.4	63.2	9.8	33.1	85.3	52.3	65.9	60.5	22.6	161.7	98.2	49.8	32.3	0.6	51.8	50.5	46.1	15.6	200.5	162.9	17.5	40.8	62.6
PNLIP	PL	ENSG00000175535	"Pancreatic lipase"	P16233	10	116545931-116567855	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Lipid degradation, Lipid metabolism"	Hydrolase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	1895	"pancreas: 3207.8"	"Cell type enriched"	"Detected in some"	4	"Exocrine glandular cells: 3478.1"	"Cancer enriched"	"Detected in some"	4854	"pancreatic cancer: 2731.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 3.1;HDLM-2: 2.8;U-2 OS: 4.6;U-251 MG: 1.1;U-266/84: 1.5"	"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"HPA062430, HPA062494"	Enhanced				"Secreted to digestive system"	NA	NA		13000000			"HPA062430: AB_2684761, HPA062494: AB_2684782"											"unprognostic (2.05e-2)"	"unprognostic (4.46e-2)"						0.2	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.2	0.1	0.1	0.0	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	1.6	3207.8	0.0	0.1	0.1	0.1	0.1	0.0	0.1	0.4	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.5	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.1	0.0	0.0	2.8	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	1.1	0.0	1.5	0.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	0.5	0.0	0.0	0.0	3478.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	25.2	0.0	0.0	826.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
PNP	"NP, PUNP"	ENSG00000198805	"Purine nucleoside phosphorylase"	P00491	14	20468954-20477094	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Glycosyltransferase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"epididymis: 153.1"	"Group enriched"	"Detected in many"	4	"Cytotrophoblasts: 276.6;Syncytiotrophoblasts: 540.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HL-60: 82.7;U-937: 94.3"					"Low region specificity"	"Detected in all"			HPA001625	Enhanced		Supported	Cytosol		NA	NA		100000000	Cytosol		"HPA001625: AB_1854577"	"unprognostic (1.20e-3)"	"unprognostic (2.68e-2)"	"unprognostic (1.04e-2)"	"unprognostic (1.70e-1)"	"unprognostic (3.10e-1)"	"unprognostic (7.06e-2)"	"prognostic unfavorable (4.43e-4)"	"unprognostic (4.94e-3)"	"unprognostic (3.87e-2)"	"unprognostic (7.45e-2)"	"unprognostic (1.85e-2)"	"unprognostic (2.21e-1)"	"prognostic favorable (2.24e-4)"	"unprognostic (1.69e-1)"	"unprognostic (7.54e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.64e-3)"	24.7	7.6	9.5	15.0	14.0	69.4	15.7	13.9	11.8	9.5	19.1	6.2	25.2	29.4	5.9	153.1	34.0	7.8	15.7	12.1	11.5	8.4	49.7	24.2	18.3	13.2	13.5	3.4	3.6	11.0	8.7	8.4	45.3	17.7	6.0	16.1	3.8	9.2	7.9	3.3	10.6	32.0	9.8	16.3	18.0	17.0	4.5	12.5	7.0	7.1	21.7	19.1	7.5	14.7	13.1	20.7	4.1	12.4	15.7	33.7	12.1	13.4	18.2	3.8	8.7	4.4	3.5	11.9	13.8	6.5	11.3	11.1	10.5	12.3	36.0	16.0	7.3	13.3	14.6	20.4	26.0	15.0	11.6	17.9	30.1	15.5	17.3	4.1	82.7	15.7	2.4	9.4	34.0	15.1	6.2	48.1	22.3	14.8	22.5	14.1	12.5	24.3	48.8	11.0	34.4	30.4	20.6	5.8	14.0	40.1	12.8	16.9	3.7	26.5	33.7	2.1	5.6	12.4	14.7	38.5	7.7	10.3	17.3	23.4	10.3	17.2	40.7	6.6	94.3	0.7	4.0	12.4	4.1	18.1	11.5	33.7	11.2	20.3	20.0	20.7	13.1	12.9	16.3	1.6	15.7	10.6	11.7	6.9	12.1	9.5	14.0	13.9	11.8	11.5	8.4	13.5	3.4	17.7	12.5	0.0	26.3	18.6	51.4	75.2	4.8	3.1	28.1	8.1	17.0	78.5	13.7	276.6	33.2	38.4	1.0	60.2	56.3	93.5	44.5	26.6	19.4	21.8	56.6	23.1	63.4	15.9	44.5	19.6	22.4	0.0	0.3	46.2	28.7	1.0	31.7	70.2	85.7	56.1	0.7	91.5	17.0	0.0	33.8	0.2	0.6	55.8	540.4	19.3	34.8	70.5
POLA1	"NSX, p180, POLA"	ENSG00000101868	"DNA polymerase alpha 1, catalytic subunit"	P09884	X	24693919-24996986	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"DNA replication, Host-virus interaction"	"DNA-binding, DNA-directed DNA polymerase, Nucleotidyltransferase, Transferase"	"Disease mutation, Dwarfism, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	4	"Erythroid cells: 46.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002947, CAB012274"	Supported		Supported	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"CAB012274: , HPA002947: AB_1079652"	"unprognostic (6.92e-2)"	"unprognostic (4.43e-3)"	"unprognostic (3.27e-3)"	"unprognostic (1.53e-2)"	"unprognostic (2.53e-1)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (4.80e-5)"	"unprognostic (1.87e-1)"	"unprognostic (9.25e-3)"	"unprognostic (2.48e-2)"	"unprognostic (8.41e-2)"	"unprognostic (7.42e-2)"	"unprognostic (2.09e-1)"	"unprognostic (1.44e-1)"	"unprognostic (3.66e-2)"	"unprognostic (3.48e-2)"	"unprognostic (3.08e-1)"	10.5	5.5	8.0	15.0	10.2	14.3	10.9	12.0	9.6	10.1	9.7	11.8	5.8	5.7	11.2	7.7	10.2	8.9	5.5	9.3	7.8	6.6	6.1	4.9	7.2	12.7	10.3	4.5	12.9	7.3	8.5	8.5	10.7	8.7	7.3	11.0	7.5	7.9	9.3	22.4	9.3	7.5	9.7	13.1	9.0	7.9	5.7	10.0	30.1	7.0	8.5	14.7	9.9	10.6	4.6	2.5	1.2	4.6	2.7	3.8	1.7	14.3	10.7	14.1	11.4	2.6	3.2	3.1	10.7	5.8	11.5	13.2	8.8	7.5	18.3	3.6	4.5	10.3	11.8	26.8	8.6	15.6	9.5	11.4	13.6	20.9	6.6	1.1	17.8	7.3	2.0	1.8	14.3	4.1	2.9	5.9	9.5	12.5	9.3	8.0	9.9	19.3	5.9	13.7	9.6	9.0	17.3	37.0	13.8	4.2	9.4	12.8	7.9	12.6	6.0	5.7	16.3	11.8	5.9	4.6	10.2	7.0	19.4	10.2	5.6	8.1	14.7	5.9	8.5	11.3	0.0	2.0	1.2	3.0	4.6	2.9	4.6	3.4	3.8	2.5	3.2	2.4	2.4	0.6	2.7	1.3	1.6	3.6	1.7	8.0	10.2	12.0	9.6	7.8	6.6	10.3	4.5	8.7	10.0	8.9	6.2	2.2	3.8	2.5	2.9	9.3	0.0	9.4	11.4	1.8	2.0	4.3	3.3	2.8	0.3	3.6	1.5	46.7	2.6	4.3	2.4	2.0	9.2	2.8	3.9	1.6	4.1	3.7	4.3	0.4	5.8	2.4	0.0	1.8	3.7	4.5	1.3	0.0	3.2	1.2	7.2	6.5	3.8	3.4	4.2	1.9	1.9	2.9	4.3	2.2
POLB		ENSG00000070501	"DNA polymerase beta"	P06746	8	42338454-42371808	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication, DNA synthesis"	"DNA-binding, DNA-directed DNA polymerase, Lyase, Nucleotidyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 73.6"	"Group enriched"	"Detected in many"	5	"Early spermatids: 173.0;Late spermatids: 102.4"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in all"	4	"cerebellum: 73.6"	"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"HMC-1: 81.2"	"Low region specificity"	"Detected in all"							"CAB011616, HPA049104"	Enhanced		Uncertain	Vesicles		NA	NA			Vesicles		"CAB011616: AB_731977, HPA049104: AB_2680632"	"unprognostic (1.67e-1)"	"unprognostic (2.68e-3)"	"unprognostic (2.43e-1)"	"prognostic unfavorable (1.46e-4)"	"unprognostic (8.49e-2)"	"unprognostic (2.64e-2)"	"unprognostic (4.24e-2)"	"unprognostic (1.02e-1)"	"unprognostic (2.31e-2)"	"unprognostic (1.99e-1)"	"unprognostic (4.57e-2)"	"unprognostic (4.77e-1)"	"prognostic unfavorable (2.15e-5)"	"unprognostic (1.06e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.22e-2)"	"prognostic favorable (5.65e-4)"	5.5	8.6	10.1	9.5	10.7	21.9	13.5	73.6	16.6	7.0	5.5	5.8	6.0	4.9	6.2	11.2	12.4	6.3	11.3	16.3	9.8	9.6	7.2	15.8	9.1	11.8	8.4	10.3	10.3	7.7	10.3	11.6	5.0	10.9	11.4	6.3	6.8	22.1	6.9	36.6	10.8	4.9	6.6	10.0	8.1	6.4	29.5	5.4	9.7	7.7	17.2	10.1	11.5	9.2	4.9	33.8	25.1	9.4	7.9	7.2	4.2	11.0	6.6	11.5	23.0	6.4	6.1	9.7	7.1	8.2	11.7	10.8	9.3	13.0	10.0	9.0	4.5	12.4	5.7	9.6	8.2	14.5	6.5	10.4	7.3	5.5	12.5	9.9	5.1	81.2	5.4	9.8	8.6	10.2	14.9	8.9	21.6	15.8	6.4	11.3	6.6	21.2	14.5	15.5	13.2	7.6	12.1	11.6	8.6	22.0	8.9	6.6	11.9	8.4	5.6	21.3	12.4	14.9	8.8	4.9	5.6	7.8	14.0	6.8	9.3	15.6	14.1	5.6	10.9	14.6	12.5	5.9	17.3	4.9	7.2	5.5	4.9	5.2	5.3	6.1	4.5	5.8	5.4	25.1	7.9	9.4	33.8	7.2	4.2	10.1	10.7	73.6	16.6	9.8	9.6	8.4	10.3	10.9	5.4	3.0	12.8	13.8	19.3	14.9	3.3	19.1	7.6	22.7	28.4	7.0	7.9	6.3	5.0	11.3	173.0	10.3	3.6	0.0	8.4	5.6	5.6	27.3	22.0	11.9	6.5	6.4	5.8	6.2	5.6	102.4	6.6	8.9	6.8	4.6	4.7	6.0	22.7	5.9	3.5	5.6	4.3	0.0	5.8	19.1	12.9	17.6	9.3	10.5	6.1	25.5
POLE	POLE1	ENSG00000177084	"DNA polymerase epsilon, catalytic subunit"	Q07864	12	132623753-132687365	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA damage, DNA repair, DNA replication"	"DNA-binding, DNA-directed DNA polymerase, Hydrolase, Nucleotidyltransferase, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Sertoli cells: 25.8;Spermatocytes: 25.4"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"cerebellum: 34.8"	"Cell type enhanced"	"Detected in some"		"NK-cell: 4.8"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA058210, HPA067385"			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			Nucleoplasm	"Plasma membrane"	"HPA058210: AB_2683639, HPA067385: AB_2685830"	"unprognostic (1.60e-1)"	"unprognostic (1.77e-3)"	"unprognostic (2.00e-1)"	"unprognostic (9.17e-2)"	"unprognostic (1.68e-1)"	"unprognostic (2.01e-2)"	"unprognostic (3.96e-3)"	"unprognostic (2.23e-1)"	"prognostic unfavorable (1.44e-4)"	"unprognostic (7.12e-2)"	"unprognostic (2.21e-1)"	"unprognostic (1.67e-1)"	"prognostic unfavorable (3.19e-8)"	"unprognostic (8.60e-2)"	"unprognostic (3.18e-1)"	"unprognostic (1.28e-1)"	"unprognostic (9.95e-2)"	6.1	3.4	6.7	10.2	4.4	29.3	6.2	34.8	14.4	7.0	6.6	2.0	7.6	7.3	6.1	4.4	7.5	6.2	6.5	4.7	5.6	1.6	3.8	8.6	5.4	8.2	3.3	4.3	8.7	6.8	3.6	3.1	6.5	5.1	6.8	7.7	4.3	8.7	7.4	8.9	17.9	8.5	6.8	3.7	16.7	7.8	25.6	4.4	29.8	5.1	6.0	10.3	6.7	8.7	0.5	1.7	0.8	0.8	4.8	0.7	0.5	11.2	15.0	22.3	10.6	4.7	3.7	19.9	11.5	5.2	13.8	10.1	18.2	6.7	12.9	4.9	6.2	5.3	15.7	15.5	7.8	8.4	6.0	19.6	20.4	19.4	8.9	0.9	15.9	11.7	2.8	3.1	14.4	4.7	3.8	4.8	16.6	22.8	7.3	6.8	18.2	26.1	29.2	17.3	5.3	9.0	21.7	12.6	5.8	4.4	18.4	18.6	10.7	13.4	11.0	2.5	11.2	16.2	9.9	4.4	12.6	12.9	9.5	11.6	9.7	6.5	20.3	6.9	22.0	8.9	0.0	0.3	0.8	0.5	0.1	0.7	0.5	0.3	0.4	0.7	0.3	0.5	0.3	0.1	4.8	0.8	1.7	0.6	0.5	6.7	4.4	34.8	14.4	5.6	1.6	3.3	4.3	5.1	4.4	0.0	7.9	4.5	3.5	5.0	8.1	5.6	0.0	2.7	0.0	1.8	0.0	6.2	0.0	2.1	6.5	3.0	4.7	0.0	2.7	9.0	4.7	3.7	2.3	8.9	10.4	0.0	6.9	12.9	7.9	7.0	6.4	3.2	5.0	1.0	6.7	3.7	2.4	5.8	3.2	0.8	5.0	25.8	3.3	25.4	7.9	6.8	3.3	5.7	9.8	2.5
POLE2	DPE2	ENSG00000100479	"DNA polymerase epsilon 2, accessory subunit"	P56282	14	49643555-49688422	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"DNA replication"	DNA-binding	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 17.6;lymphoid tissue: 17.6"	"Cell type enhanced"	"Detected in many"	9	"Erythroid cells: 23.3;Spermatogonia: 22.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"							"Low region specificity"	"Detected in all"			HPA027555	Uncertain		Supported	"Nucleoplasm,Nuclear bodies,Vesicles"		No	No			"Nucleoplasm, Nuclear bodies"	Vesicles	"HPA027555: AB_10610282"	"unprognostic (1.42e-1)"	"unprognostic (6.57e-3)"	"unprognostic (3.53e-2)"	"unprognostic (7.44e-2)"	"unprognostic (2.04e-2)"	"unprognostic (4.99e-3)"	"unprognostic (7.60e-3)"	"unprognostic (2.32e-3)"	"unprognostic (1.10e-3)"	"unprognostic (2.69e-2)"	"unprognostic (1.88e-2)"	"unprognostic (1.37e-3)"	"unprognostic (5.13e-11)"	"unprognostic (9.97e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.50e-3)"	3.3	2.2	1.5	11.6	2.8	17.6	3.4	1.7	1.6	4.4	4.2	1.1	1.5	2.6	2.8	3.5	9.0	2.4	2.3	1.6	1.0	1.2	2.5	5.1	2.2	5.3	1.1	0.3	2.7	5.0	1.4	2.5	4.1	1.4	2.1	5.2	2.6	2.6	0.7	1.1	3.7	7.7	2.9	2.7	5.4	3.0	5.3	2.4	17.6	1.6	10.3	8.4	2.1	4.2	1.2	0.9	0.7	0.0	3.2	2.7	0.5	17.3	8.9	16.9	7.8	0.8	5.0	8.6	9.9	5.0	15.8	18.3	8.9	13.6	10.8	5.6	5.5	8.5	10.7	16.9	6.1	18.7	12.6	9.3	16.1	9.8	11.0	0.4	19.2	7.0	1.4	0.4	8.6	1.4	2.0	9.1	14.5	14.1	6.9	15.8	15.2	19.5	12.5	9.9	14.2	20.8	16.6	15.5	9.8	5.7	9.8	12.2	7.0	10.0	5.9	3.1	8.5	11.8	6.8	3.2	2.5	18.8	10.5	7.8	5.1	10.3	25.0	4.8	14.2	10.2	0.0	0.0	0.7	0.9	0.0	0.7	1.2	0.9	1.7	0.6	1.2	0.1	0.8	0.0	3.2	0.0	0.9	2.7	0.5	1.5	2.8	1.7	1.6	1.0	1.2	1.1	0.3	1.4	2.4	3.0	0.3	0.8	1.6	4.2	0.8	0.8	0.0	1.4	1.2	0.0	0.0	5.3	0.0	1.2	0.9	0.8	0.8	23.3	1.3	8.5	2.6	1.2	0.0	3.2	4.7	0.0	1.2	6.7	3.7	0.2	1.4	1.2	1.7	1.0	2.0	2.1	0.6	0.0	2.8	0.8	3.3	0.0	1.9	3.0	22.2	3.1	2.9	0.9	2.9	0.8
POLE3	"CHARAC17, CHRAC17, p17, Ybl1"	ENSG00000148229	"DNA polymerase epsilon 3, accessory subunit"	Q9NRF9	9	113407235-113410672	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		DNA-binding	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA047945	Uncertain		Approved	Nucleoplasm,Nucleoli		NA	NA			"Nucleoplasm, Nucleoli"		"HPA047945: AB_2680218"	"unprognostic (9.55e-2)"	"unprognostic (3.39e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.67e-1)"	"unprognostic (6.52e-2)"	"unprognostic (1.86e-2)"	"prognostic unfavorable (8.35e-4)"	"unprognostic (1.04e-2)"	"unprognostic (1.60e-2)"	"unprognostic (1.10e-1)"	"unprognostic (4.59e-3)"	"unprognostic (2.31e-3)"	"unprognostic (1.75e-2)"	"unprognostic (1.56e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.28e-1)"	"unprognostic (1.18e-1)"	16.9	23.9	18.2	22.0	18.5	56.3	19.3	36.0	25.0	17.0	17.6	15.8	12.5	15.1	18.2	16.5	27.8	17.6	17.0	17.9	16.1	14.8	14.3	29.5	15.8	29.0	15.1	18.5	15.4	20.8	13.1	8.4	21.2	20.0	15.9	20.3	12.4	17.9	16.3	48.3	24.7	17.3	16.9	16.9	26.8	17.2	29.9	15.9	35.0	16.3	27.3	32.4	18.8	16.7	34.9	33.5	34.3	34.4	28.0	44.0	47.7	15.9	19.9	14.0	21.0	8.0	7.2	12.3	21.3	10.9	24.2	19.1	18.4	14.5	58.1	13.3	12.4	14.7	27.4	27.3	23.4	22.4	11.0	16.5	30.1	20.7	18.8	8.6	62.4	18.2	8.1	16.2	21.0	27.0	8.8	16.7	29.6	41.9	32.5	16.7	40.6	42.8	33.6	18.1	34.3	36.1	43.9	58.5	32.6	10.5	15.3	30.5	17.6	31.0	19.6	16.7	8.9	29.3	28.1	13.7	17.9	24.3	22.7	36.4	17.0	55.5	78.3	16.4	36.9	21.4	25.4	34.0	34.3	35.5	34.4	44.0	34.9	34.0	33.7	33.2	33.5	36.9	34.3	7.2	28.0	26.6	33.5	39.0	47.7	18.2	18.5	36.0	25.0	16.1	14.8	15.1	18.5	20.0	15.9	35.7	27.5	46.8	23.7	83.3	13.9	39.7	22.9	46.8	44.3	29.6	5.9	49.3	36.5	26.8	4.0	34.3	14.2	0.0	39.2	47.2	34.7	19.7	54.5	37.2	44.5	12.7	23.6	23.4	27.8	11.5	33.1	54.6	38.8	53.3	31.4	30.3	28.9	10.5	40.0	22.0	17.1	12.9	47.2	27.9	98.5	82.9	29.2	63.4	39.3	18.2
POLE4	p12	ENSG00000115350	"DNA polymerase epsilon 4, accessory subunit"	Q9NR33	2	74958492-74970128	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		DNA-binding	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"NB-4: 35.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA054979, HPA071815"	Approved		Approved	Nucleoplasm,Cytosol		NA	NA			Nucleoplasm	Cytosol	"HPA054979: AB_2682661, HPA071815: AB_2686453"	"unprognostic (2.56e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.17e-1)"	"unprognostic (4.19e-2)"	"unprognostic (4.85e-2)"	"unprognostic (1.59e-2)"	"prognostic unfavorable (6.49e-4)"	"unprognostic (3.09e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.95e-1)"	"unprognostic (1.39e-2)"	"unprognostic (4.44e-2)"	"unprognostic (8.64e-3)"	"unprognostic (6.61e-2)"	"unprognostic (3.73e-1)"	"unprognostic (3.47e-2)"	"unprognostic (1.95e-1)"	19.2	14.5	23.6	15.2	17.3	27.1	21.4	4.4	15.5	18.4	13.4	8.6	7.0	9.0	10.4	9.0	10.0	9.7	13.1	18.1	15.9	10.6	11.6	18.8	10.7	17.0	13.9	12.6	12.8	12.5	2.8	3.9	9.6	12.2	12.0	8.8	13.9	16.2	11.2	28.1	8.1	12.4	14.1	11.7	12.2	12.5	11.0	10.0	5.5	13.1	15.1	10.4	13.9	31.9	14.7	14.7	8.0	22.2	4.4	9.9	12.3	11.8	11.3	1.0	1.0	3.9	8.6	0.0	8.0	10.0	12.9	11.0	15.0	5.3	11.6	6.8	9.1	3.2	5.4	5.4	6.7	15.1	5.3	14.5	9.0	6.5	14.8	14.0	12.7	14.2	8.7	13.1	5.4	11.9	4.0	5.6	1.6	11.0	6.8	9.8	11.5	3.7	35.8	7.9	6.9	21.2	4.5	9.7	9.3	10.7	0.3	3.6	5.4	11.0	4.6	6.4	0.6	3.4	4.1	6.2	2.9	3.3	2.0	7.7	2.4	1.6	4.3	10.5	19.1	14.2	2.3	22.2	8.0	6.3	13.2	7.0	14.7	8.9	7.8	12.9	13.7	9.9	6.9	1.6	4.4	12.4	14.7	8.5	12.3	23.6	17.3	4.4	15.5	15.9	10.6	13.9	12.6	12.2	10.0	23.8	36.0	84.1	81.2	75.1	21.9	40.6	58.6	34.8	21.6	69.8	41.2	124.8	126.0	43.1	10.2	56.2	119.0	23.3	70.2	125.8	83.2	82.4	61.1	123.4	106.6	17.5	11.7	68.7	111.2	19.3	62.2	91.0	92.8	30.7	80.6	78.1	62.4	147.3	51.2	125.5	104.8	77.6	87.3	41.3	86.7	85.4	78.6	69.3	78.6	82.9
PPARA	"hPPAR, NR1C1, PPAR"	ENSG00000186951	"Peroxisome proliferator activated receptor alpha"	Q07869	22	46150521-46243756	"FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Erythroid cells: 93.5;Hepatocytes: 134.7;Rod photoreceptor cells: 152.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	4	"eosinophil: 12.1;plasmacytoid DC: 3.8"	"Group enriched"	"Detected in many"	5	"dendritic cells: 3.8;granulocytes: 12.1"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058901, HPA067049, CAB075701"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB075701: , HPA058901: AB_2683849, HPA067049: AB_2685770"	"unprognostic (1.96e-1)"	"unprognostic (2.19e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.76e-2)"	"unprognostic (3.94e-3)"	"unprognostic (4.30e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.94e-2)"	"unprognostic (2.95e-1)"	"unprognostic (5.52e-3)"	"unprognostic (4.50e-2)"	"unprognostic (1.01e-1)"	"prognostic favorable (4.39e-9)"	"unprognostic (4.84e-2)"	"unprognostic (2.76e-1)"	"unprognostic (1.23e-1)"	"unprognostic (3.18e-2)"	5.7	6.6	5.8	6.0	6.2	4.2	6.9	2.6	4.5	3.8	11.8	5.9	9.9	13.9	4.8	6.6	6.3	3.9	9.1	19.6	5.1	4.1	17.8	30.9	3.8	3.4	6.1	4.9	9.1	13.4	6.6	3.5	3.1	7.8	6.2	7.1	13.5	8.1	8.2	17.1	5.8	19.7	5.0	4.7	3.5	5.7	2.7	7.1	1.3	5.4	10.4	4.8	7.3	12.3	1.5	3.8	12.1	1.4	0.9	1.5	0.3	6.9	1.7	2.2	7.7	12.4	8.0	4.9	6.1	12.1	6.6	6.8	3.4	3.4	2.5	3.1	14.1	6.0	3.1	6.5	8.0	5.9	7.2	8.3	7.7	4.4	7.1	7.7	5.3	13.3	6.3	6.4	4.8	11.1	5.6	1.4	5.7	2.8	5.8	6.1	1.8	6.0	1.9	0.3	5.8	1.7	7.1	8.0	3.2	4.5	4.1	2.2	6.6	2.3	2.2	7.7	3.2	2.5	4.1	2.3	6.8	7.4	6.2	2.6	5.9	3.4	1.0	10.7	6.0	2.1	1.7	1.0	12.1	1.4	1.4	1.2	1.0	0.7	0.7	0.7	1.5	0.8	0.6	0.8	0.9	0.8	3.8	1.5	0.3	5.8	6.2	2.6	4.5	5.1	4.1	6.1	4.9	7.8	7.1	3.0	9.9	5.2	13.1	20.7	14.7	84.0	25.5	2.7	7.9	7.0	58.9	6.8	8.3	7.2	0.4	16.1	66.1	93.5	14.3	5.4	13.0	13.9	4.7	134.7	7.4	4.8	19.1	20.9	22.5	0.4	18.1	9.6	3.3	11.8	34.6	15.2	11.6	24.6	28.3	36.9	152.6	6.5	14.4	0.7	1.7	29.9	2.5	7.5	31.6	17.9
PPARD	"FAAR, NR1C2, NUC1, NUCII"	ENSG00000112033	"Peroxisome proliferator activated receptor delta"	Q03181	6	35342558-35428191	"FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Pancreatic endocrine cells: 63.9;Syncytiotrophoblasts: 82.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB017635	Approved					NA	NA					"CAB017635: AB_1128605"	"unprognostic (3.70e-2)"	"unprognostic (8.75e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.57e-1)"	"unprognostic (8.68e-2)"	"prognostic unfavorable (4.57e-4)"	"unprognostic (4.59e-3)"	"unprognostic (4.34e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.51e-3)"	"unprognostic (7.27e-3)"	"unprognostic (1.43e-1)"	"unprognostic (9.42e-2)"	"unprognostic (5.95e-2)"	"unprognostic (2.00e-2)"	16.4	13.4	20.4	19.4	21.8	8.8	11.3	19.0	29.5	14.0	19.0	20.4	24.5	12.7	15.0	22.7	29.6	13.4	16.7	15.7	23.8	14.5	11.9	19.9	18.1	15.6	22.5	14.6	21.6	11.1	14.2	16.2	30.4	19.8	18.0	13.9	15.4	15.2	20.6	22.5	26.3	16.5	12.8	20.9	20.0	23.4	12.8	20.8	6.2	26.8	9.5	15.8	14.5	19.4	4.4	2.9	6.7	3.5	2.3	5.6	2.5	21.0	3.7	6.0	12.7	8.8	15.6	32.3	17.3	15.5	14.9	12.4	5.0	4.0	3.4	5.0	12.3	8.5	7.6	5.6	16.7	10.5	4.9	5.1	3.2	5.0	7.4	15.6	0.7	3.6	26.5	5.6	22.0	11.3	17.1	6.9	4.2	3.3	3.9	12.4	6.6	2.3	3.4	2.9	7.9	10.3	3.3	10.2	3.4	3.6	18.9	3.3	9.3	6.9	12.0	14.7	4.3	4.5	11.8	14.9	20.4	7.7	12.2	20.5	3.3	4.5	3.7	6.6	6.8	9.1	1.1	3.5	6.7	3.1	3.3	2.2	3.4	3.3	3.0	2.9	4.4	5.6	5.1	5.4	2.3	1.9	1.8	3.2	2.5	20.4	21.8	19.0	29.5	23.8	14.5	22.5	14.6	19.8	20.8	8.9	8.5	3.2	14.7	16.7	6.9	9.9	15.3	2.7	11.4	1.8	2.0	30.8	3.3	30.4	2.6	10.5	25.3	0.0	21.2	25.6	9.7	17.3	23.0	4.5	12.9	4.8	6.3	5.5	5.6	2.9	5.5	14.3	11.8	3.6	7.1	6.5	63.9	8.5	7.8	5.6	7.3	12.9	10.8	5.6	7.6	11.2	82.0	6.9	5.2	34.9
PPARG	"NR1C3, PPARG1, PPARG2, PPARgamma"	ENSG00000132170	"Peroxisome proliferator activated receptor gamma"	P37231	3	12287368-12434356	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Biological rhythms, Transcription, Transcription regulation"	"Activator, DNA-binding, Receptor"	"Cancer-related genes, Diabetes mellitus, Disease mutation, FDA approved drug targets, Obesity"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 97.6;breast: 102.1"	"Cell type enhanced"	"Detected in many"	11	"Cytotrophoblasts: 90.9;Extravillous trophoblasts: 187.1;Urothelial cells: 210.8"	"Cancer enhanced"	"Detected in all"		"urothelial cancer: 33.5"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.8;intermediate monocyte: 2.3"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC diff: 47.9;ASC TERT1: 27.3;BEWO: 56.5;CAPAN-2: 25.2;HSkMC: 28.1;RT4: 34.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"CAB004282, HPA051239, HPA063663"	Approved		Enhanced	Nucleoplasm,Vesicles		NA	NA			"Nucleoplasm, Vesicles"		"CAB004282: AB_628115, HPA051239: AB_2681400, HPA063663: AB_2685081"	"unprognostic (7.35e-3)"	"unprognostic (3.27e-2)"	"unprognostic (4.05e-2)"	"unprognostic (8.37e-2)"	"unprognostic (2.41e-2)"	"unprognostic (5.27e-3)"	"prognostic unfavorable (3.41e-5)"	"unprognostic (9.13e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.77e-1)"	"prognostic favorable (1.59e-8)"	"unprognostic (1.51e-2)"	"unprognostic (1.46e-1)"	"unprognostic (9.68e-3)"	"prognostic favorable (5.52e-5)"	97.6	1.6	1.9	17.1	1.2	0.7	102.1	1.5	1.3	3.1	24.9	0.8	2.1	7.5	3.5	2.2	2.8	2.4	8.7	12.5	1.4	0.9	6.7	5.9	24.8	11.4	1.1	0.9	6.7	1.2	2.8	0.3	26.8	0.9	10.4	13.9	1.1	5.8	1.5	5.0	2.7	9.6	7.4	1.2	7.0	11.9	3.5	0.6	0.9	6.2	4.3	2.1	30.2	14.1	0.0	0.4	0.0	2.3	0.0	0.7	0.3	9.7	8.7	0.0	0.0	47.9	27.3	56.5	0.9	10.5	1.3	0.5	1.8	25.2	0.0	0.0	0.9	17.1	4.0	3.5	0.1	0.2	23.5	4.9	0.0	1.9	2.3	12.8	0.0	0.0	28.1	2.3	2.4	9.1	5.0	0.1	0.2	0.0	0.0	2.0	2.5	0.0	0.1	0.1	22.7	25.2	0.0	0.0	0.0	7.2	34.5	0.0	0.2	4.1	1.5	0.5	1.7	0.0	7.8	7.9	1.8	2.6	1.0	0.0	0.0	0.0	0.0	0.8	0.1	0.2	0.0	1.8	0.0	0.0	2.3	0.0	0.0	0.7	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.4	0.3	1.9	1.2	1.5	1.3	1.4	0.9	1.1	0.9	0.9	0.6	3.0	7.4	0.0	33.7	0.9	0.5	5.2	2.5	2.7	3.4	5.2	0.0	90.9	1.7	0.1	2.6	17.7	47.1	0.0	0.6	187.1	4.3	35.2	9.2	3.8	46.3	0.0	8.1	19.6	14.5	0.8	3.7	8.6	3.3	2.8	20.5	0.5	10.2	42.1	0.0	11.3	0.0	12.9	5.7	7.9	21.8	1.0	74.4	1.3	16.6	210.8
PPP3R2	PPP3RL	ENSG00000188386	"Protein phosphatase 3 regulatory subunit B, beta"	Q96LZ3	9	101591615-101595021	"FDA approved drug targets, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	90	"testis: 81.9"	"Group enriched"	"Detected in some"	25	"Early spermatids: 271.7;Late spermatids: 141.7;Spermatocytes: 319.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"Karpas-707: 1.3"	"Low region specificity"	"Detected in single"							HPA047157	Uncertain		Approved	"Plasma membrane,Cytosol"		NA	NA			"Plasma membrane, Cytosol"		"HPA047157: AB_2679960"												"unprognostic (8.81e-2)"			"unprognostic (2.65e-1)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	81.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	1.3	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	271.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	141.7	9.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.7	0.0	0.0	6.5	0.0	319.9	3.0	0.0	0.0	0.0	0.0	0.0
PRDX5	"ACR1, AOEB166, B166, MGC117264, MGC142283, MGC142285, PLP, PMP20, PRDX6, PRXV, SBBI10"	ENSG00000126432	"Peroxiredoxin 5"	P30044	11	64318088-64321811	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Antioxidant, Oxidoreductase, Peroxidase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008661, HPA037915, HPA037916"	Enhanced		Supported	Mitochondria		NA	NA		19000000	Mitochondria		"CAB008661: AB_1620988, HPA037915: AB_2675735, HPA037916: AB_2675736"	"unprognostic (2.75e-1)"	"unprognostic (4.08e-1)"	"unprognostic (1.33e-1)"	"unprognostic (1.46e-1)"	"unprognostic (9.43e-2)"	"unprognostic (6.71e-3)"	"unprognostic (1.08e-3)"	"unprognostic (3.11e-1)"	"unprognostic (9.30e-2)"	"unprognostic (1.07e-3)"	"unprognostic (1.57e-2)"	"unprognostic (2.20e-1)"	"prognostic favorable (1.24e-5)"	"unprognostic (8.19e-2)"	"unprognostic (2.30e-1)"	"unprognostic (9.63e-2)"	"unprognostic (5.03e-2)"	28.7	69.7	70.3	38.6	60.3	57.0	35.5	69.3	73.9	47.2	79.3	31.9	49.0	49.5	26.6	54.8	69.6	94.9	44.8	102.4	56.7	74.2	57.3	54.2	50.3	25.0	68.6	70.2	42.2	72.0	36.0	53.7	49.1	71.4	30.7	71.2	33.9	77.5	62.6	104.7	27.0	51.2	30.9	44.1	27.3	64.5	35.0	29.3	25.1	82.0	64.8	33.5	34.4	50.4	55.2	69.2	115.0	66.9	48.4	40.5	75.3	26.3	53.8	32.6	53.9	35.1	52.9	37.7	33.0	52.9	24.3	30.3	39.1	54.1	38.6	57.8	52.7	87.4	60.3	30.4	70.1	15.4	53.6	24.0	39.0	84.6	44.5	72.1	14.7	33.3	53.6	91.6	40.7	41.3	47.5	36.8	45.9	21.9	91.9	34.1	66.8	25.7	64.1	49.3	41.7	68.8	24.8	33.5	136.5	90.8	52.3	27.6	52.6	27.6	61.3	94.1	32.6	44.9	33.6	35.5	34.7	32.3	40.1	14.5	47.0	56.0	45.5	42.0	29.8	27.0	79.8	66.9	85.4	37.7	59.6	32.7	53.8	35.0	30.8	52.4	55.2	34.8	35.0	115.0	48.4	52.5	69.2	40.5	75.3	70.3	60.3	69.3	73.9	56.7	74.2	68.6	70.2	71.4	29.3	247.1	407.2	232.2	603.5	290.1	156.4	523.8	356.7	1310.3	342.4	427.5	66.8	1002.3	1366.1	644.2	57.6	187.4	757.5	163.5	919.1	972.3	308.0	330.5	103.7	331.1	418.0	87.4	770.7	194.0	207.8	207.7	258.3	234.8	413.3	423.8	875.2	180.0	1093.8	547.1	213.2	1094.9	109.1	194.1	199.4	113.7	345.0	225.2	818.7	191.8	959.8	988.5
PRKAA1	AMPKa1	ENSG00000132356	"Protein kinase AMP-activated catalytic subunit alpha 1"	Q13131	5	40759379-40798374	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Autophagy, Biological rhythms, Cholesterol biosynthesis, Cholesterol metabolism, Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Steroid biosynthesis, Steroid metabolism, Sterol biosynthesis, Sterol metabolism, Transcription, Transcription regulation, Wnt signaling pathway"	"Chromatin regulator, Kinase, Serine/threonine-protein kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Early spermatids: 230.0;Late spermatids: 337.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005050, HPA035409, HPA064946"	Supported		Supported	"Nuclear speckles,Cytosol"		NA	NA			"Nuclear speckles"	Cytosol	"CAB005050: AB_562037, HPA035409: AB_2674613, HPA064946: AB_2685390"	"unprognostic (2.07e-1)"	"unprognostic (1.41e-2)"	"unprognostic (2.51e-2)"	"unprognostic (3.57e-2)"	"unprognostic (3.97e-1)"	"unprognostic (1.05e-1)"	"unprognostic (3.51e-2)"	"unprognostic (7.53e-2)"	"unprognostic (1.66e-2)"	"unprognostic (2.88e-1)"	"unprognostic (3.34e-3)"	"unprognostic (2.63e-1)"	"unprognostic (2.82e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.27e-2)"	"unprognostic (1.10e-2)"	40.6	15.7	9.4	15.9	16.1	29.0	26.2	14.3	17.7	30.2	24.0	19.9	18.9	21.7	23.5	20.9	22.5	20.4	21.3	15.0	10.5	11.7	35.9	40.7	24.8	16.7	12.2	8.5	28.8	20.6	25.3	20.0	16.8	35.7	26.1	22.3	20.0	23.2	17.9	18.5	16.6	32.6	20.7	14.1	25.1	22.1	29.3	11.4	21.4	28.0	20.5	22.9	32.5	17.9	8.4	6.5	15.9	8.9	10.8	12.6	6.5	11.4	11.9	9.6	12.7	23.7	24.8	9.1	19.6	20.0	14.7	13.2	11.2	14.9	6.7	9.1	20.0	19.2	9.3	8.8	17.8	27.7	19.8	8.0	13.4	27.6	8.9	19.6	12.7	14.2	22.8	8.7	19.6	20.3	16.3	21.6	8.7	6.3	19.6	21.9	5.5	11.8	10.0	4.2	11.7	14.4	9.9	20.5	9.9	22.5	19.5	8.3	8.4	34.3	22.8	11.6	5.4	12.0	10.6	23.1	26.5	14.3	15.2	15.9	7.8	6.1	8.1	16.6	27.7	14.1	14.1	6.6	12.7	10.0	8.1	12.6	8.4	9.4	9.4	6.5	7.7	11.5	10.0	15.9	10.8	8.9	2.0	11.3	6.5	9.4	16.1	14.3	17.7	10.5	11.7	12.2	8.5	35.7	11.4	38.7	27.4	25.1	20.8	21.4	19.2	15.3	43.3	22.7	28.4	45.4	33.4	10.9	6.6	24.4	230.0	32.8	33.8	0.0	39.5	11.7	23.6	34.6	17.4	73.6	17.7	14.3	20.3	36.2	21.5	337.0	28.1	24.1	33.7	36.1	27.4	15.4	29.5	31.7	24.4	26.4	25.7	0.0	33.0	20.4	16.8	28.5	15.6	28.8	30.2	28.0
PRKAB1		ENSG00000111725	"Protein kinase AMP-activated non-catalytic subunit beta 1"	Q9Y478	12	119667753-119681630	"FDA approved drug targets, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004247, CAB005058"	Enhanced		Approved	Nucleoplasm,Cytosol		NA	NA			Cytosol	Nucleoplasm	"CAB005058: AB_562038, HPA004247: AB_1078149"	"unprognostic (1.20e-1)"	"unprognostic (3.08e-2)"	"unprognostic (7.42e-2)"	"prognostic favorable (8.66e-4)"	"unprognostic (2.33e-1)"	"unprognostic (2.89e-2)"	"unprognostic (8.97e-3)"	"unprognostic (1.46e-2)"	"unprognostic (6.26e-2)"	"unprognostic (3.63e-2)"	"unprognostic (2.85e-1)"	"unprognostic (1.23e-1)"	"prognostic favorable (5.40e-9)"	"unprognostic (5.60e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.92e-1)"	"unprognostic (1.32e-2)"	16.3	17.2	8.1	16.6	11.9	23.4	13.8	12.5	20.7	16.8	22.8	14.6	6.7	20.4	13.6	13.2	17.9	11.6	19.3	9.2	8.3	7.2	40.1	12.3	21.4	20.6	8.9	9.8	14.2	21.7	11.7	10.8	19.1	11.1	9.7	22.7	20.6	15.3	10.7	12.0	10.6	23.9	12.5	10.5	20.7	25.0	33.4	8.3	20.0	17.5	9.4	16.6	16.3	10.6	26.4	17.4	38.8	19.9	22.1	20.9	18.3	4.7	12.8	10.2	9.6	8.7	7.6	13.4	7.7	10.0	12.6	9.6	13.4	10.9	15.9	10.2	10.5	5.6	6.7	10.2	15.9	11.6	10.2	9.4	24.9	5.6	19.4	15.7	11.5	31.7	11.4	13.5	11.4	15.4	14.2	9.3	23.7	38.0	6.2	9.7	13.1	26.0	12.9	14.3	7.0	14.3	15.1	8.8	9.2	14.3	15.2	8.1	13.8	10.2	3.9	10.5	13.1	12.6	15.1	11.0	7.7	8.2	5.9	7.7	20.0	17.6	11.8	7.6	7.8	11.0	24.8	16.4	38.8	17.2	18.4	20.9	26.4	18.3	18.3	17.4	21.7	19.9	18.6	19.1	22.1	19.9	15.4	19.7	18.3	8.1	11.9	12.5	20.7	8.3	7.2	8.9	9.8	11.1	8.3	44.7	42.5	11.8	5.5	3.0	12.0	4.1	10.2	10.7	17.0	21.0	3.9	15.7	39.7	7.1	1.0	13.5	16.9	0.0	27.0	8.5	8.2	5.6	11.5	5.0	10.3	20.6	18.9	4.3	5.6	1.8	5.2	9.0	3.3	12.6	16.7	11.9	10.0	14.1	6.0	29.4	17.3	6.5	6.0	25.0	9.4	3.8	12.6	10.2	21.5	7.6
PRKCA	PKCA	ENSG00000154229	"Protein kinase C alpha"	P17252	17	66302636-66810743	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, RAS pathway related proteins"	"Angiogenesis, Apoptosis, Cell adhesion"	"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Rod photoreceptor cells: 77.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	17	"dendritic cells: 1.4;monocytes: 2.7;T-cells: 4.0"	"Cell line enhanced"	"Detected in many"		"U-87 MG: 53.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB003844, HPA006563, HPA006564, CAB016290"	Enhanced	Approved	Enhanced	"Plasma membrane,Cytosol"		NA	NA		1900000	Cytosol	"Plasma membrane"	"CAB003844: AB_562331, CAB016290: AB_628141, HPA006563: AB_1079626, HPA006564: AB_1079625"	"unprognostic (3.06e-1)"	"unprognostic (3.56e-2)"	"unprognostic (1.38e-2)"	"unprognostic (1.01e-1)"	"unprognostic (1.53e-1)"	"unprognostic (7.41e-3)"	"unprognostic (7.43e-2)"	"unprognostic (6.86e-3)"	"unprognostic (4.93e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.09e-1)"	"unprognostic (2.24e-2)"	"unprognostic (5.50e-2)"	"unprognostic (2.46e-1)"	"unprognostic (1.83e-1)"	"unprognostic (1.35e-3)"	"unprognostic (8.77e-2)"	4.0	19.6	26.5	9.0	22.8	2.5	3.0	10.8	33.9	7.0	13.8	19.0	3.5	14.6	14.8	6.7	4.7	6.1	10.8	5.8	31.6	15.6	16.7	6.5	6.0	8.4	18.7	15.6	20.4	5.5	1.7	6.0	6.5	17.6	17.2	11.2	7.0	3.1	22.3	6.6	3.8	12.7	13.7	15.0	7.9	7.9	3.7	14.4	0.4	4.5	1.3	5.9	9.5	9.5	0.0	1.4	0.1	2.7	0.1	4.0	1.0	2.3	12.5	2.6	2.6	6.3	16.1	0.3	13.4	8.8	9.7	8.3	1.4	1.5	3.1	3.6	21.7	16.3	0.3	1.3	1.6	21.2	5.2	3.0	0.0	7.4	6.5	8.6	3.9	21.1	7.0	0.6	12.1	10.4	14.2	8.3	15.1	8.1	0.0	15.0	0.7	7.8	2.4	1.0	6.1	6.7	1.4	19.1	0.0	3.4	2.1	1.5	8.6	4.4	2.6	0.1	2.8	0.3	5.5	24.8	16.9	9.8	10.5	8.4	0.0	0.0	0.3	53.7	0.0	8.3	0.1	0.6	0.0	0.5	0.8	1.5	0.0	2.5	1.2	1.1	0.0	4.0	2.3	0.0	0.1	2.7	1.4	0.5	1.0	26.5	22.8	10.8	28.2	31.6	15.6	18.7	15.6	17.6	14.4	0.0	9.6	3.9	15.4	9.4	33.9	7.9	40.8	5.3	4.5	38.4	2.0	3.3	6.6	11.3	2.5	3.0	24.2	0.0	5.9	2.8	11.0	12.4	20.7	11.9	19.7	9.5	8.1	36.8	8.2	1.3	49.5	7.7	10.1	1.8	32.8	43.1	7.2	20.1	45.6	16.8	77.1	25.8	17.0	1.1	1.7	9.2	12.7	24.1	21.3	12.3
PRLR		ENSG00000113494	"Prolactin receptor"	P16471	5	35048756-35230589	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 54.3;placenta: 45.7;seminal vesicle: 42.7"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 26.1;Proximal tubular cells: 41.8;Syncytiotrophoblasts: 40.4"	"Cancer enriched"	"Detected in many"	9	"breast cancer: 20.6"	"Region enriched"	"Detected in many"	7	"pons and medulla: 54.3"	"Group enriched"	"Detected in some"	4	"classical monocyte: 2.7;intermediate monocyte: 2.8"	"Lineage enriched"	"Detected in single"	11	"monocytes: 2.8"	"Cell line enriched"	"Detected in some"	18	"T-47d: 93.7"					"Low region specificity"	"Detected in many"								"Intracellular and membrane"	NA	NA						"unprognostic (3.81e-2)"	"unprognostic (2.41e-1)"	"unprognostic (2.37e-2)"	"unprognostic (6.04e-2)"	"unprognostic (5.05e-2)"	"unprognostic (8.21e-2)"	"unprognostic (3.99e-2)"	"unprognostic (7.94e-2)"	"unprognostic (4.89e-2)"	"unprognostic (1.67e-3)"	"unprognostic (4.84e-4)"	"unprognostic (2.50e-3)"	"unprognostic (4.15e-3)"	"unprognostic (1.89e-1)"	"unprognostic (1.12e-1)"	"unprognostic (9.84e-5)"	"unprognostic (1.24e-1)"	0.5	13.3	1.8	0.2	5.6	0.3	13.3	0.4	1.4	23.5	5.3	10.7	36.6	3.5	25.1	10.0	1.1	2.1	2.0	0.6	7.6	2.4	17.8	5.9	0.6	0.0	0.6	0.2	3.2	4.3	11.5	15.7	45.7	54.3	3.2	3.0	0.5	1.8	42.7	0.4	2.6	10.1	6.4	0.7	0.4	3.3	2.0	0.4	0.1	0.5	0.5	0.0	1.4	6.2	0.0	0.2	0.1	2.8	0.0	0.0	0.3	0.0	0.0	0.1	0.7	0.0	0.7	0.1	0.4	0.3	0.8	0.3	0.1	0.0	0.0	0.0	0.5	0.3	0.0	1.0	0.0	0.8	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	5.2	0.0	0.2	93.7	0.7	0.0	0.5	0.5	0.1	0.3	0.0	0.0	0.0	0.9	0.0	0.2	0.1	2.7	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.3	1.8	5.6	0.4	1.4	7.6	2.4	0.6	0.2	54.3	0.4	0.0	1.3	0.0	0.3	2.6	0.0	0.8	2.5	0.0	0.0	3.5	0.0	26.1	6.6	0.8	0.0	0.2	12.7	0.0	4.4	2.6	3.5	2.2	0.0	9.7	7.5	0.0	8.2	0.6	1.3	0.0	8.1	0.6	0.0	9.0	16.5	0.0	2.4	20.9	12.0	41.8	0.0	0.0	3.8	0.0	0.1	4.4	40.4	0.0	19.8	0.1
PROC		ENSG00000115718	"Protein C, inactivator of coagulation factors Va and VIIIa"	P04070	2	127418427-127429246	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"liver: 137.5"	"Cell type enriched"	"Detected in many"	4	"Hepatocytes: 348.7"	"Cancer enriched"	"Detected in many"	22	"liver cancer: 118.3"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	9	"plasmacytoid DC: 29.2"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 29.2"	"Cell line enriched"	"Detected in some"	16	"Hep G2: 58.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA005550, CAB016721, CAB016792"	Supported				"Secreted to blood"	NA	NA		6400000000			"CAB016721: , CAB016792: , HPA005550: AB_1079687"	"unprognostic (2.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.58e-1)"	"unprognostic (6.64e-2)"	"unprognostic (3.13e-2)"	"unprognostic (4.90e-3)"	"unprognostic (2.63e-1)"	"unprognostic (1.67e-1)"	"unprognostic (3.29e-1)"	"unprognostic (3.74e-3)"	"unprognostic (2.56e-2)"	"unprognostic (8.12e-3)"	"unprognostic (2.01e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.60e-3)"	"unprognostic (8.06e-2)"	0.0	0.0	0.4	0.1	0.1	0.2	0.0	0.1	0.2	0.1	0.2	0.0	0.1	0.2	0.0	0.1	0.0	0.0	0.6	0.0	0.4	0.2	4.2	137.5	0.2	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.4	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.5	0.0	0.1	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.1	0.1	0.0	0.4	29.2	3.1	0.0	0.0	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	1.6	0.0	0.3	0.0	0.1	3.7	0.0	0.1	0.0	0.0	0.0	0.0	2.8	58.9	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.6	0.1	0.9	0.2	0.0	0.0	0.0	0.0	0.3	0.1	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	3.1	0.0	0.0	29.2	0.0	0.1	0.4	0.1	0.1	0.2	0.4	0.2	0.1	0.1	0.4	0.0	0.0	0.0	4.3	0.6	0.7	0.0	0.3	40.8	1.4	0.0	0.0	0.0	0.0	5.0	0.4	0.0	0.0	2.6	0.0	0.2	0.0	0.2	0.0	0.0	348.7	3.9	0.0	9.9	9.8	4.5	0.0	0.0	1.7	0.0	0.0	8.1	0.0	1.2	8.7	0.0	78.1	0.0	0.0	0.0	0.0	0.1	0.1	0.1	2.5	1.5	0.1
PROS1	PROS	ENSG00000184500	"Protein S"	P07225	3	93873033-93974066	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	"Blood coagulation, Fibrinolysis, Hemostasis"		"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 114.6"	"Cell type enhanced"	"Detected in many"	13	"Hepatocytes: 266.4"	"Low cancer specificity"	"Detected in all"			"Region enriched"	"Detected in many"	6	"pons and medulla: 24.2"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.9"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"ASC diff: 42.8;ASC TERT1: 31.9;HSkMC: 28.9;hTERT-RPE1: 24.2;SK-MEL-30: 46.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007724, HPA023974, CAB032610"	Approved				"Secreted to blood"	NA	NA	22500000000	3400000000			"CAB032610: AB_2237647, HPA007724: AB_1079688, HPA023974: AB_1855738"	"unprognostic (2.00e-2)"	"unprognostic (2.81e-2)"	"unprognostic (9.21e-2)"	"unprognostic (8.03e-3)"	"unprognostic (3.35e-2)"	"unprognostic (2.41e-1)"	"unprognostic (6.48e-2)"	"unprognostic (3.07e-1)"	"unprognostic (5.18e-2)"	"unprognostic (3.12e-1)"	"unprognostic (1.10e-1)"	"unprognostic (1.91e-1)"	"unprognostic (1.10e-1)"	"prognostic unfavorable (8.35e-4)"	"unprognostic (4.90e-2)"	"unprognostic (1.05e-2)"	"prognostic unfavorable (4.42e-5)"	16.0	3.9	2.5	3.8	3.8	0.1	15.5	0.8	2.8	7.4	8.0	4.1	2.8	3.9	7.6	9.5	10.9	8.5	11.3	30.2	4.0	3.1	17.6	114.6	17.3	13.7	4.3	1.8	23.9	2.7	10.1	6.2	10.2	24.2	6.8	8.5	9.3	5.6	4.3	5.6	8.5	6.5	8.3	4.8	8.8	4.9	5.5	2.2	0.1	10.6	6.9	3.3	8.0	9.5	0.0	0.8	1.9	0.8	0.1	0.4	6.8	0.3	2.4	2.5	10.3	42.8	31.9	0.8	1.5	3.5	0.8	3.1	6.1	0.9	0.2	9.3	2.3	7.8	0.1	0.8	0.6	1.1	0.1	2.7	16.6	1.1	17.0	3.6	0.6	0.8	28.9	0.6	1.8	0.6	24.2	3.5	2.1	11.5	0.2	16.6	0.2	0.1	0.0	2.0	1.5	2.4	0.3	2.0	0.0	9.0	0.0	3.8	7.0	1.8	0.0	46.2	0.8	0.1	8.1	3.0	6.8	1.5	3.7	0.8	0.0	0.1	0.0	21.2	10.6	9.9	0.0	0.8	0.7	0.1	0.6	0.0	0.0	0.0	0.0	0.8	0.0	0.4	0.0	1.9	0.1	0.2	0.0	0.2	6.8	2.5	3.8	0.8	2.8	4.0	3.1	4.3	1.8	24.2	2.2	59.6	29.8	3.7	2.9	13.2	0.6	40.3	12.7	76.3	12.5	1.8	9.8	0.6	3.3	5.6	2.3	47.0	2.6	0.0	4.0	0.6	62.0	4.7	29.0	266.4	9.9	1.6	15.1	69.3	24.7	4.0	26.4	7.7	18.6	1.0	14.6	22.0	3.9	7.0	34.6	36.2	7.8	12.9	26.2	0.2	0.5	29.1	1.4	4.5	13.3	2.0
PRSS1	TRY1	ENSG00000204983	"Serine protease 1"	P07477	7	142749468-142753076	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"	Digestion	"Hydrolase, Protease, Serine protease"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	1708	"pancreas: 3057.4"	"Cell type enriched"	"Detected in some"	17	"Exocrine glandular cells: 49265.4"	"Cancer enriched"	"Detected in many"	224	"pancreatic cancer: 1920.3"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 1.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"EFO-21: 2.7;OE19: 10.1;RPMI-8226: 5.4;U-2 OS: 3.2;U-266/84: 1.9"									"CAB025487, CAB025538, HPA062452, HPA063471"	Enhanced		Approved	"Endoplasmic reticulum,Vesicles"	"Secreted to digestive system"	NA	NA		26000000000	Vesicles	"Endoplasmic reticulum"	"CAB025487: , CAB025538: , HPA062452: AB_2684768, HPA063471: AB_2685017"	"unprognostic (6.55e-5)"	"unprognostic (5.28e-1)"	"unprognostic (7.58e-2)"	"prognostic unfavorable (6.41e-6)"				"unprognostic (8.26e-2)"		"prognostic favorable (7.05e-4)"	"unprognostic (1.35e-1)"			"unprognostic (3.93e-2)"	"unprognostic (1.96e-1)"	"prognostic favorable (4.91e-4)"	"unprognostic (3.12e-1)"	0.4	0.0	0.1	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.2	0.2	0.2	0.2	0.1	0.1	0.0	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	1.6	3057.4	0.0	0.1	0.1	0.1	0.2	0.0	0.1	0.4	0.2	0.1	0.0	0.4	0.1	0.1	0.1	0.5	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.0	0.0	1.7	0.0	0.0	0.9	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	2.7	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	10.1	0.0	0.0	0.0	5.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	1.1	0.0	1.9	0.4	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.0	0.9	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.1	0.1	0.1	0.1	0.2	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	58.1	0.0	0.0	0.0	0.0	49265.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	208.2	0.0	0.5	2827.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1
PSMB1	"HC5, PMSB1"	ENSG00000008018	"Proteasome subunit beta 1"	P20618	6	170535117-170553341	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Hydrolase, Protease, Threonine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA029635, HPA029637, CAB033911"	Enhanced		Supported	Nucleoplasm		NA	NA		14000000	Nucleoplasm		"CAB033911: AB_2268890, HPA029635: AB_10599738, HPA029637: AB_10601793"	"unprognostic (2.78e-2)"	"unprognostic (3.10e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.34e-1)"	"unprognostic (1.20e-1)"	"unprognostic (5.41e-3)"	"unprognostic (2.36e-2)"	"unprognostic (3.32e-2)"	"unprognostic (8.39e-2)"	"unprognostic (4.28e-2)"	"unprognostic (3.07e-1)"	"unprognostic (1.09e-1)"	"prognostic unfavorable (3.76e-6)"	"unprognostic (3.63e-1)"	"unprognostic (7.50e-2)"	"unprognostic (1.45e-3)"	"unprognostic (9.62e-2)"	60.8	59.3	38.5	40.4	53.7	53.2	55.0	31.4	46.4	40.5	48.6	37.9	49.9	45.1	56.8	90.6	51.7	49.8	43.1	71.9	40.9	40.1	56.4	93.2	46.9	66.7	40.8	41.1	43.7	67.3	35.4	48.4	80.6	48.4	40.6	52.7	43.8	43.6	50.0	109.3	56.1	46.0	59.7	44.9	51.4	46.9	47.1	38.1	47.1	47.9	75.2	60.4	50.1	42.0	71.0	98.1	51.9	81.9	71.6	79.3	104.1	43.1	40.6	57.9	74.7	51.8	40.7	61.7	41.3	60.8	69.0	70.5	88.7	37.3	63.2	54.0	55.3	63.5	43.7	64.1	65.7	72.0	64.2	72.2	54.0	41.2	111.2	60.8	63.2	48.1	46.4	40.4	66.5	43.2	47.5	58.8	40.0	106.5	54.3	62.8	116.2	47.3	88.3	52.8	78.8	55.9	45.9	45.9	80.1	71.5	26.0	57.9	47.3	39.7	61.8	31.6	53.9	42.2	91.6	44.7	28.1	45.1	68.3	76.3	46.5	61.4	78.4	65.6	71.7	60.2	40.1	81.9	51.9	53.2	75.8	62.1	71.0	62.2	57.7	98.1	53.4	59.2	57.2	47.5	71.6	67.6	55.8	79.3	104.1	38.5	53.7	31.4	46.4	40.9	40.1	40.8	41.1	48.4	38.1	104.2	145.5	160.9	308.1	192.9	104.7	211.7	249.7	199.4	117.2	134.3	39.3	748.5	339.8	368.1	245.5	214.1	220.2	116.8	565.6	684.7	208.1	230.0	184.8	268.0	350.5	112.8	158.7	149.8	159.1	57.7	237.3	212.8	219.4	422.0	169.6	196.7	419.2	227.4	221.7	419.5	99.6	187.5	291.5	198.6	166.3	188.6	1001.7	194.1	216.2	303.9
PSMB10	"beta2i, LMP10, MECL1, MGC1665"	ENSG00000205220	"Proteasome subunit beta 10"	P40306	16	67934502-67937087	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Hydrolase, Protease, Threonine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 117.3"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"REH: 36.6;U-266/70: 41.0"									"HPA030224, HPA030225, CAB034384"	Enhanced		Approved	Vesicles,Cytosol		NA	NA		1400000	Cytosol	Vesicles	"CAB034384: AB_2171876, HPA030224: AB_2673382, HPA030225: AB_10603231"	"unprognostic (1.18e-2)"	"unprognostic (1.90e-3)"	"unprognostic (2.00e-1)"	"unprognostic (2.53e-3)"	"unprognostic (2.00e-1)"	"unprognostic (1.85e-2)"	"unprognostic (7.22e-2)"	"unprognostic (3.35e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.60e-1)"	"unprognostic (8.22e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.32e-2)"	"unprognostic (2.97e-2)"	"unprognostic (1.98e-1)"	"unprognostic (1.32e-2)"	"prognostic favorable (5.44e-4)"	11.5	13.0	9.1	24.9	11.8	23.9	11.4	4.0	7.8	8.0	21.6	5.6	8.5	42.4	9.3	9.5	10.6	12.4	16.6	12.0	6.9	4.9	16.9	17.2	19.5	38.3	9.5	5.6	8.7	61.5	0.9	6.9	11.2	8.5	13.5	6.3	5.8	27.9	11.6	6.9	7.0	35.6	7.7	6.5	49.7	23.8	2.5	7.8	39.2	13.1	10.4	20.5	13.2	8.4	50.8	75.2	100.0	98.1	69.1	68.8	117.3	6.0	5.3	0.4	0.8	0.4	3.5	21.3	2.0	8.7	7.0	9.9	2.8	29.5	22.0	3.8	2.7	2.1	8.9	0.1	2.0	0.5	9.7	0.5	7.8	1.8	3.1	12.2	14.5	24.0	5.4	1.2	3.1	0.0	2.2	4.0	5.3	0.7	8.4	2.0	7.5	28.5	14.9	0.3	0.2	2.0	36.6	2.2	30.0	4.8	10.5	0.3	0.4	6.8	12.0	2.6	0.4	2.4	31.5	6.8	4.5	1.2	1.9	2.3	41.0	7.4	14.6	11.1	19.0	9.6	57.1	89.4	67.1	68.8	98.1	50.2	50.8	54.0	57.3	74.6	49.1	45.3	50.1	100.0	69.1	71.4	75.2	60.8	117.3	9.1	11.8	4.0	7.8	6.9	4.9	9.5	5.6	8.5	7.8	20.8	23.2	54.7	11.4	15.2	0.6	1.4	38.2	73.6	15.9	17.4	0.0	24.0	19.9	48.2	11.5	22.9	90.1	23.3	91.6	28.8	24.3	10.7	49.8	10.0	80.6	0.0	15.6	31.3	88.4	25.3	27.9	74.2	45.5	124.4	58.4	1.3	49.6	106.6	19.8	53.7	1.0	19.4	23.4	16.6	6.8	8.7	18.9	122.2	72.8	19.2
PSMB2	HC7-I	ENSG00000126067	"Proteasome subunit beta 2"	P49721	1	35599544-35641844	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Hydrolase, Protease, Threonine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA026322, HPA026324"	Approved		Enhanced	Nucleoplasm		NA	NA		15000000	Nucleoplasm		"HPA026322: AB_1855821, HPA026324: AB_1855822"	"unprognostic (3.54e-2)"	"unprognostic (8.53e-2)"	"unprognostic (1.63e-3)"	"unprognostic (6.93e-2)"	"unprognostic (6.41e-2)"	"unprognostic (1.37e-1)"	"prognostic unfavorable (3.49e-7)"	"unprognostic (2.81e-2)"	"unprognostic (5.23e-2)"	"unprognostic (3.34e-3)"	"unprognostic (7.87e-2)"	"unprognostic (4.45e-1)"	"prognostic unfavorable (2.80e-6)"	"unprognostic (1.65e-1)"	"unprognostic (2.83e-1)"	"unprognostic (3.77e-2)"	"unprognostic (2.93e-2)"	26.5	30.5	29.4	28.0	35.1	37.2	25.3	20.1	50.9	23.2	26.1	35.9	15.4	27.5	27.8	25.0	30.4	26.5	20.7	23.8	30.6	33.4	27.9	63.8	24.6	30.4	30.6	24.8	22.7	24.6	22.0	21.8	37.5	32.6	23.1	27.8	22.8	23.0	24.9	54.7	28.2	27.0	28.7	32.5	29.3	22.8	23.5	21.5	42.8	22.7	29.1	34.0	23.9	22.4	24.6	30.2	19.4	35.3	25.1	28.1	25.4	40.9	25.7	28.1	19.1	14.9	17.9	35.5	19.4	22.9	40.1	32.7	30.4	49.3	40.9	45.7	22.9	24.5	25.5	36.1	32.2	33.8	33.3	33.5	37.1	28.1	29.7	26.9	38.9	21.9	19.5	20.4	47.9	23.2	16.4	31.5	33.9	44.2	23.4	25.8	18.8	50.6	29.1	37.5	18.2	27.4	31.4	28.6	28.8	27.8	22.2	24.9	18.3	22.3	21.1	30.1	33.5	15.5	17.7	21.6	20.1	23.7	18.9	45.9	20.2	32.4	41.5	29.7	41.0	34.8	17.4	27.0	19.4	23.1	33.0	23.4	24.6	23.1	24.2	29.7	19.3	16.7	20.9	9.7	25.1	35.3	30.2	28.1	25.4	29.4	35.1	20.1	50.9	30.6	33.4	30.6	24.8	32.6	21.5	59.6	61.8	70.7	120.5	98.8	48.7	51.8	71.4	68.3	47.8	62.8	15.7	342.2	122.7	240.6	77.0	88.7	69.5	23.3	197.3	290.1	75.1	97.6	33.6	136.0	195.7	55.6	94.4	84.7	99.4	12.8	93.2	93.1	72.6	231.8	76.2	58.8	222.8	74.6	85.9	183.0	36.4	90.5	72.1	168.5	124.8	97.5	369.7	82.8	96.1	159.8
PSMB5	"MB1, X"	ENSG00000100804	"Proteasome subunit beta 5"	P28074	14	23016543-23035230	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction"	"Hydrolase, Protease, Threonine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA049518, HPA061796"	Approved		Supported	Nucleoplasm,Centrosome		NA	NA		8200000	"Nucleoplasm, Centrosome"		"HPA049518: AB_2680802, HPA061796: AB_2684612"	"unprognostic (3.03e-1)"	"unprognostic (1.99e-2)"	"unprognostic (8.35e-2)"	"unprognostic (6.13e-2)"	"unprognostic (1.24e-1)"	"prognostic unfavorable (2.85e-4)"	"prognostic unfavorable (2.90e-5)"	"unprognostic (2.55e-2)"	"unprognostic (9.95e-2)"	"prognostic favorable (1.08e-4)"	"unprognostic (2.06e-1)"	"unprognostic (1.19e-1)"	"unprognostic (5.30e-2)"	"unprognostic (1.75e-1)"	"unprognostic (1.95e-1)"	"unprognostic (4.95e-2)"	"prognostic unfavorable (4.73e-4)"	28.1	38.8	33.6	19.3	35.5	9.6	29.0	19.4	42.9	24.7	28.3	26.8	25.4	21.0	24.2	49.2	31.6	31.6	22.0	37.7	32.9	33.3	35.3	45.4	20.6	18.3	37.5	35.4	22.2	36.6	35.4	26.6	32.5	33.9	27.2	32.2	21.1	28.4	28.7	101.2	22.3	17.2	34.9	32.5	16.7	25.1	27.6	27.3	15.7	29.0	47.3	22.7	20.6	25.2	32.3	53.4	24.6	39.9	19.4	46.8	39.5	22.5	48.1	34.4	32.6	46.4	40.1	34.0	32.2	38.4	56.9	48.4	40.5	36.0	28.0	30.1	43.8	39.5	30.8	54.9	40.2	55.0	17.2	37.9	17.8	35.1	142.5	36.6	21.6	21.4	44.7	37.7	42.2	35.2	37.8	58.8	24.7	26.7	16.0	46.5	66.5	12.3	29.6	38.2	43.6	78.0	16.6	26.0	18.7	44.2	32.7	43.9	34.2	22.7	46.1	31.0	47.0	22.2	28.1	31.6	27.9	28.4	25.8	31.6	13.8	27.3	21.0	21.8	17.4	34.5	24.6	39.9	17.3	29.3	39.0	34.2	32.3	35.1	28.1	42.6	30.1	46.8	35.6	15.5	19.4	27.9	53.4	28.7	39.5	33.6	35.5	19.4	42.9	32.9	33.3	37.5	35.4	33.9	27.3	71.5	50.9	58.0	134.8	124.6	57.4	134.8	129.9	149.9	80.8	90.7	27.5	350.9	233.8	261.5	57.3	106.7	63.2	0.0	201.1	383.6	136.2	130.9	30.1	134.4	190.5	66.7	148.5	90.9	54.9	77.1	109.9	70.7	109.6	199.2	94.1	137.0	244.2	80.7	114.9	331.7	53.8	97.0	134.4	207.4	76.8	137.3	359.7	49.8	123.0	163.4
PSMB8	"beta5i, D6S216E, LMP7, PSMB5i, RING10"	ENSG00000204264	"Proteasome subunit beta 8"	P28062	6	32840717-32844703	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Differentiation, Host-virus interaction, Immunity"	"Hydrolase, Protease, Threonine protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 25.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"HPA046995, HPA050327"	Enhanced		Approved	"Vesicles,Cytokinetic bridge"		No	No		3300000	Vesicles	"Cytokinetic bridge"	"HPA046995: AB_2679896, HPA050327: AB_2681088"	"prognostic favorable (5.08e-4)"	"unprognostic (4.22e-2)"	"unprognostic (2.39e-2)"	"prognostic favorable (7.16e-4)"	"unprognostic (1.92e-1)"	"unprognostic (1.68e-1)"	"unprognostic (7.78e-2)"	"unprognostic (1.09e-1)"	"unprognostic (5.71e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.47e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.35e-2)"	"unprognostic (1.97e-3)"	"unprognostic (7.11e-3)"	17.0	21.9	7.9	34.8	11.7	14.0	14.9	3.6	7.5	10.0	20.8	5.1	8.8	20.1	12.5	15.3	16.6	13.2	23.8	10.6	6.6	5.7	20.9	30.0	29.0	46.3	9.9	5.1	11.3	12.7	3.6	8.2	9.7	8.8	13.5	24.4	9.2	14.6	11.2	5.1	14.7	37.3	11.5	9.0	42.8	19.4	3.9	9.0	32.2	18.7	18.7	29.0	13.9	12.5	28.9	27.4	37.6	33.2	23.3	29.9	52.2	6.4	2.0	0.1	0.0	2.7	7.1	4.4	1.5	10.2	12.5	18.1	0.0	11.4	25.1	4.8	4.1	9.8	4.5	1.4	6.1	3.4	10.3	0.0	11.1	1.3	0.4	15.0	0.2	4.2	8.0	2.8	7.0	2.4	0.4	8.4	5.4	0.3	5.3	3.1	0.0	5.8	6.1	0.0	0.0	1.6	15.6	0.8	12.4	10.2	1.8	0.1	0.1	2.2	5.4	3.4	0.0	2.4	20.5	2.5	3.7	2.0	3.5	0.2	8.9	8.4	5.6	1.3	14.5	4.7	19.4	29.0	37.4	25.5	33.2	22.1	28.9	21.7	26.4	27.4	26.3	15.1	21.6	37.6	23.3	28.6	23.3	29.9	52.2	7.9	11.7	3.6	7.5	6.6	5.7	9.9	5.1	8.8	9.0	35.7	58.8	174.3	61.0	75.0	1.6	6.1	79.0	62.9	45.5	59.3	0.0	1.7	72.9	173.5	0.5	121.7	242.4	0.0	217.6	10.1	57.2	72.3	49.7	67.1	157.1	6.4	63.1	92.1	135.9	0.6	36.2	111.9	54.0	193.0	164.1	32.8	163.9	247.6	28.7	51.6	2.7	38.8	45.7	0.2	1.2	69.5	2.3	193.7	184.0	98.2
PSMB9	"beta1i, LMP2, PSMB6i, RING12"	ENSG00000240065	"Proteasome subunit beta 9"	P28065	6	32844136-32859585	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Host-virus interaction, Immunity"	"Hydrolase, Protease, Threonine protease"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 69.1;lymphoid tissue: 54.9"	"Cell type enhanced"	"Detected in many"	6	"monocytes: 319.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 29.5;REH: 21.8"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB015180, HPA042818, HPA053280"	Enhanced		Supported	Cytosol		NA	NA		420000	Cytosol		"CAB015180: AB_2172368, HPA042818: AB_2678186, HPA053280: AB_2682098"	"unprognostic (1.09e-2)"	"unprognostic (1.68e-2)"	"unprognostic (1.26e-2)"	"unprognostic (2.18e-3)"	"unprognostic (7.84e-2)"	"unprognostic (1.89e-1)"	"unprognostic (5.68e-2)"	"unprognostic (6.67e-2)"	"unprognostic (1.56e-2)"	"unprognostic (6.50e-3)"	"unprognostic (1.87e-3)"	"unprognostic (1.84e-1)"	"prognostic unfavorable (1.33e-4)"	"unprognostic (2.65e-1)"	"unprognostic (1.09e-1)"	"unprognostic (4.96e-3)"	"unprognostic (5.99e-2)"	13.3	9.7	5.0	30.0	7.9	10.7	11.6	1.6	5.3	7.6	16.5	6.0	3.4	15.7	8.8	7.1	10.8	7.4	10.8	8.9	5.1	4.7	12.2	12.2	17.7	32.7	7.3	3.7	9.2	5.4	1.2	4.5	5.5	6.3	12.5	5.8	7.7	9.0	3.5	6.2	7.6	36.1	5.7	9.8	54.9	11.2	3.0	6.7	35.4	14.4	9.3	35.2	15.9	8.8	31.8	17.2	69.1	30.5	23.4	31.1	45.7	0.0	1.4	0.0	0.1	1.2	3.0	2.0	0.2	3.3	4.2	9.9	0.0	9.2	29.5	0.4	2.7	10.8	6.0	0.4	6.3	0.6	16.6	0.0	18.0	0.5	1.1	15.9	3.1	1.3	1.4	0.2	2.7	0.4	2.3	1.5	8.5	0.7	5.5	1.4	0.5	13.6	4.2	0.0	0.0	0.9	21.8	0.0	7.0	2.8	0.5	0.0	0.0	2.7	1.8	2.0	0.0	2.4	6.6	1.5	4.6	0.4	8.6	2.6	10.2	15.5	9.4	4.7	11.9	3.8	21.9	22.4	39.3	28.7	30.5	23.8	31.8	23.3	27.5	17.2	23.4	17.5	22.9	69.1	23.4	29.4	12.7	31.1	45.7	5.0	7.9	1.6	5.3	5.1	4.7	7.3	3.7	6.3	6.7	38.7	64.6	199.7	29.6	64.5	1.9	5.3	73.9	30.8	34.2	24.4	0.0	0.9	16.6	87.6	1.0	123.4	127.8	46.7	101.9	4.2	38.3	33.2	76.1	23.2	118.3	0.0	32.1	108.1	113.4	0.7	27.0	117.7	33.7	319.2	103.0	19.5	69.2	118.1	14.9	33.5	1.1	32.3	41.0	1.4	6.5	51.3	1.1	214.2	55.9	33.0
PTAFR		ENSG00000169403	"Platelet activating factor receptor"	P25105	1	28147166-28193936	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	Chemotaxis	"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"blood: 98.3"	"Group enriched"	"Detected in many"	7	"granulocytes: 73.9;Hofbauer cells: 62.8;Kupffer cells: 70.6;Macrophages: 55.7;Pancreatic endocrine cells: 55.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"classical monocyte: 28.2;eosinophil: 98.3;neutrophil: 85.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 98.3;monocytes: 28.2"	"Group enriched"	"Detected in some"	4	"HBEC3-KT: 14.7;HMC-1: 53.6"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA027543	Approved		Uncertain	"Nucleoplasm,Vesicles,Plasma membrane"		NA	NA			"Nucleoplasm, Vesicles"	"Plasma membrane"	"HPA027543: AB_10610287"	"unprognostic (2.22e-2)"	"unprognostic (2.59e-2)"	"unprognostic (6.73e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.75e-1)"	"unprognostic (3.74e-2)"	"unprognostic (1.07e-1)"	"unprognostic (1.72e-1)"	"unprognostic (3.35e-1)"	"unprognostic (1.23e-1)"	"unprognostic (2.39e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.79e-2)"	"unprognostic (3.52e-1)"	"unprognostic (2.59e-2)"	"unprognostic (5.48e-2)"	"unprognostic (1.38e-2)"	5.6	2.3	2.4	16.2	1.9	20.3	2.4	0.6	2.0	6.9	3.4	1.6	3.5	1.8	2.8	1.4	16.8	2.8	7.5	3.5	2.1	2.3	6.4	1.8	9.2	6.1	4.1	1.0	1.5	2.7	0.9	0.7	3.5	1.8	2.6	3.4	0.6	3.4	2.6	1.1	2.8	5.0	3.8	5.1	15.4	2.3	2.2	1.1	2.3	1.4	22.2	21.7	5.9	3.6	1.5	13.2	98.3	28.2	0.0	0.1	10.1	7.7	0.1	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.3	0.1	0.1	2.2	0.5	0.0	0.0	0.1	5.3	0.2	14.7	0.3	0.1	0.2	2.9	0.0	0.3	0.0	0.7	53.6	0.0	2.4	0.2	0.1	0.0	0.0	0.0	0.2	0.2	0.0	0.5	0.0	7.2	0.2	0.2	0.1	0.1	0.0	0.0	3.6	0.8	0.1	0.0	0.0	7.3	0.0	0.2	0.1	2.0	0.0	0.1	0.3	0.0	0.0	0.5	0.4	2.1	0.0	0.9	0.2	5.9	28.2	98.3	0.0	8.9	0.1	1.5	0.0	0.0	13.2	0.7	0.0	0.0	85.7	0.0	3.5	0.1	0.1	10.1	2.4	1.9	0.6	2.0	2.1	2.3	4.1	1.0	1.8	1.1	6.0	7.9	4.3	1.5	5.8	1.2	2.0	2.5	6.7	2.3	1.8	2.0	0.5	0.0	8.8	0.0	5.9	0.2	0.0	4.6	0.4	2.2	0.4	73.9	0.8	62.8	0.0	0.0	1.8	70.6	0.0	0.6	55.7	0.0	4.6	0.0	0.2	55.1	0.0	0.0	0.0	0.8	0.0	0.9	2.1	0.5	2.5	1.3	1.0	0.0	8.6
PTGER1	EP1	ENSG00000160951	"Prostaglandin E receptor 1"	P34995	19	14472466-14475362	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enhanced"	"Detected in many"		"kidney: 13.6;lymphoid tissue: 14.2"	"Cell type enriched"	"Detected in some"	75	"Collecting duct cells: 188.5"	"Cancer enhanced"	"Detected in many"		"ovarian cancer: 4.1"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 1.5;NK-cell: 2.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"HEL: 5.4;NB-4: 2.9;PC-3: 7.2;SH-SY5Y: 4.2"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"									NA	NA						"unprognostic (3.44e-2)"	"unprognostic (3.31e-1)"	"unprognostic (2.68e-1)"	"unprognostic (3.50e-4)"	"unprognostic (8.69e-2)"	"unprognostic (5.58e-2)"	"unprognostic (2.39e-2)"	"unprognostic (3.19e-2)"	"unprognostic (2.05e-1)"	"unprognostic (3.53e-2)"	"unprognostic (1.41e-1)"	"unprognostic (1.42e-1)"	"unprognostic (7.74e-8)"	"unprognostic (1.19e-1)"	"unprognostic (4.41e-2)"	"unprognostic (4.27e-3)"	"unprognostic (4.88e-2)"	0.7	1.4	1.1	2.7	1.3	0.2	1.5	0.6	1.2	1.3	1.5	0.1	0.0	1.2	0.4	0.3	1.7	1.0	0.4	3.1	0.4	0.4	13.6	0.5	4.9	6.7	1.8	0.0	1.6	1.8	0.2	1.4	0.3	1.0	0.5	0.3	0.3	0.3	0.4	0.7	0.2	1.9	1.4	0.1	14.2	3.2	0.4	0.6	0.0	0.7	0.0	0.3	0.6	1.3	0.0	0.4	0.0	1.5	2.6	1.1	0.2	0.2	0.1	0.0	0.0	0.0	0.0	0.3	1.4	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.3	5.4	0.0	0.3	0.6	0.0	0.1	0.1	0.0	0.2	0.0	0.1	0.0	0.2	0.6	0.0	0.0	0.0	0.0	2.9	0.3	0.0	7.2	0.8	0.0	0.2	0.0	0.1	0.5	4.2	0.1	0.1	0.2	0.0	0.2	0.4	1.3	0.1	0.1	0.2	0.1	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	1.5	0.0	0.0	0.0	1.1	0.4	0.0	0.0	0.0	0.0	2.6	0.5	0.0	0.0	0.2	1.1	1.3	0.6	1.2	0.4	0.4	1.8	0.0	1.0	0.6	0.0	0.0	0.0	0.2	0.0	0.4	0.8	2.5	0.0	0.0	188.5	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.2	0.8	0.0	0.5	0.3	0.0	0.0	0.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.0	0.3	0.0	0.0	0.6	0.2	0.7	0.0	0.0	0.0	0.0	0.2
PTGER2	EP2	ENSG00000125384	"Prostaglandin E receptor 2"	P43116	14	52314305-52328606	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 40.3"	"Cell type enhanced"	"Detected in many"	18	"granulocytes: 19.7;Kupffer cells: 20.5;T-cells: 80.9"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"ASC diff: 12.5;ASC TERT1: 33.6;HHSteC: 21.3;HL-60: 12.0;HSkMC: 26.9"	"Low region specificity"	"Detected in some"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.48e-1)"	"unprognostic (2.48e-2)"	"unprognostic (1.36e-2)"	"unprognostic (4.04e-3)"	"unprognostic (1.55e-2)"	"unprognostic (3.24e-1)"	"unprognostic (3.11e-3)"	"unprognostic (1.79e-1)"	"unprognostic (2.42e-1)"	"unprognostic (1.20e-3)"	"unprognostic (1.18e-1)"	"unprognostic (1.83e-1)"	"prognostic unfavorable (4.16e-4)"	"unprognostic (8.48e-3)"	"unprognostic (5.26e-3)"	"unprognostic (6.71e-2)"	"unprognostic (5.74e-2)"	8.2	1.2	0.4	9.4	0.5	21.8	9.3	0.4	0.5	22.1	8.7	0.6	2.9	4.0	13.6	5.5	5.4	4.5	6.5	4.8	0.4	0.6	5.5	2.8	8.8	15.9	1.1	0.3	8.2	1.1	0.0	1.4	14.1	1.8	19.4	4.3	10.9	4.1	2.6	1.8	1.6	14.9	3.2	1.1	20.4	11.8	4.1	0.3	4.4	2.2	1.1	3.0	6.0	6.0	0.0	5.6	9.8	17.1	19.7	40.3	17.4	0.7	0.2	0.0	0.0	12.5	33.6	0.1	1.0	0.1	1.1	1.3	0.0	0.0	0.0	0.9	0.7	0.0	4.5	0.0	0.2	1.6	0.0	6.0	0.0	0.3	0.0	21.3	12.0	0.1	26.9	0.5	2.7	0.4	3.6	0.0	0.0	0.0	0.0	6.3	0.5	0.0	0.4	0.5	2.0	4.1	0.0	0.0	0.0	9.6	0.0	0.4	10.5	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.4	0.7	7.7	0.0	0.0	0.0	0.0	2.8	6.7	0.1	1.8	11.2	9.8	33.8	8.9	40.3	0.0	28.7	35.2	5.6	0.0	7.2	21.8	1.5	19.7	17.1	0.2	13.4	17.4	0.4	0.5	0.4	0.5	0.4	0.6	1.1	0.3	1.8	0.3	3.0	1.7	0.9	0.2	1.5	0.0	1.5	0.0	8.1	0.0	3.5	0.0	0.0	0.0	0.2	0.0	0.5	0.0	0.0	0.0	0.2	16.9	0.8	19.7	0.4	10.4	0.0	5.8	4.3	20.5	0.0	3.7	15.1	3.3	4.6	4.9	0.0	0.9	0.0	2.8	0.0	0.0	0.0	5.2	0.0	0.1	1.4	0.2	80.9	0.4	0.1
PTGER3	EP3	ENSG00000050628	"Prostaglandin E receptor 3"	P43115	1	70852353-71047808	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"breast: 71.2;endometrium 1: 65.2"	"Cell type enriched"	"Detected in many"	10	"Distal tubular cells: 190.6"	"Group enriched"	"Detected in some"	7	"breast cancer: 4.1;renal cancer: 9.4"	"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	49	"basophil: 22.4"	"Lineage enriched"	"Detected in single"	49	"granulocytes: 22.4"	"Cell line enhanced"	"Detected in some"		"ASC diff: 15.2;HAP1: 10.8;HDLM-2: 16.3;HEL: 7.8;T-47d: 37.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010689	Uncertain					NA	NA					"HPA010689: AB_1855883"	"unprognostic (1.53e-3)"	"unprognostic (3.48e-1)"	"unprognostic (1.11e-1)"	"unprognostic (3.86e-3)"	"unprognostic (1.47e-1)"	"unprognostic (3.37e-2)"	"unprognostic (4.80e-2)"	"unprognostic (2.01e-2)"	"unprognostic (1.24e-1)"	"unprognostic (4.64e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.97e-1)"	"prognostic unfavorable (3.50e-4)"	"unprognostic (8.83e-3)"	"unprognostic (1.86e-1)"	"unprognostic (1.92e-2)"	"unprognostic (1.41e-4)"	32.5	3.0	3.9	6.8	0.7	0.0	71.2	0.2	1.7	7.8	6.3	0.1	3.0	0.5	65.2	16.6	1.7	4.8	11.3	2.6	0.6	2.0	41.5	0.3	0.6	2.2	0.4	1.4	2.4	10.7	0.0	0.4	0.5	1.6	3.3	1.0	0.1	15.5	3.7	0.5	6.2	1.8	31.9	0.5	0.3	9.1	4.0	0.0	0.0	0.7	3.2	0.7	4.4	5.7	0.0	0.4	22.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	15.2	0.3	0.0	0.3	0.0	0.0	0.4	0.0	0.0	0.0	0.0	1.7	0.0	0.0	10.8	0.0	0.0	16.3	0.0	7.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	2.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.5	0.0	0.1	0.0	0.1	37.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.6	0.0	22.4	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.9	0.7	0.2	1.7	0.6	2.0	0.4	1.4	1.6	0.0	0.0	0.3	0.0	0.2	4.4	1.1	0.8	0.0	0.0	0.0	19.2	0.0	0.0	190.6	2.3	0.8	0.9	0.0	0.0	0.0	2.2	2.0	1.5	9.2	0.0	0.1	3.2	2.4	1.3	0.0	0.4	1.1	2.8	8.5	1.0	0.0	0.2	0.0	0.0	0.0	3.3	0.0	6.5	5.1	0.1	0.0	6.6	0.1	0.0	0.0	0.1
PTGER4	EP4	ENSG00000171522	"Prostaglandin E receptor 4"	P35408	5	40679498-40693735	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"pancreas: 57.2"	"Cell type enhanced"	"Detected in many"	6	"Basal keratinocytes: 54.4;Macrophages: 56.4;monocytes: 52.3;T-cells: 69.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HDLM-2: 19.1;HUVEC TERT2: 13.5;LHCN-M2: 13.2;RT4: 19.2;THP-1: 12.8;TIME: 24.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"HPA011226, HPA012756"	Approved					NA	NA					"HPA011226: AB_1855885, HPA012756: AB_1855884"	"unprognostic (1.79e-2)"	"unprognostic (6.53e-3)"	"unprognostic (9.43e-3)"	"unprognostic (6.77e-3)"	"unprognostic (1.44e-1)"	"unprognostic (7.16e-2)"	"unprognostic (7.28e-3)"	"unprognostic (1.86e-2)"	"unprognostic (2.19e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.02e-1)"	"unprognostic (2.76e-1)"	"unprognostic (3.61e-2)"	"unprognostic (2.17e-1)"	"unprognostic (2.48e-2)"	"unprognostic (1.44e-1)"	"prognostic favorable (2.48e-4)"	10.3	5.1	1.4	12.8	1.2	34.7	6.9	0.4	0.8	8.5	24.8	1.7	1.1	9.4	4.8	2.8	6.0	6.1	14.5	9.0	1.1	1.3	8.4	3.7	16.5	16.6	2.2	0.1	4.3	57.2	0.3	1.6	2.3	2.1	7.0	7.9	4.1	3.6	1.0	7.4	4.0	28.7	6.6	4.5	18.2	8.9	2.1	1.2	23.3	3.3	5.7	9.5	11.6	6.2	1.3	5.4	9.3	15.6	2.5	11.4	4.1	1.6	0.3	0.0	0.0	8.2	9.8	0.0	0.1	0.6	0.5	0.3	0.0	0.5	0.2	0.1	0.0	8.6	1.2	0.1	3.0	0.8	19.1	0.4	0.0	0.6	0.0	7.5	7.0	1.4	1.0	0.5	4.9	2.0	1.1	13.5	6.8	0.0	4.6	13.2	0.0	7.0	3.2	0.0	0.3	2.9	4.8	1.3	0.6	1.8	19.2	0.0	0.0	0.3	0.6	0.0	0.3	3.0	12.8	24.3	2.6	0.0	0.0	0.6	0.0	0.1	0.9	1.1	5.3	0.6	3.5	4.5	9.3	11.4	12.8	6.6	1.3	6.9	7.1	5.4	1.3	4.2	6.1	8.7	2.5	15.6	0.8	5.5	4.1	1.4	1.2	0.4	0.8	1.1	1.3	2.2	0.1	2.1	1.2	11.9	13.6	11.5	5.6	54.4	0.0	3.6	0.0	8.1	7.9	7.0	0.0	0.2	0.0	0.9	2.4	8.6	18.8	0.0	6.7	0.6	8.2	9.2	9.3	0.2	30.8	0.0	12.5	3.7	32.1	1.1	0.9	56.4	18.6	52.3	35.0	0.0	2.8	23.2	0.4	0.0	0.2	0.0	10.6	3.6	1.3	26.6	0.2	69.2	16.6	0.8
PTGFR	FP	ENSG00000122420	"Prostaglandin F receptor"	P43088	1	78303884-78539749	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 2: 10.1;Club cells: 23.9;Fibroblasts: 9.3"	"Low cancer specificity"	"Detected in many"			"Region enhanced"	"Detected in many"		"hippocampal formation: 10.1"	"Cell type enriched"	"Detected in single"	13	"classical monocyte: 1.3"	"Lineage enriched"	"Detected in single"	13	"monocytes: 1.3"	"Group enriched"	"Detected in some"	7	"ASC TERT1: 79.7;HSkMC: 24.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (4.14e-2)"	"unprognostic (1.35e-2)"	"unprognostic (5.89e-3)"	"unprognostic (6.03e-2)"	"unprognostic (5.63e-2)"	"unprognostic (1.45e-3)"	"unprognostic (7.61e-2)"	"unprognostic (2.25e-1)"	"unprognostic (9.90e-2)"	"unprognostic (8.46e-4)"	"unprognostic (2.21e-1)"	"unprognostic (5.34e-2)"	"unprognostic (2.16e-4)"	"unprognostic (3.21e-4)"	"unprognostic (8.48e-2)"	"unprognostic (2.16e-2)"	"unprognostic (1.21e-3)"	13.0	4.1	1.1	5.2	1.8	0.0	8.7	0.3	1.0	8.3	3.8	0.3	2.1	0.9	27.2	7.0	6.1	5.3	8.8	7.7	10.1	3.3	5.6	3.6	2.3	1.1	0.5	0.3	14.5	1.5	0.0	0.5	7.7	0.6	12.9	2.7	1.8	6.5	2.1	6.9	7.3	3.0	21.3	0.7	0.8	2.7	4.0	0.0	0.0	2.1	13.4	4.3	20.3	15.9	0.0	0.0	0.0	1.3	0.0	0.0	0.1	0.0	0.0	0.2	0.0	7.6	79.7	0.0	5.7	5.5	2.0	0.7	0.0	0.0	0.0	0.0	3.4	1.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.4	0.0	0.0	24.9	0.0	0.5	5.0	5.2	0.0	0.0	0.0	0.2	3.0	0.0	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.6	2.4	1.4	0.6	0.4	0.3	0.0	0.0	0.1	0.0	0.6	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.1	1.8	0.3	1.0	10.1	3.3	0.5	0.3	0.6	0.0	0.0	10.1	0.0	0.0	5.7	0.8	0.4	5.1	6.7	23.9	8.7	0.0	0.0	3.3	3.3	5.7	0.0	0.0	0.0	0.0	0.0	9.3	0.0	0.0	1.6	0.1	0.0	0.0	0.0	0.0	5.1	5.2	0.2	5.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	6.5	1.0	0.6	0.0	4.1	0.2	0.0	0.0	0.0
PTGIR	IP	ENSG00000160013	"Prostaglandin I2 receptor"	P43119	19	46620468-46625118	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 27.7;lung: 35.1"	"Cell type enriched"	"Detected in many"	4	"monocytes: 249.7"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in many"	10	"classical monocyte: 12.6;intermediate monocyte: 27.7;myeloid DC: 9.1;non-classical monocyte: 15.5"	"Group enriched"	"Detected in many"	12	"dendritic cells: 9.1;monocytes: 27.7"	"Cell line enhanced"	"Detected in some"		"BJ: 8.5;BJ hTERT+: 9.7;fHDF/TERT166: 12.0;HDLM-2: 5.9;HEL: 22.0;HHSteC: 5.9"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (3.79e-1)"	"unprognostic (1.95e-1)"	"unprognostic (2.94e-2)"	"unprognostic (2.39e-1)"	"unprognostic (1.03e-1)"	"unprognostic (3.49e-3)"	"unprognostic (4.22e-2)"	"unprognostic (6.09e-2)"	"unprognostic (2.12e-1)"	"unprognostic (7.45e-2)"	"unprognostic (4.47e-1)"	"unprognostic (1.14e-1)"	"prognostic unfavorable (2.09e-8)"	"unprognostic (1.66e-2)"	"prognostic unfavorable (1.74e-4)"	"unprognostic (1.16e-1)"	"unprognostic (5.66e-2)"	7.8	6.3	0.4	8.0	0.6	3.8	3.0	0.1	0.6	6.5	6.0	1.2	1.4	2.7	5.0	2.7	4.5	2.7	6.4	16.0	0.6	0.3	9.0	9.6	35.1	6.5	0.8	0.7	6.9	3.5	0.1	1.2	6.3	1.1	3.2	1.4	3.3	2.5	1.3	12.2	3.0	3.7	4.1	0.5	11.3	4.5	1.6	0.8	3.5	14.5	3.4	4.3	10.2	6.5	0.5	9.1	0.5	27.7	0.0	1.5	7.2	0.0	0.0	0.0	0.0	0.1	4.6	0.0	8.5	9.7	1.2	3.5	0.0	0.0	0.0	0.7	12.0	0.1	0.0	0.0	0.0	0.7	5.9	0.0	22.0	0.0	0.0	5.9	0.0	0.0	1.4	0.0	3.1	0.2	0.0	2.5	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.7	0.0	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.4	1.0	1.4	0.2	0.2	0.0	0.0	0.0	0.0	0.3	0.6	0.5	0.0	12.6	0.0	0.0	27.7	0.2	0.5	0.1	0.0	9.1	0.3	1.5	0.0	0.5	0.0	15.5	0.8	1.4	7.2	0.4	0.6	0.1	0.6	0.6	0.3	0.8	0.7	1.1	0.8	0.0	1.1	4.5	0.9	3.8	0.5	0.8	0.0	1.4	0.0	1.8	0.0	0.1	0.0	0.1	0.1	2.6	0.0	0.0	0.3	0.1	8.9	0.8	3.5	0.0	2.6	0.0	0.0	5.5	6.0	0.0	2.0	14.1	6.8	249.7	0.0	0.0	0.5	0.0	0.0	0.0	0.6	6.5	58.0	0.1	0.4	3.9	0.2	0.9	0.0	0.3
PTGIS	"CYP8A1, PGIS"	ENSG00000124212	"Prostaglandin I2 synthase"	Q16647	20	49503874-49568146	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Isomerase, Lyase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 88.2"	"Group enriched"	"Detected in many"	8	"Ito cells: 78.5;Leydig cells: 24.7;Peritubular cells: 98.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	4	"ASC diff: 17.8;ASC TERT1: 17.9;U-2197: 55.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB009517, HPA014193, HPA052244"	Enhanced		Approved	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB009517: AB_2173209, HPA014193: AB_1855746, HPA052244: AB_2732574"	"unprognostic (7.68e-2)"	"unprognostic (1.90e-1)"	"unprognostic (5.09e-3)"	"unprognostic (1.38e-2)"	"unprognostic (1.80e-2)"	"unprognostic (1.74e-1)"	"unprognostic (1.21e-2)"	"unprognostic (1.29e-2)"	"unprognostic (1.25e-1)"	"unprognostic (4.02e-2)"	"unprognostic (2.45e-2)"	"unprognostic (5.22e-2)"	"prognostic unfavorable (4.74e-8)"	"unprognostic (2.29e-2)"	"unprognostic (7.61e-2)"	"unprognostic (4.89e-3)"	"prognostic unfavorable (9.99e-5)"	18.2	2.5	0.6	8.0	1.3	0.1	28.3	0.2	1.6	23.3	14.6	0.5	6.5	1.7	36.5	21.7	13.2	32.0	36.3	23.8	0.3	0.5	3.0	3.8	7.5	1.6	0.5	0.9	51.2	1.3	0.2	0.5	1.0	1.0	27.2	3.7	3.2	3.7	4.6	7.0	3.2	4.4	88.2	1.4	0.3	8.7	16.2	0.3	0.0	6.7	5.6	1.7	64.2	36.1	1.0	0.8	2.7	0.6	0.8	0.5	0.1	0.0	0.0	0.7	0.0	17.8	17.9	0.2	0.3	2.1	0.0	0.0	0.0	0.0	0.0	7.1	5.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	1.3	0.0	0.2	0.0	5.8	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.3	0.9	55.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.5	0.6	0.4	0.4	0.4	0.3	0.4	0.3	0.3	0.1	1.0	0.4	0.5	2.7	0.8	0.3	0.8	0.2	0.1	0.6	1.3	0.2	1.6	0.3	0.5	0.5	0.9	1.0	0.3	3.0	2.4	0.0	0.6	3.3	0.8	3.4	0.0	4.0	3.4	3.5	0.0	0.3	0.0	0.4	1.7	3.8	0.0	0.0	0.0	0.1	8.3	0.3	0.0	0.6	0.3	0.0	0.0	78.5	1.5	2.2	24.7	0.7	1.7	0.0	0.0	0.3	0.7	0.0	98.6	0.0	4.6	0.0	2.5	0.7	1.1	4.3	0.2	0.5	0.0	0.6
PTGS1	"COX1, PGHS-1, PTGHS"	ENSG00000095303	"Prostaglandin-endoperoxide synthase 1"	P23219	9	122370530-122395703	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Dioxygenase, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"smooth muscle: 211.4;urinary bladder: 163.9"	"Cell type enriched"	"Detected in many"	4	"granulocytes: 205.3"	"Cancer enhanced"	"Detected in all"		"ovarian cancer: 53.4"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"dendritic cells: 13.0;granulocytes: 14.4;monocytes: 8.5"	"Cell line enhanced"	"Detected in some"		"ASC diff: 28.8;ASC TERT1: 22.8;BJ: 27.9;BJ hTERT+: 38.1;HEL: 17.5;HMC-1: 74.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002834, CAB020315"	Enhanced		Supported	"Golgi apparatus,Vesicles"	"Intracellular and membrane"	NA	NA		25000000	"Golgi apparatus"	Vesicles	"CAB020315: , HPA002834: AB_1079711"	"unprognostic (4.20e-1)"	"unprognostic (6.23e-2)"	"unprognostic (1.08e-2)"	"unprognostic (2.27e-2)"	"unprognostic (5.88e-2)"	"unprognostic (2.00e-2)"	"unprognostic (1.22e-3)"	"unprognostic (3.32e-1)"	"unprognostic (2.24e-1)"	"unprognostic (3.16e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.46e-1)"	"prognostic unfavorable (8.68e-4)"	"unprognostic (4.03e-2)"	"unprognostic (1.78e-2)"	"unprognostic (2.08e-1)"	"prognostic unfavorable (9.35e-4)"	4.5	1.1	1.8	9.1	3.1	2.6	2.5	0.5	2.7	2.6	35.3	4.6	3.0	3.9	2.5	1.6	25.7	16.7	9.4	4.9	1.9	1.6	3.9	1.8	4.0	1.4	3.5	0.7	3.6	1.0	0.7	2.4	0.8	2.5	60.9	9.3	1.5	1.9	2.3	0.7	55.9	6.5	211.4	4.9	3.6	7.8	1.0	3.1	0.4	1.5	5.3	4.2	163.9	19.5	2.5	13.0	14.4	8.5	1.9	0.1	13.7	0.0	0.1	0.1	0.0	28.8	22.8	0.0	27.9	38.1	0.2	0.2	0.0	0.0	1.0	1.3	4.7	0.0	1.7	0.1	2.5	0.2	0.0	0.0	17.5	0.1	0.0	8.3	1.2	74.3	11.6	0.3	1.4	0.0	0.0	10.3	0.0	0.0	0.0	0.5	0.0	0.0	1.5	0.4	0.0	0.1	0.0	0.3	2.0	3.6	0.0	0.1	0.1	0.1	2.3	0.0	0.1	0.0	2.0	0.2	0.1	0.1	0.4	0.0	0.0	0.0	0.0	0.1	7.6	0.0	12.0	7.6	14.4	0.0	8.5	0.0	1.7	0.0	0.0	13.0	2.5	0.0	0.0	3.5	1.9	6.1	0.9	0.1	13.7	1.8	3.1	0.5	2.7	1.9	1.6	3.5	0.7	2.5	3.1	0.0	10.0	0.9	2.4	8.9	0.0	1.1	0.0	1.4	2.3	40.1	0.0	0.1	0.0	0.5	0.0	6.0	0.0	0.0	0.4	0.2	4.7	1.9	205.3	0.0	25.3	0.0	1.7	36.8	10.7	0.0	1.4	22.9	3.3	4.6	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	51.3	0.3	0.7	0.5	0.6
PTGS2	COX2	ENSG00000073756	"Prostaglandin-endoperoxide synthase 2"	P35354	1	186671791-186680427	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Dioxygenase, Oxidoreductase, Peroxidase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	11	"ductus deferens: 324.6;seminal vesicle: 377.9"	"Cell type enhanced"	"Detected in many"	11	"Alveolar cells type 1: 318.6;Glandular cells: 122.9;granulocytes: 329.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	16	"neutrophil: 12.8"	"Lineage enriched"	"Detected in single"	16	"granulocytes: 12.8"	"Cell line enriched"	"Detected in some"	4	"BJ hTERT+: 95.4"	"Region enhanced"	"Detected in many"		"hippocampal formation: 16.5"	"Low region specificity"	"Detected in all"			"CAB000113, HPA001335"	Enhanced		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA			"Endoplasmic reticulum"		"CAB000113: , HPA001335: AB_1079712"	"unprognostic (1.36e-3)"	"unprognostic (9.97e-3)"	"unprognostic (3.97e-2)"	"unprognostic (3.31e-2)"	"unprognostic (1.55e-1)"	"unprognostic (1.11e-1)"	"unprognostic (5.96e-2)"	"unprognostic (9.50e-2)"	"unprognostic (9.03e-3)"	"unprognostic (2.81e-1)"	"unprognostic (3.24e-2)"	"unprognostic (3.07e-2)"	"prognostic unfavorable (9.79e-4)"	"unprognostic (8.04e-3)"	"unprognostic (4.38e-2)"	"unprognostic (8.89e-2)"	"unprognostic (3.74e-2)"	5.7	2.1	1.2	3.7	1.1	32.6	1.5	0.8	1.9	21.1	11.4	1.1	324.6	0.4	2.3	1.8	1.7	4.0	9.5	9.1	1.1	1.0	3.3	2.7	22.1	2.3	1.3	0.8	1.6	0.4	3.1	2.2	2.5	1.9	9.2	2.7	3.9	0.9	377.9	1.0	1.1	2.4	7.7	4.7	0.9	11.4	1.0	0.9	0.6	1.5	3.4	1.3	17.3	1.9	0.0	0.5	12.8	0.8	0.0	0.0	0.0	0.0	5.0	0.0	0.0	0.6	0.5	0.0	21.8	95.4	0.1	0.8	3.4	4.0	0.0	0.0	0.1	0.6	2.9	0.0	1.7	0.3	0.0	0.0	0.2	0.5	0.0	3.2	0.0	0.1	0.2	0.6	2.7	6.9	0.2	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	1.2	0.3	0.0	0.2	0.0	0.2	0.6	0.0	0.1	0.3	4.6	0.1	3.2	0.1	0.0	0.0	0.0	6.7	0.1	0.5	0.0	0.4	0.3	0.0	0.8	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	12.8	0.0	0.4	0.0	0.0	0.0	1.2	1.1	0.8	1.9	1.1	1.0	1.3	0.8	1.9	0.9	318.6	102.3	0.5	47.5	105.6	0.0	1.9	0.0	8.1	53.4	0.0	0.0	0.1	0.0	0.8	0.2	14.3	0.0	0.0	0.2	0.2	36.1	122.9	329.1	0.0	11.5	0.0	1.2	6.7	16.5	0.0	0.0	112.3	33.7	0.0	0.5	0.0	3.2	0.0	0.0	0.0	0.2	0.0	21.7	0.1	0.4	24.8	0.5	0.0	1.3	107.5
PTH1R	"PTHR, PTHR1"	ENSG00000160801	"Parathyroid hormone 1 receptor"	Q03431	3	46877746-46903799	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, Dwarfism, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"kidney: 90.4"	"Cell type enhanced"	"Detected in many"	20	"Distal tubular cells: 81.2;Proximal tubular cells: 259.5;Sertoli cells: 135.8"	"Cancer enhanced"	"Detected in many"		"renal cancer: 18.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"RPTEC TERT1: 51.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA075879	Enhanced					NA	NA					"HPA075879: "	"unprognostic (1.26e-1)"	"unprognostic (7.09e-2)"	"unprognostic (2.24e-5)"	"unprognostic (7.46e-2)"	"unprognostic (3.46e-1)"	"unprognostic (5.02e-2)"	"unprognostic (3.84e-3)"	"unprognostic (5.47e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.13e-2)"	"unprognostic (7.51e-2)"	"unprognostic (8.44e-2)"	"prognostic favorable (6.79e-6)"	"unprognostic (4.22e-3)"	"unprognostic (1.50e-1)"	"unprognostic (1.35e-4)"	"unprognostic (6.62e-3)"	8.5	17.9	4.2	1.4	5.9	0.8	5.0	3.7	5.0	6.2	2.3	5.2	1.1	1.5	4.5	2.5	2.3	3.8	2.8	4.3	5.5	3.9	90.4	13.4	4.1	6.9	6.0	5.0	5.4	1.6	1.0	0.9	10.1	4.7	3.2	1.2	3.4	1.5	3.0	4.0	2.6	1.8	4.6	4.1	9.6	1.5	2.2	5.7	0.0	1.2	0.6	1.0	2.8	5.5	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	7.2	0.8	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.7	0.0	0.1	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	7.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.1	0.9	0.0	0.0	0.0	2.3	0.0	51.7	0.0	0.0	0.3	0.0	0.0	0.0	2.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	4.2	5.9	3.7	5.0	5.5	3.9	6.0	5.0	4.7	5.7	0.0	0.0	0.5	0.0	1.1	0.7	2.2	0.0	0.0	0.0	31.4	0.0	0.5	81.2	0.0	8.7	1.5	0.0	0.0	0.5	48.7	10.8	0.0	0.0	0.4	1.8	1.6	0.0	22.1	1.5	22.5	5.5	0.0	0.0	0.0	0.0	3.0	0.2	0.0	2.1	259.5	0.6	135.8	3.1	0.7	1.3	0.6	0.7	0.0	0.0	0.1
PTH2R	PTHR2	ENSG00000144407	"Parathyroid hormone 2 receptor"	P49190	2	208359714-208854503	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"bone marrow: 8.6;brain: 8.9;salivary gland: 8.2"	"Cell type enhanced"	"Detected in some"	18	"Cone photoreceptor cells: 11.8;Distal tubular cells: 6.6;Proximal tubular cells: 12.3;Rod photoreceptor cells: 23.9"	"Cancer enhanced"	"Detected in many"		"renal cancer: 6.5"	"Low region specificity"	"Detected in many"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"EFO-21: 11.7;HEL: 16.6;HL-60: 4.1;SH-SY5Y: 6.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA010655	Approved					NA	NA					"HPA010655: AB_2668333"	"unprognostic (4.76e-3)"	"unprognostic (1.39e-3)"	"unprognostic (1.64e-1)"	"unprognostic (5.78e-2)"	"unprognostic (3.77e-1)"	"unprognostic (8.28e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.11e-1)"	"unprognostic (2.87e-1)"	"unprognostic (3.45e-2)"	"unprognostic (2.14e-2)"	"unprognostic (1.70e-1)"	"unprognostic (1.09e-3)"	"unprognostic (2.54e-3)"	"unprognostic (6.87e-2)"	"unprognostic (1.30e-2)"	"unprognostic (1.37e-2)"	2.5	0.9	6.0	0.6	3.5	8.6	2.1	0.2	8.6	0.2	0.2	0.0	0.0	0.0	1.6	4.9	0.2	0.2	0.2	0.2	8.9	4.3	0.5	1.4	0.3	0.3	0.5	4.3	0.1	1.4	0.0	1.0	2.7	0.1	1.2	0.1	0.0	8.2	1.4	0.1	0.3	0.2	1.2	0.4	0.4	0.1	1.7	0.0	0.0	0.2	0.1	0.2	0.2	0.2	1.4	0.6	0.9	1.3	0.0	0.8	0.4	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	11.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	16.6	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	6.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.6	0.7	1.3	0.8	1.4	0.0	0.0	0.0	1.0	0.4	0.0	0.9	0.0	0.9	0.6	0.0	0.4	6.0	3.5	0.2	8.6	8.9	4.3	0.5	4.3	0.1	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.2	0.0	0.0	0.0	5.2	11.8	0.5	6.6	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	0.0	1.7	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	12.3	23.9	0.0	0.0	0.7	0.1	0.0	0.1	0.0	0.0	0.0
PTK2B	"CADTK, CAKB, FAK2, PTK, PYK2, RAFTK"	ENSG00000120899	"Protein tyrosine kinase 2 beta"	Q14289	8	27311482-27459391	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Adaptive immunity, Angiogenesis, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"bone marrow: 46.7;brain: 65.2"	"Cell type enhanced"	"Detected in many"	5	"Kupffer cells: 73.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"Daudi: 37.7;REH: 41.9"	"Group enriched"	"Detected in many"	4	"amygdala: 202.9;basal ganglia: 236.9;cerebral cortex: 189.7;hippocampal formation: 443.3;olfactory region: 185.5"	"Low region specificity"	"Detected in all"			"CAB003850, HPA026091, HPA026276"	Approved		Supported	"Plasma membrane,Cytosol"		NA	NA		84000	"Plasma membrane, Cytosol"		"CAB003850: AB_562205, HPA026091: AB_10599739, HPA026276: AB_10601234"	"unprognostic (2.36e-2)"	"prognostic favorable (3.32e-4)"	"unprognostic (1.06e-1)"	"unprognostic (7.36e-3)"	"unprognostic (3.72e-2)"	"unprognostic (3.11e-2)"	"unprognostic (2.70e-2)"	"unprognostic (2.13e-2)"	"unprognostic (3.23e-1)"	"unprognostic (1.45e-1)"	"unprognostic (5.74e-2)"	"unprognostic (3.32e-1)"	"unprognostic (2.40e-3)"	"unprognostic (1.44e-1)"	"unprognostic (1.38e-1)"	"prognostic favorable (5.11e-4)"	"unprognostic (3.33e-3)"	7.2	4.7	20.4	24.3	30.0	46.7	4.9	65.2	48.3	5.4	14.5	7.8	5.0	16.6	4.3	4.7	7.9	6.8	6.4	4.7	30.5	7.0	6.8	5.0	11.5	35.6	4.3	25.4	2.4	5.4	5.2	5.3	4.1	3.9	10.1	11.9	8.3	12.6	6.7	2.2	15.1	18.4	5.5	4.8	32.0	10.8	4.3	3.7	37.8	5.6	2.9	35.4	13.0	6.0	26.9	18.7	24.0	25.8	14.7	19.0	21.5	11.1	3.1	0.8	0.9	24.0	1.7	6.5	0.9	0.6	0.6	0.8	2.9	6.5	37.7	1.2	1.7	0.9	10.3	0.3	9.4	0.3	2.5	0.2	7.8	3.0	0.6	4.9	8.3	14.0	13.0	14.0	0.8	5.4	4.0	0.3	10.9	9.1	26.3	0.6	1.1	14.3	16.8	0.6	9.7	0.8	41.9	0.2	25.8	2.6	8.8	6.0	1.1	4.0	2.8	1.5	2.1	3.3	21.6	5.3	0.4	0.8	0.7	0.3	21.1	9.1	20.4	1.6	18.1	0.7	22.3	23.7	18.0	19.0	22.4	12.5	25.5	9.6	13.3	18.7	26.9	12.1	14.2	24.0	14.7	25.8	6.2	9.5	21.5	20.4	30.0	65.2	48.3	30.5	7.0	4.3	25.4	3.9	3.7	3.0	30.9	54.0	32.1	33.5	4.1	3.1	12.7	13.4	13.6	14.0	0.0	2.4	0.0	6.4	1.1	7.5	48.3	0.0	7.0	23.9	3.8	16.5	27.7	21.8	20.9	7.9	7.5	3.1	73.4	0.8	1.4	42.5	8.5	34.3	18.6	3.4	9.4	35.1	0.7	14.7	4.0	0.0	1.6	4.2	5.5	26.3	1.6	39.9	14.9	14.8
QPRT	QPRTase	ENSG00000103485	"Quinolinate phosphoribosyltransferase"	Q15274	16	29679008-29698699	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Pyridine nucleotide biosynthesis"	"Glycosyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 61.2"	"Cell type enhanced"	"Detected in many"	8	"Cytotrophoblasts: 349.5;Extravillous trophoblasts: 260.2;Hepatocytes: 304.1;Proximal tubular cells: 417.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 7.7"	"Group enriched"	"Detected in many"	4	"dendritic cells: 4.6;monocytes: 7.7"	"Cell line enhanced"	"Detected in many"		"EFO-21: 98.7;Hep G2: 41.2"									"HPA011887, HPA076010"	Enhanced		Approved	Vesicles	"Intracellular and membrane"	NA	NA		230000	Vesicles		"HPA011887: AB_2668555, HPA076010: "	"prognostic unfavorable (5.10e-5)"	"unprognostic (2.00e-1)"	"unprognostic (9.48e-2)"	"unprognostic (2.88e-1)"	"prognostic unfavorable (9.31e-4)"	"unprognostic (1.44e-2)"	"unprognostic (8.75e-2)"	"unprognostic (1.22e-1)"	"unprognostic (8.16e-2)"	"unprognostic (1.01e-2)"	"unprognostic (2.39e-1)"	"unprognostic (6.81e-2)"	"unprognostic (3.37e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.65e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.58e-2)"	3.2	36.4	6.1	3.0	5.2	1.1	2.4	1.6	5.8	17.9	10.8	4.4	43.3	20.0	12.7	44.3	1.3	14.9	4.9	11.3	4.9	7.5	40.1	61.2	4.7	2.9	7.9	7.5	15.3	22.9	6.1	2.6	24.3	10.0	4.4	5.2	12.6	15.0	19.4	1.5	1.6	24.1	4.7	6.4	5.3	2.7	3.1	2.6	3.7	2.2	0.3	2.1	5.9	5.1	0.1	4.6	1.2	7.7	0.5	1.4	2.2	0.1	0.2	9.4	10.3	1.6	3.9	23.1	0.9	0.9	1.5	1.9	23.6	16.8	0.4	98.7	1.8	1.5	0.1	3.2	0.1	0.8	0.1	2.1	4.8	0.3	41.2	9.0	0.7	2.0	12.3	0.2	0.8	0.0	2.3	0.0	4.6	12.1	0.5	0.0	22.9	3.0	16.8	28.7	0.5	0.0	13.3	2.8	9.3	8.6	0.7	7.6	15.4	0.0	26.8	19.8	16.1	20.0	21.5	0.1	0.4	3.9	0.1	0.0	0.3	0.7	3.1	0.7	1.7	1.5	0.0	3.7	0.4	1.3	4.7	1.4	0.1	0.9	1.0	4.6	0.1	0.1	0.7	1.2	0.5	7.7	2.6	0.8	2.2	6.1	5.2	1.6	5.8	4.9	7.5	7.9	7.5	10.0	2.6	8.9	22.7	18.6	9.6	3.2	1.5	34.8	7.6	0.0	0.0	61.1	0.0	349.5	43.1	0.9	0.0	2.8	125.5	0.0	48.0	260.2	17.5	2.9	4.7	304.1	118.1	6.4	27.2	11.1	13.0	0.0	27.0	12.3	40.5	5.4	45.2	20.3	17.4	77.2	25.5	417.3	3.5	6.5	11.3	0.5	2.5	1.8	180.3	6.4	95.6	6.4
RAF1	"c-Raf, CRAF, Raf-1"	ENSG00000132155	"Raf-1 proto-oncogene, serine/threonine kinase"	P04049	3	12583601-12664226	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, RAS pathway related proteins"		"Kinase, Serine/threonine-protein kinase, Transferase"	"Cancer-related genes, Cardiomyopathy, Deafness, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 53.9"	"Lineage enriched"	"Detected in all"	5	"granulocytes: 53.9"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA002640, CAB019291"	Approved		Approved	"Nuclear speckles"		NA	NA			"Nuclear speckles"		"CAB019291: , HPA002640: AB_1856047"	"unprognostic (6.33e-2)"	"unprognostic (1.29e-1)"	"unprognostic (5.92e-2)"	"unprognostic (2.17e-3)"	"unprognostic (6.51e-3)"	"unprognostic (7.66e-3)"	"unprognostic (2.66e-3)"	"unprognostic (1.53e-2)"	"unprognostic (2.72e-1)"	"unprognostic (7.66e-2)"	"unprognostic (2.92e-2)"	"unprognostic (1.29e-2)"	"unprognostic (2.79e-2)"	"unprognostic (1.79e-1)"	"unprognostic (1.27e-1)"	"unprognostic (2.64e-2)"	"unprognostic (2.36e-2)"	19.5	15.6	15.1	14.7	17.1	32.2	17.5	35.2	18.9	19.9	20.3	21.1	19.6	18.4	24.9	15.7	24.6	18.6	20.2	39.3	15.3	11.0	21.7	36.2	19.7	15.7	16.0	13.4	24.9	31.3	30.7	16.9	24.8	14.3	18.8	19.2	25.0	18.3	18.4	79.7	23.9	29.6	23.7	13.8	22.1	23.7	16.7	17.8	27.7	26.9	27.9	26.1	20.5	20.4	6.6	9.3	53.9	9.9	8.5	8.6	7.7	15.4	17.8	27.1	21.0	23.6	19.1	54.6	23.6	40.0	31.3	35.5	13.9	12.8	16.2	11.3	36.5	16.9	9.9	28.5	20.9	32.6	28.3	22.4	21.8	21.4	12.9	23.9	21.2	20.7	17.6	21.2	32.2	26.1	21.6	22.4	24.9	15.8	42.6	30.1	26.4	27.2	15.7	27.6	19.3	24.2	22.0	23.8	20.4	18.7	23.4	8.5	17.8	19.3	18.7	12.5	22.0	31.0	28.1	16.0	21.5	20.5	18.0	26.2	33.2	52.9	34.9	18.5	24.8	22.8	11.3	9.7	18.4	7.4	9.9	7.5	6.6	7.3	7.2	9.3	6.3	7.5	7.6	53.9	8.5	9.6	4.2	8.6	7.7	15.1	17.1	35.2	18.9	15.3	11.0	16.0	13.4	14.3	17.8	20.8	36.5	39.7	31.1	30.6	51.6	25.8	28.1	25.4	21.6	26.2	62.8	34.3	11.6	22.9	7.1	29.1	32.5	0.0	32.0	39.8	32.9	38.2	33.5	36.5	25.2	41.3	28.2	31.3	36.8	3.4	36.2	34.2	25.3	29.7	29.6	32.1	28.8	34.8	38.9	15.7	84.2	32.3	33.0	17.7	27.4	38.0	52.1	38.3	29.5	36.9
RAMP1		ENSG00000132329	"Receptor activity modifying protein 1"	O60894	2	237858893-237912114	"FDA approved drug targets, Predicted membrane proteins"	Transport	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"endometrium 1: 91.6;pancreas: 94.7"	"Cell type enhanced"	"Detected in many"	18	"Exocrine glandular cells: 240.1;monocytes: 755.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	16	"NK-cell: 30.0"	"Lineage enriched"	"Detected in many"	16	"NK-cells: 30.0"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 13.1;HDLM-2: 37.9;PC-3: 44.2;SH-SY5Y: 55.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA057814			Approved	"Nucleoplasm,Nuclear membrane"		NA	NA			"Nucleoplasm, Nuclear membrane"		"HPA057814: AB_2683536"	"unprognostic (1.13e-2)"	"unprognostic (5.96e-2)"	"unprognostic (3.03e-3)"	"unprognostic (3.69e-1)"	"unprognostic (4.29e-1)"	"unprognostic (1.75e-1)"	"prognostic favorable (7.61e-4)"	"unprognostic (2.54e-1)"	"unprognostic (3.49e-1)"	"unprognostic (5.45e-3)"	"unprognostic (2.32e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.46e-3)"	"prognostic unfavorable (1.68e-4)"	"unprognostic (1.74e-1)"	"unprognostic (3.98e-2)"	"unprognostic (2.08e-3)"	3.5	13.8	22.4	9.4	23.9	1.2	1.6	7.8	22.5	34.1	38.8	9.9	8.9	24.9	91.6	21.7	8.9	29.1	19.0	61.7	19.6	15.4	3.1	13.4	3.1	3.3	18.0	12.7	8.4	94.7	1.0	1.6	4.5	14.6	25.5	3.5	1.5	1.5	25.1	62.4	2.4	14.4	51.8	19.5	2.4	14.2	4.3	17.1	0.0	1.1	5.4	2.0	18.3	14.0	0.1	0.4	0.2	0.0	30.0	1.8	1.4	7.9	0.0	0.1	0.0	3.4	5.3	0.3	0.5	0.9	0.5	0.4	0.0	13.1	0.0	0.1	0.2	0.0	0.0	2.0	0.0	0.0	37.9	1.0	0.0	0.0	0.2	10.7	0.0	0.0	4.1	6.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.0	0.7	0.0	0.3	0.1	0.0	44.2	0.0	0.4	0.2	0.0	0.0	0.4	55.7	0.8	0.0	0.0	0.5	0.3	0.0	0.0	0.2	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	1.8	0.0	0.0	0.1	0.3	0.0	0.4	0.0	0.2	0.1	0.2	30.0	0.0	0.0	0.0	1.4	22.4	23.9	7.8	15.3	19.6	15.4	18.0	12.7	14.6	17.1	0.0	1.0	0.5	11.4	10.3	2.1	136.4	91.7	14.7	9.1	10.4	0.0	2.1	0.0	55.5	0.2	4.2	4.9	0.0	240.1	7.5	28.8	73.7	1.1	137.8	18.7	1.6	110.7	51.5	4.0	0.4	7.8	6.3	60.8	755.6	26.2	3.3	79.4	4.0	10.6	0.0	2.3	6.5	86.3	0.0	4.9	5.1	1.9	3.2	6.6	3.8
RAMP2		ENSG00000131477	"Receptor activity modifying protein 2"	O60895	17	42758447-42763041	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	Transport	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"Endothelial cells: 348.5;Ito cells: 252.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	18	"plasmacytoid DC: 6.4"	"Lineage enriched"	"Detected in single"	18	"dendritic cells: 6.4"	"Cell line enhanced"	"Detected in many"		"ASC diff: 47.1;EFO-21: 31.4;HUVEC TERT2: 14.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA052020			Approved	Vesicles		NA	NA			Vesicles		"HPA052020: AB_2681697"	"unprognostic (8.64e-2)"	"unprognostic (2.12e-2)"	"unprognostic (8.03e-2)"	"unprognostic (1.16e-2)"	"unprognostic (5.24e-2)"	"unprognostic (4.13e-3)"	"unprognostic (2.68e-2)"	"unprognostic (1.04e-1)"	"unprognostic (4.50e-2)"	"unprognostic (5.18e-2)"	"unprognostic (1.02e-2)"	"unprognostic (6.79e-2)"	"unprognostic (1.28e-2)"	"unprognostic (6.96e-3)"	"unprognostic (4.42e-2)"	"unprognostic (2.20e-1)"	"unprognostic (1.25e-1)"	48.6	7.1	8.6	7.6	9.6	0.2	43.4	3.4	15.4	35.1	9.7	10.8	6.1	5.2	49.5	24.2	19.5	17.0	20.4	23.9	9.6	8.5	18.8	14.6	51.5	17.3	13.8	7.7	17.3	9.6	5.6	6.1	56.1	12.5	24.9	9.1	71.1	12.8	12.2	16.2	15.6	11.5	30.9	8.8	15.6	9.2	10.9	3.0	3.9	20.0	30.1	11.7	13.2	23.1	0.0	6.4	0.0	0.1	0.0	0.3	0.0	0.0	0.4	1.9	0.0	47.1	2.4	1.5	0.3	0.7	3.9	1.9	4.3	0.0	0.0	31.4	1.1	0.2	0.0	1.8	0.0	3.3	0.0	0.0	0.0	0.3	1.3	1.2	0.0	0.0	1.7	0.0	0.6	0.1	1.3	14.1	0.5	0.0	0.1	0.2	0.0	0.2	0.3	9.1	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.9	3.9	1.1	0.0	6.4	1.9	0.4	1.2	2.6	7.6	2.8	0.2	0.9	0.0	0.0	0.1	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	6.4	0.3	0.0	8.6	9.6	3.4	15.4	9.6	8.5	13.8	7.7	12.5	3.0	0.0	10.1	5.1	4.4	30.6	0.1	1.7	0.0	0.0	1.2	3.5	0.0	1.0	3.3	0.7	1.1	348.5	0.0	0.0	0.6	1.2	42.9	4.5	0.0	0.9	2.8	0.0	4.1	252.3	12.4	3.1	35.9	3.2	21.9	4.6	0.0	8.9	0.0	0.0	20.5	0.4	1.6	6.5	9.5	11.2	60.0	24.1	1.3	2.5	0.0	4.1
RAMP3		ENSG00000122679	"Receptor activity modifying protein 3"	O60896	7	45157791-45186302	"FDA approved drug targets, Predicted membrane proteins"	Transport	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in many"	8	"Endothelial cells: 183.2;Ito cells: 555.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.7"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.7"	"Cell line enriched"	"Detected in some"	7	"Karpas-707: 7.6"	"Group enriched"	"Detected in many"	5	"cerebellum: 69.9;cerebral cortex: 50.2;thalamus: 191.1"	"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.62e-3)"	"prognostic favorable (2.89e-4)"	"unprognostic (4.85e-2)"	"unprognostic (6.88e-3)"	"unprognostic (3.68e-2)"	"unprognostic (1.44e-3)"	"prognostic favorable (2.50e-6)"	"unprognostic (1.14e-1)"	"unprognostic (2.35e-1)"	"unprognostic (3.19e-1)"	"unprognostic (2.79e-2)"	"unprognostic (9.49e-2)"	"unprognostic (1.09e-2)"	"unprognostic (1.20e-2)"	"unprognostic (2.43e-1)"	"unprognostic (1.91e-1)"	"unprognostic (9.21e-2)"	34.7	10.4	5.4	11.0	3.8	0.1	23.7	1.7	5.9	17.0	8.3	10.0	5.0	5.3	14.2	7.2	12.1	7.4	18.3	34.6	5.5	7.5	23.9	12.6	53.7	24.5	11.4	2.3	6.6	6.5	10.6	8.4	6.2	16.6	11.0	4.7	26.5	7.8	8.3	13.9	7.5	9.1	13.1	37.3	4.1	8.3	6.3	6.4	1.0	24.3	14.5	15.6	18.6	17.9	0.0	0.1	2.7	0.0	0.0	0.7	1.7	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	7.6	0.0	0.0	0.2	0.6	1.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.6	0.0	0.7	0.3	0.2	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.1	0.0	0.0	0.0	2.7	0.0	0.0	0.0	0.0	1.7	5.4	3.8	1.7	5.9	5.5	7.5	11.4	2.3	16.6	6.4	0.0	3.4	4.5	0.4	14.4	0.6	7.0	2.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.1	183.2	0.0	0.0	0.6	0.0	5.1	0.4	0.0	5.9	0.4	0.0	0.0	555.5	44.3	4.7	1.1	1.7	25.3	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.4	0.0	6.2	0.3	0.9	12.7	0.0	1.9	0.0	0.4
RARA	"NR1B1, RAR"	ENSG00000131759	"Retinoic acid receptor alpha"	P10276	17	40309192-40357643	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 26.6"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 63.9;SK-BR-3: 40.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA058282, HPA071548"			Supported	"Nucleoplasm,Nucleoli,Actin filaments,Cytosol"		NA	NA			Nucleoplasm	"Nucleoli, Actin filaments, Cytosol"	"HPA058282: AB_2683666, HPA071548: "	"unprognostic (8.05e-3)"	"unprognostic (1.89e-1)"	"unprognostic (9.48e-3)"	"prognostic favorable (2.60e-4)"	"unprognostic (8.67e-3)"	"unprognostic (4.87e-3)"	"unprognostic (2.77e-1)"	"unprognostic (5.73e-2)"	"unprognostic (1.45e-1)"	"unprognostic (3.54e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.79e-1)"	"unprognostic (2.29e-3)"	"unprognostic (1.59e-2)"	"unprognostic (5.60e-2)"	"unprognostic (1.60e-1)"	"unprognostic (1.09e-2)"	27.6	13.5	5.0	18.6	7.6	32.3	23.7	11.5	15.2	30.2	29.6	5.0	16.8	18.0	23.8	23.9	17.3	23.3	30.2	24.3	5.9	6.1	14.6	24.0	32.0	23.4	4.6	7.8	50.0	9.3	7.4	18.1	16.6	6.5	22.9	8.5	26.8	12.1	32.7	43.1	14.3	31.6	18.6	3.7	31.1	14.3	21.8	2.9	9.7	16.3	15.4	20.2	31.5	20.3	1.0	6.1	26.6	9.3	2.5	2.6	1.9	5.1	12.1	3.6	6.1	7.1	10.9	3.6	4.2	6.4	6.2	4.0	8.3	4.4	2.7	6.6	9.5	5.7	15.0	4.1	10.0	3.6	20.5	6.1	7.8	6.1	8.1	11.4	2.8	24.7	15.3	2.9	6.6	8.4	23.7	9.2	2.4	4.9	6.0	7.0	63.9	1.8	9.5	3.1	4.7	3.8	3.6	21.3	10.3	3.6	4.1	1.5	12.4	9.0	40.6	12.4	3.6	38.2	11.2	10.7	7.8	13.3	13.6	4.6	14.4	4.8	2.3	13.1	5.5	23.0	8.7	4.2	15.7	1.6	6.9	2.6	1.0	1.7	1.7	6.1	0.9	0.8	1.3	26.6	2.5	9.3	1.8	1.4	1.9	5.0	7.6	11.5	15.2	5.9	6.1	4.6	7.8	6.5	2.9	3.0	9.5	5.6	22.6	17.3	24.2	3.2	10.2	4.0	2.3	7.0	5.9	1.9	11.6	14.3	58.0	20.4	52.7	0.0	16.9	5.1	23.8	11.2	34.6	22.8	11.3	3.2	9.2	22.7	35.4	50.8	38.6	37.4	27.0	0.0	14.2	9.3	16.8	24.6	21.5	11.8	8.2	32.3	33.0	2.9	6.9	16.6	4.3	11.5	13.2	19.2
RARB	"HAP, NR1B2, RRB2"	ENSG00000077092	"Retinoic acid receptor beta"	P10826	3	25174332-25597932	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Microphthalmia, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"retina: 39.1"	"Cell type enhanced"	"Detected in many"	7	"Basal glandular cells: 17.9;Cone photoreceptor cells: 23.6;Ito cells: 20.3;Muller glia cells: 27.5"	"Low cancer specificity"	"Detected in all"			"Region enhanced"	"Detected in all"		"basal ganglia: 22.6"	"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"ASC diff: 7.0;HEK 293: 7.9;hTERT-RPE1: 41.7;WM-115: 18.1"	"Region enriched"	"Detected in many"	9	"basal ganglia: 97.9"	"Low region specificity"	"Detected in all"			"CAB002617, HPA004174"	Enhanced		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB002617: , HPA004174: AB_1079744"	"unprognostic (2.04e-2)"	"unprognostic (3.53e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.56e-1)"	"unprognostic (6.72e-2)"	"unprognostic (1.30e-2)"	"unprognostic (2.70e-2)"	"unprognostic (2.43e-1)"	"unprognostic (4.71e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.86e-1)"	"prognostic favorable (3.43e-5)"	"unprognostic (9.24e-3)"	"unprognostic (2.28e-1)"	"unprognostic (9.99e-2)"	"unprognostic (6.56e-3)"	3.9	7.1	2.4	2.3	22.6	0.0	6.8	1.5	9.1	13.4	6.0	2.2	6.8	1.7	14.4	7.5	8.1	6.2	5.3	13.6	2.6	2.2	17.5	6.2	5.6	5.6	2.0	3.7	12.2	1.5	12.8	18.9	13.9	3.2	13.0	2.3	39.1	13.7	11.8	2.5	1.4	2.4	14.7	4.6	7.7	4.8	1.7	4.8	0.0	10.0	2.9	4.6	12.1	10.2	1.0	0.4	0.1	0.6	0.1	0.8	0.0	0.0	0.9	0.6	3.1	7.0	1.8	0.0	0.8	0.4	0.0	0.3	0.1	0.0	0.0	0.1	1.2	0.1	0.2	0.0	0.1	0.0	0.0	7.9	0.0	0.0	0.5	0.1	0.1	0.0	3.7	0.0	0.0	0.0	41.7	6.6	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.3	4.2	0.0	0.1	0.0	4.9	0.0	0.0	0.0	0.5	0.0	1.1	3.4	0.1	0.0	0.0	2.8	0.1	18.1	0.0	0.6	0.0	0.8	0.1	0.3	0.3	0.5	0.5	0.4	1.0	0.6	0.8	0.1	0.1	0.1	0.4	0.0	0.0	2.4	22.6	1.5	9.1	2.6	2.2	2.0	3.7	3.2	4.8	0.0	0.3	0.0	17.9	0.1	4.2	9.3	7.6	6.7	12.5	10.4	23.6	0.1	0.0	1.4	1.3	3.8	0.0	0.0	0.8	0.1	3.1	5.5	0.0	2.0	0.3	4.8	0.0	20.3	4.1	0.4	0.0	0.0	0.0	0.0	0.0	27.5	1.1	0.0	0.0	0.5	6.1	0.0	9.2	0.2	1.1	0.1	0.2	0.0	0.0	7.1
RARG	"NR1B3, RARC"	ENSG00000172819	"Retinoic acid receptor gamma"	P13631	12	53210567-53232980	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"esophagus: 49.4;skin 1: 52.1"	"Cell type enhanced"	"Detected in many"	8	"Basal keratinocytes: 30.3;Suprabasal keratinocytes: 48.8;Urothelial cells: 33.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"MAIT T-cell: 17.0"	"Group enriched"	"Detected in all"	4	"dendritic cells: 5.6;T-cells: 17.0"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 33.3;MCF7: 35.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA053883	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"HPA053883: AB_2682292"	"unprognostic (7.29e-2)"	"unprognostic (1.95e-2)"	"unprognostic (6.11e-2)"	"prognostic unfavorable (3.68e-6)"	"unprognostic (2.53e-1)"	"unprognostic (5.43e-2)"	"unprognostic (2.28e-1)"	"unprognostic (1.08e-2)"	"unprognostic (3.54e-3)"	"unprognostic (7.21e-3)"	"unprognostic (3.78e-3)"	"unprognostic (4.44e-2)"	"prognostic unfavorable (3.08e-6)"	"unprognostic (5.41e-3)"	"unprognostic (1.98e-2)"	"unprognostic (5.94e-3)"	"unprognostic (7.41e-2)"	4.8	5.0	2.7	7.0	3.6	1.3	10.8	6.3	3.8	26.8	6.3	1.8	7.3	1.0	14.6	6.0	49.4	10.6	8.6	6.9	3.0	1.4	3.7	1.9	7.4	6.7	2.4	2.3	12.6	2.7	4.2	2.8	4.4	1.6	11.3	3.4	10.3	9.5	10.6	2.6	52.1	3.0	9.7	1.5	4.7	6.0	3.9	1.7	2.3	7.3	30.6	26.8	10.9	19.8	1.8	5.6	1.5	2.5	1.7	17.0	2.9	7.2	8.0	1.8	16.9	18.9	16.2	0.5	7.6	16.6	10.0	7.9	2.7	33.3	0.1	4.2	30.6	5.4	24.5	6.1	14.6	2.5	1.9	3.1	1.0	6.1	2.3	8.0	0.0	3.0	12.0	21.5	9.5	2.1	25.3	4.2	1.5	0.2	3.2	3.9	35.1	0.4	0.3	5.4	9.8	14.2	2.3	0.6	5.8	3.0	12.0	1.5	7.6	15.5	16.8	10.2	2.4	14.5	0.4	4.5	12.0	5.7	7.9	0.4	1.5	0.8	0.5	14.8	1.2	17.0	1.5	2.5	0.7	6.6	0.8	17.0	1.8	5.7	4.8	5.6	0.6	4.8	4.1	0.0	1.7	0.0	0.4	1.5	2.9	2.7	3.6	6.3	3.8	3.0	1.4	2.4	2.3	1.6	1.7	3.0	6.5	0.0	19.4	30.3	0.7	2.8	5.1	0.0	2.3	3.5	2.0	7.2	0.0	8.7	0.0	6.9	0.4	0.0	4.5	0.7	19.6	11.9	1.1	0.0	2.3	0.0	1.7	20.9	5.2	0.2	4.9	2.8	8.5	1.8	1.6	2.9	9.8	3.5	4.9	0.6	4.9	6.5	12.2	0.4	4.1	48.8	1.5	5.7	5.2	33.4
REN		ENSG00000143839	Renin	P00797	1	204154819-204190324	"Candidate cardiovascular disease genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins"		"Aspartyl protease, Hydrolase, Protease"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"kidney: 63.6"	"Group enriched"	"Detected in some"	5	"Early spermatids: 6.1;Late spermatids: 19.3"	"Cancer enriched"	"Detected in many"	8	"renal cancer: 39.4"	"Region enriched"	"Detected in single"	12	"basal ganglia: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 2.4;BJ: 4.9;HMC-1: 6.5;RT4: 1.8;SK-BR-3: 4.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA005131	Approved				"Secreted to blood"	NA	NA	692000				"HPA005131: AB_1079174"	"unprognostic (4.45e-2)"	"unprognostic (3.35e-1)"	"unprognostic (1.62e-1)"	"unprognostic (8.58e-2)"		"unprognostic (2.89e-1)"	"unprognostic (1.23e-2)"	"unprognostic (1.24e-1)"	"unprognostic (1.13e-1)"	"unprognostic (7.20e-3)"	"unprognostic (1.37e-1)"	"unprognostic (1.57e-1)"	"prognostic unfavorable (6.45e-5)"	"unprognostic (1.22e-1)"	"unprognostic (1.70e-1)"	"unprognostic (4.98e-2)"	"unprognostic (6.49e-2)"	0.4	0.3	0.0	0.0	1.2	0.0	0.5	0.0	0.0	3.1	0.2	0.0	0.8	0.1	4.4	13.5	0.1	0.3	0.0	0.6	0.0	0.0	63.6	0.4	0.3	0.0	0.0	0.0	11.6	0.0	0.0	0.4	14.4	0.0	0.3	0.1	0.4	0.3	0.5	0.0	0.0	0.1	1.0	0.0	0.0	0.0	2.0	0.0	0.0	1.1	0.0	0.2	4.4	0.1	0.0	0.0	0.0	0.0	0.0	0.6	0.0	2.4	0.0	0.0	0.0	0.3	0.0	0.0	4.9	1.0	0.0	0.0	0.1	0.6	0.0	0.3	0.0	0.0	0.4	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.1	0.3	0.0	6.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.4	0.0	0.2	0.6	0.0	0.0	0.0	0.3	0.7	0.0	0.0	0.0	0.0	1.8	0.2	0.1	0.0	4.6	0.2	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.8	0.0	0.2	0.0	0.0	0.0	0.0	1.8	0.0	0.1	0.0	1.2	6.1	0.0	0.0	0.0	1.0	0.2	0.1	0.7	0.0	0.0	0.4	0.0	0.0	0.0	0.0	19.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.3	0.4	0.0	0.1	0.0	0.0	0.2	0.2	0.0	0.9	0.0	0.0	2.7
RET	"CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51"	ENSG00000165731	"Ret proto-oncogene"	P07949	10	43077027-43130351	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Hirschsprung disease, Proto-oncogene"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"parathyroid gland: 63.9"	"Cell type enriched"	"Detected in some"	44	"Horizontal cells: 74.7"	"Cancer enhanced"	"Detected in many"		"breast cancer: 11.0"	"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in some"		"non-classical monocyte: 6.7"	"Group enriched"	"Detected in many"	13	"dendritic cells: 2.1;monocytes: 6.7"	"Cell line enhanced"	"Detected in some"		"MCF7: 18.0;NB-4: 11.8;SH-SY5Y: 91.8;THP-1: 27.4"	"Low region specificity"	"Detected in many"			"Region enriched"	"Detected in all"	6	"midbrain: 95.5"	"CAB002581, HPA008356, HPA008495"	Approved	Supported	Approved	"Golgi apparatus,Plasma membrane,Cytosol"		No	NA		260000	"Golgi apparatus, Cytosol"	"Plasma membrane"	"CAB002581: AB_563673, HPA008356: AB_1847232, HPA008495: "	"unprognostic (7.94e-2)"	"unprognostic (3.68e-2)"	"unprognostic (4.49e-1)"	"prognostic unfavorable (5.02e-4)"	"unprognostic (1.15e-1)"	"unprognostic (9.13e-4)"	"unprognostic (1.27e-2)"	"unprognostic (3.62e-2)"	"unprognostic (2.86e-1)"	"unprognostic (2.01e-1)"	"unprognostic (1.54e-3)"	"unprognostic (4.43e-1)"	"unprognostic (9.35e-5)"	"unprognostic (1.64e-3)"	"unprognostic (8.28e-2)"	"unprognostic (3.67e-3)"	"unprognostic (2.02e-2)"	1.8	15.2	1.1	1.8	1.3	0.7	1.2	4.1	9.0	1.9	3.1	0.9	1.1	1.5	0.9	0.6	1.2	0.7	1.0	1.2	1.5	5.8	1.0	11.7	0.7	0.8	17.5	1.2	0.8	1.3	63.9	6.3	0.8	16.8	2.2	1.5	2.8	13.6	2.0	4.5	1.1	2.6	1.1	2.8	0.6	2.1	2.0	0.0	0.1	0.8	5.1	0.6	1.9	1.4	0.2	2.1	0.0	6.7	0.0	0.3	0.4	0.0	0.1	0.0	0.5	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	18.0	0.0	11.8	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	91.8	0.0	0.0	0.0	0.1	1.3	27.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.8	0.0	0.2	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	6.7	2.1	0.3	0.4	1.1	1.3	4.1	9.0	1.5	5.8	17.5	1.2	16.8	0.0	0.0	0.3	0.0	0.5	0.2	0.1	1.6	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.1	0.0	0.0	0.2	1.7	1.0	1.2	1.1	0.8	0.1	74.7	0.0	0.0	0.0	1.4	0.3	0.0	0.0	0.0	0.8	0.3	0.0	0.0	0.0	0.0	0.4	0.0	1.4	0.4	1.1	0.5	0.0	0.0	0.0	0.1
RFK	"FLJ11149, RIFK"	ENSG00000135002	"Riboflavin kinase"	Q969G6	9	76385517-76394517	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Extravillous trophoblasts: 297.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA023259, CAB033887, HPA057163"	Approved		Approved	"Golgi apparatus"		NA	NA			"Golgi apparatus"		"CAB033887: AB_2178617, HPA023259: AB_2671127, HPA057163: AB_2683357"	"unprognostic (1.79e-1)"	"unprognostic (3.98e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.34e-1)"	"unprognostic (1.76e-3)"	"unprognostic (8.61e-3)"	"unprognostic (3.11e-1)"	"unprognostic (1.39e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.02e-1)"	"unprognostic (4.61e-2)"	"unprognostic (1.22e-3)"	"unprognostic (3.22e-2)"	"unprognostic (1.83e-1)"	"unprognostic (2.70e-1)"	"unprognostic (3.88e-2)"	8.1	15.4	24.8	9.8	31.0	15.2	8.7	15.3	27.7	8.9	22.1	5.7	6.2	23.9	9.5	14.3	9.4	10.0	14.5	11.4	33.0	33.5	19.4	23.6	8.8	7.4	22.8	13.2	10.8	11.9	10.3	16.5	26.0	28.3	9.6	16.8	13.3	9.1	7.6	10.3	3.8	39.3	8.5	10.2	8.2	20.3	12.2	8.0	8.1	14.4	5.7	11.6	9.2	7.3	4.9	9.6	3.8	16.3	6.8	6.7	7.8	9.8	10.6	6.5	8.4	9.7	9.7	19.6	11.5	8.5	8.3	6.5	3.7	6.1	16.1	13.7	8.2	15.2	10.7	8.8	7.4	16.6	4.8	8.6	5.1	14.8	12.0	17.6	16.8	12.2	6.5	13.6	9.9	10.9	9.3	26.7	13.9	13.5	13.4	16.5	9.2	21.6	6.2	8.4	22.9	11.3	12.1	8.6	4.1	38.0	4.9	16.6	6.1	12.3	17.3	10.1	8.8	4.4	9.3	16.7	8.8	15.9	18.9	16.1	14.6	14.5	5.6	14.5	15.1	12.0	3.8	8.1	2.8	4.4	16.0	6.7	4.9	6.5	5.2	9.6	4.0	6.3	6.0	1.2	6.8	16.3	3.6	6.1	7.8	24.8	31.0	15.3	27.7	33.0	33.5	22.8	13.2	28.3	8.0	14.9	8.6	15.2	14.2	40.3	49.7	29.9	28.1	26.8	19.4	40.1	19.6	37.4	51.4	55.2	161.1	40.7	67.5	70.0	168.8	297.5	21.6	23.6	11.5	32.1	30.7	11.1	27.1	62.6	51.2	78.7	20.4	25.3	28.7	12.6	24.6	39.5	147.1	66.6	61.2	98.3	23.1	0.0	23.6	85.0	58.5	35.4	103.3	20.8	29.9	24.0
ROCK1	p160ROCK	ENSG00000067900	"Rho associated coiled-coil containing protein kinase 1"	Q13464	18	20946906-21111851	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	Apoptosis	"Kinase, Serine/threonine-protein kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Early spermatids: 335.7;Late spermatids: 390.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004562, HPA007567, HPA045639"	Approved					NA	NA		240000			"CAB004562: AB_628223, HPA007567: AB_1856393, HPA045639: AB_2679401"	"unprognostic (7.86e-2)"	"unprognostic (2.86e-2)"	"unprognostic (1.22e-1)"	"unprognostic (6.63e-2)"	"unprognostic (9.90e-2)"	"unprognostic (1.17e-1)"	"unprognostic (6.74e-2)"	"unprognostic (1.00e-1)"	"unprognostic (1.63e-1)"	"unprognostic (8.89e-3)"	"prognostic unfavorable (9.93e-4)"	"unprognostic (3.85e-2)"	"unprognostic (8.93e-3)"	"unprognostic (3.04e-2)"	"unprognostic (5.47e-2)"	"unprognostic (3.19e-1)"	"unprognostic (1.28e-1)"	19.3	9.7	9.7	16.3	9.7	40.0	15.1	18.3	11.0	13.9	12.6	7.1	14.4	10.1	16.0	14.9	13.3	14.4	11.7	11.9	10.3	5.6	10.5	9.2	17.0	20.5	10.1	6.0	13.7	9.5	11.2	12.2	11.5	10.3	14.2	9.4	9.5	9.4	9.8	7.9	8.5	11.6	27.7	10.7	17.3	12.0	6.6	12.4	24.8	10.9	9.6	11.2	17.9	21.0	5.4	5.3	17.9	5.0	2.6	5.1	2.0	6.4	4.0	4.0	3.9	7.6	8.2	6.6	9.0	4.4	4.0	4.4	6.7	2.8	8.0	6.5	10.6	2.2	5.3	3.6	5.2	8.2	11.3	4.2	6.4	7.4	2.9	3.9	17.6	10.0	5.9	4.8	6.0	4.9	3.3	6.1	3.2	3.6	8.3	4.7	4.1	8.3	3.8	3.4	4.3	6.8	11.8	4.7	3.1	3.9	6.0	4.7	3.7	7.2	4.9	3.6	3.8	4.8	6.7	10.1	8.2	6.8	7.3	7.3	11.4	5.1	9.2	6.1	7.6	5.0	2.8	5.0	6.3	5.1	3.1	4.1	3.7	3.8	3.9	4.0	5.4	3.7	3.6	17.9	2.6	3.6	5.3	3.2	2.0	9.7	9.7	18.3	11.0	10.3	5.6	10.1	6.0	10.3	12.4	89.3	78.4	61.5	52.6	41.1	96.1	123.9	25.5	57.6	86.4	31.4	123.7	47.6	13.3	52.8	335.7	72.9	30.7	0.0	33.3	52.8	65.1	50.5	69.5	41.2	54.5	57.2	95.0	46.1	128.2	390.9	90.3	132.9	62.4	85.6	37.7	47.5	51.9	60.4	130.4	14.9	135.4	168.1	157.5	68.9	76.9	32.0	35.9	96.4	35.1	57.6
ROCK2		ENSG00000134318	"Rho associated coiled-coil containing protein kinase 2"	O75116	2	11179761-11348330	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"Kinase, Serine/threonine-protein kinase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA007459, CAB008666, HPA044109"	Approved		Supported	Cytosol		NA	NA		3700000	Cytosol		"CAB008666: AB_1622617, HPA007459: AB_1079828, HPA044109: AB_2678813"	"unprognostic (4.55e-2)"	"unprognostic (1.05e-2)"	"unprognostic (4.18e-3)"	"unprognostic (4.87e-2)"	"unprognostic (1.49e-1)"	"unprognostic (2.71e-1)"	"unprognostic (1.39e-2)"	"unprognostic (2.72e-1)"	"unprognostic (3.62e-2)"	"unprognostic (6.66e-2)"	"unprognostic (3.83e-2)"	"unprognostic (1.48e-1)"	"prognostic unfavorable (1.57e-5)"	"unprognostic (1.51e-1)"	"unprognostic (1.99e-1)"	"unprognostic (2.52e-2)"	"unprognostic (3.47e-2)"	26.9	7.8	14.6	9.5	21.9	4.4	21.4	26.1	26.4	16.6	16.5	5.6	8.6	12.3	22.4	11.0	12.4	13.2	11.9	12.3	13.4	7.6	11.4	12.3	16.7	6.8	7.2	16.7	15.1	8.6	12.9	14.8	18.4	10.3	14.4	20.3	5.6	10.3	14.4	28.0	8.7	13.8	42.9	7.1	12.6	10.7	5.8	9.6	5.9	10.5	5.1	6.2	22.1	20.8	2.5	3.0	3.6	2.2	3.5	3.3	0.9	6.6	16.2	13.4	13.1	24.3	17.1	8.6	15.8	14.8	10.3	10.9	15.3	14.6	8.4	9.4	24.9	12.5	7.4	9.7	9.1	16.3	11.9	5.8	16.7	27.9	30.5	8.7	9.3	4.8	13.3	5.8	12.7	9.1	8.4	16.4	4.6	14.5	3.4	15.3	5.6	6.8	4.8	7.4	14.1	10.0	8.2	29.5	2.7	5.6	18.9	6.3	6.8	31.0	10.8	10.8	10.6	4.4	5.2	22.3	21.3	15.4	8.4	13.8	2.7	3.3	7.5	9.2	11.0	29.6	3.6	1.8	1.7	2.7	2.2	3.3	1.6	2.2	1.8	1.3	2.5	1.9	2.1	3.0	3.5	1.7	3.0	1.8	0.9	14.6	21.9	26.1	26.4	13.4	7.6	7.2	16.7	10.3	9.6	107.2	64.4	9.3	35.3	35.4	33.2	94.7	35.7	41.5	86.4	21.0	55.0	22.5	1.7	25.4	6.5	88.7	62.6	0.0	34.0	15.9	43.2	45.6	26.7	37.6	16.5	76.3	20.4	58.9	19.8	3.5	40.6	24.0	21.9	8.2	82.3	34.2	30.5	38.6	73.9	13.6	42.5	129.4	101.5	21.4	17.7	24.3	26.3	11.4	40.0	38.2
RPE65	"BCO3, LCA2, rd12, RP20"	ENSG00000116745	"RPE65, retinoid isomerohydrolase"	Q16518	1	68428822-68449959	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Sensory transduction, Vision"	"Hydrolase, Isomerase"	"Disease mutation, FDA approved drug targets, Leber congenital amaurosis, Retinitis pigmentosa"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	25	"retina: 268.3"	"Group enriched"	"Detected in some"	12	"Cone photoreceptor cells: 9.8;Rod photoreceptor cells: 17.3"	"Group enriched"	"Detected in some"	10	"glioma: 5.8;head and neck cancer: 1.5"	"Group enriched"	"Detected in many"	5	"hypothalamus: 6.0;midbrain: 8.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"A-431: 6.2;PC-3: 10.6;U-2 OS: 2.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (1.59e-1)"	"unprognostic (1.88e-1)"	"unprognostic (3.15e-1)"		"prognostic favorable (9.75e-4)"	"unprognostic (4.55e-2)"		"unprognostic (5.91e-2)"	"unprognostic (6.59e-4)"	"unprognostic (2.98e-2)"	"unprognostic (1.57e-1)"	"unprognostic (8.24e-2)"	"unprognostic (3.21e-4)"	"unprognostic (2.11e-1)"	"unprognostic (2.05e-1)"	"unprognostic (3.48e-2)"	"unprognostic (8.40e-3)"	0.0	0.0	0.9	0.1	0.7	0.0	1.0	0.1	3.8	0.2	0.1	1.3	1.4	0.4	1.4	0.7	0.8	0.6	0.2	0.0	1.5	6.0	0.0	0.0	0.0	0.1	8.8	0.1	0.1	0.0	0.0	0.0	0.0	1.2	4.2	0.2	268.3	0.2	10.5	0.0	0.0	0.1	0.5	1.4	0.2	0.6	0.2	0.6	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.7	0.1	0.6	1.5	6.0	8.8	0.1	1.2	0.6	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	9.8	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.2	0.1	0.0	0.0	0.0	17.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
RPL3	L3	ENSG00000100316	"Ribosomal protein L3"	P39023	22	39312882-39320389	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Ribosomal proteins"		"Ribonucleoprotein, Ribosomal protein"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA003365, HPA055361"	Uncertain		Supported	Nucleoli,Cytosol		NA	NA		120000	"Nucleoli, Cytosol"		"HPA003365: AB_1079841, HPA055361: AB_2732594"	"unprognostic (9.79e-3)"	"unprognostic (2.06e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.68e-3)"	"unprognostic (5.44e-3)"	"unprognostic (1.72e-1)"	"unprognostic (3.51e-2)"	"unprognostic (1.22e-1)"	"unprognostic (3.63e-1)"	"unprognostic (5.81e-2)"	"unprognostic (5.87e-2)"	"unprognostic (7.09e-2)"	"unprognostic (2.54e-2)"	"unprognostic (1.85e-1)"	"unprognostic (6.09e-2)"	"unprognostic (2.72e-1)"	"unprognostic (4.32e-2)"	71.7	71.8	51.3	72.3	50.3	107.0	134.5	50.8	49.3	102.2	94.4	42.7	78.1	63.1	207.5	79.6	126.9	101.6	96.2	54.5	41.4	38.8	66.6	102.5	74.5	205.9	47.4	57.7	217.8	453.1	50.9	75.0	74.5	58.0	138.7	57.0	74.8	216.3	68.5	48.9	118.1	62.6	115.6	50.7	84.3	74.4	76.4	23.3	105.5	158.5	82.3	109.8	119.9	105.7	198.9	114.8	18.9	56.4	150.3	249.0	326.4	87.2	80.8	92.5	102.2	118.4	256.8	124.7	67.7	128.8	67.7	60.9	101.6	66.7	361.2	93.8	81.4	40.8	58.2	98.7	144.7	45.1	61.4	97.2	90.9	96.7	151.9	174.9	129.1	76.7	248.1	196.1	58.5	208.7	177.2	131.6	96.4	102.3	125.6	97.9	112.4	131.1	188.1	96.8	92.9	56.4	105.3	89.8	181.3	125.1	129.4	84.7	100.1	42.5	139.0	221.5	61.4	104.7	210.6	130.4	45.5	72.0	47.7	77.0	96.5	72.9	159.9	102.6	114.2	51.4	18.9	56.4	11.9	132.5	51.7	205.6	198.9	192.1	153.7	101.2	175.8	249.0	195.2	8.1	150.3	44.5	114.8	126.1	326.4	51.3	50.3	50.8	49.3	41.4	38.8	47.4	57.7	58.0	23.3	914.2	2163.5	5410.7	7867.8	9248.8	998.0	126.1	2876.4	1092.1	2307.8	1367.8	400.5	4667.0	4993.6	2515.3	1583.9	3488.3	1382.2	934.5	5706.5	6677.9	4026.4	5687.6	1692.6	1824.7	2890.1	338.5	2624.6	2557.1	2528.9	3527.0	5167.6	3086.7	4841.9	3599.8	3269.3	905.4	3905.0	2588.2	3289.3	3749.1	924.0	1552.2	5807.1	1006.7	702.5	10743.1	4590.8	4458.7	5068.7	8140.4
RRM1		ENSG00000167325	"Ribonucleotide reductase catalytic subunit M1"	P23921	11	4094707-4138876	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"DNA replication"	"Allosteric enzyme, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 78.6"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022093, HPA057265, HPA064297"	Enhanced		Supported	Cytosol		NA	Yes		13000	Cytosol		"CAB022093: , HPA057265: AB_2683386, HPA064297: AB_2685236"	"unprognostic (4.47e-2)"	"unprognostic (1.73e-2)"	"unprognostic (1.99e-3)"	"unprognostic (3.65e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.19e-1)"	"prognostic unfavorable (1.53e-4)"	"unprognostic (1.31e-2)"	"unprognostic (3.43e-2)"	"unprognostic (6.90e-2)"	"unprognostic (1.06e-3)"	"unprognostic (4.21e-2)"	"unprognostic (6.88e-3)"	"unprognostic (9.20e-3)"	"unprognostic (6.16e-2)"	"unprognostic (8.41e-2)"	"unprognostic (9.93e-3)"	13.9	25.3	8.0	15.2	12.2	18.5	14.4	18.0	12.6	15.7	15.9	11.1	11.5	11.9	13.0	9.8	25.4	10.7	8.7	11.9	7.9	9.0	9.2	13.1	11.0	20.2	9.0	10.3	13.6	10.7	24.2	11.2	22.7	18.4	14.0	18.9	12.0	15.4	10.7	28.3	26.8	12.5	17.5	10.7	12.4	13.8	10.5	9.1	78.6	9.8	28.0	27.1	17.5	18.5	5.6	4.3	3.3	8.3	5.7	24.3	6.0	46.1	25.1	41.1	23.9	6.3	12.6	16.0	42.5	21.1	48.4	50.0	22.5	35.1	50.0	10.3	21.2	21.0	37.1	38.1	30.6	57.3	24.5	40.4	25.4	37.6	17.5	2.5	43.4	18.6	5.9	8.3	26.5	19.1	10.6	23.2	30.2	33.1	23.6	40.3	20.9	51.1	9.4	26.0	32.1	25.5	41.4	32.1	17.8	13.3	13.1	35.2	19.3	37.4	22.6	6.8	17.3	22.3	15.2	13.2	45.5	23.8	45.1	31.2	15.5	21.4	54.6	25.3	29.1	28.2	3.3	2.5	2.6	7.7	6.5	13.3	5.6	14.2	10.7	4.3	3.5	11.3	9.2	0.0	5.7	8.3	2.7	24.3	6.0	8.0	12.2	18.0	12.6	7.9	9.0	9.0	10.3	18.4	9.1	17.9	11.8	16.4	16.8	29.8	14.7	30.7	17.8	17.4	21.6	17.4	5.9	33.4	6.6	22.3	59.0	10.8	9.7	70.0	19.4	48.6	21.4	12.0	6.9	14.8	24.3	17.5	17.3	11.6	8.6	43.8	12.0	10.6	10.1	9.0	17.5	21.8	14.0	11.8	15.6	6.3	20.0	12.9	21.5	60.8	31.3	25.3	33.2	15.8	24.7	13.6
RRM2		ENSG00000171848	"Ribonucleotide reductase regulatory subunit M2"	P31350	2	10120698-10131419	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"DNA replication"	Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 120.9"	"Cell type enhanced"	"Detected in many"	19	"Erythroid cells: 93.5;Extravillous trophoblasts: 192.1;Spermatogonia: 44.5"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"T-reg: 10.4"	"Lineage enriched"	"Detected in many"	6	"T-cells: 10.4"	"Low cell line specificity"	"Detected in many"											HPA056994	Enhanced		Supported	Cytosol		Yes	Yes			Cytosol		"HPA056994: AB_2683304"	"unprognostic (2.10e-2)"	"unprognostic (1.62e-1)"	"unprognostic (6.40e-3)"	"unprognostic (4.42e-3)"	"unprognostic (5.70e-2)"	"unprognostic (1.69e-1)"	"prognostic unfavorable (1.39e-5)"	"unprognostic (1.04e-3)"	"unprognostic (6.67e-3)"	"unprognostic (4.53e-2)"	"prognostic unfavorable (1.62e-4)"	"unprognostic (5.11e-3)"	"prognostic unfavorable (0.00e+0)"	"unprognostic (3.05e-2)"	"unprognostic (2.24e-1)"	"unprognostic (1.38e-1)"	"unprognostic (2.09e-2)"	4.7	2.2	0.4	32.6	0.4	29.0	4.2	0.4	0.9	3.5	9.3	0.4	0.4	5.2	2.1	1.7	21.6	0.7	5.0	3.3	0.4	0.5	2.0	3.9	5.7	16.4	0.6	0.1	0.9	2.9	0.0	0.7	5.4	0.3	1.0	10.6	0.1	2.9	0.0	0.5	2.8	11.3	3.2	0.8	19.8	5.4	8.0	0.0	120.9	0.8	22.3	33.1	3.8	5.2	1.4	0.3	0.6	0.2	1.8	10.4	2.6	29.5	17.9	25.4	17.4	2.2	4.1	25.1	48.3	24.0	34.5	37.6	29.9	14.1	27.1	6.7	15.1	35.0	14.5	41.0	24.9	42.3	60.8	15.8	52.3	17.2	26.3	0.1	38.7	25.1	1.5	0.5	42.2	3.6	5.7	27.9	21.0	21.9	80.5	42.9	22.3	42.7	20.8	20.5	30.4	21.0	32.2	55.4	18.6	17.0	22.5	25.1	20.7	39.7	28.2	4.9	11.0	15.2	6.9	9.7	26.5	38.5	19.8	67.7	52.3	41.0	55.4	18.8	32.9	38.0	0.3	0.1	0.1	3.7	0.0	0.0	1.4	2.6	2.9	0.2	0.4	0.2	1.2	0.6	1.8	0.2	0.3	10.4	2.6	0.4	0.4	0.4	0.9	0.4	0.5	0.6	0.1	0.3	0.0	3.0	1.0	2.2	1.0	9.3	0.0	1.2	2.5	5.3	1.2	0.0	0.0	5.4	1.7	0.5	3.0	0.3	2.6	93.5	0.0	192.1	3.6	1.1	5.7	1.7	40.1	0.0	0.0	5.5	5.9	5.7	0.3	3.5	0.0	0.0	7.9	0.0	0.5	0.0	0.4	1.6	0.0	0.0	0.3	5.2	44.5	1.4	40.7	7.2	13.0	2.0
RRM2B	p53R2	ENSG00000048392	"Ribonucleotide reductase regulatory TP53 inducible subunit M2B"	Q7LG56	8	102204502-102239118	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"DNA damage, DNA repair, DNA replication"	Oxidoreductase	"Disease mutation, FDA approved drug targets, Neuropathy, Primary mitochondrial disease, Progressive external ophthalmoplegia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB006854, HPA028812"	Approved		Enhanced	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB006854: , HPA028812: AB_10602246"	"unprognostic (7.76e-3)"	"unprognostic (4.14e-2)"	"unprognostic (9.41e-3)"	"unprognostic (3.41e-1)"	"unprognostic (1.13e-2)"	"unprognostic (1.28e-1)"	"unprognostic (5.51e-2)"	"unprognostic (1.35e-2)"	"unprognostic (1.66e-1)"	"unprognostic (9.40e-2)"	"unprognostic (1.74e-2)"	"unprognostic (1.03e-1)"	"unprognostic (1.70e-2)"	"unprognostic (4.32e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.52e-1)"	"unprognostic (7.17e-2)"	11.8	18.6	11.7	11.5	11.4	4.3	9.3	8.5	13.5	9.5	10.1	9.8	9.5	10.2	8.2	10.8	8.0	9.7	8.2	11.3	17.5	12.8	17.5	15.1	15.8	12.6	14.9	10.6	9.7	9.5	34.7	24.8	11.6	23.1	11.2	11.1	7.7	9.7	10.9	34.6	7.4	7.6	8.2	26.1	10.6	7.1	6.6	9.4	6.3	37.1	8.1	13.1	10.7	7.0	7.4	6.2	18.3	8.4	3.0	3.3	2.8	5.6	10.0	11.9	7.0	16.8	16.2	9.4	13.0	15.8	7.0	8.2	3.5	4.5	35.8	12.3	14.3	7.1	2.1	5.7	13.2	9.9	5.8	6.2	9.0	4.2	7.5	13.6	2.7	19.2	20.5	24.9	7.7	11.8	16.7	19.6	6.2	6.6	5.5	22.4	5.5	4.7	5.2	6.6	6.1	7.4	3.0	4.8	7.2	16.3	6.4	3.0	5.9	6.8	3.6	7.7	31.0	9.7	6.2	14.9	10.9	21.1	7.5	3.5	5.8	5.3	32.6	16.0	4.2	11.5	10.0	5.1	5.3	2.2	4.5	3.3	5.6	2.0	2.8	6.2	7.4	2.3	2.5	18.3	3.0	8.4	1.8	1.4	2.8	11.7	11.4	8.5	13.5	17.5	12.8	14.9	10.6	23.1	9.4	53.6	24.0	7.2	8.1	17.2	13.1	17.9	20.4	38.8	25.0	38.4	13.7	11.2	21.6	6.2	1.6	16.4	6.4	0.0	7.0	4.9	10.4	10.8	10.5	20.3	11.1	9.5	28.3	18.4	21.8	1.1	13.3	17.8	16.9	7.2	10.3	23.6	5.5	7.0	13.8	18.1	14.7	6.5	10.8	8.2	10.0	16.2	4.0	12.8	11.7	5.4
RXRA	NR2B1	ENSG00000186350	"Retinoid X receptor alpha"	P19793	9	134317098-134440585	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Host-virus interaction, Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Hepatocytes: 186.8;Kupffer cells: 115.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 14.9;non-classical monocyte: 12.3"	"Group enriched"	"Detected in many"	8	"granulocytes: 14.9;monocytes: 12.3"	"Cell line enhanced"	"Detected in many"		"BEWO: 24.3;HaCaT: 27.4;RT4: 24.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004565, CAB005352"	Supported		Supported	"Nucleoplasm,Golgi apparatus"		NA	NA			Nucleoplasm	"Golgi apparatus"	"CAB004565: AB_2184877, CAB005352: AB_2184874"	"unprognostic (2.68e-1)"	"unprognostic (7.94e-2)"	"unprognostic (3.67e-2)"	"unprognostic (7.22e-2)"	"unprognostic (2.07e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.15e-1)"	"unprognostic (3.45e-2)"	"unprognostic (1.65e-3)"	"prognostic favorable (7.02e-4)"	"unprognostic (7.72e-2)"	"prognostic unfavorable (5.58e-4)"	"unprognostic (1.25e-2)"	"unprognostic (2.58e-1)"	"unprognostic (1.49e-2)"	"unprognostic (2.59e-1)"	18.5	10.1	9.9	10.4	6.7	19.6	36.8	4.6	9.8	11.0	9.3	4.9	8.1	14.0	10.1	6.1	24.2	9.3	12.9	14.2	9.0	3.7	11.7	49.3	12.8	10.4	6.0	7.0	11.7	20.6	8.0	10.7	9.6	9.4	9.7	2.0	9.5	9.3	9.7	45.8	19.0	15.2	10.6	9.5	11.5	8.8	5.9	8.1	1.5	13.6	18.3	5.9	16.0	23.7	0.1	1.7	14.9	12.3	1.3	1.1	1.8	5.6	15.8	2.0	5.0	3.6	3.3	24.3	3.0	3.5	4.4	2.5	8.8	8.8	0.0	8.3	4.4	3.8	27.4	0.7	10.7	0.2	8.0	2.0	0.0	19.3	13.3	4.6	6.6	2.4	5.4	4.6	5.5	2.6	0.6	3.7	0.9	10.9	0.5	1.0	15.1	0.5	1.4	3.8	4.1	5.5	2.9	7.5	10.9	0.2	24.4	4.5	2.0	9.6	9.2	2.4	0.1	12.8	9.0	4.8	5.4	6.5	5.7	2.7	0.7	0.0	0.1	4.1	6.7	3.5	1.1	5.2	2.8	1.1	9.3	0.0	0.1	0.7	0.7	1.7	0.0	0.2	0.9	14.9	1.3	12.3	0.1	0.9	1.8	9.9	6.7	4.6	9.8	9.0	3.7	6.0	7.0	9.4	8.1	29.8	22.2	2.2	14.1	30.7	3.8	30.8	79.0	8.1	21.6	8.7	23.6	24.3	1.7	11.9	4.5	17.5	46.7	23.3	12.2	27.0	17.3	15.8	1.1	186.8	29.1	31.8	9.2	72.4	115.8	14.1	30.0	27.5	11.8	5.4	24.8	42.2	14.1	34.5	19.8	16.2	21.2	19.4	17.9	0.7	12.3	40.9	20.0	13.1	23.9	26.0
RXRB	"H-2RIIBP, NR2B2, RCoR-1"	ENSG00000204231	"Retinoid X receptor beta"	P28702	6	33193588-33200688	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"CACO-2: 6.9;GAMG: 9.4;RH-30: 8.6;RT4: 8.1;T-47d: 8.4;U-698: 8.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002003, HPA063653"	Supported		Supported	Nucleoplasm		NA	NA			Nucleoplasm		"CAB002003: , HPA063653: AB_2685076"	"unprognostic (3.51e-1)"	"unprognostic (8.46e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.22e-2)"	"unprognostic (2.00e-2)"	"unprognostic (4.71e-3)"	"unprognostic (4.18e-2)"	"unprognostic (2.21e-2)"	"unprognostic (1.86e-1)"	"unprognostic (2.03e-1)"	"unprognostic (1.67e-3)"	"unprognostic (8.13e-3)"	"unprognostic (9.53e-3)"	"unprognostic (8.30e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.38e-2)"	"unprognostic (8.53e-3)"	24.9	18.9	13.0	14.0	16.1	9.8	16.0	24.7	23.2	22.8	17.1	17.7	17.3	19.0	17.4	56.6	13.7	18.5	17.1	27.7	13.5	12.3	14.1	17.4	16.5	9.8	16.4	15.6	19.1	16.2	3.6	17.5	19.2	15.5	20.1	8.4	16.0	16.2	22.0	19.7	25.5	14.1	28.4	10.4	19.8	13.9	10.4	18.2	18.5	22.0	10.9	24.5	14.0	14.5	1.9	1.4	5.2	1.2	1.9	2.5	0.7	0.0	0.0	0.0	0.0	0.0	0.0	4.3	0.0	0.0	0.0	0.0	6.9	0.0	5.2	4.0	0.0	9.4	3.4	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	5.0	0.0	5.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.1	0.0	5.2	0.0	0.0	0.2	3.1	0.0	0.0	0.0	8.6	0.0	5.2	8.1	0.0	4.6	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	3.7	0.0	0.0	6.7	5.8	8.4	0.0	0.0	0.0	5.2	0.8	2.9	2.5	0.9	1.8	1.9	2.5	2.4	1.3	0.8	2.4	1.5	1.9	1.9	1.2	1.4	2.5	0.7	13.0	16.1	24.7	23.2	13.5	12.3	16.4	15.6	15.5	18.2	38.7	14.1	14.7	14.6	15.3	25.5	16.1	5.1	9.4	15.9	5.2	19.6	19.4	21.6	16.6	2.2	14.7	19.6	0.0	14.1	13.3	14.6	14.4	10.3	14.9	14.0	17.5	21.1	9.8	14.2	3.2	15.0	8.5	15.1	22.6	20.2	15.7	12.5	17.3	15.2	10.7	19.7	25.8	17.6	14.7	13.6	16.4	24.0	17.9	20.7	11.7
RXRG	NR2B3	ENSG00000143171	"Retinoid X receptor gamma"	P48443	1	165400917-165445355	"Cancer-related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 14.9;pituitary gland: 29.8;retina: 13.5;skeletal muscle: 44.8"	"Cell type enhanced"	"Detected in some"	15	"Cone photoreceptor cells: 23.6;Melanocytes: 27.0;Muller glia cells: 9.1;Sertoli cells: 12.9"	"Group enriched"	"Detected in many"	13	"melanoma: 25.7;thyroid cancer: 34.8"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	7	"SK-MEL-30: 29.0"	"Region enriched"	"Detected in many"	5	"basal ganglia: 89.8"	"Low region specificity"	"Detected in all"			"CAB002615, HPA012933"	Uncertain		Approved	"Nucleoplasm,Nuclear bodies"		NA	NA			"Nucleoplasm, Nuclear bodies"		"CAB002615: , HPA012933: AB_2732406"	"unprognostic (2.29e-1)"	"unprognostic (1.08e-2)"	"unprognostic (1.51e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.29e-2)"	"unprognostic (6.19e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.05e-2)"	"unprognostic (9.13e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.95e-2)"	"unprognostic (5.41e-3)"	"unprognostic (2.52e-2)"	"unprognostic (6.12e-3)"	"unprognostic (1.18e-1)"	"prognostic favorable (9.40e-5)"	"unprognostic (5.03e-2)"	1.9	3.9	5.4	1.0	14.9	0.6	1.0	0.3	5.9	4.0	2.5	5.3	0.6	1.3	1.8	1.3	1.7	3.6	1.2	5.8	7.5	8.9	0.7	0.8	3.4	0.8	4.1	4.3	1.7	2.7	0.8	29.8	1.3	14.1	1.1	2.7	13.5	1.9	2.1	44.8	2.9	2.0	1.8	8.9	1.0	1.1	1.5	5.4	0.0	1.1	2.5	0.6	1.2	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.0	0.0	1.3	0.0	0.0	0.0	29.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	14.9	0.3	5.9	7.5	8.9	4.1	4.3	14.1	5.4	0.0	0.0	0.0	0.0	0.6	0.3	2.0	0.0	0.0	0.0	0.0	23.6	0.0	0.0	0.0	2.2	0.5	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	1.9	4.6	0.0	27.0	0.0	0.0	9.1	0.1	0.0	2.1	0.0	4.0	12.9	0.5	0.2	0.0	0.0	0.0	0.0	0.0	0.0
RYR1	"CCO, MHS, MHS1, PPP1R137, RYR"	ENSG00000196218	"Ryanodine receptor 1"	P21817	19	38433699-38587564	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	4	"skeletal muscle: 231.0"	"Cell type enriched"	"Detected in many"	5	"Muller glia cells: 46.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	6	"intermediate monocyte: 3.2;myeloid DC: 5.3;non-classical monocyte: 6.3"	"Group enriched"	"Detected in many"	7	"dendritic cells: 5.3;monocytes: 6.3"	"Cell line enhanced"	"Detected in some"		"A549: 5.7;HaCaT: 14.0;hTCEpi: 5.7;RH-30: 11.5;SiHa: 22.8;U-2 OS: 9.6"	"Low region specificity"	"Detected in some"							HPA056416	Enhanced		Approved	"Golgi apparatus,Vesicles,Cytosol"		NA	NA			"Golgi apparatus, Vesicles"	Cytosol	"HPA056416: AB_2683121"	"unprognostic (2.22e-3)"	"unprognostic (1.91e-3)"	"unprognostic (9.59e-2)"	"unprognostic (5.34e-4)"	"unprognostic (2.50e-1)"	"unprognostic (6.00e-2)"	"unprognostic (2.11e-1)"	"unprognostic (1.06e-1)"	"unprognostic (1.18e-1)"	"unprognostic (3.20e-3)"	"unprognostic (3.52e-1)"	"unprognostic (2.35e-1)"	"unprognostic (1.07e-5)"	"unprognostic (1.13e-2)"	"unprognostic (8.10e-2)"	"unprognostic (6.62e-3)"	"unprognostic (1.34e-1)"	5.3	0.7	3.0	0.6	1.9	0.4	0.6	2.7	1.7	0.6	0.4	2.7	0.0	0.4	0.4	6.7	3.0	0.6	0.5	0.4	1.8	4.0	0.5	0.4	0.7	0.6	1.5	1.3	0.4	0.4	0.3	0.3	0.6	1.9	0.9	0.4	0.4	2.2	0.6	231.0	2.4	0.5	0.4	1.1	0.6	0.5	1.6	1.9	0.0	1.6	55.1	3.2	0.6	0.5	0.7	5.3	0.1	6.3	0.0	0.6	0.6	0.0	5.7	0.0	0.0	0.0	0.0	1.4	0.0	0.0	0.0	0.0	2.0	0.3	0.3	4.8	0.0	0.0	14.0	0.2	0.0	0.0	0.0	0.3	1.0	0.0	0.0	0.0	0.0	0.4	1.3	5.7	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.1	0.0	0.0	0.4	0.7	0.0	0.0	11.5	1.1	0.6	0.0	0.0	1.1	22.8	0.0	0.0	0.4	0.5	4.3	0.0	0.0	9.6	0.2	0.0	0.3	1.0	0.3	0.1	0.0	0.0	0.0	0.6	0.0	0.4	3.2	0.5	0.4	0.3	0.6	5.3	0.7	0.0	0.0	0.1	0.0	6.3	0.0	0.6	0.6	3.0	1.9	2.7	1.7	1.8	4.0	1.5	1.3	1.9	1.9	0.0	0.6	0.0	3.4	10.1	4.1	3.4	0.0	0.0	0.0	0.0	2.0	0.1	5.0	0.1	5.2	0.0	0.0	0.0	0.0	0.2	0.3	0.6	0.0	0.0	7.1	1.6	0.0	0.6	1.9	4.7	2.8	4.5	0.0	0.0	0.0	46.0	0.0	0.0	1.8	0.0	1.5	0.0	0.3	5.5	6.9	4.1	0.2	0.0	0.0	0.1
RYR2	"ARVC2, ARVD2, VTSIP"	ENSG00000198626	"Ryanodine receptor 2"	Q92736	1	237042205-237833988	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Developmental protein, Ion channel, Ligand-gated ion channel, Receptor"	"Cardiomyopathy, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"heart muscle: 106.6"	"Cell type enriched"	"Detected in many"	30	"Cardiomyocytes: 1960.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"HDLM-2: 7.8;HEK 293: 10.7;K-562: 3.3;NB-4: 2.7;NTERA-2: 4.0;U-937: 4.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020028	Approved		Uncertain	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Plasma membrane, Cytosol"		"HPA020028: AB_1856528"	"unprognostic (5.23e-3)"	"unprognostic (2.15e-2)"	"unprognostic (5.02e-4)"	"unprognostic (6.26e-2)"	"unprognostic (8.74e-2)"	"unprognostic (2.99e-3)"	"unprognostic (5.28e-2)"	"unprognostic (1.45e-3)"	"unprognostic (2.69e-2)"	"unprognostic (1.04e-1)"	"unprognostic (1.10e-1)"	"unprognostic (4.04e-2)"	"unprognostic (0.00e+0)"	"unprognostic (2.36e-2)"	"unprognostic (1.42e-1)"	"unprognostic (3.13e-2)"	"unprognostic (1.06e-2)"	1.1	0.9	6.2	0.9	18.7	0.5	1.1	14.8	10.5	1.3	1.2	0.0	1.2	0.7	1.1	0.7	1.8	1.0	1.8	106.6	5.7	1.1	0.9	0.9	1.4	0.6	1.0	7.3	2.2	4.2	0.5	2.0	1.1	1.6	2.0	0.8	0.2	0.9	1.4	0.9	1.0	1.0	4.6	1.0	1.0	1.2	1.1	3.0	0.0	2.7	0.0	0.6	1.2	1.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.7	0.3	0.0	0.0	0.3	0.6	0.0	0.0	7.8	10.7	2.1	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	3.3	0.2	0.0	0.0	0.0	2.7	4.0	0.1	0.4	0.0	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.1	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	4.9	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	6.2	18.7	14.8	10.5	5.7	1.1	1.0	7.3	1.6	3.0	0.0	0.3	0.0	0.0	0.3	65.2	1960.0	0.0	1.4	2.3	1.8	9.8	0.0	0.0	0.0	15.8	1.5	0.0	0.0	2.5	0.0	2.1	0.0	0.0	0.0	0.1	1.6	3.4	1.3	0.0	10.2	1.1	0.0	8.5	0.0	0.0	1.5	0.3	0.0	0.0	0.0	4.7	0.0	18.6	3.2	0.9	0.0	0.0	0.0	0.0	0.0
S1PR1	"CD363, D1S3362, edg-1, EDG1"	ENSG00000170989	"Sphingosine-1-phosphate receptor 1"	P21453	1	101236888-101241518	"Cancer-related genes, CD markers, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"	"Angiogenesis, Chemotaxis"	"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 88.9"	"Group enriched"	"Detected in many"	5	"Endothelial cells: 89.9;Ito cells: 114.2;Muller glia cells: 38.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"BJ: 19.4;HUVEC TERT2: 54.9;TIME: 30.5;U-251 MG: 37.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010104, HPA075568"	Supported		Supported	Vesicles		No	NA			Vesicles		"CAB010104: AB_2238920, HPA075568: AB_2686758"	"unprognostic (1.41e-1)"	"unprognostic (9.35e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.61e-1)"	"unprognostic (9.78e-2)"	"unprognostic (4.49e-3)"	"unprognostic (1.34e-3)"	"unprognostic (1.99e-1)"	"unprognostic (1.36e-1)"	"unprognostic (9.12e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.23e-1)"	"unprognostic (5.82e-3)"	"unprognostic (2.54e-2)"	"unprognostic (1.04e-1)"	"unprognostic (3.64e-1)"	"prognostic unfavorable (8.78e-4)"	72.3	8.4	24.7	16.6	26.2	9.7	46.3	21.6	21.8	13.3	10.5	9.5	2.5	5.7	12.1	5.0	14.7	11.5	17.6	43.5	22.9	15.4	8.9	20.5	35.7	24.5	23.2	14.0	7.9	11.0	13.4	4.7	29.6	21.2	8.9	7.0	9.3	7.5	5.6	21.7	8.2	9.8	19.0	11.0	35.2	8.0	5.8	13.9	4.4	17.0	8.7	15.7	15.2	18.5	27.4	0.2	88.9	0.2	33.4	49.8	30.8	3.6	0.0	3.9	0.0	0.4	9.3	0.0	19.4	3.5	11.8	4.2	0.0	0.1	0.0	4.8	6.7	0.0	0.0	0.5	0.2	7.9	1.3	0.4	1.3	0.1	0.0	1.8	0.0	0.8	12.5	0.0	0.0	0.9	0.5	54.9	1.1	0.0	4.0	3.7	0.0	4.6	0.0	1.0	0.1	1.3	0.0	3.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	30.5	2.0	0.7	0.4	37.6	0.3	0.0	0.2	0.2	0.0	0.1	88.9	0.1	4.9	49.8	0.1	40.2	25.1	45.3	44.1	0.2	27.4	35.7	36.2	1.4	33.4	0.2	0.2	26.8	30.8	24.7	26.2	21.6	16.8	22.9	15.4	23.2	14.0	21.2	13.9	0.0	12.8	17.1	0.1	6.8	0.0	16.9	2.5	0.0	2.3	0.0	0.0	5.5	0.0	0.0	0.0	89.9	0.0	0.0	0.0	0.3	8.4	0.5	7.0	6.0	7.6	0.0	0.0	114.2	6.9	0.0	0.9	1.5	5.0	14.4	0.0	38.0	0.0	0.0	0.0	0.0	1.0	0.0	1.4	0.4	0.7	4.4	2.2	9.2	0.0	0.4
S1PR5	"Edg-8, EDG8"	ENSG00000180739	"Sphingosine-1-phosphate receptor 5"	Q9H228	19	10512742-10517931	"FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 62.0;brain: 37.8;skin 1: 25.4"	"Cell type enriched"	"Detected in some"	12	"T-cells: 52.4"	"Group enriched"	"Detected in many"	5	"cervical cancer: 11.7;head and neck cancer: 8.0;lung cancer: 3.7;urothelial cancer: 6.2"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"gdT-cell: 62.0;MAIT T-cell: 38.0;memory CD8 T-cell: 29.2;naive CD8 T-cell: 23.2"	"Lineage enriched"	"Detected in many"	8	"T-cells: 62.0"	"Cell line enhanced"	"Detected in many"		"HaCaT: 21.9;HBEC3-KT: 8.4;RT4: 14.3;T-47d: 9.1;U-2 OS: 8.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA029683	Enhanced					NA	NA					"HPA029683: AB_10603237"	"unprognostic (9.07e-3)"	"unprognostic (1.27e-1)"	"unprognostic (1.28e-2)"	"unprognostic (5.55e-4)"	"unprognostic (4.21e-1)"	"unprognostic (4.85e-2)"	"unprognostic (9.30e-2)"	"unprognostic (1.55e-1)"	"unprognostic (3.48e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.81e-1)"	"unprognostic (1.27e-1)"	"prognostic unfavorable (6.71e-7)"	"unprognostic (2.46e-2)"	"unprognostic (2.90e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.52e-1)"	1.4	1.0	10.0	1.6	17.4	21.0	1.1	1.9	15.1	2.7	1.0	37.8	0.0	0.9	1.1	6.9	6.5	1.0	1.0	0.9	15.7	8.0	1.1	2.7	3.0	1.7	28.8	9.3	0.7	0.8	0.6	0.2	2.8	13.9	2.0	0.8	0.7	1.3	1.4	1.4	25.4	1.0	0.9	26.2	11.6	0.9	0.9	21.0	0.0	0.8	0.2	3.3	3.1	5.0	0.1	0.1	0.8	0.1	8.1	62.0	10.2	1.4	2.2	0.4	0.0	0.0	0.1	0.1	0.5	0.3	0.7	0.4	0.2	0.1	0.0	6.0	0.2	1.0	21.9	1.4	8.4	1.6	0.0	1.4	0.2	1.8	0.0	0.0	0.0	0.1	0.0	4.0	2.4	0.4	0.1	0.0	0.0	0.2	0.0	0.0	2.8	0.8	0.0	3.5	0.4	0.4	0.0	1.6	0.0	0.0	14.3	0.0	0.0	3.6	0.0	0.4	1.6	9.1	2.5	0.0	1.1	8.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	2.6	0.0	0.1	0.2	62.0	0.0	38.0	0.1	7.8	29.2	0.1	0.1	2.4	23.2	0.8	8.1	0.1	0.1	0.1	10.2	10.0	17.4	1.9	15.1	15.7	8.0	28.8	9.3	13.9	21.0	3.0	3.4	0.0	1.6	3.2	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.1	0.0	0.0	0.2	0.2	0.9	0.2	2.3	0.0	0.2	0.0	0.0	1.3	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	4.4	0.1	52.4	0.0	0.4
SCN10A	"hPN3, Nav1.8, PN3, SNS"	ENSG00000185313	"Sodium voltage-gated channel alpha subunit 10"	Q9Y5Y9	3	38696807-38816217	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	7	"heart muscle: 1.5;testis: 2.0"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"HUVEC TERT2: 1.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (6.57e-2)"										"unprognostic (7.85e-2)"		"unprognostic (2.09e-4)"	"unprognostic (1.42e-1)"	"unprognostic (2.69e-2)"			0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	0.2	0.2		0.0	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
SCN11A	"NaN, Nav1.9, SCN12A, SNS-2"	ENSG00000168356	"Sodium voltage-gated channel alpha subunit 11"	Q9UI33	3	38845769-38950561	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, FDA approved drug targets, Neurodegeneration, Neuropathy"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"lymphoid tissue: 7.5;placenta: 5.2"	"Cell type enhanced"	"Detected in some"	8	"Ciliated cells: 4.0;Early spermatids: 5.4;Sertoli cells: 6.5;Spermatocytes: 3.9;Spermatogonia: 6.0"	"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AF22: 1.8;HDLM-2: 5.0;SCLC-21H: 1.1;SuSa: 1.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA036746, HPA036747"	Uncertain					NA	NA					"HPA036746: AB_10696785, HPA036747: AB_2675287"	"unprognostic (6.11e-2)"	"unprognostic (5.16e-1)"	"unprognostic (1.66e-1)"	"unprognostic (4.75e-2)"	"unprognostic (4.21e-2)"	"unprognostic (2.34e-2)"	"unprognostic (2.79e-2)"	"unprognostic (5.66e-2)"	"unprognostic (4.44e-2)"	"unprognostic (5.21e-2)"	"unprognostic (2.30e-4)"	"unprognostic (1.91e-2)"	"unprognostic (5.43e-2)"	"unprognostic (5.02e-2)"	"unprognostic (2.95e-1)"	"unprognostic (3.12e-2)"	"unprognostic (8.30e-4)"	0.9	0.2	0.8	0.5	0.8	0.0	0.6	0.1	0.3	0.0	1.1			0.4	0.0	1.4	0.0	0.1	0.1	0.0	0.4	0.5	0.4	0.3	0.0	0.2	0.4		0.0	0.1	0.0	0.4	5.2		0.1	1.3		0.0	0.0	0.1	0.8	1.0	0.5	0.6	7.5	0.0	2.6			0.1		0.1	3.4	0.1	0.2	0.4	0.9	0.1	0.1	0.2	0.0	0.0	0.0	1.8	0.0	0.1	0.2	0.1	0.1	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.3	0.1	0.1	5.0	0.4	0.1	0.0	0.1	0.3	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.1	0.3	0.0	0.2	0.0	0.0	0.0	0.6	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.5	1.1	0.6	0.0	0.0	0.0	1.3	0.0	0.2	0.3	0.0	0.1	0.0	0.0	0.7	0.1	0.3	0.0	0.0	0.1	0.7	0.1	0.0	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.2	0.1	0.1	0.9	0.1	0.1	0.4	0.0	0.0											0.0	0.0	0.0	0.8	0.7	0.1	0.8	0.0	4.0	1.2	0.0	0.0	0.2	0.0	0.0	5.4	0.6	0.0	0.0	0.2	0.0	0.6	0.3	0.0	0.2	0.3	0.0	0.0	2.5	0.0	1.0	0.0	0.0	1.7	0.0	0.0	0.7	0.1	0.0	0.0	0.1	0.4	6.5	0.9	3.9	6.0	0.6	0.2	0.0	0.0	0.9
SCN1A	"FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI"	ENSG00000144285	"Sodium voltage-gated channel alpha subunit 1"	P35498	2	165984641-166149214	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Autism, Autism spectrum disorder, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	5	"brain: 33.9"	"Group enriched"	"Detected in some"	5	"Alveolar cells type 2: 26.9;Bipolar cells: 33.9"	"Cancer enriched"	"Detected in single"	8	"glioma: 1.8"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"ASC TERT1: 11.6;Hep G2: 6.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA078664			Supported	"Nucleoplasm,Nuclear bodies,Plasma membrane"		NA	NA			"Nucleoplasm, Plasma membrane"	"Nuclear bodies"	"HPA078664: AB_2686888"	"unprognostic (9.25e-2)"	"unprognostic (3.97e-2)"		"unprognostic (6.88e-2)"	"unprognostic (7.44e-2)"	"unprognostic (1.50e-1)"	"unprognostic (2.74e-1)"	"unprognostic (4.70e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.67e-1)"	"unprognostic (9.59e-2)"	"unprognostic (1.23e-1)"	"unprognostic (5.03e-9)"	"unprognostic (6.92e-2)"	"unprognostic (3.69e-2)"	"unprognostic (5.06e-3)"	"unprognostic (6.93e-1)"	1.1	1.3	5.2	1.1	13.6	1.0	1.1	10.3	26.6	1.1	1.1	2.3	0.0	1.0	1.1	1.1	1.0	6.8	1.0	1.1	6.9	8.3	1.1	1.1	5.6	1.0	5.7	9.7	1.0	1.0	1.1	2.9	1.2	33.9	1.1	1.1	0.3	1.0	1.0	1.2	1.1	1.1	1.1	3.6	1.1	1.1	1.4	4.2	0.0	1.1	0.0	1.0	1.1	0.1	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	11.6	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	6.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	5.2	13.6	10.3	26.6	6.9	8.3	5.7	9.7	33.9	4.2	6.0	26.9	0.0	0.0	0.0	33.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	1.7	0.0	1.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0
SCN1B		ENSG00000105711	"Sodium voltage-gated channel beta subunit 1"	Q07699	19	35030466-35040449	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Cell adhesion, Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Atrial fibrillation, Brugada syndrome, Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"brain: 78.5;skeletal muscle: 161.9"	"Cell type enhanced"	"Detected in many"	9	"Bipolar cells: 35.4;Hofbauer cells: 24.6;Ito cells: 19.0;Kupffer cells: 17.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"basophil: 7.0"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 13.6;EFO-21: 10.1;TIME: 20.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Intracellular and membrane"	NA	NA						"unprognostic (8.18e-2)"	"unprognostic (1.30e-1)"	"unprognostic (1.30e-2)"	"unprognostic (6.40e-2)"	"unprognostic (1.17e-2)"	"unprognostic (2.69e-2)"	"unprognostic (4.40e-2)"	"unprognostic (1.20e-1)"	"unprognostic (3.34e-2)"	"unprognostic (4.72e-3)"	"prognostic favorable (1.38e-4)"	"unprognostic (2.25e-1)"	"unprognostic (2.05e-2)"	"unprognostic (9.68e-3)"	"unprognostic (5.81e-2)"	"unprognostic (4.12e-2)"	"unprognostic (4.78e-2)"	5.0	5.4	9.3	2.6	16.4	2.1	2.9	45.8	78.5	5.2	2.8	4.5	0.3	2.0	2.7	3.5	5.0	4.3	3.3	24.9	12.7	7.3	2.2	3.3	2.7	2.4	14.3	7.4	2.6	2.4	10.5	2.6	3.5	33.6	2.7	2.4	3.5	2.5	2.9	161.9	2.1	2.5	3.2	7.0	6.7	2.7	2.0	3.0	0.0	2.4	16.1	1.6	3.9	1.5	1.3	1.5	7.0	0.8	1.7	1.7	1.8	0.3	13.6	0.1	0.8	4.2	6.5	0.2	5.5	4.9	2.7	0.7	0.5	0.1	0.2	10.1	5.6	2.5	0.2	0.8	0.6	1.3	0.1	0.7	0.2	1.9	3.4	5.6	0.1	0.1	2.1	0.1	0.3	0.2	5.4	9.1	0.2	0.3	0.1	1.7	1.3	0.2	0.1	0.7	1.2	4.0	0.7	1.4	0.1	0.4	0.1	6.5	3.5	0.7	0.1	1.0	0.5	1.3	0.4	20.4	5.4	5.4	0.2	3.5	0.3	0.4	0.8	3.1	0.6	3.8	7.0	0.8	0.9	1.1	0.4	1.7	0.6	0.6	0.4	1.5	1.3	0.5	0.7	3.1	1.7	0.4	1.1	0.7	1.8	9.3	16.4	45.8	78.5	12.7	7.3	14.3	7.4	33.6	3.0	0.0	3.5	0.0	0.8	1.5	35.4	15.5	0.0	1.4	0.0	0.0	2.0	0.3	8.3	0.3	0.3	5.7	0.0	0.0	2.3	0.6	4.1	1.0	2.3	1.0	24.6	7.9	0.0	19.0	17.1	0.0	6.9	2.9	3.3	4.6	1.1	12.6	1.0	0.0	2.1	1.1	15.5	0.0	2.3	0.3	0.4	1.0	0.8	0.0	0.9	0.1
SCN2A	"HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2"	ENSG00000136531	"Sodium voltage-gated channel alpha subunit 2"	Q99250	2	165194993-165392310	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	8	"brain: 68.0"	"Cell type enhanced"	"Detected in some"	17	"Bipolar cells: 48.0;Cone photoreceptor cells: 45.2;Horizontal cells: 14.3"	"Cancer enhanced"	"Detected in single"		"glioma: 1.3"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.4"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"HSkMC: 3.4;SH-SY5Y: 3.1;U-138 MG: 5.8;U-266/84: 12.0;U-87 MG: 3.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB022567	Enhanced					NA	NA					"CAB022567: "	"unprognostic (1.16e-1)"	"unprognostic (3.56e-4)"	"unprognostic (5.28e-2)"	"unprognostic (6.12e-3)"	"unprognostic (2.97e-1)"	"unprognostic (8.62e-3)"	"unprognostic (1.18e-1)"	"unprognostic (7.25e-3)"	"unprognostic (1.40e-1)"	"unprognostic (2.78e-1)"	"unprognostic (1.32e-2)"	"unprognostic (5.21e-2)"	"unprognostic (3.44e-2)"	"unprognostic (1.76e-1)"	"unprognostic (1.05e-1)"	"unprognostic (4.88e-2)"	"unprognostic (2.14e-1)"	1.3	3.0	19.1	1.3	36.4	1.1	2.2	68.0	50.3	1.5	1.3	1.1	0.0	1.5	1.9	2.6	1.2	1.3	2.3	1.3	30.3	8.2	4.0	1.4	1.5	1.2	3.8	23.5	1.5	1.3	1.1	8.2	1.3	9.9	1.3	1.3	0.0	1.5	1.8	1.1	1.2	1.5	2.0	3.7	1.3	1.5	1.5	4.1	0.0	1.1	0.0	1.2	1.3	0.5	1.4	0.6	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.6	0.0	0.2	0.8	0.0	0.0	2.8	0.0	2.7	0.0	0.0	0.4	0.0	0.0	0.3	0.0	0.0	0.5	0.1	1.0	0.7	0.0	0.4	0.0	0.4	0.0	0.2	3.4	0.1	0.3	0.0	2.4	0.0	0.0	0.0	0.3	1.5	0.0	0.2	0.0	2.0	0.1	0.3	0.0	0.0	0.0	0.1	0.1	2.9	3.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	5.8	0.4	0.3	0.0	0.5	12.0	0.0	3.6	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	1.4	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	19.1	36.4	68.0	43.7	30.3	8.2	3.8	23.5	9.9	4.1	0.0	1.7	0.0	0.1	0.2	48.0	0.6	0.0	0.0	0.0	10.4	45.2	0.1	5.0	0.1	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	1.3	1.1	0.0	0.0	0.0	0.0	3.7	0.5	0.0	5.6	0.0	3.4	0.0	0.4	0.0	0.6	0.1	0.0	0.0	0.0	0.0
SCN2B		ENSG00000149575	"Sodium voltage-gated channel beta subunit 2"	O60939	11	118161951-118176673	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Atrial fibrillation, Brugada syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	6	"brain: 37.0;heart muscle: 17.5;skeletal muscle: 9.7"	"Group enriched"	"Detected in some"	5	"Bipolar cells: 7.9;Cardiomyocytes: 14.0;Horizontal cells: 12.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 2.1"	"Lineage enriched"	"Detected in single"	6	"granulocytes: 2.1"	"Group enriched"	"Detected in some"	5	"HBEC3-KT: 1.5;U-2 OS: 2.6;U-2197: 6.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (9.01e-2)"	"unprognostic (3.50e-2)"	"unprognostic (7.58e-2)"	"unprognostic (2.12e-2)"	"unprognostic (1.41e-2)"	"unprognostic (4.02e-1)"	"unprognostic (2.71e-4)"	"unprognostic (5.17e-2)"	"unprognostic (8.59e-2)"	"unprognostic (2.77e-1)"	"unprognostic (7.89e-2)"	"unprognostic (1.61e-2)"	"unprognostic (3.51e-2)"	"unprognostic (1.27e-2)"	"unprognostic (4.35e-2)"	"unprognostic (4.55e-1)"	"unprognostic (2.88e-3)"	1.8	3.0	14.7	1.4	31.5	1.0	1.9	31.1	37.0	2.9	2.0	3.1	0.0	1.7	3.2	2.9	3.6	2.9	2.7	17.5	22.5	11.6	1.6	1.0	2.5	1.0	8.7	30.6	2.8	1.1	1.0	0.8	1.0	12.8	2.4	1.9	0.4	1.8	2.7	9.7	1.4	2.5	3.5	13.9	1.1	1.3	1.3	6.9	0.0	1.9	0.7	1.0	1.5	0.6	0.3	0.2	2.1	0.3	0.2	0.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.2	0.1	0.1	0.0	0.0	0.1	0.1	0.1	1.5	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.1	0.2	0.1	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.3	0.0	0.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.2	0.0	0.2	0.0	0.7	0.1	0.0	0.0	0.1	2.6	6.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	2.1	0.3	0.9	0.2	0.1	0.1	0.2	0.1	0.1	0.1	0.3	0.2	0.2	1.3	0.2	0.0	0.2	0.1	0.0	14.7	31.5	31.1	37.0	22.5	11.6	8.7	30.6	12.8	6.9	0.0	0.0	0.0	0.5	0.3	7.9	14.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.1	12.7	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.9	0.0	0.0	2.1	0.0	1.4	0.0	1.0	0.0	0.6	0.1	0.0	0.0	0.0	0.2
SCN3A	Nav1.3	ENSG00000153253	"Sodium voltage-gated channel alpha subunit 3"	Q9NY46	2	165087522-165204067	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"blood: 13.6;brain: 28.5;pituitary gland: 13.7"	"Cell type enriched"	"Detected in some"	4	"Early spermatids: 55.3"	"Cancer enriched"	"Detected in some"	6	"glioma: 3.4"	"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in some"	31	"memory B-cell: 8.4;naive B-cell: 13.6"	"Lineage enriched"	"Detected in single"	38	"B-cells: 13.6"	"Cell line enhanced"	"Detected in some"		"JURKAT: 4.9;Karpas-707: 8.7;MOLT-4: 24.4;RPTEC TERT1: 12.3;SH-SY5Y: 5.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA035396	Approved					NA	NA					"HPA035396: AB_2674607"	"unprognostic (1.80e-3)"	"unprognostic (1.84e-2)"	"unprognostic (1.20e-3)"	"unprognostic (1.50e-2)"	"unprognostic (6.69e-2)"	"unprognostic (1.10e-2)"	"unprognostic (4.96e-4)"	"unprognostic (2.46e-1)"	"unprognostic (1.48e-1)"	"unprognostic (1.90e-1)"	"unprognostic (1.21e-4)"	"unprognostic (4.55e-2)"	"unprognostic (5.87e-3)"	"unprognostic (2.88e-2)"	"unprognostic (6.85e-2)"	"unprognostic (2.66e-1)"	"unprognostic (4.93e-2)"	2.6	4.0	16.7	1.9	28.5	1.0	2.5	19.6	19.7	2.1	2.1	0.8	0.0	1.2	1.4	0.7	1.5	1.4	1.8	2.1	9.8	11.3	1.8	1.0	1.0	2.7	4.8	9.8	1.8	1.7	2.3	13.7	0.8	9.1	0.9	2.1	0.0	0.7	1.4	0.9	0.5	1.9	1.7	4.0	1.8	2.7	1.8	4.9	2.0	1.3	0.0	3.5	1.7	0.5	13.6	0.3	0.0	0.0	0.1	0.1	0.1	0.0	0.1	2.4	0.0	0.0	0.1	0.0	0.0	0.2	0.5	1.6	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	4.3	0.0	4.9	0.0	8.7	0.1	0.0	24.4	0.0	0.0	0.1	2.0	0.1	1.1	0.0	12.3	0.0	3.1	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.1	0.7	0.0	1.3	0.4	0.0	0.6	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	8.4	0.0	0.0	0.0	13.6	0.1	0.0	0.0	0.1	0.0	0.3	0.0	0.1	16.7	28.5	19.6	17.2	9.8	11.3	4.8	9.8	9.1	4.9	0.0	0.3	1.9	0.1	0.0	0.8	3.2	0.0	0.0	0.0	1.8	11.8	0.0	0.0	0.1	55.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	4.8	8.5	0.0	0.0	5.4	0.3	0.0	1.7	0.0	0.0	0.6	0.2	0.0	0.7	0.0	0.7	12.9	5.2	0.2	0.4	0.1	0.0	0.0	0.0	0.0
SCN3B	HSA243396	ENSG00000166257	"Sodium voltage-gated channel beta subunit 3"	Q9NY72	11	123629187-123655244	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Atrial fibrillation, Brugada syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 70.3"	"Cell type enhanced"	"Detected in many"	9	"Bipolar cells: 15.3;Early spermatids: 12.8;Horizontal cells: 19.1;Late spermatids: 24.3"	"Cancer enhanced"	"Detected in some"		"glioma: 2.2"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in some"		"hTCEpi: 9.6;RH-30: 4.3;SCLC-21H: 9.5;SH-SY5Y: 7.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA041707			Approved	"Intermediate filaments,Cytosol"		NA	NA			"Intermediate filaments"	Cytosol	"HPA041707: AB_2732493"	"unprognostic (1.41e-1)"	"unprognostic (8.72e-2)"	"unprognostic (8.13e-4)"	"unprognostic (3.93e-3)"	"unprognostic (7.05e-2)"	"unprognostic (3.29e-3)"	"unprognostic (5.64e-2)"	"unprognostic (3.34e-4)"	"unprognostic (1.72e-1)"	"unprognostic (1.13e-2)"	"unprognostic (9.16e-4)"	"unprognostic (4.01e-1)"	"unprognostic (1.89e-4)"	"unprognostic (2.01e-2)"	"unprognostic (9.01e-2)"	"unprognostic (8.23e-2)"	"unprognostic (1.43e-2)"	2.2	8.5	17.7	1.5	23.5	1.3	2.0	2.8	70.3	1.6	1.5	1.2	0.0	1.6	1.5	1.5	1.5	1.8	1.4	1.9	26.2	13.2	1.6	1.0	1.4	1.2	5.2	18.8	1.7	1.9	3.9	12.6	1.1	3.8	1.8	1.6	3.7	1.2	1.4	5.8	1.7	1.5	2.1	1.5	1.3	1.4	2.2	1.2	0.0	3.7	0.0	1.2	1.1	0.4	1.2	1.3	2.7	0.6	1.1	0.8	0.1	0.0	0.2	0.3	0.2	0.1	0.1	0.3	0.2	0.3	0.0	0.0	3.0	0.1	0.3	1.5	0.4	3.1	0.2	1.0	0.1	0.2	0.1	0.6	0.0	0.5	0.3	0.1	0.0	0.6	0.4	9.6	0.1	0.1	0.0	0.3	0.3	0.4	0.5	0.0	0.1	0.1	0.2	0.8	0.3	0.1	0.2	4.3	0.0	0.0	0.2	9.5	7.2	0.6	0.1	0.0	1.0	0.1	0.0	0.2	0.1	0.4	0.1	0.1	0.1	0.0	0.2	0.2	0.1	0.1	0.6	0.6	0.5	0.6	0.4	0.4	0.7	0.7	0.7	0.3	1.2	0.5	0.8	2.7	1.1	0.5	1.3	0.4	0.1	17.7	23.5	2.8	39.5	26.2	13.2	5.2	18.8	3.8	1.2	0.0	0.3	0.0	0.8	5.0	15.3	1.4	0.0	0.0	0.0	1.8	5.9	0.1	0.0	0.3	12.8	8.7	0.0	0.0	0.9	0.1	1.1	1.0	0.0	0.0	0.2	19.1	4.1	0.6	0.0	24.3	0.0	0.5	0.0	0.0	0.0	8.3	0.4	0.0	0.4	0.1	5.9	6.5	0.7	0.3	1.5	4.8	0.0	0.0	0.0	0.4
SCN4A	"HYKPP, HYPP, Nav1.4, SkM1"	ENSG00000007314	"Sodium voltage-gated channel alpha subunit 4"	P35499	17	63938554-63972918	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	9	"skeletal muscle: 53.7"	"Cell type enhanced"	"Detected in some"	15	"Early spermatids: 3.4;Ito cells: 3.1;Late spermatids: 2.9"	"Cancer enhanced"	"Detected in some"		"thyroid cancer: 2.2"					"Cell type enhanced"	"Detected in single"		"naive B-cell: 1.9"	"Lineage enhanced"	"Detected in single"		"B-cells: 1.9"	"Group enriched"	"Detected in some"	11	"REH: 10.1;RH-30: 31.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA053992			Approved	"Nucleoplasm,Centriolar satellite"		NA	NA			Nucleoplasm	"Centriolar satellite"	"HPA053992: AB_2797249"	"unprognostic (2.47e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.57e-2)"	"unprognostic (1.78e-3)"	"unprognostic (2.80e-2)"	"unprognostic (1.63e-2)"	"unprognostic (3.87e-4)"	"unprognostic (3.84e-3)"	"unprognostic (1.61e-1)"	"unprognostic (1.36e-1)"	"unprognostic (1.59e-3)"	"unprognostic (3.15e-2)"	"unprognostic (2.70e-2)"	"unprognostic (4.38e-3)"	"unprognostic (3.46e-1)"	"unprognostic (4.15e-1)"	"unprognostic (6.45e-2)"	5.9	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.2			0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0		0.0	0.0	0.3	0.3	0.0		0.1	0.0		0.5	0.0	53.7	0.0	0.0	0.0	0.0	0.1	0.0	0.4			1.6		0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.0	0.0	0.0	10.1	31.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.9	0.9	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.2	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.1	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.2	0.1	0.0	0.0	0.0	0.0
SCN4B	LQT10	ENSG00000177098	"Sodium voltage-gated channel beta subunit 4"	Q8IWT1	11	118133377-118152888	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Atrial fibrillation, Disease mutation, FDA approved drug targets, Long QT syndrome"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 36.4;skeletal muscle: 25.6"	"Cell type enriched"	"Detected in some"	4	"Sertoli cells: 45.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 3.9;HBEC3-KT: 3.0;NTERA-2: 4.4;SH-SY5Y: 1.7;U-2 OS: 4.0"	"Region enriched"	"Detected in many"	11	"basal ganglia: 731.2"	"Region enhanced"	"Detected in many"		"basal ganglia: 122.8"	HPA017293	Approved					NA	NA					"HPA017293: AB_2184174"	"unprognostic (1.98e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.13e-1)"	"unprognostic (2.43e-1)"	"unprognostic (1.45e-1)"	"unprognostic (1.07e-1)"	"unprognostic (9.82e-3)"	"unprognostic (9.17e-3)"	"unprognostic (1.20e-2)"	"unprognostic (1.23e-2)"	"unprognostic (1.03e-2)"	"unprognostic (3.27e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.07e-2)"	"unprognostic (2.18e-3)"	"unprognostic (1.53e-1)"	"unprognostic (5.31e-4)"	20.5	5.4	1.9	1.2	36.4	0.1	6.1	11.7	21.7	2.4	2.6	2.0	0.5	2.4	3.7	1.8	5.4	5.5	3.2	11.0	3.1	2.9	1.4	0.6	8.7	2.0	5.3	2.1	0.7	5.0	6.4	2.4	1.9	28.7	2.1	2.2	4.3	2.8	2.6	25.6	3.8	4.6	7.0	5.5	0.5	3.0	0.8	8.7	1.5	10.4	9.5	1.1	3.4	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	3.9	0.0	0.0	0.2	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.6	0.6	0.3	3.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	1.1	0.5	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	1.7	0.4	0.0	0.0	1.1	0.0	0.0	0.0	0.0	4.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	36.4	11.7	21.7	3.1	2.9	5.3	2.1	28.7	8.7	0.0	0.0	0.0	0.3	1.1	1.1	2.8	0.0	6.7	1.2	0.0	0.0	0.0	0.0	0.0	1.3	0.7	0.0	0.0	0.0	0.0	1.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.3	3.3	2.0	0.8	0.0	0.0	0.0	0.3	0.0	0.0	1.4	0.0	0.3	45.3	10.8	0.0	0.6	1.0	0.0	0.0	0.0	0.1
SCN5A	"CDCD2, CMD1E, CMPD2, HB1, HB2, HBBD, HH1, ICCD, IVF, LQT3, Nav1.5, PFHB1, SSS1"	ENSG00000183873	"Sodium voltage-gated channel alpha subunit 5"	Q14524	3	38548057-38649673	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Calmodulin-binding, Ion channel, Sodium channel, Voltage-gated channel"	"Atrial fibrillation, Brugada syndrome, Cardiomyopathy, Disease mutation, FDA approved drug targets, Long QT syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	12	"heart muscle: 67.3"	"Cell type enriched"	"Detected in some"	5	"Cardiomyocytes: 66.1"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in some"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	4	"LHCN-M2: 22.0;RH-30: 18.3"	"Group enriched"	"Detected in some"	5	"amygdala: 3.2;basal ganglia: 10.5;hypothalamus: 7.0"	"Low region specificity"	"Detected in many"			HPA063346			Supported	"Nucleoplasm,Nucleoli,Plasma membrane"		NA	NA			"Plasma membrane"	"Nucleoplasm, Nucleoli"	"HPA063346: "	"unprognostic (9.29e-4)"	"unprognostic (4.05e-2)"	"unprognostic (9.95e-2)"	"unprognostic (1.74e-1)"	"unprognostic (9.21e-2)"	"unprognostic (1.24e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.48e-1)"	"unprognostic (7.36e-2)"	"unprognostic (8.48e-2)"	"unprognostic (7.12e-3)"	"unprognostic (5.28e-2)"	"unprognostic (1.16e-4)"	"unprognostic (4.85e-3)"	"unprognostic (1.09e-1)"	"unprognostic (5.35e-2)"	"unprognostic (4.95e-3)"	0.3	0.2	1.3	0.2	0.3	0.4	0.6	0.1	2.3	2.0	0.4	0.0	0.4	0.3	0.9	0.8	0.2	0.4	0.3	67.3	0.5	0.7	0.1	0.1	0.2	0.1	0.1	0.3	0.6	0.2	0.1	0.8	0.3	0.0	1.3	0.2	1.2	0.3	1.6	5.5	0.2	0.3	0.4	0.1	0.2	0.2	0.5	0.0	0.0	0.3	0.1	0.1	0.8	1.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.5	0.1	0.0	0.1	0.8	0.4	0.0	0.1	0.3	2.7	0.0	0.0	0.0	0.9	0.9	2.7	0.0	0.4	0.0	1.2	0.7	0.0	0.1	0.1	0.0	0.1	0.5	0.0	0.5	0.0	1.7	3.6	0.4	0.0	0.0	22.0	1.1	0.0	0.0	2.0	0.0	0.0	0.0	18.3	0.0	0.0	2.4	0.3	2.4	0.0	0.0	0.0	0.7	0.0	0.0	4.4	0.0	4.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.3	0.1	2.3	0.5	0.7	0.1	0.3	0.0	0.0	0.0	0.0	0.0	1.1	0.2	3.1	66.1	0.0	0.0	0.0	0.0	13.7	0.1	0.0	0.1	1.0	0.4	0.0	0.0	0.0	0.2	0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.8	0.1	0.0	0.0	0.0	0.7	0.0	0.4	0.3	0.9	0.0	0.0	0.0	0.0	1.0
SCN7A	"NaG, Nav2.1, Nav2.2, SCN6A"	ENSG00000136546	"Sodium voltage-gated channel alpha subunit 7"	Q01118	2	166403573-166494326	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"lung: 51.9"	"Group enriched"	"Detected in many"	8	"Leydig cells: 93.5;Peritubular cells: 150.3;Sertoli cells: 148.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in single"		"basophil: 2.1"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.1"	"Cell line enhanced"	"Detected in some"		"MOLT-4: 2.9;SH-SY5Y: 1.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA072715	Approved					NA	NA					"HPA072715: "	"unprognostic (1.22e-1)"	"unprognostic (6.42e-3)"	"unprognostic (9.72e-2)"	"unprognostic (7.43e-2)"	"unprognostic (2.18e-1)"	"unprognostic (1.78e-1)"	"unprognostic (1.86e-1)"	"unprognostic (4.00e-3)"	"unprognostic (5.21e-2)"	"unprognostic (6.84e-3)"	"unprognostic (6.88e-2)"	"unprognostic (1.27e-1)"	"unprognostic (5.80e-2)"	"unprognostic (3.71e-2)"	"unprognostic (1.47e-2)"	"unprognostic (1.35e-1)"	"unprognostic (1.22e-4)"	4.9	6.0	1.0	10.4	0.7	0.0	2.9	0.3	0.7	16.2	23.3	0.0	13.0	2.0	24.6	8.1	28.1	7.8	6.8	16.0	0.7	3.6	1.8	1.3	51.9	1.6	3.6	0.5	33.3	3.1	0.3	1.1	8.1	2.6	18.4	6.1	14.0	4.9	11.3	3.7	1.5	6.2	10.5	4.3	5.5	6.4	6.9	0.1	0.5	1.3	4.9	0.2	9.7	7.6	0.0	0.8	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.3	0.5	0.0	0.1	0.1	0.9	0.0	0.2	0.0	0.0	1.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.7	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	1.0	0.7	0.3	0.7	0.7	3.6	3.6	0.5	2.6	0.1	0.0	1.4	0.0	0.1	0.2	11.4	15.4	0.0	0.0	1.2	0.0	0.0	0.0	1.7	0.0	2.0	0.7	0.0	0.0	0.0	0.0	11.0	0.1	16.1	0.0	0.2	0.0	0.0	16.0	0.0	1.6	93.5	0.0	5.0	0.0	0.0	5.2	0.2	0.0	150.3	0.3	1.6	148.8	0.9	0.5	0.1	1.0	0.0	0.0	0.0	0.3
SCN8A	"CerIII, CIAT, MED, NaCh6, Nav1.6, PN4"	ENSG00000196876	"Sodium voltage-gated channel alpha subunit 8"	Q9UQD0	12	51590266-51812864	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"brain: 27.6;pituitary gland: 9.7"	"Cell type enhanced"	"Detected in some"	9	"Bipolar cells: 13.7;Cone photoreceptor cells: 9.8;Intestinal endocrine cells: 10.9;Rod photoreceptor cells: 10.5;Spermatogonia: 10.0"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"memory CD8 T-cell: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in many"		"AF22: 12.0;ASC TERT1: 12.7;BJ hTERT+: 11.2;WM-115: 11.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022169, HPA043937, HPA073590"			Approved	"Vesicles,Plasma membrane,Cell Junctions"		NA	NA			"Plasma membrane"	"Vesicles, Cell Junctions"	"CAB022169: , HPA043937: , HPA073590: "	"unprognostic (2.96e-2)"	"unprognostic (8.49e-2)"	"unprognostic (6.93e-2)"	"unprognostic (3.52e-6)"	"unprognostic (8.13e-2)"	"unprognostic (1.51e-2)"	"unprognostic (1.16e-1)"	"unprognostic (7.77e-2)"	"unprognostic (5.44e-2)"	"unprognostic (1.16e-1)"	"unprognostic (4.73e-4)"	"unprognostic (1.69e-2)"	"unprognostic (1.29e-5)"	"unprognostic (4.38e-1)"	"unprognostic (1.56e-1)"	"unprognostic (2.37e-1)"	"unprognostic (4.75e-2)"	1.1	3.0	9.1	1.5	18.1	1.9	1.9	16.7	27.6	1.0	2.0	1.6	0.0	1.1	1.5	2.0	0.9	1.1	2.5	0.9	12.6	4.5	1.9	4.3	1.0	1.3	3.2	13.7	1.8	3.2	1.5	9.7	0.9	14.8	1.8	2.5	0.9	1.7	1.2	1.0	1.1	1.2	1.0	2.2	1.7	2.7	3.8	1.6	0.0	1.7	0.0	1.2	1.0	0.6	0.4	0.2	0.0	0.0	0.0	1.0	0.0	1.4	1.0	12.0	0.1	1.6	12.7	0.2	6.8	11.2	7.9	7.3	2.0	1.4	0.3	1.6	8.9	3.5	0.0	1.9	0.0	9.3	1.2	0.6	0.1	0.1	0.2	0.1	0.2	0.9	1.7	0.0	5.2	1.1	3.1	8.4	2.8	0.1	0.1	4.9	0.8	2.0	0.1	4.1	0.7	3.8	0.0	0.6	0.0	0.0	0.4	4.8	2.0	3.5	1.8	0.2	1.8	0.3	0.1	2.2	7.7	5.1	2.8	4.3	0.1	0.1	0.0	1.5	1.6	11.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.7	1.0	0.0	0.4	0.4	0.2	0.0	0.0	0.0	0.2	0.0	0.0	9.1	18.1	16.7	25.0	12.6	4.5	3.2	13.7	14.8	1.6	0.0	0.0	0.0	0.4	0.0	13.7	1.2	0.0	0.0	0.0	0.0	9.8	0.0	0.0	0.2	0.4	0.4	0.0	0.0	0.5	0.0	0.0	0.2	0.0	3.4	0.0	4.8	10.9	1.3	0.0	0.2	0.0	0.0	0.0	0.0	1.3	5.3	0.5	0.0	0.7	0.5	10.5	0.0	0.3	1.9	10.0	0.0	0.0	0.0	0.6	0.1
SCN9A	"ETHA, Nav1.7, NE-NA, NENA, PN1"	ENSG00000169432	"Sodium voltage-gated channel alpha subunit 9"	Q15858	2	166195185-166376001	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sodium transport, Transport"	"Ion channel, Sodium channel, Voltage-gated channel"	"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Exocrine glandular cells: 27.7;Hofbauer cells: 50.6;Intestinal endocrine cells: 31.7"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in some"	17	"plasmacytoid DC: 18.6"	"Lineage enriched"	"Detected in single"	24	"dendritic cells: 18.6"	"Cell line enhanced"	"Detected in many"		"BJ: 17.2;BJ hTERT+: 12.8;HHSteC: 14.8;hTERT-RPE1: 12.0"	"Region enriched"	"Detected in some"	5	"hypothalamus: 10.9"	"Low region specificity"	"Detected in all"			"CAB013679, HPA061843"	Uncertain		Approved	"Plasma membrane,Actin filaments,Focal adhesion sites"		NA	NA			"Plasma membrane, Actin filaments, Focal adhesion sites"		"CAB013679: , HPA061843: AB_2684625"	"unprognostic (2.10e-1)"	"unprognostic (2.83e-1)"	"unprognostic (1.13e-1)"	"unprognostic (8.98e-5)"	"unprognostic (1.47e-3)"	"unprognostic (9.43e-3)"	"unprognostic (2.28e-2)"	"unprognostic (2.24e-1)"	"unprognostic (2.23e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.27e-1)"	"prognostic unfavorable (2.30e-5)"	"unprognostic (1.69e-3)"	"unprognostic (6.74e-2)"	"unprognostic (2.46e-2)"	"unprognostic (2.46e-1)"	6.6	4.2	3.8	2.8	9.1	4.2	2.7	0.9	4.4	1.8	10.2	0.5	0.1	1.4	0.9	3.8	2.6	1.2	5.8	2.9	2.8	15.9	4.8	8.3	4.5	3.5	4.1	2.3	2.1	4.8	0.6	11.3	9.2	7.3	2.0	7.0	1.7	1.8	1.9	0.9	1.8	4.2	5.2	2.5	12.4	1.7	16.2	0.4	10.3	1.4	1.9	1.2	3.6	1.8	0.0	18.6	0.7	0.1	0.4	0.0	0.0	0.0	1.9	0.1	0.0	7.4	6.5	0.0	17.2	12.8	4.0	1.3	0.5	0.0	0.0	0.0	2.1	0.2	0.0	4.9	0.6	6.6	0.0	1.6	1.3	1.5	1.4	14.8	0.0	0.0	0.4	0.2	6.8	1.3	12.0	0.8	0.9	4.3	5.0	0.6	0.0	2.6	0.0	1.5	0.0	0.5	0.7	2.5	6.5	1.8	7.2	0.8	7.2	0.0	0.0	0.3	3.8	0.2	0.0	0.0	0.0	1.1	0.1	0.3	0.1	0.0	0.0	2.5	0.0	1.4	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.7	0.4	0.1	18.6	0.0	0.0	3.8	9.1	0.9	4.4	2.8	15.9	4.1	2.3	7.3	0.4	11.9	18.4	0.9	0.2	0.9	0.2	1.6	5.1	4.0	7.9	5.2	0.0	0.2	3.3	14.9	1.7	2.2	11.3	0.0	27.7	0.4	1.2	0.2	3.5	6.0	50.6	0.0	31.7	20.3	1.5	1.9	1.1	4.3	3.3	0.0	14.6	1.3	18.8	8.6	0.0	12.2	0.0	0.0	1.0	0.0	0.4	0.4	0.9	0.0	10.7	0.1
SCNN1A	"ENaCalpha, SCNN1"	ENSG00000111319	"Sodium channel epithelial 1 alpha subunit"	P37088	12	6346843-6377730	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 100.4"	"Cell type enhanced"	"Detected in many"	9	"Collecting duct cells: 108.2;Mucus-secreting cells: 167.5"	"Low cancer specificity"	"Detected in many"			"Region enriched"	"Detected in some"	8	"pons and medulla: 9.4"	"Group enriched"	"Detected in some"	4	"naive CD4 T-cell: 1.7;neutrophil: 4.4;plasmacytoid DC: 3.0;T-reg: 1.3"	"Group enriched"	"Detected in many"	5	"dendritic cells: 3.0;granulocytes: 4.4;T-cells: 1.7"	"Cell line enhanced"	"Detected in some"		"CAPAN-2: 71.8;HBEC3-KT: 48.2;hTCEpi: 20.7;RPTEC TERT1: 25.2;RT4: 27.0;SK-BR-3: 23.3"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			HPA012743	Enhanced					NA	NA					"HPA012743: AB_1856627"	"unprognostic (1.68e-1)"	"unprognostic (4.16e-2)"	"unprognostic (1.62e-1)"	"unprognostic (2.19e-1)"	"unprognostic (5.16e-2)"	"unprognostic (6.77e-3)"	"unprognostic (3.09e-2)"	"unprognostic (2.62e-2)"	"unprognostic (5.13e-2)"	"prognostic unfavorable (8.86e-4)"	"prognostic unfavorable (2.30e-4)"	"unprognostic (5.56e-2)"	"prognostic favorable (9.21e-8)"	"unprognostic (2.38e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.16e-1)"	"unprognostic (1.01e-2)"	0.9	3.7	0.4	7.5	0.4	0.0	10.1	0.4	0.9	22.0	20.6	2.2	60.9	5.6	8.1	15.7	47.3	19.3	7.0	0.4	1.1	0.1	100.4	2.2	53.6	0.4	0.5	0.4	5.9	14.2	0.0	10.2	1.6	9.4	15.0	21.5	6.2	53.1	55.5	0.6	14.4	11.8	1.0	0.4	0.4	20.3	2.8	0.4	0.9	74.7	21.1	41.3	10.3	13.8	0.0	3.0	4.4	0.5	0.0	1.7	0.3	5.0	0.9	0.0	0.4	0.0	0.1	4.3	0.0	0.0	0.0	0.0	1.4	71.8	0.0	0.1	0.0	0.0	3.3	0.0	48.2	0.0	0.0	0.0	0.0	4.0	0.7	5.2	0.0	0.0	1.2	20.7	0.0	15.1	0.1	0.0	0.1	0.0	0.0	0.1	0.4	0.0	0.0	4.2	9.1	0.1	0.0	0.0	0.1	25.2	27.0	0.3	0.0	0.5	23.3	0.0	4.3	5.3	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.3	0.3	0.5	0.0	0.0	0.2	0.6	0.5	0.0	1.7	0.3	4.4	0.0	0.1	3.0	1.3	0.3	0.4	0.4	0.4	0.9	1.1	0.1	0.5	0.4	9.4	0.4	68.5	63.0	0.0	21.9	1.6	0.8	0.8	68.8	26.8	47.8	108.2	3.9	1.2	5.0	41.1	0.4	1.4	57.4	0.0	30.8	0.2	2.4	31.3	2.3	2.4	0.3	1.6	26.0	0.6	1.9	0.2	1.7	2.1	0.0	1.8	167.5	0.3	24.0	47.5	1.4	4.2	1.6	0.0	1.0	1.4	2.1	7.8	1.4	1.9	31.6	33.3
SCNN1B	ENaCbeta	ENSG00000168447	"Sodium channel epithelial 1 beta subunit"	P51168	16	23278231-23381299	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 42.4"	"Cell type enhanced"	"Detected in many"	12	"Alveolar cells type 1: 92.3;Club cells: 66.0;Collecting duct cells: 54.1;Enterocytes: 54.8"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 26.4"	"Region enhanced"	"Detected in single"		"cerebellum: 1.1"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"hTCEpi: 19.4;RT4: 10.4;U-266/70: 32.0;U-266/84: 11.1"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA015612	Uncertain					NA	NA					"HPA015612: AB_1856629"	"unprognostic (7.45e-2)"	"unprognostic (1.76e-3)"	"unprognostic (1.39e-1)"	"unprognostic (6.74e-3)"	"unprognostic (1.74e-2)"	"unprognostic (5.11e-3)"	"unprognostic (7.74e-2)"	"unprognostic (5.49e-3)"	"unprognostic (2.60e-1)"	"unprognostic (2.40e-1)"	"unprognostic (3.68e-1)"	"unprognostic (2.84e-1)"	"prognostic unfavorable (2.09e-6)"	"unprognostic (2.32e-1)"	"unprognostic (4.66e-2)"	"unprognostic (3.93e-3)"	"unprognostic (1.25e-2)"	35.1	0.2	0.1	4.0	0.2	0.0	21.2	1.1	0.1	28.3	27.2	0.0	1.3	1.3	2.9	2.5	42.4	1.3	3.3	0.6	0.0	0.0	13.0	0.0	31.1	1.3	0.0	0.0	2.0	0.8	0.3	1.6	25.2	0.3	5.7	19.7	0.5	29.7	2.4	3.9	13.2	1.7	4.2	0.1	1.9	8.9	1.6	0.0	0.6	16.2	17.8	15.5	5.6	19.6	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	19.4	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.0	0.0	0.0	0.0	0.0	4.0	0.0	0.0	4.9	0.0	10.4	0.1	0.0	0.0	0.3	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	32.0	11.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.1	0.2	1.1	0.1	0.0	0.0	0.0	0.0	0.3	0.0	92.3	27.0	2.2	14.0	2.7	0.0	0.8	0.0	10.7	66.0	54.1	0.0	0.7	0.0	0.0	0.0	0.7	54.8	0.0	0.4	0.2	0.2	4.3	8.1	0.0	0.1	0.0	7.5	0.0	0.0	0.0	0.0	0.0	10.1	0.0	7.9	0.0	0.2	9.3	0.0	0.0	0.0	0.0	0.3	0.0	0.2	4.6	1.8	0.0	7.6	17.0
SCNN1D	"dNaCh, ENaCdelta"	ENSG00000162572	"Sodium channel epithelial 1 delta subunit"	P51172	1	1280436-1292029	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	7	"Early spermatids: 9.6"	"Low cancer specificity"	"Detected in many"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"U-266/70: 11.4"									HPA026884	Enhanced		Supported	"Plasma membrane,Actin filaments"		NA	NA			"Plasma membrane, Actin filaments"		"HPA026884: AB_10601501"	"unprognostic (2.08e-2)"	"unprognostic (2.08e-1)"	"unprognostic (7.39e-4)"	"unprognostic (1.06e-2)"	"unprognostic (2.74e-1)"	"prognostic favorable (1.60e-4)"	"unprognostic (1.44e-2)"	"unprognostic (1.81e-1)"	"unprognostic (2.08e-2)"	"unprognostic (1.14e-1)"	"prognostic favorable (1.32e-4)"	"unprognostic (5.27e-2)"	"prognostic unfavorable (6.67e-5)"	"unprognostic (3.13e-1)"	"unprognostic (4.18e-2)"	"unprognostic (2.13e-1)"	"unprognostic (7.06e-2)"	3.2	3.8	4.0	1.9	5.1	3.6	1.2	12.8	6.3	1.7	2.0			7.0	3.2	1.1	1.1	3.9	1.5	1.5	4.1	3.3	1.4	3.2	1.5	2.5	3.1		4.6	3.0	0.8	5.9	1.3		2.3	0.2		8.6	2.4	3.9	4.6	5.1	1.0	3.2	3.8	2.4	10.2			1.3		0.7	0.7	1.8	0.5	0.9	0.0	0.2	0.0	0.8	0.2	0.6	5.0	2.0	5.2	1.4	0.8	0.9	3.3	1.0	1.7	1.9	0.9	2.8	3.6	1.8	1.5	2.5	0.8	0.9	0.8	0.3	6.7	3.1	0.4	6.0	1.3	1.4	0.1	3.6	2.3	1.1	2.6	0.0	2.2	0.5	6.5	2.4	8.5	0.4	1.8	1.4	2.4	1.0	0.6	3.7	9.3	0.4	0.8	0.8	0.2	2.7	3.8	1.4	1.5	2.2	0.8	6.6	1.8	1.4	3.2	2.7	5.0	1.1	11.4	0.7	2.9	2.9	6.1	3.6	0.0	0.2	0.0	0.8	0.0	0.0	0.0	0.3	0.0	0.0	0.5	0.3	0.1	0.0	0.0	0.0	0.9	0.0	0.2											3.0	2.9	0.0	0.2	0.7	3.2	4.0	0.0	2.7	2.3	0.0	3.9	0.1	0.0	0.4	9.6	0.0	1.7	0.0	0.4	0.2	1.0	0.1	2.3	2.1	0.3	4.8	1.2	0.6	0.6	3.2	0.9	0.9	0.0	0.0	0.2	2.0	1.2	3.5	1.8	0.6	2.5	0.0	0.9	1.8	2.1	1.4	0.0	0.0	0.6	0.3
SCNN1G	"ENaCgamma, SCNEG"	ENSG00000166828	"Sodium channel epithelial 1 gamma subunit"	P51170	16	23182715-23216883	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sensory transduction, Sodium transport, Taste, Transport"	"Ion channel, Sodium channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"kidney: 42.9;salivary gland: 26.8"	"Cell type enhanced"	"Detected in some"	29	"Alveolar cells type 1: 17.9;Club cells: 21.6;Collecting duct cells: 85.5"	"Cancer enhanced"	"Detected in many"		"urothelial cancer: 15.6"	"Region enriched"	"Detected in some"	6	"cerebellum: 9.7"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.8"	"Lineage enriched"	"Detected in single"	5	"granulocytes: 1.8"	"Group enriched"	"Detected in some"	7	"hTCEpi: 31.4;RT4: 14.2"	"Region enriched"	"Detected in single"	13	"cerebellum: 2.8"	"Low region specificity"	"Detected in all"			HPA071194			Supported	"Nucleoplasm,Plasma membrane"		NA	NA			"Plasma membrane"	Nucleoplasm	"HPA071194: AB_2686359"	"unprognostic (2.90e-1)"	"unprognostic (5.21e-3)"	"unprognostic (5.79e-2)"	"unprognostic (4.31e-2)"	"unprognostic (1.92e-3)"	"unprognostic (1.71e-3)"		"unprognostic (1.97e-1)"	"unprognostic (4.85e-2)"	"unprognostic (7.84e-3)"	"unprognostic (1.90e-1)"	"unprognostic (2.57e-2)"	"prognostic unfavorable (3.20e-7)"	"unprognostic (2.80e-2)"	"unprognostic (1.34e-1)"	"unprognostic (2.63e-1)"	"unprognostic (4.17e-3)"	1.1	0.3	0.6	0.2	0.0	0.4	2.5	9.7	0.4	14.0	5.5	0.0	4.8	0.2	3.2	1.7	10.3	0.5	0.2	0.2	1.5	0.0	42.9	0.2	15.6	0.2	0.0	0.3	0.2	3.8	0.2	6.5	0.7	0.7	10.2	1.1	0.0	26.8	12.8	2.2	6.6	0.2	0.3	0.3	0.2	6.9	0.3	0.0	1.5	25.5	3.3	3.9	1.7	11.3	0.3	0.3	1.8	0.2	0.2	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	31.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.9	0.0	0.0	0.0	0.0	14.2	1.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.2	0.3	0.2	0.1	0.1	0.1	0.1	0.0	0.3	0.2	0.1	1.8	0.2	0.1	0.3	0.1	0.0	0.6	0.0	9.7	0.4	1.5	0.0	0.0	0.3	0.7	0.0	17.9	3.4	0.0	4.0	0.3	0.0	0.8	0.0	2.7	21.6	85.5	0.0	0.1	0.0	1.3	0.0	0.0	0.3	0.0	1.5	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	1.4
SCTR		ENSG00000080293	"Secretin receptor"	P47872	2	119439843-119525301	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	6	"intestine: 13.5;pancreas: 35.3"	"Group enriched"	"Detected in some"	7	"Alveolar cells type 2: 64.4;Ductal cells: 72.3;Exocrine glandular cells: 84.2;Pancreatic endocrine cells: 51.5"	"Cancer enhanced"	"Detected in many"		"pancreatic cancer: 15.3"					"Cell type enhanced"	"Detected in some"		"basophil: 3.8"	"Lineage enriched"	"Detected in single"	7	"granulocytes: 3.8"	"Cell line enriched"	"Detected in some"	5	"Karpas-707: 8.2"	"Low region specificity"	"Detected in some"			"Group enriched"	"Detected in some"	12	"midbrain: 1.2;pons and medulla: 1.3;thalamus: 1.5"	HPA007269	Uncertain					NA	NA					"HPA007269: AB_1856640"	"unprognostic (1.51e-1)"	"unprognostic (2.22e-1)"	"unprognostic (4.99e-2)"	"unprognostic (5.82e-2)"	"unprognostic (1.71e-1)"	"unprognostic (4.12e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.09e-1)"	"unprognostic (1.68e-2)"	"unprognostic (9.08e-2)"	"unprognostic (7.35e-2)"	"unprognostic (2.38e-2)"	"unprognostic (6.11e-3)"	"unprognostic (1.65e-3)"	"unprognostic (1.77e-1)"	"unprognostic (2.24e-1)"	"unprognostic (4.38e-2)"	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0			13.5	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	3.7	0.2	4.1	0.0	0.0		0.0	35.3	0.0	0.0	0.0		0.0	0.0		0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	1.9	0.2			0.2		0.0	0.0	0.0	0.5	0.1	3.8	0.3	0.3	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.2	0.1	0.4	0.0	0.2	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.4	0.8	0.0	0.5	0.1	0.0	0.0	0.0	0.7	0.0	0.0	0.1	0.0	8.2	0.7	0.5	0.1	0.0	0.9	0.3	0.0	0.1	0.0	1.5	0.3	0.5	0.0	0.3	0.0	0.3	0.0	0.3	0.0	1.1	0.0	0.0	0.4	0.6	0.0	0.9	0.3	0.1	0.0	0.0	0.1	3.8	0.3	0.9	0.3	0.2	0.4	0.3	0.3	0.0	0.0	0.5	0.3	0.2	1.2	0.3	0.3	0.1	0.4	0.0											0.0	64.4	0.0	0.2	0.0	0.0	3.1	0.0	0.0	3.4	5.2	0.0	0.0	10.0	72.3	0.4	0.0	0.0	0.0	84.2	0.0	0.0	0.0	2.3	0.0	0.5	4.8	2.4	0.0	0.0	1.1	0.0	0.0	0.0	2.8	0.0	0.2	51.5	0.0	0.0	0.2	1.1	0.0	0.6	0.0	0.2	0.0	0.2	0.0	0.0	0.0
SDHA	"FP, SDH2, SDHF"	ENSG00000073578	"Succinate dehydrogenase complex flavoprotein subunit A"	P31040	5	218241-256700	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"	Oxidoreductase	"Cancer-related genes, Cardiomyopathy, Disease mutation, FDA approved drug targets, Leigh syndrome, Primary mitochondrial disease, Tumor suppressor"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"heart muscle: 100.1;skeletal muscle: 114.0"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB034929, HPA041981, HPA064582"	Enhanced		Supported	Nucleoli,Mitochondria		No	No		780000	Mitochondria	Nucleoli	"CAB034929: AB_2183443, HPA041981: AB_2677779, HPA064582: AB_2685293"	"prognostic unfavorable (6.00e-4)"	"unprognostic (1.93e-1)"	"unprognostic (5.97e-2)"	"unprognostic (1.36e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.62e-1)"	"unprognostic (2.80e-1)"	"unprognostic (3.14e-2)"	"unprognostic (2.88e-1)"	"unprognostic (1.67e-2)"	"unprognostic (1.97e-1)"	"unprognostic (1.24e-1)"	"prognostic favorable (9.53e-8)"	"unprognostic (1.11e-2)"	"unprognostic (2.62e-1)"	"unprognostic (3.57e-1)"	"unprognostic (1.79e-1)"	17.6	31.4	15.3	11.5	20.3	10.6	12.8	18.8	29.0	10.2	29.4	17.3	10.0	44.3	11.3	12.1	15.3	12.6	14.8	100.1	15.8	14.5	36.5	55.4	10.7	11.7	19.6	19.3	14.5	14.7	23.2	9.5	9.2	29.7	10.7	24.6	14.5	17.3	12.0	114.0	11.5	39.9	16.5	13.2	13.9	21.2	14.6	14.8	15.7	12.5	39.6	12.5	13.2	11.1	28.3	31.9	29.1	29.2	27.1	48.9	32.4	18.7	30.4	12.5	20.4	21.6	16.2	34.0	14.5	18.4	25.0	25.5	32.9	25.6	23.2	45.8	16.5	18.9	24.3	22.1	29.6	14.8	49.4	20.2	11.8	84.1	42.8	13.4	14.7	15.4	16.1	19.0	18.6	9.9	19.9	27.0	16.6	19.0	19.3	11.7	28.7	19.4	39.7	4.3	20.5	38.6	25.1	18.2	45.0	53.1	24.9	13.8	7.9	68.2	44.1	17.9	8.1	26.7	18.6	19.5	18.5	18.2	11.0	11.9	20.6	8.8	17.1	17.9	21.2	11.7	17.8	24.4	29.1	36.4	29.2	32.1	28.3	34.8	35.1	31.9	24.5	34.5	31.7	5.9	27.1	24.1	20.5	48.9	32.4	15.3	20.3	18.8	29.0	15.8	14.5	19.6	19.3	29.7	14.8	32.8	63.8	52.9	58.0	54.4	45.7	238.2	76.5	58.9	40.9	71.5	96.2	94.1	121.0	78.8	32.8	37.6	207.8	0.0	39.4	87.2	53.2	29.4	42.7	135.6	60.4	95.3	45.6	43.0	39.1	20.2	63.3	43.9	86.0	78.5	75.8	40.3	44.9	92.8	52.3	129.8	77.8	77.6	45.0	66.5	55.1	31.5	129.4	59.9	128.8	78.3
SDHD	"cybS, PGL, PGL1"	ENSG00000204370	"Succinate dehydrogenase complex subunit D"	O14521	11	112086773-112120013	"Cancer-related genes, Citric acid cycle related proteins, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Electron transport, Transport, Tricarboxylic acid cycle"		"Cancer-related genes, Disease mutation, FDA approved drug targets, Primary mitochondrial disease"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Distal tubular cells: 449.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											HPA045727	Approved				"Intracellular and membrane"	NA	NA					"HPA045727: AB_10963114"	"unprognostic (9.13e-2)"	"unprognostic (3.51e-2)"	"unprognostic (4.47e-3)"	"unprognostic (4.21e-2)"	"unprognostic (1.93e-1)"	"unprognostic (4.98e-2)"	"unprognostic (5.69e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.83e-3)"	"unprognostic (7.10e-2)"	"unprognostic (3.03e-2)"	"unprognostic (1.80e-1)"	"prognostic favorable (1.99e-10)"	"unprognostic (5.14e-2)"	"unprognostic (1.58e-2)"	"unprognostic (1.56e-2)"	"unprognostic (7.51e-2)"	20.9	23.1	17.1	21.7	19.4	10.9	19.6	14.1	18.4	18.1	33.6	14.2	23.9	36.0	22.7	17.5	35.2	17.3	17.9	42.5	15.1	13.7	66.6	75.4	19.1	23.3	17.1	15.1	18.6	23.2	22.5	16.1	20.1	18.0	23.7	33.9	15.7	32.6	21.7	65.4	15.5	61.2	24.0	15.3	22.8	22.2	8.8	14.8	21.7	46.2	33.9	24.6	23.5	20.3	55.5	74.7	62.1	91.7	46.1	53.7	68.9	16.7	17.2	11.7	17.7	43.8	35.2	19.7	20.4	29.0	21.4	26.9	59.4	43.9	30.4	63.1	27.5	31.7	42.0	36.5	28.9	26.3	27.0	18.3	28.9	12.8	31.5	34.1	45.5	22.0	38.8	32.0	25.5	40.8	25.6	30.1	22.0	29.8	42.0	26.5	21.0	27.3	41.2	15.8	64.5	42.6	25.3	31.1	56.7	43.8	40.9	16.9	11.2	28.6	38.7	20.3	17.7	39.8	32.8	23.5	20.9	27.4	23.2	18.7	12.5	16.0	55.7	11.9	59.6	19.9	46.1	73.0	48.7	41.4	91.7	44.1	55.5	44.5	43.1	74.7	45.6	53.7	49.8	62.1	46.1	70.7	36.8	44.2	68.9	17.1	19.4	14.1	18.4	15.1	13.7	17.1	15.1	18.0	14.8	74.5	39.0	90.1	83.6	72.5	10.9	198.1	91.7	68.3	63.7	85.5	7.9	134.7	449.3	67.9	8.3	67.1	194.1	46.7	51.2	94.9	111.1	52.7	63.6	160.7	147.1	11.1	48.5	66.9	103.7	21.8	96.4	98.5	72.6	129.8	105.1	39.2	45.9	122.4	93.7	350.8	18.5	90.5	100.9	53.9	50.7	65.1	149.7	72.6	141.2	82.2
SERPINB2	"HsT1201, PAI2, PLANH2"	ENSG00000197632	"Serpin family B member 2"	P05120	18	63871692-63903890	"Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Plasminogen activation"	"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"esophagus: 70.6;placenta: 222.1"	"Cell type enhanced"	"Detected in many"	27	"Basal keratinocytes: 1993.2;Suprabasal keratinocytes: 920.9;Syncytiotrophoblasts: 367.4"	"Cancer enhanced"	"Detected in many"		"head and neck cancer: 26.5"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"basophil: 16.3;eosinophil: 7.6"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 16.3"	"Cell line enhanced"	"Detected in some"		"GAMG: 33.9;HaCaT: 81.3;U-138 MG: 97.3;U-2197: 147.8"	"Region enriched"	"Detected in single"	14	"cerebellum: 2.9"	"Low region specificity"	"Detected in all"			"HPA015480, HPA076608"	Enhanced				"Intracellular and membrane"	NA	NA		110000			"HPA015480: AB_1855456, HPA076608: "	"unprognostic (2.11e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.46e-2)"	"unprognostic (1.36e-4)"	"unprognostic (1.17e-1)"	"unprognostic (1.65e-2)"		"unprognostic (1.37e-1)"	"unprognostic (1.92e-1)"	"unprognostic (9.69e-2)"	"unprognostic (3.76e-3)"	"unprognostic (1.90e-1)"	"unprognostic (4.33e-6)"	"unprognostic (3.89e-2)"	"unprognostic (3.94e-1)"	"unprognostic (3.29e-1)"	"prognostic unfavorable (1.55e-5)"	6.0	0.0	0.1	2.9	0.2	8.7	2.6	0.2	0.1	6.4	0.8	0.1	0.1	0.0	0.7	0.4	70.6	3.1	0.1	0.4	0.1	0.0	0.1	0.1	0.9	0.1	0.1	0.1	0.6	0.3	0.0	0.1	222.1	0.2	0.3	0.0	0.1	11.3	0.2	0.3	25.7	0.2	0.3	0.1	0.3	0.1	0.2	0.1	0.9	0.2	49.0	37.7	1.1	13.8	0.0	0.2	16.3	3.9	0.0	0.0	1.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	19.7	21.0	0.7	1.5	0.1	0.0	0.0	0.0	0.7	33.9	81.3	0.0	16.7	14.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	1.6	9.7	4.4	0.2	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.7	1.6	97.3	0.0	147.8	0.0	0.0	0.0	0.0	2.6	0.2	11.3	16.3	3.9	7.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	1.0	0.1	0.2	0.2	0.1	0.1	0.0	0.1	0.1	0.2	0.1	0.0	0.3	0.0	2.4	1993.2	0.0	0.4	0.0	21.4	34.2	0.0	0.0	3.1	0.0	76.7	0.0	0.5	0.0	0.0	6.1	1.5	3.5	3.8	0.0	0.0	2.8	0.0	0.0	0.0	5.6	0.0	0.0	59.8	89.4	2.8	0.0	0.0	100.0	0.0	0.0	0.0	0.0	0.0	26.8	0.0	0.0	920.9	367.4	0.0	0.0	42.5
SERPINC1	"AT3, ATIII, MGC22579"	ENSG00000117601	"Serpin family C member 1"	P01008	1	173903804-173917378	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	203	"liver: 450.5"	"Cell type enriched"	"Detected in some"	54	"Hepatocytes: 2236.3"	"Cancer enriched"	"Detected in some"	871	"liver cancer: 1504.0"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"eosinophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Cell line enriched"	"Detected in some"	35	"Hep G2: 42.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA001816, CAB016790, HPA024007"	Supported				"Secreted to blood"	NA	NA		210000000000			"CAB016790: , HPA001816: AB_1079926, HPA024007: AB_1856732"	"unprognostic (1.28e-2)"	"unprognostic (2.22e-1)"	"unprognostic (3.83e-2)"	"unprognostic (5.98e-2)"	"unprognostic (6.91e-2)"	"unprognostic (1.93e-2)"	"prognostic favorable (3.40e-5)"	"unprognostic (1.75e-2)"	"unprognostic (8.67e-2)"	"unprognostic (3.48e-2)"	"unprognostic (4.74e-2)"	"unprognostic (1.91e-1)"	"unprognostic (2.36e-2)"	"unprognostic (5.28e-3)"	"unprognostic (5.80e-2)"	"unprognostic (6.35e-2)"	"unprognostic (8.21e-2)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.2	450.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.3	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	42.6	0.0	0.8	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.1	0.9	0.0	0.0	0.0	0.0	0.1	0.6	0.0	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.2	0.0	0.5	0.1	0.5	0.0	0.0	0.0	2.2	0.5	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	14.0	0.0	0.0	0.0	0.1	38.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.3	0.0	0.0	0.2	0.0	2236.3	0.2	0.0	0.0	37.4	41.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	0.0	0.0	0.0	0.2	0.0	0.3	0.2	0.0	0.0	0.1
SERPIND1	"D22S673, HC-II, HC2, HCF2, HLS2"	ENSG00000099937	"Serpin family D member 1"	P05546	22	20773879-20787720	"Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Chemotaxis, Hemostasis"	"Heparin-binding, Protease inhibitor, Serine protease inhibitor"	"Disease mutation, FDA approved drug targets, Thrombophilia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	47	"liver: 170.8"	"Cell type enriched"	"Detected in some"	10	"Hepatocytes: 223.1"	"Cancer enriched"	"Detected in many"	80	"liver cancer: 334.4"	"Low region specificity"	"Detected in some"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	10	"Hep G2: 64.2"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"CAB008639, HPA055767"	Supported		Approved	Vesicles	"Secreted to blood"	NA	NA		94000000000	Vesicles		"CAB008639: AB_1618010, HPA055767: AB_2682912"	"unprognostic (1.68e-1)"	"unprognostic (8.27e-2)"	"unprognostic (4.40e-2)"	"prognostic favorable (4.09e-4)"	"unprognostic (5.42e-2)"	"unprognostic (1.23e-1)"	"unprognostic (1.12e-3)"	"unprognostic (1.56e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.74e-1)"	"unprognostic (1.21e-2)"	"unprognostic (2.88e-1)"	"unprognostic (3.94e-9)"	"unprognostic (2.01e-1)"	"unprognostic (4.66e-2)"	"unprognostic (8.36e-3)"	"unprognostic (1.46e-1)"	0.0	0.0	0.0	0.0	2.3	0.0	0.2	0.6	0.9	0.3	0.0	1.4	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	170.8	0.3	0.0	0.0	0.7	0.3	0.0	3.6	0.1	0.2	2.6	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.4	0.0	0.1	0.1	0.5	0.0	0.1	0.0	0.0	0.0	0.1	1.9	2.7	0.7	0.4	1.3	1.7	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	64.2	0.0	0.2	0.1	0.0	0.0	0.5	0.0	0.0	6.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.7	5.2	0.0	0.2	0.0	0.0	1.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.3	0.0	4.4	0.0	0.4	0.0	1.0	0.2	1.7	0.4	0.5	0.6	0.1	1.9	0.9	0.7	0.7	1.3	0.2	2.7	0.7	0.1	0.0	2.3	0.6	0.9	0.0	0.0	0.0	0.7	2.6	0.5	0.0	13.7	0.0	0.0	0.0	0.0	0.8	5.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.3	0.0	0.0	0.7	0.0	1.1	223.1	0.1	0.0	0.0	4.9	2.9	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0
SERPINE1	"PAI, PAI1, PLANH1"	ENSG00000106366	"Serpin family E member 1"	P05121	7	101127089-101139266	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"		"Protease inhibitor, Serine protease inhibitor"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"placenta: 253.6"	"Cell type enhanced"	"Detected in many"	22	"Pancreatic endocrine cells: 138.9;Syncytiotrophoblasts: 545.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	20	"NK-cell: 10.8"	"Lineage enriched"	"Detected in single"	20	"NK-cells: 10.8"	"Cell line enhanced"	"Detected in many"		"BJ: 142.8;HUVEC TERT2: 165.7;LHCN-M2: 160.0;TIME: 409.8;U-138 MG: 195.1;U-251 MG: 171.5"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"HPA050039, CAB068501"	Uncertain		Approved	Cytosol	"Secreted to blood"	No	No	142000000	14000000	Cytosol		"CAB068501: AB_1642775, HPA050039: AB_2680997"	"unprognostic (5.02e-2)"	"prognostic unfavorable (5.01e-4)"	"prognostic unfavorable (2.82e-4)"	"unprognostic (2.10e-2)"	"unprognostic (9.04e-3)"	"prognostic unfavorable (2.84e-5)"	"unprognostic (6.80e-3)"	"prognostic unfavorable (4.41e-6)"	"unprognostic (2.33e-1)"	"unprognostic (1.45e-1)"	"unprognostic (2.88e-3)"	"unprognostic (1.58e-1)"	"prognostic unfavorable (5.88e-8)"	"prognostic unfavorable (3.27e-6)"	"unprognostic (1.05e-1)"	"unprognostic (4.33e-2)"	"prognostic unfavorable (5.51e-4)"	45.5	14.0	1.1	16.7	1.8	0.1	11.4	0.5	1.5	13.3	7.0	3.4	3.3	1.2	6.6	14.4	6.8	9.3	69.6	29.2	1.5	0.6	7.8	65.3	56.3	3.3	4.1	1.8	19.7	24.7	1.4	2.6	253.6	5.9	7.6	0.9	2.3	2.4	6.2	12.4	4.1	2.3	13.5	4.1	5.8	6.6	8.6	2.2	0.6	11.3	3.7	2.8	71.7	18.1	0.2	0.4	0.5	0.2	10.8	0.3	1.0	3.0	2.6	0.0	0.2	32.7	65.2	3.7	142.8	27.0	72.1	63.0	0.3	0.2	0.1	34.2	45.4	99.7	0.7	0.0	11.0	74.4	0.1	0.0	0.0	0.2	2.4	65.8	0.0	0.1	25.5	4.4	110.5	58.1	39.1	165.7	0.0	0.2	0.1	160.0	0.0	0.0	0.0	0.7	0.0	1.7	0.0	0.2	0.1	0.2	1.2	0.0	0.0	11.7	3.2	0.3	18.0	0.1	0.4	409.8	195.1	8.5	66.4	171.5	0.0	0.1	0.1	48.7	0.0	1.8	0.5	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.3	0.3	0.2	0.0	0.1	0.2	10.8	0.0	0.4	0.0	1.0	1.1	1.8	0.5	1.5	1.5	0.6	4.1	1.8	5.9	2.2	0.0	11.4	0.0	30.0	35.5	0.4	1.9	7.6	8.1	7.9	5.2	0.0	34.4	0.0	22.9	0.0	53.9	0.0	0.0	3.8	35.1	24.7	5.4	10.3	90.0	15.2	0.0	5.1	60.2	4.7	0.4	16.4	7.5	6.8	1.8	0.0	0.3	138.9	0.0	11.3	0.0	0.2	38.8	16.5	0.0	0.0	21.7	545.0	0.7	0.0	5.9
SHMT1	"CSHMT, MGC15229, MGC24556, SHMT"	ENSG00000176974	"Serine hydroxymethyltransferase 1"	P34896	17	18327860-18363563	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"One-carbon metabolism"	Transferase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"kidney: 57.8;liver: 108.3"	"Cell type enhanced"	"Detected in many"	14	"Hepatocytes: 213.8;Proximal tubular cells: 332.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in many"							"HPA023314, HPA078682"	Enhanced		Supported	Nucleoplasm,Cytosol		NA	NA		240000	Cytosol	Nucleoplasm	"HPA023314: AB_1856830, HPA078682: "	"unprognostic (4.76e-2)"	"unprognostic (1.98e-2)"	"unprognostic (5.46e-2)"	"unprognostic (3.76e-1)"	"unprognostic (2.45e-1)"	"unprognostic (8.44e-3)"	"prognostic favorable (2.52e-4)"	"unprognostic (7.55e-3)"	"unprognostic (4.50e-1)"	"unprognostic (2.42e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.70e-1)"	"prognostic favorable (8.54e-6)"	"unprognostic (1.70e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.57e-3)"	"unprognostic (4.04e-2)"	10.9	3.2	2.2	4.9	4.1	2.1	10.4	6.5	3.0	4.6	15.2	5.3	7.3	12.3	2.8	7.4	16.3	3.9	4.0	2.0	2.6	1.8	57.8	108.3	4.3	3.8	3.5	1.9	4.1	3.5	30.1	1.6	2.8	3.6	3.4	3.5	7.2	9.8	8.0	5.7	6.2	15.1	2.3	2.9	8.6	3.9	6.3	3.8	11.1	10.9	10.8	8.7	4.3	6.3	8.6	6.7	6.2	10.6	13.0	18.7	7.9	22.6	23.0	7.3	11.4	18.6	11.6	27.0	4.8	5.9	16.1	17.8	22.8	10.1	17.6	14.3	4.1	11.7	22.4	15.2	19.3	9.2	10.5	22.2	7.9	18.0	17.2	4.7	5.2	8.6	9.7	7.6	12.5	5.6	6.5	11.0	22.7	6.6	4.0	5.7	16.7	26.1	7.3	9.1	34.5	7.5	21.4	28.9	14.9	25.6	15.4	10.0	5.3	32.6	6.2	8.2	38.7	25.4	7.5	2.6	3.1	9.3	28.4	15.1	8.2	7.8	7.1	6.1	12.4	7.4	6.0	8.2	6.2	10.1	10.6	17.1	8.6	12.3	12.8	6.7	6.9	12.3	13.0	0.1	13.0	7.5	3.1	18.7	7.9	2.2	4.1	6.5	3.0	2.6	1.8	3.5	1.9	3.6	3.8	11.9	26.5	19.1	16.8	9.2	2.8	2.2	25.5	2.7	9.1	34.9	3.9	17.7	69.6	11.6	4.9	4.3	8.4	0.0	7.0	62.1	4.8	6.6	8.1	213.8	31.1	0.0	1.2	10.4	27.9	4.1	5.5	5.0	11.8	5.4	10.3	31.2	5.1	7.0	2.8	332.8	3.9	19.4	3.8	15.6	21.8	9.3	7.1	10.0	29.5	4.8
SI		ENSG00000090402	Sucrase-isomaltase	P14410	3	164978898-165078495	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins"		"Glycosidase, Hydrolase, Multifunctional enzyme"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	123	"intestine: 181.4"	"Group enriched"	"Detected in some"	7	"Enterocytes: 48.7;Mucus-secreting cells: 79.9;Paneth cells: 46.3;Undifferentiated cells: 29.8"	"Cancer enhanced"	"Detected in some"		"stomach cancer: 6.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.9;CACO-2: 4.1;HeLa: 3.2;NB-4: 3.4;RPMI-8226: 4.9;SH-SY5Y: 3.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			HPA011897	Enhanced					NA	NA					"HPA011897: AB_1856840"			"unprognostic (2.71e-2)"								"unprognostic (1.62e-2)"	"unprognostic (2.68e-1)"		"unprognostic (2.05e-1)"	"unprognostic (4.41e-2)"			0.1	0.1	0.1	1.4	0.1	0.0	0.1	0.1	0.1	0.1	93.3	0.0	0.0	94.1	0.1	0.0	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.1	5.4	0.0	0.1	0.0	0.1	0.1	181.4	0.0	0.1	0.1	0.1	0.7	0.0	0.0	0.1	0.1	0.0	0.1	0.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	4.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	4.9	0.0	0.0	0.6	3.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.0	0.0	48.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.2	0.0	0.0	3.8	0.0	0.0	0.0	0.0	79.9	0.0	0.0	46.3	0.0	0.0	0.0	0.0	0.0	0.7	0.2	0.0	0.0	0.0	29.8	0.0
SIGMAR1	"OPRS1, SR-BP1"	ENSG00000147955	"Sigma non-opioid intracellular receptor 1"	Q99720	9	34634722-34637809	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Lipid transport, Transport"	Receptor	"Amyotrophic lateral sclerosis, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 89.1"	"Cell type enhanced"	"Detected in many"	5	"Extravillous trophoblasts: 82.3;Hepatocytes: 84.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB013470, HPA018002, HPA024071"	Enhanced					NA	NA					"CAB013470: AB_2533521, HPA018002: AB_1854802, HPA024071: AB_1854803"	"unprognostic (1.39e-1)"	"unprognostic (2.64e-1)"	"unprognostic (1.56e-1)"	"unprognostic (1.95e-1)"	"unprognostic (8.06e-2)"	"unprognostic (3.71e-2)"	"unprognostic (4.89e-2)"	"unprognostic (2.50e-2)"	"unprognostic (2.58e-2)"	"unprognostic (2.01e-3)"	"unprognostic (3.88e-2)"	"unprognostic (4.28e-1)"	"unprognostic (2.78e-2)"	"unprognostic (2.46e-1)"	"unprognostic (2.39e-1)"	"unprognostic (6.44e-3)"	"prognostic unfavorable (3.42e-4)"	15.3	19.7	9.2	9.8	14.5	8.5	13.0	9.4	16.1	17.0	18.2	13.4	13.3	23.0	18.6	13.4	18.6	17.4	17.1	12.1	9.4	12.0	14.2	89.1	9.6	14.5	10.7	10.7	20.1	22.9	15.0	8.3	17.8	14.0	18.9	13.2	15.7	12.0	19.6	7.7	16.8	24.9	15.1	9.2	9.8	14.6	9.4	9.3	9.6	11.8	15.0	15.8	16.4	15.2	14.0	23.8	12.4	19.3	13.1	32.6	20.1	41.1	36.5	12.7	41.4	47.0	32.6	16.4	30.0	20.3	26.5	24.5	22.9	18.0	20.2	17.8	32.5	16.8	25.8	16.2	34.0	5.8	35.1	43.7	19.3	54.4	25.0	30.9	33.1	16.8	32.9	36.4	29.1	36.2	14.0	20.0	26.7	7.2	37.4	28.3	0.2	20.1	48.0	15.9	21.8	47.5	23.5	14.2	56.8	24.1	8.2	14.9	16.8	29.8	21.3	15.7	5.2	25.2	22.6	16.8	22.0	17.6	23.2	4.4	10.4	16.4	0.5	22.8	28.8	45.5	10.5	19.1	12.4	22.2	18.4	24.2	14.0	32.6	26.7	23.8	10.8	27.8	22.6	5.4	13.1	19.3	17.5	29.9	20.1	9.2	14.5	9.4	16.1	9.4	12.0	10.7	10.7	14.0	9.3	3.0	9.9	15.9	14.7	16.4	7.7	7.3	15.3	8.1	6.8	7.0	0.0	35.2	0.0	30.9	0.6	12.4	34.1	23.3	29.3	82.3	26.6	19.8	6.9	84.9	34.7	4.8	9.9	14.7	11.0	1.1	25.3	7.9	18.6	11.8	22.5	12.7	25.2	28.5	24.1	11.0	6.2	19.4	20.6	5.7	10.0	18.7	30.6	11.7	37.5	11.6
SIRT5		ENSG00000124523	"Sirtuin 5"	Q9NXA8	6	13574529-13615158	"FDA approved drug targets, Predicted intracellular proteins"		Transferase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Cardiomyocytes: 47.2;Distal tubular cells: 44.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021798, HPA022002, HPA022992"	Approved		Supported	Mitochondria		NA	NA			Mitochondria		"HPA021798: AB_1856911, HPA022002: AB_1856913, HPA022992: AB_1856915"	"unprognostic (8.53e-2)"	"unprognostic (7.79e-2)"	"unprognostic (4.71e-2)"	"unprognostic (5.26e-3)"	"unprognostic (6.19e-2)"	"unprognostic (1.63e-1)"	"unprognostic (8.72e-2)"	"unprognostic (1.38e-1)"	"unprognostic (8.54e-3)"	"unprognostic (2.77e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.65e-1)"	"prognostic favorable (8.76e-10)"	"unprognostic (2.39e-1)"	"unprognostic (6.88e-2)"	"unprognostic (6.86e-2)"	"unprognostic (2.36e-3)"	5.9	6.2	8.8	6.8	10.4	5.9	9.2	11.1	13.5	4.9	7.2	6.4	12.5	8.1	6.8	6.7	5.7	8.0	6.6	22.9	8.5	8.3	9.9	29.9	9.8	6.9	9.5	6.9	8.8	10.5	12.9	7.6	5.3	8.3	6.5	8.3	6.2	8.6	8.7	25.8	8.8	8.5	6.2	6.9	9.5	7.6	6.6	6.1	7.5	8.5	7.0	6.5	6.8	6.0	9.2	4.6	10.9	9.3	7.3	10.0	5.6	5.8	4.6	5.9	7.6	3.7	4.8	4.4	3.0	3.2	3.3	5.0	7.3	7.0	8.4	18.3	2.4	7.3	9.5	4.1	5.9	5.0	3.8	6.8	5.3	4.2	11.8	6.1	4.3	4.6	5.2	12.1	2.9	10.4	7.2	6.0	11.9	7.5	3.2	3.9	7.1	4.7	8.5	4.9	9.1	7.3	8.4	3.8	15.3	6.8	6.4	9.7	3.5	3.4	5.9	13.4	16.7	6.8	2.8	5.3	5.1	2.9	3.1	3.3	7.8	8.8	5.7	2.9	4.3	4.8	0.5	4.5	10.9	8.1	6.1	8.2	9.2	10.0	7.9	4.6	9.1	9.5	8.5	1.5	7.3	9.3	4.6	7.2	5.6	8.8	10.4	11.1	13.5	8.5	8.3	9.5	6.9	8.3	6.1	26.8	2.7	9.1	9.2	3.7	6.4	47.2	10.2	21.4	17.0	10.4	0.0	17.1	44.7	10.5	2.2	8.7	9.6	23.3	6.0	9.0	4.9	5.7	0.0	22.2	8.5	1.6	5.8	10.4	10.4	0.5	7.5	6.1	5.0	5.4	12.6	8.4	6.7	13.9	5.3	24.0	6.2	0.0	5.0	6.5	7.8	4.0	8.9	6.9	16.5	7.3
SLAMF7	"19A, CD319, CRACC, CS1"	ENSG00000026751	"SLAM family member 7"	Q9NQ25	1	160739057-160754821	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Adaptive immunity, Immunity, Innate immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 32.9;lymphoid tissue: 45.0"	"Cell type enriched"	"Detected in many"	5	"monocytes: 204.6"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in some"	5	"U-266/70: 80.7"					"Low region specificity"	"Detected in all"			"CAB015445, HPA055945, HPA061654"	Enhanced		Approved	Vesicles		NA	NA		620000	Vesicles		"CAB015445: AB_1121905, HPA055945: AB_2682980, HPA061654: AB_2684576"	"unprognostic (5.82e-3)"	"unprognostic (1.81e-2)"	"unprognostic (1.84e-3)"	"unprognostic (2.12e-3)"	"unprognostic (2.75e-1)"	"unprognostic (1.07e-2)"	"unprognostic (7.87e-2)"	"unprognostic (7.19e-2)"	"unprognostic (2.46e-2)"	"prognostic favorable (3.93e-4)"	"unprognostic (1.08e-1)"	"unprognostic (8.13e-2)"	"prognostic unfavorable (8.57e-5)"	"unprognostic (1.35e-1)"	"unprognostic (3.91e-2)"	"unprognostic (1.02e-1)"	"unprognostic (1.50e-2)"	5.5	1.0	0.7	28.6	0.7	2.3	3.4	0.6	0.7	4.1	11.9	0.2	0.4	11.1	1.9	1.3	6.7	1.6	6.2	1.0	0.7	0.7	2.4	3.1	10.2	24.6	0.8	0.4	2.5	2.2	0.0	0.9	1.3	0.6	1.8	10.2	2.9	15.1	4.8	0.9	2.0	15.8	0.8	1.2	45.0	11.0	1.5	0.4	5.9	2.1	4.2	38.7	11.5	2.6	3.7	27.4	1.1	14.9	17.3	32.9	8.7	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.2	0.2	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	2.2	0.0	0.7	0.2	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	2.6	0.0	0.2	0.0	0.0	0.0	0.0	16.1	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	80.7	6.8	0.0	2.2	0.0	0.0	0.0	1.6	0.3	32.9	11.0	25.4	3.7	3.5	22.4	7.2	0.6	1.1	13.6	1.1	17.3	14.9	27.4	0.0	8.7	0.7	0.7	0.6	0.7	0.7	0.7	0.8	0.4	0.6	0.4	8.9	8.9	20.2	1.4	0.7	0.0	0.8	0.0	2.7	1.2	0.0	0.0	0.0	0.0	0.5	0.0	0.3	0.0	23.3	2.3	0.1	1.1	1.8	8.1	0.0	8.9	0.0	0.0	0.6	6.0	0.0	0.0	12.8	18.6	204.6	0.0	0.0	6.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.4	0.2	39.5	0.0	3.0
SLC12A1	NKCC2	ENSG00000074803	"Solute carrier family 12 member 1"	Q13621	15	48178438-48304078	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Symport, Transport"		"Bartter syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	75	"kidney: 143.2"	"Cell type enriched"	"Detected in some"	5	"Distal tubular cells: 177.4"	"Cancer enhanced"	"Detected in single"		"renal cancer: 1.0"	"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in some"	9	"basophil: 1.9;neutrophil: 1.5"	"Lineage enriched"	"Detected in single"	10	"granulocytes: 1.9"	"Cell line enriched"	"Detected in single"	26	"RPTEC TERT1: 24.3"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in some"			"HPA014967, HPA018107"	Enhanced		Approved	Nucleoplasm,Vesicles		NA	NA			Vesicles	Nucleoplasm	"HPA014967: AB_1854503, HPA018107: AB_1854504"	"unprognostic (3.52e-2)"	"unprognostic (1.30e-2)"		"unprognostic (9.65e-2)"	"unprognostic (1.74e-2)"	"unprognostic (7.77e-2)"	"unprognostic (1.04e-1)"	"unprognostic (8.72e-2)"	"unprognostic (2.06e-1)"	"unprognostic (9.85e-3)"	"unprognostic (2.81e-4)"	"unprognostic (9.75e-2)"	"unprognostic (2.61e-1)"	"unprognostic (5.47e-2)"	"unprognostic (2.03e-1)"	"unprognostic (5.20e-4)"	"unprognostic (8.52e-2)"	0.0	0.0	0.3	0.0	1.0	0.0	0.0	1.4	1.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	143.2	0.1	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.1	0.0	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	1.9	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.3	0.0	0.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.1	0.1	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	1.5	0.1	0.0	0.1	0.0	0.0	0.3	1.0	1.4	1.5	0.1	0.3	0.3	0.4	1.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	36.6	0.0	0.0	177.4	0.0	11.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	9.6	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
SLC12A2	"BSC, BSC2, NKCC1, PPP1R141"	ENSG00000064651	"Solute carrier family 12 member 2"	P55011	5	128083766-128189688	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Sodium transport, Symport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"gallbladder: 50.7;salivary gland: 61.2"	"Cell type enhanced"	"Detected in many"	8	"Glandular cells: 203.2;Mucus-secreting cells: 402.7;Undifferentiated cells: 269.5"	"Cancer enhanced"	"Detected in all"		"colorectal cancer: 54.3"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 9.8"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"OE19: 55.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA020130, HPA063697"	Approved		Approved	"Vesicles,Plasma membrane"		NA	NA			Vesicles	"Plasma membrane"	"HPA020130: AB_1854502, HPA063697: AB_2685094"	"unprognostic (4.61e-2)"	"unprognostic (2.63e-1)"	"unprognostic (4.20e-3)"	"prognostic favorable (8.60e-4)"	"unprognostic (3.99e-1)"	"unprognostic (5.65e-3)"	"unprognostic (1.44e-3)"	"unprognostic (1.81e-1)"	"unprognostic (3.30e-1)"	"unprognostic (2.95e-2)"	"unprognostic (7.22e-2)"	"unprognostic (1.39e-1)"	"prognostic favorable (7.09e-4)"	"unprognostic (1.63e-1)"	"unprognostic (2.30e-1)"	"unprognostic (3.79e-1)"	"unprognostic (3.88e-3)"	5.5	11.0	10.8	9.4	24.1	2.7	26.2	11.4	18.1	5.1	28.5	37.2	0.0	24.6	5.7	1.9	3.8	4.1	50.7	4.1	15.5	9.9	4.5	2.9	6.5	3.5	36.1	13.5	5.6	5.3	11.2	5.5	3.3	30.0	14.8	36.3	8.5	61.2	2.1	8.5	23.0	28.8	6.6	27.7	2.9	36.3	5.5	26.7	2.0	5.6	6.8	18.3	4.2	3.6	3.6	9.8	0.5	1.2	3.6	3.0	0.4	4.8	24.1	24.8	9.6	6.2	4.0	5.1	4.5	3.4	3.2	3.4	9.6	7.7	7.2	6.1	3.9	2.9	14.7	4.7	5.2	5.0	7.2	5.9	2.0	4.3	1.4	1.9	2.6	3.6	4.2	1.9	7.2	4.3	2.4	5.3	3.1	3.3	4.9	5.0	5.1	4.6	2.2	2.9	55.9	7.9	2.5	7.0	2.9	3.8	16.5	4.4	2.8	9.1	4.0	3.5	2.8	2.2	1.3	8.8	8.1	5.4	6.1	5.7	4.1	3.7	8.0	4.2	1.5	6.5	0.5	0.7	0.2	1.9	1.2	3.0	2.7	1.8	2.3	0.9	3.6	2.0	2.7	0.3	3.6	0.8	9.8	1.6	0.4	10.8	24.1	11.4	18.1	15.5	9.9	36.1	13.5	30.0	26.7	14.9	37.4	13.4	18.3	20.4	45.1	14.0	99.3	10.7	38.7	31.4	119.8	0.9	1.7	45.3	45.7	23.6	29.9	0.0	41.4	2.1	14.8	203.2	18.4	7.4	3.6	76.3	71.5	6.7	7.3	70.8	79.1	10.2	194.0	0.0	402.7	27.8	49.2	77.2	27.3	9.6	76.9	71.1	24.5	27.0	21.5	26.2	1.1	12.1	269.5	16.9
SLC12A3	NCCT	ENSG00000070915	"Solute carrier family 12 member 3"	P55017	16	56865207-56915850	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"kidney: 88.6"	"Group enriched"	"Detected in some"	9	"Collecting duct cells: 3.5;Distal tubular cells: 5.0;monocytes: 7.2"	"Cancer enhanced"	"Detected in some"		"renal cancer: 2.5"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in single"	17	"plasmacytoid DC: 14.6"	"Lineage enriched"	"Detected in single"	17	"dendritic cells: 14.6"	"Group enriched"	"Detected in some"	10	"BEWO: 10.2;HAP1: 5.6;HeLa: 11.4;SuSa: 3.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA028748	Enhanced					NA	NA					"HPA028748: AB_10603886"	"unprognostic (1.54e-3)"	"unprognostic (7.09e-5)"	"unprognostic (1.35e-1)"	"unprognostic (1.41e-2)"	"unprognostic (2.91e-1)"	"unprognostic (2.38e-4)"	"unprognostic (1.81e-1)"	"unprognostic (9.70e-2)"	"unprognostic (1.34e-1)"	"unprognostic (7.25e-2)"	"unprognostic (6.84e-2)"	"unprognostic (1.83e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.09e-1)"	"unprognostic (1.38e-1)"	"unprognostic (1.40e-2)"	"unprognostic (1.70e-1)"	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	88.6	0.0	0.1	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.8	14.6	0.2	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	10.2	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.0	0.7	5.6	0.0	0.0	0.0	0.0	0.0	11.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.4	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.1	0.0	14.6	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	3.5	0.0	0.0	5.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SLC12A4	KCC1	ENSG00000124067	"Solute carrier family 12 member 4"	Q9UP95	16	67943474-67969601	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Symport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	5	"Syncytiotrophoblasts: 53.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA041138	Approved		Approved	Endosomes		NA	NA			Endosomes		"HPA041138: AB_10794544"	"unprognostic (5.07e-2)"	"unprognostic (6.18e-2)"	"unprognostic (1.25e-1)"	"unprognostic (2.68e-2)"	"unprognostic (9.28e-2)"	"unprognostic (1.48e-2)"	"unprognostic (4.28e-2)"	"unprognostic (3.26e-3)"	"unprognostic (9.58e-2)"	"unprognostic (1.55e-1)"	"unprognostic (2.01e-2)"	"unprognostic (1.81e-2)"	"prognostic favorable (2.25e-6)"	"unprognostic (6.42e-2)"	"unprognostic (1.42e-1)"	"unprognostic (7.64e-2)"	"unprognostic (2.26e-1)"	16.6	18.3	9.2	8.0	8.8	3.1	26.5	7.0	12.7	19.4	16.5	20.1	12.0	5.1	20.7	9.7	11.8	13.8	15.5	24.4	12.2	5.2	10.7	17.1	19.5	6.6	11.4	8.2	14.2	11.9	30.1	8.1	32.6	18.1	17.8	4.3	23.0	10.5	20.7	14.6	16.9	8.6	27.4	10.0	10.2	10.9	17.6	9.8	8.8	21.0	9.1	8.4	16.5	16.6	1.0	2.4	8.3	5.4	2.7	1.6	1.6	5.0	6.8	5.3	10.0	17.6	15.5	28.6	15.6	16.2	13.5	11.8	13.6	8.2	1.8	7.7	21.5	7.5	9.3	2.5	19.3	10.2	1.8	2.0	1.3	8.9	14.9	20.0	0.1	6.4	17.1	12.7	18.1	6.6	15.8	8.3	3.4	4.1	1.5	18.5	0.8	1.9	5.1	4.0	1.5	3.6	2.0	10.0	1.6	7.4	4.4	0.0	3.2	29.7	1.8	2.6	13.8	14.2	2.0	11.2	19.3	13.7	8.5	6.7	9.3	2.3	3.0	11.2	1.4	16.6	8.3	3.9	2.0	1.5	5.4	1.0	0.4	0.9	0.9	2.4	1.0	0.8	0.7	1.4	2.7	3.8	1.1	1.6	1.6	9.2	8.8	7.0	8.6	12.2	5.2	11.4	8.2	18.1	9.8	14.9	7.8	2.2	12.2	9.0	1.0	25.6	2.5	6.7	10.3	14.0	0.0	24.6	0.0	10.9	2.1	14.3	0.0	0.0	7.1	13.5	13.6	12.7	1.1	7.5	6.9	0.0	0.0	14.1	4.6	1.3	18.4	4.4	10.1	16.2	0.0	21.0	12.7	0.0	34.3	3.4	0.8	38.8	27.6	9.7	6.6	4.5	53.1	1.5	0.0	8.6
SLC12A5	"KCC2, KIAA1176"	ENSG00000124140	"Solute carrier family 12 member 5"	Q9H2X9	20	46021690-46060152	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Potassium transport, Symport, Transport"		"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 64.6"	"Group enriched"	"Detected in many"	13	"Bipolar cells: 205.2;Cone photoreceptor cells: 361.3;Rod photoreceptor cells: 172.9"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"naive CD4 T-cell: 5.7"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"Hep G2: 13.7;NB-4: 28.3;SK-BR-3: 14.3;U-2 OS: 16.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA072058	Enhanced					NA	NA					"HPA072058: AB_2686485"	"unprognostic (2.01e-1)"	"unprognostic (3.58e-1)"	"unprognostic (7.55e-2)"	"unprognostic (9.44e-4)"	"prognostic unfavorable (5.60e-4)"	"unprognostic (2.48e-1)"	"unprognostic (5.16e-3)"	"unprognostic (3.61e-1)"	"unprognostic (2.49e-1)"	"unprognostic (6.63e-2)"	"unprognostic (3.72e-3)"	"unprognostic (5.61e-4)"	"unprognostic (8.78e-4)"	"unprognostic (3.25e-2)"	"unprognostic (9.22e-2)"	"unprognostic (1.99e-1)"	"unprognostic (2.34e-2)"	1.4	11.2	21.1	2.0	28.8	1.5	1.7	52.1	64.6	2.3	2.1	2.7	0.0	2.2	1.6	2.2	1.3	1.7	1.9	2.1	20.5	19.2	1.4	2.2	2.7	3.1	9.5	32.1	2.0	3.6	1.5	4.8	3.3	15.3	1.5	2.1	4.9	1.9	1.8	1.5	1.5	2.1	1.6	6.3	2.8	3.1	3.4	5.8	0.0	1.3	0.0	2.6	1.2	0.5	1.3	0.2	0.1	1.5	0.7	5.7	1.3	0.0	8.6	3.8	2.8	0.3	0.0	0.8	0.3	0.0	0.0	0.3	1.1	0.0	3.2	13.1	0.2	3.4	0.8	2.5	1.3	0.2	2.0	3.3	2.7	1.6	13.7	1.5	0.0	3.8	0.5	0.0	0.0	0.2	5.9	0.8	3.1	5.1	0.0	0.0	13.0	1.9	28.3	1.4	1.2	4.4	3.2	2.4	0.7	1.3	0.0	4.7	6.7	1.7	14.3	4.1	3.7	5.2	8.1	1.3	1.5	16.3	0.1	0.6	0.0	2.1	4.5	3.5	3.3	0.1	0.0	1.5	0.0	2.6	0.8	1.0	1.0	0.3	0.4	0.2	1.3	5.7	3.2	0.1	0.7	0.2	0.0	3.5	1.3	21.1	28.8	52.1	36.4	20.5	19.2	9.5	32.1	15.3	5.8	0.0	0.0	0.0	0.0	0.5	205.2	0.8	0.0	0.0	0.0	0.0	361.3	1.1	1.7	0.0	1.6	1.6	0.0	0.0	0.2	2.6	0.4	0.4	0.0	0.5	15.2	12.7	19.1	3.7	0.6	3.4	0.0	3.2	5.0	1.0	0.4	12.9	0.5	0.0	0.0	0.2	172.9	0.0	0.4	1.4	2.5	0.5	1.4	0.0	0.4	0.0
SLC18A1	"CGAT, VAT1, VMAT1"	ENSG00000036565	"Solute carrier family 18 member A1"	P54219	8	20144855-20183206	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"adrenal gland: 25.4;intestine: 10.8"	"Cell type enriched"	"Detected in some"	37	"Intestinal endocrine cells: 133.5"	"Cancer enhanced"	"Detected in some"		"colorectal cancer: 0.8"	"Region enriched"	"Detected in single"	4	"midbrain: 2.0"	"Group enriched"	"Detected in some"	12	"intermediate monocyte: 2.3;non-classical monocyte: 6.0"	"Lineage enriched"	"Detected in single"	18	"monocytes: 6.0"	"Cell line enriched"	"Detected in some"	8	"SH-SY5Y: 39.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"HPA006877, HPA063797"	Enhanced					NA	NA					"HPA006877: AB_2667690, HPA063797: AB_2685125"	"unprognostic (8.03e-4)"	"unprognostic (1.02e-1)"	"unprognostic (3.75e-3)"	"unprognostic (3.50e-1)"	"unprognostic (6.61e-2)"	"unprognostic (3.09e-3)"	"unprognostic (1.67e-1)"	"unprognostic (2.16e-2)"	"unprognostic (3.45e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.32e-3)"	"unprognostic (1.61e-1)"	"unprognostic (2.48e-2)"	"unprognostic (8.25e-2)"	"unprognostic (4.41e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.05e-1)"	0.0	25.4	0.2	0.8	0.1	0.0	0.0	0.0	0.2	0.2	8.8	1.3	1.3	1.4	0.4	0.0	0.0	0.0	0.7	0.1	0.1	0.4	0.0	0.0	0.0	0.0	2.0	0.0	0.2	0.0	0.0	0.0	0.0	0.4	1.0	2.7	0.0	0.0	2.8	0.0	0.0	10.8	0.0	0.1	0.3	1.1	0.2	0.0	0.2	0.2	0.0	0.1	1.3	0.4	0.0	0.3	0.2	6.0	0.0	0.0	0.3	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.6	0.0	0.0	0.0	2.2	39.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.2	0.0	6.0	0.0	0.0	0.3	0.2	0.1	0.0	0.2	0.1	0.4	2.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	133.5	0.0	0.0	0.0	0.0	0.0	0.0	1.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0
SLC18A2	"SVAT, SVMT, VMAT2"	ENSG00000165646	"Solute carrier family 18 member A2"	Q05940	10	117241073-117279430	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Transport"		"Disease mutation, Dystonia, FDA approved drug targets, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 26.3;brain: 28.3;cervix, uterine: 31.2"	"Cell type enriched"	"Detected in some"	22	"granulocytes: 603.6"	"Low cancer specificity"	"Detected in some"			"Group enriched"	"Detected in many"	10	"hypothalamus: 9.0;midbrain: 28.3;pons and medulla: 26.5"	"Cell type enriched"	"Detected in some"	13	"basophil: 26.3"	"Lineage enriched"	"Detected in many"	13	"granulocytes: 26.3"	"Cell line enriched"	"Detected in some"	20	"HMC-1: 91.2"	"Region enhanced"	"Detected in many"		"midbrain: 75.4"	"Group enriched"	"Detected in all"	5	"midbrain: 143.8;pons and medulla: 34.7"	HPA073224	Enhanced		Approved	Vesicles,Centrosome		NA	NA			"Vesicles, Centrosome"		"HPA073224: AB_2732222"	"unprognostic (1.49e-1)"	"unprognostic (2.48e-1)"	"unprognostic (2.33e-3)"	"unprognostic (9.00e-2)"	"unprognostic (2.85e-1)"	"unprognostic (5.33e-3)"	"unprognostic (2.23e-1)"	"unprognostic (1.71e-2)"	"unprognostic (1.40e-1)"	"unprognostic (4.55e-2)"	"unprognostic (2.00e-1)"	"unprognostic (6.06e-3)"	"unprognostic (7.94e-5)"	"unprognostic (2.95e-2)"	"unprognostic (2.31e-1)"	"unprognostic (2.43e-1)"	"unprognostic (3.57e-2)"	1.7	13.9	1.7	3.1	2.0	2.0	2.0	1.7	1.6	31.2	2.3	0.5	2.2	1.5	11.2	4.9	3.0	1.1	15.9	1.0	1.9	9.0	1.1	3.3	7.6	1.5	28.3	0.2	9.7	3.7	0.5	1.6	2.1	26.5	10.8	3.4	3.1	1.0	4.0	1.1	5.8	2.5	5.4	2.9	0.5	3.5	1.5	0.3	14.1	0.6	3.4	2.9	3.1	5.4	0.0	2.0	26.3	0.0	0.0	0.3	1.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.2	4.6	0.0	0.0	0.0	0.2	91.2	0.0	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.2	0.1	0.1	0.0	0.1	0.4	0.0	26.3	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.3	0.2	0.0	0.0	2.0	0.0	1.1	1.7	2.0	1.7	1.6	1.9	9.0	28.3	0.2	26.5	0.3	8.9	27.6	0.0	0.0	1.6	0.6	0.2	0.0	1.4	4.5	0.0	3.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	4.4	603.6	0.0	0.7	0.0	8.5	11.6	1.8	0.0	0.6	0.6	1.7	0.0	0.0	0.3	0.1	0.0	4.6	0.0	0.7	0.0	0.2	0.2	0.1	2.4	0.0	0.0	0.0	0.0
SLC1A5	"AAAT, ASCT2, M7V1, RDRC"	ENSG00000105281	"Solute carrier family 1 member 5"	Q15758	19	46774883-46788594	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Host-virus interaction, Symport, Transport"	"Host cell receptor for virus entry, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	5	"Basal glandular cells: 134.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 34.6"	"Group enriched"	"Detected in many"	4	"dendritic cells: 34.6;monocytes: 22.4"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			"HPA035239, HPA035240"	Enhanced		Enhanced	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA035239: AB_10670587, HPA035240: AB_10604092"	"unprognostic (8.26e-3)"	"unprognostic (6.38e-2)"	"unprognostic (7.24e-2)"	"unprognostic (7.94e-2)"	"unprognostic (2.32e-1)"	"unprognostic (1.24e-1)"	"prognostic unfavorable (1.66e-8)"	"unprognostic (2.08e-1)"	"unprognostic (1.06e-2)"	"unprognostic (9.82e-2)"	"unprognostic (9.40e-3)"	"unprognostic (9.57e-3)"	"prognostic unfavorable (1.18e-7)"	"unprognostic (1.28e-2)"	"unprognostic (6.30e-2)"	"unprognostic (1.06e-2)"	"unprognostic (9.83e-2)"	39.3	5.7	3.4	16.0	5.4	16.2	45.0	0.9	3.0	20.7	15.8	5.0	50.4	4.9	14.3	33.7	33.9	18.1	31.2	10.0	4.5	2.2	23.7	4.1	23.4	17.7	8.2	0.9	33.3	24.6	0.2	9.1	25.8	4.9	35.2	13.8	5.2	99.0	55.7	6.9	18.6	12.1	23.1	5.3	19.8	17.9	21.7	6.1	14.9	6.5	28.4	25.9	48.3	44.9	7.0	34.6	0.9	22.4	6.9	5.6	7.4	23.8	44.1	10.6	16.0	27.7	23.6	25.1	34.1	39.0	25.6	37.2	40.0	27.0	26.2	16.7	84.6	14.7	38.5	30.9	40.5	19.1	17.3	28.0	43.4	16.9	37.5	71.7	30.2	25.6	38.3	101.3	30.0	76.2	8.6	13.6	35.0	45.8	69.4	13.6	40.6	13.8	81.3	18.5	85.5	19.4	15.7	12.0	37.2	14.3	52.2	16.4	12.0	16.8	46.0	36.5	8.6	26.5	39.9	10.1	15.4	24.7	12.0	27.7	43.1	41.6	21.8	29.0	37.7	37.7	0.0	11.5	0.9	5.3	19.9	4.4	7.0	3.1	3.7	17.8	2.5	0.7	2.3	0.3	6.9	22.4	34.6	5.6	7.4	3.4	5.4	0.9	3.0	4.5	2.2	8.2	0.9	4.9	6.1	0.0	15.9	11.9	134.3	51.3	0.1	19.9	20.4	4.0	7.9	0.0	0.0	80.4	3.3	26.8	14.6	17.1	22.0	93.5	55.3	97.4	44.3	44.4	28.8	0.5	33.9	0.0	10.3	26.4	16.8	10.3	17.5	27.3	18.6	10.8	88.4	0.6	35.9	74.6	18.4	23.9	0.8	6.5	22.6	4.4	4.3	24.7	20.4	20.8	50.3	96.8
SLC22A11	OAT4	ENSG00000168065	"Solute carrier family 22 member 11"	Q9NSA0	11	64555626-64572875	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	10	"epididymis: 22.2;kidney: 47.6;placenta: 64.7"	"Group enriched"	"Detected in some"	17	"Cytotrophoblasts: 554.5;Syncytiotrophoblasts: 1271.5"	"Group enriched"	"Detected in some"	14	"liver cancer: 3.7;renal cancer: 15.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BEWO: 4.8;CACO-2: 1.1;Hep G2: 3.4;SuSa: 1.9"					"Not detected"	"Not detected"			HPA026076	Enhanced					NA	NA					"HPA026076: AB_1854756"	"unprognostic (8.21e-5)"	"unprognostic (3.29e-2)"	"unprognostic (3.57e-1)"	"unprognostic (1.57e-1)"	"unprognostic (3.20e-2)"	"unprognostic (4.57e-3)"	"unprognostic (3.48e-1)"	"unprognostic (1.93e-1)"	"unprognostic (4.86e-2)"	"unprognostic (4.51e-2)"	"unprognostic (7.56e-2)"	"unprognostic (1.13e-1)"	"prognostic favorable (3.68e-5)"	"unprognostic (4.62e-2)"	"unprognostic (6.52e-2)"	"unprognostic (3.50e-2)"	"unprognostic (8.24e-3)"	0.1	0.2	0.1	0.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.0	4.4	0.0	0.1	22.2	0.1	0.1	0.0	0.1	0.1	0.1	47.6	0.4	0.1	0.0	0.2	0.0	0.1	0.3	0.0	0.1	64.7	0.0	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.1	0.3	0.1	0.4	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.2	4.8	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.3	0.0	0.7	0.0	0.0	0.0	0.0	0.2	0.4	0.0	0.2	0.0	1.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	554.5	5.0	0.0	1.0	0.0	0.0	0.0	0.3	13.6	0.6	0.0	0.0	0.0	44.6	0.0	0.0	0.0	0.0	1.3	0.3	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	54.2	0.0	0.0	0.0	0.0	0.1	0.0	1271.5	0.0	0.0	0.0
SLC22A12	"OAT4L, RST, URAT1"	ENSG00000197891	"Solute carrier family 22 member 12"	Q96S37	11	64590641-64602353	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in single"	349	"kidney: 70.1"	"Cell type enriched"	"Detected in some"	18	"Proximal tubular cells: 149.1"	"Group enriched"	"Detected in some"	207	"liver cancer: 4.0;renal cancer: 16.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			HPA024575	Enhanced					NA	NA					"HPA024575: AB_1858650"					"unprognostic (5.88e-2)"		"unprognostic (2.33e-1)"						"prognostic favorable (2.63e-4)"	"unprognostic (6.19e-2)"	"unprognostic (3.91e-2)"			0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	70.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	1.8	0.0	0.0	8.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	149.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SLC22A6	"OAT1, PAHT, ROAT1"	ENSG00000197901	"Solute carrier family 22 member 6"	Q4U2R8	11	62936385-62984983	"FDA approved drug targets, Predicted membrane proteins, Transporters"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	10	"kidney: 94.2"	"Cell type enriched"	"Detected in some"	14	"Proximal tubular cells: 213.4"	"Cancer enriched"	"Detected in single"	102	"renal cancer: 18.8"	"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA074559, CAB075704"	Enhanced					NA	NA					"CAB075704: , HPA074559: AB_2732260"					"unprognostic (2.42e-2)"								"unprognostic (2.25e-3)"	"unprognostic (4.43e-1)"				0.2	0.2	0.8	0.2	1.3	0.2	0.2	0.4	1.4	0.2	0.2	0.7	0.0	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.8	1.8	94.2	0.2	0.2	0.2	2.4	0.6	0.2	0.2	0.2	0.1	0.2	4.1	0.2	0.2	9.4	0.2	0.2	0.2	0.2	0.2	0.2	2.4	0.2	0.2	0.2	0.5	0.0	0.2	0.0	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	1.3	0.4	1.4	0.8	1.8	2.4	0.6	4.1	0.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	7.0	0.0	0.0	14.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	213.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SLC22A8	OAT3	ENSG00000149452	"Solute carrier family 22 member 8"	Q8TCC7	11	62989154-63015839	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Detoxification, Ion transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	341	"brain: 33.7;kidney: 127.3;retina: 93.5"	"Cell type enriched"	"Detected in some"	30	"Proximal tubular cells: 197.4"	"Cancer enhanced"	"Detected in single"		"renal cancer: 0.6"	"Region enriched"	"Detected in some"	25	"pons and medulla: 33.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	13	"EFO-21: 1.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA044174	Enhanced					NA	NA					"HPA044174: AB_10963058"							"unprognostic (5.35e-4)"					"unprognostic (4.66e-1)"	"unprognostic (6.88e-3)"	"unprognostic (1.72e-1)"	"unprognostic (2.20e-1)"			0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.4	1.0	0.1	0.1	3.8	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.7	0.1	127.3	0.1	0.1	0.1	0.1	1.3	0.1	0.1	0.1	0.2	0.1	33.7	0.1	0.1	93.5	0.1	0.1	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.4	1.0	0.7	0.1	0.1	1.3	33.7	0.0	0.0	0.0	0.0	0.0	0.0	3.7	0.8	0.0	0.0	0.0	5.2	0.0	0.0	6.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	197.4	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SLC25A4	"ANT1, PEO2, PEO3, T1"	ENSG00000151729	"Solute carrier family 25 member 4"	P12235	4	185143241-185150382	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Host-virus interaction, Transport"		"Cardiomyopathy, Disease mutation, FDA approved drug targets, Primary mitochondrial disease, Progressive external ophthalmoplegia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in all"	5	"heart muscle: 163.7;skeletal muscle: 92.5;tongue: 62.4"	"Cell type enriched"	"Detected in many"	5	"Cardiomyocytes: 4236.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Group enriched"	"Detected in many"	5	"B-cells: 3.5;dendritic cells: 3.0;T-cells: 4.1"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA046835, HPA071684"	Approved		Supported	Mitochondria		NA	NA			Mitochondria		"HPA046835: AB_2679831, HPA071684: AB_2686431"	"unprognostic (4.19e-2)"	"unprognostic (1.06e-2)"	"unprognostic (3.11e-1)"	"unprognostic (8.85e-2)"	"unprognostic (1.37e-1)"	"unprognostic (2.90e-3)"	"unprognostic (8.25e-2)"	"unprognostic (1.26e-2)"	"unprognostic (7.87e-2)"	"unprognostic (1.60e-1)"	"prognostic favorable (3.41e-4)"	"unprognostic (2.05e-1)"	"prognostic favorable (0.00e+0)"	"unprognostic (1.98e-1)"	"unprognostic (1.05e-1)"	"unprognostic (1.73e-1)"	"unprognostic (8.28e-3)"	3.0	4.2	6.9	2.0	10.8	1.4	3.1	19.4	14.4	2.6	6.6	3.7	2.9	2.8	3.0	3.4	6.7	3.7	3.5	163.7	7.4	7.3	8.3	4.3	3.0	2.0	6.3	6.1	3.6	3.0	4.6	4.6	2.2	12.8	6.2	3.4	7.9	4.4	8.5	92.5	2.3	4.1	5.5	4.5	2.1	5.3	3.1	2.3	0.0	4.6	62.4	3.4	4.4	2.1	3.5	3.0	0.4	0.0	0.7	4.1	1.5	0.7	3.3	2.7	5.5	3.0	0.3	5.0	2.7	0.9	3.3	3.3	7.1	1.8	2.4	2.0	3.3	2.6	2.6	10.4	2.9	2.2	4.0	8.9	1.6	4.9	8.3	6.1	1.4	1.6	2.2	7.1	5.1	1.4	7.8	2.4	4.2	3.8	1.9	2.0	5.1	1.6	3.2	4.4	2.3	7.1	2.6	1.4	3.3	7.5	5.1	8.8	6.7	3.2	1.4	12.6	5.1	2.6	1.2	1.8	0.2	1.5	1.7	3.5	7.9	3.6	3.1	2.4	0.3	3.0	0.0	0.0	0.0	4.1	0.0	3.1	3.5	1.4	3.5	0.1	2.2	1.2	3.0	0.4	0.7	0.0	3.0	1.2	1.5	6.9	10.8	19.4	14.1	7.4	7.3	6.3	6.1	12.8	2.3	80.4	55.4	33.5	125.8	39.2	174.4	4236.1	140.1	112.4	42.1	68.0	98.2	59.7	837.3	68.4	15.8	25.9	41.2	0.0	65.1	47.9	24.6	55.0	11.5	83.9	50.1	151.0	51.6	24.5	7.6	7.7	43.1	7.9	180.5	15.4	35.7	473.2	51.1	24.6	106.1	140.9	178.4	103.5	194.8	24.0	35.3	15.8	33.9	10.7	48.8	46.9
SLC25A5	"2F1, ANT2, T2, T3"	ENSG00000005022	"Solute carrier family 25 member 5"	P05141	X	119468400-119471319	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Chromosome partition, Host-virus interaction, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	5	"Distal tubular cells: 2147.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA046835, HPA071684"	Approved		Supported	Mitochondria		NA	NA		7800000	Mitochondria		"HPA046835: AB_2679831, HPA071684: AB_2686431"	"unprognostic (1.25e-2)"	"prognostic favorable (7.35e-4)"	"prognostic favorable (7.47e-4)"	"unprognostic (1.48e-1)"	"unprognostic (4.58e-2)"	"unprognostic (1.45e-2)"	"unprognostic (2.73e-2)"	"unprognostic (1.36e-1)"	"unprognostic (6.52e-2)"	"unprognostic (2.47e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.17e-1)"	"prognostic favorable (8.06e-6)"	"unprognostic (1.41e-1)"	"unprognostic (2.65e-1)"	"unprognostic (4.36e-2)"	"unprognostic (3.03e-1)"	26.0	28.9	26.8	32.2	29.5	36.5	36.6	21.8	39.0	23.0	74.1	16.3	26.0	120.7	22.5	18.3	64.1	17.5	39.5	31.4	22.5	18.8	80.7	71.0	38.3	53.8	27.2	23.8	18.1	128.2	22.5	14.6	30.7	24.2	18.9	84.9	20.1	58.3	21.5	16.6	42.1	157.5	33.6	20.5	34.3	68.2	16.8	17.1	87.0	31.1	59.9	47.0	30.8	33.8	51.6	97.8	18.5	113.2	33.4	48.0	84.9	82.0	78.9	30.9	53.1	19.8	29.2	57.4	30.7	33.5	64.8	58.0	65.5	52.1	104.2	41.3	29.4	46.8	57.8	75.8	64.1	59.2	27.5	73.1	35.1	47.7	46.6	25.1	95.3	58.0	31.7	72.1	66.7	42.6	24.7	67.2	53.7	28.1	43.2	35.3	182.7	84.3	96.8	65.0	112.7	127.2	46.3	39.1	80.8	49.3	66.0	37.4	35.4	52.7	80.3	62.1	32.9	33.1	48.3	27.9	30.7	44.4	68.3	110.0	50.7	62.9	83.4	33.9	97.5	49.5	10.1	68.1	18.5	20.7	113.2	23.9	51.6	30.1	26.9	97.8	39.7	30.1	28.3	11.3	33.4	84.9	53.9	48.0	84.9	26.8	29.5	21.8	39.0	22.5	18.8	27.2	23.8	24.2	17.1	151.8	244.7	335.6	401.9	724.7	105.3	125.5	328.6	187.4	221.8	177.9	56.9	945.1	2147.0	467.3	2.7	209.6	1628.0	163.5	919.2	321.7	246.2	228.4	191.3	343.1	785.8	25.4	385.2	119.1	477.4	13.9	134.6	447.5	519.6	300.2	755.1	85.2	524.3	956.2	104.0	1138.1	131.4	129.4	460.4	8.9	116.7	839.4	1329.0	292.0	958.7	657.9
SLC25A6	"ANT3, ANT3Y, MGC17525"	ENSG00000169100	"Solute carrier family 25 member 6"	P12236	X	1386152-1392724	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Apoptosis, Host-virus interaction, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 85.7"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											"HPA046835, HPA071684"	Approved		Supported	Mitochondria		NA	NA		7200000	Mitochondria		"HPA046835: AB_2679831, HPA071684: AB_2686431"	"unprognostic (1.13e-1)"	"unprognostic (1.65e-2)"	"unprognostic (4.79e-2)"	"unprognostic (1.45e-1)"	"unprognostic (2.14e-1)"	"unprognostic (1.41e-1)"	"unprognostic (1.01e-3)"	"unprognostic (1.34e-1)"	"unprognostic (8.07e-2)"	"unprognostic (1.48e-1)"	"unprognostic (1.37e-3)"	"unprognostic (2.51e-1)"	"unprognostic (3.96e-2)"	"unprognostic (2.73e-1)"	"unprognostic (1.69e-1)"	"unprognostic (2.85e-1)"	"unprognostic (4.57e-3)"	18.5	19.7	12.1	12.2	14.0	23.7	14.4	8.2	12.2	9.8	16.5			28.9	14.3	4.8	16.4	10.4	7.0	9.4	10.3	8.2	18.4	5.4	11.1	14.4	9.4		25.6	38.7	10.1	14.0	8.6		12.4	8.8		45.0	12.5	6.1	14.9	23.3	7.7	5.8	15.4	19.2	2.4			16.3		9.5	14.2	11.2	62.2	85.7	3.7	69.0	30.1	43.6	71.2	22.2	48.7	34.6	35.3	24.0	46.8	37.5	34.1	32.7	25.2	25.1	64.4	27.2	82.8	27.6	22.4	38.0	14.5	23.2	40.7	7.9	20.7	73.8	45.2	33.4	73.5	56.3	32.5	55.2	77.2	75.0	19.7	29.0	32.7	37.3	26.1	31.5	19.5	24.6	47.4	60.1	62.3	43.9	8.8	65.7	30.4	28.6	64.2	30.7	56.0	56.6	88.9	23.1	70.1	97.0	21.0	38.9	67.0	42.7	25.7	14.4	50.2	34.0	50.6	8.1	55.8	3.8	31.4	13.9	2.4	58.1	3.7	29.4	69.0	43.6	62.2	40.4	34.8	85.7	47.5	38.1	37.2	3.0	30.1	67.9	41.0	38.7	71.2											137.0	195.3	871.5	1042.4	1022.6	282.9	87.0	257.4	128.5	280.9	300.1	92.3	1322.2	1405.9	633.0	8.9	418.0	863.0	303.7	1275.3	963.9	807.0	855.9	337.0	132.8	1090.5	228.8	892.0	411.9	1235.3	26.5	618.4	976.3	715.3	1354.4	1107.0	100.8	835.0	866.6	344.4	1021.3	199.6	336.3	860.1	13.3	52.8	1155.2	1458.6	553.5	1380.0	1328.6
SLC52A2	"D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2"	ENSG00000185803	"Solute carrier family 52 member 2"	Q9HAB3	8	144354135-144361286	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	Transport	"Host cell receptor for virus entry, Receptor"	"Deafness, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"PC-3: 51.0"	"Low region specificity"	"Detected in all"							HPA063036	Approved					NA	NA					"HPA063036: AB_2684928"	"unprognostic (7.80e-3)"	"prognostic unfavorable (7.55e-4)"	"unprognostic (2.15e-1)"	"unprognostic (2.94e-1)"	"unprognostic (3.09e-2)"	"unprognostic (3.94e-2)"	"prognostic unfavorable (2.04e-6)"	"unprognostic (7.74e-3)"	"unprognostic (9.20e-2)"	"unprognostic (2.24e-2)"	"unprognostic (4.85e-2)"	"unprognostic (3.99e-2)"	"prognostic unfavorable (1.23e-4)"	"unprognostic (3.12e-2)"	"unprognostic (1.73e-1)"	"unprognostic (1.51e-1)"	"unprognostic (1.07e-1)"	16.0	12.8	7.3	13.2	8.8	9.9	23.7	19.2	10.5	10.9	18.1	7.5	19.3	19.6	10.7	19.9	14.6	7.4	16.3	8.0	7.7	9.0	14.7	12.4	10.7	10.7	13.0	5.9	10.6	22.4	7.9	10.9	19.5	9.5	10.8	9.3	7.2	21.3	14.1	7.0	12.6	17.8	8.5	7.9	15.2	16.8	17.0	7.4	11.5	12.4	11.6	14.6	8.6	13.1	7.7	9.0	9.2	7.4	5.7	6.3	1.9	12.8	18.5	2.6	6.9	4.9	3.7	13.4	9.9	7.0	9.0	7.2	14.7	15.5	6.1	16.3	7.1	6.6	15.3	4.4	7.6	1.9	7.5	10.5	10.6	10.6	13.3	16.0	3.9	9.1	5.1	9.2	8.2	6.8	4.4	5.2	5.8	14.5	7.8	4.7	37.4	6.0	10.3	5.6	16.0	51.0	11.2	3.1	13.8	7.3	9.5	8.2	9.8	12.2	12.7	11.4	2.5	10.0	5.1	7.4	7.4	16.8	18.4	14.2	3.9	5.4	4.6	12.2	9.7	8.5	1.2	4.2	9.2	5.9	6.1	3.7	4.2	4.7	6.3	5.2	7.7	4.6	3.1	1.4	5.7	7.4	9.0	5.7	1.9	7.3	8.8	19.2	10.5	7.7	9.0	13.0	5.9	9.5	7.4	6.0	5.4	19.3	19.4	27.7	10.9	2.5	12.7	4.0	14.8	12.2	2.0	74.0	0.0	60.6	2.5	20.6	60.0	0.0	58.0	74.5	27.7	31.3	10.3	4.0	47.5	11.1	16.7	17.8	14.8	4.2	11.8	20.9	28.7	55.1	32.0	13.5	64.4	42.1	18.7	12.9	8.9	19.4	26.4	31.7	39.6	31.6	43.9	20.8	38.1	32.6
SLC5A2	SGLT2	ENSG00000140675	"Solute carrier family 5 member 2"	P31639	16	31483002-31490860	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Sugar transport, Symport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	17	"kidney: 33.7"	"Group enriched"	"Detected in some"	11	"Early spermatids: 46.9;Late spermatids: 103.8;Proximal tubular cells: 139.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"memory CD4 T-cell: 1.6"	"Group enriched"	"Detected in many"	16	"NK-cells: 1.4;T-cells: 1.6"	"Cell line enhanced"	"Detected in some"		"BEWO: 1.2;EFO-21: 2.0;Hep G2: 2.6;NB-4: 1.3;U-2 OS: 1.2;U-266/84: 1.8;U-937: 1.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			HPA041603	Enhanced					NA	NA					"HPA041603: AB_10960540"	"unprognostic (1.61e-1)"	"unprognostic (2.95e-1)"	"unprognostic (2.84e-1)"	"unprognostic (3.00e-2)"	"unprognostic (8.04e-2)"	"unprognostic (8.23e-3)"	"unprognostic (1.49e-1)"	"unprognostic (2.25e-3)"	"unprognostic (2.57e-1)"	"unprognostic (1.12e-2)"	"unprognostic (6.43e-2)"	"unprognostic (2.47e-1)"	"unprognostic (1.42e-3)"	"unprognostic (5.88e-2)"	"unprognostic (2.14e-1)"	"unprognostic (4.18e-2)"	"unprognostic (3.22e-1)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	33.7	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	1.6	0.6	0.1	0.4	0.0	0.9	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.2	0.0	2.0	0.0	0.1	0.0	0.0	0.0	0.0	0.6	0.5	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.3	1.2	0.1	0.0	0.0	1.8	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.0	1.6	0.5	0.0	0.0	0.5	0.1	0.0	1.4	0.0	0.0	1.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	0.0	0.0	0.2	0.0	0.3	0.0	1.4	0.0	8.7	0.0	0.2	6.6	0.7	46.9	0.0	0.3	0.0	0.4	0.1	0.1	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	103.8	2.0	0.4	0.0	0.0	0.2	0.0	0.7	0.0	1.4	139.8	0.0	0.0	0.0	3.2	0.9	0.3	0.1	0.0	0.6	0.0
SLC6A1	"GABATHG, GABATR, GAT1"	ENSG00000157103	"Solute carrier family 6 member 1"	P30531	3	10992186-11039249	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Symport, Transport"		"Disease mutation, Epilepsy, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	7	"brain: 56.2;liver: 75.6"	"Cell type enhanced"	"Detected in some"	16	"Cholangiocytes: 17.8;Hepatocytes: 24.5;Muller glia cells: 41.9;Sertoli cells: 12.9"	"Group enriched"	"Detected in some"	16	"glioma: 16.1;liver cancer: 24.4"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HeLa: 4.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA013341, CAB022293"	Enhanced		Uncertain	Mitochondria		No	NA			Mitochondria		"CAB022293: , HPA013341: AB_1849509"	"unprognostic (1.66e-3)"	"unprognostic (1.30e-3)"	"unprognostic (4.12e-3)"	"unprognostic (1.70e-1)"	"unprognostic (2.53e-1)"	"unprognostic (2.53e-1)"	"prognostic favorable (3.20e-4)"	"unprognostic (1.05e-1)"	"unprognostic (4.27e-2)"	"unprognostic (8.26e-2)"	"unprognostic (2.90e-1)"	"unprognostic (2.69e-1)"	"prognostic unfavorable (5.05e-6)"	"unprognostic (7.32e-3)"	"unprognostic (2.36e-1)"	"unprognostic (1.35e-1)"	"unprognostic (5.34e-2)"	1.8	2.1	32.2	1.6	31.0	3.0	1.8	15.1	56.2	2.0	1.7	25.4	0.0	1.7	1.9	3.9	4.3	2.4	2.3	3.3	22.2	16.6	2.1	75.6	2.5	1.7	22.7	25.3	2.4	1.4	9.3	1.0	2.0	17.0	2.1	1.8	1.7	1.6	5.0	3.3	1.7	1.7	1.8	13.7	1.9	1.7	4.4	14.3	0.5	1.9	0.0	1.7	1.9	0.9	1.0	0.8	1.2	0.3	0.2	0.8	0.2	0.8	0.6	1.9	1.3	1.5	0.4	1.1	0.7	0.2	0.8	1.1	1.5	1.0	1.6	0.3	0.4	1.8	1.3	2.3	0.9	0.7	0.2	1.8	1.3	4.6	2.8	0.7	2.2	2.3	1.1	0.2	0.2	1.3	0.5	0.3	1.7	1.1	3.7	0.2	1.1	0.7	1.8	0.8	1.2	1.4	1.2	0.2	0.1	0.6	1.8	0.8	0.3	1.0	0.7	0.2	1.1	1.0	1.0	0.3	0.8	0.5	0.7	0.7	1.1	0.3	1.2	0.9	1.7	0.4	0.3	0.3	1.1	0.5	0.1	0.8	0.9	0.6	0.5	0.3	1.0	0.3	0.5	1.2	0.2	0.3	0.8	0.3	0.2	32.2	31.0	15.1	41.5	22.2	16.6	22.7	25.3	17.0	14.3	0.0	0.3	0.0	0.0	0.2	1.8	1.4	17.8	0.0	1.2	0.0	0.0	0.0	0.0	0.0	1.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	2.3	24.5	0.0	0.0	0.0	0.0	1.0	0.2	5.2	0.0	0.0	0.0	0.0	41.9	0.0	0.0	9.6	0.1	3.3	12.9	2.1	5.0	0.0	0.0	0.0	0.0	0.0	0.0
SLC6A2	"NAT1, NET, NET1, SLC6A5"	ENSG00000103546	"Solute carrier family 6 member 2"	P23975	16	55655604-55706192	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Symport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adrenal gland: 20.4;placenta: 41.8"	"Group enriched"	"Detected in some"	5	"Early spermatids: 3.2;Extravillous trophoblasts: 6.9;Late spermatids: 3.7;Spermatocytes: 10.4;Syncytiotrophoblasts: 4.7"	"Cancer enhanced"	"Detected in some"		"liver cancer: 1.9"	"Region enriched"	"Detected in single"	27	"pons and medulla: 9.7"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in some"	30	"SH-SY5Y: 107.1"	"Region enriched"	"Detected in some"	4	"pons and medulla: 8.2"	"Region enriched"	"Detected in single"	32	"pons and medulla: 23.1"	"HPA004057, HPA076311, CAB078195"	Enhanced	Supported	Approved	Mitochondria,Cytosol		NA	NA			Cytosol	Mitochondria	"CAB078195: AB_2665806, HPA004057: AB_1080012, HPA076311: AB_2732307"	"unprognostic (9.58e-3)"	"unprognostic (5.48e-2)"		"unprognostic (1.26e-4)"	"unprognostic (4.07e-1)"	"unprognostic (4.16e-1)"	"unprognostic (8.38e-2)"	"unprognostic (2.97e-2)"	"unprognostic (3.29e-1)"	"unprognostic (2.31e-1)"	"unprognostic (3.27e-1)"	"unprognostic (2.12e-2)"	"unprognostic (2.95e-2)"	"unprognostic (1.72e-1)"	"unprognostic (6.02e-2)"	"unprognostic (8.48e-2)"	"unprognostic (1.43e-2)"	2.4	20.4	0.3	0.1	0.1	0.0	1.8	0.1	0.3	3.2	0.3	0.3	0.1	0.0	4.5	7.2	0.8	0.4	0.4	0.1	0.1	0.0	0.4	1.0	0.5	0.1	0.1	0.1	0.2	0.1	0.0	0.1	41.8	9.7	0.5	0.1	0.1	1.6	1.7	0.1	11.4	0.4	1.0	0.2	0.1	0.2	8.3	0.2	0.1	0.2	0.9	0.5	0.5	1.7	0.0	0.2	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	1.1	0.8	107.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.1	0.1	0.3	0.1	0.0	0.1	0.1	9.7	0.2	0.0	0.0	0.0	0.1	1.3	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	3.2	0.0	0.0	0.0	0.0	6.9	0.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	3.7	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	10.4	0.1	0.4	4.7	0.0	0.0	0.0
SLC6A3	"DAT, DAT1"	ENSG00000142319	"Solute carrier family 6 member 3"	Q01959	5	1392790-1445430	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Symport, Transport"		"Disease mutation, Dystonia, FDA approved drug targets, Neurodegeneration, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	14	"brain: 48.4"	"Cell type enriched"	"Detected in single"	5	"Alveolar cells type 2: 2.9"	"Cancer enriched"	"Detected in some"	18	"renal cancer: 25.7"	"Region enriched"	"Detected in some"	47	"midbrain: 48.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	5	"NTERA-2: 1.2;RPMI-8226: 2.1;SCLC-21H: 3.8"	"Group enriched"	"Detected in some"	8	"midbrain: 96.4;thalamus: 31.8"	"Region enriched"	"Detected in single"	138	"midbrain: 362.2"	"HPA012763, HPA013602, CAB016249, CAB078172"	Enhanced	Supported	Approved	Vesicles		NA	NA			Vesicles		"CAB016249: AB_627402, CAB078172: AB_2665810, HPA012763: AB_2732405, HPA013602: AB_1847484"	"unprognostic (2.25e-4)"	"unprognostic (2.22e-1)"	"unprognostic (8.45e-2)"	"unprognostic (5.24e-2)"	"unprognostic (7.75e-2)"	"unprognostic (1.41e-2)"	"unprognostic (4.64e-5)"	"unprognostic (9.31e-2)"	"unprognostic (7.89e-2)"	"unprognostic (4.81e-2)"	"unprognostic (1.30e-1)"	"unprognostic (2.12e-2)"	"prognostic unfavorable (3.40e-7)"	"unprognostic (6.98e-2)"	"unprognostic (1.64e-1)"	"unprognostic (2.22e-2)"	"unprognostic (4.74e-2)"	0.2	0.1	0.0	0.0	0.7	0.0	0.1	0.0	0.3	0.7	0.0	0.0	0.0	0.3	1.1	0.8	0.1	0.8	0.6	0.1	0.0	0.6	0.3	0.0	3.4	0.0	48.4	0.0	1.5	0.0	0.0	0.0	0.1	1.0	0.7	0.0	1.7	0.0	0.1	0.0	0.0	0.0	1.3	0.0	0.1	0.0	0.8	0.0	2.4	2.2	0.0	0.3	0.2	0.0	0.2	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	1.2	0.0	0.0	0.0	0.0	2.1	0.0	0.1	3.8	0.0	0.0	0.1	0.0	0.4	0.0	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.3	0.0	0.6	48.4	0.0	1.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0
SLC6A4	"5-HTT, HTT, OCD1, SERT1"	ENSG00000108576	"Solute carrier family 6 member 4"	P31645	17	30194319-30236002	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Neurotransmitter transport, Symport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 25.0;lung: 50.5"	"Group enriched"	"Detected in some"	6	"Cytotrophoblasts: 90.5;Syncytiotrophoblasts: 89.0"	"Cancer enhanced"	"Detected in some"		"breast cancer: 2.3"	"Region enriched"	"Detected in single"	36	"pons and medulla: 11.2"	"Cell type enhanced"	"Detected in single"		"neutrophil: 1.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BEWO: 2.9;CACO-2: 5.5;Hep G2: 14.7"	"Region enriched"	"Detected in some"	5	"midbrain: 69.9"	"Low region specificity"	"Detected in all"			"HPA054723, HPA071354, HPA074728"	Supported	Supported	Supported	"Golgi apparatus,Vesicles"		NA	NA			"Golgi apparatus, Vesicles"		"HPA054723: , HPA071354: , HPA074728: AB_2686708"	"unprognostic (7.45e-2)"	"unprognostic (7.13e-2)"	"unprognostic (2.26e-1)"	"unprognostic (3.72e-4)"	"unprognostic (2.07e-1)"	"unprognostic (8.42e-3)"	"unprognostic (2.73e-2)"	"unprognostic (3.39e-2)"	"unprognostic (3.37e-3)"	"unprognostic (1.17e-3)"	"unprognostic (2.70e-3)"	"unprognostic (1.16e-1)"	"unprognostic (8.78e-2)"	"unprognostic (4.98e-2)"	"unprognostic (1.76e-1)"	"unprognostic (4.05e-2)"	"unprognostic (7.18e-2)"	0.2	0.1	0.1	0.1	0.1	0.0	0.2	0.2	0.3	0.2	0.2	0.1	0.1	6.3	0.1	0.3	1.6	0.9	0.1	0.7	0.1	0.1	0.3	0.1	50.5	0.1	0.1	0.1	0.1	0.6	0.0	0.1	11.3	11.2	0.1	0.0	0.2	0.7	0.1	0.1	0.4	25.0	0.4	0.1	0.1	0.5	0.3	0.1	0.1	0.2	0.1	0.3	0.1	0.3	0.0	0.1	1.0	0.2	0.4	0.3	2.3	0.0	0.0	0.0	0.1	0.0	0.0	2.9	0.0	0.0	0.0	0.0	5.5	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.1	14.7	1.5	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.1	0.2	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.4	0.1	0.1	0.0	1.0	0.0	0.7	0.8	0.0	0.0	0.1	0.2	0.2	0.0	0.1	0.1	0.0	0.1	0.0	0.0	0.3	0.1	0.1	0.3	0.0	0.1	0.0	0.1	0.1	0.0	0.0	0.2	0.1	1.0	0.4	0.2	0.1	0.0	2.3	0.1	0.1	0.2	0.3	0.1	0.1	0.1	0.1	11.2	0.1	14.9	5.3	0.0	0.4	0.1	0.2	0.8	0.0	1.4	3.4	1.8	0.0	90.5	0.0	0.0	2.3	0.5	1.0	0.0	0.0	7.0	1.6	0.3	2.3	0.0	8.4	0.0	0.0	2.5	0.6	1.0	0.3	0.4	0.0	0.0	0.0	0.5	0.5	0.0	0.4	0.3	0.9	0.0	1.4	0.0	0.4	0.3	89.0	0.0	0.0	0.3
SLC6A8	"CRTR, CT1"	ENSG00000130821	"Solute carrier family 6 member 8"	P48029	X	153688099-153696593	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Sodium transport, Symport, Transport"		"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Bipolar cells: 127.1;Enterocytes: 208.5;Horizontal cells: 112.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	4	"neutrophil: 2.6"	"Lineage enriched"	"Detected in single"	4	"granulocytes: 2.6"	"Cell line enhanced"	"Detected in many"		"AN3-CA: 42.8;SK-BR-3: 44.4"															NA	NA						"unprognostic (5.80e-2)"	"unprognostic (1.24e-1)"	"unprognostic (2.39e-2)"	"unprognostic (9.98e-2)"	"unprognostic (1.47e-1)"	"unprognostic (7.16e-2)"	"unprognostic (1.59e-2)"	"unprognostic (1.59e-2)"	"unprognostic (2.08e-1)"	"unprognostic (2.10e-1)"	"unprognostic (1.21e-1)"	"unprognostic (1.43e-1)"	"prognostic unfavorable (1.53e-4)"	"unprognostic (1.41e-1)"	"unprognostic (1.06e-1)"	"prognostic unfavorable (7.39e-4)"	"unprognostic (2.87e-1)"	17.6	19.5	26.3	5.8	39.0	19.3	7.3	23.9	31.9	6.1	26.8	36.6	7.6	32.4	11.2	9.1	20.0	10.6	20.2	53.1	29.3	16.1	27.3	1.9	3.1	1.9	55.6	22.0	5.1	8.3	17.0	7.2	22.6	25.8	12.8	20.2	20.9	31.8	24.9	76.4	28.0	48.3	13.5	28.2	5.1	11.0	16.7	38.9	4.6	2.8	11.0	5.0	40.4	10.1	0.5	0.0	2.6	0.2	0.0	0.0	0.1	40.6	1.7	12.5	42.8	4.0	2.8	2.9	6.1	10.1	7.9	9.8	5.2	0.5	0.0	4.7	7.3	9.3	15.1	25.0	21.0	4.9	0.7	23.8	0.1	14.1	15.5	13.9	0.3	2.8	5.9	4.5	7.9	28.7	15.0	3.9	0.2	9.9	0.6	4.4	2.4	0.2	0.9	12.8	8.1	17.9	1.9	1.4	0.5	8.6	7.9	16.1	18.0	8.9	44.4	28.8	3.0	8.6	6.2	3.9	13.1	20.9	16.8	18.0	1.5	0.7	0.4	29.3	1.2	13.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	2.6	0.0	0.0	0.0	0.0	0.1	26.3	39.0	23.9	30.4	29.3	16.1	55.6	22.0	25.8	38.9	0.0	3.4	2.7	10.6	20.6	127.1	89.0	25.5	8.1	0.0	5.2	104.1	11.0	3.3	3.6	0.6	5.6	208.5	23.3	18.9	27.8	11.2	21.2	4.6	0.8	4.3	112.8	24.9	4.9	1.3	2.2	8.3	1.6	23.6	5.4	32.8	17.4	55.3	41.8	7.8	49.9	48.6	32.3	15.3	2.9	2.8	13.7	76.0	0.0	15.7	17.6
SLC7A11	xCT	ENSG00000151012	"Solute carrier family 7 member 11"	Q9UPY5	4	138164097-138242349	"FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 27.2"	"Cell type enhanced"	"Detected in many"	13	"Glandular cells: 37.7;monocytes: 90.2;Muller glia cells: 48.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in single"	8	"plasmacytoid DC: 3.8"	"Lineage enriched"	"Detected in single"	8	"dendritic cells: 3.8"	"Cell line enhanced"	"Detected in many"		"hTCEpi: 28.6;TIME: 31.4;WM-115: 46.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA064215			Approved	Vesicles		NA	NA			Vesicles		"HPA064215: AB_2685213"	"unprognostic (3.55e-3)"	"unprognostic (4.64e-3)"	"unprognostic (2.43e-2)"	"unprognostic (7.18e-3)"	"unprognostic (2.59e-1)"	"unprognostic (8.80e-3)"	"unprognostic (2.07e-8)"	"unprognostic (1.98e-2)"	"unprognostic (1.09e-2)"	"prognostic favorable (1.77e-4)"	"unprognostic (1.90e-2)"	"unprognostic (4.07e-2)"	"unprognostic (2.22e-8)"	"unprognostic (3.81e-2)"	"unprognostic (3.76e-2)"	"unprognostic (2.29e-2)"	"unprognostic (1.54e-2)"	1.1	0.9	16.3	4.7	15.8	2.2	1.5	8.2	26.0	2.4	2.0	17.9	0.0	1.5	1.3	13.4	3.3	8.9	3.8	2.5	17.4	6.9	0.9	0.9	2.3	1.5	12.6	16.8	1.7	5.4	1.0	1.2	2.1	17.2	2.0	2.8	0.3	1.6	1.0	0.8	1.9	1.4	1.0	27.2	1.4	9.2	2.2	14.0	0.0	8.9	6.0	2.2	4.0	0.8	0.1	3.8	0.4	0.0	0.1	0.0	0.0	1.6	13.8	6.2	4.8	1.3	1.7	1.7	7.6	5.3	1.7	4.0	1.5	5.8	3.1	10.0	26.5	9.4	2.2	3.3	6.5	7.4	5.9	0.7	2.2	13.1	3.4	20.6	5.8	2.1	4.1	28.6	4.9	22.1	2.6	21.6	3.2	3.0	8.2	9.1	1.2	0.8	0.5	1.2	8.1	3.9	0.9	2.0	3.6	1.0	6.6	2.5	0.5	3.3	0.9	11.7	1.4	1.5	12.4	31.4	2.3	6.5	3.4	6.0	6.9	3.1	3.2	3.9	3.2	46.1	0.3	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.1	0.0	3.8	0.0	0.0	16.3	15.8	8.2	15.9	17.4	6.9	12.6	16.8	17.2	14.0	0.0	5.9	3.7	7.0	4.0	4.0	3.6	2.5	1.4	3.4	0.0	2.0	2.2	0.0	3.6	2.1	1.6	1.1	0.0	21.4	0.5	1.0	37.7	4.6	0.4	0.5	1.6	25.9	3.7	0.0	0.4	2.3	9.0	5.0	90.2	5.4	48.4	27.4	1.1	2.1	0.0	1.9	0.0	1.0	0.7	0.7	2.8	0.9	0.0	1.3	11.1
SLC7A3	"ATRC3, CAT-3, FLJ14541"	ENSG00000165349	"Solute carrier family 7 member 3"	Q8WY07	X	70925582-70931125	"FDA approved drug targets, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"lymphoid tissue: 45.5"	"Group enriched"	"Detected in some"	6	"Early spermatids: 5.3;Late spermatids: 1.9"	"Cancer enriched"	"Detected in some"	12	"testis cancer: 43.0"	"Region enhanced"	"Detected in many"		"hypothalamus: 6.7"	"Cell type enriched"	"Detected in single"	16	"naive CD8 T-cell: 1.5"	"Lineage enriched"	"Detected in single"	16	"T-cells: 1.5"	"Group enriched"	"Detected in some"	4	"HAP1: 20.7;NTERA-2: 42.6;SuSa: 53.1"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (1.42e-4)"	"unprognostic (4.30e-4)"	"unprognostic (3.59e-3)"	"unprognostic (1.81e-2)"	"unprognostic (6.45e-2)"			"unprognostic (1.45e-2)"		"unprognostic (3.66e-1)"	"unprognostic (9.18e-3)"	"unprognostic (1.89e-1)"		"unprognostic (7.99e-5)"	"unprognostic (1.31e-2)"	"unprognostic (5.42e-4)"	"unprognostic (3.57e-2)"	0.1	0.0	1.0	0.1	1.0	1.3	1.4	0.1	2.1	2.0	0.1	1.1	0.8	0.1	9.1	6.2	0.7	2.7	0.1	0.0	1.2	6.7	0.2	0.0	0.1	0.5	0.5	0.5	1.7	0.0	0.0	0.6	0.0	1.2	10.4	0.0	0.5	0.2	9.4	0.0	0.0	0.3	4.6	0.2	0.1	5.6	2.4	0.4	45.5	0.0	0.2	0.5	4.0	1.4	0.0	0.0	0.0	0.0	0.0	1.5	0.3	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	7.5	0.1	0.0	0.0	0.0	20.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	8.1	0.0	42.6	0.0	0.0	8.9	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	53.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	0.0	0.3	1.0	1.0	0.1	2.1	1.2	6.7	0.5	0.5	1.2	0.4	0.0	0.0	0.0	0.4	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.6	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0
SLC7A7	"LPI, y+LAT-1"	ENSG00000155465	"Solute carrier family 7 member 7"	Q9UM01	14	22773222-22829820	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Amino-acid transport, Transport"		"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 63.8;intestine: 93.5;kidney: 67.3"	"Cell type enhanced"	"Detected in many"	13	"Hofbauer cells: 200.4;Kupffer cells: 312.3;Macrophages: 142.1;Proximal tubular cells: 254.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"intermediate monocyte: 59.5;non-classical monocyte: 63.8"	"Lineage enriched"	"Detected in many"	4	"monocytes: 63.8"	"Cell line enhanced"	"Detected in some"		"BEWO: 44.5;CACO-2: 72.0;EFO-21: 15.6;OE19: 63.3"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA036227	Enhanced					NA	NA					"HPA036227: AB_10696653"	"unprognostic (1.34e-1)"	"unprognostic (7.65e-2)"	"unprognostic (4.25e-2)"	"unprognostic (2.52e-1)"	"unprognostic (6.12e-2)"	"unprognostic (3.69e-2)"	"unprognostic (7.84e-3)"	"unprognostic (1.47e-1)"	"unprognostic (2.88e-2)"	"unprognostic (1.73e-2)"	"unprognostic (2.60e-3)"	"unprognostic (7.15e-2)"	"prognostic unfavorable (6.28e-6)"	"unprognostic (2.68e-3)"	"unprognostic (1.86e-2)"	"unprognostic (2.61e-1)"	"unprognostic (1.12e-1)"	10.4	2.8	1.9	8.3	3.1	3.6	3.2	0.7	2.7	2.6	48.0	4.1	0.2	24.1	2.7	2.3	2.1	4.6	7.6	3.0	2.2	1.6	67.3	6.5	15.3	20.5	3.7	1.0	2.6	2.7	26.3	1.0	6.5	3.2	2.7	3.4	2.1	3.3	0.9	1.6	1.8	93.5	3.5	4.5	32.4	3.0	13.4	2.7	2.1	2.8	0.8	5.7	4.1	3.6	3.0	14.6	5.4	63.8	0.0	0.1	17.8	0.0	2.4	0.2	0.1	0.4	0.8	44.5	0.5	3.6	0.1	0.3	72.0	7.3	3.5	15.6	0.3	0.2	2.7	0.0	0.0	0.1	0.1	0.0	0.2	0.0	0.7	2.1	0.3	0.3	1.6	0.2	0.2	0.1	0.3	5.5	0.2	0.0	2.8	0.5	0.1	0.0	0.3	0.7	63.3	0.0	0.6	7.8	2.1	0.1	0.2	0.0	0.1	0.1	0.1	0.5	2.1	0.1	1.7	0.3	0.1	0.3	0.1	0.1	0.6	0.1	1.8	0.2	0.1	0.0	0.0	41.2	0.1	0.0	59.5	0.0	3.0	0.0	0.0	14.6	2.3	0.1	0.0	5.4	0.0	63.8	0.5	0.1	17.8	1.9	3.1	0.7	2.7	2.2	1.6	3.7	1.0	3.2	2.7	11.9	10.3	23.7	0.1	0.9	0.0	0.8	58.6	9.4	4.5	3.5	0.0	1.0	10.0	6.7	40.8	4.5	8.6	0.0	5.8	4.5	4.8	0.2	1.1	1.3	200.4	0.0	1.2	22.1	312.3	7.5	3.4	142.1	5.0	34.3	0.4	0.5	7.3	0.0	0.0	254.4	1.2	6.5	2.8	12.2	1.7	0.4	1.5	5.0	0.3	0.0
SLC8A1	NCX1	ENSG00000183023	"Solute carrier family 8 member A1"	P32418	2	40097270-40611053	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Antiport, Calcium transport, Ion transport, Sodium transport, Transport"	Calmodulin-binding	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"heart muscle: 67.7"	"Cell type enriched"	"Detected in many"	11	"Cardiomyocytes: 601.5"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	4	"neutrophil: 25.2"	"Lineage enriched"	"Detected in many"	4	"granulocytes: 25.2"	"Cell line enhanced"	"Detected in many"		"BJ: 15.4;fHDF/TERT166: 37.3;hTERT-HME1: 10.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB022694, HPA070007"	Uncertain		Supported	"Nucleoplasm,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Nucleoplasm, Plasma membrane"		"CAB022694: , HPA070007: AB_2686227"	"unprognostic (2.46e-1)"	"unprognostic (1.33e-2)"	"unprognostic (1.42e-2)"	"unprognostic (7.57e-6)"	"unprognostic (1.56e-1)"	"unprognostic (3.94e-1)"	"unprognostic (2.28e-2)"	"unprognostic (4.60e-2)"	"unprognostic (1.31e-1)"	"unprognostic (7.71e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.07e-1)"	"unprognostic (3.66e-2)"	"unprognostic (7.04e-3)"	"unprognostic (3.93e-2)"	"unprognostic (5.46e-2)"	"unprognostic (6.77e-2)"	3.9	2.9	7.7	4.4	14.3	1.4	2.0	3.5	15.3	5.5	7.3	1.8	7.1	3.3	12.2	3.9	4.0	3.9	5.3	67.7	7.7	6.6	11.0	2.2	3.7	2.5	5.2	8.2	2.1	1.5	1.1	1.9	6.8	7.6	12.2	3.4	1.0	1.5	17.2	1.5	2.1	3.6	20.5	2.8	4.4	2.5	1.4	2.5	0.1	1.6	0.0	1.3	9.8	2.8	0.0	2.4	25.2	6.0	0.0	0.0	0.5	1.5	1.2	1.1	0.1	1.7	3.6	0.0	15.4	6.0	5.1	3.3	0.0	2.5	0.0	1.2	37.3	5.5	0.6	0.3	2.5	5.3	0.0	2.1	0.0	0.0	0.0	0.0	0.0	0.2	2.0	0.0	5.9	10.9	2.3	0.4	0.0	0.0	0.2	6.5	0.0	0.4	0.0	0.8	0.1	2.1	4.1	8.1	0.0	1.8	0.2	1.7	0.3	0.0	0.0	0.0	5.6	0.0	0.3	5.2	4.8	0.1	0.0	1.6	0.8	0.0	0.0	0.8	0.9	0.7	0.0	4.9	0.0	0.0	5.1	0.0	0.0	0.0	0.0	2.4	0.0	0.0	0.0	25.2	0.0	6.0	0.1	0.0	0.5	7.7	14.3	3.5	15.3	7.7	6.6	5.2	8.2	7.6	2.5	3.0	3.2	2.9	0.0	1.1	50.8	601.5	2.5	0.0	1.2	33.2	3.9	0.4	0.0	0.0	0.8	3.3	0.0	0.0	0.0	1.4	4.8	0.1	0.0	0.0	28.3	0.0	0.0	20.3	56.6	0.7	0.0	46.7	1.7	1.0	0.6	35.9	0.1	0.0	7.8	0.1	6.9	12.9	19.6	0.2	0.4	2.8	0.9	0.0	0.0	0.0
SLCO2B1	"OATP-B, OATP2B1, SLC21A9"	ENSG00000137491	"Solute carrier organic anion transporter family member 2B1"	O94956	11	75100563-75206549	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Ion transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 98.1"	"Group enriched"	"Detected in many"	5	"Hepatocytes: 171.3;Hofbauer cells: 103.0;Kupffer cells: 116.2;Macrophages: 55.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"CACO-2: 36.0;GAMG: 8.9;Hep G2: 8.1;HMC-1: 10.9;OE19: 43.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA020659	Uncertain					NA	NA					"HPA020659: AB_1857219"	"unprognostic (8.25e-2)"	"unprognostic (5.30e-2)"	"unprognostic (2.02e-2)"	"unprognostic (3.57e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.58e-2)"	"unprognostic (1.09e-1)"	"unprognostic (2.61e-1)"	"unprognostic (2.00e-3)"	"unprognostic (1.99e-1)"	"unprognostic (2.09e-1)"	"unprognostic (9.75e-3)"	"unprognostic (2.54e-2)"	"unprognostic (4.57e-3)"	"unprognostic (1.04e-1)"	"unprognostic (3.87e-2)"	21.4	15.2	15.0	13.4	23.1	1.4	7.8	4.8	15.8	8.6	12.9	22.8	0.8	18.0	5.8	7.7	8.8	8.3	12.3	7.1	15.6	11.9	9.6	98.1	24.9	21.4	23.9	7.4	4.9	9.6	3.7	4.0	18.3	17.7	4.9	10.4	9.1	6.3	4.7	2.6	3.0	21.2	10.9	24.1	23.6	6.5	4.4	21.3	4.0	6.8	3.6	11.8	12.5	4.8	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.3	1.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	36.0	0.0	0.0	0.0	0.0	8.9	0.0	0.0	0.0	0.0	0.4	0.0	5.9	0.3	8.1	0.0	0.4	10.9	0.0	0.0	0.2	0.0	0.0	0.0	0.0	3.1	3.6	0.0	0.0	0.0	0.0	0.0	43.2	0.0	0.0	1.0	3.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.3	0.0	0.0	0.7	0.0	0.0	0.1	0.0	0.6	0.6	0.0	0.6	0.0	0.0	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	15.0	23.1	4.8	15.8	15.6	11.9	23.9	7.4	17.7	21.3	0.0	12.8	1.5	0.0	1.6	1.6	2.0	20.4	1.4	3.4	0.0	0.0	0.6	1.7	0.0	2.4	12.9	20.2	0.0	0.2	2.1	1.8	0.0	23.0	171.3	103.0	0.0	0.0	3.1	116.2	1.1	10.0	55.1	0.0	3.6	4.4	0.3	0.1	14.0	9.9	7.0	0.2	0.0	0.3	0.5	0.2	0.4	2.1	0.7	9.3	0.0
SMN1	"BCD541, GEMIN1, SMA, SMA@, SMA1, SMA2, SMA3, SMNT, TDRD16A"	ENSG00000172062	"Survival of motor neuron 1, telomeric"	Q16637	5	70925030-70953942	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Neurogenesis"	RNA-binding	"Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Ciliated cells: 42.8;Club cells: 46.6"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"EFO-21: 23.8;HEL: 21.4;MOLT-4: 37.9;T-47d: 29.3;WM-115: 39.0"									"CAB016324, HPA045271, CAB069888, HPA073601"	Supported		Supported	"Nuclear bodies,Cytosol"		NA	NA			"Nuclear bodies, Cytosol"		"CAB016324: AB_627931, CAB069888: AB_10001257, HPA045271: AB_2679280, HPA073601: "	"unprognostic (1.32e-1)"	"unprognostic (1.59e-1)"	"unprognostic (3.18e-1)"	"unprognostic (2.09e-1)"	"unprognostic (2.85e-1)"	"unprognostic (9.52e-3)"	"unprognostic (2.10e-2)"	"unprognostic (2.43e-1)"	"unprognostic (9.91e-3)"	"unprognostic (1.13e-2)"	"unprognostic (1.01e-1)"	"unprognostic (4.41e-1)"	"prognostic unfavorable (6.62e-13)"	"unprognostic (2.04e-1)"	"unprognostic (2.17e-1)"	"unprognostic (8.06e-2)"	"unprognostic (4.14e-2)"	4.3	3.3	5.1	4.7	4.4	23.9	5.1	6.0	4.3	6.1	4.0			2.8	5.2	7.4	4.7	5.7	8.0	3.5	5.2	5.0	6.8	7.0	3.7	16.4	4.6		8.0	5.3	6.4	5.2	4.7		4.6	6.0		3.8	3.5	5.8	5.9	3.1	9.2	5.2	5.2	6.1	6.9			4.9		2.5	10.7	5.1	15.8	14.7	5.2	11.3	9.0	16.1	7.1	2.9	0.7	1.1	1.3	3.1	4.6	15.4	1.1	1.8	1.8	1.3	1.3	1.3	1.4	23.8	2.3	1.9	1.5	1.8	1.2	1.6	0.3	1.7	21.4	1.7	1.9	0.4	2.5	1.9	0.5	3.8	0.6	0.6	4.7	1.0	1.3	0.9	2.1	0.9	1.0	37.9	15.9	1.4	0.2	0.6	2.0	4.7	11.3	0.9	1.7	1.8	3.7	1.5	4.2	19.9	0.8	29.3	4.0	10.7	11.1	1.3	1.0	2.4	1.4	0.9	14.2	1.6	1.5	39.0	5.2	9.1	3.4	10.1	11.3	16.1	15.8	10.3	9.4	13.4	12.5	14.2	13.4	3.1	9.0	10.5	14.7	12.5	7.1											8.9	7.8	1.4	3.2	12.4	3.9	20.1	10.2	42.8	46.6	1.8	9.8	7.1	5.0	5.3	13.1	7.1	2.2	0.0	3.9	6.8	5.7	2.2	18.5	2.4	4.4	3.2	5.8	3.7	3.8	11.2	8.6	4.2	5.0	5.4	3.8	1.2	5.7	0.0	6.0	3.6	6.5	12.9	14.4	14.2	18.8	10.9	7.3	7.9	4.2	3.0
SMN2	"BCD541, GEMIN1, SMNC, TDRD16B"	ENSG00000205571	"Survival of motor neuron 2, centromeric"	Q16637	5	70049612-70078522	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins"	"mRNA processing, mRNA splicing, Neurogenesis"	RNA-binding	"Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Cardiomyocytes: 35.4;Club cells: 30.7"	"Low cancer specificity"	"Detected in all"							"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"BEWO: 38.4;MOLT-4: 34.4;NB-4: 32.3"									"CAB009344, HPA045271, HPA073601"	Supported		Supported	"Nuclear bodies,Cytosol"		NA	NA			"Nuclear bodies, Cytosol"		"CAB009344: AB_2193083, HPA045271: AB_2679280, HPA073601: "	"unprognostic (2.07e-2)"	"unprognostic (5.70e-3)"	"unprognostic (1.23e-1)"	"unprognostic (1.59e-1)"	"unprognostic (2.77e-1)"	"unprognostic (1.89e-1)"	"unprognostic (1.40e-3)"	"unprognostic (2.08e-1)"	"unprognostic (1.22e-4)"	"unprognostic (1.17e-1)"	"unprognostic (2.21e-1)"	"unprognostic (5.19e-2)"	"unprognostic (2.98e-5)"	"unprognostic (2.36e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.67e-1)"	"unprognostic (1.19e-1)"	3.9	2.7	5.4	3.7	4.8	10.4	4.2	5.6	9.8	3.9	4.0			0.2	4.9	19.1	10.0	2.9	11.5	3.2	5.2	5.1	6.6	5.4	6.2	8.6	4.1		7.0	7.9	11.4	5.0	3.8		4.7	6.9		8.5	5.4	5.2	3.3	2.6	12.1	5.5	4.0	5.4	9.8			5.1		0.0	10.9	4.8	15.0	14.0	4.7	14.9	9.2	15.6	6.2	16.9	0.2	0.1	0.0	6.7	8.1	38.4	9.0	5.8	11.7	11.6	0.1	0.1	0.3	26.1	9.3	0.3	7.6	0.2	0.0	7.8	0.2	0.3	18.4	0.0	0.6	0.0	0.3	0.0	0.0	15.0	0.0	0.3	6.7	0.2	0.0	0.0	0.1	0.0	0.1	34.4	32.3	0.1	0.0	0.1	0.0	13.2	19.6	7.7	0.0	9.6	21.0	17.1	3.8	24.1	0.0	12.2	7.6	16.1	8.0	0.3	0.1	0.2	0.1	0.3	21.6	0.1	0.0	21.9	3.9	6.1	4.7	8.1	14.9	15.0	13.7	13.1	9.3	13.1	15.0	15.6	13.1	1.2	9.2	10.1	14.0	13.1	6.2											6.0	5.6	1.9	3.1	12.0	0.1	35.4	0.0	20.1	30.7	1.8	0.0	5.9	5.0	2.4	10.8	5.2	1.0	0.0	0.9	4.2	6.6	1.2	8.1	2.4	2.3	1.6	1.7	3.1	2.2	5.4	6.6	5.1	1.7	4.6	2.7	0.5	2.9	0.0	4.9	3.1	0.9	0.0	7.2	9.4	10.2	11.0	5.9	5.0	3.3	2.0
SMO	"FZD11, SMOH"	ENSG00000128602	"Smoothened, frizzled class receptor"	Q99835	7	129188872-129213545	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters"		"Developmental protein, G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"	8	"Collecting duct cells: 10.4;Leydig cells: 19.2;Muller glia cells: 15.1;Peritubular cells: 20.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in many"		"AF22: 20.3;AN3-CA: 37.6;NTERA-2: 28.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB011446	Approved					NA	NA					"CAB011446: "	"unprognostic (2.48e-2)"	"unprognostic (2.69e-2)"	"unprognostic (7.09e-2)"	"unprognostic (1.10e-1)"	"unprognostic (8.16e-2)"	"unprognostic (2.02e-1)"	"unprognostic (3.63e-1)"	"unprognostic (5.89e-2)"	"unprognostic (5.38e-3)"	"unprognostic (1.59e-1)"	"unprognostic (1.17e-2)"	"unprognostic (8.74e-3)"	"unprognostic (1.62e-1)"	"unprognostic (5.15e-3)"	"unprognostic (2.09e-1)"	"unprognostic (2.25e-1)"	"unprognostic (2.61e-2)"	4.0	4.1	4.2	3.8	4.8	0.5	7.4	5.3	4.6	18.2	5.8	5.1	9.2	2.5	20.9	18.7	10.3	11.4	10.0	5.2	8.4	3.7	10.6	13.7	2.4	2.0	4.3	4.5	23.0	7.1	14.4	13.5	2.6	9.0	18.4	2.2	17.2	9.4	12.8	3.5	16.6	3.5	9.8	7.0	2.0	4.2	7.9	3.4	5.3	9.2	6.8	4.6	6.3	17.6	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.6	8.0	20.3	37.6	0.5	0.1	6.4	2.2	2.9	4.5	2.6	6.1	0.1	0.0	6.2	4.5	10.2	12.4	12.2	0.7	1.7	0.0	9.9	3.9	0.0	9.8	2.5	0.1	0.0	7.4	5.0	1.4	0.0	9.0	2.6	11.2	0.6	0.0	1.4	0.0	10.3	0.0	28.8	0.0	2.3	15.0	8.7	0.0	2.3	0.0	0.6	13.6	0.0	0.0	5.3	8.1	4.9	2.6	0.0	0.3	6.5	7.8	4.3	0.4	0.0	0.0	0.0	0.0	7.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.2	4.8	5.3	4.6	8.4	3.7	4.3	4.5	9.0	3.4	0.0	0.0	0.0	2.3	1.6	0.6	1.2	2.5	0.0	4.5	10.4	0.0	0.3	1.7	3.2	0.3	0.4	0.0	0.0	1.0	0.3	4.4	2.8	0.0	5.1	3.3	0.0	0.0	1.3	1.3	0.9	19.2	0.4	0.0	1.0	0.0	15.1	1.9	0.0	20.5	3.7	0.3	6.5	2.1	0.0	0.4	2.5	0.5	0.0	0.0	0.4
SMOX	"C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO"	ENSG00000088826	"Spermine oxidase"	Q9NWM0	20	4120980-4187747	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Ductal cells: 48.0;Pancreatic endocrine cells: 84.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"myeloid DC: 2.1;neutrophil: 3.5"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"A549: 35.5;Karpas-707: 60.7;RPTEC TERT1: 28.0"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA047117, HPA060198"	Approved		Supported	"Nucleoplasm,Nuclear membrane,Vesicles,Cytosol"		NA	NA			Nucleoplasm	"Nuclear membrane, Vesicles, Cytosol"	"HPA047117: AB_2679940, HPA060198: AB_2684220"	"unprognostic (1.24e-2)"	"unprognostic (6.55e-2)"	"unprognostic (7.24e-3)"	"unprognostic (2.77e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.32e-1)"	"prognostic unfavorable (3.33e-6)"	"prognostic unfavorable (1.36e-4)"	"unprognostic (4.92e-2)"	"unprognostic (3.37e-1)"	"unprognostic (7.18e-2)"	"unprognostic (7.58e-2)"	"prognostic unfavorable (1.06e-4)"	"unprognostic (4.08e-2)"	"unprognostic (2.64e-3)"	"unprognostic (1.26e-2)"	"unprognostic (3.07e-1)"	3.5	3.1	26.0	4.1	22.7	24.2	3.4	10.1	29.0	9.6	6.7	23.5	17.6	9.5	10.2	6.9	6.1	4.7	14.0	2.9	28.8	16.2	3.8	4.4	2.1	4.0	25.1	16.5	9.2	28.9	8.7	6.0	5.7	20.7	8.1	1.4	6.5	10.6	10.2	2.5	7.8	7.1	3.9	25.9	2.9	7.4	3.9	24.1	0.3	3.9	3.4	2.6	5.3	5.2	0.1	2.1	3.5	0.9	0.2	0.2	15.3	3.2	35.5	2.5	1.8	1.7	2.6	4.5	4.6	8.9	3.4	2.3	14.6	8.9	0.0	1.5	4.2	5.5	6.5	2.0	2.2	1.4	0.0	1.1	6.2	1.1	14.8	10.9	1.2	2.5	9.8	4.0	7.1	3.0	4.1	6.0	5.0	1.3	60.7	2.0	1.0	2.3	3.5	3.1	3.1	4.9	2.0	3.1	8.4	28.0	2.4	0.5	2.1	8.6	1.0	15.9	1.3	0.1	1.5	7.1	3.9	3.7	0.7	3.6	2.8	0.4	0.0	3.2	1.5	3.0	0.0	0.9	0.1	0.0	0.4	0.0	0.1	0.2	0.2	2.1	0.0	0.0	0.0	3.5	0.2	0.1	1.0	0.0	15.3	26.0	22.7	10.1	17.6	28.8	16.2	25.1	16.5	20.7	24.1	0.0	0.3	1.5	9.5	11.2	0.5	1.4	12.7	1.4	4.5	10.4	0.0	0.3	0.0	48.0	3.1	5.6	2.1	23.3	26.4	0.6	9.5	12.1	5.7	2.0	16.2	0.0	5.8	14.1	3.4	5.6	13.6	10.4	8.5	36.9	2.1	28.2	84.5	0.8	12.7	1.4	1.3	0.0	8.1	4.2	4.9	9.3	0.2	0.0	2.9	8.8
SMS	"MRSR, SPMSY, SpS, SRS"	ENSG00000102172	"Spermine synthase"	P52788	X	21940573-21994835	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Polyamine biosynthesis"	Transferase	"FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Cytotrophoblasts: 588.3;Distal tubular cells: 515.6;Syncytiotrophoblasts: 727.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							"HPA029849, HPA029852"	Approved		Approved	"Nuclear bodies,Cytosol"		No	No		26000	"Nuclear bodies"	Cytosol	"HPA029849: AB_10602072, HPA029852: AB_10611521"	"unprognostic (2.51e-2)"	"unprognostic (2.91e-1)"	"unprognostic (1.89e-2)"	"unprognostic (1.39e-1)"	"unprognostic (1.43e-1)"	"prognostic unfavorable (7.49e-4)"	"prognostic unfavorable (7.79e-8)"	"unprognostic (1.02e-2)"	"unprognostic (2.72e-1)"	"unprognostic (3.18e-3)"	"unprognostic (3.95e-3)"	"unprognostic (2.45e-1)"	"prognostic unfavorable (7.85e-5)"	"unprognostic (2.70e-1)"	"unprognostic (1.22e-1)"	"unprognostic (1.67e-1)"	"unprognostic (8.50e-2)"	21.7	48.1	29.7	18.7	25.0	18.6	28.4	36.6	35.4	20.8	23.1	8.1	26.0	23.5	20.8	31.3	19.2	13.3	20.9	26.3	22.3	25.0	55.1	19.5	17.6	18.5	25.6	28.5	42.4	16.7	13.6	19.2	63.6	24.2	61.3	24.4	15.7	20.7	20.6	18.0	9.7	25.1	36.8	17.4	18.9	18.8	18.4	11.0	19.6	27.6	11.7	20.8	28.2	16.5	13.2	19.4	37.0	25.7	11.7	20.3	12.3	83.0	21.3	36.2	13.8	9.6	16.3	11.2	22.8	13.6	35.0	33.6	26.3	27.2	30.2	7.9	23.2	96.8	18.3	35.5	41.6	69.4	13.9	16.6	15.6	25.6	18.7	17.7	30.2	13.7	10.7	12.7	36.0	67.7	25.5	33.5	12.2	33.2	4.2	47.8	17.7	22.2	30.2	61.5	18.8	31.6	22.2	24.9	22.9	46.7	11.8	17.3	14.0	18.2	23.4	60.0	96.2	21.1	12.6	29.6	25.4	25.6	52.7	37.0	3.2	6.5	17.9	49.6	13.4	35.2	2.9	21.4	37.0	7.6	22.1	9.4	13.2	12.0	13.2	19.4	8.3	7.9	9.3	21.1	11.7	25.7	4.0	20.3	12.3	29.7	25.0	36.6	35.4	22.3	25.0	25.6	28.5	24.2	11.0	23.8	21.6	43.8	142.7	58.5	33.8	30.5	48.4	48.2	55.7	104.7	11.8	588.3	515.6	219.3	1.6	38.1	67.1	0.0	132.3	261.4	79.8	237.6	39.3	44.0	322.1	20.6	56.6	52.8	131.4	3.6	88.3	123.6	87.7	344.5	84.4	32.3	142.0	65.4	97.2	354.3	33.3	64.7	46.4	5.9	214.2	44.3	727.3	67.0	102.6	134.1
SNAP25	"bA416N4.2, dJ1068F16.2, RIC-4, RIC4, SEC9, SNAP, SNAP-25"	ENSG00000132639	"Synaptosome associated protein 25"	P60880	20	10218830-10307418	"Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Transporters"			"Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	22	"brain: 356.9"	"Cell type enhanced"	"Detected in many"	23	"Bipolar cells: 497.2;Cone photoreceptor cells: 100.1;Rod photoreceptor cells: 186.3"	"Group enriched"	"Detected in many"	6	"glioma: 28.9;pancreatic cancer: 6.4"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"plasmacytoid DC: 1.6"	"Low lineage specificity"	"Detected in single"			"Group enriched"	"Detected in many"	4	"Karpas-707: 11.0;SCLC-21H: 36.6;SH-SY5Y: 21.8;U-87 MG: 26.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB000360, HPA001830, HPA071013"	Enhanced	Supported	Approved	"Vesicles,Plasma membrane"		NA	NA			"Plasma membrane"	Vesicles	"CAB000360: AB_2286342, HPA001830: AB_1080039, HPA071013: "	"unprognostic (1.64e-3)"	"unprognostic (7.26e-3)"	"unprognostic (4.36e-2)"	"unprognostic (2.49e-7)"	"unprognostic (6.86e-3)"	"unprognostic (5.87e-3)"	"unprognostic (1.15e-2)"	"unprognostic (9.94e-2)"	"unprognostic (3.13e-1)"	"unprognostic (5.82e-3)"	"unprognostic (4.80e-3)"	"unprognostic (8.06e-2)"	"unprognostic (1.09e-1)"	"unprognostic (6.18e-3)"	"unprognostic (2.48e-1)"	"unprognostic (6.28e-3)"	"unprognostic (1.02e-2)"	2.2	16.4	81.0	3.3	60.0	2.1	3.4	202.9	356.9	2.2	2.8	3.4	3.7	3.2	4.6	6.4	2.2	4.0	2.8	2.4	86.5	37.1	2.5	2.3	2.6	2.2	46.7	65.2	3.7	4.1	2.1	5.5	2.3	97.7	3.1	2.8	4.0	2.2	11.9	2.1	2.2	3.3	4.7	13.9	2.1	4.3	3.2	7.4	0.0	2.3	0.0	2.2	2.6	0.1	0.0	1.6	0.7	0.0	0.0	0.6	0.3	0.0	2.1	1.8	0.0	0.2	0.0	0.0	0.9	0.0	2.2	0.6	0.0	0.0	0.0	2.0	0.0	1.6	0.4	0.2	0.0	4.5	0.2	0.1	0.0	3.0	0.3	1.6	0.0	0.2	2.1	0.0	1.8	0.0	5.0	0.0	1.3	0.0	11.0	0.7	0.0	0.0	0.0	0.4	1.3	0.0	0.0	0.0	0.0	0.4	0.0	36.6	21.8	0.3	0.0	0.0	1.1	0.0	2.9	0.0	2.3	3.1	0.0	1.0	0.0	5.6	0.0	26.3	0.0	2.1	0.0	0.0	0.7	0.1	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.6	0.6	0.3	81.0	60.0	202.9	163.5	86.5	37.1	46.7	65.2	97.7	7.4	0.0	0.0	0.0	1.7	0.7	497.2	0.4	7.6	0.0	0.0	0.0	100.1	0.0	0.0	0.1	16.5	0.6	0.0	0.0	0.0	0.1	1.0	0.5	0.0	0.0	0.1	62.0	41.6	0.0	0.0	56.7	15.8	0.2	1.7	0.0	0.0	42.9	1.6	0.2	64.7	1.4	186.3	0.0	1.0	0.9	0.3	0.6	0.0	0.0	0.0	0.0
SOAT1	"ACAT, SOAT, STAT"	ENSG00000057252	"Sterol O-acyltransferase 1"	P35610	1	179293714-179358680	"Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Cholesterol metabolism, Lipid metabolism, Steroid metabolism, Sterol metabolism"	"Acyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"adrenal gland: 87.4"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009533, HPA047171"	Enhanced		Enhanced	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"CAB009533: AB_633499, HPA047171: AB_2679967"	"unprognostic (3.29e-2)"	"unprognostic (7.60e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.21e-2)"	"unprognostic (2.83e-1)"	"unprognostic (1.81e-3)"	"unprognostic (7.81e-3)"	"unprognostic (3.29e-1)"	"unprognostic (9.00e-2)"	"unprognostic (9.84e-2)"	"unprognostic (1.06e-1)"	"unprognostic (5.45e-3)"	"unprognostic (7.02e-3)"	"unprognostic (4.67e-3)"	"unprognostic (9.64e-2)"	"unprognostic (4.67e-2)"	"unprognostic (1.82e-1)"	23.9	87.4	4.1	8.3	5.7	7.0	9.6	2.9	4.0	6.8	7.2	5.6	7.8	5.5	8.2	6.0	3.4	8.3	9.8	5.7	5.5	4.1	12.1	8.8	18.6	13.0	6.2	2.3	10.8	15.5	8.1	14.6	11.6	4.9	13.1	6.9	9.6	51.1	8.9	4.1	5.8	7.0	7.5	10.5	13.6	8.1	6.8	4.9	4.0	6.2	2.9	7.2	9.4	8.7	6.6	24.3	19.8	26.8	18.5	16.0	14.8	20.4	9.6	7.9	11.7	30.9	16.9	42.5	9.9	17.5	22.0	25.7	9.8	23.4	11.6	15.7	18.0	26.8	7.5	25.1	5.9	23.8	13.2	5.2	5.4	8.1	10.2	12.7	9.2	2.1	13.3	3.8	25.7	22.1	9.3	9.4	14.3	11.6	6.0	34.2	4.3	9.8	3.0	3.8	3.3	3.2	12.2	10.3	6.8	19.4	12.8	2.4	6.2	15.3	6.5	5.7	9.8	6.8	6.3	8.9	26.2	12.6	28.6	21.8	8.5	31.0	9.9	10.4	5.0	48.5	19.6	26.8	0.7	14.0	17.0	13.5	6.6	13.1	13.1	24.3	5.5	12.7	12.6	19.8	18.5	11.1	4.4	16.0	14.8	4.1	5.7	2.9	4.0	5.5	4.1	6.2	2.3	4.9	4.9	20.8	33.1	10.4	8.5	8.9	7.2	5.6	22.9	48.2	14.8	19.2	13.7	14.8	1.7	33.4	19.5	13.0	7.9	0.0	21.9	46.9	18.6	33.8	13.9	21.9	69.5	6.4	57.5	21.5	66.9	10.8	30.2	63.1	21.9	44.1	27.7	6.8	20.1	10.5	24.4	12.8	13.0	25.8	13.0	5.6	8.2	4.5	7.3	27.9	16.8	6.5
SQLE		ENSG00000104549	"Squalene epoxidase"	Q14534	8	124998497-125022283	"Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA018038, HPA020762"	Enhanced		Uncertain	Vesicles,Cytosol		NA	NA			"Vesicles, Cytosol"		"HPA018038: AB_2669753, HPA020762: AB_2670512"	"unprognostic (1.37e-2)"	"unprognostic (6.26e-3)"	"unprognostic (5.12e-2)"	"unprognostic (9.51e-3)"	"unprognostic (4.63e-1)"	"prognostic unfavorable (7.42e-4)"	"unprognostic (4.76e-3)"	"prognostic unfavorable (4.67e-4)"	"unprognostic (3.45e-2)"	"unprognostic (7.21e-2)"	"prognostic unfavorable (2.73e-4)"	"unprognostic (7.51e-2)"	"prognostic unfavorable (5.70e-4)"	"unprognostic (9.71e-2)"	"unprognostic (4.62e-2)"	"unprognostic (1.19e-3)"	"unprognostic (7.74e-3)"	4.6	15.7	11.1	9.9	13.9	10.4	12.1	8.9	19.9	15.1	11.5	28.8	4.4	15.8	8.9	5.1	40.3	10.0	6.3	4.2	15.4	14.5	7.8	38.1	16.0	8.6	10.8	9.7	17.5	6.3	16.5	9.5	24.7	28.5	13.8	10.1	9.3	10.4	4.7	1.3	23.8	8.7	6.6	36.0	5.6	11.5	29.3	18.7	9.8	5.7	24.2	15.0	5.3	21.6	15.1	12.4	1.2	9.7	9.5	9.0	6.1	25.8	10.0	60.2	17.3	18.7	31.8	6.1	6.8	21.0	9.3	17.1	13.6	37.9	17.8	9.9	8.4	37.4	19.8	25.1	37.7	10.8	14.7	53.0	50.9	6.8	34.7	27.6	5.9	15.0	21.7	40.4	27.7	22.9	6.0	10.1	12.6	29.0	34.7	7.5	42.7	20.6	7.5	24.9	17.8	6.9	9.1	11.0	24.3	65.6	29.8	18.8	9.5	14.0	45.0	14.0	20.2	12.0	15.6	9.9	3.8	13.6	4.5	6.0	6.3	12.8	24.4	6.4	18.2	6.6	1.2	5.1	0.5	9.0	8.5	4.4	13.6	5.4	8.3	12.4	15.1	7.5	7.8	0.1	9.5	9.7	8.8	5.6	6.1	11.1	13.9	8.9	16.4	15.4	14.5	10.8	9.7	28.5	18.7	56.6	84.1	38.7	41.4	20.4	26.3	6.1	28.1	108.4	52.4	50.6	47.1	81.6	6.6	50.5	18.8	11.2	44.6	46.7	73.0	111.6	54.5	79.8	41.4	15.7	48.5	139.8	30.4	12.3	13.0	9.6	22.2	16.0	20.3	154.1	29.4	23.5	64.9	21.0	10.3	2.9	47.5	25.8	29.0	131.6	152.1	77.9	181.6	17.5	20.4	100.4
SRC	"ASV, c-src, SRC1"	ENSG00000197122	"SRC proto-oncogene, non-receptor tyrosine kinase"	P12931	20	37344685-37406050	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Transporters"	"Cell adhesion, Cell cycle, Host-virus interaction, Immunity"	"Kinase, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 5.3;non-classical monocyte: 4.4"	"Group enriched"	"Detected in many"	6	"dendritic cells: 3.0;monocytes: 5.3"	"Cell line enhanced"	"Detected in many"		"A549: 35.9;HBEC3-KT: 33.4;RT4: 34.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004023, HPA030875"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cell Junctions,Cytosol"		NA	NA		20000000	"Plasma membrane, Cell Junctions"	"Nucleoplasm, Cytosol"	"CAB004023: AB_2106059, HPA030875: AB_2673640"	"unprognostic (5.58e-2)"	"unprognostic (9.83e-2)"	"unprognostic (3.56e-1)"	"unprognostic (4.54e-3)"	"unprognostic (1.52e-1)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (4.90e-5)"	"unprognostic (3.89e-2)"	"unprognostic (7.04e-2)"	"unprognostic (8.13e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (1.63e-4)"	"prognostic unfavorable (1.22e-4)"	"unprognostic (2.33e-2)"	"unprognostic (4.72e-2)"	"unprognostic (3.65e-2)"	"prognostic favorable (5.22e-5)"	6.9	17.5	12.8	11.1	12.0	5.4	9.9	6.4	16.0	16.0	16.4	3.5	15.1	29.5	20.3	9.7	16.2	14.2	42.1	5.8	11.3	6.6	13.4	2.9	10.4	7.0	3.3	9.9	15.8	19.1	6.6	11.3	6.3	5.1	19.9	13.1	13.1	7.5	22.5	3.4	7.7	28.1	27.2	3.6	12.2	29.8	27.3	4.8	4.0	6.6	10.5	10.4	26.4	20.0	0.3	3.0	0.1	5.3	0.6	0.1	1.6	7.7	35.9	8.3	7.4	3.1	5.0	17.2	7.2	6.2	8.8	5.6	13.5	7.0	0.2	4.5	13.0	10.0	14.2	4.9	33.4	3.4	0.0	4.5	2.0	1.3	20.9	7.5	0.1	3.1	5.3	11.4	5.7	7.7	9.8	8.0	4.6	0.2	0.0	1.4	5.3	1.9	0.2	3.9	21.5	32.6	8.4	2.2	0.2	3.7	34.4	7.7	27.9	8.1	11.4	8.9	6.6	10.2	2.8	11.6	10.5	7.1	3.8	6.4	0.1	0.2	0.1	7.4	0.0	7.8	0.0	2.6	0.0	0.0	5.3	0.0	0.3	0.0	0.1	1.1	0.3	0.0	0.0	0.1	0.6	4.4	3.0	0.1	1.6	12.8	12.0	6.4	16.0	11.3	6.6	3.3	9.9	5.1	4.8	3.0	1.7	4.4	10.8	7.2	5.4	1.6	15.3	1.4	0.0	12.2	2.0	1.6	1.7	9.7	1.3	1.4	30.0	0.0	16.2	7.0	8.2	11.2	0.0	0.9	5.8	3.2	16.1	1.3	6.9	1.5	10.0	12.1	1.7	7.2	25.9	4.1	29.0	18.1	16.3	9.5	4.7	12.9	6.4	0.2	0.7	8.0	1.9	0.0	14.9	27.7
SRD5A1		ENSG00000145545	"Steroid 5 alpha-reductase 1"	P18405	5	6633343-6674386	"Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Differentiation, Sexual differentiation"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 42.4"	"Cell type enhanced"	"Detected in many"	9	"Hepatocytes: 75.4;monocytes: 55.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"							HPA051402	Approved					NA	NA					"HPA051402: AB_2681470"	"unprognostic (1.40e-2)"	"unprognostic (1.33e-2)"	"unprognostic (2.30e-3)"	"prognostic unfavorable (8.73e-6)"	"unprognostic (9.38e-3)"	"unprognostic (8.90e-2)"	"unprognostic (3.78e-2)"	"unprognostic (5.90e-2)"	"unprognostic (3.83e-1)"	"unprognostic (1.42e-1)"	"unprognostic (7.70e-3)"	"unprognostic (1.54e-1)"	"unprognostic (1.56e-3)"	"unprognostic (3.01e-1)"	"unprognostic (2.24e-1)"	"unprognostic (1.59e-1)"	"unprognostic (5.47e-2)"	2.4	3.3	7.7	2.9	8.2	3.2	14.8	9.2	11.8	5.6	5.2	5.3	0.7	5.7	3.1	4.6	24.2	2.9	4.0	1.9	9.3	7.5	6.4	42.4	3.0	3.5	6.2	5.5	4.1	4.3	3.0	1.9	2.1	13.4	2.6	3.6	2.4	5.0	2.1	2.2	17.5	10.4	2.6	3.1	2.9	3.9	2.7	2.9	3.3	2.4	15.3	12.1	2.6	10.1	1.9	3.7	7.0	3.3	1.3	1.3	1.3	5.6	5.5	7.4	6.3	7.1	7.0	3.4	5.4	4.2	5.4	3.4	5.5	5.0	6.8	9.0	7.9	8.8	9.1	6.0	3.6	5.8	4.2	2.6	2.1	13.9	3.4	3.3	3.0	1.8	5.1	10.4	3.8	3.0	4.0	2.6	2.7	3.6	6.3	6.9	6.6	1.4	3.5	4.7	3.7	4.4	4.7	5.7	2.0	7.2	5.2	14.0	6.3	16.6	7.4	5.1	7.7	3.0	0.9	5.5	8.2	4.1	13.3	6.8	3.4	4.5	2.4	6.8	3.6	7.4	7.0	3.3	1.4	1.0	2.4	0.7	1.7	1.0	1.3	3.7	1.9	0.9	1.0	2.0	1.3	2.6	1.8	1.1	1.3	7.7	8.2	9.2	11.8	9.3	7.5	6.2	5.5	13.4	2.9	3.0	2.4	8.2	5.5	16.5	4.4	2.4	5.1	8.1	2.3	5.2	3.9	0.7	6.6	9.1	7.8	3.1	7.8	0.0	4.1	6.1	3.7	6.5	1.1	75.4	12.0	6.4	2.4	4.3	19.6	1.9	3.1	7.9	6.8	55.1	5.6	3.5	6.5	8.7	7.4	19.5	3.7	0.0	4.2	2.7	2.6	26.6	0.7	4.4	11.7	9.6
SRD5A2		ENSG00000277893	"Steroid 5 alpha-reductase 2"	P31213	2	31522480-31581067	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Differentiation, Sexual differentiation"	Oxidoreductase	"Cancer-related genes, Disease mutation, FDA approved drug targets, Pseudohermaphroditism"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"epididymis: 17.9;liver: 30.9;prostate: 28.4"	"Cell type enhanced"	"Detected in some"	23	"Ciliated cells: 13.4;Early spermatids: 70.2;Hepatocytes: 14.7;Late spermatids: 41.4"	"Group enriched"	"Detected in some"	6	"endometrial cancer: 1.1;liver cancer: 4.2;prostate cancer: 3.2"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	7	"BJ hTERT+: 2.9;RT4: 5.5"	"Not detected"	"Not detected"			"Not detected"	"Not detected"									NA	NA						"unprognostic (6.75e-3)"	"unprognostic (2.00e-2)"	"unprognostic (1.66e-1)"	"unprognostic (1.08e-3)"	"unprognostic (5.92e-3)"	"unprognostic (3.37e-2)"	"unprognostic (2.79e-3)"	"unprognostic (6.56e-2)"	"unprognostic (9.10e-2)"	"unprognostic (1.39e-2)"	"unprognostic (3.06e-2)"	"unprognostic (9.79e-3)"	"unprognostic (6.61e-6)"	"unprognostic (4.37e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.85e-1)"	"unprognostic (3.48e-3)"	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.2	0.0	0.0	10.1	0.0	0.2	17.9	0.0	10.4	0.0	0.0	0.0		0.0	30.9	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.4	0.0	0.0	0.0	11.2	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.4	0.0	0.3	0.0	0.0	0.1	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.6	2.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.1	0.0	0.0	0.0	0.1	0.0	0.3	5.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.2	0.1	0.1	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0											0.0	0.0	0.0	3.1	0.0	0.0	0.4	2.5	13.4	1.2	0.0	0.0	0.0	0.0	0.0	70.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	14.7	0.0	0.0	0.0	0.0	0.0	41.4	0.6	0.0	0.0	0.0	0.0	0.0	0.1	0.0	1.1	0.2	0.0	0.0	0.0	1.1	0.6	0.0	0.0	0.0	0.0	4.7
SSTR1		ENSG00000139874	"Somatostatin receptor 1"	P30872	14	38207999-38213067	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 15.0;intestine: 14.3;stomach 1: 22.8"	"Group enriched"	"Detected in some"	5	"Cholangiocytes: 5.1;Enterocytes: 9.0;Hepatocytes: 6.4;Intestinal endocrine cells: 17.4;Ito cells: 9.8;Mucus-secreting cells: 8.0;Paneth cells: 8.7;Undifferentiated cells: 6.0"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"BJ: 47.9;BJ hTERT+: 13.3;BJ hTERT+ SV40 Large T+: 8.8;fHDF/TERT166: 28.3;HeLa: 10.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"HPA003207, HPA031506"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA003207: , HPA031506: AB_2673913"	"unprognostic (1.40e-1)"	"unprognostic (1.37e-1)"	"unprognostic (3.36e-1)"	"unprognostic (2.50e-3)"	"unprognostic (4.34e-2)"	"unprognostic (9.90e-2)"	"unprognostic (3.66e-3)"	"unprognostic (1.91e-1)"	"unprognostic (6.16e-3)"	"unprognostic (3.20e-2)"	"unprognostic (1.72e-2)"	"unprognostic (9.19e-2)"	"prognostic favorable (4.28e-4)"	"unprognostic (2.17e-1)"	"unprognostic (1.67e-1)"	"unprognostic (4.71e-2)"	"unprognostic (3.28e-2)"	0.7	0.4	6.8	0.6	6.9	0.0	0.6	0.5	15.0	0.9	3.7	0.6	0.1	14.3	1.0	0.6	0.4	0.7	0.5	0.8	4.3	10.4	2.2	6.7	5.5	0.1	6.8	4.0	0.6	3.8	0.1	1.4	2.8	2.8	1.2	2.5	0.2	0.2	0.5	0.7	0.4	8.2	0.6	1.3	0.7	22.8	0.1	0.7	0.1	0.3	0.1	0.1	1.3	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	47.9	13.3	8.8	0.7	0.5	0.0	0.0	0.0	28.3	0.0	0.1	0.0	0.0	6.4	0.0	0.0	0.0	10.9	0.0	2.6	0.0	0.0	0.1	0.0	0.0	0.1	0.1	0.6	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	3.8	0.1	0.0	0.0	0.0	1.9	0.0	1.4	0.0	0.5	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	6.9	0.5	15.0	4.3	10.4	6.8	4.0	2.8	0.7	0.0	0.0	0.0	0.0	0.2	0.6	0.6	5.1	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.8	9.0	0.0	0.7	0.0	0.6	0.1	0.0	6.4	0.0	0.0	17.4	9.8	0.0	0.0	0.0	0.0	0.0	0.0	8.0	0.0	0.3	8.7	0.0	1.3	0.0	0.0	0.4	0.0	0.0	0.1	0.1	0.0	6.0	0.0
SSTR2		ENSG00000180616	"Somatostatin receptor 2"	P30874	17	73165012-73176633	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 26.6"	"Cell type enhanced"	"Detected in many"	15	"Bipolar cells: 49.1;Intestinal endocrine cells: 34.5;Sertoli cells: 32.3;Smooth muscle cells: 97.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	7	"SCLC-21H: 17.2"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA007264	Uncertain		Supported	Cytosol		NA	NA			Cytosol		"HPA007264: AB_1080053"	"unprognostic (2.13e-3)"	"unprognostic (2.61e-3)"	"unprognostic (7.43e-2)"	"unprognostic (9.37e-3)"	"unprognostic (6.25e-2)"	"unprognostic (1.52e-1)"	"unprognostic (2.29e-3)"	"unprognostic (7.46e-2)"	"unprognostic (2.96e-1)"	"unprognostic (6.55e-2)"	"prognostic favorable (6.63e-4)"	"unprognostic (1.07e-1)"	"prognostic unfavorable (9.04e-7)"	"unprognostic (1.35e-1)"	"unprognostic (1.00e-1)"	"unprognostic (3.71e-3)"	"unprognostic (2.95e-2)"	4.5	7.4	6.1	2.3	15.8	2.5	4.2	23.1	26.6	1.4	2.2	0.5	0.6	3.3	1.9	4.1	1.5	2.3	1.8	2.2	9.3	5.3	13.6	3.3	1.4	2.7	2.6	13.1	1.5	2.0	1.4	5.7	1.0	4.9	2.8	2.7	1.1	1.8	3.6	1.7	1.9	2.5	2.2	3.3	8.3	7.2	1.4	1.9	0.3	2.3	0.0	2.9	2.0	1.9	1.4	1.0	4.7	0.9	0.9	1.0	0.3	0.3	0.5	0.6	1.2	0.2	0.2	0.7	0.2	0.3	0.5	0.5	0.5	0.5	0.7	0.3	0.1	1.4	0.5	0.1	0.1	0.2	0.6	1.0	0.6	1.1	0.5	0.1	0.4	2.3	0.2	0.1	0.2	0.1	0.3	0.0	0.7	0.7	1.2	0.2	0.6	0.4	1.3	1.6	0.2	0.6	0.7	0.9	0.4	0.4	0.6	17.2	1.5	0.3	0.3	0.2	1.0	2.2	0.3	0.3	0.4	2.2	0.6	0.3	0.8	0.4	1.6	0.3	1.8	0.4	3.8	0.9	1.2	1.0	0.7	0.8	0.8	0.8	0.8	0.3	1.4	0.8	0.9	4.7	0.9	0.8	1.0	0.5	0.3	6.1	15.8	23.1	22.1	9.3	5.3	2.6	13.1	4.9	1.9	6.0	2.4	0.0	3.0	1.0	49.1	2.6	0.0	1.4	2.3	1.8	3.9	0.4	0.0	0.0	7.0	4.0	0.0	0.0	0.0	0.3	2.2	3.0	2.3	0.8	1.1	6.4	34.5	3.7	1.0	3.0	0.9	2.6	5.0	1.8	7.2	1.7	0.6	0.0	0.7	17.4	3.9	32.3	97.1	0.7	1.9	1.0	0.8	1.5	0.4	3.1
SSTR3		ENSG00000278195	"Somatostatin receptor 3"	P32745	22	37204238-37212322	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"brain: 11.1;lymphoid tissue: 29.6;testis: 11.3"	"Cell type enriched"	"Detected in single"	5	"Late spermatids: 1.9"	"Cancer enhanced"	"Detected in some"		"pancreatic cancer: 1.9"					"Cell type enhanced"	"Detected in some"		"naive CD4 T-cell: 3.9;naive CD8 T-cell: 3.0"	"Lineage enriched"	"Detected in single"	10	"T-cells: 3.9"	"Group enriched"	"Detected in some"	11	"RPMI-8226: 22.3;SCLC-21H: 8.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			CAB022647	Approved					NA	NA					"CAB022647: "	"unprognostic (1.63e-2)"	"unprognostic (5.58e-3)"	"unprognostic (1.32e-2)"	"unprognostic (3.18e-2)"	"unprognostic (7.03e-2)"	"unprognostic (6.26e-5)"	"unprognostic (1.11e-1)"	"unprognostic (1.72e-2)"	"unprognostic (1.90e-2)"	"unprognostic (8.95e-2)"	"unprognostic (3.88e-3)"	"unprognostic (2.93e-1)"	"unprognostic (1.51e-7)"	"unprognostic (1.55e-1)"	"unprognostic (1.24e-2)"	"unprognostic (5.61e-3)"	"unprognostic (1.06e-2)"	0.1	0.8	2.8	1.9	1.9	0.9	0.1	2.7	11.1	0.0	0.5	0.2	0.0	2.6	1.9	0.2	0.1	0.1	0.1	0.0	5.6		0.1	0.0	0.1	3.5	0.0	7.9	5.8	3.9	0.0	6.4	0.0	7.9	0.2	0.6	0.0	0.6	0.1	0.0	0.0	1.0	2.2	4.3	1.2	0.5	11.3	0.1	29.6	0.0	0.0	2.0	0.3	0.0	0.3	0.1	0.1	0.0	0.0	3.9	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	22.3	0.0	0.0	8.4	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.4	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.9	0.0	0.0	0.3	3.9	3.0	0.1	0.0	0.0	0.1	0.3	0.8											0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.1	0.0	0.0	0.0	0.0	0.0
SSTR4		ENSG00000132671	"Somatostatin receptor 4"	P31391	20	23035386-23036812	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in single"	4	"brain: 3.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in single"		"SCLC-21H: 1.0"	"Low region specificity"	"Detected in many"							HPA064252	Uncertain					NA	NA					"HPA064252: AB_2685227"																		0.0	0.0	1.7	0.0	1.1	0.0	0.0	3.0	3.8	0.0	0.0			0.0	0.7	0.0	0.0	0.1	0.0	0.0	1.3	0.4	0.0	0.0	0.8	0.0	0.1		0.0	0.0	0.0	0.0	0.1		0.0	0.1		0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.3	0.1	0.2			0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SSTR5		ENSG00000162009	"Somatostatin receptor 5"	P35346	16	1078781-1080142	"FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"gallbladder: 8.2;lymphoid tissue: 5.2;pituitary gland: 9.0"	"Not detected"	"Not detected"			"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	15	"Hep G2: 9.4;PC-3: 35.0"	"Group enriched"	"Detected in some"	5	"basal ganglia: 4.2;hypothalamus: 2.7"	"Low region specificity"	"Detected in all"			HPA066503			Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"HPA066503: AB_2685679"		"unprognostic (2.16e-2)"	"unprognostic (7.31e-2)"		"unprognostic (3.69e-2)"	"unprognostic (2.39e-2)"		"unprognostic (2.14e-1)"			"unprognostic (9.89e-3)"	"unprognostic (1.72e-2)"	"unprognostic (1.72e-2)"	"unprognostic (2.06e-1)"	"unprognostic (2.05e-1)"		"unprognostic (4.09e-2)"	0.0	4.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	1.4	0.4	0.0	0.7	0.6	0.9	0.5	0.0	8.2	2.9	0.0	0.2	3.3	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	9.0	0.0	0.0	1.1	0.0	0.0	1.1	0.9	0.1	0.1	0.8	0.0	0.0	0.0	1.7	0.3	0.0	0.0	0.0	0.0	5.2	1.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	1.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	9.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	35.0	0.0	1.3	0.3	0.0	1.3	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
SV2A	"KIAA0736, SV2"	ENSG00000159164	"Synaptic vesicle glycoprotein 2A"	Q7L0J3	1	149903318-149917882	"FDA approved drug targets, Predicted membrane proteins"	"Neurotransmitter transport, Transport"		"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 75.3;parathyroid gland: 34.0"	"Group enriched"	"Detected in many"	6	"Bipolar cells: 95.8;Horizontal cells: 90.6;Muller glia cells: 25.1"	"Cancer enriched"	"Detected in many"	6	"glioma: 27.8"	"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"NTERA-2: 26.1"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002226, HPA007863"	Enhanced		Approved	Cytosol		NA	NA			Cytosol		"CAB002226: AB_564144, HPA007863: AB_1080135"	"unprognostic (8.05e-3)"	"unprognostic (3.86e-3)"	"unprognostic (2.24e-1)"	"unprognostic (5.39e-2)"	"unprognostic (2.66e-1)"	"unprognostic (2.02e-1)"	"unprognostic (6.24e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.06e-1)"	"unprognostic (9.00e-3)"	"unprognostic (1.00e-1)"	"prognostic unfavorable (3.22e-4)"	"unprognostic (1.44e-2)"	"unprognostic (9.86e-2)"	"unprognostic (1.95e-2)"	"unprognostic (4.81e-3)"	2.0	7.3	20.4	2.8	24.7	4.5	1.5	36.8	75.3	3.2	2.3	4.8	0.9	1.9	5.6	18.0	2.0	3.2	3.2	1.5	22.3	30.5	1.7	1.2	1.8	2.3	21.6	25.1	2.6	1.9	34.0	7.2	1.9	32.9	3.1	2.2	3.1	1.7	3.7	1.1	1.5	2.2	6.6	16.8	2.0	2.0	1.6	6.0	0.3	4.0	0.0	2.0	2.5	1.2	1.2	0.8	2.1	0.7	1.7	2.5	0.6	0.1	0.0	10.3	0.0	1.0	3.0	1.1	4.3	15.2	13.0	18.8	0.3	0.4	0.1	3.9	6.5	13.7	0.2	0.1	0.9	11.2	0.0	2.4	13.5	0.7	0.7	9.9	0.1	0.2	6.8	0.1	20.7	1.5	14.5	1.1	12.4	0.1	14.1	8.5	0.1	13.0	0.6	26.1	0.0	0.0	4.5	6.5	0.2	0.1	0.3	21.6	17.4	0.0	0.1	9.9	10.3	0.1	8.2	0.0	12.1	12.2	0.5	15.8	0.1	0.1	0.0	21.2	0.1	4.8	1.5	0.7	0.4	1.8	0.3	1.9	0.7	1.9	1.1	0.2	1.2	1.0	2.2	2.1	1.7	0.3	0.8	2.5	0.6	20.4	24.7	36.8	40.0	22.3	30.5	21.6	25.1	32.9	6.0	0.0	1.4	0.0	2.0	0.1	95.8	0.6	0.0	1.4	0.0	0.0	3.9	0.3	0.0	0.0	0.3	1.4	0.0	0.0	0.3	0.7	1.5	1.0	0.0	0.0	0.2	90.6	4.1	5.5	0.0	0.0	0.0	0.3	0.0	0.0	0.2	25.1	0.2	0.0	5.3	0.0	11.4	0.0	4.1	1.2	0.8	0.4	0.3	2.5	0.3	0.6
SYT2		ENSG00000143858	"Synaptotagmin 2"	Q8N9I0	1	202590596-202710417	"Disease related genes, FDA approved drug targets, Predicted membrane proteins"	Differentiation		"Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	6	"brain: 40.1"	"Cell type enhanced"	"Detected in some"	8	"Bipolar cells: 3.4;Cardiomyocytes: 2.4;Horizontal cells: 3.2;Leydig cells: 3.1;Rod photoreceptor cells: 4.1"	"Cancer enriched"	"Detected in some"	7	"testis cancer: 3.8"	"Group enriched"	"Detected in many"	5	"cerebellum: 36.2;cerebral cortex: 14.7;pons and medulla: 40.1"	"Cell type enriched"	"Detected in single"	8	"neutrophil: 2.4"	"Lineage enriched"	"Detected in single"	8	"granulocytes: 2.4"	"Cell line enhanced"	"Detected in some"		"AF22: 12.7;NTERA-2: 8.8;U-2 OS: 2.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA063655	Enhanced	Supported				NA	NA					"HPA063655: AB_2685077"	"unprognostic (1.32e-2)"	"unprognostic (4.99e-2)"	"unprognostic (4.89e-2)"	"unprognostic (1.03e-2)"	"unprognostic (2.21e-1)"	"unprognostic (2.24e-2)"	"unprognostic (3.00e-1)"	"unprognostic (2.35e-3)"	"unprognostic (8.81e-3)"	"unprognostic (1.17e-1)"	"unprognostic (1.53e-2)"	"unprognostic (6.33e-2)"	"unprognostic (1.56e-2)"	"unprognostic (6.23e-2)"	"unprognostic (3.26e-1)"	"unprognostic (2.54e-1)"	"unprognostic (5.17e-3)"	1.1	6.1	0.4	1.1	5.9	0.5	0.3	36.2	14.7	0.6	0.7	0.3	0.0	1.1	1.7	4.1	0.4	0.8	1.1	1.5	0.6	1.5	0.5	0.4	0.6	0.7	5.5	0.4	3.1	0.4	0.2	0.3	0.5	40.1	0.9	0.7	1.6	1.1	0.5	1.1	0.7	1.3	0.5	7.1	1.2	0.7	2.4	1.1	0.0	0.6	0.0	0.5	1.0	0.3	0.1	0.0	2.4	0.1	0.1	0.2	0.0	0.0	0.2	12.7	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.5	0.0	0.0	0.2	1.7	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.1	8.8	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.2	0.9	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.0	2.7	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.1	0.0	0.0	2.4	0.1	0.0	0.0	0.0	0.0	0.4	5.9	36.2	14.7	0.6	1.5	5.5	0.4	40.1	1.1	0.0	0.0	0.0	1.3	0.5	3.4	2.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.1	0.0	0.3	0.0	0.0	0.0	3.2	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.8	0.0	4.1	0.0	0.0	0.2	1.3	0.5	0.1	0.0	0.2	2.0
TAAR1	"TA1, TAR1, TRAR1"	ENSG00000146399	"Trace amine associated receptor 1"	Q96RJ0	6	132644984-132646003	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"	"Evidence at transcript level"		"Tissue enriched"	"Detected in some"	6	"stomach 1: 13.6"	"Not detected"	"Not detected"			"Cancer enhanced"	"Detected in single"		"cervical cancer: 1.1"					"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"EFO-21: 1.7;HBF TERT88: 1.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			HPA055614	Approved					NA	NA					"HPA055614: AB_2682862"											"unprognostic (2.19e-2)"	"unprognostic (1.87e-1)"	"unprognostic (1.47e-1)"	"unprognostic (2.68e-2)"				0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0			0.3	0.1	0.0	0.2	2.3	0.0	0.0	0.0	0.0	0.3	0.3	0.1	0.0	0.0		0.0	0.1	0.0	0.0	0.0		0.4	0.0		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	13.6	0.0			0.0		0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TACR1	"NK1R, NKIR, SPR, TAC1R"	ENSG00000115353	"Tachykinin receptor 1"	P25103	2	75046463-75199700	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 23.9"	"Cell type enhanced"	"Detected in some"	18	"Basal keratinocytes: 2.3;Cone photoreceptor cells: 2.0;Melanocytes: 6.8;Rod photoreceptor cells: 2.6;Suprabasal keratinocytes: 1.6"	"Low cancer specificity"	"Detected in some"			"Low region specificity"	"Detected in many"			"Cell type enriched"	"Detected in single"	40	"basophil: 4.4"	"Lineage enriched"	"Detected in single"	40	"granulocytes: 4.4"	"Cell line enhanced"	"Detected in some"		"BJ: 1.3;EFO-21: 3.2;fHDF/TERT166: 2.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			HPA074573	Enhanced					NA	NA					"HPA074573: AB_2686701"	"unprognostic (5.74e-4)"	"unprognostic (2.41e-3)"	"unprognostic (1.46e-2)"	"unprognostic (1.08e-1)"	"unprognostic (1.24e-1)"	"unprognostic (8.62e-3)"	"unprognostic (1.10e-1)"	"unprognostic (3.33e-2)"	"unprognostic (4.38e-2)"	"unprognostic (1.46e-1)"	"unprognostic (2.14e-3)"	"unprognostic (1.63e-2)"	"unprognostic (5.91e-4)"	"unprognostic (1.03e-2)"	"unprognostic (2.75e-1)"	"unprognostic (1.06e-1)"	"unprognostic (2.76e-2)"	23.9	1.0	2.0	1.8	8.5	0.3	8.2	0.3	4.8	15.2	1.9	0.1	1.5	0.8	17.7	3.6	4.8	6.9	2.5	0.9	1.5	2.5	1.5	0.4	2.1	2.9	0.9	1.0	4.2	0.7	1.3	1.1	1.6	2.3	6.1	1.4	0.3	2.6	2.5	2.6	8.7	1.4	6.5	0.9	0.4	1.2	2.0	1.5	0.2	1.1	4.3	3.4	4.8	14.3	0.1	0.0	4.4	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	1.3	0.2	0.0	0.0	1.1	0.0	0.5	3.2	2.7	0.5	0.1	0.0	0.0	0.0	0.0	0.3	0.3	0.5	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.0	0.1	0.0	0.1	0.0	0.3	0.0	0.8	0.3	0.3	0.6	0.1	0.4	0.0	0.0	0.2	0.1	0.0	0.1	0.2	0.0	1.0	0.0	0.8	0.1	0.1	0.0	0.5	0.0	0.0	0.5	0.1	0.0	0.0	1.2	0.1	0.1	4.4	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.0	8.5	0.3	3.6	1.5	2.5	0.9	1.0	2.3	1.5	0.0	0.0	0.0	0.0	2.3	0.5	0.8	0.0	0.0	0.0	0.0	2.0	0.9	0.0	0.0	0.0	0.8	0.0	0.0	0.0	0.1	0.5	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.8	0.0	0.0	0.3	0.0	0.0	0.0	0.0	2.6	0.0	0.2	0.0	0.0	1.6	0.1	0.0	0.0	0.1
TBXA2R		ENSG00000006638	"Thromboxane A2 receptor"	P21731	19	3594506-3606840	"Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	7	"Ito cells: 35.0"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Cell type enhanced"	"Detected in many"		"naive B-cell: 12.6"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HeLa: 11.9;U-2197: 8.6;U-937: 7.4"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in many"			HPA077366			Supported	"Nuclear speckles,Plasma membrane"		NA	NA			"Plasma membrane"	"Nuclear speckles"	"HPA077366: AB_2686836"	"unprognostic (1.59e-1)"	"unprognostic (3.86e-2)"	"unprognostic (1.21e-2)"	"unprognostic (1.74e-1)"	"unprognostic (8.97e-2)"	"unprognostic (4.19e-2)"	"unprognostic (1.52e-2)"	"unprognostic (2.17e-3)"	"unprognostic (8.41e-2)"	"unprognostic (6.25e-2)"	"prognostic favorable (7.17e-4)"	"unprognostic (3.89e-2)"	"prognostic unfavorable (1.45e-4)"	"unprognostic (4.32e-2)"	"unprognostic (9.63e-2)"	"unprognostic (1.76e-1)"	"unprognostic (2.02e-1)"	8.7	11.8	1.4	3.9	1.6	2.1	3.9	0.5	1.6	13.5	3.8	1.7	3.9	2.6	7.4	4.8	8.0	4.7	6.0	6.8	2.4	1.5	10.1	18.4	6.7	7.3	1.4	1.9	8.3	2.2	2.5	1.7	10.6	2.7	3.6	1.4	5.0	1.7	4.2	3.1	1.8	4.4	6.5	2.1	14.9	3.7	3.4	1.9	2.2	3.9	3.2	1.8	6.8	9.6	12.6	0.3	3.2	0.4	3.1	9.6	3.9	0.1	0.2	0.2	4.1	0.9	2.2	0.7	3.0	0.8	2.3	1.8	0.1	0.3	0.1	4.4	1.2	2.3	0.1	0.9	0.0	0.9	0.2	1.0	2.9	11.9	0.3	1.2	0.0	5.3	1.1	0.0	3.0	0.0	1.7	0.9	0.0	4.5	0.4	0.4	0.2	0.2	1.5	0.1	0.1	2.6	0.1	0.0	0.2	0.0	0.1	0.2	1.7	0.2	0.4	0.1	0.3	1.8	5.1	2.6	4.8	1.1	8.6	2.8	0.2	0.3	0.2	4.0	7.4	1.1	2.9	0.4	0.2	2.6	0.2	0.3	1.8	0.8	2.3	0.0	12.6	4.6	9.6	3.2	3.1	0.2	0.3	0.2	3.9	1.4	1.6	0.5	1.6	2.4	1.5	1.4	1.9	2.7	1.9	0.0	0.0	1.3	0.1	0.5	0.4	0.8	0.0	0.0	0.0	1.8	0.0	0.1	0.0	0.0	0.0	4.8	0.0	0.0	0.0	0.1	2.3	0.1	0.0	0.0	0.7	0.0	0.0	35.0	1.2	0.0	0.3	0.0	1.7	0.0	0.0	0.3	0.1	0.0	0.7	0.0	0.1	0.0	3.1	0.1	1.3	0.5	0.1	0.0	0.0	0.0
TBXAS1	"CYP5, CYP5A1, THAS, TS, TXAS, TXS"	ENSG00000059377	"Thromboxane A synthase 1"	P24557	7	139777051-140020325	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"	"Fatty acid biosynthesis, Fatty acid metabolism, Lipid biosynthesis, Lipid metabolism, Prostaglandin biosynthesis, Prostaglandin metabolism"	"Isomerase, Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 67.1;lymphoid tissue: 51.7"	"Group enriched"	"Detected in many"	5	"granulocytes: 69.3;Hofbauer cells: 78.3;Kupffer cells: 159.9;Macrophages: 116.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	13	"basophil: 38.1;classical monocyte: 44.5;eosinophil: 45.2;intermediate monocyte: 67.1;myeloid DC: 18.7;neutrophil: 38.8;non-classical monocyte: 56.4"	"Group enriched"	"Detected in all"	20	"dendritic cells: 18.7;granulocytes: 45.2;monocytes: 67.1"	"Cell line enhanced"	"Detected in some"		"NB-4: 35.3;PC-3: 11.4;RPTEC TERT1: 10.1;U-937: 28.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in some"			"HPA031257, HPA031258, HPA031259"	Enhanced					NA	NA		32000000			"HPA031257: AB_2673812, HPA031258: AB_2673813, HPA031259: AB_2673814"	"unprognostic (4.46e-2)"	"unprognostic (3.07e-1)"	"unprognostic (8.80e-2)"	"unprognostic (1.12e-1)"	"unprognostic (2.72e-1)"	"unprognostic (9.41e-2)"	"unprognostic (5.10e-2)"	"unprognostic (3.12e-1)"	"unprognostic (2.38e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.11e-1)"	"unprognostic (3.03e-2)"	"prognostic unfavorable (1.14e-4)"	"unprognostic (1.52e-1)"	"unprognostic (5.00e-3)"	"unprognostic (8.53e-2)"	"unprognostic (5.34e-2)"	13.5	7.7	6.6	17.6	8.9	13.8	5.4	1.5	5.6	3.7	6.3	13.9	0.8	6.5	3.2	4.1	3.4	5.0	13.9	3.7	7.6	5.7	6.1	8.1	20.3	43.9	12.6	2.0	2.5	3.1	1.4	3.5	9.0	9.0	5.2	8.6	4.4	8.2	2.6	1.6	1.9	9.3	7.9	19.3	51.7	7.1	2.0	12.7	7.5	2.4	2.2	6.1	9.3	2.5	1.3	18.7	45.2	67.1	1.5	2.2	25.1	0.1	3.0	0.1	0.0	0.6	1.9	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.0	5.9	0.0	0.1	0.0	0.0	0.0	0.0	4.6	0.4	8.3	0.0	0.0	0.8	2.8	7.4	1.0	0.0	0.0	0.4	0.5	1.1	0.0	0.2	1.0	0.3	0.0	1.0	35.3	0.1	8.3	11.4	1.3	0.0	0.5	10.1	0.0	0.1	0.5	0.1	0.0	0.3	0.0	0.0	6.7	0.9	0.3	0.1	0.7	0.5	2.4	0.4	0.1	0.2	28.7	0.9	38.1	44.5	45.2	1.1	67.1	1.7	1.3	2.2	0.6	18.7	0.5	0.3	0.2	38.8	1.5	56.4	3.3	2.0	25.1	6.6	8.9	1.5	5.6	7.6	5.7	12.6	2.0	9.0	12.7	3.0	16.2	6.0	0.9	0.3	1.0	0.8	7.6	1.4	2.3	1.8	5.9	0.4	8.3	4.3	0.4	2.9	0.1	0.0	8.4	0.6	0.8	7.4	69.3	4.0	78.3	3.2	1.7	18.4	159.9	0.4	0.3	116.3	3.3	16.2	2.0	3.2	3.9	7.0	0.0	4.6	3.8	19.4	0.9	0.4	0.4	0.5	0.5	14.9	2.7	1.0
TEK	"CD202b, TIE-2, TIE2, VMCM, VMCM1"	ENSG00000120156	"TEK receptor tyrosine kinase"	Q02763	9	27109141-27230175	"Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins"	Angiogenesis	"Kinase, Receptor, Transferase, Tyrosine-protein kinase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Glaucoma"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in many"			"Group enriched"	"Detected in some"	8	"Endothelial cells: 58.3;Ito cells: 110.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 2.2"	"Lineage enhanced"	"Detected in single"		"granulocytes: 2.2"	"Group enriched"	"Detected in some"	4	"HUVEC TERT2: 36.5;NTERA-2: 18.2;TIME: 39.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010359, HPA073265"	Approved		Supported	"Plasma membrane,Centriolar satellite"	"Secreted to blood"	NA	NA	7750000	8300000	"Plasma membrane"	"Centriolar satellite"	"CAB010359: AB_2203226, HPA073265: AB_2686592"	"unprognostic (2.24e-1)"	"unprognostic (1.74e-1)"	"unprognostic (5.55e-2)"	"unprognostic (1.83e-2)"	"unprognostic (1.68e-1)"	"unprognostic (1.26e-3)"	"prognostic favorable (2.31e-5)"	"unprognostic (7.48e-2)"	"unprognostic (1.72e-2)"	"unprognostic (1.41e-1)"	"unprognostic (5.58e-2)"	"unprognostic (2.72e-1)"	"prognostic favorable (7.81e-4)"	"unprognostic (7.50e-3)"	"unprognostic (6.87e-3)"	"unprognostic (1.83e-1)"	"unprognostic (5.24e-3)"	28.6	7.8	8.1	4.6	5.9	0.4	17.9	3.4	5.4	10.8	4.7	4.6	3.4	3.2	14.5	5.3	6.7	5.9	9.1	13.0	7.1	6.1	25.4	8.7	27.8	2.9	6.9	3.4	6.1	4.5	3.5	4.0	36.3	6.9	5.4	4.7	12.4	3.4	5.5	7.8	3.0	5.3	10.6	5.3	23.4	4.0	3.7	3.5	0.3	9.7	8.4	2.4	6.4	12.4	0.0	0.1	2.2	0.6	0.0	0.0	0.0	0.1	0.0	1.4	0.0	0.2	2.3	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.4	1.0	0.0	0.7	0.0	0.0	0.7	0.0	0.9	0.3	0.0	36.5	0.0	0.0	0.0	0.3	0.0	0.0	0.0	18.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	7.8	0.0	0.0	39.6	0.0	0.2	3.6	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	8.1	5.9	3.4	5.4	7.1	6.1	6.9	3.4	6.9	3.5	3.0	2.2	0.0	0.0	1.3	0.0	7.8	0.0	0.0	1.2	1.8	0.0	0.4	0.0	0.0	0.6	58.3	0.0	0.0	0.0	1.5	2.4	0.2	0.0	0.8	0.2	0.0	0.0	110.5	10.4	0.4	0.6	0.9	0.0	0.0	0.0	0.0	0.7	0.0	0.4	0.0	0.2	0.0	0.4	0.0	0.2	1.1	1.1	0.0	0.0	0.0
TFPI	"EPI, LACI, TFI, TFPI1"	ENSG00000003436	"Tissue factor pathway inhibitor"	P10646	2	187464230-187565760	"Candidate cardiovascular disease genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Hemostasis"	"Protease inhibitor, Serine protease inhibitor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"liver: 98.2;placenta: 192.3"	"Cell type enhanced"	"Detected in many"	13	"Extravillous trophoblasts: 1654.1;Ito cells: 765.5;Syncytiotrophoblasts: 735.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 5.5;plasmacytoid DC: 5.1"	"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HHSteC: 56.4;HUVEC TERT2: 106.1;LHCN-M2: 65.0;TIME: 63.5"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"HPA005575, CAB020842"	Supported				"Secreted to blood"	NA	NA		95000000			"CAB020842: , HPA005575: AB_1080290"	"unprognostic (8.75e-2)"	"prognostic unfavorable (2.02e-4)"	"unprognostic (7.95e-2)"	"unprognostic (4.99e-2)"	"unprognostic (2.32e-2)"	"unprognostic (1.48e-1)"	"unprognostic (3.05e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.86e-3)"	"unprognostic (9.22e-2)"	"unprognostic (2.43e-2)"	"unprognostic (2.72e-2)"	"unprognostic (7.05e-2)"	"unprognostic (3.39e-3)"	"unprognostic (4.05e-2)"	"unprognostic (4.49e-2)"	"unprognostic (5.81e-2)"	52.8	5.0	1.3	5.2	2.2	1.6	18.5	1.9	2.4	22.8	32.1	0.3	7.2	12.8	13.3	14.8	25.9	12.5	15.0	14.0	1.2	1.1	35.6	98.2	89.7	40.2	2.4	1.0	17.3	7.7	0.9	4.9	192.3	2.3	18.2	6.9	3.8	6.0	3.8	15.8	6.6	37.0	13.6	5.4	16.5	7.7	13.7	1.6	3.4	22.6	10.4	4.0	30.0	14.7	1.5	5.1	5.5	0.6	1.0	0.6	4.9	5.1	3.6	4.1	0.1	32.9	39.4	0.0	9.3	22.2	6.1	9.4	3.3	27.6	0.0	3.7	7.2	11.0	0.3	1.2	0.4	15.9	0.2	1.0	1.6	11.1	28.0	56.4	0.1	0.0	18.0	0.7	32.8	8.8	13.6	106.1	0.0	4.1	0.1	65.0	4.8	0.6	0.1	2.6	0.0	9.0	0.0	5.8	0.0	10.3	0.2	0.0	0.0	7.6	0.2	0.4	12.7	0.1	0.0	63.5	4.4	4.1	8.6	1.8	0.0	0.1	0.0	35.4	0.0	5.0	5.5	0.6	0.5	0.5	0.3	0.2	0.9	0.4	0.2	0.5	1.5	0.5	0.6	2.6	1.0	0.3	5.1	0.2	4.9	1.3	2.2	1.9	2.4	1.2	1.1	2.4	1.0	2.3	1.6	32.8	262.9	24.4	2.5	18.4	0.7	8.4	191.1	58.9	112.6	36.6	0.0	45.9	11.6	114.4	16.0	204.3	1.7	23.3	242.7	1654.1	163.0	4.2	12.8	338.6	44.3	1.6	101.1	765.5	77.7	9.8	159.0	19.5	25.3	57.7	1.2	31.4	108.2	2.9	65.7	100.4	1.1	213.4	163.5	1.1	0.4	16.2	735.3	15.4	1.3	6.0
TH	DYT5b	ENSG00000180176	"Tyrosine hydroxylase"	P07101	11	2163929-2171877	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Catecholamine biosynthesis, Neurotransmitter biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, Dystonia, FDA approved drug targets, Parkinson disease, Parkinsonism"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	31	"adrenal gland: 83.5;brain: 41.4"	"Cell type enhanced"	"Detected in some"	21	"Collecting duct cells: 1.8;Extravillous trophoblasts: 7.9;Leydig cells: 3.1;Syncytiotrophoblasts: 1.8"	"Cancer enhanced"	"Detected in some"		"urothelial cancer: 4.0"	"Group enriched"	"Detected in many"	6	"hypothalamus: 15.5;midbrain: 41.4;pons and medulla: 41.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	32	"PC-3: 35.9;SK-BR-3: 12.8"	"Region enhanced"	"Detected in many"		"olfactory region: 220.1"	"Region enriched"	"Detected in many"	19	"midbrain: 692.0"	"CAB002522, HPA013768, HPA014010, HPA061003, CAB072340"	Enhanced	Supported	Approved	Cytosol		NA	NA			Cytosol		"CAB002522: AB_564047, CAB072340: , HPA013768: , HPA014010: , HPA061003: AB_2630374"	"unprognostic (1.31e-1)"	"unprognostic (1.30e-1)"	"unprognostic (9.08e-2)"	"unprognostic (1.75e-4)"	"unprognostic (8.82e-3)"	"unprognostic (5.88e-2)"	"unprognostic (1.93e-1)"	"unprognostic (1.74e-3)"	"unprognostic (3.83e-2)"	"unprognostic (4.39e-4)"	"unprognostic (4.97e-1)"	"unprognostic (3.61e-2)"	"unprognostic (1.92e-1)"	"unprognostic (1.60e-1)"	"unprognostic (2.43e-1)"	"unprognostic (2.70e-2)"	"unprognostic (2.18e-2)"	1.3	83.5	0.0	0.3	5.4	0.2	0.2	0.0	0.7	1.8	0.2	6.2	0.0	0.2	0.3	0.3	0.2	0.3	0.4	0.2	0.3	15.5	0.2	0.2	0.2	0.2	41.4	0.0	0.3	0.3	0.2	0.2	0.9	41.2	0.6	0.2	0.3	0.2	2.0	0.2	0.5	0.4	0.2	0.0	0.3	0.2	0.3	1.5	0.0	0.2	0.0	0.2	0.9	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.3	35.9	0.0	0.0	0.0	0.1	0.0	0.7	0.1	0.0	12.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.4	0.0	0.7	0.3	15.5	41.4	0.0	41.2	1.5	0.0	0.0	0.0	0.1	0.1	0.0	0.8	0.0	0.0	0.0	1.8	0.0	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	7.9	0.4	0.0	0.0	0.0	0.4	0.0	0.0	1.3	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.5	0.0	1.8	0.0	0.0	0.1
THRA	"AR7, EAR-7.1/EAR-7.2, ERBA, ERBA1, NR1A1, THRA1, THRA2, THRA3"	ENSG00000126351	"Thyroid hormone receptor, alpha"	P10827	17	40058290-40093867	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 90.7"	"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"ASC diff: 37.3"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA009654, CAB023349"	Approved		Supported	Cytosol		NA	NA			Cytosol		"CAB023349: AB_619577, HPA009654: AB_1854603"	"unprognostic (2.75e-2)"	"unprognostic (2.20e-1)"	"unprognostic (6.64e-2)"	"unprognostic (4.22e-2)"	"unprognostic (8.78e-2)"	"unprognostic (1.64e-1)"	"unprognostic (3.41e-3)"	"prognostic favorable (1.84e-4)"	"unprognostic (1.47e-1)"	"unprognostic (5.47e-2)"	"unprognostic (7.85e-2)"	"unprognostic (2.65e-2)"	"prognostic favorable (6.05e-8)"	"unprognostic (3.05e-1)"	"unprognostic (1.35e-1)"	"unprognostic (4.21e-1)"	"unprognostic (1.88e-3)"	17.1	20.7	58.6	5.7	90.7	9.9	12.9	37.4	73.1	19.8	12.6	24.1	8.2	15.1	19.3	11.5	9.7	29.3	12.7	30.1	43.8	38.1	12.1	2.7	11.6	4.5	34.3	45.5	46.5	12.3	13.0	10.7	8.5	29.6	12.4	9.6	10.4	13.7	18.8	38.5	10.0	16.7	17.4	29.4	6.1	11.9	7.8	43.6	1.8	12.5	7.9	3.3	10.0	18.6	1.0	1.5	3.7	0.7	5.1	4.7	1.4	2.1	17.3	5.4	13.5	37.3	13.7	2.0	8.9	10.7	9.2	8.7	14.3	12.6	2.5	14.8	17.2	4.1	5.2	10.5	5.4	5.0	1.0	10.0	4.7	20.6	6.1	12.6	7.5	5.2	21.7	4.5	8.6	3.4	21.6	12.4	7.7	9.4	2.4	7.6	3.2	10.1	12.5	4.9	11.2	5.4	14.4	10.7	12.4	3.1	1.5	9.2	8.4	6.8	10.9	15.4	8.6	12.8	8.9	8.5	9.2	9.2	8.3	2.6	5.6	3.9	1.5	5.7	8.7	4.9	0.3	0.6	3.7	4.7	0.3	2.0	0.6	1.9	2.8	0.8	1.0	3.4	4.1	2.5	5.1	0.7	1.5	2.2	1.4	58.6	90.7	37.4	41.8	43.8	38.1	34.3	45.5	29.6	43.6	17.9	5.3	2.2	23.4	9.4	70.7	41.6	45.9	6.7	2.3	31.4	19.6	0.7	43.1	9.9	0.6	15.7	41.1	0.0	13.1	1.1	21.6	16.7	13.9	11.5	10.8	58.8	24.1	24.5	7.8	0.8	47.8	4.6	18.6	0.0	17.6	75.1	6.8	17.5	46.7	18.8	20.2	19.4	34.9	0.0	14.9	9.2	0.2	12.5	29.5	9.5
THRB	"ERBA-BETA, ERBA2, GRTH, NR1A2, PRTH, THR1, THRB1, THRB2"	ENSG00000151090	"Thyroid hormone receptor beta"	P10828	3	24117153-24495756	"Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Cancer-related genes, Deafness, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	12	"Cone photoreceptor cells: 155.1;Urothelial cells: 57.2"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"basophil: 7.2;naive B-cell: 4.3"	"Group enriched"	"Detected in many"	11	"B-cells: 4.3;granulocytes: 7.2"	"Cell line enhanced"	"Detected in many"		"K-562: 26.5;RT4: 19.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002008, CAB002009, HPA061035"	Approved		Supported	"Nuclear bodies"		NA	NA			"Nuclear bodies"		"CAB002008: , CAB002009: , HPA061035: AB_2684422"	"unprognostic (1.82e-1)"	"unprognostic (4.22e-1)"	"unprognostic (2.83e-1)"	"unprognostic (2.20e-6)"	"unprognostic (3.37e-1)"	"unprognostic (2.66e-2)"	"unprognostic (1.93e-2)"	"unprognostic (1.73e-1)"	"unprognostic (5.78e-3)"	"unprognostic (2.95e-2)"	"unprognostic (4.43e-1)"	"unprognostic (2.01e-2)"	"prognostic favorable (9.46e-8)"	"unprognostic (1.32e-3)"	"unprognostic (6.75e-2)"	"unprognostic (2.73e-2)"	"unprognostic (3.34e-2)"	10.7	5.5	12.5	3.2	14.8	1.1	12.0	2.6	27.0	3.6	11.2	1.9	5.5	2.7	7.5	2.2	7.0	4.3	2.5	7.9	9.2	5.7	12.9	20.8	5.4	1.6	4.3	20.1	2.9	9.6	6.8	20.3	4.7	3.5	8.2	9.0	3.2	6.1	10.4	21.9	7.1	4.0	11.1	3.0	5.7	8.1	1.0	4.0	0.0	4.9	4.7	1.6	9.8	14.6	4.3	0.5	7.2	0.1	0.0	0.0	3.5	6.0	1.8	0.4	0.0	11.0	5.7	4.1	0.3	1.3	1.0	2.0	4.0	6.0	0.0	1.5	4.3	0.7	9.2	6.6	2.5	0.7	0.0	4.0	0.0	1.6	5.2	0.3	0.0	0.0	10.1	4.5	0.1	0.8	2.4	0.0	0.0	26.5	0.0	0.9	0.3	0.0	0.0	4.0	0.4	2.2	0.0	0.0	0.0	6.3	19.7	1.1	0.4	10.0	5.4	0.1	3.0	6.0	0.0	0.5	2.5	1.9	0.0	1.1	0.1	0.3	0.0	1.8	0.0	0.2	7.2	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.5	4.3	0.0	0.0	1.6	0.0	0.0	0.0	0.0	3.5	12.5	14.8	2.6	27.0	9.2	5.7	4.3	20.1	3.5	4.0	3.0	10.7	3.0	21.7	8.9	18.7	11.5	2.5	9.4	9.1	22.7	155.1	9.6	1.7	1.8	2.0	7.3	9.2	0.0	10.7	19.3	7.7	26.4	0.0	31.6	1.5	0.0	24.2	2.5	8.8	2.0	0.6	3.2	1.7	0.0	8.2	15.3	9.1	17.5	2.1	7.5	22.1	6.5	10.0	0.2	0.2	20.8	4.6	0.0	7.8	57.2
TLR2	"CD282, TIL4"	ENSG00000137462	"Toll like receptor 2"	O60603	4	153684070-153705702	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 72.9"	"Group enriched"	"Detected in many"	5	"Alveolar cells type 2: 64.7;Kupffer cells: 106.5;Macrophages: 52.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Group enriched"	"Detected in many"	5	"classical monocyte: 29.5;intermediate monocyte: 28.1;myeloid DC: 19.1;neutrophil: 72.9;non-classical monocyte: 18.4"	"Group enriched"	"Detected in many"	46	"dendritic cells: 19.1;granulocytes: 72.9;monocytes: 29.5"	"Cell line enhanced"	"Detected in some"		"HL-60: 6.9;HSkMC: 7.5;hTCEpi: 7.5;RPTEC TERT1: 7.7;RT4: 9.5;THP-1: 36.3;U-937: 6.9"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"HPA060231, HPA071546"			Supported	Nucleoplasm,Mitochondria		No	NA			"Nucleoplasm, Mitochondria"		"HPA060231: , HPA071546: "	"unprognostic (4.15e-1)"	"unprognostic (3.29e-2)"	"unprognostic (5.32e-2)"	"unprognostic (1.52e-2)"	"unprognostic (3.46e-2)"	"unprognostic (4.88e-2)"	"unprognostic (1.39e-2)"	"unprognostic (4.24e-2)"	"unprognostic (2.48e-1)"	"unprognostic (2.02e-2)"	"unprognostic (2.04e-1)"	"unprognostic (1.33e-1)"	"prognostic unfavorable (1.11e-4)"	"unprognostic (7.87e-2)"	"unprognostic (3.80e-3)"	"unprognostic (1.42e-1)"	"unprognostic (5.93e-3)"	16.3	6.9	6.9	30.0	11.1	34.6	7.3	1.4	5.3	4.7	4.7	3.0	9.3	2.2	3.1	8.0	3.2	7.2	10.0	7.2	6.7	3.3	9.8	7.3	31.1	37.8	12.4	1.4	4.2	5.1	1.1	4.4	6.4	9.9	5.5	1.9	3.3	15.0	9.9	2.5	3.1	4.0	6.6	21.9	29.3	3.9	4.8	9.5	0.9	3.3	1.0	8.5	7.3	3.5	0.2	19.1	72.9	29.5	0.8	0.2	9.3	4.0	0.0	0.2	0.0	0.5	1.6	0.0	0.0	0.3	0.3	0.5	1.9	0.2	0.0	0.4	0.0	0.0	3.6	0.4	0.3	0.2	0.0	0.0	0.1	0.0	0.4	0.0	6.9	0.5	7.5	7.5	0.0	0.1	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.4	0.0	1.6	0.1	0.0	0.0	7.7	9.5	0.0	0.2	0.4	0.0	1.8	0.2	0.0	36.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	6.9	0.9	6.2	29.5	0.2	0.0	28.1	0.0	0.0	0.1	0.0	19.1	0.2	0.2	0.0	72.9	0.8	18.4	0.1	0.0	9.3	6.9	11.1	1.4	5.3	6.7	3.3	12.4	1.4	9.9	9.5	6.0	64.7	0.8	1.1	1.0	0.0	1.2	5.1	2.7	12.5	3.5	0.0	0.1	0.0	4.8	0.3	0.6	0.0	0.0	3.2	0.1	0.9	2.0	3.5	0.9	16.3	0.0	0.0	2.5	106.5	0.0	0.6	52.5	1.7	0.0	0.1	0.0	3.1	0.0	0.4	1.0	0.3	12.9	0.4	0.2	0.4	1.0	0.1	0.7	0.0	1.4
TLR4	"ARMD10, CD284, hToll, TLR-4"	ENSG00000136869	"Toll like receptor 4"	O00206	9	117704175-117724730	"CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters"	"Immunity, Inflammatory response, Innate immunity"	"Hydrolase, Receptor"	"Age-related macular degeneration, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	15	"Hofbauer cells: 31.7;Ito cells: 59.5;Kupffer cells: 88.0;Macrophages: 33.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 30.1"	"Group enriched"	"Detected in many"	30	"dendritic cells: 7.5;granulocytes: 30.1;monocytes: 21.4"	"Cell line enhanced"	"Detected in many"		"Karpas-707: 29.6;TIME: 21.4"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB004025, HPA049174"	Approved		Supported	"Golgi apparatus,Plasma membrane"	"Intracellular and membrane"	NA	NA			"Plasma membrane"	"Golgi apparatus"	"CAB004025: , HPA049174: AB_2680662"	"unprognostic (1.60e-1)"	"unprognostic (8.34e-2)"	"unprognostic (7.22e-2)"	"prognostic favorable (6.29e-4)"	"unprognostic (3.39e-1)"	"unprognostic (7.48e-2)"	"unprognostic (8.68e-2)"	"unprognostic (1.80e-1)"	"unprognostic (3.38e-1)"	"unprognostic (5.18e-2)"	"unprognostic (8.00e-2)"	"unprognostic (9.42e-2)"	"unprognostic (4.08e-2)"	"unprognostic (8.63e-2)"	"prognostic unfavorable (3.79e-4)"	"unprognostic (1.09e-2)"	"unprognostic (1.96e-2)"	29.2	12.1	15.5	23.5	12.5	17.8	21.9	9.4	10.3	6.9	6.8	10.6	3.0	4.4	5.8	7.7	5.0	6.8	10.6	10.9	19.9	7.5	9.0	16.5	16.0	30.9	12.4	11.4	6.7	3.0	2.9	3.8	22.8	10.5	5.7	7.4	7.2	9.0	3.6	7.4	5.2	6.6	10.4	11.1	41.4	4.5	2.4	13.0	1.1	8.3	5.6	7.5	12.1	16.1	0.6	7.5	30.1	21.4	0.0	0.0	6.9	0.0	0.0	12.7	0.0	5.9	12.0	0.1	5.0	8.8	1.3	0.7	0.0	1.2	1.7	0.2	13.0	3.9	0.0	0.0	1.1	1.9	0.0	0.0	2.7	2.7	0.1	4.4	9.1	0.0	7.4	0.0	2.8	0.3	11.4	15.5	0.0	0.0	29.6	15.4	0.0	0.0	1.8	1.5	1.2	0.6	0.0	14.3	9.3	0.5	14.8	0.0	0.0	3.2	0.0	0.5	1.2	0.0	5.0	21.4	0.7	9.6	0.0	2.4	0.0	0.0	0.0	0.4	9.6	7.6	17.6	21.4	7.2	0.0	19.6	0.0	0.6	0.0	0.0	7.5	0.2	0.0	0.0	30.1	0.0	20.2	0.3	0.0	6.9	15.5	12.5	9.4	10.3	19.9	7.5	12.4	11.4	10.5	13.0	0.0	5.3	1.5	0.1	0.7	0.2	2.5	5.1	2.7	4.5	0.0	0.0	0.2	0.0	0.0	0.0	19.7	0.3	0.0	0.2	0.2	1.9	0.2	15.1	1.8	31.7	0.0	0.0	59.5	88.0	0.0	0.0	33.1	1.7	0.0	0.6	13.8	0.3	1.7	0.0	0.4	0.8	6.5	0.9	0.0	0.2	0.0	0.7	0.0	0.1	2.2
TLR7		ENSG00000196664	"Toll like receptor 7"	Q9NYK1	X	12867083-12890380	"FDA approved drug targets, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"brain: 26.5"	"Cell type enhanced"	"Detected in some"	16	"Hofbauer cells: 20.2;Macrophages: 14.8"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"plasmacytoid DC: 15.7"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	5	"Daudi: 16.0;U-266/70: 16.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA059613	Supported					NA	NA					"HPA059613: AB_2684083"	"unprognostic (1.22e-1)"	"unprognostic (1.09e-2)"	"unprognostic (2.36e-3)"	"unprognostic (9.29e-2)"	"unprognostic (2.06e-1)"	"unprognostic (1.06e-2)"	"unprognostic (8.27e-2)"	"unprognostic (6.20e-3)"	"unprognostic (3.75e-1)"	"unprognostic (6.91e-2)"	"unprognostic (3.55e-1)"	"unprognostic (8.47e-2)"	"unprognostic (2.54e-1)"	"unprognostic (4.17e-3)"	"unprognostic (1.19e-3)"	"unprognostic (1.53e-3)"	"unprognostic (1.34e-1)"	2.9	3.1	7.6	7.2	11.3	1.0	7.6	1.7	7.9	2.5	3.3	10.6	0.0	3.2	1.8	2.9	1.8	1.7	5.3	4.1	8.4	5.1	2.2	1.5	7.7	6.9	17.4	2.6	1.6	1.9	1.5	2.2	11.0	12.9	2.2	4.0	1.5	2.7	2.0	1.4	1.4	4.9	3.5	26.5	6.7	3.0	1.5	17.2	7.7	1.7	0.5	9.4	5.2	1.6	6.9	15.7	3.2	8.9	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	16.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.9	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.2	0.0	16.5	0.0	3.1	0.0	0.3	0.0	0.2	7.2	3.2	0.0	8.9	0.0	6.9	0.0	0.0	3.7	5.8	0.0	0.0	0.4	0.0	6.8	15.7	0.0	2.2	7.6	11.3	1.7	7.9	8.4	5.1	17.4	2.6	12.9	17.2	0.0	4.6	2.4	1.1	1.1	0.0	0.5	0.0	4.0	1.2	0.0	2.0	0.3	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.2	1.0	0.7	1.1	0.0	20.2	0.0	0.0	0.6	2.4	0.0	0.6	14.8	1.7	1.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.0	0.8	0.0	0.1	0.9	0.2	0.0	0.0	1.4
TLR9	CD289	ENSG00000239732	"Toll like receptor 9"	Q9NR96	3	52221080-52226163	"CD markers, FDA approved drug targets, Predicted membrane proteins"	"Immunity, Inflammatory response, Innate immunity"	Receptor	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"blood: 33.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Cell type enriched"	"Detected in some"	10	"plasmacytoid DC: 33.8"	"Lineage enriched"	"Detected in many"	10	"dendritic cells: 33.8"	"Group enriched"	"Detected in some"	12	"Daudi: 24.7;RPMI-8226: 15.7;U-698: 9.5"															NA	NA						"unprognostic (6.03e-2)"	"unprognostic (5.08e-2)"	"unprognostic (3.58e-3)"	"unprognostic (6.69e-7)"	"unprognostic (1.16e-1)"	"unprognostic (1.89e-2)"	"unprognostic (2.69e-1)"	"unprognostic (1.58e-1)"	"unprognostic (7.02e-2)"	"unprognostic (1.89e-1)"	"unprognostic (4.40e-2)"	"unprognostic (7.60e-2)"	"unprognostic (2.65e-3)"	"unprognostic (2.44e-2)"	"unprognostic (3.70e-1)"	"unprognostic (2.27e-1)"	"unprognostic (7.91e-3)"	0.5	0.2	0.0	2.8	0.5	2.5	0.4	4.9	0.4	0.8	1.2			0.7	0.9	0.0	0.2	1.0	0.9	0.3	0.2	0.3	0.3	0.1	0.6	6.5	0.1		2.5	0.0	0.0	0.3	0.1		0.9	0.1		1.4	0.4	1.8	0.1	2.2	0.1	0.4	3.9	0.5	0.3			0.7		3.9	1.2	1.2	3.3	33.8	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	24.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.1	0.0	0.5	0.0	0.1	0.0	0.0	1.3	0.2	0.0	0.0	0.0	0.0	0.0	15.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.0	0.0	0.0	1.0	0.7	9.5	0.0	0.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.3	0.0	0.0	0.0	1.7	0.0	0.0	0.0	0.0	0.0	33.8	0.0	0.1											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TNF	"DIF, TNF-alpha, TNFA, TNFSF2"	ENSG00000232810	"Tumor necrosis factor"	P01375	6	31575567-31578336	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins"		Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 14.6;lymphoid tissue: 28.0"	"Cell type enhanced"	"Detected in many"	10	"Hofbauer cells: 32.8;Macrophages: 42.1;T-cells: 34.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in some"			"Cell type enhanced"	"Detected in many"		"non-classical monocyte: 10.8"	"Group enriched"	"Detected in many"	5	"granulocytes: 3.5;monocytes: 10.8;T-cells: 6.6"	"Group enriched"	"Detected in some"	5	"HDLM-2: 10.2;HMC-1: 9.8;NB-4: 29.6"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			CAB078469	Supported				"Secreted to blood"	NA	NA	10100				"CAB078469: AB_908070"	"unprognostic (1.93e-1)"	"unprognostic (1.07e-2)"	"unprognostic (3.85e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.92e-1)"	"unprognostic (2.19e-2)"	"unprognostic (1.67e-1)"	"unprognostic (3.46e-1)"	"unprognostic (1.19e-2)"	"unprognostic (1.94e-1)"	"unprognostic (3.07e-2)"	"unprognostic (1.38e-1)"	"unprognostic (1.46e-2)"	"unprognostic (1.82e-1)"	"unprognostic (9.85e-3)"	"unprognostic (1.09e-1)"	"unprognostic (2.04e-1)"	2.3	1.2	0.6	15.6	1.0	14.6	1.2	0.4	1.8	1.7	1.3	3.7	0.3	1.3	1.1	0.4	1.5	0.9	2.3	2.0	0.5	0.3	2.6	1.9	9.5	8.0	0.8	0.0	0.6	0.7	0.5	0.5	3.2	2.0	0.7	0.7	0.4	2.2	0.8	0.4	2.7	4.1	0.7	1.0	28.0	1.0	0.4	0.5	2.1	0.6	5.3	14.7	1.2	0.4	1.3	1.2	3.5	10.8	0.5	6.6	2.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.1	0.0	0.2	0.0	0.0	0.0	0.0	10.2	0.0	1.9	0.0	0.0	0.0	0.8	9.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	29.6	0.0	0.0	0.0	1.8	0.0	0.0	1.1	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.3	3.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	1.7	0.0	4.1	6.5	6.6	1.3	3.1	2.4	1.2	1.3	0.9	1.0	3.5	0.5	10.8	0.7	2.2	2.1	0.6	1.0	0.4	1.8	0.5	0.3	0.8	0.0	2.0	0.5	0.0	4.0	13.4	0.2	7.4	0.1	2.0	5.1	1.4	2.3	0.0	2.0	0.3	0.0	6.7	0.1	2.8	0.0	0.0	2.9	1.5	2.1	0.9	11.6	0.0	32.8	0.0	0.0	1.3	8.7	0.0	0.3	42.1	5.0	1.0	0.1	0.1	10.2	0.0	0.0	0.0	0.1	0.0	2.3	0.0	0.0	3.6	0.9	34.1	0.0	0.3
TNFRSF1A	"CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60"	ENSG00000067182	"TNF receptor superfamily member 1A"	P19438	12	6328757-6342114	"Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins"	"Apoptosis, Host-virus interaction"	Receptor	"Amyloidosis, Cancer-related genes, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 86.5"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA004102, CAB010309"	Approved				"Secreted to blood"	NA	NA		170000			"CAB010309: AB_2206639, HPA004102: AB_1846232"	"unprognostic (2.19e-2)"	"unprognostic (3.76e-2)"	"unprognostic (8.14e-2)"	"prognostic favorable (8.22e-4)"	"unprognostic (3.07e-2)"	"prognostic unfavorable (3.68e-4)"	"unprognostic (1.50e-1)"	"unprognostic (1.41e-3)"	"unprognostic (1.00e-1)"	"unprognostic (8.05e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.54e-2)"	"prognostic unfavorable (2.70e-7)"	"unprognostic (1.43e-2)"	"unprognostic (2.92e-2)"	"unprognostic (5.14e-3)"	"unprognostic (1.74e-1)"	55.1	43.9	16.8	28.9	16.8	13.7	40.6	7.2	15.6	40.3	41.5	14.1	22.6	39.2	38.2	27.5	39.4	34.2	37.1	26.8	14.0	7.5	49.3	61.6	40.9	37.2	19.2	6.4	59.5	21.4	20.3	19.9	45.3	18.3	37.0	23.0	31.1	25.7	22.2	34.2	30.9	81.7	38.8	25.1	43.6	28.2	21.8	15.7	31.6	42.7	25.4	22.3	49.1	58.5	0.0	20.8	86.5	27.1	1.8	11.6	15.9	7.4	57.8	8.1	11.5	56.0	57.3	15.3	15.9	27.5	21.4	18.6	6.9	29.7	0.6	5.5	34.3	17.1	20.8	2.5	18.6	14.8	0.1	4.8	4.1	16.0	15.3	49.7	19.3	13.0	59.0	18.7	17.7	26.1	49.7	26.0	8.0	6.2	5.7	24.5	10.6	6.1	18.2	19.7	27.7	16.9	5.3	12.9	5.7	16.5	13.5	0.0	0.4	22.5	11.8	11.8	21.7	3.2	21.1	28.3	16.8	14.4	12.6	14.7	0.0	1.8	2.4	20.1	18.0	20.8	2.2	27.1	15.0	11.6	21.8	11.1	0.0	4.9	9.5	20.8	0.0	4.5	6.6	86.5	1.8	17.5	6.0	4.8	15.9	16.8	16.8	7.2	15.6	14.0	7.5	19.2	6.4	18.3	15.7	47.6	42.8	9.0	92.6	109.3	0.1	8.4	63.7	10.7	42.1	26.2	0.0	53.2	13.3	86.6	0.6	80.7	166.1	23.3	104.3	104.8	112.3	113.8	7.0	128.2	148.0	0.0	32.3	138.1	133.7	3.3	94.6	103.1	67.4	101.0	44.9	16.3	93.0	210.5	61.9	94.3	0.3	122.9	122.4	0.5	1.1	117.7	124.3	45.7	42.3	123.4
TNFRSF8	"CD30, D1S166E, KI-1"	ENSG00000120949	"TNF receptor superfamily member 8"	P28908	1	12063377-12144207	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins"		Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"blood: 33.3"	"Cell type enhanced"	"Detected in some"	14	"Early spermatids: 2.8;Kupffer cells: 6.0;Late spermatids: 7.2"	"Cancer enriched"	"Detected in some"	12	"testis cancer: 9.3"	"Region enriched"	"Detected in single"	14	"basal ganglia: 13.1"	"Cell type enhanced"	"Detected in some"		"intermediate monocyte: 21.7;non-classical monocyte: 33.3"	"Lineage enriched"	"Detected in many"	5	"monocytes: 33.3"	"Cell line enriched"	"Detected in some"	21	"HDLM-2: 112.6"					"Low region specificity"	"Detected in many"			"CAB000016, HPA014823, HPA032081, HPA032082"	Approved		Supported	"Plasma membrane"		NA	NA			"Plasma membrane"		"CAB000016: AB_563546, HPA014823: , HPA032081: AB_2674141, HPA032082: AB_2674142"	"unprognostic (1.07e-2)"	"unprognostic (2.06e-2)"	"unprognostic (2.52e-2)"	"unprognostic (5.98e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.46e-3)"	"unprognostic (2.19e-1)"	"unprognostic (3.93e-2)"	"unprognostic (1.18e-1)"	"unprognostic (9.18e-3)"	"unprognostic (1.86e-1)"	"unprognostic (2.06e-1)"	"unprognostic (3.17e-8)"	"unprognostic (3.31e-1)"	"unprognostic (8.56e-2)"	"unprognostic (2.07e-1)"	"unprognostic (2.31e-2)"	10.7	0.2	0.1	7.2	13.1	1.4	5.8	0.2	0.4	1.1	0.8	0.0	1.5	0.2	1.7	1.3	0.9	2.1	1.4	3.8	0.1	0.2	0.9	0.2	3.9	2.9	0.5	0.5	1.2	0.4	0.0	0.1	6.2	0.5	1.0	0.5	0.0	0.7	0.3	3.1	1.6	1.3	1.3	1.4	2.9	6.4	2.5	0.9	3.0	0.7	2.7	5.3	2.6	3.8	0.0	3.2	6.8	33.3	0.0	0.3	2.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	2.5	0.0	0.0	0.0	0.0	0.0	0.0	112.6	0.0	0.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.8	5.2	0.3	0.0	0.0	0.3	0.0	4.5	0.0	0.1	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.3	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.5	0.3	0.0	21.7	0.1	0.0	0.0	0.0	3.2	0.0	0.0	0.0	6.8	0.0	33.3	0.8	0.3	2.7	0.1	13.1	0.2	0.4	0.1	0.2	0.5	0.5	0.5	0.9	0.0	0.0	0.0	0.0	0.2	0.0	1.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.8	0.0	0.0	0.0	0.0	0.1	0.3	0.1	0.0	0.0	1.4	0.0	0.0	1.3	6.0	7.2	0.3	1.9	0.0	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.5	0.7	0.1	0.2	0.0	0.0	0.0
TNFSF11	"CD254, ODF, OPGL, RANKL, TRANCE"	ENSG00000120659	"TNF superfamily member 11"	O14788	13	42562736-42608013	"Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Differentiation	"Cytokine, Developmental protein, Receptor"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Osteopetrosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 14.3;lymphoid tissue: 19.8"	"Cell type enhanced"	"Detected in some"	22	"Ductal cells: 3.3;Early spermatids: 5.8;Late spermatids: 14.2"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	8	"NK-cell: 14.3"	"Lineage enriched"	"Detected in many"	8	"NK-cells: 14.3"	"Cell line enhanced"	"Detected in some"		"Daudi: 1.8;HSkMC: 5.4;NTERA-2: 7.5"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB009193, HPA045142"	Enhanced				"Secreted to blood"	NA	NA	17200				"CAB009193: , HPA045142: AB_2679231"	"unprognostic (3.97e-4)"	"unprognostic (1.40e-1)"	"unprognostic (9.01e-3)"	"unprognostic (3.81e-3)"	"unprognostic (1.12e-1)"	"unprognostic (1.09e-1)"	"unprognostic (7.09e-2)"	"unprognostic (7.70e-2)"	"unprognostic (2.29e-1)"	"unprognostic (1.25e-3)"	"unprognostic (1.00e-1)"	"unprognostic (1.50e-1)"	"unprognostic (3.94e-5)"	"unprognostic (1.87e-1)"	"unprognostic (9.67e-2)"	"unprognostic (5.46e-2)"	"unprognostic (7.74e-2)"	0.5	0.2	0.2	19.5	0.2	0.0	4.6	0.1	0.2	0.8	0.8	0.1	2.4	0.2	0.2	0.1	3.7	0.2	1.3	0.3	0.1	0.7	0.6	5.3	0.4	19.8	0.1	0.1	0.1	0.6	0.0	0.3	0.3	0.4	0.5	2.2	0.1	1.6	1.0	0.2	0.5	6.0	0.1	0.1	0.8	0.3	3.3	0.1	2.8	0.4	0.1	5.2	2.3	0.7	0.0	0.1	1.8	0.0	14.3	0.1	0.1	0.0	0.3	0.0	0.1	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.5	1.8	0.0	0.0	0.1	0.2	0.0	0.2	0.0	0.1	0.0	0.1	0.5	0.0	0.6	0.0	0.1	5.4	0.5	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.2	7.5	0.0	0.1	0.0	0.2	0.0	0.0	0.1	0.1	0.2	0.0	0.0	0.0	0.5	0.0	0.7	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.8	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.0	0.0	0.0	14.3	0.0	0.0	0.0	0.1	0.2	0.2	0.1	0.2	0.1	0.7	0.1	0.1	0.4	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.4	2.5	0.0	0.0	0.0	0.0	0.0	0.0	3.3	5.8	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	1.0	0.0	0.0	1.2	0.0	0.0	14.2	0.0	0.0	0.0	0.0	0.3	0.0	2.5	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.1	0.3	0.0	0.0	0.0	0.0
TNFSF13B	"BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20"	ENSG00000102524	"TNF superfamily member 13b"	Q9Y275	13	108251240-108308484	"Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins"	Immunity	Cytokine	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	4	"blood: 76.5;lymphoid tissue: 39.6"	"Cell type enhanced"	"Detected in many"	23	"Hofbauer cells: 88.9;Kupffer cells: 144.9;Macrophages: 141.3;monocytes: 457.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"neutrophil: 76.5"	"Group enriched"	"Detected in many"	10	"dendritic cells: 31.0;granulocytes: 76.5;monocytes: 53.7"	"Cell line enriched"	"Detected in some"	7	"U-937: 61.0"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in many"			"CAB009188, HPA030526"	Enhanced		Supported	"Vesicles,Plasma membrane,Focal adhesion sites"	"Secreted to blood"	NA	NA	393000	530000	"Plasma membrane"	"Vesicles, Focal adhesion sites"	"CAB009188: , HPA030526: "	"unprognostic (6.48e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.38e-1)"	"unprognostic (1.90e-1)"	"unprognostic (2.61e-2)"	"unprognostic (7.99e-2)"	"unprognostic (8.19e-2)"	"unprognostic (1.37e-1)"	"unprognostic (1.63e-1)"	"unprognostic (1.02e-2)"	"unprognostic (2.64e-2)"	"unprognostic (1.21e-1)"	"prognostic unfavorable (2.53e-11)"	"unprognostic (1.23e-1)"	"unprognostic (4.14e-2)"	"unprognostic (1.88e-1)"	"unprognostic (1.25e-1)"	7.2	8.2	3.0	18.5	8.2	13.2	3.4	1.4	5.2	1.6	4.2	2.1	1.0	7.8	1.2	6.5	3.5	2.9	9.4	9.4	5.7	2.9	3.1	5.0	13.2	39.6	7.2	2.6	2.9	2.7	0.5	2.1	6.4	5.7	3.7	6.4	2.6	5.4	1.8	1.6	1.6	6.8	3.5	11.6	23.5	3.4	1.0	4.9	7.2	5.1	1.7	12.7	8.5	3.8	1.0	31.0	76.5	53.7	0.6	5.3	20.8	0.0	0.1	0.0	0.0	0.2	0.3	0.0	0.1	0.3	0.2	0.8	0.0	0.6	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	4.2	0.0	0.3	0.1	0.0	0.1	3.6	0.1	0.7	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.2	0.4	0.0	0.0	1.9	0.0	0.4	0.0	0.0	0.0	0.0	0.2	0.1	0.5	0.1	0.0	0.0	0.1	0.1	0.0	8.1	0.0	0.1	0.0	0.0	0.1	3.8	0.1	0.0	3.9	61.0	0.6	1.2	53.7	14.4	0.8	39.8	5.3	0.6	3.5	0.7	31.0	1.0	1.7	0.5	76.5	0.6	31.7	11.5	2.8	20.8	3.0	8.2	1.4	5.2	5.7	2.9	7.2	2.6	5.7	4.9	14.9	17.5	3.7	0.7	6.4	0.3	0.5	12.7	2.7	5.7	5.2	0.0	0.5	1.7	2.0	1.0	1.3	0.5	0.0	29.2	0.9	13.3	1.6	4.7	1.5	88.9	0.0	1.2	4.9	144.9	0.2	4.9	141.3	8.5	457.1	0.2	0.4	1.9	0.0	1.8	1.0	0.0	6.5	5.0	0.1	0.1	4.1	0.9	6.2	1.2	1.3
TNNC1	TNNC	ENSG00000114854	"Troponin C1, slow skeletal and cardiac type"	P63316	3	52451102-52454070	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Muscle protein"	"Cardiomyopathy, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	7	"heart muscle: 431.6;skeletal muscle: 765.7"	"Cell type enriched"	"Detected in many"	8	"Cardiomyocytes: 2506.5"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"MAIT T-cell: 4.0"	"Lineage enriched"	"Detected in single"	7	"T-cells: 4.0"	"Cell line enhanced"	"Detected in some"		"CACO-2: 24.3;CAPAN-2: 12.2;EFO-21: 24.4;HeLa: 16.0;Hep G2: 16.2;HSkMC: 25.3;U-2 OS: 37.5"	"Region enriched"	"Detected in many"	4	"cerebral cortex: 88.3"	"Not detected"	"Not detected"			"CAB002450, HPA044848, HPA056897"	Enhanced		Approved	"Nucleoplasm,Actin filaments,Mitochondria"		NA	NA		260000	"Nucleoplasm, Actin filaments, Mitochondria"		"CAB002450: AB_564152, HPA044848: AB_2679110, HPA056897: AB_2683269"	"unprognostic (2.18e-2)"	"unprognostic (1.70e-1)"	"unprognostic (8.66e-2)"	"unprognostic (3.43e-1)"	"unprognostic (4.00e-2)"	"unprognostic (1.88e-2)"	"unprognostic (1.11e-1)"	"unprognostic (1.43e-1)"	"unprognostic (1.53e-1)"	"unprognostic (3.92e-1)"	"unprognostic (1.03e-1)"	"unprognostic (1.07e-1)"	"unprognostic (2.15e-2)"	"unprognostic (4.95e-2)"	"unprognostic (2.31e-1)"	"unprognostic (4.15e-2)"	"unprognostic (4.86e-1)"	2.0	0.3	0.1	0.0	0.1	0.0	0.7	0.2	0.1	0.2	0.1	0.0	0.0	0.0	0.1	17.8	12.8	0.1	0.0	431.6	0.1	0.1	0.6	0.1	2.6	0.0	0.1	0.0	0.1	0.2	0.0	0.6	0.2	0.5	5.5	0.1	0.7	10.4	0.0	765.7	0.4	0.1	0.1	0.7	0.1	0.1	0.7	0.0	0.0	3.0	86.9	8.7	0.4	0.2	0.2	0.6	0.0	0.0	0.0	4.0	0.5	0.2	1.8	1.3	0.2	0.0	0.2	2.9	0.1	0.1	0.1	0.1	24.3	12.2	0.2	24.4	3.5	0.0	0.1	0.0	0.1	0.0	0.4	0.6	0.1	16.0	16.2	0.1	0.1	0.0	25.3	0.4	0.0	0.2	0.2	0.0	0.7	0.0	1.9	0.7	0.0	0.0	0.2	0.2	5.4	0.2	0.0	1.0	0.8	1.2	4.6	0.0	0.0	0.1	2.5	0.0	1.5	9.8	0.2	0.0	0.0	37.5	0.3	0.0	1.0	0.4	0.3	0.1	0.2	0.0	0.0	0.0	0.0	0.7	0.0	4.0	0.2	0.9	0.5	0.0	0.1	1.4	0.5	0.0	0.0	0.0	0.6	2.5	0.5	0.1	0.1	0.2	0.1	0.1	0.1	0.1	0.0	0.5	0.0	116.1	13.0	0.0	0.6	1.3	0.2	2506.5	0.0	0.0	7.9	3.5	2.0	44.2	23.2	6.6	0.6	0.0	0.7	0.0	11.8	4.0	14.0	0.6	0.0	0.6	4.1	0.0	318.5	0.6	0.0	3.6	20.8	1.0	5.0	0.0	0.3	1.5	4.4	0.0	166.9	0.5	0.0	0.0	15.5	1.2	0.4	0.6	26.0	0.8	1.5	4.1
TNNC2		ENSG00000101470	"Troponin C2, fast skeletal type"	P02585	20	45823214-45833745	"FDA approved drug targets, Predicted intracellular proteins"		"Muscle protein"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	5	"skeletal muscle: 851.6"	"Group enriched"	"Detected in many"	6	"Enterocytes: 242.7;Mucus-secreting cells: 94.6;Paneth cells: 103.7"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in many"		"memory B-cell: 6.0"	"Low lineage specificity"	"Detected in many"			"Group enriched"	"Detected in some"	7	"Hep G2: 9.9;HSkMC: 15.7;SCLC-21H: 11.8"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"HPA043174, HPA058481"	Enhanced		Approved	Nucleoplasm,Vesicles		No	NA		63000	Nucleoplasm	Vesicles	"HPA043174: AB_10806380, HPA058481: AB_2683729"	"unprognostic (1.13e-1)"	"unprognostic (7.25e-2)"	"unprognostic (3.43e-1)"	"unprognostic (1.27e-1)"	"unprognostic (3.21e-5)"	"unprognostic (1.80e-2)"	"unprognostic (5.72e-3)"	"unprognostic (3.12e-3)"	"unprognostic (2.19e-1)"	"unprognostic (2.06e-1)"	"unprognostic (2.38e-1)"	"unprognostic (1.05e-1)"	"unprognostic (9.03e-3)"	"unprognostic (7.15e-3)"	"unprognostic (4.79e-1)"	"unprognostic (5.23e-2)"	"unprognostic (1.13e-1)"	12.0	0.2	0.1	0.1	0.4	0.1	0.3	0.1	0.2	0.1	0.2	0.0	0.0	0.1	0.1	2.7	4.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.0	0.2	0.1	0.1	0.1	0.1	0.0	1.4	0.1	0.0	7.8	0.1	851.6	0.2	0.3	0.1	0.1	0.1	0.1	0.1	0.0	0.0	1.6	169.1	6.6	0.1	0.1	6.0	0.8	2.4	1.1	0.3	4.1	11.9	0.1	0.0	0.3	0.5	1.7	1.2	1.8	0.2	0.4	0.0	0.1	0.2	1.2	0.4	1.2	1.0	0.4	0.4	0.0	0.4	0.0	0.0	0.3	0.0	1.0	9.9	0.4	0.3	0.2	15.7	0.2	0.1	0.8	0.4	0.0	1.2	0.1	0.5	0.2	1.2	0.7	0.1	0.0	0.4	0.6	0.3	0.6	0.2	0.3	0.1	11.8	0.6	1.7	0.1	0.4	0.5	1.4	0.4	0.5	0.3	0.4	0.9	0.2	1.6	0.4	0.3	1.6	0.1	0.2	0.0	0.7	1.4	0.2	1.1	0.7	6.0	1.5	0.2	0.3	3.8	0.0	0.3	2.4	0.3	0.8	0.8	4.1	11.9	0.1	0.4	0.1	0.2	0.1	0.1	0.1	0.0	0.0	0.0	3.0	1.1	4.2	0.5	0.7	1.3	0.4	2.5	0.0	4.5	3.5	0.0	2.1	3.3	1.3	2.9	0.1	242.7	0.0	4.7	0.2	2.6	0.7	0.0	0.8	0.2	0.0	22.0	0.0	0.0	26.3	1.1	0.5	0.0	0.0	94.6	1.4	2.5	103.7	2.8	0.7	1.7	0.0	3.6	2.3	5.8	7.3	0.1	0.0	25.8	0.5
TOP1		ENSG00000198900	"DNA topoisomerase I"	P11387	20	41028818-41124487	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Biological rhythms, Host-virus interaction"	"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	6	"Syncytiotrophoblasts: 670.2"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB009058, HPA019039"	Supported		Supported	"Nucleoplasm,Nucleoli fibrillar center"		No	Yes			"Nucleoplasm, Nucleoli fibrillar center"		"CAB009058: AB_2303554, HPA019039: AB_1858187"	"unprognostic (1.46e-1)"	"unprognostic (8.65e-2)"	"unprognostic (1.33e-2)"	"unprognostic (1.92e-3)"	"unprognostic (5.05e-2)"	"unprognostic (1.49e-3)"	"prognostic unfavorable (6.42e-4)"	"unprognostic (5.86e-2)"	"unprognostic (1.51e-1)"	"unprognostic (4.60e-2)"	"unprognostic (3.74e-3)"	"unprognostic (6.51e-2)"	"unprognostic (8.65e-2)"	"unprognostic (4.70e-2)"	"unprognostic (5.14e-1)"	"unprognostic (3.64e-1)"	"unprognostic (1.29e-1)"	26.6	31.0	24.6	46.3	25.3	55.3	37.4	39.6	31.1	21.3	30.0	11.1	26.7	29.7	22.9	22.5	36.0	20.5	29.2	21.0	23.0	18.3	31.8	32.7	37.9	38.6	21.9	20.9	25.5	22.5	22.2	39.9	43.9	25.2	23.3	27.2	13.6	25.3	34.3	26.2	24.6	48.4	23.1	27.4	36.9	26.7	14.2	24.2	54.2	31.5	25.1	40.6	25.2	41.7	9.0	17.2	18.4	11.1	5.8	8.2	4.6	22.0	15.4	28.9	23.7	11.7	14.0	28.7	20.0	17.6	23.2	21.2	40.5	27.8	62.9	21.4	10.3	24.8	21.5	34.7	31.9	34.1	13.6	17.7	80.2	12.4	28.7	30.6	34.5	27.6	15.8	17.0	22.6	37.2	20.8	24.2	23.0	34.7	21.9	26.2	49.0	48.8	21.9	23.3	22.1	28.8	41.7	27.2	33.4	24.8	20.5	24.1	16.7	31.3	19.4	20.3	21.8	21.6	30.9	23.7	18.8	16.0	17.4	21.4	13.9	15.6	73.3	25.3	19.4	17.8	9.1	9.2	14.3	6.5	9.2	8.2	9.0	7.2	6.8	8.6	8.7	7.7	6.9	18.4	5.8	11.1	17.2	7.9	4.6	24.6	25.3	39.6	31.1	23.0	18.3	21.9	20.9	25.2	24.2	110.2	181.3	71.6	274.4	218.4	93.3	38.9	84.1	73.6	228.6	94.2	56.9	139.0	63.0	78.8	6.3	78.8	108.1	210.2	57.1	149.4	129.3	136.7	76.2	114.3	86.4	68.3	88.0	63.8	84.7	6.5	55.3	93.8	69.2	72.1	73.8	94.4	93.7	112.2	65.4	91.4	80.4	84.1	77.1	95.2	57.3	187.2	670.2	61.2	78.0	206.2
TOP1MT		ENSG00000184428	"DNA topoisomerase I mitochondrial"	Q969P6	8	143304384-143359979	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"DNA-binding, Isomerase, Topoisomerase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in all"		"MOLT-4: 58.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001915, HPA021542"	Approved		Supported	Mitochondria		NA	NA			Mitochondria		"HPA001915: AB_1080331, HPA021542: AB_1858186"	"unprognostic (5.02e-3)"	"unprognostic (3.79e-2)"	"unprognostic (6.57e-2)"	"unprognostic (6.92e-3)"	"unprognostic (2.32e-2)"	"unprognostic (1.04e-2)"	"unprognostic (3.05e-3)"	"unprognostic (1.44e-1)"	"unprognostic (1.44e-1)"	"unprognostic (1.13e-1)"	"unprognostic (1.50e-2)"	"unprognostic (4.42e-2)"	"prognostic unfavorable (1.52e-7)"	"unprognostic (3.66e-2)"	"unprognostic (3.62e-2)"	"unprognostic (8.55e-3)"	"unprognostic (5.66e-3)"	11.7	13.5	8.1	13.7	9.8	33.0	22.1	2.2	10.3	14.7	10.7	4.5	3.9	6.0	10.0	7.4	14.9	11.3	11.0	5.9	8.8	5.6	9.6	22.5	8.5	11.4	6.9	8.1	27.0	15.9	5.9	8.6	5.9	7.3	14.7	8.0	5.9	11.0	10.8	5.7	15.4	8.3	8.8	6.8	11.4	9.3	18.1	6.4	25.1	19.2	9.6	11.4	14.0	30.9	16.7	18.8	11.7	5.5	0.2	14.3	4.7	7.6	11.8	4.9	18.6	7.1	8.0	8.8	3.5	4.6	6.5	6.7	14.8	11.1	22.5	13.5	4.9	4.6	8.2	10.5	6.6	5.6	8.8	16.1	19.8	6.6	14.9	8.0	13.2	21.6	8.1	7.0	5.4	7.9	5.6	7.8	6.5	23.7	8.8	5.7	32.1	58.6	26.4	8.6	16.7	20.2	7.4	6.5	33.7	4.8	12.4	8.9	10.8	10.2	9.1	18.4	6.4	6.0	22.0	5.1	4.5	18.4	5.1	9.1	4.8	5.0	11.5	7.6	19.8	5.4	11.7	5.5	0.2	3.5	3.2	3.6	16.7	6.4	4.8	18.8	8.0	14.3	10.4	0.4	0.2	0.6	16.4	1.7	4.7	8.1	9.8	2.2	10.3	8.8	5.6	6.9	8.1	7.3	6.4	6.0	7.5	9.0	28.1	21.1	1.4	2.0	7.6	4.0	13.6	8.7	0.0	10.3	6.6	9.5	19.8	7.3	2.7	23.3	7.8	19.8	11.7	15.2	6.9	7.8	10.8	3.2	4.7	6.7	5.9	6.7	8.1	10.1	20.3	4.6	8.7	1.4	9.6	8.6	4.2	12.3	0.1	6.5	13.4	31.6	39.0	20.8	8.5	6.4	19.3	18.6
TOP2A	TOP2	ENSG00000131747	"DNA topoisomerase II alpha"	P11388	17	40388516-40417950	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Biological rhythms"	"DNA-binding, Isomerase, Topoisomerase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in many"	5	"lymphoid tissue: 146.3;testis: 36.8"	"Group enriched"	"Detected in many"	4	"Erythroid cells: 280.4;Spermatocytes: 527.8;Spermatogonia: 241.9"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"T-reg: 5.7"	"Low lineage specificity"	"Detected in many"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"CAB002448, HPA006458, HPA026773"	Enhanced	Approved	Supported	Nucleoplasm,Nucleoli		Yes	Yes			Nucleoplasm	Nucleoli	"CAB002448: AB_564035, HPA006458: AB_1858189, HPA026773: AB_1858190"	"unprognostic (2.09e-1)"	"unprognostic (1.24e-1)"	"unprognostic (2.28e-3)"	"unprognostic (9.42e-3)"	"unprognostic (1.80e-1)"	"unprognostic (1.52e-1)"	"prognostic unfavorable (5.92e-6)"	"prognostic unfavorable (4.99e-4)"	"unprognostic (6.21e-3)"	"unprognostic (2.09e-1)"	"prognostic unfavorable (3.83e-5)"	"unprognostic (5.03e-2)"	"prognostic unfavorable (0.00e+0)"	"unprognostic (7.46e-2)"	"unprognostic (1.07e-1)"	"unprognostic (2.18e-1)"	"unprognostic (2.29e-1)"	2.7	2.0	0.4	20.0	0.5	14.6	4.1	0.4	0.5	3.0	6.9	0.5	0.5	7.0	2.0	3.4	18.2	0.7	2.4	2.3	0.6	0.5	1.4	1.9	5.5	15.4	0.6	0.4	1.2	1.1	0.0	0.4	10.7	0.6	1.2	8.0	0.6	3.2	0.3	0.6	5.9	9.2	2.6	1.8	7.3	4.5	36.8	0.3	146.3	0.9	11.8	16.7	3.2	5.7	1.3	0.3	0.3	0.3	3.2	5.7	1.1	34.3	45.6	58.1	26.6	2.9	5.9	12.9	47.1	25.4	43.4	38.5	21.4	26.3	55.4	24.0	15.9	26.0	54.7	44.6	18.8	58.3	29.5	29.8	36.6	29.2	35.6	0.2	51.2	39.0	1.3	1.5	30.5	31.1	9.4	22.8	36.1	39.5	38.0	46.8	11.9	59.3	34.4	24.1	24.9	18.2	50.4	90.2	23.0	10.4	22.0	34.3	24.7	38.0	47.5	15.0	35.3	39.8	23.6	14.9	28.6	40.4	33.0	45.2	21.8	24.6	48.3	16.1	35.3	47.7	0.3	0.0	0.0	0.6	0.0	0.0	1.3	0.9	0.9	0.3	0.4	0.2	0.1	0.3	3.2	0.3	0.0	5.7	1.1	0.4	0.5	0.4	0.5	0.6	0.5	0.6	0.4	0.6	0.3	0.0	1.3	28.7	1.4	10.4	0.0	1.1	2.5	0.0	6.8	0.0	0.0	8.4	0.0	0.9	12.5	0.7	2.1	280.4	0.0	81.4	9.7	1.2	0.0	3.9	64.5	0.0	0.0	27.6	30.0	15.2	4.4	13.1	1.7	2.8	5.9	0.0	0.2	3.6	1.8	0.0	0.0	71.1	1.4	527.8	241.9	5.4	7.4	7.7	24.2	2.6
TOP2B		ENSG00000077097	"DNA topoisomerase II beta"	Q02880	3	25597905-25664907	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"DNA-binding, Isomerase, Topoisomerase"	"Autism spectrum disorder, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"REH: 106.6"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004601, HPA024120, HPA050441"	Supported		Enhanced	Nucleoplasm		NA	NA			Nucleoplasm		"CAB004601: AB_628384, HPA024120: AB_1858191, HPA050441: AB_2681127"	"unprognostic (2.90e-2)"	"unprognostic (5.17e-2)"	"unprognostic (7.21e-3)"	"unprognostic (2.42e-1)"	"unprognostic (1.60e-1)"	"unprognostic (1.43e-2)"	"prognostic unfavorable (1.86e-7)"	"unprognostic (7.86e-2)"	"unprognostic (1.89e-1)"	"unprognostic (2.84e-1)"	"unprognostic (7.14e-2)"	"unprognostic (1.08e-1)"	"prognostic favorable (2.43e-4)"	"unprognostic (1.01e-1)"	"unprognostic (1.59e-1)"	"unprognostic (1.49e-1)"	"unprognostic (7.93e-2)"	19.3	18.8	23.4	23.1	29.7	26.5	21.1	48.4	33.5	24.1	22.4	21.1	18.9	17.1	29.6	25.6	21.1	20.6	20.7	22.7	22.0	19.9	20.3	18.4	17.7	28.2	21.0	28.5	26.8	17.2	43.0	21.6	22.3	26.4	24.7	20.8	17.6	21.3	22.3	31.3	20.9	19.3	24.4	23.4	24.6	20.1	11.3	22.7	60.2	28.3	20.7	27.3	34.8	21.5	5.5	5.6	5.3	4.6	7.8	7.2	2.2	10.7	11.1	24.6	30.1	8.2	10.4	9.8	10.4	13.4	9.7	10.6	5.7	8.5	33.3	7.3	15.0	6.0	9.1	20.3	11.6	16.3	15.9	10.9	50.4	13.8	9.5	5.8	39.4	27.0	7.4	5.8	10.8	9.5	9.8	15.7	22.8	16.9	16.4	12.4	11.9	25.5	9.7	18.6	7.2	8.5	106.6	13.8	15.4	8.7	37.9	12.4	21.5	15.5	11.1	9.5	14.8	11.5	35.3	15.0	13.5	10.5	10.7	11.1	25.4	14.4	35.3	8.8	29.5	8.9	4.2	2.9	5.3	6.3	3.3	6.9	4.3	6.1	6.4	4.3	5.5	7.2	6.4	2.0	7.8	4.6	5.6	4.4	2.2	23.4	29.7	48.4	33.5	22.0	19.9	21.0	28.5	26.4	22.7	59.6	57.9	25.1	36.1	34.8	53.5	109.0	43.3	34.8	40.9	24.4	53.0	41.2	11.6	29.3	2.9	32.2	17.7	23.3	28.8	20.8	35.0	47.5	31.4	33.5	23.1	57.2	57.0	21.5	40.9	4.8	36.2	38.8	21.9	21.6	32.6	46.4	32.0	17.5	31.5	21.9	89.3	32.3	36.7	66.2	27.0	33.0	39.0	45.0	37.9	57.7
TPH1	"TPH, TPRH"	ENSG00000129167	"Tryptophan hydroxylase 1"	P17752	11	18017564-18042426	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Serotonin biosynthesis"	"Monooxygenase, Oxidoreductase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	6	"brain: 4.2;intestine: 16.2;pituitary gland: 5.4;stomach 1: 13.3"	"Cell type enriched"	"Detected in many"	164	"Intestinal endocrine cells: 1412.4"	"Low cancer specificity"	"Detected in some"			"Region enriched"	"Detected in single"	6	"cerebral cortex: 4.2"	"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HL-60: 4.5"	"Low region specificity"	"Detected in some"							"CAB010767, HPA022483"	Approved		Uncertain	Cytosol		NA	NA			Cytosol		"CAB010767: AB_261587, HPA022483: AB_1858378"	"unprognostic (2.14e-4)"	"unprognostic (9.97e-2)"	"unprognostic (6.92e-2)"	"unprognostic (6.78e-2)"	"unprognostic (1.55e-1)"	"unprognostic (6.26e-5)"	"unprognostic (1.73e-1)"	"unprognostic (5.33e-2)"	"unprognostic (1.60e-1)"	"unprognostic (2.12e-2)"	"unprognostic (1.19e-4)"	"unprognostic (6.72e-2)"	"unprognostic (5.40e-8)"	"unprognostic (3.76e-2)"	"unprognostic (7.42e-2)"	"unprognostic (3.10e-1)"	"unprognostic (2.46e-5)"	0.7	0.0	0.7	0.7	0.7	0.6	0.9	0.7	4.2	0.7	7.1	0.7	0.7	8.2	0.7	0.7	0.7	1.5	0.7	0.7	0.7	0.3	0.7	0.7	0.7	0.7	0.7	0.7	1.0	0.7	0.0	5.4	0.7	0.7	1.3	16.2	0.7	0.7	0.7	0.7	1.0	9.1	0.7	0.7	1.0	13.3	0.9	0.7	0.7	0.7	0.7	0.7	0.7	0.7	1.4	0.8	1.5	0.5	0.9	1.6	0.2	0.4	0.1	1.7	1.5	0.1	0.0	0.6	0.6	0.5	0.2	1.1	1.8	0.3	1.4	0.3	0.0	0.1	0.6	0.4	1.5	0.7	1.3	3.1	2.2	0.8	3.5	0.0	4.5	1.2	0.0	1.8	0.2	0.6	0.3	0.7	2.7	0.9	0.8	0.1	0.5	1.0	0.7	0.5	0.1	0.3	1.7	0.3	0.0	0.0	1.0	1.3	0.9	0.2	0.4	0.9	0.2	0.3	2.9	0.2	0.4	1.3	0.5	1.7	0.2	0.3	1.1	0.2	1.0	1.4	1.5	0.4	0.4	1.6	0.2	0.8	0.5	0.5	0.4	0.1	1.4	0.6	0.6	1.5	0.9	0.5	0.8	0.6	0.2	0.7	0.7	0.7	4.2	0.7	0.3	0.7	0.7	0.7	0.7	0.0	0.0	0.0	0.4	0.3	4.7	0.4	0.0	1.4	0.0	5.2	2.0	0.2	0.0	0.2	0.7	0.3	1.0	0.0	0.5	0.0	0.7	2.0	0.0	0.0	0.2	1.6	1412.4	0.0	0.0	0.4	0.9	0.9	0.0	0.0	2.8	1.5	0.4	8.6	1.1	0.2	6.0	6.5	1.0	2.7	3.4	1.3	0.0	0.5	1.7	0.0
TPH2	"FLJ37295, NTPH"	ENSG00000139287	"Tryptophan hydroxylase 2"	Q8IWU9	12	71938846-72186618	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"	"Serotonin biosynthesis"	"Monooxygenase, Oxidoreductase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	14	"brain: 46.2"	"Group enriched"	"Detected in some"	4	"Early spermatids: 5.6;Late spermatids: 4.5"	"Not detected"	"Not detected"			"Region enriched"	"Detected in many"	15	"pons and medulla: 46.2"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	8	"EFO-21: 2.9;NTERA-2: 3.1;SCLC-21H: 1.5;SuSa: 1.0"	"Group enriched"	"Detected in some"	32	"midbrain: 127.6;pons and medulla: 36.3"	"Group enriched"	"Detected in some"	10	"midbrain: 95.6;pons and medulla: 91.5"	CAB078198	Enhanced					NA	NA					"CAB078198: AB_2665804"	"unprognostic (1.19e-1)"	"unprognostic (6.01e-1)"		"unprognostic (3.46e-2)"	"unprognostic (2.31e-1)"				"unprognostic (5.91e-2)"	"unprognostic (2.02e-1)"	"unprognostic (5.01e-2)"			"unprognostic (7.32e-2)"	"unprognostic (1.34e-1)"			0.1	0.2	0.4	0.3	0.5	0.1	0.1	0.3	4.4	0.1	0.2	0.0	0.0	0.1	0.1	0.1	0.1	0.2	0.2	0.2	3.0	1.5	0.1	0.3	0.1	0.1	0.9	0.0	0.1	1.7	0.1	3.2	0.1	46.2	0.1	0.1	0.0	0.1	0.3	0.1	0.1	0.1	0.2	0.3	0.1	0.1	1.0	0.0	0.0	0.2	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	3.1	0.0	0.0	0.0	0.0	0.0	0.0	0.1	1.5	0.0	0.0	0.2	0.0	1.0	0.2	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.5	0.3	1.4	3.0	1.5	0.9	0.0	46.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	5.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	4.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.2	0.0	0.0	0.0	0.0	0.1
TPK1	"HTPK1, PP20"	ENSG00000196511	"Thiamin pyrophosphokinase 1"	Q9H3S4	7	144451941-144836395	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Kinase, Transferase"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 70.4;Late spermatids: 75.1"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in some"		"AN3-CA: 27.3;CACO-2: 6.5;EFO-21: 8.3;TIME: 6.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA021545, HPA021849"	Approved		Approved	Vesicles		NA	NA		78000	Vesicles		"HPA021545: AB_1858209, HPA021849: AB_1858210"	"unprognostic (4.05e-2)"	"unprognostic (3.28e-2)"	"unprognostic (2.38e-2)"	"unprognostic (3.32e-2)"	"unprognostic (2.42e-1)"	"unprognostic (1.63e-1)"	"unprognostic (7.62e-2)"	"unprognostic (6.08e-2)"	"unprognostic (2.37e-1)"	"unprognostic (1.68e-1)"	"unprognostic (3.76e-2)"	"unprognostic (6.06e-2)"	"unprognostic (1.45e-3)"	"unprognostic (3.15e-1)"	"unprognostic (2.87e-1)"	"unprognostic (1.59e-1)"	"unprognostic (9.22e-3)"	12.2	7.4	5.1	9.6	4.7	3.6	7.6	4.0	7.2	4.3	8.4	4.2	2.4	18.2	5.1	5.0	3.3	3.9	5.4	6.4	5.6	6.6	6.0	6.2	8.8	23.3	4.9	3.1	4.4	3.3	3.6	4.6	7.0	4.4	3.7	8.5	8.9	7.1	4.1	3.0	2.9	13.9	5.1	6.0	15.1	4.0	5.9	2.0	5.1	4.9	4.1	14.2	5.5	3.3	5.4	9.6	3.4	7.4	4.0	5.5	3.8	0.2	0.2	0.3	27.3	0.2	0.2	2.2	0.1	0.1	0.0	0.0	6.5	1.1	0.4	8.3	0.4	0.5	0.0	0.5	0.3	0.2	1.6	0.4	0.1	0.1	0.1	0.7	2.0	0.6	0.5	0.5	0.3	0.4	0.7	5.2	1.0	0.5	1.2	0.1	0.8	0.6	3.0	0.7	0.8	2.3	0.2	0.6	0.9	4.2	2.4	0.2	0.0	0.4	0.0	0.5	0.5	0.3	3.9	6.2	0.3	0.7	0.5	0.3	0.6	1.5	0.6	0.9	5.2	0.2	0.3	7.3	0.2	3.9	5.3	4.0	5.0	4.4	3.5	9.6	5.4	5.2	4.2	3.4	4.0	7.4	2.3	5.5	3.8	5.1	4.7	4.0	7.2	5.6	6.6	4.9	3.1	4.4	2.0	8.9	3.2	15.9	2.3	2.1	3.2	4.5	10.2	2.7	0.0	3.5	7.9	35.1	16.6	4.2	70.4	7.7	15.5	0.0	5.7	11.9	5.3	2.4	7.0	3.9	14.8	1.6	1.2	6.7	13.9	75.1	4.6	16.2	8.5	7.2	4.3	2.4	6.9	7.4	1.1	6.9	4.5	0.0	3.4	7.9	11.8	1.5	26.8	6.4	6.3	3.6
TPMT		ENSG00000137364	"Thiopurine S-methyltransferase"	P51580	6	18128311-18155074	"Enzymes, FDA approved drug targets, Predicted intracellular proteins"		"Methyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"thyroid gland: 48.2"	"Cell type enhanced"	"Detected in many"	8	"Proximal tubular cells: 230.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA019851, HPA062364"	Enhanced					NA	NA					"HPA019851: AB_1858213, HPA062364: "	"unprognostic (6.24e-2)"	"unprognostic (3.16e-2)"	"unprognostic (5.46e-3)"	"prognostic unfavorable (8.45e-5)"	"unprognostic (4.98e-2)"	"unprognostic (2.25e-1)"	"unprognostic (8.16e-2)"	"unprognostic (4.36e-3)"	"unprognostic (9.62e-2)"	"prognostic favorable (1.41e-4)"	"unprognostic (4.49e-2)"	"unprognostic (3.40e-2)"	"prognostic favorable (1.10e-4)"	"unprognostic (7.56e-2)"	"unprognostic (1.31e-1)"	"unprognostic (1.07e-1)"	"unprognostic (8.39e-3)"	5.3	13.2	11.5	6.6	10.2	4.9	5.6	13.1	14.3	4.6	18.2	4.1	6.2	18.4	6.5	10.1	8.9	4.1	7.6	6.5	9.0	8.0	40.2	36.2	6.5	6.2	9.3	7.5	3.8	9.4	12.9	11.6	3.3	8.5	6.2	19.4	6.9	12.9	7.2	7.0	5.7	29.4	6.2	7.2	9.4	6.6	4.1	7.5	5.4	48.2	6.3	5.3	6.4	5.6	1.6	16.9	3.7	23.8	5.4	8.3	8.3	11.9	3.6	4.1	10.0	6.7	13.1	10.0	13.9	15.5	11.9	18.6	8.4	3.0	1.5	10.4	18.3	9.2	6.0	5.7	10.0	19.9	7.9	8.2	9.9	6.2	12.3	7.4	4.5	8.9	7.5	10.8	13.3	8.5	7.8	16.5	6.8	19.5	2.9	8.6	5.5	4.6	6.2	6.7	16.6	10.5	5.8	10.0	6.7	13.8	12.3	6.6	5.1	9.1	16.2	17.8	10.6	11.7	4.5	7.0	27.4	5.3	14.3	19.7	4.1	18.5	3.9	9.8	6.2	27.4	3.4	12.0	3.7	6.5	23.8	8.3	1.5	5.3	6.2	16.9	1.6	4.8	6.5	1.2	5.4	19.6	3.7	8.2	8.3	11.5	10.2	13.1	14.3	9.0	8.0	9.3	7.5	8.5	7.5	14.9	13.3	18.0	32.1	37.9	15.1	15.4	22.9	4.0	6.8	33.2	21.6	17.3	97.8	34.1	1.2	11.7	80.0	0.0	32.7	21.7	11.7	34.2	23.0	79.7	40.7	6.4	23.1	12.3	34.5	1.5	3.7	56.7	23.6	19.8	31.8	22.9	51.4	78.6	9.6	230.3	16.8	0.0	14.7	0.4	8.1	30.2	14.6	23.5	36.6	71.2
TPO	TPX	ENSG00000115705	"Thyroid peroxidase"	P07202	2	1374223-1543711	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"	"Hydrogen peroxide, Thyroid hormones biosynthesis"	"Oxidoreductase, Peroxidase"	"Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	58	"thyroid gland: 411.3"	"Group enriched"	"Detected in some"	5	"Cardiomyocytes: 2.2;Early spermatids: 3.0;Endothelial cells: 1.1;Late spermatids: 3.8;Peritubular cells: 3.5"	"Cancer enriched"	"Detected in some"	364	"thyroid cancer: 188.3"	"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	13	"memory CD4 T-cell: 5.1;T-reg: 3.0"	"Lineage enriched"	"Detected in single"	21	"T-cells: 5.1"	"Group enriched"	"Detected in some"	5	"Karpas-707: 14.3;RPMI-8226: 6.0"	"Low region specificity"	"Detected in single"			"Not detected"	"Not detected"			"HPA007987, CAB009587"	Enhanced				"Intracellular and membrane"	NA	NA					"CAB009587: , HPA007987: AB_1080270"	"unprognostic (1.55e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.88e-1)"	"unprognostic (1.77e-2)"	"unprognostic (3.56e-2)"	"unprognostic (9.11e-2)"	"unprognostic (2.24e-2)"	"unprognostic (1.85e-1)"	"unprognostic (1.32e-1)"	"unprognostic (1.19e-4)"	"unprognostic (2.61e-2)"	"unprognostic (3.29e-1)"	"unprognostic (5.44e-4)"	"unprognostic (1.21e-1)"	"unprognostic (3.73e-2)"	"unprognostic (4.98e-3)"	"unprognostic (7.10e-3)"	1.1	0.0	0.1	0.1	0.1	0.0	0.9	0.1	0.1	0.1	0.3	0.1	0.1	0.0	0.1	0.1	0.1	0.0	0.4	1.0	0.1	0.0	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	1.2	0.1	0.5	0.0	0.2	0.1	0.1	7.1	0.2	0.1	0.1	0.1	411.3	0.1	0.1	0.1	0.1	0.1	0.0	0.2	0.0	0.0	5.1	0.9	0.1	0.1	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.1	0.0	0.0	0.4	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	14.3	0.0	1.4	0.0	0.0	0.1	0.0	0.2	0.0	0.0	6.0	0.0	0.0	0.0	0.1	0.0	2.1	0.0	0.1	1.1	0.0	0.1	0.1	0.0	0.1	0.0	0.1	0.3	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.1	5.1	0.3	0.0	0.1	0.0	0.3	0.2	0.0	0.0	0.0	3.0	0.9	0.1	0.1	0.1	0.1	0.1	0.0	0.1	0.1	0.1	0.1	0.0	0.0	0.0	0.0	0.0	0.0	2.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.0	1.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.8	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0
TRHR		ENSG00000174417	"Thyrotropin releasing hormone receptor"	P34981	8	109086621-109119584	"FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters"		"G-protein coupled receptor, Receptor, Transducer"	"Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	5	"brain: 1.0;pituitary gland: 3.3;thyroid gland: 1.6"	"Not detected"	"Not detected"			"Not detected"	"Not detected"							"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enhanced"	"Detected in some"		"PC-3: 1.6;SH-SY5Y: 1.5"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			HPA055162	Approved					NA	NA					"HPA055162: AB_2732592"										"unprognostic (1.92e-2)"				"unprognostic (8.58e-2)"		"unprognostic (1.17e-1)"		0.0	0.0	0.1	0.4	0.1	0.0	0.0	0.0	1.0	0.0	0.2			0.3	0.0	0.0	0.0	0.0	0.0	0.3	0.2	0.3	0.0	0.0	0.0	0.0	0.0		0.0	0.0	0.0	3.3	0.0		0.0	0.3		0.2	0.0	0.2	0.0	0.1	0.0	0.0	0.0	0.0	0.0			1.6		0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.4	0.1	0.0	0.0	0.2	0.0	0.0	0.0	0.2	0.0	0.3	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.4	0.0	0.0	0.1	0.0	0.0	1.6	0.0	0.4	0.0	0.0	0.0	0.0	1.5	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.2	0.3	0.2	0.3	0.6	0.2	0.0	0.5	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0											0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
TRPA1	ANKTM1	ENSG00000104321	"Transient receptor potential cation channel subfamily A member 1"	O75762	8	72019917-72075617	"Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Ion transport, Sensory transduction, Transport"	"Ion channel"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"intestine: 20.8;urinary bladder: 20.1;vagina: 12.1"	"Group enriched"	"Detected in some"	10	"Early spermatids: 6.4;Mucus-secreting cells: 5.9"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in some"		"memory CD8 T-cell: 2.6"	"Low lineage specificity"	"Detected in many"			"Cell line enriched"	"Detected in some"	5	"HHSteC: 24.5"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"									NA	NA						"unprognostic (2.14e-2)"	"unprognostic (2.50e-2)"	"prognostic favorable (6.57e-4)"	"unprognostic (1.28e-2)"	"unprognostic (2.34e-1)"	"unprognostic (1.95e-1)"	"unprognostic (1.37e-2)"	"unprognostic (8.11e-3)"	"unprognostic (4.22e-2)"	"unprognostic (2.47e-1)"	"unprognostic (2.78e-3)"	"unprognostic (1.49e-1)"	"unprognostic (2.16e-4)"	"unprognostic (2.37e-1)"	"unprognostic (9.67e-2)"	"unprognostic (1.57e-1)"	"unprognostic (2.90e-1)"	0.3	0.2	0.2	9.1	0.2	0.0	0.2	0.2	0.4	0.4	16.8	0.3	0.0	4.8	0.2	0.3	2.2	0.2	5.7	0.3	0.2	0.2	0.2	0.2	0.3	0.8	0.3	0.0	0.4	0.2	0.0	0.2	0.3	0.1	4.7	7.5	0.0	0.2	0.0	0.2	0.2	20.8	3.8	0.2	0.4	7.9	0.4	0.0	0.6	0.2	0.3	1.4	20.1	12.1	0.5	0.6	0.1	1.1	0.3	2.6	0.2	0.0	2.5	0.7	0.0	0.0	0.1	0.0	0.3	2.3	0.2	0.3	0.0	0.0	0.0	0.0	0.0	0.9	0.0	0.0	1.8	0.4	1.4	0.1	0.0	0.5	0.0	24.5	0.0	0.2	1.6	0.0	1.1	0.2	5.1	0.0	0.0	0.0	0.0	2.9	0.0	0.0	0.1	0.5	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.1	0.1	0.4	0.0	2.4	0.2	0.0	0.3	0.0	0.1	3.8	1.1	0.0	0.3	0.3	0.0	1.8	0.0	1.7	0.0	0.0	0.0	0.3	0.0	1.1	0.5	0.5	2.6	0.0	0.5	0.0	0.4	0.1	0.3	1.1	0.6	1.0	0.2	0.2	0.2	0.2	0.4	0.2	0.2	0.3	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	6.4	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	5.9	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.0	0.0
TRPM8		ENSG00000144481	"Transient receptor potential cation channel subfamily M member 8"	Q7Z2W7	2	233917398-234019522	"FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels"	"Ion transport, Sensory transduction, Transport"	"Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Group enriched"	"Detected in some"	9	"liver: 16.7;prostate: 44.1"	"Group enriched"	"Detected in some"	7	"Glandular cells: 24.4;Hepatocytes: 42.4"	"Cancer enriched"	"Detected in some"	27	"prostate cancer: 72.4"	"Not detected"	"Not detected"			"Cell type enhanced"	"Detected in single"		"NK-cell: 3.0"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"GAMG: 4.4;Karpas-707: 7.1;RPTEC TERT1: 10.7;SK-MEL-30: 10.7;WM-115: 6.5"	"Region enhanced"	"Detected in single"		"cerebellum: 0.8"	"Low region specificity"	"Detected in many"									NA	NA						"unprognostic (4.41e-3)"	"unprognostic (7.91e-2)"	"unprognostic (1.11e-1)"	"unprognostic (5.49e-3)"	"unprognostic (1.05e-1)"	"unprognostic (4.60e-3)"	"prognostic favorable (7.15e-4)"	"unprognostic (3.28e-2)"	"unprognostic (3.71e-1)"	"unprognostic (9.88e-3)"	"unprognostic (7.10e-3)"	"unprognostic (4.69e-2)"	"unprognostic (3.36e-5)"	"unprognostic (1.11e-1)"	"unprognostic (1.65e-1)"	"unprognostic (1.18e-1)"	"unprognostic (5.53e-2)"	3.3	0.0	0.0	0.0	0.6	0.0	0.0	0.0	0.4	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.1	16.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.7	44.1	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.8	0.0	0.0	0.6	0.9	0.0	0.0	0.0	0.0	0.0	0.0	0.4	0.2	0.9	0.2	3.0	0.3	0.0	0.0	0.7	0.1	0.1	0.0	0.0	1.5	0.0	0.0	0.0	0.3	0.1	0.2	0.0	0.0	0.0	4.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.1	0.0	0.1	0.0	0.0	0.0	7.1	0.1	0.0	0.0	1.2	0.2	0.0	0.0	0.0	0.6	0.7	10.7	0.0	0.7	0.4	0.0	0.1	10.7	0.0	0.4	0.7	0.0	0.0	0.1	0.3	0.1	1.6	2.5	0.0	0.9	0.0	6.5	0.5	0.2	0.1	0.3	0.1	0.2	0.2	0.3	0.2	0.0	0.4	0.3	0.3	0.9	3.0	0.1	0.2	0.1	0.0	0.0	0.6	0.0	0.4	0.0	0.1	0.0	0.0	0.7	0.9	0.0	0.0	0.0	5.0	0.3	0.7	0.8	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	1.7	0.0	0.0	0.0	1.6	0.0	0.0	24.4	0.0	42.4	0.2	0.0	0.0	1.3	0.6	2.3	0.0	0.0	0.0	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.2	0.0	0.3	1.1	0.4	0.1	0.0	0.0	0.0	2.5
TRPV1	VR1	ENSG00000196689	"Transient receptor potential cation channel subfamily V member 1"	Q8NER1	17	3565444-3609411	"FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Calmodulin-binding, Ion channel"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in many"		"liver: 11.7"	"Cell type enhanced"	"Detected in many"	12	"Cone photoreceptor cells: 15.7;Rod photoreceptor cells: 25.1"	"Not detected"	"Not detected"							"Low cell type specificity"	"Detected in some"			"Low lineage specificity"	"Detected in many"			"Cell line enhanced"	"Detected in many"		"HaCaT: 13.2"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in single"									NA	NA						"unprognostic (3.96e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.18e-1)"	"unprognostic (1.33e-2)"	"unprognostic (6.83e-2)"	"unprognostic (3.21e-4)"	"unprognostic (9.90e-2)"	"unprognostic (2.95e-1)"	"unprognostic (2.03e-1)"	"unprognostic (2.56e-2)"	"unprognostic (3.43e-3)"	"unprognostic (6.17e-3)"	"unprognostic (6.97e-4)"	"unprognostic (4.25e-1)"	"unprognostic (4.78e-1)"	"unprognostic (3.81e-2)"	"unprognostic (5.12e-3)"	1.4	1.2	3.5	0.7	2.9	0.3	1.7	2.7	2.1	2.1	1.4			6.5	2.3	1.5	0.8	2.8	1.1	1.9	3.2	3.6	2.5	11.7	0.7	1.3	4.7		5.1	2.5	1.0	2.0	1.2		1.5	1.7		2.1	1.0	2.8	4.7	5.1	0.9	2.3	1.2	2.2	1.2			1.3		0.8	1.2	1.1	1.1	1.4	1.5	0.8	0.5	2.2	0.3	3.0	5.6	4.5	5.0	4.9	4.7	4.1	1.7	2.4	2.6	2.4	1.4	1.7	1.2	2.3	1.8	1.8	13.2	2.8	0.9	1.9	7.3	6.7	0.7	2.9	5.6	2.2	0.4	5.7	5.6	3.0	3.8	1.5	2.5	0.5	2.9	0.3	2.2	1.5	3.8	2.1	1.0	3.0	0.6	2.7	6.2	2.9	0.9	2.2	2.7	1.9	4.2	2.3	4.4	2.2	3.5	8.3	2.3	1.7	1.1	2.7	4.5	2.2	1.9	1.3	0.5	1.9	2.4	2.4	0.9	0.8	1.5	0.7	0.2	0.9	0.4	0.6	0.2	0.1	1.1	0.8	2.2	1.5	0.5	0.3	1.4	0.2	0.3											0.0	1.6	0.0	0.4	0.0	8.6	0.2	2.5	4.0	2.3	5.2	15.7	1.0	0.0	0.4	1.8	0.0	2.6	0.0	0.6	0.3	0.4	0.6	0.0	6.4	0.7	6.4	1.2	2.5	0.6	0.2	4.4	1.2	0.0	0.0	1.5	2.8	0.4	0.0	3.5	1.4	25.1	0.0	0.1	0.7	0.7	0.0	0.7	0.0	2.2	0.3
TRPV3	VRL3	ENSG00000167723	"Transient receptor potential cation channel subfamily V member 3"	Q8NET8	17	3510502-3557995	"Disease related genes, FDA approved drug targets, Predicted membrane proteins"	"Calcium transport, Ion transport, Transport"	"Calcium channel, Ion channel"	"Disease mutation, FDA approved drug targets, Palmoplantar keratoderma"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"		"Tissue enhanced"	"Detected in some"		"intestine: 15.4;skeletal muscle: 29.1"	"Cell type enhanced"	"Detected in many"	10	"Basal keratinocytes: 16.7;Enterocytes: 10.8;Suprabasal keratinocytes: 21.5"	"Low cancer specificity"	"Detected in some"			"Region enhanced"	"Detected in some"		"basal ganglia: 2.4"	"Cell type enhanced"	"Detected in some"		"basophil: 2.9"	"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"A-431: 3.6;BEWO: 5.4;CACO-2: 4.3;RH-30: 13.3;T-47d: 5.6;U-266/70: 3.5"	"Low region specificity"	"Detected in some"			"Region enriched"	"Detected in many"	6	"cerebellum: 14.0"	HPA069550			Approved	"Plasma membrane,Centrosome,Cytosol"		NA	NA			"Plasma membrane"	"Centrosome, Cytosol"	"HPA069550: AB_2686149"	"unprognostic (1.84e-4)"	"unprognostic (2.25e-1)"	"unprognostic (5.22e-2)"	"unprognostic (3.92e-4)"	"unprognostic (4.87e-3)"	"unprognostic (2.96e-2)"	"unprognostic (6.66e-2)"	"unprognostic (4.88e-2)"	"unprognostic (7.02e-2)"	"unprognostic (2.68e-1)"	"unprognostic (4.88e-2)"	"unprognostic (3.69e-2)"	"unprognostic (0.00e+0)"	"unprognostic (1.12e-1)"	"unprognostic (1.77e-1)"	"unprognostic (8.64e-2)"	"unprognostic (2.93e-2)"	0.4	0.2	0.4	3.2	2.4	0.9	4.1	0.3	1.2	0.6	10.6	0.1	0.3	3.2	0.2	0.2	2.3	0.3	0.8	0.3	0.4	0.3	0.2	1.1	0.3	0.5	0.4	0.2	0.3	0.9	0.0	0.7	0.4	0.0	0.2	2.9	0.3	0.5	0.4	29.1	8.4	15.4	0.5	0.5	0.4	1.6	0.8	0.0	0.0	0.2	9.7	3.0	0.7	2.1	0.7	0.6	2.9	0.6	0.6	0.7	0.1	3.6	0.0	0.5	0.1	0.3	0.6	5.4	0.2	0.0	0.0	0.0	4.3	1.0	0.2	1.1	0.1	0.1	0.4	0.0	0.1	0.0	0.1	0.1	0.0	0.4	0.6	0.1	0.2	0.8	0.3	0.0	0.7	1.8	0.0	0.0	0.0	0.1	0.1	0.0	0.7	0.1	0.2	0.1	0.3	0.5	0.1	13.3	0.2	0.0	0.2	0.1	0.0	0.2	0.6	0.0	0.0	5.6	0.2	0.1	0.1	0.2	0.1	0.1	3.5	2.8	0.0	0.1	0.1	0.0	2.9	0.4	0.4	0.7	0.2	0.5	0.7	0.4	0.7	0.1	0.5	0.4	0.6	1.0	0.6	0.6	0.6	0.2	0.1	0.4	2.4	0.3	1.2	0.4	0.3	0.4	0.2	0.0	0.0	0.0	4.5	1.4	4.0	16.7	0.8	2.4	2.5	0.0	0.0	0.0	0.0	0.3	1.7	0.0	0.2	1.6	10.8	0.0	0.0	0.7	4.3	2.9	0.0	0.4	0.2	4.8	0.0	0.0	0.0	0.0	2.8	2.2	6.8	0.0	0.7	2.0	0.8	0.8	3.2	0.8	0.9	0.0	0.9	0.0	1.1	21.5	0.5	2.1	0.6	2.2
TSHR	LGR3	ENSG00000165409	"Thyroid stimulating hormone receptor"	P16473	14	80954989-81146302	"Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins"		"G-protein coupled receptor, Receptor, Transducer"	"Cancer-related genes, Congenital hypothyroidism, Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in some"	6	"thyroid gland: 158.0"	"Cell type enhanced"	"Detected in some"	15	"Club cells: 2.3;Intestinal endocrine cells: 1.7"	"Cancer enriched"	"Detected in some"	116	"thyroid cancer: 100.4"	"Not detected"	"Not detected"			"Cell type enriched"	"Detected in some"	5	"T-reg: 9.9"	"Lineage enriched"	"Detected in many"	5	"T-cells: 9.9"	"Cell line enhanced"	"Detected in some"		"JURKAT: 34.0;MOLT-4: 13.3;SCLC-21H: 13.7;U-266/70: 6.7"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			CAB000473	Approved				"Intracellular and membrane"	NA	NA					"CAB000473: AB_2303782"	"unprognostic (3.36e-3)"	"unprognostic (1.31e-3)"	"unprognostic (1.02e-2)"	"unprognostic (4.17e-6)"	"unprognostic (3.01e-3)"	"unprognostic (1.85e-3)"	"unprognostic (1.83e-1)"	"unprognostic (2.66e-2)"	"unprognostic (3.39e-2)"	"unprognostic (2.60e-2)"	"unprognostic (1.70e-1)"	"unprognostic (7.11e-3)"	"unprognostic (5.08e-7)"	"unprognostic (1.32e-1)"	"unprognostic (7.40e-2)"	"unprognostic (1.19e-1)"	"unprognostic (1.66e-1)"	0.1	0.2	0.1	0.2	0.4	0.3	0.2	0.1	0.3	0.1	0.1	0.0	0.0	0.0	0.1	0.1	0.0	0.3	0.1	0.1	0.1	0.1	0.1	0.2	0.1	0.4	0.1	0.0	0.1	0.1	0.1	0.3	0.3	0.5	0.1	0.0	0.8	0.2	0.0	0.1	0.3	0.1	0.0	0.2	0.2	0.1	0.1	0.1	27.3	158.0	0.2	0.4	0.1	0.1	1.8	0.8	1.3	0.3	0.1	9.9	0.1	0.2	0.1	0.4	0.3	0.0	0.0	0.2	0.1	0.0	0.0	0.1	0.2	0.3	0.4	0.1	0.1	0.2	0.1	0.5	0.0	0.1	0.2	0.1	0.2	0.4	0.2	0.0	0.1	0.2	0.2	0.0	0.1	0.2	0.1	0.0	34.0	0.2	0.4	0.1	0.3	13.3	0.3	0.3	0.1	0.1	0.5	0.1	0.5	0.0	0.3	13.7	0.2	0.1	0.1	0.1	0.3	0.2	0.0	0.1	0.4	0.3	0.3	0.2	6.7	3.5	0.3	0.2	0.1	0.2	0.6	0.2	0.2	0.2	0.1	0.2	1.0	0.8	0.5	0.1	1.8	0.3	0.2	1.3	0.1	0.3	0.8	9.9	0.1	0.1	0.4	0.1	0.1	0.1	0.1	0.1	0.0	0.5	0.1	0.0	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	2.3	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	1.7	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.5	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.0	0.0
TSPO	"BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS"	ENSG00000100300	"Translocator protein"	"B1AH88, P30536"	22	43151514-43163242	"Cancer-related genes, FDA approved drug targets, Predicted membrane proteins"	"Lipid transport, Transport"	Receptor	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"blood: 139.5"	"Low cell type specificity"	"Detected in all"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"RPMI-8226: 81.4"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"CAB011232, HPA046260, HPA072304"	Uncertain		Supported	Vesicles,Mitochondria,Cytosol		NA	NA			Mitochondria	"Vesicles, Cytosol"	"CAB011232: , HPA046260: , HPA072304: "	"unprognostic (5.29e-3)"	"unprognostic (1.41e-1)"	"unprognostic (3.31e-1)"	"unprognostic (4.02e-3)"	"unprognostic (3.95e-1)"	"unprognostic (1.46e-2)"	"prognostic unfavorable (1.61e-4)"	"unprognostic (2.16e-1)"	"unprognostic (1.17e-1)"	"unprognostic (3.75e-2)"	"unprognostic (1.07e-2)"	"unprognostic (1.33e-1)"	"unprognostic (1.69e-1)"	"unprognostic (1.53e-2)"	"unprognostic (3.03e-1)"	"unprognostic (1.04e-1)"	"unprognostic (2.34e-3)"	33.9	21.2	9.8	17.8	11.0	117.3	48.7	2.7	8.1	24.9	23.9	12.3	10.3	20.5	12.3	13.6	83.2	14.3	36.8	32.1	8.0	5.4	18.0	22.0	39.8	40.0	15.4	5.2	13.3	13.2	4.0	6.7	15.5	9.7	23.1	9.7	16.4	34.6	9.2	13.2	46.6	23.0	12.7	11.4	27.2	39.0	10.5	10.0	9.4	17.9	44.3	50.0	19.1	41.3	22.9	99.9	91.4	139.5	28.5	43.8	104.8	47.6	23.6	1.6	22.4	9.0	29.9	1.8	35.6	17.4	17.9	19.1	4.6	36.5	0.0	24.7	27.6	8.8	39.5	4.5	27.6	2.3	7.9	18.6	4.8	25.9	1.6	32.7	10.8	24.4	23.2	45.5	10.6	9.5	21.1	42.4	0.0	3.9	9.0	18.3	39.9	0.1	30.2	1.9	24.6	59.0	10.7	0.0	81.4	22.9	28.8	2.3	11.0	16.9	33.8	41.5	0.0	12.7	42.0	43.7	22.3	16.7	22.7	14.9	3.6	0.6	0.4	28.9	35.1	28.5	43.8	139.5	75.3	28.4	86.3	22.2	16.3	39.5	27.8	99.9	22.9	30.4	24.5	91.4	28.5	57.1	17.7	43.8	104.8	9.8	11.0	2.7	8.1	8.0	5.4	15.4	5.2	9.7	10.0	148.9	135.1	105.0	344.2	325.8	2.2	79.7	336.3	127.2	167.2	195.4	2.0	9.0	313.4	570.0	2.1	215.5	499.4	46.7	512.5	126.3	307.4	297.1	261.1	99.0	745.0	3.2	187.3	163.2	688.0	6.1	76.5	573.3	686.7	477.9	485.1	116.9	963.2	644.9	148.2	97.5	17.1	103.5	217.3	1.1	4.9	468.6	16.7	155.6	529.3	666.0
TUBA1A	"B-ALPHA-1, FLJ25113, TUBA3"	ENSG00000167552	"Tubulin alpha 1a"	Q71U36	12	49184796-49189324	"Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted intracellular proteins"			"Cancer-related genes, Disease mutation, FDA approved drug targets, Lissencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 270.7;smooth muscle: 166.4"	"Cell type enhanced"	"Detected in many"	5	"Ciliated cells: 819.1;Ductal cells: 1030.6;monocytes: 926.1"	"Cancer enriched"	"Detected in all"	9	"glioma: 942.8"	"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"		"neutrophil: 151.2"	"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"AF22: 226.7;SCLC-21H: 152.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB008686, HPA039247, HPA043684, HPA063394"	Enhanced		Enhanced	Microtubules		NA	NA			Microtubules		"CAB008686: AB_1624202, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003"	"unprognostic (3.11e-1)"	"unprognostic (1.61e-1)"	"unprognostic (3.77e-1)"	"unprognostic (1.14e-1)"	"unprognostic (4.73e-1)"	"unprognostic (1.15e-2)"	"unprognostic (2.56e-2)"	"unprognostic (2.12e-1)"	"unprognostic (3.49e-2)"	"unprognostic (3.80e-1)"	"unprognostic (1.11e-3)"	"unprognostic (9.79e-2)"	"prognostic unfavorable (2.90e-4)"	"unprognostic (1.07e-2)"	"unprognostic (4.27e-2)"	"unprognostic (1.12e-2)"	"unprognostic (1.27e-3)"	27.8	25.5	82.1	29.4	81.3	24.7	35.4	63.2	163.0	40.6	48.8	210.9	6.9	9.9	71.7	34.8	27.7	65.3	37.9	26.3	99.3	118.3	10.3	4.2	39.8	13.4	131.0	50.2	35.7	9.9	16.0	20.6	23.1	165.2	35.1	26.7	16.7	13.6	53.4	5.9	20.0	14.5	166.4	270.7	11.6	18.3	15.7	50.4	19.4	7.4	7.3	10.6	35.1	14.5	14.8	28.9	151.2	69.2	7.5	15.7	38.4	0.2	10.2	226.7	32.2	20.6	49.9	0.8	19.1	24.5	12.6	29.3	0.6	4.1	8.1	23.8	61.7	23.2	0.4	26.9	6.9	9.8	6.7	9.2	2.7	2.1	2.3	4.0	4.8	0.2	28.1	2.7	24.7	2.5	47.4	74.4	17.7	3.1	9.2	67.2	4.5	20.5	3.9	23.9	0.3	7.6	16.5	16.2	1.0	56.1	0.9	152.7	83.6	5.3	0.4	7.2	37.0	16.1	6.5	63.3	13.5	8.5	1.6	5.5	3.1	8.9	16.2	7.3	7.9	13.4	38.8	23.0	73.1	15.7	48.9	11.5	14.8	13.9	14.3	28.9	14.6	13.6	12.5	151.2	7.5	69.2	9.3	15.2	38.4	82.1	81.3	63.2	126.2	99.3	118.3	131.0	50.2	165.2	50.4	214.4	242.9	85.9	170.9	77.4	225.2	156.6	25.5	819.1	121.7	61.1	72.6	8.0	21.6	1030.6	8.3	170.4	2.2	0.0	13.8	13.6	257.4	39.2	532.6	1.0	383.6	235.2	754.8	152.9	63.0	14.2	179.2	227.9	173.7	926.1	14.3	698.4	320.1	4.2	134.0	28.1	331.3	161.7	313.6	10.0	11.3	86.8	13.3	132.0	9.6	82.6
TUBA4A	"FLJ30169, H2-ALPHA, TUBA1"	ENSG00000127824	"Tubulin alpha 4a"	P68366	2	219249711-219278170	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Amyotrophic lateral sclerosis, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"skeletal muscle: 124.1"	"Cell type enhanced"	"Detected in many"	8	"Early spermatids: 416.2;Late spermatids: 672.1;Pancreatic endocrine cells: 390.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 79.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004621, CAB005887, HPA039247, HPA043684, HPA063394"	Approved		Enhanced	Microtubules		NA	NA		500000000	Microtubules		"CAB004621: AB_628411, CAB005887: AB_2288001, HPA039247: AB_2676410, HPA043684: AB_2678617, HPA063394: AB_2685003"	"unprognostic (8.08e-2)"	"unprognostic (2.31e-1)"	"unprognostic (4.03e-2)"	"unprognostic (2.56e-2)"	"unprognostic (5.18e-3)"	"unprognostic (3.99e-2)"	"prognostic unfavorable (4.54e-6)"	"unprognostic (1.52e-3)"	"unprognostic (4.47e-1)"	"unprognostic (8.85e-2)"	"unprognostic (1.49e-2)"	"unprognostic (5.27e-2)"	"unprognostic (1.94e-1)"	"unprognostic (2.70e-1)"	"unprognostic (2.36e-1)"	"unprognostic (7.38e-3)"	"unprognostic (9.32e-2)"	5.0	9.4	22.4	13.4	30.5	37.7	7.5	23.2	63.3	7.4	13.8	4.5	5.2	8.1	3.4	5.2	27.1	6.1	6.1	23.5	24.9	23.6	13.2	10.5	7.2	20.9	20.4	21.9	6.1	8.0	18.1	6.5	2.9	43.1	7.9	12.4	5.7	15.6	10.7	124.1	63.5	9.5	6.2	6.2	15.7	10.1	8.2	3.3	6.2	3.7	34.8	25.0	9.1	13.9	25.8	4.2	66.8	13.0	14.8	32.0	49.2	19.2	16.1	0.0	0.0	1.7	1.3	0.0	2.9	9.4	0.5	0.3	3.6	20.2	25.4	33.0	2.0	31.9	48.8	9.0	79.7	0.7	14.7	0.1	31.8	30.0	2.6	1.4	10.6	11.5	1.2	29.6	4.3	9.4	5.1	3.3	0.4	3.6	17.4	19.1	0.7	0.0	19.1	6.2	15.1	19.2	1.1	26.2	15.5	24.5	1.4	16.3	0.2	37.9	3.3	0.1	0.3	1.4	9.0	2.2	9.6	5.1	11.1	10.3	7.1	8.6	30.6	35.2	20.2	0.4	22.1	12.5	32.4	22.5	8.6	23.2	25.8	32.0	30.2	4.2	17.7	30.4	29.5	66.8	14.8	13.0	0.7	27.5	49.2	22.4	30.5	23.2	63.3	24.9	23.6	20.4	21.9	43.1	3.3	41.7	43.9	91.6	169.1	161.5	104.5	57.4	17.8	0.0	31.8	47.1	72.6	0.4	119.3	200.8	416.2	26.3	83.1	93.5	178.3	0.4	11.2	32.6	15.1	28.8	6.2	63.5	103.5	29.4	16.6	672.1	15.5	24.6	74.2	4.6	89.4	31.3	390.1	46.0	7.1	67.0	61.4	0.0	21.7	4.5	4.5	213.7	2.1	167.5	43.8	126.3
TUBB	"M40, MGC16435, OK/SW-cl.56, Tubb5"	ENSG00000196230	"Tubulin beta class I"	P07437	6	30720201-30725426	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 198.7"	"Cell type enhanced"	"Detected in all"	6	"Extravillous trophoblasts: 1893.7"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005417, CAB012406, HPA043640, HPA046280"	Enhanced		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		NA	Yes		510000000	Microtubules	"Cytokinetic bridge, Mitotic spindle"	"CAB005417: AB_2241191, CAB012406: AB_2210370, HPA043640: AB_2678594, HPA046280: AB_2679612"	"unprognostic (1.01e-1)"	"unprognostic (2.33e-1)"	"unprognostic (2.17e-3)"	"unprognostic (1.92e-2)"	"unprognostic (1.56e-1)"	"unprognostic (2.16e-2)"	"prognostic unfavorable (5.97e-4)"	"unprognostic (2.57e-2)"	"unprognostic (2.52e-1)"	"unprognostic (2.18e-3)"	"unprognostic (1.27e-2)"	"unprognostic (2.47e-1)"	"prognostic unfavorable (2.62e-8)"	"unprognostic (8.63e-2)"	"unprognostic (1.47e-1)"	"unprognostic (2.49e-1)"	"unprognostic (2.50e-1)"	51.6	27.7	30.0	31.8	33.2	78.8	30.0	30.9	57.2	43.3	37.0	24.3	18.7	10.8	58.5	39.7	39.9	41.0	29.6	33.1	23.7	48.2	31.4	74.1	32.7	62.1	27.8	24.0	81.5	27.0	15.3	16.3	41.1	39.9	32.2	34.2	30.6	27.9	24.3	29.6	37.6	24.3	37.6	27.4	47.7	29.1	19.7	14.4	198.7	26.9	36.8	91.5	39.7	34.3	15.4	17.5	8.6	15.4	12.3	18.2	19.8	42.4	15.7	61.3	26.6	17.4	30.0	0.5	0.0	0.0	0.0	0.0	29.9	16.2	21.2	26.3	19.6	16.4	14.7	49.5	44.5	0.0	11.9	31.3	0.5	0.0	17.2	8.3	57.8	28.5	22.3	10.4	0.0	0.5	13.5	21.6	46.9	16.7	0.0	27.0	30.7	41.8	0.2	0.0	13.5	18.5	0.0	0.6	12.5	35.8	24.2	10.7	35.9	23.1	10.2	0.4	39.9	26.7	5.3	13.3	64.5	28.7	0.0	0.2	19.8	38.1	49.2	12.7	57.5	81.6	4.9	7.7	8.6	15.5	12.2	18.2	15.4	12.1	17.6	6.2	10.0	12.3	12.2	4.3	12.3	15.4	17.5	14.2	19.8	30.0	33.2	30.9	57.2	23.7	48.2	27.8	24.0	39.9	14.4	122.1	48.4	184.6	261.7	511.8	64.2	96.8	186.0	50.9	100.1	162.3	37.3	493.5	263.6	1083.5	6.9	247.2	97.2	700.8	929.9	1893.7	657.3	117.4	203.1	240.5	829.2	103.3	156.9	268.2	310.8	15.4	372.8	361.3	305.4	1224.5	123.1	172.7	843.8	91.2	223.1	178.3	51.0	116.4	444.0	46.2	42.8	376.4	184.3	200.5	178.2	168.9
TUBB1	dJ543J19.4	ENSG00000101162	"Tubulin beta 1 class VI"	Q9H4B7	20	59019254-59026654	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in some"		"blood: 58.6;lymphoid tissue: 28.2"	"Cell type enhanced"	"Detected in some"	23	"Early spermatids: 11.5;Erythroid cells: 23.3;Late spermatids: 4.9"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Group enriched"	"Detected in some"	13	"basophil: 8.7;neutrophil: 6.5"	"Lineage enriched"	"Detected in single"	14	"granulocytes: 8.7"	"Cell line enriched"	"Detected in some"	19	"HEL: 25.0"	"Not detected"	"Not detected"			"Low region specificity"	"Detected in all"			"CAB004286, HPA043640, HPA046280"	Approved		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		NA	NA		480000000	Microtubules	"Cytokinetic bridge, Mitotic spindle"	"CAB004286: AB_2288090, HPA043640: AB_2678594, HPA046280: AB_2679612"	"unprognostic (3.76e-1)"	"unprognostic (2.69e-1)"	"unprognostic (6.10e-4)"	"unprognostic (1.02e-1)"	"unprognostic (5.00e-2)"	"unprognostic (2.02e-1)"	"unprognostic (5.86e-2)"	"unprognostic (7.51e-4)"	"unprognostic (1.90e-2)"	"unprognostic (2.63e-1)"	"unprognostic (6.80e-5)"	"unprognostic (3.46e-1)"	"unprognostic (1.16e-1)"	"unprognostic (2.55e-1)"	"unprognostic (1.40e-1)"	"unprognostic (2.31e-1)"	"unprognostic (1.00e-1)"	0.6	0.3	0.2	0.4	0.6	12.2	0.2	0.7	0.7	0.2	0.2	0.1	0.0	0.2	0.2	0.9	0.2	0.5	0.6	10.8	0.2	0.2	0.2	1.0	8.3	0.4	0.2	0.4	0.8	0.4	0.0	0.7	3.2	0.6	0.3	0.0	0.5	0.2	0.6	0.6	0.2	0.5	0.0	0.6	28.2	0.3	1.8	0.0	0.0	0.5	0.3	0.2	0.4	1.8	0.1	0.6	8.7	0.5	0.0	0.1	58.6	0.1	0.2	0.1	0.2	0.0	0.0	0.1	0.1	0.0	0.0	0.0	0.6	0.1	0.3	0.2	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	25.0	0.6	1.3	0.0	0.1	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.2	1.2	0.0	0.0	0.1	0.3	0.2	0.0	0.1	0.3	0.2	0.1	0.2	0.0	0.3	0.3	0.2	0.1	0.5	0.1	0.1	0.1	0.1	0.0	0.2	0.2	0.2	0.1	0.2	0.2	0.2	0.1	0.2	0.3	8.7	0.5	0.4	0.1	0.1	0.1	0.1	0.0	0.0	0.2	0.1	0.1	0.0	6.5	0.0	0.0	0.6	0.1	58.6	0.2	0.6	0.7	0.7	0.2	0.2	0.2	0.4	0.6	0.0	0.0	0.6	0.0	0.0	0.0	1.4	0.0	0.0	0.0	1.2	0.0	3.9	0.0	0.0	0.0	11.5	0.0	0.0	23.3	0.0	0.0	0.0	0.0	1.1	0.0	0.2	0.0	0.0	0.6	0.0	4.9	0.3	0.0	0.0	0.0	0.0	0.5	0.0	0.0	0.4	0.0	1.6	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	0.0
TUBB3	"beta-4, CFEOM3, CFEOM3A, FEOM3"	ENSG00000258947	"Tubulin beta 3 class III"	Q13509	16	89921392-89938761	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enriched"	"Detected in many"	4	"brain: 85.1"	"Cell type enhanced"	"Detected in some"	20	"Ductal cells: 22.7;Exocrine glandular cells: 18.4;Late spermatids: 9.5;Pancreatic endocrine cells: 44.3"	"Low cancer specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	5	"naive B-cell: 5.2"	"Lineage enriched"	"Detected in single"	7	"B-cells: 5.2"	"Cell line enhanced"	"Detected in many"		"A549: 66.2;SCLC-21H: 67.5;SH-SY5Y: 68.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA043640, HPA046280"	Approved		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		NA	NA		250000000	Microtubules	"Cytokinetic bridge, Mitotic spindle"	"HPA043640: AB_2678594, HPA046280: AB_2679612"	"unprognostic (7.08e-2)"	"unprognostic (3.37e-4)"	"unprognostic (1.05e-1)"	"unprognostic (1.06e-1)"	"unprognostic (8.01e-2)"	"unprognostic (3.12e-2)"	"unprognostic (4.04e-3)"	"unprognostic (1.12e-3)"	"unprognostic (1.22e-2)"	"unprognostic (6.06e-2)"	"unprognostic (1.99e-2)"	"unprognostic (1.38e-2)"	"unprognostic (7.57e-2)"	"unprognostic (1.27e-3)"	"unprognostic (3.70e-2)"	"unprognostic (3.05e-1)"	"unprognostic (1.91e-2)"	5.1	19.4	23.9	8.9	23.3	3.2	1.2	24.1	85.1	2.4	4.1	7.8	0.0	3.6	7.9	1.1	2.2	1.0	7.3	1.8	25.0	66.5	1.1	1.1	1.6	5.7	44.5	15.9	1.1	2.5	1.0	9.9	2.2	60.9	1.6	2.8	5.5	1.9	1.3	1.0	4.1	4.8	9.3	12.9	1.1	2.5	11.2	3.3	0.0	1.0	1.7	4.4	5.3	0.6	5.2	0.7	0.2	0.3	0.0	0.2	0.2	4.6	66.2	24.7	28.1	2.9	28.5	1.0	28.4	4.8	17.1	7.8	9.0	8.6	14.0	14.8	21.4	12.0	17.5	23.8	4.2	4.3	3.4	2.3	0.1	5.6	58.7	0.9	0.0	11.0	16.3	1.2	26.2	2.3	22.3	14.1	0.9	1.4	0.5	19.5	44.1	0.1	4.7	43.3	1.7	36.4	0.0	8.7	1.5	21.3	1.3	67.5	68.2	39.9	0.7	19.4	4.7	2.2	0.2	17.6	23.5	25.3	31.4	28.7	0.2	2.8	5.3	24.3	1.8	41.5	0.2	0.0	0.0	0.2	0.0	0.0	1.0	0.0	0.2	0.0	5.2	0.0	0.0	0.0	0.0	0.3	0.7	0.0	0.2	23.9	23.3	24.1	51.0	25.0	66.5	44.5	15.9	60.9	3.3	0.0	0.0	0.0	0.0	0.0	1.1	0.0	0.0	0.0	1.2	0.0	0.0	0.0	0.0	22.7	5.3	0.0	0.0	0.0	18.4	0.3	0.0	0.0	0.0	0.0	0.2	4.8	4.7	0.0	0.0	9.5	0.3	0.0	0.0	0.0	0.0	0.2	44.3	0.0	0.4	0.0	0.9	0.0	0.0	0.0	0.4	0.0	0.8	0.0	0.0	0.0
TUBB4B	"Beta2, TUBB2C"	ENSG00000188229	"Tubulin beta 4B class IVb"	P68371	9	137241213-137243707	"FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Deafness, Disease mutation, FDA approved drug targets, Leber congenital amaurosis"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 207.7"	"Cell type enhanced"	"Detected in all"	5	"Early spermatids: 1754.5;Late spermatids: 2132.3;Spermatocytes: 1761.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB010880, HPA043640, HPA046280"	Enhanced		Supported	"Microtubules,Cytokinetic bridge,Mitotic spindle"		NA	Yes			Microtubules	"Cytokinetic bridge, Mitotic spindle"	"CAB010880: AB_609915, HPA043640: AB_2678594, HPA046280: AB_2679612"	"unprognostic (2.24e-1)"	"unprognostic (1.77e-3)"	"unprognostic (1.50e-1)"	"prognostic favorable (4.91e-4)"	"unprognostic (1.29e-2)"	"unprognostic (8.93e-2)"	"prognostic unfavorable (9.98e-4)"	"unprognostic (9.92e-3)"	"unprognostic (2.90e-1)"	"unprognostic (3.63e-1)"	"unprognostic (2.34e-1)"	"unprognostic (4.09e-2)"	"unprognostic (2.47e-3)"	"unprognostic (6.37e-2)"	"unprognostic (1.36e-2)"	"prognostic favorable (6.36e-6)"	"unprognostic (1.69e-1)"	31.1	22.1	33.0	22.1	32.7	87.5	24.4	22.3	67.2	23.0	44.0	35.9	25.2	33.4	22.7	52.7	65.7	122.5	32.1	66.4	35.2	55.5	46.6	49.7	28.4	21.0	33.8	46.6	33.7	33.0	13.4	25.3	31.9	48.4	29.8	27.3	40.9	41.8	31.8	37.1	55.9	38.9	28.4	21.5	21.0	30.5	207.7	12.2	61.1	40.1	56.7	40.1	21.8	25.7	17.2	18.3	37.0	14.6	11.2	21.7	14.4	59.3	89.0	38.1	27.4	19.2	20.3	53.1	55.8	47.0	77.2	53.4	94.0	73.1	36.4	42.7	54.1	75.3	113.0	47.1	89.8	29.4	25.9	39.8	26.4	70.9	73.8	12.1	31.0	29.4	13.0	25.5	58.9	16.2	19.2	55.1	26.1	36.8	21.0	63.6	163.2	28.1	42.3	40.2	105.3	155.3	35.8	72.7	33.7	58.0	55.6	26.7	28.7	73.9	42.6	14.8	22.6	61.3	33.8	42.7	55.2	61.5	62.5	73.3	8.1	22.5	40.2	45.0	24.3	47.8	37.0	14.1	20.5	21.4	14.6	20.6	17.2	16.7	18.2	17.5	14.1	10.7	14.3	28.6	11.2	14.6	18.3	21.7	14.4	33.0	32.7	22.3	67.2	35.2	55.5	33.8	46.6	48.4	12.2	205.4	139.7	150.7	842.9	289.7	457.2	82.3	132.5	1026.5	175.1	136.1	282.7	235.6	187.3	348.8	1754.5	152.3	547.1	490.6	391.5	458.3	161.8	365.4	188.9	114.3	228.8	230.4	375.8	129.5	67.2	2132.3	235.3	111.2	131.6	359.7	292.5	271.2	343.5	375.2	143.9	259.6	647.3	109.9	245.2	1761.9	564.6	260.1	268.5	97.8	359.3	575.4
TUBD1	"FLJ12709, TUBD"	ENSG00000108423	"Tubulin delta 1"	Q9UJT1	17	59859482-59892945	"FDA approved drug targets, Predicted intracellular proteins"	"Cilium biogenesis/degradation"	"Developmental protein"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	6	"Alveolar cells type 2: 45.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"MCF7: 42.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004609, HPA023980, HPA027090"	Approved		Enhanced	Nucleoplasm,Cytosol		NA	NA			"Nucleoplasm, Cytosol"		"CAB004609: AB_628416, HPA023980: AB_1858456, HPA027090: AB_1858457"	"unprognostic (1.92e-1)"	"unprognostic (5.95e-2)"	"prognostic favorable (2.04e-4)"	"unprognostic (1.39e-1)"	"unprognostic (1.32e-2)"	"unprognostic (5.64e-2)"	"prognostic unfavorable (1.00e-5)"	"unprognostic (2.86e-2)"	"unprognostic (8.87e-3)"	"unprognostic (1.02e-1)"	"unprognostic (1.77e-3)"	"unprognostic (2.59e-1)"	"prognostic unfavorable (6.06e-4)"	"unprognostic (4.97e-2)"	"unprognostic (1.63e-1)"	"unprognostic (1.36e-1)"	"unprognostic (8.83e-2)"	8.7	8.0	9.3	8.1	13.8	6.8	12.4	19.9	12.2	12.3	11.2	13.5	16.6	6.7	13.6	16.4	18.2	10.0	8.3	8.4	8.9	7.2	8.5	9.3	8.8	10.2	16.1	8.5	16.3	13.2	10.4	18.7	7.2	12.3	12.3	8.2	11.7	11.4	12.2	9.9	11.6	7.5	9.3	13.4	9.3	9.6	9.2	16.4	16.2	15.5	10.3	13.8	14.1	13.0	10.1	8.8	14.1	7.6	8.1	17.6	6.9	6.0	8.3	6.5	6.8	3.7	2.6	5.5	4.7	2.8	6.3	5.2	9.0	3.9	5.5	8.1	1.1	4.3	5.1	9.1	2.8	6.0	3.2	11.1	6.4	7.0	10.6	2.0	3.8	3.5	1.4	4.5	5.4	2.0	2.2	4.9	5.5	13.8	3.8	2.1	42.9	7.8	4.4	5.7	6.7	3.7	8.4	9.6	8.6	2.4	2.8	6.1	3.7	3.4	2.7	3.2	8.2	6.4	3.7	1.5	4.5	10.1	3.1	5.1	4.5	6.8	8.4	2.1	4.3	4.0	5.6	7.6	14.1	10.9	5.0	12.4	10.1	13.5	11.5	5.2	8.6	17.6	14.2	8.2	8.1	5.3	8.8	14.1	6.9	9.3	13.8	19.9	12.2	8.9	7.2	16.1	8.5	12.3	16.4	11.9	45.1	5.4	12.7	14.0	7.1	4.8	7.6	12.0	20.5	3.5	5.9	5.1	10.0	4.6	1.3	7.7	2.6	0.0	4.2	6.5	8.2	11.1	10.5	3.2	3.5	3.2	9.9	6.7	4.8	0.4	5.2	6.2	6.8	3.6	5.5	7.7	3.3	4.9	7.8	3.1	7.7	6.5	10.3	11.4	28.1	14.8	3.3	13.6	5.4	5.7
TUBE1	"dJ142L7.2, FLJ22589, TUBE"	ENSG00000074935	"Tubulin epsilon 1"	Q9UJT0	6	112070777-112087529	"FDA approved drug targets, Predicted intracellular proteins"			"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in all"	8	"Early spermatids: 158.3;Spermatocytes: 75.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in many"		"U-2197: 29.3"	"Low region specificity"	"Detected in single"			"Low region specificity"	"Detected in all"			"HPA032073, HPA032074"	Approved					NA	NA					"HPA032073: AB_10601773, HPA032074: AB_10601216"	"unprognostic (4.79e-2)"	"unprognostic (1.61e-1)"	"unprognostic (3.76e-2)"	"unprognostic (1.29e-1)"	"unprognostic (2.22e-2)"	"unprognostic (7.36e-2)"	"unprognostic (1.22e-1)"	"unprognostic (8.36e-3)"	"unprognostic (2.18e-1)"	"unprognostic (1.04e-1)"	"unprognostic (4.99e-3)"	"unprognostic (1.70e-1)"	"unprognostic (5.15e-3)"	"unprognostic (1.64e-1)"	"unprognostic (7.68e-2)"	"unprognostic (2.50e-1)"	"unprognostic (1.59e-3)"	10.3	10.7	12.4	7.0	18.5	5.1	11.9	32.4	18.9	15.5	10.3	12.2	11.4	6.7	21.4	11.5	6.6	12.7	11.6	17.4	10.5	12.2	11.4	47.4	8.4	8.8	15.4	14.5	14.9	12.5	11.8	20.4	11.7	14.0	12.1	8.5	9.3	9.9	12.6	7.1	13.8	7.0	14.4	18.2	8.0	10.5	32.7	15.5	5.3	10.6	4.3	7.3	11.5	12.6	3.2	1.7	2.2	1.4	3.6	7.5	2.8	1.2	1.8	4.7	14.0	10.6	5.8	4.0	5.7	8.3	4.2	7.2	3.0	2.5	4.5	3.6	2.2	6.2	3.9	5.3	2.6	7.1	2.7	4.9	2.1	1.1	3.5	17.4	9.8	6.4	6.2	15.5	5.5	13.5	5.0	5.1	15.8	9.3	6.5	3.2	1.1	5.5	11.5	4.3	7.9	3.7	6.0	2.9	3.0	5.3	1.3	7.0	6.3	4.4	3.6	14.6	4.2	2.7	20.0	2.8	3.3	3.2	29.3	5.4	2.1	0.7	5.3	5.0	10.9	8.1	0.1	0.9	2.2	2.7	1.2	7.5	3.2	5.3	3.5	1.7	2.5	7.4	5.8	0.6	3.6	1.4	1.5	5.1	2.8	12.4	18.5	32.4	18.9	10.5	12.2	15.4	14.5	14.0	15.5	6.0	14.7	11.2	16.2	21.9	20.7	14.9	10.2	10.7	11.4	21.0	33.4	4.2	13.3	9.3	158.3	15.6	8.7	23.3	15.8	9.6	11.5	11.9	16.1	56.2	6.4	12.7	5.8	16.0	6.4	39.6	14.4	7.4	6.8	4.6	9.8	11.0	9.6	8.0	18.7	19.4	29.4	19.4	14.4	75.1	27.4	10.9	2.7	15.0	6.9	12.4
TUBG1	"TUBG, TUBGCP1"	ENSG00000131462	"Tubulin gamma 1"	P23258	17	42609676-42615234	"Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"			"Disease mutation, FDA approved drug targets, Lissencephaly"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"testis: 102.4"	"Cell type enhanced"	"Detected in all"	12	"Early spermatids: 583.2;Late spermatids: 391.6;Spermatocytes: 311.8"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in all"							CAB004608	Enhanced					NA	Yes					"CAB004608: AB_628417"	"unprognostic (1.00e-1)"	"unprognostic (5.57e-2)"	"unprognostic (1.79e-2)"	"prognostic favorable (8.99e-4)"	"unprognostic (2.86e-2)"	"unprognostic (2.01e-1)"	"prognostic unfavorable (1.08e-8)"	"unprognostic (2.62e-3)"	"unprognostic (5.67e-2)"	"unprognostic (1.83e-1)"	"unprognostic (3.79e-1)"	"unprognostic (2.16e-1)"	"prognostic unfavorable (6.48e-5)"	"unprognostic (2.64e-1)"	"unprognostic (3.52e-1)"	"unprognostic (2.61e-3)"	"unprognostic (1.97e-2)"	11.7	14.1	8.8	10.7	11.2	23.9	13.0	12.4	19.3	7.5	9.8	6.9	7.8	9.6	9.7	7.8	15.4	7.7	10.4	18.3	13.2	12.6	16.2	20.5	8.6	9.2	8.7	12.0	8.8	30.1	13.1	9.5	14.2	12.2	9.6	8.6	8.3	9.2	11.1	24.3	15.9	7.7	14.1	6.8	10.3	12.8	102.4	5.2	14.6	9.7	11.8	10.8	10.8	9.5	9.7	26.2	1.8	15.4	6.8	8.3	6.3	23.6	62.6	24.3	26.5	15.8	10.9	21.9	27.2	18.8	44.6	34.7	37.9	16.5	17.0	20.1	22.3	38.4	38.0	26.1	38.1	32.5	44.7	33.4	13.7	41.6	62.9	7.7	14.9	19.5	8.5	11.9	54.8	16.6	11.1	28.1	26.1	25.0	17.3	32.9	69.6	36.5	15.8	12.6	36.0	31.3	17.6	36.0	27.2	19.2	29.3	34.7	16.8	17.0	16.1	13.2	25.6	50.2	14.6	17.9	44.7	28.7	36.6	42.2	25.2	30.9	25.4	23.5	14.8	31.1	1.3	8.4	1.8	7.3	15.4	7.6	9.7	6.7	7.5	9.7	8.3	7.1	7.3	0.4	6.8	15.2	26.2	8.3	6.3	8.8	11.2	12.4	19.3	13.2	12.6	8.7	12.0	12.2	5.2	14.9	3.4	8.9	12.1	15.7	12.2	15.7	10.2	13.4	6.8	7.0	3.9	32.5	33.2	32.7	583.2	15.0	10.5	140.2	48.1	68.4	11.3	12.1	2.3	13.0	34.6	19.1	9.2	14.7	7.0	391.6	21.0	9.9	16.9	43.3	10.6	15.2	33.2	8.0	20.5	45.9	10.6	58.2	13.0	311.8	108.4	25.0	16.8	4.9	9.8	11.9
TXNRD1	"GRIM-12, Trxr1, TXNR"	ENSG00000198431	"Thioredoxin reductase 1"	Q16881	12	104215779-104350305	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Electron transport, Transport"	Oxidoreductase	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Basal glandular cells: 272.3;Urothelial cells: 489.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"fHDF/TERT166: 144.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"HPA001395, CAB004607, CAB015834, HPA043871"	Approved		Supported	Nucleoplasm		NA	NA		5900000	Nucleoplasm		"CAB004607: AB_628405, CAB015834: , HPA001395: AB_1858377, HPA043871: AB_2678709"	"unprognostic (2.52e-2)"	"unprognostic (1.16e-1)"	"unprognostic (5.48e-2)"	"unprognostic (1.01e-1)"	"unprognostic (3.15e-1)"	"unprognostic (1.94e-2)"	"prognostic unfavorable (1.12e-5)"	"unprognostic (5.55e-2)"	"unprognostic (1.18e-1)"	"unprognostic (1.08e-1)"	"unprognostic (6.42e-2)"	"unprognostic (2.21e-1)"	"prognostic unfavorable (1.20e-5)"	"unprognostic (2.13e-1)"	"unprognostic (1.27e-1)"	"unprognostic (1.18e-2)"	"unprognostic (8.80e-2)"	19.1	79.2	14.1	15.6	16.9	22.6	18.5	11.1	13.7	13.0	21.8	9.7	19.7	23.5	23.5	14.7	16.7	19.0	23.2	32.4	11.0	11.7	25.3	19.6	29.3	18.1	12.0	10.9	16.4	7.9	10.5	16.2	30.8	16.4	25.3	19.1	18.1	10.6	26.5	30.0	5.7	17.0	99.6	10.9	14.9	24.2	14.8	8.9	15.6	16.5	16.9	13.2	73.2	72.0	8.1	14.2	37.6	16.2	8.3	10.2	8.7	22.2	103.7	12.1	11.3	58.1	32.6	42.0	41.4	26.2	18.7	19.4	10.9	33.2	16.7	19.3	144.9	70.2	7.8	23.8	15.9	22.2	8.1	10.3	14.1	81.4	46.1	93.3	21.9	15.4	18.5	16.4	41.4	13.2	57.6	64.1	23.0	19.3	7.9	28.0	10.7	22.4	10.0	11.6	44.8	106.9	22.3	8.4	14.5	21.8	12.3	18.8	11.4	33.5	53.0	33.0	23.9	12.5	13.0	85.6	9.2	19.1	20.6	33.9	8.7	17.0	25.1	19.3	12.2	54.4	33.0	10.6	24.7	9.1	14.0	10.2	8.1	8.4	9.0	14.2	5.2	7.6	6.6	37.6	8.3	16.2	9.2	7.1	8.7	14.1	16.9	11.1	11.2	11.0	11.7	12.0	10.9	16.4	8.9	59.6	55.0	27.6	272.3	92.4	28.0	55.7	38.2	104.4	96.7	15.7	21.6	22.9	34.9	73.1	34.3	40.9	44.4	23.3	68.7	28.0	34.6	217.3	50.9	45.7	36.8	27.0	19.7	50.3	37.2	13.4	63.0	64.0	18.6	55.9	17.9	23.3	183.4	20.3	27.6	28.5	19.7	0.0	58.8	11.6	28.8	63.7	42.9	23.5	24.1	489.6
TYMP	"ECGF1, MNGIE"	ENSG00000025708	"Thymidine phosphorylase"	P19971	22	50525752-50530056	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Angiogenesis, Chemotaxis, Differentiation"	"Developmental protein, Glycosyltransferase, Growth factor, Transferase"	"Cancer-related genes, Disease mutation, FDA approved drug targets, Neuropathy, Primary mitochondrial disease, Progressive external ophthalmoplegia"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"lymphoid tissue: 57.8"	"Cell type enriched"	"Detected in many"	5	"monocytes: 2738.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in many"			"Group enriched"	"Detected in many"	6	"classical monocyte: 23.0;eosinophil: 18.2;intermediate monocyte: 22.4;myeloid DC: 12.2;neutrophil: 6.7;non-classical monocyte: 15.9"	"Group enriched"	"Detected in many"	18	"dendritic cells: 12.2;granulocytes: 18.2;monocytes: 23.0"	"Cell line enhanced"	"Detected in many"		"CAPAN-2: 16.2;HHSteC: 40.2;Karpas-707: 38.8;U-266/70: 18.6"	"Low region specificity"	"Detected in some"							"HPA000530, HPA001072, CAB002518"	Enhanced		Approved	"Nuclear bodies,Golgi apparatus,Cytosol"		NA	NA		16000000	"Nuclear bodies, Golgi apparatus"	Cytosol	"CAB002518: AB_563953, HPA000530: AB_2666017, HPA001072: AB_1080274"	"unprognostic (7.02e-3)"	"unprognostic (1.00e-1)"	"unprognostic (3.61e-1)"	"prognostic favorable (4.34e-5)"	"unprognostic (7.60e-2)"	"unprognostic (1.16e-2)"	"unprognostic (2.40e-1)"	"unprognostic (7.17e-2)"	"unprognostic (4.64e-2)"	"unprognostic (1.33e-1)"	"unprognostic (3.31e-2)"	"unprognostic (2.17e-1)"	"prognostic unfavorable (3.50e-8)"	"unprognostic (1.32e-1)"	"unprognostic (4.02e-2)"	"unprognostic (1.52e-2)"	"unprognostic (4.60e-2)"	25.2	7.9	2.8	41.6	8.4	12.1	19.0	1.5	4.4	10.7	10.7	3.8	2.3	10.4	4.4	15.7	22.0	13.7	9.6	15.0	7.0	2.6	18.6	38.1	28.8	57.8	6.5	0.4	7.5	5.8	1.7	3.9	11.5	9.1	7.9	4.9	5.4	16.5	3.8	10.0	8.8	13.9	7.3	15.2	43.9	12.4	3.0	5.0	13.3	12.5	25.5	28.8	12.4	9.4	0.9	12.2	18.2	23.0	0.8	0.9	2.6	6.7	0.8	0.0	0.1	1.0	1.3	0.6	1.2	0.1	2.4	5.4	0.0	16.2	0.5	0.8	2.7	0.8	5.9	0.2	0.3	0.0	2.8	1.4	0.3	1.1	0.4	40.2	0.1	7.7	2.5	2.4	3.2	0.0	0.1	0.0	0.0	0.2	38.8	0.2	0.1	0.0	1.0	0.0	0.9	2.1	0.2	0.0	7.8	0.0	0.0	0.0	1.4	6.2	8.5	0.6	0.0	0.7	4.9	1.5	0.0	0.6	0.1	0.2	18.6	3.8	0.4	0.2	0.1	0.2	2.5	23.0	18.2	0.3	22.4	0.2	0.8	0.3	0.2	12.2	0.9	0.2	0.1	6.7	0.8	15.9	1.1	0.9	2.6	2.8	8.4	1.5	4.4	7.0	2.6	6.5	0.4	9.1	5.0	11.9	35.6	80.8	45.0	52.0	2.9	2.0	40.8	21.4	19.4	31.4	3.9	11.5	24.9	326.6	1.8	45.0	161.9	0.0	563.3	281.5	67.3	63.5	54.1	80.8	472.8	0.0	16.1	38.1	417.7	8.6	4.6	429.6	108.0	2738.6	29.6	2.0	289.0	94.7	1.8	76.1	5.4	25.8	44.2	1.4	8.3	49.4	28.0	34.5	27.7	63.3
TYMS	"HsT422, TMS, TS, Tsase"	ENSG00000176890	"Thymidylate synthetase"	P04818	18	657604-673578	"Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Nucleotide biosynthesis"	"Methyltransferase, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 34.9;lymphoid tissue: 75.5"	"Cell type enhanced"	"Detected in many"	12	"Extravillous trophoblasts: 109.0;Spermatocytes: 197.1"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"		"T-reg: 13.8"	"Group enriched"	"Detected in many"	6	"NK-cells: 6.8;T-cells: 13.8"	"Low cell line specificity"	"Detected in all"			"Low region specificity"	"Detected in single"			"Group enriched"	"Detected in some"	5	"cerebellum: 6.7;olfactory region: 8.8"	"CAB002784, HPA074922"	Enhanced					NA	Yes					"CAB002784: , HPA074922: "	"unprognostic (7.58e-2)"	"unprognostic (2.06e-3)"	"unprognostic (9.31e-2)"	"unprognostic (2.34e-2)"	"unprognostic (7.35e-2)"	"unprognostic (1.05e-1)"	"prognostic unfavorable (5.10e-6)"	"unprognostic (1.62e-3)"	"unprognostic (1.68e-2)"	"unprognostic (9.82e-2)"	"unprognostic (1.07e-3)"	"unprognostic (3.28e-2)"	"unprognostic (1.23e-2)"	"unprognostic (6.34e-2)"	"unprognostic (1.66e-1)"	"unprognostic (5.65e-3)"	"unprognostic (2.47e-1)"	3.0	2.6	4.6	15.5	5.8	34.9	2.8	1.2	6.3	3.4	10.1	10.2	1.5	4.8	2.5	3.6	12.3	2.4	4.6	2.0	5.8	2.9	4.8	5.1	4.2	15.4	3.4	4.5	2.0	3.1	1.1	1.3	14.3	3.4	3.0	12.9	1.1	3.4	0.8	0.7	3.6	6.9	5.5	4.6	8.9	4.2	21.5	5.3	75.5	1.7	10.9	19.3	4.8	4.3	1.2	1.8	1.0	0.1	6.8	13.8	2.5	13.9	21.5	44.9	21.7	5.0	8.4	22.8	32.9	19.7	35.6	42.7	18.1	11.2	21.7	12.9	17.7	20.2	6.3	31.3	12.4	30.8	20.4	34.8	36.8	20.2	31.1	1.1	75.6	40.4	7.4	2.9	22.4	7.0	6.8	29.7	46.2	29.5	34.9	44.8	16.0	91.0	41.9	16.2	17.0	16.1	60.2	40.4	26.1	13.3	12.4	15.3	24.9	27.8	12.9	8.3	29.1	8.8	34.5	11.7	41.2	81.4	37.7	64.2	43.3	53.3	49.6	10.9	32.7	47.0	0.0	0.0	1.0	1.1	0.1	0.0	1.2	2.9	2.2	1.8	0.0	0.0	0.7	0.6	6.8	0.1	0.3	13.8	2.5	4.6	5.8	1.2	6.3	5.8	2.9	3.4	4.5	3.4	5.3	0.0	2.9	3.0	11.2	12.8	0.4	2.1	5.1	0.0	7.9	0.0	0.0	36.1	1.7	2.4	18.3	1.5	8.4	23.3	0.7	109.0	7.2	4.0	6.9	1.7	57.9	0.0	1.2	6.2	15.9	22.3	5.8	9.2	10.1	6.4	13.0	42.9	1.4	3.5	3.5	19.4	1.9	12.9	4.1	197.1	30.9	6.4	22.5	7.5	39.0	3.5
TYR	"OCA1, OCA1A, OCAIA"	ENSG00000077498	Tyrosinase	P14679	11	89177452-89295759	"Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins"	"Melanin biosynthesis"	"Monooxygenase, Oxidoreductase, Tumor antigen"	"Albinism, Deafness, Disease mutation, FDA approved drug targets, Waardenburg syndrome"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Group enriched"	"Detected in some"	70	"retina: 82.0;skin 1: 25.2"	"Cell type enriched"	"Detected in some"	8	"Melanocytes: 175.5"	"Cancer enriched"	"Detected in single"	1755	"melanoma: 351.3"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Not detected"	"Not detected"			"Cell line enriched"	"Detected in single"	864	"SK-MEL-30: 86.4"	"Not detected"	"Not detected"			"Not detected"	"Not detected"			"CAB000079, HPA043241, HPA050889, HPA064583"	Enhanced		Enhanced	Vesicles		NA	NA			Vesicles		"CAB000079: AB_564045, HPA043241: AB_2678383, HPA050889: AB_2681264, HPA064583: "	"unprognostic (1.16e-1)"								"unprognostic (1.01e-1)"		"unprognostic (1.85e-3)"		"unprognostic (9.75e-3)"					0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	82.0	0.7	0.0	0.0	25.2	0.0	0.0	0.2	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	86.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	7.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	23.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	3.6	0.3	0.0	175.5	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.2	0.2	1.8	0.0	0.0	0.0	0.0
UGCG	GCS	ENSG00000148154	"UDP-glucose ceramide glucosyltransferase"	Q16739	9	111896766-111935369	"Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters"	"Lipid biosynthesis, Lipid metabolism, Sphingolipid metabolism"	"Glycosyltransferase, Transferase"	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	9	"Urothelial cells: 446.9"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in some"	19	"plasmacytoid DC: 39.7"	"Lineage enriched"	"Detected in many"	19	"dendritic cells: 39.7"	"Cell line enhanced"	"Detected in all"		"LHCN-M2: 50.2"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			HPA024124	Approved					NA	NA					"HPA024124: AB_1858595"	"unprognostic (1.22e-2)"	"prognostic favorable (6.62e-4)"	"unprognostic (5.39e-2)"	"prognostic favorable (4.44e-5)"	"unprognostic (1.53e-2)"	"unprognostic (9.70e-2)"	"unprognostic (3.20e-2)"	"unprognostic (2.04e-1)"	"unprognostic (3.40e-1)"	"unprognostic (1.31e-1)"	"unprognostic (1.95e-2)"	"unprognostic (3.22e-1)"	"unprognostic (9.84e-3)"	"unprognostic (2.24e-2)"	"unprognostic (4.92e-2)"	"unprognostic (1.99e-1)"	"unprognostic (3.77e-2)"	33.7	37.7	5.9	21.4	7.8	55.2	20.5	9.5	11.2	14.6	19.6	5.0	3.3	13.3	10.6	8.6	34.0	11.1	24.5	17.5	8.6	9.0	23.8	18.4	28.1	35.4	7.1	5.8	15.9	11.4	3.5	11.9	15.3	6.8	12.4	10.5	11.9	10.8	5.4	14.0	21.7	25.5	12.4	12.9	33.1	26.1	11.7	6.2	17.9	8.5	16.9	27.7	34.2	25.9	2.0	39.7	0.4	0.3	0.5	1.2	0.5	23.1	2.4	4.0	2.7	8.8	10.6	2.1	14.5	15.3	17.0	23.1	4.9	17.8	5.5	11.5	9.6	37.3	11.9	4.7	6.3	18.3	2.2	2.7	2.2	3.7	2.4	6.3	2.4	3.6	10.5	4.9	16.2	23.4	39.5	5.2	2.7	12.1	10.7	50.2	3.9	2.6	2.7	4.6	7.8	2.6	3.0	28.9	1.7	39.1	8.8	1.9	3.1	6.4	5.4	15.9	25.1	29.2	2.5	24.4	7.8	4.0	21.9	10.3	2.0	7.3	2.5	9.7	1.5	10.6	0.0	0.1	0.0	0.4	0.2	0.7	1.6	0.8	0.6	0.6	2.0	0.7	0.7	0.4	0.5	0.3	39.7	1.2	0.5	5.9	7.8	9.5	11.2	8.6	9.0	7.1	5.8	6.8	6.2	38.7	48.5	29.9	123.9	67.2	26.0	9.2	30.6	115.1	113.7	27.9	58.9	5.7	14.9	98.3	14.5	72.6	52.6	0.0	43.7	10.2	46.0	156.5	10.4	15.5	19.6	17.5	17.7	92.7	30.2	3.6	45.5	30.8	55.6	69.5	41.5	7.8	67.4	21.0	36.0	56.0	14.2	12.9	60.8	1.6	1.5	106.9	2.9	26.6	12.8	446.9
VAMP1	"SYB1, VAMP-1"	ENSG00000139190	"Vesicle associated membrane protein 1"	P23763	12	6462237-6470987	"FDA approved drug targets, Predicted membrane proteins, Transporters"			"Congenital myasthenic syndrome, Disease mutation, FDA approved drug targets, Neurodegeneration"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"bone marrow: 38.7;brain: 85.2"	"Cell type enhanced"	"Detected in many"	6	"Bipolar cells: 16.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low lineage specificity"	"Detected in all"			"Cell line enriched"	"Detected in many"	6	"U-698: 67.8"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB002779, CAB016119, CAB079000"	Approved	Supported				NA	NA					"CAB002779: , CAB016119: AB_628309, CAB079000: "	"unprognostic (2.33e-1)"	"unprognostic (6.72e-3)"	"prognostic unfavorable (6.37e-5)"	"unprognostic (8.09e-3)"	"unprognostic (2.17e-1)"	"unprognostic (1.14e-3)"	"prognostic unfavorable (6.97e-4)"	"unprognostic (1.22e-2)"	"unprognostic (6.33e-2)"	"unprognostic (1.05e-1)"	"unprognostic (1.40e-3)"	"unprognostic (3.48e-2)"	"prognostic unfavorable (1.04e-11)"	"unprognostic (1.47e-2)"	"unprognostic (5.99e-2)"	"unprognostic (1.62e-1)"	"unprognostic (3.65e-2)"	3.4	6.8	10.2	13.7	12.8	38.7	4.2	9.8	53.1	5.7	8.0	11.1	1.6	4.7	8.7	5.4	3.9	5.1	5.2	4.0	14.1	25.4	3.2	4.3	5.3	24.3	33.5	10.0	3.8	2.4	1.1	3.1	2.4	85.2	8.6	8.8	4.8	6.3	7.6	4.0	4.2	7.9	7.7	31.3	12.4	5.4	3.7	8.3	3.7	7.9	0.8	23.0	5.0	4.7	5.5	2.5	13.4	1.0	2.1	7.0	2.5	0.9	3.5	1.9	2.6	5.7	6.6	2.2	1.8	3.5	1.9	5.5	1.1	3.2	9.9	0.4	4.4	1.9	3.0	2.3	1.0	2.8	7.8	5.5	1.5	10.4	1.2	2.7	3.8	3.8	4.8	0.4	2.5	1.4	6.5	1.7	4.4	0.5	2.9	4.3	1.0	5.0	4.4	9.4	0.4	1.5	5.5	3.1	1.8	1.2	1.3	0.4	0.8	3.8	2.0	1.4	10.8	0.6	1.5	2.1	0.9	3.0	2.0	1.2	2.6	1.0	67.8	3.6	8.0	0.7	6.9	1.0	13.4	6.7	0.4	5.3	5.5	5.5	6.2	1.1	1.3	5.8	4.8	5.5	2.1	0.5	2.5	7.0	2.5	10.2	12.8	9.8	53.1	14.1	25.4	33.5	10.0	85.2	8.3	6.0	1.3	8.2	2.7	1.0	16.3	1.4	2.5	4.0	2.3	0.0	5.9	0.3	1.7	0.2	0.3	2.2	1.7	0.0	0.4	0.7	2.6	2.4	10.4	3.2	1.4	1.6	4.6	2.5	1.8	0.4	3.4	2.4	0.0	4.6	1.2	6.1	0.5	0.9	4.6	0.3	6.8	6.5	3.6	2.3	2.6	0.6	0.1	9.2	1.5	0.8
VAMP2	"SYB2, VAMP-2"	ENSG00000220205	"Vesicle associated membrane protein 2"	P63027	17	8159149-8163546	"FDA approved drug targets, Predicted membrane proteins, Transporters"			"Disease mutation, FDA approved drug targets, Mental retardation"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"brain: 168.0"	"Cell type enhanced"	"Detected in all"	7	"Bipolar cells: 1189.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											CAB078785		Supported				NA	NA					"CAB078785: "	"unprognostic (8.25e-2)"	"unprognostic (4.41e-2)"	"unprognostic (1.58e-2)"	"prognostic favorable (1.08e-4)"	"unprognostic (2.81e-2)"	"unprognostic (1.15e-1)"	"unprognostic (1.43e-2)"	"unprognostic (7.28e-2)"	"unprognostic (5.15e-2)"	"unprognostic (1.55e-1)"	"prognostic favorable (3.83e-6)"	"unprognostic (8.27e-2)"	"prognostic favorable (9.76e-8)"	"unprognostic (1.21e-2)"	"unprognostic (7.00e-2)"	"unprognostic (1.54e-1)"	"unprognostic (1.08e-1)"	22.0	38.3	65.1	16.2	111.7	57.4	20.2	72.2	168.0	20.1	16.3	51.6	11.6	15.7	27.4	24.1	11.6	26.8	14.4	22.1	61.7	56.5	23.5	11.4	21.0	23.1	52.7	71.1	48.4	22.6	52.2	40.6	15.4	88.4	25.1	19.3	37.5	19.5	27.0	33.6	25.0	17.9	25.2	30.7	27.2	17.4	15.1	35.1	9.2	22.0	8.8	22.8	11.7	16.0	25.1	15.4	37.8	8.8	25.1	33.4	9.3	13.8	10.4	25.8	13.8	22.7	17.8	11.6	13.0	16.5	13.3	18.3	4.1	9.5	15.8	9.3	20.8	12.5	16.9	16.9	14.0	15.4	18.3	18.5	11.0	26.7	5.6	20.4	7.3	17.1	19.6	21.1	15.3	23.0	27.5	12.9	27.7	8.5	18.4	22.5	7.3	19.1	10.1	5.9	9.3	7.7	24.4	11.8	12.4	17.2	9.3	12.0	19.2	10.2	5.7	12.7	11.8	13.0	9.5	19.7	8.1	11.2	14.8	12.0	20.3	11.5	11.4	20.6	12.8	18.3	13.7	7.4	24.5	28.4	6.9	24.4	25.1	28.2	30.0	5.7	22.1	33.4	30.8	37.8	25.1	8.8	15.4	20.1	9.3	65.1	111.7	72.2	168.0	61.7	56.5	52.7	71.1	88.4	35.1	38.7	21.2	219.6	147.9	101.1	1189.4	24.3	147.7	17.4	34.2	219.8	233.7	157.6	334.9	66.7	5.4	128.8	97.5	23.3	73.0	75.1	142.8	110.4	150.8	68.4	95.0	440.2	310.2	154.7	94.0	5.9	242.4	101.2	183.9	129.8	134.5	437.1	85.1	111.2	202.6	152.5	445.5	291.1	199.4	106.5	119.6	131.7	267.6	252.2	82.9	115.3
VDR	"NR1I1, PPP1R163"	ENSG00000111424	"Vitamin D receptor"	P11473	12	47841537-47943048	"Disease related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors, Transporters"	"Transcription, Transcription regulation"	"DNA-binding, Receptor"	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 57.1;parathyroid gland: 45.8"	"Cell type enhanced"	"Detected in many"	10	"Enterocytes: 101.9;Paneth cells: 43.0;Undifferentiated cells: 54.4"	"Low cancer specificity"	"Detected in all"			"Not detected"	"Not detected"			"Group enriched"	"Detected in many"	6	"classical monocyte: 3.7;eosinophil: 2.1;intermediate monocyte: 7.0;myeloid DC: 5.7;neutrophil: 7.5;non-classical monocyte: 6.9"	"Group enriched"	"Detected in many"	8	"dendritic cells: 5.7;granulocytes: 7.5;monocytes: 7.0"	"Cell line enhanced"	"Detected in many"		"HBEC3-KT: 23.0;HDLM-2: 32.4;U-937: 31.8"	"Region enhanced"	"Detected in single"		"olfactory region: 2.5"	"Not detected"	"Not detected"			"CAB004617, HPA047740, HPA072102"			Supported	"Nucleoplasm,Intermediate filaments,Cytosol"		NA	NA			Nucleoplasm	"Intermediate filaments, Cytosol"	"CAB004617: AB_628040, HPA047740: AB_2680142, HPA072102: "	"unprognostic (1.11e-2)"	"unprognostic (5.49e-2)"	"unprognostic (1.01e-1)"	"unprognostic (7.59e-3)"	"unprognostic (3.33e-3)"	"unprognostic (2.74e-2)"	"unprognostic (4.78e-2)"	"unprognostic (1.69e-1)"	"unprognostic (1.40e-1)"	"unprognostic (1.62e-1)"	"unprognostic (5.53e-3)"	"unprognostic (6.72e-2)"	"prognostic favorable (4.89e-6)"	"unprognostic (1.46e-1)"	"unprognostic (8.76e-2)"	"unprognostic (3.28e-1)"	"unprognostic (3.82e-2)"	3.0	9.2	0.2	10.0	0.3	2.5	7.8	0.3	0.6	3.5	40.9	0.4	4.1	21.2	1.2	7.7	10.2	1.1	10.7	1.5	0.5	0.3	13.0	0.6	8.3	3.8	0.5	0.1	1.3	6.5	45.8	11.7	4.4	0.6	2.1	12.6	0.4	4.9	2.8	5.3	15.2	57.1	1.2	1.5	3.1	2.6	1.5	0.2	2.0	1.9	9.4	8.2	4.0	5.2	0.7	5.7	7.5	7.0	0.2	0.8	1.2	5.5	0.9	0.0	0.0	4.8	7.0	0.1	6.8	3.5	5.8	5.0	4.0	4.7	1.4	7.4	4.6	4.1	10.4	0.2	23.0	2.7	32.4	1.7	2.4	1.3	0.3	3.5	4.9	7.8	9.4	10.8	6.4	10.5	9.2	0.4	0.5	0.7	1.5	2.6	3.7	0.1	2.4	0.0	13.8	7.5	0.1	0.0	3.5	5.2	5.5	2.6	0.1	5.8	16.7	2.1	0.0	18.8	2.7	0.4	11.1	2.9	3.2	3.8	0.9	0.0	1.2	3.4	31.8	2.8	0.2	3.7	2.1	0.0	7.0	0.1	0.7	0.3	0.0	5.7	0.1	0.1	0.0	7.5	0.2	6.9	0.6	0.8	1.2	0.2	0.3	0.3	0.6	0.5	0.3	0.5	0.1	0.6	0.2	11.9	15.3	1.9	8.2	32.1	0.4	1.2	0.0	9.4	11.4	7.0	0.0	0.1	6.6	3.7	0.1	0.8	101.9	0.0	9.4	0.1	7.8	3.9	6.9	0.4	3.6	0.0	20.8	0.0	6.6	0.0	0.0	18.7	8.5	6.4	30.0	0.2	14.7	43.0	0.4	17.5	0.2	0.0	2.8	0.7	0.3	35.5	0.2	3.2	54.4	8.4
VEGFA	"VEGF, VEGF-A, VPF"	ENSG00000112715	"Vascular endothelial growth factor A"	P15692	6	43770184-43786487	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"	"Angiogenesis, Differentiation"	"Developmental protein, Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	7	"Alveolar cells type 1: 324.6;Muller glia cells: 340.3"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in some"		"classical monocyte: 1.2;eosinophil: 1.9"	"Group enriched"	"Detected in many"	9	"granulocytes: 1.9;monocytes: 1.2"	"Cell line enhanced"	"Detected in many"		"hTERT-RPE1: 65.7;U-87 MG: 103.7"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB005429, CAB039240, HPA069116, CAB069907"	Supported				"Secreted to blood"	NA	NA	562000				"CAB005429: AB_2212984, CAB039240: , CAB069907: AB_10001947, HPA069116: AB_2686089"	"unprognostic (1.12e-1)"	"prognostic unfavorable (4.50e-4)"	"unprognostic (2.42e-2)"	"prognostic unfavorable (2.10e-4)"	"unprognostic (4.35e-2)"	"unprognostic (1.49e-1)"	"prognostic unfavorable (2.34e-5)"	"unprognostic (5.10e-2)"	"unprognostic (5.27e-3)"	"unprognostic (2.30e-2)"	"unprognostic (1.40e-1)"	"unprognostic (1.00e-2)"	"prognostic unfavorable (1.76e-5)"	"unprognostic (2.20e-1)"	"unprognostic (1.80e-1)"	"unprognostic (1.43e-1)"	"prognostic favorable (2.73e-4)"	35.0	17.5	16.6	11.4	20.1	12.8	39.5	6.5	32.3	11.8	25.9	8.7	15.0	16.0	54.1	9.4	19.4	10.4	27.5	57.0	13.4	5.4	25.8	58.6	30.0	2.9	15.8	3.7	16.4	25.1	20.6	7.3	16.7	19.8	40.5	7.2	24.4	15.1	23.8	52.9	11.9	26.3	19.2	35.1	19.0	20.5	4.5	15.4	0.3	87.9	19.6	13.6	47.5	15.7	0.0	0.1	1.9	1.2	0.0	0.0	0.0	11.8	2.1	2.0	11.6	3.5	5.5	13.7	7.3	13.0	4.8	9.6	6.8	1.6	3.9	5.9	4.4	50.2	4.9	5.4	14.7	8.6	4.2	1.7	2.9	2.8	4.5	36.9	3.2	6.6	9.7	29.3	47.4	47.2	65.7	1.2	3.3	5.5	19.7	17.6	4.9	0.3	4.4	1.2	34.8	3.3	0.3	1.9	9.3	18.7	10.0	3.6	7.6	10.5	7.2	25.2	2.7	2.8	11.9	1.7	20.2	5.4	29.1	11.9	11.2	6.6	7.6	103.7	7.5	7.0	0.0	1.2	1.9	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.5	0.0	0.0	0.0	0.0	0.0	16.6	20.1	6.5	32.3	13.4	5.4	15.8	3.7	19.8	15.4	324.6	89.9	11.2	34.6	62.6	31.5	146.9	81.5	4.0	93.3	21.0	29.5	1.1	1.7	39.1	0.0	22.8	60.6	23.3	35.0	3.1	45.9	128.0	107.6	99.1	13.4	170.0	26.2	18.4	22.8	0.0	1.7	44.4	27.0	11.8	42.9	340.3	70.3	34.8	3.2	15.2	37.5	0.0	52.8	0.9	0.9	68.4	6.6	6.9	40.0	115.1
VEGFB	"VEGFL, VRF"	ENSG00000173511	"Vascular endothelial growth factor B"	P49765	11	64234538-64238793	"Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins"		"Growth factor, Heparin-binding, Mitogen"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at transcript level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	8	"Cardiomyocytes: 177.8;Peritubular cells: 102.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	9	"plasmacytoid DC: 31.7"	"Lineage enriched"	"Detected in many"	9	"dendritic cells: 31.7"	"Cell line enhanced"	"Detected in all"		"U-266/70: 53.9"	"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"								"Secreted to blood"	NA	NA	186000					"unprognostic (4.88e-2)"	"unprognostic (6.04e-2)"	"unprognostic (1.33e-2)"	"unprognostic (3.55e-1)"	"unprognostic (1.47e-1)"	"unprognostic (1.27e-1)"	"unprognostic (5.38e-2)"	"unprognostic (2.45e-1)"	"unprognostic (4.68e-1)"	"unprognostic (5.01e-3)"	"unprognostic (2.35e-3)"	"unprognostic (1.08e-2)"	"unprognostic (1.67e-2)"	"unprognostic (8.08e-3)"	"unprognostic (2.00e-1)"	"unprognostic (4.15e-2)"	"unprognostic (4.31e-3)"	98.5	23.4	25.9	15.3	22.7	5.2	77.1	9.1	21.6	21.4	27.6	16.6	31.3	15.3	21.7	21.2	19.4	13.8	26.2	56.9	20.4	23.1	16.8	8.1	19.1	22.5	25.0	15.4	23.3	43.0	15.6	22.3	13.4	15.5	27.1	5.9	32.2	29.5	34.5	94.0	18.4	15.4	29.9	14.9	18.1	17.4	12.7	14.1	10.3	22.9	26.9	11.8	28.8	33.8	3.3	31.7	0.6	0.1	0.4	1.8	0.4	9.0	12.5	5.2	17.5	26.5	19.1	7.1	8.5	14.4	7.1	8.2	6.7	20.0	11.3	16.5	7.7	16.6	12.3	7.3	6.2	1.3	11.0	6.7	9.8	16.0	6.2	26.1	2.8	11.8	21.5	6.2	10.1	6.1	17.1	9.2	11.8	10.5	19.8	10.5	15.1	14.6	7.1	4.4	6.2	11.0	18.9	12.8	27.6	5.5	9.7	7.9	26.1	6.8	25.2	32.9	4.2	16.8	3.2	8.1	30.8	19.6	14.0	5.1	53.9	25.5	8.4	28.8	3.2	16.3	0.4	0.1	0.6	1.1	0.0	0.9	3.3	0.8	1.0	0.5	2.7	1.1	1.8	0.0	0.4	0.0	31.7	0.4	0.4	25.9	22.7	9.1	21.6	20.4	23.1	25.0	15.4	15.5	14.1	17.9	31.2	13.7	6.1	11.3	45.9	177.8	7.6	6.7	6.8	14.0	31.4	8.1	33.2	10.0	1.1	14.7	15.1	0.0	11.1	13.1	16.9	10.1	18.4	11.9	43.1	62.0	51.2	14.1	19.1	3.2	56.4	23.8	33.7	26.2	12.0	67.9	15.7	5.8	102.6	21.4	29.5	6.5	20.6	0.3	1.2	12.2	7.4	10.1	10.2	6.4
VKORC1	VKCFD2	ENSG00000167397	"Vitamin K epoxide reductase complex subunit 1"	Q9BQB6	16	31090842-31095980	"Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins"		Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in all"		"liver: 173.3"	"Cell type enhanced"	"Detected in all"	8	"Hepatocytes: 682.4"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Cell line enhanced"	"Detected in all"		"ASC diff: 98.9"					"Low region specificity"	"Detected in all"			HPA042720	Approved		Supported	"Endoplasmic reticulum"	"Intracellular and membrane"	NA	NA			"Endoplasmic reticulum"		"HPA042720: AB_10961864"	"unprognostic (5.99e-2)"	"unprognostic (2.98e-1)"	"unprognostic (7.11e-3)"	"unprognostic (7.68e-3)"	"unprognostic (5.49e-2)"	"unprognostic (3.23e-3)"	"unprognostic (3.02e-2)"	"unprognostic (2.32e-2)"	"unprognostic (2.42e-1)"	"unprognostic (2.66e-1)"	"unprognostic (1.04e-1)"	"unprognostic (1.19e-1)"	"prognostic unfavorable (2.09e-10)"	"unprognostic (1.11e-2)"	"unprognostic (6.65e-2)"	"unprognostic (3.12e-2)"	"unprognostic (9.66e-2)"	21.3	23.0	9.3	11.5	11.0	12.9	28.1	9.4	14.5	24.3	19.3	17.1	16.5	12.6	24.0	27.4	18.5	17.8	22.6	20.1	9.8	10.2	29.9	173.3	16.4	17.5	13.7	9.1	25.5	55.5	14.0	25.0	22.5	13.3	22.3	12.6	20.8	34.8	21.4	11.4	15.9	26.8	27.7	12.5	15.4	17.5	18.2	10.6	15.8	25.6	13.8	14.6	28.4	18.7	32.3	49.9	59.6	40.6	24.7	43.7	33.6	10.5	27.1	8.9	25.5	98.9	58.9	9.9	39.1	34.0	19.3	32.8	11.2	12.1	8.3	21.2	48.9	13.6	9.8	12.3	15.3	22.0	11.7	29.9	7.5	37.5	53.9	15.6	14.6	11.3	34.0	8.2	26.6	22.9	52.3	20.8	11.8	9.8	19.8	37.6	38.2	10.7	30.0	16.1	14.6	26.1	19.4	23.7	41.2	19.0	9.2	18.2	22.1	17.1	12.5	19.0	15.0	20.6	17.8	18.1	25.9	9.3	23.7	14.7	12.0	11.1	7.3	67.4	25.3	13.3	21.5	40.6	59.6	40.3	28.1	39.7	29.9	40.5	40.7	39.6	32.3	36.4	35.4	34.2	24.7	28.3	49.9	43.7	33.6	9.3	11.0	9.4	14.5	9.8	10.2	13.7	9.1	13.3	10.6	53.6	38.2	37.9	58.4	75.2	11.2	20.0	119.8	32.1	40.9	102.9	7.9	64.0	53.0	183.3	4.8	87.9	36.0	46.7	112.2	211.1	138.5	58.9	55.3	682.4	166.1	9.5	64.4	119.7	79.0	8.3	146.4	85.1	109.6	129.8	41.2	64.7	107.2	24.6	161.9	160.1	16.9	58.2	95.7	23.7	24.7	97.9	33.1	47.3	51.3	46.5
VKORC1L1		ENSG00000196715	"Vitamin K epoxide reductase complex subunit 1 like 1"	Q8N0U8	7	65873267-65959563	"Enzymes, FDA approved drug targets, Predicted membrane proteins"		Oxidoreductase	"FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Cell type enhanced"	"Detected in many"	4	"Alveolar cells type 1: 68.5"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in all"											HPA053954	Approved		Supported	"Endoplasmic reticulum"		NA	NA			"Endoplasmic reticulum"		"HPA053954: AB_2682319"	"unprognostic (3.01e-1)"	"unprognostic (1.76e-3)"	"unprognostic (4.64e-2)"	"unprognostic (4.65e-2)"	"unprognostic (3.00e-3)"	"unprognostic (7.15e-3)"	"unprognostic (1.30e-3)"	"unprognostic (8.84e-3)"	"unprognostic (5.12e-2)"	"unprognostic (5.59e-2)"	"unprognostic (9.23e-3)"	"unprognostic (1.07e-1)"	"unprognostic (1.59e-2)"	"unprognostic (1.17e-1)"	"unprognostic (7.03e-3)"	"unprognostic (4.30e-1)"	"unprognostic (5.06e-2)"	38.2	9.2	10.5	8.3	16.7	3.0	23.7	9.0	19.7	10.4	11.1	14.2	9.2	8.6	10.1	8.8	10.0	8.8	8.0	9.3	10.3	11.4	8.2	17.8	14.3	6.2	12.0	12.1	14.4	11.7	28.5	8.0	9.7	14.1	9.9	10.0	8.0	9.0	10.5	14.9	11.4	9.7	9.3	13.2	5.7	9.9	9.4	7.6	9.1	11.1	4.5	6.6	9.7	9.3	2.8	7.5	5.6	4.2	6.5	3.4	1.8	22.4	14.5	11.7	14.7	37.4	14.9	21.3	24.4	15.8	14.6	14.8	14.0	22.2	19.6	19.8	17.5	22.2	15.5	16.7	9.9	24.5	12.2	16.5	13.3	13.3	11.9	18.3	18.4	10.3	11.9	12.8	14.8	20.7	11.4	14.5	11.2	28.0	15.0	17.4	8.8	15.1	21.5	28.1	21.3	10.9	16.6	17.1	24.4	14.1	9.0	14.1	20.2	18.9	34.3	10.7	17.4	17.2	14.3	16.4	23.7	16.2	14.8	24.7	13.6	22.1	22.5	14.5	21.0	20.6	3.8	2.7	5.6	2.9	2.5	2.4	2.8	3.4	3.2	2.8	2.5	2.3	2.3	3.1	6.5	4.2	7.5	3.1	1.8	10.5	16.7	9.0	19.7	10.3	11.4	12.0	12.1	14.1	7.6	68.5	29.5	0.8	14.6	22.0	20.5	21.3	30.6	8.1	26.1	15.7	11.8	10.0	5.0	15.9	28.9	15.9	16.9	23.3	21.7	18.4	16.7	23.4	4.7	44.5	14.4	28.6	13.3	8.6	7.0	5.5	16.4	9.0	6.8	4.6	23.5	8.5	24.2	2.9	17.3	10.2	17.4	6.5	13.4	17.9	6.6	28.0	7.3	5.2	18.7	16.9
VWF	F8VWF	ENSG00000110799	"Von Willebrand factor"	P04275	12	5948874-6124770	"Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted secreted proteins"	"Blood coagulation, Cell adhesion, Hemostasis"		"Cancer-related genes, Disease mutation, FDA approved drug targets, von Willebrand disease"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"adipose tissue: 91.7"	"Cell type enhanced"	"Detected in many"	24	"Cardiomyocytes: 99.1;Endothelial cells: 414.7;Ito cells: 229.6"	"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enhanced"	"Detected in single"		"neutrophil: 1.3"	"Lineage enhanced"	"Detected in single"		"granulocytes: 1.3"	"Cell line enriched"	"Detected in some"	57	"HUVEC TERT2: 113.7"	"Low region specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"CAB001694, HPA001815, HPA002082, CAB072874, CAB072875"	Supported				"Secreted to blood"	NA	NA	28300000000	6400000000			"CAB001694: , CAB072874: AB_2665726, CAB072875: AB_2665727, HPA001815: AB_611880, HPA002082: AB_1080575"	"unprognostic (3.66e-1)"	"unprognostic (1.11e-1)"	"unprognostic (1.46e-2)"	"unprognostic (2.27e-1)"	"unprognostic (1.43e-1)"	"unprognostic (2.91e-3)"	"unprognostic (7.09e-2)"	"unprognostic (4.63e-1)"	"unprognostic (5.63e-2)"	"unprognostic (3.92e-2)"	"unprognostic (4.69e-1)"	"unprognostic (1.12e-1)"	"unprognostic (2.98e-2)"	"prognostic unfavorable (2.31e-4)"	"unprognostic (1.55e-1)"	"unprognostic (3.12e-1)"	"unprognostic (2.73e-3)"	91.7	3.1	6.1	9.7	8.1	0.8	41.5	3.7	8.6	19.7	13.9	7.3	6.8	6.6	21.5	16.7	14.4	15.1	15.3	38.7	7.4	5.0	4.6	1.5	41.2	9.9	9.4	7.1	13.6	5.8	17.7	2.6	36.4	10.2	18.7	5.1	26.3	7.2	10.5	28.9	8.1	11.8	22.1	7.4	19.0	9.6	12.7	5.9	1.8	18.6	13.2	6.5	18.9	35.0	0.0	0.0	1.3	0.3	0.0	0.0	1.8	0.0	0.0	0.0	0.0	0.1	0.1	0.1	0.0	0.1	0.0	0.1	0.0	0.0	0.0	0.2	0.0	0.0	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	113.7	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.3	0.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.3	0.0	0.0	0.0	0.0	1.8	6.1	8.1	3.7	8.6	7.4	5.0	9.4	7.1	10.2	5.9	11.9	41.6	0.0	0.4	6.0	0.0	99.1	2.5	1.4	2.3	10.4	0.0	0.8	0.0	0.3	5.0	414.7	0.0	0.0	0.0	0.7	3.3	0.7	5.7	1.5	0.4	0.0	0.0	229.6	2.1	10.0	5.5	0.8	5.0	0.0	0.0	0.5	0.0	0.0	0.7	0.0	0.8	0.0	3.3	1.8	3.4	3.8	0.8	2.2	0.0	1.6
XDH	"XO, XOR"	ENSG00000158125	"Xanthine dehydrogenase"	P47989	2	31334321-31414715	"Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		Oxidoreductase	"Disease mutation, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Tissue enhanced"	"Detected in many"		"intestine: 78.6;liver: 32.5"	"Group enriched"	"Detected in many"	5	"Enterocytes: 95.3;Hepatocytes: 35.8"	"Low cancer specificity"	"Detected in many"			"Not detected"	"Not detected"			"Low cell type specificity"	"Detected in single"			"Low lineage specificity"	"Detected in single"			"Cell line enhanced"	"Detected in some"		"BJ: 6.2;HBEC3-KT: 15.3;hTERT-HME1: 24.5;U-251 MG: 6.7"	"Low region specificity"	"Detected in all"			"Not detected"	"Not detected"			"HPA062641, HPA069323"	Supported		Uncertain	Nucleoplasm,Nucleoli	"Intracellular and membrane"	No	No			Nucleoplasm	Nucleoli	"HPA062641: AB_2684816, HPA069323: AB_2686121"	"unprognostic (8.58e-2)"	"unprognostic (4.07e-2)"	"unprognostic (1.34e-2)"	"unprognostic (1.79e-1)"	"unprognostic (2.08e-2)"	"unprognostic (7.06e-2)"	"unprognostic (4.38e-3)"	"unprognostic (7.48e-3)"	"unprognostic (3.55e-1)"	"unprognostic (3.60e-2)"	"unprognostic (3.95e-3)"	"unprognostic (3.51e-2)"	"unprognostic (1.24e-6)"	"unprognostic (2.25e-1)"	"unprognostic (5.25e-2)"	"unprognostic (2.54e-1)"	"prognostic favorable (8.73e-6)"	0.2	0.2	0.2	2.4	0.2	0.0	17.8	0.2	0.2	2.6	17.9	0.1	0.0	20.1	0.3	6.3	9.3	0.2	1.8	0.2	0.1	0.2	0.4	32.5	0.2	0.0	0.2	0.0	0.2	0.4	0.0	1.5	3.7	0.1	1.2	4.2	0.1	20.9	0.0	0.7	1.0	78.6	0.1	0.2	0.2	1.3	0.2	0.0	0.2	0.3	2.4	6.1	1.8	1.1	0.7	0.3	1.0	0.6	0.7	0.5	0.0	1.5	0.3	0.0	0.0	0.0	0.1	0.1	6.2	3.6	0.7	1.1	0.2	1.7	0.0	1.2	0.2	0.6	3.2	0.0	15.3	0.8	0.7	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.0	1.4	0.9	24.5	0.3	0.0	0.0	0.0	0.2	0.2	0.0	0.0	0.1	0.3	0.9	0.1	0.0	1.1	3.3	4.5	3.9	0.0	0.0	0.0	0.2	0.0	1.3	0.0	0.0	0.0	3.0	1.9	0.1	6.7	2.0	0.1	0.0	0.2	0.0	0.0	0.5	0.6	0.2	0.2	0.2	0.4	0.1	0.3	0.3	0.0	0.7	0.2	0.5	1.0	0.7	0.2	0.3	0.2	0.0	0.2	0.2	0.2	0.2	0.1	0.2	0.2	0.0	0.1	0.0	0.0	3.7	0.0	2.6	0.5	0.3	0.3	2.5	0.0	2.3	0.0	0.0	0.1	0.0	2.4	0.2	0.0	95.3	0.0	7.2	0.5	0.0	0.5	0.0	35.8	0.0	0.0	11.3	1.8	1.6	0.0	0.0	0.0	0.0	0.0	5.2	0.1	8.8	7.0	0.0	0.0	0.5	0.0	0.2	0.0	0.1	0.1	0.3	0.0	12.8	14.2
XIAP	"API3, BIRC4, hILP"	ENSG00000101966	"X-linked inhibitor of apoptosis"	P98170	X	123859724-123913979	"Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"	"Apoptosis, Ubl conjugation pathway, Wnt signaling pathway"	"Protease inhibitor, Thiol protease inhibitor, Transferase"	"Cancer-related genes, FDA approved drug targets"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Low cell type specificity"	"Detected in all"			"Low lineage specificity"	"Detected in all"			"Low cell line specificity"	"Detected in many"											"CAB009203, HPA042428"	Approved		Supported	"Nucleoplasm,Plasma membrane,Cytosol"		NA	NA			"Nucleoplasm, Cytosol"	"Plasma membrane"	"CAB009203: AB_2257167, HPA042428: AB_2677993"	"prognostic unfavorable (9.21e-4)"	"unprognostic (8.43e-2)"	"unprognostic (1.50e-2)"	"unprognostic (2.14e-1)"	"unprognostic (1.40e-1)"	"unprognostic (9.41e-2)"	"unprognostic (1.95e-2)"	"unprognostic (8.51e-2)"	"unprognostic (9.17e-2)"	"unprognostic (3.90e-2)"	"unprognostic (7.50e-2)"	"unprognostic (4.41e-2)"	"unprognostic (3.15e-3)"	"unprognostic (8.21e-3)"	"unprognostic (2.26e-1)"	"unprognostic (4.99e-2)"	"unprognostic (4.65e-2)"	17.4	14.4	20.0	18.1	20.2	12.0	15.9	21.3	18.9	17.2	19.4	14.5	22.9	16.1	17.4	17.0	18.9	12.6	14.7	15.7	18.9	22.1	19.8	19.4	16.5	15.5	18.8	14.6	13.9	19.7	36.6	26.1	18.2	15.9	15.6	16.8	16.9	14.6	22.9	21.5	14.2	23.4	17.0	19.0	15.8	16.2	7.0	12.3	13.9	24.3	11.4	14.0	15.4	20.5	5.7	4.3	11.1	3.9	3.3	5.5	1.9	11.7	10.0	7.9	6.8	9.4	12.1	10.3	12.8	9.5	7.0	6.0	4.5	13.8	11.0	19.0	10.9	13.3	4.4	11.7	8.0	12.9	11.4	6.4	7.4	8.4	6.8	11.9	13.4	15.4	8.3	12.5	11.6	15.0	8.1	9.6	8.3	11.7	12.7	13.5	12.2	7.5	6.5	6.5	11.7	7.9	8.0	9.2	11.6	10.5	17.1	5.4	7.9	17.5	10.1	10.3	7.3	6.2	6.6	11.9	0.4	4.8	21.0	14.2	10.7	10.7	12.2	14.4	9.6	8.8	11.1	2.6	3.5	5.0	2.3	4.7	4.6	3.8	5.5	1.4	5.7	4.4	3.0	8.2	3.3	3.9	4.3	2.5	1.9	20.0	20.2	21.3	18.9	18.9	22.1	18.8	14.6	15.9	12.3	74.5	82.4	26.9	28.9	23.7	71.7	36.7	56.0	46.8	63.7	50.6	90.3	15.7	23.2	32.6	2.2	45.7	74.1	0.0	46.9	25.4	27.8	42.3	57.9	73.4	26.6	71.5	45.5	66.3	41.2	1.5	39.4	43.8	8.5	27.9	52.4	42.8	52.8	48.9	48.4	48.2	129.5	64.7	27.8	10.4	19.9	31.0	31.8	33.1	39.8	58.3
YES1	"c-yes, HsT441, Yes"	ENSG00000176105	"YES proto-oncogene 1, Src family tyrosine kinase"	P07947	18	721588-812546	"Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins"		"Kinase, Transferase, Tyrosine-protein kinase"	"FDA approved drug targets, Proto-oncogene"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Evidence at protein level"	"Low tissue specificity"	"Detected in all"			"Low cell type specificity"	"Detected in many"			"Low cancer specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"Cell type enriched"	"Detected in many"	6	"basophil: 14.7"	"Lineage enriched"	"Detected in many"	6	"granulocytes: 14.7"	"Low cell line specificity"	"Detected in many"			"Low region specificity"	"Detected in all"			"Low region specificity"	"Detected in all"			"CAB004370, HPA026480"	Approved		Supported	"Plasma membrane,Cytosol"		NA	NA		4300000	"Plasma membrane, Cytosol"		"CAB004370: AB_627370, HPA026480: AB_1858921"	"unprognostic (3.28e-1)"	"unprognostic (1.62e-2)"	"unprognostic (5.87e-2)"	"unprognostic (2.47e-2)"	"unprognostic (6.24e-2)"	"unprognostic (4.24e-2)"	"unprognostic (6.01e-2)"	"unprognostic (1.03e-2)"	"unprognostic (1.95e-2)"	"unprognostic (1.85e-3)"	"prognostic unfavorable (2.46e-4)"	"unprognostic (2.14e-1)"	"unprognostic (8.12e-2)"	"unprognostic (4.65e-2)"	"unprognostic (1.81e-1)"	"unprognostic (4.79e-2)"	"unprognostic (4.11e-1)"	26.2	13.1	17.0	9.4	15.6	2.6	47.2	6.7	12.8	15.8	23.8	8.9	13.7	18.2	13.1	17.4	22.0	10.7	14.9	17.9	14.8	12.4	22.6	43.2	23.6	13.7	15.8	6.6	13.2	21.4	16.7	10.7	31.3	16.8	12.2	17.3	6.5	23.7	21.0	10.6	12.3	24.8	18.8	16.8	34.5	15.5	13.6	12.0	8.1	16.8	15.6	7.1	21.9	17.5	0.1	0.1	14.7	0.0	1.0	2.5	0.6	14.4	7.2	22.8	17.8	13.7	17.0	26.8	9.6	19.7	11.4	15.7	17.1	10.7	0.0	10.3	16.3	14.6	8.5	21.3	17.1	22.4	0.0	7.2	4.3	7.1	11.9	11.1	3.3	7.7	13.0	18.4	17.2	19.2	14.2	38.4	2.4	18.7	6.4	16.2	9.9	2.0	4.3	14.4	8.8	9.2	2.5	17.9	1.2	16.6	17.2	4.6	5.4	19.9	15.1	12.6	15.7	10.4	6.9	33.0	28.1	31.2	21.2	25.9	5.6	2.7	0.8	10.6	4.7	16.6	14.7	0.0	0.9	2.5	0.0	1.6	0.1	0.5	1.4	0.0	0.0	1.2	1.9	0.0	1.0	0.0	0.1	0.1	0.6	17.0	15.6	6.7	12.8	14.8	12.4	15.8	6.6	16.8	12.0	23.8	30.8	1.5	33.5	53.3	6.2	16.5	20.4	26.8	34.2	27.9	5.9	28.2	3.3	25.6	20.2	77.6	27.4	0.0	34.0	20.3	31.2	52.1	12.8	33.4	4.3	3.2	21.9	41.1	5.6	7.9	17.0	5.3	23.6	1.0	35.7	16.3	40.3	21.0	12.0	38.5	8.0	19.4	20.6	12.8	11.7	43.4	38.1	15.2	31.0	58.7
